0.15918402.15728575.html.plaintext.txt	0	Functional Relevance Amino Acid Residues Involved Interactions Ordered Nucleic Acid Spherical Virus Juan Reguera Esther Grueso Aura Carreira Cristina Sanchez Martinez Jose M
0.15918402.15728575.html.plaintext.txt	1	From Centro de Biologia Molecular Severo Ochoa Consejo Superior de Investigaciones Cientificas Universidad Autonoma de Madrid Universidad Autonoma de Madrid Cantoblanco 28049 Madrid Spain
0.15918402.15728575.html.plaintext.txt	2	Received publication January 24 2005 revised form February 22 2005
0.15918402.15728575.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In spherical virion parvovirus minute virus mice several amino acid side chains capsid previously found involved interactions viral single stranded DNA molecule
0.15918402.15728575.html.plaintext.txt	4	We individually truncated mutation alanine many ten side chains analyzed effects capsid assembly stability conformation viral DNA encapsidation virion infectivity
0.15918402.15728575.html.plaintext.txt	5	Mutation residues Tyr 270 Asp 273 Asp 474 led drastic reduction infectivity
0.15918402.15728575.html.plaintext.txt	6	Mutant Y270A defective capsid assembly mutant D273A formed stable capsids essentially unable encapsidate viral DNA externalize N terminus capsid protein VP2 connected conformational event
0.15918402.15728575.html.plaintext.txt	7	Mutation residues Asp 58 Trp 60 Asn 183 Thr 267 Lys 471 led moderate reduction infectivity
0.15918402.15728575.html.plaintext.txt	8	None mutations effect capsid assembly stability DNA encapsidation process
0.15918402.15728575.html.plaintext.txt	9	However five mutant virions substantially less stable parental virion thermal inactivation assays
0.15918402.15728575.html.plaintext.txt	10	The results model spherical virus indicate several capsid residues found involved polar interactions multiple hydrophobic contacts viral DNA molecule contribute preserving active conformation infectious viral particle
0.15918402.15728575.html.plaintext.txt	11	Their effect appears mediated non covalent interactions establish viral DNA
0.15918402.15728575.html.plaintext.txt	12	In addition least one acidic residue DNA binding region needed DNA packaging
0.15918402.15728575.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Many fundamental biological processes involve protein nucleic acid recognition
0.15918402.15728575.html.plaintext.txt	14	Double stranded DNA protein interactions extensively studied single stranded ss1 DNA RNA protein interactions much less characterized
0.15918402.15728575.html.plaintext.txt	15	In particular little known molecular interactions nucleic acid genome ssDNA RNA virus protein shell functional role interactions
0.15918402.15728575.html.plaintext.txt	16	Such knowledge may essential better understanding life cycle viruses design drugs aimed disrupting nucleic acid protein interfaces
0.15918402.15728575.html.plaintext.txt	17	The structure helical virus tobacco mosaic virus revealed defined interactions repeating sets three nucleotides ssRNA genome capsid subunit reviewed Ref
0.15918402.15728575.html.plaintext.txt	18	In crystal structures spherical viruses reviewed Refs
0.15918402.15728575.html.plaintext.txt	19	2 6 large part nucleic acid component invisible randomly oriented within viral particles form crystal
0.15918402.15728575.html.plaintext.txt	20	Fortunately icosahedral viruses segments nucleic acid molecule 10 60 total arranged symmetry capsid could visualized
0.15918402.15728575.html.plaintext.txt	21	The structural analysis reviewed Refs
0.15918402.15728575.html.plaintext.txt	22	4 7 10 revealed visible capsid nucleic acid interfaces generally include limited number amino acids 7 30 nucleotides several cases form intramolecular double helical segments
0.15918402.15728575.html.plaintext.txt	23	The tertiary structure acquired nucleic acid within virion may least partly independent nucleotide sequence 11
0.15918402.15728575.html.plaintext.txt	24	Consistent observation capsid binding nucleotide motif repeated exactly along sequence thus modeled nucleic acid stretch represents average true individual sequences bound
0.15918402.15728575.html.plaintext.txt	25	Accordingly many interactions detected viral nucleic acid capsid interfaces van der Waals polar interactions nonspecific phosphate pentose moieties specific interactions bases also observed
0.15918402.15728575.html.plaintext.txt	26	Ionic interactions phosphates basic side chains protruding internal surface capsid located disordered N terminal Nt arms capsid proteins occur several ssRNA plant viruses 12 17 nodaviruses 18 20 ssDNA bacteriophage X174 21 23
0.15918402.15728575.html.plaintext.txt	27	Such interactions observed ssRNA bean pod mottle virus 24 ssDNA parvoviruses 25 30 many nucleic acid capsid van der Waals contacts hydrogen bonds detected latter 25 30
0.15918402.15728575.html.plaintext.txt	28	A high resolution structural model ssRNA satellite tobacco mosaic virus showed binding RNA occurs mainly intricate network direct water mediated hydrogen bonds 15
0.15918402.15728575.html.plaintext.txt	29	Specific nonspecific capsid protein oligonucleotide interactions also analyzed detail artificial complexes formed recombinant capsid bacteriophage MS2 identical copies unique viral ssRNA fragment OR involved translational repression initiation capsid assembly 31 32
0.15918402.15728575.html.plaintext.txt	30	This allowed structural interpretation mutational analyses formation biologically relevant complex OR MS2 capsid protein dimer 32 37
0.15918402.15728575.html.plaintext.txt	31	Several studies provided evidence functional role viral nucleic acid interactions viral proteins assembly conformation stability andor disassembly spherical virions examples see Refs
0.15918402.15728575.html.plaintext.txt	32	However partly due limited structural information available mutational analyses dissect individual roles specific capsid side chains interact nucleic acid molecule scarce e
0.15918402.15728575.html.plaintext.txt	33	Also single residue scanning capsid side chains involved major interactions viral nucleic acid capsid interface knowledge described
0.15918402.15728575.html.plaintext.txt	34	The parvoviruses canine parvovirus CPV minute virus mice MVM constitute good models structure function studies residues involved viral nucleic acid capsid interactions structural simplicity virion relatively well defined viral DNA capsid interfaces 25 30
0.15918402.15728575.html.plaintext.txt	35	The icosahedral T 1 capsid MVM 29 30 CPV 25 28 formed 60 protein subunits contributed three non identical polypeptides derived single gene show identical fold core sequence
0.15918402.15728575.html.plaintext.txt	36	VP2 major capsid component VP1 includes VP2 sequence plus Nt extension VP3 results cleavage Nt VP2 subunits 48 49
0.15918402.15728575.html.plaintext.txt	37	The DNA recognition site essentially equivalent CPV MVM strain major ordered ssDNA stretch 11 nucleotides adopts similar conformation viruses 25 26 30
0.15918402.15728575.html.plaintext.txt	38	This DNA segment interacts multiple hydrophobic contacts andor hydrogen bonds mainly 7 9 side chains capsid either CPV MVM 25 26 30 see Table I
0.15918402.15728575.html.plaintext.txt	39	Most side chains chemically sterically identical similar viruses 50 participate similar interactions DNA
0.15918402.15728575.html.plaintext.txt	40	For MVMi shorter DNA stretches spatially close major ordered DNA segment could also modeled 29 30
0.15918402.15728575.html.plaintext.txt	41	We individually truncated alanine many residues MVM capsid previously 26 30 found involved interactions ordered nucleic acid structural model virion
0.15918402.15728575.html.plaintext.txt	42	The individual effects mutations virus infectivity viral particle assembly conformational stability DNA packaging analyzed
0.15918402.15728575.html.plaintext.txt	43	View table TABLE I DNA protein interactions observed structural models MVMi CPV
0.15918402.15728575.html.plaintext.txt	44	Contact analysis carried using program Whatif 64 PDB files 1mvm PDB 29 30 4dpv 26 27 including symmetry related subunits completeness
0.15918402.15728575.html.plaintext.txt	45	The MVM CPV residues row occupy equivalent positions aligned sequence three dimensional structure
0.15918402.15728575.html.plaintext.txt	46	Three DNA stretches 11 4 1 nucleotides denoted A B C respectively included atomic coordinates MVMi 29 30 equivalent stretch A included unrefined 25 refined 26 27 atomic coordinates CPV
0.15918402.15728575.html.plaintext.txt	47	Residues parentheses seen participate interactions visible DNA stretches either MVM CPV
0.15918402.15728575.html.plaintext.txt	48	Conservation sequence conformation consistent possibility CPV residues parentheses could interact equivalent DNA stretches B C even though regions could modeled crystal structure CPV
0.15918402.15728575.html.plaintext.txt	49	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Recombinant Plasmids Mutagenesis Site directed mutagenesis VP1VP2 gene MVM strain p carried using QuikChange system Stratagene recombinant plasmid pSVtk VP12 mutant sequences confirmed automated DNA sequencing
0.15918402.15728575.html.plaintext.txt	50	The mutations introduced subcloning MVMp infectious clone pMM984 originally provided P
0.15918402.15728575.html.plaintext.txt	51	Tattersall 51 modified include VP2 sequence MVMp variant used laboratories 52
0.15918402.15728575.html.plaintext.txt	52	Two HindIII restriction sites unique sites XbaI EcoRI VP2 gene respectively used mutations located upstream downstream codon corresponding amino acid residue 402
0.15918402.15728575.html.plaintext.txt	53	The mutant infectious clones subjected restriction analysis presence mutations entire sequence inserted confirmed DNA sequencing
0.15918402.15728575.html.plaintext.txt	54	The concentration purified DNA estimated first agarose gel electrophoresis quantitated ultraviolet absorbance 260 nm
0.15918402.15728575.html.plaintext.txt	55	Electroporation Mammalian Cells Immunofluorescence Infectivity Assays For mutational analyses mammalian NB324K cells concentration 2 x 107 cellsml electroporated described previously 53 54 equal non saturating amounts 10 microg infectious recombinant plasmid carrying appropriate mutations using experiment non mutated infectious plasmid control
0.15918402.15728575.html.plaintext.txt	56	Virions recovered 72 h transfected monolayers titrated standard plaque formation assays 55
0.15918402.15728575.html.plaintext.txt	57	The results normalized quantitation using SDS PAGE 10 polyacrylamide immunoblotting anti MVM antiserum amount viral capsid proteins present extracts transfected cells 56
0.15918402.15728575.html.plaintext.txt	58	Immunofluorescence assays described previously 56 minor modifications
0.15918402.15728575.html.plaintext.txt	59	The primary antibodies used polyclonal antibody recognizes MVM capsid proteins VPs 52 ii monoclonal antibody B7 recognizes discontinuous epitope specific assembled capsid 57 iii polyclonal antibody elicited VP2 Nt recognizes virions encapsidated genome concomitantly externalized VP2 Nt segment 56
0.15918402.15728575.html.plaintext.txt	60	Purification Virions Empty Capsids Natural infections MVMp transfection infectious recombinant plasmid yield large proportion empty capsids mixed minor proportion infectious virions 49
0.15918402.15728575.html.plaintext.txt	61	Partially purified mixtures empty capsids infectious virions obtained essentially described 56 58 centrifugation clarified cell extracts sucrose gradients followed extensive dialysis phosphate buffered saline PBS
0.15918402.15728575.html.plaintext.txt	62	Empty capsids infectious virions purified centrifugation cesium chloride CsCl density gradients see dialyzed PBS
0.15918402.15728575.html.plaintext.txt	63	The capsid virion preparations found essentially free contaminants SDS PAGE concentration estimated densitometry stained gels andor UV spectrophotometry 59
0.15918402.15728575.html.plaintext.txt	64	Conformational Stability MVM Empty Capsids Virions Followed Spectrofluorometry A Varian Cary Eclipse luminescence spectrophotometer equipped computer operated Peltier temperature control unit used
0.15918402.15728575.html.plaintext.txt	65	Empty capsids purified virions added 2 x 10 mm cell irradiated UV light excitation wavelength 295 nm
0.15918402.15728575.html.plaintext.txt	66	The temperature continuously increased 25 degrees C 85 degrees C 90 degrees C constant rate 1 degrees Cmin intrinsic tryptophan fluorescence emission wavelength 330 nm determined 1 min intervals 59 60
0.15918402.15728575.html.plaintext.txt	67	During experiments small aliquots taken determination infectious virus titers see
0.15918402.15728575.html.plaintext.txt	68	The changes fluorescence fitted sigmoidal cooperative transitions using program KaleidaGraph Abelbeck Software allowed determination half transition temperature Tm 59 60
0.15918402.15728575.html.plaintext.txt	69	Thermal Inactivation MVM Virions Followed Infectivity Two procedures used virion preparations subjected thermal gradient described see also 59 60 infectious viruses remaining different temperatures determined titration aliquots taken heated sample
0.15918402.15728575.html.plaintext.txt	70	ii The kinetics virus inactivation determined follows 61
0.15918402.15728575.html.plaintext.txt	71	Virus preparations diluted PBS concentration 1500 plaque forming unitsml
0.15918402.15728575.html.plaintext.txt	72	100 microl aliquots thin walled PCR tubes incubated constant temperature 70 degrees C different amounts time remaining virus titers determined plaque assays
0.15918402.15728575.html.plaintext.txt	73	Non mutated viral particles obtained parallel transfection experiments included heat inactivation experiment positive control
0.15918402.15728575.html.plaintext.txt	74	The use culture medium Dulbeccos modified Eagles medium supplemented fetal calf serum instead PBS significantly affect results
0.15918402.15728575.html.plaintext.txt	75	Analysis DNA Encapsidation NB324K cells 1
0.15918402.15728575.html.plaintext.txt	76	2 x 107 cells transfected electroporation 40 microg purified MVM plasmids cultured 48 h Dulbeccos modified Eagles medium containing 10 fetal calf serum
0.15918402.15728575.html.plaintext.txt	77	The monolayers washed PBS harvested 20 mM Tris pH 7
0.15918402.15728575.html.plaintext.txt	78	2 SDS TES buffer completely homogenized freeze thawing three times cell extracts used purification MVM particles described 56
0.15918402.15728575.html.plaintext.txt	79	Approximately 20 fractions collected CsCl gradients amounts VPs viral DNA estimated slot dot Hoeffer analysis
0.15918402.15728575.html.plaintext.txt	80	Samples diluted ten times PBS bound vacuum nitrocellulose filters Schleicher Schull soaked buffer left room temperature dry
0.15918402.15728575.html.plaintext.txt	81	The amount bound VP capsid estimated immunochemically polyclonal anti MVM capsid serum 52 using enhanced chemiluminescence method ECL Amersham Biosciences
0.15918402.15728575.html.plaintext.txt	82	To estimate amount viral DNA samples bound membranes denatured 0
0.15918402.15728575.html.plaintext.txt	83	5 M NaCl 5 min room temperature neutralized incubation 0
0.15918402.15728575.html.plaintext.txt	84	5 M NaCl 5 min bound membrane heating 80 degrees C 2 h
0.15918402.15728575.html.plaintext.txt	85	Filters hybridized high stringency described 51 using probe 2
0.15918402.15728575.html.plaintext.txt	86	4 kpb EcoRI restriction fragment MVM genome nucleotides 1105 3547 62 labeled random priming digoxigenin incubated solution nitroblue tetrazolium chloride 5 bromo 4 chloro 3 indolylphosphate Roche Applied Science
0.15918402.15728575.html.plaintext.txt	87	Molecular Graphics Structural Analyses A Silicon Graphics workstation PDB coordinates immunosuppressive strain MVM 1mvm PDB 29 30 CPV 4dpv 27 programs InsightII Biosym Technologies RasMol 63 Whatif 64 used
0.15918402.15728575.html.plaintext.txt	88	The capsid MVM prototypic strain p used study 98 identical immunosuppressive strain 62 non conserved capsid residues located surface exposed loops far away DNA capsid interface 30
0.15918402.15728575.html.plaintext.txt	89	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Selection Mutational Analysis Amino Acid Residues Parvovirus Nucleic Acid Capsid Interface Based analyses three dimensional structures MVMi CPV virions 25 30 ten residues MVM capsid chosen mutagenesis alanine Table I Fig
0.15918402.15728575.html.plaintext.txt	90	Each mutation would disrupt interaction truncated side chain beyond C DNA minimizing possibility altering conformation polypeptide backbone 65
0.15918402.15728575.html.plaintext.txt	91	Some side chains additionally involved interactions neighboring amino acid residues would also disrupted mutation also contemplated experimental approach see
0.15918402.15728575.html.plaintext.txt	92	View larger version 50K FIG
0.15918402.15728575.html.plaintext.txt	93	Amino acid residues MVM virion chosen mutational analysis
0.15918402.15728575.html.plaintext.txt	94	The amino acid residues color coded according atom green C blue N red O labeled
0.15918402.15728575.html.plaintext.txt	95	The ordered ssDNA stretches A B C Table I virion shown yellow cyan violet respectively
0.15918402.15728575.html.plaintext.txt	96	The PDB coordinates 1mvm PDB 29 30 used
0.15918402.15728575.html.plaintext.txt	97	The interactions major ordered DNA stretch residues Asn 183 Thr 267 Asn 491 MVMi structural model similar equivalent conserved residues Asn 180 Thr 263 Asn 492 refined CPV model
0.15918402.15728575.html.plaintext.txt	98	The sterically similar replacements Asp 58 Tyr 270 MVM Asn 56 Phe 266 CPV disrupt major interactions residues DNA Table I
0.15918402.15728575.html.plaintext.txt	99	Residues Trp 60 Asn 491 MVM appear involved major interactions two neighboring shorter DNA stretches could clearly visualized CPV structure 30
0.15918402.15728575.html.plaintext.txt	100	However residues conserved CPV Trp 58 Asn 492 interactions could also conserved
0.15918402.15728575.html.plaintext.txt	101	Finally residues Lys 278 Lys 471 Asp 273 Asp 474 MVM equivalents Arg 274 Lys 472 Asp 269 Asp 475 CPV either identical similar Asp 269 CPV contain charged groups closest visible DNA phosphates could involved either attractive repulsive electrostatic interactions DNA molecule
0.15918402.15728575.html.plaintext.txt	102	In brief ten residues MVM capsid chosen mutation include many involved major interactions viral nucleic acid residues interactions DNA conserved MVM CPV
0.15918402.15728575.html.plaintext.txt	103	Several Residues Involved DNA Capsid Interactions Are Important Infectivity MVMp The chosen mutations individually introduced infectious DNA clone MVMp susceptible mammalian cells transfected quantitated equivalent amounts mutant infectious DNA clones non mutated control virus yields 72 h transfection determined titration
0.15918402.15728575.html.plaintext.txt	104	The entire experiment repeated using new set infectious DNA preparations quantitated electroporated completely independent way
0.15918402.15728575.html.plaintext.txt	105	The relative efficiency transfection process determined described Materials Methods
0.15918402.15728575.html.plaintext.txt	106	The normalized relative viral titers significantly different obtained first experiment
0.15918402.15728575.html.plaintext.txt	107	The results Table II revealed infectivity mutants K278A N491A similar non mutated control slightly reduced mutants D58A W60A N183A T267A K471A clearly reduced one order magnitude mutants Y270A D273A D474A drastically reduced 3 4 orders magnitude
0.15918402.15728575.html.plaintext.txt	108	The experiments described following paragraphs carried aim identifying steps viral life cycle could responsible reduced infectivity mutants
0.15918402.15728575.html.plaintext.txt	109	View table TABLE II Effects truncation capsid side chains involved interactions nucleic acid MVM virion
0.15918402.15728575.html.plaintext.txt	110	Expression VPs Nuclear Transport Capsid Assembly In situ immunofluorescence assays cells transfected equal amounts plasmids carried
0.15918402.15728575.html.plaintext.txt	111	VP expression detected 48 h transfection antibody recognizes VPs even non assembled 56
0.15918402.15728575.html.plaintext.txt	112	All mutants wild type expressed similar amounts capsid proteins Fig
0.15918402.15728575.html.plaintext.txt	113	In addition presence intense nuclear fluorescence Fig
0.15918402.15728575.html.plaintext.txt	114	2A shown revealed mutant VPs able translocate nucleus
0.15918402.15728575.html.plaintext.txt	115	View larger version 65K FIG
0.15918402.15728575.html.plaintext.txt	116	In situ immunofluorescence mammalian cells transfected non mutated mutant infectious plasmids MVMp
0.15918402.15728575.html.plaintext.txt	117	A B correspond results obtained two different double labeling experiments using specific antibodies detect expression viral proteins VPs assembled capsids Capsid externalization Nt VP2 2Nt see text wt mock indicate transfection non mutated control plasmid viral DNA images correspond transfection indicated mutant plasmid
0.15918402.15728575.html.plaintext.txt	118	Capsid assembly within nucleus detected monoclonal antibody B7 recognizes capsid specific discontinuous epitope located virion external surface vertex 3 fold spikes 57 far away residues mutated located internal capsid surface closer 2 fold axes
0.15918402.15728575.html.plaintext.txt	119	All mutants except Y270A able assemble capsids levels comparable non mutated control Fig
0.15918402.15728575.html.plaintext.txt	120	Most Y270A transfected cells showed positive nuclear reactivity anti VP antibody showed weak reactivity anti capsid antibody relative non mutated control Fig
0.15918402.15728575.html.plaintext.txt	121	This result consistent previous observations uncoupling nuclear transport capsid assembly 54 nature subviral oligomers translocate across nuclear membrane
0.15918402.15728575.html.plaintext.txt	122	2 Extracts cells transfected mutant Y270A either two mutants W60A D273A positive anti capsid antibody non mutated control subjected sedimentation CsCl gradients amount MVM capsids produced estimated quantitation hemagglutination HA activity present density band corresponding empty capsids
0.15918402.15728575.html.plaintext.txt	123	The non mutated control W60A D273A particles produced normal levels 6400 HA units per 107 transfected cells whereas Y270A yielded 100 300 HA units per 107 transfected cells shown
0.15918402.15728575.html.plaintext.txt	124	This confirmed mutant Y270A defective capsid assembly
0.15918402.15728575.html.plaintext.txt	125	Externalization VP2 Nt Packaging Viral DNA The maturation within nucleus MVM virions encapsidating genome triggers externalization Nt VP2 48 event required infectivity externalized peptide segment allows traffic particle outward nucleus 56
0.15918402.15728575.html.plaintext.txt	126	Thus DNA containing virions specifically detected cells situ immunofluorescence antibody specific epitopes located VP2 Nt 56
0.15918402.15728575.html.plaintext.txt	127	All mutants except D273A Y270A reacted strongly antibody Fig
0.15918402.15728575.html.plaintext.txt	128	2B Table II indicating able efficiently externalize VP2 Nt encapsidate viral genome
0.15918402.15728575.html.plaintext.txt	129	As described Y270A yielded low amounts assembled capsids reactivity anti VP2 Nt antibody proportionally reduced Fig
0.15918402.15728575.html.plaintext.txt	130	Remarkably D273A mutant showed normal reactivity anti VP anti capsid antibodies Fig
0.15918402.15728575.html.plaintext.txt	131	2A showed extremely reduced reactivity anti VP2 Nt antibody Fig
0.15918402.15728575.html.plaintext.txt	132	It could argued mutation D273A may prevent externalization VP2 Nt DNA encapsidation
0.15918402.15728575.html.plaintext.txt	133	We considered possibility unlikely two events correlated 48 56 mutations located far away pores capsid 5 fold axes Nt externalized
0.15918402.15728575.html.plaintext.txt	134	However analyze issue mutants D273A Y270A W60A non mutated control subjected density gradient centrifugation analysis
0.15918402.15728575.html.plaintext.txt	135	3 non mutated control mutant W60A large amount viral DNA detected fractions density corresponding virions whereas viral DNA detected low levels equivalent Y270A fractions barely detectable D273A fractions
0.15918402.15728575.html.plaintext.txt	136	This result entirely consistent immunofluorescence analysis Fig
0.15918402.15728575.html.plaintext.txt	137	2 indicates Y270A maintains DNA encapsidation capacity proportional low amounts capsid assembled whereas D273A form normal amounts empty capsids severely impaired ability encapsidate viral genome
0.15918402.15728575.html.plaintext.txt	138	View larger version 26K FIG
0.15918402.15728575.html.plaintext.txt	139	Mammalian cells transfected infectious non mutated wt mutant W60A Y270A D273A plasmids MVMp
0.15918402.15728575.html.plaintext.txt	140	The assembled empty capsids buoyant density 1
0.15918402.15728575.html.plaintext.txt	141	32 gml ssDNA full virions buoyant density 1
0.15918402.15728575.html.plaintext.txt	142	41 gml present cellular homogenates separated according density CsCl centrifugation 1
0.15918402.15728575.html.plaintext.txt	143	A samples obtained 1
0.15918402.15728575.html.plaintext.txt	144	2 x 106 transfected cells amount viral particles fractions corresponding empty capsids fractions 3 7 virions fractions 9 14 estimated slot immunoblot assay
0.15918402.15728575.html.plaintext.txt	145	VLPs MVMp purified quantitated described 56 used calibration bovine serum albumin used negative control
0.15918402.15728575.html.plaintext.txt	146	B samples obtained 1 x 107 transfected cells amount viral DNA fractions corresponding full virions estimated DNA hybridization
0.15918402.15728575.html.plaintext.txt	147	Different amounts MVMp infectious plasmid quantitated absorbance 259 nm ethidium bromide staining agarose gels used calibration
0.15918402.15728575.html.plaintext.txt	148	Exposure 40 h using intensifying screen
0.15918402.15728575.html.plaintext.txt	149	Analysis Stability Empty Capsid Most side chains involved interactions viral DNA analyzed study either interact neighboring capsid residues establish latter van der Waals contacts Table III
0.15918402.15728575.html.plaintext.txt	150	However side chains Tyr 270 Trp 60 involved multiple hydrophobic intrasubunit contacts hydrogen bond Lys 278 Asp 474 interact intersubunit salt bridge Table II
0.15918402.15728575.html.plaintext.txt	151	Truncation side chains could potentially affect stability viral particles disruption DNA capsid interactions disruption intracapsid interactions
0.15918402.15728575.html.plaintext.txt	152	Thus contribution mutated residues stability protein shell estimated using empty capsids follows
0.15918402.15728575.html.plaintext.txt	153	View table TABLE III Intracapsid interactions MVMi virion amino acid side chains analyzed study
0.15918402.15728575.html.plaintext.txt	154	The analysis carried using program Whatif 64 PDB file 1mvm PDB 29 30
0.15918402.15728575.html.plaintext.txt	155	Intersubunit interactions analyzed using pairs symmetry related subunits
0.15918402.15728575.html.plaintext.txt	156	Only interactions side chain beyond C considered
0.15918402.15728575.html.plaintext.txt	157	Cut distances abbreviations Table I
0.15918402.15728575.html.plaintext.txt	158	Additional abbreviations mc main chain sc side chain sb salt bridge
0.15918402.15728575.html.plaintext.txt	159	The thermal stability purified natural empty capsids MVMp containing VP2 VP1 determined first following intrinsic fluorescence particles controlled thermal gradients previously described VP2 empty capsids virus like particles VLPs MVMp 59 60
0.15918402.15728575.html.plaintext.txt	160	Superimposed linear decrease fluorescence due thermal quenching two transitions observed
0.15918402.15728575.html.plaintext.txt	161	The first transition yielded Tm 42 plus minus 3 degrees C Fig
0.15918402.15728575.html.plaintext.txt	162	4A second transition Tm 76
0.15918402.15728575.html.plaintext.txt	163	Comparison detailed analyses structurally similar viral like particles VLPs MVMp 59 indicates two transitions correspond conformational rearrangement capsid associated externalization VP2 Nt capsid dissociation respectively
0.15918402.15728575.html.plaintext.txt	164	Partially purified non mutated empty capsids containing small fraction virions significantly contribute variation fluorescence signal assayed described purified empty capsids
0.15918402.15728575.html.plaintext.txt	165	The first transition occurred similar temperature second transition corresponding dissociation capsid yielded Tm within error Table II
0.15918402.15728575.html.plaintext.txt	166	This result validated use partially purified capsids determine capsid stability type assay
0.15918402.15728575.html.plaintext.txt	167	Finally thermostability partially purified mutant empty capsids compared non mutated control using assay
0.15918402.15728575.html.plaintext.txt	168	The eight mutant capsids tested showed evidence first conformational transition occurred similar temperature cases dissociated Tm indistinguishable within error non mutated control Fig
0.15918402.15728575.html.plaintext.txt	169	View larger version 16K FIG
0.15918402.15728575.html.plaintext.txt	170	Conformational change dissociation MVMp empty capsid probed intrinsic Trp fluorescence
0.15918402.15728575.html.plaintext.txt	171	A B relative fluorescence intensity arbitrary units
0.15918402.15728575.html.plaintext.txt	172	emitted 330 nm function temperature
0.15918402.15728575.html.plaintext.txt	173	For reasons scale clarity complete curve obtained experiment split two parts corresponding low A high B temperature ranges transition corresponding conformational change without dissociation transition corresponding capsid dissociation respectively occur 59
0.15918402.15728575.html.plaintext.txt	174	C dissociation non mutated empty capsid circles mutants triangles T267A inverted triangles N491A diamonds D474A followed emission fluorescence indicated B
0.15918402.15728575.html.plaintext.txt	175	For clarity representation curves vertically offset
0.15918402.15728575.html.plaintext.txt	176	The experimental data fitted sigmoidal transitions continuous lines
0.15918402.15728575.html.plaintext.txt	177	Analysis Conformational Stability Virion The thermal stability non mutated MVMp virion neutral pH analyzed first
0.15918402.15728575.html.plaintext.txt	178	The purified virions exposed controlled thermal gradient variation intrinsic fluorescence determined
0.15918402.15728575.html.plaintext.txt	179	The virions exhibited small detectable reproducible transition temperature 54 degrees C Fig
0.15918402.15728575.html.plaintext.txt	180	This transition correspond conformational transition observed VLPs 59 empty capsids substantially lower temperature see consistent fact virions VP2 Nt already externalized 48 56
0.15918402.15728575.html.plaintext.txt	181	Instead transition detected virion may related externalization VP1 Nt shown occur similar temperature 66
0.15918402.15728575.html.plaintext.txt	182	The transition corresponding dissociation virion Fig
0.15918402.15728575.html.plaintext.txt	183	5B 66 yielded Tm 77 degrees C similar found VLPs empty capsids using approach 59
0.15918402.15728575.html.plaintext.txt	184	Also significant difference stability DNA full virions empty capsids found hemagglutination activity heated purified particles compared neutral pH
0.15918402.15728575.html.plaintext.txt	185	View larger version 16K FIG
0.15918402.15728575.html.plaintext.txt	186	Conformational stability MVMp virion
0.15918402.15728575.html.plaintext.txt	187	A B relative fluorescence intensity arbitrary units
0.15918402.15728575.html.plaintext.txt	188	emitted 330 nm purified MVMp virions function temperature neutral pH pH 7
0.15918402.15728575.html.plaintext.txt	189	For reasons scale clarity complete curve obtained experiment split two parts corresponding low A high B temperature ranges
0.15918402.15728575.html.plaintext.txt	190	The experimental data fitted sigmoidal transitions continuous lines
0.15918402.15728575.html.plaintext.txt	191	C relative infectivity purified MVMp virions function temperature pH 7
0.15918402.15728575.html.plaintext.txt	192	The titer temperature obtained using several dilutions sample
0.15918402.15728575.html.plaintext.txt	193	No infectious virions detected three highest temperatures tested
0.15918402.15728575.html.plaintext.txt	194	The experiment repeated similar results obtained
0.15918402.15728575.html.plaintext.txt	195	Even though virion particle disrupted high temperatures infectivity may slightly reduced capsid dissociation occurs 66 67
0.15918402.15728575.html.plaintext.txt	196	Thus thermal gradient experiments using purified non mutated virions aliquots taken different temperatures remaining infectivity determined plaque assays
0.15918402.15728575.html.plaintext.txt	197	The results suggest infectivity may lost two steps Fig
0.15918402.15728575.html.plaintext.txt	198	The first step involved moderate 5 fold reduction infectivity 50 55 degrees C temperature approximately coincident first transition observed fluorescence see
0.15918402.15728575.html.plaintext.txt	199	The second step involved drastic reduction infectivity several orders magnitude started 70 degrees C led nearly complete loss infectivity 80 degrees C temperatures corresponded approximately dissociation virion empty capsids VLPs see Refs
0.15918402.15728575.html.plaintext.txt	200	The small virionempty capsid ratio obtained infections cell lines MVM 49 reduced infectivity mutants analyzed made difficult obtain relatively large amounts purified mutant virions needed analysis
0.15918402.15728575.html.plaintext.txt	201	However conformational stability mutant infectious virions could compared following reduction infectivity thermal inactivation kinetic assays required small amount partially purified virions 61
0.15918402.15728575.html.plaintext.txt	202	The results assays shown Fig
0.15918402.15728575.html.plaintext.txt	203	6 representative variants summarized Table II mutants analyzed
0.15918402.15728575.html.plaintext.txt	204	The stability mutants D273A Y270A possibly N491A substantially different non mutated control
0.15918402.15728575.html.plaintext.txt	205	In contrast stability mutants namely D58A W60A N183A T267A K278A K471A D474A clearly reduced Table II
0.15918402.15728575.html.plaintext.txt	206	To summarize mutation tested affected thermal stability empty capsid affected thermal sensitivity infectious virion
0.15918402.15728575.html.plaintext.txt	207	View larger version 17K FIG
0.15918402.15728575.html.plaintext.txt	208	Thermal inactivation non mutated two representative mutant infectious virions MVMp function time
0.15918402.15728575.html.plaintext.txt	209	Aliquots virus preparations incubated 70 degrees C periods time indicated titers determined normalized using titer obtained absence heating 0
0.15918402.15728575.html.plaintext.txt	210	Black bars non mutated virion gray bars mutant K471A white bars mutant N183A
0.15918402.15728575.html.plaintext.txt	211	Titers determined triplicate
0.15918402.15728575.html.plaintext.txt	212	The standard deviation case 15 average except 99 min
0.15918402.15728575.html.plaintext.txt	213	In latter case number plaque forming units low leading somewhat larger errors
0.15918402.15728575.html.plaintext.txt	214	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Two aspects related experimental approach used work may require discussion
0.15918402.15728575.html.plaintext.txt	215	First error atomic positions MVM crystal structure 29 30 absence complete refinement necessary averaging true DNA sequences bound symmetry related sites capsid introduce uncertainty amino acid residues interactions participate DNA capsid interface defined Table I
0.15918402.15728575.html.plaintext.txt	216	However several evidences indicate major DNA capsid interactions hydrogen bonds multiple hydrophobic contacts involve capsid residues analyzed study occur MVM virion conformations major visible DNA stretch MVMi CPV models extremely similar 25 26 30 ii many visible nucleotides electron density distinctive purine pyrimidine cases individual base type 26 30 iii complete refinement CPV structure change essence major DNA capsid interactions observed residues involved 25 27 iv capsid residues involved interactions ordered DNA either conserved conservatively substituted viruses 50 v interactions residues DNA similar MVMi refined CPV structural models 26 30
0.15918402.15728575.html.plaintext.txt	217	Second use empty capsids analyze contribution virion stability interactions capsid amino acid residues assumes interactions similar types viral particles
0.15918402.15728575.html.plaintext.txt	218	The structure CPV 68 MVM capsid 29 58 nearly identical empty particle DNA full virion
0.15918402.15728575.html.plaintext.txt	219	For CPV comparison refined structures virion empty capsid showed local differences conformation several residues DNA binding region 68
0.15918402.15728575.html.plaintext.txt	220	However detailed contact analysis using structural models indicated residues equivalent MVM subjected mutational analysis involved similar interactions virion empty capsid The side chains Tyr 270 Trp 60 MVM equivalent Phe 266 Trp 58 CPV participate multiple hydrophobic contacts neighboring amino acid residues virion empty capsid CPV nearly contacts preserved contacts observed
0.15918402.15728575.html.plaintext.txt	221	Lys 278 Asp 474 MVM equivalent Arg 274 Asp 475 CPV linked virion intersubunit salt bridge salt bridge also preserved empty capsid CPV
0.15918402.15728575.html.plaintext.txt	222	The results obtained together considerations discussed allow us propose defined structural roles residues found involved major interactions viral DNA explain observed functional involvement residues virus life cycle
0.15918402.15728575.html.plaintext.txt	223	Residues Moderate Effects Infectivity Truncation Ala Asp 58 Trp 60 Asn 183 Thr 267 Lys 278 Lys 471 Asn 491 significantly affect capsid protein expression assembly capsids inside nucleus externalization VP2 Nt
0.15918402.15728575.html.plaintext.txt	224	This latter fact indicates mutants also able encapsidate DNA confirmed direct encapsidation analysis using mutant W60A
0.15918402.15728575.html.plaintext.txt	225	The side chains Trp 60 Lys 278 others may interact DNA also involved multiple interactions capsid residues well
0.15918402.15728575.html.plaintext.txt	226	However none seven mutations significant effect stability capsid
0.15918402.15728575.html.plaintext.txt	227	In contrast mutations possible exception N491A lesser inhibitory effect infectivity caused substantial reduction thermal sensitivity infectious virion
0.15918402.15728575.html.plaintext.txt	228	These results indicate interactions mutated residues DNA interactions capsid residues role preserving virion conformation needed infectivity virus particle
0.15918402.15728575.html.plaintext.txt	229	The aromatic ring Trp 60 oriented perpendicularly ring neighboring purine base allows extensive van der Waals contacts favorable dipole interactions
0.15918402.15728575.html.plaintext.txt	230	Asp 58 Asn 183 Asn 491 may hydrogen bonded respectively purine base sugar phosphate backbone
0.15918402.15728575.html.plaintext.txt	231	Thr 267 involved several van der Waals contacts
0.15918402.15728575.html.plaintext.txt	232	Lys 278 Lys 471 showed contacts DNA relatively close DNA phosphates could contribute medium range electrostatic interactions
0.15918402.15728575.html.plaintext.txt	233	The results also showed even though neutralization charge DNA phosphates detected thermal stability MVM virion reduced relative empty capsid neutral pH
0.15918402.15728575.html.plaintext.txt	234	We propose manyfold repeated hydrophobic electrostatic interactions viral DNA Asp 58 Trp 60 Asn 183 Thr 267 Lys 278 Lys 471 perhaps residues involved capsid protein viral DNA interactions Table I analyzed present study may help counteract potential destabilization caused repulsion non neutralized DNA phosphates virion
0.15918402.15728575.html.plaintext.txt	235	Truncation side chain residues except Lys 278 led reduction infectivity one order magnitude
0.15918402.15728575.html.plaintext.txt	236	The individual contribution virion stability infectivity residues involved major interactions viral DNA capsid subunit thus relatively moderate
0.15918402.15728575.html.plaintext.txt	237	However combined effect additive expected could dramatically important
0.15918402.15728575.html.plaintext.txt	238	Mutation K278A also reduced virion stability infectivity
0.15918402.15728575.html.plaintext.txt	239	One possibility explain anomalous result study reduction stability could compensated another favorable effect mutation another step viral cycle
0.15918402.15728575.html.plaintext.txt	240	Residues Drastic Effects Infectivity Truncation Tyr 270 Asp 273 Asp 474 affect capsid protein expression nuclear transport
0.15918402.15728575.html.plaintext.txt	241	However contrary mutations discussed three mutants reduction infectivity dramatic appear caused reduction thermal stability infectious virion
0.15918402.15728575.html.plaintext.txt	242	Mutant Y270A clearly defective capsid assembly
0.15918402.15728575.html.plaintext.txt	243	Tyr 270 involved multiple interactions DNA also neighboring capsid residues
0.15918402.15728575.html.plaintext.txt	244	Thus likely explanation inefficient assembly mutant dramatic reduction viral yield removal critical intracapsid interactions
0.15918402.15728575.html.plaintext.txt	245	The D474A mutation prevent capsid assembly capsid stability reduced either
0.15918402.15728575.html.plaintext.txt	246	The D474A virion show reduced stability similar higher reductions stability observed many mutants whose infectivity viral yield reduced 10 fold
0.15918402.15728575.html.plaintext.txt	247	Thus drastic reduction infectivity D474A may related mainly another yet unidentified step viral cycle
0.15918402.15728575.html.plaintext.txt	248	Finally D273A mutation prevent capsid assembly severely impaired externalization Nt VP2 encapsidation viral DNA explains drastic effect infectivity
0.15918402.15728575.html.plaintext.txt	249	Asp 273 close DNA phosphate acidic basic amino acid residue closest basic residue Lys 494 distance 4
0.15918402.15728575.html.plaintext.txt	250	7 A makes visible contacts DNA amino acid residues
0.15918402.15728575.html.plaintext.txt	251	One possibility charge distribution capsid internal surface may significantly altered 60 negative charges removed D273A mutation may critical DNA packaging
0.15918402.15728575.html.plaintext.txt	252	In addition D273A phenotype provides support previous suggestion encapsidation MVM genome occurs empty capsids previously assembled inside cell nucleus 56
0.15918402.15728575.html.plaintext.txt	253	To conclude results found spherical virus model indicate several amino acid residues per capsid subunit involved interactions viral nucleic acid molecule important virus infectivity role preserving integrity infectious virus particle
0.15918402.15728575.html.plaintext.txt	254	Because residues involved substantial intracapsid interactions none contributes stability capsid effect may directly mediated multiple non covalent interactions establish viral DNA
0.15918402.15728575.html.plaintext.txt	255	In addition least one acidic residue DNA binding region needed DNA packaging
0.15918402.15728575.html.plaintext.txt	256	FOOTNOTES This work supported independent grants Ministerio de Ciencia y Tecnologia Comunidad Autonoma de Madrid laboratories M
0.15918402.15728575.html.plaintext.txt	257	Grants BIO2003 04445 07B00122002 J
0.15918402.15728575.html.plaintext.txt	258	Grants SAF2001 1325 07B00202002 EU contract QLK3 CT 2001 01010 J
0.15918402.15728575.html.plaintext.txt	259	institutional grant Fundacion Ramon Areces
0.15918402.15728575.html.plaintext.txt	260	The costs publication article defrayed part payment page charges
0.15918402.15728575.html.plaintext.txt	261	This article must therefore hereby marked advertisement accordance 18 U
0.15918402.15728575.html.plaintext.txt	262	Section 1734 solely indicate fact
0.15918402.15728575.html.plaintext.txt	263	To correspondence addressed Tel
0.15918402.15728575.html.plaintext.txt	264	34 91 4978462 Fax 34 91 4974799 E mail mgarciaatcbm
0.15918402.15728575.html.plaintext.txt	265	1 The abbreviations used ss single stranded CPV canine parvovirus Nt N terminal MVM minute virus mice MVMi MVMp MVM strains p respectively HA hemagglutination PBS phosphate buffered saline VLP virus like particle VP viral capsid protein TES 2 2 hydroxy 11 bishydroxymethylethylaminoethanesulfonic acid
0.15918402.15728575.html.plaintext.txt	266	Almendral manuscript preparation
0.15918402.15728575.html.plaintext.txt	267	Almendral unpublished results
0.15918402.15728575.html.plaintext.txt	268	ACKNOWLEDGMENTS We acknowledge A
0.15918402.15728575.html.plaintext.txt	269	Maroto antibody preparations P
0.15918402.15728575.html.plaintext.txt	270	Tattersall DNA clone pMM984 C
0.15918402.15728575.html.plaintext.txt	271	Parrish hybridoma B7 A
0.15918402.15728575.html.plaintext.txt	272	Hodnett critical reading manuscript
0.15918402.15728575.html.plaintext.txt	273	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Stubbs G
0.15918402.15728575.html.plaintext.txt	274	1989 Protein Nucleic Acid Interactions Saenger W
0.15918402.15728575.html.plaintext.txt	275	87 109 CRC Press Boca Raton Liljas L
0.15918402.15728575.html.plaintext.txt	276	48 1 36CrossRefMedline Order article via Infotrieve Rossmann M
0.15918402.15728575.html.plaintext.txt	277	58 533 573CrossRefMedline Order article via Infotrieve Casjens S
0.15918402.15728575.html.plaintext.txt	278	1997 Structural Biology Viruses Chiu W
0.15918402.15728575.html.plaintext.txt	279	3 37 Oxford University Press NY Johnson J
0.15918402.15728575.html.plaintext.txt	280	1999 Encyclopedia Virology 2nd Ed
0.15918402.15728575.html.plaintext.txt	281	1946 1956 Academic Press London Chapman M
0.15918402.15728575.html.plaintext.txt	282	64 125 196Medline Order article via Infotrieve Stockley P
0.15918402.15728575.html.plaintext.txt	283	2 143 149CrossRef Johnson J
0.15918402.15728575.html.plaintext.txt	284	1997 Structural Biology Viruses Chiu W
0.15918402.15728575.html.plaintext.txt	285	269 287 Oxford University Press NY Jones S
0.15918402.15728575.html.plaintext.txt	286	29 943 954AbstractFree Full Text Bink H
0.15918402.15728575.html.plaintext.txt	287	147 2261 2279CrossRefMedline Order article via Infotrieve Tihova M
0.15918402.15728575.html.plaintext.txt	288	78 2897 2905AbstractFree Full Text Vriend G
0.15918402.15728575.html.plaintext.txt	289	191 453 460CrossRefMedline Order article via Infotrieve Sacher R
0.15918402.15728575.html.plaintext.txt	290	63 4545 4552Medline Order article via Infotrieve Larson S
0.15918402.15728575.html.plaintext.txt	291	1993 Nature 361 179 182CrossRefMedline Order article via Infotrieve Larson S
0.15918402.15728575.html.plaintext.txt	292	277 37 59CrossRefMedline Order article via Infotrieve Timmins P
0.15918402.15728575.html.plaintext.txt	293	1994 Structure 2 1191 1201CrossRefMedline Order article via Infotrieve Speir J
0.15918402.15728575.html.plaintext.txt	294	1995 Structure 3 63 78CrossRefMedline Order article via Infotrieve Fisher A
0.15918402.15728575.html.plaintext.txt	295	1993 Nature 361 176 179CrossRefMedline Order article via Infotrieve Wery J
0.15918402.15728575.html.plaintext.txt	296	235 565 586CrossRefMedline Order article via Infotrieve Tang L
0.15918402.15728575.html.plaintext.txt	297	8 77 83CrossRefMedline Order article via Infotrieve McKenna R
0.15918402.15728575.html.plaintext.txt	298	1992 Nature 355 137 143CrossRefMedline Order article via Infotrieve McKenna R
0.15918402.15728575.html.plaintext.txt	299	237 517 543CrossRefMedline Order article via Infotrieve Bernal R
0.15918402.15728575.html.plaintext.txt	300	337 1109 1122CrossRefMedline Order article via Infotrieve Chen Z
0.15918402.15728575.html.plaintext.txt	301	1989 Science 245 154 159Medline Order article via Infotrieve Tsao J
0.15918402.15728575.html.plaintext.txt	302	1991 Science 251 1456 1464Medline Order article via Infotrieve Chapman M
0.15918402.15728575.html.plaintext.txt	303	1995 Structure 3 151 162CrossRefMedline Order article via Infotrieve Chapman M
0.15918402.15728575.html.plaintext.txt	304	D 52 129 142CrossRefMedline Order article via Infotrieve Xie Q
0.15918402.15728575.html.plaintext.txt	305	264 497 520CrossRefMedline Order article via Infotrieve Llamas Saiz A
0.15918402.15728575.html.plaintext.txt	306	D 53 93 102CrossRefMedline Order article via Infotrieve Agbandje McKenna M
0.15918402.15728575.html.plaintext.txt	307	1998 Structure 6 1369 1381CrossRefMedline Order article via Infotrieve Valegard K
0.15918402.15728575.html.plaintext.txt	308	1994 Nature 371 623 626CrossRefMedline Order article via Infotrieve Valegard K
0.15918402.15728575.html.plaintext.txt	309	270 724 738CrossRefMedline Order article via Infotrieve Whiterell G
0.15918402.15728575.html.plaintext.txt	310	40 185 220Medline Order article via Infotrieve Peabody D
0.15918402.15728575.html.plaintext.txt	311	12 595 600Abstract Johansson H
0.15918402.15728575.html.plaintext.txt	312	95 9244 9249AbstractFree Full Text van der Worm S
0.15918402.15728575.html.plaintext.txt	313	26 1345 1351AbstractFree Full Text Dertinger D
0.15918402.15728575.html.plaintext.txt	314	314 649 654CrossRefMedline Order article via Infotrieve Hohn T
0.15918402.15728575.html.plaintext.txt	315	43 191 200CrossRefMedline Order article via Infotrieve Virudachalam R
0.15918402.15728575.html.plaintext.txt	316	1985 Virology 146 138 140CrossRefMedline Order article via Infotrieve Li T
0.15918402.15728575.html.plaintext.txt	317	1992 Biochemistry 31 6673 6682CrossRefMedline Order article via Infotrieve Ilag L
0.15918402.15728575.html.plaintext.txt	318	229 671 684CrossRefMedline Order article via Infotrieve DaPoian A
0.15918402.15728575.html.plaintext.txt	319	1994 Biochemistry 33 8339 8346CrossRefMedline Order article via Infotrieve Curry S
0.15918402.15728575.html.plaintext.txt	320	69 430 438Abstract Dong X
0.15918402.15728575.html.plaintext.txt	321	72 6024 6033AbstractFree Full Text DaPoian A
0.15918402.15728575.html.plaintext.txt	322	277 47596 47602AbstractFree Full Text Hafenstein S
0.15918402.15728575.html.plaintext.txt	323	76 5350 5356AbstractFree Full Text Lima S
0.15918402.15728575.html.plaintext.txt	324	271 135 145AbstractFree Full Text Tattersall P
0.15918402.15728575.html.plaintext.txt	325	111 375 394CrossRefMedline Order article via Infotrieve Cotmore S
0.15918402.15728575.html.plaintext.txt	326	33 91 174Medline Order article via Infotrieve Chapman M
0.15918402.15728575.html.plaintext.txt	327	1993 Virology 194 491 508CrossRefMedline Order article via Infotrieve Gardiner E
0.15918402.15728575.html.plaintext.txt	328	62 2605 2613Medline Order article via Infotrieve Ramirez J
0.15918402.15728575.html.plaintext.txt	329	1995 Virology 206 57 68CrossRefMedline Order article via Infotrieve Lombardo E
0.15918402.15728575.html.plaintext.txt	330	74 3804 3814AbstractFree Full Text Lombardo E
0.15918402.15728575.html.plaintext.txt	331	76 7049 7059AbstractFree Full Text Tattersall P
0.15918402.15728575.html.plaintext.txt	332	46 944 955Medline Order article via Infotrieve Maroto B
0.15918402.15728575.html.plaintext.txt	333	78 10685 10694AbstractFree Full Text Lopez Bueno A
0.15918402.15728575.html.plaintext.txt	334	77 2701 2708AbstractFree Full Text Hernando E
0.15918402.15728575.html.plaintext.txt	335	2000 Virology 267 299 309CrossRefMedline Order article via Infotrieve Carreira A
0.15918402.15728575.html.plaintext.txt	336	279 6517 6525AbstractFree Full Text Reguera J
0.15918402.15728575.html.plaintext.txt	337	101 2724 2729AbstractFree Full Text Mateo R
0.15918402.15728575.html.plaintext.txt	338	278 41019 41027AbstractFree Full Text Astell C
0.15918402.15728575.html.plaintext.txt	339	57 656 669Medline Order article via Infotrieve Sayle R
0.15918402.15728575.html.plaintext.txt	340	20 374 376CrossRefMedline Order article via Infotrieve Vriend G
0.15918402.15728575.html.plaintext.txt	341	8 52 56CrossRefMedline Order article via Infotrieve Cunningham B
0.15918402.15728575.html.plaintext.txt	342	1989 Science 244 1081 1085Medline Order article via Infotrieve Cotmore S
0.15918402.15728575.html.plaintext.txt	343	1999 Virology 254 169 181CrossRefMedline Order article via Infotrieve Farr G
0.15918402.15728575.html.plaintext.txt	344	2004 Virology 323 243 256CrossRefMedline Order article via Infotrieve Wu H
0.15918402.15728575.html.plaintext.txt	345	233 231 244CrossRefMedline Order article via Infotrieve This Article Abstract Full Text PDF All Versions Article 2801817969 recent M500867200v1 Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Copyright Permissions Google Scholar Articles Reguera J
0.15918402.15728575.html.plaintext.txt	346	Articles citing Article PubMed PubMed Citation Articles Reguera J
0.15918402.15728575.html.plaintext.txt	347	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS All ASBMB Journals Molecular Cellular Proteomics Journal Lipid Research Biochemistry Molecular Biology Education Copyright 2005 American Society Biochemistry Molecular Biology
0.19297737.12740387.html.plaintext.txt	0	Central Role Serine Phosphorylation Site within Duck Hepatitis B Virus Core Protein Capsid Trafficking Genome Release Josef Kock Michael Kann Gerhard Putz Hubert E
0.19297737.12740387.html.plaintext.txt	1	Blum Fritz von Weizsacker
0.19297737.12740387.html.plaintext.txt	2	From Department Medicine II University Hospital 79106 Freiburg Germany Institute Medical Virology Justus Liebig University 35392 Giessen Germany
0.19297737.12740387.html.plaintext.txt	3	Received publication January 3 2003 revised form April 10 2003
0.19297737.12740387.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Viral nucleocapsids compartmentalize protect viral genomes assembly mediate targeted genome release viral infection
0.19297737.12740387.html.plaintext.txt	5	This dual role capsid viral life cycle must tightly regulated ensure efficient virus spread
0.19297737.12740387.html.plaintext.txt	6	Here used duck hepatitis B virus DHBV infection model analyze effects capsid phosphorylation hydrogen bond formation
0.19297737.12740387.html.plaintext.txt	7	The potential key phosphorylation site serine 245 within core protein building block DHBV capsids substituted alanine S245A aspartic acid S245D asparagine S245N respectively
0.19297737.12740387.html.plaintext.txt	8	Mutant capsids analyzed replication competence stability nuclear transport infectivity
0.19297737.12740387.html.plaintext.txt	9	All mutants formed DHBV DNA containing nucleocapsids
0.19297737.12740387.html.plaintext.txt	10	Wild type S245N S245A S245D fully protected capsid associated mature viral DNA nuclease action
0.19297737.12740387.html.plaintext.txt	11	A negative ionic charge contributed phosphorylated serine aspartic acid supported nuclear localization viral capsid generation nuclear superhelical DNA
0.19297737.12740387.html.plaintext.txt	12	Finally wild type S245D S245N virions infectious primary duck hepatocytes
0.19297737.12740387.html.plaintext.txt	13	These results suggest hydrogen bonds formed non phosphorylated serine 245 stabilize quarterny structure DHBV nucleocapsids viral assembly serine phosphorylation plays important role nuclear targeting DNA release capsids viral infection
0.19297737.12740387.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Hepadnaviruses group small enveloped DNA viruses narrow host range relative tropism liver
0.19297737.12740387.html.plaintext.txt	15	Hepatitis B virus HBV1 prototypic member hepadnavirus family major cause liver disease worldwide ranging acute chronic hepatitis liver cirrhosis hepatocellular carcinoma 1 2
0.19297737.12740387.html.plaintext.txt	16	Other members family include duck hepatitis B virus DHBV woodchuck hepatitis virus WHV 3 4
0.19297737.12740387.html.plaintext.txt	17	Similar viruses hepadnaviral genome protected nucleocapsid formed icosahedrally arranged core proteins
0.19297737.12740387.html.plaintext.txt	18	The C terminal domain core protein rich basic residues bears three conserved serine phosphorylation sites 5 6
0.19297737.12740387.html.plaintext.txt	19	While dispensable capsid assembly region required packaging pregenomic RNA 7 11
0.19297737.12740387.html.plaintext.txt	20	Inside capsid viral polymerase converts pregenomic RNA minus strand DNA turn completed double stranded relaxed circular rc DNA molecule 12
0.19297737.12740387.html.plaintext.txt	21	Newly assembled mature hepadnaviral capsids containing rcDNA two possible fates either enveloped surface proteins enter secretory pathway redirected nucleus repair rcDNA molecule results formation covalently closed circular ccc DNA template viral RNA synthesis
0.19297737.12740387.html.plaintext.txt	22	Nuclear translocation viral rcDNA also mediated incoming capsids newly infected cells
0.19297737.12740387.html.plaintext.txt	23	However precise mechanisms regulating capsid trafficking uncoating settings unknown
0.19297737.12740387.html.plaintext.txt	24	Earlier studies DHBV model shown capsids infected livers highly phosphorylated serum derived capsids particles secreted cultured cells dephosphorylated 13 14
0.19297737.12740387.html.plaintext.txt	25	Furthermore binding vitro generated HBV capsids nucleus digitonin permeabilized hepatoma cells previously found depend phosphorylation status core protein 15
0.19297737.12740387.html.plaintext.txt	26	Hepadnaviral capsid phosphorylation therefore represents candidate mechanism regulated nuclear targeting release viral rcDNA natural infection
0.19297737.12740387.html.plaintext.txt	27	In present report used genetically engineered phosphorylation mutants DHBV core protein test hypothesis
0.19297737.12740387.html.plaintext.txt	28	The duck model offers advantage primary duck hepatocytes PDH readily available DHBV infection PDH supernatants transfected cells highly efficient reproducible
0.19297737.12740387.html.plaintext.txt	29	Position 245 within C terminus DHBV core selected detailed analysis since site serves phosphate acceptor transfected cells 5 earlier study revealed apparent effect phosphoserine 245 plus strand DNA elongation 16
0.19297737.12740387.html.plaintext.txt	30	Furthermore previously shown phenotype two C terminal deletion mutants compatible potential key role position capsid stability 17
0.19297737.12740387.html.plaintext.txt	31	In addition effect ionic charge position also analyzed potential effect hydrogen bond formation
0.19297737.12740387.html.plaintext.txt	32	Our data suggest hydrogen bonding required stabilization newly assembled mature capsids negative ionic charge position 245 DHBV core protein plays essential role nuclear capsid transport infectivity
0.19297737.12740387.html.plaintext.txt	33	Based results propose model multiple capsid functions based coordinated core protein phosphorylation dephosphorylation hydrogen bond formation well DNA maturation
0.19297737.12740387.html.plaintext.txt	34	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Cloning Transfection Mutant S245A mutant S245D generated cloning 391 bp EcoRIAvrII fragment corresponding core protein expression vectors described Yu Summers 11 16 overlength DHBV genome plasmid pOL16 18
0.19297737.12740387.html.plaintext.txt	35	Mutant S245N generated cloning PCR amplification product serine 245 coding triplet TCC substituted asparagine coding triplet AAC
0.19297737.12740387.html.plaintext.txt	36	The digested PCR fragment ligated EcoRIBglII digested overlength DHBV genome plasmid pOL16
0.19297737.12740387.html.plaintext.txt	37	The mutations confirmed DNA sequencing
0.19297737.12740387.html.plaintext.txt	38	To eliminate expression large surface protein 809 bp AvrIIXhoI fragment plasmid 1165A 19 ligated mutants described
0.19297737.12740387.html.plaintext.txt	39	Chicken hepatoma LMH cells seeded 10 cm dishes transfected calcium phosphate method 20
0.19297737.12740387.html.plaintext.txt	40	Cells harvested day 3 post transfection described
0.19297737.12740387.html.plaintext.txt	41	Western Blot Analysis Transfected cells detached culture dish treatment trypsin resuspended culture medium containing 8 fetal calf serum
0.19297737.12740387.html.plaintext.txt	42	The cells sedimented dissolved 0
0.19297737.12740387.html.plaintext.txt	43	4 ml Laemmli loading buffer containing 5 mercaptoethanol
0.19297737.12740387.html.plaintext.txt	44	To reduce viscosity lysate passed QIAshredder centrifugal devices Qiagen loading 12 SDS polyacrylamide gel
0.19297737.12740387.html.plaintext.txt	45	Proteins transferred onto polyvinylidene difluoride membranes Schleicher Schuell electroblotting
0.19297737.12740387.html.plaintext.txt	46	Proteins detected DHBV core specific rabbit antiserum described Schlicht et al
0.19297737.12740387.html.plaintext.txt	47	21 visualized ECLplus chemiluminescence Amersham Biosciences
0.19297737.12740387.html.plaintext.txt	48	Extraction Detection Viral DNA Transfected cells harvested described
0.19297737.12740387.html.plaintext.txt	49	To disrupt plasma membranes cells resuspended chilled 1 ml isotonic buffer 140 mM NaCl 1
0.19297737.12740387.html.plaintext.txt	50	5 mM MgCl2 50 mM Tris HCl pH 8
0.19297737.12740387.html.plaintext.txt	51	Nuclei removed centrifugation 5 min 1000 x g supernatant cleared cell debris centrifugation another 5 min 14000 x g
0.19297737.12740387.html.plaintext.txt	52	4 ml aliquot cytoplasmic extract digested 300 unitsml micrococcal nuclease Amersham Biosciences 5 h 37 degrees C presence 2 mM CaCl2
0.19297737.12740387.html.plaintext.txt	53	The precipitate formed incubation removed centrifugation followed inactivation nuclease EDTA final concentration 5 mM
0.19297737.12740387.html.plaintext.txt	54	Viral DNA extracted using QIAamp DNA Mini Kit Qiagen including RNase A treatment recommended manufacturer
0.19297737.12740387.html.plaintext.txt	55	4 ml aliquot cytoplasmic extract DNA isolated directly without micrococcal nuclease treatment
0.19297737.12740387.html.plaintext.txt	56	Purified DNA digested restriction enzyme PstI one recognition motif within vector sequence none DHBV genome
0.19297737.12740387.html.plaintext.txt	57	0 kbp linear DHBV fragment included size marker
0.19297737.12740387.html.plaintext.txt	58	DNA blotted onto positively charged nylon membranes Amersham Biosciences probed 32P labeled full length DHBV genome QuickHyb hybridization solution Stratagene
0.19297737.12740387.html.plaintext.txt	59	Extraction Detection Packed Pregenomic RNA Cytoplasmic extracts prepared described treated 150 unitsml micrococcal nuclease 1 h 37 degrees C presence 2 mM CaCl2 followed inactivation nuclease EDTA
0.19297737.12740387.html.plaintext.txt	60	RNA extracted using RNeasy Kit Qiagen
0.19297737.12740387.html.plaintext.txt	61	The purified RNA treated RNase free DNase Roche Applied Science purified using RNeasy columns
0.19297737.12740387.html.plaintext.txt	62	From aliquot cytoplasmic extract total RNA isolated directly without micrococcal nuclease treatment
0.19297737.12740387.html.plaintext.txt	63	Purified RNA resolved MOPS buffered 1 agarose gel containing 1 formaldehyde transferred onto positively charged nylon membrane
0.19297737.12740387.html.plaintext.txt	64	Cellular RNA visualized staining blotting membrane methylene blue viral RNA detected hybridization 32P labeled DHBV genome
0.19297737.12740387.html.plaintext.txt	65	Nuclease Titration Assay Immunoprecipitation Experiment Cytoplasmic extracts prepared transfected non transfected cells
0.19297737.12740387.html.plaintext.txt	66	The extract non transfected cells mixed purified viral DNA adjusted 2 mM CaCl2 incubated serially diluted micrococcal nuclease 5 0
0.19297737.12740387.html.plaintext.txt	67	005 unitsml for1hat37 degrees C
0.19297737.12740387.html.plaintext.txt	68	Extract transfected cells treated exactly way parallel approach
0.19297737.12740387.html.plaintext.txt	69	DNA prepared inactivating nuclease EDTA described visualized Southern blotting
0.19297737.12740387.html.plaintext.txt	70	The immunoprecipitation experiment performed DHBV core specific antibodies 21 coupled protein A Sepharose Sigma
0.19297737.12740387.html.plaintext.txt	71	Serum non vaccinated rabbit served mock control
0.19297737.12740387.html.plaintext.txt	72	Incubations done 4 degrees C Sepharose sediment extensively washed chilled buffer 140 mM NaCl 1
0.19297737.12740387.html.plaintext.txt	73	5 mM MgCl2 50 mM Tris HCl pH 8
0.19297737.12740387.html.plaintext.txt	74	Viral DNA isolated sediment protease digestion ATL lysis buffer QIAamp DNA Mini Kit
0.19297737.12740387.html.plaintext.txt	75	Detection Covalently Closed Circular DNA Nuclei Transfected Cells Transfected LMH cells harvested described resuspended 1 ml isotonic buffer 140 mM NaCl 1
0.19297737.12740387.html.plaintext.txt	76	5 mM MgCl2 50 mM Tris HCl pH 8
0.19297737.12740387.html.plaintext.txt	77	The suspension centrifuged 5 min 1000 x g
0.19297737.12740387.html.plaintext.txt	78	The pellet containing cell nuclei dissolved 0
0.19297737.12740387.html.plaintext.txt	79	4 ml ATL lysis buffer QIAamp DNA Mini Kit digested 1 mgml proteinase K 56 degrees C 2 h
0.19297737.12740387.html.plaintext.txt	80	After adding RNaseA final concentration 0
0.19297737.12740387.html.plaintext.txt	81	2 mgml lysate passed QIAshredder centrifugal devices DNA extracted adsorption onto silica columns
0.19297737.12740387.html.plaintext.txt	82	Purified DNA digested restriction enzyme DpnI cuts transfected plasmid DNA small fragments leaves non methylated viral DNA intact
0.19297737.12740387.html.plaintext.txt	83	Gel electrophoresis using circular 3
0.19297737.12740387.html.plaintext.txt	84	0 kbp plasmid DNA size marker followed Southern blot analysis performed described
0.19297737.12740387.html.plaintext.txt	85	With protocol rcDNA cccDNA well transfected plasmid DNA could clearly separated single gel
0.19297737.12740387.html.plaintext.txt	86	For quantitative comparisons x ray film scanned transparent modus analyzed BAS 1500 Bio imaging computer program Fujifilm
0.19297737.12740387.html.plaintext.txt	87	Immunofluorescence Staining Intracellular Core Protein HuH 7 cells seeded collagen coated cover slips transfected Tfx 20 reagent Promega
0.19297737.12740387.html.plaintext.txt	88	Starting day 1 post transfection cells kept starving culture medium Dulbeccos modified Eagles medium containing 1 fetal calf serum 4 days
0.19297737.12740387.html.plaintext.txt	89	Afterward cells fixed 3 paraformaldehyde PBS 20 min room temperature followed rinsing cover slips PBS
0.19297737.12740387.html.plaintext.txt	90	Cell membranes permeabilized 0
0.19297737.12740387.html.plaintext.txt	91	1 Triton X 100 PBS 10 min room temperature followed two washes PBS
0.19297737.12740387.html.plaintext.txt	92	Unspecific binding sites blocked blocking buffer 1 bovine serum albumin 10 goat serum PBS 37 degrees C 30 min
0.19297737.12740387.html.plaintext.txt	93	For immunostaining cover slips incubated 90 min 37 degrees C blocking buffer containing 1200 diluted rabbit anti DHBV core serum D69 kind gift H
0.19297737.12740387.html.plaintext.txt	94	Schaller ZMBH Heidelberg Germany
0.19297737.12740387.html.plaintext.txt	95	After four washes PBS room temperature second antibody affinity purified FITC labeled goat anti rabbit HL Dianova exposed cells 40 min 37 degrees C dilution 1200
0.19297737.12740387.html.plaintext.txt	96	All incubations 37 degrees C performed humidified box
0.19297737.12740387.html.plaintext.txt	97	After immunostaining cells washed four times room temperature PBS followed 10 min incubation 10 microgml propidium iodide PBS four additional washes PBS
0.19297737.12740387.html.plaintext.txt	98	Afterward cells embedded DABCO Sigma containing 50 mgml Moviol Hoechst
0.19297737.12740387.html.plaintext.txt	99	Localization core protein cell nuclei performed confocal immunofluorescence microscopy Leica DM IRBE microscope using TRITC FITC fittings pinhole size 1
0.19297737.12740387.html.plaintext.txt	100	Gradient Sedimentation Cellular Nucleocapsids Cytoplasmic extracts prepared described sedimented 10 50 wv Nycodenz Nycomed Pharma AS gradient
0.19297737.12740387.html.plaintext.txt	101	Nycodenz dissolved isotonic buffer 140 mM NaCl 1
0.19297737.12740387.html.plaintext.txt	102	5 mM MgCl2 50 mM Tris HCl pH 8
0.19297737.12740387.html.plaintext.txt	103	4 ml cytoplasmic extract loaded onto 1 ml gradient polycarbonate tubes
0.19297737.12740387.html.plaintext.txt	104	Samples centrifuged 55000 rpm 40 min 20 degrees C TLS55 swing rotor Beckman Instruments
0.19297737.12740387.html.plaintext.txt	105	15 ml fractions harvested top gradient majority cellular proteins floated top gradient whereas viral nucleocapsids sediment lower fractions
0.19297737.12740387.html.plaintext.txt	106	An aliquot fraction mixed Laemmli loading buffer containing 5 mercaptoethanol analyzed Western blotting
0.19297737.12740387.html.plaintext.txt	107	A second aliquot processed DNA extraction
0.19297737.12740387.html.plaintext.txt	108	Purified DNA digested PstI agarose gel electrophoresis Southern blotting
0.19297737.12740387.html.plaintext.txt	109	Gradient Centrifugation Extracellular Particles Supernatant LMH cells collected day 3 post transfection concentrated using UltraFree Biomax 100K centrifugal filter devices Millipore
0.19297737.12740387.html.plaintext.txt	110	From one cell culture dish 5 ml supernatant concentrated final volume 0
0.19297737.12740387.html.plaintext.txt	111	Concentrated supernatant loaded onto preformed 1 ml gradient consisting 112 560 mgml cesium chloride 100 mM NaCl 10 mM Tris HCl pH 7
0.19297737.12740387.html.plaintext.txt	112	Centrifugation performed 20 h 55000 rpm 10 degrees C TLS55 swing rotor
0.19297737.12740387.html.plaintext.txt	113	Enveloped DHBV particles accumulate middle gradient density 1
0.19297737.12740387.html.plaintext.txt	114	2 gml non enveloped nucleocapsids sediment density 1
0.19297737.12740387.html.plaintext.txt	115	The gradient fractions harvested described diluted water final volume 0
0.19297737.12740387.html.plaintext.txt	116	4 ml followed DNA extraction PstI digestion Southern blotting
0.19297737.12740387.html.plaintext.txt	117	Infection Primary Hepatocytes Primary hepatocytes prepared DHBV negative ducklings two step collagenase liver perfusion described 23
0.19297737.12740387.html.plaintext.txt	118	Hepatocytes maintained Williams E medium supplemented 1 microM dexamethasone 15 mM HEPES pH 7
0.19297737.12740387.html.plaintext.txt	119	3 1 microM insulin 2 mM glutamine
0.19297737.12740387.html.plaintext.txt	120	Supernatants transfected LMH cells collected day 3 post transfection concentrated using UltraFree Biomax 100K centrifugal devices Millipore
0.19297737.12740387.html.plaintext.txt	121	Viral particles added primary hepatocytes day 1 post seeding
0.19297737.12740387.html.plaintext.txt	122	Supernatant one 10 cm dish transferred three wells 6 well plate primary hepatocytes
0.19297737.12740387.html.plaintext.txt	123	4 h postincubation culture medium exchanged followed daily medium changes
0.19297737.12740387.html.plaintext.txt	124	To harvest cells culture medium removed hepatocytes dissolved 0
0.19297737.12740387.html.plaintext.txt	125	DNA extracted adsorption onto QIAamp columns digested PstI agarose gel electrophoresis Southern blotting
0.19297737.12740387.html.plaintext.txt	126	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Design Replication Competence DHBV Capsid Mutants Three overlength constructs generated serine 245 DHBV core protein substituted alanine S245A aspartic acid S245D asparagine S245N
0.19297737.12740387.html.plaintext.txt	127	Aspartic acid alanine generally accepted standard substitutions serine mimic phosphorylated non phosphorylated state respectively
0.19297737.12740387.html.plaintext.txt	128	Asparagine structurally similar aspartic acid included also assess potential influence hydrogen bonds formed non phosphorylated serine
0.19297737.12740387.html.plaintext.txt	129	The 3 region hepadnaviral core open reading frame encodes C terminal domain core overlaps 5 region viral polymerase open reading frame
0.19297737.12740387.html.plaintext.txt	130	For reason site directed mutagenesis mutants S245D S245N resulted concomitant substitution polymerase proline 64 threonine
0.19297737.12740387.html.plaintext.txt	131	In mutant S245A polymerase protein unchanged
0.19297737.12740387.html.plaintext.txt	132	First investigated expression levels respective core protein mutants Western blot analysis transfection LMH cells
0.19297737.12740387.html.plaintext.txt	133	1 mutants produced wild type levels core protein
0.19297737.12740387.html.plaintext.txt	134	View larger version 45K FIG
0.19297737.12740387.html.plaintext.txt	135	Expression levels mutant DHBV core proteins
0.19297737.12740387.html.plaintext.txt	136	LMH cells transfected overlength DHBV genome constructs analyzed Western blotting
0.19297737.12740387.html.plaintext.txt	137	Core protein residue 245 wild type serine S aspartic acid D alanine A asparagine N
0.19297737.12740387.html.plaintext.txt	138	nt non transfected control 33 kDa protein size marker
0.19297737.12740387.html.plaintext.txt	139	Next analyzed replication competence respective mutants
0.19297737.12740387.html.plaintext.txt	140	2A left panel mutants replication competent
0.19297737.12740387.html.plaintext.txt	141	The overall level replication reduced different degrees however
0.19297737.12740387.html.plaintext.txt	142	For mutants S245D S245N finding likely due altered polymerase sequence revealed trans complementation experiments core deficient overlength construct data shown
0.19297737.12740387.html.plaintext.txt	143	In case S245A however direct effect core protein must assumed
0.19297737.12740387.html.plaintext.txt	144	Northern blot analysis total capsid associated viral RNA showed RNA encapsidation reduced Fig
0.19297737.12740387.html.plaintext.txt	145	2B suggesting later step replication andor capsid stability affected
0.19297737.12740387.html.plaintext.txt	146	View larger version 58K FIG
0.19297737.12740387.html.plaintext.txt	147	Viral DNA synthesis packaging pregenomic RNA nuclease sensitivity capsid associated DNA
0.19297737.12740387.html.plaintext.txt	148	LMH cells transfected indicated top figure
0.19297737.12740387.html.plaintext.txt	149	Cytoplasmic extracts either treated micrococcal nuclease MN right panel left untreated MN left panel prior DNA extraction subsequent Southern blot analysis
0.19297737.12740387.html.plaintext.txt	150	For nomenclature respective mutants see Fig
0.19297737.12740387.html.plaintext.txt	151	Pl transfected plasmid DNA RC relaxed circular DNA SS single stranded DNA
0.19297737.12740387.html.plaintext.txt	152	As quantified densitometry overall replication level respective constructs follows
0.19297737.12740387.html.plaintext.txt	153	Left panel S 100 D 81 A 49 N 69 right panel S 94 D 57 A 25 N 56
0.19297737.12740387.html.plaintext.txt	154	B packaging pregenomic RNA
0.19297737.12740387.html.plaintext.txt	155	LMH cells transfected indicated top figure
0.19297737.12740387.html.plaintext.txt	156	Cytoplasmic extracts either treated micrococcal nuclease MN right panel left untreated MN middle panel prior extraction RNA subsequent Northern blot analysis
0.19297737.12740387.html.plaintext.txt	157	Left panel methylene blue staining cellular 28 S 18 S ribosomal RNAs partially degraded nuclease treatment
0.19297737.12740387.html.plaintext.txt	158	C nuclease titration assay S245A associated rcDNA
0.19297737.12740387.html.plaintext.txt	159	Cytoplasmic extract S245A transfected cells left panel cytoplasmic extract non transfected cells mixed purified rcDNA right panel treated serially diluted micrococcal nuclease DNA extraction Southern blotting
0.19297737.12740387.html.plaintext.txt	160	For abbreviations see legend Fig
0.19297737.12740387.html.plaintext.txt	161	Relaxed Circular DNA Associated S245A S245D Is Sensitive Nuclease Treatment We previously shown two deletion mutants DHBV core protein encompassing serine 245 yield capsids mature viral DNA nuclease sensitive 17
0.19297737.12740387.html.plaintext.txt	162	Prompted observation tested nuclease sensitivity respective S245 substitution mutants
0.19297737.12740387.html.plaintext.txt	163	Incubation capsids micrococcal nuclease 5 h resulted 50 decrease total viral DNA Fig
0.19297737.12740387.html.plaintext.txt	164	Strikingly however capsid associated rcDNA ssDNA nuclease sensitive mutants S245D S245A
0.19297737.12740387.html.plaintext.txt	165	By contrast relative abundance respective DNA species unchanged wild type S245N compare right left panel Fig
0.19297737.12740387.html.plaintext.txt	166	Degradation S245D associated rcDNA observed prolonged nuclease treatment S245A associated rcDNA degradable within one hour suggesting S245D capsids nuclease resistant S245A capsids
0.19297737.12740387.html.plaintext.txt	167	To address question whether S245A capsids offer protection rcDNA nuclease titration assay performed
0.19297737.12740387.html.plaintext.txt	168	2C S245A associated rcDNA nuclease resistant naked rcDNA difference small
0.19297737.12740387.html.plaintext.txt	169	These observations indicate mutations serine 245 affect stability mature rcDNA containing DHBV capsids
0.19297737.12740387.html.plaintext.txt	170	Structural Properties Mutant Capsids It unclear whether destabilized capsids completely disintegrate viral plus strand DNA synthesis become physically separate rcDNA whether rcDNA remains associated core protein
0.19297737.12740387.html.plaintext.txt	171	To address issue S245A capsids analyzed immunoprecipitation density gradient sedimentation
0.19297737.12740387.html.plaintext.txt	172	3 shows rcDNA specifically co precipitated wild type well mutant core protein
0.19297737.12740387.html.plaintext.txt	173	When subjected density gradient sedimentation rcDNA co localized particulate core protein Fig
0.19297737.12740387.html.plaintext.txt	174	Furthermore evidence accumulation monomericdimeric core protein relative particulate core protein would expected case complete capsid disintegration
0.19297737.12740387.html.plaintext.txt	175	Identical results obtained mutants S245D S245N data illustrated
0.19297737.12740387.html.plaintext.txt	176	It noted however empty RNA containing capsids cannot clearly distinguished rcDNA containing capsids assay
0.19297737.12740387.html.plaintext.txt	177	Plasmid DNA also entered gradient experimental setting likely calcium phosphate complexes
0.19297737.12740387.html.plaintext.txt	178	Importantly however rcDNA peak co localized core protein plasmid DNA indicating sedimentation pattern rcDNA due nonspecific mechanism
0.19297737.12740387.html.plaintext.txt	179	This interpretation confirmed fact purified rcDNA enter gradient data shown
0.19297737.12740387.html.plaintext.txt	180	View larger version 56K FIG
0.19297737.12740387.html.plaintext.txt	181	Relaxed circular DNA coprecipitates S245A mutant core protein
0.19297737.12740387.html.plaintext.txt	182	Cytoplasmic extracts LMH cells transfected wild type WT left panel S245A construct right panel subjected immunoprecipitation
0.19297737.12740387.html.plaintext.txt	183	DNA extracted first supernatant Su pelleted Sepharose beads Pe extensive washing visualized Southern blotting
0.19297737.12740387.html.plaintext.txt	184	Anti core polyclonal DHBV core specific rabbit antibodies mock serum non vaccinated rabbit
0.19297737.12740387.html.plaintext.txt	185	For abbreviations see legend Fig
0.19297737.12740387.html.plaintext.txt	186	View larger version 51K FIG
0.19297737.12740387.html.plaintext.txt	187	Gradient sedimentation viral nucleocapsids
0.19297737.12740387.html.plaintext.txt	188	Cytoplasmic extracts transfected LMH cells loaded onto 10 50 Nycodenz gradient centrifuged 40 min 200000 x g
0.19297737.12740387.html.plaintext.txt	189	Nine fractions collected top gradient analyzed viral DNA Southern blotting upper panel core protein Western blotting lower panel respectively
0.19297737.12740387.html.plaintext.txt	190	A wild type control B mutant S245A
0.19297737.12740387.html.plaintext.txt	191	Fractions 7 8 9 contain bulk viral DNA well bulk core protein
0.19297737.12740387.html.plaintext.txt	192	The faint signals fractions 2 3 represent non specifically detected cellular proteins also present non transfected control see Fig
0.19297737.12740387.html.plaintext.txt	193	Note viral DNA co sediments particulate core protein
0.19297737.12740387.html.plaintext.txt	194	Mutant S245D mutant S245N yielded exactly sedimentation profile wild type control data shown
0.19297737.12740387.html.plaintext.txt	195	For abbreviations see legend Fig
0.19297737.12740387.html.plaintext.txt	196	Mutants S245A S245N Are Defective Nuclear Targeting cccDNA Formation Next investigated potential effect DHBV core protein phosphorylation intracellular trafficking cccDNA formation
0.19297737.12740387.html.plaintext.txt	197	Preventing viral surface protein synthesis enhances capsid recycling nucleus cccDNA formation 19
0.19297737.12740387.html.plaintext.txt	198	We therefore introduced stop codon within surface open reading frame respective overlength constructs
0.19297737.12740387.html.plaintext.txt	199	The subcellular localization core protein mutants assessed confocal immunofluorescence laserscan microscopy transfected HuH 7 cells
0.19297737.12740387.html.plaintext.txt	200	5 shows representative panel core positive cells mutant
0.19297737.12740387.html.plaintext.txt	201	While staining pattern strictly homogenous blinded analysis individual mutant revealed wild type mutant S245D reproducibly generated intranuclear well cytosolic core protein
0.19297737.12740387.html.plaintext.txt	202	By contrast subcellular localization core predominantly cytoplasmic mutants S245A S245N individual cells displaying moderate nuclear core staining
0.19297737.12740387.html.plaintext.txt	203	This observation may due impaired nuclear import accelerated nuclear export core protein 24
0.19297737.12740387.html.plaintext.txt	204	Identical results obtained LMH cells data shown
0.19297737.12740387.html.plaintext.txt	205	View larger version 80K FIG
0.19297737.12740387.html.plaintext.txt	206	Subcellular localization core protein
0.19297737.12740387.html.plaintext.txt	207	HuH 7 cells transfected surface deficient core mutants
0.19297737.12740387.html.plaintext.txt	208	Intracellular core protein detected confocal immunofluorescence laserscan microscopy
0.19297737.12740387.html.plaintext.txt	209	A representative panel cells shown construct
0.19297737.12740387.html.plaintext.txt	210	Left columns staining DHBc specific polyclonal antibody
0.19297737.12740387.html.plaintext.txt	211	Middle columns propidium iodide staining
0.19297737.12740387.html.plaintext.txt	212	To assess cccDNA formation presence absence large surface protein expression analyzed nuclei transfected LMH cells Southern blotting
0.19297737.12740387.html.plaintext.txt	213	As expected surface negative variants yielded strong cccDNA signals Fig
0.19297737.12740387.html.plaintext.txt	214	For wild type mutant S245D high levels cccDNA observed
0.19297737.12740387.html.plaintext.txt	215	By contrast cccDNA formation remained lower levels S245A S245N Fig
0.19297737.12740387.html.plaintext.txt	216	This finding confirmed three independent experiments
0.19297737.12740387.html.plaintext.txt	217	View larger version 72K FIG
0.19297737.12740387.html.plaintext.txt	218	LMH cells transfected indicated top figure
0.19297737.12740387.html.plaintext.txt	219	Surface negative positive constructs tested
0.19297737.12740387.html.plaintext.txt	220	A DNA prepared nuclear pellet digested restriction enzyme DpnI visualized Southern blot analysis
0.19297737.12740387.html.plaintext.txt	221	CCC covalently closed circular DNA RC relaxed circular DNA DL double stranded linear DNA Pl DpnI digested plasmid DNA
0.19297737.12740387.html.plaintext.txt	222	rcDNA cccDNA quantified densitometry
0.19297737.12740387.html.plaintext.txt	223	For surface negative constructs cccDNArcDNA follows
0.19297737.12740387.html.plaintext.txt	224	The cccDNArcDNA ratio informative case S245A since mutant produces less rcDNA even absence nuclease treatment shown Fig
0.19297737.12740387.html.plaintext.txt	225	2A B respective DNA species generated mutants S245D S245N quantified densitometry depicted vertical profile
0.19297737.12740387.html.plaintext.txt	226	Note cccDNA peak significantly higher surface negative S245D left panel compared surface negative S245N right panel
0.19297737.12740387.html.plaintext.txt	227	All Mutants Produce Enveloped Particles We investigated competence mutant capsids enter secretory pathway
0.19297737.12740387.html.plaintext.txt	228	Culture media transfected cells centrifuged equilibrium cesium chloride gradient fractions analyzed Southern blotting
0.19297737.12740387.html.plaintext.txt	229	7 shows mutants enveloped
0.19297737.12740387.html.plaintext.txt	230	Compared wild type however respective levels virion production reduced
0.19297737.12740387.html.plaintext.txt	231	In particular enveloped S245A particles detectable prolonged exposure Southern blot
0.19297737.12740387.html.plaintext.txt	232	This result best explained reduced overall replication rate mutant S245A selective deficiency mature rcDNA containing capsids
0.19297737.12740387.html.plaintext.txt	233	View larger version 67K FIG
0.19297737.12740387.html.plaintext.txt	234	Culture supernatants transfected LMH cells subjected CsCl density gradient centrifugation
0.19297737.12740387.html.plaintext.txt	235	The transfected plasmids code wild type surface protein
0.19297737.12740387.html.plaintext.txt	236	Nine fractions collected beginning top gradient analyzed DNA Southern blotting
0.19297737.12740387.html.plaintext.txt	237	Enveloped particles accumulate middle gradient naked particles fractions 8 9 respectively
0.19297737.12740387.html.plaintext.txt	238	A wild type control B mutant S245D C mutant S245A D mutant S245N
0.19297737.12740387.html.plaintext.txt	239	For abbreviations see legend Fig
0.19297737.12740387.html.plaintext.txt	240	Mutant S245N Is Not Infectious Primary Hepatocytes Finally respective mutants tested ability infect primary duck hepatocytes
0.19297737.12740387.html.plaintext.txt	241	Due low amounts enveloped virions obtained mutant S245A study restricted mutants S245D S245N
0.19297737.12740387.html.plaintext.txt	242	Supernatants transfected LMH cells added primary duck hepatocytes cells harvested time points indicated
0.19297737.12740387.html.plaintext.txt	243	Successful infection demonstrated accumulation cccDNA newly synthesized replicative intermediates
0.19297737.12740387.html.plaintext.txt	244	Productive infection primary duck hepatocytes PDH wild type virions shown Fig
0.19297737.12740387.html.plaintext.txt	245	Mutant S245D also infectious efficiency infection reduced faint signal cccDNA becoming visible day 7 postinfection Fig
0.19297737.12740387.html.plaintext.txt	246	S245N virions attached efficiently primary duck hepatocytes Fig
0.19297737.12740387.html.plaintext.txt	247	Nevertheless cccDNA newly synthesized replicative intermediates detectable cells inoculated mutant virus though rcDNA originating inoculating virus remained visible 9 days culture
0.19297737.12740387.html.plaintext.txt	248	Thus mutant S245N generated stable capsids unable initiate productive infection PDH
0.19297737.12740387.html.plaintext.txt	249	In addition result rules generation replicative intermediates observed wild type mutant S245D originated transfection residual plasmid DNA present inoculum rather true infection
0.19297737.12740387.html.plaintext.txt	250	View larger version 50K FIG
0.19297737.12740387.html.plaintext.txt	251	Infectivity mutant viral particles
0.19297737.12740387.html.plaintext.txt	252	LMH cells transfected wild type mutant S245D mutant S245N constructs
0.19297737.12740387.html.plaintext.txt	253	Culture supernatants collected added primary duck hepatocytes
0.19297737.12740387.html.plaintext.txt	254	A infection wild type left panel mutant S245D right panel
0.19297737.12740387.html.plaintext.txt	255	B infection wild type left panel mutant S245N right panel
0.19297737.12740387.html.plaintext.txt	256	The cells harvested four hours 4h 4 days 4d 7 days 7d 9 days 9d postinfection
0.19297737.12740387.html.plaintext.txt	257	DNA infected hepatocytes analyzed Southern blotting
0.19297737.12740387.html.plaintext.txt	258	For abbreviations see legends Figs
0.19297737.12740387.html.plaintext.txt	259	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Taken together results indicate serine position 245 DHBV core protein plays key role regulating structural integrity intracellular trafficking mature rcDNA containing nucleocapsids different stages viral life cycle likely via phosphorylation status
0.19297737.12740387.html.plaintext.txt	260	Wild type S245N capsids nuclease resistant encapsidated mature viral DNA generated mutants S245D S245A nuclease sensitive
0.19297737.12740387.html.plaintext.txt	261	Possible reasons accounting observation include differences local protein structure preferred alanine aspartic acid compared serine asparagine andor electrostatic repulsion DNA aspartic acid
0.19297737.12740387.html.plaintext.txt	262	Furthermore hydrogen bonding mediated non phosphorylated serine well asparagine may contribute stabilization quarterny structure mature DHBV capsids
0.19297737.12740387.html.plaintext.txt	263	The precise structural properties mutant capsids associated nuclease sensitivity mature viral DNA remain elucidated
0.19297737.12740387.html.plaintext.txt	264	We obtained evidence complete disintegration mature S245A capsids immunoprecipitation experiments density gradient sedimentation assay
0.19297737.12740387.html.plaintext.txt	265	It noted however partially dissociated S245A capsids may reassembled DNA release rcDNA remaining attached outside capsid
0.19297737.12740387.html.plaintext.txt	266	Alternatively sensitivity rcDNA may simply based increased breathing capsid
0.19297737.12740387.html.plaintext.txt	267	This phenomenon involves slow release capsid subunits followed rapid reformation capsid integrity discussed previously HBV capsids 25
0.19297737.12740387.html.plaintext.txt	268	The fact mature rcDNA ssDNA associated mutant capsids S245D S245A accessible nuclease action indicates DNA maturation important trigger capsid destabilization
0.19297737.12740387.html.plaintext.txt	269	Possibly interactions viral DNA C terminus core protein importance context 26
0.19297737.12740387.html.plaintext.txt	270	Our results shed new light previous data implicated C terminal domain DHBV core protein required DNA maturation
0.19297737.12740387.html.plaintext.txt	271	Rather report previous study deletion insertion mutants DHBV core protein 17 suggest phenotype several mutants least part due nuclease sensitivity mature viral DNA
0.19297737.12740387.html.plaintext.txt	272	The fact nuclease treatment commonly used remove plasmid DNA prior extraction nucleocapsid associated hepadnaviral DNA explains fully mature DNA forms observed earlier
0.19297737.12740387.html.plaintext.txt	273	Indeed found nuclease sensitivity rcDNA also accounts phenotype previously described P246G mutant DHBV core 16
0.19297737.12740387.html.plaintext.txt	274	2 It interesting determine relevance observations HBV core protein mutants
0.19297737.12740387.html.plaintext.txt	275	Our data suggest negative charges position 245 contributed phosphorylated serine aspartic acid support nuclear targeting DHBV core protein cccDNA formation infectivity
0.19297737.12740387.html.plaintext.txt	276	The residual cccDNA formation mutant S245N could due nuclear import small amounts core protein mediated remaining unchanged phosphorylation sites
0.19297737.12740387.html.plaintext.txt	277	This may difficult detect immunofluorescence since polyclonal anti DHBV core antibody may react well core protein dimers fixed cells
0.19297737.12740387.html.plaintext.txt	278	Alternatively capsids might become entrapped non specifically within nucleus dividing cells degraded subsequently
0.19297737.12740387.html.plaintext.txt	279	Nevertheless infection experiments PDH demonstrate residual cccDNA formation S245N suffice initiate productive infection
0.19297737.12740387.html.plaintext.txt	280	Collectively observations suggest following model maturation rcDNA within nucleocapsid important trigger capsid destabilization ultimately results DNA release
0.19297737.12740387.html.plaintext.txt	281	During viral assembly hydrogen bonds formed non phosphorylated serine 245 contribute stabilization nucleocapsids thus preventing DNA liberation cytoplasm
0.19297737.12740387.html.plaintext.txt	282	During infection phosphorylation serine 245 directs capsid nucleus
0.19297737.12740387.html.plaintext.txt	283	At time nucleocapsids destabilized thus facilitating rcDNA release nucleus
0.19297737.12740387.html.plaintext.txt	284	These mechanisms would also apply progeny capsids redirected nucleus cccDNA amplification
0.19297737.12740387.html.plaintext.txt	285	How newly formed DHBV capsids directed secretory pathway remains elucidated however since Mabit Schaller 13 shown dephosphorylation alone sufficient confer membrane affinity
0.19297737.12740387.html.plaintext.txt	286	The suggested model line previous observation duck model serum derived nucleocapsids non phosphorylated whereas nucleocapsids liver tissue highly phosphorylated 14
0.19297737.12740387.html.plaintext.txt	287	It tempting speculate incoming recycling capsids phosphorylated capsid associated kinase activity cellular origin described WHV HBV system 27 33
0.19297737.12740387.html.plaintext.txt	288	The present report demonstrates central role serine 245 regulating DHBV capsid trafficking stability
0.19297737.12740387.html.plaintext.txt	289	Clearly however remaining phosphorylation sites within DHBV core may play important role well since earlier reports indicate serine 259 also affects viral infectivity 10 16
0.19297737.12740387.html.plaintext.txt	290	It remains elucidated many residues individual nucleocapsids phosphorylated given time point core protein phosphorylation orchestrated capsid assembly disassembly
0.19297737.12740387.html.plaintext.txt	291	Further studies HBV WHV system establish whether mammalian core protein phosphorylation essential infectivity well
0.19297737.12740387.html.plaintext.txt	292	The recently described infection primary tupaia hepatocytes 34 might represent suitable model address question
0.19297737.12740387.html.plaintext.txt	293	Interestingly phosphorylation capsid protein capsid associated kinase activities also suggested play key role early steps HIV infection 35
0.19297737.12740387.html.plaintext.txt	294	Thus phosphorylation might represent general mechanism regulating targeted genome release viral capsids
0.19297737.12740387.html.plaintext.txt	295	FOOTNOTES This study supported grants Deutsche Forschungsgemeinschaft We 13652 2 Bundesministerium fur Bildung und Forschung 01K19951 F
0.19297737.12740387.html.plaintext.txt	296	grant Deutsche Forschungsgemeinschaft SFB 535 B5 M
0.19297737.12740387.html.plaintext.txt	297	The costs publication article defrayed part payment page charges
0.19297737.12740387.html.plaintext.txt	298	This article must therefore hereby marked advertisement accordance 18 U
0.19297737.12740387.html.plaintext.txt	299	Section 1734 solely indicate fact
0.19297737.12740387.html.plaintext.txt	300	To correspondence addressed Dept
0.19297737.12740387.html.plaintext.txt	301	Medicine II University Freiburg Hugstetter Strasse 55 D 79106 Freiburg Germany
0.19297737.12740387.html.plaintext.txt	302	49 761 2703401 Fax 49 761 2703610 E mail weizatukl
0.19297737.12740387.html.plaintext.txt	303	1 The abbreviations used HBV hepatitis B virus DHBV duck hepatitis B virus MOPS 4 morpholinepropanesulfonic acid PBS phosphate buffered saline cccDNA covalently closed circular DNA TRITC tetramethylrhodamine isothiocyanate FITC fluorescein isothiocyanate
0.19297737.12740387.html.plaintext.txt	304	von Weizsacker unpublished data
0.19297737.12740387.html.plaintext.txt	305	ACKNOWLEDGMENTS We thank J
0.19297737.12740387.html.plaintext.txt	306	Summers stimulating discussions providing expression vectors encoding mutant DHBV proteins
0.19297737.12740387.html.plaintext.txt	307	Schaller core specific antibodies
0.19297737.12740387.html.plaintext.txt	308	MacNelly gratefully acknowledged
0.19297737.12740387.html.plaintext.txt	309	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Wright T
0.19297737.12740387.html.plaintext.txt	310	1993 Lancet 342 1340 1344CrossRefMedline Order article via Infotrieve Seeger C
0.19297737.12740387.html.plaintext.txt	311	64 51 68AbstractFree Full Text Mason W
0.19297737.12740387.html.plaintext.txt	312	36 829 836Medline Order article via Infotrieve Summers J
0.19297737.12740387.html.plaintext.txt	313	75 4533 4537Abstract Yu M
0.19297737.12740387.html.plaintext.txt	314	68 2965 2969Abstract Liao W
0.19297737.12740387.html.plaintext.txt	315	69 1025 1029Abstract Gallina A
0.19297737.12740387.html.plaintext.txt	316	63 4645 4652Medline Order article via Infotrieve Beames B
0.19297737.12740387.html.plaintext.txt	317	1993 Virology 194 597 607CrossRefMedline Order article via Infotrieve Nassal M
0.19297737.12740387.html.plaintext.txt	318	66 4107 4116Abstract Schlicht H
0.19297737.12740387.html.plaintext.txt	319	63 2995 3000Medline Order article via Infotrieve Yu M
0.19297737.12740387.html.plaintext.txt	320	65 2511 2517Medline Order article via Infotrieve Nassal M
0.19297737.12740387.html.plaintext.txt	321	1 221 228CrossRefMedline Order article via Infotrieve Mabit H
0.19297737.12740387.html.plaintext.txt	322	74 11472 11478AbstractFree Full Text Pugh J
0.19297737.12740387.html.plaintext.txt	323	63 1371 1376Medline Order article via Infotrieve Kann M
0.19297737.12740387.html.plaintext.txt	324	145 45 55AbstractFree Full Text Yu M
0.19297737.12740387.html.plaintext.txt	325	68 4341 4348Abstract Kock J
0.19297737.12740387.html.plaintext.txt	326	72 9116 9120AbstractFree Full Text Schlicht H
0.19297737.12740387.html.plaintext.txt	327	1989 Cell 56 85 92Medline Order article via Infotrieve Summers J
0.19297737.12740387.html.plaintext.txt	328	64 2819 2824Medline Order article via Infotrieve Condreay L
0.19297737.12740387.html.plaintext.txt	329	64 3249 3258Medline Order article via Infotrieve Schlicht H
0.19297737.12740387.html.plaintext.txt	330	61 2280 2285Medline Order article via Infotrieve Summers J
0.19297737.12740387.html.plaintext.txt	331	65 1310 1317Medline Order article via Infotrieve Tuttleman J
0.19297737.12740387.html.plaintext.txt	332	58 17 25Medline Order article via Infotrieve Mabit H
0.19297737.12740387.html.plaintext.txt	333	75 1968 1977AbstractFree Full Text Zlotnick A
0.19297737.12740387.html.plaintext.txt	334	1999 Biochemistry 38 14644 14652CrossRefMedline Order article via Infotrieve Hatton T
0.19297737.12740387.html.plaintext.txt	335	66 5232 5241Abstract Albin C
0.19297737.12740387.html.plaintext.txt	336	34 297 302Medline Order article via Infotrieve Daub H
0.19297737.12740387.html.plaintext.txt	337	76 8124 8137AbstractFree Full Text Duclos Vallee J
0.19297737.12740387.html.plaintext.txt	338	79 1665 1670Abstract Feitelson M
0.19297737.12740387.html.plaintext.txt	339	43 741 748Medline Order article via Infotrieve Gerlich W
0.19297737.12740387.html.plaintext.txt	340	42 761 766Medline Order article via Infotrieve Kann M
0.19297737.12740387.html.plaintext.txt	341	8 53 62Medline Order article via Infotrieve Kau J
0.19297737.12740387.html.plaintext.txt	342	72 3796 3803AbstractFree Full Text Kock J
0.19297737.12740387.html.plaintext.txt	343	75 5084 5089AbstractFree Full Text Cartier C
0.19297737.12740387.html.plaintext.txt	344	274 19434 19440AbstractFree Full Text
0.2511286.15831941.html.plaintext.txt	0	Overlapping reading frames closely related human papillomaviruses result modular rates selection within E2 Apurva Narechania1 Masanori Terai1 Robert D
0.2511286.15831941.html.plaintext.txt	1	1 Department Microbiology Immunology The Albert Einstein Cancer Center Albert Einstein College Medicine 1300 Morris Park Ave Bronx NY 10461 USA 2 Department Pediatrics The Albert Einstein Cancer Center Albert Einstein College Medicine 1300 Morris Park Ave Bronx NY 10461 USA 3 Department Obstetrics Gynecology Womens Health The Albert Einstein Cancer Center Albert Einstein College Medicine 1300 Morris Park Ave Bronx NY 10461 USA 4 Department Epidemiology Population Health The Albert Einstein Cancer Center Albert Einstein College Medicine 1300 Morris Park Ave Bronx NY 10461 USA
0.2511286.15831941.html.plaintext.txt	2	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS AND DISCUSSION REFERENCES A core group four open reading frames ORFs present known papillomaviruses PVs E1 E2 replicationtranscription proteins L1 L2 structural proteins
0.2511286.15831941.html.plaintext.txt	3	Because involved processes essential PV propagation sequences proteins well conserved
0.2511286.15831941.html.plaintext.txt	4	However sequencing novel subtypes human papillomaviruses HPV 54 AE9 82 AE2IS39 coupled analysis four closely related genital HPV pairs indicated E2 higher dNdS ratio E1 L1 L2
0.2511286.15831941.html.plaintext.txt	5	The elevated ratio homogeneous across length ORF instead varies respect E2s three domains
0.2511286.15831941.html.plaintext.txt	6	The E2 hinge region particular interest hypervariability dNdS 1 differs markedly two domains joins transcription activation domain DNA binding domain
0.2511286.15831941.html.plaintext.txt	7	Deciphering whether hinge regions high rate non synonymous change result positive Darwinian selection relaxed constraint depends evolutionary behaviour E4 ORF overlaps E2
0.2511286.15831941.html.plaintext.txt	8	The E2 hinge region contained within E4 non synonymous changes hinge associated disproportionate amount synonymous change E4 case simultaneous positive purifying selection overlapping reading frames
0.2511286.15831941.html.plaintext.txt	9	Modular rates selection among E2 domains likely consequence presence embedded E4
0.2511286.15831941.html.plaintext.txt	10	E4 appears positioned part HPV genome tolerate non synonymous change purifying selection E4 may indicative functional importance
0.2511286.15831941.html.plaintext.txt	11	The GenBankEMBLDDBJ accession numbers sequences reported work AF436129 HPV54A AF293961 HPV82A
0.2511286.15831941.html.plaintext.txt	12	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS AND DISCUSSION REFERENCES Human papillomaviruses HPVs include group closed circular double stranded DNA viruses established aetiological agents cervical neoplasia invasive cervical cancer Bosch de Sanjose 2003 Munoz et al
0.2511286.15831941.html.plaintext.txt	13	Over 100 putative HPVs described 90 cloned officially designated de Villiers et al
0.2511286.15831941.html.plaintext.txt	14	Despite array types development cervical carcinoma restricted subset high risk viruses HPV16 HPV18 together account nearly two thirds observed cases Munoz et al
0.2511286.15831941.html.plaintext.txt	15	Classification HPV types categories cancer causing non cancer causing cutaneous mucosal based epidemiological phylogenetic studies Chan et al
0.2511286.15831941.html.plaintext.txt	16	1995 Pfister Fuchs 1994 Van Ranst et al
0.2511286.15831941.html.plaintext.txt	17	Most oncogenic types share common ancestor common ancestors radiate within ecological niche skin mucosa
0.2511286.15831941.html.plaintext.txt	18	The typical HPV genome contains six open reading frames ORFs encoding structural proteins L1 L2 proteins mediate viral life cycle E1 E2 proteins regulate host cell DNA replication transformation E6 E7 Knipe et al
0.2511286.15831941.html.plaintext.txt	19	E6 E7 bind cell cycle regulators p53 pRb respectively
0.2511286.15831941.html.plaintext.txt	20	Among highly cancerous types oncogenes degrade p53 pRb resulting host cell immortalization proliferation reviewed Fehrmann Laimins 2003
0.2511286.15831941.html.plaintext.txt	21	Some papillomaviruses PVs also encode E4 E5 genes whose roles although largely unknown seem involve functions later phases viral life cycle Longworth Laimins 2004 Peh et al
0.2511286.15831941.html.plaintext.txt	22	The E5 ORF situated E2 L2 typical PV genomes
0.2511286.15831941.html.plaintext.txt	23	In cases E5 overlap neighbours however E4 ORF contained completely within E2
0.2511286.15831941.html.plaintext.txt	24	A great deal effort spent studying evolutionary implications overlapping reading frames viruses Hein Stovlbaek 1995 Krakauer 2000 Miyata Yasunaga 1978
0.2511286.15831941.html.plaintext.txt	25	A fundamental question natural selection operates two protein sequences encoded stretch DNA
0.2511286.15831941.html.plaintext.txt	26	We address question context HPV E2 E4 highlighting rates synonymous non synonymous substitution overlapping reading frames
0.2511286.15831941.html.plaintext.txt	27	To end utilized two recently cloned sequenced viral isolates HPV AE2IS39 HPV AE9
0.2511286.15831941.html.plaintext.txt	28	Although initially thought novel types 10 variance L1 nucleotide sequences based sequence analysis MY09MY11 region L1 ORF upon analysis complete genomes HPV AE2IS39 HPV AE9 found subtypes 2 10 variance L1 sequences HPV82 HPV54 respectively
0.2511286.15831941.html.plaintext.txt	29	In report examine rates evolution ORF using dNdS ratios across subtype pairs closely related mucosal types
0.2511286.15831941.html.plaintext.txt	30	Closely related genomes allow examination evolutionary change prior saturation genetic changes
0.2511286.15831941.html.plaintext.txt	31	We focus specifically modular rates selection exhibited E2 possible explanation modularity overlapping ORF E4
0.2511286.15831941.html.plaintext.txt	32	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS AND DISCUSSION REFERENCES A cervicovaginal sample containing HPV AE2IS39 HPV82 subtype originated white 22 year old female persistent stage 1 cervical intraepithelial neoplasia sample containing HPV AE9 HPV54 subtype obtained white 19 year old female normal cervical cytology
0.2511286.15831941.html.plaintext.txt	33	HPV AE2IS39 HPV AE9 containing samples originally detected MY09MY11 PCR dot blot analyses described previously Tachezy et al
0.2511286.15831941.html.plaintext.txt	34	1994 Terai Burk 2002
0.2511286.15831941.html.plaintext.txt	35	To clone potentially novel genomes PCR primers designed alignment closely related HPV genomes using sequences partial L1 region amplified MY09MY11 primers
0.2511286.15831941.html.plaintext.txt	36	Additional primers used amplify entire genome fragments using overlapping PCR amplification described previously Terai Burk 2002
0.2511286.15831941.html.plaintext.txt	37	PCR products separated agarose gel electrophoresis stained ethidium bromide visualized UV illumination
0.2511286.15831941.html.plaintext.txt	38	After confirmation appropriate product sizes PCR product purified Qiagen gel extraction kit ligated pGEM T Easy vector Promega according manufacturers instructions
0.2511286.15831941.html.plaintext.txt	39	Initially SP6 T7 primers flanking HPV DNA insert used determine nucleotide sequence
0.2511286.15831941.html.plaintext.txt	40	Additional primers designed sequence walking
0.2511286.15831941.html.plaintext.txt	41	Sequencing performed Albert Einstein Cancer Center DNA sequencing facility
0.2511286.15831941.html.plaintext.txt	42	Overlapping fragments assembled manually several additional primers used clarify sequence ambiguities
0.2511286.15831941.html.plaintext.txt	43	The primer sequences used available authors request
0.2511286.15831941.html.plaintext.txt	44	Pairwise sequence alignments performed using CLUSTAL W Thompson et al
0.2511286.15831941.html.plaintext.txt	45	1994 gap cost 10 0 IUB weight matrix
0.2511286.15831941.html.plaintext.txt	46	Multiple sequence alignments providing prototype subtype phylogenetic context generated way
0.2511286.15831941.html.plaintext.txt	47	Calculation overall ORF wide non synonymous synonymous changes rates non synonymous synonymous change done using SNAP SynonymousNon synonymous Analysis Program Korber 2002 Nei Gojobori 1986 K Estimator used perform sliding window analysis dNdS Comeron 1999
0.2511286.15831941.html.plaintext.txt	48	Phylogenetic trees constructed PAUP version 4
0.2511286.15831941.html.plaintext.txt	49	10 Swofford 1998 multiple sequence alignments E6 E7 E1 E2 L2 L1 concatenated ORFs using distance neighbour joining parsimony methods
0.2511286.15831941.html.plaintext.txt	50	Alignment gaps coded missing distance parsimony trees reconstructed using equal weighted characters 100 bootstrap replicates
0.2511286.15831941.html.plaintext.txt	51	To ensure adequate searches tree space 100 random addition heuristic searches TBR tree bisection reconnection swapping employed
0.2511286.15831941.html.plaintext.txt	52	HPVs used study GenBank accession numbers follows HPV7 NC001595 HPV11 NC001525 HPV27 NC001584 HPV40 NC001589 HPV44 NC001689 HPV54 NC001676 HPV55 NC001692 HPV82 NC002172 HPV13 NC001349 HPV26 NC001583 HPV30 NC001585 HPV32 NC001586 HPV42 NC001534 HPV51 NC001533 HPV53 NC001593 HPV56 NC001594 HPV66 NC001695 HPV69 NC002171 HPV74 NC004501 HPV91 NC004085 HPV54A AF436129 HPV82A AF293961
0.2511286.15831941.html.plaintext.txt	53	RESULTS AND DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS AND DISCUSSION REFERENCES The genomes HPV AE2IS39 abbreviated HPV82A HPV AE9 abbreviated HPV54A amplified cloned three overlapping PCR fragments
0.2511286.15831941.html.plaintext.txt	54	For HPV82A fragments measured 3 8 3 9 0 5 kb HPV54A 4 3 3 6 0 5 kb
0.2511286.15831941.html.plaintext.txt	55	The complete genome sequences available GenBank accession numbers AF436129 HPV54A AF293961 HPV82A
0.2511286.15831941.html.plaintext.txt	56	The genomes HPV54A HPV82A share high level similarity prototypes
0.2511286.15831941.html.plaintext.txt	57	A comparison whole genomes reveals 93 5 nucleic acid similarity HPV54 HPV54A 89 8 similarity HPV82 HPV82A
0.2511286.15831941.html.plaintext.txt	58	The currently accepted criterion HPV classification relies comparison L1 nucleotide ORFs
0.2511286.15831941.html.plaintext.txt	59	The L1 ORF HPV54 pair diverges 4 6 whilst HPV82 pair diverges 7 7 placing isolates within subtype range
0.2511286.15831941.html.plaintext.txt	60	As expected subtype prototype genome lengths also comparable
0.2511286.15831941.html.plaintext.txt	61	HPV82 HPV82A 7871 7904 bp respectively whilst HPV54 HPV54A 7759 7717 bp length
0.2511286.15831941.html.plaintext.txt	62	Each pair contains anticipated PV ORFs including E6 E7 proteins replication proteins E1 E2 components viral capsid L1 L2
0.2511286.15831941.html.plaintext.txt	63	The major difference genomic architecture across two pairs HPV54s lack E5 homologue
0.2511286.15831941.html.plaintext.txt	64	HPV82 contains unambiguous E5 ORF lacks proximal start codon whereas corresponding genomic region HPV54 variable sections upstream regulatory region
0.2511286.15831941.html.plaintext.txt	65	Lack evidence E5 HPV54 reinforces status unique outlier rooting members PV species clades 1 8 10 Fig
0.2511286.15831941.html.plaintext.txt	66	1 contain intact E5 ORF
0.2511286.15831941.html.plaintext.txt	67	The identification HPV54 subtype implies ancient part tree still appears evolving
0.2511286.15831941.html.plaintext.txt	68	In greater phylogenetic context HPV82A HPV54A sort species groups 5 13 respectively
0.2511286.15831941.html.plaintext.txt	69	This evolutionary relationship held phylogenies constructed either concatenated ORFs L1 nucleotide sequences alone data shown Fig
0.2511286.15831941.html.plaintext.txt	70	View larger version 15K Fig
0.2511286.15831941.html.plaintext.txt	71	Phylogenetic trees constructed using maximum parsimony distance methods resulted identical topologies
0.2511286.15831941.html.plaintext.txt	72	Representative cladograms HPV82 taxonomic context b HPV54 taxonomic context shown
0.2511286.15831941.html.plaintext.txt	73	Both trees based alignment nucleotide sequences compiled ORFs E6 E7 E1 E2 L2 L1 indicated PV genomes
0.2511286.15831941.html.plaintext.txt	74	Bootstrap values parsimony calculation provided nodes
0.2511286.15831941.html.plaintext.txt	75	Numbers right indicate taxonomic species group PVs de Villiers et al
0.2511286.15831941.html.plaintext.txt	76	The distribution polymorphisms across ORF within HPV54 HPV82 shown Table 1 accompanied four closely related genital HPV pairs
0.2511286.15831941.html.plaintext.txt	77	The subtypes HPV44 HPV55 sister taxa HPV6 HPV11 HPV7 HPV40 HPV2 HPV27 chosen exhibit whole genome divergence 15
0.2511286.15831941.html.plaintext.txt	78	These closely related pairs allow unambiguous alignment less likely subject saturation genetic variation
0.2511286.15831941.html.plaintext.txt	79	To examine possibility directional selection calculated ratio non synonymous substitutions per non synonymous site dN synonymous substitutions per synonymous site dS
0.2511286.15831941.html.plaintext.txt	80	A dNdS ratio equal 1 indicates neutrality ratio 1 indicates purifying selection ratio 1 indicates positive Darwinian selection Yang 1998
0.2511286.15831941.html.plaintext.txt	81	Overall small ratios non synonymous synonymous changes dNdS values indicate E1 L1 L2 strong purifying selection forming functional core essential viral life cycle
0.2511286.15831941.html.plaintext.txt	82	Previously also included E2 group presence known PVs role viral genome replication Narechania et al
0.2511286.15831941.html.plaintext.txt	83	However current analysis remarkably consistent pattern elevated non synonymous E2 variation observed pattern line values seen E6E7 ORFs stable core E1 L1 L2 ORFs
0.2511286.15831941.html.plaintext.txt	84	The median E2 dNdS value 0 31 significantly different E1L1L2 group 0 09 Mann Whitney P 0 0004 Siegel 1956
0.2511286.15831941.html.plaintext.txt	85	All values calculated SNAP described Korber 2000
0.2511286.15831941.html.plaintext.txt	86	Much E2s variation attributable hinge region connecting transcription activation domain TAD DNA binding domain DBD Table 2 Fig
0.2511286.15831941.html.plaintext.txt	87	In cases except HPV54 pair hinge region manifest purifying selection constrains rest E2 ORF dNdS median 1 11
0.2511286.15831941.html.plaintext.txt	88	HPV16 variant genomes also showed elevated dNdS ratios E2 hinge region Z
0.2511286.15831941.html.plaintext.txt	89	The TAD DBD regions display intermediate median dNdS values 0 18 lower hinge significantly higher observed E1 L1 L2 Mann Whitney P 0 002
0.2511286.15831941.html.plaintext.txt	90	This pattern holds cases except HPV54 pair
0.2511286.15831941.html.plaintext.txt	91	Aside low hinge dNdS high TAD dNdS HPV54 pair also exhibits relatively high E1 L1 dNdS ratios highlighting status unique outlier species clades 1 8 10
0.2511286.15831941.html.plaintext.txt	92	Although relatively elevated E2 dNdS values trend consistent across analysed pairs many functional protein motifs conserved across types
0.2511286.15831941.html.plaintext.txt	93	For example 1 recognition helix E2 DBD well conserved across types used current study cognate DBD sites ACCgNNNNcGGT long control region reviewed Hegde 2002
0.2511286.15831941.html.plaintext.txt	94	All values calculated SNAP described Korber 2000
0.2511286.15831941.html.plaintext.txt	95	View larger version 21K Fig
0.2511286.15831941.html.plaintext.txt	96	Distributions nucleotide amino acid changes within E2 ORF
0.2511286.15831941.html.plaintext.txt	97	HPV54 HPV54A b HPV82 HPV82A
0.2511286.15831941.html.plaintext.txt	98	Positions three functional domains E2 TAD hinge DBD delimited along horizontal axis white black grey respectively
0.2511286.15831941.html.plaintext.txt	99	These positions derived alignment HPV18 E2 Hegde 2002
0.2511286.15831941.html.plaintext.txt	100	Vertical lines horizontal axis indicate non synonymous changes
0.2511286.15831941.html.plaintext.txt	101	amino acid changes whereas axis correspond synonymous changes
0.2511286.15831941.html.plaintext.txt	102	The height vertical lines horizontal axis represents number non synonymous synonymous changes per codon respectively
0.2511286.15831941.html.plaintext.txt	103	The compelling observations current analysis high overall dNdS ratio E2 concentration non synonymous changes hinge region ORF
0.2511286.15831941.html.plaintext.txt	104	E2 unique PV genome ORF completely contains another case E4
0.2511286.15831941.html.plaintext.txt	105	Moreover E4 frames hinge region completely pairs analysed two examples see Fig
0.2511286.15831941.html.plaintext.txt	106	In sliding window analysis except HPV54 little time apparently passed since subtype divergence non synonymous changes dominate E2 reading frame whereas E4 favours synonymous changes
0.2511286.15831941.html.plaintext.txt	107	This observation odds prevailing notion concerning overlapping genes severe evolutionary constraint operate nucleotide sequences encoding two layers protein dense genetic environment viruses Mizokami et al
0.2511286.15831941.html.plaintext.txt	108	1997 Pavesi 2000 Pavesi et al
0.2511286.15831941.html.plaintext.txt	109	For overlapping genes codon changes third position one reading frame unusual result changes second position 1 reading frame
0.2511286.15831941.html.plaintext.txt	110	However see pattern E4 purifying selection superimposed E2 hinge one domain physically accommodate high levels non synonymous change
0.2511286.15831941.html.plaintext.txt	111	The relaxed constraint observed hinge therefore attributable role flexible connector functionally conserved TAD DBD domains existence overlapping E4 reading frame
0.2511286.15831941.html.plaintext.txt	112	In PVs evidence E4 ORF might expect phenomenon disappear
0.2511286.15831941.html.plaintext.txt	113	However knowledge PVs contain E4 like ORF except two avian PVs characterized date Psittacus erithacus papillomavirus PePV Fringilla coelebs papillomavirus FPV Terai et al
0.2511286.15831941.html.plaintext.txt	114	An alignment PePV FPV E2 ORFs yielded 52 identity
0.2511286.15831941.html.plaintext.txt	115	At level divergence saturation becomes problem satisfactory dNdS analysis could performed
0.2511286.15831941.html.plaintext.txt	116	View larger version 20K Fig
0.2511286.15831941.html.plaintext.txt	117	Sliding window traces rates synonymous dS dashed line non synonymous dN solid line change overlapping E2 hinge E4 reading frames
0.2511286.15831941.html.plaintext.txt	118	The analysis employed 100 nt window sliding 10 positions time registering dN dS values centre position
0.2511286.15831941.html.plaintext.txt	119	100 nt window centre position would 50 5 bp
0.2511286.15831941.html.plaintext.txt	120	Lines horizontal axis delimit position E2 hinge within particular trace
0.2511286.15831941.html.plaintext.txt	121	Plots shown include pairwise alignments HPV44 HPV55 E2 reading frame top left E4 reading frame bottom left alignments HPV2 HPV27 E2 top right E4 bottom right reading frames
0.2511286.15831941.html.plaintext.txt	122	Despite claim constraint rule overlapping reading frames recent reports indicate viral genomes demonstrate simultaneous positive purifying selection
0.2511286.15831941.html.plaintext.txt	123	Simian immunodeficiency virus Hughes et al
0.2511286.15831941.html.plaintext.txt	124	2001 potato leafroll virus Guyader Ducray 2002 Sendai virus Fujii et al
0.2511286.15831941.html.plaintext.txt	125	2001 show increased non synonymous change one ORF concurrent dominance synonymous change overlapping reading frame
0.2511286.15831941.html.plaintext.txt	126	We suggest modularity displayed E2 dNdS profile probable consequence presence E4 overlapping reading frame E2 hinge ideal genomic position fix overlapping gene
0.2511286.15831941.html.plaintext.txt	127	As E4 subject purifying selection relative E2 hinge tested cases evidence E4 ORF mammalian PVs ORF may greater functional importance thought previously
0.2511286.15831941.html.plaintext.txt	128	ACKNOWLEDGEMENTS This work supported part grant National Cancer Institute National Institutes Health R
0.2511286.15831941.html.plaintext.txt	129	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS AND DISCUSSION REFERENCES Bosch F
0.2511286.15831941.html.plaintext.txt	130	Chapter 1 human papillomavirus cervical cancer burden assessment causality
0.2511286.15831941.html.plaintext.txt	131	J Natl Cancer Inst Monogr 31 3 13
0.2511286.15831941.html.plaintext.txt	132	Analysis genomic sequences 95 papillomavirus types uniting typing phylogeny taxonomy
0.2511286.15831941.html.plaintext.txt	133	K Estimator calculation number nucleotide substitutions per site confidence intervals
0.2511286.15831941.html.plaintext.txt	134	Classification papillomaviruses
0.2511286.15831941.html.plaintext.txt	135	Human papillomavirus type 16 variant lineages characterized nucleotide sequence analysis E5 coding segment E2 hinge region
0.2511286.15831941.html.plaintext.txt	136	Human papillomaviruses targeting differentiating epithelial cells malignant transformation
0.2511286.15831941.html.plaintext.txt	137	Conserved non conserved regions Sendai virus genome evolution gene possessing overlapping reading frames
0.2511286.15831941.html.plaintext.txt	138	Structural analysis human papillomavirus type 16 E2 transactivator antipeptide antibodies reveals high mobility region linking transactivation DNA binding domains
0.2511286.15831941.html.plaintext.txt	139	Nucleic Acids Res 19 7073 7079
0.2511286.15831941.html.plaintext.txt	140	Sequence analysis Potato leafroll virus isolates reveals genetic stability major evolutionary events differential selection pressure overlapping reading frame products
0.2511286.15831941.html.plaintext.txt	141	The papillomavirus E2 protein factor many talents
0.2511286.15831941.html.plaintext.txt	142	Trends Biochem Sci 16 440 444
0.2511286.15831941.html.plaintext.txt	143	The papillomavirus E2 proteins structure function biology
0.2511286.15831941.html.plaintext.txt	144	Annu Rev Biophys Biomol Struct 31 343 360
0.2511286.15831941.html.plaintext.txt	145	A maximum likelihood approach analyzing nonoverlapping overlapping reading frames
0.2511286.15831941.html.plaintext.txt	146	Simultaneous positive purifying selection overlapping reading frames tat vpr genes simian immunodeficiency virus
0.2511286.15831941.html.plaintext.txt	147	Philadelphia PA Lippincott Williams Wilkins
0.2511286.15831941.html.plaintext.txt	148	HIV signature sequence variation analysis
0.2511286.15831941.html.plaintext.txt	149	In Computational Analysis HIV Molecular Sequences pp
0.2511286.15831941.html.plaintext.txt	150	Dordrecht Kluwer Academic Publishers
0.2511286.15831941.html.plaintext.txt	151	Stability evolution overlapping genes
0.2511286.15831941.html.plaintext.txt	152	Evolution Int J Org Evolution 54 731 739
0.2511286.15831941.html.plaintext.txt	153	Pathogenesis human papillomaviruses differentiating epithelia
0.2511286.15831941.html.plaintext.txt	154	Microbiol Mol Biol Rev 68 362 372
0.2511286.15831941.html.plaintext.txt	155	Evolution overlapping genes
0.2511286.15831941.html.plaintext.txt	156	Constrained evolution respect gene overlap hepatitis B virus
0.2511286.15831941.html.plaintext.txt	157	J Mol Evol 44 Suppl 1 S83 S90
0.2511286.15831941.html.plaintext.txt	158	Epidemiologic classification human papillomavirus types associated cervical cancer
0.2511286.15831941.html.plaintext.txt	159	Lack canonical pRB binding domain E7 ORF artiodactyl papillomaviruses associated development fibropapillomas
0.2511286.15831941.html.plaintext.txt	160	Simple methods estimating numbers synonymous nonsynonymous nucleotide substitutions
0.2511286.15831941.html.plaintext.txt	161	Detection signature sequences overlapping genes prediction novel overlapping gene hepatitis G virus
0.2511286.15831941.html.plaintext.txt	162	On informational content overlapping genes prokaryotic eukaryotic viruses
0.2511286.15831941.html.plaintext.txt	163	The viral E4 protein required completion cottontail rabbit papillomavirus productive cycle vivo
0.2511286.15831941.html.plaintext.txt	164	Anatomy taxonomy evolution papillomaviruses
0.2511286.15831941.html.plaintext.txt	165	Nonparametric Statistics Behavioral Sciences
0.2511286.15831941.html.plaintext.txt	166	Phylogenetic Analysis Using Parsimony methods version 4
0.2511286.15831941.html.plaintext.txt	167	Sunderland MA Sinauer Associates
0.2511286.15831941.html.plaintext.txt	168	Analysis short novel human papillomavirus sequences
0.2511286.15831941.html.plaintext.txt	169	Biochem Biophys Res Commun 204 820 827
0.2511286.15831941.html.plaintext.txt	170	Identification characterization 3 novel genital human papillomaviruses overlapping polymerase chain reaction candHPV89 candHPV90 candHPV91
0.2511286.15831941.html.plaintext.txt	171	J Infect Dis 185 1794 1797
0.2511286.15831941.html.plaintext.txt	172	Lack canonical E6 E7 open reading frames bird papillomaviruses Fringilla coelebs papillomavirus Psittacus erithacus timneh papillomavirus
0.2511286.15831941.html.plaintext.txt	173	CLUSTAL W improving sensitivity progressive multiple sequence alignment sequence weighting position specific gap penalties weight matrix choice
0.2511286.15831941.html.plaintext.txt	174	Nucleic Acids Res 22 4673 4680
0.2511286.15831941.html.plaintext.txt	175	Phylogenetic classification human papillomaviruses correlation clinical manifestations
0.2511286.15831941.html.plaintext.txt	176	Taxonomy human papillomaviruses
0.2511286.15831941.html.plaintext.txt	177	Papillomavirus Rep 4 61 65
0.2511286.15831941.html.plaintext.txt	178	Evidence new hepatitis C virus antigen encoded overlapping reading frame
0.2511286.15831941.html.plaintext.txt	179	Likelihood ratio tests detecting positive selection application primate lysozyme evolution
0.2511286.15831941.html.plaintext.txt	180	Received 5 November 2004 accepted 8 February 2005
0.15323845.11739895.html.plaintext.txt	0	Binding external ligands onto engineered virus capsid
0.15323845.11739895.html.plaintext.txt	1	Uli Schmidt134 Rainer Rudolph1 Gerald Bohm12
0.15323845.11739895.html.plaintext.txt	2	1 Institut fur Biotechnologie Martin Luther Universitat Halle Wittenberg Kurt Mothes Str
0.15323845.11739895.html.plaintext.txt	3	3 06120 Halle 2 ACGT Progenomics AG Weinbergweg 22 06120 Halle Saale Germany
0.15323845.11739895.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials methods Results Discussion References The development novel delivery systems therapeutic substances includes targeting carriers specific site tissue within body recipient
0.15323845.11739895.html.plaintext.txt	5	This accomplished appropriate receptor binding domains requires linking domains carrier
0.15323845.11739895.html.plaintext.txt	6	We used recombinantly expressed polyomavirus like particles model system inserted sequence WW domain different surface loops viral capsid protein VP1
0.15323845.11739895.html.plaintext.txt	7	In one variant WW domain maintained highly selective binding properties proline rich ligands showed increased affinity also accelerated associationdissociation equilibrium compared isolated WW domain thus allowing short term coupling external ligands onto surface virus like particles
0.15323845.11739895.html.plaintext.txt	8	Keywords cellular targetingdrug deliverypolyomavirus VP1protein designWW domain
0.15323845.11739895.html.plaintext.txt	9	Introduction Top Abstract Introduction Materials methods Results Discussion References In recent years intense efforts generate targetable injectable vectors gene drug delivery based variety viral non viral systems Anderson 1998
0.15323845.11739895.html.plaintext.txt	10	It envisaged ideal targeted vector would administered intravenous infusion injection concentrates tissues organs harboring targeted cells Peng Russel 1999
0.15323845.11739895.html.plaintext.txt	11	Strategies achieve cell type specific targeting often use direct genetic modification coat proteins receptor binding domains sequences e
0.15323845.11739895.html.plaintext.txt	12	insertion integrin binding RGD sequences adenoviral capsid Wickham et al
0.15323845.11739895.html.plaintext.txt	13	Another approach use soluble bifunctional crosslinkers bind vector cell surface receptor Douglas et al
0.15323845.11739895.html.plaintext.txt	14	A combined approach display immunoglobulin binding domain protein A vector genetic fusion coat protein use monoclonal antibody crosslink vector targeted cell Ohno Meruelo 1997 Ohno et al
0.15323845.11739895.html.plaintext.txt	15	Here investigate general strategy using genetic fusion viral capsid protein WW domain order bind recombinantly produced polyproline tagged protein example antibody receptor binding domain
0.15323845.11739895.html.plaintext.txt	16	Surface loops viral capsid proteins often show high sequence variability due influence immune system viral life cycles makes loops susceptible insertion foreign sequences Stirk Thornton 1994
0.15323845.11739895.html.plaintext.txt	17	Recombinantly expressed polyomavirus like particles used model viral protein shell
0.15323845.11739895.html.plaintext.txt	18	The outer capsid protein VP1 murine polyomavirus expressed recombinant Escherichia coli Leavitt et al
0.15323845.11739895.html.plaintext.txt	19	It pentameric protein forms virus like particles vitro consisting 72 pentamers Salunke et al
0.15323845.11739895.html.plaintext.txt	20	The vitro assembly process studied great detail thought involve pre existing equilibrium free capsomeres capsids completely shifted capsids upon oxidation single disulfide bridge Schmidt et al
0.15323845.11739895.html.plaintext.txt	21	The crystal structures capsid truncated pentameric VP1 reported Stehle et al
0.15323845.11739895.html.plaintext.txt	22	1994 Stehle Harrison 1996 1997
0.15323845.11739895.html.plaintext.txt	23	Polyomavirus VP1 gained attention vitro packaging plasmid DNA oligonucleotides development non viral gene transfer vectors Forstova et al
0.15323845.11739895.html.plaintext.txt	24	In order specifically bind proline rich ligands onto outer surface VP1 capsids sequence WW domain genetically fused ss turns VP1
0.15323845.11739895.html.plaintext.txt	25	WW domains smallest protein domains known far first discovered Yes kinase associated protein YAP Saccharomyces cerevisiae Bork Sudol 1994 Sudol et al
0.15323845.11739895.html.plaintext.txt	26	They named two conserved tryptophan residues essential maintenance native fold ligand binding Koepf et al
0.15323845.11739895.html.plaintext.txt	27	Until WW domains found several proteins different species contribute signal transduction processes protein protein interactions general
0.15323845.11739895.html.plaintext.txt	28	In analogy SH3 domains WW domains bind proline rich peptide sequences differ consensus sequences Pawson Scott 1997
0.15323845.11739895.html.plaintext.txt	29	WW domains either subdivided four classes according binding specificity Bedford et al
0.15323845.11739895.html.plaintext.txt	30	2000 three subclasses according sequence similarity Macias et al
0.15323845.11739895.html.plaintext.txt	31	The NMR structures WW domains representing three sequence subtypes reported including YAP WW domain complex proline rich peptide Macias et al
0.15323845.11739895.html.plaintext.txt	32	1996 FBP28 YJQ8 WW domains Macias et al
0.15323845.11739895.html.plaintext.txt	33	The WW domain contains three stranded antiparallel ss sheet proline rich peptide mostly bound hydrophobic interactions
0.15323845.11739895.html.plaintext.txt	34	In study first two WW domains mouse formin binding protein 11 FBP11 used binds PPLP motifs Chan et al
0.15323845.11739895.html.plaintext.txt	35	The affinity WW domain ligand highest reported far WW domains
0.15323845.11739895.html.plaintext.txt	36	Its equilibrium dissociation constant KD 21 nM Bedford et al
0.15323845.11739895.html.plaintext.txt	37	Materials methods Top Abstract Introduction Materials methods Results Discussion References Protein modeling
0.15323845.11739895.html.plaintext.txt	38	The structure VP1 WW150 modeled using program Modeller 4 Sali Blundell 1993 based published structures VP1 1
0.15323845.11739895.html.plaintext.txt	39	65 A Stehle Harrison 1996 1997
0.15323845.11739895.html.plaintext.txt	40	The inserted FBP11 WW domain modeled using NMR structure YAP WW domain Macias et al
0.15323845.11739895.html.plaintext.txt	41	Figures generated MolScript Kraulis 1991 Raster3D Merritt Bacon 1997
0.15323845.11739895.html.plaintext.txt	42	Cloning vector construction
0.15323845.11739895.html.plaintext.txt	43	The first FBP11 WW domain genetically fused VP1 sequence shown Figure 2 using oligonucleotides FBP11 WWa 5 5 ATACTCTTCA GGCAGCGGCT GGACAGAACA TAAATCACCT GATGG 3 FBP11 WWa 3 5 ATACTCTTCT ACCACTACCA TCATCCGGCT TTTCCCAGGT AGACTG 3 VP1 150 WWaC 5 ATACTCTTCA GGTAGCGGCG TAAACACAAA AGGAATTTCC ACTCCAG 3 VP1 150 WWaN 5 ATACTCTTCA GCCGCTGCCT GTATCTGTCG GTTTGTTGAA CCCATG 3 VP1 292 WWaC 5 ATACTCTTCA GGTAGCGGCG TTACAAGAAA CTATGATGTC CATCAC 3 VP1 292 WWaN 5 ATACTCTTCA GCCGCTGCCC CAGCCCATTA TATCTACGCT CGAG 3 VP1 Nde I 5 5 TATACATATG GCCCCCAAAA GAAAAAGC 3 VP1 Sma I 3 5 ATATCCCGGG AGGAAATACA GTCTTTGTTT TTCC 3
0.15323845.11739895.html.plaintext.txt	44	The resulting final PCR product cloned via introduced NdeI SmaI restriction sites plasmid pET21 Int contained T7lac promoter high level expression E
0.15323845.11739895.html.plaintext.txt	45	coli C terminal fusion intein chitin binding domain affinity chromatography Schmidt et al
0.15323845.11739895.html.plaintext.txt	46	View larger version 55K Fig
0.15323845.11739895.html.plaintext.txt	47	Cloning fusion constructs VP1 WW150 VP1 WW292
0.15323845.11739895.html.plaintext.txt	48	The strategy avoids changes original sequences involves ligation reamplification three separate fragments generated PCR
0.15323845.11739895.html.plaintext.txt	49	The recognition sequence endonuclease Eam1 104 I printed bold letters
0.15323845.11739895.html.plaintext.txt	50	Protein expression purification
0.15323845.11739895.html.plaintext.txt	51	All proteins expressed recombinant E
0.15323845.11739895.html.plaintext.txt	52	coli C terminal fusion proteins modified intein chitin binding domains purified described Chong et al
0.15323845.11739895.html.plaintext.txt	53	In vitro assembly size exclusion chromatography
0.15323845.11739895.html.plaintext.txt	54	Particles assembled vitro according Salunke et al
0.15323845.11739895.html.plaintext.txt	55	For binding onto virus like particles proline rich ligands added completion assembly process
0.15323845.11739895.html.plaintext.txt	56	The capsid assembly quantitatively analyzed size exclusion chromatography using 14 ml TSKgel 50006000PWXL columns Tosoh Biosep Stuttgart Germany described Schmidt et al
0.15323845.11739895.html.plaintext.txt	57	In order determine affinity VP1 WW fusion proteins polyproline sequences surface plasmon resonance measured using Biacore X Biacore AB Uppsala Sweden CM5 sensorchip coated PPLP peptide sequence CSGP6PPLP following manufacturers protocol
0.15323845.11739895.html.plaintext.txt	58	The protein concentrations varied 5 50 nM
0.15323845.11739895.html.plaintext.txt	59	For screening different buffers additives protein solution diluted buffer also used measurement
0.15323845.11739895.html.plaintext.txt	60	Kinetic parameters calculated BIAevaluation software using simple Langmuir binding model
0.15323845.11739895.html.plaintext.txt	61	Circular dichroism CD spectroscopy
0.15323845.11739895.html.plaintext.txt	62	Far UV CD spectra VP1 variants measured 195 260 nm 0
0.15323845.11739895.html.plaintext.txt	63	The proteins concentration 0
0.15323845.11739895.html.plaintext.txt	64	0 mgml dialyzed buffer containing 10 mM HEPES 100 mM NaCl pH 7
0.15323845.11739895.html.plaintext.txt	65	The secondary structure contents proteins calculated program CDNN Bohm et al
0.15323845.11739895.html.plaintext.txt	66	1992 buffer corrected spectra
0.15323845.11739895.html.plaintext.txt	67	For electron microscopy studies EM 912 instrument Zeiss used magnification factor 63 000
0.15323845.11739895.html.plaintext.txt	68	Staining specimen performed uranyl acetate bacitracin incubated 0
0.15323845.11739895.html.plaintext.txt	69	1 mgml 1 min copper carbon grids according standard protocols
0.15323845.11739895.html.plaintext.txt	70	Results Top Abstract Introduction Materials methods Results Discussion References Protein design model building
0.15323845.11739895.html.plaintext.txt	71	Two variants fusion protein designed presentation WW domain surface polyomavirus like particles
0.15323845.11739895.html.plaintext.txt	72	The first incorporates WW domain DE loop position 150 VP1 sequence second HI loop position 292
0.15323845.11739895.html.plaintext.txt	73	Both loops well accessible outer surface flexible according temperature factors determined crystallographic data Stehle Harrison 1996
0.15323845.11739895.html.plaintext.txt	74	These positions also distant CD loop C terminal sequences required formation virus like particles
0.15323845.11739895.html.plaintext.txt	75	Therefore insertions positions inhibit formation virus like particles
0.15323845.11739895.html.plaintext.txt	76	A sequence alignment reveal conservation regions polyomavirus strains different species data shown
0.15323845.11739895.html.plaintext.txt	77	The WW domain insert flanked spacers five amino acids consisting serineglycine repeats allow maximal flexibility solubility
0.15323845.11739895.html.plaintext.txt	78	The overall size inserted sequence 38 amino acids
0.15323845.11739895.html.plaintext.txt	79	A model VP1 WW150 structure presented Figure 1
0.15323845.11739895.html.plaintext.txt	80	View larger version 35K Fig
0.15323845.11739895.html.plaintext.txt	81	Model structure VP1 WW150 monomeric subunit b pentameric capsomere
0.15323845.11739895.html.plaintext.txt	82	The WW domain represented purple serineglycine linker blue
0.15323845.11739895.html.plaintext.txt	83	The WW domain folds towards central hole capsomere interfere pentameric structure
0.15323845.11739895.html.plaintext.txt	84	Cloning protein expression
0.15323845.11739895.html.plaintext.txt	85	For genetic fusion WW domain VP1 sequence PCR products overhangs containing serineglycine linker sequences recognition sites type IIs restriction endonuclease Eam1 104 I generated Figure 2
0.15323845.11739895.html.plaintext.txt	86	Eam1 104 I cleaves outside recognition sequence therefore allows ligation fragments without introduction suitable restriction sites
0.15323845.11739895.html.plaintext.txt	87	The expression proteins C terminal fusions intein chitin binding domains allowed single step purification Chong et al
0.15323845.11739895.html.plaintext.txt	88	2000 yielded approximately 6 mg purified protein per liter culture medium
0.15323845.11739895.html.plaintext.txt	89	CD analysis reveals increased ss sheet contents
0.15323845.11739895.html.plaintext.txt	90	Far UV CD spectra recorded compared authentic VP1 order verify native fold VP1 WW fusion proteins Figure 3
0.15323845.11739895.html.plaintext.txt	91	The spectra VP1 VP1 WW292 similar shapes whereas VP1 WW150 spectrum significantly increased negative ellipticity difference 207 nm indicating higher portion ss sheet secondary structure
0.15323845.11739895.html.plaintext.txt	92	Secondary structure deconvolution spectra revealed increase antiparallel ss sheets VP1 WW150 VP1 WW292 however significantly higher VP1 WW150
0.15323845.11739895.html.plaintext.txt	93	The difference spectra VP1 WW150VP1 WW292 minus VP1 represent spectrum single WW domain Figure 3
0.15323845.11739895.html.plaintext.txt	94	The difference CD spectrum VP1 WW150 maximum 225 nm intense negative ellipticity 198 nm
0.15323845.11739895.html.plaintext.txt	95	This spectrum corresponds typical WW domain spectrum shifted approximately 5 nm towards shorter wavelengths Macias et al
0.15323845.11739895.html.plaintext.txt	96	2000 indicating WW domain obtains native fold fusion protein VP1 WW150
0.15323845.11739895.html.plaintext.txt	97	In contrast difference spectrum VP1 WW292 showed much smaller amplitude suggesting WW domain partially folded construct
0.15323845.11739895.html.plaintext.txt	98	View larger version 30K Fig
0.15323845.11739895.html.plaintext.txt	99	CD spectra pentameric VP1 VP1 WW150 VP1 WW292
0.15323845.11739895.html.plaintext.txt	100	b Deconvolution program CDNN Bohm et al
0.15323845.11739895.html.plaintext.txt	101	1992 indicates increased secondary structure content antiparallel ss sheet fusion constructs
0.15323845.11739895.html.plaintext.txt	102	c Difference spectra VP1 WW150VP1 WW292 minus VP1 representing spectra WW domains fusion proteins described literature
0.15323845.11739895.html.plaintext.txt	103	d Thermal denaturation experiments demonstrate thermal stability VP1 WW150 6 degrees C lower VP1 51 degrees C
0.15323845.11739895.html.plaintext.txt	104	VP1 WW292 starts aggregate 40 degrees C
0.15323845.11739895.html.plaintext.txt	105	Ellipticity changes thermal denaturation yielded Tm 51 degrees C VP1 capsomer Figure 3
0.15323845.11739895.html.plaintext.txt	106	The thermal transition midpoint VP1 WW150 lowered 6 degrees C 45 degrees C
0.15323845.11739895.html.plaintext.txt	107	This value corresponds well typical midpoint transition temperature determined prototype WW domain 44 degrees C Macias et al
0.15323845.11739895.html.plaintext.txt	108	The denaturation VP1 WW292 sigmoidal shape began decrease already 40 degrees C increased beyond 60 degrees C probably due aggregation followed sedimentation protein may caused large unfolded regions protein
0.15323845.11739895.html.plaintext.txt	109	The starting aggregation 40 degrees C therefore set starting point thermal denaturation VP1 WW292
0.15323845.11739895.html.plaintext.txt	110	VP1 WW150 specifically binds proline rich ligands
0.15323845.11739895.html.plaintext.txt	111	For analysis binding properties inserted WW domains proline rich peptide sequence H3N CSGP6PPLP COOminus immobilized via N terminal cysteine residue surface sensorchip surface plasmon resonance measurements
0.15323845.11739895.html.plaintext.txt	112	This peptide contains PPLP consensus motif makes ideal ligand binding FBP11 WW domain used study Bedford et al
0.15323845.11739895.html.plaintext.txt	113	The sensorchip tested linear construct WW domain N terminal fusion glutathione S transferase GST WW
0.15323845.11739895.html.plaintext.txt	114	For protein equilibrium dissociation constant KD determined 18 nM Table I good agreement value 21 nM published earlier Bedford et al
0.15323845.11739895.html.plaintext.txt	115	Kinetic parameters binding reaction WW domain proline rich peptide using Langmuir binding model The kinetic parameters interaction WW domains within VP1 sequence peptide determined serial dilutions fusion proteins different buffer conditions
0.15323845.11739895.html.plaintext.txt	116	VP1 without WW domain interact sensorchip surface immobilized peptide data shown
0.15323845.11739895.html.plaintext.txt	117	The protein VP1 WW292 bind ligand condition tested far indicating WW domain construct obtain native fold dramatically lowered affinity therefore could measured using surface plasmon resonance
0.15323845.11739895.html.plaintext.txt	118	However VP1 WW150 showed high affinity ligand Figure 4
0.15323845.11739895.html.plaintext.txt	119	Using conditions GST WW equilibrium dissociation constant KD VP1 WW150 increased 7
0.15323845.11739895.html.plaintext.txt	120	7 plus minus 5 nM Table I
0.15323845.11739895.html.plaintext.txt	121	VP1 WW150 exhibited high affinity proline rich ligand range KD 4 15 nM buffer conditions tested
0.15323845.11739895.html.plaintext.txt	122	In order mimic cell culture physiological system measurement carried phosphate buffered saline PBS Dulbeccos modified Eagle cell culture medium supplemented 10 fetal calf serum
0.15323845.11739895.html.plaintext.txt	123	The serum proteins compete binding sites VP1 surface presence inhibit specific binding VP1 WW150 PPLP ligand prerequisite therapeutic applications
0.15323845.11739895.html.plaintext.txt	124	Although equilibrium constants similar inserted linear WW domain interaction inserted WW domain accompanied accelerated exchange ligands Table I
0.15323845.11739895.html.plaintext.txt	125	Association dissociation reactions represented associationdissociation rate constants ka kd Table I VP1 WW150 approximately 10 times faster respective values GST WW
0.15323845.11739895.html.plaintext.txt	126	View larger version 26K Fig
0.15323845.11739895.html.plaintext.txt	127	Surface plasmon resonance immobilized PPLP ligand
0.15323845.11739895.html.plaintext.txt	128	Analysis WW domain concentrations 20 15 10 5 nM respectively buffer containing 20 mM HEPES 1 mM EDTA 200 mM NaCl pH 7
0.15323845.11739895.html.plaintext.txt	129	2 cysteine free VP1 WW150 b VP1 WW150 containing cysteines 19 114
0.15323845.11739895.html.plaintext.txt	130	Altered vitro assembly properties VP1 WW fusion proteins
0.15323845.11739895.html.plaintext.txt	131	An essential function VP1 ability form virus like particles vitro
0.15323845.11739895.html.plaintext.txt	132	For easier handling VP1 WW fusion proteins used far contain cysteine residues therefore unable form intrapentameric disulfide bridge needed complete capsid assembly
0.15323845.11739895.html.plaintext.txt	133	However upon addition Ca2 ions equilibrium 55 reduced capsids 45 free capsomeres reached early step assembly process Schmidt et al
0.15323845.11739895.html.plaintext.txt	134	However removal EDTA addition Ca2 resulted loss 90 protein due significant aggregation VP1 WW150 indicated strong decrease solubility reduced capsid species resulted precipitation protein concentration fell critical limit
0.15323845.11739895.html.plaintext.txt	135	This due aggregation via WW domain presence Ca2 since solubility similar concentrations GST WW protein decrease upon addition CaCl2 data shown
0.15323845.11739895.html.plaintext.txt	136	Also contrast VP1 WW150 protein VP1 WW292 aggregate remained solution
0.15323845.11739895.html.plaintext.txt	137	The vitro assembly quantitatively analyzed size exclusion chromatography Schmidt et al
0.15323845.11739895.html.plaintext.txt	138	Analysis assembly VP1 WW proteins revealed VP1 WW150 still remained solution assembled 15 Figure 5
0.15323845.11739895.html.plaintext.txt	139	VP1 WW292 form capsids represents first described variant VP1 totally blocked capsid formation although C terminal domain interaction capsomeres present Figure 5
0.15323845.11739895.html.plaintext.txt	140	These results demonstrate large inserts like 38 amino acids containing WW domain viral capsid protein long distance effects parts protein essential capsid formation
0.15323845.11739895.html.plaintext.txt	141	View larger version 73K Fig
0.15323845.11739895.html.plaintext.txt	142	In vitro assembly VP1 WW fusion proteins
0.15323845.11739895.html.plaintext.txt	143	Size exclusion chromatography TSKgel 5000PWXL demonstrates VP1 WW150 contains cysteines 19 114 forms quantitatively virus like particles
0.15323845.11739895.html.plaintext.txt	144	Elution volumes capsids 6 8 ml free capsomeres 10 11 ml marked
0.15323845.11739895.html.plaintext.txt	145	b Electron microscopy shows homogeneous population disulfide stabilized VP1 WW150 capsids
0.15323845.11739895.html.plaintext.txt	146	An intrapentameric disulfide bridge cysteines 19 114 neighboring monomers needed complete capsid assembly wild type protein Stehle et al
0.15323845.11739895.html.plaintext.txt	147	In order improve inefficient cysteine free vitro assembly test whether oxidized disulfide linked VP1 WW150 capsids also prone aggregation cysteines 19 114 reintroduced VP1 WW150
0.15323845.11739895.html.plaintext.txt	148	The disulfide bridge forming variant VP1 WW150 differences binding properties proline rich ligands Figure 4 Table I aggregate upon initiation vitro assembly dialysis
0.15323845.11739895.html.plaintext.txt	149	Size exclusion chromatography demonstrated assembly efficiency modified protein improved 95 similar wild type protein
0.15323845.11739895.html.plaintext.txt	150	Electron micrographs also showed homogeneous population virus like particles consisting VP WW150 Figure 5
0.15323845.11739895.html.plaintext.txt	151	This single intrapentameric disulfide bridge could therefore completely restore assembly properties wild type protein
0.15323845.11739895.html.plaintext.txt	152	VP1 WW150 capsids bind external ligands solution
0.15323845.11739895.html.plaintext.txt	153	In order test ability polyomavirus like particles bind external ligands solution would necessary therapeutic applications completely assembled disulfide stabilized capsids VP1 WW150 mixed equal molar amount green fluorescent protein GFP tagged PPLP motif C terminus
0.15323845.11739895.html.plaintext.txt	154	The formation complex consisting capsids GFP analyzed size exclusion chromatography Figure 6
0.15323845.11739895.html.plaintext.txt	155	GFP could detected specific absorbance 490 nm detecting protein absorbance 280 nm capsids GFP parallel
0.15323845.11739895.html.plaintext.txt	156	Absorbance 490 nm elution volume capsids represented GFP bound particles surfaces
0.15323845.11739895.html.plaintext.txt	157	Control experiments VP1 wild type capsids showed co elution GFP capsids data shown
0.15323845.11739895.html.plaintext.txt	158	Integration peak areas calculation molar ratio capsids GFP respectively indicated 25 plus minus 5 molecules GFP bound capsid surface demonstrating general applicability approach
0.15323845.11739895.html.plaintext.txt	159	The binding ratio probably limited rapid dissociation reaction inserted WW domain
0.15323845.11739895.html.plaintext.txt	160	View larger version 31K Fig
0.15323845.11739895.html.plaintext.txt	161	Coupling polyproline tagged GFP onto surface virus like particles
0.15323845.11739895.html.plaintext.txt	162	GFP loaded capsids elution volume 8 10 ml separated excess GFP minor impurities size exclusion chromatography TSKgel 6000PWXL
0.15323845.11739895.html.plaintext.txt	163	Discussion Top Abstract Introduction Materials methods Results Discussion References In work polyomavirus like particles used model viral protein shells order study influence insertion mutants module binding external ligands onto particles surfaces
0.15323845.11739895.html.plaintext.txt	164	The binding module must fulfil certain criteria It specifically bind peptide ligands high regulatable affinity
0.15323845.11739895.html.plaintext.txt	165	Preferably also small compact structure avoid interferences functions protein shell
0.15323845.11739895.html.plaintext.txt	166	A module combines many properties WW domain smallest independently folding protein domain known date
0.15323845.11739895.html.plaintext.txt	167	The highest affinity reported first FBP11 WW domain proline rich sequence PPLP consensus motif Bedford et al
0.15323845.11739895.html.plaintext.txt	168	Although theoretical considerations calculations suggested WW domain could fold independently ss turns chose insertion VP1 sequence one variant VP1 WW150 could specifically interact proline rich ligands
0.15323845.11739895.html.plaintext.txt	169	This expected CD thermal denaturation experiments demonstrated WW domain folded VP1 WW150
0.15323845.11739895.html.plaintext.txt	170	Probably conformation DE loop VP1 compatible WW domain structure alternative HI loop
0.15323845.11739895.html.plaintext.txt	171	This might general conclusion since previous experiments demonstrated insertion enzyme namely dihydrofolate reductase polyomavirus HI loop yielded pentamers enzymatic activity however pentamers formed smaller virus like particles VP1 wild type protein Gleiter et al
0.15323845.11739895.html.plaintext.txt	172	In contrast data observe morphological differences VP1 WW150 VP1 wild type capsids assembly efficiency modified capsomeres similar wild type protein provided intrapentameric disulfide bridge could formed vitro assembly
0.15323845.11739895.html.plaintext.txt	173	The binding kinetics WW domain within fusion protein implications use external ligand binding therapeutic applications
0.15323845.11739895.html.plaintext.txt	174	The binding PPLP motif integrated WW domain VP1 WW150 compared linear construct GST WW resulted increased affinity equilibrium ligand exchange accelerated 10 times Table I
0.15323845.11739895.html.plaintext.txt	175	Nevertheless could demonstrated complex polyproline tagged GFP virus like particles isolated complex stable procedure Figure 6
0.15323845.11739895.html.plaintext.txt	176	However coupling efficiency well stability complex limited fast dissociation reaction would possibly reduce effectiveness bound ligand vivo
0.15323845.11739895.html.plaintext.txt	177	This general problem non covalently linked external ligands also discussed IgG binding protein A fusion constructs viral vector surfaces Wickham 1997
0.15323845.11739895.html.plaintext.txt	178	In order extend stability complexes modified WW domains designed allow formation disulfide bridge ligand analysis binding covalent linking looks promising C
0.15323845.11739895.html.plaintext.txt	179	Schmidt unpublished results
0.15323845.11739895.html.plaintext.txt	180	It also proposed WW domain fold may constitute template binding sites unrelated proteins may introduced order mimic proteins use drug design high degree sequence variability allowed WW domains Macias et al
0.15323845.11739895.html.plaintext.txt	181	Therefore random mutagenesis WW domains selection desired binding activity reintroduction altered domain protein shell could result viral particles new cellular tropism without need external receptor binding domains antibody fragments
0.15323845.11739895.html.plaintext.txt	182	Alternatively two step therapeutic approach would conceivable marks first step target cells antibody fragment presenting proline rich sequence thereby directing WW domain target cells second step
0.15323845.11739895.html.plaintext.txt	183	Similar strategies involving biotinstreptavidin interactions used tissue specific radiation therapy Paganelli et al
0.15323845.11739895.html.plaintext.txt	184	In summary experiments underline applicability protein design modification incorporation new functions viral capsid proteins
0.15323845.11739895.html.plaintext.txt	185	WW domains modules binding external ligands constitute flexible tool future investigations direction
0.15323845.11739895.html.plaintext.txt	186	These similar approaches useful individual vector targeting systems could broad range applications drug delivery field
0.15323845.11739895.html.plaintext.txt	187	Notes 3 Present address WAIMR Cancer Biology Division Institute Child Health Research 100 Roberts Road Subiaco WA 6008 Australia
0.15323845.11739895.html.plaintext.txt	188	4 To correspondence addressed
0.15323845.11739895.html.plaintext.txt	189	Acknowledgments We thank Dr Mark Bedford Harvard Medical School USA providing plasmid containing gene FBP11 WW domain Dr Dieter Neumann IPB Halle Germany help electron microscopy
0.15323845.11739895.html.plaintext.txt	190	We also thank Constanze Gunther laboratory providing GFP PPLP tag excellent technical assistance
0.15323845.11739895.html.plaintext.txt	191	This work supported grant Land Sachsen Anhalt
0.15323845.11739895.html.plaintext.txt	192	References Top Abstract Introduction Materials methods Results Discussion References AndersonW
0.15323845.11739895.html.plaintext.txt	193	1999 Biochemistry 38 14338 14351
0.15323845.11739895.html.plaintext.txt	194	1996 Nature 382 646 649
0.15323845.11739895.html.plaintext.txt	195	1997 Science 278 2075 2080
0.15323845.11739895.html.plaintext.txt	196	1996 Structure 4 183 194
0.15323845.11739895.html.plaintext.txt	197	1994 Nature 369 160 163
0.15323845.11739895.html.plaintext.txt	198	Received June 30 2000 revised June 11 2001 accepted July 10 2001
0.2327217.12730224.html.plaintext.txt	0	Inhibition Human Papillomavirus DNA Replication Small Molecule Antagonists E1 E2 Protein Interaction Peter W
0.2327217.12730224.html.plaintext.txt	1	White Steve Titolo Karine Brault Louise Thauvette Alex Pelletier Ewald Welchner Lise Bourgon Louise Doyon William W
0.2327217.12730224.html.plaintext.txt	2	Ogilvie Christiane Yoakim Michael G
0.2327217.12730224.html.plaintext.txt	3	Cordingley Jacques Archambault
0.2327217.12730224.html.plaintext.txt	4	From Department Biological Sciences Department Chemistry Boehringer Ingelheim Ltd
0.2327217.12730224.html.plaintext.txt	5	Received publication April 7 2003
0.2327217.12730224.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Human papillomavirus HPV DNA replication initiated recruitment E1 helicase E2 protein viral origin
0.2327217.12730224.html.plaintext.txt	7	Screening corporate compound collection assay measuring cooperative binding E1 E2 origin identified class small molecule inhibitors protein interaction E1 E2
0.2327217.12730224.html.plaintext.txt	8	Isothermal titration calorimetry changes protein fluorescence showed inhibitors bind transactivation domain E2 region interacts E1
0.2327217.12730224.html.plaintext.txt	9	These compounds inhibit E2 low risk HPV types 6 11 high risk HPV types cottontail rabbit papillomavirus
0.2327217.12730224.html.plaintext.txt	10	Functional evidence transactivation domain target inhibition obtained swapping domain sensitive HPV11 resistant cottontail rabbit papillomavirus E2 type identifying amino acid substitution E100A increases inhibition 10 fold
0.2327217.12730224.html.plaintext.txt	11	This class inhibitors found antagonize specifically E1 E2 interaction vivo inhibit HPV DNA replication transiently transfected cells
0.2327217.12730224.html.plaintext.txt	12	These results highlight potential E1 E2 interaction small molecule antiviral target
0.2327217.12730224.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Papillomaviruses family small double stranded DNA viruses induce benign malignant hyperproliferative lesions differentiating epithelium reviewed Refs
0.2327217.12730224.html.plaintext.txt	14	Approximately 25 types human papillomavirus HPV1 infect anogenital region
0.2327217.12730224.html.plaintext.txt	15	These HPV types classified low risk high risk types depending whether cause benign warts lesions progress invasive cancer respectively
0.2327217.12730224.html.plaintext.txt	16	Current therapies remove HPV induced lesions include variety ablative cytodestructive procedures use immunomodulatory molecules imiquimod 5 6 stimulate host immune response
0.2327217.12730224.html.plaintext.txt	17	Small molecule antivirals treatment HPV infections currently exist
0.2327217.12730224.html.plaintext.txt	18	The life cycle HPV coupled cellular differentiation program occurs epithelium 7
0.2327217.12730224.html.plaintext.txt	19	Maintenance viral genome infected cells basal layer essential viral life cycle ensuing pathology
0.2327217.12730224.html.plaintext.txt	20	Maintenance HPV episome primary keratinocyte cultures depends function E1 E2 3 5 helicase 8 sequence specific DNA binding protein 9 respectively required replication genome 10
0.2327217.12730224.html.plaintext.txt	21	HPV DNA replication initiated co operative binding E1 E2 specific DNA sequences within viral origin 11 14
0.2327217.12730224.html.plaintext.txt	22	Formation E1 E2 ori ternary complex dependent interaction proteins DNA also critical interaction N terminal transactivation domain TAD E2 C terminal enzymatic domain E1 15 22
0.2327217.12730224.html.plaintext.txt	23	Assembly initial E1 E2 ori complex serves starting point recruitment additional E1 molecules 23 24 assembly hexamers double hexamers ATPase helicase activity 25 26
0.2327217.12730224.html.plaintext.txt	24	Any protein protein protein DNA interactions occurring origin could principle targeted development small molecule antivirals treat HPV infections
0.2327217.12730224.html.plaintext.txt	25	In reality however targets readily amenable inhibition small molecules
0.2327217.12730224.html.plaintext.txt	26	Protein interactions example considered difficult inhibit often involve large surfaces devoid small molecule binding pockets 27 28
0.2327217.12730224.html.plaintext.txt	27	In absence structural information one often rely screening large compound collections determine whether protein antagonized small molecules identification lead inhibitors
0.2327217.12730224.html.plaintext.txt	28	Here present class small molecules bind reversibly E2 transactivation domain inhibit E1 E2 protein interaction vitro vivo
0.2327217.12730224.html.plaintext.txt	29	The chemical features synthetic procedures molecules described elsewhere
0.2327217.12730224.html.plaintext.txt	30	2 To knowledge first small molecule inhibitors HPV DNA replication cellular activity
0.2327217.12730224.html.plaintext.txt	31	As highlight potential E1 E2 interaction antiviral drug target
0.2327217.12730224.html.plaintext.txt	32	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Inhibitors The syntheses inhibitors 1 2 described elsewhere
0.2327217.12730224.html.plaintext.txt	33	2 Inhibitor 3 made similar procedures using appropriate indandione benzaldehyde maleimide fragments
0.2327217.12730224.html.plaintext.txt	34	4 Fluoro 7 nitrobenzofurazan purchased Aldrich
0.2327217.12730224.html.plaintext.txt	35	Plasmid Constructions The plasmid used expression HPV11 E2 TAD amino acids 2 201 fused N terminus 6 histidine tag amino acid sequence MGHHHHHH constructed inserting PCR fragment encoding TAD tag pET28b Novagen
0.2327217.12730224.html.plaintext.txt	36	The plasmid express CRPV E2 vitro transcriptiontranslation constructed inserting PCR fragment corresponding nucleotides 3107 4287 CRPV genome plasmid pCR3
0.2327217.12730224.html.plaintext.txt	37	The plasmid containing CRPV origin replication constructed inserting PstI restriction fragment corresponding nucleotides 192 7111 CRPV pBluescript SK Stratagene
0.2327217.12730224.html.plaintext.txt	38	Plasmids pOri SEAP pGAL4 SEAP encoding respectively HPV11 origin five GAL4 binding sites upstream secreted alkaline phosphatase constructed inserting PCR fragment spanning nucleotides 7884 61 HPV11 genome five GAL4 binding sites pG5CAT Clontech pSEAP2 Basic Clontech
0.2327217.12730224.html.plaintext.txt	39	The plasmid encoding E1 fused transactivation domain HSV VP16 pE1 VP16 constructed inserting PCR fragment encoding E1 pVP16 Clontech
0.2327217.12730224.html.plaintext.txt	40	HPVCRPV E2 chimeras constructed PCR mediated ligation described previously 29 cloned pCR3
0.2327217.12730224.html.plaintext.txt	41	Site directed mutagenesis E2 performed QuickChange site directed mutagenesis kit Stratagene
0.2327217.12730224.html.plaintext.txt	42	For plasmids described details construction sequence oligonucleotide primers used PCR mutagenesis made available upon request
0.2327217.12730224.html.plaintext.txt	43	Proteins His E2 TAD HPV11 expressed Escherichia coli strain BL21DE3 pLysS purified nickel affinity size exclusion chromatography Hi Trap Superdex 75 Amersham Biosciences buffer composed 25 mM Tris 500 mM NaCl 5 mM TCEP pH 8
0.2327217.12730224.html.plaintext.txt	44	Yield 11 mg per liter culture His TAD essentially pure judged SDS PAGE analytical scale size exclusion chromatography
0.2327217.12730224.html.plaintext.txt	45	Preparation purified SV40 T antigen 30 purified E1 E1 containing nuclear extracts 31 purified E2 31 GST E2 TAD 20 described previously
0.2327217.12730224.html.plaintext.txt	46	The TNT coupled reticulocyte lysate system Promega used vitro translation E1 E2 described 20
0.2327217.12730224.html.plaintext.txt	47	E1 E2 Ori Complex Formation Related Assays E1 E2 ori complex formation monitored essentially described previously 31
0.2327217.12730224.html.plaintext.txt	48	Unless stated otherwise E1 E2 ori complex formation assays performed purified E2 E1 containing nuclear extracts
0.2327217.12730224.html.plaintext.txt	49	E1 containing nuclear extracts titrated assay used concentration yielding 70 maximal activity
0.2327217.12730224.html.plaintext.txt	50	Wells without E1 E2 served negative controls
0.2327217.12730224.html.plaintext.txt	51	In assays performed vitro translated E2 2 microl translation reaction used per binding reaction
0.2327217.12730224.html.plaintext.txt	52	In case wells containing E2 E1 used negative controls reticulocyte lysate present translation reaction decreased background signal
0.2327217.12730224.html.plaintext.txt	53	An assay detect binding E2 origin absence E1 carried similar manner using SPA beads linked anti mouse IgG anti E2 monoclonal antibody 53
0.2327217.12730224.html.plaintext.txt	54	7E8 raised full length HPV11 E2
0.2327217.12730224.html.plaintext.txt	55	A similar assay detect binding SV40 large T antigen cognate origin carried using 100 ng purified large T antigen SV40 ori probe encompassing nucleotides 5191 31 SV40 genome
0.2327217.12730224.html.plaintext.txt	56	This probe generated PCR using pCH110 Amersham Biosciences contains SV40 ori primers 5 GCC CCT AAC TCC GCC CAT CCC GC 3 5 ACC AGA CCG CCA CGG CTT ACG GC 3
0.2327217.12730224.html.plaintext.txt	57	Detection performed using monoclonal antibody PAb 101 32 protein A SPA beads
0.2327217.12730224.html.plaintext.txt	58	For assays using vitro translated CRPV E2 proteins HPV11CRPV E2 chimeras containing CRPV DNA binding domain radiolabeled probe CRPV origin used
0.2327217.12730224.html.plaintext.txt	59	A modified detection procedure used experiment Fig
0.2327217.12730224.html.plaintext.txt	60	6 compensate weaker signal obtained assays proteins containing CRPV DNA binding domain
0.2327217.12730224.html.plaintext.txt	61	After 1 h binding reaction mixture transferred HVB filter plates Whatman SPA bead E1 antibody suspension added previously
0.2327217.12730224.html.plaintext.txt	62	After incubating mixture 1 h slight shaking bead bound protein DNA complexes washed vacuum filtration removed red colored reticulocyte lysate slightly quenches detection also reduced background unbound probe washed away
0.2327217.12730224.html.plaintext.txt	63	Scintillation fluid added Microscint 20 Packard Instrument Co
0.2327217.12730224.html.plaintext.txt	64	150 microl per well plates shaken vigorously several minutes counted using Topcount NXT scintillation detector Packard Instrument Co
0.2327217.12730224.html.plaintext.txt	65	View larger version 17K FIG
0.2327217.12730224.html.plaintext.txt	66	Activity inhibitor 2 HPV CRPV E2 chimeric proteins
0.2327217.12730224.html.plaintext.txt	67	A tripartite domain structure E2
0.2327217.12730224.html.plaintext.txt	68	The amino acid boundaries transactivation domain TAD hinge domain H DNA binding domain DBD indicated HPV11 CRPV E2
0.2327217.12730224.html.plaintext.txt	69	B diagram four vitro translated E2 proteins tested inhibition compound 2
0.2327217.12730224.html.plaintext.txt	70	The regions protein originating HPV11 colored black CRPV E2 shown white
0.2327217.12730224.html.plaintext.txt	71	The effect 2 microM compound 2 shown percent inhibition signal obtained absence compound subtraction reaction blanks
0.2327217.12730224.html.plaintext.txt	72	Signalbackground ratios 17 18 proteins HPV11 DBD 3 4 assays CRPV DBD
0.2327217.12730224.html.plaintext.txt	73	Each value average 12 measurements standard error indicated
0.2327217.12730224.html.plaintext.txt	74	Data Analysis IC50 IC50 50 inhibitory concentration values determined non linear least square regression fitting inhibition data using program SAS software release 6
0.2327217.12730224.html.plaintext.txt	75	E1 E2 ELISA PBS Invitrogen used buffer steps additions noted
0.2327217.12730224.html.plaintext.txt	76	Wash buffer contained PBS plus 0
0.2327217.12730224.html.plaintext.txt	77	96 Well plates Nunc Immunoplates coated overnight 4 degrees C using anti E2 monoclonal antibody 53
0.2327217.12730224.html.plaintext.txt	78	7E8 1 microg 100 microlwell
0.2327217.12730224.html.plaintext.txt	79	Wells blocked room temperature 300 microl PBS plus 3 bovine serum albumin
0.2327217.12730224.html.plaintext.txt	80	Subsequent steps performed room temperature plate shaker gentle setting total volume 100 microl PBS supplemented 1 mM dithiothreitol 0
0.2327217.12730224.html.plaintext.txt	81	After blocking plates washed incubated 25 ng purified E2 4 microl vitro translated E2
0.2327217.12730224.html.plaintext.txt	82	Negative controls lacked E2 assays purified E2 E1 assays vitro translated E2
0.2327217.12730224.html.plaintext.txt	83	5 h plates washed solutions containing test inhibitors used 0
0.2327217.12730224.html.plaintext.txt	84	5 microl E1 containing nuclear extract added
0.2327217.12730224.html.plaintext.txt	85	Buffer step contained 6 Me2SO
0.2327217.12730224.html.plaintext.txt	86	After 2 h bound E1 detected successive incubations anti E1 serum used E1 E2 DNA complex formation assay horseradish peroxidase linked goat anti rabbit antibody Sigma
0.2327217.12730224.html.plaintext.txt	87	Antibody buffers supplemented 0
0.2327217.12730224.html.plaintext.txt	88	After washing horseradish peroxidase activity detected using o phenylenediamine substrate Sigma according manufacturers instructions
0.2327217.12730224.html.plaintext.txt	89	Fluorescence Quenching Experiments Fluorescence spectra acquired using SLM Aminco 8100 spectrometer neutral density filter place excitation emission slits set 4
0.2327217.12730224.html.plaintext.txt	90	Samples proteins 400 nM excited 280 nm emission intensity recorded range 300 380 nm
0.2327217.12730224.html.plaintext.txt	91	For proteininhibitor combination spectra acquired three individually prepared 0
0.2327217.12730224.html.plaintext.txt	92	Signals three replicates averaged wavelength displayed signal average 3 nm range
0.2327217.12730224.html.plaintext.txt	93	Isothermal Titration Calorimetry The calorimetry experiment carried using VP ITC microcalorimeter Microcal Inc
0.2327217.12730224.html.plaintext.txt	94	temperature 25 degrees C
0.2327217.12730224.html.plaintext.txt	95	Purified His tagged HPV11 TAD exchanged aqueous buffer consisting 20 mM Tris 100 mM NaCl 0
0.2327217.12730224.html.plaintext.txt	96	Inhibitor 2 diluted Me2SO stock solution give solution 200 microM bufferMe2SO mixture
0.2327217.12730224.html.plaintext.txt	97	Both solutions degassed protein solution passed 0
0.2327217.12730224.html.plaintext.txt	98	22 microm syringe filter inhibitor solution spun microcentrifuge 5 min maximum speed remove particulate matter
0.2327217.12730224.html.plaintext.txt	99	The concentration protein solution filtration determined 10
0.2327217.12730224.html.plaintext.txt	100	0 microM absorbance 280 nm based predicted molar extinction coefficient 4
0.2327217.12730224.html.plaintext.txt	101	An initial 4 microl injection followed series 8 microl injections spacing 240
0.2327217.12730224.html.plaintext.txt	102	Data fit using software Origin version 5
0.2327217.12730224.html.plaintext.txt	103	one binding site model subtraction heat dilution determined average value late injections
0.2327217.12730224.html.plaintext.txt	104	Reversibility Inhibition Reversibility inhibition monitored using modified version E1 E2 ori complex formation assay described
0.2327217.12730224.html.plaintext.txt	105	E2 23 ng microl mixed inhibitor assay buffer concentration equal greater IC50
0.2327217.12730224.html.plaintext.txt	106	The mixture diluted 19 fold combined E1 radiolabeled probe overall dilution inhibitor 32 fold
0.2327217.12730224.html.plaintext.txt	107	Controls without inhibitor run parallel used reference calculation inhibition
0.2327217.12730224.html.plaintext.txt	108	The final concentration E2 5 fold higher preincubation assays 10 versus 2 nM compensate significant decrease signal observed preincubation E2
0.2327217.12730224.html.plaintext.txt	109	Transient HPV DNA Replication Assay Transient HPV DNA replication performed described previously 20 33 34
0.2327217.12730224.html.plaintext.txt	110	Amount replicated HPV DNA pN9 quantified exposure STORM 860 PhosphorImager Amersham Biosciences normalized amplified E1 signal
0.2327217.12730224.html.plaintext.txt	111	When applicable inhibitors added culture medium transfection final concentration 1 Me2SO
0.2327217.12730224.html.plaintext.txt	112	Each compound concentration tested quadruplicate
0.2327217.12730224.html.plaintext.txt	113	Cellular DNA replication measured using colorimetric cell proliferation ELISA kit Roche Applied Science
0.2327217.12730224.html.plaintext.txt	114	Cellular E1 E2 Interaction Assay CHO K1 cells transfected using LipofectAMINE Roche Applied Science three plasmids encoding respectively E1 VP16 2
0.2327217.12730224.html.plaintext.txt	115	5 microg E2 250 ng SEAP reporter control minimal origin DNA replication HPV11 62
0.2327217.12730224.html.plaintext.txt	116	3 h post transfection cells treated trypsin seeded 96 well plates 20 x 103 cellswell
0.2327217.12730224.html.plaintext.txt	117	When applicable inhibitors added culture medium transfection final concentration 1 Me2SO
0.2327217.12730224.html.plaintext.txt	118	The amount SEAP culture medium measured chemiluminescence 48 h post transfection using Tropix Phospha Light System Applied Biosystems according instructions supplied manufacturer
0.2327217.12730224.html.plaintext.txt	119	Each condition performed duplicate typically varied less 10
0.2327217.12730224.html.plaintext.txt	120	As control specificity inhibitors also tested cells transfected two plasmids encoding respectively unrelated SEAP reporter 250 ng pGAL4 SEAP unrelated transactivator GAL4 VP16 2
0.2327217.12730224.html.plaintext.txt	121	5 microg pM3 VP16 Clontech composed GAL4 DNA binding domain fused activation domain VP16
0.2327217.12730224.html.plaintext.txt	122	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Identification Class Small Molecules That Inhibit Co operative Binding HPV11 E1 E2 Origin Cooperative binding E1 E2 viral origin essential step initiation HPV DNA replication
0.2327217.12730224.html.plaintext.txt	123	To identify inhibitors process high throughput screening assay developed measures binding E1 E2 33P radiolabeled origin DNA
0.2327217.12730224.html.plaintext.txt	124	Binding E1 origin probe detected immuno capture E1 DNA complexes using anti E1 antibody coupled scintillation proximity assay 34 beads Fig
0.2327217.12730224.html.plaintext.txt	125	Binding reactions performed presence excess unlabeled nonspecific competitor DNA ensure binding E1 origin probe dependent association E2
0.2327217.12730224.html.plaintext.txt	126	1B shows strong signal detected E1 E2 added reaction
0.2327217.12730224.html.plaintext.txt	127	This signal dependent association E1 E2 reduced background levels E39A amino acid substitution E2 abrogates E1 binding 36 38
0.2327217.12730224.html.plaintext.txt	128	In contrast I73A substitution affects primarily transactivation function E2 ability bind E1 37 38 little effect
0.2327217.12730224.html.plaintext.txt	129	View larger version 16K FIG
0.2327217.12730224.html.plaintext.txt	130	Assay measuring co operative binding E1 E2 origin
0.2327217.12730224.html.plaintext.txt	131	Diagram illustrating co operative binding E1 E2 33P radiolabeled DNA fragment containing minimal HPV11 origin DNA replication
0.2327217.12730224.html.plaintext.txt	132	E2 dependent binding E1 probe detected immunocapture E1 containing protein DNA complexes using anti E1 antibody E1 Ab coupled SPA beads
0.2327217.12730224.html.plaintext.txt	133	Bound radiolabeled DNA excites scintillant contained within beads
0.2327217.12730224.html.plaintext.txt	134	Bar graph representing signal measured countsmin obtained presence black bars absence white bars recombinant HPV11 E1 presence absence mock wild type WT HPV11 E2 similar E2 proteins bearing E39A I73A amino acid substitutions
0.2327217.12730224.html.plaintext.txt	135	Screening corporate compound collection assay yielded inhibitor 1 shown Fig
0.2327217.12730224.html.plaintext.txt	136	Modification inhibitor led potent compounds2 2 3 Fig
0.2327217.12730224.html.plaintext.txt	137	These three compounds inactive weakly active mechanistically related SPA measures binding SV40 large T antigen cognate origin Fig
0.2327217.12730224.html.plaintext.txt	138	2 demonstrating interfere scintillation proximity detection procedure bind promiscuously DNA protein
0.2327217.12730224.html.plaintext.txt	139	Inhibitors 1 3 also active E1 E2 HPV6 Fig
0.2327217.12730224.html.plaintext.txt	140	2 prevalent low risk anogenital type albeit 10 30 fold lower potency HPV11 proteins
0.2327217.12730224.html.plaintext.txt	141	View larger version 19K FIG
0.2327217.12730224.html.plaintext.txt	142	Inhibitors identified study
0.2327217.12730224.html.plaintext.txt	143	The figure shows chemical structure three related inhibitors different potencies
0.2327217.12730224.html.plaintext.txt	144	Compounds 1 2 racemic mixtures whereas compound 3 single enantiomer absolute configuration shown
0.2327217.12730224.html.plaintext.txt	145	The activities inhibitors various biochemical assays described text indicated structure
0.2327217.12730224.html.plaintext.txt	146	The E1 E2 Protein Interaction Is Target Inhibition Co operative binding E1 E2 DNA involves interaction proteins DNA
0.2327217.12730224.html.plaintext.txt	147	The inhibitors found inactive weakly active assays measure binding E2 DNA Fig
0.2327217.12730224.html.plaintext.txt	148	Compound 1 also inactive inhibiting helicase activity E1 IC50 100 microM
0.2327217.12730224.html.plaintext.txt	149	Hence class compounds affect binding either E1 E2 DNA
0.2327217.12730224.html.plaintext.txt	150	These results suggested E1 E2 protein interaction might target inhibition
0.2327217.12730224.html.plaintext.txt	151	This hypothesis tested using ELISA
0.2327217.12730224.html.plaintext.txt	152	The E2 protein used assay either purified baculovirus infected insect cells obtained vitro translation sources yielded similar results
0.2327217.12730224.html.plaintext.txt	153	Binding recombinant E1 immobilized E2 detected using anti E1 antiserum followed secondary antibody coupled horseradish peroxidase
0.2327217.12730224.html.plaintext.txt	154	3A signal dependent interaction E1 E2 reduced E39A substitution E2
0.2327217.12730224.html.plaintext.txt	155	As anticipated I73A substitution little effect
0.2327217.12730224.html.plaintext.txt	156	3 B C three compounds inhibited binding E1 E2 potency comparable measured E1 E2 ori complex formation assay
0.2327217.12730224.html.plaintext.txt	157	The compounds inhibited E1 E2 interaction regardless whether assay performed hexameric E1 purified baculovirus infected insect cells monomeric E1 made vitro translation data shown
0.2327217.12730224.html.plaintext.txt	158	Thus molecular target inhibitors E1 E2 protein interaction
0.2327217.12730224.html.plaintext.txt	159	View larger version 19K FIG
0.2327217.12730224.html.plaintext.txt	160	ELISA demonstrating inhibition E1 E2 protein interaction inhibitors 1 3
0.2327217.12730224.html.plaintext.txt	161	A validation ELISA mutated E2 proteins produced vitro translation
0.2327217.12730224.html.plaintext.txt	162	The bar graph indicates signal obtained presence black bars absence white bars recombinant E1 presence absence wild type WT E2 similar E2 protein bearing E39A I73A amino acid substitution
0.2327217.12730224.html.plaintext.txt	163	ELISA performed A except purified wild type HPV11 E2 60 ngwell used place vitro translated protein
0.2327217.12730224.html.plaintext.txt	164	Inhibitory activity tested series 2 fold dilutions compounds 1 circles 2 squares 3 triangles
0.2327217.12730224.html.plaintext.txt	165	C IC50 values determined nonlinear regression data B
0.2327217.12730224.html.plaintext.txt	166	Inhibitors Bind Transactivation Domain E2 Having found inhibitor 1 derivatives antagonize E1 E2 protein interaction wished determine protein compounds binding
0.2327217.12730224.html.plaintext.txt	167	First investigated whether addition compound 2 effect spectroscopic behavior either E1 E2
0.2327217.12730224.html.plaintext.txt	168	Fluorescent amino acids tryptophan often found close binding pockets binding ligands sites shown perturb protein fluorescence cases 39
0.2327217.12730224.html.plaintext.txt	169	Compound 2 titrated solutions 400 nM E1 E2 Fig
0.2327217.12730224.html.plaintext.txt	170	Although slight effect observed fluorescence E1 much greater level quenching observed E2 consistent compound binding E2
0.2327217.12730224.html.plaintext.txt	171	The slight effect observed E1 lack saturation E2 high compound concentrations could explained weak nonspecific binding compound 2 protein sites reminiscent low level activity observed SV40 T antigen DNA binding assay Fig
0.2327217.12730224.html.plaintext.txt	172	View larger version 44K FIG
0.2327217.12730224.html.plaintext.txt	173	Effect compound 2 protein fluorescence
0.2327217.12730224.html.plaintext.txt	174	Fluorescence emission spectra purified polyhistidine tagged HPV11 E1 A HPV11 E2 B GST HPV11 E2 TAD C GST D obtained addition 0 microM diamonds 0
0.2327217.12730224.html.plaintext.txt	175	2 microM crosses inhibitor 2
0.2327217.12730224.html.plaintext.txt	176	Fluorescence intensity shown relative rhodamine B standard used compensate variation lamp intensity
0.2327217.12730224.html.plaintext.txt	177	The insets show proportional decrease fluorescence function compound concentration calculated average intensity values recorded 330 340 nm
0.2327217.12730224.html.plaintext.txt	178	E2 divided N terminal transactivation domain TAD approximately amino acids 1 200 C terminal DNA bindingdimerization domain DBD last 100 amino acids separated 50 70 amino acid hinge little predicted secondary structure 9
0.2327217.12730224.html.plaintext.txt	179	Because HPV11 known TAD DBD interacts E1 16 40 repeated titration GST fusion protein encoding E2 TAD well GST negative control Fig
0.2327217.12730224.html.plaintext.txt	180	The results clearly indicated saturable binding 2 GST TAD GST indicating compound binds TAD
0.2327217.12730224.html.plaintext.txt	181	Similar results also obtained polyhistidine tagged version E2 TAD data shown
0.2327217.12730224.html.plaintext.txt	182	Next quantified binding inhibitor 2 polyhistidine tagged TAD using isothermal titration calorimetry Fig
0.2327217.12730224.html.plaintext.txt	183	A dissociation constant 230 nM obtained nonlinear regression good agreement IC50 obtained E1 E2 ori complex formation assay
0.2327217.12730224.html.plaintext.txt	184	The observed 21 stoichiometry consistent formation 11 inhibitor protein complex compound 2 racemic observed compounds series one two enantiomers active see
0.2327217.12730224.html.plaintext.txt	185	3 Collectively results presented provide strong evidence class inhibitor antagonizes E1 E2 protein interaction binding E2 TAD
0.2327217.12730224.html.plaintext.txt	186	View larger version 21K FIG
0.2327217.12730224.html.plaintext.txt	187	Determination affinity inhibitor 2 E2 TAD calorimetry
0.2327217.12730224.html.plaintext.txt	188	Top raw data obtained 25 degrees C injections inhibitor 2 200 microM sample cell containing His tagged HPV11 E2 TAD 10 microM
0.2327217.12730224.html.plaintext.txt	189	Bottom calculated enthalpies squares subtraction heat dilution determined later injections
0.2327217.12730224.html.plaintext.txt	190	Data fit simple one binding site model give Ka 4
0.2327217.12730224.html.plaintext.txt	191	07 kcalmol stoichiometry 2
0.2327217.12730224.html.plaintext.txt	192	This stoichiometry consistent 11 TAD inhibitor binding ratio active enantiomer compound 2 racemic mixture
0.2327217.12730224.html.plaintext.txt	193	Functional Evidence That E2 TAD Is Target Inhibition During course study found vitro translated CRPV E2 bind co operatively purified HPV11 E1 either HPV11 CRPV origins albeit weakly
0.2327217.12730224.html.plaintext.txt	194	CRPV E2 however found resistant inhibition compound 2 Fig
0.2327217.12730224.html.plaintext.txt	195	6 perhaps surprisingly given low level amino acid identity TAD HPV11 CRPV
0.2327217.12730224.html.plaintext.txt	196	Similarly found inhibitors inactive E2 protein high risk HPV types 16 18 31 data shown amino acid level 41 50 identical HPV11 E2
0.2327217.12730224.html.plaintext.txt	197	We made use observation E2 types resistant inhibition substantiate finding TAD indeed target inhibitors
0.2327217.12730224.html.plaintext.txt	198	Specifically constructed chimeric E2 proteins encoding HPV11 TAD hinge DNA binding domain CRPV opposite combination
0.2327217.12730224.html.plaintext.txt	199	These chimeras expressed vitro tested E1 E2 ori complex formation assay using HPV11 E1
0.2327217.12730224.html.plaintext.txt	200	Both chimeras could bind co operatively E1 origin one containing TAD HPV11 sensitive inhibition compound 2 Fig
0.2327217.12730224.html.plaintext.txt	201	This result provides functional evidence TAD indeed target inhibition
0.2327217.12730224.html.plaintext.txt	202	Inhibition Is Reversible It generally expected difficult identify inhibitors protein interactions act reversible binding rather reacting target protein irreversible mechanism 27
0.2327217.12730224.html.plaintext.txt	203	To determine whether inhibition E1 E2 ori complex formation reversible performed preincubation experiment shown Fig
0.2327217.12730224.html.plaintext.txt	204	In experiment E2 target protein incubated high concentration inhibitor diluted E1 E2 ori complex formation assay final compound concentration 10 fold IC50
0.2327217.12730224.html.plaintext.txt	205	We reasoned inhibitor acting reversible mechanism activity E2 recovered upon dilution inhibitor
0.2327217.12730224.html.plaintext.txt	206	However mechanism inhibition irreversible significant inhibition observed even dilution
0.2327217.12730224.html.plaintext.txt	207	As control used known reactive electrophile 4 fluoro 7 nitro 213 benzoxadiazole
0.2327217.12730224.html.plaintext.txt	208	Preincubation compound resulted significant inhibition even dilution concentration well IC50
0.2327217.12730224.html.plaintext.txt	209	In contrast preincubation E2 compound 2 lead significant inhibition upon dilution compare 3rd bar 1st 2nd bars left Fig
0.2327217.12730224.html.plaintext.txt	210	Thus compound 2 acts reversible mechanism
0.2327217.12730224.html.plaintext.txt	211	View larger version 17K FIG
0.2327217.12730224.html.plaintext.txt	212	Effect compound preincubation E1 E2 ori complex formation
0.2327217.12730224.html.plaintext.txt	213	E2 mixed indicated concentration inhibitor 2 4 fluoro 7 nitrobenzofurazan positive control
0.2327217.12730224.html.plaintext.txt	214	After 1 h room temperature mixture diluted assay final concentration compound 32 fold lower preincubation
0.2327217.12730224.html.plaintext.txt	215	In parallel assays run without preincubation standard assay procedure either high low concentration compound
0.2327217.12730224.html.plaintext.txt	216	Error bars indicate standard error based 12 24 reactions absence 4 8 reactions presence compound
0.2327217.12730224.html.plaintext.txt	217	Inhibition HPV11 DNA Replication Transiently Transfected Cells Next wished determine whether potent inhibitor compound 3 would able inhibit HPV DNA replication transiently transfected cells
0.2327217.12730224.html.plaintext.txt	218	In assay plasmids expressing HPV11 E1 E2 transfected Chinese hamster ovary cells along plasmid carrying HPV11 minimal origin DNA replication
0.2327217.12730224.html.plaintext.txt	219	Transfected cells incubated increasing concentrations compound 3 ranging 0
0.2327217.12730224.html.plaintext.txt	220	195 25 microM amount replicated DNA DpnI resistant quantified PCR 48 h post transfection
0.2327217.12730224.html.plaintext.txt	221	As control specificity tested parallel effect compound cellular DNA replication measured BrdUrd incorporation
0.2327217.12730224.html.plaintext.txt	222	8 shows compound 3 able inhibit HPV DNA replication dose dependent manner 50 inhibitory concentration 1 microM
0.2327217.12730224.html.plaintext.txt	223	In contrast cellular DNA replication BrdUrd incorporation largely unaffected concentration inhibitor 12
0.2327217.12730224.html.plaintext.txt	224	The inhibition BrdUrd incorporation seen two highest inhibitor concentrations likely due cytotoxicity compound rather specific inhibition cellular DNA replication
0.2327217.12730224.html.plaintext.txt	225	View larger version 36K FIG
0.2327217.12730224.html.plaintext.txt	226	Inhibition HPV11 DNA replication compound 3
0.2327217.12730224.html.plaintext.txt	227	The amount replicated origin DNA measured PCR DpnI digested genomic DNA isolated 48 h post transfection cells transected three plasmids encoding respectively E1 E2 origin
0.2327217.12730224.html.plaintext.txt	228	A portion E1 expressing plasmid devoid DpnI site amplified internal control
0.2327217.12730224.html.plaintext.txt	229	A E1 origin Ori PCR products obtained transfected cells incubated indicated amount inhibitor 3 analyzed 1 agarose gel stained fluorescent dye SYBRGreen I Molecular Probes
0.2327217.12730224.html.plaintext.txt	230	Each inhibitor concentration tested quadruplicate
0.2327217.12730224.html.plaintext.txt	231	As negative control four transfections performed absence E2 expression plasmid No E2
0.2327217.12730224.html.plaintext.txt	232	B graph indicating amount cellular DNA replication measured BrdUrd incorporation white circles HPV DNA replication black circles obtained data A different concentrations inhibitor 3
0.2327217.12730224.html.plaintext.txt	233	The intensity HPV origin fragments shown A quantified using Storm PhosphorImager Amersham Biosciences
0.2327217.12730224.html.plaintext.txt	234	Each value average four replicates standard deviation indicated
0.2327217.12730224.html.plaintext.txt	235	BrdUrd incorporation HPV DNA replication values presented percentage control activity obtained absence inhibitors set arbitrarily 100
0.2327217.12730224.html.plaintext.txt	236	Data fit non linear regression determine compound 3 inhibits HPV DNA replication IC50 value 1 microM
0.2327217.12730224.html.plaintext.txt	237	Inhibition E1 E2 Protein Interaction Vivo To ascertain mechanism action inhibitors vivo established cellular assay measures interaction HPV11 E1 E2
0.2327217.12730224.html.plaintext.txt	238	Specifically assay measures expression SEAP reporter gene placed control HPV11 minimal origin replication upon co transfection two plasmids encoding respectively E2 E1 protein fused strong transactivation domain HSV VP16 Fig
0.2327217.12730224.html.plaintext.txt	239	In assay neither E2 E1 VP16 could activate expression reporter gene Fig
0.2327217.12730224.html.plaintext.txt	240	The lack transactivation E2 consistent previous observation E2 low risk HPV types weak transactivators 41
0.2327217.12730224.html.plaintext.txt	241	Maximal expression reporter gene dependent expression E1 VP16 E2 interaction greatly reduced E39A substitution E2 affects E1 binding Fig
0.2327217.12730224.html.plaintext.txt	242	As expected I73A substitution E2 negative effect
0.2327217.12730224.html.plaintext.txt	243	View larger version 19K FIG
0.2327217.12730224.html.plaintext.txt	244	Cellular assay monitor E1 E2 interaction origin vivo
0.2327217.12730224.html.plaintext.txt	245	The diagram shows SEAP reporter transcriptional control HPV11 minimal origin DNA replication
0.2327217.12730224.html.plaintext.txt	246	The three E2 binding sites origin shown black boxes
0.2327217.12730224.html.plaintext.txt	247	In assay transient expression E2 white ellipse E1 black ellipse fused transcriptional activation TA domain HSV VP16 dotted ellipse results transactivation reporter gene expression SEAP
0.2327217.12730224.html.plaintext.txt	248	Bar graph indicating amount SEAP maximal E1 VP16 E2 co expressed
0.2327217.12730224.html.plaintext.txt	249	This high level SEAP reduced E39A substitution E2 I73A substitution suggesting SEAP expression dependent interaction E1 E2
0.2327217.12730224.html.plaintext.txt	250	Little SEAP activity obtained E1 fused VP16 activation domain data shown
0.2327217.12730224.html.plaintext.txt	251	Having confirmed expression reporter gene dependent interaction E1 E2 tested effect compounds 2 3 assay similar one based E1 E2 HPV6
0.2327217.12730224.html.plaintext.txt	252	Compounds 2 3 inhibited SEAP synthesis induced HPV11 proteins IC50 values 14 2 microM respectively Fig
0.2327217.12730224.html.plaintext.txt	253	The similar potency compound 3 reporter transient HPV DNA replication assays suggests inhibitory activity viral DNA replication indeed due abrogation E1 E2 protein interaction
0.2327217.12730224.html.plaintext.txt	254	Inhibitors 2 3 also found active HPV6 proteins albeit reduced potency IC50 values 22 6 microM respectively
0.2327217.12730224.html.plaintext.txt	255	Interestingly difference potency HPV11 HPV6 protein 4 7 fold cellular assay compared 25 30 fold vitro Fig
0.2327217.12730224.html.plaintext.txt	256	The exact reason smaller difference potency HPV6 HPV11 proteins vivo currently unknown could related slight alterations conformation E2 vivo compared vitro see Discussion
0.2327217.12730224.html.plaintext.txt	257	As control specificity verified inhibitors little effect expression unrelated SEAP reporter transactivated GAL4 VP16 fusion protein Fig
0.2327217.12730224.html.plaintext.txt	258	As additional control specificity showed enantiomer inhibitor 3 nearly inactive vitro IC50 29 microM E1 E2 ori complex formation assay also inactive cellular assay data shown
0.2327217.12730224.html.plaintext.txt	259	View larger version 21K FIG
0.2327217.12730224.html.plaintext.txt	260	Effect inhibitors 2 3 E1 E2 interaction vivo
0.2327217.12730224.html.plaintext.txt	261	The graph shows amount SEAP activity measured presence increasing amounts inhibitor 2 A inhibitor 3 B
0.2327217.12730224.html.plaintext.txt	262	Levels SEAP activity reported percentage control activity measured absence inhibitor set arbitrarily 100
0.2327217.12730224.html.plaintext.txt	263	Levels SEAP activity expressed ori SEAP reporter upon expression HPV11 E2 HPV11 E1 VP16 shown black circles using wild type E2 white squares using E100A E2 mutant hypersensitive inhibitors
0.2327217.12730224.html.plaintext.txt	264	Levels SEAP expressed reporter upon expression HPV6 E2 HPV6 E1 VP16 shown white triangles
0.2327217.12730224.html.plaintext.txt	265	As control specificity inhibitors tested unrelated SEAP reporter gene black triangles transactivated fusion protein composed yeast GAL4 protein DNA binding domain fused VP16 transactivation domain
0.2327217.12730224.html.plaintext.txt	266	Lines represent best fits data logistic determined nonlinear regression
0.2327217.12730224.html.plaintext.txt	267	C IC50 values determined nonlinear regression data A B
0.2327217.12730224.html.plaintext.txt	268	To gain additional evidence inhibitors acting vivo mechanism vitro made use mutant E2 protein higher affinity class inhibitors
0.2327217.12730224.html.plaintext.txt	269	This mutant protein contains single amino substitution TAD E100A makes 10 fold sensitive class inhibitors wild type E2 vitro E1 E2 ori complex formation assay
0.2327217.12730224.html.plaintext.txt	270	The E100A substitution discovered mutational analysis E2 TAD aimed identifying residues involved compound binding data shown
0.2327217.12730224.html.plaintext.txt	271	Importantly amino acid substitution also increased sensitivity E2 reporter assay Fig
0.2327217.12730224.html.plaintext.txt	272	This result provides strong evidence mechanism action class inhibitors vivo vitro
0.2327217.12730224.html.plaintext.txt	273	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Discovery Inhibitors E1 E2 Interaction In work presented identification first small molecule inhibitors E1 E2 protein interaction capable inhibiting HPV DNA replication vivo
0.2327217.12730224.html.plaintext.txt	274	We shown two independent biophysical methods changes intrinsic protein fluorescence isothermal titration calorimetry compounds 1 3 bind transactivation domain E2
0.2327217.12730224.html.plaintext.txt	275	Functional evidence binding E2 TAD also obtained swapping domain sensitive E2 type HPV11 resistant one CRPV well identifying amino acid within TAD E100A increases inhibition 10 fold vitro
0.2327217.12730224.html.plaintext.txt	276	The discovery inhibitors E1 E2 protein interaction HPV types 6 11 highlights potential E2 drug target treatment anogenital warts
0.2327217.12730224.html.plaintext.txt	277	The genome HPV6 HPV11 present episomal form 90 genital warts 42 43 inhibition E1 E2 interaction expected provide therapeutic benefits 44
0.2327217.12730224.html.plaintext.txt	278	In respect worth noting E1 E2 likely expressed much lower levels natural infections transfected cells fact could lead us underestimate true potency inhibitors
0.2327217.12730224.html.plaintext.txt	279	Determining real antiviral activity inhibitors awaits development straightforward quantitative HPV viral replication assay
0.2327217.12730224.html.plaintext.txt	280	Specificity Inhibition The inhibitors presented study active E2 protein two prevalent low risk HPV types 6 11 nevertheless potent HPV11 protein 10 40 fold vitro
0.2327217.12730224.html.plaintext.txt	281	This difference potency observed purified proteins proteins produced vitro translation
0.2327217.12730224.html.plaintext.txt	282	Because found evidence HPV6 E1 E2 interacts strongly HPV11 proteins data shown surmise inhibitors must bind less tightly HPV6 E2
0.2327217.12730224.html.plaintext.txt	283	The HPV6 HPV11 TAD 84 identical primary amino acid sequence levels amino acid differences combinations thereof could affect binding inhibitor
0.2327217.12730224.html.plaintext.txt	284	Surprisingly found difference potency observed cellular assays less pronounced
0.2327217.12730224.html.plaintext.txt	285	Indeed difference IC50 values 3 fold transient HPV DNA replication assay
0.2327217.12730224.html.plaintext.txt	286	3 This reduced difference type 6 11 also observed E1 E2 interaction reporter gene assay suggesting class compound indeed inhibit E1 E2 interaction HPV types comparable potency cells
0.2327217.12730224.html.plaintext.txt	287	It possible conformational change necessary inhibitor binding similar energetic cost HPV types vivo vitro perhaps conformation E2 vivo slightly different result interaction cellular proteins
0.2327217.12730224.html.plaintext.txt	288	Further studies required address possibility
0.2327217.12730224.html.plaintext.txt	289	Amino Acids E2 Involved Inhibition Prior report 15 amino acid peptide derived HPV16 E2 spanning residue Glu 39 shown capable inhibiting E1 E2 interaction vitro 45
0.2327217.12730224.html.plaintext.txt	290	Several studies suggested essential role Glu 39 interaction E1
0.2327217.12730224.html.plaintext.txt	291	Specifically changing residue alanine shown abrogate ability E2 bind E1 36 38 confirmed study little effect transcriptional activity
0.2327217.12730224.html.plaintext.txt	292	These findings suggested Glu 39 might form part E1 binding surface E2
0.2327217.12730224.html.plaintext.txt	293	Two lines evidence suggest inhibitors may bind near Glu 39 antagonize E1 E2 interaction
0.2327217.12730224.html.plaintext.txt	294	First Glu 100 residue changed alanine increases sensitivity HPV11 E2 inhibitors located surface Glu 39 crystal structure HPV16 E2 TAD 46
0.2327217.12730224.html.plaintext.txt	295	Second found inhibitors bind reduced affinity E39A mutant E2 TAD fluorescence studies similar presented Fig
0.2327217.12730224.html.plaintext.txt	296	The simplest interpretation results surface E2 TAD onto Glu 39 Glu 100 located involved binding E1 inhibitors
0.2327217.12730224.html.plaintext.txt	297	Because inhibitors inactive HPV16 E2 attempt model published structure HPV16 E2 TAD
0.2327217.12730224.html.plaintext.txt	298	However studies progress localize inhibitor binding pocket HPV11 E2 TAD
0.2327217.12730224.html.plaintext.txt	299	Protein Interactions Drug Targets The compounds presented belong relatively small group small molecules effectively inhibit protein interactions
0.2327217.12730224.html.plaintext.txt	300	With exceptions protein interaction inhibitors identified cases binding surface one protein known small contiguous region receptor ligand interactions 47 48
0.2327217.12730224.html.plaintext.txt	301	Many small molecules reported inhibit protein interactions peptides identified either screening procedures phage display panels overlapping peptides based protein sequence selected based results structural mutational studies 49
0.2327217.12730224.html.plaintext.txt	302	Most peptides relatively weak inhibitors although principle serve lead compounds drug discovery practice transformation molecules potent non peptidic inhibitors quite challenging
0.2327217.12730224.html.plaintext.txt	303	A variety reasons proposed relatively low number small molecule inhibitors protein interactions
0.2327217.12730224.html.plaintext.txt	304	One small molecules would difficulty competing large surface area typically involved protein protein interface
0.2327217.12730224.html.plaintext.txt	305	However shown number cases e
0.2327217.12730224.html.plaintext.txt	306	50 substitution single critical residue interface conceptually analogous tight binding small molecule sufficient greatly weaken interaction
0.2327217.12730224.html.plaintext.txt	307	An example may E39A substitution E2 argued may abrogate E1 binding located E1 E2 interface
0.2327217.12730224.html.plaintext.txt	308	A second reason protein interactions thought difficult targets small molecules interfaces fairly flat devoid concave pockets analogous enzyme active sites receptor binding sites 51
0.2327217.12730224.html.plaintext.txt	309	Although true complexes others found bumpy small cavities often present 52 53
0.2327217.12730224.html.plaintext.txt	310	Perhaps relatively protein interaction inhibitors identified date effort devoted traditional targets enzymes receptors
0.2327217.12730224.html.plaintext.txt	311	We fact succeeded identifying potent small molecule inhibitors E1 E2 interaction high throughput screening
0.2327217.12730224.html.plaintext.txt	312	This strongly suggests investigations also yield novel small molecule inhibitors protein interactions drug candidates
0.2327217.12730224.html.plaintext.txt	313	FOOTNOTES The costs publication article defrayed part payment page charges
0.2327217.12730224.html.plaintext.txt	314	This article must therefore hereby marked advertisement accordance 18 U
0.2327217.12730224.html.plaintext.txt	315	Section 1734 solely indicate fact
0.2327217.12730224.html.plaintext.txt	316	To correspondence addressed Dept
0.2327217.12730224.html.plaintext.txt	317	Biological Sciences Boehringer Ingelheim Ltd
0.2327217.12730224.html.plaintext.txt	318	450 682 4640 Fax 450 682 4642 E mail jarchambaultatlav
0.2327217.12730224.html.plaintext.txt	319	1 The abbreviations used HPV human papillomavirus TAD transactivation domain CRPV cottontail rabbit papillomavirus HSV herpes simplex virus SV40 simian virus 40 GST glutathione S transferase SPA scintillation proximity assay SEAP secreted alkaline phosphatase ELISA enzyme linked immunosorbent assay DBD DNA binding domain TCEP tris2 carboxyethylphosphine BrdUrd 5 bromo 2 deoxyuridine PBS phosphate buffered saline ori origin
0.2327217.12730224.html.plaintext.txt	320	White submitted publication
0.2327217.12730224.html.plaintext.txt	321	ACKNOWLEDGMENTS We thank Drs
0.2327217.12730224.html.plaintext.txt	322	Craig Fenwick Steven Mason critical reading manuscript
0.2327217.12730224.html.plaintext.txt	323	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Chow L
0.2327217.12730224.html.plaintext.txt	324	1997 Viral Pathogenesis Nathanson N
0.2327217.12730224.html.plaintext.txt	325	267 301 Lippincott Raven Publishers Philadelphia Howley P
0.2327217.12730224.html.plaintext.txt	326	1996 Fields Virology Fields B
0.2327217.12730224.html.plaintext.txt	327	2045 2076 Raven Press Ltd
0.2327217.12730224.html.plaintext.txt	328	1996 Fields Virology Fields B
0.2327217.12730224.html.plaintext.txt	329	2077 2109 Raven Press Ltd
0.2327217.12730224.html.plaintext.txt	330	48 427 447CrossRefMedline Order article via Infotrieve Beutner K
0.2327217.12730224.html.plaintext.txt	331	102 28 37Medline Order article via Infotrieve Beutner K
0.2327217.12730224.html.plaintext.txt	332	42 789 794AbstractFree Full Text Stubenrauch F
0.2327217.12730224.html.plaintext.txt	333	9 379 386CrossRefMedline Order article via Infotrieve Sverdrup F
0.2327217.12730224.html.plaintext.txt	334	1997 Human Papillomaviruses Myers G
0.2327217.12730224.html.plaintext.txt	335	37 53 Los Alamos National Laboratory Los Alamos NM McBride A
0.2327217.12730224.html.plaintext.txt	336	1997 Human Papillomaviruses Myers G
0.2327217.12730224.html.plaintext.txt	337	54 73 Los Alamos National Laboratory Los Alamos NM Chow L
0.2327217.12730224.html.plaintext.txt	338	1994 Intervirology 37 150 158Medline Order article via Infotrieve Yang L
0.2327217.12730224.html.plaintext.txt	339	1991 Nature 353 628 633CrossRefMedline Order article via Infotrieve Seo Y
0.2327217.12730224.html.plaintext.txt	340	90 2865 2869Abstract Sedman J
0.2327217.12730224.html.plaintext.txt	341	14 6218 6228Abstract Sedman T
0.2327217.12730224.html.plaintext.txt	342	71 2887 2896Abstract Benson J
0.2327217.12730224.html.plaintext.txt	343	69 4364 4372Abstract Berg M
0.2327217.12730224.html.plaintext.txt	344	71 3853 3863Abstract Masterson P
0.2327217.12730224.html.plaintext.txt	345	72 7407 7419AbstractFree Full Text Mohr I
0.2327217.12730224.html.plaintext.txt	346	1990 Science 250 1694 1699Medline Order article via Infotrieve Sarafi T
0.2327217.12730224.html.plaintext.txt	347	1995 Virology 211 385 396CrossRefMedline Order article via Infotrieve Titolo S
0.2327217.12730224.html.plaintext.txt	348	73 5282 5293AbstractFree Full Text Yasugi T
0.2327217.12730224.html.plaintext.txt	349	71 891 899Abstract Zou N
0.2327217.12730224.html.plaintext.txt	350	72 3436 3441AbstractFree Full Text Lusky M
0.2327217.12730224.html.plaintext.txt	351	91 8895 8899Abstract Sanders C
0.2327217.12730224.html.plaintext.txt	352	17 7044 7055AbstractFree Full Text Fouts E
0.2327217.12730224.html.plaintext.txt	353	274 4447 4458AbstractFree Full Text Sedman J
0.2327217.12730224.html.plaintext.txt	354	72 6893 6897AbstractFree Full Text Way J
0.2327217.12730224.html.plaintext.txt	355	4 40 46CrossRefMedline Order article via Infotrieve Gadek T
0.2327217.12730224.html.plaintext.txt	356	65 1 8CrossRefMedline Order article via Infotrieve Darveau A
0.2327217.12730224.html.plaintext.txt	357	1985 Virology 144 88 100Medline Order article via Infotrieve White P
0.2327217.12730224.html.plaintext.txt	358	276 22426 22438AbstractFree Full Text Gurney E
0.2327217.12730224.html.plaintext.txt	359	34 752 763Medline Order article via Infotrieve Titolo S
0.2327217.12730224.html.plaintext.txt	360	74 7349 73461AbstractFree Full Text Titolo S
0.2327217.12730224.html.plaintext.txt	361	77 5178 5191AbstractFree Full Text Udenfriend S
0.2327217.12730224.html.plaintext.txt	362	161 494 500Medline Order article via Infotrieve Cooper C
0.2327217.12730224.html.plaintext.txt	363	1998 Virology 241 312 322CrossRefMedline Order article via Infotrieve Ferguson M
0.2327217.12730224.html.plaintext.txt	364	70 4193 4199Abstract Sakai H
0.2327217.12730224.html.plaintext.txt	365	70 1602 1611Abstract Eftink M
0.2327217.12730224.html.plaintext.txt	366	278 221 257CrossRefMedline Order article via Infotrieve Sanders C
0.2327217.12730224.html.plaintext.txt	367	276 23689 23699AbstractFree Full Text Kovelman R
0.2327217.12730224.html.plaintext.txt	368	70 7549 7560Abstract Gissmann L
0.2327217.12730224.html.plaintext.txt	369	80 560 563Abstract Brown D
0.2327217.12730224.html.plaintext.txt	370	31 2667 2673Abstract Phelps W
0.2327217.12730224.html.plaintext.txt	371	9 359 377Medline Order article via Infotrieve Kasukawa H
0.2327217.12730224.html.plaintext.txt	372	72 8166 8173AbstractFree Full Text Antson A
0.2327217.12730224.html.plaintext.txt	373	2000 Nature 403 805 809CrossRefMedline Order article via Infotrieve Cochran A
0.2327217.12730224.html.plaintext.txt	374	7 R85 R94CrossRefMedline Order article via Infotrieve Cochran A
0.2327217.12730224.html.plaintext.txt	375	5 654 659CrossRefMedline Order article via Infotrieve Zutshi R
0.2327217.12730224.html.plaintext.txt	376	2 62 66CrossRefMedline Order article via Infotrieve Cunningham B
0.2327217.12730224.html.plaintext.txt	377	234 554 563CrossRefMedline Order article via Infotrieve Janin J
0.2327217.12730224.html.plaintext.txt	378	265 16027 16030Free Full Text Argos P
0.2327217.12730224.html.plaintext.txt	379	2 101 113Abstract Hubbard S
0.2327217.12730224.html.plaintext.txt	380	3 2194 2206AbstractFree Full Text
0.1914435.10846215.html.plaintext.txt	0	Tripartite haemolysin BL isolation characterization two distinct homologous sets components single Bacillus cereus isolate Douglas J
0.1914435.10846215.html.plaintext.txt	1	Food Research Institute Department Food Microbiology Toxicology University Wisconsin Madison 1925 Willow Drive Madison WI 53706 USA1
0.1914435.10846215.html.plaintext.txt	2	Author correspondence Douglas J
0.1914435.10846215.html.plaintext.txt	3	Tel 1 608 263 6939 Fax 1 608 263 1114
0.1914435.10846215.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Haemolysin BL HBL three component enterotoxicnecrotizingvascular permeability toxin likely virulence factor Bacillus cereus diarrhoeal food poisoning necrotic infections
0.1914435.10846215.html.plaintext.txt	5	This paper describes isolation two distinct homologous sets three HBL components single B
0.1914435.10846215.html.plaintext.txt	6	The proteins one set designated HBL consisting B L1 L2 87 100 identical N terminal amino acid sequences respective prototype components strain F83776 proteins homologous set HBLa consisting Ba L1a L2a 62 65 identical
0.1914435.10846215.html.plaintext.txt	7	Only latter homologues differed immunochemically physicochemically prototypes
0.1914435.10846215.html.plaintext.txt	8	HBL HBLa exhibited similar haemolytic vascular permeability potencies homologues could interchanged freely
0.1914435.10846215.html.plaintext.txt	9	There notable differences activity L component homologues
0.1914435.10846215.html.plaintext.txt	10	However components B Ba significantly different
0.1914435.10846215.html.plaintext.txt	11	Both secreted monomers unlike B Ba isolated relatively inactive complex could reactivated urea
0.1914435.10846215.html.plaintext.txt	12	When Ba substituted B gel diffusion assays distinct discontinuous haemolysis pattern typical presence B occur
0.1914435.10846215.html.plaintext.txt	13	In suspension assays excess B inhibited haemolysis B primed cells L1 previously described Ba primed cells
0.1914435.10846215.html.plaintext.txt	14	Excess Ba opposite effect enhanced lysis Ba primed cells B primed cells
0.1914435.10846215.html.plaintext.txt	15	These differences reveal details toxin components interact target cell membranes
0.1914435.10846215.html.plaintext.txt	16	The authors observations indicate HBL represents new family multicomponent toxins generated process gene operon duplication occurred either intracellularly horizontal transfer raise possibility existence related toxins genetically diverse B
0.1914435.10846215.html.plaintext.txt	17	Keywords Bacillus cereus hemolysin BL enterotoxin gene duplication discontinuous hemolysis
0.1914435.10846215.html.plaintext.txt	18	Abbreviations BCA bicinchoninic acid HA hydroxyapatite HBL haemolysin BL TBS Tris buffered saline
0.1914435.10846215.html.plaintext.txt	19	INTRODUCTION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Bacillus cereus ubiquitous soil borne bacterium appropriate circumstances causes diarrhoeal emetic food poisoning variety typically necrotic non gastrointestinal infections Drobniewski 1993 Kramer Gilbert 1989 Turnbull 1986
0.1914435.10846215.html.plaintext.txt	20	Among many potential virulence factors B
0.1914435.10846215.html.plaintext.txt	21	cereus haemolysin BL HBL unique potent three component pore forming toxin Beecher Macmillan 1991 Beecher Wong 1994c Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	22	The toxic activities far identified HBL include haemolysis vascular permeability necrosis rabbit skin Beecher Macmillan 1991 Beecher Wong 1994c fluid accumulation rabbit ileal loops Beecher et al
0.1914435.10846215.html.plaintext.txt	23	1995b toxicity number transformed cell lines Beecher 1990 vitro degradation explanted rabbit retinal tissue vivo ocular necrosis inflammation rabbits Beecher et al
0.1914435.10846215.html.plaintext.txt	24	HBL secreted 45 200 B
0.1914435.10846215.html.plaintext.txt	25	mycoides isolates tested laboratory Beecher Wong 1994b Schoeni Wong 1999
0.1914435.10846215.html.plaintext.txt	26	A distinctive feature HBL unusual discontinuous haemolysis pattern produced blood agar Beecher Macmillan 1991 Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	27	When HBL diffuses bacterial colony well blood agar lysis begins away well colony followed slow lysis nearer source
0.1914435.10846215.html.plaintext.txt	28	cereus strain F83776 three HBL components encoded operon tandemly arranged genes order hblC hblD hblA respectively encode components designated L2 L1 B Heinrichs et al
0.1914435.10846215.html.plaintext.txt	29	Immediately downstream hblA open reading frame hblB 85 identical hblA first 158 predicted amino acids
0.1914435.10846215.html.plaintext.txt	30	The hblB gene product yet isolated
0.1914435.10846215.html.plaintext.txt	31	Many isolates Bacillus collection produce one antigen reactive antibodies individual HBL components Schoeni Wong 1999
0.1914435.10846215.html.plaintext.txt	32	For example Western blots denaturing electrophoresis gels B
0.1914435.10846215.html.plaintext.txt	33	cereus MGBC 145 produces two bands reactive antibodies HBL components B L1 one band reactive antibodies component L2
0.1914435.10846215.html.plaintext.txt	34	This strain used studies experimental endophthalmitis laboratory others Beecher et al
0.1914435.10846215.html.plaintext.txt	35	Because production multiple toxin homologues might confound efforts characterize molecular basis B
0.1914435.10846215.html.plaintext.txt	36	cereus virulence intraocular infections decided characterize antigens responsible producing multiple bands Western blots
0.1914435.10846215.html.plaintext.txt	37	We isolated characterized two distinct homologous variants HBL component single B
0.1914435.10846215.html.plaintext.txt	38	cereus strain demonstrating variant antigens distinct gene products
0.1914435.10846215.html.plaintext.txt	39	The activities variants essentially prototype components homologues interchangeable requirement three components produce activity maintained
0.1914435.10846215.html.plaintext.txt	40	A homologue one component possessed several important differences details activity elucidate interactions components erythrocyte membranes
0.1914435.10846215.html.plaintext.txt	41	METHODS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Bacterial isolates
0.1914435.10846215.html.plaintext.txt	42	cereus strain MGBC 145 used source HBL homologues
0.1914435.10846215.html.plaintext.txt	43	This strain isolated infected eye patient post traumatic endophthalmitis Beecher et al
0.1914435.10846215.html.plaintext.txt	44	cereus strain F83776 isolate infected prostate used source prototype HBL components present study
0.1914435.10846215.html.plaintext.txt	45	This isolate originally chosen source HBL exceptionally toxigenic Beecher Macmillan 1990
0.1914435.10846215.html.plaintext.txt	46	Production crude haemolysin BL
0.1914435.10846215.html.plaintext.txt	47	cereus isolates grown 32 degrees C 5 h 3 litres caseinglucoseyeast extract broth shaking 200 r
0.1914435.10846215.html.plaintext.txt	48	The culture supernatants concentrated ammonium sulfate precipitation 50 ml
0.1914435.10846215.html.plaintext.txt	49	The concentrates used sources crude HBL
0.1914435.10846215.html.plaintext.txt	50	The culture medium growth conditions concentration procedure described detail elsewhere Beecher Wong 1994c
0.1914435.10846215.html.plaintext.txt	51	Details columns flow rates elution gradients etc
0.1914435.10846215.html.plaintext.txt	52	purification steps involving anion exchange Whatman DE 52 Pharmacia Mono Q hydroxyapatite HA chromatography previously described Beecher Wong 1994c following exceptions
0.1914435.10846215.html.plaintext.txt	53	The pH 5 9 Bistris anion exchange equilibration buffer 20 mM instead 25 mM HA Macro Prep ceramic HA 20 microm beads Bio Rad instead BioGel HTP
0.1914435.10846215.html.plaintext.txt	54	Salt concentrations fractions estimated assuming gradients linear began eluting one column volume started
0.1914435.10846215.html.plaintext.txt	55	Column volumes estimated empirically changes apparent absorbance eluate abrupt changes salt concentration
0.1914435.10846215.html.plaintext.txt	56	Three additional chromatographic steps used
0.1914435.10846215.html.plaintext.txt	57	First rather dialysis buffer exchange concentrated culture supernatant gel filtration chromatography 2 6x78 cm column medium grade Sephadex G 25 Pharmacia equilibrated 20 mM BistrisHCl pH 5 9 eluted flow rate 7 5 ml min 1
0.1914435.10846215.html.plaintext.txt	58	Second final isolation L1a component see nomenclature fractions pH 5 9 Mono Q column dialysed 25 mM TrisHCl pH 7 4 applied Mono Q column equilibrated buffer
0.1914435.10846215.html.plaintext.txt	59	Proteins eluted linear gradient NaCl 0 0 5 M 50 ml flow rate 1 ml min 1
0.1914435.10846215.html.plaintext.txt	60	Third isolation L2a nonbound DE 52 fraction containing L2a applied 1 ml 0 5x5 cm HA column compared 1 6x8 cm column usually used equilibrated 10 mM NaCl eluted 1 ml min 1 linear gradient sodium phosphate 0 0 3 M 30 ml collected 1 ml fractions
0.1914435.10846215.html.plaintext.txt	61	Concentrations purified proteins routinely determined measuring A280 using previously estimated absorption coefficients 1 mg ml 1 1 3 1 8 0 8 B L1 L2 strain F83776 respectively
0.1914435.10846215.html.plaintext.txt	62	Initial experiments suggested absorption coefficients B Ba may differ significantly
0.1914435.10846215.html.plaintext.txt	63	Thus homologue doses compared concentrations measured using bicinchoninic acid assay Pierce Chemical Co
0.1914435.10846215.html.plaintext.txt	64	components strain F83776 used concentration standards respective homologues
0.1914435.10846215.html.plaintext.txt	65	The BCA assay measures primarily peptide bonds rather aromatic amino acid residues thus decreasing protein protein variation
0.1914435.10846215.html.plaintext.txt	66	Assay HBL components sphingomyelinase
0.1914435.10846215.html.plaintext.txt	67	HBL components sphingomyelinase identified chromatography fractions immunochemically dot blots
0.1914435.10846215.html.plaintext.txt	68	The different B L1 homologues distinguished one another different apparent molecular masses Western blots
0.1914435.10846215.html.plaintext.txt	69	The L2 homologues identical size could distinguished widely different chromatographic behaviour
0.1914435.10846215.html.plaintext.txt	70	The antibodies procedures used immunoassays described previously Beecher et al
0.1914435.10846215.html.plaintext.txt	71	Electrophoresis protein blotting
0.1914435.10846215.html.plaintext.txt	72	PAGE performed using precast ReadyGels Bio Rad composed polyacrylamide Trisglycine buffer system using Mini Protean II dual slab electrophoresis cells Bio Rad
0.1914435.10846215.html.plaintext.txt	73	SDS gels Laemmli 1970 composed 12 polyacrylamide native gels Davis 1964 Ornstein 1964 composed 4 15 acrylamide gradients
0.1914435.10846215.html.plaintext.txt	74	The minigels stained Coomassie brilliant blue R 250 0 1 wv silver Nesterenko et al
0.1914435.10846215.html.plaintext.txt	75	1994 used protein blotting
0.1914435.10846215.html.plaintext.txt	76	The Pharmacia LMW Marker Kit used size standards phosphorylase b bovine serum albumin ovalbumin carbonic anhydrase lactalbumin
0.1914435.10846215.html.plaintext.txt	77	Proteins resolved SDS native PAGE gels transferred PVDF membranes Millipore Mini Trans Blot electrophoretic transfer cell Bio Rad 100 V constant voltage 1 h 1 25 h respectively
0.1914435.10846215.html.plaintext.txt	78	Isoelectric points determined PhastSystem Pharmacia using Pharmacia IEF standards Phastgel IEF gels pH ranges 3 9 4 6 5
0.1914435.10846215.html.plaintext.txt	79	All gels run 2000 V 2 mA 3 5 W 75 V h prior loading samples 200 V 2 mA 3 5 W 15 V h sample loading
0.1914435.10846215.html.plaintext.txt	80	Proteins focused 2000 V 5 mA 3 5 W 510 V h pH 3 9 gels 410 V h pH 4 6 5 gels
0.1914435.10846215.html.plaintext.txt	81	Purified proteins prepared N terminal sequence analysis described Matsudaira 1990
0.1914435.10846215.html.plaintext.txt	82	Electroblotted proteins sent ProteinNucleic Acid Shared Facility Cancer Center Medical College Wisconsin N terminal sequence analysis Edman degradation
0.1914435.10846215.html.plaintext.txt	83	Haemolysis assays gel diffusion
0.1914435.10846215.html.plaintext.txt	84	For haemolysis assays diffusion turbidimetric defibrinated sheep blood Crane Laboratories washed 50 mM TrisHCl 150 mM NaCl pH 7 4 TBS prior use
0.1914435.10846215.html.plaintext.txt	85	Gel diffusion assays haemolysin BL described previously Beecher 1990 Beecher Wong 1994c except 0 3 U ml 1 B
0.1914435.10846215.html.plaintext.txt	86	cereus phosphatidylcholine preferring phospholipase C Boehrenger Mannheim added gels
0.1914435.10846215.html.plaintext.txt	87	This enzyme enhances preserves discontinuous haemolysis pattern HBL yet unknown mechanism Beecher Wong 1996
0.1914435.10846215.html.plaintext.txt	88	All gel diffusion assays 22 25 degrees C
0.1914435.10846215.html.plaintext.txt	89	Haemolysis assays turbidimetric
0.1914435.10846215.html.plaintext.txt	90	Haemolysis also measured turbidimetric assays Beecher Wong 1997 modified microtitre plate format
0.1914435.10846215.html.plaintext.txt	91	Washed sheep erythrocytes diluted TBS 200 microl well 96 well microtitre plate OD620 0 7
0.1914435.10846215.html.plaintext.txt	92	At OD620 approximately 6 1x107 sheep erythrocytes ml 1
0.1914435.10846215.html.plaintext.txt	93	Cell suspensions warmed assay temperature prior addition assay plate
0.1914435.10846215.html.plaintext.txt	94	Lysis measured decrease OD620 time using temperature controlled SpectraFluor spectrophotometermicroplate reader Tecan
0.1914435.10846215.html.plaintext.txt	95	Haemolysis rates calculated maximum rate change assay period OD620 min 1x1000 mOD620 min 1 using DeltaSoft 3 microplate analysis software package Macintosh Biometallics Inc
0.1914435.10846215.html.plaintext.txt	96	Assay samples consisted either individual HBL components combinations components control samples
0.1914435.10846215.html.plaintext.txt	97	Samples either first mixed diluted transferred empty microtitre wells assay diluted added separately empty assay wells
0.1914435.10846215.html.plaintext.txt	98	Premixed samples added assay wells volumes 5 20 microl usually 10 microl always volume given assay
0.1914435.10846215.html.plaintext.txt	99	Samples added separately generally 5 microl
0.1914435.10846215.html.plaintext.txt	100	Sample volumes made identical TBS necessary
0.1914435.10846215.html.plaintext.txt	101	Immediately prior start assay 200 microl naive erythrocytes cells treated HBL component warmed assay temperature added wells containing samples lysis monitored described
0.1914435.10846215.html.plaintext.txt	102	Priming erythrocytes B components
0.1914435.10846215.html.plaintext.txt	103	The priming activity HBL B component described detail Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	104	Erythrocytes treated B component lyse slowly become sensitized rapid lytic action combined L1 L2 components
0.1914435.10846215.html.plaintext.txt	105	The priming reaction nearly stops 25 degrees C whereas L components rapidly 1 5 min lyse primed cells unprimed cells
0.1914435.10846215.html.plaintext.txt	106	Here B Ba added erythrocytes 42 degrees C cooled 25 degrees C lysis reaction
0.1914435.10846215.html.plaintext.txt	107	The extent priming quantitated adding 5 nM L12 B treated erythrocytes 25 degrees C measuring percentage cells lysed less 5 min
0.1914435.10846215.html.plaintext.txt	108	Quantitation L component activity
0.1914435.10846215.html.plaintext.txt	109	To determine activity L components rate rapid lysis B primed erythrocytes measured Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	110	Sheep erythrocytes treated B homologues 42 degrees C 100 cells primed
0.1914435.10846215.html.plaintext.txt	111	Primed cells added wells containing desired amount L components lysis measured described expressed mOD620 min 1
0.1914435.10846215.html.plaintext.txt	112	Some samples component Ba treated 8 M urea dissociate complexes tested haemolysis priming activity
0.1914435.10846215.html.plaintext.txt	113	When samples compared non urea treated components final concentration urea added erythrocytes separately components
0.1914435.10846215.html.plaintext.txt	114	During priming reaction present urea concentration 0 11 M
0.1914435.10846215.html.plaintext.txt	115	When 25 nM excess B Ba tested urea present final concentration 0 4 M
0.1914435.10846215.html.plaintext.txt	116	None urea concentrations used effect lysis rate L12 components priming rate B
0.1914435.10846215.html.plaintext.txt	117	Urea 4 M wells gel diffusion assays effect activity binary combinations components
0.1914435.10846215.html.plaintext.txt	118	lysis effects ternary combinations shown Results
0.1914435.10846215.html.plaintext.txt	119	Vascular permeability activity assayed described Glatz et al
0.1914435.10846215.html.plaintext.txt	120	Briefly 50 microl samples injected intradermally shaved backs rabbits 3 h Evans blue dye injected marginal ear vein
0.1914435.10846215.html.plaintext.txt	121	Samples possessing vascular permeability activity produced areas oedema bluing proportion concentration toxin
0.1914435.10846215.html.plaintext.txt	122	High toxin concentrations also produced areas necrosis
0.1914435.10846215.html.plaintext.txt	123	Female New Zealand White rabbits 3 4 kg Covance Research Products used assays
0.1914435.10846215.html.plaintext.txt	124	All activities reported means duplicate triplicate samples
0.1914435.10846215.html.plaintext.txt	125	Prototype HBL components isolated strain F83776 referred BF L1F L2F else strain purified stated
0.1914435.10846215.html.plaintext.txt	126	Among proteins isolated strain MGBC 145 homologues exhibiting closest relationship prototypes F83776
0.1914435.10846215.html.plaintext.txt	127	87 100 identity N terminal sequences designated B L1 L2
0.1914435.10846215.html.plaintext.txt	128	The distantly related homologues
0.1914435.10846215.html.plaintext.txt	129	62 65 identity N terminal sequences designated subscript
0.1914435.10846215.html.plaintext.txt	130	Component Ba isolated complex
0.1914435.10846215.html.plaintext.txt	131	Under assumption complex dimer Ba complex form sometimes referred 2Ba urea treated monomer Ba
0.1914435.10846215.html.plaintext.txt	132	Combinations L components similarly indicated L12F L12 L1a2a
0.1914435.10846215.html.plaintext.txt	133	Other combinations specifically identified e
0.1914435.10846215.html.plaintext.txt	134	Combinations HBL L12 composed equimolar concentrations component unless otherwise specified
0.1914435.10846215.html.plaintext.txt	135	RESULTS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Isolation HBL homologues The following description applies isolation components B
0.1914435.10846215.html.plaintext.txt	136	For comparisons components MGBC 145 prototype HBL components also isolated B
0.1914435.10846215.html.plaintext.txt	137	cereus F83776 data shown
0.1914435.10846215.html.plaintext.txt	138	DE 52 anion exchange chromatography
0.1914435.10846215.html.plaintext.txt	139	The desalted fraction G 25 column applied directly DE 52 column eluted linear gradient NaCl described Methods Beecher Wong 1994c
0.1914435.10846215.html.plaintext.txt	140	The elution characteristics B L1 L2 components MGBC 145 essentially identical F83776 elution components varied different extents
0.1914435.10846215.html.plaintext.txt	141	The following list indicates fractions pooled isolate component calculated concentration range NaCl comprised fractions
0.1914435.10846215.html.plaintext.txt	142	L2a nonbound fraction isocratic elution L1a L2 fractions 23 26 0 10 0 13 mM NaCl L1 L2 fractions 27 32 0 13 0 17 mM NaCl B fractions 33 38 0 17 0 21 mM NaCl Ba fractions 39 46 0 21 0 26 mM NaCl
0.1914435.10846215.html.plaintext.txt	143	Except L2a fraction pools listed applied 1 6x8 cm HA column eluted identical gradients phosphate buffer
0.1914435.10846215.html.plaintext.txt	144	L2a applied smaller HA column described Methods
0.1914435.10846215.html.plaintext.txt	145	Upon elution HA proteins nearly pure comparison A280 elution profiles becomes informative
0.1914435.10846215.html.plaintext.txt	146	1a compares elution profiles component HA relative phosphate eluent concentration
0.1914435.10846215.html.plaintext.txt	147	Only elution profiles L2 L2a exceptionally different one another
0.1914435.10846215.html.plaintext.txt	148	At point L2a essentially pure separations performed
0.1914435.10846215.html.plaintext.txt	149	Also interest L1a sphingomyelinase behaved identically HA
0.1914435.10846215.html.plaintext.txt	150	View larger version 22K Fig
0.1914435.10846215.html.plaintext.txt	151	Chromatographic elution profiles HBL HBLa components
0.1914435.10846215.html.plaintext.txt	152	Elution profiles HA columns
0.1914435.10846215.html.plaintext.txt	153	The top four profiles 16 ml HA column bottom profile 1 ml HA column details Methods
0.1914435.10846215.html.plaintext.txt	154	b Elution profiles Mono Q anion exchange columns
0.1914435.10846215.html.plaintext.txt	155	All Mono Q columns run pH 5 9 except one depicted inset run pH 7 4
0.1914435.10846215.html.plaintext.txt	156	Proteins eluted linear salt gradients flow rates described Methods
0.1914435.10846215.html.plaintext.txt	157	Labels adjacent peaks identify major proteins peaks
0.1914435.10846215.html.plaintext.txt	158	The L1aS peaks contained L1a sphingomyelinase S
0.1914435.10846215.html.plaintext.txt	159	Inset separation L1a sphingomyelinase Mono Q column pH 7 4
0.1914435.10846215.html.plaintext.txt	160	The L1a S peaks labelled eluted 110 140 mM respectively
0.1914435.10846215.html.plaintext.txt	161	The first peak contained proteins larger 10 kDa
0.1914435.10846215.html.plaintext.txt	162	The x y axes apply profile included illustrate effectiveness separation pH 7 4
0.1914435.10846215.html.plaintext.txt	163	Mono Q anion exchange chromatography
0.1914435.10846215.html.plaintext.txt	164	Except L2a fractions containing respective HBL component homologues pooled applied Mono Q column
0.1914435.10846215.html.plaintext.txt	165	1b compares Mono Q elution profiles component
0.1914435.10846215.html.plaintext.txt	166	All homologous component pairs behaved differently column essentially reflecting behaviour DE 52
0.1914435.10846215.html.plaintext.txt	167	Note peaks eluted column depicted top panel Fig
0.1914435.10846215.html.plaintext.txt	168	1b represent B component
0.1914435.10846215.html.plaintext.txt	169	The later peak represents intact B early peak represents B first two N terminal residues Ser Glu cleaved endogenous protease unpublished observations
0.1914435.10846215.html.plaintext.txt	170	Also note HA L1a sphingomyelinase behaved identically Mono Q column pH 5 9 could easily separated pH 7 4 inset Fig
0.1914435.10846215.html.plaintext.txt	171	Under conditions L1a peak occurred 110 mM NaCl sphingomyelinase peak 140 mM NaCl
0.1914435.10846215.html.plaintext.txt	172	Physicochemical comparison components Fig
0.1914435.10846215.html.plaintext.txt	173	2 shows purified HBL homologues strains F83776 MGBC 145 SDS PAGE
0.1914435.10846215.html.plaintext.txt	174	Table 1 compares N terminal sequences estimated molecular masses isoelectric points
0.1914435.10846215.html.plaintext.txt	175	Also shown comparison predicted N terminal sequence hblB open reading frame immediately downstream B gene hblA
0.1914435.10846215.html.plaintext.txt	176	View larger version 83K Fig
0.1914435.10846215.html.plaintext.txt	177	SDS PAGE gel purified HBL HBLa components
0.1914435.10846215.html.plaintext.txt	178	Lanes 3 5 7 9 11 13 contain 1 microg purified component labelled top gel
0.1914435.10846215.html.plaintext.txt	179	Components dot isolated B
0.1914435.10846215.html.plaintext.txt	180	All components B
0.1914435.10846215.html.plaintext.txt	181	Lanes 1 2 6 10 14 15 contained low molecular mass protein standards
0.1914435.10846215.html.plaintext.txt	182	The gel run stained described Methods
0.1914435.10846215.html.plaintext.txt	183	N terminal sequence alignments characteristics HBL HBLa components
0.1914435.10846215.html.plaintext.txt	184	Between aligned residues B L1 L2 92 100 87 identical respective prototype components F83776
0.1914435.10846215.html.plaintext.txt	185	Ba L1a L2a respectively 60 65 63 identical B L1 L2
0.1914435.10846215.html.plaintext.txt	186	Interestingly L2a similar L2F 36 residues 67 identical L2 63 identical
0.1914435.10846215.html.plaintext.txt	187	Ba 67 identical hblB predicted amino acid sequence F83776
0.1914435.10846215.html.plaintext.txt	188	It doubtful identities reflect overall identities respective sequences example BF predicted hblB amino acid sequence approximately 85 identical 158 residues 60 identical 43 aligned N terminal residues
0.1914435.10846215.html.plaintext.txt	189	Isolation Ba complex We recently found experiments unrelated study treatment B component strain F83776 65 degrees C converts stable relatively inactive complexes primarily dimers analysis presented elsewhere
0.1914435.10846215.html.plaintext.txt	190	The complexes identified slowly migrating bands native PAGE gels dissociated monomer 8 M urea also restores activity
0.1914435.10846215.html.plaintext.txt	191	3a shows preparation Ba complex dissociated urea
0.1914435.10846215.html.plaintext.txt	192	Unlike B forms mixtures increasingly larger complexes time Ba present primarily single complexed species migrated rate initial complex formed B
0.1914435.10846215.html.plaintext.txt	193	The proteins purified study monomers migration distances native PAGE affected 6 8 M urea shown
0.1914435.10846215.html.plaintext.txt	194	View larger version 95K Fig
0.1914435.10846215.html.plaintext.txt	195	Production Ba monomer isolation dimer
0.1914435.10846215.html.plaintext.txt	196	Lanes 1 5 native PAGE components B Ba complex monomer forms
0.1914435.10846215.html.plaintext.txt	197	Each lane loaded 0 25 microg protein gel stained silver
0.1914435.10846215.html.plaintext.txt	198	Lane 1 B65 component B treated 65 degrees C 10 min form complexes
0.1914435.10846215.html.plaintext.txt	199	Lane 2 B untreated component B
0.1914435.10846215.html.plaintext.txt	200	Lane 3 Ba untreated component Ba
0.1914435.10846215.html.plaintext.txt	201	Lane 5 BaU component Ba added gel presence 6 M urea
0.1914435.10846215.html.plaintext.txt	202	Note 8 M urea eliminates upper band shown
0.1914435.10846215.html.plaintext.txt	203	Lanes 6 7 Western blot probed polyclonal antiserum B
0.1914435.10846215.html.plaintext.txt	204	Lane 6 F 20 microl culture supernatant B
0.1914435.10846215.html.plaintext.txt	205	cereus F83776 HBL prototype strain
0.1914435.10846215.html.plaintext.txt	206	Lane 7 M 20 microl culture supernatant B
0.1914435.10846215.html.plaintext.txt	207	cereus MGBC 145 HBLa producing strain
0.1914435.10846215.html.plaintext.txt	208	Fresh culture supernatants run native PAGE gel analysed Western blotting determine whether Ba secreted dimer
0.1914435.10846215.html.plaintext.txt	209	3b compares supernatants strains MGBC 145 F83776 produces B
0.1914435.10846215.html.plaintext.txt	210	No complex detected either supernatant
0.1914435.10846215.html.plaintext.txt	211	Both supernatants exhibit one slow moving band correspond complexes
0.1914435.10846215.html.plaintext.txt	212	The identities bands unknown
0.1914435.10846215.html.plaintext.txt	213	Haemolysis HBL HBLa components similarities Activity component combinations
0.1914435.10846215.html.plaintext.txt	214	In turbidimetric haemolysis assays sheep erythrocytes treated possible binary ternary combinations prototype like components MGBC 145
0.1914435.10846215.html.plaintext.txt	215	None binary combinations lytic
0.1914435.10846215.html.plaintext.txt	216	Among 20 possible three component combinations eight possessing B L1 L2 homologues lytic
0.1914435.10846215.html.plaintext.txt	217	None 12 combinations possessed redundant homologues e
0.1914435.10846215.html.plaintext.txt	218	Thus three component requirement HBL activity maintained homologous components could interchanged freely
0.1914435.10846215.html.plaintext.txt	219	During priming reaction occurs independently L components naive erythrocytes gradually become sensitive rapid lytic action L components Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	220	This slow priming occurred B Ba MGBC 145
0.1914435.10846215.html.plaintext.txt	221	B 5 nM completely primed erythrocytes 40 degrees C 1 h whereas 10 nM Ba monomer urea treated required 1 25 h prime cells
0.1914435.10846215.html.plaintext.txt	222	Untreated Ba complex also primed erythrocytes
0.1914435.10846215.html.plaintext.txt	223	However activity yet characterized thoroughly limited quantities monomer appears natural form Fig
0.1914435.10846215.html.plaintext.txt	224	Rapid lytic activities L components
0.1914435.10846215.html.plaintext.txt	225	We tested combinations L La components abilities lyse B Ba primed cells
0.1914435.10846215.html.plaintext.txt	226	For combinations possessing L1 L2 homologues e
0.1914435.10846215.html.plaintext.txt	227	lysis 0 5 10 nM L components rapid complete data shown
0.1914435.10846215.html.plaintext.txt	228	L1a appeared half potent L1
0.1914435.10846215.html.plaintext.txt	229	However minor concentration inaccuracies cannot yet ruled
0.1914435.10846215.html.plaintext.txt	230	There apparent differences activities L2 L2a
0.1914435.10846215.html.plaintext.txt	231	Haemolysis HBL HBLa components differences Haemolysis blood agar
0.1914435.10846215.html.plaintext.txt	232	When B present discontinuous haemolysis pattern typical HBL occurred L component combinations
0.1914435.10846215.html.plaintext.txt	233	L12 L12a L1a2 L1a2a
0.1914435.10846215.html.plaintext.txt	234	This suggests L1 L1a components interact similar ways B component produce pattern L2 neither inhibits B L1 inhibited thus contribute discontinuous pattern Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	235	However Ba replaced B discontinuous pattern occur L combination
0.1914435.10846215.html.plaintext.txt	236	lysis continuous well edge edge lysis zone
0.1914435.10846215.html.plaintext.txt	237	4 shows effect varying concentration L1 haemolysis pattern presence B Ba L1a produced effects blood agar shown
0.1914435.10846215.html.plaintext.txt	238	The discontinuous pattern occurred L1 concentrations presence B lysis occurred quickly near well lower L1 concentrations appear nearly continuous figure
0.1914435.10846215.html.plaintext.txt	239	A discontinuous pattern evident time around wells containing Ba
0.1914435.10846215.html.plaintext.txt	240	View larger version 79K Fig
0.1914435.10846215.html.plaintext.txt	241	Effect urea L1 concentration haemolysis pattern sheep blood produced B Ba
0.1914435.10846215.html.plaintext.txt	242	Wells rows received 100 ng either B Ba presence absence 8 M urea indicated left
0.1914435.10846215.html.plaintext.txt	243	Wells columns received L1 concentrations indicated bottom
0.1914435.10846215.html.plaintext.txt	244	All four horizontal strips blood agar gel
0.1914435.10846215.html.plaintext.txt	245	The image recorded 6 h 25 degrees C
0.1914435.10846215.html.plaintext.txt	246	4 also indicates 8 M urea significantly enhanced activity Ba quantitation enhancement possible inhibitory effects excess L1
0.1914435.10846215.html.plaintext.txt	247	The relative potencies B Ba blood agar estimated placing serial dilutions wells surrounding central well containing 100 ng L12
0.1914435.10846215.html.plaintext.txt	248	In method B primes cells surrounding well without inhibitory effect excess L1 Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	249	The lowest amounts B Ba Ba8 M urea exhibiting lytic activity 0 3 4 1 25 ng per well respectively
0.1914435.10846215.html.plaintext.txt	250	Inhibition L1 components B Ba
0.1914435.10846215.html.plaintext.txt	251	Just excess L1 inhibits priming reaction B produce discontinuous haemolysis blood agar also inhibits priming erythrocyte suspensions Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	252	Likewise addition excess B previously primed erythrocytes inhibits lysis rate L1 Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	253	We examined abilities excess B Ba components inhibit lysis B Ba primed cells L1 preliminary experiments indicated discernible differences L1 L1a components therefore results using L1 shown
0.1914435.10846215.html.plaintext.txt	254	The results shown Table 2
0.1914435.10846215.html.plaintext.txt	255	Effect excess B Ba 2Ba erythrocyte lysis components L12
0.1914435.10846215.html.plaintext.txt	256	Sheep erythrocytes primed 42 degrees C 5 nM B 10 nM Ba
0.1914435.10846215.html.plaintext.txt	257	The primed erythrocytes lysed 5 nM L12 presence absence 25 nM B Ba
0.1914435.10846215.html.plaintext.txt	258	The Ba added either 8 M urea test monomer buffer test complex 2Ba
0.1914435.10846215.html.plaintext.txt	259	Final urea concentrations samples controls described Methods
0.1914435.10846215.html.plaintext.txt	260	There striking differences effects excess B excess Ba lysis rate produced L1
0.1914435.10846215.html.plaintext.txt	261	As expected excess B inhibited lysis B primed cells
0.1914435.10846215.html.plaintext.txt	262	However excess Ba actually enhanced haemolysis Ba primed cells
0.1914435.10846215.html.plaintext.txt	263	Neither excess B excess Ba significantly affected lysis rate cells primed protein
0.1914435.10846215.html.plaintext.txt	264	Complexed Ba 2Ba Table 2 significantly affect lysis cells primed either B Ba
0.1914435.10846215.html.plaintext.txt	265	Most proteins unfold 8 M urea possible enhanced activity urea treated Ba due unfolding refolding Ba rather dissolution complex per se
0.1914435.10846215.html.plaintext.txt	266	When B already monomer form first dissolved 8 M urea inhibition lysis differed less 10 compared untreated B
0.1914435.10846215.html.plaintext.txt	267	This suggests urea little effect monomer
0.1914435.10846215.html.plaintext.txt	268	Vascular permeability activity HBL HBLa The ability HBL HBLa components cause vascular permeability necrosis rabbit skin tested using combinations appeared likely active based haemolytic characteristics
0.1914435.10846215.html.plaintext.txt	269	Samples containing 0 5 1 5 microg single components binary combinations produced reaction
0.1914435.10846215.html.plaintext.txt	270	There clear differences samples containing 0 5 microg component HBL F83776 HBL HBLa MGBC 145 produced respectively 20 plus minus 1 6 21 plus minus 1 2 20 plus minus 2 0 mm bluing 3 7 plus minus 2 5 4 4 plus minus 3 7 4 0 plus minus 1 2 mm necrosis means plus minus SD n3
0.1914435.10846215.html.plaintext.txt	271	Similar reactions obtained Ba mixed L12 BF mixed L1a2a
0.1914435.10846215.html.plaintext.txt	272	When B Ba concentrations varied constant L12 necrosis occurred 0 5 microg B Ba 0 25 0 125 microg
0.1914435.10846215.html.plaintext.txt	273	The difference appeared bluing response 0 125 microg B 0 125 microg Ba produced 23 plus minus 0 5 9 plus minus 2 6 mm zones respectively
0.1914435.10846215.html.plaintext.txt	274	Ba treated urea prior vascular permeability testing avoid complications high concentrations urea might produce
0.1914435.10846215.html.plaintext.txt	275	This component characterized conditions developed produce significant concentrations Ba monomer physiological salt concentrations
0.1914435.10846215.html.plaintext.txt	276	DISCUSSION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES We noted numerous B
0.1914435.10846215.html.plaintext.txt	277	cereus strains produce multiple bands Western blots probed antibodies specific components HBL
0.1914435.10846215.html.plaintext.txt	278	The presence multiple toxin homlogues might complicate attempts understand virulence mechanisms
0.1914435.10846215.html.plaintext.txt	279	Therefore tried determine whether different bands seen Western blots represent distinct gene products
0.1914435.10846215.html.plaintext.txt	280	Using antibodies track chromatographic behaviour different forms HBL components isolated two distinct homologues component medically important B
0.1914435.10846215.html.plaintext.txt	281	Both sets homologues HBL HBLa haemolytic dermonecrotic caused vascular permeability rabbit skin similar potencies
0.1914435.10846215.html.plaintext.txt	282	Overall discernible differences activity L homologues significant differences activity B Ba
0.1914435.10846215.html.plaintext.txt	283	The homologous components differed one another size net charge chromatographic behaviour
0.1914435.10846215.html.plaintext.txt	284	L1 L1a behaved similarly L1a coeluted sphingomyelinase HA anion exchangers pH 5 9
0.1914435.10846215.html.plaintext.txt	285	However could separated sphingomyelinase pH 7 4
0.1914435.10846215.html.plaintext.txt	286	L2 L2a essentially identical size differed pI full pH unit readily separated ion exchange chromatography exceptionally late elution L2a HA made easy isolate two chromatographic steps
0.1914435.10846215.html.plaintext.txt	287	It isolated complex may explain incongruous chromatographic elution
0.1914435.10846215.html.plaintext.txt	288	Its apparent pI 6 0 Table 1 one would expect would elute earlier anion exchange columns B pI 5 3
0.1914435.10846215.html.plaintext.txt	289	Instead eluted later 1 3 times elution volume B
0.1914435.10846215.html.plaintext.txt	290	The heat generated complexes B upper bands Fig
0.1914435.10846215.html.plaintext.txt	291	3a lane B65 behave way data published elsewhere
0.1914435.10846215.html.plaintext.txt	292	It appears however Ba naturally produced monomer appeared fresh B
0.1914435.10846215.html.plaintext.txt	293	cereus culture supernatant Fig
0.1914435.10846215.html.plaintext.txt	294	We investigating factors result complex formation purification
0.1914435.10846215.html.plaintext.txt	295	All components 62 65 identical respective homologues 30 43 residues
0.1914435.10846215.html.plaintext.txt	296	Similar identity 60 strain F83776 N termini B predicted hblB sequence rises approximately 85 first 158 residues Heinrichs et al
0.1914435.10846215.html.plaintext.txt	297	1993 suggesting HBLa components may prove closely related HBL components indicated N termini
0.1914435.10846215.html.plaintext.txt	298	The high sequence similarity among homologues suggests three genes may either simultaneously duplicated simultaneously transferred horizontally would facilitated tandem arrangement operon Ryan et al
0.1914435.10846215.html.plaintext.txt	299	We also determined four hbl genes strain F83776 arose via duplication single gene Beecher 1997
0.1914435.10846215.html.plaintext.txt	300	Note HBL mapped portion B
0.1914435.10846215.html.plaintext.txt	301	cereus chromosome exhibits exceptional variability compared regions variable region sometimes located large extrachromosomal DNA fragments appear stable might also prove large mobile plasmids Carlson et al
0.1914435.10846215.html.plaintext.txt	302	1996a b Carlson Kolsto 1994
0.1914435.10846215.html.plaintext.txt	303	This raises fundamental questions extent role gene duplication horizontal transfer evolution B
0.1914435.10846215.html.plaintext.txt	304	In addition HBL HBLa found data shown strain MGBC 145 expresses another homologous three component toxin designated nonhaemolytic enterotoxin NHE Lund Granum 1996
0.1914435.10846215.html.plaintext.txt	305	Data several studies suggest among strains express either HBL NHE 80 express Buchanan Schultz 1994 Day et al
0.1914435.10846215.html.plaintext.txt	306	1994 Rusul Yaacob 1995
0.1914435.10846215.html.plaintext.txt	307	These data based detection L2 protein HBL NHEA protein two commercial kits Beecher Wong 1994a
0.1914435.10846215.html.plaintext.txt	308	Our observations highlight practical problems diagnosis toxigenic strains identification B
0.1914435.10846215.html.plaintext.txt	309	cereus virulence factors particularly since may additional unidentified HBL homologues
0.1914435.10846215.html.plaintext.txt	310	Since discontinuous haemolysis pattern typical HBL appears produced presence prototype B component discontinuous lysis around colonies culture supernatants Beecher Wong 1994b appears limited diagnostic value
0.1914435.10846215.html.plaintext.txt	311	For maximum value methods detect relevant toxin components component combinations
0.1914435.10846215.html.plaintext.txt	312	However components combinations completely defined
0.1914435.10846215.html.plaintext.txt	313	In attempts identify virulence factors possible contributions multiple potentially interacting multicomponent toxins must kept mind
0.1914435.10846215.html.plaintext.txt	314	Although numerous physical phenomena documented HBL little known components interact molecular level beyond fact bind cells independently must physically interact form pores
0.1914435.10846215.html.plaintext.txt	315	It also clear change physical state B initial association membrane Bm primed state B
0.1914435.10846215.html.plaintext.txt	316	This change may involve conformational changes oligomerization membrane insertion three
0.1914435.10846215.html.plaintext.txt	317	The experiment represented Table 2 provides insight additional interactions discussed
0.1914435.10846215.html.plaintext.txt	318	We previously found lysis B primed erythrocytes L12 inhibited excess B added simultaneously L components L1 inhibited L2 Beecher Wong 1997
0.1914435.10846215.html.plaintext.txt	319	Table 2 shows excess B Ba different effects specific effect depends used prime cells
0.1914435.10846215.html.plaintext.txt	320	A significant effect occurred protein added excess used prime cells
0.1914435.10846215.html.plaintext.txt	321	This indicates excess Bm must physically interact B likewise excess Ba B Ba sufficiently unrelated interact one another
0.1914435.10846215.html.plaintext.txt	322	The excess B may inhibit lysis simply obstructing L1 contact B producing inefficient lytic complexes composed Bm B L1
0.1914435.10846215.html.plaintext.txt	323	Enhancement lysis Ba unexpected mechanism occurs unclear
0.1914435.10846215.html.plaintext.txt	324	It might occur either enhances incorporation L1 lesion Ba L1 complexes efficient Ba L1 complexes
0.1914435.10846215.html.plaintext.txt	325	There structural basis suggesting L1 binds efficiently Ba complexes
0.1914435.10846215.html.plaintext.txt	326	B L1 strain F83776 appear distant homologues significant structural difference B missing 40 residues 60 residue apparent transmembrane segment present L1 Beecher 1997
0.1914435.10846215.html.plaintext.txt	327	The observed size difference approximately 4 4 kDa B Ba Table 1 equates difference approximately 40 residues
0.1914435.10846215.html.plaintext.txt	328	In essence Ba may act hybrid B L1 virtue retaining full transmembrane segment characteristic L1
0.1914435.10846215.html.plaintext.txt	329	While observations emphasize practical difficulties diagnosis identification virulence factors also provide promising opportunities structure function analysis HBL family toxins
0.1914435.10846215.html.plaintext.txt	330	The structural functional differences B Ba significant may provide insight mechanism HBL toxicity well explanation unique haemolytic phenomena toxin
0.1914435.10846215.html.plaintext.txt	331	ACKNOWLEDGEMENTS This work supported grant 96 35201 3765 National Research Initiative Competitive Grants Program US Department Agriculture College Agricultural Life Sciences University Wisconsin Madison
0.1914435.10846215.html.plaintext.txt	332	REFERENCES TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Beecher D
0.1914435.10846215.html.plaintext.txt	333	Isolation characterization hemolysin BL novel three component diarrheagenic hemolysin Bacillus cereus
0.1914435.10846215.html.plaintext.txt	334	PhD thesis The State University New Jersey Rutgers
0.1914435.10846215.html.plaintext.txt	335	Hemolysin BL structure function diversity dermonecrotic enterotoxin Bacillus cereus
0.1914435.10846215.html.plaintext.txt	336	In First International Workshop The Molecular Biology Bacillus cereus Bacillus anthracis Bacillus thuringiensis p
0.1914435.10846215.html.plaintext.txt	337	Copenhagen National Institute Occupational Health
0.1914435.10846215.html.plaintext.txt	338	A novel bicomponent hemolysin Bacillus cereus
0.1914435.10846215.html.plaintext.txt	339	Characterization components hemolysin BL Bacillus cereus
0.1914435.10846215.html.plaintext.txt	340	Identification analysis antigens detected two commercial Bacillus cereus diarrheal enterotoxin immunoassay kits
0.1914435.10846215.html.plaintext.txt	341	Appl Environ Microbiol 60 4614 4616
0.1914435.10846215.html.plaintext.txt	342	Identification hemolysin BL producing Bacillus cereus isolates discontinuous hemolytic pattern blood agar
0.1914435.10846215.html.plaintext.txt	343	Appl Environ Microbiol 60 1646 1651
0.1914435.10846215.html.plaintext.txt	344	Improved purification characterization hemolysin BL hemolytic dermonecrotic vascular permeability factor Bacillus cereus
0.1914435.10846215.html.plaintext.txt	345	Interactions affecting hemolysis enterotoxic hemolysin BL two phospholipases C Bacillus cereus
0.1914435.10846215.html.plaintext.txt	346	In 96th General Meeting American Society Microbiology abstract
0.1914435.10846215.html.plaintext.txt	347	Tripartite hemolysin BL Bacillus cereus hemolytic analysis component interactions model characteristic paradoxical zone phenomenon
0.1914435.10846215.html.plaintext.txt	348	Extracellular virulence factors Bacillus cereus endophthalmitis methods implication involvement hemolysin BL
0.1914435.10846215.html.plaintext.txt	349	Enterotoxic activity hemolysin BL Bacillus cereus
0.1914435.10846215.html.plaintext.txt	350	Comparison Tecra VIA kit Oxoid BCET RPLA CHO cell culture assay detection Bacillus cereus diarrhoeal enterotoxin
0.1914435.10846215.html.plaintext.txt	351	Lett Appl Microbiol 19 353 356
0.1914435.10846215.html.plaintext.txt	352	Pathogenesis gram positive bacterial endophthalmitis
0.1914435.10846215.html.plaintext.txt	353	Role hemolysin BL pathogenesis extraintestinal Bacillus cereus infection assessed endophthalmitis model
0.1914435.10846215.html.plaintext.txt	354	A small 2 4 Mb Bacillus cereus chromosome corresponds conserved region larger 5 3 Mb Bacillus cereus chromosome
0.1914435.10846215.html.plaintext.txt	355	The chromosome map Bacillus thuringiensis subsp
0.1914435.10846215.html.plaintext.txt	356	canadensis HD224 highly similar Bacillus cereus type strain ATCC 14579
0.1914435.10846215.html.plaintext.txt	357	FEMS Microbiol Lett 141 163 167
0.1914435.10846215.html.plaintext.txt	358	Genomic organization entomopathogenic bacterium Bacillus thuringiensis subsp
0.1914435.10846215.html.plaintext.txt	359	Method application human serum proteins
0.1914435.10846215.html.plaintext.txt	360	A comparison ELISA RPLA detection Bacillus cereus diarrhoeal enterotoxin
0.1914435.10846215.html.plaintext.txt	361	Bacillus cereus related species
0.1914435.10846215.html.plaintext.txt	362	Alteration vascular permeability rabbits culture filtrates Bacillus cereus related species
0.1914435.10846215.html.plaintext.txt	363	Molecular cloning characterization gene encoding B component hemolysin BL Bacillus cereus
0.1914435.10846215.html.plaintext.txt	364	Bacillus cereus Bacillus species
0.1914435.10846215.html.plaintext.txt	365	In Foodborne Bacterial Pathogens pp
0.1914435.10846215.html.plaintext.txt	366	New York Basel Marcel Dekker
0.1914435.10846215.html.plaintext.txt	367	Cleavage structural proteins assembly head bacteriophage T4
0.1914435.10846215.html.plaintext.txt	368	Characterisation non haemolytic enterotoxin complex Bacillus cereus isolated foodborne outbreak
0.1914435.10846215.html.plaintext.txt	369	FEMS Microbiol Lett 141 151 156
0.1914435.10846215.html.plaintext.txt	370	Limited N terminal sequence analysis
0.1914435.10846215.html.plaintext.txt	371	A simple modification Blum silver stain method allows 30 minute detection proteins polyacrylamide gels
0.1914435.10846215.html.plaintext.txt	372	J Biochem Biophys Methods 28 239 242
0.1914435.10846215.html.plaintext.txt	373	Prevalence Bacillus cereus selected foods detection enterotoxin using TECRA VIA BECT RPLA
0.1914435.10846215.html.plaintext.txt	374	Int J Food Microbiol 25 131 139
0.1914435.10846215.html.plaintext.txt	375	Molecular cloning characterization genes encoding L1 L2 components hemolysin BL Bacillus cereus
0.1914435.10846215.html.plaintext.txt	376	Heterogeneity observed components hemolysin BL enterotoxin produced Bacillus cereus
0.1914435.10846215.html.plaintext.txt	377	Int J Food Microbiol 53 159 167
0.1914435.10846215.html.plaintext.txt	378	In Pharmacology Bacterial Toxins pp
0.1914435.10846215.html.plaintext.txt	379	Received 24 August 1999 revised 7 December 1999 accepted 16 March 2000
0.175064.12082080.html.plaintext.txt	0	The Rockefeller University Press 0021 9525200261223 5
0.175064.12082080.html.plaintext.txt	1	00 The Journal Cell Biology Volume 157 Number 7 June 24 2002 1223 1232 Article
0.175064.12082080.html.plaintext.txt	2	L1 endocytosis controlled phosphorylation dephosphorylation cycle stimulated outside signaling L1 Andrew W
0.175064.12082080.html.plaintext.txt	3	Schaefer1 Yoshimasa Kamei1 Hiroyuki Kamiguchi1 Eric V
0.175064.12082080.html.plaintext.txt	4	Wong1 Iris Rapoport67 Tomas Kirchhausen67 Carol M
0.175064.12082080.html.plaintext.txt	5	Beach5 Gary Landreth1 Sandra K
0.175064.12082080.html.plaintext.txt	6	1 Department Neurosciences School Medicine Case Western Reserve University Cleveland OH 44106 2 Department Molecular Biology Microbiology School Medicine Case Western Reserve University Cleveland OH 44106 3 Department Ophthalmology School Medicine Case Western Reserve University Cleveland OH 44106 4 Cancer Center School Medicine Case Western Reserve University Cleveland OH 44106 5 Macromolecular Structural Analysis Facility University Kentucky Lexington KY 40536 6 Department Cell Biology Harvard Medical School Boston MA 02115 7 The Center Blood Research Harvard Medical School Boston MA 02115
0.175064.12082080.html.plaintext.txt	7	Address correspondence Vance Lemmon Department Neurosciences Case Western Reserve University School Medicine Rm
0.175064.12082080.html.plaintext.txt	8	Abstract Top Abstract Introduction Results Discussion Materials methods References Dynamic regulation cell surface expression adhesion molecules important mechanism controlling neuronal growth cone motility guidance
0.175064.12082080.html.plaintext.txt	9	Clathrin mediated vesicular internalization L1 via tyrosine based endocytosis motif YRSL regulates adhesion signaling Ig superfamily molecule
0.175064.12082080.html.plaintext.txt	10	Here present evidence tyrosine 1176 Y1176 YRSL motif phosphorylated vivo
0.175064.12082080.html.plaintext.txt	11	The nonreceptor tyrosine kinase p60src implicated L1 mediated neurite outgrowth find p60src phosphorylates Y1176 vitro
0.175064.12082080.html.plaintext.txt	12	Phosphorylation Y1176 prevents L1 binding AP 2 adaptor required clathrin mediated internalization L1
0.175064.12082080.html.plaintext.txt	13	mAb 74 5H7 recognizes sequence immediately NH2 terminal tyrosine based motif binds L1 Y1176 dephosphorylated
0.175064.12082080.html.plaintext.txt	14	74 5H7 identifies subset L1 present points cell cell contact vesicle like structures colocalize endocytosis marker
0.175064.12082080.html.plaintext.txt	15	L1 L1 binding L1 cross linking induces rapid increase 74 5H7 immunoreactivity
0.175064.12082080.html.plaintext.txt	16	Our data suggest model homophilic binding L1 cross linking triggers transient dephosphorylation YRSL motif makes L1 available endocytosis
0.175064.12082080.html.plaintext.txt	17	Thus regulation L1 endocytosis dephosphorylation Y1176 critical regulatory point L1 mediated adhesion signaling
0.175064.12082080.html.plaintext.txt	18	Key Words IGSF protein cell adhesion growth cones endocytosis tyrosine based sorting motifs
0.175064.12082080.html.plaintext.txt	19	Introduction Top Abstract Introduction Results Discussion Materials methods References The immunoglobulin superfamily cell adhesion molecule IgSF CAM L1 participates several processes essential normal development nervous system
0.175064.12082080.html.plaintext.txt	20	Processes neurite extension neuronal migration require dynamic regulation cell adhesion mediated L1
0.175064.12082080.html.plaintext.txt	21	This controlled part internalization L1 regulate availability L1 cell surface
0.175064.12082080.html.plaintext.txt	22	L1 internalization controlled interactions cytoplasmic domain signaling cytoskeletal internalization machinery Long Lemmon 2000
0.175064.12082080.html.plaintext.txt	23	The L1 cytoplasmic domain L1CD required adhesion needed regulation adhesion signal transduction internalization
0.175064.12082080.html.plaintext.txt	24	Interestingly mutations cytoplasmic domain human L1 gene impair formation major axon tracts neural development review see Kamiguchi et al
0.175064.12082080.html.plaintext.txt	25	One important function L1CD analyzed detail regulation endocytosis intracellular trafficking cell surface distribution L1
0.175064.12082080.html.plaintext.txt	26	Neuronal L1 differs L1 found nonneuronal cells Schwann cells neuroblastoma cell lines contains four amino acids RSLE cytoplasmic domain encoded alternatively spliced exon 28 Miura et al
0.175064.12082080.html.plaintext.txt	27	The RSLE stretch immediately follows tyrosine 1176
0.175064.12082080.html.plaintext.txt	28	The composite sequence YRSLE forms tyrosine based sorting motif required endocytosis L1 via clathrin coated pits Kamiguchi et al
0.175064.12082080.html.plaintext.txt	29	Like tyrosine based sorting signals characterized proteins Ohno et al
0.175064.12082080.html.plaintext.txt	30	1996 YRSLE sequence found L1 serves binding site micro2 chain clathrin associated AP 2 complex vitro number endocytic machinery components coimmunoprecipitated L1
0.175064.12082080.html.plaintext.txt	31	Furthermore mutating tyrosine 1176 Y1176 removing RSLE exon also prevents L1 interacting AP 2 consequently prevents clathrin mediated endocytosis L1 Kamiguchi et al
0.175064.12082080.html.plaintext.txt	32	In dorsal root ganglion DRG neurons growing L1 Fc substrate clathrin mediated endocytosis L1 occurs preferentially rear growth cones suggesting local regulation L1 endocytosis recycling may important growth cone motility Kamiguchi Lemmon 2000
0.175064.12082080.html.plaintext.txt	33	Indeed blocking AP 2 mediated internalization L1 inhibits L1 based neurite growth part disrupting gradient L1 adhesivity growth cone periphery central domain Kamiguchi Yoshihara 2001
0.175064.12082080.html.plaintext.txt	34	Finally neuronal form L1 YRSLE significantly less adhesive nonneuronal form due rapid internalization shorter dwell time cell surface Long et al
0.175064.12082080.html.plaintext.txt	35	Phosphorylation likely play critical role regulating L1 mediated processes neurite outgrowth Atashi et al
0.175064.12082080.html.plaintext.txt	36	L1 phosphorylated serine tyrosine residues cultured neurons clustering L1 cultured cells cross linking antibodies trigger changes kinase phosphatase activity Klinz et al
0.175064.12082080.html.plaintext.txt	37	1999 well phosphorylation state L1 Zisch et al
0.175064.12082080.html.plaintext.txt	38	Several kinase activities coimmunoprecipitate L1
0.175064.12082080.html.plaintext.txt	39	We identified three L1 associated kinases CKII p90rsk ERK2 phosphorylate certain serine residues L1CD vitro Wong et al
0.175064.12082080.html.plaintext.txt	40	Inhibition p90rsk phosphorylation L1 impairs DRG neurite outgrowth L1 laminin substrates
0.175064.12082080.html.plaintext.txt	41	Furthermore activation MAP kinase cascade includes p90rsk ERK2 requires L1 endocytosis
0.175064.12082080.html.plaintext.txt	42	Tyrosine kinases p60src FGF receptor also implicated L1 signaling Ignelzi et al
0.175064.12082080.html.plaintext.txt	43	1994 Doherty Walsh 1996 receptor tyrosine kinase EphB2 capable phosphorylating L1 Zisch et al
0.175064.12082080.html.plaintext.txt	44	Tyrosine phosphorylation may regulate associations L1 cytoskeleton
0.175064.12082080.html.plaintext.txt	45	For example L1 L1 family members neurofascin NrCAM associate membrane cytoskeleton protein ankyrin phosphorylation tyrosine within ankyrin binding site neurofascin conserved L1 disrupts association Tuvia et al
0.175064.12082080.html.plaintext.txt	46	Here present evidence outside signaling dynamically regulates functional state L1CD via dephosphorylation
0.175064.12082080.html.plaintext.txt	47	We characterized mAb 74 5H7 recognizes subset L1 points cell cell contact vesicular structures
0.175064.12082080.html.plaintext.txt	48	The 74 5H7 epitope regulated phosphorylation L1 maps region immediately preceding tyrosine based sorting motif
0.175064.12082080.html.plaintext.txt	49	In vitro studies show phosphorylation within epitope prevents recognition 74 5H7 also binding AP 2 L1
0.175064.12082080.html.plaintext.txt	50	We identified nonreceptor tyrosine kinase p60src L1 phosphorylating kinase preferentially phosphorylates Y1176 tyrosine based sorting motif vitro
0.175064.12082080.html.plaintext.txt	51	Cell cell contact able induce changes phosphorylation state L1 recognized 74 5H7
0.175064.12082080.html.plaintext.txt	52	These data demonstrate L1 L1 binding induces functional change L1CD mediated phosphorylation dephosphorylation cycle
0.175064.12082080.html.plaintext.txt	53	Results Top Abstract Introduction Results Discussion Materials methods References mAb 74 5H7 recognizes special fraction L1 neurons Chick DRG neurons growing culture L1 distributed entire surfaces Fig
0.175064.12082080.html.plaintext.txt	54	When mAb 74 5H7 used immunocytochemistry however surprised find immunoreactivity IR concentrated points contact DRG neuron cell bodies culture Fig
0.175064.12082080.html.plaintext.txt	55	Previous characterization 74 5H7 indicated recognizes L1 exclusively Western blots whole brain extracts immunoprecipitate mammalian chick L1 Lemmon et al
0.175064.12082080.html.plaintext.txt	56	It bind Western blots membranes L1 knockout mice demonstrating cross react L1 subfamily members unpublished data
0.175064.12082080.html.plaintext.txt	57	The 74 5H7 recognizes 200 220 kD full length L1 well 85 kD carboxy terminal portion including cytoplasmic tail bind live neurons
0.175064.12082080.html.plaintext.txt	58	Therefore mAb epitope likely reside near within L1 cytoplasmic domain
0.175064.12082080.html.plaintext.txt	59	The immunolabeling pattern cultured neurons suggests mAb epitope present accessible majority cell surface L1 exposed induced L1 clustered engaged binding partners points cell cell contact
0.175064.12082080.html.plaintext.txt	60	This implies cell cell contact induces changes cytoplasmic domain L1 visualized mAb
0.175064.12082080.html.plaintext.txt	61	View larger version 40K Figure 1
0.175064.12082080.html.plaintext.txt	62	74 5H7 recognizes subpopulation L1 localized cell cell contact sites growth cones
0.175064.12082080.html.plaintext.txt	63	Immunocytochemistry two DRG neuron cell bodies plated L1 Fc substrate double labeled A 74 5H7 B rabbit polyclonal anti L1 antibody 8D9
0.175064.12082080.html.plaintext.txt	64	C Superimposition images 74 5H7 red polyclonal anti L1 antibody 8D9 green
0.175064.12082080.html.plaintext.txt	65	Immunocytochemistry DRG growth cones extended L1 Fc substrate double labeled D 74 5H7 E rabbit polyclonal anti L1 antibody 8D9
0.175064.12082080.html.plaintext.txt	66	F Superimposition images 74 5H7 red polyclonal anti L1 antibody 8D9 green
0.175064.12082080.html.plaintext.txt	67	74 5H7 IR brightest association vesicle like structures growth cone
0.175064.12082080.html.plaintext.txt	68	L1 IR brightest association L1 surface
0.175064.12082080.html.plaintext.txt	69	Consequently two channels set quite differently one emphasizing L1 surface L1 inside growth cone
0.175064.12082080.html.plaintext.txt	70	This leads situations 74 5H7 positive structures inside growth cone comparatively weakly stained pan L1 antibody leading misimpression 74 5H7 IR present L1
0.175064.12082080.html.plaintext.txt	71	Bar 10 microm circle radius 0
0.175064.12082080.html.plaintext.txt	72	In addition points cell cell contact striking punctatevesicular pattern 74 5H7 immunoreactivity 74 5H7 IR evident growth cones visualized confocal microscopy
0.175064.12082080.html.plaintext.txt	73	In growth cones DRG neurons extending L1 Fc substrate 74 5H7 IR revealed vesicle like distribution predominately restricted lamellipodial central domains growth cones rather filopodia Fig
0.175064.12082080.html.plaintext.txt	74	In contrast immunolabeling rabbit anti L1 antibody 8D9 showed total L1 distributed along entire surface growth cone axon shaft strong labeling extending filopodia tips Fig
0.175064.12082080.html.plaintext.txt	75	Measurement size 74 5H7 IR vesicle like structures using image analysis software confocal microscope revealed 0
0.175064.12082080.html.plaintext.txt	76	3 microm radius consistent size clathrin coated vesicles
0.175064.12082080.html.plaintext.txt	77	Our detailed analysis pattern 74 5H7 IR conjunction earlier report showing 74 5H7 IR colocalize rear growth cones endocytosis marker protein Eps15 Kamiguchi et al
0.175064.12082080.html.plaintext.txt	78	1998b indicates 74 5H7 recognizes subset L1 vesicle like structures cell surface points cell cell contact
0.175064.12082080.html.plaintext.txt	79	Therefore expression 74 5H7 epitope correlates functional state L1 occurs L1 engaged adhesion cell surface trafficking
0.175064.12082080.html.plaintext.txt	80	Characterization 74 5H7 epitope In principle several possible explanations unique distribution 74 5H7 IR including change posttranslational modification phosphorylation blocking epitope protein protein interactions conformational change
0.175064.12082080.html.plaintext.txt	81	Two lines evidence suggest phosphorylation likely explanation
0.175064.12082080.html.plaintext.txt	82	First 74 5H7 recognizes L1 Western blot fractionation SDS PAGE Fig
0.175064.12082080.html.plaintext.txt	83	Under conditions posttranslational modifications L1CD would preserved whereas global conformational changes protein associations would lost
0.175064.12082080.html.plaintext.txt	84	Second bacterially produced purified recombinant L1CD recognized 74 5H7 Western blots Fig
0.175064.12082080.html.plaintext.txt	85	2 B indicating 74 5H7 epitope part primary structure L1CD suggesting epitope masked posttranslational modifications L1 vivo
0.175064.12082080.html.plaintext.txt	86	View larger version 14K Figure 2
0.175064.12082080.html.plaintext.txt	87	A Western blot myeloma cell extracts expressing different L1 constructs 1 full length L1 2 L1CD truncated lysine 1147 leaving first four amino acids cytoplasmic domain 3 L1CD truncated Y1176 leaving first 33 amino acids cytoplasmic domain
0.175064.12082080.html.plaintext.txt	88	The blot probed 74 5H7
0.175064.12082080.html.plaintext.txt	89	The 220 kD molecular mass marker indicated left
0.175064.12082080.html.plaintext.txt	90	B Dot blot showing 74 5H7 binds bacterially expressed L1CD rL1CD 14 amino acid L1CD sequence SEARPMKDETFGEY immediately preceding alternatively spliced RSLE region peptide corresponding juxtamembrane region KRSK
0.175064.12082080.html.plaintext.txt	91	C A series peptides synthesized alanine substituting individual amino acids determine amino acid residues critical 74 5H7 binding SEARPMKDETFGEY sequence
0.175064.12082080.html.plaintext.txt	92	Dot blot analysis shows substituting alanine lysine 1169 glutamine 1171 threonine 1172 phenylalanine 1173 glycine 1174 inhibits 74 5H7 binding peptides
0.175064.12082080.html.plaintext.txt	93	Additional peptides synthesized containing phosphoserine 1163 phosphothreonine 1172 phospho Y1176
0.175064.12082080.html.plaintext.txt	94	The dot blot shows phosphorylation threonine 1172 Y1176 inhibits 74 5H7 recognition peptide whereas phosphorylation serine 1163 effect
0.175064.12082080.html.plaintext.txt	95	D Western blot showing lane 1 74 5H7 binding purified rat L1 lane 2 preincubation monoclonal antibody SEARPMKDETFGEY peptide competes binding purified rat L1
0.175064.12082080.html.plaintext.txt	96	The 220 85 kD molecular masses shown left
0.175064.12082080.html.plaintext.txt	97	To determine region cytoplasmic domain contained 74 5H7 epitope prepared series plasmid constructs containing sequences coding L1 various cytoplasmic domain truncations expressed myeloma cells examined ones preserved 74 5H7 epitope
0.175064.12082080.html.plaintext.txt	98	Western blot analysis extracts myeloma cells expressing different L1 truncations shows 74 5H7 recognizes full length L1 L1 truncated Y1176 leaves first 33 amino acids L1CD intact Fig
0.175064.12082080.html.plaintext.txt	99	The mAb also recognizes nonneuronal form L1 lacks alternatively spliced exon 28 amino acids 1177 1181 unpublished data
0.175064.12082080.html.plaintext.txt	100	In contrast 74 5H7 recognize L1 truncated lysine 1147 removes first four amino acids cytoplasmic domain Fig
0.175064.12082080.html.plaintext.txt	101	These results suggest 74 5H7 epitope resides first 33 amino acids L1 cytoplasmic domain
0.175064.12082080.html.plaintext.txt	102	A series peptides made map precise epitope recognized 74 5H7
0.175064.12082080.html.plaintext.txt	103	First synthesized two peptides spanning first 33 amino acids cytoplasmic domain asked whether 74 5H7 recognized either dot blots
0.175064.12082080.html.plaintext.txt	104	Our analysis indicates 74 5H7 recognizes 14 amino acid peptide SEARPMKDETFGEY residues 1163 1176 Fig
0.175064.12082080.html.plaintext.txt	105	2 B peptide KRSKGGKYSVKDKEDTQVDS residues 1144 1163 consisting first 20 amino acids L1CD
0.175064.12082080.html.plaintext.txt	106	We used synthetic peptides alanine scanning substitutions 14 amino acid peptide determine residues essential recognition 74 5H7
0.175064.12082080.html.plaintext.txt	107	This analysis identified five amino acids SEARPMKDETFGEY underlined individually changed alanine abolish 74 5H7 binding Fig
0.175064.12082080.html.plaintext.txt	108	Although five amino acids identified critical 74 5H7 binding unable detect binding peptides shorter SEARPMKDETFGEY sequence suggesting may structural contributions epitope residues unpublished data
0.175064.12082080.html.plaintext.txt	109	The SEARPMKDETFGEY peptide also competed purified L1 74 5H7 binding confirming importance sequence mAb recognition L1 Fig
0.175064.12082080.html.plaintext.txt	110	Thus 74 5H7 epitope present L1 points cell cell contact small vesicle like structures positioned immediately NH2 terminal tyrosine based sorting motif
0.175064.12082080.html.plaintext.txt	111	This motif YRSL present neuronal form L1 critical regulation L1 endocytosis Kamiguchi et al
0.175064.12082080.html.plaintext.txt	112	Phosphorylation L1 peptides inhibits 74 5H7 binding The 14 amino acid peptide contains three potential phosphorylation sites SEARPMKDETFGEY underlined
0.175064.12082080.html.plaintext.txt	113	We synthesized peptides one residues phosphorylated found peptide containing phosphorylated threonine 1172 longer recognized 74 5H7
0.175064.12082080.html.plaintext.txt	114	In addition 74 5H7 recognition phosphorylated Y1176 peptide reduced 80 although peptide containing phosphoserine 1163 strongly reactive Fig
0.175064.12082080.html.plaintext.txt	115	These results suggest phosphorylation one sites threonine 1172 Y1176 L1 could responsible inability react 74 5H7 epitope may transiently unmasked dephosphorylation
0.175064.12082080.html.plaintext.txt	116	However phosphothreonine never reported L1 review see Schaefer et al
0.175064.12082080.html.plaintext.txt	117	p60src phosphorylates L1CD Although phosphorylation threonine 1172 Y1176 disrupt 74 5H7 epitope phosphorylation threonine residues L1 reported either vitro vivo Salton et al
0.175064.12082080.html.plaintext.txt	118	In contrast least two reports indicate L1 tyrosine phosphorylated vivo Heiland et al
0.175064.12082080.html.plaintext.txt	119	Therefore interested determining kinases phosphorylate L1 Y1176
0.175064.12082080.html.plaintext.txt	120	The nonreceptor tyrosine kinase p60src implicated L1 function Ignelzi et al
0.175064.12082080.html.plaintext.txt	121	Tyrosine phosphorylation CTLA 4 T lymphocyte receptor endocytosis motif src family kinases implicated regulation cell surface expression Bradshaw et al
0.175064.12082080.html.plaintext.txt	122	To determine L1 could substrate p60src tested ability purified p60src phosphorylate recombinant L1CD vitro found L1 phosphorylated kinase Fig
0.175064.12082080.html.plaintext.txt	123	The phosphorylated L1CD digested endoproteinase Asp N resulting fragments separated reverse phase HPLC
0.175064.12082080.html.plaintext.txt	124	One major peptide DETFGEYRSLES identified associated radioactivity
0.175064.12082080.html.plaintext.txt	125	The site phosphorylation peptide determined seventh residue assessing elution radioactivity using covalent sequencing supports allow tracking radiolabeled residues corresponds Y1176
0.175064.12082080.html.plaintext.txt	126	Phosphorylated peptide fragments containing three tyrosines present within L1CD coelute radioactivity indicating p60src preferentially phosphorylates Y1176 amino acid residue plays critical role regulating L1 trafficking endocytosis
0.175064.12082080.html.plaintext.txt	127	View larger version 18K Figure 3
0.175064.12082080.html.plaintext.txt	128	A Ra pYRSLE binds L1CD phosphorylated p60src L1 brain
0.175064.12082080.html.plaintext.txt	129	L1CD phosphorylated p60src lanes 1 3 mock phosphorylated lanes 2 4
0.175064.12082080.html.plaintext.txt	130	Both anti phosphotyrosine monoclonal antibody 4G10 lanes 1 2 Ra pYRSLE lanes 3 4 reacted phosphorylated peptide unphosphorylated peptide
0.175064.12082080.html.plaintext.txt	131	B C Homogenates human H rat R mouse M chick C brain analyzed Western blots
0.175064.12082080.html.plaintext.txt	132	B Rabbit anti rat L1 aRat L1 recognized band 85 kD corresponded major proteolytic cleavage fragment L1
0.175064.12082080.html.plaintext.txt	133	C Rabbit anti pYRSLE pYRSLE recognized 85 kD band
0.175064.12082080.html.plaintext.txt	134	L1 Y1176 phosphorylated vivo The finding 74 5H7 recognizes dephosphorylated L1 restricted distribution 74 5H7 IR relative total L1 IR predicts neuronal L1 phosphorylated Y1176 vivo
0.175064.12082080.html.plaintext.txt	135	To demonstrate Y1176 indeed phosphorylated vivo produced new Ra pYRSLE antibody
0.175064.12082080.html.plaintext.txt	136	This affinity purified antibody showed strong binding KDETFGEpYRSLESDN virtually immunoreactivity KDETFGEYRSLESDN ELISA assays unpublished data
0.175064.12082080.html.plaintext.txt	137	The Ra pYRSLE also bound rL1CD phosphorylated using src anti pY antibody Fig
0.175064.12082080.html.plaintext.txt	138	Neither Ra pYRSLE anti pY antibody bound unphosphorylated rL1CD
0.175064.12082080.html.plaintext.txt	139	Finally Ra pYRSLE bind band corresponding molecular weight L1 human rat mouse chick brain homogenates prepared presence tyrosine phosphatase inhibitors Fig
0.175064.12082080.html.plaintext.txt	140	3 B C demonstrating y1176 indeed phosphorylated vivo
0.175064.12082080.html.plaintext.txt	141	L1 affinity purified mouse brain using 74 5H7 bind Ra pYRSLE one would expect unpublished data
0.175064.12082080.html.plaintext.txt	142	To support idea phosphorylation Y1176 responsible regulating 74 5H7 epitope vivo fresh chick brains homogenized presence absence cocktail tyrosine phosphatase inhibitors 0
0.175064.12082080.html.plaintext.txt	143	2 mM phenyl arsine oxide 5 nM microcystin 100 pM cypermethrin 10 mM pervanadate Tonks et al
0.175064.12082080.html.plaintext.txt	144	The anti pY antibody recognized two prominent bands brain extract L1 served indicators effectiveness phosphatase inhibitors
0.175064.12082080.html.plaintext.txt	145	When inhibitors absent strong signal 74 5H7 epitope seen whereas anti pY antibody gave relatively weak signal Fig
0.175064.12082080.html.plaintext.txt	146	Alternatively inhibitors present 74 5H7 IR relatively weak pY IR strong Fig
0.175064.12082080.html.plaintext.txt	147	The simplest interpretation data phosphatase inhibitors prevent dephosphorylation Y1176 L1 thereby block 74 5H7 binding
0.175064.12082080.html.plaintext.txt	148	View larger version 54K Figure 4
0.175064.12082080.html.plaintext.txt	149	Effect tyrosine phosphatase inhibitors 74 5H7 IR
0.175064.12082080.html.plaintext.txt	150	Fresh chick brains homogenized absence A presence B cocktail phosphatase inhibitors
0.175064.12082080.html.plaintext.txt	151	As expected monoclonal anti pY antibody 4G10 showed stronger binding different proteins extract including phosphatase inhibitors B
0.175064.12082080.html.plaintext.txt	152	74 5H7 binds much strongly L1 extract lacking inhibitors
0.175064.12082080.html.plaintext.txt	153	A rabbit antibody L1 85 kD shows approximately equal amounts L1 two preparations
0.175064.12082080.html.plaintext.txt	154	Phosphorylation L1 Y1176 inhibits L1 binding AP 2 We shown previously using vitro peptide competition assay peptide FGEYRSLESDNEE blocks binding biotin labeled TGN38 peptide AP 2 purified rat brain Kamiguchi et al
0.175064.12082080.html.plaintext.txt	155	This data showed YRSLE sequence mediates L1 binding AP 2 Kamiguchi et al
0.175064.12082080.html.plaintext.txt	156	It known phosphorylation tyrosine tyrosine based sorting motif CTLA 4 inhibit binding AP 2 result inhibit clathrin mediated endocytosis CTLA 4 Shiratori et al
0.175064.12082080.html.plaintext.txt	157	To test L1 compared ability phosphorylated unphosphorylated L1 peptides compete peptide spanning TGN38 tyrosine based sorting motif binding AP 2 Fig
0.175064.12082080.html.plaintext.txt	158	The FGEpYRSLESDNEE peptide phosphorylated Y1176 failed block interaction TGN38 peptide AP 2 indicating L1 phosphorylated Y1176 cannot bind AP 2
0.175064.12082080.html.plaintext.txt	159	In contrast phosphorylation S1181 shown residue phosphorylated CKII Wong et al
0.175064.12082080.html.plaintext.txt	160	1996b gave peptide retained ability block TGN38 binding AP 2 demonstrating CKII phosphorylation L1 would inhibit binding AP 2
0.175064.12082080.html.plaintext.txt	161	View larger version 13K Figure 5
0.175064.12082080.html.plaintext.txt	162	L1 peptide phosphorylated Y1176 cannot bind AP 2
0.175064.12082080.html.plaintext.txt	163	The micro2 chain AP 2 incubated YQRL peptide see Materials methods absence right band presence competitor peptides EpYRSLES EYRSLEpS EYRSLE
0.175064.12082080.html.plaintext.txt	164	The concentrations competitor peptide indicated figures
0.175064.12082080.html.plaintext.txt	165	The EYRSLEpS EYRSLE peptides strong competitors YQRL peptide showing bound micro2 chain AP 2 even concentrations low 10 microM
0.175064.12082080.html.plaintext.txt	166	In contrast EpYRSLES peptide act competitor even 1000 microM
0.175064.12082080.html.plaintext.txt	167	74 5H7 binding L1 dynamically regulated cell cell contact L1 L1 homophilic interactions L1 cross linking The results immunocytochemical studies reported Fig
0.175064.12082080.html.plaintext.txt	168	1 suggested 74 5H7 IR might induced cell cell contact
0.175064.12082080.html.plaintext.txt	169	To directly test idea used cell pelleting paradigm rapidly induce cell cell contact asked whether change 74 5H7 IR could detected Western blots
0.175064.12082080.html.plaintext.txt	170	Mechanically dissociated chick brain cells induced reform cell cell contacts low speed centrifugation
0.175064.12082080.html.plaintext.txt	171	When cells lysed various times cell pelleting lysates analyzed Western blot clear increase 74 5H7 IR observed beginning early 5 min continuing 60 min
0.175064.12082080.html.plaintext.txt	172	The increase followed decrease toward basal levels 3 h cells pelleted Fig
0.175064.12082080.html.plaintext.txt	173	The presence intact L1 throughout time course confirmed reprobing blots polyclonal anti L1 antibody 8D9
0.175064.12082080.html.plaintext.txt	174	These results indicate change 74 5H7 IR rapidly transiently induced cell cell contact
0.175064.12082080.html.plaintext.txt	175	View larger version 33K Figure 6
0.175064.12082080.html.plaintext.txt	176	Cell cell contact induces transient increase 74 5H7 IR
0.175064.12082080.html.plaintext.txt	177	Mechanically dissociated chick brain cells forced reform contacts low speed centrifugation
0.175064.12082080.html.plaintext.txt	178	After various periods time cell pellets extracted analyzed Western blot 74 5H7 IR
0.175064.12082080.html.plaintext.txt	179	The blots stripped reprobed total L1 labeling polyclonal anti L1 antibody 8D9
0.175064.12082080.html.plaintext.txt	180	The graph shows relative 74 5H7 IR L1 compared polyclonal anti L1 8D9 labeling various times pelleting
0.175064.12082080.html.plaintext.txt	181	Although cell pelleting experiments described indicate cell cell contact dramatically increases 74 5H7 IR cell pelleting paradigm involves inducing contact among many types cell surface receptors present brain cells addition L1
0.175064.12082080.html.plaintext.txt	182	Therefore ask whether increase 74 5H7 IR induced specifically L1 L1 interactions used stable lines myeloma cells transfected express L1
0.175064.12082080.html.plaintext.txt	183	These cells normally nonadhesive form L1 dependent aggregates express L1 Wong et al
0.175064.12082080.html.plaintext.txt	184	Immunocytochemistry myeloma cells expressing full length L1 shows 74 5H7 IR localized regions cell cell contact Fig
0.175064.12082080.html.plaintext.txt	185	7 A whereas labeling L1 polyclonal antibody raised recombinant L1CD shows uniform cell surface distribution L1 Fig
0.175064.12082080.html.plaintext.txt	186	Colocalization two antibodies shown yellow cell cell contact site Fig
0.175064.12082080.html.plaintext.txt	187	This result consistent L1 L1 homophilic binding sufficient mediate changes 74 5H7 IR cell cell contact sites
0.175064.12082080.html.plaintext.txt	188	View larger version 15K Figure 7
0.175064.12082080.html.plaintext.txt	189	L1 L1 mediated cell adhesion induces 74 5H7 IR
0.175064.12082080.html.plaintext.txt	190	Immunocytochemistry myeloma cells expressing full length L1 double labeled A 74 5H7 B polyclonal anti L1CD
0.175064.12082080.html.plaintext.txt	191	The confocal images show 74 5H7 IR concentrated points cell cell contact whereas polyclonal anti L1CD IR present around entire cell surface
0.175064.12082080.html.plaintext.txt	192	C Superimposition images 74 5H7 green polyclonal anti L1CD red
0.175064.12082080.html.plaintext.txt	193	The cell pelleting data indicate 74 5H7 epitope rapidly transiently induced
0.175064.12082080.html.plaintext.txt	194	Previous work lab shown L1 phosphorylated multiple sites Wong et al
0.175064.12082080.html.plaintext.txt	195	Regulation epitope preserved myeloma cells expressing L1 first 33 amino acids cytoplasmic domain indicating potential posttranslational modification restricted region L1CD Fig
0.175064.12082080.html.plaintext.txt	196	Similar results obtained myeloma cells expressing full length L1 L1 expressing 3T3 cells Cos 7 cells
0.175064.12082080.html.plaintext.txt	197	View larger version 43K Figure 8
0.175064.12082080.html.plaintext.txt	198	Myeloma cells expressing L1 1 1176
0.175064.12082080.html.plaintext.txt	199	truncation Y1176 centrifuged low speed induce cell cell contact
0.175064.12082080.html.plaintext.txt	200	After various periods time cell pellets extracted analyzed Western blot 74 5H7 IR polyclonal anti human L1 IR
0.175064.12082080.html.plaintext.txt	201	The graph shows relative change 74 5H7 IR compared polyclonal anti human L1 immunostaining
0.175064.12082080.html.plaintext.txt	202	To determine whether change 74 5H7 IR induced L1 binding neurons used L1 cross linking polyclonal antibodies mimic L1 binding
0.175064.12082080.html.plaintext.txt	203	Cross linking L1 antibodies shown induce changes number intracellular second messengers including Ca2 IP2 IP3 von Bohlen und Halbach et al
0.175064.12082080.html.plaintext.txt	204	1992 well activate MAPK signaling cascade Schaefer et al
0.175064.12082080.html.plaintext.txt	205	1999 phosphatases Klinz et al
0.175064.12082080.html.plaintext.txt	206	In addition cross linking L1 L1 heterophilic binding partners axonin 1 F3F11 also regulate phosphorylation state L1 Zisch et al
0.175064.12082080.html.plaintext.txt	207	74 5H7 IR observed points cell cell contact cultured neurons without L1 antibody cross linking Fig
0.175064.12082080.html.plaintext.txt	208	74 5H7 IR dramatically regulated cross linking L1 DRG neurons culture polyclonal anti L1 antibodies 8D9 Fig
0.175064.12082080.html.plaintext.txt	209	9 C compared isolated neurons without L1 antibody cross linking Fig
0.175064.12082080.html.plaintext.txt	210	In variation L1 cross linking experiment took mechanically dissociated chick brain cells preincubated 4 degrees C cross linking polyclonal L1 antibodies 8D9 brought cells 37 degrees C induce cross linking L1 cell surface
0.175064.12082080.html.plaintext.txt	211	The cells lysed various times L1 immunoprecipitated
0.175064.12082080.html.plaintext.txt	212	The immunoprecipitates analyzed Western blot clear time course 74 5H7 IR observed
0.175064.12082080.html.plaintext.txt	213	74 5H7 IR L1 peaked 5 min returned baseline levels 30 min Fig
0.175064.12082080.html.plaintext.txt	214	Together results indicate 74 5H7 epitope dynamically regulated cell surface L1 induced L1 L1 homophilic binding L1 cross linking
0.175064.12082080.html.plaintext.txt	215	View larger version 39K Figure 9
0.175064.12082080.html.plaintext.txt	216	L1 cross linking induces 74 5H7 IR
0.175064.12082080.html.plaintext.txt	217	Immunocytochemistry DRG neurons plated laminin substrate labeled 74 5H7
0.175064.12082080.html.plaintext.txt	218	A An isolated cell showing typically low 74 5H7 IR
0.175064.12082080.html.plaintext.txt	219	B A group cells showing 74 5H7 IR cell cell contact sites
0.175064.12082080.html.plaintext.txt	220	C A cell preincubated alive L1 cross linking polyclonal antibodies 8D9 60 min shows increased levels 74 5H7 IR
0.175064.12082080.html.plaintext.txt	221	D Mechanically dissociated chick brain cells suspension incubated L1 polyclonal antibodies 8D9 30 min 4 degrees C
0.175064.12082080.html.plaintext.txt	222	The cells incubated 37 degrees C various periods time induce L1 cross linking
0.175064.12082080.html.plaintext.txt	223	The cells extracted L1 immunoprecipitated protein A beads immunoprecipitates analyzed Western blot 74 5H7 IR
0.175064.12082080.html.plaintext.txt	224	Discussion Top Abstract Introduction Results Discussion Materials methods References We presented evidence L1 homophilic binding L1 cross linking cell surface induce transient change phosphorylation state L1CD regulate association endocytic machinery
0.175064.12082080.html.plaintext.txt	225	This regulation L1 internalization provides means control adhesion facilitate growth cone movement
0.175064.12082080.html.plaintext.txt	226	Our present studies depend large measure mAb 74 5H7
0.175064.12082080.html.plaintext.txt	227	Several lines evidence showed antibody binds subset L1 binding L1 negatively regulated phosphorylation
0.175064.12082080.html.plaintext.txt	228	First several epitope mapping experiments demonstrate 74 5H7 recognizes sequence SEARPMKDETFGEY phosphorylation Y1176 inhibits recognition
0.175064.12082080.html.plaintext.txt	229	Second L1 purified brain extract presence phosphatase inhibitors weak 74 5H7 IR whereas L1 purified absence inhibitors shows stronger 74 5H7 IR
0.175064.12082080.html.plaintext.txt	230	We showed L1CD could phosphorylated src Y1176 antibody specific pYRSLE showed corresponding epitope L1 present brain
0.175064.12082080.html.plaintext.txt	231	Immunohistochemical studies growth cones 74 5H7 revealed form L1 restricted absent filopodia concentrated vesicle like structures
0.175064.12082080.html.plaintext.txt	232	Finally experiments using neurons L1 expressing myelomas showed cell contact antibody cross linking L1 caused significant transient changes phosphorylation state L1 Y1176
0.175064.12082080.html.plaintext.txt	233	Together data show L1 mediated contact causes outside signal alters phosphorylation state L1 turn alters L1 internalization adhesion form inside signaling
0.175064.12082080.html.plaintext.txt	234	The SEARPMKDETFGEY sequence 74 5H7 binds perfectly conserved human mouse rat chicken fugu fish L1 homologues
0.175064.12082080.html.plaintext.txt	235	Although complete SEARPMKDETFGEY sequence conserved vertebrate L1 homologues acidic residues NH2 terminal Y1176 hydrophobic residue Y 3 position conserved direct L1 homologues also L1 family members Nr CAM neurofascin Hortsch 1996
0.175064.12082080.html.plaintext.txt	236	Previous data implicate p60 src L1 function src neurons extend poorly L1 substrates suggesting response L1 impaired Ignelzi et al
0.175064.12082080.html.plaintext.txt	237	Our finding p60src phosphorylate Y1176 provides potential mechanistic insight phenotype
0.175064.12082080.html.plaintext.txt	238	We suggest L1 src neurons grown L1 may relatively hypophosphorylated Y1176
0.175064.12082080.html.plaintext.txt	239	This could alter regulation L1 endocytosis disruption L1 trafficking could turn impair neurite outgrowth L1
0.175064.12082080.html.plaintext.txt	240	Suter Forscher 2001 recently showed p60src activity could involved positive feedback loop strengthening CAM interactions cytoskeletal linkages
0.175064.12082080.html.plaintext.txt	241	Our data support similar role p60src could phosphorylate L1 certain conditions thereby inhibiting internalization increasing adhesion
0.175064.12082080.html.plaintext.txt	242	The 74 5H7 epitope adjacent tyrosine based motif Yxx bulky hydrophobic amino acid L1CD mediates L1 endocytosis Kamiguchi et al
0.175064.12082080.html.plaintext.txt	243	Studies tyrosine based sorting motifs proteins indicate tyrosine nonphosphorylated state signals active sorting endocytosis
0.175064.12082080.html.plaintext.txt	244	phosphorylation tyrosine prevents binding adaptin proteins motif Boll et al
0.175064.12082080.html.plaintext.txt	245	Indeed vitro peptide competition experiments using peptides derived L1 show Y1176 phosphorylated peptide corresponding potential p60src phosphorylation site FGEpYRSLESDNEE longer able bind micro2 chain AP 2 whereas serine 1181 phosphorylated peptide corresponding CKII phosphorylation site FGEYRSLEpSDNEE retains capacity associate micro2
0.175064.12082080.html.plaintext.txt	246	It highly unlikely T1172 influences L1 AP 2 interactions evidence suggesting phosphorylated extensive studies show fourth residue amino terminal direction influence micro2 binding tyrosine based sorting motifs Boll et al
0.175064.12082080.html.plaintext.txt	247	Our results show 74 5H7 IR inhibited phosphorylation Y1176 src family kinases may mediate
0.175064.12082080.html.plaintext.txt	248	Similarly clathrin mediated endocytosis T lymphocyte receptor CTLA 4 shown negatively regulated phosphorylation critical tyrosine endocytosis motif Bradshaw et al
0.175064.12082080.html.plaintext.txt	249	1997 likely src family kinases Miyatake et al
0.175064.12082080.html.plaintext.txt	250	Overall results imply L1 bind 74 5H7 capable interacting clathrin mediated endocytic machinery
0.175064.12082080.html.plaintext.txt	251	This consistent finding growth cones growing L1 substrates 74 5H7 IR rear growth cones L1 internalized colocalizes Eps15 marker clathrin coated pits Kamiguchi et al
0.175064.12082080.html.plaintext.txt	252	We shown previously inhibition L1 endocytosis dramatically increases L1 mediated adhesion Long et al
0.175064.12082080.html.plaintext.txt	253	L1 rear growth cones growing L1 less adhesive L1 front growth cones differential observed growth cones growing N cadherin Kamiguchi Yoshihara 2001
0.175064.12082080.html.plaintext.txt	254	Therefore phosphorylation Y1176 provides rapid reversible means increasing L1 mediated adhesion
0.175064.12082080.html.plaintext.txt	255	The hypothesis 74 5H7 epitope regulated phosphorylationdephosphorylation implies involvement L1 phosphatases regulation consistent early results show cross linking L1 activates tyrosine serine phosphatases Klinz et al
0.175064.12082080.html.plaintext.txt	256	A number potential candidate phosphatases exist
0.175064.12082080.html.plaintext.txt	257	These include phosphotyrosine phosphatases PTPases prefer substrates containing acidic residues NH2 terminal phosphotyrosine PTP1B rat brain PTP1 review see Zhou Cantley 1995
0.175064.12082080.html.plaintext.txt	258	Another candidate receptor protein tyrosine phosphatase ss ability bind heterophilically L1 family CAMs
0.175064.12082080.html.plaintext.txt	259	The phosphatase may also coexpressed cell types L1 Peles et al
0.175064.12082080.html.plaintext.txt	260	It suggested acidic residues NH2 terminal phosphotyrosine residue hallmark targeted dephosphorylation Pinna Ruzzene 1996 number nature position acidic residues may create consensus sequences recognized selectively individual PTPases Pinna Donella Deana 1994
0.175064.12082080.html.plaintext.txt	261	The simplest interpretation biochemical analysis 74 5H7 epitope unengaged L1 phosphorylated Y1176 Y1176 becomes dephosphorylated subsequent L1 ligand binding
0.175064.12082080.html.plaintext.txt	262	Dephosphorylation allows interaction AP 2 clathrin mediated endocytosis
0.175064.12082080.html.plaintext.txt	263	In paradigm time course 74 5H7 IR observed cell pelleting experiments could reflect internalization subsequent recycling rephosphorylation L1
0.175064.12082080.html.plaintext.txt	264	Our immunohistochemical observations distribution 74 5H7 IR suggest situation complex however L1 L1 binding always induce L1 endocytosis
0.175064.12082080.html.plaintext.txt	265	First L1 mediate stable axon fasciculation suggesting invariably endocytosed points L1 L1 binding
0.175064.12082080.html.plaintext.txt	266	Second although growing DRG neurons L1 increases L1 internalization subsequent recycling Kamiguchi Lemmon 2000 Kamiguchi Yoshihara 2001 endocytosis L1 occurs preferentially rear growth cone
0.175064.12082080.html.plaintext.txt	267	74 5H7 IR colocalized vesicle like structures neurons rather points contact growth cone L1 Fc substrate Kamiguchi et al
0.175064.12082080.html.plaintext.txt	268	These observations suggest dephosphorylation Y1176 L1 endocytosis growth cones regulated solely L1 L1 binding also restricted localization dephosphorylation machinery
0.175064.12082080.html.plaintext.txt	269	We cannot rule possibility vivo 74 5H7 epitope L1 masked interactions proteins cytoskeletal components Brophy 2001
0.175064.12082080.html.plaintext.txt	270	Thus although 74 5H7 clearly identifies subset L1 cells dephosphorylated Y1176 may populations L1 dephosphorylated Y1176 accessible antibody thus visualized immunocytochemical experiments
0.175064.12082080.html.plaintext.txt	271	In summary used 74 5H7 show L1 dephosphorylated Y1176 L1 internalized trafficking growth cones
0.175064.12082080.html.plaintext.txt	272	We also shown phosphorylation state Y1176 determines whether L1 interact clathrin internalization machinery
0.175064.12082080.html.plaintext.txt	273	A variety experiments showed phosphorylationdephosphorylation state L1 regulated cell contact restricted specific sites neurons
0.175064.12082080.html.plaintext.txt	274	The phosphorylation L1CD Y1176 p60src important L1 mediated neurite outgrowth raises possibility regulation L1 internalization phosphorylation dephosphorylation represents critical regulatory point L1
0.175064.12082080.html.plaintext.txt	275	The ability L1 L1 adhesion influence endocytosis reminiscent surfaces influence integrin expression neurites Condic Letourneau 1997
0.175064.12082080.html.plaintext.txt	276	In Aplysia distribution apCAM IgSF CAM member acutely regulated endocytosis learning induced synaptic remodeling Bailey et al
0.175064.12082080.html.plaintext.txt	277	1992 whereas Drosophila changing distribution another IgSF member fasciclin II alters synapse size Schuster et al
0.175064.12082080.html.plaintext.txt	278	It appears regulated endocytosis may general mechanism underlying CAM functions dynamic processes cell migration neurite outgrowth synaptic plasticity
0.175064.12082080.html.plaintext.txt	279	Materials methods Top Abstract Introduction Results Discussion Materials methods References Materials Protease inhibitors Pefabloc SC leupeptin aprotinin well HRP conjugated goat anti rabbit antibodies Boehringer
0.175064.12082080.html.plaintext.txt	280	Texas red Oregon green conjugated anti rabbit IgGs Molecular Probes Inc
0.175064.12082080.html.plaintext.txt	281	Anti phosphotyrosine antibody 4G10 recombinant human p60src Upstate Biotechnology
0.175064.12082080.html.plaintext.txt	282	The anti L1 antibodies produced laboratory include polyclonal anti chicken L1 antibody 8D9 Lemmon McLoon 1986 polyclonal anti human L1 antibody Hlavin Lemmon 1991 polyclonal anti recombinant L1 cytoplasmic domain 74 5H7 mouse monoclonal anti L1 Lemmon et al
0.175064.12082080.html.plaintext.txt	283	The new rabbit anti pYRSLE antibody made conjunction Eurogentec 32PH3PO4 purchased ICN Biomedicals
0.175064.12082080.html.plaintext.txt	284	Genosys synthesized L1 cytoplasmic domain synthetic peptides used characterize mAb 74 5H7 custom alanine substitution peptides well phosphopeptides directly onto solid cellulose based support using SPOTsTM technology
0.175064.12082080.html.plaintext.txt	285	The Immobilon P polyvinyldifluoridene PVDF membrane Millipore
0.175064.12082080.html.plaintext.txt	286	RenaissanceTM enhanced chemiluminescent detection reagents NEN Life Science Products
0.175064.12082080.html.plaintext.txt	287	Tissue culture reagents GIBCO BRL
0.175064.12082080.html.plaintext.txt	288	The following tyrosine phosphatase inhibitors used microcystin cypermethrin Calbiochem molybdate phenylarsine oxide orthovanadate Sigma Aldrich
0.175064.12082080.html.plaintext.txt	289	All chemicals purchased Sigma Aldrich
0.175064.12082080.html.plaintext.txt	290	DRG cell culture DRG dissected embryonic day 10 chicks dissociated 0
0.175064.12082080.html.plaintext.txt	291	1 DNase Ca2Mg2 free HBSS grown glass coverslips sequentially coated poly L lysine 10 microgml goat anti human IgG Fc specific L1 Fc chimera Kamiguchi et al
0.175064.12082080.html.plaintext.txt	292	Some DRG neurons grown glass coverslips coated poly L lysine 10 microgml laminin
0.175064.12082080.html.plaintext.txt	293	L1 expressing myeloma cell lines L1 expressing myeloma cells described previously Wong et al
0.175064.12082080.html.plaintext.txt	294	Cell surface expression L1 transfected myelomas evaluated live cell staining immunofluorescence stable cell lines cloned using FACS subsequently sorted FACS produce lines identical expression levels
0.175064.12082080.html.plaintext.txt	295	Chick brain cell suspension Whole brains dissected E10 chick embryos meninges carefully removed
0.175064.12082080.html.plaintext.txt	296	The brains broken small fragments passing 300 microm nylon mesh
0.175064.12082080.html.plaintext.txt	297	The fragments incubated ice DME supplemented 1 mM EDTA 5 min run 50 microm nylon mesh
0.175064.12082080.html.plaintext.txt	298	The fragments pelleted centrifugation washed DME10 FCS pelleted remove EDTA
0.175064.12082080.html.plaintext.txt	299	A single cell suspension obtained trituration flame polished Pasteur pipettes
0.175064.12082080.html.plaintext.txt	300	The cells centrifuged DME50 FCS cushion remove cell fragments vesicles
0.175064.12082080.html.plaintext.txt	301	Finally cells resuspended DME10 FCS counted plated 15 cm tissue culture dishes tissue culture incubator 37 degrees C 5 CO2 1 h
0.175064.12082080.html.plaintext.txt	302	Cell pelleting L1 cross linking time course experiments The chick brain cells suspension transferred 15 ml conical tubes 5 x 106 cells 5 ml centrifuged clinical centrifuge 30 replaced tissue culture incubator
0.175064.12082080.html.plaintext.txt	303	At time point 0 5 15 30 45 60 120 180 min pelleted cells removed incubator
0.175064.12082080.html.plaintext.txt	304	The cells extracted 20 mM Tris pH 7
0.175064.12082080.html.plaintext.txt	305	4 1 mM EGTA 2 mM sodium orthovanadate 10 mM p nitrophenyl phosphate TEV PNP containing 0
0.175064.12082080.html.plaintext.txt	306	25 SDS 1 NP 40 40 mM sodium fluoride protease inhibitors 200 microM Pefabloc SC 1 microgml leupeptin 100 microgml aprotinin 5 microgml turkey trypsin inhibitor
0.175064.12082080.html.plaintext.txt	307	The cell extracts incubated 30 min ice centrifuged microfuge maximum speed 10 min 4 degrees C
0.175064.12082080.html.plaintext.txt	308	SDS PAGE sample buffer added supernatants samples boiled 5 min
0.175064.12082080.html.plaintext.txt	309	The samples separated SDS PAGE 5 15 gradient gel transferred PVDF membrane membrane blocked 5 evaporated nonfat milk 0
0.175064.12082080.html.plaintext.txt	310	The membrane incubated 74 5H7 washed probed HRP goat anti mouse antibodies reactive proteins visualized chemiluminescence
0.175064.12082080.html.plaintext.txt	311	Blots stripped reprobed polyclonal anti L1 antibodies assess protein loading
0.175064.12082080.html.plaintext.txt	312	The relative intensity bands quantified using transmittance densitometry NIH Image analysis software
0.175064.12082080.html.plaintext.txt	313	In experiments samples divided half immunostained 74 5H7 polyclonal anti L1 antibodies separately
0.175064.12082080.html.plaintext.txt	314	The 74 5H7 IR time course observed stripping reprobing procedure
0.175064.12082080.html.plaintext.txt	315	In L1 cross linking experiments chick brain cells suspension 106ml preincubated ice polyclonal anti L1 8D9 cross linking antibodies 30 min
0.175064.12082080.html.plaintext.txt	316	The cells brought 37 degrees C various periods time induce L1 clustering antibodies spun microfuge 30 extracted L1 immunoprecipitated protein A beads 1 h
0.175064.12082080.html.plaintext.txt	317	Immunocytochemistry DRG neurons L1 expressing myeloma cells Cells fixed modified Bouins solution containing 75 ml saturated picric acid 5 ml formalin 5 ml glacial acidic acid 20 ml distilled water 5 min
0.175064.12082080.html.plaintext.txt	318	The cells washed PBS permeabilized blocked solution 10 horse serum0
0.175064.12082080.html.plaintext.txt	319	02 Triton X 100 PBS 1 h
0.175064.12082080.html.plaintext.txt	320	Cells incubated primary antibodies overnight 4 degrees C
0.175064.12082080.html.plaintext.txt	321	Polyclonal anti L1 antibodies added undiluted 74 5H7 hybridoma culture supernatant
0.175064.12082080.html.plaintext.txt	322	In experiments live cells incubated 1 h polyclonal anti L1 antibodies 1250 cross link L1 cell surface
0.175064.12082080.html.plaintext.txt	323	The cells rinsed prewarmed tissue culture medium fixed stained 74 5H7 followed fluorescent secondary antibodies Schaefer et al
0.175064.12082080.html.plaintext.txt	324	Confocal microscopy Images DRG neurons L1 expressing myeloma cells taken confocal laser microscope model LSM 410 ZEISS using argonkrypton laser excitation lines 488 568 nm 100x Plan Neofluor NA 1
0.175064.12082080.html.plaintext.txt	325	Peptide sequencing 20 microg recombinant L1CD prepared described previously Wong et al
0.175064.12082080.html.plaintext.txt	326	1996b phosphorylated recombinant human p60src TEV PNP containing 10 mM MgCl2 2 mM MnCl2 5 mM ATP 20 microCi 32PATP
0.175064.12082080.html.plaintext.txt	327	The L1CD isolated running sample SDS PAGE 5 15 gradient gel transferring proteins PVDF membrane cutting radiolabeled L1CD band
0.175064.12082080.html.plaintext.txt	328	The sample digested endoproteinase Asp N 18 h 37 degrees C resulting peptides separated HPLC C 18 reverse phase column
0.175064.12082080.html.plaintext.txt	329	The fractions containing significant protein radioactivity sequenced ABI protein sequencer University Kentucky Macromolecular Structural Analysis Facility
0.175064.12082080.html.plaintext.txt	330	Rabbit anti phosphoYRSLE pYRSLE production characterization A new affinity purified rabbit antibody pYRSLE made immunizing rabbit peptide KDETFGEpYRSLESDN purifying antibody column peptide
0.175064.12082080.html.plaintext.txt	331	The bound antibodies eluted run peptide column KDETFGEYRSLESDN remove antibodies recognize unphosphorylated L1
0.175064.12082080.html.plaintext.txt	332	To demonstrate Ra pYRSLE antibody recognized appropriate epitope recombinant L1CD phosphorylated src ATP run SDS gel transferred PVDF membrane Western blots done
0.175064.12082080.html.plaintext.txt	333	Studies effect phosphorylation L1CD interactions AP 2 The photoactivation cross linking reaction performed described previously Rapoport et al
0.175064.12082080.html.plaintext.txt	334	In brief AP 2 complexes purified calf brain incubated peptide including tyrosine based sorting motif TGN38 biotin photo activatible cross linking reagent
0.175064.12082080.html.plaintext.txt	335	Competitor peptides Research Genetics simultaneously added varying concentrations
0.175064.12082080.html.plaintext.txt	336	The peptides included FGEYRSLESDNEE corresponds amino acids 1173 1185 L1CD two phosphopeptides FGEpYRSLESDNEE FGEYRSLEpSDNEE
0.175064.12082080.html.plaintext.txt	337	After allowing mixtures incubate dark cross linked UV
0.175064.12082080.html.plaintext.txt	338	The samples run SDS PAGE transferred nitrocellulose incubated streptavidin conjugated HRP Boehringer
0.175064.12082080.html.plaintext.txt	339	The labeled bands detected via chemiluminescence
0.175064.12082080.html.plaintext.txt	340	ECL films densitometry scanned imaging densitometer model GS 710 Bio Rad Laboratories using Quantity One V4
0.175064.12082080.html.plaintext.txt	341	All images prepared Adobe Photoshop 5
0.175064.12082080.html.plaintext.txt	342	Wongs present address Department Biology University Louisville Louisville KY 40292
0.175064.12082080.html.plaintext.txt	343	Schaefers present address Department Molecular Cellular Developmental Biology Yale University New Haven CT 06520
0.175064.12082080.html.plaintext.txt	344	Kamiguchis present address Developmental Brain Science Group RIKEN Brain Science Institute 2 1 Hirosawa Wako Saitama 351 0198 Japan
0.175064.12082080.html.plaintext.txt	345	Abbreviations used paper 74 5H7 IR 74 5H7 immunoreactivity DRG dorsal root ganglion IR immunoreactivity L1CD L1 cytoplasmic domain PVDF polyvinyldifluoridene Y1176 tyrosine 1176
0.175064.12082080.html.plaintext.txt	346	Acknowledgments We grateful excellent technical assistance G
0.175064.12082080.html.plaintext.txt	347	Weaver helpful discussions U
0.175064.12082080.html.plaintext.txt	348	Storms assistance early phases project helpful comments reviewers
0.175064.12082080.html.plaintext.txt	349	This work supported grants National Institutes Health EY 05285 EY 11373 V
0.175064.12082080.html.plaintext.txt	350	Kirchhausen RIKEN Brain Science Institute H
0.175064.12082080.html.plaintext.txt	351	Submitted 6 March 2002Revised 7 May 2002Accepted 7 May 2002
0.175064.12082080.html.plaintext.txt	352	References Top Abstract Introduction Results Discussion Materials methods References
0.175064.12082080.html.plaintext.txt	353	Serotonin mediated endocytosis apCAM An early step learning related synaptic growth Aplysia
0.175064.12082080.html.plaintext.txt	354	Sequence requirements recognition tyrosine based endocytic signals clathrin AP 2 complexes
0.175064.12082080.html.plaintext.txt	355	Axoglial junctions separate channels scramble message
0.175064.12082080.html.plaintext.txt	356	CAM FGF receptor interactions model axonal growth
0.175064.12082080.html.plaintext.txt	357	Biosynthesis membrane topography neural cell adhesion molecule L1
0.175064.12082080.html.plaintext.txt	358	Molecular structure functional testing human L1CAM interspecies comparison
0.175064.12082080.html.plaintext.txt	359	Impaired neurite outgrowth src minus cerebellar neurons cell adhesion molecule L1
0.175064.12082080.html.plaintext.txt	360	Recycling cell adhesion molecule L1 axonal growth cones
0.175064.12082080.html.plaintext.txt	361	The role endocytic L1 trafficking polarized adhesion migration nerve growth cones
0.175064.12082080.html.plaintext.txt	362	The neural cell adhesion molecule L1 interacts AP 2 adaptor endocytosed via clathrin mediated pathway
0.175064.12082080.html.plaintext.txt	363	Intracellular signaling changed clustering neural cell adhesion molecules axonin 1 NgCAM neurite fasciculation
0.175064.12082080.html.plaintext.txt	364	The appearance L1 like molecule chick primary visual pathway
0.175064.12082080.html.plaintext.txt	365	Developmental study cell adhesion molecule L1
0.175064.12082080.html.plaintext.txt	366	The role endocytosis regulating L1 mediated adhesion
0.175064.12082080.html.plaintext.txt	367	Src family tyrosine kinases associate phosphorylate CTLA 4 CD152
0.175064.12082080.html.plaintext.txt	368	Structural determinants interaction tyrosine based sorting signals adaptor medium chains
0.175064.12082080.html.plaintext.txt	369	Phosphorylated synthetic peptides tools studying protein phosphatases
0.175064.12082080.html.plaintext.txt	370	Regulatory interactions recognition endocytic sorting signals AP 2 complexes
0.175064.12082080.html.plaintext.txt	371	Biochemical properties nerve growth factor inducible large external NILE glycoprotein
0.175064.12082080.html.plaintext.txt	372	Activation MAPK signal cascade neural cell adhesion molecule L1 requires L1 internalization
0.175064.12082080.html.plaintext.txt	373	Tyrosine phosphorylation controls internalization CTLA 4 regulating interaction clathrin associated adaptor complex AP 2
0.175064.12082080.html.plaintext.txt	374	Transmission growth cone traction force apCAM cytoskeletal linkages regulated Src family tyrosine kinase activity
0.175064.12082080.html.plaintext.txt	375	Purification major protein tyrosine phosphatases human placenta
0.175064.12082080.html.plaintext.txt	376	The phosphorylation state FIGQY tyrosine neurofascin determines ankyrin binding activity patterns cell segregation
0.175064.12082080.html.plaintext.txt	377	The cytoplasmic domain cell adhesion molecule L1 required homophilic adhesion
0.175064.12082080.html.plaintext.txt	378	Involvement p90rsk neurite outgrowth mediated cell adhesion molecule L1
0.175064.12082080.html.plaintext.txt	379	Recognition specificity protein tyrosine kinase mediated signaling
0.175064.12082080.html.plaintext.txt	380	Tyrosine phosphorylation L1 family adhesion molecules implication Eph kinase Cek5
0.175064.12082080.html.plaintext.txt	381	CO2 7linktypeDOI CrossRefMedline
0.175064.12082080.html.plaintext.txt	382	L1 sticks around Nicole LeBrasseur J
0.22649837.12466192.html.plaintext.txt	0	Activation knirps locus links patterning morphogenesis second wing vein Drosophila Karen Lunde12 Jennifer L
0.22649837.12466192.html.plaintext.txt	1	Trimble1 Annabel Guichard1 Kirsten A
0.22649837.12466192.html.plaintext.txt	2	Guss3 Ulrich Nauber4 Ethan Bier1
0.22649837.12466192.html.plaintext.txt	3	1 Section Cell Developmental Biology University California San Diego 9500 Gilman Drive La Jolla CA 92093 0349 USA 2 Albert Ludwigs Universitat Freiburg Institut fur Biologie I Hauptstrasse 1 D 79104 Freiburg Germany 3 Department Biology Dickinson College PO Box 1773 Carlisle PA 17013 USA 4 Max Planck Institut fur biophysikalische Chemie Abt
0.22649837.12466192.html.plaintext.txt	4	Molekulare Entwicklungsbiologie Am Fassberg 11 D 37077 Gottingen Germany
0.22649837.12466192.html.plaintext.txt	5	Author correspondence e mail bieratbiomail
0.22649837.12466192.html.plaintext.txt	6	SUMMARY TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES The adjacent knirps kni knirps related knrl genes encode functionally related zinc finger transcription factors collaborate initiate development second longitudinal wing vein L2
0.22649837.12466192.html.plaintext.txt	7	kni knrl expressed third instar larval wing disc narrow stripe cells anterior broad central zone cells expressing high levels related spalt genes
0.22649837.12466192.html.plaintext.txt	8	4 kb cis acting enhancer element kni locus faithfully directs gene expression L2 primordium
0.22649837.12466192.html.plaintext.txt	9	We find three independent ri alleles alterations mapping within L2 enhancer element show two observed lesions eliminate ability enhancer element direct gene expression L2 primordium
0.22649837.12466192.html.plaintext.txt	10	The L2 enhancer subdivided distinct activation repression domains
0.22649837.12466192.html.plaintext.txt	11	The activation domain mediates combined action general wing activator Scalloped putative locally provided factor activity abrogated single nucleotide alteration ri53j mutant
0.22649837.12466192.html.plaintext.txt	12	We also find misexpression genes L2 normally expressed veins L2 results abnormal L2 development
0.22649837.12466192.html.plaintext.txt	13	These experiments provide mechanistic basis understanding kni knrl link AP patterning morphogenesis L2 vein orchestrating expression selective subset vein promoting genes L2 primordium
0.22649837.12466192.html.plaintext.txt	14	Key words knirps radius incompletus L2 vein wing Drosophila melanogaster Patterning Morphogenesis
0.22649837.12466192.html.plaintext.txt	15	INTRODUCTION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES One important remaining questions developmental biology understand positional information linked genesis specific morphological structures different locations organism
0.22649837.12466192.html.plaintext.txt	16	The Drosophila wing system particularly well suited studying relationship patterning morphogenesis
0.22649837.12466192.html.plaintext.txt	17	For example mechanisms establishing positional information along anterior posterior AP axis analyzed detail reviewed Lawrence Struhl 1996 Strigini Cohen 1999 Klein 2001 morphological structures five major longitudinal veins L1 L5 form invariant positions along AP axis adult wing reviewed Garcia Bellido de Celis 1992 Bier 2000
0.22649837.12466192.html.plaintext.txt	18	As described five wing veins distinguished one another several criteria including expression specific combinations genes development whether located primarily dorsal ventral surfaces wing odd versus even numbered veins respectively types absence sensory organs form along e
0.22649837.12466192.html.plaintext.txt	19	sensory organs form L1 L3 veins L2 L4 L5 veins
0.22649837.12466192.html.plaintext.txt	20	An interesting question vein specific well general vein developmental programs initiated various locations response different positional information
0.22649837.12466192.html.plaintext.txt	21	Wing vein development Drosophila subdivided two temporally distinct stages initiation differentiation
0.22649837.12466192.html.plaintext.txt	22	Vein initiation begins mid third larval instar Waddington 1940 Garcia Bellido 1977 Garcia Bellido de Celis 1992 Sturtevant et al
0.22649837.12466192.html.plaintext.txt	23	1993 Sturtevant Bier 1995 Bier 2000 wing imaginal disc monolayer cells
0.22649837.12466192.html.plaintext.txt	24	The wing blade proper derives oval region wing disc known wing pouch remainder disc generates elements wing hinge thoracic body wall
0.22649837.12466192.html.plaintext.txt	25	Vein differentiation second phase vein development occurs metamorphosis wing disc buds everts folding along future wing margin
0.22649837.12466192.html.plaintext.txt	26	Ultimately eversion leads apposition dorsal ventral surfaces wing pupal development creating bilayer cells comprising mature wing blade
0.22649837.12466192.html.plaintext.txt	27	Genes involved initiating wing vein development vein genes expressed third larval instar narrow stripes corresponding vein primordia broader provein stripes consisting cells competent become vein cells Biehs et al
0.22649837.12466192.html.plaintext.txt	28	Some vein genes expressed vein primordia others expressed subsets veins single veins
0.22649837.12466192.html.plaintext.txt	29	For example rhomboid rho encodes integral membrane protein Bier et al
0.22649837.12466192.html.plaintext.txt	30	1996 expressed vein primordia promotes vein formation throughout wing development locally activating Egfr signaling pathway Sturtevant et al
0.22649837.12466192.html.plaintext.txt	31	1994 Bier 1998a Bier 1998b Guichard et al
0.22649837.12466192.html.plaintext.txt	32	caupolican caup neighboring gene araucan ara encode related homeobox genes promote expression vein genes rho odd numbered veins
0.22649837.12466192.html.plaintext.txt	33	Proneural genes achaete ac scute sc promote neural development L1 L3 primordium Gomez Skarmata et al
0.22649837.12466192.html.plaintext.txt	34	Delta Dl encodes ligand Notch N receptor mediates lateral inhibitory interactions among cells vein competent domains pupal development Shellenbarger Mohler 1978 Kooh et al
0.22649837.12466192.html.plaintext.txt	35	1993 Parody Muskavitch 1993
0.22649837.12466192.html.plaintext.txt	36	Delta also expressed earlier larval stages wing development longitudinal veins except L2 likely play role limiting vein thickness stage well since loss Notch function larval development leads greatly broadened expression vein marker rho Sturtevant Bier 1995
0.22649837.12466192.html.plaintext.txt	37	kni knrl encode related zinc finger transcription factors steroid hormone superfamily Nauber et al
0.22649837.12466192.html.plaintext.txt	38	1989 expressed single stripe corresponding L2 primordium beginning mid third larval instar required initiate L2 development Lunde et al
0.22649837.12466192.html.plaintext.txt	39	kni also functions gap gene early embryonic development Nusslein Volhard Wieschaus 1980 Nauber et al
0.22649837.12466192.html.plaintext.txt	40	The L2 stripe kniknrl expressing cells forms along anterior border broad domain cells expressing high levels related functionally overlapping spalt major salm Kuhnlein et al
0.22649837.12466192.html.plaintext.txt	41	1994 spalt related salr Barrio et al
0.22649837.12466192.html.plaintext.txt	42	1996 zinc finger transcription factors
0.22649837.12466192.html.plaintext.txt	43	A variety evidence indicates central domain cells expressing patterning genes salm salr together referred sal induce anterior neighbors express low levels sal become L2 primordium Sturtevant et al
0.22649837.12466192.html.plaintext.txt	44	For example wings containing salm mutant clones ectopic branches L2 induced track along inside salm clone borders mimicking normal situation L2 vein forms outside domain high level sal expressing cells Sturtevant et al
0.22649837.12466192.html.plaintext.txt	45	This ability sal expressing cells induce anterior low level sal expressing neighbors initiate L2 development requires activity kni locus Lunde et al
0.22649837.12466192.html.plaintext.txt	46	The induction kniknrl expression L2 primordium therefore provides excellent system studying transition spatial patterning tissue morphogenesis
0.22649837.12466192.html.plaintext.txt	47	Once activated along anterior sal border kni knrl organize development L2 vein part activating expression key vein promoting gene rho suppressing expression intervein gene blistered bs Montagne et al
0.22649837.12466192.html.plaintext.txt	48	The kni locus highly selective regulating downstream gene expression L2 primordium revealed observation several genes expressed veins caup ara ac sc Delta excluded L2 primordium
0.22649837.12466192.html.plaintext.txt	49	Thus kni locus links patterning vein specific morphogenesis functioning downstream sal upstream genes involved vein versus intervein development
0.22649837.12466192.html.plaintext.txt	50	The role kni locus L2 formation clarified analysis likely regulatory alleles kni locus previously known radius incompletus ri Arajarvi Hannah Alava 1969 Lunde et al
0.22649837.12466192.html.plaintext.txt	51	Flies mutation lack large sections L2 vein
0.22649837.12466192.html.plaintext.txt	52	kniri mutants homozygous viable contrast kni null mutants die embryos gap gene phenotype Nusslein Volhard Wieschaus 1980 Nauber et al
0.22649837.12466192.html.plaintext.txt	53	In support kniri mutations wing specific regulatory alleles kniknrl locus expression kni knrl L2 primordium absent kniri1 mutants L2 vein loss phenotype partially rescued ubiquitous expression kni wing Lunde et al
0.22649837.12466192.html.plaintext.txt	54	The findings summarized suggest kni knrl organize L2 vein developmental program orchestrating expression genes execute distinct subsets functions required proper L2 development
0.22649837.12466192.html.plaintext.txt	55	Several important unanswered questions remain including functions disrupted kniri1 existing kniri mutants mutations eliminate function L2 specific cis regulatory element kni locus finally respect definition L2 versus veins important exclude expression genes expressed veins L2 primordium
0.22649837.12466192.html.plaintext.txt	56	In study report identification enhancer element upstream kni coding region selectively directs gene expression L2 primordium third instar larval wing discs
0.22649837.12466192.html.plaintext.txt	57	We show three separate ri alleles defects mapping within minimal 1
0.22649837.12466192.html.plaintext.txt	58	We demonstrate two mutations eliminate activity L2 enhancer kniri1 contains 252 bp deletion kniri53j harbors single base pair substitution
0.22649837.12466192.html.plaintext.txt	59	We find truncation minimal L2 enhancer 0
0.22649837.12466192.html.plaintext.txt	60	69 kb fragment leads ectopic reporter gene expression extreme anterior posterior regions wing indicating repression contributes restricting activation L2 enhancer
0.22649837.12466192.html.plaintext.txt	61	In addition show general wing promoting transcription factor Scalloped Sd binds high affinity several sites L2 enhancer sd required kni expression wing disc
0.22649837.12466192.html.plaintext.txt	62	We also employed L2 enhancer element tool drive expression various UAS transgenes L2 primordium
0.22649837.12466192.html.plaintext.txt	63	We find loss L2 vein ri mutants rescued L2 specific expression either kni knrl genes downstream target gene rho
0.22649837.12466192.html.plaintext.txt	64	In addition find misexpression genes L2 primordium normally expressed veins L2 results abnormal L2 development
0.22649837.12466192.html.plaintext.txt	65	These results provide framework understanding positional information converted morphogenesis L2 wing vein vein organizing genes kni knrl
0.22649837.12466192.html.plaintext.txt	66	MATERIALS AND METHODS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Fly stocks The weak kniriM3 allele isolated J
0.22649837.12466192.html.plaintext.txt	67	Diaz Benjumea kindly provided Antonio Garcia Bellido Universidad Autonoma de Madrid Ruth Lehmann Skirball Institute New York provided strong viable Df3LkniriXT2 allele Df3LkniFC82 stock Lehmann 1985 Peter Portin University Turku provided kniri92f allele Yuh Nung Jan provided UAS scute stock Chien et al
0.22649837.12466192.html.plaintext.txt	68	1996 Juan Modolell Universidad Autonoma De Madrid provided UAS ara UAS caup stocks Amanda Simcox Ohio State University provided UAS vein stock Simcox et al
0.22649837.12466192.html.plaintext.txt	69	1996 Joachim Urban Universitat Mainz provided UAS eg stock Dittrich et al
0.22649837.12466192.html.plaintext.txt	70	1997 Ken Irvine Waksman Institute provided w sd58 Pry hs neo FRT 18A stock Seth Blair University Wisconsin Madison provided hsflp3MKRSTM6B stock
0.22649837.12466192.html.plaintext.txt	71	kniriM kniri53j obtained Bowling Green Stock Center since abandoned
0.22649837.12466192.html.plaintext.txt	72	kniri53j medium strength homozygous viable allele isolated Irwin Oster student H
0.22649837.12466192.html.plaintext.txt	73	Muller kniriM medium strength homozygous ri allele collection H
0.22649837.12466192.html.plaintext.txt	74	Other mutant lines including medium strength kniri1 allele balancers chromosomal markers obtained either Bloomington Indiana Stock Center Tubingen Stock Center described Lindsley Grell Lindsley Grell 1968 Lindsley Zimm Lindsley Zimm 1992
0.22649837.12466192.html.plaintext.txt	75	Vector construction Genomic fragments spanning majority putative regulatory region kni locus Fig
0.22649837.12466192.html.plaintext.txt	76	1 delimited Df3LkniriXT2 Nauber et al
0.22649837.12466192.html.plaintext.txt	77	1988 subcloned pC4PLZ expression vector Wharton Crews 1993
0.22649837.12466192.html.plaintext.txt	78	EcoRI fragments F E S R Q isolated phages provided U
0.22649837.12466192.html.plaintext.txt	79	Nauber inserted pBluescript II KS pBS Stratagene NotI T7 promoter containing side vector proximal knirps coding region
0.22649837.12466192.html.plaintext.txt	80	The constructs subcloned lacZ transformation vector pC4PLZ
0.22649837.12466192.html.plaintext.txt	81	8 kb EcoRI fragment fragment E Fig
0.22649837.12466192.html.plaintext.txt	82	1 drive expression L2 primordium subcloned pC4PLZ define minimal L2 enhancer element
0.22649837.12466192.html.plaintext.txt	83	To assay fragments E pBS E digested proximal EcoRI SalI ES 2
0.22649837.12466192.html.plaintext.txt	84	69 kb fragments isolated re inserted pBS
0.22649837.12466192.html.plaintext.txt	85	8 kb fragment E also subcloned pC4PG4 expression vector lacZ gene pC4PLZ replaced GAL4 Emery 1996 used drive expression various UAS transgenes L2 primordium
0.22649837.12466192.html.plaintext.txt	86	View larger version 45K Fig
0.22649837.12466192.html.plaintext.txt	87	Map knirps locus ri alleles
0.22649837.12466192.html.plaintext.txt	88	A A wild type adult male wing
0.22649837.12466192.html.plaintext.txt	89	Longitudinal wing veins L1 L5 margin M indicated
0.22649837.12466192.html.plaintext.txt	90	B A kniri1 homozygous adult male wing incomplete L2 vein
0.22649837.12466192.html.plaintext.txt	91	Note phenotype somewhat milder Df3LkniriXT2 mutants C
0.22649837.12466192.html.plaintext.txt	92	C A Df3LkniriXT2 homozygous adult male wing
0.22649837.12466192.html.plaintext.txt	93	Note virtual absence L2 vein
0.22649837.12466192.html.plaintext.txt	94	D A kniri53j homozygous adult male wing
0.22649837.12466192.html.plaintext.txt	95	E Diagram region 77E1 left arm third chromosome showing kni knrl transcripts regions deleted Df3LkniriXT2 Df3LkniFC82 well lacZ test constructs EcoRI fragments E red F green S orange R brown Q pink
0.22649837.12466192.html.plaintext.txt	96	The fragment labeled abd lacZ white box shown contain embryonic enhancer yellow box driving expression abdominal segments Pankratz et al
0.22649837.12466192.html.plaintext.txt	97	This fragment drive gene expression wing primordium
0.22649837.12466192.html.plaintext.txt	98	Genomic DNA fragments E S tested lacZ fusions
0.22649837.12466192.html.plaintext.txt	99	8 kb fragment E drives reporter gene expression L2
0.22649837.12466192.html.plaintext.txt	100	abd yellow box embryonic abdominal enhancer Pankratz et al
0.22649837.12466192.html.plaintext.txt	101	1992 CG13252 predicted protein coding transcript expressed ubiquitously wild type kniri53j wing discs data shown
0.22649837.12466192.html.plaintext.txt	102	The knrl transcript comprises 23 kb genomic DNA Rothe et al
0.22649837.12466192.html.plaintext.txt	103	The 5 end knrl gene 74
0.22649837.12466192.html.plaintext.txt	104	4 kb minimal L2 driver black 252 bp kniri1 deletion dark blue C A base substitution 0
0.22649837.12466192.html.plaintext.txt	105	596 kb E kniri53j light blue region insertions rearrangements kniriM3 turquoise 0
0.22649837.12466192.html.plaintext.txt	106	E EcoRI B BamHI C HincII X XhoI S SalI H HindIII
0.22649837.12466192.html.plaintext.txt	107	G lacZ transgenic constructs made assay expression driven region containing kniri1 deficiency substituted E Eri1 successively smaller 3 subfragments E EX 1
0.22649837.12466192.html.plaintext.txt	108	Mapping kni ri breakpoints Restriction fragments isolated lambda phage walk Nauber et al
0.22649837.12466192.html.plaintext.txt	109	1988 covering 50 kb kni upstream region delimited Df3LkniriXT2 deletion used probes determine locations potential chromosomal abnormalities deletions rearrangements ri mutants Southern blots Southern 1975
0.22649837.12466192.html.plaintext.txt	110	Several different restriction enzymes used scan region distinguish single nucleotide polymorphisms larger scale abnormalities present kniri1 kniriM3 mutants
0.22649837.12466192.html.plaintext.txt	111	Isolation kniri genomic fragments construction Eri lacZ vectors Primers AA RK used amplify region surrounding proximal EcoRI BglII 1
0.22649837.12466192.html.plaintext.txt	112	197 kb fragment E kniri1 kniri92f kniriM kniri53j genomic DNA AAGACACAATGCTCCGAATTCC 5 end F 3 end contains EcoRI site RKCCCAATGGACCCCAATCTGGTTGGGG 5 end 1
0.22649837.12466192.html.plaintext.txt	113	Note TGGGG added produce KpnI site distal end resulting fragment
0.22649837.12466192.html.plaintext.txt	114	PCR fragments purified sequencing using QIAquick PCR Purification kit
0.22649837.12466192.html.plaintext.txt	115	The blunt ended kniri1 fragment cloned pCR BluntII TOPO TOPO oriented NotI site within TOPO BglII site within fragment N B opposite sides
0.22649837.12466192.html.plaintext.txt	116	The resulting TOPO NB construct pBS E digested NotI BglII fragments isolated ligated form pBS Eri1
0.22649837.12466192.html.plaintext.txt	117	The Eri1 insert sequenced confirm differed wild type sequence 252 bp deletion
0.22649837.12466192.html.plaintext.txt	118	KpnI NotI used remove Eri1 cloned corresponding sites C4PLZ form Eri1 lacZ
0.22649837.12466192.html.plaintext.txt	119	Similarly primers ECO ri XBA ri used PCR amplify EcoRI XhoI fragment E termed EX kniri53j genomic DNA ECO riGAATTCCAACGCGAAGCGTC XBA riTCTAGATGGGGCTGCTGCCA
0.22649837.12466192.html.plaintext.txt	120	4 kb product cloned TOPO vector
0.22649837.12466192.html.plaintext.txt	121	The EXri53j fragment digested EcoRI XbaI subcloned corresponding sites pC4PLZ form EXri53j lacZ
0.22649837.12466192.html.plaintext.txt	122	A single subclone sequenced verify single nucleotide change C596A incorporated
0.22649837.12466192.html.plaintext.txt	123	Generation analysis sd clones Generation reduction function sd58 clones immunohistochemical analysis performed described previously Guss et al
0.22649837.12466192.html.plaintext.txt	124	Analysis Sd binding sites L2 enhancer Identification analysis Sd binding sites performed described Guss et al
0.22649837.12466192.html.plaintext.txt	125	Sequences upper strand oligonucleotides used probes gel mobility shift assays PCR primers introduce mutations Sd binding sites kni 0
0.22649837.12466192.html.plaintext.txt	126	69 kb element fragment EC Fig
0.22649837.12466192.html.plaintext.txt	127	1F listed 5 3 orientation
0.22649837.12466192.html.plaintext.txt	128	Altered bases shown lowercase mutant version corresponding bases underlined native sequence follows
0.22649837.12466192.html.plaintext.txt	129	kni 271 wild type TTCCCCTCTTACATTTGTCGCATAGTTCCCATCTTGGCCA kni 271 mutant TTCCCCTCTTtCATTaGgCtCATAaggCCCATCTTGGCCA kni 570 wild type TTGCGGACACAGGACACGAAATGCGTTTTGTGCCTTAATT kni 570 mutant TTGCGGACACAGGACACctAATGaGgTTTGTGCCTTAATT kni 640 wild type TTGCTGGTGCACTGAAAGAAATAGTTGAAGGGATTATTG kni 640 mutant TTGCTGGTGCACTGAAcctAATAGgTGAAGGGATTATTG
0.22649837.12466192.html.plaintext.txt	130	Reporter constructs three mutated Sd binding sites made cloning PCR generated fragments fragment EC Hsp lacZ CaSpeR plasmid Nelson Laughton 1993
0.22649837.12466192.html.plaintext.txt	131	Four independent EC 3Sdmut lacZ transformants recovered tested lacZ expression
0.22649837.12466192.html.plaintext.txt	132	Mounting fly wings Wings adult flies dissected isopropanol mounted 100 Canada Balsam mounting medium Aldrich 28292 8 described previously Roberts 1986
0.22649837.12466192.html.plaintext.txt	133	In situ hybridization whole mount larval wing discs In situ hybridization using digoxigenin labeled antisense RNA probes ONeill Bier 1994 performed alone combination anti ss galactosidase Promega labeling described previously Sturtevant et al
0.22649837.12466192.html.plaintext.txt	134	RESULTS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES An L2 enhancer element lies upstream knirps coding region In previous study presented genetic evidence kniri1 mutation well approximately 50 kb deletion kni upstream sequences Df3LkniriXT2 disrupt function wing specific regulatory element kni locus responsible driving expression kni knrl genes L2 primordium Lunde et al
0.22649837.12466192.html.plaintext.txt	135	As consequence loss kniknrl expression kniri1 Fig
0.22649837.12466192.html.plaintext.txt	136	1C flies severely truncated L2 veins compare wild type vein pattern Fig
0.22649837.12466192.html.plaintext.txt	137	As first step extending studies gathered characterized four putative independently generated viable ri alleles kni locus lack portions L2 vein including kniri53j Fig
0.22649837.12466192.html.plaintext.txt	138	1D kniriM3 kniri92f kniriM shown
0.22649837.12466192.html.plaintext.txt	139	As kniri1 wing discs found kni expression eliminated L2 primordium kniri alleles data shown
0.22649837.12466192.html.plaintext.txt	140	The studies mentioned suggested might L2 specific wing vein enhancer controls expression kni knrl L2 primordium
0.22649837.12466192.html.plaintext.txt	141	We searched enhancer element two ways
0.22649837.12466192.html.plaintext.txt	142	First screened ability genomic fragments upstream kni coding region drive lacZ expression L2 primordium summarized Fig
0.22649837.12466192.html.plaintext.txt	143	Second used Southern blot analysis identify deletions rearrangement breakpoints genomic DNA ri mutants kni upstream region uncovered Df3LkniriXT2 Fig
0.22649837.12466192.html.plaintext.txt	144	As result former effort identified single 4
0.22649837.12466192.html.plaintext.txt	145	8 kb EcoRI fragment fragment E Fig
0.22649837.12466192.html.plaintext.txt	146	1E G drives lacZ reporter gene expression sharp stripe Fig
0.22649837.12466192.html.plaintext.txt	147	2B similar endogenous kni expression L2 primordium Fig
0.22649837.12466192.html.plaintext.txt	148	Double label experiments confirm lacZ expression driven E lacZ construct coincides endogenous kni expression Fig
0.22649837.12466192.html.plaintext.txt	149	Additionally E lacZ expression pattern includes weaker stripe posterior region wing Fig
0.22649837.12466192.html.plaintext.txt	150	A faint endogenous kni stripe also observed location overstained preparations wildtype discs data shown
0.22649837.12466192.html.plaintext.txt	151	Consistent previous studies Lunde et al
0.22649837.12466192.html.plaintext.txt	152	1998 E lacZ L2 stripe located anterior broad domain strong salm expression Fig
0.22649837.12466192.html.plaintext.txt	153	Notably weaker posterior E lacZ stripe forms immediately adjacent posterior border salm domain Fig
0.22649837.12466192.html.plaintext.txt	154	View larger version 63K Fig
0.22649837.12466192.html.plaintext.txt	155	Expression wild type mutant L2 enhancer constructs
0.22649837.12466192.html.plaintext.txt	156	A kni expression wild type mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	157	The L2 primordium L2 margin M indicated
0.22649837.12466192.html.plaintext.txt	158	B lacZ expression driven E lacZ construct mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	159	Note lower levels lacZ expression diffuse stripe posterior region wing pouch arrow
0.22649837.12466192.html.plaintext.txt	160	C E lacZ expression relative endogenous kni expression mid third instar larval wing disc double stained kni mRNA expression blue anti ss galactosidase protein brown
0.22649837.12466192.html.plaintext.txt	161	Note high degree coincidence two expression patterns
0.22649837.12466192.html.plaintext.txt	162	D E lacZ expression relative salm expression mid third instar larval wing disc double stained anti ss galactosidase protein brown salm expression blue
0.22649837.12466192.html.plaintext.txt	163	Note abutting mutually exclusive expression two genes
0.22649837.12466192.html.plaintext.txt	164	E EX lacZ expression driven fragment EX 1
0.22649837.12466192.html.plaintext.txt	165	4 kb 3 subfragment E see Fig
0.22649837.12466192.html.plaintext.txt	166	1G mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	167	F EC lacZ expression driven fragment EC 0
0.22649837.12466192.html.plaintext.txt	168	69 kb 3 subfragment E see Fig
0.22649837.12466192.html.plaintext.txt	169	1G mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	170	Note broad anterior posterior domains ectopic lacZ expression relative driven E lacZ EX lacZ constructs
0.22649837.12466192.html.plaintext.txt	171	G E ri1 lacZ expression driven fragment E ri1 deleted 252 bp segment missing ri1 allele mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	172	Note entire absence patterned staining including observed posterior region wings discs e
0.22649837.12466192.html.plaintext.txt	173	compare staining panel D
0.22649837.12466192.html.plaintext.txt	174	H EXri53j lacZ expression driven fragment EXri53j contains single base pair alteration present kniri53j allele mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	175	Note L2 staining selectively lost expression extreme anterior posterior domains wing pouch retained arrowheads compare staining G
0.22649837.12466192.html.plaintext.txt	176	In order delimit minimal L2 enhancer element tested ability 5 truncated derivatives 4
0.22649837.12466192.html.plaintext.txt	177	1G drive reporter gene expression larval wing imaginal discs
0.22649837.12466192.html.plaintext.txt	178	We observed subfragments 2
0.22649837.12466192.html.plaintext.txt	179	0 kb EcoRI SalI data shown 1
0.22649837.12466192.html.plaintext.txt	180	4 kb EcoRI XhoI fragment EX Fig
0.22649837.12466192.html.plaintext.txt	181	1G drive expression lacZ Fig
0.22649837.12466192.html.plaintext.txt	182	2E patterns nearly indistinguishable 4
0.22649837.12466192.html.plaintext.txt	183	Further truncation generating 0
0.22649837.12466192.html.plaintext.txt	184	69 kb EcoRI HincII fragment EC Fig
0.22649837.12466192.html.plaintext.txt	185	1G however results high levels ectopic lacZ expression broad anterior posterior domains Fig
0.22649837.12466192.html.plaintext.txt	186	This observation indicates regulatory elements required repress gene expression extreme anterior posterior domains wing primordium reside distal 0
0.22649837.12466192.html.plaintext.txt	187	4 kb fragment EX repression domain Fig
0.22649837.12466192.html.plaintext.txt	188	3B sequences sufficient activation contained within proximal 0
0.22649837.12466192.html.plaintext.txt	189	69 kb fragment EC activation domain Fig
0.22649837.12466192.html.plaintext.txt	190	As discussed identified sequences necessary L2 activity activation domain well potential repressor binding sites proposed repression domain Fig
0.22649837.12466192.html.plaintext.txt	191	View larger version 71K Fig
0.22649837.12466192.html.plaintext.txt	192	The L2 enhancer element activated Sd
0.22649837.12466192.html.plaintext.txt	193	A Sequence EcoRI HincII fragment EC E contains sites necessary activation minimal L2 enhancer 0 0
0.22649837.12466192.html.plaintext.txt	194	B Sequence HincII XhoI fragment contains sequences required repress ectopic activity L2 enhancer element 0
0.22649837.12466192.html.plaintext.txt	195	Key The deletion kniri1 mutant indicated blue text nucleotide mutated kniri53j mutant C A 596 highlighted turquoise
0.22649837.12466192.html.plaintext.txt	196	Sd binding sites fragment EC underlined brown determined empirically footprinting gel shifts
0.22649837.12466192.html.plaintext.txt	197	A tandem doublet binding sites begins 271 TACATTTGTCGCATAGTT sites beginning 463 TGTATGTAT opposite strand 523 AAAATGTCG 570 GAAATGCGT 640 ACTATTTCT opposite strand single sites
0.22649837.12466192.html.plaintext.txt	198	These experimentally determined sites define consensus ATAGNATGTTNT matches well consensus WRVWATKYR derived Sd binding wing enhancers require vestigial sd function bsDSRF Halder et al
0.22649837.12466192.html.plaintext.txt	199	1998 cut sal vg quadrant element Guss et al
0.22649837.12466192.html.plaintext.txt	200	Other predicted DNA binding sites indicated based matches known consensus sequences
0.22649837.12466192.html.plaintext.txt	201	Engrailed En TAATTA yellow type Ades Sauer 1994 Spalt related Salr TTATGatAacT pink type Barrio et al
0.22649837.12466192.html.plaintext.txt	202	1996 Brinker Brk ctGCCAgc green type Rushlow et al
0.22649837.12466192.html.plaintext.txt	203	No predicted DNA binding sites identified fragment EX Mad Kim et al
0.22649837.12466192.html.plaintext.txt	204	1997 Ci Kinzler Vogelstein 1990 Kni Small et al
0.22649837.12466192.html.plaintext.txt	205	C F Reporter gene expression driven 4
0.22649837.12466192.html.plaintext.txt	206	8 kb element E dependent upon sd function
0.22649837.12466192.html.plaintext.txt	207	C A mitotic clone homozygous hypomorphic sd58 allele located wing pouch marked absence MYC epitope tag outlined red
0.22649837.12466192.html.plaintext.txt	208	D Expression E lacZ reporter gene eliminated reduced reduction sd function except clones along wing margin unaffected data shown
0.22649837.12466192.html.plaintext.txt	209	The yellow arrowhead indicates position sd clone
0.22649837.12466192.html.plaintext.txt	210	E The position cells marked nuclear dye TOPRO
0.22649837.12466192.html.plaintext.txt	211	F Merged image panels A C
0.22649837.12466192.html.plaintext.txt	212	G Gel mobility shift assays oligonucleotide probes spanning tandem binding sites 271 single sites 570 640 Sd TEA domain left panels pair
0.22649837.12466192.html.plaintext.txt	213	Mutations introduced sites right panels pair reduce Sd binding
0.22649837.12466192.html.plaintext.txt	214	F free probe 1 probe one Sd TEA domain bound 2 probe two Sd TEA domains bound
0.22649837.12466192.html.plaintext.txt	215	H A wing disc one transformant lines 271 doublet 570 640 single Sd sites mutated context fragment EC
0.22649837.12466192.html.plaintext.txt	216	View larger version 29K Fig
0.22649837.12466192.html.plaintext.txt	217	A model L2 initiation global activation regional repression local induction
0.22649837.12466192.html.plaintext.txt	218	A Activation kni expression L2 primordium consequence action patterning genes initiates morphogenesis L2 vein
0.22649837.12466192.html.plaintext.txt	219	Analysis kniknrl locus L2 enhancer element reveals element activated narrow stripe combination global wing specific activation regional repression localized signal mediated activation
0.22649837.12466192.html.plaintext.txt	220	Global wing specific activation provided least part SdVg study
0.22649837.12466192.html.plaintext.txt	221	Regional repression mediated either directly indirectly SalmSalr Sal central wing cells Lunde et al
0.22649837.12466192.html.plaintext.txt	222	1998 repressors acting peripheral wing cells green domain possibly Brk study
0.22649837.12466192.html.plaintext.txt	223	In addition short range signal X blue produced Sal expressing cells pink domain required induce kniknrl expression blue line cells anterior sal expressing cells
0.22649837.12466192.html.plaintext.txt	224	Since kniknrl expression activated cells anterior sal expression domain posterior cells adjacent sal domain dashed blue line must either repressor e
0.22649837.12466192.html.plaintext.txt	225	En acting posterior compartment hatched activator acting anterior compartment together X provides AP specificity kniknrl activation
0.22649837.12466192.html.plaintext.txt	226	The AP compartment border indicated solid black line
0.22649837.12466192.html.plaintext.txt	227	B The kniknrl L2 enhancer subdivided separate domains mediating least certain components activation black region repression red region
0.22649837.12466192.html.plaintext.txt	228	Global wing specific activation requires SdVg function study mediated combination empirically determined Sd binding sites brown ovals four single sites one double site activation region
0.22649837.12466192.html.plaintext.txt	229	The action hypothetical signal X presumably mediated transcription factor X binds sequences activation domain
0.22649837.12466192.html.plaintext.txt	230	The binding site factor X blue circle may include sequences containing single nucleotide mutated kniri53j mutant C596A since L2 enhancer activity selectively lost L2 primordium flies
0.22649837.12466192.html.plaintext.txt	231	This site also eliminated 252 bp deletion kniri1 mutant dark blue region additional sequences required activity enhancer throughout wing e
0.22649837.12466192.html.plaintext.txt	232	The repression domain contains five predicted binding sites repressor Brk green diamonds two sites En hatched yellow triangles one site Salr pink diamond
0.22649837.12466192.html.plaintext.txt	233	Since reporter gene expression driven activation region alone repressed central cells fragment must also contain yet unidentified binding sites Salm Salr factor mediating repressive effect SalmSalr
0.22649837.12466192.html.plaintext.txt	234	ri mutants lesions L2 enhancer disrupt function As complement screening genomic fragments upstream kni locus ability drive gene expression L2 primordium using lacZ promoter fusion constructs scanned approximately 50 kb region deleted Df3LkniriXT2 allele detectable aberrations five putative independently isolated ri alleles
0.22649837.12466192.html.plaintext.txt	235	Using series probes spanning complete genomic region Fig
0.22649837.12466192.html.plaintext.txt	236	1E found single EcoRI fragment fragment E drives expression L2 primordium contains aberrations kniri1 kniri92f kniriM kniriM3 mutants
0.22649837.12466192.html.plaintext.txt	237	For alleles mutations map within minimal 1
0.22649837.12466192.html.plaintext.txt	238	4 kb L2 enhancer element see Fig
0.22649837.12466192.html.plaintext.txt	239	Although large scale lesions detected Southern blot analysis within fragment E kniri53j mutant subsequent sequence analysis identified single base pair alteration within minimal L2 enhancer element EX see
0.22649837.12466192.html.plaintext.txt	240	The kniri53j allele also associated small deletion approx
0.22649837.12466192.html.plaintext.txt	241	Further molecular analysis various ri alleles revealed putative independently derived kniri1 kniri92f kniriM alleles contain 252 bp deletion
0.22649837.12466192.html.plaintext.txt	242	As deletion flanked duplicated sequences could promote frequent identical recombination events may kniri92f kniriM alleles actually re isolates original kniri1 mutation
0.22649837.12466192.html.plaintext.txt	243	Consistent three alleles common origin also share restriction enzyme polymorphism
0.22649837.12466192.html.plaintext.txt	244	loss HindIII site fragment Q Fig
0.22649837.12466192.html.plaintext.txt	245	1E shared ri mutants white control stock
0.22649837.12466192.html.plaintext.txt	246	To test whether 252 bp deletion within minimal L2 enhancer element responsible loss kni knrl gene expression kniri1 mutants made kniri1 mutated E lacZ construct
0.22649837.12466192.html.plaintext.txt	247	We amplified genomic DNA containing kniri1 mutation substituted corresponding part original E lacZ construct generate Eri1 lacZ Fig
0.22649837.12466192.html.plaintext.txt	248	1G transformed construct flies
0.22649837.12466192.html.plaintext.txt	249	We examined lacZ expression third instar larval wing discs Eri1 lacZ flies found failed express lacZ L2 primordium anywhere else wing pouch Fig
0.22649837.12466192.html.plaintext.txt	250	2G indicating 252 bp deletion kniri1 mutants eliminates activity L2 enhancer element
0.22649837.12466192.html.plaintext.txt	251	Since Southern blot analysis reveal obvious lesions fragment E kniri53j allele considered possibility allele might subtler lesion L2 enhancer region
0.22649837.12466192.html.plaintext.txt	252	Accordingly PCR amplified sequenced 1
0.22649837.12466192.html.plaintext.txt	253	1G corresponding minimal L2 enhancer kniri53j
0.22649837.12466192.html.plaintext.txt	254	We found single nucleotide difference sequence mutant allele wild type fragment EX C596A Fig
0.22649837.12466192.html.plaintext.txt	255	3A lies within 252 bp region deleted kniri1
0.22649837.12466192.html.plaintext.txt	256	Although observed single nucleotide mutations eliminate endogenous enhancer function Shimell et al
0.22649837.12466192.html.plaintext.txt	257	1994 cases sufficiently rare important case kniri1 demonstrate whether point mutation responsible loss enhancer function
0.22649837.12466192.html.plaintext.txt	258	We used EX kniri53j PCR fragment make lacZ construct confirmed sequence mutant construct generated four independent transformants tested flies lacZ expression third instar wing discs
0.22649837.12466192.html.plaintext.txt	259	We found EXri53j lacZ mutant wing discs fail express lacZ L2 primordium Fig
0.22649837.12466192.html.plaintext.txt	260	2H strongly suggesting single base pair mutation responsible observed L2 vein loss phenotype observed kniri53j flies
0.22649837.12466192.html.plaintext.txt	261	One notable difference EXri53j lacZ Eri1 lacZ mutant wing discs point mutant construct ri53j lacZ expression lost selectively L2 primordium weaker posterior stripe note normal levels pattern expression extreme anterior posterior regions disc Fig
0.22649837.12466192.html.plaintext.txt	262	2H deletion mutant construct Eri1 reporter gene expression eliminated throughout wing disc Fig
0.22649837.12466192.html.plaintext.txt	263	As noted kniri53j mutant also associated deletion 50 bp fragment R lies approximately 15 kb 5 fragment E within predicted intron sequences putative transcription unit see kni locus map Fig
0.22649837.12466192.html.plaintext.txt	264	As ubiquitous expression transcription unit affected kniri53j mutants K
0.22649837.12466192.html.plaintext.txt	265	unpublished observations fusion fragment R lacZ result gene expression L2 primordium evidence suggest aberration relevance L2 vein loss phenotype kniri53j mutants
0.22649837.12466192.html.plaintext.txt	266	Analysis kniriM3 allele indicates mutation involves insertion possibly rearrangements within fragment E
0.22649837.12466192.html.plaintext.txt	267	One breakpoint kniriM3 allele falls within 1
0.22649837.12466192.html.plaintext.txt	268	4 kb EX minimal L2 enhancer element Fig
0.22649837.12466192.html.plaintext.txt	269	Because relatively weak ri allele associated complex lesion characterize nature rearrangement
0.22649837.12466192.html.plaintext.txt	270	The wing selector protein Scalloped binds L2 enhancer required activity The 4
0.22649837.12466192.html.plaintext.txt	271	8 kb L2 enhancer fragment E truncated derivatives fragments EX EC drive reporter gene expression specifically wing pouch
0.22649837.12466192.html.plaintext.txt	272	Recent work shown gene expression wing primordium controlled Sd functions Vestigial Vg define wing identity Kim et al
0.22649837.12466192.html.plaintext.txt	273	2001 Halder Carroll 2001
0.22649837.12466192.html.plaintext.txt	274	We tested whether Sd might similarly required activate endogenous kni expression generating clones cells homozygous strong hypomorphic allele sd using FLP FRT mediated mitotic recombination Golic 1991
0.22649837.12466192.html.plaintext.txt	275	In sd clones ss galactosidase expression driven E lacZ element reduced Fig
0.22649837.12466192.html.plaintext.txt	276	In clones falling along future wing margin however reporter gene expression unaffected shown see Discussion
0.22649837.12466192.html.plaintext.txt	277	These results indicate Sd plays vivo role activating kni expression within wing blade
0.22649837.12466192.html.plaintext.txt	278	Because Sd TEA domain protein functions direct transcriptional regulator several key developmental genes expressed wing disc Halder et al
0.22649837.12466192.html.plaintext.txt	279	2001 tested whether Sd binds kni L2 enhancer
0.22649837.12466192.html.plaintext.txt	280	We searched specific Sd DNA binding sites 0
0.22649837.12466192.html.plaintext.txt	281	69 kb EC activation domain using DNAse I footprinting gel shift analysis Fig
0.22649837.12466192.html.plaintext.txt	282	3G data shown identified five sites bound Sd TEA domain conform well known Sd consensus binding site consist tandem doublet Sd binding sites four single binding sites Fig
0.22649837.12466192.html.plaintext.txt	283	The four single Sd sites removed 252 bp deletion kniri1 allele however none covers kniri53j point mutation
0.22649837.12466192.html.plaintext.txt	284	To determine whether Sd plays direct role activating L2 enhancer mutated subset Sd binding sites context EC lacZ construct transformed mutated constructs flies stained lacZ expression third instar wing discs
0.22649837.12466192.html.plaintext.txt	285	We found mutation doublet 271 combination two single sites 570 640 resulted complete loss lacZ expression wing disc Fig
0.22649837.12466192.html.plaintext.txt	286	These results indicate Sd required activation kni expression wing disc
0.22649837.12466192.html.plaintext.txt	287	kniri1 mutants rescued kni knrl downstream target gene rho Having shown minimal L2 enhancer mutated several independently derived ri alleles kniri1 kniriM3 kniri53j wished know whether driving expression either kni knrl genes element could rescue ri vein loss phenotype
0.22649837.12466192.html.plaintext.txt	288	We addressed question using conditional GAL4UAS expression system Brand Perrimon Brand Perrimon 1993
0.22649837.12466192.html.plaintext.txt	289	We created transgenic flies carry fragment E driving GAL4 expression L2 GAL4 used driver activate expression UAS kni UAS knrl transgenes L2 primordium kniri1 mutants
0.22649837.12466192.html.plaintext.txt	290	As expected GAL4 RNA expressed L2 primordium L2 GAL4 wing discs Fig
0.22649837.12466192.html.plaintext.txt	291	We placed L2 GAL4 driver UAS kni UAS knrl transgenes kniri1 mutant background generated flies genotype L2 GAL4 UAS kni kniri1kniri1 Fig
0.22649837.12466192.html.plaintext.txt	292	4B L2 GAL4 UAS knrl kniri1kniri1 Fig
0.22649837.12466192.html.plaintext.txt	293	These flies fully restored L2 veins resemble wild type L2 veins bulk vein formed ventral surface wing
0.22649837.12466192.html.plaintext.txt	294	View larger version 64K Fig
0.22649837.12466192.html.plaintext.txt	295	Rescue L2 kniri1 targeted gene expression L2 primordium
0.22649837.12466192.html.plaintext.txt	296	A GAL4 expression L2 GAL4 mid third instar larval wing disc
0.22649837.12466192.html.plaintext.txt	297	B Rescue L2 vein arrow L2 GAL4 UAS kni kniri1 male adult wing
0.22649837.12466192.html.plaintext.txt	298	C Rescue L2 vein L2 GAL4 UAS knrl kniri1 male adult wing
0.22649837.12466192.html.plaintext.txt	299	D Rescue L2 vein L2 GAL4 UAS rho kniri1 male adult wing
0.22649837.12466192.html.plaintext.txt	300	Since rho known play critical role activating Egfr signaling vein primordia also determined whether expression downstream effector kni locus could bypass requirement kni kniri1 mutants
0.22649837.12466192.html.plaintext.txt	301	We found L2 formation indeed rescued L2 GAL4 UAS rho kniri1kniri1 flies Fig
0.22649837.12466192.html.plaintext.txt	302	As case rescue kni knrl rescued L2 vein forms primarily ventral surface wing
0.22649837.12466192.html.plaintext.txt	303	Misexpression genes expressed veins L2 alters L2 development As mentioned see Introduction several genes important vein development expressed veins L2
0.22649837.12466192.html.plaintext.txt	304	For example vein sensory organ promoting gene ara expressed odd numbered veins L1 L3 L5 proneural genes ac sc expressed L1 L3 Notch ligand Delta expressed L1 L3 L5 L2
0.22649837.12466192.html.plaintext.txt	305	We interested know whether necessary exclude expression genes L2 primordium normal L2 development
0.22649837.12466192.html.plaintext.txt	306	To address question misexpressed UAS transgene copies genes L2 primordium L2 GAL4 driver examined L2 vein adult wings
0.22649837.12466192.html.plaintext.txt	307	In case observed defects L2 development
0.22649837.12466192.html.plaintext.txt	308	Misexpression lateral inhibitory signal Delta L2 GAL4 UAS Dl flies results modest truncation L2 vein females Fig
0.22649837.12466192.html.plaintext.txt	309	5A almost entirely eliminates L2 vein sibling males Fig
0.22649837.12466192.html.plaintext.txt	310	5B consistently severely affected sex
0.22649837.12466192.html.plaintext.txt	311	The near elimination L2 development severely affected Dl misexpressing males accompanied loss rho expression L2 primordium third instar larval wing discs Fig
0.22649837.12466192.html.plaintext.txt	312	5D compare wild type rho expression Fig
0.22649837.12466192.html.plaintext.txt	313	Misexpression proneural gene sc L2 primordium L2 GAL4 UAS sc flies results L2 veins covered ectopic bristles Fig
0.22649837.12466192.html.plaintext.txt	314	The great majority ectopic bristles strictly confined L2 primordium consistent double label experiments Fig
0.22649837.12466192.html.plaintext.txt	315	2C indicating L2 enhancer element drives gene expression precisely L2 primordium
0.22649837.12466192.html.plaintext.txt	316	In addition ectopic bristles form sporadically broad posterior domain wing derives region wing disc L2 enhancer element also expressed weak diffuse pattern Fig
0.22649837.12466192.html.plaintext.txt	317	Finally misexpression ara gene L2 GAL4 UAS ara flies causes reproducible thinning L2 vein Fig
0.22649837.12466192.html.plaintext.txt	318	Cumulatively results underscore importance excluding expression non L2 vein genes L2 primordium
0.22649837.12466192.html.plaintext.txt	319	View larger version 93K Fig
0.22649837.12466192.html.plaintext.txt	320	Misexpression non L2 vein genes L2 primordium alters L2 development
0.22649837.12466192.html.plaintext.txt	321	A An L2 GAL4 UAS Dl adult female wing
0.22649837.12466192.html.plaintext.txt	322	The distal tip L2 vein typically missing arrow
0.22649837.12466192.html.plaintext.txt	323	B An L2 GAL4 UAS Dl adult male wing
0.22649837.12466192.html.plaintext.txt	324	The L2 vein consistently truncated severe extent
0.22649837.12466192.html.plaintext.txt	325	C rho expression wild type mid third larval instar disc
0.22649837.12466192.html.plaintext.txt	326	Vein primordia L2 L5 margin indicated
0.22649837.12466192.html.plaintext.txt	327	D rho expression 2X L2 GAL4 UAS Dl mid third instar larval wing disc lost selectively L2 primordium arrow
0.22649837.12466192.html.plaintext.txt	328	E An L2 GAL4 UAS sc adult male wing
0.22649837.12466192.html.plaintext.txt	329	Ectopic bristles largely confined L2 vein well broad posterior domain presumably corresponds cells L2 GAL4 wing discs expressing high L2 moderate posterior domain levels GAL4 e
0.22649837.12466192.html.plaintext.txt	330	F An L2 GAL4 UAS ara adult male wing
0.22649837.12466192.html.plaintext.txt	331	Note width L2 vein reduced middle arrowhead
0.22649837.12466192.html.plaintext.txt	332	This thinning L2 misexpression ara consistent phenotype observed misexpress related gene caup pattern shown
0.22649837.12466192.html.plaintext.txt	333	The L2 GAL4 driver used tool dissect gene function range action As discussed L2 GAL4 driver activates UAS transgene expression precisely L2 primordium
0.22649837.12466192.html.plaintext.txt	334	The ability drive highly localized expression genes non essential tissue L2 GAL4 suggests driver could used effective tool dissect function range action various genes
0.22649837.12466192.html.plaintext.txt	335	For example since eagle eg gene encodes steroid hormone receptor closely related Kni Knrl Rothe et al
0.22649837.12466192.html.plaintext.txt	336	1989 wondered whether gene could substitute kni knrl rescuing kniri1 mutants
0.22649837.12466192.html.plaintext.txt	337	eg involved neuroblast specification embryogenesis Higashijima et al
0.22649837.12466192.html.plaintext.txt	338	1997 Lundell Hirsh 1998 expressed wing pouch data shown known play role development wing proper
0.22649837.12466192.html.plaintext.txt	339	We found L2 GAL4 UAS kni kniri1kniri1 individuals L2 formation rescued L2 GAL4 UAS eg kniri1kniriXT2 flies however restored L2 vein decorated line ectopic sensory bristles Fig
0.22649837.12466192.html.plaintext.txt	340	As ectopic bristles observed L2 GAL4 UAS eg individuals data shown phenotype attributed misexpressing eg L2 primordium
0.22649837.12466192.html.plaintext.txt	341	By employing L2 expression system possible map domain Eg responsible inducing ectopic bristles using chimeric EgKni receptors
0.22649837.12466192.html.plaintext.txt	342	View larger version 106K Fig
0.22649837.12466192.html.plaintext.txt	343	Use L2 GAL4 expression system assay gene function wing
0.22649837.12466192.html.plaintext.txt	344	A Rescue L2 vein L2 GAL4 UAS eg kniri1kniriXT2 male adult wing
0.22649837.12466192.html.plaintext.txt	345	Note ectopic sensory bristles along reinstated L2 vein
0.22649837.12466192.html.plaintext.txt	346	B An L2 GAL4 UAS top adult male wing
0.22649837.12466192.html.plaintext.txt	347	C An L2 GAL4 UAS vein adult male wing
0.22649837.12466192.html.plaintext.txt	348	Note minor degree ectopic venation e
0.22649837.12466192.html.plaintext.txt	349	anterior L2 junction L2 margin
0.22649837.12466192.html.plaintext.txt	350	D An L2 GAL4 UAS secreted spitz adult female wing
0.22649837.12466192.html.plaintext.txt	351	Note ectopic vein running parallel anterior L2
0.22649837.12466192.html.plaintext.txt	352	E An L2 GAL4 UAS rhoUAS Star wing
0.22649837.12466192.html.plaintext.txt	353	Note patches ectopic vein material anterior L2
0.22649837.12466192.html.plaintext.txt	354	F An L2 GAL4 UAS wingless adult male wing
0.22649837.12466192.html.plaintext.txt	355	Note change shape margin ectopic vein material anterior posterior L2 ectopic bristles near junction L2 margin magnified insert
0.22649837.12466192.html.plaintext.txt	356	The L2 expression system also useful distinguishing cell autonomous non cell autonomous gene activity
0.22649837.12466192.html.plaintext.txt	357	As test idea compared phenotypes resulting driving expression activated form Egfr top L2 primordium versus expression secreted Egf like ligands Vein Schnepp et al
0.22649837.12466192.html.plaintext.txt	358	1996 sSpitz Schweitzer et al
0.22649837.12466192.html.plaintext.txt	359	Consistent top acting cell autonomous fashion promote vein versus intervein development expression gene L2 primordium L2 GAL4 UAS top wings Fig
0.22649837.12466192.html.plaintext.txt	360	6B effect development L2 vein neighboring intervein cells
0.22649837.12466192.html.plaintext.txt	361	In contrast secreted Egf ligands expressed similar fashion L2 GAL4 UAS vn wings Fig
0.22649837.12466192.html.plaintext.txt	362	6C L2 GAL4 UAS sspi wings Fig
0.22649837.12466192.html.plaintext.txt	363	6D observed ectopic veins formed 2 3 cell diameters away L2 vein
0.22649837.12466192.html.plaintext.txt	364	Similarly co expressed rho Star L2 primordium e
0.22649837.12466192.html.plaintext.txt	365	L2 GAL4 UAS rho UAS Star wings Fig
0.22649837.12466192.html.plaintext.txt	366	6E also generates potent secreted Egfr promoting activity Guichard et al
0.22649837.12466192.html.plaintext.txt	367	1999 observed ectopic veins displaced endogenous L2 vein cells
0.22649837.12466192.html.plaintext.txt	368	The ability secreted ligands top construct induce ectopic vein formation distance cannot attributed simply latter weaker activator Egfr signaling since UAS top considerably effective generating ectopic veins UAS vn wing GAL4 drivers used e
0.22649837.12466192.html.plaintext.txt	369	MS1096 GAL4 CY2 GAL4 data shown
0.22649837.12466192.html.plaintext.txt	370	We also observed non cell autonomous activity Wingless Wg ligand L2 GAL4 UAS wg wings Fig
0.22649837.12466192.html.plaintext.txt	371	6F ectopic veins displaced endogenous L2 well ectopic marginal bristles near intersection L2 margin
0.22649837.12466192.html.plaintext.txt	372	These ectopic marginal bristles always formed appropriate surface wing Fig
0.22649837.12466192.html.plaintext.txt	373	6F insert suggesting phenotype may result inappropriate activation wing margin genetic program
0.22649837.12466192.html.plaintext.txt	374	DISCUSSION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES An important step understanding link patterning morphogenesis identify key cis regulatory elements lie interface sequential processes
0.22649837.12466192.html.plaintext.txt	375	Formation L2 vein provides potential paradigm connecting patterning initiated morphogen e
0.22649837.12466192.html.plaintext.txt	376	centrally positioned BMP activity gradient activation vein differentiation program narrow stripe cells wing imaginal disc e
0.22649837.12466192.html.plaintext.txt	377	In study identified cis acting regulatory element drives expression kni locus L2 primordium
0.22649837.12466192.html.plaintext.txt	378	We found three distinct mutations causing L2 vein truncations alter regulatory element least two cases mutations disrupt function enhancer
0.22649837.12466192.html.plaintext.txt	379	Dissection enhancer element indicates locally provided activating signal acts conjunction broadly distributed activating sd dependent repressive systems limit activation L2 enhancer sharp stripe cells wing imaginal disc
0.22649837.12466192.html.plaintext.txt	380	We also found excluding expression non L2 vein genes L2 primordium essential normal L2 development
0.22649837.12466192.html.plaintext.txt	381	ri mutants L2 enhancer specific regulatory alleles kni locus The results described study demonstrate definitively ri mutations regulatory alleles kni locus disrupting function cis regulatory enhancer element drives gene expression L2 primordium wing imaginal discs
0.22649837.12466192.html.plaintext.txt	382	A crucial line evidence supporting conclusion mutant versions L2 enhancer incorporating either 252 bp deletion present kniri1 single base pair substitution present kniri53j eliminate ability element direct gene expression L2 primordium
0.22649837.12466192.html.plaintext.txt	383	In addition possible completely rescue vein loss phenotype kniri1 expressing either UAS kni UAS knrl transgenes L2 GAL4 driver
0.22649837.12466192.html.plaintext.txt	384	Consistent activation rho one key effectors kniknrl function also possible rescue L2 vein loss phenotype kniri1 expressing UAS rho transgene L2 although rescue less complete penetrant observed UAS kni UAS knrl
0.22649837.12466192.html.plaintext.txt	385	The isolation L2 enhancer also addresses unresolved question regarding basis failure Df3LkniriXT2 Df3LkniFC82 complement Lunde et al
0.22649837.12466192.html.plaintext.txt	386	As two deletions endpoints break within 1
0.22649837.12466192.html.plaintext.txt	387	7 kb EcoRI fragment indicated dashed vertical lines Fig
0.22649837.12466192.html.plaintext.txt	388	1E one explanation failure complementation could 1
0.22649837.12466192.html.plaintext.txt	389	7 kb fragment contains L2 enhancer
0.22649837.12466192.html.plaintext.txt	390	The alternative explanation ri phenotype Df3LkniriXT2Df3LkniFC82 transvection Lewis 1954 Geyer et al
0.22649837.12466192.html.plaintext.txt	391	1990 Pirrotta 1999 normally occurs regulatory coding region alleles kni locus Lunde et al
0.22649837.12466192.html.plaintext.txt	392	1998 interrupted large divergent deletions little overlap
0.22649837.12466192.html.plaintext.txt	393	8 EcoRI fragment containing L2 enhancer maps nearly 10 kb upstream 1
0.22649837.12466192.html.plaintext.txt	394	7 kb EcoRI fragment lacZ fusion construct abd lacZ Fig
0.22649837.12466192.html.plaintext.txt	395	7 kb EcoRI fragment drive gene expression wing disc Lunde et al
0.22649837.12466192.html.plaintext.txt	396	1998 latter hypothesis Df3LkniriXT2 Df3LkniFC82 unable engage effective transvection likely explanation failure two mutations complement
0.22649837.12466192.html.plaintext.txt	397	Global activation regional repression localized induction restrict L2 enhancer activity narrow stripe cells The results previous studies L2 vein initiation lead model localized vein inductive signaling acts background regional repression global wing specific activation Fig
0.22649837.12466192.html.plaintext.txt	398	Previous genetic experiments suggested model sal expressing cells produce short range L2 inducing signal X sal expressing cells cannot respond Sturtevant et al
0.22649837.12466192.html.plaintext.txt	399	According export signaling model signal X diffuses adjacent anterior cells activates expression kniknrl genes L2 primordium much fashion Hh expressed refractory posterior compartment activates expression target genes dpp ptc anterior compartment reviewed Bier 2000
0.22649837.12466192.html.plaintext.txt	400	Based analysis L2 enhancer element described study 252 bp region deleted kniri1 mutants may contain response elements putative factor X
0.22649837.12466192.html.plaintext.txt	401	It worth noting however lacZ expression lost cells wing disc posterior circumferential cells well L2 primordium sequences deleted 4
0.22649837.12466192.html.plaintext.txt	402	This observation suggests sequences mediating general activation e
0.22649837.12466192.html.plaintext.txt	403	Sd binding sites see may also contained within 252 bp region
0.22649837.12466192.html.plaintext.txt	404	The sequence surrounding single nucleotide alteration kniri53j mutants C596A however particularly intriguing candidate mediating L2 specific activation kni since introducing mutation context minimal 1
0.22649837.12466192.html.plaintext.txt	405	4 kb enhancer leads selective loss lacZ expression stripe cells adjacent sal domain
0.22649837.12466192.html.plaintext.txt	406	The hypothetical transcription factor X Fig
0.22649837.12466192.html.plaintext.txt	407	7B binds region surrounding kniri53j point mutation mediates inductive signal X presumably collaborates generally required wing selector Sd Halder et al
0.22649837.12466192.html.plaintext.txt	408	2001 since mutation four Sd binding sites doublet two single sites L2 activation domain completely eliminates enhancer activity wing disc
0.22649837.12466192.html.plaintext.txt	409	Clonal analysis hypomorphic sd allele also indicates sd required high level expression full 4
0.22649837.12466192.html.plaintext.txt	410	8 kb L2 enhancer element wing disc
0.22649837.12466192.html.plaintext.txt	411	It notable reduction lacZ expression clones dramatic complete loss L2 activity observed Sd binding sites activation domain mutated
0.22649837.12466192.html.plaintext.txt	412	There several possible explanations discrepancy
0.22649837.12466192.html.plaintext.txt	413	Firstly sd mutation used experiments hypomorphic allele therefore residual activity
0.22649837.12466192.html.plaintext.txt	414	Unfortunately stronger sd alleles produce even smaller viable clones wing disc thus used
0.22649837.12466192.html.plaintext.txt	415	Secondly small clones generated must typically produced two three intervening cycles cell division
0.22649837.12466192.html.plaintext.txt	416	Consequently sd cells may still contain functional levels wild type Sd protein perdurance
0.22649837.12466192.html.plaintext.txt	417	Another possibility activators partially substitute Sd least certain regions wing
0.22649837.12466192.html.plaintext.txt	418	Based absence L2 activity Sd binding sites mutated reduction L2 activity sd hypomorphic clones conclude Sd plays important role activator L2 enhancer
0.22649837.12466192.html.plaintext.txt	419	These results support view Sd functions general transcriptional activator genes expressed wing field
0.22649837.12466192.html.plaintext.txt	420	Repression also plays key role restricting L2 enhancer expression narrow stripe wing disc cells
0.22649837.12466192.html.plaintext.txt	421	It shown previously salm salr expressed strongly central region wing repress expression kni knrl Lunde et al
0.22649837.12466192.html.plaintext.txt	422	1998 although low levels sal may also required activate kni expression de Celis Barrio 2000
0.22649837.12466192.html.plaintext.txt	423	In current study also find evidence repression L2 enhancer activity peripheral wing disc cells abutting expressing high levels sal
0.22649837.12466192.html.plaintext.txt	424	4 kb fragment EX L2 enhancer element results reporter gene expression expanding fill anterior posterior regions wing pouch pattern complementary sal
0.22649837.12466192.html.plaintext.txt	425	The region deleted EX fragment contains several consensus binding sites Brinker Fig
0.22649837.12466192.html.plaintext.txt	426	2001 may mediate repression since pattern brinker brk expression wing pouch Campbell Tomlinson 1999 Jazwinska et al
0.22649837.12466192.html.plaintext.txt	427	1999 similar lacZ expression driven 0
0.22649837.12466192.html.plaintext.txt	428	One way integrate action localized inductive signal XX pathway abutting central peripheral repressive factors propose signal dependent activator X overcome repressive action peripheral inhibitor repression SalmSalr see legend Fig
0.22649837.12466192.html.plaintext.txt	429	One feature common several prominent signaling pathways activation pathway converts resting repressor transcriptional activator Barolo Posakony 2002
0.22649837.12466192.html.plaintext.txt	430	In kni L2 enhancer activation hypothetical signal X pathway may relieve repression heterologous repressor since putative activator
0.22649837.12466192.html.plaintext.txt	431	Brk sequences L2 enhancer separable
0.22649837.12466192.html.plaintext.txt	432	One example signaling pathway functions relieving inhibition heterologous repressor recent report Egfr signaling inactivating repression Suppressor Hairless SuH Tsuda et al
0.22649837.12466192.html.plaintext.txt	433	In addition central peripheral repression wing disc may also repressor posterior compartment cells e
0.22649837.12466192.html.plaintext.txt	434	7AB prevent activation L2 enhancer cells posterior sal expression domain
0.22649837.12466192.html.plaintext.txt	435	8 kb L2 enhancer element lacks sites putative repressor since E lacZ drives significantly higher levels gene expression posterior stripe observed endogenous kni knrl expression
0.22649837.12466192.html.plaintext.txt	436	Expression non L2 vein genes must excluded L2 primordium All longitudinal veins share several morphological characteristics composed densely packed cells dorsal ventral surfaces wing secrete thickened cuticle
0.22649837.12466192.html.plaintext.txt	437	The primordia longitudinal veins also express rhomboid gene required activating Egfr pathway vein intervein cells
0.22649837.12466192.html.plaintext.txt	438	In addition shared properties vein distinguished expression vein genes Biehs et al
0.22649837.12466192.html.plaintext.txt	439	For example vein L2 specific characteristics include expression kni knrl lack Delta expression lack cauplara expression lack acsc expression
0.22649837.12466192.html.plaintext.txt	440	Given veins ultimately quite similar morphologically relevant ask whether differences gene expression patterns observed different veins important
0.22649837.12466192.html.plaintext.txt	441	In study examined necessity excluding expression non L2 vein genes L2 primordium forcing expression genes Dl ara ac sc L2 asking whether manipulation impact L2 development
0.22649837.12466192.html.plaintext.txt	442	These experiments strongly suggest exclusion non L2 vein genes L2 primordium indeed important since misexpression genes resulted abnormal L2 development
0.22649837.12466192.html.plaintext.txt	443	The phenotypes resulting misexpressing non L2 vein genes L2 primordium largely reconciled normal functions genes
0.22649837.12466192.html.plaintext.txt	444	For example forced expression Dl leads loss L2 consistent suppression vein formation Notch signaling
0.22649837.12466192.html.plaintext.txt	445	The ectopic bristles form strictly along L2 vein wings misexpressing ac sc also consistent neural promoting function proneural genes
0.22649837.12466192.html.plaintext.txt	446	It less clear misexpression ara gene causes thinning L2 primordium since gene normally activates expression vein promoting gene rho odd numbered veins ac sc L3 primordium
0.22649837.12466192.html.plaintext.txt	447	Perhaps expression gene normally involved development odd numbered dorsal veins somehow incompatible development ventral L2 vein
0.22649837.12466192.html.plaintext.txt	448	The L2 expression system provides localized assay gene function wing The sharp stripe gene expression driven L2 GAL4 also used rapid assay test function range action various genes wing
0.22649837.12466192.html.plaintext.txt	449	For example case Egfr pathway possible distinguish components exerting cell autonomous versus non cell autonomous functions
0.22649837.12466192.html.plaintext.txt	450	In line fact activation Egfr pathway wing leads formation veins L2 GAL4 driven expression secreted ligand sSpi generates ectopic veins neighborhood L2 expression equally potent constitutively active top form EGF receptor result non autonomous phenotype
0.22649837.12466192.html.plaintext.txt	451	The L2 expression system may also used compare functions related genes nuclear receptors Kni Knrl Eg
0.22649837.12466192.html.plaintext.txt	452	Although three transcription factors share nearly identical DNA binding domains rescue vein loss phenotype ri mutants differ misexpression eg L2 primordium induces formation ectopic bristles along L2
0.22649837.12466192.html.plaintext.txt	453	This distinct activity eg may relate normal embryonic function directing cell fate choices CNS
0.22649837.12466192.html.plaintext.txt	454	Using L2 expression system assay straightforward map domain eg responsible neural inducing capacity constructing chimeric molecules composed different domains Eg Kni
0.22649837.12466192.html.plaintext.txt	455	Finally observation L2 driven expression Dl leads highly penetrant loss L2 males consistently weaker phenotype females provides basis modifier screen identify mutations either suppress phenotype males enhance phenotype females
0.22649837.12466192.html.plaintext.txt	456	Some modifier loci identified screen specifically involved Notch signaling may encode components hypothesized factor XX pathway
0.22649837.12466192.html.plaintext.txt	457	ACKNOWLEDGMENTS We thank Orna Cook Margaret Roark critical comments manuscript Dan Ang help preparing figures
0.22649837.12466192.html.plaintext.txt	458	This work supported NIH grant NIH R01 GM60585 NSF grant NSF IBN 0094634
0.22649837.12466192.html.plaintext.txt	459	acknowledges support Sean B
0.22649837.12466192.html.plaintext.txt	460	Carroll whose lab studies role sd performed
0.22649837.12466192.html.plaintext.txt	461	This work funded NIH 1F32HD08326 K
0.22649837.12466192.html.plaintext.txt	462	Howard Hughes Medical Institute Sean B
0.22649837.12466192.html.plaintext.txt	463	REFERENCES TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES
0.22649837.12466192.html.plaintext.txt	464	Differential DNA binding specificity Engrailed homeodomain role residue 50
0.22649837.12466192.html.plaintext.txt	465	Cytogenetic mapping ri
0.22649837.12466192.html.plaintext.txt	466	Three habits highly effective signaling pathways principles transcriptional control developmental cell signaling
0.22649837.12466192.html.plaintext.txt	467	The spalt related gene Drosophila melanogaster member ancient gene family defined adjacent region specific homeotic gene spalt
0.22649837.12466192.html.plaintext.txt	468	Boundaries Drosophila wing imaginal discs organize vein specific genetic programs
0.22649837.12466192.html.plaintext.txt	469	Localized activation RTKMAPK pathways development
0.22649837.12466192.html.plaintext.txt	470	CO2 NlinktypeDOICrossRefMedline
0.22649837.12466192.html.plaintext.txt	471	EGF Receptor TGF ss like Dpp signaling Drosophila development
0.22649837.12466192.html.plaintext.txt	472	In Hormones Growth Factors Development Neoplasia ed
0.22649837.12466192.html.plaintext.txt	473	Drawing lines Drosophila wing initiation wing vein development
0.22649837.12466192.html.plaintext.txt	474	rhomboid gene required dorsoventral axis establishment peripheral nervous system development Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	475	Targeted gene expression means altering cell fates generating dominant phenotypes
0.22649837.12466192.html.plaintext.txt	476	Transducing Dpp morphogen gradient wing Drosophila regulation Dpp targets brinker
0.22649837.12466192.html.plaintext.txt	477	Neuronal type information encoded basic helix loop helix domain proneural genes
0.22649837.12466192.html.plaintext.txt	478	Function spaltspalt related gene complex positioning veins Drosophila wing
0.22649837.12466192.html.plaintext.txt	479	Notch signaling regulates veinlet expression establishes boundaries veins interveins Drosophila wing
0.22649837.12466192.html.plaintext.txt	480	The differentiation serotonergic neurons Drosophila ventral nerve cord depends combined function zinc finger proteins Eagle Huckebein
0.22649837.12466192.html.plaintext.txt	481	An Analysis Cis Regulatory Regions Pan Neural Genes Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	482	Thesis University California San Diego La Jolla CA
0.22649837.12466192.html.plaintext.txt	483	Inductive mechanisms process wing vein formation Drosophila
0.22649837.12466192.html.plaintext.txt	484	Developmental genetics venation pattern Drosophila
0.22649837.12466192.html.plaintext.txt	485	Tissue specific enhancers may act trans gene located homologous chromosome molecular basis transvection Drosophila
0.22649837.12466192.html.plaintext.txt	486	Site specific recombination homologous chromosomes Drosophila
0.22649837.12466192.html.plaintext.txt	487	araucan caupolican two members novel iroquois complex encode homeoproteins control proneural vein forming genes
0.22649837.12466192.html.plaintext.txt	488	rhomboid Star interact synergistically promote EGF RMAPK signaling Drosophila wing vein development
0.22649837.12466192.html.plaintext.txt	489	Control genetic regulatory network selector gene
0.22649837.12466192.html.plaintext.txt	490	The Vestigial Scalloped proteins act together directly regulate wing specific gene expression Drosophila
0.22649837.12466192.html.plaintext.txt	491	Binding Vestigial co factor switches DNA target selectivity Scalloped selector protein
0.22649837.12466192.html.plaintext.txt	492	eagle member steroid receptor gene superfamily expressed subset neuroblasts regulates fate putative progeny Drosophila CNS
0.22649837.12466192.html.plaintext.txt	493	The Drosophila gene brinker reveals novel mechanism Dpp target gene regulation
0.22649837.12466192.html.plaintext.txt	494	Integration positional signals regulation wing formation identity Drosophila vestigial gene
0.22649837.12466192.html.plaintext.txt	495	Drosophila Mad binds DNA directly mediates activation vestigial Decapentaplegic
0.22649837.12466192.html.plaintext.txt	496	The GLI gene encodes nuclear proten binds specific sequences human genome
0.22649837.12466192.html.plaintext.txt	497	Wing disc development fly early stages
0.22649837.12466192.html.plaintext.txt	498	Implications dynamic patterns Delta Notch expression cellular interactions Drosophila development
0.22649837.12466192.html.plaintext.txt	499	spalt encodes evolutionarily conserved zinc finger protein novel structure provides homeotic gene function head tail region Drosophila embryo
0.22649837.12466192.html.plaintext.txt	500	Morphogens compartments pattern lessons DrosophilaCell 85951 961
0.22649837.12466192.html.plaintext.txt	501	Regionsspezifische Segmentierungsmutanten bei Drosophila melanogaster Meigen
0.22649837.12466192.html.plaintext.txt	502	Thesis University Tubingen Germany
0.22649837.12466192.html.plaintext.txt	503	The theory application new method detecting chromosomal rearrangements Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	504	Genetic Variations Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	505	Carnegie Institute Washington
0.22649837.12466192.html.plaintext.txt	506	The Genome Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	507	The knirps knirps related genes organize development second wing vein Drosophila
0.22649837.12466192.html.plaintext.txt	508	eagle required specification serotonin neurons neuroblast 7 3 progeny Drosophila CNS
0.22649837.12466192.html.plaintext.txt	509	The Drosophila Serum Response Factor gene required formation intervein tissue wing allelic blistered
0.22649837.12466192.html.plaintext.txt	510	Induced mutations Drosophila
0.22649837.12466192.html.plaintext.txt	511	Abdominal segmentation Drosophila embryo requires hormone receptor like protein encoded gap gene knirps
0.22649837.12466192.html.plaintext.txt	512	Drosophila glial architecture development analysis using collection new cell specific markers
0.22649837.12466192.html.plaintext.txt	513	New functions Drosophila rhomboid gene embryonic adult development revealed novel genetic method enhancer piracy
0.22649837.12466192.html.plaintext.txt	514	Mutations affecting segment number polarity Drosophila
0.22649837.12466192.html.plaintext.txt	515	Double label situ hybridization using biotin digoxigenin tagged RNA probes
0.22649837.12466192.html.plaintext.txt	516	The Drosophila gene knirps related member steroid receptor gene superfamily
0.22649837.12466192.html.plaintext.txt	517	Spatial control gap gene knirps Drosophila embryo posterior morphogen system
0.22649837.12466192.html.plaintext.txt	518	The pleiotropic function Delta postembryonic development Drosophila melanogaster
0.22649837.12466192.html.plaintext.txt	519	Transvection chromosomal trans interaction effects
0.22649837.12466192.html.plaintext.txt	520	Basic Drosophila care techniques
0.22649837.12466192.html.plaintext.txt	521	In Drosophila A Practical Approach ed
0.22649837.12466192.html.plaintext.txt	522	Three hormone receptor like Drosophila genes encode identical DNA binding finger
0.22649837.12466192.html.plaintext.txt	523	Loss gene function rapid mitotic cycles Drosophila embryo
0.22649837.12466192.html.plaintext.txt	524	Transcriptional regulation Drosophila gene zen competing Smad Brinker inputs
0.22649837.12466192.html.plaintext.txt	525	Vein novel component Drosophila epidermal growth factor receptor pathway similarity neuregulins
0.22649837.12466192.html.plaintext.txt	526	EGF domain swap converts Drosophila EGF receptor activator inhibitor
0.22649837.12466192.html.plaintext.txt	527	Secreted Spitz triggers DER signaling pathway limiting component embryonic ventral ectoderm determination
0.22649837.12466192.html.plaintext.txt	528	Temperature sensitive periods autonomy pleiotropic effects l1Nts 1 conditional Notch lethal Drosophila
0.22649837.12466192.html.plaintext.txt	529	Enhancer point mutation results homeotic transformation Drosophila
0.22649837.12466192.html.plaintext.txt	530	Molecular phenotypic expression analysis vein gene required growth Drosophila wing disc
0.22649837.12466192.html.plaintext.txt	531	Molecular interactions Vestigial Scalloped promote wing formation Drosophila
0.22649837.12466192.html.plaintext.txt	532	Regulation two pair rule stripes single enhancer Drosophila embryo
0.22649837.12466192.html.plaintext.txt	533	Detection specific sequences among DNA fragments separated gel electrophoresis
0.22649837.12466192.html.plaintext.txt	534	Formation morphogen gradients Drosophila wing
0.22649837.12466192.html.plaintext.txt	535	The Drosophila rhomboid gene mediates localized formation wing veins interacts genetically components EGF R signaling pathway
0.22649837.12466192.html.plaintext.txt	536	Analysis genetic hierarchy guiding wing vein formation Drosophila
0.22649837.12466192.html.plaintext.txt	537	The Drosophila Rhomboid protein concentrated patches apical cell surface
0.22649837.12466192.html.plaintext.txt	538	The spalt gene links AP compartment boundary linear adult structure Drosophila wing
0.22649837.12466192.html.plaintext.txt	539	An EGFREbiSno pathway promotes Delta expression inactivating SuHSMRTER repression inductive Notch signaling
0.22649837.12466192.html.plaintext.txt	540	The genetic control wing development Drosophila
0.22649837.12466192.html.plaintext.txt	541	CNS midline enhancers Drosophila slit Toll genes
0.22649837.12466192.html.plaintext.txt	542	Brinker sequence specific transcriptional repressor Drosophila embryo
0.19757515.15073154.html.plaintext.txt	0	elegans heterochronic gene lin 46 affects developmental timing two larval stages encodes relative scaffolding protein gephyrin Anita S
0.19757515.15073154.html.plaintext.txt	1	McCane1 Kevin Kemper13 Denise Au Yeung2 Rosalind C
0.19757515.15073154.html.plaintext.txt	2	Lee2 Victor Ambros2 Eric G
0.19757515.15073154.html.plaintext.txt	3	1 Fox Chase Cancer Center Philadelphia PA 19111 USA 2 Department Genetics Dartmouth Medical School Hanover NH 03755 USA 3 Department Molecular Biology UMDNJ Stratford NJ 08084 USA
0.19757515.15073154.html.plaintext.txt	4	Author correspondence e mail mossegatumdnj
0.19757515.15073154.html.plaintext.txt	5	SUMMARY TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES The succession developmental events C
0.19757515.15073154.html.plaintext.txt	6	elegans larva governed heterochronic genes
0.19757515.15073154.html.plaintext.txt	7	When mutated genes cause either precocious retarded developmental phenotypes stage specific patterns cell division differentiation either skipped reiterated respectively
0.19757515.15073154.html.plaintext.txt	8	We identified new heterochronic gene lin 46 mutations suppress precocious phenotypes caused mutations heterochronic genes lin 14 lin 28
0.19757515.15073154.html.plaintext.txt	9	lin 46 mutants display retarded phenotypes cell division patterns reiterated differentiation prevented certain cell lineages
0.19757515.15073154.html.plaintext.txt	10	Our analysis indicates lin 46 acts step immediately downstream lin 28 affecting regulation heterochronic gene pathway execution stage specific developmental events two stages third larval stage adult
0.19757515.15073154.html.plaintext.txt	11	We also show lin 46 required prior third stage normal adult cell fates suggesting acts control fates stages affects adult fates let 7 branch heterochronic pathway
0.19757515.15073154.html.plaintext.txt	12	Interestingly lin 46 encodes protein homologous MoeA bacteria C terminal domain mammalian gephyrin multifunctional scaffolding protein
0.19757515.15073154.html.plaintext.txt	13	Our findings suggest LIN 46 protein acts scaffold multiprotein assembly controls developmental timing expand known roles gephyrin related proteins development
0.19757515.15073154.html.plaintext.txt	14	elegans Larval development Hypodermis Heterochronic genes lin 14 lin 28 lin 42 lin 46 lin 57 let 7 Gephyrin MoeA moc 1 moc 2
0.19757515.15073154.html.plaintext.txt	15	Introduction TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES The succession synchrony diverse developmental events larva Caenorhabditis elegans controlled heterochronic genes Ambros 2000
0.19757515.15073154.html.plaintext.txt	16	In many cell lineages cell division patterns differentiation events differ four larval stages L1 L4
0.19757515.15073154.html.plaintext.txt	17	A mutation heterochronic gene results either precocious retarded development stage specific patterns cell division differentiation either skipped reiterated respectively
0.19757515.15073154.html.plaintext.txt	18	For example lin 14 lin 28 two heterochronic genes act early larval development lin 14 loss function lf mutant animals precociously execute events specific second larval stage L2 later lin 28lf animals precociously execute events specific third larval stage L3 later Fig
0.19757515.15073154.html.plaintext.txt	19	The heterochronic genes like developmental regulators define component fate cell unlike spatial cell type regulators govern temporal component fate
0.19757515.15073154.html.plaintext.txt	20	View larger version 23K Fig
0.19757515.15073154.html.plaintext.txt	21	Lineages hypodermal cells heterochronic mutants
0.19757515.15073154.html.plaintext.txt	22	Schematics post embryonic cell lineages lateral seam VnV1 V4 V6 ventral PnP3 P8 cells shown animals genotype indicated
0.19757515.15073154.html.plaintext.txt	23	Vulva precursor cells VPC posterior daughters P5 P7
0.19757515.15073154.html.plaintext.txt	24	A horizontal line depicts cell division
0.19757515.15073154.html.plaintext.txt	25	To left set lineages indicated cell type specific lineage pattern interpreted data 1 L1 specific cell lineage pattern etc
0.19757515.15073154.html.plaintext.txt	26	23 4A indicate cells indicated stage may execute mix alternative fates see text
0.19757515.15073154.html.plaintext.txt	27	Broken lines indicate cells depicted
0.19757515.15073154.html.plaintext.txt	28	Three horizontal lines indicate fusion seam cells secretion adult lateral alae
0.19757515.15073154.html.plaintext.txt	29	The anterior daughters Vn seam lineages indicated short lines appear fuse main hypodermal syncytium
0.19757515.15073154.html.plaintext.txt	30	Wild type lin 28lf lineages taken previous studies Sulston Horvitz 1977 Ambros Horvitz 1984
0.19757515.15073154.html.plaintext.txt	31	In general heterochronic gene governs cell fates particular larval stage gene acts early larval development may affect later stages consequence
0.19757515.15073154.html.plaintext.txt	32	For example lin 28 involved immediately L2 fate decision indirectly affects adult differentiation programs Ambros 1989
0.19757515.15073154.html.plaintext.txt	33	In particular lin 28lf causes precocious execution larva adult LA switch lateral hypodermal seam cells cease dividing differentiate produce adult alae cuticle structure
0.19757515.15073154.html.plaintext.txt	34	However molecular analysis shown lin 28 expression repressed three stages LA switch Moss et al
0.19757515.15073154.html.plaintext.txt	35	lin 28 affects LA switch via expression heterochronic genes let 7 lin 41 lin 57 lin 29 see Fig
0.19757515.15073154.html.plaintext.txt	36	5 Ambros 1989 Rougvie Ambros 1995 Slack et al
0.19757515.15073154.html.plaintext.txt	37	View larger version 21K Fig
0.19757515.15073154.html.plaintext.txt	38	Genetic molecular models LIN 46 activity developmental timing
0.19757515.15073154.html.plaintext.txt	39	A Genetic models heterochronic pathway governing fate choices two stages
0.19757515.15073154.html.plaintext.txt	40	Left Interactions governing L2L3 fate choice
0.19757515.15073154.html.plaintext.txt	41	The circled regulators x y identified may fact represent multiple factors
0.19757515.15073154.html.plaintext.txt	42	lin 14 depicted role L2L3 fate decision lin 14B activity
0.19757515.15073154.html.plaintext.txt	43	The position daf 12 based previous studies Antebi et al
0.19757515.15073154.html.plaintext.txt	44	2002 role appear analogous lin 46
0.19757515.15073154.html.plaintext.txt	45	Right Interactions governing LA switch
0.19757515.15073154.html.plaintext.txt	46	The effect lin 28 lin 46 let 7 expression activity determined may indirect
0.19757515.15073154.html.plaintext.txt	47	The linear pathway let 7 adult fates based previous studies Abrahante et al
0.19757515.15073154.html.plaintext.txt	48	B A molecular model LIN 46 protein function
0.19757515.15073154.html.plaintext.txt	49	LIN 46 may scaffold multiprotein assembly constituting developmental timing complex regulates expression downstream heterochronic genes promotes L3 adult specific cell fates
0.19757515.15073154.html.plaintext.txt	50	Broken arrow indicates effects complex may either positive negative either direct indirect
0.19757515.15073154.html.plaintext.txt	51	LIN 28 may act negative regulator one components complex probably level gene expression
0.19757515.15073154.html.plaintext.txt	52	lin 14 two roles larval development first determine L1 fates later affect L2 subsequent events Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	53	These two activities differ occur nature interactions genes
0.19757515.15073154.html.plaintext.txt	54	Specifically lin 14 apparently acts alone govern L1 cell fates interacts lin 28 choose cell fates occur L2 Ambros 2000
0.19757515.15073154.html.plaintext.txt	55	lin 14 lin 28 engaged complex genetic circuitry involves positive negative regulatory interactions see Fig
0.19757515.15073154.html.plaintext.txt	56	This circuitry involves microRNA lin 4 well yet unidentified components Lee et al
0.19757515.15073154.html.plaintext.txt	57	In later larval stages lin 14 lin 28 repressed allowing late stage events executed
0.19757515.15073154.html.plaintext.txt	58	The changes activity interactions heterochronic genes larval stages lead normal succession larval developmental events
0.19757515.15073154.html.plaintext.txt	59	The products heterochronic genes include least two microRNAs lin 4 let 7 evolutionarily conserved protein unique pairing RNA binding motifs LIN 28 protein related circadian rhythm regulator period Drosophila LIN 42 nuclear protein unknown function LIN 14 Ruvkun et al
0.19757515.15073154.html.plaintext.txt	60	1989 Ruvkun Giusto 1989 Lee et al
0.19757515.15073154.html.plaintext.txt	61	Although insight gained expression certain heterochronic genes regulated yet known whether identified heterochronic genes constitute components pathway
0.19757515.15073154.html.plaintext.txt	62	Nor known products heterochronic genes interact among cellular components effect precise timing developmental events worm larvae
0.19757515.15073154.html.plaintext.txt	63	We identified new heterochronic gene lin 46 occupies unique position larval developmental timing mechanism C
0.19757515.15073154.html.plaintext.txt	64	Our analysis indicates lin 46 functions step immediately downstream lin 28 acts branch point heterochronic pathway
0.19757515.15073154.html.plaintext.txt	65	lin 46 encodes protein homologous bacterial mammalian proteins developmental regulator novel
0.19757515.15073154.html.plaintext.txt	66	Materials methods TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES Culturing mutants strain construction C
0.19757515.15073154.html.plaintext.txt	67	elegans strains cultured described Wood et al
0.19757515.15073154.html.plaintext.txt	68	1988 grown 20 degrees C unless otherwise noted
0.19757515.15073154.html.plaintext.txt	69	Genetic screens performed EMS ma164 UV ma174 mutagenesis new alleles outcrossed prior analysis
0.19757515.15073154.html.plaintext.txt	70	All mutant alleles except lin 46 described previously
0.19757515.15073154.html.plaintext.txt	71	A lin 46 mutant allele followed crosses retarded phenotype although strain constructions relied linked marker unc 76e911 developmental timing effects A
0.19757515.15073154.html.plaintext.txt	72	unpublished Bloom Horvitz 1997
0.19757515.15073154.html.plaintext.txt	73	The presence lin 46 mutant allele strains confirmed upon outcrossing
0.19757515.15073154.html.plaintext.txt	74	Strains The lin 28lf alleles used null based molecular analysis Moss et al
0.19757515.15073154.html.plaintext.txt	75	The nature different lin 14 alleles used indicated text tables
0.19757515.15073154.html.plaintext.txt	76	The lin 46 allele ma164 used experiments except indicated
0.19757515.15073154.html.plaintext.txt	77	N2 wild type ME1 lin 28ga54 I lin 46ma164 V ME11 lin 42n1089 II lin 46ma164 unc 76e911 V ME12 lin 46ma164 unc 76e911 V lin 14n360 X ME13 aeEx1 pJJ
0.19757515.15073154.html.plaintext.txt	78	1lin 46GFP pRF4rol 6su1006 ME20 lin 46ma164 V ME21 lin 46ma174 V ME42 lin 46ma164 unc 76e911 V lin 14ma135szT1 X ME58 lin 42n1089 II lin 46ma164 unc 76e911 V lin 14n179 X ME63 lin 42n1089 I lin 14n179ts X ME89 lin 28n719 I wIs78 ME90 lin 28n719 I wIs78 lin 14n536n540 X ME91 wIs78 lin 46ma164 unc 76e911 V ME92 lin 28n719 I wIs78 lin 46ma164 unc76e911 V ME94 aeEx33 pLT
0.19757515.15073154.html.plaintext.txt	79	18 lin 46GFP pRF4rol 6su1006 ME97 lin 28n719 I wIs78 lin 46ma164 unc 76e911 V lin 14n536n540 X ME98 wIs78 lin 14ma135szT1 X ME99 wIs78 lin 46ma164 unc 76e911 V lin 14ma135szT1 X ME101 lin 41ma104 I lin 46ma164 V ME105 wIs78 lin 14n179ts X ME107 wIs78 lin 46ma164 unc 76e911 V lin 14n179ts X CT8 lin 41ma104 I MT2257 lin 42n1089 II MT1848 lin 14n360 X PV5 lin 28ga54 I RG733 ced 1e1735 I wIs78 VT284 lin 14ma135szT1 X
0.19757515.15073154.html.plaintext.txt	80	wIs78 pDPMM016B unc 119 pJS191 ajm 1gfp pMF1scmgfp F58E10 Abrahante et al
0.19757515.15073154.html.plaintext.txt	81	Microscopy phenotype analysis Egg laying ability scored using dissecting microscope
0.19757515.15073154.html.plaintext.txt	82	Gonad development seam cell number adult lateral alae formation scored using DIC fluorescence microscopy high magnification
0.19757515.15073154.html.plaintext.txt	83	Lateral hypodermal cell lineages deduced counting seam cells animals multiple ages L1 L4
0.19757515.15073154.html.plaintext.txt	84	These cells identified GFP expression wIs78 contains scm 1GFP ajm 1GFP mark seam cell nuclei seam cell junctions respectively Koh Rothman 2001
0.19757515.15073154.html.plaintext.txt	85	The stage development determined extent gonad germline development
0.19757515.15073154.html.plaintext.txt	86	Data collected animals early late larval stage
0.19757515.15073154.html.plaintext.txt	87	Because cell division ongoing near beginning stage present seam cell numbers cell divisions appeared complete
0.19757515.15073154.html.plaintext.txt	88	Cold sensitive period lin 46ma174 animals raised either restrictive 15 degrees C permissive 25 degrees C temperature specific stages development shifted temperature remainder larval development
0.19757515.15073154.html.plaintext.txt	89	The animals shifted lethargus period precedes molt
0.19757515.15073154.html.plaintext.txt	90	At adulthood animals scored presence gaps alae
0.19757515.15073154.html.plaintext.txt	91	Genetic physical mapping Genetic mapping physical mapping performed using standard methods Fig
0.19757515.15073154.html.plaintext.txt	92	3A data available wormbase
0.19757515.15073154.html.plaintext.txt	93	View larger version 42K Fig
0.19757515.15073154.html.plaintext.txt	94	Cloning lin 46 homology MoeA gephyrin
0.19757515.15073154.html.plaintext.txt	95	A Regions genetic physical maps linkage group V C
0.19757515.15073154.html.plaintext.txt	96	elegans depicting location lin 46
0.19757515.15073154.html.plaintext.txt	97	Two cosmids shown rescued lin 46 mutant
0.19757515.15073154.html.plaintext.txt	98	One subcloned yield minimal rescuing BglI NgoMI restriction fragment
0.19757515.15073154.html.plaintext.txt	99	The gene structure determined RT PCR sequence analysis
0.19757515.15073154.html.plaintext.txt	100	B An alignment predicted amino acid sequences LIN 46 C
0.19757515.15073154.html.plaintext.txt	101	Black identical residues gray similar residues
0.19757515.15073154.html.plaintext.txt	102	Vertical lines indicate exon boundaries
0.19757515.15073154.html.plaintext.txt	103	Arrows indicate positions lesions mutant alleles ma164 ma174 ve1
0.19757515.15073154.html.plaintext.txt	104	Dots asterisks indicate residues partially highly conserved among gephyrinMoeA homologues respectively
0.19757515.15073154.html.plaintext.txt	105	C Schematics LIN 46 related proteins gephyrin mammals Cinnamon Drosophila CNX1 Arabidopsis MoeA MogA E
0.19757515.15073154.html.plaintext.txt	106	coli MOC 1 MOC 2 LIN 46 C
0.19757515.15073154.html.plaintext.txt	107	MoeA like E MogA like G regions indicated
0.19757515.15073154.html.plaintext.txt	108	Plasmids transformation Cosmid genomic clones obtained C
0.19757515.15073154.html.plaintext.txt	109	elegans genome sequencing consortium
0.19757515.15073154.html.plaintext.txt	110	Subclones made pBluescript
0.19757515.15073154.html.plaintext.txt	111	In rescue experiments clones co injected pRF4rol 6su1006 strain genotype lin 28 lin 46
0.19757515.15073154.html.plaintext.txt	112	Rolling animals scored egg laying ability presence adult alae L4 stage
0.19757515.15073154.html.plaintext.txt	113	Clones caused transgenic F1 animals display precocious phenotype scored positive ability rescue lin 46 suppression phenotype
0.19757515.15073154.html.plaintext.txt	114	PolyA RNA mixed stage population subjected RT PCR using oligodT SL1 lin 46 specific primers
0.19757515.15073154.html.plaintext.txt	115	PCR products cloned sequenced determine structure gene
0.19757515.15073154.html.plaintext.txt	116	A translational fusion reporter construct pJJ
0.19757515.15073154.html.plaintext.txt	117	1 made introducing GFP frame EagI site nine codons stop codon BglI NgoMI subclone shown Fig
0.19757515.15073154.html.plaintext.txt	118	A transcriptional fusion construct pLT
0.19757515.15073154.html.plaintext.txt	119	18 derived translational fusion creating 1
0.19757515.15073154.html.plaintext.txt	120	5 kb deletion within gene BglII site second exon 20 codons AUG EcoRV site last exon 15 codons start GFP
0.19757515.15073154.html.plaintext.txt	121	Both constructs co injected pRF4rol 6su1006
0.19757515.15073154.html.plaintext.txt	122	Four translational fusion lines two transcriptional fusion lines showed consistent expression patterns described Results
0.19757515.15073154.html.plaintext.txt	123	RNA interference RNA interference lin 57 achieved culturing worms bacterial strain HT115DE3 containing plasmid expressing lin 57 dsRNA gift A
0.19757515.15073154.html.plaintext.txt	124	Rougvie presence IPTG ampicillin tetracycline Timmons et al
0.19757515.15073154.html.plaintext.txt	125	Results TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES lin 46 mutations suppress precocious development To identify additional early acting components heterochronic pathway conducted genetic screens mutations suppress precocious developmental phenotypes lin 14lf lin 28lf mutations
0.19757515.15073154.html.plaintext.txt	126	These mutations cause multiple cell lineage defects result protruding vulva inability lay eggs adults Ambros Horvitz 1984
0.19757515.15073154.html.plaintext.txt	127	Suppressor mutations identified animals normal vulva could lay eggs
0.19757515.15073154.html.plaintext.txt	128	Two mutations characterized ma164 ma174
0.19757515.15073154.html.plaintext.txt	129	Each recessive wild type define complementation group linkage group V see Fig
0.19757515.15073154.html.plaintext.txt	130	Because mutations cause changes normal cell lineage patterns described gene define given name lin 46 cell lineage abnormal according standard nomenclature Horvitz et al
0.19757515.15073154.html.plaintext.txt	131	Both mutant alleles lin 46 completely suppressed protruding vulva Pvul egg laying defective Egl phenotype three different lin 28 null alleles Table 1 lines 2 3 data shown Moss et al
0.19757515.15073154.html.plaintext.txt	132	The Pvul Egl phenotypes lin 28lf due part precocious vulva precursor cell VPC divisions vulva development Euling Ambros 1996
0.19757515.15073154.html.plaintext.txt	133	We observed lin 28lf lin 46lf animals wild type timing vulva development VPC divisions occurring L3 stage Fig
0.19757515.15073154.html.plaintext.txt	134	lin 28 also governs choice L2 L3 specific fates lateral hypodermal seam cells Ambros Horvitz 1984
0.19757515.15073154.html.plaintext.txt	135	Normally L1 L3 L4 stages seam cells undergo single asymmetric cell division anterior daughter joins hypodermal syncytium posterior daughter remains seam cell Fig
0.19757515.15073154.html.plaintext.txt	136	However L2 wild type animals asymmetric division certain seam cells V1 4 V6 preceded symmetric division increases number seam cells side animal five additional seam cells also added stage descendants hypodermal cells H1 T Table 1 line 1 Fig
0.19757515.15073154.html.plaintext.txt	137	1 Sulston Horvitz 1977
0.19757515.15073154.html.plaintext.txt	138	lin 28lf animals fewer seam cells wild type skip L2 lineage patterns generate additional seam cells lin 28lf animals also cease molting three cycles precocious execution LA switch Table 1 line 2 Fig
0.19757515.15073154.html.plaintext.txt	139	We found lin 28lf lin 46lf animals normal number seam cells every stage well normal four molts indicating suppression L2 lineage defects lin 28lf lin 46 mutation Table 1 line 3 Fig
0.19757515.15073154.html.plaintext.txt	140	Furthermore lin 46lf completely suppressed precocious LA switch indicated synthesis adult alae caused lin 28lf Table 2 lines 3 4 Fig
0.19757515.15073154.html.plaintext.txt	141	These data indicate lin 46 affects fate decisions governed lin 28 absence lin 46 activity completely bypasses requirement animal lin 28
0.19757515.15073154.html.plaintext.txt	142	lin 46lf suppresses lin 28lf lin 14ts precocious phenotypes
0.19757515.15073154.html.plaintext.txt	143	Genetic interactions lin 46 heterochronic mutants
0.19757515.15073154.html.plaintext.txt	144	By contrast observed suppression precocious heterochronic defects lin 14 null allele
0.19757515.15073154.html.plaintext.txt	145	For example like lin 140 animals lin 46lf lin 140 animals completely egg laying defective execute LA switch precociously Table 2 lines 5 6 data shown
0.19757515.15073154.html.plaintext.txt	146	However surprisingly one lin 46 mutant alleles ma174 isolated suppressor lin 14n179ts animals
0.19757515.15073154.html.plaintext.txt	147	lin 14n179ts loss function temperature sensitive allele Ambros Horvitz 1984 Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	148	As mentioned lin 14 acts twice larval development affect L1 cell fates lin 14A activity affect L2 later fates lin 14B activity Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	149	When lin 14n179ts animals raised 25 degrees C display loss lin 14A activity causing precocious increase seam cell number loss lin 14B activity leads precocious execution LA switch Table 1 line 5 Table 2 line7
0.19757515.15073154.html.plaintext.txt	150	We found mutation lin 46lf suppressed lin 14B defects lin 14A defects lin 14n179ts allele
0.19757515.15073154.html.plaintext.txt	151	Specifically lin 46lf lin 14n179ts animals abnormal number seam cells L1 normal number molts Table 1 line 6
0.19757515.15073154.html.plaintext.txt	152	Furthermore compared lin 14n179ts animals lin 46lf lin 14n179ts animals significantly less egg laying defective showed reduced amounts precocious adult alae Table 1 line 6 Table 2 line 8
0.19757515.15073154.html.plaintext.txt	153	Similarly precocious adult alae formation lin 14n360 lin 14lf allele displays lin 14B defects suppressed lin 46lf Table 2 lines 9 10 Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	154	In addition observed intestinal nuclei lin 46lf lin 14n179ts animals fail divide L1 normally lin 14A defect display precocious vulva development lin 14B defect data shown Ambros Horvitz 1987 Euling Ambros 1996
0.19757515.15073154.html.plaintext.txt	155	Thus lin 46lf suppressed defects lin 14 hypomorphic alleles common lin 28lf unique lin 14 although suppressed none defects lin 14 null allele
0.19757515.15073154.html.plaintext.txt	156	Interestingly suppression lin 28lf phenotype quite complete whereas 100 lin 28lf animals precocious adult alae lin 28lf lin 46lf double mutant animals devoid adult alae L4 stage Table 2 lines 3 4
0.19757515.15073154.html.plaintext.txt	157	By contrast suppression lin 14 hypomorphic alleles substantial albeit incomplete
0.19757515.15073154.html.plaintext.txt	158	For example lin 14n360 percentage animals full length precocious adult alae reduced 77 5 however 95 double mutant animals amount precocious alae Table 2 lines 9 10
0.19757515.15073154.html.plaintext.txt	159	Because lin 14 lin 28 act together govern cell fates L2 later findings suggest lin 46 different relationships two genes
0.19757515.15073154.html.plaintext.txt	160	The ability lin 46lf suppress lin 14 hypomorphic alleles null allele may reflect least lin 14 activity required suppression furthermore lin 46lf suppresses phenotype lin 28lf raising lin 14 activity compensatory level
0.19757515.15073154.html.plaintext.txt	161	Importantly requirement lin 14 suppression would suggest lin 14 act independently lin 28 control late stage fates
0.19757515.15073154.html.plaintext.txt	162	Because implications heterochronic pathway functions investigated possibility
0.19757515.15073154.html.plaintext.txt	163	Suppression lin 28 require lin 14 To determine whether lin 14 indeed required suppression lin 28lf phenotype lin 46lf assessed hypodermal development strains bearing null allele lin 14
0.19757515.15073154.html.plaintext.txt	164	lin 140 animals skip L1 specific lineage patterns precociously execute L2 specific division patterns increase seam cell number Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	165	It previously shown lin 28lf lin 140 strain executes LA switch one stage earlier lin 140 strain however effect mutant combination seam cell number assessed Ambros 1989
0.19757515.15073154.html.plaintext.txt	166	We observed increase 10 15 seam cells occurs abnormally early L1 lin 140 animals occur absence lin 28 consistent L3 lineage pattern occurring two stages early Table 3 lines 1 3
0.19757515.15073154.html.plaintext.txt	167	This observation indicates hypodermal lineage patterns executed L1 lin 140 animals controlled lin 28 evidence lin 28 acts independently lin 14 govern cell fate choices
0.19757515.15073154.html.plaintext.txt	168	Suppression lin 280 lin 460 require lin 14
0.19757515.15073154.html.plaintext.txt	169	Importantly although lin 46lf effect number seam cells lin 140 animals wild type lin 28 increased number seam cells lin 28lf lin 140 strain lin 140 strain Table 3
0.19757515.15073154.html.plaintext.txt	170	Thus lin 46lf suppressed lin 28lf defect despite absence lin 14
0.19757515.15073154.html.plaintext.txt	171	In addition LA switch indicated seam cell fusion adult alae formation occurred one stage later triple mutant animals relative lin 28lf lin 140 animals data shown
0.19757515.15073154.html.plaintext.txt	172	Therefore elevation lin 14 activity mechanism lin 46lf compensates loss lin 28
0.19757515.15073154.html.plaintext.txt	173	Interactions lin 46 heterochronic mutants To establish position lin 46 developmental timing pathway examined interactions precocious heterochronic mutants
0.19757515.15073154.html.plaintext.txt	174	In addition lin 14 lin 28 several genes identified result precocious expression LA switch mutated lin 41 lin 42 lin 57 Z
0.19757515.15073154.html.plaintext.txt	175	Liu PhD thesis Harvard University 1990 Abrahante et al
0.19757515.15073154.html.plaintext.txt	176	For analysis examined ability lin 46lf suppress precocious execution LA switch characteristic mutants
0.19757515.15073154.html.plaintext.txt	177	lin 46lf partially suppressed precocious synthesis adult alae lin 42lf whereas little effect precocious alae caused loss activities lin 41lf lin 57lf Table 2 lines 11 16
0.19757515.15073154.html.plaintext.txt	178	Thus lin 46 appears function upstream lin 41 lin 57 downstream parallel lin 42 controlling LA switch
0.19757515.15073154.html.plaintext.txt	179	These results consistent lin 46 acting early heterochronic pathway lin 41 lin 57 thought act late development downstream lin 28 controlling LA switch see Fig
0.19757515.15073154.html.plaintext.txt	180	The earliest time action lin 42 determined previous genetic analysis well data consistent acting early heterochronic pathway Z
0.19757515.15073154.html.plaintext.txt	181	Liu PhD thesis Harvard University 1990
0.19757515.15073154.html.plaintext.txt	182	lin 46 mutations cause retarded development two stages In examining effects lin 46lf absence heterochronic mutations observed increase number seam cells L2 stage animals grown 15 degrees C Table 1 line 8
0.19757515.15073154.html.plaintext.txt	183	This increase probably reflects reiteration L2 specific lineage pattern L3 stage five seam cells divide twice L2 L3 Fig
0.19757515.15073154.html.plaintext.txt	184	This retarded lineage defect observed animals raised 20 degrees C indicating strict cold sensitivity defect Table 1 line 7
0.19757515.15073154.html.plaintext.txt	185	Because mutant alleles lin 46 likely result complete loss function gene see reiteration L2 lineages lin 460 would indicate normal role lin 46 promote expression L3 specific cell fates appropriate time
0.19757515.15073154.html.plaintext.txt	186	Moreover observed two mutant alleles lin 46 caused similar failure LA switch end larval development resulting gaps adult alae Table 4 lines 4 7 Figs 1 2
0.19757515.15073154.html.plaintext.txt	187	The penetrance expressivity phenotype significantly enhanced growth low temperature
0.19757515.15073154.html.plaintext.txt	188	For example retarded LA switch defect lin 46ma164 showed 6 penetrance 25 degrees C 32 20 degrees C 86 15 degrees C Table 4 lines 4 6
0.19757515.15073154.html.plaintext.txt	189	Because cold sensitivity true mutant alleles lin 46 described likely null molecular criteria appears property strain lacking lin 46 activity rather property molecular lesions
0.19757515.15073154.html.plaintext.txt	190	Cold sensitivity suppression lin 46 retarded phenotype
0.19757515.15073154.html.plaintext.txt	191	View larger version 63K Fig
0.19757515.15073154.html.plaintext.txt	192	Retarded development lateral hypodermis lin 46 mutant
0.19757515.15073154.html.plaintext.txt	193	A DIC micrograph adult animal genotype lin 46ma164 grown 20 degrees C showing field two planes focus
0.19757515.15073154.html.plaintext.txt	194	Left pair recently divided lateral hypodermal seam cells
0.19757515.15073154.html.plaintext.txt	195	Right gap adult lateral alae overlying cells
0.19757515.15073154.html.plaintext.txt	196	These gaps initially overly even number seam nuclei later anterior cell fuses main hypodermal syncytium
0.19757515.15073154.html.plaintext.txt	197	Remarkably early late retarded lineage defects lin 46lf equivalently penetrant
0.19757515.15073154.html.plaintext.txt	198	Specifically 32 lin 46ma164 animals raised 20 degrees C show LA switch defects whereas none grown temperature showed reiteration L2 lineage patterns Table 1 line 7 Table 4 line 5
0.19757515.15073154.html.plaintext.txt	199	Thus late stage defect dependent earlier lineage defect Fig
0.19757515.15073154.html.plaintext.txt	200	As discussed consistent lin 46 either acting twice early late acting one time separately affecting two downstream processes differently sensitive level activity
0.19757515.15073154.html.plaintext.txt	201	Interestingly retarded phenotype lin 46lf nearly completely suppressed lin 28lf
0.19757515.15073154.html.plaintext.txt	202	For example penetrance LA switch defect lin 28lf lin 46ma164 8 15 degrees C significantly reduced relative 86 lin 46ma164 alone Table 4 lines 4 13
0.19757515.15073154.html.plaintext.txt	203	Likewise observed early cell lineage defects double mutant grown 15 degrees C Table 1 line 4 Fig
0.19757515.15073154.html.plaintext.txt	204	This mutual suppression lin 46lf lin 28lf suggests lin 46 simple linear pathway downstream lin 28 rather activities converge possibly common targets
0.19757515.15073154.html.plaintext.txt	205	By contrast retarded phenotype lin 46lf suppressed lin 14 null mutation
0.19757515.15073154.html.plaintext.txt	206	Rather lin 46lf causes severe retarded defect lin 14 null mutant background 67 otherwise wild type background 86 Table 4 lines 4 17
0.19757515.15073154.html.plaintext.txt	207	This result indicates lin 14 required effect lin 46 developmental timing
0.19757515.15073154.html.plaintext.txt	208	lin 46 encodes homologue bacterial MoeA vertebrate gephyrin
0.19757515.15073154.html.plaintext.txt	209	lin 46 cloned genetic mapping transformation rescue Fig
0.19757515.15073154.html.plaintext.txt	210	3A see Materials methods
0.19757515.15073154.html.plaintext.txt	211	The smallest rescuing fragment encodes one complete gene annotated R186
0.19757515.15073154.html.plaintext.txt	212	Northern analysis cDNA library screening failed detect transcript gene data shown
0.19757515.15073154.html.plaintext.txt	213	RT PCR analysis revealed gene expressed four introns mRNA trans spliced polyadenylated 1
0.19757515.15073154.html.plaintext.txt	214	The sequence amplified genomic DNA three lin 46 mutant strains revealed mutations three would affect protein encoded gene Fig
0.19757515.15073154.html.plaintext.txt	215	Two lesions alleles ma164 ma174 probably result severe truncations protein strongly suggesting molecular nulls
0.19757515.15073154.html.plaintext.txt	216	Furthermore frameshift mutations introduced rescuing clone rendered unable complement lin 46 mutant data shown
0.19757515.15073154.html.plaintext.txt	217	A clone orthologous gene related species C
0.19757515.15073154.html.plaintext.txt	218	elegans lin 46 mutant phenotype indicating function conserved species data shown
0.19757515.15073154.html.plaintext.txt	219	We therefore concluded lin 46 corresponds R186
0.19757515.15073154.html.plaintext.txt	220	lin 46 potential encode 391 amino acid protein homology along entire length MoeA bacteria C terminal domains referred E domain mammalian protein gephyrin related proteins Cinnamon Drosophila CNX1 Arabidopsis Fig
0.19757515.15073154.html.plaintext.txt	221	Gephyrin submembraneous scaffolding protein aids clustering glycine GABA receptors postsynaptic neurons Kneussel Betz 2000
0.19757515.15073154.html.plaintext.txt	222	MoeA involved last step biosynthesis molybdenum co factor metal coordinating molecule many molybdo enzymes although exact function MoeA process known
0.19757515.15073154.html.plaintext.txt	223	We discuss possible molecular functions LIN 46 protein
0.19757515.15073154.html.plaintext.txt	224	Gephyrin well Cinnamon CNX1 essentially fusions homologues bacterial proteins MoeA MogA
0.19757515.15073154.html.plaintext.txt	225	Indeed three proteins higher eukaryotes believed participate molybdenum cofactor biosynthesis bacterial proteins Kamdar et al
0.19757515.15073154.html.plaintext.txt	226	elegans unusual among multicellular eukaryotes MoeA MogA homologues encoded separately furthermore two MoeA paralogues one encoded lin 46 Fig
0.19757515.15073154.html.plaintext.txt	227	We named genes encoding MoeA homologue MogA homologue C
0.19757515.15073154.html.plaintext.txt	228	elegans moc 1 moc 2 respectively molybdenum cofactor biosynthesis related Fig
0.19757515.15073154.html.plaintext.txt	229	The biological roles genes C
0.19757515.15073154.html.plaintext.txt	230	lin 46 expressed hypodermal cells larval development Green fluorescent protein GFP reporter constructs indicated lin 46 expressed hypodermal cells particularly lateral ventral hypodermis brief periods larval development Fig
0.19757515.15073154.html.plaintext.txt	231	Animals bearing transcriptional fusion see Materials methods showed intense fluorescence lateral hypodermal cells around time molt especially L2 L4 lethargus Fig
0.19757515.15073154.html.plaintext.txt	232	In L2 animals seam cells fluoresced simultaneously often cluster even number cells fluoresced given animal suggesting expression fusion related seam cell division occurs somewhat asynchronously larval development Sulston Horvitz 1977
0.19757515.15073154.html.plaintext.txt	233	A translational fusion reporter showed similar expression pattern although less intense Fig
0.19757515.15073154.html.plaintext.txt	234	The translational fusion also showed strong constitutive expression cell bodies axons bilateral motor interneurons AVB know significance expression
0.19757515.15073154.html.plaintext.txt	235	The LIN 46GFP fusion protein localized cytoplasm nucleus mostly non nucleolar part nucleus Fig
0.19757515.15073154.html.plaintext.txt	236	Thus LIN 46 present cells whose fates governs near time execute stage specific fates
0.19757515.15073154.html.plaintext.txt	237	Its appearance multiple times suggested possibility lin 46 functions larval development
0.19757515.15073154.html.plaintext.txt	238	View larger version 93K Fig
0.19757515.15073154.html.plaintext.txt	239	Expression lin 46GFP hypodermal cells larval development
0.19757515.15073154.html.plaintext.txt	240	Fluorescence DIC micrographs animals bearing lin 46GFP transgenes
0.19757515.15073154.html.plaintext.txt	241	Transgene arrays include rol 6 marker causes twists body
0.19757515.15073154.html.plaintext.txt	242	A L2 animal expressing lin 46GFP transcriptional fusion showing fluorescent lateral hypodermal seam cells
0.19757515.15073154.html.plaintext.txt	243	B An L4 stage animal bearing transcriptional fusion showing fluorescent seam cells apparently undergoing fusion
0.19757515.15073154.html.plaintext.txt	244	C L2 animals expressing lin 46GFP translational fusion
0.19757515.15073154.html.plaintext.txt	245	Fluorescence seen seam cells well two neurons see text
0.19757515.15073154.html.plaintext.txt	246	The exposure time three eight times longer animals expressing transcriptional fusion
0.19757515.15073154.html.plaintext.txt	247	D Higher magnification showing nuclear cytoplasmic localization LIN 46GFP L2 animal expressing translational fusion
0.19757515.15073154.html.plaintext.txt	248	Pairs seam cells often show similar fluorescence intensity
0.19757515.15073154.html.plaintext.txt	249	Scale bars A 100 microm A C D 10 microm
0.19757515.15073154.html.plaintext.txt	250	The cold sensitive period late stage retarded phenotype early larval development To assess whether lin 46 might function twice larval development used pronounced cold sensitivity lin 46 mutant phenotype define cold sensitive period late stage retarded defect
0.19757515.15073154.html.plaintext.txt	251	We observed sufficient animals restrictive temperature L2 lethargus nearly 90 population display gaps adult alae Table 5 15 degrees C 25 degrees C
0.19757515.15073154.html.plaintext.txt	252	Futhermore found necessary animals 15 degrees C least L2 lethargus high penetrance alae defect animals shifted permissive restrictive temperature L2 lethargus 7 less showed defect Table 5 25 degrees C 15 degrees C
0.19757515.15073154.html.plaintext.txt	253	These data indicate period lin 46 mutant animals cold sensitive adult alae defect prior L3 stage
0.19757515.15073154.html.plaintext.txt	254	Because early fate defect lin 46lf executed early L3 stage observations suggest lin 46 required L2 stage affect cell fates executed early late stages
0.19757515.15073154.html.plaintext.txt	255	Cold sensitive period late stage developmental defect lin 460
0.19757515.15073154.html.plaintext.txt	256	Discussion TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES We identified new heterochronic gene lin 46 determined acts early C
0.19757515.15073154.html.plaintext.txt	257	elegans larval developmental timing pathway promote L3 specific adult specific cell fates
0.19757515.15073154.html.plaintext.txt	258	Our genetic results support model lin 46 supports activity downstream complex factors promotes specific fates
0.19757515.15073154.html.plaintext.txt	259	The nature factors whether involved signaling gene regulation known however may direct regulatory targets lin 28
0.19757515.15073154.html.plaintext.txt	260	lin 46 encodes novel developmental regulator protein resembles multifunctional vertebrate protein gephyrin therefore may act like gephyrin scaffold multiprotein complex
0.19757515.15073154.html.plaintext.txt	261	Interactions governing L2L3 fate choice The heterochronic pathway characterized dynamic interactions among regulators make binary choices stage specific cell fates Ambros 1989
0.19757515.15073154.html.plaintext.txt	262	We previously presented model interactions governing choice L2 versus L3 cell fates Seggerson et al
0.19757515.15073154.html.plaintext.txt	263	In model lin 14 lin 28 repressed microRNA lin 4 time support others expression via lin 4 independent feedback circuit
0.19757515.15073154.html.plaintext.txt	264	This positive regulatory circuit proposed occur repression two negative regulators x y whose identities known
0.19757515.15073154.html.plaintext.txt	265	Here extend model proposing lin 46 acts specifically promote activity y furthermore y acts regulate lin 14 expression control developmental timing two larval stages Fig
0.19757515.15073154.html.plaintext.txt	266	Therefore y represents point convergence lin 28 lin 46 activities well branch point pathway affects lin 14 expression L3 cell fates
0.19757515.15073154.html.plaintext.txt	267	We reason yet believe lin 14 expression L3 cell fates regulated distinct factors
0.19757515.15073154.html.plaintext.txt	268	Therefore continue indicate single activity hypothetical factor y may consist multiple factors
0.19757515.15073154.html.plaintext.txt	269	In model placed lin 46 outside feedback circuit based relative penetrance lin 28lf lin 46lf phenotypes mutual suppression Tables 1 4
0.19757515.15073154.html.plaintext.txt	270	Based molecular analysis alleles lin 28 lin 46 used experiments null Fig
0.19757515.15073154.html.plaintext.txt	271	Thus mutual suppression implies lin 28 lin 46 affect common process act simple linear pathway
0.19757515.15073154.html.plaintext.txt	272	If simple pathway lin 28lf lin 46lf animals would display degree retarded development lin 46lf animals
0.19757515.15073154.html.plaintext.txt	273	Furthermore difference penetrance lin 28lf lin 46lf phenotypes suggests different degrees influence cell fates
0.19757515.15073154.html.plaintext.txt	274	Specifically whereas lin 28lf always fully precocious lin 46lf retarded phenotype incomplete conditional
0.19757515.15073154.html.plaintext.txt	275	For reasons propose lin 46 directly part lin 14lin 28 positive feedback circuit therefore y rather acts promote activity y Fig
0.19757515.15073154.html.plaintext.txt	276	The difference penetrance suppression lin 46lf lin 28lf retarded L2 phenotype lin 46lf also suggests changes occur L2L3 fate decision made different times
0.19757515.15073154.html.plaintext.txt	277	In words cell fates L2 stage lin 28lf sensitive loss lin 46 fates L3 wild type Table 1 Fig
0.19757515.15073154.html.plaintext.txt	278	Perhaps decision execute L3 fates robust third larval stage wild type additional activities present second larval stage lin 28 mutant
0.19757515.15073154.html.plaintext.txt	279	Furthermore situation absence lin 46 cause L2 specific cell fates reiterated indefinitely suggesting additional factors come influence L2L3 fate decision ultimately favor L3 fates
0.19757515.15073154.html.plaintext.txt	280	The role lin 14 late stage cell fates Our observations help illuminate relationship lin 14 lin 28 controlling execution cell fates first larval stage
0.19757515.15073154.html.plaintext.txt	281	Two models proposed explain activities lin 14 lin 14A lin 14B independently affect L1 later developmental events Ambros Horvitz 1987
0.19757515.15073154.html.plaintext.txt	282	One different isoforms LIN 14 protein possess distinct activities Wightman et al
0.19757515.15073154.html.plaintext.txt	283	1991 Reinhart Ruvkun 2001
0.19757515.15073154.html.plaintext.txt	284	However model supported finding molecular clone single isoform LIN 14 fully rescue lin 14lf Hong et al
0.19757515.15073154.html.plaintext.txt	285	A second model LIN 14 protein forms temporal gradient larval development analogous morphogen gradients Drosophila embryo Ruvkun Giusto 1989 Reinhart Ruvkun 2001
0.19757515.15073154.html.plaintext.txt	286	However findings indicate lin 14 affects L2 developmental events lin 28 requires genetic circuit genes engages late first larval stage Table 3 Seggerson et al
0.19757515.15073154.html.plaintext.txt	287	In words lin 14B activity essentially reflects participation lin 14 positive feedback circuit lin 28
0.19757515.15073154.html.plaintext.txt	288	This model explains lin 46lf bypasses requirement lin 28 suppresses L2 defects lin 14lf L1 defects
0.19757515.15073154.html.plaintext.txt	289	Hypomorphic alleles lin 14 lin 14n360 lin 14n179ts used studies reduce activity lin 14 eliminate
0.19757515.15073154.html.plaintext.txt	290	At end first larval stage positive feedback circuit lin 14 lin 28 engaged mutation lin 14 would lead reduction lin 28 expression reduction lin 14
0.19757515.15073154.html.plaintext.txt	291	We previously proposed y model mediates reduction lin 14 circuit Fig
0.19757515.15073154.html.plaintext.txt	292	However lin 46 absent activity y would attenuated reduction lin 14 would amplified
0.19757515.15073154.html.plaintext.txt	293	Therefore lin 46lf suppresses lin 14 hypomorph essentially upregulating existing lin 14 activity
0.19757515.15073154.html.plaintext.txt	294	As corollary propose part reduction lin 14 activity hypomorphic alleles due downregulation via positive feedback circuit
0.19757515.15073154.html.plaintext.txt	295	Importantly reason lin 46 mutation suppress lin 14 null allele twofold first lin 14 normally acts feedback circuit lin 28 control L2L3 fate choice shown Table 3 second lin 28 repressive component feedback circuit engaged early first larval stage lin 14 mutant shown previously Seggerson et al
0.19757515.15073154.html.plaintext.txt	296	Therefore effects lin 28 lin 46 L2L3 fate decision independent feedback circuit occur early L1 lin 14 absent
0.19757515.15073154.html.plaintext.txt	297	Supporting conclusion observation lin 46lf causes severe retarded phenotype lin 140 background 15 degrees C Table 4
0.19757515.15073154.html.plaintext.txt	298	Thus different genetic interactions lin 46 lin 14 lin 28 reflect underlying change relationship lin 14 lin 28 occurs end L1 stage engagement lin 4 independent feedback circuit Fig
0.19757515.15073154.html.plaintext.txt	299	lin 46 affects L3 adult fates independently Our data also indicate role lin 46 regulating LA switch appears independent role L2L3 fate decision
0.19757515.15073154.html.plaintext.txt	300	Specifically lin 46lf animals grown 20 degrees C display normal cell lineage patterns early temperature significant failure LA switch L4 stage Tables 1 4 Fig
0.19757515.15073154.html.plaintext.txt	301	Thus failure LA switch lin 46lf animals occur without prior lineage defect
0.19757515.15073154.html.plaintext.txt	302	Because lin 46GFP reporters expressed L4 stage Fig
0.19757515.15073154.html.plaintext.txt	303	4B independence early late retarded defects may reflect lin 46 acts twice promote L3 fates later promote adult specific fates
0.19757515.15073154.html.plaintext.txt	304	However found cold sensitive period lin 46lf strain adult fates prior L3 stage
0.19757515.15073154.html.plaintext.txt	305	This finding suggests lin 46 normally acts branch point heterochronic pathway targets influence L3 fates immediately targets sensitive absence govern adult fates Fig
0.19757515.15073154.html.plaintext.txt	306	This latter possibility consistent lin 46 acting step immediately downstream lin 28
0.19757515.15073154.html.plaintext.txt	307	In model therefore y may represent multiple factors affect L2L3 fate decision regulation lin 14 others affect LA switch known heterochronic genes Fig
0.19757515.15073154.html.plaintext.txt	308	One possibility lin 28 lin 46 directly affect microRNA let 7 regulates genes control LA switch Fig
0.19757515.15073154.html.plaintext.txt	309	This consistent failure lin 46lf suppress precocious phenotypes later acting genes lin 41 lin 57 Table 2
0.19757515.15073154.html.plaintext.txt	310	Further analysis determine whether lin 46 lin 28 indeed affect expression activity let 7
0.19757515.15073154.html.plaintext.txt	311	Because let 7 let 7 like microRNAs hypothesized regulate lin 14 intriguing possibility factors constitute y microRNAs
0.19757515.15073154.html.plaintext.txt	312	LIN 46 may form scaffold multiprotein assembly The homology LIN 46 protein MoeA gephyrin provides basis explaining function
0.19757515.15073154.html.plaintext.txt	313	The crystal structure MoeA shows exist homodimer likely proteins sequence similarity MoeA well Schrag et al
0.19757515.15073154.html.plaintext.txt	314	We observed LIN 46 protein strongly interacts yeast two hybrid assay suggesting LIN 46 forms multimers L
0.19757515.15073154.html.plaintext.txt	315	Gephyrin believed dimerize via C terminal MoeA like region trimerize N terminal MogA like region see Fig
0.19757515.15073154.html.plaintext.txt	316	The ability gephyrin multimerize form scaffold basis ability cluster aid activity interacting proteins Schwarz et al
0.19757515.15073154.html.plaintext.txt	317	Although gephyrin known act synaptic transmission molybdenum co factor biosynthesis LIN 46 appear role either processes C
0.19757515.15073154.html.plaintext.txt	318	elegans possibly paralog MOC 1 roles
0.19757515.15073154.html.plaintext.txt	319	We speculate general feature proteins related gephyrin therefore may ability form scaffolds avail participating diverse biological roles including development
0.19757515.15073154.html.plaintext.txt	320	Based several lines evidence including homology gephyrin propose molecular model LIN 46 acts scaffolding protein multiprotein complex determines cell fates Fig
0.19757515.15073154.html.plaintext.txt	321	Supporting model striking cold sensitivity lin 46 null alleles Table 2
0.19757515.15073154.html.plaintext.txt	322	Cold sensitivity feature mutations affecting dynamics multiprotein structures microtubules bacteriophage capsids Huffaker et al
0.19757515.15073154.html.plaintext.txt	323	LIN 46 may potentiate activity complex includes cell fate regulators developmental timing factors
0.19757515.15073154.html.plaintext.txt	324	LIN 46 essential activity complex development lin 46 null mutant nearly normal 20 degrees C absence LIN 46 protein may substantially reduce activity complex low temperature possibly causing retention negative regulator complex
0.19757515.15073154.html.plaintext.txt	325	Because LIN 28 protein appears specific mRNA binding protein Moss et al
0.19757515.15073154.html.plaintext.txt	326	1997 expression components complex may repressed lin 28 normally active Fig
0.19757515.15073154.html.plaintext.txt	327	The suppression loss lin 28 activity would therefore result balance overexpression components complex reduced efficiency function
0.19757515.15073154.html.plaintext.txt	328	In summary believe lin 46 occupies unique position heterochronic pathway furthers understanding complex genetic network governs temporal regulation developmental events
0.19757515.15073154.html.plaintext.txt	329	The fact LIN 46 protein resembles gephyrin expands biological function protein family development
0.19757515.15073154.html.plaintext.txt	330	LIN 46 likely interact proteins controlling cell fate choices identities proteins may also regulatory targets LIN 28 provide insight temporal components cell fates determined
0.19757515.15073154.html.plaintext.txt	331	ACKNOWLEDGMENTS We thank Bernadine Tsung identifying first allele lin 46 Lingjuan Tang technical assistance Ann Rougvie strains DNAs C
0.19757515.15073154.html.plaintext.txt	332	elegans genome sequencing consortium Morris Maduro sequence information Simon Tuck strains mapping information Ron Ellis help digital imaging Caenorhabditis Genetics Center strains Meera Sundaram helpful comments manuscript
0.19757515.15073154.html.plaintext.txt	333	This work supported part NSF IBN 0212373 E
0.19757515.15073154.html.plaintext.txt	334	REFERENCES TOP SUMMARY Introduction Materials methods Results Discussion REFERENCES
0.19757515.15073154.html.plaintext.txt	335	Identification heterochronic mutants Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	336	Temporal misexpression collagengreen fluorescent protein fusion gene
0.19757515.15073154.html.plaintext.txt	337	The Caenorhabditis elegans Hunchback like gene lin 57hbl 1 controls developmental time regulated microRNAs
0.19757515.15073154.html.plaintext.txt	338	Heterochronic mutants nematode Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	339	The lin 14 locus Caenorhabditis elegans controls time expression specific postembryonic developmental events
0.19757515.15073154.html.plaintext.txt	340	A hierarchy regulatory genes controls larva adult developmental switch C
0.19757515.15073154.html.plaintext.txt	341	Control developmental timing Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	342	daf 12 regulates developmental age dauer alternative Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	343	Temporal regulation lin 14 antagonistic action two heterochronic genes lin 4 lin 28
0.19757515.15073154.html.plaintext.txt	344	Novel second site suppression cold sensitive defect phage p22 procapsid assembly
0.19757515.15073154.html.plaintext.txt	345	The Caenorhabditis elegans gene unc 76 human homologs define new gene family involved axonal outgrowth fasciculation
0.19757515.15073154.html.plaintext.txt	346	Heterochronic genes control cell cycle progress developmental competence C
0.19757515.15073154.html.plaintext.txt	347	Dual requirement gephyrin glycine receptor clustering molybdoenzyme activity
0.19757515.15073154.html.plaintext.txt	348	Structure function analysis LIN 14 temporal regulator postembryonic developmental events Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	349	A uniform genetic nomenclature nematode Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	350	Diverse effects beta tubulin mutations microtubule formation function
0.19757515.15073154.html.plaintext.txt	351	elegans developmental timing protein lin 42 circadian rhythm proteins
0.19757515.15073154.html.plaintext.txt	352	The Drosophila molybdenum cofactor gene Cinnamon homologous three Escherichia coli cofactor proteins rat protein gephyrin
0.19757515.15073154.html.plaintext.txt	353	Clustering inhibitory neurotransmitter receptors developing postsynaptic sites The membrane activation model
0.19757515.15073154.html.plaintext.txt	354	elt 5 elt 6 required continuously regulate epidermal seam cell differentiation cell fusion C
0.19757515.15073154.html.plaintext.txt	355	elegans heterochronic gene lin 4 encodes small RNAs antisense complementarity lin 14
0.19757515.15073154.html.plaintext.txt	356	elegans hunchback homolog hbl 1 controls temporal patterning probable microRNA target
0.19757515.15073154.html.plaintext.txt	357	The cold shock domain protein lin 28 controls developmental timing C
0.19757515.15073154.html.plaintext.txt	358	elegans regulated lin 4 RNA
0.19757515.15073154.html.plaintext.txt	359	Isoform specific mutations Caenorhabditis elegans heterochronic gene lin 14 affect stage specific patterning
0.19757515.15073154.html.plaintext.txt	360	The 21 nucleotide let 7 RNA regulates developmental timing Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	361	The heterochronic gene lin 29 encodes zinc finger protein controls terminal differentiation event Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	362	Molecular genetics Caenorhabditis elegans heterochronic gene lin 14
0.19757515.15073154.html.plaintext.txt	363	The Caenorhabditis elegans heterochronic gene lin 14 encodes nuclear protein forms temporal developmental switch
0.19757515.15073154.html.plaintext.txt	364	The crystal structure Escherichia coli MoeA protein molybdopterin synthesis pathway
0.19757515.15073154.html.plaintext.txt	365	Crystal structures human gephyrin plant CNX1 G domains Comparative analysis functional implications
0.19757515.15073154.html.plaintext.txt	366	Two genetic circuits repress C
0.19757515.15073154.html.plaintext.txt	367	elegans heterochronic gene lin 28 translation initiation
0.19757515.15073154.html.plaintext.txt	368	The lin 41 RBCC gene acts C
0.19757515.15073154.html.plaintext.txt	369	elegans heterochronic pathway let 7 regulatory RNA lin 29 transcription factor
0.19757515.15073154.html.plaintext.txt	370	Molybdenum co factor biosynthesis The Arabidopsis thaliana cDNA CNX1 encodes multifunctional two domain protein homologous mammalian neuroprotein insect protein Cinnamon three Escherichia coli proteins
0.19757515.15073154.html.plaintext.txt	371	Post embryonic cell lineages nematode Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	372	Ingestion bacterially expressed dsRNAs produce specific potent genetic interference Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	373	Negative regulatory sequences lin 14 3 untranslated region necessary generate temporal switch Caenorhabditis elegans development
0.19757515.15073154.html.plaintext.txt	374	The Nematode Caenorhabditis elegans
0.19757515.15073154.html.plaintext.txt	375	Cold Spring Harbor New York Cold Spring Harbor Laboratory Press
0.19757515.15073154.html.plaintext.txt	376	The crystal structure Escherichia coli MoeA relationship multifunctional protein gephyrin
0.20710783.12477730.html.plaintext.txt	0	Mutation Interfacial Residues Disrupts Subunit Folding Particle Assembly Physalis mottle tymovirus Mahadevaiah Umashankar Mathur R
0.20710783.12477730.html.plaintext.txt	1	From Department Biochemistry Molecular Biophysics Unit Indian Institute Science Bangalore 560 012 India
0.20710783.12477730.html.plaintext.txt	2	Received publication August 6 2002 revised form December 6 2002
0.20710783.12477730.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.20710783.12477730.html.plaintext.txt	4	Virus like particles VLPs serve excellent model systems identify pathways virus assembly
0.20710783.12477730.html.plaintext.txt	5	To gain insights assembly mechanisms Physalis mottle tymovirus PhMV six interfacial residues identified based crystal structure native recombinant capsids targeted mutagenesis
0.20710783.12477730.html.plaintext.txt	6	The Q37E Y67A R68Q D83A I123A S145A mutants PhMV recombinant coat protein rCP expressed Escherichia coli soluble
0.20710783.12477730.html.plaintext.txt	7	However except S145A mutant assembled VLPs similar wild type rCP capsids mutants failed assemble VLPs
0.20710783.12477730.html.plaintext.txt	8	Furthermore purified Q37E Y67A R68Q D83A I123A rCP mutants existed essentially partially folded monomers revealed sucrose density gradient analysis circular dichroism fluorescence thermal urea denaturation studies
0.20710783.12477730.html.plaintext.txt	9	The rCP mutants locked conformations probably lack structural signalsfeatures would allow assemble capsids
0.20710783.12477730.html.plaintext.txt	10	Thus mutation residues involved inter subunit interactions PhMV disrupts subunit folding particle assembly
0.20710783.12477730.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.20710783.12477730.html.plaintext.txt	12	Physalis mottle tymovirus PhMV1 small spherical plant virus consisting single stranded plus sense RNA genome size 6
0.20710783.12477730.html.plaintext.txt	13	The RNA genome encapsidated protein shell comprising 180 chemically identical coat protein CP subunits 20000 Da arranged icosahedral symmetry
0.20710783.12477730.html.plaintext.txt	14	Depending bonding interactions subunits designated A B C 2
0.20710783.12477730.html.plaintext.txt	15	The A type subunits form pentamers 5 fold B C subunits form hexamers 3 fold icosahedral axes
0.20710783.12477730.html.plaintext.txt	16	The protein subunits held strong protein protein interactions
0.20710783.12477730.html.plaintext.txt	17	Purified preparations tymoviruses including PhMV consist empty capsids top component addition full capsids bottom component containing complete genomic RNA
0.20710783.12477730.html.plaintext.txt	18	An interesting feature tymoviruses empty capsids also formed vitro intact virus subjected freeze thaw cycle exposed high temperatures alkaline pH denaturants 3 6
0.20710783.12477730.html.plaintext.txt	19	The presence empty shells vivo vitro suggests information required error free assembly contained within primary structure protein subunits viruses
0.20710783.12477730.html.plaintext.txt	20	It difficult isolate assembly competent PhMV CP subunit non denaturing conditions isolated viral capsids used deciphering assembly pathway
0.20710783.12477730.html.plaintext.txt	21	Hence CP gene PhMV number deletion mutants cloned expressed Escherichia coli
0.20710783.12477730.html.plaintext.txt	22	Interestingly bacterially expressed rCP could self assemble stable virus like particles VLPs 7
0.20710783.12477730.html.plaintext.txt	23	Furthermore deletion 30 amino acid residues addition 41 amino acid residues N terminus rCP affect assembly T 3 capsids
0.20710783.12477730.html.plaintext.txt	24	Several site specific mutants also studied
0.20710783.12477730.html.plaintext.txt	25	One mutations His 69 Ala led formation 19
0.20710783.12477730.html.plaintext.txt	26	4 S subassembly intermediate 8
0.20710783.12477730.html.plaintext.txt	27	Recently crystal structures native recombinant capsids PhMV elucidated 9 10
0.20710783.12477730.html.plaintext.txt	28	To gain insights assembly mechanism virus careful analysis crystal structures made present study identify residues involved inter subunit interactions residues targeted mutagenesis
0.20710783.12477730.html.plaintext.txt	29	Gln 37 Tyr 67 Arg 68 Asp 83 Ile 123 Ser 145 mutated Glu Ala Gln Ala Ala Ala respectively view examine whether mutations could lead formation assembly intermediates monomers
0.20710783.12477730.html.plaintext.txt	30	The mutant rCPs expressed E
0.20710783.12477730.html.plaintext.txt	31	The mutants characterized sucrose density gradient analysis electron microscopy high pressure liquid chromatography circular dichroism CD fluorescence spectroscopy
0.20710783.12477730.html.plaintext.txt	32	Our results imply Gln 37 Tyr 67 Arg 68 Asp 83 Ile 123 important assembly also crucial proper folding subunits whereas interactions Ser 145 important either folding assembly
0.20710783.12477730.html.plaintext.txt	33	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.20710783.12477730.html.plaintext.txt	34	Materials 32PdATP obtained PerkinElmer Life Sciences
0.20710783.12477730.html.plaintext.txt	35	Restriction endonucleases SequenaseTM Version 2 DNA sequencing kit obtained Amersham Biosciences
0.20710783.12477730.html.plaintext.txt	36	Deep Vent DNA polymerase DpnI Ni NTA agarose obtained New England Biolabs Qiagen respectively
0.20710783.12477730.html.plaintext.txt	37	Ampicillin isopropyl 1 thio D galactopyranoside Coomassie Brilliant Blue R 250 ultra pure urea obtained USB
0.20710783.12477730.html.plaintext.txt	38	Diaminobenzidine bromphenol blue EDTA obtained Sigma
0.20710783.12477730.html.plaintext.txt	39	The oligonucleotide primers conjugated double antibodies purchased Bangalore Genei Pvt
0.20710783.12477730.html.plaintext.txt	40	All chemicals analytical grade
0.20710783.12477730.html.plaintext.txt	41	Primers The following primers used obtain rCP mutants PCR based approach S sense AS antisense Q37E S 5 TCCCTTTTGAGTTTGAAG 3 Q37E AS 5 CTTCAAACTCAAAAGGGA 3 Y67A S 5 CGCCCCCGCCCGACATGC 3 Y67A AS 5 GCATGTCGGGCGGGGGCG 3 R68Q S 5 CCCCTACCAACATGCTCAG 3 R68Q AS 5 CTGAGCATGTTGGTAGGGG 3 D83A S 5 TCCAACTGCTCTTGCTGTC 3 D83A AS 5 GACAGCAAGAGCAGTTGGA 3 I123A S 5 CGGCGCCGCCTCAGCCGCC 3 I123A AS 5 GGCGGCTGAGGCGGCGCCG 3 S145A S 5 TTGAAAGACGCCGTGACCTAC 3 S145A AS 5 GTAGGTCACGGCGTCTTTCAA 3
0.20710783.12477730.html.plaintext.txt	42	Site directed Mutagenesis The rCP mutants constructed PCR based method using corresponding sets mutant primers 11
0.20710783.12477730.html.plaintext.txt	43	CP gene pRSET B vector used template PCR amplification sense antisense primers 2
0.20710783.12477730.html.plaintext.txt	44	5 units Deep Vent DNA polymerase optimal conditions
0.20710783.12477730.html.plaintext.txt	45	The PCR amplified mixtures treated DpnI 10 units 37 degrees C 1 h digest methylated template DNA transformed E
0.20710783.12477730.html.plaintext.txt	46	The plasmid DNA isolated colonies sequenced Sangers dideoxy chain termination method SequenaseTM Version 2
0.20710783.12477730.html.plaintext.txt	47	0 DNA sequencing kit confirm presence mutations
0.20710783.12477730.html.plaintext.txt	48	Overexpression Purification Wild Type Mutant rCPs The wild type mutant constructs transformed BL21 DE3 pLys S strain
0.20710783.12477730.html.plaintext.txt	49	500 ml Terrific broth containing 50 microgml ampicillin inoculated 1 preculture
0.20710783.12477730.html.plaintext.txt	50	After 4 h growth cells induced 0
0.20710783.12477730.html.plaintext.txt	51	3 mM isopropyl 1 thio D galactopyranoside 4 h
0.20710783.12477730.html.plaintext.txt	52	The virus like particles formed purified using procedure similar used purification virus 6
0.20710783.12477730.html.plaintext.txt	53	Briefly cell pellet obtained induction resuspended 50 mM sodium citrate buffer pH 5
0.20710783.12477730.html.plaintext.txt	54	5 sonicated supernatant subjected 10 polyethylene glycol precipitation
0.20710783.12477730.html.plaintext.txt	55	The precipitate resuspended 50 mM citrate buffer pH 5
0.20710783.12477730.html.plaintext.txt	56	5 subjected high speed pelleting
0.20710783.12477730.html.plaintext.txt	57	The pellet dissolved citrate buffer layered onto 10 40 sucrose gradient centrifuged 26000 rpm SW28 rotor 3 h
0.20710783.12477730.html.plaintext.txt	58	The light scattering zone collected Pasteur pipette diluted subjected ultra centrifugation 3 h 26000 rpm
0.20710783.12477730.html.plaintext.txt	59	The pellet obtained resuspended 50 mM sodium citrate buffer pH 5
0.20710783.12477730.html.plaintext.txt	60	The mutant rCPs failed assemble purified Ni NTA affinity chromatography
0.20710783.12477730.html.plaintext.txt	61	The cell pellet induction resuspended 100 mM Tris HCl buffer pH 6
0.20710783.12477730.html.plaintext.txt	62	8 containing 300 mM NaCl 5 glycerol
0.20710783.12477730.html.plaintext.txt	63	The sample frozen 20 degrees C overnight thawed room temperature sonicated 30 min
0.20710783.12477730.html.plaintext.txt	64	The sample centrifuged 27000 x g 15 min remove insoluble debris
0.20710783.12477730.html.plaintext.txt	65	The soluble fraction mixed 2 ml Ni NTA resin pre equilibrated buffer allowed rotate end end rocker 2 h
0.20710783.12477730.html.plaintext.txt	66	The protein resin complex washed extensively 100 mM Tris HCl pH 6
0.20710783.12477730.html.plaintext.txt	67	8 containing 300 mM NaCl 60 mM imidazole 5 glycerol
0.20710783.12477730.html.plaintext.txt	68	The protein eluted 100 mM Tris HCl pH 6
0.20710783.12477730.html.plaintext.txt	69	8 containing 300 mM NaCl 250 mM imidazole 5 glycerol
0.20710783.12477730.html.plaintext.txt	70	The purity mutant rCPs thus obtained checked 12 SDS PAGE 12
0.20710783.12477730.html.plaintext.txt	71	Western Blot Analysis The mutant rCPs separated SDS 12 acrylamide gel transferred onto nitrocellulose membranes 13
0.20710783.12477730.html.plaintext.txt	72	The Western blot analysis carried using monoclonal antibody PA3B2 specific CP primary antibody goat antimouse IgG conjugated horseradish peroxidase secondary antibody described earlier 14
0.20710783.12477730.html.plaintext.txt	73	The blot developed using diamino benzidine presence hydrogen peroxide 0
0.20710783.12477730.html.plaintext.txt	74	05 M sodium citrate buffer pH 4
0.20710783.12477730.html.plaintext.txt	75	8 containing trace amounts cobalt chloride
0.20710783.12477730.html.plaintext.txt	76	Gel Filtration Analysis The wild type mutant rCPs analyzed Bio Sil 400 gel filtration column using Shimdzu LC6A system
0.20710783.12477730.html.plaintext.txt	77	The column equilibrated Tris HCl buffer pH 6
0.20710783.12477730.html.plaintext.txt	78	8 containing 300 mM NaCl 5 glycerol
0.20710783.12477730.html.plaintext.txt	79	The column calibrated standard molecular weight markers supplied Bio Rad
0.20710783.12477730.html.plaintext.txt	80	Circular Dichroism CD spectra protein samples 0
0.20710783.12477730.html.plaintext.txt	81	8 containing 200 mM NaCl 5 glycerol recorded Jasco 715 spectropolarimeter Japan Spectroscopic Co
0.20710783.12477730.html.plaintext.txt	82	Tokyo Japan room temperature 25 degrees C
0.20710783.12477730.html.plaintext.txt	83	Thermal stability rCP mutants assessed using CD following changes secondary structure function temperature
0.20710783.12477730.html.plaintext.txt	84	The CD measurements carried Jasco 810 spectropolarimeter Japan Spectroscopic Co
0.20710783.12477730.html.plaintext.txt	85	Tokyo Japan using bandwidth 1 nm response time 1 cuvette 0
0.20710783.12477730.html.plaintext.txt	86	3 mgml 100 mM Tris HCl pH 6
0.20710783.12477730.html.plaintext.txt	87	8 containing 200 mM NaCl 5 glycerol heated 25 95 degrees C rate 1 degrees Cmin
0.20710783.12477730.html.plaintext.txt	88	The thermal unfolding monitored 222 nm ellipticity observed used calculate molar ellipticity seen Equation 1 Eq
0.20710783.12477730.html.plaintext.txt	89	1 measured ellipticity Mr protein molecular weight c concentration protein milligrams per milliliter l path length centimeters
0.20710783.12477730.html.plaintext.txt	90	Fluorescence Fluorescence measurements recorded SPEX FluoroMax 3 Spectrofluorimeter 1 ml cuvette path length 1 cm 25 degrees C
0.20710783.12477730.html.plaintext.txt	91	For measuring intrinsic fluorescence protein excited 280 nm emission spectrum recorded 300 400 nm
0.20710783.12477730.html.plaintext.txt	92	In case urea induced unfolding experiments fluorescence intensities recorded 324 nm difference partially folded untreated 8 M urea treated proteins maximum
0.20710783.12477730.html.plaintext.txt	93	The readings converted relative fluorescence plotted urea concentration
0.20710783.12477730.html.plaintext.txt	94	In experiments protein concentration 0
0.20710783.12477730.html.plaintext.txt	95	8 containing 200 mM NaCl 5 glycerol room temperature 25 degrees C
0.20710783.12477730.html.plaintext.txt	96	8 Anilino 1 naphthalenesulfonate ANS Binding ANS binding monitored measuring fluorescence intensities 440 540 nm excitation 370 nm
0.20710783.12477730.html.plaintext.txt	97	In case urea unfolding proteins 0
0.20710783.12477730.html.plaintext.txt	98	2 mgml incubated various concentrations urea 2 h 25 degrees C
0.20710783.12477730.html.plaintext.txt	99	ANS added protein samples final concentration 10 microM
0.20710783.12477730.html.plaintext.txt	100	The samples excited 370 nm ANS binding monitored measuring fluorescence emission 470 nm
0.20710783.12477730.html.plaintext.txt	101	The readings converted relative fluorescence plotted urea concentration
0.20710783.12477730.html.plaintext.txt	102	Fluorescence Quenching Acrylamide Potassium Iodide Fluorescence measurements rCP mutants presence increasing concentrations acrylamideiodide 0 0
0.20710783.12477730.html.plaintext.txt	103	5M recorded SPEX FluoroMax 3 Spectrofluorimeter 1 ml cuvette path length 1 cm 25 degrees C
0.20710783.12477730.html.plaintext.txt	104	The fluorescence intensity recorded 324 nm excitation 280 nm
0.20710783.12477730.html.plaintext.txt	105	The fractional quenching F0F plotted acrylamideiodide concentration Stern Volmer plot F0 F represent fluorescence absence presence acrylamideiodide respectively
0.20710783.12477730.html.plaintext.txt	106	In experiments protein concentration 0
0.20710783.12477730.html.plaintext.txt	107	8 containing 200 mM NaCl 5 glycerol room temperature 25 degrees C
0.20710783.12477730.html.plaintext.txt	108	Light Scattering Measurements Urea Unfolded rCP Purified rCP capsids incubated 0 8 M urea room temperature 4 5 h
0.20710783.12477730.html.plaintext.txt	109	The absorbance recorded 325 nm
0.20710783.12477730.html.plaintext.txt	110	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.20710783.12477730.html.plaintext.txt	111	Expression Characterization Site specific Mutants rCP The site specific mutants Q37E Y67A R68Q D83A I123A S145A generated PCR based sense antisense primer method 11
0.20710783.12477730.html.plaintext.txt	112	The mutant clones sequenced Sangers dideoxy chain termination method confirm presence desired mutation 15
0.20710783.12477730.html.plaintext.txt	113	The mutants overexpressed E
0.20710783.12477730.html.plaintext.txt	114	All mutants expressed high levels 25 30 total proteins partially soluble
0.20710783.12477730.html.plaintext.txt	115	Approximately 60 I123A S145A present soluble fraction
0.20710783.12477730.html.plaintext.txt	116	The solubility mutant rCPs varied depending expression level different batches
0.20710783.12477730.html.plaintext.txt	117	On average 10 15 expressed protein present soluble fraction data shown
0.20710783.12477730.html.plaintext.txt	118	The mutant proteins present soluble fractions purified procedure similar used purification wild type rCP capsids 6
0.20710783.12477730.html.plaintext.txt	119	coli 41 additional amino acid residues including six histidines N terminus shown earlier 8 assembled capsids sedimented single peak subjected sucrose density gradient centrifugation fractions 12 16 Fig
0.20710783.12477730.html.plaintext.txt	120	The S145A mutant rCP co sedimented rCP capsids Fig 1b
0.20710783.12477730.html.plaintext.txt	121	However none mutant proteins exhibited peaks corresponding assembled particles Fig
0.20710783.12477730.html.plaintext.txt	122	Furthermore assembled particles seen mutant proteins viewed electron microscope whereas particles 30 nm observed mutant S145A capsids Fig
0.20710783.12477730.html.plaintext.txt	123	The mutant rCPs failed assemble T 3 capsids could purified procedures used purification rCP capsids
0.20710783.12477730.html.plaintext.txt	124	Hence mutant proteins purified Ni NTA chromatography making use histidine tag N terminus
0.20710783.12477730.html.plaintext.txt	125	The purified proteins analyzed 12 SDS polyacrylamide gel authenticated Western blot analysis data shown
0.20710783.12477730.html.plaintext.txt	126	The yields purified proteins 10 15 mgliter Q37E Y67A R68Q D83A rCPs whereas slightly higher 20 25 mgliter I123A rCP
0.20710783.12477730.html.plaintext.txt	127	These purified proteins also observed electron microscope confirmed mutant rCPs failed assemble virus like particles
0.20710783.12477730.html.plaintext.txt	128	These purified mutants rCPs retained loading wells run 1 agarose gel 8 native polyacrylamide gels data shown suggesting may represent proteins folding defective
0.20710783.12477730.html.plaintext.txt	129	View larger version 29K Fig
0.20710783.12477730.html.plaintext.txt	130	Sucrose gradient analysis recombinant capsids
0.20710783.12477730.html.plaintext.txt	131	rCP mutants layered onto 10 40 sucrose gradient centrifuged 26000 rpm 3 h using SW 28 rotor
0.20710783.12477730.html.plaintext.txt	132	1 ml fractions collected bottom tubes absorbance 280 nm measured
0.20710783.12477730.html.plaintext.txt	133	rCP Q37E Y67A R68Q D83A I123A rCPs shown respectively
0.20710783.12477730.html.plaintext.txt	134	b sucrose gradient analysis rCP S145A capsids
0.20710783.12477730.html.plaintext.txt	135	rCP S145A capsids mutants layered onto 10 40 sucrose gradient centrifuged 26000 rpm 2
0.20710783.12477730.html.plaintext.txt	136	1 ml fractions collected bottom tubes absorbance 280 nm measured
0.20710783.12477730.html.plaintext.txt	137	rCP S145A rCP shown respectively
0.20710783.12477730.html.plaintext.txt	138	The inset shows electron micrograph S145A capsids
0.20710783.12477730.html.plaintext.txt	139	Oligomeric Status rCP Mutant Proteins Purified rCP capsids mutant rCPs loaded onto Bio Sil 400 gel filtration column
0.20710783.12477730.html.plaintext.txt	140	The column calibrated standard protein molecular weight markers
0.20710783.12477730.html.plaintext.txt	141	The rCP capsids eluted immediately void volume expected
0.20710783.12477730.html.plaintext.txt	142	However I123A mutant rCP behaved abnormally eluted vitamin B12 Fig
0.20710783.12477730.html.plaintext.txt	143	2 confirmed I123A mutant rCP Western blot analysis data shown
0.20710783.12477730.html.plaintext.txt	144	The Q37E Y67A R68Q D83A mutant rCPs also behaved similar manner
0.20710783.12477730.html.plaintext.txt	145	S145A rCP capsids co eluted rCP capsids data shown
0.20710783.12477730.html.plaintext.txt	146	Therefore likely Q37E Y67A R68Q D83A I123A rCP mutants exist partially folded monomers bind column eluted later run
0.20710783.12477730.html.plaintext.txt	147	View larger version 17K Fig
0.20710783.12477730.html.plaintext.txt	148	Size exclusion chromatography rCP mutant
0.20710783.12477730.html.plaintext.txt	149	The I123A mutant upper panel run Bio SIL 400 column calibrated previously molecular mass markers bottom panel
0.20710783.12477730.html.plaintext.txt	150	Peaks b c d e correspond thyroblobulin 670 kDa IgG 150 kDa ovalbumin 44 kDa myoglobin 17 kDa vitamin B12 1
0.20710783.12477730.html.plaintext.txt	151	The top panel shows elution profile I123A
0.20710783.12477730.html.plaintext.txt	152	The peaks 1 2 3 obtained authenticated Western analysis
0.20710783.12477730.html.plaintext.txt	153	Similar gel filtration profiles obtained Y67A R68Q D83A I123A mutants data shown
0.20710783.12477730.html.plaintext.txt	154	rCP Mutants Q37E Y67A R68Q D83A I123A Exist Partially Folded State Far UV CD used examine secondary structural features mutant rCPs failed assemble capsids
0.20710783.12477730.html.plaintext.txt	155	The far UV CD spectra mutants showed troughs 208 225 nm range suggesting considerable amount secondary structure Fig
0.20710783.12477730.html.plaintext.txt	156	Furthermore fluorescence emission spectra mutants showed emission maxima 332 336 nm similar observed rCP capsids Fig
0.20710783.12477730.html.plaintext.txt	157	This indicated aromatic residues especially single tryptophan residue inaccessible solvent
0.20710783.12477730.html.plaintext.txt	158	Upon incubation 8 M urea emission maximum shifted 350 356 nm suggesting tryptophan side chain exposed solvent Fig
0.20710783.12477730.html.plaintext.txt	159	The fluorescence intensity measured 324 nm maximum difference intensity observed native 0 M urea 8 M urea unfolded proteins
0.20710783.12477730.html.plaintext.txt	160	The fluorescence intensities various concentrations urea calculated percent fluorescence intensity 0 M urea
0.20710783.12477730.html.plaintext.txt	161	A discrete unfolding transition found 3 5 M urea case rCP capsids Fig
0.20710783.12477730.html.plaintext.txt	162	5b whereas transition observed mutants rCPs Fig
0.20710783.12477730.html.plaintext.txt	163	This observation corroborates earlier studies rCP capsids found stable 4 M urea room temperature 7
0.20710783.12477730.html.plaintext.txt	164	Interestingly urea induced denaturation rCP capsids measured fluorescence overlapped changes light scattering monitored absorbance 325 nm Fig
0.20710783.12477730.html.plaintext.txt	165	This indicated disassembly denaturation could concerted events virus
0.20710783.12477730.html.plaintext.txt	166	The lack discrete unfolding transition case rCP mutants monitored fluorescence reflects conformational flexibility mutant proteins
0.20710783.12477730.html.plaintext.txt	167	Furthermore absorbance 325 nm mutant rCPs 0
0.20710783.12477730.html.plaintext.txt	168	005 suggesting spectral changes observed due aggregation
0.20710783.12477730.html.plaintext.txt	169	View larger version 16K Fig
0.20710783.12477730.html.plaintext.txt	170	Far UV CD spectra purified rCP mutants
0.20710783.12477730.html.plaintext.txt	171	CD measurements made using Jasco Spectropolarimeter
0.20710783.12477730.html.plaintext.txt	172	The spectra recorded 200 280 nm room temperature 25 degrees C
0.20710783.12477730.html.plaintext.txt	173	rCP Q37E Y67A R68Q D83A I123A mutant rCPs shown solid long dashed medium dashed short dashed dotted dash dot dash lines respectively
0.20710783.12477730.html.plaintext.txt	174	View larger version 15K Fig
0.20710783.12477730.html.plaintext.txt	175	Fluorescence emission spectra rCP capsids mutants
0.20710783.12477730.html.plaintext.txt	176	2 mgml protein excited 280 nm emission monitored 300 400 nm
0.20710783.12477730.html.plaintext.txt	177	rCP Q37E Y67A R68Q D83A I123A shown solid long dashed medium dashed short dashed dotted dash dot dash lines respectively
0.20710783.12477730.html.plaintext.txt	178	b fluorescence emission spectra rCP capsids mutants presence 8 M urea
0.20710783.12477730.html.plaintext.txt	179	2 mgml protein incubated buffer containing 8 M urea 2 h room temperature excited 280 nm emissions monitored 300 400 nm
0.20710783.12477730.html.plaintext.txt	180	rCP Q37E Y67A R68Q D83A I123A rCP mutants shown solid long dashed medium dashed short dashed dotted dash dot dash lines respectively
0.20710783.12477730.html.plaintext.txt	181	View larger version 10K Fig
0.20710783.12477730.html.plaintext.txt	182	Urea denaturation studies rCP mutants
0.20710783.12477730.html.plaintext.txt	183	purified rCP mutants treated 0 8 M urea 2 h 25 degrees C
0.20710783.12477730.html.plaintext.txt	184	Protein excited 280 nm emission monitored 324 nm
0.20710783.12477730.html.plaintext.txt	185	Fluorescence 0 M urea concentration taken 100 relative fluorescence calculated expressed function urea concentration
0.20710783.12477730.html.plaintext.txt	186	Q37E Y67A R68Q D83A I123A mutant rCPs shown respectively
0.20710783.12477730.html.plaintext.txt	187	b urea denaturation rCP capsids
0.20710783.12477730.html.plaintext.txt	188	Purified rCP capsids treated 0 8 M urea fluorescence monitored described panel
0.20710783.12477730.html.plaintext.txt	189	Fluorescence emission tryptophan 324 nm closed circles left axis light scattering measurements 325 nm open circles right axis indicated
0.20710783.12477730.html.plaintext.txt	190	The accessibility tryptophan residues mutant rCPs assessed quenching experiments acrylamide potassium iodide
0.20710783.12477730.html.plaintext.txt	191	Stern Volmer plots wild type mutant rCPs Fig
0.20710783.12477730.html.plaintext.txt	192	6a showed similar slope Y67A R68Q I123A mutant proteins suggesting tryptophan proteins protected quencher similar extent
0.20710783.12477730.html.plaintext.txt	193	The tryptophan Q37E D83A mutant rCPs however seemed accessible
0.20710783.12477730.html.plaintext.txt	194	Similarly potassium iodide used quencher subtle differences accessibility tryptophan mutants could observed
0.20710783.12477730.html.plaintext.txt	195	Although rCP I123A D83A similar slopes Q37E Y67A R68Q showed increased slopes Fig
0.20710783.12477730.html.plaintext.txt	196	View larger version 10K Fig
0.20710783.12477730.html.plaintext.txt	197	Stern Volmer plot tryptophan fluorescence quenching acrylamide
0.20710783.12477730.html.plaintext.txt	198	purified rCP capsids rCP mutants treated 0 0
0.20710783.12477730.html.plaintext.txt	199	The proteins excited 280 nm emission recorded 324 nm
0.20710783.12477730.html.plaintext.txt	200	Fractional quenching F0F plotted function acrylamide concentration F0 F represent fluorescence absence presence acrylamide respectively
0.20710783.12477730.html.plaintext.txt	201	rCP capsids Q37E Y67A R68Q D83A I123A mutant rCPs shown respectively
0.20710783.12477730.html.plaintext.txt	202	b Stern Volmer plot tryptophan fluorescence quenching iodide
0.20710783.12477730.html.plaintext.txt	203	Purified rCP capsids rCP mutants treated 0 0
0.20710783.12477730.html.plaintext.txt	204	The proteins excited 280 nm emission recorded 324 nm
0.20710783.12477730.html.plaintext.txt	205	Fractional quenching F0F plotted function acrylamide concentration F0 F represent fluorescence absence presence iodide respectively
0.20710783.12477730.html.plaintext.txt	206	rCP capsids Q37E Y67A R68Q D83A I123A mutant rCPs shown respectively
0.20710783.12477730.html.plaintext.txt	207	Furthermore rCP mutants strongly bound ANS suggesting presence exposed hydrophobic pockets Fig
0.20710783.12477730.html.plaintext.txt	208	ANS binding rCP capsids less compared ANS binding rCP mutants Fig
0.20710783.12477730.html.plaintext.txt	209	This understandable capsids held strong hydrophobic interactions hence hydrophobic surfaces unavailable ANS bind
0.20710783.12477730.html.plaintext.txt	210	The urea induced unfolding rCP capsids mutant rCPs also monitored measuring ANS fluorescence
0.20710783.12477730.html.plaintext.txt	211	As globular proteins initial increase 3 M urea followed decrease ANS binding 5 M urea case wild type rCP capsids Fig
0.20710783.12477730.html.plaintext.txt	212	The unfolding transition observed agreement results urea induced denaturation monitored intrinsic fluorescence Fig
0.20710783.12477730.html.plaintext.txt	213	In contrast mutant rCPs showed continuous decrease ANS fluorescence suggesting already partially unfolded state Fig
0.20710783.12477730.html.plaintext.txt	214	View larger version 14K Fig
0.20710783.12477730.html.plaintext.txt	215	Fluorescence emission spectra rCP capsids rCP mutants presence ANS
0.20710783.12477730.html.plaintext.txt	216	ANS added purified mutants 0
0.20710783.12477730.html.plaintext.txt	217	2 mgml stock solution 1 mM final concentration 10 microM
0.20710783.12477730.html.plaintext.txt	218	The excitation wavelength 370 nm fluorescence emissions measured 440 540 nm
0.20710783.12477730.html.plaintext.txt	219	rCP Q37E Y67A R68Q D83A I123A mutant rCPs shown solid dotted short dashed dash dot dot medium dashed dash dot dash lines respectively
0.20710783.12477730.html.plaintext.txt	220	b ANS binding rCP capsids rCP mutants presence urea
0.20710783.12477730.html.plaintext.txt	221	The mutant proteins incubated 0 8 M urea 25 degrees C 2 3h
0.20710783.12477730.html.plaintext.txt	222	ANS added final concentration 10 microM
0.20710783.12477730.html.plaintext.txt	223	The samples excited 370 nm fluorescence emission monitored 470 nm
0.20710783.12477730.html.plaintext.txt	224	The readings converted relative fluorescence plotted urea concentration
0.20710783.12477730.html.plaintext.txt	225	rCP Q37E Y67A R68Q D83A I123A mutant rCPs shown respectively
0.20710783.12477730.html.plaintext.txt	226	Thermal Stability Mutant rCPs The partially folded nature mutant rCPs assessed monitoring effect temperature molar ellipticity 222 nm wild type mutant rCPs
0.20710783.12477730.html.plaintext.txt	227	The wild type rCP S145A capsids exhibited Tm 88 83 degrees C respectively Fig
0.20710783.12477730.html.plaintext.txt	228	Q37E Y67A R68Q mutant rCPs show discrete transition whereas D83A I123A mutant rCPs showed broad transition 50 70 degrees C Fig
0.20710783.12477730.html.plaintext.txt	229	These results emphasize conformational flexibility mutant rCPs
0.20710783.12477730.html.plaintext.txt	230	View larger version 12K Fig
0.20710783.12477730.html.plaintext.txt	231	Thermal denaturation rCP capsids mutants
0.20710783.12477730.html.plaintext.txt	232	Tm wild type rCP line 1 S145A rCP mutant line 2 shown
0.20710783.12477730.html.plaintext.txt	233	Wild type rCP Tm 88 degrees C whereas S145A mutant rCP found 83 degrees C
0.20710783.12477730.html.plaintext.txt	234	b thermal denaturation rCP mutants
0.20710783.12477730.html.plaintext.txt	235	The thermal scans Q37E line 1 Y67A line 2 R68Q line 3 D83A line 4 I123A line 5 rCP mutants indicated
0.20710783.12477730.html.plaintext.txt	236	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.20710783.12477730.html.plaintext.txt	237	We resorted molecular biology approach decipher roles specific amino acids formation capsids PhMV
0.20710783.12477730.html.plaintext.txt	238	Earlier studies site directed mutagenesis shown presence 19
0.20710783.12477730.html.plaintext.txt	239	4 S intermediate assemblydisassembly pathway 8
0.20710783.12477730.html.plaintext.txt	240	In study carried structure based mutagenesis six residues namely Gln 37 Tyr 67 Arg 68 Asp 83 Ile 123 Ser 145 predominantly involved inter subunit interactions
0.20710783.12477730.html.plaintext.txt	241	Except S145A mutant rCPs failed assemble T 3 capsids although found soluble Fig
0.20710783.12477730.html.plaintext.txt	242	Furthermore mutant proteins partially folded evidenced following gel filtration elution behavior Fig
0.20710783.12477730.html.plaintext.txt	243	2 ii presence secondary structure shown far UV CD Fig
0.20710783.12477730.html.plaintext.txt	244	3 iii lack sharp transition thermal denaturation shown CD Fig
0.20710783.12477730.html.plaintext.txt	245	8 iv persistent high levels innate fluorescence due single tryptophan present protein Fig
0.20710783.12477730.html.plaintext.txt	246	4 v lack discrete unfolding transition upon denaturation urea Fig
0.20710783.12477730.html.plaintext.txt	247	5 vi accessibility tryptophan residue mutants measured fluorescence quenching acrylamide potassium iodide Fig
0.20710783.12477730.html.plaintext.txt	248	6 vii enhanced fluorescence ANS presence mutant proteins Fig
0.20710783.12477730.html.plaintext.txt	249	7 viii lack sharp structural transition ANS binding experiments presence urea Fig
0.20710783.12477730.html.plaintext.txt	250	Thus mutation residues involved extensive inter subunit interactions affect subunit folding particle assembly PhMV
0.20710783.12477730.html.plaintext.txt	251	A detailed analysis position residues mutated probable consequence mutation folding assembly presented
0.20710783.12477730.html.plaintext.txt	252	Gln 37 conserved tymoviruses present hydrogen bonding distance conserved glycines 113 114 leucine 109 respectively A A5 interface Fig
0.20710783.12477730.html.plaintext.txt	253	Gln 37 also interacts Gly 113 Leu 109 B5 C interface Asn 188 C C2 contacts Fig
0.20710783.12477730.html.plaintext.txt	254	This residue seem interact residues within subunit
0.20710783.12477730.html.plaintext.txt	255	The mutation Gln 37 Glu therefore disrupted inter subunit interactions
0.20710783.12477730.html.plaintext.txt	256	Replacement Gln Glu structure using molecular modeling software program O showed short contacts also interactions Gln 37 retained Glu
0.20710783.12477730.html.plaintext.txt	257	However introduces negative charge dense interface subunits
0.20710783.12477730.html.plaintext.txt	258	The results presented demonstrate mutation Gln 37 involved multiple inter subunit interactions also affects proper folding subunit
0.20710783.12477730.html.plaintext.txt	259	Probably negative charge introduced somehow interferes folding
0.20710783.12477730.html.plaintext.txt	260	View larger version 51K Fig
0.20710783.12477730.html.plaintext.txt	261	Coat protein subunits PhMV
0.20710783.12477730.html.plaintext.txt	262	ribbon diagram A B C subunits PhMV coat protein assymetric unit showing mutations
0.20710783.12477730.html.plaintext.txt	263	The A B C subunits colored green red cyan respectively
0.20710783.12477730.html.plaintext.txt	264	The residues selected mutation indicated
0.20710783.12477730.html.plaintext.txt	265	b diagram illustrating convention used designate subunits T 3 capsid PhMV
0.20710783.12477730.html.plaintext.txt	266	The A subunits form pentamers 5 fold axis whereas B C subunits form hexamers 3 fold icosahedral axes
0.20710783.12477730.html.plaintext.txt	267	View larger version 16K Fig
0.20710783.12477730.html.plaintext.txt	268	Interfacial interactions PhMV
0.20710783.12477730.html.plaintext.txt	269	interactions Gln 37 Q37 residues neighboring subunits
0.20710783.12477730.html.plaintext.txt	270	Hydrogen bonding interactions Gln 37 residues A A5 B5 C C C2 contacts
0.20710783.12477730.html.plaintext.txt	271	The A B C subunits colored green blue red respectively
0.20710783.12477730.html.plaintext.txt	272	b interaction Asp 83 D83I Arg 159 R159 neighboring subunits
0.20710783.12477730.html.plaintext.txt	273	Asp 83 D83 involved salt linkage Arg R159 A A5 B5 C contacts
0.20710783.12477730.html.plaintext.txt	274	The A B C subunits colored green blue red respectively
0.20710783.12477730.html.plaintext.txt	275	c hydrophobic interaction Ile 123 I123 neighboring subunit A A5 contact
0.20710783.12477730.html.plaintext.txt	276	d interaction Ser 145 S145 residues neighboring subunits
0.20710783.12477730.html.plaintext.txt	277	Interactions Ser 145 residues A B B C C A contacts shown
0.20710783.12477730.html.plaintext.txt	278	The A B C subunits colored green blue red respectively
0.20710783.12477730.html.plaintext.txt	279	Arg 68 another conserved residue tymoviruses hydrogen bonding distance Asp 136 Ser 137 Val 138 A B interface involved salt bridge Asp 150 B C interface Fig
0.20710783.12477730.html.plaintext.txt	280	This residue obvious intra subunit interactions
0.20710783.12477730.html.plaintext.txt	281	The replacement Arg Gln done without short contact within subunit
0.20710783.12477730.html.plaintext.txt	282	However mutation Gln led partially folded assembly incompetent protein
0.20710783.12477730.html.plaintext.txt	283	These results support observation mutation residues involved multiple inter subunit interactions disrupts subunit folding particle assembly
0.20710783.12477730.html.plaintext.txt	284	Even uncompensated negative charge might interfere folding protein
0.20710783.12477730.html.plaintext.txt	285	Asp 83 Ile 123 although conserved among tymoviruses involved extensive interactions residues subunits Fig
0.20710783.12477730.html.plaintext.txt	286	The mutation two residues alanine also led partially folded proteins assembly incompetent
0.20710783.12477730.html.plaintext.txt	287	Tyr 67 also conserved across tymovirus group
0.20710783.12477730.html.plaintext.txt	288	It involved inter subunit interactions C C2 B5 A also intra subunit hydrogen bonding interactions
0.20710783.12477730.html.plaintext.txt	289	Its mutation alanine disrupts hydrogen bonding interaction quasi 2 fold axis
0.20710783.12477730.html.plaintext.txt	290	This creates cavity vicinity residues Leu 34 Leu 63 Leu 180 Ile 32
0.20710783.12477730.html.plaintext.txt	291	This may destabilizing effect subunit could hinder proper folding subunit
0.20710783.12477730.html.plaintext.txt	292	Hence mutation Ala led misfolding subunits consequent arrest assembly
0.20710783.12477730.html.plaintext.txt	293	Interestingly tertiary structure partially folded mutant proteins similar rCP capsids Figs
0.20710783.12477730.html.plaintext.txt	294	The single tryptophan residue Trp 96 located inside barrel mutation led soluble aggregates defective folding assembly 8
0.20710783.12477730.html.plaintext.txt	295	Furthermore Trp interfacial residue
0.20710783.12477730.html.plaintext.txt	296	Therefore possible partially folded mutant rCPs wild type rCP similar accessibility tryptophan
0.20710783.12477730.html.plaintext.txt	297	In contrast Q37E Y67A R68Q D83A I123A mutant rCPs S145A mutant assembled capsids indistinguishable wild type rCP capsids
0.20710783.12477730.html.plaintext.txt	298	An analysis intact PhMV capsid structure shows Ser 145 hydrogen bonding interactions Thr 149 Asp 150 A B interface Ser 19 Thr 149 A C interface Asp 150 Asn 139 B C interface Fig
0.20710783.12477730.html.plaintext.txt	299	These interactions presumably less important compensated interactions mutant rCP thus affect folding assembly
0.20710783.12477730.html.plaintext.txt	300	Earlier studies D144N N1881 N188A mutant rCPs shown assemble capsids although residues occur inter subunit interfaces 8
0.20710783.12477730.html.plaintext.txt	301	Thus none mutant proteins studied thus far resulted fully folded assembly competent monomeric subunit
0.20710783.12477730.html.plaintext.txt	302	It however possible mutant rCPs correctly folded synthesized vivo hence assembly incompetent
0.20710783.12477730.html.plaintext.txt	303	To examine wild type rCP capsids incubated 8 M urea 4 h room temperature subjected stepwise dialysis immediate dilution 20 fold remove denaturant
0.20710783.12477730.html.plaintext.txt	304	However possible obtain assembled particles refolding mixtures
0.20710783.12477730.html.plaintext.txt	305	Invariably removal denaturant led complete precipitation protein
0.20710783.12477730.html.plaintext.txt	306	Because possible refold assemble wild type rCP similar experiments mutant rCPs attempted
0.20710783.12477730.html.plaintext.txt	307	In vivo studies related turnip yellow mosaic virus shown coat protein synthesized endoplasmic reticulum accumulates cytoplasm overlying clustered vesicles chloroplast 17
0.20710783.12477730.html.plaintext.txt	308	These become inserted outer chloroplast membrane hydrophobic sides normally buried complete virus particle within lipid bilayer
0.20710783.12477730.html.plaintext.txt	309	It suggested nascent RNA strand emerges vesicle neck virus assembly takes place vesicular membrane 17
0.20710783.12477730.html.plaintext.txt	310	Thus partially folded CP attached membrane upon interaction RNA could fold assemble mature capsids
0.20710783.12477730.html.plaintext.txt	311	In absence RNA proteins might self assemble form empty capsids
0.20710783.12477730.html.plaintext.txt	312	The results presented communication clearly demonstrate mutation residues crucial interfacial interactions disrupts subunit folding assembly PhMV
0.20710783.12477730.html.plaintext.txt	313	Furthermore mutants partially folded probably locked conformations lack signalsfeatures would allow assemble T 3 capsids
0.20710783.12477730.html.plaintext.txt	314	The unfolding transition monitored fluorescence overlapped changes light scattering wild type rCP capsids denatured urea suggesting disassembly unfolding also concerted Fig
0.20710783.12477730.html.plaintext.txt	315	Thus close connection folding assembly PhMV
0.20710783.12477730.html.plaintext.txt	316	In flock house virus also disassembly unfolding mature capsids shown concerted 18
0.20710783.12477730.html.plaintext.txt	317	Viral structural proteins herpes simplex virus triplex forming protein VP23 expressed E
0.20710783.12477730.html.plaintext.txt	318	coli shown exist predominantly molten globule state 19
0.20710783.12477730.html.plaintext.txt	319	The P22 coat protein also shown quite flexible solution 20
0.20710783.12477730.html.plaintext.txt	320	Thus concerted coat protein folding capsid assembly may general phenomenon viruses stabilized predominantly inter subunit interactions
0.20710783.12477730.html.plaintext.txt	321	Sridevi Annapurna Singh Mrs
0.20710783.12477730.html.plaintext.txt	322	Radha help carrying thermal denaturation studies
0.20710783.12477730.html.plaintext.txt	323	Eaazhisai help experiments
0.20710783.12477730.html.plaintext.txt	324	This work supported Departments Science Technology Biotechnology New Delhi India
0.20710783.12477730.html.plaintext.txt	325	The costs publication article defrayed part payment page charges
0.20710783.12477730.html.plaintext.txt	326	The article must therefore hereby marked advertisement accordance 18 U
0.20710783.12477730.html.plaintext.txt	327	Section 1734 solely indicate fact
0.20710783.12477730.html.plaintext.txt	328	To correspondence addressed
0.20710783.12477730.html.plaintext.txt	329	91 80 3601561 91 80 3942310 Fax 91 80 3600814 91 80 3600683 E mail bchssbiochem
0.20710783.12477730.html.plaintext.txt	330	Published JBC Papers Press December 10 2002 DOI 10
0.20710783.12477730.html.plaintext.txt	331	The abbreviations used PhMV Physalis mottle tymovirus CP coat protein rCP recombinant coat protein CD circular dichroism Ni NTA nickel nitrilotriacetic acid ANS 8 anilino 1 naphthalenesulfonate Tm melting temperature
0.20710783.12477730.html.plaintext.txt	332	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.20710783.12477730.html.plaintext.txt	333	143 1489 1500CrossRefMedline Order article via Infotrieve 2
0.20710783.12477730.html.plaintext.txt	334	1975 The Chemical Basis Virus Structure Dissociation Assembly Vol
0.20710783.12477730.html.plaintext.txt	335	39 North Holland Publishing Co
0.20710783.12477730.html.plaintext.txt	336	272 541 552CrossRefMedline Order article via Infotrieve 8
0.20710783.12477730.html.plaintext.txt	337	289 905 918CrossRefMedline Order article via Infotrieve 9
0.20710783.12477730.html.plaintext.txt	338	289 919 934CrossRefMedline Order article via Infotrieve 10
0.20710783.12477730.html.plaintext.txt	339	307 1035 1047CrossRefMedline Order article via Infotrieve 11
0.20710783.12477730.html.plaintext.txt	340	1994 Gene 151 119 123CrossRefMedline Order article via Infotrieve 12
0.20710783.12477730.html.plaintext.txt	341	1970 Nature 227 680 685Medline Order article via Infotrieve 13
0.20710783.12477730.html.plaintext.txt	342	1993 Virology 193 959 966CrossRefMedline Order article via Infotrieve 15
0.20710783.12477730.html.plaintext.txt	343	189 113 130Medline Order article via Infotrieve 17
0.20710783.12477730.html.plaintext.txt	344	1991 Plant Virology 3rd Ed
0.20710783.12477730.html.plaintext.txt	345	231 239 Academic Press New York 18
0.20710783.12477730.html.plaintext.txt	346	275 16037 16043AbstractFree Full Text 19
0.20710783.12477730.html.plaintext.txt	347	72 10066 10072AbstractFree Full Text
0.20710783.12477730.html.plaintext.txt	348	Copyright 2003 The American Society Biochemistry Molecular Biology Inc
0.20245472.14602899.html.plaintext.txt	0	Kissing complex mediated dimerisation HIV 1 RNA coupling extended duplex formation ribozyme cleavage Nikolai Windbichler Michael Werner Renee Schroeder
0.20245472.14602899.html.plaintext.txt	1	Perutz Laboratories University Departments Vienna Biocenter Department Microbiology Genetics University Vienna Dr
0.20245472.14602899.html.plaintext.txt	2	Bohrgasse 94 A 1030 Vienna Austria
0.20245472.14602899.html.plaintext.txt	3	To correspondence addressed
0.20245472.14602899.html.plaintext.txt	4	Tel 43 1 4277 54690 Fax 43 1 4277 9546 Email reneeatgem
0.20245472.14602899.html.plaintext.txt	5	u d The authors wish known opinion first two authors regarded joint First Authors
0.20245472.14602899.html.plaintext.txt	6	Received September 5 2003 Revised Accepted October 1 2003
0.20245472.14602899.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Initiation retroviral genomic RNA dimerisation mediated mutual interaction dimerisation initiation site DIS stem loops near 5 end RNA
0.20245472.14602899.html.plaintext.txt	8	This process thought involve formation transient kissing complex self complementary loop bases refolds stable extended interaction
0.20245472.14602899.html.plaintext.txt	9	We developed novel experimental system allows us clearly detect extended duplex vitro
0.20245472.14602899.html.plaintext.txt	10	Ribozyme sequences incorporated adjacent type 1 human immunodeficiency virus DIS stem leading formation functional ribozyme extended duplex conformer
0.20245472.14602899.html.plaintext.txt	11	Here show extended duplex formation results ribozyme cleavage thus demonstrating double stranded nature extended complex confirming refolding occurs via melting DIS stems
0.20245472.14602899.html.plaintext.txt	12	Loop complementarity essential extended duplex formation sequence requirements loops observed
0.20245472.14602899.html.plaintext.txt	13	Efficiency extended duplex formation dependent strength loop loop interaction temperature magnesium concentration strongly accelerated viral nucleocapsid protein NCp7
0.20245472.14602899.html.plaintext.txt	14	Our ribozyme coupled approach applicable analyses refolding processes involving RNA loop loop interactions
0.20245472.14602899.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Mature retroviral particles contain two positive strand genomic RNAs non covalently linked within region close 5 ends termed dimer linkage structure DLS
0.20245472.14602899.html.plaintext.txt	16	Retroviral RNA dimerisation considered play important role essential processes like encapsidation maturation reverse transcription 12
0.20245472.14602899.html.plaintext.txt	17	Within DLS type 1 human immunodeficiency virus HIV 1 highly conserved stem loop structure shown specifically required initiation genomic RNA dimerisation
0.20245472.14602899.html.plaintext.txt	18	Deletion sequence element called dimerisation initiation site DIS prevents dimerisation leads reduced infectivity well drastically reduced replication rates 3 7
0.20245472.14602899.html.plaintext.txt	19	The DIS element 35 nt stem loop structure internal bulge hexameric palindromic sequence within loop flanked highly conserved purine nucleotides Fig
0.20245472.14602899.html.plaintext.txt	20	The common self complementary sequences DIS loop GCGCGC subtype B LAI variant well subtype D GUGCAC subtype A MAL variant well subtype G C group O
0.20245472.14602899.html.plaintext.txt	21	Two purine nucleotides usually located 5 adjacent palindromic sequence one purine nucleotide 3 side
0.20245472.14602899.html.plaintext.txt	22	The DIS stem loops shown interact Watson Crick base pairing palindromic loop sequences forming structure called kissing complex
0.20245472.14602899.html.plaintext.txt	23	In current model DIS mediated dimerisation kissing complex converted stable extended structure
0.20245472.14602899.html.plaintext.txt	24	While loop loop base pairing maintained intramolecular base pairs DIS stems opened become involved intermolecular interactions forming double stranded RNA 89
0.20245472.14602899.html.plaintext.txt	25	View larger version 20K Figure 1
0.20245472.14602899.html.plaintext.txt	26	Secondary structure wild type HIV 1 LAI HIV 1 MAL DIS hairpin loops
0.20245472.14602899.html.plaintext.txt	27	b Principle ribozyme coupled dimerisation assay
0.20245472.14602899.html.plaintext.txt	28	Heterodimers formed kissing interaction loop bases two RNA stem loops containing one part ribozyme red blue boxes
0.20245472.14602899.html.plaintext.txt	29	Only structural rearrangement double stranded extended dimer kissing complex leads formation functional ribozyme
0.20245472.14602899.html.plaintext.txt	30	Short synthetic RNAs containing DIS hairpin able dimerise spontaneously vitro whereas RNAs resembling retroviral 5 region lacking hairpin fail
0.20245472.14602899.html.plaintext.txt	31	In vitro experiments revealed RNAs corresponding whole DIS stem loop structure able form complexes different stabilities depending incubation conditions
0.20245472.14602899.html.plaintext.txt	32	At 37 degrees C less stable complex formed via base pairing complementary loop sequences found corresponds kissing complex
0.20245472.14602899.html.plaintext.txt	33	Incubation RNAs 55 degrees C generates stable complex 10
0.20245472.14602899.html.plaintext.txt	34	X ray NMR structural data available subtypes A B HIV 1 DIS kissing complex well extended conformation 11 13
0.20245472.14602899.html.plaintext.txt	35	The crystal structures obtained 23mer RNAs contain loop well apical stem kissing complex viral subtypes MAL LAI virtually identical
0.20245472.14602899.html.plaintext.txt	36	In cases two hairpins perfect coaxial alignment thereby strongly resembling structure extended duplex
0.20245472.14602899.html.plaintext.txt	37	In contrast solution structure obtained NMR reveals different picture loop closing bases unpaired kissing loop helix A form geometry distorted kinked
0.20245472.14602899.html.plaintext.txt	38	Compared X ray structure NMR structure shows entirely different orientation 5 unpaired loop purines suggesting bases involved non canonical base pairing partial stacking 11
0.20245472.14602899.html.plaintext.txt	39	Recently fluorescence techniques used demonstrate refolding small DIS like RNAs presence HIV nucleocapsid protein NCp7 14
0.20245472.14602899.html.plaintext.txt	40	In work presented developed experimental system ribozyme activity dependent formation extended duplex allowing detection via formation cleavage product Fig
0.20245472.14602899.html.plaintext.txt	41	Two different ribozyme systems used study hammerhead ribozyme 15 synthetic leadzyme isolated via vitro selection 16
0.20245472.14602899.html.plaintext.txt	42	Using two systems investigated structural requirements influence temperature magnesium concentration well impact nucleocapsid protein NCp7 1718 extended duplex formation vitro
0.20245472.14602899.html.plaintext.txt	43	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Strains plasmids Escherichia coli strain DH5TM pUC19 plasmid used cloning work
0.20245472.14602899.html.plaintext.txt	44	Synthetic DNA oligonucleotides purchased VBC Genomics
0.20245472.14602899.html.plaintext.txt	45	Double stranded DNA fragments obtained PCR used cloning
0.20245472.14602899.html.plaintext.txt	46	The oligonucleotides used cloning H1 H2 H1a 5 CCCAAGCTTCCAAGTAATACGACTCACTATAGCGTCGGCTTGCTGAAGCGCGCACGGC 3 H1b 5 CGGGGTACCGATATCGCGAGACCACGGTGGTTTCGGCGTCGC CTCTTGCCGTGCGCGCTTCAGCAAGCCG 3 H2a 5 CCCAAGCTTCCAAGTAATACGACTCACTATAGCGACTGATGAGGCGTCGGCTTGCTGAAGCGCGC 3 H2b 5 CCAATGCATTGGTTCTGCAGCGTCGCCTCTTGCCGTGCGCGCTTCAGCAAGCCGACGCCTCATCAG 3
0.20245472.14602899.html.plaintext.txt	47	The oligonucleotides annealed filled T4 DNA polymerase
0.20245472.14602899.html.plaintext.txt	48	The resulting double stranded DNA contained restriction sites HindIII KpnI H1 HindIII PstI H2 used clone fragment pUC19 plasmid
0.20245472.14602899.html.plaintext.txt	49	The resulting clones sequenced
0.20245472.14602899.html.plaintext.txt	50	Transcription performed PCR amplification step using following primers H1fw 5 CCAAGTAATACGACTCACTATAGGCGTCGGCTTGCTGAACGCGCACGG 3 H1rev 5 TTTTTTCGCGAGACCACGGTGGT TTCGGCGTCGCCTCTTGCCGTGCGCGCTTCAGCAAGCC 3 H2fw 5 CCAAGTAATACGACTCACTATAGGCGACTGATGAGGCGTCGGC TTG 3 H2rev 5 GCGTCG CCTCTTGCCGTGCGCGCTTCAGCAAGCCGACGCCTCATCAGTCGC 3
0.20245472.14602899.html.plaintext.txt	51	The following oligonucleotides used construction L1 L2 L1a 5 CCCAAGCTTCCAAGTAATACGACTCACTATAGCGACCGAGCCAGCTGAAGCGCGCACGGCTGGCGTCGCGAATTCC 3 L1b 5 GGAATTC GCGACGCCAGCCGTGCGCGCTTCAGCTGGCTCGGTCGCTATAGTGAGTCGTATTACTTGGAAGCTTGGG 3 L2a 5 CCCAAGCTTCCAAGTAATACGACTCACTATAGCGACGCCAGCUGAAGCGCGCACGGCUGGGAGUCGCGAATTCC 3 L2b 5 GGAATTCGCGACTCCCA GCCGTGCGCGCTTCAGCTGGCGTCGCTATAGTGAGTCGTATTACTTGGAAGCTTGGG 3
0.20245472.14602899.html.plaintext.txt	52	The oligonucleotides annealed resulting double stranded DNA cleaved HindIII EcoRI cloned pUC19 plasmid
0.20245472.14602899.html.plaintext.txt	53	The following primers used amplify template transcription T7fw 5 CCAAGTAATACGACTCACTATAG 3 L1rev 5 GCGACGCCAGCCGTGCG 3 L2rev 5 GCGACTCCCAGCCGTGCGCGC 3
0.20245472.14602899.html.plaintext.txt	54	GC1 mutant constructs obtained cloned wild type sequences removing four six palindromic loop bases using BssH II cleavage subsequent treatment nuclease S1 described Berkhout van Wamel 5
0.20245472.14602899.html.plaintext.txt	55	In vitro transcription labelling Template DNA vitro transcription amplified PCR plasmid vectors required insert
0.20245472.14602899.html.plaintext.txt	56	The gel purified DNA template transcribed using T7 Megashortscript Kit Ambion
0.20245472.14602899.html.plaintext.txt	57	The transcribed RNA purified denaturing PAGE eluted gel 0
0.20245472.14602899.html.plaintext.txt	58	After precipitation RNA redissolved water concentrations determined UV spectrometry
0.20245472.14602899.html.plaintext.txt	59	Subsequently H1 L1 RNAs dephosphorylated using alkaline phosphatase 5 labelled using T4 polynucleotide kinase 32PATP following manufacturer instructions
0.20245472.14602899.html.plaintext.txt	60	In vitro dimerisation assay Both RNAs H1 H2 L1 L2 heated separately 1 min 90 degrees C immediately chilled ice water order prevent homodimerisation
0.20245472.14602899.html.plaintext.txt	61	After 5 min ice RNAs added reaction mixture
0.20245472.14602899.html.plaintext.txt	62	The reaction performed 50 mM Tris pH 7
0.20245472.14602899.html.plaintext.txt	63	5 10 mM MgCl2 unless indicated otherwise
0.20245472.14602899.html.plaintext.txt	64	A 100 fold excess unlabelled L2 RNA usually 10 nM L1 1000 nM L2 leadzyme system 20 fold excess unlabelled H2 RNA 10 nM H1 200 nM H2 hammerhead system regularly used heterodimer formation
0.20245472.14602899.html.plaintext.txt	65	The reaction allowed progress indicated temperature samples taken different time points
0.20245472.14602899.html.plaintext.txt	66	In case leadzyme system lead acetate 200 microM PbOAc added samples refolding reaction cleavage allowed occur 30 min room temperature
0.20245472.14602899.html.plaintext.txt	67	The reaction stopped adding RNA loading buffer 7 M urea reaction products separated denaturing PAGE 20 polyacrylamide
0.20245472.14602899.html.plaintext.txt	68	The results visualised quantified using phosphoimager
0.20245472.14602899.html.plaintext.txt	69	In case least two independent experiments performed
0.20245472.14602899.html.plaintext.txt	70	The cleavage rates Kobs determined assuming simple exponential decay full length RNA data fitted using least squares method Kaleidagraph software
0.20245472.14602899.html.plaintext.txt	71	Semi native polyacrylamide gel The 15 wv polyacrylamide gel poured assembled using BioRad Mighty Small gel apparatus
0.20245472.14602899.html.plaintext.txt	72	Samples taken 15 glycerol gel run 100 V using 1x TBE 89 mM Tris 89 mM borate 2 mM EDTA running buffer
0.20245472.14602899.html.plaintext.txt	73	Unlabelled nucleic acids stained soaking gel 1x TBE containing ethidium bromide 10 microgml subsequent washing water
0.20245472.14602899.html.plaintext.txt	74	Partial RNAse T1 digest End labelled RNA 0
0.20245472.14602899.html.plaintext.txt	75	2 pmol incubated together 3 microg tRNA 15 U RNAseT1 loading buffer total volume 10 microl 10 min 50 degrees C directly applied onto denaturing 20 polyacrylamide gel
0.20245472.14602899.html.plaintext.txt	76	Dimerisation presence NCp7 protein Lyophilised chemically synthesised NCp7 obtained L
0.20245472.14602899.html.plaintext.txt	77	Rossi Beckman Research Center City Hope 19 dissolved stored degassed storage buffer 20 mM Tris pH 7
0.20245472.14602899.html.plaintext.txt	78	25 mM PMSF 10 glycerol 20 microM ZnCl2
0.20245472.14602899.html.plaintext.txt	79	Dimerisation assays NCp7 performed way described
0.20245472.14602899.html.plaintext.txt	80	The protein added ice immediately reaction started 10 microM NCp7 10 fold excess protein RNA
0.20245472.14602899.html.plaintext.txt	81	The reaction performed 37 degrees C
0.20245472.14602899.html.plaintext.txt	82	Five microlitre samples taken different time points proteinase K added incubated 1 h 37 degrees C
0.20245472.14602899.html.plaintext.txt	83	PbOAc added final concentration 200 microM cleavage allowed occur 30 min room temperature
0.20245472.14602899.html.plaintext.txt	84	The reaction stopped RNA loading buffer samples kept ice loaded denaturing 20 polyacrylamide gel
0.20245472.14602899.html.plaintext.txt	85	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Construction HIV 1 like DIS stem loops containing ribozyme domains RNA molecules containing DIS stem loop elements Fig
0.20245472.14602899.html.plaintext.txt	86	2 fold active ribozymes constructed loop sequences HIV 1 5 aaGCGCGCa 3 subtype B LAI variant using hammerhead Fig
0.20245472.14602899.html.plaintext.txt	87	2a Pb2 dependent leadzyme Fig
0.20245472.14602899.html.plaintext.txt	88	The entire wild type DIS stem loop fused either 5 3 parts hammerhead ribozyme Fig
0.20245472.14602899.html.plaintext.txt	89	2a second approach leadzyme sequences directly incorporated DIS like stem loops Fig
0.20245472.14602899.html.plaintext.txt	90	While hammerhead system uses complete DIS wild type sequence including GAGG internal bulge partially single stranded ribozyme sequences attached DIS stem loop leadzyme system differs wild type stem loop sequence structurally similar RNAs fully closed stem loops
0.20245472.14602899.html.plaintext.txt	91	Additionally Pb2 dependence leadzyme allows us uncouple refolding cleavage step
0.20245472.14602899.html.plaintext.txt	92	View larger version 24K Figure 2
0.20245472.14602899.html.plaintext.txt	93	Hammerhead ribozyme leadzyme systems
0.20245472.14602899.html.plaintext.txt	94	H1 H2 RNAs containing parts hammerhead ribozyme left hammerhead forming extended dimer right
0.20245472.14602899.html.plaintext.txt	95	b L1 L2 RNAs containing parts leadzyme left leadzyme forming extended dimer right
0.20245472.14602899.html.plaintext.txt	96	Leadzyme hammerhead core ribozyme sequences shown blue red respectively
0.20245472.14602899.html.plaintext.txt	97	The arrows indicate cleavage sites ribozymes
0.20245472.14602899.html.plaintext.txt	98	Extended duplex formation results specific ribozyme cleavage To determine whether heterodimerisation subsequent refolding leads specific ribozyme cleavage performed dimerisation assays 37 55 degrees C shown Figure 3
0.20245472.14602899.html.plaintext.txt	99	In vitro transcribed H1 L1 RNAs cleaved upon formation functional ribozymes radioactively labelled 5 ends
0.20245472.14602899.html.plaintext.txt	100	We regularly used 20 hammerhead system 100 fold leadzyme system excess unlabelled H2 L2 RNAs compete H1 L1 homodimer formation
0.20245472.14602899.html.plaintext.txt	101	We observed appearance ribozyme specific cleavage products hammerhead leadzyme systems Fig
0.20245472.14602899.html.plaintext.txt	102	The observed products correspond predicted 54 nt shortened H1 RNA 6 nt L1 fragment confirmed RNAse T1 analysis
0.20245472.14602899.html.plaintext.txt	103	The amount cleavage product therefore efficiency extended duplex formation strongly increased reaction carried 55 degrees C compared 37 degrees C shown hammerhead system Figure 3a right
0.20245472.14602899.html.plaintext.txt	104	This agreement previous data show induction extended duplex formation DIS stem loop RNAs 55 degrees C 10
0.20245472.14602899.html.plaintext.txt	105	Furthermore specific ribozyme cleavage dependent presence L1 L2 Fig
0.20245472.14602899.html.plaintext.txt	106	3b H1 H2 data shown RNAs
0.20245472.14602899.html.plaintext.txt	107	Additionally cleavage products formed Pb2 added leadzyme system Fig
0.20245472.14602899.html.plaintext.txt	108	3b compare lanes 13 14 thereby demonstrating observed cleavage products result formation functional ribozyme consequence extended duplex formation
0.20245472.14602899.html.plaintext.txt	109	View larger version 30K Figure 3
0.20245472.14602899.html.plaintext.txt	110	Dimerisation assay hammerhead leadzyme constructs
0.20245472.14602899.html.plaintext.txt	111	Secondary structure H1 RNA proposed mfold 33 confirmed RNase T1 digestion left
0.20245472.14602899.html.plaintext.txt	112	Extended duplex formation H1 H2 RNAs 37 55 degrees C
0.20245472.14602899.html.plaintext.txt	113	Cleavage products radiolabelled H1 RNA separated denaturing PAGE right
0.20245472.14602899.html.plaintext.txt	114	b Secondary structure L1 RNA left
0.20245472.14602899.html.plaintext.txt	115	Denaturing PAGE analysis leadzyme dependent cleavage reaction 55 degrees C L1 L2 RNAs presence lanes 8 13 absence lane 14 200 microM Pb2
0.20245472.14602899.html.plaintext.txt	116	Control reaction L1 RNA alone presence lanes 1 6 absence lane 7 Pb2
0.20245472.14602899.html.plaintext.txt	117	T1 OH UT lanes represent RNA partially digested RNAse T1 partial alkaline hydrolysis untreated RNA respectively
0.20245472.14602899.html.plaintext.txt	118	Red DIS loop orange ribozyme sequences dots indicate T1 cleavage sites gels corresponding G residues within secondary structures blue arrows mark sites specific ribozyme cleavage
0.20245472.14602899.html.plaintext.txt	119	Asterisks indicate radioactively labelled RNAs
0.20245472.14602899.html.plaintext.txt	120	To test starting state hairpin RNAs semi native PAGE analysis performed showing heating RNAs 90 degrees C followed immediate cooling ice water RNAs monomers Fig
0.20245472.14602899.html.plaintext.txt	121	Lanes 1 2 show homodimer formation slow cooling incubation 37 degrees C lanes 3 4 show monomers fast cooling putting samples ice water immediately heating
0.20245472.14602899.html.plaintext.txt	122	View larger version 38K Figure 4
0.20245472.14602899.html.plaintext.txt	123	Influence loop complementarity extended duplex formation
0.20245472.14602899.html.plaintext.txt	124	Semi native PAGE H1 lanes 1 4 H1GC1 lanes 5 8 RNAs
0.20245472.14602899.html.plaintext.txt	125	All samples heated 1 min 90 degrees C subsequently cooled slowly 37 degrees C lanes 1 5 cooled slowly 37 degrees C incubated 37 degrees C 2 h lanes 2 6 put ice water 2 min lanes 3 7 put ice water incubated 37 degrees C 2 h lanes 4 8
0.20245472.14602899.html.plaintext.txt	126	The closed arrow indicates homodimeric open arrow monomeric form H1
0.20245472.14602899.html.plaintext.txt	127	b Secondary structure representations H2GC1 H1GC1 RNAs quantification cleavage efficiency following dimerisation assays 37 degrees C different hammerhead construct combinations right
0.20245472.14602899.html.plaintext.txt	128	c L1L2 LAL2 dimerisation assays 55 degrees C left
0.20245472.14602899.html.plaintext.txt	129	Secondary structure representations L1A L2GC1 L1GC1 RNAs middle
0.20245472.14602899.html.plaintext.txt	130	Quantification cleavage efficiency following dimerisation assays wild type loop sequences L1L2 sequences reduced L1GC1L2GC1 complementarity L1AL2 right
0.20245472.14602899.html.plaintext.txt	131	The remaining labelling described Figure 3
0.20245472.14602899.html.plaintext.txt	132	Kissing loop interaction essential subsequent extended duplex formation If extended duplex formation dependent preceding kissing complex mutations reduce abolish loop complementarity affect reaction efficiencies
0.20245472.14602899.html.plaintext.txt	133	We used previously described GC1 mutant lacks four six palindromic loop nucleotides H1GC1 H2GC1 L1GC1 L2GC1 constructs Fig
0.20245472.14602899.html.plaintext.txt	134	Compared wild type loop sequences GC1 constructs showed strongly reduced reaction efficiencies still capable forming extended duplexes
0.20245472.14602899.html.plaintext.txt	135	This observed 37 degrees C presence 50 mM MgCl2 shown hammerhead system Fig
0.20245472.14602899.html.plaintext.txt	136	4b well 55 degrees C presence 10 mM MgCl2 shown leadzyme RNAs Fig
0.20245472.14602899.html.plaintext.txt	137	We also tested combinations H1 H2GC1 H2 H1GC1 RNAs two complementary nucleotides loops extended dimers two combinations contain two unpaired GC pairs
0.20245472.14602899.html.plaintext.txt	138	These combinations show strongly reduced capacity form duplexes compared wild type
0.20245472.14602899.html.plaintext.txt	139	These results indicate reduced complementarity sufficient induce extended duplex formation although stability kissing complex influences efficiency
0.20245472.14602899.html.plaintext.txt	140	To determine whether complete abolishment loop loop complementarity would also abrogate extended duplex formation wild type DIS loop substituted six adenosines
0.20245472.14602899.html.plaintext.txt	141	This construct termed L1A unable form loop base pairs L2 RNA
0.20245472.14602899.html.plaintext.txt	142	By testing dimerisation 55 degrees C L1AL2 RNAs show extended duplex formation Fig
0.20245472.14602899.html.plaintext.txt	143	Therefore kissing complex formation essential prerequisite extended duplex formation
0.20245472.14602899.html.plaintext.txt	144	Influence different loop sequences extended duplex formation Of 64 possible palindromic loop sequences two found occur naturally namely 5 GCGCGC 3 5 GUGCAC 3 20
0.20245472.14602899.html.plaintext.txt	145	To compare extended duplex formation two major HIV 1 subtypes AAGCGCGCA sequence subtype B substituted loop sequence major HIV 1 subtype AGGUGCACA subtype A
0.20245472.14602899.html.plaintext.txt	146	The constructs derived L1 L2 termed L1MAL L2MAL respectively
0.20245472.14602899.html.plaintext.txt	147	The efficiency extended duplex formation comparable observed L1 L2 RNAs although activity MAL constructs slightly reproducibly less efficient L1 L2 RNAs LAI sequences compare Fig
0.20245472.14602899.html.plaintext.txt	148	View larger version 30K Figure 5
0.20245472.14602899.html.plaintext.txt	149	Influence different loop apical stem sequences extended duplex formation
0.20245472.14602899.html.plaintext.txt	150	Secondary structure representation L1MALL2MAL L1nscL2nsc RNAs left corresponding cleavage rates dimerisation assays 55 degrees C right
0.20245472.14602899.html.plaintext.txt	151	b Secondary structure constructs shorter apical stems L1sL2s derived L1L2 left cleavage efficiency following dimerisation assays 37 55 degrees C right
0.20245472.14602899.html.plaintext.txt	152	In order investigate whether extended duplex formation possible non naturally occurring sequences another set constructs designed
0.20245472.14602899.html.plaintext.txt	153	L1nsc L2nsc RNAs contain non self complementary loop sequences 5 AAGAGAGGA 3 5 AACUCUCCA 3 respectively Fig
0.20245472.14602899.html.plaintext.txt	154	These non self complementary sequences unable form homodimers might interfere dimerisation reaction
0.20245472.14602899.html.plaintext.txt	155	Additionally RNAs central GC pair within complementary hexanucleotide sequence loop previously suggested essential dimerisation 8921
0.20245472.14602899.html.plaintext.txt	156	As shown Figure 5a extended duplex formation nsc constructs slightly efficient MAL constructs
0.20245472.14602899.html.plaintext.txt	157	Therefore dimerisation promoted kissing complexes formed sequences wild type palindromes
0.20245472.14602899.html.plaintext.txt	158	Neither self complementarity central GC nucleotides required refolding reaction
0.20245472.14602899.html.plaintext.txt	159	Finally L1MAL L2nsc RNAs tested ability form extended duplexes
0.20245472.14602899.html.plaintext.txt	160	These two constructs complementary two loop bases four mismatched bases
0.20245472.14602899.html.plaintext.txt	161	As GC1 RNAs sequence combination still shows extended duplex formation extent although reaction efficiency strongly reduced Fig
0.20245472.14602899.html.plaintext.txt	162	This demonstrates strength loop loop interaction key parameter dimerisation
0.20245472.14602899.html.plaintext.txt	163	Influence temperature magnesium concentration stem length extended duplex formation As mentioned previously incubation 55 degrees C enhances extended duplex formation various small DIS like RNAs
0.20245472.14602899.html.plaintext.txt	164	Some RNAs short stems form extended dimer even lower temperatures 22
0.20245472.14602899.html.plaintext.txt	165	This unexpected extended duplex formation requires opening DIS stem base pairs 12 case L1 RNA undergo intermolecular base pairing
0.20245472.14602899.html.plaintext.txt	166	This refolding process represents kinetic barrier overcome establish thermodynamically stable extended duplex conformation
0.20245472.14602899.html.plaintext.txt	167	We wanted test effect higher temperature shortened stem extended duplex formation well influence Mg2 concentration duplex formation
0.20245472.14602899.html.plaintext.txt	168	RNAs derived L1 L2 constructs Fig
0.20245472.14602899.html.plaintext.txt	169	5b designed 2 bp upper DIS stem deleted
0.20245472.14602899.html.plaintext.txt	170	These shorter constructs termed L1s L2s tested 37 55 degrees C ability form extended duplex
0.20245472.14602899.html.plaintext.txt	171	At 37 degrees C L1L2 L1sL2s show similar behaviour
0.20245472.14602899.html.plaintext.txt	172	At 55 degrees C observed slight reproducible increase cleavage efficiency lies within error range experiments
0.20245472.14602899.html.plaintext.txt	173	Therefore weakening upper stem 2 bp sufficient significantly increase efficiency extended duplex formation Fig
0.20245472.14602899.html.plaintext.txt	174	Figure 6a shows extended duplex formation L1 L2 RNAs enhanced increasing temperature 55 degrees C
0.20245472.14602899.html.plaintext.txt	175	A strong temperature dependence also observed hammerhead system shows complete extended duplex formation 55 degrees C 90 min Fig
0.20245472.14602899.html.plaintext.txt	176	Since temperature known rate constants ribozyme cleavage far exceed rates cleavage observed systems limiting step appears refolding rather catalysis
0.20245472.14602899.html.plaintext.txt	177	Therefore temperature dependent differences observed rate constants likely reflect rate refolding
0.20245472.14602899.html.plaintext.txt	178	View larger version 14K Figure 6
0.20245472.14602899.html.plaintext.txt	179	Influence external parameters extended dimer formation
0.20245472.14602899.html.plaintext.txt	180	Cleavage efficiencies leadzyme L1L2 constructs following dimerisation different temperatures
0.20245472.14602899.html.plaintext.txt	181	Kobs min 1 values plotted temperature
0.20245472.14602899.html.plaintext.txt	182	b Influence magnesium concentration dimerisation H1H2 hammerhead constructs
0.20245472.14602899.html.plaintext.txt	183	Kobs min 1 values plotted magnesium concentration
0.20245472.14602899.html.plaintext.txt	184	c Influence added HIV 1 NCp7 protein extended dimer formation 37 degrees C
0.20245472.14602899.html.plaintext.txt	185	L1L2 L1AL2 dimerisation absence presence nucleo capsid protein NCp7 Pb2
0.20245472.14602899.html.plaintext.txt	186	Quantification cleavage efficiencies plotted time
0.20245472.14602899.html.plaintext.txt	187	The dependence extended duplex formation Mg2 concentration tested using hammerhead system high Mg2 concentrations interfere lead cleavage data shown
0.20245472.14602899.html.plaintext.txt	188	The optimal Mg2 concentration hammerhead ribozyme activity usually 10 mM MgCl2 23
0.20245472.14602899.html.plaintext.txt	189	We found extended duplex formation strongly enhanced presence high Mg2 concentrations 100 mM MgCl2 Fig
0.20245472.14602899.html.plaintext.txt	190	Mg2 might stabilise kissing complex would increase likelihood subsequent extended duplex formation
0.20245472.14602899.html.plaintext.txt	191	NCp7 strongly accelerates extended duplex formation It suggested NCp7 plays critical role HIV genomic RNA maturation
0.20245472.14602899.html.plaintext.txt	192	Indeed shown NCp7 able convert low stability retroviral RNA dimers stable dimers vitro 24 27
0.20245472.14602899.html.plaintext.txt	193	NCp7 also catalyses conversion small DIS like RNAs 25 nt extended duplex form 14
0.20245472.14602899.html.plaintext.txt	194	However specificity interaction uncertain since NCp7 also acts general nucleic acid chaperone
0.20245472.14602899.html.plaintext.txt	195	It shown posses nucleic acid annealing strand exchange activity vitro 2829 RNA chaperone activity vivo 30 also accelerates cleavage hammerhead ribozyme 19
0.20245472.14602899.html.plaintext.txt	196	We set test whether NCp7 protein would also enhance extended duplex formation system
0.20245472.14602899.html.plaintext.txt	197	To discriminate general RNA RNA annealing activity specific action used L1 L2 RNAs also combination L1A L2 completely lacks loop complementarity
0.20245472.14602899.html.plaintext.txt	198	As shown Figure 6c NCp7 strongly increases extended duplex formation L1 L2 RNAs
0.20245472.14602899.html.plaintext.txt	199	Sixty percent RNAs refolded 5 min 37 degrees C compared 10 absence NCp7 Fig
0.20245472.14602899.html.plaintext.txt	200	6c compare triangles squares
0.20245472.14602899.html.plaintext.txt	201	The reaction levels reach 70 completion 30 min
0.20245472.14602899.html.plaintext.txt	202	L1AL2 RNAs lack loop complementarity show extended duplex formation 55 degrees C absence NCp7 react presence NCp7
0.20245472.14602899.html.plaintext.txt	203	We conclude NCp7 strongly enhances specific extended duplex formation system extent also RNAs without loop complementarity via general nucleic acid structure destabilising activity
0.20245472.14602899.html.plaintext.txt	204	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Here present novel experimental approach monitor refolding two RNA hairpins extended duplex
0.20245472.14602899.html.plaintext.txt	205	The system consists two HIV 1 derived DIS hairpins fused one half ribozyme
0.20245472.14602899.html.plaintext.txt	206	Refolding heterodimeric DIS kissing complex partially double stranded extended RNA duplex leads formation active ribozyme specific cleavage event
0.20245472.14602899.html.plaintext.txt	207	The advantage system previous analysis methods using native gel electrophoresis clear discrimination kissing complex extended duplex due formation cleavage product
0.20245472.14602899.html.plaintext.txt	208	The reversibility folding process reduces applicability native gel electrophoresis
0.20245472.14602899.html.plaintext.txt	209	The ribozyme system results irreversible easily detectable product allowing wide range external parameters structural requirements tested
0.20245472.14602899.html.plaintext.txt	210	Our approach clearly demonstrates ribozymes useful tools monitoring RNA refolding processes
0.20245472.14602899.html.plaintext.txt	211	Formation active ribozyme refolding hairpins extended duplex clearly demonstrated double stranded nature extended dimers
0.20245472.14602899.html.plaintext.txt	212	Our results confirm current model HIV 1 DIS dimerisation involving refolding kissing complex melting stems partially double stranded dimer rule hypothetical mechanism extended duplex formation involving symmetric cleavage chains subsequent religation 13
0.20245472.14602899.html.plaintext.txt	213	From crystal structure data found 2 OH group second purine residue 5 complementary sequence favourable position line attack neighbouring 3 phosphate
0.20245472.14602899.html.plaintext.txt	214	A mechanism involving nucleophilic attack leading strand scission followed dangling movement base cross religation RNAs proposed
0.20245472.14602899.html.plaintext.txt	215	Such mechanism would join DIS stem loop RNAs within loop regions keeping initial stems intact
0.20245472.14602899.html.plaintext.txt	216	If true parts ribozyme would remain separated would unable form functional ribozyme
0.20245472.14602899.html.plaintext.txt	217	Our observation extended duplex formation leads indeed ribozyme cleavage therefore strongly supports refolding model melting stems
0.20245472.14602899.html.plaintext.txt	218	We show formation kissing complex interaction complementary loop nucleotides essential prerequisite extended duplex formation
0.20245472.14602899.html.plaintext.txt	219	In contrast previous reports investigating viral RNA dimerisation vitro found neither self complementarity central GC pairs within palindrome essential refolding
0.20245472.14602899.html.plaintext.txt	220	It suggested central GC pairs essential efficient dimerisation vitro possibly involvement non canonical base pair interactions forming potential nucleation point dimer 8921
0.20245472.14602899.html.plaintext.txt	221	Our results accordance vitro selection data show dinucleotide favours dimerisation essential 3132
0.20245472.14602899.html.plaintext.txt	222	Self complementarity loops evidently required viral RNA dimerisation homologous strands apparently refolding process per se
0.20245472.14602899.html.plaintext.txt	223	These observations particularly interesting given fact two different loop sequences found HIV 1 isolates raising question nature selective pressure two sequences since substituted sequences extended duplex formation vitro
0.20245472.14602899.html.plaintext.txt	224	It shown entire HIV 5 leader RNA adopt two different conformations suggesting sequence conservation might reflect need preserve two structures 33
0.20245472.14602899.html.plaintext.txt	225	Extended duplex formation still possible partially complementary sequences sequences strongly reduced loop complementarity used
0.20245472.14602899.html.plaintext.txt	226	This suggests loop loop interaction partial base pairing sufficient extended duplex formation 55 degrees C although full complementarity case wild type loop sequences strongly enhances efficiency refolding process
0.20245472.14602899.html.plaintext.txt	227	Assuming reduction loop complementarity affect refolding reduces kissing complex stability previous findings Berkhout van Wamel 5 might explained
0.20245472.14602899.html.plaintext.txt	228	These authors reported strongly reduced infectivity two GC pairs deleted palindrome HIV 1 LAI subtype however purified virions still contained stable dimeric RNA
0.20245472.14602899.html.plaintext.txt	229	Reduced stability kissing complex might lead strong impairment packaging efficiency loose dimers happened encapsidated still able refold forming stable dimers
0.20245472.14602899.html.plaintext.txt	230	The study influence external parameters refolding process revealed efficiency temperature dependent suggesting refolding proceeds destabilisation stems
0.20245472.14602899.html.plaintext.txt	231	Additionally could shown presence magnesium ions enhances extended duplex formation although essential process
0.20245472.14602899.html.plaintext.txt	232	High magnesium concentrations accelerated reaction way efficient extended duplex formation could already observed 37 degrees C
0.20245472.14602899.html.plaintext.txt	233	This could explained efficient stabilisation kissing complex stems
0.20245472.14602899.html.plaintext.txt	234	Indeed strong stabilisation kissing complex compared stem observed presence magnesium ions UV melting experiments A
0.20245472.14602899.html.plaintext.txt	235	Schroeder unpublished results
0.20245472.14602899.html.plaintext.txt	236	Transition kissing complex extended duplex vitro clearly observed physiological temperatures presence viral nucleocapsid protein NCp7
0.20245472.14602899.html.plaintext.txt	237	This small basic 55 amino acid long highly conserved RNA binding protein reported general RNA chaperone activity 1928
0.20245472.14602899.html.plaintext.txt	238	In vivo experiments demonstrated viral protease dependent maturation resulting cleavage gag precursor generate nucleocapsid protein accompanied conversion dimeric RNA particles heat stable dimer 2434
0.20245472.14602899.html.plaintext.txt	239	Our data show NCp7 induced extended duplex formation extremely efficient compared temperature induced refolding
0.20245472.14602899.html.plaintext.txt	240	The amount extended duplex formed constructs lacking loop complementarity explained general RNA RNA annealing activity NCp7 19
0.20245472.14602899.html.plaintext.txt	241	This might propose model extended duplex formation promoted NCp7
0.20245472.14602899.html.plaintext.txt	242	It conceivable NCp7 induces kissing complex formation RNA RNA annealing activity andor helix destabilising activity 29
0.20245472.14602899.html.plaintext.txt	243	The kissing interaction might provide stable specific interaction surface starting point efficient refolding
0.20245472.14602899.html.plaintext.txt	244	In contrast might temporal availability spatial location NCp7 viral maturation cycle allows use general nucleic acid refolding activity specific manner
0.20245472.14602899.html.plaintext.txt	245	However mentioned currently unclear data DIS mediated dimerisation obtained vitro translate vivo situation given direct evidence mature form dimer inside viral particle extended duplex
0.20245472.14602899.html.plaintext.txt	246	RNA loop loop interactions involved variety biological processes interactions accompanied structural rearrangements leading stable structures reviewed 20
0.20245472.14602899.html.plaintext.txt	247	It often difficult distinguish two alternative conformations
0.20245472.14602899.html.plaintext.txt	248	Since sequence requirements leadzyme relatively small derivates system could easily used investigate whether refolding follows RNA loop loop interactions biological contexts antisense regulation bicoid mRNA localisation
0.20245472.14602899.html.plaintext.txt	249	Using hammerhead system investigation refolding processes following RNA loop loop interactions could addressed vivo well
0.20245472.14602899.html.plaintext.txt	250	ACKNOWLEDGEMENTS We thank Lisa Scherer John Rossi generously providing NCp7 peptide Lisa Scherer help handling NCp7
0.20245472.14602899.html.plaintext.txt	251	We grateful Tim Skern useful comments revision
0.20245472.14602899.html.plaintext.txt	252	The input members Schroeder laboratory gratefully appreciated
0.20245472.14602899.html.plaintext.txt	253	This work funded Austrian Science Foundation FWF grant
0.20245472.14602899.html.plaintext.txt	254	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES CoffinJ
0.20245472.14602899.html.plaintext.txt	255	Cold Spring Harbor Laboratory Press Plainview NY
0.20245472.14602899.html.plaintext.txt	256	1996 Structure function human immunodeficiency virus leader RNA
0.20245472.14602899.html.plaintext.txt	257	1994 Mutational analysis bipartite dimer linkage structure human immunodeficiency virus type 1 genomic RNA
0.20245472.14602899.html.plaintext.txt	258	1996 Dimerization retroviral genomic RNAs structural functional implications
0.20245472.14602899.html.plaintext.txt	259	1996 Role DIS hairpin replication human immunodeficiency virus type 1
0.20245472.14602899.html.plaintext.txt	260	1996 Kissing loop model HIV 1 genome dimerization HIV 1 RNAs assume alternative dimeric forms sequences upstream downstream hairpin 248 271 dispensable dimer formation
0.20245472.14602899.html.plaintext.txt	261	Biochemistry 35 1589 1598
0.20245472.14602899.html.plaintext.txt	262	1997 Mutations kissing loop hairpin human immunodeficiency virus type 1 reduce viral infectivity well genomic RNA packaging dimerization
0.20245472.14602899.html.plaintext.txt	263	1996 Requirements kissing loop mediated dimerization human immunodeficiency virus RNA
0.20245472.14602899.html.plaintext.txt	264	1997 Non canonical interactions kissing loop complex dimerization initiation site HIV 1 genomic RNA
0.20245472.14602899.html.plaintext.txt	265	1996 A kissing complex together stable dimer involved HIV 1Lai RNA dimerization process vitro
0.20245472.14602899.html.plaintext.txt	266	Biochemistry 35 5075 5082
0.20245472.14602899.html.plaintext.txt	267	1998 Structure dimer initiation complex HIV 1 genomic RNA
0.20245472.14602899.html.plaintext.txt	268	1999 The crystal structure dimerization initiation site genomic HIV 1 RNA reveals extended duplex two adenine bulges
0.20245472.14602899.html.plaintext.txt	269	2001 Crystal structures coaxially stacked kissing complexes HIV 1 RNA dimerization initiation site
0.20245472.14602899.html.plaintext.txt	270	2002 Mechanism nucleocapsid protein catalyzed structural isomerization dimerization initiation site HIV 1
0.20245472.14602899.html.plaintext.txt	271	Biochemistry 41 14762 14770
0.20245472.14602899.html.plaintext.txt	272	1992 A small metalloribozyme two step mechanism
0.20245472.14602899.html.plaintext.txt	273	1995 First glimpses structure function relationships nucleocapsid protein retroviruses
0.20245472.14602899.html.plaintext.txt	274	1994 Human immunodeficient virus nucleocapsid protein accelerates strand tranfer terminally redundant sequences involved reverse transcription
0.20245472.14602899.html.plaintext.txt	275	1994 Facilitation hammerhead ribozyme cleavage catalysis nucleocapsid protein HIV 1 heterogeneous nucleo ribonucleoprotein A1
0.20245472.14602899.html.plaintext.txt	276	2002 RNA loop loop interactions dynamic functional motifs
0.20245472.14602899.html.plaintext.txt	277	1999 Dimerization HIV 1 genomic RNA subtypes A B RNA loop structure magnesium binding
0.20245472.14602899.html.plaintext.txt	278	2000 Structural requirement two step dimerization human immunodeficiency virus type 1 genome
0.20245472.14602899.html.plaintext.txt	279	1991 Role divalent metal ions hammerhead RNA cleavage reaction
0.20245472.14602899.html.plaintext.txt	280	Biochemistry 30 9464 9469
0.20245472.14602899.html.plaintext.txt	281	1994 Characterization human immunodeficiency virus type 1 dimeric RNA wild type protease defective virions
0.20245472.14602899.html.plaintext.txt	282	1996 HIV 1 nucleocapsid protein induces maturation dimeric retroviral RNA vitro
0.20245472.14602899.html.plaintext.txt	283	1995 Analysis nucleic acid annealing activities nucleocapsid protein HIV 1
0.20245472.14602899.html.plaintext.txt	284	1996 NCp7 activates HIV 1Lai RNA dimerization converting transient loop loop complex stable dimer
0.20245472.14602899.html.plaintext.txt	285	1993 Protein enhancement hammerhead ribozyme catalysis
0.20245472.14602899.html.plaintext.txt	286	1994 DNA strand exchange selective DNA annealing promoted human immunodeficiency virus type 1 nucleocapsid protein
0.20245472.14602899.html.plaintext.txt	287	1999 Assaying RNA chaperone activity vivo using novel RNA folding trap
0.20245472.14602899.html.plaintext.txt	288	2000 Convergence natural artificial evolution RNA loop loop interaction HIV 1 dimerization initiation site
0.20245472.14602899.html.plaintext.txt	289	2001 Structure dimerization HIV 1 kissing loop aptamers
0.20245472.14602899.html.plaintext.txt	290	2000 The leader HIV 1 RNA genome forms compactly folded tertiary structure
0.20245472.14602899.html.plaintext.txt	291	1993 Maturation dimeric viral RNA Moloney murine leukemia virus
0.33479095.11602792.html.plaintext.txt	0	Chimeric papillomavirus like particles expressing foreign epitope capsid surface loops Katharina Slupetzky1 Saeed Shafti Keramat1 Petra Lenzb1 Sabine Brandt2 Andreas Grassauer2 Margit Sara3 Reinhard Kirnbauer1
0.33479095.11602792.html.plaintext.txt	1	Laboratory Viral Oncology Division Immunology Allergy Infectious Diseases DIAID1 Division General Dermatology Department Dermatology2 University Vienna Medical School Wahringer Gurtel 18 20 A 1090 Vienna Austria Center Ultrastructure Research Ludwig Boltzmann Institute Molecular Nanotechnology University Agricultural Sciences Gregor Mendel Strasse 33 A 1180 Vienna Austria3
0.33479095.11602792.html.plaintext.txt	2	Author correspondence Reinhard Kirnbauer
0.33479095.11602792.html.plaintext.txt	3	Abstract Top Abstract Main text References Neutralization capsid epitopes important determinants antibody mediated immune protection papillomavirus PV infection induced disease
0.33479095.11602792.html.plaintext.txt	4	Chimeric L1 major capsid proteins human PV type 16 HPV 16 bovine PV type 1 BPV 1 foreign peptide incorporated several capsid surface loops self assembled pentamers virus like particles VLP
0.33479095.11602792.html.plaintext.txt	5	Binding patterns neutralizing monoclonal antibodies MAb immunization mice confirmed regions around aa 282 286 351 355 contribute neutralization epitopes identified latter region immunodominant site ii placing foreign peptide context assembled structure markedly enhanced immunogenicity
0.33479095.11602792.html.plaintext.txt	6	Pentamers disassembled wild type HPV 16 BPV 1 VLPs displayed neutralization epitopes detected fully assembled VLPs deficient binding subset neutralizing MAb inhibit cell attachment
0.33479095.11602792.html.plaintext.txt	7	Main text Top Abstract Main text References Papillomavirus PV infections widespread animals humans causing mostly benign epithelial proliferations papillomas warts skin mucous membranes Howley 1991 Lowy et al
0.33479095.11602792.html.plaintext.txt	8	Infection oncogenic types often human PV type 16 HPV 16 aetiologically associated development anogenital malignancies particular cervical cancer zur Hausen 1994
0.33479095.11602792.html.plaintext.txt	9	PVs nonenveloped 8 kb double stranded DNA viruses T7 icosahedral symmetry diameter approximately 55 nm Baker et al
0.33479095.11602792.html.plaintext.txt	10	The capsid consists 60 hexavalent 12 pentavalent capsomers capsomer pentamer composed 5 L1 major capsid proteins
0.33479095.11602792.html.plaintext.txt	11	The second viral structural protein minor capsid protein L2 required genome encapsidation generation infectious virions Day et al
0.33479095.11602792.html.plaintext.txt	12	Despite development vitro vivo methods still efficient tissue culture system laboratory animal easily propagate HPV hampered immunological structural studies virion Kreider et al
0.33479095.11602792.html.plaintext.txt	13	In recent years progress achieved towards development prophylactic HPV vaccine prevent genital HPV infection associated benign dysplastic lesions Kirnbauer 1996 Schiller Okun 1996
0.33479095.11602792.html.plaintext.txt	14	Capsid proteins L1 alone L1 plus L2 expressed eukaryotic cells self assembles virus like particles VLP morphologically antigenically similar native virions lack potentially oncogenic DNA
0.33479095.11602792.html.plaintext.txt	15	Immunization L1 L1L2 VLP generated sera containing neutralizing antibodies conferred type specific long lasting protection several animal models Bell et al
0.33479095.11602792.html.plaintext.txt	16	1992 1993 1996 Rose et al
0.33479095.11602792.html.plaintext.txt	17	Neutralizing antibodies thus considered major protective component prophylactic PV vaccination
0.33479095.11602792.html.plaintext.txt	18	Because neutralization PV epitopes non linear conformation dependent amino acid composition surface localization incompletely characterized
0.33479095.11602792.html.plaintext.txt	19	Monoclonal antibody MAb binding immunization studies tentatively mapped neutralization epitopes low risk HPV 11 along 20 aa stretch L1 residues 120 140 immunodominant sites aa 131 132 346 349 Ludmerer et al
0.33479095.11602792.html.plaintext.txt	20	1997 2000 implicated L1 residues 50 266 282 HPV 16 neutralization epitopes Roden et al
0.33479095.11602792.html.plaintext.txt	21	To explore epitopes potential VLP immunogenic vaccine carrier engineered 8 aa B cell epitope LELDKWAS Leu Glu Leu Asp Lys Trp Ala Ser human immunodeficiency virus type 1 HIV 1 gp41 envelope glycoprotein L1 protein HPV 16 bovine PV type 1 BPV 1 using inverse touch PCR Ochman et al
0.33479095.11602792.html.plaintext.txt	22	Oligonucleotides encoding epitope cloned several hypervariable regions L1 ORF HPV 16 baculovirus transfer vector 114K L1 pSynwtVI Kirnbauer et al
0.33479095.11602792.html.plaintext.txt	23	1993 BPV 1 L1 pEVmod Kirnbauer et al
0.33479095.11602792.html.plaintext.txt	24	These regions likely encode surface structures assembled capsid Fig
0.33479095.11602792.html.plaintext.txt	25	For HPV 16 L1 recombinant baculovirus expression vectors generated peptide inserted amino acid residues 286287 281287 replacing aa 282 286 fused C terminus control Fig
0.33479095.11602792.html.plaintext.txt	26	We also designed BPV 1 L1 chimeras incorporate peptide three different hypervariable regions amino acid residues 133134 282286 replacing aa 283 285 351355 replacing aa 352 354 Fig
0.33479095.11602792.html.plaintext.txt	27	Recombinant proteins immunoblotted using MAb Camvir 1 Pharmingen AU 1 BAbCO directed linear epitopes HPV 16 L1 BPV 1 L1 MAb 2F5 recognizes LELDKWAS epitope AIDS Research Reference Reagent Program NIAID NIH USA Muster et al
0.33479095.11602792.html.plaintext.txt	28	Following purification high molecular mass complexes density gradients HPV 16 BPV 1 L1 chimeric proteins analysed transmission electron microscopy TEM
0.33479095.11602792.html.plaintext.txt	29	Micrographs demonstrated pentamers full size smaller VLP indicating peptide insertion prevent L1 self assembly higher ordered structures data shown
0.33479095.11602792.html.plaintext.txt	30	Further evidence assembly chimeric BPV 1 L1 proteins obtained analytical centrifugation 20 40 sucrose density gradients demonstrating migration pattern corresponded wild type wt L1 VLP bottom gradient well disassembled wt L1 pentamers top gradient run parallel data shown
0.33479095.11602792.html.plaintext.txt	31	These results supported presence VLP pentamers chimeric L1 preparations observed TEM
0.33479095.11602792.html.plaintext.txt	32	View larger version 16K Fig
0.33479095.11602792.html.plaintext.txt	33	Construction chimeric HPV 16 A C BPV 1 D F L1 LELDKWAS baculovirus expression vectors
0.33479095.11602792.html.plaintext.txt	34	HPV 16 capsid surface loops DE FG HI dotted lines amino acid numbering indicated Chen et al
0.33479095.11602792.html.plaintext.txt	35	The LELDKWAS peptide indicated bold line engineered L1 ORF indicated amino acid residues encoding following deduced chimeric L1 epitope sequences added amino acids brackets A TANLELDKWASSN B KGSGLELDKWASSN C KKRKLELDKWAS D DATLELDKWASVHF E RKVTLELDKWASTQTT F TPLTLELDKWASSKF oligonucleotide primer sequences available request
0.33479095.11602792.html.plaintext.txt	36	Loops inserts drawn scale
0.33479095.11602792.html.plaintext.txt	37	N C amino carboxy terminus
0.33479095.11602792.html.plaintext.txt	38	We next examined amino acid deletion andor peptide insertion hypervariable region HPV 16 L1 would interrupt neutralizing MAb binding conformation dependent epitopes ELISA Roden et al
0.33479095.11602792.html.plaintext.txt	39	Two classes MAb neutralize HPV 16 virions described MAbs E70 V5 inhibit virus cell binding referred class A U4 inhibit binding class B Roden et al
0.33479095.11602792.html.plaintext.txt	40	By ELISA classes MAb bound HPV 16 C terminal fusion protein similar wt VLP Fig
0.33479095.11602792.html.plaintext.txt	41	There complete loss binding class A antibodies E70 V5 chimeras A 286287 B 281287
0.33479095.11602792.html.plaintext.txt	42	In contrast binding class B MAb U4 chimeras A 286287 B 281287 similar wt VLP
0.33479095.11602792.html.plaintext.txt	43	These results confirm extend previous observation amino acids around 282 part E70 epitope also contribute V5 epitope Roden et al
0.33479095.11602792.html.plaintext.txt	44	View larger version 33K Fig
0.33479095.11602792.html.plaintext.txt	45	Binding HPV 16 neutralizing MAb wt HPV 16 L1 VLP chimeric HPV 16 L1 proteins A B C disassembled wt capsomers ELISA
0.33479095.11602792.html.plaintext.txt	46	MAbs E70 V5 inhibit haemagglutination class A U4 inhibit haemagglutination class B
0.33479095.11602792.html.plaintext.txt	47	b Binding BPV neutralizing MAb wt BPV L1 VLP chimeric BPV 1 L1 proteins D E F disassembled wt capsomers ELISA
0.33479095.11602792.html.plaintext.txt	48	Neutralizing MAbs 6 9 inhibit haemagglutination class A 5B6 inhibit haemagglutination class B
0.33479095.11602792.html.plaintext.txt	49	It shown HPV 11 capsomers contain conformational epitopes found intact VLP Rose et al
0.33479095.11602792.html.plaintext.txt	50	To examine whether VLP required MAb binding whether HPV 16 L1 pentamers sufficient display epitopes wt HPV 16 L1 capsids disassembled pentamers absence VLP verified TEM sucrose gradient data shown
0.33479095.11602792.html.plaintext.txt	51	By ELISA MAbs V5 U4 bound wt L1 pentamers kinetics similar wt VLP whereas absorbance values MAb E70 significantly reduced
0.33479095.11602792.html.plaintext.txt	52	These results indicated E70 epitope partially sensitive VLP disassembly Fig
0.33479095.11602792.html.plaintext.txt	53	2a HPV 16 L1 pentamers appear sufficient display MAb V5 class A U4 class B epitopes
0.33479095.11602792.html.plaintext.txt	54	As shown previously low risk HPV 11 demonstrate first time high risk HPV 16 L1 capsomers display least subset neutralization epitopes found full size VLP
0.33479095.11602792.html.plaintext.txt	55	As HPV two classes MAb neutralize BPV virions described represented MAbs 6 9 class A MAb 5B6 class B Roden et al
0.33479095.11602792.html.plaintext.txt	56	When BPV 1 chimeric L1 proteins pentamers disassembled wt L1 VLP reducing conditions 3 2 mercaptoethanol150 mM NaCl McCarthy et al
0.33479095.11602792.html.plaintext.txt	57	1998 analysed ELISA Fig
0.33479095.11602792.html.plaintext.txt	58	2b binding MAb 6 class A wt L1 VLP chimeric BPV 1 L1 proteins D 133134 E 282286 wt L1 pentamers observed
0.33479095.11602792.html.plaintext.txt	59	Data MAb 6 binding chimera F 351355 inconclusive absorbance values decline across 3 logs antibody dilution
0.33479095.11602792.html.plaintext.txt	60	These results indicate wt pentamers appear sufficient display 6 epitope determinants contained within targeted L1 regions chimeras D 133134 E 282286
0.33479095.11602792.html.plaintext.txt	61	Antibody 9 class A recognized VLP wt L1 chimera D 133134 binding seen chimeras E 282286 F 351355
0.33479095.11602792.html.plaintext.txt	62	This finding raises possibility peptide insertion aa 282286 351355 either directly targeted respective BPV neutralization epitope indirectly affected quaternary structure particles
0.33479095.11602792.html.plaintext.txt	63	In addition wt pentamers react indicating MAb 9 requires assembly VLP binding
0.33479095.11602792.html.plaintext.txt	64	The findings add published results indicating residues 282 286 351 355 form part neutralization epitopes Ludmerer et al
0.33479095.11602792.html.plaintext.txt	65	Reactivity MAb 5B6 class B specifically absent construct F 351355 indicating peptide targeting aa 351355 interrupted 5B6 epitope
0.33479095.11602792.html.plaintext.txt	66	This interpretation consistent observation aa 346 analogous region HPV 11 L1 critical binding neutralizing MAb Ludmerer et al
0.33479095.11602792.html.plaintext.txt	67	1996 although indirect effect quaternary structure remains possible
0.33479095.11602792.html.plaintext.txt	68	Interestingly high resolution reconstructions MAb 5B6 binds monovalently divalently neighbouring hexavalent capsomers intercapsomer cross bridges Trus et al
0.33479095.11602792.html.plaintext.txt	69	Taken together data suggest aa 351 355 contribute 5B6 epitope virion surface location close interpentamer connections
0.33479095.11602792.html.plaintext.txt	70	In addition pentamers appear sufficient display neutralization epitope
0.33479095.11602792.html.plaintext.txt	71	Our results also identify existence two sub classes neutralizing antibodies within antibodies interfere binding particles cell surface class A
0.33479095.11602792.html.plaintext.txt	72	One sub class MAb 6 bind intact VLPs pentamerscapsomers sub class MAb 9 requires higher ordered structure VLP binding
0.33479095.11602792.html.plaintext.txt	73	The BPV pentamer results similar HPV 16 pentamers deficient E70 binding bound V5 similarly intact VLPs
0.33479095.11602792.html.plaintext.txt	74	To examine effect peptide insertion immunogenicity BPV 1 L1 proteins three mice injected native denatured protein preparations boosted twice 2 week intervals
0.33479095.11602792.html.plaintext.txt	75	Two weeks last immunization pooled sera analysed antibodies LELDKWAS peptide BPV neutralizing activity using vitro focus forming assay Dvoretzky et al
0.33479095.11602792.html.plaintext.txt	76	Sera raised native preparations chimeras D 133134 E 282286 wt VLP neutralized BPV virions titre 1000 100 10000 respectively
0.33479095.11602792.html.plaintext.txt	77	This indicated chimeric proteins retain PV neutralization epitopes although potency induce neutralization activity lower wt VLP
0.33479095.11602792.html.plaintext.txt	78	These results suggest feasibility inserting epitopes choice immunogenic regions L1 e
0.33479095.11602792.html.plaintext.txt	79	generate HPV vaccines broad spectrum protection
0.33479095.11602792.html.plaintext.txt	80	In contrast sera raised chimera F 351355 non neutralizing suggesting peptide insertion residues 351355 disrupted major immunogenic determinants
0.33479095.11602792.html.plaintext.txt	81	To evaluate potential assembled chimeric BPV 1 L1 proteins induce antibodies inserted epitope sera analysed ELISA using alkaline phosphatase AP LELDKWAS antigen Fig
0.33479095.11602792.html.plaintext.txt	82	Antisera raised chimera E 282286 showed insignificant binding LELDKWAS peptide whereas sera raised chimera F 351355 showed reactivity comparable obtained MAb 2F5
0.33479095.11602792.html.plaintext.txt	83	Thus insertion foreign peptide 351355 chimera F generated protein efficiently induced anti peptide antibodies binding MAb 5B6 capacity induce BPV neutralizing antisera completely abrogated
0.33479095.11602792.html.plaintext.txt	84	This change function provides additional evidence amino acids around 351355 contribute immunodominant neutralization surface structure
0.33479095.11602792.html.plaintext.txt	85	Sera raised chimera D 133134 also demonstrated significant binding implicating residues 133134 part another immunogenic region
0.33479095.11602792.html.plaintext.txt	86	Remarkably denatured proteins induce immunoreactivity peptide although sera contained antibodies linear L1 epitopes
0.33479095.11602792.html.plaintext.txt	87	This indicated placing foreign peptide context assembled structure markedly enhanced immunogenicity whereas peptide appeared subdominant presented denatured linear chimeric L1 LELDKWAS protein
0.33479095.11602792.html.plaintext.txt	88	View larger version 22K Fig
0.33479095.11602792.html.plaintext.txt	89	Reactivity immune sera LELDKWAS epitope ELISA
0.33479095.11602792.html.plaintext.txt	90	Three BALBc mice injected subcutaneously 50 microg estimated SDS PAGE native heatSDS denatured protein complete Freund adjuvant followed two boosts incomplete Freund adjuvant 2 week intervals
0.33479095.11602792.html.plaintext.txt	91	Two weeks last immunization serum samples collected pooled heat inactivated
0.33479095.11602792.html.plaintext.txt	92	Twofold serial dilutions immune sera raised native denatured chimeric L1 proteins D E F dilutions MAb 2F5 1 ngml reacted LELDKWAS peptide fused C terminus AP expressed affinity purified E
0.33479095.11602792.html.plaintext.txt	93	coli attached ELISA plates
0.33479095.11602792.html.plaintext.txt	94	The sera neither reacted AP scF control protein neutralized macrophage BAL T cell tropic IIIb HIV 1 laboratory strains vitro assays whereas MAb 2F5 directed epitope neutralizing data shown
0.33479095.11602792.html.plaintext.txt	95	It likely context chimeric VLP epitope present native conformation detected infectious HIV virions
0.33479095.11602792.html.plaintext.txt	96	Alternatively possible antibody concentration sera low score assay
0.33479095.11602792.html.plaintext.txt	97	This observation represents important extension previous results generating autoantibodies self antigen Chackerian et al
0.33479095.11602792.html.plaintext.txt	98	1999 supporting potential virus structure vaccine carrier Zinkernagel Hengartner 1997
0.33479095.11602792.html.plaintext.txt	99	Our results corroborate functional relevance crystal structure HPV 16 L1 assembled small T1 particles Chen et al
0.33479095.11602792.html.plaintext.txt	100	2000 demonstrating highly variable positions exposed pentamer surface tolerate insertion heterologous amino acids without losing salient structural characteristics L1
0.33479095.11602792.html.plaintext.txt	101	By L1 sequence comparison grafted epitope three distinct surface loops connect strands jelly roll L1 monomer
0.33479095.11602792.html.plaintext.txt	102	DE loop comprised HPV 16 aa 111 151 FG loop aa 257 298 HI loop aa 349 359 Fig
0.33479095.11602792.html.plaintext.txt	103	Insertion resulted either loss change function immunogenic capsid regions Figs 2 3 supporting role surface loops virion neutralization determinants
0.33479095.11602792.html.plaintext.txt	104	The identification neutralization immunogenic mutation permissive capsid regions may relevant HPV vaccine design allows rational approach insertion epitopes choice
0.33479095.11602792.html.plaintext.txt	105	The display foreign peptides context immunogenic self assembled L1 oligomer induce vigorous humoral immune response may thus become general procedure overcome low immunogenicity free peptide antigens
0.33479095.11602792.html.plaintext.txt	106	This may become attractive strategy generate cross protective vaccine multiple HPV types e
0.33479095.11602792.html.plaintext.txt	107	sexually transmitted diseases
0.33479095.11602792.html.plaintext.txt	108	Acknowledgments We thank Doug Lowy John Schiller Thomas Muster critical reading manuscript
0.33479095.11602792.html.plaintext.txt	109	This work supported grants R
0.33479095.11602792.html.plaintext.txt	110	Austrian Science Foundation FWF P13365 MED Austrian National Bank Jubilaumsfonds
0.33479095.11602792.html.plaintext.txt	111	7688 Kommission Onkologie University Vienna Medical School
0.33479095.11602792.html.plaintext.txt	112	Footnotes b Present address Laboratory Cellular Oncology National Cancer Institute Bldg 37Room 1D 28 20892 4040 Bethesda Maryland USA
0.33479095.11602792.html.plaintext.txt	113	References Top Abstract Main text References Baker T
0.33479095.11602792.html.plaintext.txt	114	Structures bovine human papillomaviruses
0.33479095.11602792.html.plaintext.txt	115	Analysis cryoelectron microscopy three dimensional image reconstruction
0.33479095.11602792.html.plaintext.txt	116	Biophysical Journal 60 1445 1456
0.33479095.11602792.html.plaintext.txt	117	A formalin inactivated vaccine protects mucosal papillomavirus infection canine model
0.33479095.11602792.html.plaintext.txt	118	Immunization viruslike particles cottontail rabbit papillomavirus CRPV protect experimental CRPV infection
0.33479095.11602792.html.plaintext.txt	119	Journal Virology 69 3959 3963
0.33479095.11602792.html.plaintext.txt	120	Induction autoantibodies mouse CCR5 recombinant papillomavirus particles
0.33479095.11602792.html.plaintext.txt	121	Proceedings National Academy Sciences USA 96 2373 2378
0.33479095.11602792.html.plaintext.txt	122	Structure small virus like particles assembled L1 protein human papillomavirus 16
0.33479095.11602792.html.plaintext.txt	123	Immunization viruslike particles induces long term protection rabbits challenge cottontail rabbit papillomavirus
0.33479095.11602792.html.plaintext.txt	124	Journal Virology 70 960 965
0.33479095.11602792.html.plaintext.txt	125	The papillomavirus minor capsid protein L2 induces localization major capsid protein L1 viral transcriptionreplication protein E2 PML oncogenic domains
0.33479095.11602792.html.plaintext.txt	126	Journal Virology 72 142 150
0.33479095.11602792.html.plaintext.txt	127	Focus assay mouse cells bovine papillomavirus
0.33479095.11602792.html.plaintext.txt	128	Role human papillomaviruses human cancer
0.33479095.11602792.html.plaintext.txt	129	pDAP2 vector construction alkaline phosphatase fusion proteins
0.33479095.11602792.html.plaintext.txt	130	Papillomavirus like particles serology vaccine development
0.33479095.11602792.html.plaintext.txt	131	Papillomavirus L1 major capsid protein self assembles virus like particles highly immunogenic
0.33479095.11602792.html.plaintext.txt	132	Proceedings National Academy Sciences USA 89 12180 12184
0.33479095.11602792.html.plaintext.txt	133	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.33479095.11602792.html.plaintext.txt	134	Journal Virology 67 6929 6936
0.33479095.11602792.html.plaintext.txt	135	Virus like particles bovine papillomavirus type 4 prophylactic therapeutic immunization
0.33479095.11602792.html.plaintext.txt	136	Laboratory production vivo infectious human papillomavirus type 11
0.33479095.11602792.html.plaintext.txt	137	Journal Virology 61 590 593
0.33479095.11602792.html.plaintext.txt	138	Genital human papillomavirus infection
0.33479095.11602792.html.plaintext.txt	139	Proceedings National Academy Sciences USA 91 2436 2440
0.33479095.11602792.html.plaintext.txt	140	Two amino acid residues confer type specificity neutralizing conformationally dependent epitope human papillomavirus type 11
0.33479095.11602792.html.plaintext.txt	141	Journal Virology 70 4791 4794
0.33479095.11602792.html.plaintext.txt	142	A neutralizing epitope human papillomavirus type 11 principally described continuous set residues overlap distinct linear surface exposed epitope
0.33479095.11602792.html.plaintext.txt	143	Journal Virology 71 3834 3839
0.33479095.11602792.html.plaintext.txt	144	HPV11 mutant virus like particles elicit immune responses neutralize virus delineate novel neutralizing domain
0.33479095.11602792.html.plaintext.txt	145	Quantitative disassembly reassembly human papillomavirus type 11 viruslike particles vitro
0.33479095.11602792.html.plaintext.txt	146	Synthesis infectious human papillomavirus type 18 differentiating epithelium transfected viral DNA
0.33479095.11602792.html.plaintext.txt	147	Journal Virology 71 7381 7386
0.33479095.11602792.html.plaintext.txt	148	Cross neutralizing activity divergent human immunodeficiency virus type 1 isolates induced gp41 sequence ELDKWAS
0.33479095.11602792.html.plaintext.txt	149	Journal Virology 68 4031 4034
0.33479095.11602792.html.plaintext.txt	150	Genetic applications inverse polymerase chain reaction
0.33479095.11602792.html.plaintext.txt	151	In vitro generation type specific neutralization human papillomavirus type 16 virion pseudotype
0.33479095.11602792.html.plaintext.txt	152	Journal Virology 70 5875 5883
0.33479095.11602792.html.plaintext.txt	153	Assessment serological relatedness genital human papillomaviruses hemagglutination inhibition
0.33479095.11602792.html.plaintext.txt	154	Journal Virology 70 3298 3301
0.33479095.11602792.html.plaintext.txt	155	Characterization human papillomavirus type 16 variant dependent neutralizing epitope
0.33479095.11602792.html.plaintext.txt	156	Journal Virology 71 6247 6252
0.33479095.11602792.html.plaintext.txt	157	Human papillomavirus type 11 recombinant L1 capsomeres induce virus neutralizing antibodies
0.33479095.11602792.html.plaintext.txt	158	Journal Virology 72 6151 6154
0.33479095.11602792.html.plaintext.txt	159	Papillomavirus vaccines current status future prospects
0.33479095.11602792.html.plaintext.txt	160	Advances Dermatology 11 355 380
0.33479095.11602792.html.plaintext.txt	161	Systemic immunization papillomavirus L1 protein completely prevents development viral mucosal papillomas
0.33479095.11602792.html.plaintext.txt	162	Proceedings National Academy Sciences USA 92 11553 11557
0.33479095.11602792.html.plaintext.txt	163	Novel structural features bovine papillomavirus capsid revealed three dimensional reconstruction 9 resolution
0.33479095.11602792.html.plaintext.txt	164	Nature Structural Biology 4 413 420
0.33479095.11602792.html.plaintext.txt	165	In vitro infection type restricted antibody mediated neutralization authentic human papillomavirus type 16
0.33479095.11602792.html.plaintext.txt	166	Journal Virology 72 959 964
0.33479095.11602792.html.plaintext.txt	167	Human papillomaviruses pathogenesis anogenital cancer
0.33479095.11602792.html.plaintext.txt	168	Molecular pathogenesis cancer cervix causation specific human papillomavirus types
0.33479095.11602792.html.plaintext.txt	169	Current Topics Microbiology Immunology 186 131 156
0.33479095.11602792.html.plaintext.txt	170	Received 4 June 2001 accepted 31 July 2001
0.53923285.15604432.html.plaintext.txt	0	Heparin based ELISA reduces background reactivity virus like particle based papillomavirus serology Xiaohong Wang1 Martin Sapp2 Neil D
0.53923285.15604432.html.plaintext.txt	1	Christensen3 Joakim Dillner1
0.53923285.15604432.html.plaintext.txt	2	1 Department Medical Microbiology University Hospital 20502 Malmo Sweden 2 Institute Medical Microbiology Hygiene University Mainz 55101 Mainz Germany 3 Department Microbiology Immunology The Milton S
0.53923285.15604432.html.plaintext.txt	3	Hershey Center 500 University Drive Hershey PA 17033 USA
0.53923285.15604432.html.plaintext.txt	4	Correspondence Joakim Dillner joakim
0.53923285.15604432.html.plaintext.txt	5	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES The interaction human papillomavirus HPV particles cell surface heparan sulfate requires intact conformation HPV particles
0.53923285.15604432.html.plaintext.txt	6	Type specific HPV serology currently based virus like particles VLPs intact conformation
0.53923285.15604432.html.plaintext.txt	7	Presence incorrectly folded VLPs VLP preparations recognized important cause cross reactivity HPV serology
0.53923285.15604432.html.plaintext.txt	8	Heparin coated microtitre plates evaluated capturing conformationally correct VLPs improving type specificity HPV serology
0.53923285.15604432.html.plaintext.txt	9	Hybrid VLPs HPV16 HPV11 found significant reactivity childrens sera batch HPV18 VLPs failed quality control significant reactivity sera virginal women tested parallel heparin ELISA ordinary ELISA type specific mAb capture ELISA
0.53923285.15604432.html.plaintext.txt	10	Control sera children detectable reactivity HPV1611 hybrid VLPs ordinary ELISA react heparin based ELISA hybrid VLPs also background reactivity capture ELISAs
0.53923285.15604432.html.plaintext.txt	11	Control sera virginal women reactivity poor quality HPV18 VLP preparation ordinary ELISA reactivity heparin capture ELISA suggesting certain VLP preparations expose cross reactive epitopes exposed VLPs heparin binding ability
0.53923285.15604432.html.plaintext.txt	12	As sensitivity similar marginally affected use heparin plates use heparin coated plates may improve type specificity VLP based ELISAs reduce interassay variability attributable variable quality different VLP batches
0.53923285.15604432.html.plaintext.txt	13	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Genital human papillomavirus HPV infections common viral sexually transmitted diseases worldwide found central aetiological risk factor cervical cancer Schiffman et al
0.53923285.15604432.html.plaintext.txt	14	The major capsid protein L1 HPV self assemble virus like particles VLPs morphologically immunologically similar native virions Kirnbauer et al
0.53923285.15604432.html.plaintext.txt	15	VLPs useful tools evaluate humoral responses HPV investigate early events infectivity cell binding internalization Galloway McDougall 1996 Muller et al
0.53923285.15604432.html.plaintext.txt	16	1995 used successfully vaccinate humans HPV infection Koutsky et al
0.53923285.15604432.html.plaintext.txt	17	Studies using papillomavirus neutralizing monoclonal antibodies N mAbs demonstrated predominant neutralizing epitopes type specific surface conformational epitopes intact virions VLPs Christensen et al
0.53923285.15604432.html.plaintext.txt	18	There need define quality control methods HPV serology vaccinology detect virus like particle VLP batches produced intact conformation appropriate exposure type specific neutralizing epitopes minimal exposure broadly cross reactive non neutralizing epitopes
0.53923285.15604432.html.plaintext.txt	19	As HPVs grow efficiently cell culture systems using HPV VLPs used study viral infectivity Roden et al
0.53923285.15604432.html.plaintext.txt	20	Cell surface heparan sulfates essential infection HPV16 HPV33 pseudovirions Giroglou et al
0.53923285.15604432.html.plaintext.txt	21	2001 well HPV11 virions Shafti Keramat et al
0.53923285.15604432.html.plaintext.txt	22	2003 binding uptake VLPs various HPV types Combita et al
0.53923285.15604432.html.plaintext.txt	23	1999 Selinka Sapp 2003
0.53923285.15604432.html.plaintext.txt	24	Heparin highly sulfated form heparan sulfate proteoglycan secreted mast cells interferes pseudoinfection shown efficiently bind VLPs Giroglou et al
0.53923285.15604432.html.plaintext.txt	25	The interaction heparin requires intact conformation VLPs Giroglou et al
0.53923285.15604432.html.plaintext.txt	26	VLP based serology widespread importance studies HPV epidemiology vaccinology
0.53923285.15604432.html.plaintext.txt	27	VLP ELISAs successfully used epidemiological studies HPV infections different populations Dillner 1999
0.53923285.15604432.html.plaintext.txt	28	However incorrectly folded VLPs expose cross reactive epitopes may compromise type specificity VLP based HPV serological assays Wang et al
0.53923285.15604432.html.plaintext.txt	29	1997a problem recently highlighted study HPV1611 hybrid VLPs Wang et al
0.53923285.15604432.html.plaintext.txt	30	An alternative method avoid background caused incorrectly folded VLPs use type specific mAbs conformational epitopes catching antibodies ELISAs Carter et al
0.53923285.15604432.html.plaintext.txt	31	However previously found adequate isotype specificity ELISAs improved using mAbs specific different human Ig isotypes Heino et al
0.53923285.15604432.html.plaintext.txt	32	Also two step detection bound antibodies mouse mAb anti mouse reagent important sensitivity Heino et al
0.53923285.15604432.html.plaintext.txt	33	Two step methods cannot used ELISA plates coated mouse mAbs
0.53923285.15604432.html.plaintext.txt	34	Finally type specific mAbs HPV available limited number HPV types
0.53923285.15604432.html.plaintext.txt	35	In present study evaluated whether heparin coated plates could used improve performance VLP serology
0.53923285.15604432.html.plaintext.txt	36	HPV1611 hybrid VLPs significant reactivity childrens sera batch HPV18 VLPs failed quality control significant reactivity sera virginal women tested parallel heparin based ELISA direct ELISA type specific mAb capture ELISA using positive negative control validation panels serum samples
0.53923285.15604432.html.plaintext.txt	37	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Preparation heparinBSA coated plates
0.53923285.15604432.html.plaintext.txt	38	HeparinBSA coated plates prepared coating microtitre plates Polysorb Nunc heparinBSA 1 microg ml 1 PBS 100 ng per well Sigma overnight room temperature
0.53923285.15604432.html.plaintext.txt	39	Plates subsequently washed three times 150 microl PBS0 1 Tween 20 PBS T
0.53923285.15604432.html.plaintext.txt	40	Free binding sites blocked 150 microl BSA 100 microg ml 1 PBS T 3 h room temperature
0.53923285.15604432.html.plaintext.txt	41	Plates washed three times PBS T distilled water subsequently dried vacuum
0.53923285.15604432.html.plaintext.txt	42	Plates individually sealed plastic plate sealing tape stored 4 degrees C
0.53923285.15604432.html.plaintext.txt	43	Reactivity plates change monitored time span 18 months
0.53923285.15604432.html.plaintext.txt	44	Serum samples HPV16HPV11 HPV16 HPV11 selected three previous serological studies
0.53923285.15604432.html.plaintext.txt	45	Study 1 investigated attack rates seroprevalences human papillomavirus types 11 16 33 among high risk population cervical cancer Shanxi province China
0.53923285.15604432.html.plaintext.txt	46	In total 1196 high school studentsteachers 570 men 626 women mean age 16 years range 14 35 years 170 couples mean age 24 years range 20 35 years attending mandatory serological screening marriage donated serum samples enrolment 12 months later
0.53923285.15604432.html.plaintext.txt	47	Study 2 investigated human papillomavirus antibody response among 216 women mean age 53 years range 23 88 years untreated primary invasive cervical cancer admitted Karolinska Hospital Stockholm Sweden
0.53923285.15604432.html.plaintext.txt	48	Study 2 also contained 243 age sex matched healthy control women Wang et al
0.53923285.15604432.html.plaintext.txt	49	Study 3 investigated sexual behaviour risk HPV infection 188 serum samples 94 teenage girls mean age 16 1 years donated enrolment follow 2 years later
0.53923285.15604432.html.plaintext.txt	50	Forty five samples virgins whereas samples sexually experienced girls
0.53923285.15604432.html.plaintext.txt	51	None virgin girls HPV DNA cervix PCR serum antibodies HPV16 HPV33 Andersson Ellstrom et al
0.53923285.15604432.html.plaintext.txt	52	HPV16HPV11 HPV16 HPV11 samples studies re tested HPV16 HPV11 parallel hybrid VLPs
0.53923285.15604432.html.plaintext.txt	53	Besides childrens serum samples selected study surveyed seroprevalence human papillomavirus types 16 18 33 among 1031 children 13 years age whose serum samples submitted serological analyses non HPV related diseases obtained Department Clinical Virology Karolinska Hospital Department Pediatrics Huddinge Hospital Stockholm Sweden af Geijersstam et al
0.53923285.15604432.html.plaintext.txt	54	Serum samples children age group 2 10 years found HPV16 seronegative also tested HPV11 re tested HPV16 parallel hybrid VLPs ensure HPV16 HPV11 seronegative
0.53923285.15604432.html.plaintext.txt	55	In total 32 HPV16HPV11 serum samples 64 HPV16 HPV11 serum samples 23 HPV16 HPV11 serum samples included study
0.53923285.15604432.html.plaintext.txt	56	In case HPV18 serum samples 13 women tested HPV18 DNA PCR cervical samples seven serum samples HPV18 DNA virginal women analysed
0.53923285.15604432.html.plaintext.txt	57	In heparin based ELISA intact HPV16 HPV11 capsids hybrid VLPs H11 16172 505 contains N terminal part HPV11 C terminal part HPV16 H11 16FGHI two non contiguous hypervariable regions HPV16 L1 containing FG HI loops transplanted HPV11 L1 backbone H16 11171 505 contains N terminal part HPV16 C terminal part HPV11 coated onto heparin BSA microtitre plates PBS pH 7 2
0.53923285.15604432.html.plaintext.txt	58	The coating concentrations VLPs normalized described Wang et al
0.53923285.15604432.html.plaintext.txt	59	The low quality HPV18 batch coated 1 microg ml 1
0.53923285.15604432.html.plaintext.txt	60	For generation disrupted VLPs three different disruption methods used alkali treatment VLPs incubated 4 h room temperature 0 1 M carbonate buffer pH 9 6 ii alkali reducing agent treatment VLPs incubated 30 min room temperature 0 2 M Na2CO3 pH 10 6 0 01 M DTT iii boiling alkali reducing agent treatment VLPs heated 15 min 96 degrees C 0 2 M Na2CO3 pH 10 6 0 01 M DTT
0.53923285.15604432.html.plaintext.txt	61	Disrupted bovine papillomavirus BPV capsids used negative control assays
0.53923285.15604432.html.plaintext.txt	62	After 1 h 37 degrees C plates washed three times 150 microl PBS T blocked adding 150 microl 10 horse serum PBS HS PBS 37 degrees C 15 min
0.53923285.15604432.html.plaintext.txt	63	Serum samples added duplicate 1 30 dilution HS PBS 1 h reaction 37 degrees C
0.53923285.15604432.html.plaintext.txt	64	Six wells plate incubated 10 HS PBS
0.53923285.15604432.html.plaintext.txt	65	Following three washes PBS T mAb human IgG 1 800 diluted 10 HS PBS added
0.53923285.15604432.html.plaintext.txt	66	The mAb positive controls V5 1 1 000 000 dilution H11
0.53923285.15604432.html.plaintext.txt	67	F1 1 100 000 dilution H11
0.53923285.15604432.html.plaintext.txt	68	H3 1 10 000 dilution added wells incubated HS PBS
0.53923285.15604432.html.plaintext.txt	69	The plates incubated 45 min 37 degrees C
0.53923285.15604432.html.plaintext.txt	70	After washing three times goat anti mouse IgG HRP conjugate 1 2000 diluted HS PBS added 30 min 37 degrees C followed addition substrate
0.53923285.15604432.html.plaintext.txt	71	The absorbance serum disrupted BPV VLPs subtracted HPV VLP reactivity mean value duplicates calculated
0.53923285.15604432.html.plaintext.txt	72	For estimation antibody levels units serum samples tested duplicate three different dilutions 1 10 1 31 6 1 100 mAb human IgG 1 500 diluted 10 HS PBS added plates read 60 min
0.53923285.15604432.html.plaintext.txt	73	The absorbance serum disrupted BPV subtracted VLP reactivity mean value duplicates calculated OD values transformed ELISA units using PLL parallel line method Grabowska et al
0.53923285.15604432.html.plaintext.txt	74	For capture ELISAs HPV16 mAb V5 diluted 1 1000 cold PBS pH 7 2 HPV18 N mAb R5 diluted 1 2000 coated onto microtitre plates overnight
0.53923285.15604432.html.plaintext.txt	75	After plates washed PBS T blocked 10 HS PBS 1 h room temperature VLPs added 2 h room temperature
0.53923285.15604432.html.plaintext.txt	76	Following five thorough washings plates serum samples added either duplicate 1 30 dilution duplicate 1 10 1 31 6 1 100 dilutions 2 h room temperature
0.53923285.15604432.html.plaintext.txt	77	A rabbit anti human IgG HRP conjugate DAKO diluted 1 1000 HS PBS normal mouse serum 25 microl ml 1 rotated end end 4 h
0.53923285.15604432.html.plaintext.txt	78	In washing plates conjugate added plates incubated 1 h room temperature followed addition substrate
0.53923285.15604432.html.plaintext.txt	79	Plates handled identically except VLPs added used background
0.53923285.15604432.html.plaintext.txt	80	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Reactivity intact disrupted hybrid VLPs direct heparin based ELISAs Intact alkali disrupted VLPs HPV16 HPV11 well three hybrid VLPs two viruses tested reactivity mAbs V5 HPV16 neutralizing type specific conformation dependent F1 H3 HPV11 neutralizing type specific conformation dependent recognize different epitopes H16
0.53923285.15604432.html.plaintext.txt	81	D9 cross reactive non conformational non neutralizing exposed disrupted incorrectly folded VLPs H16
0.53923285.15604432.html.plaintext.txt	82	B20 strongly reactive intact disrupted HPV16 non neutralizing direct heparin based ELISAs Table 1
0.53923285.15604432.html.plaintext.txt	83	Reactivity mAbs direct heparin based ELISAs
0.53923285.15604432.html.plaintext.txt	84	Hybrid VLP H11 16172 505 contains N terminal part HPV11 C terminal part HPV16 hybrid VLP H16 11171 505 contains N terminal part HPV16 C terminal part HPV11 hybrid VLP H11 16FGHI contains two non contiguous hypervariable regions HPV16 L1 containing FG HI loops transplanted HPV11 L1 backbone
0.53923285.15604432.html.plaintext.txt	85	DE Direct ELISA HE heparin based ELISA
0.53923285.15604432.html.plaintext.txt	86	The type specific N mAbs reacted similarly intact hybrid VLPs heparin based direct ELISAs although reactivity usually somewhat lower heparin based ELISA
0.53923285.15604432.html.plaintext.txt	87	D9 intact VLPs also similar heparin based direct ELISAs
0.53923285.15604432.html.plaintext.txt	88	In contrast reactivity H16
0.53923285.15604432.html.plaintext.txt	89	D9 disrupted virus eliminated strongly reduced heparin coated plates
0.53923285.15604432.html.plaintext.txt	90	Indeed none mAbs reacted disrupted virus direct ELISAs reactive disrupted viruses heparin plates used exception reactivity disrupted H11 16FGHI hybrid virus H16
0.53923285.15604432.html.plaintext.txt	91	D9 reactivity heparin based ELISA suggested intact VLP might present alkali disrupted H11 16FGHI hybrid VLPs
0.53923285.15604432.html.plaintext.txt	92	Therefore also examined harsh methods disruption VLPs alkali treatment reducing agent treatment boiling alkali reducing agent treatment
0.53923285.15604432.html.plaintext.txt	93	With harsh method boilalkalireducing agent antigenic reactivity detectable heparin coated plates although antigenic reactivity similarly disrupted VLPs readily detectable ordinary ELISA plates Table 1
0.53923285.15604432.html.plaintext.txt	94	Reactivity HPV1611 hybrid VLPs human serum samples heparin based capture ELISAs Thirty two HPV16HPV11 serum samples 64 HPV16 HPV11 serum samples 23 HPV16 HPV11 childrens serum samples tested heparin based ELISA comparison direct ELISA reactivity HPV16 HPV11 VLPs three hybrid VLPs
0.53923285.15604432.html.plaintext.txt	95	Similar experiments direct ELISAs published previously Wang et al
0.53923285.15604432.html.plaintext.txt	96	The antibody responses among HPV16 HPV11 human sera hybrid VLPs rather similar heparin based direct ELISAs Table 2
0.53923285.15604432.html.plaintext.txt	97	The HPV11 HPV16 sera similar reactivity HPV11 hybrids contained HPV11 C terminus H11 16FGHI H16 11171 505 Fig
0.53923285.15604432.html.plaintext.txt	98	There minor differences correlation depending whether heparin based direct ELISAs used
0.53923285.15604432.html.plaintext.txt	99	For example H11 16FGHI versus HPV11 correlation coefficient direct ELISA 0 58 Wang et al
0.53923285.15604432.html.plaintext.txt	100	2003 heparin based ELISA 0 68
0.53923285.15604432.html.plaintext.txt	101	The correlation coefficient hybrid H16 11171 505 HPV11 0 71 direct ELISA Wang et al
0.53923285.15604432.html.plaintext.txt	102	2003 0 63 heparin based ELISA Fig
0.53923285.15604432.html.plaintext.txt	103	Comparison reactivity mean ELISA absorbance value HPV1611 hybrid VLPs human serum samples direct heparin based ELISA
0.53923285.15604432.html.plaintext.txt	104	The HPV16 HPV11 HPV1611 hybrid VLPs tested direct heparin based ELISA reactivity 32 HPV16HPV11 human serum samples 64 HPV16 HPV11 human serum samples 23 HPV16 HPV11 control serum samples children
0.53923285.15604432.html.plaintext.txt	105	The table shows mean ELISA absorbance values standard deviations parentheses serum sample group
0.53923285.15604432.html.plaintext.txt	106	View larger version 11K Fig
0.53923285.15604432.html.plaintext.txt	107	Reactivity HPV1611 hybrid VLPs HPV16 HPV11 human serum samples heparin based ELISAs
0.53923285.15604432.html.plaintext.txt	108	Hybrid VLP H11 16FGHI versus HPV11
0.53923285.15604432.html.plaintext.txt	109	b Hybrid VLP H16 11171 505 versus HPV11
0.53923285.15604432.html.plaintext.txt	110	c Hybrid VLPs H11 16FGHI versus H16 11171 505
0.53923285.15604432.html.plaintext.txt	111	dOD Difference OD plates coated specific antigen plates coated control antigen
0.53923285.15604432.html.plaintext.txt	112	In previous studies Wang et al
0.53923285.15604432.html.plaintext.txt	113	2003 found remarkable difference level antibody reactivity three hybrid VLPs among HPV16 HPV11 human sera H11 16FGHI giving average almost three times higher reactivity HPV11 although similar amounts VLPs titrated optimal concentrations VLP antigen used ELISA assay
0.53923285.15604432.html.plaintext.txt	114	We suggested increased reactivity would due subtle differences surface exposure conformationally constrained epitopes hybrid VLPs
0.53923285.15604432.html.plaintext.txt	115	It therefore interest study whether increased reactivity would also present heparin based ELISAs used
0.53923285.15604432.html.plaintext.txt	116	The antibody responses among HPV16 HPV11 sera hybrid VLPs quite similar heparin based direct ELISAs H11 16FGHI mean OD value 1 48 direct ELISA 1 41 heparin based ELISA
0.53923285.15604432.html.plaintext.txt	117	Hybrid H11 16FGHI still gave two times higher reactivity HPV11 VLP Table 2
0.53923285.15604432.html.plaintext.txt	118	The level antibody responses among HPV16HPV11 sera three hybrid VLPs remarkably decreased correlation reactivity HPV16HPV11 human sera HPV16 compared reactivity three hybrids HPV16 lower heparin based ELISA direct ELISA Table 2
0.53923285.15604432.html.plaintext.txt	119	For example H11 16172 505 versus HPV16 correlation coefficient direct ELISA 0 78 Wang et al
0.53923285.15604432.html.plaintext.txt	120	2003 heparin based ELISA 0 60 Fig
0.53923285.15604432.html.plaintext.txt	121	View larger version 13K Fig
0.53923285.15604432.html.plaintext.txt	122	Reactivity HPV1611 hybrid VLP H11 16172 505 versus HPV16 HPV11 HPV16 human serum samples heparin based ELISA
0.53923285.15604432.html.plaintext.txt	123	dOD Difference OD plates coated specific antigen plates coated control antigen
0.53923285.15604432.html.plaintext.txt	124	Interestingly HPV16 HPV11 control sera children detectable reactivity hybrid VLPs direct ELISAs longer positive heparin based ELISA Tables 2 3
0.53923285.15604432.html.plaintext.txt	125	All childrens sera OD values 0 1 heparin based ELISA
0.53923285.15604432.html.plaintext.txt	126	The 1123 childrens samples highest reactivity direct ELISA also tested reactivity hybrid VLPs H11 16172 505 H11 16FGHI containing V5 epitope capture ELISA using V5 mAb capture
0.53923285.15604432.html.plaintext.txt	127	The childrens reactivities capture ELISA quite similar ordinary ELISA Table 3
0.53923285.15604432.html.plaintext.txt	128	Eleven childrens samples high reactivity direct ELISA tested parallel heparin based ELISA V5 catching antibody ELISA
0.53923285.15604432.html.plaintext.txt	129	Reactivity low quality HPV18 VLPs heparin based direct capture ELISAs Production high quality conformationally correct VLPs particularly difficult HPV18 result many batches HPV18 VLPs fail quality control cannot used serology
0.53923285.15604432.html.plaintext.txt	130	Because improved specificity heparin based ELISA also evaluated reactivity batch HPV18 VLPs previously failed quality control testing measurable reactivity serum samples unexposed women
0.53923285.15604432.html.plaintext.txt	131	In direct ELISAs one negative control sample virginal woman strong reactivity HPV18 batch samples negative control panel also detectable reactivity direct ELISA Table 4
0.53923285.15604432.html.plaintext.txt	132	When HPV18 VLP batch tested mAbs expected strong type specific reactivity HPV18 N mAb R5 detected Table 5
0.53923285.15604432.html.plaintext.txt	133	However weak reactivities H16
0.53923285.15604432.html.plaintext.txt	134	H3 type specific HPV16 11 also detectable Table 5
0.53923285.15604432.html.plaintext.txt	135	However reactivity detectable negative control sera mAbs HPV types tested VLPs coated onto heparin binding plates Tables 4 5
0.53923285.15604432.html.plaintext.txt	136	Thirteen serum samples HPV18 DNA women seven samples HPV18 DNA virginal women also tested reactivity low quality HPV18 VLP capture ELISA using HPV18 type specific mAb R5 capture molecule
0.53923285.15604432.html.plaintext.txt	137	The reactivities quite similar heparin based ELISA Table 4
0.53923285.15604432.html.plaintext.txt	138	Both methods lower background serum samples unexposed women essentially similar reactivity samples infected women Table 4
0.53923285.15604432.html.plaintext.txt	139	Levels antibodies low quality HPV18 VLP batch direct ELISA heparin based ELISA catching antibody ELISA
0.53923285.15604432.html.plaintext.txt	140	Serum samples 13 women tested HPV18 DNA PCR cervical samples seven serum samples HPV18 DNA virginal women tested direct ELISA heparin based ELISA R5 catching ELISA low quality HPV18 VLP batch
0.53923285.15604432.html.plaintext.txt	141	Antibody levels expressed ELISA units relative reference standard serum
0.53923285.15604432.html.plaintext.txt	142	Cut positivity 0 54 ELISA units assays positive sera marked bold
0.53923285.15604432.html.plaintext.txt	143	Reactivity intact disrupted low quality HPV18 VLPs mAbs
0.53923285.15604432.html.plaintext.txt	144	DE Direct ELISA HE heparin based ELISA
0.53923285.15604432.html.plaintext.txt	145	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES In present study found HPV16 HPV11 control serum samples children serological reactivity HPV1611 hybrid VLPs direct ELISAs longer reactive VLPs heparin based ELISA suggesting non type specific serological reactivity certain VLP preparations may due exposure cross reactive epitopes exposed intact heparin binding VLPs
0.53923285.15604432.html.plaintext.txt	146	Also reactivity serum samples virginal women low quality HPV18 VLPs direct ELISA detectable VLPs coated onto heparin binding plates implying use heparin coated plates may improve HPV type specificity VLP based ELISAs reduce interassay variability attributable variable quality VLP batches
0.53923285.15604432.html.plaintext.txt	147	The HPV11HPV16 human sera similar reactivity HPV11 HPV1611 VLP hybrids contained HPV11 C terminus H11 16FGHI H16 11171 505 heparin based direct ELISAs suggesting major human serum reactive HPV11 epitopes present VLPs VLPs containing epitope heparin binding
0.53923285.15604432.html.plaintext.txt	148	In contrast data HPV16 much less clear
0.53923285.15604432.html.plaintext.txt	149	The reactivities much lower heparin based ELISAs showed lower correlations reactivities parent virus heparin based ELISAs used
0.53923285.15604432.html.plaintext.txt	150	The hybrid virus H11 16FGHI unique adequate disruption appeared require exceptionally harsh disruption methods
0.53923285.15604432.html.plaintext.txt	151	Also VLP one results heparin based capture ELISAs distinctly different
0.53923285.15604432.html.plaintext.txt	152	Capture ELISAs improve background reactivity childrens sera whereas heparin ELISA
0.53923285.15604432.html.plaintext.txt	153	Conceivably artificial addition V5 binding site HPV11 backbone may also resulted V5 epitope exposed incorrectly folded H11 16FGHI VLPs
0.53923285.15604432.html.plaintext.txt	154	Quality control ELISAs depends maintaining intact VLPs good quality quality assurance system
0.53923285.15604432.html.plaintext.txt	155	We found mAbs reacted disrupted virus direct ELISAs react disrupted viruses heparin coated plates used suggesting use heparin coated microtitre plates could add quality control component VLP based ELISAs preventing binding denatured L1 antigen contaminating protein
0.53923285.15604432.html.plaintext.txt	156	Numerous approaches towards decreasing non specific binding ELISA plates described notably use blocking vinyl polymers Studentsov et al
0.53923285.15604432.html.plaintext.txt	157	The approach heparin coated plates advantage specific biological property virus exploited increase specificity binding
0.53923285.15604432.html.plaintext.txt	158	VLPs HPV types tested far bind heparin similar efficiency Rommel et al
0.53923285.15604432.html.plaintext.txt	159	2004 suggesting heparin used universal capture molecule HPV serology
0.53923285.15604432.html.plaintext.txt	160	In summary heparin coated plates select subset VLPs intact heparin binding activity
0.53923285.15604432.html.plaintext.txt	161	At least HPVs intact heparin binding ability found correlated serological specificity allowing straightforward simple improvement performance HPV serology
0.53923285.15604432.html.plaintext.txt	162	ACKNOWLEDGEMENTS Supported Swedish Cancer Society
0.53923285.15604432.html.plaintext.txt	163	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES af Geijersstam V
0.53923285.15604432.html.plaintext.txt	164	A survey seroprevalence human papillomavirus types 16 18 33 among children
0.53923285.15604432.html.plaintext.txt	165	CO2 0linktypeDOI CrossRefMedline
0.53923285.15604432.html.plaintext.txt	166	Comparison development serum antibodies HPV16 HPV33 acquisition cervical HPV DNA among sexually experienced virginal young girls
0.53923285.15604432.html.plaintext.txt	167	Use HPV 1 capsids produced recombinant vaccinia viruses ELISA detect serum antibodies people foot warts
0.53923285.15604432.html.plaintext.txt	168	Monoclonal antibody mediated neutraliation infectious human papillomavirus type 11
0.53923285.15604432.html.plaintext.txt	169	Gene transfer using human papillomavirus pseudovirions varies according virus genotype requires cell surface heparan sulfate
0.53923285.15604432.html.plaintext.txt	170	FEMS Microbiol Lett 204 183 188
0.53923285.15604432.html.plaintext.txt	171	The serological response papillomaviruses
0.53923285.15604432.html.plaintext.txt	172	Semin Cancer Biol 9 423 430
0.53923285.15604432.html.plaintext.txt	173	Carboxy fluorescein diacetate succinimidyl ester labeled papillomavirus virus like particles fluoresce internalization interact heparan sulfate binding entry
0.53923285.15604432.html.plaintext.txt	174	The disruption cell cycle checkpoints papillomavirus oncoproteins contributes anogenital neoplasia
0.53923285.15604432.html.plaintext.txt	175	Semin Cancer Biol 7 309 315
0.53923285.15604432.html.plaintext.txt	176	Human papillomavirus infection requires cell surface heparan sulfate
0.53923285.15604432.html.plaintext.txt	177	Evaluation cost precision rations different strategies ELISA measurement serum antibody levels
0.53923285.15604432.html.plaintext.txt	178	J Immunol Methods 271 1 15
0.53923285.15604432.html.plaintext.txt	179	Association serum immunoglobulin G antibodies human papillomavirus type 16 capsids anal epidermoid carcinoma
0.53923285.15604432.html.plaintext.txt	180	J Natl Cancer Inst 87 437 440
0.53923285.15604432.html.plaintext.txt	181	The L1 major capsid protein human papillomavirus type 11 recombinant virus like particles interacts heparin cell surface glycosaminoglycans human keratinocytes
0.53923285.15604432.html.plaintext.txt	182	Papillomavirus L1 major capsid protein self assembles virus like particles highly immunogenic
0.53923285.15604432.html.plaintext.txt	183	Proc Natl Acad Sci U S A 89 12180 12184
0.53923285.15604432.html.plaintext.txt	184	A controlled trial human papillomavirus type 16 vaccine
0.53923285.15604432.html.plaintext.txt	185	N Engl J Med 347 1645 1651
0.53923285.15604432.html.plaintext.txt	186	Two amino acid residues confer type specificity neutralizing conformationally dependent epitope human papillomavirus type 11
0.53923285.15604432.html.plaintext.txt	187	Papillomavirus capsid binding uptake cells different tissues species
0.53923285.15604432.html.plaintext.txt	188	Interaction papillomaviruses cell surface
0.53923285.15604432.html.plaintext.txt	189	In vitro generation type specific neutralization human papillomavirus type 16 virion pseudotype
0.53923285.15604432.html.plaintext.txt	190	Characterization human papillomavirus type 16 variant dependent neutralizing epitope
0.53923285.15604432.html.plaintext.txt	191	Heparan sulfate proteoglycans interact exclusively conformationally intact HPVL1 assemblies basis virus like particle ELISA
0.53923285.15604432.html.plaintext.txt	192	Expression human papillomavirus type 11 L1 protein insect cells vivo vitro assembly virus like particles
0.53923285.15604432.html.plaintext.txt	193	Assembly human papillomavirus type 16 pseudovirions Saccharomyces cerevisiae
0.53923285.15604432.html.plaintext.txt	194	Hum Gene Ther 11 1165 1176
0.53923285.15604432.html.plaintext.txt	195	Epidemiologic evidence showing human papillomavirus infection causes cervical intraepithelial neoplasia
0.53923285.15604432.html.plaintext.txt	196	J Natl Cancer Inst 85 958 964
0.53923285.15604432.html.plaintext.txt	197	Papillomaviruscell interactions initiating infectious entry pathway
0.53923285.15604432.html.plaintext.txt	198	Papillomavirus Report 14 259 266
0.53923285.15604432.html.plaintext.txt	199	Different heparan sulfate proteoglycans serve cellular receptors human papillomaviruses
0.53923285.15604432.html.plaintext.txt	200	Infectious human papillomavirus type 18 pseudovirions
0.53923285.15604432.html.plaintext.txt	201	Enhanced enzyme linked immunosorbent assay detection antibodies virus like particles human papillomavirus
0.53923285.15604432.html.plaintext.txt	202	J Clin Microbiol 40 1755 1760
0.53923285.15604432.html.plaintext.txt	203	Generation neutralization pseudovirions human papillomavirus type 33
0.53923285.15604432.html.plaintext.txt	204	Binding internalization human papillomavirus type 33 virus like particles eukaryotic cells
0.53923285.15604432.html.plaintext.txt	205	Human papillomavirus necessary cause invasive cervical cancer worldwide
0.53923285.15604432.html.plaintext.txt	206	CO2 FlinktypeDOI CrossRefMedline
0.53923285.15604432.html.plaintext.txt	207	A monoclonal antibody intact human papillomavirus type 16 capsids blocks serological reactivity human sera
0.53923285.15604432.html.plaintext.txt	208	Human papillomavirus antibody responses among patients incident cervical carcinoma
0.53923285.15604432.html.plaintext.txt	209	Type specificity significance different isotypes serum antibodies human papillomavirus capsids
0.53923285.15604432.html.plaintext.txt	210	Mapping human serum reactive epitopes virus like particles human papillomavirus types 16 11
0.53923285.15604432.html.plaintext.txt	211	Received 26 July 2004 accepted 1 October 2004
0.14988111.12917469.html.plaintext.txt	0	Implication product bovine herpesvirus type 1 UL25 gene capsid assembly Nathalie Desloges Claire Simard
0.14988111.12917469.html.plaintext.txt	1	Institut National de la Recherche Scientifique Centre INRS Institut Armand Frappier 531 Bd des Prairies Laval Quebec Canada H7V 1B7
0.14988111.12917469.html.plaintext.txt	2	Correspondence Nathalie Desloges deslogesatuni wh
0.14988111.12917469.html.plaintext.txt	3	ABSTRACT Top ABSTRACT MAIN TEXT REFERENCES The UL25 ORF bovine herpesvirus type 1 BHV 1 demonstrated recently represent gene encoding 63 kDa viral protein
0.14988111.12917469.html.plaintext.txt	4	To investigate role gene virus replication BHV 1 UL25 deletion mutant constructed
0.14988111.12917469.html.plaintext.txt	5	Although UL25 mutant synthesizes late viral proteins viral DNA fails produce virus progeny cells express UL25 gene demonstrating UL25 protein essential replicative cycle BHV 1
0.14988111.12917469.html.plaintext.txt	6	Moreover Southern blotting analyses HindIII digested DNA infected non complementing cells probed leftward terminal fragment BHV 1 linear genome revealed cleavage viral DNA produced impaired
0.14988111.12917469.html.plaintext.txt	7	However packaging cleaved DNA compromised severely since full C capsids observed infected non complementing cells transmission electron microscopy
0.14988111.12917469.html.plaintext.txt	8	Present address University WittenHerdecke Institute Microbiology Virology Stockumer Str
0.14988111.12917469.html.plaintext.txt	9	MAIN TEXT Top ABSTRACT MAIN TEXT REFERENCES Similar herpes simplex virus type 1 HSV 1 bovine herpesvirus type 1 BHV 1 member subfamily Alphaherpesvirinae
0.14988111.12917469.html.plaintext.txt	10	Infection host cells two viruses similar beginning entry nucleocapsid cytoplasm translocation viral DNA nucleus
0.14988111.12917469.html.plaintext.txt	11	After expression viral proteins assembly release new virions occurs Roizman Sears 1996
0.14988111.12917469.html.plaintext.txt	12	During replication process cleavage packaging viral DNA tightly linked functions least requiring following seven genes HSV 1 UL6 UL15 UL17 UL25 UL28 UL32 UL33 Poon Roizman 1993 Taus et al
0.14988111.12917469.html.plaintext.txt	13	1990 Lamberti Weller 1996 1998 al Kobaisi et al
0.14988111.12917469.html.plaintext.txt	14	Viruses mutated one genes synthesize near wild type levels viral DNA fail cleave package concatemeric DNA capsids resulting accumulation B intermediate capsids infected cells exception UL25 mutant shown cleave newly synthesized viral DNA McNab et al
0.14988111.12917469.html.plaintext.txt	15	Moreover contrast latter study packaging matur DNA observed Stow 2001 reported significant amount DNA synthesized UL25 mutant packaged stably capsids
0.14988111.12917469.html.plaintext.txt	16	To propagate BHV 1 deletion mutant potentially lethal mutation UL25 gene study function gene necessary develop complementing cell line expressing UL25 protein trans
0.14988111.12917469.html.plaintext.txt	17	For purpose RK13 cells rabbit kidney cells ATCC CCL 377 stably transfected 2 microg ScaI linearized pRetroTET OFFUL25 encoding complete UL25 ORF control tetracycline regulated promoter Fig
0.14988111.12917469.html.plaintext.txt	18	A selected cell line grown absence doxycycline tetracycline derivative compound Gossen et al
0.14988111.12917469.html.plaintext.txt	19	1995 expressed 63 kDa protein reacted specifically UL25 antiserum results shown Desloges et al
0.14988111.12917469.html.plaintext.txt	20	This polypeptide represents full length product UL25 since size correlated protein observed BHV 1 infected cells Desloges et al
0.14988111.12917469.html.plaintext.txt	21	This cell line named RK13UL25 used subsequently complementing host cell construction UL25 deletion mutant
0.14988111.12917469.html.plaintext.txt	22	View larger version 33K Fig
0.14988111.12917469.html.plaintext.txt	23	The linear genome BHV 1 represented top unique long segment UL unique short segment US latter flanked internal external inverted repeats IR TR respectively
0.14988111.12917469.html.plaintext.txt	24	The HindIII restriction map two possible isomers shown
0.14988111.12917469.html.plaintext.txt	25	The UL25 ORF located within fragment A positions 6060262398 leftward orientation
0.14988111.12917469.html.plaintext.txt	26	The 4299 bp ApaI BamHI fragment representing region 58917 63216 viral genome shown expanded view subcloned pKSAhd carrying HindIII fragment A Simard et al
0.14988111.12917469.html.plaintext.txt	27	1990 generate pKSBHV58 63kApa Bam
0.14988111.12917469.html.plaintext.txt	28	This recombinant plasmid used illustrated create recombinant eukaryotic expression vector pRetroTET OFFUL25 development cell line inducibly expressing UL25
0.14988111.12917469.html.plaintext.txt	29	The strategy used generate recombinant pKS58 63kUL25 gal plasmid used create BHV 1UL25 shown right
0.14988111.12917469.html.plaintext.txt	30	The Gal gene cassette flanked promoter gene encoding BHV 1 gB glycoprotein pgB consensus polyadenylation signal pA
0.14988111.12917469.html.plaintext.txt	31	The illustrations vertical arrows drawn scale
0.14988111.12917469.html.plaintext.txt	32	The UL25 encoding sequence located positions 6239860602 BHV 1 genome
0.14988111.12917469.html.plaintext.txt	33	To genetically engineer BHV 1 UL25 deletion mutant constructed plasmid pKS58 63kUL25 gal pKSBHV58 63kApa Bam replacing SalI fragment encoding aa 86 393 UL25 protein Gal reporter gene cassette Fig
0.14988111.12917469.html.plaintext.txt	34	In way deletion introduced UL25 alter expression neighbouring genes
0.14988111.12917469.html.plaintext.txt	35	The plasmid pKS58 63kUL25 gal linearized used BHV 1 viral DNA co transfect RK13UL25 cells grown absence doxycycline state calcium phosphate precipitation method described previously Desloges Simard 2003
0.14988111.12917469.html.plaintext.txt	36	Regenerated progeny viruses plated RK13UL25 cells tested ability form blue plaques presence chromogenic compound X Gal
0.14988111.12917469.html.plaintext.txt	37	A Gal positive mutant virus designated BHV 1UL25 plaque purified five times RK13UL25 cells virus production
0.14988111.12917469.html.plaintext.txt	38	The known complete sequence wild type BHV 1 genome allowed us determine restriction profiles expected mutated genome
0.14988111.12917469.html.plaintext.txt	39	We compared HindIII restriction profiles mutant versus BHV 1 DNA purified infected cell lysates
0.14988111.12917469.html.plaintext.txt	40	No divergence patterns observed expected mutant genome noted results shown
0.14988111.12917469.html.plaintext.txt	41	These findings demonstrate Gal reporter gene cassette interrupts intended UL25 encoding sequence virus mutant
0.14988111.12917469.html.plaintext.txt	42	To verify engineered mutant indeed incapable expressing UL25 gene product performed Western blotting analyses protein extracts RK13 cells infected different periods time either BHV 1 BHV 1UL25
0.14988111.12917469.html.plaintext.txt	43	2A extracts infected BHV 1 revealed presence abundant 63 kDa protein detected specifically UL25 antiserum accumulating cells 12 18 h post infection p
0.14988111.12917469.html.plaintext.txt	44	In contrast UL25 antiserum detected protein extracts BHV 1UL25 infected RK13 cells thus demonstrating virus mutant incapable expressing UL25 protein RK13 cells Fig
0.14988111.12917469.html.plaintext.txt	45	This protein absent lysates prepared presence phosphonoacetic acid PAA DNA synthesis inhibitor confirming previous findings BHV 1 UL25 belongs viral genes 2 class since expression dependent strictly viral DNA synthesis Desloges et al
0.14988111.12917469.html.plaintext.txt	46	View larger version 12K Fig
0.14988111.12917469.html.plaintext.txt	47	Expression viral proteins replication kinetics infected cells
0.14988111.12917469.html.plaintext.txt	48	A C RK13 cells infected either BHV 1UL25 BHV 1 m
0.14988111.12917469.html.plaintext.txt	49	2 0 6 12 18 h presence absence PAA
0.14988111.12917469.html.plaintext.txt	50	Protein cell lysates fractionated SDS PAGE electrotransferred onto PVDF membrane reacted BHV 1 specific UL25 antiserum A monospecific antiserum directed product BHV 1 UL48 gene C
0.14988111.12917469.html.plaintext.txt	51	Sizes kDa standards indicated
0.14988111.12917469.html.plaintext.txt	52	B RK13 cells closed symbols complementing RK13UL25 cells open symbols infected synchronously m
0.14988111.12917469.html.plaintext.txt	53	5 either BHV 1 squares BHV 1UL25 circles
0.14988111.12917469.html.plaintext.txt	54	Cultures harvested indicated times p
0.14988111.12917469.html.plaintext.txt	55	mean yield virus per cell generated either BHV 1 BHV 1UL25 infected samples determined plaque assays RK13 RK13UL25 cells respectively
0.14988111.12917469.html.plaintext.txt	56	To investigate consequence UL25 defect replicative cycle BHV 1 virus production examined establishing one step growth curves BHV 1UL25 BHV 1 non complementing RK13 well complementing RK13UL25 cells
0.14988111.12917469.html.plaintext.txt	57	Cells infected synchronously one virus m
0.14988111.12917469.html.plaintext.txt	58	5 harvested different times p
0.14988111.12917469.html.plaintext.txt	59	total number virus particles present either extracellularly intracellularly sample determined titration assays described previously Desloges Simard 2003
0.14988111.12917469.html.plaintext.txt	60	BHV 1 capable replicating efficiently RK13 RK13UL25 cells reaching similar maximal virus yields 21 h p
0.14988111.12917469.html.plaintext.txt	61	In contrast BHV 1UL25 could replicate RK13UL25 cells progeny produced RK13 cells Fig
0.14988111.12917469.html.plaintext.txt	62	These results demonstrate UL25 gene product necessary virus replication non complementing cells observed also HSV 1 UL25 deletion mutant Ali et al
0.14988111.12917469.html.plaintext.txt	63	In addition virus yield obtained BHV 1UL25 RK13UL25 cells similar BHV 1 virus yield recovered either cell line indicating RK13UL25 cell line capable fully complementing UL25 defect mutant virus
0.14988111.12917469.html.plaintext.txt	64	These results demonstrate amount UL25 protein within complementary cell line sufficient allow replication BHV 1UL25 BHV 1 levels indicating mutations essential genes introduced recombination event giving rise mutant
0.14988111.12917469.html.plaintext.txt	65	To identify step UL25 deletion mutant replication aborts RK13 cells examined whether mutation compromised expression late viral genes products
0.14988111.12917469.html.plaintext.txt	66	For purpose expression BHV 1 gene trans inducing factor protein encoded UL48 gene late gene Misra et al
0.14988111.12917469.html.plaintext.txt	67	protein lysates prepared BHV 1UL25 BHV 1 infected RK13 cells analysed immunoblot presence UL48 gene product using BHV 1 specific UL48 antiserum directed Escherichia coli expressed T7 tag UL48 fusion protein
0.14988111.12917469.html.plaintext.txt	68	The antiserum detected 50 kDa protein lysates collected 18 h p
0.14988111.12917469.html.plaintext.txt	69	BHV 1UL25 BHV 1 infected RK13 cells Fig
0.14988111.12917469.html.plaintext.txt	70	Moreover production UL48 gene product abrogated PAA treatment Fig
0.14988111.12917469.html.plaintext.txt	71	2C PAA confirming UL48 2 gene
0.14988111.12917469.html.plaintext.txt	72	Thus results demonstrate UL25 defect impair expression viral genes 2 class consequently expression genes earlier classes 1 2 1
0.14988111.12917469.html.plaintext.txt	73	These results also demonstrate indirectly mutation compromise viral DNA synthesis since genes whose expression dependent strictly viral DNA synthesis UL48 expressed efficiently
0.14988111.12917469.html.plaintext.txt	74	To obtain direct evidence UL25 defect compromise viral DNA synthesis RK13 cells Southern blotting analysis HindIII digests total cell DNA isolated BHV 1UL25 infected RK13 RK13UL25 cells performed
0.14988111.12917469.html.plaintext.txt	75	The HindIII fragment N representing leftward terminal region BHV 1 linear viral genome used probe Fig
0.14988111.12917469.html.plaintext.txt	76	Probe N hybridized major 2 4 kbp two minor non well resolved 14 15 kbp fragments present DNA BHV 1UL25 infected RK13 cells obtained 12 24 h p
0.14988111.12917469.html.plaintext.txt	77	In contrast hybridization signal observed 0 h p
0.14988111.12917469.html.plaintext.txt	78	3A lane 1 demonstrating bands observed represented newly synthesized viral DNA
0.14988111.12917469.html.plaintext.txt	79	The DNA profile observed 24 h p
0.14988111.12917469.html.plaintext.txt	80	3A lane 3 similar observed BHV 1UL25 infected RK13UL25 cells Fig
0.14988111.12917469.html.plaintext.txt	81	The 2 4 kbp bands common two profiles co migrated KpnI HindIII insert recombinant plasmid pKSNhd harbours complete HindIII fragment N Fig
0.14988111.12917469.html.plaintext.txt	82	3A lane 5 demonstrating bands represented leftward terminal 2 4 kbp HindIII fragment N BHV 1 linear genome
0.14988111.12917469.html.plaintext.txt	83	The sizes two bands correlated expected head tail HindIII genomic fragments Fig
0.14988111.12917469.html.plaintext.txt	84	1 N F N H head tail fragments range 14 15 kbp respectively indicating presence within infected cell lysates viral DNA form either immature DNA concatemers circular unit length genomes
0.14988111.12917469.html.plaintext.txt	85	Interestingly levels 2 4 kbp fragment observed similar two cell lines
0.14988111.12917469.html.plaintext.txt	86	These findings indicate DNA replication BHV 1UL25 effective RK13 cells complementing RK13UL25 cells
0.14988111.12917469.html.plaintext.txt	87	Moreover much higher abundance terminal versus head tail HindIII fragments indicate mutant viral DNA synthesized infected cells processed efficiently linear unit length genomes
0.14988111.12917469.html.plaintext.txt	88	View larger version 56K Fig
0.14988111.12917469.html.plaintext.txt	89	Synthesis processing packaging BHV 1UL25 DNA
0.14988111.12917469.html.plaintext.txt	90	A Total DNA extracts RK13 RK13UL25 cell lysates infected BHV 1UL25 different times p
0.14988111.12917469.html.plaintext.txt	91	purified digested HindIII analysed Southern blotting
0.14988111.12917469.html.plaintext.txt	92	The blot hybridized DIG labelled probe representing leftward HindIII terminal fragment N BHV 1 linear viral genome see Fig
0.14988111.12917469.html.plaintext.txt	93	Lane 5 contains HindIII digest purified BHV 1 DNA
0.14988111.12917469.html.plaintext.txt	94	The blot reacted chemiluminescent substrate exposed X ray films 16 h
0.14988111.12917469.html.plaintext.txt	95	Sizes kbp standards indicated
0.14988111.12917469.html.plaintext.txt	96	B BHV 1 infected RK13 cells upper left panel BHV 1UL25 infected RK13UL25 cells upper right panel BHV 1UL25 infected RK13 cells lower panels fixed 18 h p
0.14988111.12917469.html.plaintext.txt	97	Thin sections prepared electron microscopy analysis
0.14988111.12917469.html.plaintext.txt	98	In lower left panel arrowhead points empty A capsid whereas tailed arrow points intermediate B capsid
0.14988111.12917469.html.plaintext.txt	99	In lower right panel arrow points full C capsid
0.14988111.12917469.html.plaintext.txt	100	Magnification x70 000 bars 100 nm
0.14988111.12917469.html.plaintext.txt	101	To determine whether mutant viral DNA packaged capsids thin sections BHV 1UL25 infected RK13 RK13UL25 cells well BHV 1 infected RK13 cells collected 18 h p
0.14988111.12917469.html.plaintext.txt	102	examined transmission electron microscopy assess presence full C intermediate B empty A capsids described previously Desloges Simard 2003
0.14988111.12917469.html.plaintext.txt	103	Significant numbers three capsid types found sections BHV 1 infected RK13 cells A capsids 35 7 B capsids 16 7 C capsids 47 6 BHV 1UL25 infected RK13UL25 cells A capsids 29 6 B capsids 51 7 C capsids 18 7
0.14988111.12917469.html.plaintext.txt	104	Each infected cell samples Fig
0.14988111.12917469.html.plaintext.txt	105	3B upper left right panels respectively presented several C capsids surrounded bilayer envelope
0.14988111.12917469.html.plaintext.txt	106	In contrast capsids BHV 1UL25 infected RK13 cells types A B 40 0 57 2 respectively illustrated Fig
0.14988111.12917469.html.plaintext.txt	107	3B lower left panel showing accumulation capsid types infected cells
0.14988111.12917469.html.plaintext.txt	108	The generation empty A capsids devoid DNA internal structure believed result abortive packaging event
0.14988111.12917469.html.plaintext.txt	109	Abortive packaging observed also mutants dsDNA bacteriophage P22 presents similarities alphaherpesviruses concerning DNA packaging capsid assembly process
0.14988111.12917469.html.plaintext.txt	110	In Salmonella cells infected mutants phage P22 defective genes 4 10 26 shown procapsids assembled viral concatemeric DNA packaged newly filled capsids unstable lose DNA Strauss King 1984
0.14988111.12917469.html.plaintext.txt	111	The phenotype observed bacterial cells infected mutants accumulation empty A capsids similar observed BHV 1UL25 infected RK13 cells
0.14988111.12917469.html.plaintext.txt	112	However careful examination infected cells revealed presence electron dense cored C capsids 2 8
0.14988111.12917469.html.plaintext.txt	113	3B lower right panel complete enveloped C capsid shown extracellular compartment BHV 1UL25 infected RK13 cells
0.14988111.12917469.html.plaintext.txt	114	It reported previously HSV 1 UL25 mutant KUL25NS package matur DNA McNab et al
0.14988111.12917469.html.plaintext.txt	115	Recently Stow 2001 detected successfully low levels KUL25NS DNA packaged retained capsids
0.14988111.12917469.html.plaintext.txt	116	The latter findings corroborated present study observation full C capsids electron micrographs thin sections BHV 1UL25 infected RK13 cells
0.14988111.12917469.html.plaintext.txt	117	However appears enveloped C capsids either non infectious number low cytopathogenesis virus detected one step growth curve analyses
0.14988111.12917469.html.plaintext.txt	118	Also could UL25 mutant genomes packaged efficiently capsids released subsequently degraded rapidly suggested Stow 2001
0.14988111.12917469.html.plaintext.txt	119	In summary describe engineering characterization UL25 deletion mutant BHV 1
0.14988111.12917469.html.plaintext.txt	120	Our results show mutant impaired ability synthesize viral proteins replicate cleave viral DNA unit length genomes
0.14988111.12917469.html.plaintext.txt	121	Moreover mutant still able encapsidate viral DNA albeit low levels
0.14988111.12917469.html.plaintext.txt	122	Further studies required elucidate precisely role played UL25 encapsidation process especially stabilization packaged DNA capsid
0.14988111.12917469.html.plaintext.txt	123	ACKNOWLEDGEMENTS The authors wish thank N
0.14988111.12917469.html.plaintext.txt	124	Gagnon excellent technical assistance R
0.14988111.12917469.html.plaintext.txt	125	Alain appreciated help electron microscopy experiments L
0.14988111.12917469.html.plaintext.txt	126	Bello kindly providing Gal cassette
0.14988111.12917469.html.plaintext.txt	127	This work funded Natural Sciences Engineering Research Council Canada NSERC Conseil des Recherches en Peche et en Agroalimentaire du Quebec CORPAQ
0.14988111.12917469.html.plaintext.txt	128	supported NSERC Fonds pour la Formation de Chercheurs et lAide la Recherche FCAR Fondation Armand Frappier
0.14988111.12917469.html.plaintext.txt	129	REFERENCES Top ABSTRACT MAIN TEXT REFERENCES Addison C
0.14988111.12917469.html.plaintext.txt	130	Herpes simplex virus type 1 UL28 gene product important formation mature capsids
0.14988111.12917469.html.plaintext.txt	131	Characterization essential HSV 1 protein encoded UL25 gene reported involved virus penetration capsid assembly
0.14988111.12917469.html.plaintext.txt	132	The herpes simplex virus UL33 gene product required assembly full capsids
0.14988111.12917469.html.plaintext.txt	133	Role UL28 homologue bovine herpesvirus 1 viral DNA cleavage packaging
0.14988111.12917469.html.plaintext.txt	134	Transcriptional translational expression kinetics UL25 homologue bovine herpesvirus 1
0.14988111.12917469.html.plaintext.txt	135	Transcriptional activation tetracyclines mammalian cells
0.14988111.12917469.html.plaintext.txt	136	The herpes simplex virus 1 UL6 protein essential cleavage packaging genomic inversion
0.14988111.12917469.html.plaintext.txt	137	The herpes simplex virus type 1 cleavagepackaging protein UL32 involved efficient localization capsids replication compartments
0.14988111.12917469.html.plaintext.txt	138	The product herpes simplex virus type 1 UL25 gene required encapsidation cleavage replicated viral DNA
0.14988111.12917469.html.plaintext.txt	139	Protein DNA elements involved transactivation promoter bovine herpesvirus BHV 1 IE 1 transcription unit BHV gene trans inducing factor
0.14988111.12917469.html.plaintext.txt	140	Characterization temperature sensitive mutant UL15 open reading frame herpes simplex virus 1
0.14988111.12917469.html.plaintext.txt	141	Herpes simplex viruses replication
0.14988111.12917469.html.plaintext.txt	142	In Fields Virology 3rd edn pp
0.14988111.12917469.html.plaintext.txt	143	Philadelphia Philadelphia Lippincott Raven
0.14988111.12917469.html.plaintext.txt	144	Gene mapping infectious bovine rhinotracheitis viral DNA genome
0.14988111.12917469.html.plaintext.txt	145	Packaging genomic amplicon DNA herpes simplex virus type 1 UL25 null mutant KUL25NS
0.14988111.12917469.html.plaintext.txt	146	Steps stabilization newly packaged DNA phage P22 morphogenesis
0.14988111.12917469.html.plaintext.txt	147	The herpes simplex virus 1 UL17 gene required localization capsids major minor capsid proteins intranuclear sites viral DNA cleaved packaged
0.14988111.12917469.html.plaintext.txt	148	Herpes simplex virus type 1 DNA cleavage encapsidation require product UL28 gene isolation characterization two UL28 deletion mutants
0.14988111.12917469.html.plaintext.txt	149	Received 21 February 2003 accepted 7 May 2003
0.14988111.12917469.html.plaintext.txt	150	This Article Abstract Full Text PDF Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles Desloges N
0.14988111.12917469.html.plaintext.txt	151	Articles citing Article PubMed PubMed Citation Articles Desloges N
0.14988111.12917469.html.plaintext.txt	152	Agricola Articles Desloges N
0.14988111.12917469.html.plaintext.txt	153	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL J MED MICROBIOL ALL SGM JOURNALS
0.18519257.14623875.html.plaintext.txt	0	Characterization Cyclin L2 Novel Cyclin ArginineSerine rich Domain PHOSPHORYLATION BY DYRK1A AND COLOCALIZATION WITH SPLICING FACTORS Katrin de Graaf Paul Hekerman Oliver Spelten Andreas Herrmann Len C
0.18519257.14623875.html.plaintext.txt	1	Packman Konrad Bussow Gerhard Muller Newen Walter Becker
0.18519257.14623875.html.plaintext.txt	2	From Institut fur Pharmakologie und Toxikologie Medizinische Fakultat der RWTH Aachen Wendlingweg 2 52074 Aachen Germany Institut fur Biochemie Medizinische Fakultat der RWTH Aachen Pauwelstrasse 30 52074 Aachen Germany Department Biochemistry University Cambridge 80 Tennis Court Road Cambridge CB2 1GA United Kingdom Max Planck Institut fur Molekulare Genetik Heubnerweg 6 14059 Berlin Germany
0.18519257.14623875.html.plaintext.txt	3	Received publication October 1 2003 revised form November 14 2003
0.18519257.14623875.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES A novel method employing filter arrays cDNA expression library identification substrates protein kinases developed
0.18519257.14623875.html.plaintext.txt	5	With technique identified new member cyclin family cyclin L2 substrate nuclear protein kinase DYRK1A
0.18519257.14623875.html.plaintext.txt	6	Cyclin L2 contains N terminal cyclin domain C terminal arginineserine rich domain RS domain hallmark many proteins involved pre mRNA processing
0.18519257.14623875.html.plaintext.txt	7	The gene cyclin L2 encodes full length cyclin L2 predominantly expressed testis well truncated splicing variant cyclin L2S lacks RS domain ubiquitously expressed human tissues
0.18519257.14623875.html.plaintext.txt	8	Full length cyclin L2 cyclin L2S associated cyclin dependent kinase PITSLRE
0.18519257.14623875.html.plaintext.txt	9	Cyclin L2 interacted splicing factor 2 vitro co localized splicing factor SC35 nuclear speckle compartment
0.18519257.14623875.html.plaintext.txt	10	Photobleaching experiments showed fusion protein green fluorescent protein cyclin L2 nuclear speckles rapidly exchanged unbleached molecules nucleus similar RS domain containing proteins
0.18519257.14623875.html.plaintext.txt	11	In striking contrast closely related green fluorescent protein cyclin L1 immobile speckle compartment
0.18519257.14623875.html.plaintext.txt	12	DYRK1A interacted cyclin L2 pull assays overexpression DYRK1A stimulated phosphorylation cyclin L2 COS 7 cells
0.18519257.14623875.html.plaintext.txt	13	These data characterize cyclin L2 highly mobile component nuclear speckles suggest DYRK1A may regulate splicing phosphorylation cyclin L2
0.18519257.14623875.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES DYRK1A dual specificity tyrosine phosphorylation regulated kinase 1A nuclear protein kinase appears play important role brain development review see Ref
0.18519257.14623875.html.plaintext.txt	15	The first evidence role DYRK1A neurogenesis came similarity Drosophila orthologue minibrain kinase 2
0.18519257.14623875.html.plaintext.txt	16	Mutant flies reduced expression minibrain show significant reduction neurons distinct areas brain correlated specific behavioral defects 2
0.18519257.14623875.html.plaintext.txt	17	In addition human DYRK1A gene located chromosome 21 Down syndrome critical region 3 5
0.18519257.14623875.html.plaintext.txt	18	Consistent potential involvement DYRK1A gene pathogenesis mental retardation Down syndrome overexpression DYRK1A transgenic mice causes learning deficits neurodevelopmental alterations 5 6
0.18519257.14623875.html.plaintext.txt	19	Furthermore mice heterozygous targeted deletion Dyrk1a gene Dyrk1a mice develop abnormal brain morphology 7
0.18519257.14623875.html.plaintext.txt	20	In early embryonal development DYRK1A expressed neural progenitor cells transition proliferating neurogenic divisions 8
0.18519257.14623875.html.plaintext.txt	21	Altogether findings suggest relevant function DYRK1A neuronal development related proliferation andor differentiation
0.18519257.14623875.html.plaintext.txt	22	In recent years several transcription factors identified substrates DYRK1A review see Ref
0.18519257.14623875.html.plaintext.txt	23	Particularly overexpression DYRK1A shown modulate transactivation potential FKHR forkhead rhabdomyosarcoma 10 11 cAMP response element binding protein 12 GLI1 13
0.18519257.14623875.html.plaintext.txt	24	Cytoplasmic proteins like eukaryotic initiation factor 2B tau 14 dynamin 15 also reported phosphorylated DYRK1A proteins might equally well targets cytoplasmic kinases DYRK2 DYRK3
0.18519257.14623875.html.plaintext.txt	25	However although DYRK1A contains canonical nuclear localization signal indeed predominantly targeted nucleus 16 17 significant fraction kinase also present cytoplasm 18
0.18519257.14623875.html.plaintext.txt	26	Within nucleus DYRK1A localized nuclear speckles represent splicing factor compartment 17 19
0.18519257.14623875.html.plaintext.txt	27	The precise function DYRK1A nucleus still largely unknown open question whether known substrates DYRK1A key mediator functions cell differentiation proliferation
0.18519257.14623875.html.plaintext.txt	28	We therefore performed extensive search interacting proteins substrates address problem
0.18519257.14623875.html.plaintext.txt	29	Several methods employed identify novel substrates protein kinases
0.18519257.14623875.html.plaintext.txt	30	Routine interaction screens like yeast two hybrid system phage display phage expression library screening yield many cases substrates kinases 20 23
0.18519257.14623875.html.plaintext.txt	31	Other approaches based specificity substrate recognition kinases aim identify substrate proteins searching data bases experimentally determined predicted consensus phosphorylation sequences 24 25
0.18519257.14623875.html.plaintext.txt	32	More direct strategies include phosphorylation screening phage expression libraries 26 cell lysates 27 identification phosphoproteins functional proteomics mass spectrometry 28
0.18519257.14623875.html.plaintext.txt	33	Here employed new method allowed us screen parallel interaction partners substrates kinase DYRK1A
0.18519257.14623875.html.plaintext.txt	34	In approach used arrayed protein expression library 29 30 interaction screening overlaying radiolabeled recombinant kinase 31 substrate screen solid phase phosphorylation 26
0.18519257.14623875.html.plaintext.txt	35	The use filter array allowed us directly identify positive clones without need rounds purification
0.18519257.14623875.html.plaintext.txt	36	Several DYRK1A interacting andor phosphorylated proteins identified approach one protein found screens
0.18519257.14623875.html.plaintext.txt	37	This protein turned novel member cyclin family designated cyclin L2
0.18519257.14623875.html.plaintext.txt	38	Here characterize cyclin L2 novel substrate DYRK1A
0.18519257.14623875.html.plaintext.txt	39	Furthermore describe alternative transcripts generated cyclin L2 gene show full length cyclin L2 truncated splicing variant cyclin L2S co localized splicing factor SC35 nuclear speckles
0.18519257.14623875.html.plaintext.txt	40	Using photobleaching techniques demonstrate cyclin L2 closely related isoform cyclin L1 differ strikingly regard intranuclear mobility
0.18519257.14623875.html.plaintext.txt	41	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Production Filter Array The construction cDNA expression library production high density filter arrays described previously 29
0.18519257.14623875.html.plaintext.txt	42	Human fetal brain cDNA directionally cloned pQE 30NST vector GenBankTM accession number AF074376 GenBank isopropyl 1 thio D galactopyranoside inducible expression His6 tagged fusion proteins
0.18519257.14623875.html.plaintext.txt	43	The filter array 22 x 22 cm used present study contained library 37830 double spotted plasmid clones library number 800 RZPD Berlin Germany enriched putative expression clones described earlier 29
0.18519257.14623875.html.plaintext.txt	44	The colonies lysed alkali treatment 0
0.18519257.14623875.html.plaintext.txt	45	5 M NaCl 10 min filter neutralized 2 x 5 min 1 M Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	46	Bacterial debris carefully wiped TBS1 supplemented 0
0.18519257.14623875.html.plaintext.txt	47	1 vv Tween 20 TBS contains 20 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	48	5 M NaCl filter washed twice 10 min TBS 0
0.18519257.14623875.html.plaintext.txt	49	1 vv Tween 20 10 min TBS
0.18519257.14623875.html.plaintext.txt	50	Probe Labeling Overlay Assays The probe interaction screen GST DYRK1A C K188R expressed pGEX 2TK vector GenBankTM accession number U13851 GenBank allows labeling fusion protein vector encoded phosphorylation site cAMP dependent protein kinase
0.18519257.14623875.html.plaintext.txt	51	The C terminally truncated mutant DYRK1A used probe order avoid potential nonspecific binding repeat structures C terminal domain DYRK1A 32
0.18519257.14623875.html.plaintext.txt	52	The kinase negative point mutant K188R DYRK1A exhibit enhanced enzyme substrate interactions
0.18519257.14623875.html.plaintext.txt	53	For labeling 20 25 microg GST DYRK1A C K188R bound glutathione S Sepharose beads Amersham Biosciences incubated volume 110 microl 10 units cAMP dependent protein kinase New England Biolabs 50 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	54	5 10 mM MgCl2 6 mgml dithiothreitol 30 min 4 degrees C presence 45 microCi 32PATP 3000 Cimmol
0.18519257.14623875.html.plaintext.txt	55	The reaction stopped adding 10 mM EDTA final concentration 2 mM
0.18519257.14623875.html.plaintext.txt	56	The Sepharose beads washed seven times 500 microl ice cold PBST 137 mM NaCl 2
0.18519257.14623875.html.plaintext.txt	57	5 wv Triton X 100 order remove free 32PATP
0.18519257.14623875.html.plaintext.txt	58	The labeled protein eluted 10 min ice 500 microl glutathione elution buffer 10 mM reduced glutathione 50 mM Tris HCl pH 8
0.18519257.14623875.html.plaintext.txt	59	The typical yield reaction 15 microCi incorporated 32P eluted protein
0.18519257.14623875.html.plaintext.txt	60	Interaction Screening DYRK1A Overlay In order allow refolding denatured proteins 33 filter array nitrocellulose membranes electroblotted proteins first incubated 1 h room temperature 6 M guanidinium HCl 50 mM Tris HCl pH 8
0.18519257.14623875.html.plaintext.txt	61	3 50 mM dithiothreitol 2 mM EDTA rinsed TBS followed overnight incubation 4 degrees C 150 mM NaCl 10 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	62	To reduce false positive signals due binding GST membrane blocked incubation interaction buffer 0
0.18519257.14623875.html.plaintext.txt	63	5 BSA 75 mM KCl 20 mM HEPES pH 7
0.18519257.14623875.html.plaintext.txt	64	5 mM MgCl2 1 mM dithiothreitol 0
0.18519257.14623875.html.plaintext.txt	65	05 Nonidet P 40 containing 1 microg microl GST 1 h room temperature
0.18519257.14623875.html.plaintext.txt	66	The membrane incubated 6 x 104 cpmml 32P labeled GST DYRK1A C K188R interaction buffer 18 h 4 degrees C
0.18519257.14623875.html.plaintext.txt	67	After washing three times 10 min room temperature interaction buffer membrane dried subjected autoradiography
0.18519257.14623875.html.plaintext.txt	68	Substrate Screening Solid Phase Phosphorylation The filter expression array polyvinylidene fluoride membranes electroblotted proteins preincubated kinase buffer 25 mM HEPES pH 7
0.18519257.14623875.html.plaintext.txt	69	5 mM dithiothreitol 5 mM MgCl2 5 mM MnCl2 100 mM NaCl 3 BSA containing 3 microM cold ATP 1 h room temperature mask proteins autophosphorylating andor ATP binding activities 26
0.18519257.14623875.html.plaintext.txt	70	The solid phase phosphorylation done incubation 0
0.18519257.14623875.html.plaintext.txt	71	2 unitsml GST DYRK1A C kinase buffer containing 3 microM 32PATP 5 microCiml 45 min room temperature
0.18519257.14623875.html.plaintext.txt	72	This construct shown substrate specificity higher activity full length kinase produced Escherichia coli 34
0.18519257.14623875.html.plaintext.txt	73	One unit protein kinase activity amount catalyzed phosphorylation 1 nmol DYRKtide standard synthetic peptide substrate 34 1 min kinase buffer containing 100 microM ATP 200 microM DYRKtide
0.18519257.14623875.html.plaintext.txt	74	After phosphorylation membrane washed twice 30 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	75	4 30 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	76	05 Nonidet P 40 twice 30 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	77	4 without Nonidet P 40 1 M HCl twice 30 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	78	4 washing step 10 min
0.18519257.14623875.html.plaintext.txt	79	The membrane air dried exposed x ray film
0.18519257.14623875.html.plaintext.txt	80	Bacterial Expression The plasmids bacterial expression GSTDYRK1A C 34 GST DYRK1A C K188R GST DYRK1A CN 35 GST DYRK2 17 described previously
0.18519257.14623875.html.plaintext.txt	81	GSTDYRK1A NT contains amino acids 1 177 N terminus DYRK1A GST DYRK1Acat contains amino acids 133 499 DYRK1A
0.18519257.14623875.html.plaintext.txt	82	Plasmids human fetal brain expression library encode His6 tagged fusion proteins Table I obtained RZPD Deutsches Ressourcenzentrum fur Genomforschung Berlin Germany cloning vector information see World Wide Web www
0.18519257.14623875.html.plaintext.txt	83	The expression plasmids GST SF2ASF GST hTRA21 kindly provided Stefan Stamm Erlangen Germany 36
0.18519257.14623875.html.plaintext.txt	84	The bacterial expression plasmid coding GST CycL2 constructed cloning cDNA clone N16596 corresponding amino acids 270 520 cyclin L2 pGEX 2TK
0.18519257.14623875.html.plaintext.txt	85	View table TABLE I Identification DYRK1A interacting proteins substrates DYRK1A
0.18519257.14623875.html.plaintext.txt	86	GST His tagged fusion proteins expressed E
0.18519257.14623875.html.plaintext.txt	87	coli affinity purified using glutathione Sepharose 4B Amersham Biosciences nickel charged nitrilotriacetic acid agarose beads Qiagen Hilden Germany
0.18519257.14623875.html.plaintext.txt	88	Proteins eluted beads native conditions reduced glutathione imidazole
0.18519257.14623875.html.plaintext.txt	89	His6 tagged cyclin L2 expressed pQE 30NST vector RZPD clone N16596 purified inclusion bodies described previously 37
0.18519257.14623875.html.plaintext.txt	90	The purified protein refolded gel filtration Sephadex G25 column NAPTM 5 column Amersham Biosciences 10 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	91	4 100 mM NaCl equilibration elution buffer
0.18519257.14623875.html.plaintext.txt	92	For kinase assays imidazole removed His6 tagged fusion protein ultrafiltration using Centricon concentrators Amicon Beverly MA
0.18519257.14623875.html.plaintext.txt	93	Mammalian Expression The expression clone GFP DYRK1A described 17
0.18519257.14623875.html.plaintext.txt	94	GFP CLK3 constructed cloning insert pGEX CLK3 38 pEGFP C1 Clontech expresses C terminal GFP tag amino acids 33 490 rat CLK3
0.18519257.14623875.html.plaintext.txt	95	GFP constructs cyclin L2 cloned pEGFP C1 comprise indicated amino acids C terminal GFP numbered Fig
0.18519257.14623875.html.plaintext.txt	96	3A GFP CycL2 amino acids 1 520 GFP CycL2 N amino acids 223 520 GFP CycL2S amino acids 1 220 cyclin L2 plus 6 specific amino acids indicated Fig
0.18519257.14623875.html.plaintext.txt	97	GFP CycL1 contains full open reading frame human cyclin L1 amino acids 1 526 GenBankTM accession number AF180920 GenBank
0.18519257.14623875.html.plaintext.txt	98	A plasmid expression untagged cyclin L2 generated deletion GFP GFP CycL2
0.18519257.14623875.html.plaintext.txt	99	View larger version 37K FIG
0.18519257.14623875.html.plaintext.txt	100	Structure CCNL2 gene gene products
0.18519257.14623875.html.plaintext.txt	101	A amino acid sequence cyclin L2 cyclin L2S
0.18519257.14623875.html.plaintext.txt	102	The sequence cyclin L2 deduced uncharacterized data base entry AY037150 GenBank
0.18519257.14623875.html.plaintext.txt	103	Cyclin L2S consists amino acids 1 220 cyclin L2 6 additional amino acids italics
0.18519257.14623875.html.plaintext.txt	104	The cyclin domain boxed RS domain underlined
0.18519257.14623875.html.plaintext.txt	105	The amino acids antigenic peptide used antibody production highlighted boldface type
0.18519257.14623875.html.plaintext.txt	106	B structural comparison cyclin L2 cyclin L2S cyclin L1
0.18519257.14623875.html.plaintext.txt	107	The sequence similarity cyclin domain Cyc RS domain RS indicated percentage identical amino acids
0.18519257.14623875.html.plaintext.txt	108	C structural organization human CCNL2 gene derived transcripts
0.18519257.14623875.html.plaintext.txt	109	Exons shown filled boxes alternatively spliced exon 6a shaded
0.18519257.14623875.html.plaintext.txt	110	Three differentially spliced transcripts T1 T2 T3 identified work searching public expressed sequence tag data bases shown
0.18519257.14623875.html.plaintext.txt	111	Stop codons terminate open reading frames indicated asterisks
0.18519257.14623875.html.plaintext.txt	112	Putative polyadenylation signals T1T2 nucleotides 2073 2284 AY037150 GenBank T3 nucleotide 1173 BC016333 GenBank indicated AAUAAA AAUACA
0.18519257.14623875.html.plaintext.txt	113	The localization hybridization probes used Northern blot analysis Fig
0.18519257.14623875.html.plaintext.txt	114	4A indicated gene E6a 5 E6a 3 E11
0.18519257.14623875.html.plaintext.txt	115	In Vitro Kinase Assays For vitro kinase assays Fig
0.18519257.14623875.html.plaintext.txt	116	2 amounts substrates adjusted 750 ng myelin basic protein Sigma according intensities Coomassie Blue stained bands SDS PAGE
0.18519257.14623875.html.plaintext.txt	117	Substrates incubated 15 min 30 degrees C 0
0.18519257.14623875.html.plaintext.txt	118	5 unitsml GST DYRK1A C kinase buffer supplemented 100 microM 32PATP 66
0.18519257.14623875.html.plaintext.txt	119	The samples separated SDS PAGE stained Coomassie Blue phosphorylated proteins detected autoradiography dried gels
0.18519257.14623875.html.plaintext.txt	120	View larger version 104K FIG
0.18519257.14623875.html.plaintext.txt	121	In vitro phosphorylation RS domain containing proteins DYRK1A
0.18519257.14623875.html.plaintext.txt	122	The indicated RS rich proteins expressed E
0.18519257.14623875.html.plaintext.txt	123	coli GST fusion proteins hTRA21 SF2ASF CYCL2 His6 tagged fusion proteins SFRS4 SFRS5 SWAP2
0.18519257.14623875.html.plaintext.txt	124	The affinity purified proteins phosphorylated vitro GST DYRK1A C separated SDS PAGE stained Coomassie Blue assess amounts different substrate proteins lower panel
0.18519257.14623875.html.plaintext.txt	125	Note preparations recombinant proteins contain many truncated products
0.18519257.14623875.html.plaintext.txt	126	Incorporation 32P visualized autoradiography dried gel upper panel
0.18519257.14623875.html.plaintext.txt	127	For comparison myelin basic protein MBP analyzed well characterized vitro substrate DYRK1A
0.18519257.14623875.html.plaintext.txt	128	GST phosphorylation shown background control GST fusion proteins
0.18519257.14623875.html.plaintext.txt	129	Mass Spectrometry For identification DYRK1A phosphorylation sites His6 tagged cyclin L2 produced RZPD clone N16596 phosphorylated GST DYRK1Acat
0.18519257.14623875.html.plaintext.txt	130	In order maximize yield phosphorylated protein reaction carried 1 h high amounts kinase 11 molar ratio
0.18519257.14623875.html.plaintext.txt	131	Coomassie stained bands cut processed analysis mass spectrometry described previously 35
0.18519257.14623875.html.plaintext.txt	132	Northern Blot Analysis Northern blots containing RNA different human tissues purchased Clontech
0.18519257.14623875.html.plaintext.txt	133	For differential detection splicing variants CCNL2 CCNL1 templates specific hybridization probes generated PCR human testis cDNA library catalog number HL1161x Clontech
0.18519257.14623875.html.plaintext.txt	134	Probe CCNL2 E11 matches 3 untranslated region CCNL2 nucleotides 1477 2070 AY037150 GenBank probe CCNL2 E6a 5 matches 5 end exon 6a nucleotides 663 787 AK074112 GenBank probe CCNL2 E6a 3 matches 3 end exon 6a nucleotides 1913 2600 AK074112 GenBank
0.18519257.14623875.html.plaintext.txt	135	Probe CCNL1 E14 matches 3 end coding region CCNL1 nucleotides 1237 1660 AF180920 GenBank
0.18519257.14623875.html.plaintext.txt	136	CCNL1 E78 contains exon 7 exon 8 intron exon definition Dickinson et al
0.18519257.14623875.html.plaintext.txt	137	39 nucleotides 39525 39874 human bac clone AC104411 GenBank
0.18519257.14623875.html.plaintext.txt	138	Probes labeled 32P random oligonucleotide priming Northern blots hybridized probe concentrations 1 5 x 106 cpmml
0.18519257.14623875.html.plaintext.txt	139	PCR Analysis Cyclin L2 Transcripts Mouse cDNAs produced using First Strand cDNA synthesis kit Amersham Biosciences
0.18519257.14623875.html.plaintext.txt	140	A panel human cDNAs purchased Clontech Human MTCTM Panel I
0.18519257.14623875.html.plaintext.txt	141	For specific detection transcripts T1 T3 combined common forward primer matching exon 2 E2for 5 ATTCCGGAATGGCTACCGGGCAGGTGTTG 3 primers specific either exon 6a E6arev 5 AGTCTAGAGCCAGCCTTCG 3 exon 6b E6brev 5 AAGACGTCGGTGCGAAGG 3
0.18519257.14623875.html.plaintext.txt	142	These oligonucleotides designed match murine human mRNA sequences
0.18519257.14623875.html.plaintext.txt	143	PCRs performed JumpStart REDAccuTaqTM DNA polymerase Sigma annealing temperature 52 degrees C step denaturing annealing polymerization 30
0.18519257.14623875.html.plaintext.txt	144	Products separated electrophoresis 1
0.18519257.14623875.html.plaintext.txt	145	5 agarose gels visualized ethidium bromide staining
0.18519257.14623875.html.plaintext.txt	146	The PCR products amplified human cDNAs hardly detectable ethidium bromide staining therefore evaluated Southern blot analysis probe matching exons 3 5 nucleotides 301 664 AY037150 GenBank
0.18519257.14623875.html.plaintext.txt	147	The identity PCR products verified sequencing
0.18519257.14623875.html.plaintext.txt	148	Antibodies The following antibodies commercially obtained monoclonal antibodies GFP MBL Nagoya Japan SC35 Sigma phosphothreonine proline p Thr Pro 101 Cell Signaling Technology rabbit polyclonal antibodies GFP Molecular Probes Inc
0.18519257.14623875.html.plaintext.txt	149	Eugene OR PITSLRE Santa Cruz Biotechnology Inc
0.18519257.14623875.html.plaintext.txt	150	Horseradish peroxidase coupled secondary antibodies purchased Perbio Science Bonn Germany anti rabbit IgG Amersham Biosciences anti mouse IgG
0.18519257.14623875.html.plaintext.txt	151	Alexa Red conjugated secondary antibody immunofluorescence obtained Molecular Probes
0.18519257.14623875.html.plaintext.txt	152	An antiserum specific long form see Results cyclin L2 raised immunization rabbits peptide PYKGSEIRGSRK corresponding amino acids 437 448 within C terminal serinearginine rich RS domain see Fig
0.18519257.14623875.html.plaintext.txt	153	Cell Culture Immunoprecipitation Immunoblotting COS 7 cells grown Dulbeccos modified Eagles medium high glucose supplemented 10 fetal calf serum
0.18519257.14623875.html.plaintext.txt	154	Cells transfected using FuGENE 6 Roche Applied Science suggested manufacturer
0.18519257.14623875.html.plaintext.txt	155	For detection phosphorylated proteins cells washed twice 50 mM HEPES pH 7
0.18519257.14623875.html.plaintext.txt	156	5 150 mM NaCl lysed 500 microl boiling SDS lysis buffer 20 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	157	5 1 wv SDS incubated boiling water bath 100 degrees C 5 min
0.18519257.14623875.html.plaintext.txt	158	Insoluble material removed centrifugation lysates diluted 2 ml water 2
0.18519257.14623875.html.plaintext.txt	159	5 ml 2x immunoprecipitation buffer 40 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	160	4 mM phenylmethylsulfonyl fluoride PMSF 1 vv Triton X 100
0.18519257.14623875.html.plaintext.txt	161	The proteins immunoprecipitated incubating 2 microl polyclonal GFP specific antiserum 40 microl protein A Sepharose Amersham Biosciences 4 degrees C overnight
0.18519257.14623875.html.plaintext.txt	162	The Sepharose washed twice wash buffer 20 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	163	2 mM phenylmethylsulfonyl fluoride 0
0.18519257.14623875.html.plaintext.txt	164	1 Triton X 100 twice wash buffer without Triton X 100 bound proteins eluted boiling Laemmli sample buffer
0.18519257.14623875.html.plaintext.txt	165	Samples subjected Western blot analysis indicated primary antibodies
0.18519257.14623875.html.plaintext.txt	166	For co immunoprecipitations cells washed twice PBS lysed native conditions lysis buffer 50 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	167	5 100 mM NaCl 5 mM EDTA 10 mM NaF supplemented 0
0.18519257.14623875.html.plaintext.txt	168	1 Nonidet P 40 inhibitors 1 mM NaVO4 1 mM phenylmethylsulfonyl fluoride 5 microgml aprotinin 5 microgml leupeptin 3 microgml pepstatin
0.18519257.14623875.html.plaintext.txt	169	The lysate sonicated centrifuged remove insoluble material
0.18519257.14623875.html.plaintext.txt	170	After immunoprecipitation 4 degrees C overnight described Sepharose beads washed lysis buffer containing 0
0.18519257.14623875.html.plaintext.txt	171	1 Nonidet P 40 boiled Laemmli sample buffer
0.18519257.14623875.html.plaintext.txt	172	In Vivo Phosphorylation Cyclin L2 Two days transfection GFP expression plasmids 1
0.18519257.14623875.html.plaintext.txt	173	5 microg either pEGFP pEGFP DYRK1A pEGFP CLK3 COS 7 cells seeded 6 cm plates washed preincubated phosphate free medium 20 min
0.18519257.14623875.html.plaintext.txt	174	Phosphate free medium obtained Sigma catalog
0.18519257.14623875.html.plaintext.txt	175	D3656 supplemented 3
0.18519257.14623875.html.plaintext.txt	176	11 gliter sodium pyruvate 10 dialyzed phosphate free fetal calf serum catalog
0.18519257.14623875.html.plaintext.txt	177	The medium replaced 2 ml medium containing 30 microCi radioactive carrier free H332PO4 Hartmann Analytic GmbH Braunschweig Germany
0.18519257.14623875.html.plaintext.txt	178	The cells incubated 2
0.18519257.14623875.html.plaintext.txt	179	5 h presence 32P SDS lysates prepared immunoprecipitation
0.18519257.14623875.html.plaintext.txt	180	Immunoprecipitated proteins separated SDS PAGE blotted onto nitrocellulose membrane incorporation 32P detected exposure dried blots phosphor storage screens
0.18519257.14623875.html.plaintext.txt	181	Detection GFP Fusion Proteins Immunofluorescence COS 7 cells seeded 24 well plates onto coverslips transiently transfected 0
0.18519257.14623875.html.plaintext.txt	182	3 microg expression plasmids GFP fusion proteins
0.18519257.14623875.html.plaintext.txt	183	Two days transfection cells washed PBS fixed 3 paraformaldehyde PBS 20 min room temperature
0.18519257.14623875.html.plaintext.txt	184	After washing PBS cells permeabilized 0
0.18519257.14623875.html.plaintext.txt	185	2 Triton X 100 PBS 10 min
0.18519257.14623875.html.plaintext.txt	186	For detection endogenous SC35 cells blocked 3 wv BSA PBS 20 min incubated 1 h primary antibody 1100 blocking solution room temperature
0.18519257.14623875.html.plaintext.txt	187	After washing incubation secondary antibody Alexa Red conjugated anti mouse antibody 1100 3 BSAPBS cells washed extensively PBS mounted Fluoromount G Southern Biotechnology Associates revealed confocal laser scanning microscope Zeiss LSM510
0.18519257.14623875.html.plaintext.txt	188	Photobleaching Analysis Photobleaching experiments essentially performed described 40
0.18519257.14623875.html.plaintext.txt	189	Briefly living COS 7 cells analyzed 48 h transfection pEGFP CycL1 pEGFP CycL2
0.18519257.14623875.html.plaintext.txt	190	GFP excited 488 nm line argon laser emission detected using 505 550 nm band path filter
0.18519257.14623875.html.plaintext.txt	191	For fluorescence recovery photobleaching FRAP analysis region interest nuclear speckle bleached using 488 nm laser 100 intensity pictures taken 10 min period observation
0.18519257.14623875.html.plaintext.txt	192	For quantitative FRAP analysis optical slice set 1 microm bleaching performed 35 iterations
0.18519257.14623875.html.plaintext.txt	193	The fluorescence intensity measured every second within region 1 microm diameter
0.18519257.14623875.html.plaintext.txt	194	For fluorescence loss photobleaching FLIP analysis region 1 microm diameter nucleoplasm distinct nuclear speckles bleached consecutively using 488 nm laser 100 intensity
0.18519257.14623875.html.plaintext.txt	195	Pictures taken 5 min period
0.18519257.14623875.html.plaintext.txt	196	Pull Assay To generate baits pull experiments bacterially expressed GST fusion proteins purified affinity purification glutathione Sepharose described without elution beads
0.18519257.14623875.html.plaintext.txt	197	These immobilized proteins incubated lysates transfected COS 7 cells 3 h 4 degrees C continuous agitation 20 mM Tris HCl pH 7
0.18519257.14623875.html.plaintext.txt	198	2 mM phenylmethylsulfonyl fluoride 0
0.18519257.14623875.html.plaintext.txt	199	After washing five times buffer bound proteins eluted incubation Laemmli sample buffer 96 degrees C samples subjected Western blot analysis
0.18519257.14623875.html.plaintext.txt	200	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Screening DYRK1A interacting Proteins In order detect DYRK1A binding proteins domains screened high density colony filter array containing 37830 clones cDNA expression library human fetal brain overlaying radiolabeled GST DYRK1A C K188R
0.18519257.14623875.html.plaintext.txt	201	The coordinates positive clones determined autoradiogram Fig
0.18519257.14623875.html.plaintext.txt	202	1A left panel section array shown 23 clones selected characterization
0.18519257.14623875.html.plaintext.txt	203	To verify screening results recombinant proteins expressed E
0.18519257.14623875.html.plaintext.txt	204	coli subjected blot overlay assays GST DYRK1A CK188R
0.18519257.14623875.html.plaintext.txt	205	The probe bound proteins Fig
0.18519257.14623875.html.plaintext.txt	206	1B left panel part clones shown
0.18519257.14623875.html.plaintext.txt	207	cDNA sequencing showed six cDNA clones encoded fusion proteins derived artificial reading frames untranslated region frame fusion
0.18519257.14623875.html.plaintext.txt	208	The clones correctly fused reading frames listed Table I
0.18519257.14623875.html.plaintext.txt	209	Eight 17 clones contained cDNAs known putative nuclear proteins including splicing factor SRp75 transcription factor RP58 nucleolar protein
0.18519257.14623875.html.plaintext.txt	210	View larger version 83K FIG
0.18519257.14623875.html.plaintext.txt	211	Screening human fetal brain expression library overlay assay solid phase phosphorylation
0.18519257.14623875.html.plaintext.txt	212	A screening expression array
0.18519257.14623875.html.plaintext.txt	213	Two replicas expression array subjected either interaction screening overlaying 32P labeled DYRK1A C K188R left panel solid phase phosphorylation DYRK1A C right panel
0.18519257.14623875.html.plaintext.txt	214	Positive colonies identified autoradiography marked RZPD clone numbers see Table I
0.18519257.14623875.html.plaintext.txt	215	Clone P23533 GenBank encodes cyclin L2
0.18519257.14623875.html.plaintext.txt	216	Only section array shown
0.18519257.14623875.html.plaintext.txt	217	B confirmation array results
0.18519257.14623875.html.plaintext.txt	218	Total cellular lysates bacteria transformed indicated clones separated SDS PAGE blotted onto nitrocellulose membranes
0.18519257.14623875.html.plaintext.txt	219	Proteins stained Ponceau Red lower panels evaluation expression levels blots subjected overlay assay solid phase phosphorylation
0.18519257.14623875.html.plaintext.txt	220	A randomly chosen clone F10592 GenBank phosphorylated array experiment served negative control
0.18519257.14623875.html.plaintext.txt	221	Clone P23533 GenBank encodes cyclin L2
0.18519257.14623875.html.plaintext.txt	222	Representative data selected clones shown
0.18519257.14623875.html.plaintext.txt	223	Migration molecular mass markers indicated kDa
0.18519257.14623875.html.plaintext.txt	224	Substrate Screening Protein Expression Library An identical filter one used interaction screening subjected solid phase phosphorylation GST DYRK1A C presence 32PATP phosphorylated fusion proteins detected autoradiography Fig
0.18519257.14623875.html.plaintext.txt	225	1A right panel section array shown
0.18519257.14623875.html.plaintext.txt	226	34 strongly reacting cDNA clones characterized including three clones also identified interaction screen
0.18519257.14623875.html.plaintext.txt	227	By solid phase phosphorylation bacterially expressed fusion proteins selected proteins confirmed vitro substrates DYRK1A Fig
0.18519257.14623875.html.plaintext.txt	228	1B right panel part clones shown
0.18519257.14623875.html.plaintext.txt	229	A randomly chosen clone gave detectable signal array phosphorylated DYRK1A demonstrating reproducibility array results control Fig
0.18519257.14623875.html.plaintext.txt	230	Sequencing cDNA inserts resulted six known one represented two clones two hypothetical proteins identified Table I
0.18519257.14623875.html.plaintext.txt	231	The remaining 26 fusion proteins represented cloning artifacts ribosomal RNA untranslated regions mRNA frame fusions
0.18519257.14623875.html.plaintext.txt	232	All identified proteins either contain nuclear localization signals known nuclear proteins
0.18519257.14623875.html.plaintext.txt	233	Phosphorylation Splicing Factors DYRK1A Three clones encoding proteins RS domains identified DYRK1A interacting proteins substrates kinase Table I clone M24584 codes splicing factor SRp75 N16596 P23533 GenBank contain partial cDNA coding RS domain containing protein designated cyclin L2 see
0.18519257.14623875.html.plaintext.txt	234	A total four proteins RS domains identified SFRS4 cyclin L2 SFRS5 SWAP2 vitro substrates DYRK1A suggesting DYRK1A may involved splicing catalysis
0.18519257.14623875.html.plaintext.txt	235	We therefore performed vitro kinase assays compare phosphorylation RS domain containing proteins DYRK1A
0.18519257.14623875.html.plaintext.txt	236	In addition proteins identified present screen two additional RS domain containing proteins hTRA21 SF2ASF well characterized vitro substrate DYRK1A myelin basic protein 34 included experiment
0.18519257.14623875.html.plaintext.txt	237	2 cyclin L2 hTRA21 phosphorylated markedly higher intensities RS proteins
0.18519257.14623875.html.plaintext.txt	238	Thus DYRK1A indiscriminately phosphorylate serine residues context RS domains
0.18519257.14623875.html.plaintext.txt	239	In present study concentrated characterization cyclin L2 interaction DYRK1A protein independently identified screens cyclin L2 excellent substrate DYRK1A see Fig
0.18519257.14623875.html.plaintext.txt	240	Structure Cyclin L2 The amino acid sequence derived cDNA clones N16596 P23533 GenBank definitely encodes RS domain 21 RS dipeptide motifs within 141 amino acids Fig
0.18519257.14623875.html.plaintext.txt	241	3A shows extended sequence similarity RS domain containing protein
0.18519257.14623875.html.plaintext.txt	242	By data base search identified uncharacterized full length mRNA sequence corresponding partial cDNAs GenBankTM accession number AY037150 GenBank
0.18519257.14623875.html.plaintext.txt	243	The deduced protein encoded cDNA exhibits high sequence similarity cyclin L1 HUGO gene symbol CCNL1 recently characterized protein N terminal cyclin domain C terminal RS domain Fig
0.18519257.14623875.html.plaintext.txt	244	Therefore designated protein encoded AY037150 GenBank cyclin L2 HUGO gene symbol CCNL2
0.18519257.14623875.html.plaintext.txt	245	The mouse homologues cyclin L1 cyclin L2 previously named Ania 6a Ania 6b respectively 41
0.18519257.14623875.html.plaintext.txt	246	The cyclin domain cyclin L2 amino acids 69 296 indicated Fig
0.18519257.14623875.html.plaintext.txt	247	3A defined comparison cyclin H modeled Andersen et al
0.18519257.14623875.html.plaintext.txt	248	The cyclin domains cyclin L1 L2 closely related cyclin K HUGO gene symbol CCNK 33 identical amino acids cyclin T1T2 HUGO gene symbols CCNT1 CCNT2 30 32 identical amino acids
0.18519257.14623875.html.plaintext.txt	249	The RS domains cyclin L1 L2 contain 45 identical amino acids range also found RS domains known splicing factors
0.18519257.14623875.html.plaintext.txt	250	Genomic Organization CCNL2 The human CCNL2 gene located chromosome 1 1p36
0.18519257.14623875.html.plaintext.txt	251	The gene spans 13 kb comprises 11 exons Fig
0.18519257.14623875.html.plaintext.txt	252	The comparison genomic sequence public expressed sequence tag sequences allowed us deduce existence three different transcripts T1 T3 Fig
0.18519257.14623875.html.plaintext.txt	253	The different transcripts generated alternative splicing exon 6a use alternative polyadenylation sites within exon 6a
0.18519257.14623875.html.plaintext.txt	254	Inclusion exon 6a introduces stop codon therefore transcripts T1 T3 encode truncated version cyclin L2 lacks RS domain cyclin L2S represents short Fig
0.18519257.14623875.html.plaintext.txt	255	Because exon 6a skipped transcript T2 resulting mRNA AY037150 GenBank encodes long version protein named cyclin L2 includes RS domain
0.18519257.14623875.html.plaintext.txt	256	Alternatively Spliced Transcripts CCNL2 CCNL1 We performed Northern blot analyses exon specific hybridization probes Fig
0.18519257.14623875.html.plaintext.txt	257	3C PCR analysis order determine expression pattern CCNL2 different tissues verify existence hypothesized transcripts CCNL2 gene
0.18519257.14623875.html.plaintext.txt	258	On Northern blots RNA different human tissues two major bands 4
0.18519257.14623875.html.plaintext.txt	259	4 kb detected probe corresponding 3 untranslated region exon 11 CCNL2 Fig
0.18519257.14623875.html.plaintext.txt	260	These sizes correspond well calculated lengths transcripts T1 T2 see Fig
0.18519257.14623875.html.plaintext.txt	261	Transcript T1 encodes cyclin L2S ubiquitously found tissues tested although signal intensities varied
0.18519257.14623875.html.plaintext.txt	262	In ovary testis prostate pancreas skeletal muscle liver T1 appeared abundant blood colon lung brain
0.18519257.14623875.html.plaintext.txt	263	In contrast transcript T2 weakly detected tissues skeletal muscle spleen testis RNA contained comparable levels transcripts T1 T2
0.18519257.14623875.html.plaintext.txt	264	4 kb transcript T2 appears double band autoradiogram two polyadenylation sites exon 11 separated 211 bp see Fig
0.18519257.14623875.html.plaintext.txt	265	To confirm identification T1 T2 hybridized identical blots probe derived 5 end exon 6a Fig
0.18519257.14623875.html.plaintext.txt	266	As expected probe detected 4
0.18519257.14623875.html.plaintext.txt	267	5 kb band T1 3 untranslated region probe hybridize 2
0.18519257.14623875.html.plaintext.txt	268	In addition identified band approximate size 1
0.18519257.14623875.html.plaintext.txt	269	We hypothesize band corresponds transcript comprising exons 1 5 total 677 bp 500 bp exon 6a transcript T3 Fig
0.18519257.14623875.html.plaintext.txt	270	Indeed exon 6a harbors potential polyadenylation signal AAUACA 43 nucleotide 1165 BC016333 GenBank GenBankTM accession number
0.18519257.14623875.html.plaintext.txt	271	We identified clone human data bases full length mRNA represents transcript T3
0.18519257.14623875.html.plaintext.txt	272	Consistent identification 1
0.18519257.14623875.html.plaintext.txt	273	2 kb band probe specific 3 end exon 6a E6a 3 detected 4
0.18519257.14623875.html.plaintext.txt	274	5 kb band reacted neither 1
0.18519257.14623875.html.plaintext.txt	275	4 kb transcript data shown
0.18519257.14623875.html.plaintext.txt	276	View larger version 78K FIG
0.18519257.14623875.html.plaintext.txt	277	Differential expression cyclin L1 cyclin L2 splicing variants
0.18519257.14623875.html.plaintext.txt	278	A Northern blot analysis cyclin L1 cyclin L2 human tissues
0.18519257.14623875.html.plaintext.txt	279	Northern blots containing total RNA human tissues hybridized gene specific probes derived exon 11 CCNL2 E11 last exon CCNL1 L1 E14 upper panels 5 end exon 6a CCNL2 E6a 5 corresponding region CCNL1 L1 E78 lower panels
0.18519257.14623875.html.plaintext.txt	280	The localization probes shown Fig
0.18519257.14623875.html.plaintext.txt	281	The identification transcripts T1 T2 T3 according scheme Fig
0.18519257.14623875.html.plaintext.txt	282	pa pancreas ki kidney sm skeletal muscle li liver lu lung pl placenta br brain heart bl peripheral blood lymphocytes co colon si small intestine ov ovary te testis pr prostate th thymus sp spleen
0.18519257.14623875.html.plaintext.txt	283	B design primers detection cyclin L2 splicing variants PCR
0.18519257.14623875.html.plaintext.txt	284	The common forward primer E2for two reverse primers matching either exon 6a E6arev exon 6b E6brev designed specifically amplify transcripts T1T3 T2
0.18519257.14623875.html.plaintext.txt	285	The short polymerization time 30 allow amplification T1 primer E6brev
0.18519257.14623875.html.plaintext.txt	286	Control PCRs T1T3 primers E2for E6arev T2 primers E2for E6brev human testis cDNA library template shown right panel
0.18519257.14623875.html.plaintext.txt	287	C PCR analysis cyclin L2 splicing variants
0.18519257.14623875.html.plaintext.txt	288	First strand cDNAs indicated human mouse tissues subjected PCR analysis primers E2for E6arev E6brev single reaction
0.18519257.14623875.html.plaintext.txt	289	Reaction products human tissues detected Southern blot hybridization probe recognizing products
0.18519257.14623875.html.plaintext.txt	290	PCR products mouse tissues visualized ethidium bromide staining
0.18519257.14623875.html.plaintext.txt	291	The structure CCNL1 gene resembles CCNL2 alternative splicing variants cyclin L1 result long short form protein 41 39 similar cyclin L2 cyclin L2S
0.18519257.14623875.html.plaintext.txt	292	To directly compare expression patterns CCNL1 CCNL2 hybridized Northern blots CCNL1 specific probes corresponded probes used detection CCNL2 mRNA
0.18519257.14623875.html.plaintext.txt	293	Similar CCNL2 probe specific last exon CCNL1 detected two bands 4
0.18519257.14623875.html.plaintext.txt	294	This result suggests alternative transcripts CCNL1 generated way T1 T2 CCNL2
0.18519257.14623875.html.plaintext.txt	295	Consistent identification bands Northern blot probe equivalent E6a 5 detected longer transcript CCNL1 Fig
0.18519257.14623875.html.plaintext.txt	296	No transcript CCNL1 detected corresponded T3 CCNL2
0.18519257.14623875.html.plaintext.txt	297	As CCNL2 stop codon longer transcript results truncated version protein
0.18519257.14623875.html.plaintext.txt	298	These data suggest alternative splicing occurs way isoforms cyclin L inclusion exon 6a CCNL2 corresponding region CCNL1 leads larger transcript encodes truncated protein lacking RS domain part cyclin domain
0.18519257.14623875.html.plaintext.txt	299	To confirm identification bands detected Northern blot analysis characterized ratio cyclin L2 transcripts different tissues PCR analysis
0.18519257.14623875.html.plaintext.txt	300	We designed exon specific primers amplify transcripts T1T3 coding short protein cyclin L2S transcript T2 coding long form cyclin L2 Fig
0.18519257.14623875.html.plaintext.txt	301	Combination three primers single reaction multiplex PCR allowed us compare expression ratios T1T3 T2 different tissues Fig
0.18519257.14623875.html.plaintext.txt	302	It noted ratio PCR products necessarily equal ratio respective cDNA sequences different products may amplified different efficiencies
0.18519257.14623875.html.plaintext.txt	303	However data indicate whether ratio differs different samples e
0.18519257.14623875.html.plaintext.txt	304	4C transcript T2 detected tissues analyzed except human brain
0.18519257.14623875.html.plaintext.txt	305	Nevertheless transcript T2 readily amplified brain cDNA T2 specific primers used PCR data shown
0.18519257.14623875.html.plaintext.txt	306	Consistent Northern blot data stronger signals obtained tissues transcripts T1T3 T2 except testis contained relatively higher levels T2
0.18519257.14623875.html.plaintext.txt	307	In mouse tissues ratio T2 T1T3 also higher testis brain Fig
0.18519257.14623875.html.plaintext.txt	308	Moreover antibody specific C terminal domain cyclin L2 detected band 65 kDa Western blots mouse testis matching size full length cyclin L2 deduced transcript T2 data shown
0.18519257.14623875.html.plaintext.txt	309	Localization Cyclin L1 Cyclin L2 Nuclear Speckle Compartment Many splicing factors RS domains localized subnuclear structures called nuclear speckles 44
0.18519257.14623875.html.plaintext.txt	310	Therefore generated GFP fusion constructs cyclin L2 cyclin L2S cyclin L1 order study subcellular localization proteins fluorescence microscopy
0.18519257.14623875.html.plaintext.txt	311	5 fluorescent signal GFP CycL1 GFP CycL2 appeared discrete punctate staining within nucleus
0.18519257.14623875.html.plaintext.txt	312	Moreover structures co stained antibody directed splicing factor SC 35 well characterized marker protein splicing factor compartment 45
0.18519257.14623875.html.plaintext.txt	313	Interestingly cells overexpressing GFP CycL1 consistently exhibited altered appearance SC 35 containing speckles compared untransfected cells
0.18519257.14623875.html.plaintext.txt	314	Nuclei transfected cells contained higher number speckles smaller size Fig
0.18519257.14623875.html.plaintext.txt	315	Overexpression GFPCycL2 significantly affect pattern speckles Fig
0.18519257.14623875.html.plaintext.txt	316	In contrast GFP CycL2 GFP CycL2S lacks RS domain evenly distributed cytoplasm nucleus previously observed short splice variant cyclin L1 41
0.18519257.14623875.html.plaintext.txt	317	No speckled appearance GFP CycL2S observed nucleus
0.18519257.14623875.html.plaintext.txt	318	View larger version 42K FIG
0.18519257.14623875.html.plaintext.txt	319	Differential subnuclear localization cyclin L1 cyclin L2 cyclin L2S
0.18519257.14623875.html.plaintext.txt	320	COS 7 cells transfected indicated GFP fusion proteins fixed permeabilization labeled using anti SC35 antibody
0.18519257.14623875.html.plaintext.txt	321	GFP green Alexa Red coupled secondary antibody red visualized confocal laser scanning microscopy
0.18519257.14623875.html.plaintext.txt	322	Cyclin L2 Nuclear Speckles Is Highly Mobile Protein Nuclear speckles considered storage compartments proteins involved RNA transcription processing constantly recruited sites active RNA synthesis 44 46
0.18519257.14623875.html.plaintext.txt	323	We used FRAP analyze mobility GFP CycL1 GFP CycL2 living COS 7 cells
0.18519257.14623875.html.plaintext.txt	324	After bleaching GFP fluorescence single nuclear speckle recovery fluorescence time monitored live cell imaging
0.18519257.14623875.html.plaintext.txt	325	For GFPCycL2 recovery fluorescence observed within 20 60 bleaching Fig
0.18519257.14623875.html.plaintext.txt	326	6A indicating protein speckles highly mobile rapidly exchanges unbleached GFP CycL2 molecules nucleus
0.18519257.14623875.html.plaintext.txt	327	Quantitative analysis showed recovery fluorescence fast initial 3 5 incomplete Fig
0.18519257.14623875.html.plaintext.txt	328	This result shows GFP CycL2 nuclear speckles consists highly mobile immobile fraction
0.18519257.14623875.html.plaintext.txt	329	In striking contrast recovery fluorescence observed bleaching GFP CycL1 Fig
0.18519257.14623875.html.plaintext.txt	330	Even 10 min bleaching recovery detected 14 15 cells monitored data shown
0.18519257.14623875.html.plaintext.txt	331	This result indicates GFP CycL1 immobile component nuclear speckles
0.18519257.14623875.html.plaintext.txt	332	View larger version 72K FIG
0.18519257.14623875.html.plaintext.txt	333	FRAP FLIP analysis GFP CycL1 GFP CycL2
0.18519257.14623875.html.plaintext.txt	334	COS 7 cells transfected GFP CycL1 GFP CycL2 imaged fluorescence recovery photobleaching nuclear speckle high intensity laser light time points indicated A
0.18519257.14623875.html.plaintext.txt	335	The area bleach spot indicated circle
0.18519257.14623875.html.plaintext.txt	336	The circled area within nucleus COS 7 cells transfected GFP CycL1 GFP CycL2 continuously photobleached
0.18519257.14623875.html.plaintext.txt	337	Fluorescence intensity shown false color code prior bleaching 0 three consecutive bleach periods 10 20 60
0.18519257.14623875.html.plaintext.txt	338	Regions 1 microm diameter within nuclear speckles GFP CycL2 transfected COS 7 cells bleached subsequently recovery fluorescence measured every second
0.18519257.14623875.html.plaintext.txt	339	The diagram depicts data five speckles single cell representative result analysis three different cells
0.18519257.14623875.html.plaintext.txt	340	To confirm GFP CycL1 GFP CycL2 indeed differed intranuclear mobility performed FLIP analysis proteins living COS 7 cells
0.18519257.14623875.html.plaintext.txt	341	Repetitive bleaching small area nucleus 1 microm free nuclear speckles significantly reduced total nuclear GFP fluorescence GFPCycL2 expressing cells indicating substantial fraction protein moved area subjected bleaching within period 60 Fig
0.18519257.14623875.html.plaintext.txt	342	In contrast GFP CycL1 fluorescence affected exclusively bleaching area remained unchanged remaining volume nucleus
0.18519257.14623875.html.plaintext.txt	343	Consistent FRAP data result indicates cyclin L1 freely diffuse within nucleus
0.18519257.14623875.html.plaintext.txt	344	Mapping Binding Domain Cyclin L2 To identify domain responsible interaction DYRK1A cyclin L2 performed pull experiments deletion mutants DYRK1A Fig
0.18519257.14623875.html.plaintext.txt	345	GST DYRK1A C construct used interaction screening lacks noncatalytic C terminal domain
0.18519257.14623875.html.plaintext.txt	346	GST DYRK1A CN expresses catalytic domain GST DYRK1A NT contains N terminus small part catalytic domain Fig
0.18519257.14623875.html.plaintext.txt	347	The serinearginine rich splicing factor SF2 also called ASF SRp30a used comparison known several splicing factors bind heterodimerization RS domains 47
0.18519257.14623875.html.plaintext.txt	348	View larger version 29K FIG
0.18519257.14623875.html.plaintext.txt	349	Mapping cyclin L2 binding domain DYRK1A
0.18519257.14623875.html.plaintext.txt	350	Total cellular lysate GFP CycL2 N transfected COS 7 cells incubated GST indicated GST fusion constructs DYRK1A DYRK2 SF2 immobilized glutathione Sepharose beads
0.18519257.14623875.html.plaintext.txt	351	After washing five times proteins retained Sepharose 5 input GFP CycL2 N containing lysate resolved SDS PAGE followed immunoblotting WB using GFP specific antibody upper panel
0.18519257.14623875.html.plaintext.txt	352	Ponceau staining shows amounts bait proteins lower panel
0.18519257.14623875.html.plaintext.txt	353	The bands corresponding full length protein marked asterisks
0.18519257.14623875.html.plaintext.txt	354	DYRK1A NT calculated size 44 kDa indicating protein truncated
0.18519257.14623875.html.plaintext.txt	355	The baits used schematically shown right panel
0.18519257.14623875.html.plaintext.txt	356	The percentage identical amino acids DYRK1A DYRK2 DH box catalytic domain cat indicated
0.18519257.14623875.html.plaintext.txt	357	7 similar amounts GFP CycL2N pulled SF2 DYRK1A C
0.18519257.14623875.html.plaintext.txt	358	This result indicates C terminal part cyclin L2 interact comparably well RS domain containing proteins protein kinase DYRK1A
0.18519257.14623875.html.plaintext.txt	359	Cyclin L2 bound also related kinase DYRK2
0.18519257.14623875.html.plaintext.txt	360	Notably sequence similarity DYRK2 DYRK1A limited catalytic domain short segment immediately N terminal catalytic domain earlier designated DYRK homology box DH box 48
0.18519257.14623875.html.plaintext.txt	361	The DH box contains large number negative charges 35 may thus bind RS domain cyclin L2 ionic interactions
0.18519257.14623875.html.plaintext.txt	362	Both DYRK1A NC lacks DH box N terminal domain alone bound cyclin L2 weakly
0.18519257.14623875.html.plaintext.txt	363	Taken together results suggest optimal binding cyclin L2 DYRK1A DYRK2 requires presence catalytic domain DH box
0.18519257.14623875.html.plaintext.txt	364	Interaction Cyclin L2 PITSLREp110 Cyclin L1 reported associate p110 isoform PITSLRE PITSLREp110 orphan cyclin dependent kinase 41 39 official gene symbol CDC2L1
0.18519257.14623875.html.plaintext.txt	365	Because high sequence similarity cyclin domains cyclin L1 cyclin L2 tested whether cyclin L2 also interacted PITSLREp110 Fig
0.18519257.14623875.html.plaintext.txt	366	In co immunoprecipitation experiments GFP fusion proteins cyclin L1 cyclin L2 cyclin L2S observed PITSLREp110 co precipitated cyclin L2 although less efficiently cyclin L1
0.18519257.14623875.html.plaintext.txt	367	Neither cyclin L2S unrelated control protein non RS splicing factor SF3B1 bound detectably PITSLREp110
0.18519257.14623875.html.plaintext.txt	368	View larger version 70K FIG
0.18519257.14623875.html.plaintext.txt	369	Co immunoprecipitation cyclin L1 L2 L2S PITSLREp110
0.18519257.14623875.html.plaintext.txt	370	COS 7 cells transfected GFP constructs cyclin L1 cyclin L2 cyclin L2S unrelated control protein SF3B1
0.18519257.14623875.html.plaintext.txt	371	Fusion proteins immunoprecipitated GFP specific antiserum immunoprecipitates IP analyzed Western blotting WB anti PITSLRE antibody upper panel anti GFP antibody lower panel
0.18519257.14623875.html.plaintext.txt	372	The p110 band PITSLRE marked arrow
0.18519257.14623875.html.plaintext.txt	373	Lysate one fiftieth input loaded gel
0.18519257.14623875.html.plaintext.txt	374	Identification Vitro Phosphorylation Sites Our finding different arginineserine rich splicing factors equally well phosphorylated DYRK1A Fig
0.18519257.14623875.html.plaintext.txt	375	2 raises question sites cyclin L2 targeted DYRK1A
0.18519257.14623875.html.plaintext.txt	376	Bacterially expressed His6 cyclin L2 phosphorylated DYRK1A vitro subjected SDS PAGE
0.18519257.14623875.html.plaintext.txt	377	9 two slower migrating bands appeared phosphorylation cyclin L2 DYRK1A
0.18519257.14623875.html.plaintext.txt	378	The three bands individually analyzed phosphorylated amino acids mass spectroscopy comparison unphosphorylated cyclin L2
0.18519257.14623875.html.plaintext.txt	379	Three phosphoserines identified slower migrating bands Fig
0.18519257.14623875.html.plaintext.txt	380	9 Ser 330 Ser 338 Ser 369
0.18519257.14623875.html.plaintext.txt	381	All serine residues located N terminal proline residues consistent previous classification DYRK1A proline directed kinase
0.18519257.14623875.html.plaintext.txt	382	It noted phosphorylation sites may escaped detection since predicted size tryptic fragments RS domain would small successfully purify analyze present methodology
0.18519257.14623875.html.plaintext.txt	383	View larger version 26K FIG
0.18519257.14623875.html.plaintext.txt	384	Phosphorylation cyclin L2 DYRK1A vitro
0.18519257.14623875.html.plaintext.txt	385	Bacterially expressed His6 CycL2 phosphorylated GSTDYRK1Acat 11 molar ratio resulting bands resolved SDS PAGE right lane parallel unphosphorylated His6 CycL2
0.18519257.14623875.html.plaintext.txt	386	The three bands cut indicated phosphorylation sites single band determined mass spectrometry tryptic peptides
0.18519257.14623875.html.plaintext.txt	387	The amino acid sequences surrounding three phosphorylated sites shown
0.18519257.14623875.html.plaintext.txt	388	In Vivo Phosphorylation Cyclin L2 To analyze whether cyclin L2 phosphoprotein vivo COS 7 cells transfected GFP constructs cyclin L2 alone co transfected DYRK1A respectively incubated 32P labeled phosphate
0.18519257.14623875.html.plaintext.txt	389	CLK3 compared DYRK1A kinases CLK family known phosphorylate RS domains arginineserine rich splicing factors 49
0.18519257.14623875.html.plaintext.txt	390	10A immunoprecipitated cyclin L2 fact phosphoprotein expressed mammalian cells
0.18519257.14623875.html.plaintext.txt	391	Coexpression DYRK1A CLK3 detectably alter level phosphate incorporation possibly cyclin L2 already strongly phosphorylated endogenous protein kinases
0.18519257.14623875.html.plaintext.txt	392	However slowly migrating form GFP CycL2 observed immunoprecipitates DYRK1A overexpressing cells
0.18519257.14623875.html.plaintext.txt	393	This band also detected total cellular lysates DYRK1A expressing COS 7 cells directly analyzed Western blotting Fig
0.18519257.14623875.html.plaintext.txt	394	10B transfection kinase negative point mutant DYRK1A DYRK1A K188R
0.18519257.14623875.html.plaintext.txt	395	This result strongly suggests cyclin L2 directly phosphorylated DYRK1A living cells
0.18519257.14623875.html.plaintext.txt	396	View larger version 34K FIG
0.18519257.14623875.html.plaintext.txt	397	Phosphorylation cyclin L2 DYRK1A vivo
0.18519257.14623875.html.plaintext.txt	398	COS 7 cells co transfected 1
0.18519257.14623875.html.plaintext.txt	399	5 microg plasmids encoding GFP CycL2 either GFP GFP DYRK1A GFP DYRK1A K188R GFP CLK3 indicated lanes
0.18519257.14623875.html.plaintext.txt	400	A cells incubated radioactive H3PO4 2
0.18519257.14623875.html.plaintext.txt	401	5 h GFP fusion proteins immunoprecipitated denaturing conditions GFP antiserum
0.18519257.14623875.html.plaintext.txt	402	Phosphorylation detected autoradiography
0.18519257.14623875.html.plaintext.txt	403	B total cellular lysates subjected Western blot WB analysis GFP specific antibody
0.18519257.14623875.html.plaintext.txt	404	Two differently exposed films blot shown visualize shifted band GFP CycL2 upper panel detection DYRK1A DYRK1A K188R lower panel
0.18519257.14623875.html.plaintext.txt	405	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES In study made use arrayed cDNA expression library identify interaction partners well substrates nuclear protein kinase DYRK1A
0.18519257.14623875.html.plaintext.txt	406	Screening phage libraries overlay assay radiolabeled proteins well substrate screening solid phase phosphorylation previously employed identify kinase substrates 21 26
0.18519257.14623875.html.plaintext.txt	407	The main advantage using filter array screening possibility directly isolate positive clones without rounds purification
0.18519257.14623875.html.plaintext.txt	408	The second advantage expression plasmids isolated library directly used functional assays
0.18519257.14623875.html.plaintext.txt	409	These advantages made feasible select 58 positive clones verify original screening results recombinant proteins Fig
0.18519257.14623875.html.plaintext.txt	410	All tested clones able bind DYRK1A andor phosphorylated DYRK1A demonstrating reliability screening results
0.18519257.14623875.html.plaintext.txt	411	Disregarding cloning artifacts identified high proportion nuclear proteins potential downstream targets DYRK1A particular splicing proteins transcription factors listed Table I
0.18519257.14623875.html.plaintext.txt	412	The present work provides detailed characterization novel member cyclin family cyclin L2 interaction partner substrate DYRK1A
0.18519257.14623875.html.plaintext.txt	413	Cyclin L2 closely related isoform cyclin L1 originally named cyclin L 39 differ members cyclin family presence C terminal RS domain
0.18519257.14623875.html.plaintext.txt	414	This unusual domain structure conserved homologous proteins invertebrates plants Drosophila Caenorhabditis Arabidopsis 41 providing evidence conserved function RS domain proteins
0.18519257.14623875.html.plaintext.txt	415	The RS domain hallmark many proteins involved pre mRNA processing including serinearginine rich splicing factors SR proteins contain least one RNA binding motif SR protein related polypeptides 50 51 47 52
0.18519257.14623875.html.plaintext.txt	416	SR protein related polypeptides constitute inhomogeneous family proteins contain RS domain combination additional domains e
0.18519257.14623875.html.plaintext.txt	417	protein kinase domains CLK1 CLK4 CrkRSCRK7 DEADH box RNA helicases 47 52
0.18519257.14623875.html.plaintext.txt	418	The modular domain architecture cyclin L1 L2 thus typical feature SR protein related proteins although unusual members cyclin family
0.18519257.14623875.html.plaintext.txt	419	RS domains mediate protein protein interactions proteins contain RS repeats target proteins nuclear speckle compartment 50
0.18519257.14623875.html.plaintext.txt	420	Here show cyclin L2 interacts alternative splicing factor SF2ASF Fig
0.18519257.14623875.html.plaintext.txt	421	7 co localized SR protein SC35 nuclear speckles Fig
0.18519257.14623875.html.plaintext.txt	422	This subcellular distribution likely mediated RS domain since construct cyclin L2 lacked major part cyclin domain cyclin L21 222 exhibited subnuclear distribution indistinguishable full length construct data shown
0.18519257.14623875.html.plaintext.txt	423	In contrast cyclin L2S lacks RS domain distributed nucleus cytoplasm Fig
0.18519257.14623875.html.plaintext.txt	424	Cyclin L1 also found co localized SC35 previously shown Berke et al
0.18519257.14623875.html.plaintext.txt	425	However cyclin L1 cyclin L2 differed strikingly regard intranuclear mobility
0.18519257.14623875.html.plaintext.txt	426	Photobleaching experiments showed significant fraction GFP CycL2 nuclear speckles rapidly exchanged unbleached molecules within nucleus FRAP analysis Fig
0.18519257.14623875.html.plaintext.txt	427	Moreover FLIP analysis showed considerable portion nuclear GFP CycL2 transits given small region nucleus within time period 60 Fig
0.18519257.14623875.html.plaintext.txt	428	6B indicating protein diffuses freely nucleoplasm associated speckles
0.18519257.14623875.html.plaintext.txt	429	In contrast GFP CycL1 found immobile FRAP FLIP analysis
0.18519257.14623875.html.plaintext.txt	430	To knowledge observation GFP CycL1 immobile component nuclear speckles unprecedented analysis proteins RS domains review see Ref
0.18519257.14623875.html.plaintext.txt	431	The different mobilities cyclin L1 cyclin L2 indicate proteins different functions despite highly similar structures
0.18519257.14623875.html.plaintext.txt	432	Presently speculate reason different mobilities cyclin L1 cyclin L2
0.18519257.14623875.html.plaintext.txt	433	The fact cyclin L1 co immunoprecipitated PITSLREp110 argues possibility GFP fusion protein grossly misfolded cell
0.18519257.14623875.html.plaintext.txt	434	Instead association cyclin L1 cyclin dependent kinase PITSLREp110 may constrain mobility cyclin L1 whereas association cyclin L2 PITSLREp110 appears weaker Fig
0.18519257.14623875.html.plaintext.txt	435	Altogether presence RS domain interaction SF2ASF localization nuclear speckle compartment suggest role cyclin L2 regulation RNA splicing
0.18519257.14623875.html.plaintext.txt	436	Cyclin L1 previously reported stimulate vitro splicing reaction 39
0.18519257.14623875.html.plaintext.txt	437	Notably however speckles also shown contain proteins splicing factors including 3 end mRNA processing factors cyclin T1 CDK9 complex hyperphosphorylated form RNA polymerase II 53 55
0.18519257.14623875.html.plaintext.txt	438	Thus function cyclin L2 control transcription another step pre mRNA processing cannot excluded
0.18519257.14623875.html.plaintext.txt	439	Based sequence comparisons cyclin box cyclin L2 belongs group cyclins involved transcriptional regulation comprising cyclins H K T1 T2 Fig
0.18519257.14623875.html.plaintext.txt	440	View larger version 10K FIG
0.18519257.14623875.html.plaintext.txt	441	Relationship cyclin L2 members cyclin family
0.18519257.14623875.html.plaintext.txt	442	The dendrogram constructed alignment cyclin Cyc domains help Clustal program 66
0.18519257.14623875.html.plaintext.txt	443	The branch transcriptional cyclins highlighted boldface type
0.18519257.14623875.html.plaintext.txt	444	Data base Swiss Prot accession numbers follows cyclin K O75909 GenBank cyclin T1 O60563 GenBank cyclin T2 O60583 GenBank cyclin H P51946 GenBank cyclin A1 P78396 GenBank cyclin B1 P14635 GenBank cyclin D1 P24385 GenBank cyclin E1 P24864 GenBank
0.18519257.14623875.html.plaintext.txt	445	These cyclins association corresponding cyclin dependent kinases components basal transcription factor TFIIH cyclin H CDK7 transcriptional elongation factor P TEFb phosphorylates C terminal domain large subunit RNA polymerase II cyclin T CDK9 cyclin K CDK9 56
0.18519257.14623875.html.plaintext.txt	446	The present data show cyclin L2 binds vivo cyclin dependent kinase PITSLREp110 previously also demonstrated cyclin L1 41 39
0.18519257.14623875.html.plaintext.txt	447	PITSLRE also named CDK11 57 Cdc2 like 1 official gene symbol CDC2L1 exists 20 splicing variants 58
0.18519257.14623875.html.plaintext.txt	448	PITSLREp110 isoforms localized nucleus co localized nuclear speckles splicing protein RNPS1 59
0.18519257.14623875.html.plaintext.txt	449	Here show cyclin L2 co localized SC35 splicing factor compartment supporting hypothesis cyclin L2 PITSLREp110 associated vivo
0.18519257.14623875.html.plaintext.txt	450	Recent reports provide evidence PITSLRE participates signaling pathway coordinates transcription RNA processing events 57 60
0.18519257.14623875.html.plaintext.txt	451	It noted coimmunoprecipitation experiments Fig
0.18519257.14623875.html.plaintext.txt	452	8 cyclin L2 interact strongly PITSLREp110 cyclin L1 cannot exclude possibility related kinases CDK10PISSLRE CDK7 may act catalytically active partner cyclin L2
0.18519257.14623875.html.plaintext.txt	453	Interestingly identified short variant cyclin L2 cyclin L2S lacks RS domain part cyclin box
0.18519257.14623875.html.plaintext.txt	454	Sequence comparisons human gene cyclin L2 CCNL2 transcripts allowed us deduce alternatively spliced transcripts long short variant Fig
0.18519257.14623875.html.plaintext.txt	455	The exonintron structure gene cyclin L1 CCNL1 nearly identical CCNL2 CCNL1 results alternative splicing variants coding full length cyclin L1 short isoform cyclin L1 cyclin L1S designated Ania 6a25 Berke et al
0.18519257.14623875.html.plaintext.txt	456	By Northern blot analysis exon specific probes could unambiguously identify larger transcripts 4
0.18519257.14623875.html.plaintext.txt	457	4A mRNA short polypeptides cyclin L1S L2S
0.18519257.14623875.html.plaintext.txt	458	This result agreement analysis murine cyclin L1 transcripts Berke et al
0.18519257.14623875.html.plaintext.txt	459	41 improves characterization human CCNL1 gene transcripts performed Dickinson et al
0.18519257.14623875.html.plaintext.txt	460	The alternative splicing variants cyclin L1 L2 differentially expressed human tissues Fig
0.18519257.14623875.html.plaintext.txt	461	In tissues mRNA levels full length cyclin L1 T2 comparable higher cyclin L1S
0.18519257.14623875.html.plaintext.txt	462	In contrast mRNA full length cyclin L2 detected mainly testis whereas short variant cyclin L2S nearly ubiquitously expressed
0.18519257.14623875.html.plaintext.txt	463	Furthermore found transcripts CCNL1 CCNL2 differentially regulated extracellular stimuli phorbol ester cycloheximide specifically induced mRNA full length cyclin L1 human RT112 keratinocytes whereas levels cyclin L2 transcripts weakly affected cycloheximide phorbol ester
0.18519257.14623875.html.plaintext.txt	464	2 These results accordance extensive analysis cyclin L1 expression rat neurons Berke et al
0.18519257.14623875.html.plaintext.txt	465	41 identified CCNL1 immediate early gene induced cocaine dopamine
0.18519257.14623875.html.plaintext.txt	466	Taken together present characterization cyclin L2 gene suggests CCNL1 CCNL2 originated gene duplication acquired different patterns expression divergent evolution promoters
0.18519257.14623875.html.plaintext.txt	467	The fact splicing variants conserved paralogous genes CCNL1 CCNL2 together differential patterns expression argues possibility cyclin L1S L2S products irregular splicing
0.18519257.14623875.html.plaintext.txt	468	However cyclin domain RS domain truncated completely absent respectively cyclin L1S L2S
0.18519257.14623875.html.plaintext.txt	469	Cyclin L2S neither interacts PITSLREp110 likely incomplete cyclin box defined Andersen et al
0.18519257.14623875.html.plaintext.txt	470	42 localized nuclear speckles
0.18519257.14623875.html.plaintext.txt	471	Identical results reported cyclin L1S 39 41
0.18519257.14623875.html.plaintext.txt	472	The existence short variants apparent function reminiscent alternative splicing CLK kinases 61
0.18519257.14623875.html.plaintext.txt	473	CLK1 regulated alternative splicing CLK1 pre mRNA yielding mRNAs encoding catalytically active kinase truncated polypeptides lacking kinase domain
0.18519257.14623875.html.plaintext.txt	474	CLK1 regulates splicing phosphorylation SR proteins controls expression since presence active kinase favors production truncated inactive polypeptide 61
0.18519257.14623875.html.plaintext.txt	475	There known cases splicing factors subject autoregulation alternative splicing 62 63 hypothesize existence short splicing variants cyclins L1 L2 provides means control levels full length proteins level splicing
0.18519257.14623875.html.plaintext.txt	476	We characterized cyclin L2 substrate interaction partner protein kinase DYRK1A
0.18519257.14623875.html.plaintext.txt	477	It appears plausible proteins also interact vivo since DYRK1A previously found localized nuclear speckles 17 19
0.18519257.14623875.html.plaintext.txt	478	The original cyclin L2 clone isolated expression library lacked cyclin domain thus allowing conclusion DYRK1A interacts RS domain cyclin L2
0.18519257.14623875.html.plaintext.txt	479	The results pull assays indicate catalytic domain DYRK1A alone able bind cyclin L2 interaction greatly enhanced presence small conserved region preceding catalytic domain called DH box
0.18519257.14623875.html.plaintext.txt	480	This region contains large number acidic residues 35 conserved kinases DYRK family several related kinases involved regulation splicing CLK family PRP4 48
0.18519257.14623875.html.plaintext.txt	481	It appears reasonable assume negatively charged DH box engaged ionic interactions positively charged RS domain
0.18519257.14623875.html.plaintext.txt	482	DYRK1A phosphorylated cyclin L2 vitro within C terminal domain three vitro phosphorylation sites identified present study located within RS repeat motifs Fig
0.18519257.14623875.html.plaintext.txt	483	This finding confirms previous classification DYRK1A proline directed kinase 35
0.18519257.14623875.html.plaintext.txt	484	Notably none target sites cyclin L2 contains arginine residue position P 2 P 3 others previously found critical substrate recognition 14 34 64
0.18519257.14623875.html.plaintext.txt	485	We could show cyclin L2 indeed phosphoprotein expressed COS 7 cells
0.18519257.14623875.html.plaintext.txt	486	The phosphate content cyclin L2 significantly altered co expressed DYRK1A Fig
0.18519257.14623875.html.plaintext.txt	487	10A probably RS domains generally highly phosphorylated endogenous kinases 47
0.18519257.14623875.html.plaintext.txt	488	However overexpression COS 7 cells catalytically active DYRK1A kinase inactive mutant induced mobility shift cyclin L2 resembling result vitro phosphorylation His6 CycL2 DYRK1A Fig
0.18519257.14623875.html.plaintext.txt	489	This result strongly suggests DYRK1A directly phosphorylates cyclin L2 living cells
0.18519257.14623875.html.plaintext.txt	490	The phosphorylation SR proteins necessary recruitment nuclear speckles sites transcriptionpre mRNA processing 44 65
0.18519257.14623875.html.plaintext.txt	491	19 recently reported kinase active DYRK1A inactive point mutant induced speckle disassembly
0.18519257.14623875.html.plaintext.txt	492	However remains determined whether phosphorylation cyclin L2 involved action DYRK1A
0.18519257.14623875.html.plaintext.txt	493	FOOTNOTES This work supported Deutsche Forschungsgemeinschaft Grants Be 19671 3 SFB542
0.18519257.14623875.html.plaintext.txt	494	The costs publication article defrayed part payment page charges
0.18519257.14623875.html.plaintext.txt	495	This article must therefore hereby marked advertisement accordance 18 U
0.18519257.14623875.html.plaintext.txt	496	Section 1734 solely indicate fact
0.18519257.14623875.html.plaintext.txt	497	To correspondence addressed Institut fur Pharmakologie und Toxikologie Medizinische Fakultat der RWTH Aachen Wendlingweg 2 52074 Aachen Germany
0.18519257.14623875.html.plaintext.txt	498	49 241 8089136 Fax 49 241 8082433 E mail walter
0.18519257.14623875.html.plaintext.txt	499	1 The abbreviations used TBS Tris buffered saline CDK cyclin dependent kinase FLIP fluorescence loss photobleaching FRAP fluorescence recovery photobleaching GFP green fluorescent protein GST glutathione S transferase PBS phosphate buffered saline RS domain arginine serine rich domain BSA bovine serum albumin DH box DYRK homology box
0.18519257.14623875.html.plaintext.txt	500	ACKNOWLEDGMENTS We thank Stefan Stamm Erlangen Germany gift expression plasmids GST TRA21 GST SF2
0.18519257.14623875.html.plaintext.txt	501	The excellent technical assistance Hanna Czajkowska Birgit Feulner gratefully acknowledged
0.18519257.14623875.html.plaintext.txt	502	We thank Hans Georg Joost Peter C
0.18519257.14623875.html.plaintext.txt	503	Heinrich critical discussion continuous support work
0.18519257.14623875.html.plaintext.txt	504	We grateful Bob Kosier critical reading manuscript
0.18519257.14623875.html.plaintext.txt	505	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Hammerle B
0.18519257.14623875.html.plaintext.txt	506	1995 Neuron 14 287 301Medline Order article via Infotrieve Guimera J
0.18519257.14623875.html.plaintext.txt	507	5 1305 1310CrossRefMedline Order article via Infotrieve Ohira M
0.18519257.14623875.html.plaintext.txt	508	16 28 36Medline Order article via Infotrieve Altafaj X
0.18519257.14623875.html.plaintext.txt	509	10 1915 1923AbstractFree Full Text Fotaki V
0.18519257.14623875.html.plaintext.txt	510	22 6636 6647AbstractFree Full Text Hammerle B
0.18519257.14623875.html.plaintext.txt	511	246 259 273CrossRefMedline Order article via Infotrieve Galceran J
0.18519257.14623875.html.plaintext.txt	512	355 597 607CrossRefMedline Order article via Infotrieve von Groote Bidlingmaier F
0.18519257.14623875.html.plaintext.txt	513	300 764 769CrossRefMedline Order article via Infotrieve Yang E
0.18519257.14623875.html.plaintext.txt	514	276 39819 39824AbstractFree Full Text Mao J
0.18519257.14623875.html.plaintext.txt	515	277 35156 35161AbstractFree Full Text Woods Y
0.18519257.14623875.html.plaintext.txt	516	355 609 615CrossRefMedline Order article via Infotrieve Chen Hwang M
0.18519257.14623875.html.plaintext.txt	517	277 17597 17604AbstractFree Full Text Song W
0.18519257.14623875.html.plaintext.txt	518	231 640 644CrossRefMedline Order article via Infotrieve Becker W
0.18519257.14623875.html.plaintext.txt	519	273 25893 25902AbstractFree Full Text Marti E
0.18519257.14623875.html.plaintext.txt	520	964 250 263CrossRefMedline Order article via Infotrieve Alvarez M
0.18519257.14623875.html.plaintext.txt	521	116 3099 3107AbstractFree Full Text Yang X
0.18519257.14623875.html.plaintext.txt	522	1992 Science 25 680 682 Chen Z
0.18519257.14623875.html.plaintext.txt	523	Cell 3 339 350Medline Order article via Infotrieve Airhart N
0.18519257.14623875.html.plaintext.txt	524	278 38693 38698AbstractFree Full Text Zhou T
0.18519257.14623875.html.plaintext.txt	525	Cell 5 127 138Medline Order article via Infotrieve Yaffe M
0.18519257.14623875.html.plaintext.txt	526	19 348 353CrossRefMedline Order article via Infotrieve Brinkworth R
0.18519257.14623875.html.plaintext.txt	527	100 74 79AbstractFree Full Text Fukunaga R
0.18519257.14623875.html.plaintext.txt	528	16 1921 1933AbstractFree Full Text Knebel A
0.18519257.14623875.html.plaintext.txt	529	20 4360 4369AbstractFree Full Text Lewis T
0.18519257.14623875.html.plaintext.txt	530	Cell 6 1343 1454Medline Order article via Infotrieve Bussow K
0.18519257.14623875.html.plaintext.txt	531	26 5007 5008AbstractFree Full Text Bussow K
0.18519257.14623875.html.plaintext.txt	532	2000 Genomics 65 1 8CrossRefMedline Order article via Infotrieve Zhao Z
0.18519257.14623875.html.plaintext.txt	533	2001 Methods 24 194 200CrossRefMedline Order article via Infotrieve Kentrup H
0.18519257.14623875.html.plaintext.txt	534	271 3488 3495AbstractFree Full Text Takayama S
0.18519257.14623875.html.plaintext.txt	535	69 171 184Medline Order article via Infotrieve Himpel S
0.18519257.14623875.html.plaintext.txt	536	275 2431 2438AbstractFree Full Text Himpel S
0.18519257.14623875.html.plaintext.txt	537	359 497 505CrossRefMedline Order article via Infotrieve Beil B
0.18519257.14623875.html.plaintext.txt	538	16 679 690Medline Order article via Infotrieve Himpel S
0.18519257.14623875.html.plaintext.txt	539	274 138 141CrossRefMedline Order article via Infotrieve Becker W
0.18519257.14623875.html.plaintext.txt	540	Acta 1312 63 67CrossRefMedline Order article via Infotrieve Dickinson L
0.18519257.14623875.html.plaintext.txt	541	277 25465 25473AbstractFree Full Text Giese B
0.18519257.14623875.html.plaintext.txt	542	278 39205 39213AbstractFree Full Text Berke J
0.18519257.14623875.html.plaintext.txt	543	2001 Neuron 32 277 287Medline Order article via Infotrieve Andersen G
0.18519257.14623875.html.plaintext.txt	544	16 958 967AbstractFree Full Text Beaudoing E
0.18519257.14623875.html.plaintext.txt	545	10 1001 1010AbstractFree Full Text Lamond A
0.18519257.14623875.html.plaintext.txt	546	4 605 612CrossRefMedline Order article via Infotrieve Fu X
0.18519257.14623875.html.plaintext.txt	547	1990 Nature 343 437 441CrossRefMedline Order article via Infotrieve Misteli T
0.18519257.14623875.html.plaintext.txt	548	2000 Science 291 843 847 Graveley B
0.18519257.14623875.html.plaintext.txt	549	2000 RNA 6 1197 1211Free Full Text Becker W
0.18519257.14623875.html.plaintext.txt	550	62 1 17Medline Order article via Infotrieve Colwill K
0.18519257.14623875.html.plaintext.txt	551	1995 RNA 1 663 680Medline Order article via Infotrieve Blencowe B
0.18519257.14623875.html.plaintext.txt	552	77 277 291CrossRefMedline Order article via Infotrieve Boucher L
0.18519257.14623875.html.plaintext.txt	553	2001 RNA 7 1693 1701AbstractFree Full Text Mortillaro M
0.18519257.14623875.html.plaintext.txt	554	93 8253 8257AbstractFree Full Text Schul W
0.18519257.14623875.html.plaintext.txt	555	238 1 12CrossRefMedline Order article via Infotrieve Herrmann C
0.18519257.14623875.html.plaintext.txt	556	114 1491 1503AbstractFree Full Text Oelgeschlager T
0.18519257.14623875.html.plaintext.txt	557	190 160 169CrossRefMedline Order article via Infotrieve Hu D
0.18519257.14623875.html.plaintext.txt	558	278 8623 8629AbstractFree Full Text Gururajan R
0.18519257.14623875.html.plaintext.txt	559	8 929 939AbstractFree Full Text Loyer P
0.18519257.14623875.html.plaintext.txt	560	111 1495 1506AbstractFree Full Text Trembley J
0.18519257.14623875.html.plaintext.txt	561	277 2589 2596AbstractFree Full Text Duncan P
0.18519257.14623875.html.plaintext.txt	562	17 5996 6001Abstract Jumaa H
0.18519257.14623875.html.plaintext.txt	563	16 5077 5085AbstractFree Full Text Mattox W
0.18519257.14623875.html.plaintext.txt	564	5 786 796Abstract Campbell L
0.18519257.14623875.html.plaintext.txt	565	510 31 36CrossRefMedline Order article via Infotrieve Misteli T
0.18519257.14623875.html.plaintext.txt	566	143 297 307AbstractFree Full Text Higgins D
0.18519257.14623875.html.plaintext.txt	567	266 383 402Medline Order article via Infotrieve
0.16787788.12060559.html.plaintext.txt	0	ET 1 receptor gene expression distribution L1 L2 cells hypertensive sheep pulmonary artery Elena V
0.16787788.12060559.html.plaintext.txt	1	Balyakina1 Daohong Chen2 Mayme L
0.16787788.12060559.html.plaintext.txt	2	Lawrence2 Suzanne Manning2 Richard E
0.16787788.12060559.html.plaintext.txt	3	Shappell2 Barbara Meyrick12
0.16787788.12060559.html.plaintext.txt	4	Departments 2 Pathology 1 Medicine Center Lung Research Vanderbilt University Medical Center Nashville Tennessee 37232 2650
0.16787788.12060559.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	6	We examined gene surface expression activity endothelin ET 1 receptors ETA ETB subendothelial L1 inner medial L2 cells main pulmonary artery sheep continuous air embolization CAE induced chronic pulmonary hypertension CPH
0.16787788.12060559.html.plaintext.txt	7	According quantitative real time RT PCR basal gene expression receptors significantly higher L2 L1 cells hypertensive L2 cells showed significantly higher gene expression ETB controls
0.16787788.12060559.html.plaintext.txt	8	Expression genes hypertensive L1 cells similar controls
0.16787788.12060559.html.plaintext.txt	9	Fluorescence activated cell sorter analysis confirmed increased distribution ETB hypertensive L2 cells
0.16787788.12060559.html.plaintext.txt	10	Although ETA receptors control L2 cells showed significant binding 125I labeled ET 1 1 h receptors bound ET 1 hypertensive cells
0.16787788.12060559.html.plaintext.txt	11	Exposure exogenous ET 1 18 h revealed L2 cells internalized ET 1 internalization hypertensive L2 cells significantly reduced compared controls
0.16787788.12060559.html.plaintext.txt	12	Treatment ETA BQ 610 ETB BQ 788 receptor antagonists demonstrated receptors contributed internalization ET 1 control L2 cells whereas hypertensive cells receptor antagonists used combination significant suppression ET 1 internalization found
0.16787788.12060559.html.plaintext.txt	13	We conclude sheep receiving CAE alterations ETB receptors cells L2 layer may contribute maintenance CPH via alterations expression distribution activity
0.16787788.12060559.html.plaintext.txt	14	ETA receptor ETB receptor smooth muscle cells pulmonary hypertension endothelin
0.16787788.12060559.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	16	SINCE ITS DISCOVERY 12 YEARS AGO endothelin ET shown contribute wide variety physiological pathophysiological processes various systems 22
0.16787788.12060559.html.plaintext.txt	17	The ET family 21 amino acid peptides exists three distinct isoforms ET 1 ET 2 ET 3
0.16787788.12060559.html.plaintext.txt	18	It extremely potent vasoconstrictor resulting slowly developing sustained contraction
0.16787788.12060559.html.plaintext.txt	19	Although endothelial cell originally described source ET 1 known several cell types including pulmonary vascular smooth muscle cells synthesize peptide 33 36
0.16787788.12060559.html.plaintext.txt	20	The biological effects ET 1 mediated two distinct ET receptor subtypes ETA ETB 1 35
0.16787788.12060559.html.plaintext.txt	21	The affinity ETA receptor ET 1 shown 100 times ET 3 ET 1 ET 2 ET 3 whereas affinity ETB receptor equipotent three isoforms ET 34
0.16787788.12060559.html.plaintext.txt	22	Early reports indicated ETA receptor smooth muscle responsible vasoconstrictor effect ET 1 whereas ETB receptor endothelial cells modulated ET 1 induced vasodilation
0.16787788.12060559.html.plaintext.txt	23	However recent pharmacological studies suggest two classes ETB cell specific effects ETB1 endothelial cells mediating vasodilation ETB2 smooth muscle cells mediating vasoconstriction 9
0.16787788.12060559.html.plaintext.txt	24	The ETB receptor also functions clearance receptor particularly important lung 50 ET 1 retained 22 29
0.16787788.12060559.html.plaintext.txt	25	ET 1 linked development chronic pulmonary hypertension CPH
0.16787788.12060559.html.plaintext.txt	26	Increased expression peptide demonstrated endothelial cells pulmonary arteries patients idiopathic secondary forms pulmonary hypertension 15 arterial venous ratios ET 1 protein found elevated normal range patients pulmonary hypertension 40
0.16787788.12060559.html.plaintext.txt	27	Several studies linked increased expression ET 1 development hypoxia induced CPH rats 5 24 use ET 1 receptor antagonists shown inhibit progression disease promote recovery 4 10 43
0.16787788.12060559.html.plaintext.txt	28	Although studies support central role ET 1 pathogenesis CPH picture likely complicated first suspected prepro ET 1 ppET 1 mRNA decreased monocrotaline model CPH addition recently reported regional variability ppET 1 gene expression pulmonary artery normal sheep
0.16787788.12060559.html.plaintext.txt	29	Furthermore found model CPH sheep receiving continuous air embolization CAE main pulmonary artery ppET 1 gene expression main pulmonary artery peripheral lung gradually decreased onset pulmonary hypertension midregion artery 9th 10th generation showed gradual increase 42
0.16787788.12060559.html.plaintext.txt	30	At least four cell types identified bovine main pulmonary artery subendothelial L1 cells inner medial L2 cells outer medial L3S L3R cells 12 13
0.16787788.12060559.html.plaintext.txt	31	We recently showed L1 cells cell characteristics endothelial smooth muscle cells cultured control sheep produce strikingly ET 1 L2 cells mature smooth muscle cells basal conditions exposed exogenous ET 1 L2 cells internalize exogenous ET 1 41
0.16787788.12060559.html.plaintext.txt	32	The present study examines whether ETA ETB gene surface expression altered L1 L2 cells control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	33	This study also examines whether ET 1 receptor distribution activity altered L1 L2 cells cultured hypertensive sheep induced 12 days CAE
0.16787788.12060559.html.plaintext.txt	34	METHODS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	35	The protocol delivery CAE sheep pulmonary artery described previously physiological structural changes model CPH reported detail 16 32
0.16787788.12060559.html.plaintext.txt	36	Briefly left thoracotomy performed yearling mixed breed sheep general anesthesia pulmonary artery left atrial catheters inserted
0.16787788.12060559.html.plaintext.txt	37	A jugular venous introducer carotid artery catheter placed neck incision
0.16787788.12060559.html.plaintext.txt	38	After recovery period 3 5 days Swan Ganz catheter positioned pulmonary artery jugular vein introducer
0.16787788.12060559.html.plaintext.txt	39	Baseline measurements pulmonary arterial pressure Ppa cardiac output CO left atrial pressure Pla made pulmonary vascular resistance PVR calculated using formula PVR Ppa PlaCO
0.16787788.12060559.html.plaintext.txt	40	After baseline measurements sheep received CAE n 3 pulmonary artery way proximal port lying right heart Swan Ganz catheter 12 day period
0.16787788.12060559.html.plaintext.txt	41	The rate air embolization administered sufficient cause increase PVR 2
0.16787788.12060559.html.plaintext.txt	42	Physiological measurements performed day rate air flow adjusted necessary maintain elevation PVR
0.16787788.12060559.html.plaintext.txt	43	Surgically prepared animals receiving air maintained time period served controls n 3
0.16787788.12060559.html.plaintext.txt	44	At end experiment animals killed overdose sodium barbiturate pentobarbital sodium 325 mg ml1 5 kg1 body wt Euthanazia 5 solution Henry Schein Port Washington NY lungs removed
0.16787788.12060559.html.plaintext.txt	45	The main pulmonary artery dissected point 1 cm exit right ventricle point entry right left lungs section taken routine light microscopy 1 microm sections epoxy embedded tissue
0.16787788.12060559.html.plaintext.txt	46	Cells isolated subendothelial L1 inner medial L2 layers main pulmonary artery control hypertensive sheep previously described 41 42
0.16787788.12060559.html.plaintext.txt	47	Briefly artery opened endothelial layer removed gentle scraping subendothelial L1 cells isolated pulmonary artery segments deep scraping
0.16787788.12060559.html.plaintext.txt	48	The inner media L2 cells isolated either modified explant technique enzymatic dissociation
0.16787788.12060559.html.plaintext.txt	49	Using phase contrast microscopy identified L1 L2 cell colonies morphology trypsinized cloning rings transferred culture dishes
0.16787788.12060559.html.plaintext.txt	50	Both cells types seeded cultured RPMI 1640 containing 100 Uml penicillin 100 microgml streptomycin 40 microgml gentamicin 2 mmoll L glutamine GIBCO BRL Grand Island NY 15 heat inactivated calf serum Atlanta Biologicals Norcross GA
0.16787788.12060559.html.plaintext.txt	51	Confluent cells passages 3 6 used experiments higher passage numbers associated substantial increase ETB receptor density 27
0.16787788.12060559.html.plaintext.txt	52	Cell lines cultured three different control three different hypertensive animals used assay
0.16787788.12060559.html.plaintext.txt	53	All experiments carried RPMI 1640 containing 0
0.16787788.12060559.html.plaintext.txt	54	Experiments initiated overnight incubation cells medium
0.16787788.12060559.html.plaintext.txt	55	For real time RT PCR analysis ETA ETB gene expression cells harvested 90 min addition 0
0.16787788.12060559.html.plaintext.txt	56	For dose response studies ET 1 internalization intracellular levels ET 1 measured 18 h exposure exogenous ET 1 concentrations 0
0.16787788.12060559.html.plaintext.txt	57	Experiments ETA BQ 610 ETB BQ 788 antagonists included 2 h preincubation period addition exogenous ET 1 10 nM 18 h
0.16787788.12060559.html.plaintext.txt	58	The dose antagonist used experiments based dose response curves
0.16787788.12060559.html.plaintext.txt	59	The concentrations BQ 610 tested 1 100 microM BQ 788 0
0.16787788.12060559.html.plaintext.txt	60	The dose chosen dose gave 50 reduction uptake exogenous ET 1 control L2 cells
0.16787788.12060559.html.plaintext.txt	61	For ET 1 binding assays cells two P150 dishes pretreated either BQ 610 BQ 788 2 h isolation cell membranes
0.16787788.12060559.html.plaintext.txt	62	Untreated L1 L2 cells cells treated antagonist alone served controls
0.16787788.12060559.html.plaintext.txt	63	Quantitative real time RT PCR ETA ETB
0.16787788.12060559.html.plaintext.txt	64	Total RNA isolated RNA STAT 60 reagent TEL TEST B Friendswood TX
0.16787788.12060559.html.plaintext.txt	65	mRNA copy numbers ETA ETB L1 L2 cultured cells control hypertensive sheep determined real time quantitative RT PCR using Lightcycler fluorescence temperature rapid air cycler Roche Molecular Biochemicals Indianapolis IN cDNA ETA RNA ETB standard curves double stranded DNA binding fluorescent probe SYBR green 38
0.16787788.12060559.html.plaintext.txt	66	Amplifications done glass capillary tubes 20 microl reaction 200 ng L2 L1 total RNA samples 6 mM magnesium chloride 2
0.16787788.12060559.html.plaintext.txt	67	0 microl 1 x SYBR green RNA master mix Roche Molecular Biochemicals 0
0.16787788.12060559.html.plaintext.txt	68	4 microl RT enzyme Roche Molecular Biochemicals 0
0.16787788.12060559.html.plaintext.txt	69	The cDNA template ETA standard curves derived reverse transcription total RNA control L2 cells 17
0.16787788.12060559.html.plaintext.txt	70	Total RNA L2 cells used template standard curves RT PCR assay ETB
0.16787788.12060559.html.plaintext.txt	71	Copy number ETA ETB standard templates assigned based concentration total cDNA RNA known number base pairs bp full length cDNAs RNA ETA ETB respectively
0.16787788.12060559.html.plaintext.txt	72	The primers ETA based human sequence 5 AGC TTC CTG GTT ACC ACT CAT CAA 3 forward 5 TCA ACA TCT CAC AAG TCA TGA G 3 reverse give 714 bp product corresponding nucleotides 136 850 45
0.16787788.12060559.html.plaintext.txt	73	Primers ETB derived newly generated sheep cDNA sequence first attempts real time RT PCR using primers generated human ETB cDNA sequence revealed several nonspecific products
0.16787788.12060559.html.plaintext.txt	74	Briefly RT PCR amplimers sheep ETB cloned pGEM T Easy Vector System Promega Madison WI transformed DH5a competent cells
0.16787788.12060559.html.plaintext.txt	75	Positive colonies selected color screening plasmid DNA isolated using QIAprep Spin Miniprep Kit QIAGEN
0.16787788.12060559.html.plaintext.txt	76	Digestion plasmid DNA EcoRI gave inserts expected size 701 bp
0.16787788.12060559.html.plaintext.txt	77	Comparison sequence clones human sequence demonstrated 89 90 homology
0.16787788.12060559.html.plaintext.txt	78	New ETB primers designed amplify 297 bp fragment sequence using DNA STAR software
0.16787788.12060559.html.plaintext.txt	79	The utilized ETB primers 5 TTT GGC CAC TTC CCG TCT CTG TTT 3 forward 5 ATT TGG GTG GTC TCC GTG GTT CTG 3 reverse
0.16787788.12060559.html.plaintext.txt	80	The one step real time RT PCR reactions consisted following steps reverse transcription 55 degrees C 15 min denaturation 95 degrees C 1 min amplification 55 cycles melting curve analysis 95 65 degrees C rate 0
0.16787788.12060559.html.plaintext.txt	81	1 degrees Cs continuous fluorescence monitoring
0.16787788.12060559.html.plaintext.txt	82	The amplification program ETA consisted heating 20 degrees Cs 95 degrees C cooling 20 degrees Cs 57 degrees C annealing 57 degrees C 5 heating 20 degrees Cs 72 degrees C elongation 72 degrees C 29 heating 5 degrees Cs 86 degrees C fluorescence acquisition
0.16787788.12060559.html.plaintext.txt	83	The amplification program ETB consisted heating 20 degrees Cs 95 degrees C cooling 20 degrees Cs 55 degrees C annealing 55 degrees C 5 heating 20 degrees Cs 72 degrees C elongation 72 degrees C 14 heating 5 degrees Cs 79 degrees C fluorescence acquisition
0.16787788.12060559.html.plaintext.txt	84	The specificity amplimer reaction confirmed melting curve analysis initial gel confirmation large peak corresponded expected amplimer representative melting curve analysis ETB shown Fig
0.16787788.12060559.html.plaintext.txt	85	The contribution fluorescence signal nonspecific products andor primer dimers eliminated increasing temperature 2 degrees C melting temperature specific product eliminated minor cDNAs lower melting temperatures 38
0.16787788.12060559.html.plaintext.txt	86	Copy numbers mRNA calculated serially diluted standard curves generated cDNA RNA templates 17 38
0.16787788.12060559.html.plaintext.txt	87	Serial dilutions 110 range three orders magnitude used generate standard curves
0.16787788.12060559.html.plaintext.txt	88	The serially diluted standards simultaneously amplified unknown samples generate linear standard curve fit points method analysis five points
0.16787788.12060559.html.plaintext.txt	89	Standard curves ETA ETB consistently correlation coefficients 0
0.16787788.12060559.html.plaintext.txt	90	00 representative sample ETB shown Fig
0.16787788.12060559.html.plaintext.txt	91	Control samples run triplicate variance 10
0.16787788.12060559.html.plaintext.txt	92	All biological samples fell standard curves copy numbers unknown samples calculated Lightcycler software version 3
0.16787788.12060559.html.plaintext.txt	93	ETA ETB values normalized copy numbers housekeeping gene glyceraldehyde 3 phosphate dehydrogenase G3PDH multiplied 100 correct variation amount RNA utilized per assay
0.16787788.12060559.html.plaintext.txt	94	All samples individual receptor subtype analyzed assay eliminating contribution interassay variability
0.16787788.12060559.html.plaintext.txt	95	ET 1 ligand receptor maximal binding assay
0.16787788.12060559.html.plaintext.txt	96	Control hypertensive L2 cells pretreated BQ 610 BQ 788 alone together 2 h isolation crude cell membrane fractions CMF previously described 42
0.16787788.12060559.html.plaintext.txt	97	Maximal ET 1 receptor binding Bmax examined mixing 20 microg CMF protein 0
0.16787788.12060559.html.plaintext.txt	98	1 microCi 125I labeled ET 1 Amersham Pharmacia Biotech 37 degrees C 1 h
0.16787788.12060559.html.plaintext.txt	99	The reaction performed total volume 200 microl 50 mM Tris buffer
0.16787788.12060559.html.plaintext.txt	100	Controls nonspecific binding carried parallel using 20 microg CMF protein mixed 0
0.16787788.12060559.html.plaintext.txt	101	5 microM unlabeled ET 1 plus 0
0.16787788.12060559.html.plaintext.txt	102	The reaction terminated passing reaction mix Glass Fiber C grade filter paper Whatman Maidstone England washing PBS
0.16787788.12060559.html.plaintext.txt	103	The bound radioactive disintegrations filter paper counted autoradiocounter 125I
0.16787788.12060559.html.plaintext.txt	104	The counts correlated saturation curves using Ligand software Bmax ET 1 receptors calculated experimental group
0.16787788.12060559.html.plaintext.txt	105	Assessment ETA ETB flow cytometry
0.16787788.12060559.html.plaintext.txt	106	Confluent monolayers L1 L2 cells P100 dishes treated modified cell dissociation buffer Life Technologies Rockville MD containing 0
0.16787788.12060559.html.plaintext.txt	107	5 EDTA disodium salt 6 glycerol 0
0.16787788.12060559.html.plaintext.txt	108	06 M sodium citrate 15 min room temperature
0.16787788.12060559.html.plaintext.txt	109	The dissociated cells centrifuged 800 rpm 10 min 4 degrees C pellet resuspended 1 ml cold 1 BSA PBS
0.16787788.12060559.html.plaintext.txt	110	A 1 ml cold PBS 1 BSA added cell suspensions divided two microcentrifuge tubes
0.16787788.12060559.html.plaintext.txt	111	The samples washed twice centrifugation 15 4 degrees C cell pellet resuspended 100 microl cold PBS 1 BSA
0.16787788.12060559.html.plaintext.txt	112	Sheep ETA ETB receptor antibodies Oxford Biomedical Research Oxford MI added sample give final concentration 1 microg106 cells samples incubated 4 degrees C 1 h
0.16787788.12060559.html.plaintext.txt	113	The cells washed twice cold PBS 1 BSA rabbit Fab2 anti sheep IgG heavy light FITC Southern Biotechnology Associates Birmingham AL added final concentration 0
0.16787788.12060559.html.plaintext.txt	114	5 mgml samples incubated dark 4 degrees C 30 min
0.16787788.12060559.html.plaintext.txt	115	The samples washed twice cold PBS 1 BSA fixed 1 paraformaldehyde PBS Electron Microscopy Sciences Fort Washington PA 4 degrees C 10 min dark
0.16787788.12060559.html.plaintext.txt	116	The samples put light protected tube placed ice submitted fluorescence activated cell sorter FACS analysis
0.16787788.12060559.html.plaintext.txt	117	Controls included untreated cells cells treated secondary antibody alone background controls
0.16787788.12060559.html.plaintext.txt	118	Flow cytometric measurements performed Becton Dickinson FACStar instrument equipped single 5 W argon ion water cooled laser tuned 488 nm blue green three fluorescence detectors
0.16787788.12060559.html.plaintext.txt	119	The data analyzed using Cell Quest software Becton Dickinson San Jose CA
0.16787788.12060559.html.plaintext.txt	120	Each sample measured duplicate
0.16787788.12060559.html.plaintext.txt	121	All cells included analysis 3
0.16787788.12060559.html.plaintext.txt	122	Specific fluorescence Fsp calculated subtracting mean fluorescence cells sample reacted secondary antibody alone Fbkgd obtained specific antibodies Ftot
0.16787788.12060559.html.plaintext.txt	123	Percent specific signal Fsp also calculated using formula Fsp FspFtot x 100 20
0.16787788.12060559.html.plaintext.txt	124	ET 1 extraction measurement intracellular ET 1
0.16787788.12060559.html.plaintext.txt	125	Intracellular levels mature ET 1 determined homogenates L1 L2 cells described previously 42
0.16787788.12060559.html.plaintext.txt	126	Briefly end experiment cells washed three times serum free medium trypsinized cell number counted using hemocytometer
0.16787788.12060559.html.plaintext.txt	127	After centrifugation 1000 rpm 10 min cell pellets homogenized 0
0.16787788.12060559.html.plaintext.txt	128	1 Triton X 100 Teflon glass pestle
0.16787788.12060559.html.plaintext.txt	129	The homogenates centrifuged 3000 rpm 15 min supernatants collected solid phase extraction
0.16787788.12060559.html.plaintext.txt	130	The cell supernatants acidified 2 M HCl loaded Sep Pak C18 cartridges prewashed 100 methanol acetonitrile 5 mmoll trifluoroacetic acid TFA distilled H2O 5 mmoll TFA
0.16787788.12060559.html.plaintext.txt	131	Each cartridge washed distilled H2O 5 mmoll TFA eluted 2 ml 80 methanol containing 0
0.16787788.12060559.html.plaintext.txt	132	The samples divided two tubes dried vacuum
0.16787788.12060559.html.plaintext.txt	133	Levels ET 1 determined 100 microl aliquots L1 L2 homogenates using commercially available ET 1 ELISA system Biotrak ELISA System Amersham International
0.16787788.12060559.html.plaintext.txt	134	The ELISA performed according manufacturers instructions
0.16787788.12060559.html.plaintext.txt	135	The assay sensitive values 1 fmol cross reacts 100 ET 1 ET 2 ET 2 generally found walls pulmonary vasculature ET 3 0
0.16787788.12060559.html.plaintext.txt	136	Each sample run duplicate
0.16787788.12060559.html.plaintext.txt	137	Results expressed femtomoles ET 1 per 106 cells
0.16787788.12060559.html.plaintext.txt	138	Values presented means plus minus SE
0.16787788.12060559.html.plaintext.txt	139	Data control hypertensive L1 L2 cells compared using Students test
0.16787788.12060559.html.plaintext.txt	140	Dose response curves ET 1 binding ET 1 internalization studies analyzed ANOVA followed Duncan multiple comparison test
0.16787788.12060559.html.plaintext.txt	141	05 considered statistically significant
0.16787788.12060559.html.plaintext.txt	142	Analysis performed using Number Cruncher Statistical System version 6
0.16787788.12060559.html.plaintext.txt	143	RESULTS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	144	In previous studies documented 12 days CAE causes development sustained pulmonary hypertension characterized doubling PVR 32
0.16787788.12060559.html.plaintext.txt	145	The sheep utilized present study showed similar significant increase PVR 12 days CAE controls 2
0.16787788.12060559.html.plaintext.txt	146	The control animals exhibited increase PVR 12 day period
0.16787788.12060559.html.plaintext.txt	147	Morphology L1 L2 cells control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	148	Light microscopy revealed 12 days CAE resulted striking increase thickness L1 L2 layers main pulmonary artery Fig
0.16787788.12060559.html.plaintext.txt	149	Marked hypertrophy hyperplasia L1 L2 cells apparent increase extracellular ground substance
0.16787788.12060559.html.plaintext.txt	150	View larger version 87K Fig
0.16787788.12060559.html.plaintext.txt	151	Light micrographs showing subendothelial L1 inner medial L2 layers control A hypertensive B sheep pulmonary artery
0.16787788.12060559.html.plaintext.txt	152	Section 1 microm stained toluidine blue
0.16787788.12060559.html.plaintext.txt	153	As shown previously L1 L2 cells cultured main pulmonary artery control sheep showed cell specific differences morphology
0.16787788.12060559.html.plaintext.txt	154	By phase contrast microscopy L2 cells exhibited characteristic spindle shape hill valley formation mature smooth muscle whereas L1 cells initially rhomboidal later formed multilayer rhomboidal large stellate cells Fig
0.16787788.12060559.html.plaintext.txt	155	L1 cells cultured hypertensive sheep maintained shape size similar control cells Fig
0.16787788.12060559.html.plaintext.txt	156	2D whereas hypertensive L2 cells larger rounded control cells Fig
0.16787788.12060559.html.plaintext.txt	157	2B typical hill valley formation less pronounced
0.16787788.12060559.html.plaintext.txt	158	View larger version 183K Fig
0.16787788.12060559.html.plaintext.txt	159	Phase contrast micrographs L1 L2 cells isolated control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	160	A control L2 cells exhibit characteristic spindle shape hill valley formation mature smooth muscle cells
0.16787788.12060559.html.plaintext.txt	161	B hypertensive L2 cells larger rounded hill valley formation less pronounced controls
0.16787788.12060559.html.plaintext.txt	162	C control L1 cells show rhomboidal shape
0.16787788.12060559.html.plaintext.txt	163	ETA ETB receptor gene expression control hypertensive L1 L2 cells
0.16787788.12060559.html.plaintext.txt	164	Both L1 L2 cells control sheep express ETA ETB genes quantitative real time RT PCR revealed copy number ETA ETB genes 0
0.16787788.12060559.html.plaintext.txt	165	14 x 1012 copies200 ng RNA 1
0.16787788.12060559.html.plaintext.txt	166	17 x 1012 respectively L2 cells significantly higher obtained L1 cells 0
0.16787788.12060559.html.plaintext.txt	167	007 x 1012 copies200 ng RNA 0
0.16787788.12060559.html.plaintext.txt	168	08 x 1012 respectively P 0
0.16787788.12060559.html.plaintext.txt	169	Similar findings demonstrated data related G3PDH Fig
0.16787788.12060559.html.plaintext.txt	170	View larger version 20K Fig
0.16787788.12060559.html.plaintext.txt	171	Quantitative real time RT PCR analysis endothelin ET receptor subtypes ETA ETB gene expression control hypertensive L2 L1 cells
0.16787788.12060559.html.plaintext.txt	172	Open bars control cells solid bars hypertensive cells
0.16787788.12060559.html.plaintext.txt	173	ETA ETB gene expression greater control L2 L1 cells remained hypertensive cells P 0
0.16787788.12060559.html.plaintext.txt	174	ETB expression significantly increased hypertensive L2 cells compared controls
0.16787788.12060559.html.plaintext.txt	175	Data expressed means plus minus SE copy numbers per 200 ng sample RNA normalized glyceraldehyde 3 phosphate dehydrogenase G3PDH n 3 8 P 0
0.16787788.12060559.html.plaintext.txt	176	05 compared ETB expression control L2 cells
0.16787788.12060559.html.plaintext.txt	177	In L2 cells hypertensive sheep expression ETA ETB genes remained higher hypertensive L1 cells Fig
0.16787788.12060559.html.plaintext.txt	178	Although copy number ETA gene hypertensive L2 cells similar controls hypertensive 1
0.16787788.12060559.html.plaintext.txt	179	23 x 1012 copies200 ng RNA expression ETB gene twice controls hypertensive 2
0.16787788.12060559.html.plaintext.txt	180	Copy number ETA gene hypertensive L1 cells similar control values
0.16787788.12060559.html.plaintext.txt	181	Copy number ETB gene hypertensive L1 cells tended higher controls reach significance
0.16787788.12060559.html.plaintext.txt	182	Similar findings found copy numbers related G3PDH Fig
0.16787788.12060559.html.plaintext.txt	183	Representative real time RT PCR standard curves 0
0.16787788.12060559.html.plaintext.txt	184	1 ng 1 microg ETB curves control hypertensive L2 cells shown Fig
0.16787788.12060559.html.plaintext.txt	185	When fluorescence related cycle number hypertensive curve shifted left compared control indicating increase ETB expression Fig
0.16787788.12060559.html.plaintext.txt	186	View larger version 56K Fig
0.16787788.12060559.html.plaintext.txt	187	Representative standard curves 0
0.16787788.12060559.html.plaintext.txt	188	1 ng 1 microg real time RT PCR ETB control hypertensive L2 cells
0.16787788.12060559.html.plaintext.txt	189	A fluorescence Fl related cycle number real time shift left seen hypertensive cells compared controls representing increase copy number
0.16787788.12060559.html.plaintext.txt	190	B linear regression representative standard curve giving correlation coefficient 0
0.16787788.12060559.html.plaintext.txt	191	C melting curve analysis first negative derivative dFldT melting curve sample related temperature shows single peak standard Std 10 ng control hypertensive amplification product RNA samples
0.16787788.12060559.html.plaintext.txt	192	ETA ETB expression FACS analysis control hypertensive L1 L2 cells
0.16787788.12060559.html.plaintext.txt	193	FACS analysis control hypertensive L1 L2 cells expressed Fsp revealed significant difference ETA ETB receptors save modest trend increase ETB expression hypertensive L2 cells compared controls Fig
0.16787788.12060559.html.plaintext.txt	194	5A distribution ETA also tended fall hypertensive cells
0.16787788.12060559.html.plaintext.txt	195	The modest nature changes doubt reflects variability expression primary cell lines sheep clones single animal
0.16787788.12060559.html.plaintext.txt	196	However data expressed percent specific fluorescence modest significant increase ETB apparent hypertensive L2 cells compared controls Fig
0.16787788.12060559.html.plaintext.txt	197	5B confirming real time RT PCR data
0.16787788.12060559.html.plaintext.txt	198	View larger version 16K Fig
0.16787788.12060559.html.plaintext.txt	199	Fluorescence activated cell sorter analysis showing distribution ETA ETB control open bars hypertensive solid bars L2 L1 cells
0.16787788.12060559.html.plaintext.txt	200	A specific fluorescence Fsp
0.16787788.12060559.html.plaintext.txt	201	B percent specific fluorescence Fsp
0.16787788.12060559.html.plaintext.txt	202	Data expressed means plus minus SE n 5 6
0.16787788.12060559.html.plaintext.txt	203	05 compared ETB expression control L2 cells
0.16787788.12060559.html.plaintext.txt	204	ET 1 receptor Bmax L2 cells control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	205	Bmax ET 1 cellular membranes control L2 cells 289
0.16787788.12060559.html.plaintext.txt	206	Pretreatment BQ 610 alone combination BQ 788 caused significant decrease Bmax baseline P 0
0.16787788.12060559.html.plaintext.txt	207	Inhibition ETB antagonist failed show fall ET 1 binding
0.16787788.12060559.html.plaintext.txt	208	In hypertensive cells treatment ETA ETB inhibitors alone combination led significant reduction Bmax baseline value Fig
0.16787788.12060559.html.plaintext.txt	209	View larger version 22K Fig
0.16787788.12060559.html.plaintext.txt	210	Effect ETA ETB receptor antagonists BQ 610 BQ 788 respectively maximal binding Bmax ET 1 control open bars hypertensive hatched bars L2 cells
0.16787788.12060559.html.plaintext.txt	211	Data expressed means plus minus SE P 0
0.16787788.12060559.html.plaintext.txt	212	Internalization ET 1 L1 L2 cells control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	213	Exposure L2 cells control animals various concentrations ET 1 resulted dose dependent increase intracellular ET 1 50 effective dose ED50 2 nM Fig
0.16787788.12060559.html.plaintext.txt	214	L2 cells hypertensive sheep also showed dose dependent increase intracellular ET 1 level uptake 10 fold less seen control cells ANOVA P 0
0.16787788.12060559.html.plaintext.txt	215	View larger version 15K Fig
0.16787788.12060559.html.plaintext.txt	216	Intracellular levels ET 1 L2 cells A L1 B cells control hypertensive sheep exposure various concentrations ET 1 18 h
0.16787788.12060559.html.plaintext.txt	217	control cells hypertensive cells
0.16787788.12060559.html.plaintext.txt	218	Data expressed means plus minus SE n 3
0.16787788.12060559.html.plaintext.txt	219	Measurement ET 1 L1 cells control sheep exposure various concentrations exogenous ET 1 revealed increase intracellular ET 1 Fig
0.16787788.12060559.html.plaintext.txt	220	Similarly L1 cells hypertensive sheep failed take ET 1
0.16787788.12060559.html.plaintext.txt	221	ET 1 receptor antagonists ET 1 internalization L2 cells control hypertensive sheep
0.16787788.12060559.html.plaintext.txt	222	Because L2 cells responded exogenous ET 1 experiments ETA ETB receptors antagonists performed cells
0.16787788.12060559.html.plaintext.txt	223	Pretreatment control L2 cells various concentrations either ETA antagonist BQ 610 ETB antagonist BQ 788 revealed IC50 BQ 610 system 0
0.16787788.12060559.html.plaintext.txt	224	8 BQ 788 25 microM data shown
0.16787788.12060559.html.plaintext.txt	225	The concentration receptor antagonist giving IC50 chosen experiments
0.16787788.12060559.html.plaintext.txt	226	View larger version 14K Fig
0.16787788.12060559.html.plaintext.txt	227	Dose responses curve ETA antagonist BQ 610 control L2 cells demonstrating effectiveness internalization exogenous ET 1
0.16787788.12060559.html.plaintext.txt	228	Cells treated BQ 610 2 h washed exposed 10 nM ET 1 18 h
0.16787788.12060559.html.plaintext.txt	229	Uptake shown intracellular levels ET 1
0.16787788.12060559.html.plaintext.txt	230	Basal levels intracellular ET 1 control hypertensive L2 cells altered exposure either BQ 610 BQ 788 Fig
0.16787788.12060559.html.plaintext.txt	231	Exposure control L2 cells exogenous ET 1 resulted significant increase intracellular ET 1 P 0
0.16787788.12060559.html.plaintext.txt	232	9A pretreatment either BQ 610 BQ 788 significantly suppressed increase intracellular ET 1 18 25 respectively
0.16787788.12060559.html.plaintext.txt	233	Simultaneous exposure antagonists caused additive inhibitory effect 40 although level intracellular ET 1 remained significantly elevated basal levels P 0
0.16787788.12060559.html.plaintext.txt	234	View larger version 20K Fig
0.16787788.12060559.html.plaintext.txt	235	Effect ETA ETB receptor antagonists BQ 610 BQ 788 alone combination uptake exogenous ET 1 10 nM L2 cells control sheep A hypertensive sheep B
0.16787788.12060559.html.plaintext.txt	236	Cells pretreated antagonists 2 h washed exposed ET 1 18 h hatched bars
0.16787788.12060559.html.plaintext.txt	237	Controls open bars receive ET 1 treatment
0.16787788.12060559.html.plaintext.txt	238	Data expressed means plus minus SE n 6 except experiments antagonists n 3
0.16787788.12060559.html.plaintext.txt	239	Basal levels intracellular ET 1 hypertensive L2 cells similar control cells Fig
0.16787788.12060559.html.plaintext.txt	240	9B although uptake hypertensive cells 50 less control cells Fig
0.16787788.12060559.html.plaintext.txt	241	Unlike response control cells pretreatment hypertensive L2 cells either BQ 610 BQ 788 failed inhibit ET 1 stimulated increase intracellular ET 1 Fig
0.16787788.12060559.html.plaintext.txt	242	Simultaneous exposure antagonists however caused significant striking inhibition ET 1 stimulated increase intracellular ET 1 level intracellular ET 1 returned basal values
0.16787788.12060559.html.plaintext.txt	243	DISCUSSION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	244	In previous study group identified differences ET 1 system L1 L2 cells control sheep 41
0.16787788.12060559.html.plaintext.txt	245	L1 cells like endothelial cells found synthesize release ET 1 whereas L2 cells less synthetic capacity ET 1 rather propensity internalize exogenous ET 1
0.16787788.12060559.html.plaintext.txt	246	The present study extends findings examines ETA ETB gene surface expression Bmax sites activity assessed ET 1 internalization L1 L2 cells main pulmonary artery control sheep sustained pulmonary hypertension induced CAE
0.16787788.12060559.html.plaintext.txt	247	The present vitro study documents hypertensive L2 cells seen vivo maintain hypertrophic appearance whereas L1 cells thickened subendothelial layer revert appearance similar controls
0.16787788.12060559.html.plaintext.txt	248	In addition show L2 cells control hypertensive animals exhibit significantly higher basal expression ETA ETB genes L1 cells ETB gene surface expression hypertensive L2 cells significantly increased compared controls
0.16787788.12060559.html.plaintext.txt	249	The present findings also confirm L2 L1 cells control sheep internalize exogenous ET 1 dose dependent manner demonstrate L2 cells hypertensive sheep internalize less ET 1 controls
0.16787788.12060559.html.plaintext.txt	250	In addition found control cells ETA receptors mainly responsible binding ET 1 L2 cells 18 h exposure ET 1 receptors played role internalization
0.16787788.12060559.html.plaintext.txt	251	Using ETA ETB receptor antagonists study also demonstrates hypertensive cells receptors bound radiolabeled ET 1 internalization ET 1 however inhibited ETA ETB antagonists used combination
0.16787788.12060559.html.plaintext.txt	252	Function ETA ETB receptors
0.16787788.12060559.html.plaintext.txt	253	In humans ETA ETB encoded distinct genes located chromosomes 4 13 respectively 32
0.16787788.12060559.html.plaintext.txt	254	In pulmonary vascular smooth muscle cells ETA receptor linked vasoconstriction well hypertrophy smooth muscle proliferation whereas ETB receptor linked clearance ET 1 circulation well vasoconstriction vasodilation 22 36 39
0.16787788.12060559.html.plaintext.txt	255	Studies pulmonary vasculature suggest actions ET 1 mediated least three receptors one ETA receptor two ETB receptor subtypes
0.16787788.12060559.html.plaintext.txt	256	Pharmacological studies several species indicate endothelial ETB receptor designated ETB1 mediates vasodilatation whereas ETB2 receptor expressed smooth muscle acts vasoconstrictor 5 7 9
0.16787788.12060559.html.plaintext.txt	257	ETA ETB receptors G protein coupled receptors undergo agonist stimulated desensitization inactivation 26
0.16787788.12060559.html.plaintext.txt	258	Desensitization thought prevent overstimulation damage activated cells well saturation weak stimuli
0.16787788.12060559.html.plaintext.txt	259	Phosphorylation identified major mechanism rapid desensitization many G protein coupled receptors
0.16787788.12060559.html.plaintext.txt	260	In humans ETA receptors shown prolonged period desensitization occurring within 5 min exposure ET 1 sensitization restored 80 120 min 8
0.16787788.12060559.html.plaintext.txt	261	This prolonged desensitization period seems unique ETA receptor may explain least part prolonged contraction smooth muscle cells response ET 1 6
0.16787788.12060559.html.plaintext.txt	262	The ETB receptors hand rapidly deactivated via phosphorylation dehydration lose 80 initial activity within 5 min agonist stimulation
0.16787788.12060559.html.plaintext.txt	263	This rapid deactivation ETB linked short term vasodilatory effect ET 1 7
0.16787788.12060559.html.plaintext.txt	264	The present study shows ETA ETB receptors bind responsible internalization exogenous ET 1 however data hypertensive cells suggest receptors types become desensitized
0.16787788.12060559.html.plaintext.txt	265	ETA ETB receptors L1 L2 cells control sheep
0.16787788.12060559.html.plaintext.txt	266	Both ETA ETB receptors identified pulmonary systemic vascular smooth muscle cells e
0.16787788.12060559.html.plaintext.txt	267	rat aorta 30 human internal mammary artery vein porcine coronary arteries 37 rat human pulmonary artery 28
0.16787788.12060559.html.plaintext.txt	268	In humans ETA receptors found resistance conduit arteries main pulmonary artery ETA receptors predominated 90 5
0.16787788.12060559.html.plaintext.txt	269	Tracheal smooth muscle rats mice however exhibited approximately equal numbers two receptor subtypes 18 whereas ETB receptors 50 numerous ETA rat pulmonary artery smooth muscle cells 23
0.16787788.12060559.html.plaintext.txt	270	Thus distribution density ET 1 receptors various smooth muscle types may vary species location 5 31
0.16787788.12060559.html.plaintext.txt	271	The present study demonstrates L1 L2 cells control sheep express ETA ETB genes
0.16787788.12060559.html.plaintext.txt	272	The significantly lower expression genes L1 cells compared L2 cells substantiates previous suggestion L1 cell contributes little maintenance vascular tone main pulmonary artery
0.16787788.12060559.html.plaintext.txt	273	The paucity ET 1 receptors L1 cells also corroborates finding cells fail internalize exogenous ET 1
0.16787788.12060559.html.plaintext.txt	274	Our binding studies confirm notion activity ETA receptors predominates L2 cells main pulmonary artery control sheep
0.16787788.12060559.html.plaintext.txt	275	With long term exposure however seems receptors participate equally internalization process
0.16787788.12060559.html.plaintext.txt	276	This difference likely reflect effects long short term exposure ETB receptor becoming active exposure ET 1 prolonged perhaps result increase requirement internalization degradation ET 1
0.16787788.12060559.html.plaintext.txt	277	Previous studies isolated perfused rat lungs 29 also shown receptors play role clearance ET 1 14
0.16787788.12060559.html.plaintext.txt	278	ETA ETB receptors hypertensive L2 cells
0.16787788.12060559.html.plaintext.txt	279	Alterations ET 1 receptors demonstrated several models CPH
0.16787788.12060559.html.plaintext.txt	280	For example increased ETA gene expression demonstrated rat lungs increased ETB gene expression rat main pulmonary artery exposure hypoxia 48 h 25
0.16787788.12060559.html.plaintext.txt	281	After 14 days hypoxia increased expression ETA ETB found distal pulmonary arteries rats ETA expression occurring mainly media ETB intima change expression either receptor found large muscular pulmonary arteries 39
0.16787788.12060559.html.plaintext.txt	282	In contrast hypoxic models monocrotaline induced CPH ETB receptor mRNA shown decreased lung 46
0.16787788.12060559.html.plaintext.txt	283	The present study demonstrates selective significant increase ETB gene surface expression receptor binding hypertensive L2 cells compared controls
0.16787788.12060559.html.plaintext.txt	284	Further confirmation increase ETB receptors hypertensive L2 cells shown finding increase early internalization ET 1 ETB
0.16787788.12060559.html.plaintext.txt	285	Similar increases ETB gene expression reported pulmonary arteries patients chronic thromboembolic pulmonary hypertension 44
0.16787788.12060559.html.plaintext.txt	286	The ETB signaling pathway linked regulation ppET 1 gene expression rat mesangial cells 19
0.16787788.12060559.html.plaintext.txt	287	The present study confirms notion since previous study showed ppET 1 gene expression main pulmonary artery decreased hypertensive sheep compared controls
0.16787788.12060559.html.plaintext.txt	288	Although studies demonstrate short term internalization clearance ET 1 ETB hypertensive cells may increased studies ETA ETB receptor antagonists suggest longer term scenario occur
0.16787788.12060559.html.plaintext.txt	289	Rather data demonstrate ET 1 stimulated internalization exogenous ET 1 decreased hypertensive L2 cells compared controls sensitivity individual ET 1 receptors lost
0.16787788.12060559.html.plaintext.txt	290	It ETA ETB antagonists added simultaneously suppression ET 1 uptake occurs
0.16787788.12060559.html.plaintext.txt	291	Similar findings demonstrated isolated perfused lungs rats hypoxic CPH 23
0.16787788.12060559.html.plaintext.txt	292	One possible explanation failure antagonist alone inhibit ET 1 uptake concentration antagonists used study sufficient inhibit ETA ETB receptors hypertensive L2 cells
0.16787788.12060559.html.plaintext.txt	293	This would seem unlikely antagonists failed exert inhibitory effect
0.16787788.12060559.html.plaintext.txt	294	Another possibility phosphorylation receptorligand complex andor receptor recycling altered hypertensive cells
0.16787788.12060559.html.plaintext.txt	295	This notion requires study
0.16787788.12060559.html.plaintext.txt	296	Another possible explanation concurrent treatment ETA ETB antagonists involves simultaneous activation heterodimerization two receptors 26
0.16787788.12060559.html.plaintext.txt	297	Recent studies suggest ET 1 binds simultaneously ETA ETB receptor 2 11
0.16787788.12060559.html.plaintext.txt	298	This heterodimerization two fully functional G protein coupled receptors suggested result new receptorligand binding complex functional properties different either receptor alone 21
0.16787788.12060559.html.plaintext.txt	299	Thus possible individual ETA ETB receptors hypertensive L2 cells desensitized exogenous ET 1 simultaneous stimulation results heterodimerization ETA ETB receptors internalization ET 1 different pathway
0.16787788.12060559.html.plaintext.txt	300	This new pathway would seem extremely effective since intracellular levels ET 1 hypertensive L2 cells returned almost basal values
0.16787788.12060559.html.plaintext.txt	301	Further studies needed elucidate possible explanation
0.16787788.12060559.html.plaintext.txt	302	In summary shown gene surface expression activity ETB ETA receptors L1 L2 cells control hypertensive sheep different
0.16787788.12060559.html.plaintext.txt	303	Control hypertensive L2 cells exhibit significantly higher steady state basal expression ETA ETB genes L1 cells
0.16787788.12060559.html.plaintext.txt	304	In agreement finding found L2 cells internalize exogenous ET 1
0.16787788.12060559.html.plaintext.txt	305	In short term ETA receptors mainly responsible binding ET 1 longer exposure receptors contribute internalization
0.16787788.12060559.html.plaintext.txt	306	In hypertensive L2 cells showed ETB gene surface expression Bmax receptor significantly elevated baseline
0.16787788.12060559.html.plaintext.txt	307	Uptake exogenous ET 1 cells however less pronounced control cells
0.16787788.12060559.html.plaintext.txt	308	Furthermore found concurrent treatment ETA ETB antagonists suppressed ET 1 uptake hypertensive cells suggesting alteration structure
0.16787788.12060559.html.plaintext.txt	309	We conclude changes gene surface expression activity ETB receptors L2 cells hypertensive sheep may contribute development maintenance CPH altered sensitivity locally produced ET 1
0.16787788.12060559.html.plaintext.txt	310	Guohuan Fan Department Cell Biology Vanderbilt University help ET 1 receptor binding data processing
0.16787788.12060559.html.plaintext.txt	311	This work supported National Heart Lung Blood Institute Grant HL 48536
0.16787788.12060559.html.plaintext.txt	312	Address reprint requests correspondence B
0.16787788.12060559.html.plaintext.txt	313	Meyrick Center Lung Research Vanderbilt Univ
0.16787788.12060559.html.plaintext.txt	314	Medical Center MCN T 1217 Nashville TN 37232 2650 E mail meyricboatvanderbilt
0.16787788.12060559.html.plaintext.txt	315	The costs publication article defrayed part payment page charges
0.16787788.12060559.html.plaintext.txt	316	The article must therefore hereby marked advertisement accordance 18 U
0.16787788.12060559.html.plaintext.txt	317	Section 1734 solely indicate fact
0.16787788.12060559.html.plaintext.txt	318	First published February 8 200210
0.16787788.12060559.html.plaintext.txt	319	Received 27 August 2001 accepted final form 4 February 2002
0.16787788.12060559.html.plaintext.txt	320	REFERENCES TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.16787788.12060559.html.plaintext.txt	321	Arai H Hori S Aramori I Ohkubo H Nakanishi S
0.16787788.12060559.html.plaintext.txt	322	Cloning expression cDNA encoding endothelin receptor
0.16787788.12060559.html.plaintext.txt	323	Nature 348 730 732 1990ISIMedline
0.16787788.12060559.html.plaintext.txt	324	Blomstrand F Giaume C Hansson E Ronnback L
0.16787788.12060559.html.plaintext.txt	325	Distinct pharmacological properties ET 1 ET 3 astroglial gap junctions Ca2 signaling
0.16787788.12060559.html.plaintext.txt	326	Am J Physiol Cell Physiol 277 C616 C627 1999AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	327	Bruce MC Honaker CE Cross RJ
0.16787788.12060559.html.plaintext.txt	328	Lung fibroblasts undergo apoptosis following alveolarization
0.16787788.12060559.html.plaintext.txt	329	Am J Respir Cell Mol Biol 20 228 236 1999AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	330	Channick R Badesch DB Tapson VF Simonneau G Robbins I Frost A Roux S Rainisio M Bodin F Rubin LJ
0.16787788.12060559.html.plaintext.txt	331	Effects dual endothelin receptor antagonist bosentan patients pulmonary hypertension placebo controlled study
0.16787788.12060559.html.plaintext.txt	332	J Heart Lung Transplant 20 262 263 2001Medline
0.16787788.12060559.html.plaintext.txt	333	Endothelial dysfunction pulmonary vascular bed
0.16787788.12060559.html.plaintext.txt	334	Am J Med Sci 320 223 232 2000ISIMedline
0.16787788.12060559.html.plaintext.txt	335	Chun M Lin HY Henis YI Lodish HF
0.16787788.12060559.html.plaintext.txt	336	Endothelin induced endocytosis cell surface ETA receptors
0.16787788.12060559.html.plaintext.txt	337	Endothelin remains intact bound ETA receptor
0.16787788.12060559.html.plaintext.txt	338	J Biol Chem 270 10855 10860 1995AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	339	Cramer H Muller Esterl W Schroeder C
0.16787788.12060559.html.plaintext.txt	340	Subtype specific desensitization human endothelin ETA ETB receptors reflects differential receptor phosphorylation
0.16787788.12060559.html.plaintext.txt	341	Biochemistry 36 13325 13332 1997ISIMedline
0.16787788.12060559.html.plaintext.txt	342	Desensitization human endothelin A receptor
0.16787788.12060559.html.plaintext.txt	343	J Cardiovasc Pharmacol 22 S11 S14 1993
0.16787788.12060559.html.plaintext.txt	344	Davenport AP Maguire JJ
0.16787788.12060559.html.plaintext.txt	345	Is endothelin induced vasoconstriction mediated ETA receptors humans Trends Pharmacol Sci 15 9 11 1994ISIMedline
0.16787788.12060559.html.plaintext.txt	346	Endothelin receptor antagonists developing role cardiovascular therapeutics
0.16787788.12060559.html.plaintext.txt	347	Can J Cardiol 16 903 910 2000ISIMedline
0.16787788.12060559.html.plaintext.txt	348	The astrocytic endothelin system toward solving mystery
0.16787788.12060559.html.plaintext.txt	349	Focus distinct pharmacological properties ET 1 ET 3 astroglial gap junctions Ca2 signaling
0.16787788.12060559.html.plaintext.txt	350	Am J Physiol Cell Physiol 277 C614 C615 1999Free Full Text
0.16787788.12060559.html.plaintext.txt	351	Frid MG Aldashev AA Dempsey EC Stenmark KR
0.16787788.12060559.html.plaintext.txt	352	Smooth muscle cells isolated discrete compartments mature vascular media exhibit unique phenotypes distinct growth capabilities
0.16787788.12060559.html.plaintext.txt	353	Circ Res 81 940 952 1997AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	354	Frid MG Moiseeva EP Stenmark KR
0.16787788.12060559.html.plaintext.txt	355	Multiple phenotypically distinct smooth muscle cell populations exist adult developing bovine pulmonary arterial media vivo
0.16787788.12060559.html.plaintext.txt	356	Circ Res 75 669 681 1994Abstract
0.16787788.12060559.html.plaintext.txt	357	Fukuroda T Fujikawa T Ozaki S Ishikawa K Yano M Nishikibe M
0.16787788.12060559.html.plaintext.txt	358	Clearance circulating endothelin 1 ETB receptors rats
0.16787788.12060559.html.plaintext.txt	359	Biochem Biophys Res Commun 199 1461 1465 1994ISIMedline
0.16787788.12060559.html.plaintext.txt	360	Giaid A Yanagisava M Langleben D Michel RP Levy R Shennib H Kimura S Masaki T Duguid W Stewart DJ
0.16787788.12060559.html.plaintext.txt	361	Expression endothelin 1 lungs patients pulmonary hypertension
0.16787788.12060559.html.plaintext.txt	362	N Engl J Med 328 1732 1739 1993AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	363	Gossage JR Perkett EA Davidson JM Starcher BC Carmichael D Brigham KL Meyrick B
0.16787788.12060559.html.plaintext.txt	364	Secretory leukoprotease inhibitor attenuates lung injury induced continuous air embolization sheep
0.16787788.12060559.html.plaintext.txt	365	J Appl Physiol 79 1163 1172 1995AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	366	Hartel C Bein G Kirchner H Kluter H
0.16787788.12060559.html.plaintext.txt	367	A human whole blood assay analysis T cell function quantification cytokine mRNA
0.16787788.12060559.html.plaintext.txt	368	Scand J Immunol 49 649 654 1999ISIMedline
0.16787788.12060559.html.plaintext.txt	369	Endothelin receptor distribution function airways
0.16787788.12060559.html.plaintext.txt	370	Clin Exp Pharmacol Physiol 26 162 167 1999ISIMedline
0.16787788.12060559.html.plaintext.txt	371	Iwasaki S Hommo T Matsuda Y Kon V
0.16787788.12060559.html.plaintext.txt	372	Endothelin receptor subtype B mediates autoinduction endothelin 1 rat mesangial cells
0.16787788.12060559.html.plaintext.txt	373	J Biol Chem 270 6997 7003 1995AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	374	Jacobberger JW Sramkoski RM Zhang D Zumstein LA Doerksen LD Merritt JA Wright SA Shults KE
0.16787788.12060559.html.plaintext.txt	375	Bivariate analysis p53 pathway evaluate Ad p53 gene therapy efficacy
0.16787788.12060559.html.plaintext.txt	376	Cytometry 38 201 213 1999ISIMedline
0.16787788.12060559.html.plaintext.txt	377	G protein coupled receptor heterodimerization modulates receptor function
0.16787788.12060559.html.plaintext.txt	378	Nature 399 697 700 1999ISIMedline
0.16787788.12060559.html.plaintext.txt	379	Kedzierski RM Yanagisawa M
0.16787788.12060559.html.plaintext.txt	380	Endothelin system double edged sword health disease
0.16787788.12060559.html.plaintext.txt	381	Annu Rev Pharmacol Toxicol 41 851 876 2001ISIMedline
0.16787788.12060559.html.plaintext.txt	382	LaDouceur DM Flynn MA Keiser JA Reynolds E Haleen SJ
0.16787788.12060559.html.plaintext.txt	383	ETA ETB receptors coexist rabbit pulmonary artery vascular smooth muscle mediating contraction
0.16787788.12060559.html.plaintext.txt	384	Biochem Biophys Res Commun 196 209 215 1993ISIMedline
0.16787788.12060559.html.plaintext.txt	385	Lariviere R Thibault G Schiffrin EL
0.16787788.12060559.html.plaintext.txt	386	Increased endothelin 1 content blood vessels deoxycorticosterone acetate salt hypertensive spontaneously hypertensive rats
0.16787788.12060559.html.plaintext.txt	387	Hypertension 21 294 300 1993Abstract
0.16787788.12060559.html.plaintext.txt	388	Li H Elton TS Chen YF Oparil S
0.16787788.12060559.html.plaintext.txt	389	Increased endothelin receptor gene expression hypoxic rat lung
0.16787788.12060559.html.plaintext.txt	390	Am J Physiol Lung Cell Mol Physiol 266 L553 L560 1994AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	391	Endothelins endothelin receptor antagonists
0.16787788.12060559.html.plaintext.txt	392	Therapeutic considerations novel class cardiovascular drugs
0.16787788.12060559.html.plaintext.txt	393	Circulation 102 2434 2440 2000AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	394	Maxwell MJ Goldie RG Henry PJ
0.16787788.12060559.html.plaintext.txt	395	Altered ETB ETA receptor density function sheep airway smooth muscle cells culture
0.16787788.12060559.html.plaintext.txt	396	Am J Physiol Lung Cell Mol Physiol 274 L951 L957 1998AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	397	McCulloch KM MacLean MR
0.16787788.12060559.html.plaintext.txt	398	EndothelinB receptor mediated contraction human rat pulmonary resistance arteries effect pulmonary hypertension endothelin responses rat
0.16787788.12060559.html.plaintext.txt	399	J Cardiovasc Pharmacol 26 S169 S176 1995ISIMedline
0.16787788.12060559.html.plaintext.txt	400	Muramatsu M Rodman DM Oka M McMurtry IF
0.16787788.12060559.html.plaintext.txt	401	Endothelin 1 mediates nitro L arginine vasoconstriction hypertensive rat lungs
0.16787788.12060559.html.plaintext.txt	402	Am J Physiol Lung Cell Mol Physiol 272 L807 L812 1997AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	403	Nakahashi T Fukuo K Nishimaki H Hata S Shimizu M Suhara T Takimoto M Morimoto S Ogihara T
0.16787788.12060559.html.plaintext.txt	404	Endothelin 1 enhances nitric oxide induced cell death cultured vascular smooth muscle cells
0.16787788.12060559.html.plaintext.txt	405	J Cardiovasc Pharmacol 31 S351 S353 1998ISIMedline
0.16787788.12060559.html.plaintext.txt	406	Nishimura J Aoki H Shikasho T Kobayashi S Kanaide H
0.16787788.12060559.html.plaintext.txt	407	Evidence presence endothelin ETA receptors endothelial cells situ aortic side porcine aortic valve
0.16787788.12060559.html.plaintext.txt	408	Br J Pharmacol 115 1369 1376 1995Abstract
0.16787788.12060559.html.plaintext.txt	409	Perkett EA Brigham KL Meyrick B
0.16787788.12060559.html.plaintext.txt	410	Continuous air embolization sheep causes sustained pulmonary hypertension increased pulmonary vasoreactivity
0.16787788.12060559.html.plaintext.txt	411	Am J Pathol 132 444 454 1988Abstract
0.16787788.12060559.html.plaintext.txt	412	Endothelins molecular biology biochemistry pharmacology physiology pathophysiology
0.16787788.12060559.html.plaintext.txt	413	Pharmacol Rev 46 328 394 1994
0.16787788.12060559.html.plaintext.txt	414	Sakurai T Yanagisawa M Masaki T
0.16787788.12060559.html.plaintext.txt	415	Molecular characterization endothelin receptors
0.16787788.12060559.html.plaintext.txt	416	Trends Pharmacol Sci 13 103 108 1992ISIMedline
0.16787788.12060559.html.plaintext.txt	417	Sakurai T Yanagisawa M Takuwa Y Miyazaki H Kimura S Goto K Masaki T
0.16787788.12060559.html.plaintext.txt	418	Cloning cDNA encoding non isopeptide selective subtype endothelin receptor
0.16787788.12060559.html.plaintext.txt	419	Role endothelin 1 hypertension
0.16787788.12060559.html.plaintext.txt	420	Hypertension 34 876 881 1999AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	421	Seo B Oemar BS Siebenmann R Segesser L Luscher TF
0.16787788.12060559.html.plaintext.txt	422	Both ETA ETB receptors mediate contraction endothelin 1 human blood vessels
0.16787788.12060559.html.plaintext.txt	423	Circulation 89 1203 1208 1994Abstract
0.16787788.12060559.html.plaintext.txt	424	Shappell SB Gupta RA Manning S Whitehead R Boeglin WE Schneider C Case T Price J Jack GS Wheeler TM Matusik RJ Brash AR DuBois RN
0.16787788.12060559.html.plaintext.txt	425	15S hydroxyeicosatetraenoic acid activates peroxisome proliferator activated receptor inhibits proliferation PC3 prostate carcinoma cells
0.16787788.12060559.html.plaintext.txt	426	Cancer Res 61 497 503 2001AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	427	Soma S Takahashi H Muramatsu M Oka M Fukuchi Y
0.16787788.12060559.html.plaintext.txt	428	Localization distribution endothelin receptor subtypes pulmonary vasculature normal hypoxia exposed rats
0.16787788.12060559.html.plaintext.txt	429	Am J Respir Cell Mol Biol 20 620 630 1999AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	430	Stewart DJ Levy RD Cernacek P Langleben D
0.16787788.12060559.html.plaintext.txt	431	Increased plasma endothelin 1 pulmonary hypertension marker mediator disease Ann Intern Med 114 464 469 1991ISIMedline
0.16787788.12060559.html.plaintext.txt	432	Tchekneva E Lawrence ML Meyrick B
0.16787788.12060559.html.plaintext.txt	433	Cell specific differences ET 1 system adjacent layers main pulmonary artery
0.16787788.12060559.html.plaintext.txt	434	Am J Physiol Lung Cell Mol Physiol 278 L813 L821 2000AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	435	Tchekneva E Quertermous T Christman BW Lawrence ML Meyrick B
0.16787788.12060559.html.plaintext.txt	436	Regional variability preproendothelin 1 gene expression sheep pulmonary artery lung onset air induced chronic pulmonary hypertension
0.16787788.12060559.html.plaintext.txt	437	Participation arterial smooth muscle cells
0.16787788.12060559.html.plaintext.txt	438	J Clin Invest 101 1389 1397 1998AbstractFree Full Text
0.16787788.12060559.html.plaintext.txt	439	Tilton RG Munsch CL Sherwood SJ Chen SJ Wu C Block N Dixon RA Brock TA
0.16787788.12060559.html.plaintext.txt	440	Attenuation pulmonary vascular hypertension cardiac hypertrophy sitaxsentan sodium orally active ETA receptor antagonist
0.16787788.12060559.html.plaintext.txt	441	Pulm Pharmacol Ther 13 87 97 2000ISIMedline
0.16787788.12060559.html.plaintext.txt	442	Wilkens H Bauer M Forestier N Schneider S Schafers HJ Sybrecht GW
0.16787788.12060559.html.plaintext.txt	443	Transpulmonary gradient big endothelin selective upregulation endothelin type B receptors pulmonary hypertension Abstract
0.16787788.12060559.html.plaintext.txt	444	Am J Respir Crit Care Med 163 A118 2001
0.16787788.12060559.html.plaintext.txt	445	Winkles JA Alberts GF Brogi E Libby P
0.16787788.12060559.html.plaintext.txt	446	Endothelin 1 endothelin receptor mRNA expression normal atherosclerotic human arteries
0.16787788.12060559.html.plaintext.txt	447	Biochem Biophys Res Commun 191 1081 1088 1993ISIMedline
0.16787788.12060559.html.plaintext.txt	448	Yorikane R Miyauchi T Sakai S Sakurai T Yamaguchi I Sugishita Y Goto K
0.16787788.12060559.html.plaintext.txt	449	Altered expression ETB receptor mRNA lung rats pulmonary hypertension
0.16787788.12060559.html.plaintext.txt	450	J Cardiovasc Pharmacol 22 S336 S338 1993ISIMedline
0.16787788.12060559.html.plaintext.txt	451	Am J Physiol Lung Cell Mol Physiol 2831L42 L51 1040 060502 5
0.16787788.12060559.html.plaintext.txt	452	00 Copyright 2002 American Physiological Society
0.16384977.11502759.html.plaintext.txt	0	The Rockefeller University Press 0021 952520018741 5
0.16384977.11502759.html.plaintext.txt	1	00 The Journal Cell Biology Volume 154 Number 4 August 20 2001 741 752 Article
0.16384977.11502759.html.plaintext.txt	2	A conserved herpesvirus protein necessary axonal localization viral membrane proteins M
0.16384977.11502759.html.plaintext.txt	3	Department Molecular Biology Princeton University Princeton NJ 08544
0.16384977.11502759.html.plaintext.txt	4	Address correspondence Lynn W
0.16384977.11502759.html.plaintext.txt	5	Enquist 314 Schultz Laboratory Department Molecular Biology Princeton University Princeton NJ 08544
0.16384977.11502759.html.plaintext.txt	6	Abstract Top Abstract Introduction Results Discussion Materials methods References Pseudorabies virus herpesvirus capable infecting nervous system spreading synaptically connected neurons diverse hosts
0.16384977.11502759.html.plaintext.txt	7	At least three viral membrane proteins gE gI Us9 necessary spread infection presynaptic postsynaptic neurons anterograde spread infected rodents
0.16384977.11502759.html.plaintext.txt	8	To understand proteins effect anterograde spread neurons analyzed subcellular localization viral proteins infection cultured rat sympathetic neurons wild type mutant viruses
0.16384977.11502759.html.plaintext.txt	9	After Us9 null mutant infections gE null mutant infections subset viral structural proteins entered axons
0.16384977.11502759.html.plaintext.txt	10	Surprisingly capsid tegument proteins viral membrane proteins detected axons
0.16384977.11502759.html.plaintext.txt	11	The spread Us9 missense mutants rodent nervous system correlated amount viral membrane proteins localized axons
0.16384977.11502759.html.plaintext.txt	12	We conclude Us9 membrane protein controls axonal localization diverse viral membrane proteins capsid tegument proteins
0.16384977.11502759.html.plaintext.txt	13	The data support model virion subassemblies complete virions transported axon
0.16384977.11502759.html.plaintext.txt	14	Our results provide new insight process virion assembly exit neurons leads directional spread herpesviruses nervous system
0.16384977.11502759.html.plaintext.txt	15	Key Words axonal transport virus assembly membrane proteins herpesvirus pseudorabies virus
0.16384977.11502759.html.plaintext.txt	16	Introduction Top Abstract Introduction Results Discussion Materials methods References Herpesviruses unique parasites vertebrate peripheral nervous system PNS
0.16384977.11502759.html.plaintext.txt	17	After primary infection epithelial surface virus invades termini sensory autonomic neurons innervating infected tissue
0.16384977.11502759.html.plaintext.txt	18	Subsequently virion components transported axons cell bodies neurons usually substantial distance termini
0.16384977.11502759.html.plaintext.txt	19	Movement virion components axon terminal cell body thought occur via microtubule based motors dynein moving material plus minus direction Enquist et al
0.16384977.11502759.html.plaintext.txt	20	Within week invading cell bodies PNS ganglionic neurons production infectious virus ceases quiescent latent state established
0.16384977.11502759.html.plaintext.txt	21	Months years later latent infection reactivated new virions produced PNS ganglionic neurons
0.16384977.11502759.html.plaintext.txt	22	The virions travel via axons periphery infect epithelia producing infectious virus spread hosts
0.16384977.11502759.html.plaintext.txt	23	Long distance movement newly replicated virions cell body distant axon terminals well understood suggested occur using microtubule based motors kinesins move cargo minus plus direction Enquist et al
0.16384977.11502759.html.plaintext.txt	24	1998 Sodeik 2000 Smith et al
0.16384977.11502759.html.plaintext.txt	25	The movement virions PNS axons toward cell body primary infection away neuronal cell body via PNS axons replication implies herpesviruses may encode gene products capable regulating directional axonal transport
0.16384977.11502759.html.plaintext.txt	26	Evidence viral proteins capable affecting direction virus movement living animals came studies circuit specific transneuronal infection pseudorabies virus PRV broad host range herpesvirus
0.16384977.11502759.html.plaintext.txt	27	The proteins gE gI Us9 universally conserved known neurotropic herpesvirus genomes
0.16384977.11502759.html.plaintext.txt	28	gE gI type I transmembrane proteins typically form heterodimer whereas Us9 type II tail anchored membrane protein
0.16384977.11502759.html.plaintext.txt	29	Several groups discovered herpesvirus gE gI Us9 mutants able replicate primary neurons incapable spreading secondary postsynaptic neurons Card et al
0.16384977.11502759.html.plaintext.txt	30	For example infection rat eye wild type PRV replicates retinal neurons spreads via optic nerve secondary neurons visual nuclei central nervous system review see Enquist et al
0.16384977.11502759.html.plaintext.txt	31	By contrast gE gI Us9 null mutants replicate well retinal neurons spread second order neurons superior colliculus midbrain Whealy et al
0.16384977.11502759.html.plaintext.txt	32	This defect significant since 90 retinal ganglion cells rat retina synaptic contact neurons superior colliculus Linden Perry 1983
0.16384977.11502759.html.plaintext.txt	33	Similar defects spread gE gI mutant viruses presynaptic postsynaptic neurons often called anterograde spread also reported nasal infection swine natural host PRV Kritas et al
0.16384977.11502759.html.plaintext.txt	34	Although PRV gE gI Us9 proteins required efficient spread presynaptic postsynaptic neurons neural circuits tested three proteins required spread postsynaptic presynaptic neurons often called retrograde spread Whealy et al
0.16384977.11502759.html.plaintext.txt	35	All available evidence suggests defect anterograde transsynaptic spread exhibited gE gI Us9 mutants occurs within primary presynaptic infected neuron Husak et al
0.16384977.11502759.html.plaintext.txt	36	One hypothesis gE gI Us9 mutant infections virions assembled cell body fail transported axons
0.16384977.11502759.html.plaintext.txt	37	An alternative suggestion mutant infections assembled virions enter axons released axon terminals
0.16384977.11502759.html.plaintext.txt	38	In report tested hypotheses examining localization virion structural proteins wild type mutant infection cultured neurons
0.16384977.11502759.html.plaintext.txt	39	If first hypothesis true virion structural proteins found axons mutant infections
0.16384977.11502759.html.plaintext.txt	40	If second hypothesis true structural proteins found axons mutant wild type infections
0.16384977.11502759.html.plaintext.txt	41	Our work revealed neither hypothesis correct suggested unique function Us9 protein
0.16384977.11502759.html.plaintext.txt	42	Although presence absence gE obvious effect localization virion structural proteins axons infected neurons Us9 null mutant infections subset viral structural proteins entered axons
0.16384977.11502759.html.plaintext.txt	43	Surprisingly capsid tegument proteins viral membrane proteins detected axons
0.16384977.11502759.html.plaintext.txt	44	We previously used alanine substitution mutagenesis define Us9 residues essential vivo anterograde spread PRV rat visual system Brideau et al
0.16384977.11502759.html.plaintext.txt	45	This work indicated two adjacent tyrosines Y49Y50 acidic motif residues 46 56 absolutely essential Us9 function Fig
0.16384977.11502759.html.plaintext.txt	46	In addition found two serines S51S53 acidic domain phosphorylated alanine substitutions residues affected rate Us9 dependent vivo anterograde spread
0.16384977.11502759.html.plaintext.txt	47	Finally alanine substitution mutagenesis two adjacent leucine residues L30L31 function endocytosis motif Brideau et al
0.16384977.11502759.html.plaintext.txt	48	2000b dispensable anterograde spread vivo
0.16384977.11502759.html.plaintext.txt	49	We infected cultured PNS neurons mutant viruses determine Us9 dependent localization viral membrane proteins correlated ability promote anterograde spread infection vivo
0.16384977.11502759.html.plaintext.txt	50	We found tyrosines 48 50 serines 51 53 absolutely required Us9 mediated membrane protein localization axons
0.16384977.11502759.html.plaintext.txt	51	Leucines 30 31 completely dispensable axonal localization viral membrane proteins anterograde spread vivo
0.16384977.11502759.html.plaintext.txt	52	View larger version 32K Figure 1
0.16384977.11502759.html.plaintext.txt	53	A The amino acid sequence PRV Us9
0.16384977.11502759.html.plaintext.txt	54	Amino acids substituted alanine bolded
0.16384977.11502759.html.plaintext.txt	55	The acidic region Us9 underlined solid line predicted transmembrane domain underlined dashed line
0.16384977.11502759.html.plaintext.txt	56	B The PRV Us9 missense mutants amino acid changes
0.16384977.11502759.html.plaintext.txt	57	These results provide new insight process virion assembly exit neurons leads directional spread herpesviruses nervous system
0.16384977.11502759.html.plaintext.txt	58	We suggest single viral protein Us9 responsible localization viral membrane proteins axon
0.16384977.11502759.html.plaintext.txt	59	If membrane proteins localized axons transported axon terminals viral infection cannot spread synaptically connected neurons
0.16384977.11502759.html.plaintext.txt	60	An important finding Us9 required localization capsid tegument proteins axon
0.16384977.11502759.html.plaintext.txt	61	An interpretation observations mature virions assembled cell body subsequently transported axons axon terminal
0.16384977.11502759.html.plaintext.txt	62	Rather components mature virions transported separately axons terminals infection postsynaptic cells occurs
0.16384977.11502759.html.plaintext.txt	63	Results Top Abstract Introduction Results Discussion Materials methods References Determining subcellular distribution gB essential virion envelope protein infected superior cervical ganglia neurons Predictions previous work gE Us9 mutants would defective either transport intracellular virions axons mutant virions could exit axon terminals Husak et al
0.16384977.11502759.html.plaintext.txt	64	Accordingly determined localization viral structural components neurons infected wild type mutant viruses
0.16384977.11502759.html.plaintext.txt	65	Initially examined subcellular distribution viral glycoprotein gB neurons infected wild type gE null Us9 null viruses
0.16384977.11502759.html.plaintext.txt	66	gB abundant viral membrane protein required virus entry cell cell spread cells Rauh Mettenleiter 1991
0.16384977.11502759.html.plaintext.txt	67	The kinetics expression cellular localization gB indistinguishable cell body neurons infected three viruses Fig
0.16384977.11502759.html.plaintext.txt	68	In neurons infected wild type gE null mutants puncta gB immunoreactivity appeared axons 11 h infection unpublished data
0.16384977.11502759.html.plaintext.txt	69	At 16 h infection gB puncta could found throughout extent axons neurons infected either virus Fig
0.16384977.11502759.html.plaintext.txt	70	However Us9 null infections little gB could detected axons infected neurons even latest times infection Fig
0.16384977.11502759.html.plaintext.txt	71	Occasionally puncta gB immunoreactivity appeared axons Us9 null mutant infection proximal portion axon
0.16384977.11502759.html.plaintext.txt	72	These experiments provided first direct evidence Us9 gE may different functions infected neurons leading transsynaptic spread
0.16384977.11502759.html.plaintext.txt	73	View larger version 82K Figure 2
0.16384977.11502759.html.plaintext.txt	74	The axonal localization essential viral membrane protein gB requires Us9 gE
0.16384977.11502759.html.plaintext.txt	75	Less 10 neurons culture infected 12 h wild type A D gE null mutant B E Us9 null mutant C F fixed permeabilized
0.16384977.11502759.html.plaintext.txt	76	Infected neurons labeled antibodies recognize gB
0.16384977.11502759.html.plaintext.txt	77	A C image planes level cell bodies whereas D F image planes substrate axons visualized
0.16384977.11502759.html.plaintext.txt	78	Arrows point axons infected neurons N indicates nucleus infected neurons
0.16384977.11502759.html.plaintext.txt	79	Us9 required axonal localization two viral membrane proteins We next determined whether gC gE two abundant nonessential virion membrane proteins localize axons absence Us9 Fig
0.16384977.11502759.html.plaintext.txt	80	The results similar gB described amount gC gE distance membrane proteins traveled axon dramatically reduced Us9 null mutant infections compared wild type infections
0.16384977.11502759.html.plaintext.txt	81	Thus three diverse virion membrane proteins gB gC gE required Us9 protein localize fill axons even though obvious defect expression localization glycoproteins within cell body apparent confocal microscopy
0.16384977.11502759.html.plaintext.txt	82	View larger version 77K Figure 3
0.16384977.11502759.html.plaintext.txt	83	The axonal localization viral membrane proteins requires Us9
0.16384977.11502759.html.plaintext.txt	84	A Neurons infected wild type b c Us9 null virus PRV160 d e f every neuron infected 16 h fixed permeabilized
0.16384977.11502759.html.plaintext.txt	85	Infected neurons labeled antibodies recognize gB d gC b e gE c f
0.16384977.11502759.html.plaintext.txt	86	Arrows point axons labeled viral membrane proteins wild type infections
0.16384977.11502759.html.plaintext.txt	87	B The experiment lower magnification
0.16384977.11502759.html.plaintext.txt	88	Bars A 25 microm B 150 microm
0.16384977.11502759.html.plaintext.txt	89	Viral membrane proteins traffic secretory system Us9 null infections The absence viral membrane proteins axons Us9 null infections may reflect aberrant trafficking viral membrane proteins secretory system
0.16384977.11502759.html.plaintext.txt	90	Accordingly examined kinetics cell surface expression viral membrane protein infection
0.16384977.11502759.html.plaintext.txt	91	If Us9 null infections lead retention viral membrane proteins secretory system viral membrane proteins found surface infected cell
0.16384977.11502759.html.plaintext.txt	92	Neurons infected wild type Us9 null virus varying lengths time cell surface localization gE examined
0.16384977.11502759.html.plaintext.txt	93	gE appeared neuronal surface infection either virus Fig
0.16384977.11502759.html.plaintext.txt	94	The kinetics surface expression similar viruses detectable levels gE appeared 7 h infection experiments neurons culture infected
0.16384977.11502759.html.plaintext.txt	95	Despite similar kinetics gE initially surfaced axons neurons infected wild type virus little gE detected surface axons infected Us9 null virus unpublished data
0.16384977.11502759.html.plaintext.txt	96	By 9 h infection markedly different surface staining patterns evident gE covered surface neurons wild type infection cell body axon Fig
0.16384977.11502759.html.plaintext.txt	97	During Us9 null infections little detectable staining appeared axons Fig
0.16384977.11502759.html.plaintext.txt	98	4 A c d despite significant staining surface cell body
0.16384977.11502759.html.plaintext.txt	99	These results demonstrate gE able traffic secretory system cell body surface Us9 null mutant infections yet targeted axon
0.16384977.11502759.html.plaintext.txt	100	View larger version 62K Figure 4
0.16384977.11502759.html.plaintext.txt	101	Analysis neuronal secretory system PRV infection
0.16384977.11502759.html.plaintext.txt	102	A Cell surface gE wild type Us9 null infections
0.16384977.11502759.html.plaintext.txt	103	Neurons infected every neuron infected 9 h wild type b Us9 null virus c d
0.16384977.11502759.html.plaintext.txt	104	Antibodies recognize gE placed directly culture medium 5 min unbound antibodies removed infected neurons fixed
0.16384977.11502759.html.plaintext.txt	105	B The steady state localization synaptic vesicle marker SV2
0.16384977.11502759.html.plaintext.txt	106	Neurons mock infected infected wild type virus b Us9 null virus c every neuron infected 16 h neurons fixed permeabilized
0.16384977.11502759.html.plaintext.txt	107	An antibody recognizes SV2 used indirect immunofluorescence experiments
0.16384977.11502759.html.plaintext.txt	108	C The subcellular localization cellular protein NgCAM expressed PRV infection
0.16384977.11502759.html.plaintext.txt	109	A replication defective virus expressing cellular protein NgCAM used infect cultured neurons
0.16384977.11502759.html.plaintext.txt	110	After 1 h medium removed cultures mock infected c infected wild type d f Us9 null virus g
0.16384977.11502759.html.plaintext.txt	111	c show NgCAM localization absence PRV infection
0.16384977.11502759.html.plaintext.txt	112	NgCAM appears surface cell body vesicles within axon b note image large fasiculation therefore many axons present within bundle surface axon c
0.16384977.11502759.html.plaintext.txt	113	NgCAM labeled surface neurons infected wild type virus d Us9 null virus g
0.16384977.11502759.html.plaintext.txt	114	The expression gE wild type e Us9 null h infections demonstrates infected PRV
0.16384977.11502759.html.plaintext.txt	115	Merged images wild type infection f Us9 null infection shown NgCAM green gE red
0.16384977.11502759.html.plaintext.txt	116	Bars A b B C 25 microm A c d 150 microm
0.16384977.11502759.html.plaintext.txt	117	Targeting cellular proteins disrupted Us9 null infections We examined possibility axonal targeting cellular proteins disrupted Us9 null mutant infections
0.16384977.11502759.html.plaintext.txt	118	We first assessed steady state localization synaptic vesicle marker SV2
0.16384977.11502759.html.plaintext.txt	119	Neurons infected wild type Us9 null mock infected 16 h fixed
0.16384977.11502759.html.plaintext.txt	120	Antibodies recognized SV2 used indirect immunofluorescence experiments levels staining compared
0.16384977.11502759.html.plaintext.txt	121	SV2 staining appeared along length axon control sample Fig
0.16384977.11502759.html.plaintext.txt	122	No notable difference staining found either wild type Fig
0.16384977.11502759.html.plaintext.txt	123	4 B b Us9 null infections Fig
0.16384977.11502759.html.plaintext.txt	124	4 B c compared control
0.16384977.11502759.html.plaintext.txt	125	Although evidence consistent hypothesis cellular proteins targeted normally Us9 null mutant infections examined steady state localization cellular protein infection
0.16384977.11502759.html.plaintext.txt	126	To assess fate de novo translated protein expressed cellular protein normally localizes axon NgCAM replication defective herpes simplex virus PRV infections
0.16384977.11502759.html.plaintext.txt	127	The defective virus first used infect neurons 1 h later either wild type Us9 null virus used superinfect cultured neurons
0.16384977.11502759.html.plaintext.txt	128	Because NgCAM chicken protein protein expressed defective virus detectable antibody chicken protein unpublished data
0.16384977.11502759.html.plaintext.txt	129	After 16 h PRV infection antibodies NgCAM used determine targeting cellular protein axon
0.16384977.11502759.html.plaintext.txt	130	4 C shows expression NgCAM 18 h infection replication defective virus
0.16384977.11502759.html.plaintext.txt	131	Staining found predominantly cell surface Fig
0.16384977.11502759.html.plaintext.txt	132	4 C c also vesicles within axon Fig
0.16384977.11502759.html.plaintext.txt	133	The intensity expression drastically reduced infection PRV many neurons expressed NgCAM adequately
0.16384977.11502759.html.plaintext.txt	134	NgCAM found surface axons cell bodies neurons infected either wild type Fig
0.16384977.11502759.html.plaintext.txt	135	4 C d Us9 null mutant Fig
0.16384977.11502759.html.plaintext.txt	136	Taken together two experiments indicate axonal targeting cellular proteins markedly disrupted infection either wild type Us9 null virus
0.16384977.11502759.html.plaintext.txt	137	Critical domains defined Us9 function vivo also required localization viral membrane proteins axons Brideau et al
0.16384977.11502759.html.plaintext.txt	138	2000b used alanine substitution mutagenesis define residues Us9 required promote anterograde viral spread rat visual system see Fig
0.16384977.11502759.html.plaintext.txt	139	1 details mutant viruses
0.16384977.11502759.html.plaintext.txt	140	These Us9 mutants PRV 166 172 173 differ rate extent anterograde spread vivo
0.16384977.11502759.html.plaintext.txt	141	We infected cultured superior cervical ganglia SCG neurons viruses determine axonal localization viral membrane proteins correlated anterograde spread vivo
0.16384977.11502759.html.plaintext.txt	142	PRV166 L30L31 AA spreads rat visual system like wild type virus Brideau et al
0.16384977.11502759.html.plaintext.txt	143	4 A C shows results SCG infection PRV166
0.16384977.11502759.html.plaintext.txt	144	All viral membrane proteins examined Fig
0.16384977.11502759.html.plaintext.txt	145	5 A gB B gC C gE localized axons infected neurons
0.16384977.11502759.html.plaintext.txt	146	These infections similar wild type infections Fig
0.16384977.11502759.html.plaintext.txt	147	PRV173 S51S53 AA defective rate ultimately approximates wild type extent anterograde spread infection rat visual system Brideau et al
0.16384977.11502759.html.plaintext.txt	148	Infection cultured neurons PRV173 led intermediate phenotype viral membrane proteins examined localize axon Fig
0.16384977.11502759.html.plaintext.txt	149	5 G I extent reduced compared wild type infection Fig
0.16384977.11502759.html.plaintext.txt	150	5 G I compared A C
0.16384977.11502759.html.plaintext.txt	151	PRV172 Y49Y50 AA Us9 null phenotype restricted anterograde spread infection rat visual system Brideau et al
0.16384977.11502759.html.plaintext.txt	152	Infections cultured neurons mutant identical Us9 null virus infections viral membrane proteins found axons scattered vesicles found near cell body Fig
0.16384977.11502759.html.plaintext.txt	153	These data demonstrate Us9 mediated membrane protein localization axons correlates well anterograde spread infection rat visual system
0.16384977.11502759.html.plaintext.txt	154	View larger version 95K Figure 5
0.16384977.11502759.html.plaintext.txt	155	Axonal localization viral membrane proteins promoted Us9 missense mutants correlates degree anterograde spread rodent nervous system
0.16384977.11502759.html.plaintext.txt	156	Neurons infected PRV166 L30L31 AA A C PRV 172 Y49Y50 AA D F PRV173 S51S53 AA G I every neuron infected 16 h fixed permeabilized
0.16384977.11502759.html.plaintext.txt	157	I detailed description Us9 mutant viruses
0.16384977.11502759.html.plaintext.txt	158	Infected neurons labeled antibodies recognize gB A D G gC B E H gE C F I
0.16384977.11502759.html.plaintext.txt	159	Us9 found vesicles within axon We examined colocalization Us9 viral membrane proteins wild type infections
0.16384977.11502759.html.plaintext.txt	160	Us9 observed vesicles close cell body infected neuron Fig
0.16384977.11502759.html.plaintext.txt	161	6 A C gB D F gC G I gE often colocalize viral membrane proteins containing vesicles distal axon
0.16384977.11502759.html.plaintext.txt	162	View larger version 111K Figure 6
0.16384977.11502759.html.plaintext.txt	163	Colocalization Us9 viral membrane proteins within axon
0.16384977.11502759.html.plaintext.txt	164	Neurons infected wild type virus every neuron infected 6 h antibodies Us9 A D G gB B gC E gE H added
0.16384977.11502759.html.plaintext.txt	165	The merged images shown C F I Us9 green corresponding membrane protein red
0.16384977.11502759.html.plaintext.txt	166	Us9 required tegument protein localization One hypothesis consistent results presented far Us9 gE protein required transport mature fully assembled virions axons infected neurons
0.16384977.11502759.html.plaintext.txt	167	If true predicted nonmembrane structural components virus capsid tegument would also require Us9 localization axons
0.16384977.11502759.html.plaintext.txt	168	To test prediction followed localization virion components time cultured neurons infected wild type Us9 null mutants
0.16384977.11502759.html.plaintext.txt	169	We first focused localization tegument proteins infected neurons
0.16384977.11502759.html.plaintext.txt	170	The tegument collection proteins virus envelope outside capsid herpes virion Roizman Furlong 1974
0.16384977.11502759.html.plaintext.txt	171	Early infection wild type Us9 mutants 4 8 h infection tegument proteins VP22 UL25 localized strongly nucleus also observed throughout cell body unpublished data
0.16384977.11502759.html.plaintext.txt	172	Tegument proteins could detected axons early stages infection
0.16384977.11502759.html.plaintext.txt	173	However 8 h infection immunoreactivity tegument proteins nucleus decreased concomitant increase antibody staining infected axons wild type Us9 null infections Fig
0.16384977.11502759.html.plaintext.txt	174	Both VP22 UL25 also localized axons infections Us9 missense mutants PRV 166 172 173 unpublished data
0.16384977.11502759.html.plaintext.txt	175	We conclude Us9 required localize tegument proteins VP22 UL25 axons
0.16384977.11502759.html.plaintext.txt	176	Thus original hypothesis Us9 required localization fully assembled virions axon likely correct
0.16384977.11502759.html.plaintext.txt	177	View larger version 91K Figure 7
0.16384977.11502759.html.plaintext.txt	178	The axonal localization tegument proteins UL25 VP22 require Us9
0.16384977.11502759.html.plaintext.txt	179	Less 10 neurons cultures infected 8 h wild type A Us9 null virus C fixed permeabilized
0.16384977.11502759.html.plaintext.txt	180	Antibodies recognize UL25 A C revealed subcellular localization tegument protein infected neurons
0.16384977.11502759.html.plaintext.txt	181	In second series experiments 10 neurons cultures infected 12 h wild type B Us9 null virus D fixed permeabilized
0.16384977.11502759.html.plaintext.txt	182	The neurons labeled antibodies recognize VP22 B D
0.16384977.11502759.html.plaintext.txt	183	Us9 required localization capsid proteins axons The PRV capsid icosahedral structure contains delivers viral genome nucleus infected cell
0.16384977.11502759.html.plaintext.txt	184	Early infection 4 8 h infection antibody major capsid protein VP5 stained nucleus intensely weaker staining cytoplasm
0.16384977.11502759.html.plaintext.txt	185	This observation consistent initial synthesis VP5 cytoplasm subsequent transport nucleus assembles capsids
0.16384977.11502759.html.plaintext.txt	186	Despite significant localization VP5 nucleus cell body VP5 detected axons time unpublished data
0.16384977.11502759.html.plaintext.txt	187	Approximately 8 h infection VP5 immunoreactivity detected axons neurons infected wild type Us9 mutants Fig
0.16384977.11502759.html.plaintext.txt	188	Wild type levels VP5 immunoreactivity also found axons neurons infected Us9 missense mutants unpublished data
0.16384977.11502759.html.plaintext.txt	189	View larger version 68K Figure 8
0.16384977.11502759.html.plaintext.txt	190	The axonal localization two capsid proteins require Us9
0.16384977.11502759.html.plaintext.txt	191	A Less 10 neurons infected 12 h wild type Us9 null virus b fixed permeabilized
0.16384977.11502759.html.plaintext.txt	192	An antibody recognizes major capsid protein VP5 used label capsids infected neurons
0.16384977.11502759.html.plaintext.txt	193	B Viruses express GFP capsid fusion GFP VP26 wild type Us9 null viral genomes used infect neurons culture 17 h fixed permeabilized
0.16384977.11502759.html.plaintext.txt	194	Antibodies recognize GFP labeled capsids infected neurons
0.16384977.11502759.html.plaintext.txt	195	gE localization fields shown c compared d required Us9 localize axons
0.16384977.11502759.html.plaintext.txt	196	Bars A 25 microm B 150 microm
0.16384977.11502759.html.plaintext.txt	197	To confirm findings constructed viruses express green fluorescent protein GFP fused another capsid protein VP26 wild type Us9 null virus genomes
0.16384977.11502759.html.plaintext.txt	198	The capsids produced viruses predicted contain 900 copies GFP VP26 fusion protein Desai Person 1998 Smith et al
0.16384977.11502759.html.plaintext.txt	199	After infection neurons fixed antibodies recognizing GFP revealed subcellular localization VP26 assembled capsids
0.16384977.11502759.html.plaintext.txt	200	Again observed strong immunoreactivity nucleus weaker signal throughout cell body early times infection
0.16384977.11502759.html.plaintext.txt	201	No GFP VP26 detected axons times unpublished data
0.16384977.11502759.html.plaintext.txt	202	However 8 h infection immunoreactivity nucleus decreased GFP VP26 found axons neurons presence absence Us9
0.16384977.11502759.html.plaintext.txt	203	6 B shows experiment 17 h infection
0.16384977.11502759.html.plaintext.txt	204	GFP VP26 presumably assembled capsids localized cell body axons infected neurons wild type Fig
0.16384977.11502759.html.plaintext.txt	205	8 B Us9 null virus Fig
0.16384977.11502759.html.plaintext.txt	206	As control also examined simultaneously localization membrane protein gE infections
0.16384977.11502759.html.plaintext.txt	207	3 axonal localization gE requires expression Us9 Fig
0.16384977.11502759.html.plaintext.txt	208	In Us9 null mutant infections gE protein confined mainly cell body found axons Fig
0.16384977.11502759.html.plaintext.txt	209	By contrast capsids infected cell deduced GFP VP26 staining found abundantly axons presence absence Us9
0.16384977.11502759.html.plaintext.txt	210	Evidence GFP VP26 axons assembled capsids described Smith et al
0.16384977.11502759.html.plaintext.txt	211	These experiments demonstrate Us9 required axonal localization viral membrane proteins capsids
0.16384977.11502759.html.plaintext.txt	212	Taken together data previous section results consistent hypothesis enveloped virions transported axons
0.16384977.11502759.html.plaintext.txt	213	Us9 involved attachment entry replication PRV SCG neurons Us9 null mutants grow normally obvious defects attachment entry replication nonneuronal cells Brideau et al
0.16384977.11502759.html.plaintext.txt	214	We observed Us9 null mutant produced infectious virus essentially rate extent wild type virus SCG neurons Fig
0.16384977.11502759.html.plaintext.txt	215	Wild type Us9 null mutant viruses produced relatively infectious particles per neuron compared infection nonneuronal cell lines PK15 cells
0.16384977.11502759.html.plaintext.txt	216	The quantity infectious virus released medium also low compared nonneuronal cell lines
0.16384977.11502759.html.plaintext.txt	217	We note measurement released virus likely underestimate virus bind avidly poly lysine substrate required neuronal growth unpublished data
0.16384977.11502759.html.plaintext.txt	218	Since differences rate extent infectious virus production among wild type Us9 null viruses conclude Us9 affect viral attachment entry replication SCG neurons duration experiments
0.16384977.11502759.html.plaintext.txt	219	Therefore Us9 null phenotype due replication defect
0.16384977.11502759.html.plaintext.txt	220	View larger version 17K Figure 9
0.16384977.11502759.html.plaintext.txt	221	Us9 involved viral attachment entry replication SCG neurons
0.16384977.11502759.html.plaintext.txt	222	Neurons infected wild type Us9 null virus every neuron infected amount infectious virus plaque forming units produced 1 8 16 24 h infection determined
0.16384977.11502759.html.plaintext.txt	223	Each sample performed triplicate viruses data cell associated virus shown graph
0.16384977.11502759.html.plaintext.txt	224	Discussion Top Abstract Introduction Results Discussion Materials methods References Directional spread herpesviruses PNS fundamental aspect viral life cycle
0.16384977.11502759.html.plaintext.txt	225	Upon primary infection natural host virus travels peripheral epithelia neuronal cell bodies PNS usually establishes latent infection
0.16384977.11502759.html.plaintext.txt	226	During reactivation virus travels back periphery likely neuron infected time
0.16384977.11502759.html.plaintext.txt	227	Movement virion components cell body PNS neurons requires viral proteins enter axons move substantial distances Tomishima et al
0.16384977.11502759.html.plaintext.txt	228	Because access axon restricted subset neuronal proteins typically involved synapse formation function likely herpesviruses evolved mechanisms interact axonal targeting transport machinery ensure transport viral proteins axons
0.16384977.11502759.html.plaintext.txt	229	We demonstrated previously Us9 involved spread virus presynaptic postsynaptic neurons Brideau et al
0.16384977.11502759.html.plaintext.txt	230	Here provide simple explanation phenotype demonstrate Us9 required localization viral membrane proteins axon infected neurons
0.16384977.11502759.html.plaintext.txt	231	We surprised find Us9 required localize nonmembrane structural components virion example capsid tegument proteins axon
0.16384977.11502759.html.plaintext.txt	232	This finding important implications herpesvirus assembly addresses long standing problem large complex herpes virion assembled infected PNS neurons
0.16384977.11502759.html.plaintext.txt	233	A widely held idea completely assembled virions accumulate cell body nascent enveloped virions transported vesicles cell body axons
0.16384977.11502759.html.plaintext.txt	234	Then microtubule based motors vesicles carry enveloped virions axon terminals exit infect postsynaptic cell Lycke et al
0.16384977.11502759.html.plaintext.txt	235	In another model first suggested Penfold et al
0.16384977.11502759.html.plaintext.txt	236	1994 herpes simplex virus type 1 complete virions assembled cell body rather assembled near axon terminal
0.16384977.11502759.html.plaintext.txt	237	These workers observed capsids axons separate envelope proteins never observed fully assembled enveloped virions axons cultured human PNS neurons
0.16384977.11502759.html.plaintext.txt	238	1994 proposed capsids destined axon terminals enveloped cell body rather acquired envelope near axon terminal mature enveloped virions released cleft neuron epithelial cell
0.16384977.11502759.html.plaintext.txt	239	Our data consistent proposal
0.16384977.11502759.html.plaintext.txt	240	Moreover extend model suggest Us9 protein required axonal localization virion envelope subassemblies tegument capsid proteins
0.16384977.11502759.html.plaintext.txt	241	We others found herpesvirus genes gE gI Us9 necessary anterograde spread infection vivo Card et al
0.16384977.11502759.html.plaintext.txt	242	One limitation vivo experiments technical difficulty examining cell biology infection
0.16384977.11502759.html.plaintext.txt	243	These previous experiments looked replication virus within first second order neurons
0.16384977.11502759.html.plaintext.txt	244	Consequently possible determine second order neurons infected
0.16384977.11502759.html.plaintext.txt	245	Here report Us9 responsible localizing viral membrane proteins axons infected neurons yet gE gI proteins needed function
0.16384977.11502759.html.plaintext.txt	246	One idea gE gI accumulate nerve terminals promote spread infection pre postsynaptic neurons Dingwell et al
0.16384977.11502759.html.plaintext.txt	247	2000a Tirabassi Enquist 2000
0.16384977.11502759.html.plaintext.txt	248	The mechanism Us9 enables viral envelope proteins enter axons study
0.16384977.11502759.html.plaintext.txt	249	We tested three ideas initially
0.16384977.11502759.html.plaintext.txt	250	First Us9 open axon membrane protein discriminate among host viral proteins To test idea determined localization well known somatodendritic axonal marker proteins infection found even late infection example 20 h marker proteins remained proper compartments unpublished data
0.16384977.11502759.html.plaintext.txt	251	Second absence Us9 membrane proteins including host membrane proteins blocked entering axons infected cells We performed two sets experiments address question
0.16384977.11502759.html.plaintext.txt	252	The first experiments examined steady state localization synaptic vesicle protein uninfected cultures wild type Us9 null mutant infections
0.16384977.11502759.html.plaintext.txt	253	No difference could found uninfected wild type Us9 null infections
0.16384977.11502759.html.plaintext.txt	254	We also demonstrated axonal protein NgCAM translated PRV infection capable trafficking axons infected either wild type Us9 null virus
0.16384977.11502759.html.plaintext.txt	255	Finally tested idea viral membrane proteins unable progress secretory system Us9 null infections
0.16384977.11502759.html.plaintext.txt	256	We found gE reaches cell surface Us9 null infections kinetics similar identical wild type infections
0.16384977.11502759.html.plaintext.txt	257	Together data argue secretory pathway functional Us9 null infections trafficking cellular proteins axon normal Us9 null infections
0.16384977.11502759.html.plaintext.txt	258	It appears Us9 specifically promotes axonal delivery viral membrane proteins
0.16384977.11502759.html.plaintext.txt	259	2000b identified L30L31 acidic domain amino acids 46 56 important residues retrieval TGN localization Us9 plasma membrane nonneuronal cells
0.16384977.11502759.html.plaintext.txt	260	In addition authors found amino acids Y49Y50 acidic motif essential Us9 promote transneuronal spread infection
0.16384977.11502759.html.plaintext.txt	261	By contrast phosphorylated S51S53 residues affected rate viral spread whereas dileucine motif role viral spread rat visual system Brideau et al
0.16384977.11502759.html.plaintext.txt	262	Experiments report extend understanding phenotypes
0.16384977.11502759.html.plaintext.txt	263	Infection PRV172 Y49Y50 AA Us9 null phenotype vivo also null phenotype infection cultured neurons viral membrane proteins tested markedly reduced axons
0.16384977.11502759.html.plaintext.txt	264	PRV173 Us9 alanine substitution mutant partial loss function phenotype anterograde spread animals also intermediate phenotype cultured neurons
0.16384977.11502759.html.plaintext.txt	265	Finally PRV166 phenotype vivo indistinguishable wild type infection cultured neurons
0.16384977.11502759.html.plaintext.txt	266	We surmise first time Us9 null mutants defective directional transneuronal spread membrane proteins gB absolutely required transneuronal spread Babic et al
0.16384977.11502759.html.plaintext.txt	267	1993 enter axons absence Us9
0.16384977.11502759.html.plaintext.txt	268	How Us9 promote localization viral membrane proteins axons Us9 obvious homology protein nucleic acid sequences GenBank might provide insight functions
0.16384977.11502759.html.plaintext.txt	269	However motifs identified alanine substitution mutations discussed suggest Us9 may participate recruiting cytoplasmic coat proteins allowing formation vesicles destined different subcellular locations review see Kirchhausen et al
0.16384977.11502759.html.plaintext.txt	270	1997 Schmid 1997 Lewin Mellman 1998
0.16384977.11502759.html.plaintext.txt	271	The deletion 10 amino acid highly conserved acidic motif residues 46 56 region Us9 blocks retrieval Us9 plasma membrane compartment near TGN implicating region recruitment adaptor protein AP 2 necessary clathrin dependent endocytosis
0.16384977.11502759.html.plaintext.txt	272	This deletion mutation also removes two serines likely phosphorylated Brideau et al
0.16384977.11502759.html.plaintext.txt	273	The cell adhesion molecule L1 endoprotease furin mannose 6 phosphate receptor many viral proteins YXX motif near acidic cluster contains serine residues capable phosphorylated casein kinase I II
0.16384977.11502759.html.plaintext.txt	274	The trafficking proteins regulated casein kinase II phosphorylation tyrosine based sorting signal Trowbridge et al
0.16384977.11502759.html.plaintext.txt	275	The Y49Y50 motif acidic domain conserved throughout known Us9 homologues herpesviruses Brideau et al
0.16384977.11502759.html.plaintext.txt	276	This YY motif different YXX motif classically shown mediate interactions adaptor proteins Bonifacino DellAngelica 1999
0.16384977.11502759.html.plaintext.txt	277	Nevertheless given phenotypes YY AA mutants suggest two tyrosines critical Us9 function interact particular cytoplasmic adaptor proteins necessary movement vesicles compartments cell
0.16384977.11502759.html.plaintext.txt	278	There precedent herpesviruses usurping adaptor mediated targeting infection PRV membrane protein gE shown direct vesicles containing virions basolateral domain polarized epithelial cells sorting dependent adaptor complex AP 1 Johnson et al
0.16384977.11502759.html.plaintext.txt	279	10 viral membrane proteins achieve steady state localization trans Golgi network post Golgi compartment cell body
0.16384977.11502759.html.plaintext.txt	280	Once compartment viral membrane proteins selectively incorporated vesicles destined axon
0.16384977.11502759.html.plaintext.txt	281	In simplest case presence Us9 compartment recruits neuron specific adaptor complex binds Us9 via dityrosine motif example forms AP 3 possible candidates Pevsner et al
0.16384977.11502759.html.plaintext.txt	282	1994 leading formation transport vesicles carrying Us9 viral membrane proteins coated axonal adaptors
0.16384977.11502759.html.plaintext.txt	283	Therefore absence Us9 vesicles containing viral membrane proteins would directed axon
0.16384977.11502759.html.plaintext.txt	284	The cytoplasmic tails viral membrane proteins could still bind adaptor complexes allowing vesiculation transport cell surface movement compartments axon
0.16384977.11502759.html.plaintext.txt	285	In model one molecule transport vesicle need carry cis acting axonal sorting signal
0.16384977.11502759.html.plaintext.txt	286	Such piggyback model axonal targeting neuronal proteins proposed recently Roos Kelly 2000
0.16384977.11502759.html.plaintext.txt	287	Other proteins within vesicle gain access axon simply vesicle protein sorting signal
0.16384977.11502759.html.plaintext.txt	288	We propose Us9 represents axon specific sorting molecule viral membrane proteins merely cargo
0.16384977.11502759.html.plaintext.txt	289	However observation vesicles within axon contain Us9 noteworthy
0.16384977.11502759.html.plaintext.txt	290	Perhaps vesicles moving axon contain Us9 whereas non Us9 containing vesicles enriched distal axon represent viral membrane proteins accumulated within organelle example endosome
0.16384977.11502759.html.plaintext.txt	291	Alternatively Us9 may function cell body neuron alter trafficking patterns viral membrane proteins
0.16384977.11502759.html.plaintext.txt	292	We process testing ideas
0.16384977.11502759.html.plaintext.txt	293	View larger version 24K Figure 10
0.16384977.11502759.html.plaintext.txt	294	A model Us9 dependent axonal sorting viral membrane proteins
0.16384977.11502759.html.plaintext.txt	295	Us9 depicted white rectangle viral membrane proteins black lollipops
0.16384977.11502759.html.plaintext.txt	296	The adaptor complex AP 1 shown hexagon AP 3 shown star
0.16384977.11502759.html.plaintext.txt	297	A The targeting viral membrane proteins axon requires Us9
0.16384977.11502759.html.plaintext.txt	298	A tyrosine based cytoplasmic sorting signal Us9 interacts AP 3 allowing formation axonal transport vesicles coated adaptor complex
0.16384977.11502759.html.plaintext.txt	299	Other viral membrane proteins passive cargo targeted axon due association Us9 cis acting peptide sequence
0.16384977.11502759.html.plaintext.txt	300	The cytoplasmic tails viral membrane proteins still interact adaptor complexes wild type infections allowing transport vesicles traffic regions neuron addition axon
0.16384977.11502759.html.plaintext.txt	301	B Without Us9 axonal sorting signal present cytoplasmic tails viral membrane proteins
0.16384977.11502759.html.plaintext.txt	302	Vesicles still form longer targeted axon
0.16384977.11502759.html.plaintext.txt	303	The cytoplasmic tails viral membrane proteins still interact adaptor complexes allowing transport vesicles traffic regions neuron
0.16384977.11502759.html.plaintext.txt	304	In summary find virion assembly intimately associated directional spread infection neurons
0.16384977.11502759.html.plaintext.txt	305	It assumed complete virus particles assembled cell body moved axons long distance travel axon terminals
0.16384977.11502759.html.plaintext.txt	306	Our results support alternative model proposed Penfold et al
0.16384977.11502759.html.plaintext.txt	307	1994 whereby structural components virus moved separately axons infected neurons later assembly
0.16384977.11502759.html.plaintext.txt	308	Our genetic data indicate loss single gene Us9 leads wholesale change subcellular localization PNS neurons viral membrane proteins examined yet change localization capsid tegument proteins
0.16384977.11502759.html.plaintext.txt	309	Since viruses must subvert host processes replication understanding Us9 changes polarity viral membrane proteins infection reveal conserved neuronal proteins involved axonal targeting transport may provide insight general mechanism directional axonal transport
0.16384977.11502759.html.plaintext.txt	310	Cell biologists long relied selected viral proteins facilitate understanding intracellular trafficking polarized protein delivery
0.16384977.11502759.html.plaintext.txt	311	Herpesviruses evolved mechanisms parasitize coexist neurons broad range hosts may offer new tools probe cellular molecular mechanisms polarized protein traffic neurons
0.16384977.11502759.html.plaintext.txt	312	Materials methods Top Abstract Introduction Results Discussion Materials methods References Virus strains cells The Porcine kidney cell line PK15 viruses grown maintained described previously Whealy et al
0.16384977.11502759.html.plaintext.txt	313	The laboratory strain PRV used wildtype parent virus constructions PRV Becker Card et al
0.16384977.11502759.html.plaintext.txt	314	The isogenic mutants PRV 160 Us9 null PRV 166 L30L31 AA PRV 172 Y49Y50 AA PRV 173 S51S53 AA described see Fig
0.16384977.11502759.html.plaintext.txt	315	1 amino acid sequence Us9 location alanine substitution mutations Brideau et al
0.16384977.11502759.html.plaintext.txt	316	PRV 91 gE null described Whealy et al
0.16384977.11502759.html.plaintext.txt	317	PRV 160R revertant PRV 160 restores tested wild type virus phenotypes Brideau et al
0.16384977.11502759.html.plaintext.txt	318	In study PRV 160R PRV Becker also indistinguishable
0.16384977.11502759.html.plaintext.txt	319	PRV GS443 constructed G
0.16384977.11502759.html.plaintext.txt	320	2001 expresses hybrid protein comprising GFP fused capsid protein VP26
0.16384977.11502759.html.plaintext.txt	321	PRV 368 carries Us9 null mutation PRV 160 GFP UL35 hybrid gene PRV GS443 replacing UL35 gene
0.16384977.11502759.html.plaintext.txt	322	It constructed recombination PRV 160 PRV GS443
0.16384977.11502759.html.plaintext.txt	323	The replication defective herpes simplex virus vector expresses axonal chicken protein NgCAM gift G
0.16384977.11502759.html.plaintext.txt	324	Banker described previously Jareb Banker 1998
0.16384977.11502759.html.plaintext.txt	325	Antibodies The polyclonal rabbit antiserum recognizing gE Rb 501 polyclonal goat antisera recognizing gB Ab284 gC Ab282 described Whealy et al
0.16384977.11502759.html.plaintext.txt	326	1993 Tirabassi Enquist 2000
0.16384977.11502759.html.plaintext.txt	327	The monoclonal antibody IN 13 recognizing major capsid protein VP5 gift H
0.16384977.11502759.html.plaintext.txt	328	Rziha Federal Research Centre Virus Diseases Animals Tubingen Germany
0.16384977.11502759.html.plaintext.txt	329	The monoclonal antibody recognizing VP22 gift T
0.16384977.11502759.html.plaintext.txt	330	Mettenleiter Federal Research Centre Virus Diseases Animals Insel Riems Germany
0.16384977.11502759.html.plaintext.txt	331	The polyclonal mouse antiserum recognizing tegument protein UL25 gift A
0.16384977.11502759.html.plaintext.txt	332	Flamand Centre National de la Recherche Scientifique Gif sur Yvette France
0.16384977.11502759.html.plaintext.txt	333	The monoclonal antibody recognizing GFP purchased Molecular Probes
0.16384977.11502759.html.plaintext.txt	334	The monoclonal antibody 8D9 recognizing chick adhesion molecule NgCAM gift G
0.16384977.11502759.html.plaintext.txt	335	Banker Oregon Health Sciences University Portland OR
0.16384977.11502759.html.plaintext.txt	336	Neuronal culture Rat sympathetic neurons SCG rat embryos 15 16 d gestation dissociated according methods DiCicco Bloom et al
0.16384977.11502759.html.plaintext.txt	337	35 mm plastic dishes 353001 Falcon coated 100 microgml poly D lysine P 6407 Sigma Aldrich tissue culture grade water W 3500 Sigma Aldrich
0.16384977.11502759.html.plaintext.txt	338	Approximately 80000 neurons per dish plated
0.16384977.11502759.html.plaintext.txt	339	Cultures maintained 50 Hams F 12 medium 11765 054 GIBCO BRL 50 DME 11965 084 GIBCO BRL supplemented 10 mgml BSA A 2153 Sigma Aldrich 10 microgml insulin I 6634 Sigma Aldrich 100 microgml transferrin 616397 Calbiochem 100 microM putrescine P 7505 Sigma Aldrich 20 nM progesterone P 6149 Sigma Aldrich 30 nM selenium S 5261 Sigma Aldrich 2 mM glutamine 15039 027 GIBCO BRL 6 mgml glucose 4912 Mallinckrodt 50 microgml penicillin 50 microgml streptomycin 15140 122 GIBCO BRL 100 ngml NGF 2
0.16384977.11502759.html.plaintext.txt	340	Culture medium replaced three times per week equilibrated 1 h 37 degrees C 5 CO2 incubator use
0.16384977.11502759.html.plaintext.txt	341	Cytosine ss D arabino furanoside C 6645 Sigma Aldrich added 2 microM days 2 3 5 6 eliminate dividing cells
0.16384977.11502759.html.plaintext.txt	342	Experimental protocols approved Animal Welfare Committee Princeton University consistent regulations American Association Accredition Laboratory Animal Care Animal Welfare Act public law 99 198
0.16384977.11502759.html.plaintext.txt	343	Expression cellular proteins PRV infection Neurons cultured 35 mm plastic dishes least 3 wk described
0.16384977.11502759.html.plaintext.txt	344	30 microl replication defective herpes simplex virus vectors added directly neuronal culture medium 1 h Jareb Banker 1998
0.16384977.11502759.html.plaintext.txt	345	After incubation medium removed medium containing PRV Becker wild type PRV 160 Us9 null virus placed neurons concentration virus permits infection neurons culture see
0.16384977.11502759.html.plaintext.txt	346	After 1 h PRV containing medium removed original medium containing replication defective virus placed back neurons
0.16384977.11502759.html.plaintext.txt	347	16 h PRV infection neurons fixed NgCAM expressed viral vector visualized using antibody recognizes chicken protein NgCAM rat orthologue
0.16384977.11502759.html.plaintext.txt	348	Indirect immunofluorescence microscopy Neurons cultured 35 mm plastic dishes 3 wk described
0.16384977.11502759.html.plaintext.txt	349	At time axonal network extensive
0.16384977.11502759.html.plaintext.txt	350	Two concentrations virus inoculum used low multiplicity infection 10 cells infected high multiplicity infection almost neurons infected
0.16384977.11502759.html.plaintext.txt	351	We found majority input virions bound directly tissue culture dish never came contact cultured neurons unpublished data
0.16384977.11502759.html.plaintext.txt	352	Therefore precise calculations multiplicity infection difficult
0.16384977.11502759.html.plaintext.txt	353	After 1 h inoculum removed aspiration replaced original culture medium incubated 37 degrees C
0.16384977.11502759.html.plaintext.txt	354	At various times infection neurons rinsed PBS fixed 3
0.16384977.11502759.html.plaintext.txt	355	2 paraformaldehyde rinsed three times PBS
0.16384977.11502759.html.plaintext.txt	356	The neurons permeabilized 3 min PBS containing 3 BSA 0
0.16384977.11502759.html.plaintext.txt	357	In subsequent manipulations PBS containing 3 BSA 0
0.16384977.11502759.html.plaintext.txt	358	5 saponin included solutions
0.16384977.11502759.html.plaintext.txt	359	Fixed cells incubated appropriate primary antibody 1 h humidified chamber 37 degrees C
0.16384977.11502759.html.plaintext.txt	360	The dishes rinsed three times PBSBSAsaponin incubated Alexa 488 Alexa 568 conjugated secondary antibodies Molecular Probes 1 h humidified chamber 37 degrees C
0.16384977.11502759.html.plaintext.txt	361	Finally dishes rinsed three times PBSBSAsaponin distilled water
0.16384977.11502759.html.plaintext.txt	362	A drop Vectashield mounting medium H 1000 Vector Laboratories placed floor dish coverslip placed Vectashield sealed nail polish
0.16384977.11502759.html.plaintext.txt	363	Experiments examining cell surface localization proteins performed follows infection antibodies diluted small volume neuron culture medium 600 microl per 35 mm dish placed infected neurons 5 min 37 degrees C neurons rinsed PBS fixed 10 min 3
0.16384977.11502759.html.plaintext.txt	364	After fixation neurons rinsed PBS three times incubated 3 BSA PBS overnight
0.16384977.11502759.html.plaintext.txt	365	Secondary antibodies diluted 3 BSA PBS incubated fixed neurons 1 h
0.16384977.11502759.html.plaintext.txt	366	Finally neurons processed described
0.16384977.11502759.html.plaintext.txt	367	Low multiplicity infections useful large number uninfected neurons provided internal controls nonspecific antibody binding
0.16384977.11502759.html.plaintext.txt	368	Low multiplicity infections also enabled us locate follow long axons single infected cell bodies
0.16384977.11502759.html.plaintext.txt	369	High multiplicity infections confirmed phenotypes uniform throughout neurons culture
0.16384977.11502759.html.plaintext.txt	370	Unless otherwise indicated times infection based low multiplicity infections
0.16384977.11502759.html.plaintext.txt	371	Single optical sections captured using Nikon Optiphot 2 microscope equipped Bio Rad Laboratories MRC600 scan head
0.16384977.11502759.html.plaintext.txt	372	Images processed Adobe Photoshop version 4
0.16384977.11502759.html.plaintext.txt	373	Determining polarity cultured neurons targeting retention control cytoskeletal components cell bodies axons Many types neurons sort proteins axonal dendritic compartments least 2 wk growth vitro Caceres et al
0.16384977.11502759.html.plaintext.txt	374	Rat sympathetic neurons derived SCG reported sort endogenous proteins axonal somatodendritic compartments 3 wk vitro Bruckenstein Higgins 1988
0.16384977.11502759.html.plaintext.txt	375	The polarity cultured neurons used report determined analysis three control proteins axonal markers tau 1 Boehringer SMI 31 Sternberger Meyer Immunochemicals b cell bodydendrite markers MAP2 Boehringer SMI 32 Sternberger Meyer Immunochemicals
0.16384977.11502759.html.plaintext.txt	376	The antibody SMI 31 recognizes phosphoforms M H neurofilament whereas antibody SMI 32 reacts nonphosphoforms M H neurofilament Sternberger Sternberger 1983
0.16384977.11502759.html.plaintext.txt	377	Since neuronal cell bodies raised much 20 microm floor tissue culture dish axons grow two different image planes shown Fig
0.16384977.11502759.html.plaintext.txt	378	11 D K top panels Fig
0.16384977.11502759.html.plaintext.txt	379	11 D G show image plane center cell bodies substratum whereas bottom panels Fig
0.16384977.11502759.html.plaintext.txt	380	11 H K image plane substratum neurites visualized
0.16384977.11502759.html.plaintext.txt	381	View larger version 124K Figure 11
0.16384977.11502759.html.plaintext.txt	382	Characterization cultured SCG neurons
0.16384977.11502759.html.plaintext.txt	383	Phase contrast images neurons 3 h A 5 d B 21 d C culture
0.16384977.11502759.html.plaintext.txt	384	The establishment cell polarity SCG neurons 21 d culture demonstrated D K
0.16384977.11502759.html.plaintext.txt	385	After fixing permeabilizing neurons labeled antibodies recognized axonal markers tau 1 D H phospho M H neurofilament E I somatodendritic markers MAP2 F J nonphospho M H neurofilament G K
0.16384977.11502759.html.plaintext.txt	386	Two confocal images field shown D G image planes level cell bodies whereas H K show neuron level substratum axons visualized
0.16384977.11502759.html.plaintext.txt	387	The axonal marker tau 1 found nearly neurites examined cultures
0.16384977.11502759.html.plaintext.txt	388	Faint immunoreactivity found within cell bodies neurons Fig
0.16384977.11502759.html.plaintext.txt	389	11 D staining confined neurites Fig
0.16384977.11502759.html.plaintext.txt	390	Similar neurite localization seen second axonal marker SMI 31 Fig
0.16384977.11502759.html.plaintext.txt	391	The cell bodydendrite marker MAP2 Fig
0.16384977.11502759.html.plaintext.txt	392	11 F J localized mainly cell body
0.16384977.11502759.html.plaintext.txt	393	Some immunoreactivity also found proximal distal gradient within neurites strongest immunoreactivity proximal axon
0.16384977.11502759.html.plaintext.txt	394	The true second cell bodydendrite marker SMI 32 Fig
0.16384977.11502759.html.plaintext.txt	395	However extent proximal axon staining SMI 32 pronounced MAP2 staining pattern
0.16384977.11502759.html.plaintext.txt	396	These data consistent previously published studies polarity culture system Peng et al
0.16384977.11502759.html.plaintext.txt	397	1986 Bruckenstein Higgins 1988
0.16384977.11502759.html.plaintext.txt	398	Kinetics infectious PRV production SCG neurons The embryonic ganglia pregnant rat pooled dissociated SCG neurons resulting preparation plated 24 well dish 2500 neurons per well
0.16384977.11502759.html.plaintext.txt	399	We determined empirically 250000 plaque forming units determined PK15 cells required well infect neurons culture
0.16384977.11502759.html.plaintext.txt	400	Added virus incubated neurons 1 h facilitate attachment virus cells
0.16384977.11502759.html.plaintext.txt	401	The inoculum removed fresh medium added
0.16384977.11502759.html.plaintext.txt	402	The supernatant neurons collected 1 8 16 24 h infection
0.16384977.11502759.html.plaintext.txt	403	Each time infection assayed triplicate quantitation infectious virus sample determined PK15 cells
0.16384977.11502759.html.plaintext.txt	404	Footnotes Abbreviations used paper GFP green fluorescent protein NgCAM neural glycoprotein cell adhesion molecule PNS peripheral nervous system PRV pseudorabies virus SCG superior cervical ganglia
0.16384977.11502759.html.plaintext.txt	405	Acknowledgments We thank G
0.16384977.11502759.html.plaintext.txt	406	Banker helpful discussions generously supplying us reagents E
0.16384977.11502759.html.plaintext.txt	407	DiCicco Bloom help neural culture T
0.16384977.11502759.html.plaintext.txt	408	Rziha sharing antibodies us
0.16384977.11502759.html.plaintext.txt	409	Smith members Enquist lab provided advice reagents support
0.16384977.11502759.html.plaintext.txt	410	This work supported National Institute Neurological Diseases Stroke grant 1RO133506 L
0.16384977.11502759.html.plaintext.txt	411	Submitted 29 November 2000Revised 5 June 2001Accepted 2 July 2001
0.16384977.11502759.html.plaintext.txt	412	References Top Abstract Introduction Results Discussion Materials methods References
0.16384977.11502759.html.plaintext.txt	413	A tyrosine based motif casein kinase II phosphorylation site regulate intracellular trafficking varicella zoster virus glycoprotein I protein localized trans Golgi network
0.16384977.11502759.html.plaintext.txt	414	Role essential glycoproteins gII gp50 transneuronal transfer pseudorabies virus hypoglossal nerves mice
0.16384977.11502759.html.plaintext.txt	415	Deletion glycoprotein gE reduces propagation pseudorabies virus nervous system mice intranasal inoculation
0.16384977.11502759.html.plaintext.txt	416	Squid axoplasm supports retrograde axonal transport herpes simplex virus
0.16384977.11502759.html.plaintext.txt	417	Retrograde axonal transport herpes simplex virus evidence single mechanism role tegument
0.16384977.11502759.html.plaintext.txt	418	Molecular bases recognition tyrosine based sorting signals
0.16384977.11502759.html.plaintext.txt	419	Serine phosphorylation site 46 kDa mannose 6 phosphate receptor required transport plasma membrane Madin Darby canine kidney mouse fibroblast cells
0.16384977.11502759.html.plaintext.txt	420	Intracellular trafficking localization pseudorabies virus Us9 type II envelope protein host viral membranes
0.16384977.11502759.html.plaintext.txt	421	Role pseudorabies virus Us9 type II membrane protein infection tissue culture cells rat nervous system
0.16384977.11502759.html.plaintext.txt	422	Directional transneuronal infection pseudorabies virus dependent acidic internalization motif Us9 cytoplasmic tail
0.16384977.11502759.html.plaintext.txt	423	Morphological differentiation embryonic rat sympathetic neurons tissue culture
0.16384977.11502759.html.plaintext.txt	424	Conditions neurons form axons dendrites
0.16384977.11502759.html.plaintext.txt	425	Immunocytochemical localization tubulin microtubule associated protein 2 development hippocampal neurons culture
0.16384977.11502759.html.plaintext.txt	426	Neurotropic properties pseudorabies virus uptake transneuronal passage rat central nervous system
0.16384977.11502759.html.plaintext.txt	427	Two alpha herpesvirus strains transported differentially rodent visual system
0.16384977.11502759.html.plaintext.txt	428	Pseudorabies virus envelope glycoprotein gI influences neurotropism virulence infection rat visual system
0.16384977.11502759.html.plaintext.txt	429	Pseudorabies virus infection rat central nervous system ultrastructural characterization viral replication transport pathogenesis
0.16384977.11502759.html.plaintext.txt	430	Incorporation green fluorescent protein herpes simplex virus type 1 capsid
0.16384977.11502759.html.plaintext.txt	431	NT 3 stimulates sympathetic neuroblast proliferation promoting precursor survival
0.16384977.11502759.html.plaintext.txt	432	Glycoproteins E I facilitate neuron neuron spread herpes simplex virus
0.16384977.11502759.html.plaintext.txt	433	Specific infection rat neuronal circuits pseudorabies virus
0.16384977.11502759.html.plaintext.txt	434	Infection spread alphaherpesviruses nervous system
0.16384977.11502759.html.plaintext.txt	435	Changes distribution GAP 43 development neuronal polarity
0.16384977.11502759.html.plaintext.txt	436	Pseudorabies virus membrane proteins gI gE facilitate anterograde spread infection projection specific neurons rat
0.16384977.11502759.html.plaintext.txt	437	The polarized sorting membrane proteins expressed cultured hippocampal neurons using viral vectors
0.16384977.11502759.html.plaintext.txt	438	Herpes simplex virus gEgI sorts nascent virions epithelial cell junctions promoting virus spread
0.16384977.11502759.html.plaintext.txt	439	Intracellular trafficking furin modulated phosphorylation state casein kinase II site cytoplasmic tail
0.16384977.11502759.html.plaintext.txt	440	Contribution single genes within unique short region Aujeszkys disease virus suid herpesvirus type 1 virulence pathogenesis immunogenicity
0.16384977.11502759.html.plaintext.txt	441	Linking cargo vesicle formation receptor tail interactions coat proteins
0.16384977.11502759.html.plaintext.txt	442	Invasion spread single glycoprotein deleted mutants Aujeszkys disease virus ADV trigeminal nervous pathway pigs intranasal inoculation
0.16384977.11502759.html.plaintext.txt	443	Role envelope glycoproteins gI gp63 gIII invasion spread Aujeszkys disease virus olfactory nervous pathway pig
0.16384977.11502759.html.plaintext.txt	444	Dissemination wild type gC gE gI deleted mutants Aujeszkys disease virus maxillary nerve trigeminal ganglion pigs intranasal inoculation
0.16384977.11502759.html.plaintext.txt	445	Maturation axonal plasma membrane requires upregulation sphingomyelin synthesis formation protein lipid complexes
0.16384977.11502759.html.plaintext.txt	446	Massive retinotectal projection rats
0.16384977.11502759.html.plaintext.txt	447	Uptake transport herpes simplex virus neurites rat dorsal root ganglia cells culture
0.16384977.11502759.html.plaintext.txt	448	Herpes simplex virus infection human sensory neuron
0.16384977.11502759.html.plaintext.txt	449	Glycoprotein gE negative pseudorabies virus reduced capability infect second third order neurons olfactory trigeminal routes porcine central nervous system
0.16384977.11502759.html.plaintext.txt	450	Glycoprotein D negative pseudorabies virus spread transneuronally via direct neuron neuron transmission natural host pig additional inactivation gE gI
0.16384977.11502759.html.plaintext.txt	451	Axonal transport herpes simplex virions epidermal cells evidence specialized mode virus transport assembly
0.16384977.11502759.html.plaintext.txt	452	Biochemical immunological analyses cytoskeletal domains neurons
0.16384977.11502759.html.plaintext.txt	453	Two rat homologs clathrin associated adaptor proteins
0.16384977.11502759.html.plaintext.txt	454	Pseudorabies virus glycoproteins gII gp50 essential virus penetration
0.16384977.11502759.html.plaintext.txt	455	The replication herpesviruses
0.16384977.11502759.html.plaintext.txt	456	Preassembly transport nerve terminals new concept axonal transport
0.16384977.11502759.html.plaintext.txt	457	Clathrin coated vesicle formation protein sorting integrated process
0.16384977.11502759.html.plaintext.txt	458	Herpesviruses use bi directional fast axonal transport spread sensory neurons
0.16384977.11502759.html.plaintext.txt	459	Mechanisms viral transport cytoplasm
0.16384977.11502759.html.plaintext.txt	460	Monoclonal antibodies distinguish phosphorylated nonphosphorylated forms neurofilaments situ
0.16384977.11502759.html.plaintext.txt	461	Localization furin trans Golgi network recycling cell surface involves Ser Tyr residues within cytoplasmic domain
0.16384977.11502759.html.plaintext.txt	462	Role pseudorabies virus gI cytoplasmic domain neuroinvasion virulence posttranslational N linked glycosylation
0.16384977.11502759.html.plaintext.txt	463	Sorting transport alpha herpesviruses axons
0.16384977.11502759.html.plaintext.txt	464	Signal dependent membrane protein trafficking endocytic pathway
0.16384977.11502759.html.plaintext.txt	465	Specific pseudorabies virus infection rat visual system requires gI gp63 glycoproteins
0.16384977.11502759.html.plaintext.txt	466	Casein kinase II phosphorylates neural cell adhesion molecule L1
0.16384977.11502759.html.plaintext.txt	467	Retrograde transneuronal spread pseudorabies virus defined neuronal circuitry rat brain facilitated gE mutations reduce virulence
0.15670726.12835390.html.plaintext.txt	0	Modes intercellular transcription factor movement Arabidopsis apex Xuelin Wu1 Jose R
0.15670726.12835390.html.plaintext.txt	1	Crawford3 Yoon Rhee4 Vitaly Citovsky4 Patricia C
0.15670726.12835390.html.plaintext.txt	2	Zambryski3 Detlef Weigel15
0.15670726.12835390.html.plaintext.txt	3	1 Plant Biology Laboratory The Salk Institute Biological Studies La Jolla CA 92037 USA 2 Department Biology University California San Diego La Jolla CA 92093 USA 3 Department Plant Microbial Biology University California Berkeley CA 94720 USA 4 Department Biochemistry Cell Biology State University New York Stony Brook NY 11794 5215 USA 5 Department Molecular Biology Max Planck Institute Developmental Biology D 72076 Tubingen Germany
0.15670726.12835390.html.plaintext.txt	4	Author correspondence e mail weigelatweigelworld
0.15670726.12835390.html.plaintext.txt	5	SUMMARY TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES A recent intriguing discovery plant biology transcription factors move cells
0.15670726.12835390.html.plaintext.txt	6	In Arabidopsis thaliana floral identity protein LEAFY strong non autonomous effects expressed epidermis mediated movement underlying tissue layers
0.15670726.12835390.html.plaintext.txt	7	By contrast structurally unrelated floral identity protein APETALA1 limited non autonomous effects
0.15670726.12835390.html.plaintext.txt	8	Using GFP fusions monitor protein movement shoot apical meristem floral primordia Arabidopsis found strong correlation cytoplasmic localization proteins ability move adjacent cells
0.15670726.12835390.html.plaintext.txt	9	The graded distribution several GFP fusions highest levels cells produced compatible notion movement driven diffusion
0.15670726.12835390.html.plaintext.txt	10	We also present evidence protein movement restricted laterally within layers L1 underlying layers Arabidopsis apex
0.15670726.12835390.html.plaintext.txt	11	Based observations propose intercellular movement transcription factors occur non targeted fashion result simple diffusion
0.15670726.12835390.html.plaintext.txt	12	This hypothesis raises possibility diffusion default state many macromolecules Arabidopsis apex unless specifically retained
0.15670726.12835390.html.plaintext.txt	13	Key words Arabidopsis Protein trafficking Movement protein LEAFY APETALA1
0.15670726.12835390.html.plaintext.txt	14	INTRODUCTION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Intercellular communication essential determining enforcing developmental fates multicellular organisms
0.15670726.12835390.html.plaintext.txt	15	In animals process relies mainly secreted signaling peptides interact extracellular matrix specific cell surface receptors
0.15670726.12835390.html.plaintext.txt	16	The interaction first triggers signal transduction response cytoplasm target cells eventually leads changes gene expression
0.15670726.12835390.html.plaintext.txt	17	Complex protein protein interactions multiple protein phosphorylation steps involved many pathways EGF TGFss Notch Hedgehog WNT family signaling pathways
0.15670726.12835390.html.plaintext.txt	18	An alternative form communication achieved diffusion transcription factors sources target nuclei continuous cytoplasm syncytium Drosophila blastoderm embryos one best understood model systems transcriptional regulation Rivera Pomar Jackle 1996
0.15670726.12835390.html.plaintext.txt	19	However syncytial organization restricted tissues metazoans
0.15670726.12835390.html.plaintext.txt	20	Although plants lack homologs well known metazoan peptide ligands EGF TGFss Hedgehog plant cells also communicate via secreted molecules Fletcher et al
0.15670726.12835390.html.plaintext.txt	21	2001 McCarty Chory 2000
0.15670726.12835390.html.plaintext.txt	22	However contrast animals cytoplasmic continuity plant cells rule exception
0.15670726.12835390.html.plaintext.txt	23	Most plant cells connected plasmodesmata plasma membrane lined channels provide cytoplasmic continuity adjacent cells
0.15670726.12835390.html.plaintext.txt	24	Plasmodesmata used transport nutrients signaling molecules including RNAs proteins divided two major groups Crawford Zambryski 1999 Haywood et al
0.15670726.12835390.html.plaintext.txt	25	The primary plasmodesmata form cytokinesis whereas secondary plasmodesmata develop cells necessarily clonally related
0.15670726.12835390.html.plaintext.txt	26	The size exclusion limit SEL different types plasmodesmata measured using fluorescent tracer molecules
0.15670726.12835390.html.plaintext.txt	27	In cases plasmodesmata younger tissues larger SEL morphologically simpler older tissue Crawford Zambryski 2001
0.15670726.12835390.html.plaintext.txt	28	Two modes movement plasmodesmata proposed
0.15670726.12835390.html.plaintext.txt	29	Targeted movement involves specific interactions transported macromolecules plasmodesmata components
0.15670726.12835390.html.plaintext.txt	30	This leads increase SEL therefore limited endogenous SEL given cell
0.15670726.12835390.html.plaintext.txt	31	By contrast non targeted movement resembles passive diffusion governed endogenous SEL plasmodesmata involved Crawford Zambryski 2000 Imlau et al
0.15670726.12835390.html.plaintext.txt	32	The best understood case targeted movement probably trafficking plant viral movement proteins MPs move long distances plants key spreading plant viral infections
0.15670726.12835390.html.plaintext.txt	33	A good example non targeted movement provided green fluorescent protein GFP
0.15670726.12835390.html.plaintext.txt	34	Using transient transfection bombardment shown native GFP move several cells away source
0.15670726.12835390.html.plaintext.txt	35	In addition SEL multimerization addition nuclear ER localization signals hinder even prevent GFP leaving source cell Crawford Zambryski 2000 Crawford Zambryski 2001
0.15670726.12835390.html.plaintext.txt	36	Apart viral proteins studies macromolecule movement plants focused traditionally long distance transport photosynthates larger molecules complexes phloem Lucas 1995 Zambryski Crawford 2000
0.15670726.12835390.html.plaintext.txt	37	A good example sucrose transporter SUT1 whose mRNA transported phloem translated Kuhn et al
0.15670726.12835390.html.plaintext.txt	38	Moreover grafting experiments demonstrated existence long distance mRNA movement plants Kim et al
0.15670726.12835390.html.plaintext.txt	39	More recently studies conducted several plant species demonstrated non cell autonomous effects transcription factors involved plant development mediated protein movement reviewed Haywood et al
0.15670726.12835390.html.plaintext.txt	40	The first example transcription factor movement discovered studies homeodomain protein KNOTTED1 KN1 maize
0.15670726.12835390.html.plaintext.txt	41	Most plant organs originate post embryonically meristems include stem cells set aside embryogenesis
0.15670726.12835390.html.plaintext.txt	42	In aerial part plant new organs emerge shoot apical meristem SAM consists three tissue layers L1 L3
0.15670726.12835390.html.plaintext.txt	43	KN1 protein found throughout maize SAM kn1 mRNA absent L1 layer Jackson et al
0.15670726.12835390.html.plaintext.txt	44	In leaf injection experiments KN1 transported surrounding tissue plasmodesmata KN1 also increased SEL plasmodesmata enabling transport kn1 sense RNA protein complexes Kragler et al
0.15670726.12835390.html.plaintext.txt	45	KN1 also move away source expression expressed heterologous promoters Arabidopsis Kim et al
0.15670726.12835390.html.plaintext.txt	46	There similar evidence Antirrhinum MADS box transcription factor DEFICIENS DEF moves inner outer tissue layers developing flowers although extent movement stage organ dependent Perbal et al
0.15670726.12835390.html.plaintext.txt	47	In Arabidopsis two endogenous transcription factors move neighboring cells SHORTROOT SHR Nakajima et al
0.15670726.12835390.html.plaintext.txt	48	2001 LEAFY LFY Sessions et al
0.15670726.12835390.html.plaintext.txt	49	RNA GRAS family transcription factor SHR expressed stele root Helariutta et al
0.15670726.12835390.html.plaintext.txt	50	2000 SHR protein found stele surrounding endodermis missing shr mutants
0.15670726.12835390.html.plaintext.txt	51	Further studies using transgenic misexpression confirmed movement SHR root stele endodermis required endodermis development Nakajima et al
0.15670726.12835390.html.plaintext.txt	52	RNA plant specific transcription factor LFY expressed three layers young floral primordia mis specified shoots strong lfy mutants Weigel et al
0.15670726.12835390.html.plaintext.txt	53	Surprisingly LFY RNA expression L1 developing flowers sufficient fully rescue lfy mutant phenotype
0.15670726.12835390.html.plaintext.txt	54	In transgenic plants LFY protein LFY RNA detected layers rescued flowers indicating LFY protein moves L1 inner layers Sessions et al
0.15670726.12835390.html.plaintext.txt	55	By contrast transcription factor APETALA1 AP1 similar vivo functions LFY structurally unrelated behaves largely cell autonomously Sessions et al
0.15670726.12835390.html.plaintext.txt	56	Although movement transcription factors Arabidopsis plants well established still major gaps understanding underlying mechanisms
0.15670726.12835390.html.plaintext.txt	57	Here characterize mode LFY movement Arabidopsis SAMs floral primordia
0.15670726.12835390.html.plaintext.txt	58	Using functional LFY GFP fusion proteins show LFY moves readily L1 deeper cell layers laterally adjacent clonally related cells
0.15670726.12835390.html.plaintext.txt	59	By contrast functional AP1 GFP fusion unable move source cells
0.15670726.12835390.html.plaintext.txt	60	Comparison dynamics LFY GFP fusion proteins GFP fusions suggests movement driven diffusion
0.15670726.12835390.html.plaintext.txt	61	Deletion experiments failed identify specific movement signal LFY compatible conclusion LFY movement non targeted
0.15670726.12835390.html.plaintext.txt	62	The hypothesis non targeted movement also supported finding correlation cytoplasmic localization ability proteins move adjacent cells
0.15670726.12835390.html.plaintext.txt	63	MATERIALS AND METHODS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Transgenes See Table 1 list transgenes used study
0.15670726.12835390.html.plaintext.txt	64	LFY GFP fusions PstI sites added ends mGFP5 coding sequence Haseloff et al
0.15670726.12835390.html.plaintext.txt	65	1997 using oligonucleotide primers
0.15670726.12835390.html.plaintext.txt	66	The GFP PstI fragment inserted internal PstI site LFY cDNA pAS116 Sessions et al
0.15670726.12835390.html.plaintext.txt	67	2000 contains LFY cDNA 300 bp LFY 3UTR nos terminator creating pBS GLFY
0.15670726.12835390.html.plaintext.txt	68	The GLFYnos fragment ligated binary vector pMX202 includes RBCS terminator sequence M
0.15670726.12835390.html.plaintext.txt	69	Busch personal communication along ML1 promoter fragment pAS98 Sessions et al
0.15670726.12835390.html.plaintext.txt	70	ML1GFPLFY created ligating ML1 promoter pAS99 Sessions et al
0.15670726.12835390.html.plaintext.txt	71	1999 5 portion GFPLFY 5 XbaI site LFY pRTL2 sGFPLFY 3 portion LFY pAS116 binary vector pMX202
0.15670726.12835390.html.plaintext.txt	72	In fusion additional serine inserted GFP LFY
0.15670726.12835390.html.plaintext.txt	73	35SGFPLFY created ligating GFPLFY 5 LFY 3 fragments binary vector pCHF3 contains CaMV 35S promoter Fankhauser et al
0.15670726.12835390.html.plaintext.txt	74	ML1LFYGFP created ligating 5 portion ML1LFY 5 HindIII site pAS104 Sessions et al
0.15670726.12835390.html.plaintext.txt	75	2000 3 portion LFYGFP pBS ML1LFY link sGFP binary vector pJIHOON212 J
0.15670726.12835390.html.plaintext.txt	76	35SLFYGFP created ligating 5 portion LFY cDNA pAS107 HindIII site 3 portion LFYGFP pCHF3
0.15670726.12835390.html.plaintext.txt	77	lfy mutant alleles Four lfy alleles included study lfy 2 lfy 3 lfy 9 lfy 20 Weigel et al
0.15670726.12835390.html.plaintext.txt	78	GFP fusions mutant versions generated way ML1GLFY fusion
0.15670726.12835390.html.plaintext.txt	79	LFY truncations Truncations LFY coding sequence created context pBS LFY includes full length cDNA 300 bp LFY 3UTR
0.15670726.12835390.html.plaintext.txt	80	LFY1 generated opening filling religating BamHI site overlapping start codon XbaI site position 379 results frame deletion amino acids 4 127
0.15670726.12835390.html.plaintext.txt	81	LFY2 created opening filling religating XbaI site position 379 StyI site position 860 results frame deletion amino acids 128 287
0.15670726.12835390.html.plaintext.txt	82	LFY3 created opening filling religating StyI site position 860 HindIII site position 974 leads frame shift amino acids 289 424 replaced sequence SFKCSQKSV
0.15670726.12835390.html.plaintext.txt	83	Fusions GFPLFY truncations ML1 promoter created combining promoter fragment pAS99 5 fragment GFPLFY pRTL2 sGFPLFY respective LFY truncations pMX202
0.15670726.12835390.html.plaintext.txt	84	AP1 GFP fusions For AP1GFP restriction sites added AP1 cDNA sequence PCR amplification using pAM571 template M
0.15670726.12835390.html.plaintext.txt	85	Yanofsky personal communication resulted EcoRI BamHI site front 5 UTR PstI site 3 end replacing stop codon
0.15670726.12835390.html.plaintext.txt	86	GFP coding sequence amplified pCAMBIA1302 replacing start codon PstI site adding XbaI site 3UTR
0.15670726.12835390.html.plaintext.txt	87	For GFPAP1 start codon AP1 replaced PstI site XbaI site added 3UTR
0.15670726.12835390.html.plaintext.txt	88	An EcoRI site added 5 end GFP coding region PstI site replaced stop codon
0.15670726.12835390.html.plaintext.txt	89	In fusions PstI site also created alanine linker 2 3 amino acids
0.15670726.12835390.html.plaintext.txt	90	ML1AP1GFP ML1GFPAP1 created ligating ML1 promoter pAS99 AP1 GFP fragments background pMX202
0.15670726.12835390.html.plaintext.txt	91	AP1AP1GFP AP1GFPAP1 created way ML1 versions using AP1 promoter pAM571
0.15670726.12835390.html.plaintext.txt	92	Other ML1 constructs ML12xGFP created ligating ML1 promoter TEV52xsGFP pRTL2 2xsGFP Crawford Zambryski 2000 inserting pMX202
0.15670726.12835390.html.plaintext.txt	93	The NLS 2xsGFP fragment pRTL2 NLS2xsGFP Crawford Zambryski 2000 used generate ML1NLS2xGFP
0.15670726.12835390.html.plaintext.txt	94	ML1TVCVMPGFP generated ligating ML1 promoter coding sequences Turnip Vein Clearing Virus Movement Protein TVCVMPGFP fusion pMX202
0.15670726.12835390.html.plaintext.txt	95	Ectopic expression center shoot flower meristems A 833 bp BamHIHindIII fragment 3 end second AG intron Busch et al
0.15670726.12835390.html.plaintext.txt	96	1999 used drive expression AG domain
0.15670726.12835390.html.plaintext.txt	97	This enhancer fragment pMX141 carries point mutation CCTTATTTGG AATTATTTGG results ectopic activity inflorescence meristem lfy independent manner Hong et al
0.15670726.12835390.html.plaintext.txt	98	The enhancer placed upstream 46 bp cauliflower mosaic virus 35S minimal promoter pMX202
0.15670726.12835390.html.plaintext.txt	99	AG intron2xGFP AG intronNLS2xGFP AG intronLFY AG intronGLFY created inserting respective coding sequence fragments cassette
0.15670726.12835390.html.plaintext.txt	100	LFY rescue constructs The LFY GLFY rescue constructs generated expressing LFY cDNA GLFY control 2
0.15670726.12835390.html.plaintext.txt	101	3 kb LFY promoter Blazquez et al
0.15670726.12835390.html.plaintext.txt	102	Plant material Plants grown long days 16 hour light 8 hour darkness 120 microE m 2 seconds 1 light provided 31 mixture cool white GroLux Osram Sylvania fluorescent bulbs 21 degrees C
0.15670726.12835390.html.plaintext.txt	103	lfy 12 ap1 15 strong alleles Columbia background Huala Sussex 1992 Ng Yanofsky 2001
0.15670726.12835390.html.plaintext.txt	104	Plant transformations carried using floral dip method Weigel Glazebrook 2002
0.15670726.12835390.html.plaintext.txt	105	For transgene 40 70 T1 lines initially analyzed least three plants three independent lines used characterization imaging
0.15670726.12835390.html.plaintext.txt	106	Transgenic seedlings selected MS agar plates containing 50 microgml kanamycin transplanted soil
0.15670726.12835390.html.plaintext.txt	107	For transgenes presented work multiple samples agar soil grown plants least three generations examined always similar results
0.15670726.12835390.html.plaintext.txt	108	In cases mutant allele involved transgenic lines wild type mutant backgrounds examined
0.15670726.12835390.html.plaintext.txt	109	We never observed effect endogenous allele GFP signal
0.15670726.12835390.html.plaintext.txt	110	In situ hybridization In situ hybridization performed described Sessions et al
0.15670726.12835390.html.plaintext.txt	111	2000 Weigel Glazebrook 2002
0.15670726.12835390.html.plaintext.txt	112	Digoxigenin labeled antisense RNA probe TVCVMPGFP generated digesting pBSTVCVMPGFP XhoI transcribing using T3 polymerase
0.15670726.12835390.html.plaintext.txt	113	Immunoblot analysis Crude protein extract obtained 2 week old seedlings separated 4 12 gradient gels NuPAGE Invitrogen Benchmark Protein Marker Invitrogen
0.15670726.12835390.html.plaintext.txt	114	Samples transferred PVDF membrane electroblotting incubated rabbit anti GFP primary antibody 11000 dilution Molecular Probes
0.15670726.12835390.html.plaintext.txt	115	An HRP conjugated goat anti rabbit secondary antibody 15000 dilution BioRad used signal detection SuperSignal Chemiluminescent Substrate Pierce
0.15670726.12835390.html.plaintext.txt	116	Microscopy GFP fluorescence images For ML1 transgenic plants emerging leaves apices dissected 10 12 day old seedlings grown MS agar plates
0.15670726.12835390.html.plaintext.txt	117	For AG intron transgenic plants primary inflorescence apices dissected 4 week old plants image analysis
0.15670726.12835390.html.plaintext.txt	118	Confocal images collected using 40x 63x oil immersion lens Leica SPII spectral confocal laser scanning microscope
0.15670726.12835390.html.plaintext.txt	119	GFP fluorescence excited 488 nm Argon laser images collected 500 550 nm range
0.15670726.12835390.html.plaintext.txt	120	In cases images transmissible light channel collected simultaneously
0.15670726.12835390.html.plaintext.txt	121	For ML1 transgenic plants vegetative inflorescence apices examined
0.15670726.12835390.html.plaintext.txt	122	In figure panels collected microscopy session plants grown exactly conditions
0.15670726.12835390.html.plaintext.txt	123	Light microscopic images Pictures flowers taken Polaroid DMC digital camera mounted Olympus SZH10 stereomicroscope
0.15670726.12835390.html.plaintext.txt	124	Images situ hybridization taken SPOT digital camera mounted Nikon compound microscope
0.15670726.12835390.html.plaintext.txt	125	Quantification subcellular distribution GFP LFY fusions Confocal image series epidermal cells emerging leaves collected transgenic plants carrying ML1GLFY ML1GFPLFY ML1LFYGFP using 63x objective 1 microm steps
0.15670726.12835390.html.plaintext.txt	126	Separate masks generated nuclei cytoplasm using image processing software Khoros www
0.15670726.12835390.html.plaintext.txt	127	Total signal intensity part calculated every section summed within image series
0.15670726.12835390.html.plaintext.txt	128	Data approximately thirty cells averaged transgene
0.15670726.12835390.html.plaintext.txt	129	RESULTS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Movement viral MP GFP L1 layer Plant viral movement proteins MPs green fluorescence protein GFP widely used studies intercellular protein movement plants represent examples targeted non targeted movement respectively
0.15670726.12835390.html.plaintext.txt	130	To provide data relevant transcription factor movement Arabidopsis meristems first set examine movement two types proteins L1 layer expressed intact plants
0.15670726.12835390.html.plaintext.txt	131	When expressed Turnip Vein Clearing Virus Movement Protein fused GFP TVCVMPGFP L1 using L1 specific ML1 promoter Sessions et al
0.15670726.12835390.html.plaintext.txt	132	1999 GFP fluorescence detected cells vegetative inflorescence apices although signal slightly higher L1 layer Fig
0.15670726.12835390.html.plaintext.txt	133	1A inset demonstrated TVCVMPGFP RNA restricted L1 plants confirming specificity ML1 promoter also confirming TVCVMP transport RNA
0.15670726.12835390.html.plaintext.txt	134	In maturing leaf epidermis part L1 layer cellular boundaries clearly visible TVCVMPGFP found specifically associated cell wall punctate pattern Fig
0.15670726.12835390.html.plaintext.txt	135	1D may coincide location plasmodesmata pit fields Crawford Zambryski 2001 Heinlein et al
0.15670726.12835390.html.plaintext.txt	136	Deeper optical sections also revealed substantial fraction TVCVMPGFP enter mesophyll cells leaf epidermis data shown
0.15670726.12835390.html.plaintext.txt	137	These data confirm plant viral movement proteins able move many cell diameters Citovsky 1999 Haywood et al
0.15670726.12835390.html.plaintext.txt	138	View larger version 111K Fig
0.15670726.12835390.html.plaintext.txt	139	Movement TVCVMPGFP 2xGFP NLS2xGFP
0.15670726.12835390.html.plaintext.txt	140	Confocal images GFP fluorescence inflorescence apices A C leaf epidermis D F 2 week old ML1TVCVMPGFP AD ML12xGFP BE ML1NLS2xGFP CF transgenic plants
0.15670726.12835390.html.plaintext.txt	141	Inset A shows TVCVMPGFP RNA restricted L1 detected situ hybridization
0.15670726.12835390.html.plaintext.txt	142	In D F GFP fluorescence channel overlaid transmissible light channel
0.15670726.12835390.html.plaintext.txt	143	TVCVMPGFP found cells inflorescence apex A associated cell wall punctate pattern D
0.15670726.12835390.html.plaintext.txt	144	2xGFP forms gradient six ten cells apex highest concentration L1 B
0.15670726.12835390.html.plaintext.txt	145	It located nucleus cytoplasm E
0.15670726.12835390.html.plaintext.txt	146	NLS2xGFP move efficiently one cell layer L1 apex C appears mostly nuclear F
0.15670726.12835390.html.plaintext.txt	147	We examined behavior GFP display targeted movement
0.15670726.12835390.html.plaintext.txt	148	We chose dimerized version GFP 2xGFP molecular weight approximately 54 kDa similar LFY 47 kDa size
0.15670726.12835390.html.plaintext.txt	149	In previous leaf bombardment studies demonstrated 2xGFP move least occasionally neighboring cells whereas adding nuclear localization signal NLS nearly fully blocks movement Crawford Zambryski 2000
0.15670726.12835390.html.plaintext.txt	150	Here 2xGFP NLS2xGFP expressed stably L1 behaved similarly
0.15670726.12835390.html.plaintext.txt	151	In vegetative inflorescence apices 2xGFP could move least six cells L2 L3 layers forming gradient highest levels L1 Fig
0.15670726.12835390.html.plaintext.txt	152	It appeared cytoplasmic nuclear leaf epidermis Fig
0.15670726.12835390.html.plaintext.txt	153	In agreement bombardment studies small amount NLS2xGFP able enter L2 layer apices GFP signal detected L3 layer Fig
0.15670726.12835390.html.plaintext.txt	154	Its subcellular localization assayed leaf epidermis GFP signal came nuclei Fig
0.15670726.12835390.html.plaintext.txt	155	To confirm GFP signal indeed dimerized GFP instead breakdown product resulting monomeric GFP whole cell protein extracts prepared transgenic seedlings imaging analyzed western blot anti GFP antibody
0.15670726.12835390.html.plaintext.txt	156	For NLS2xGFP major band 57 kDa observed predicted size 58 kDa indicating stable Fig
0.15670726.12835390.html.plaintext.txt	157	Similarly 2xGFP migrated 50 kDa predicted size 54 kDa small amount degradation product observed 2xGFP
0.15670726.12835390.html.plaintext.txt	158	View larger version 58K Fig
0.15670726.12835390.html.plaintext.txt	159	Western blots whole cell extracts 2 week old transgenic seedlings ML12xGFP ML1NLS2xGFP A ML1AP1GFP ML1GFPAP1 B ML1GLFY ML1LFYGFP ML1GFPLFY C probed anti GFP antibody
0.15670726.12835390.html.plaintext.txt	160	Extract wild type Col 0 seedlings used negative control A
0.15670726.12835390.html.plaintext.txt	161	Blots deliberately overexposed reveal presence minor bands
0.15670726.12835390.html.plaintext.txt	162	No major degradation products form single GFP found
0.15670726.12835390.html.plaintext.txt	163	Bands detected higher molecular weight 2xGFP GLFY lanes probably represent dimers formed extraction procedure
0.15670726.12835390.html.plaintext.txt	164	In B GFPAP1 bands marked arrow minor single GFP band GFPAP1 marked arrowhead
0.15670726.12835390.html.plaintext.txt	165	Absence movement functional AP1 GFP fusion To exclude possibility GFP fusion proteins move examined N C terminal fusions GFP transcription factor AP1
0.15670726.12835390.html.plaintext.txt	166	We previously reported AP1 largely cell autonomous effects expressed L1 layer indicating AP1 move internal layers although protein localization directly examined Sessions et al
0.15670726.12835390.html.plaintext.txt	167	In strong ap1 mutants sepals petals fail develop secondary flowers develop axil sepals converted bracts
0.15670726.12835390.html.plaintext.txt	168	7 kb promoter fragment drives expression reporter gene pattern similar endogenous AP1 Hempel et al
0.15670726.12835390.html.plaintext.txt	169	1997 fused AP1 cDNA largely rescue phenotype strong ap1 15 allele M
0.15670726.12835390.html.plaintext.txt	170	Yanofsky personal communication
0.15670726.12835390.html.plaintext.txt	171	Expression C terminal AP1GFP fusion AP1 promoter rescued aspects ap1 15 mutant phenotype although rescue variable different lines Fig
0.15670726.12835390.html.plaintext.txt	172	In contrast N terminal GFPAP1 fusion unable rescue ap1 15 phenotype Fig
0.15670726.12835390.html.plaintext.txt	173	View larger version 75K Fig
0.15670726.12835390.html.plaintext.txt	174	Absence movement functional AP1GFP fusion
0.15670726.12835390.html.plaintext.txt	175	The C terminal AP1GFP fusion rescue ap1 15 mutant flowers near wild type expressed AP1 promoter A leads development bracts subtending flowers expressed L1 wild type C
0.15670726.12835390.html.plaintext.txt	176	The N terminal fusion GFPAP1 rescue ap1 15 mutant flowers expressed AP1 promoter B
0.15670726.12835390.html.plaintext.txt	177	Confocal images GFP fluorescence inflorescence apices 2 week old ML1AP1GFP DE ML1GFPAP1 F plants shown
0.15670726.12835390.html.plaintext.txt	178	AP1GFP move L1 D optical section shoot apex tightly associated nuclei E tangential section L1 floral primordium
0.15670726.12835390.html.plaintext.txt	179	By contrast GFPAP1 largely cytoplasmic moves deeper tissues layers L1 F
0.15670726.12835390.html.plaintext.txt	180	We subsequently expressed fusions control ML1 promoter test movement
0.15670726.12835390.html.plaintext.txt	181	When AP1GFP 55 kDa expressed ML1 promoter observed gain function phenotypes associated overexpression AP1 L1 Sessions et al
0.15670726.12835390.html.plaintext.txt	182	2000 development bracts subtending flowers Fig
0.15670726.12835390.html.plaintext.txt	183	The GFP signal apices plants restricted L1 layer Fig
0.15670726.12835390.html.plaintext.txt	184	2D tightly associated cell nuclei Fig
0.15670726.12835390.html.plaintext.txt	185	This observation supports previous conclusion AP1 move L1 layer inner tissue transcription factors move tissue layers Arabidopsis apex
0.15670726.12835390.html.plaintext.txt	186	GFPAP1 appeared non functional expressed AP1 promoter moved tissue layers L1 ML1GFPAP1 apices Fig
0.15670726.12835390.html.plaintext.txt	187	The subcellular localization GFPAP1 also abnormal instead exclusively nuclear like functional AP1GFP fusion produced mostly cytoplasmic signal
0.15670726.12835390.html.plaintext.txt	188	The cytoplasmic localization may well causally related ability fusion move inability rescue mutant phenotype however unlikely movement interferes AP1 function
0.15670726.12835390.html.plaintext.txt	189	Western blots probed anti GFP antibody showed fusions migrated approximately 52 kDa expected size 55 kDa arrow Fig
0.15670726.12835390.html.plaintext.txt	190	There small amount free GFP 27 kDa arrowhead Fig
0.15670726.12835390.html.plaintext.txt	191	4B confirming observed fluorescence signal reflected behavior fusion protein
0.15670726.12835390.html.plaintext.txt	192	Movement LFY GFP fusions L1 layer To avoid artifacts caused addition GFP specific domain LFY protein generated three different LFYGFP fusions GFPLFY N terminal fusion GLFY insertion GFP amino acid 31 LFYGFP C terminal fusion
0.15670726.12835390.html.plaintext.txt	193	We used fusions increase size LFY half 47 74 kDa characterize movement LFY previously detected using anti LFY antibodies Sessions et al
0.15670726.12835390.html.plaintext.txt	194	The fusions introduced lfy 12 plants control ML1 promoter
0.15670726.12835390.html.plaintext.txt	195	To test independently functionality N C terminally tagged versions also expressed control constitutive CaMV 35S promoter
0.15670726.12835390.html.plaintext.txt	196	All five transgenes able rescue lfy 12 mutant phenotype cause typical gain function phenotypes associated overexpression LFY Weigel Nilsson 1995 indicates three GFP fusions fully functional
0.15670726.12835390.html.plaintext.txt	197	Using ML1 promoter lines examined subcellular localization LFY GFP fusions well movement L1 layer Fig
0.15670726.12835390.html.plaintext.txt	198	All three fusions detected nucleus cytoplasm best seen leaf epidermal cells GLFY shown Fig
0.15670726.12835390.html.plaintext.txt	199	3C produced cytoplasmic signal NLS2xGFP Fig
0.15670726.12835390.html.plaintext.txt	200	In leaf epidermal cells punctate signal appeared along cell wall observed three fusions GLFY shown Fig
0.15670726.12835390.html.plaintext.txt	201	3C suggests possible association plasmodesmata pit fields
0.15670726.12835390.html.plaintext.txt	202	GLFY GFPLFY moved three four cell layers L2 L3 vegetative inflorescence apices forming gradient highest concentration L1 Fig
0.15670726.12835390.html.plaintext.txt	203	Both GLFY GFPLFY restricted epidermal layer maturing leaves data shown
0.15670726.12835390.html.plaintext.txt	204	LFYGFP moved approximately 10 cell layers apices Fig
0.15670726.12835390.html.plaintext.txt	205	In leaves distribution epidermis similar GLFY GFPLFY could also detected underlying mesophyll cells data shown
0.15670726.12835390.html.plaintext.txt	206	Overall LFYGFP appeared cytoplasmic GLFY GFPLFY
0.15670726.12835390.html.plaintext.txt	207	This observation confirmed quantifying total signal intensity nucleus cytoplasm epidermal cells emerging leaves three fusions see Materials Methods
0.15670726.12835390.html.plaintext.txt	208	For GLFY GFPLFY nuclear cytoplasmic signal ratios similar 12
0.15670726.12835390.html.plaintext.txt	209	By contrast nuclear cytoplasmic ratio LFYGFP 15
0.15670726.12835390.html.plaintext.txt	210	4 twofold increase compared GLFY GFPLFY
0.15670726.12835390.html.plaintext.txt	211	Western blots probed anti GFP antibody demonstrated little degradation fusion proteins indicating vivo fluorescence signal came intact fusion proteins Fig
0.15670726.12835390.html.plaintext.txt	212	Taken together behavior LFY GFP fusions intermediate 2xGFP NLS2xGPF respect cytoplasmic localization ability move L1 layer
0.15670726.12835390.html.plaintext.txt	213	View larger version 153K Fig
0.15670726.12835390.html.plaintext.txt	214	Confocal images GFP fluorescence inflorescence apices ABD leaf epidermis C 2 week old ML1GLFY AC ML1GFPLFY B ML1LFYGFP D transgenic plants
0.15670726.12835390.html.plaintext.txt	215	GLFY moves several cell layers underlying tissue L1 apex A
0.15670726.12835390.html.plaintext.txt	216	GFPLFY shows similar gradient L1 GLFY B
0.15670726.12835390.html.plaintext.txt	217	The signal LFYGFP longest moving range appears fuzzy higher cytoplasmic localization D
0.15670726.12835390.html.plaintext.txt	218	All three fusions localized nucleus cytoplasm leaf epidermal cells bright spots sometimes found along cell wall GLFY shown C
0.15670726.12835390.html.plaintext.txt	219	Lateral movement GLFY within tissue layers Movement LFY GFP fusions L1 deeper layers indicated pass secondary plasmodesmata connect cells clonally related
0.15670726.12835390.html.plaintext.txt	220	To study lateral movement LFY within tissue layer took advantage mutated enhancer AGAMOUS AG gene drives reporter gene expression inflorescence meristem addition normal AG domain center floral meristems Hong et al
0.15670726.12835390.html.plaintext.txt	221	We expressed 2xGFP NLS2xGFP GLFY control CaMV 35S minimal promoter fused mutated AG enhancer AG intron
0.15670726.12835390.html.plaintext.txt	222	Except subcellular localization expression patterns NLS2xGFP Fig
0.15670726.12835390.html.plaintext.txt	223	5B indistinguishable fluorescent signal inflorescence meristem central domain young floral primordia
0.15670726.12835390.html.plaintext.txt	224	The signal shoot floral meristems discrete boundaries indicating GFP neither moved inflorescence meristem emerging floral primordia moved center stage 3 flowers periphery Fig
0.15670726.12835390.html.plaintext.txt	225	However gradient 2xGFP could seen extending deeper cell layers L3 stage 3 flowers Fig
0.15670726.12835390.html.plaintext.txt	226	5E consistent earlier observation
0.15670726.12835390.html.plaintext.txt	227	Thus compared movement L1 internal layers lateral movement 2xGFP NLS2xGFP within tissue layers much limited possibly even absent
0.15670726.12835390.html.plaintext.txt	228	The much reduced movement 2xGFP NLS2xGFP within L1 L2 compared movement layers suggests plasmodesmata SEL within two layers lower layers
0.15670726.12835390.html.plaintext.txt	229	View larger version 118K Fig
0.15670726.12835390.html.plaintext.txt	230	Restricted lateral protein movement Arabidopsis shoot apex
0.15670726.12835390.html.plaintext.txt	231	Confocal images GFP fluorescence inflorescence meristems surrounding young floral primordia AG intronNLS2xGFP AD AG intron2xGFP BE AG intronGLFY CF plants
0.15670726.12835390.html.plaintext.txt	232	The confocal images overlaid images transmitted light channel orientation
0.15670726.12835390.html.plaintext.txt	233	Note confocal images optical sections true transmitted light images
0.15670726.12835390.html.plaintext.txt	234	The mutated AG sequences reporters activate expression shoot apical meristem center young flowers
0.15670726.12835390.html.plaintext.txt	235	Close views stage 3 flowers reveal discrete lateral boundaries GFP signal D F
0.15670726.12835390.html.plaintext.txt	236	No lateral movement obvious three cases
0.15670726.12835390.html.plaintext.txt	237	Similarly GLFY could move laterally within tissue layer Fig
0.15670726.12835390.html.plaintext.txt	238	We previously found periclinal well anticlinal sectors LFY rescue mutant parts flowers indicating LFY moves directions Sessions et al
0.15670726.12835390.html.plaintext.txt	239	One possibility apparently different behavior LFY GLFY greater size GLFY compared endogenous LFY reduces ability move laterally within tissue layers
0.15670726.12835390.html.plaintext.txt	240	We used functional assay test assumption
0.15670726.12835390.html.plaintext.txt	241	For took advantage fact mutated AG enhancer active lfy mutants
0.15670726.12835390.html.plaintext.txt	242	When expressed LFY GLFY control enhancer lfy 12 plants fraction transgenic lines showed rescue flowers 4 12 lines LFY 4 11 lines GLFY significant difference using Fishers exact test suggesting GLFY similar activity LFY
0.15670726.12835390.html.plaintext.txt	243	However rescued flowers differed phenotype
0.15670726.12835390.html.plaintext.txt	244	Both GLFY LFY rescued development two inner whorls contain stamens carpels AG enhancer active Fig
0.15670726.12835390.html.plaintext.txt	245	6 LFY able rescue petal development
0.15670726.12835390.html.plaintext.txt	246	All four lfy 12 AG intronLFY lines showed phenotypic rescue produced least flowers petals many flowers normal complement four petals
0.15670726.12835390.html.plaintext.txt	247	By contrast none four lfy 12 AG intronGLFY lines produced flowers petals
0.15670726.12835390.html.plaintext.txt	248	As GLFY appears active LFY inner two whorls produced difference activity outer two whorls consistent conclusion LFY move extensively GLFY
0.15670726.12835390.html.plaintext.txt	249	View larger version 75K Fig
0.15670726.12835390.html.plaintext.txt	250	Rescue lfy 12 mutant flowers LFY GLFY expression center floral primordia
0.15670726.12835390.html.plaintext.txt	251	A wild type Arabidopsis flower A shoot like structure replaces flower lfy 12 mutants B shown
0.15670726.12835390.html.plaintext.txt	252	Both AG intronLFY AG intronGLFY rescue stamens carpels lfy 12 mutant flowers CD LFY rescues petals completely arrow C
0.15670726.12835390.html.plaintext.txt	253	Requirement LFY movement normal flower development Although established LFY move within flowers Sessions et al
0.15670726.12835390.html.plaintext.txt	254	2000 work unclear whether LFY movement required normal flower development LFY protein RNA expressed throughout young flowers Parcy et al
0.15670726.12835390.html.plaintext.txt	255	The difference LFY GLFY apparent ability move within layers allowed us address question expressing LFY GLFY control LFY promoter comparing ability rescue lfy 12 mutants
0.15670726.12835390.html.plaintext.txt	256	Of ten LFYLFY transgenic lines lfy 12 background three showed complete rescue remaining seven showed nearly complete rescue flowers reduced petal stamen number
0.15670726.12835390.html.plaintext.txt	257	By contrast six fourteen LFYGLFY lines lfy 12 background showed similar degree rescue remaining eight lines resembled weak intermediate lfy mutants sterile
0.15670726.12835390.html.plaintext.txt	258	This difference ability rescue statistically significant based Fishers exact test
0.15670726.12835390.html.plaintext.txt	259	Although opposite result full ability movement compromised LFY rescue lfy mutants would entirely conclusive finding consistent notion LFY movement may required normal flower development
0.15670726.12835390.html.plaintext.txt	260	However cannot exclude possibility GLFY somewhat less active transcription factor native LFY although difference activity could observed tested 35S AtML1 promoters
0.15670726.12835390.html.plaintext.txt	261	Movement mutant LFY proteins To test whether LFY movement regulated investigated whether deleting parts LFY protein abolishes intercellular movement
0.15670726.12835390.html.plaintext.txt	262	Three large non overlapping deletions made LFY coding sequence removing approximately one third protein Fig
0.15670726.12835390.html.plaintext.txt	263	All three linked GFP N terminus expressed ML1 promoter
0.15670726.12835390.html.plaintext.txt	264	Although differed extent moved L1 inner layers three deletion variants still able move L1 inner layers vegetative inflorescence apices
0.15670726.12835390.html.plaintext.txt	265	GFPLFY1 N terminal deletion behaved similar GFPLFY
0.15670726.12835390.html.plaintext.txt	266	It mostly located nucleus formed gradient four five cell layers L2 L3 Fig
0.15670726.12835390.html.plaintext.txt	267	GFPLFY2 central deletion expressed lower levels largely cytoplasmic presumably deletion NLS
0.15670726.12835390.html.plaintext.txt	268	GFP signal could clearly detected least three cell layers L2 L3 Fig
0.15670726.12835390.html.plaintext.txt	269	7C low expression levels may limiting ability determine actual range movement
0.15670726.12835390.html.plaintext.txt	270	GFPLFY3 C terminal deletion showed least degree movement moving one two cell layers L1 Fig
0.15670726.12835390.html.plaintext.txt	271	However GFP signal found large aggregates sometimes associated cell membrane imaged leaf epidermis data shown suggesting GFPLFY3 improperly folded localizes specific subcellular compartment may affect movement
0.15670726.12835390.html.plaintext.txt	272	Furthermore three truncated versions able enter mesophyll cells epidermis maturing leaves data shown
0.15670726.12835390.html.plaintext.txt	273	View larger version 70K Fig
0.15670726.12835390.html.plaintext.txt	274	Movement truncated LFY L1
0.15670726.12835390.html.plaintext.txt	275	A Diagram GFPLFY three truncated forms GFPLFY fusion protein
0.15670726.12835390.html.plaintext.txt	276	GFP coding sequence shown green LFY coding sequence light blue along restriction sites used make deletions B BamHI P PstI X XbaI S StyI H HindIII
0.15670726.12835390.html.plaintext.txt	277	B D Confocal images GFP fluorescence inflorescence apices 2 week old plants
0.15670726.12835390.html.plaintext.txt	278	All three forms truncated GFPLFY move L1 inner tissue layers
0.15670726.12835390.html.plaintext.txt	279	GFPLFY1 mostly located nucleus B whereas GFPLFY2 appears largely cytoplasmic C
0.15670726.12835390.html.plaintext.txt	280	Both move several cell layers L1
0.15670726.12835390.html.plaintext.txt	281	GFPLFY3 mainly found form large aggregates still move one two cell layers L1 D
0.15670726.12835390.html.plaintext.txt	282	As large deletions may cause mis folding protein also generated GFP fusions four weak intermediate lfy alleles mutating specific residues GLFY
0.15670726.12835390.html.plaintext.txt	283	All four fusions functional rescued lfy 12 plants phenotype corresponding lfy allele used fusion
0.15670726.12835390.html.plaintext.txt	284	When expressed L1 layer could move underlying tissue layers
0.15670726.12835390.html.plaintext.txt	285	Products fusions two weak lfy alleles glfy 2 glfy 20 showed near wild type movement Fig
0.15670726.12835390.html.plaintext.txt	286	3A whereas products two intermediate alleles glfy 3 glfy 9 moved somewhat less well L2 L3 two three cell layers Fig
0.15670726.12835390.html.plaintext.txt	287	Taken together data suggest either presence redundant movement signals absence specific movement signal
0.15670726.12835390.html.plaintext.txt	288	View larger version 104K Fig
0.15670726.12835390.html.plaintext.txt	289	Movement mutant GLFY fusions L1
0.15670726.12835390.html.plaintext.txt	290	A Diagram fusions GFP weak alleles lfy 2 P240L lfy 20 N306D intermediate alleles lfy 3 T244M lfy 9 R331K GLFY background
0.15670726.12835390.html.plaintext.txt	291	B E Confocal images GFP fluorescence inflorescence apices 2 week old plants
0.15670726.12835390.html.plaintext.txt	292	All fusion proteins move L1 interior layers although different degrees
0.15670726.12835390.html.plaintext.txt	293	DISCUSSION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Since discovery transcription factor movement plants almost decade ago questions arisen regarding move whether movement regulated
0.15670726.12835390.html.plaintext.txt	294	There least two scenarios transcription factors reach neighboring cells targeted movement guided specific movement export signal non targeted movement diffusion Crawford Zambryski 1999
0.15670726.12835390.html.plaintext.txt	295	We performed several tests determine whether evidence targeted movement LFY
0.15670726.12835390.html.plaintext.txt	296	None results point specific regulation LFY movement suggests LFY movement non targeted
0.15670726.12835390.html.plaintext.txt	297	Furthermore found important differences dynamics apical basal lateral movement apex
0.15670726.12835390.html.plaintext.txt	298	Mode LFY movement Several lines evidence compatible view LFY movement non targeted
0.15670726.12835390.html.plaintext.txt	299	First GFP LFY fusions produced L1 formed limited gradients extending deeper layers
0.15670726.12835390.html.plaintext.txt	300	Their movement range 2xGFP NLS2xGFP move non targeted fashion Crawford Zambryski 1999 Crawford Zambryski 2000 Kim et al
0.15670726.12835390.html.plaintext.txt	301	This contrast nearly uniform distribution shoot apex reflecting active mechanism cell cell transport observed viral movement protein fusion expressed L1
0.15670726.12835390.html.plaintext.txt	302	Second size affects LFY movement native LFY effective rescuing lfy defects adjacent cells tissue layer larger GLFY fusion
0.15670726.12835390.html.plaintext.txt	303	The effect size one prominent characteristics non targeted movement Zambryski Crawford 2000
0.15670726.12835390.html.plaintext.txt	304	Third although differing stability sub cellular localization three GFP LFY truncations fusions four mutant lfy alleles able move L1 interior cell layers
0.15670726.12835390.html.plaintext.txt	305	Although one cannot exclude possibility LFY several redundant movement signals simpler explanation LFY protein sequence contain specific movement export signal
0.15670726.12835390.html.plaintext.txt	306	It suggested non targeted movement like targeted movement occurs plasmodesmata
0.15670726.12835390.html.plaintext.txt	307	The potential localization foci GFP LFY fusion proteins along cell wall leaf epidermis supports hypothesis
0.15670726.12835390.html.plaintext.txt	308	This also suggests size exclusion limit secondary plasmodesmata connecting tissue layers Arabidopsis apex greater 74 kDa size LFY GFP fusions consistent previous estimates nascent leaves Zambryski Crawford 2000
0.15670726.12835390.html.plaintext.txt	309	Movement within tissue layers An important new finding GFP variants well GLFY move easily apical basal direction laterally
0.15670726.12835390.html.plaintext.txt	310	Using vivo function criterion found GLFY fusion less efficient native LFY moving center floral primordia periphery
0.15670726.12835390.html.plaintext.txt	311	This functional difference likely result size difference proteins fully functional cells produced
0.15670726.12835390.html.plaintext.txt	312	Similar previous studies demonstrated inner central zone L3 allow fluorescent tracer uploading vascular tissue Gisel et al
0.15670726.12835390.html.plaintext.txt	313	2002 observed much limited lateral movement within L3
0.15670726.12835390.html.plaintext.txt	314	Thus intercellular movement needs considered context specific location developmental stage within plant
0.15670726.12835390.html.plaintext.txt	315	That lateral movement less easily achieved apical basal movement may also explain fact LFY move floral primordia inflorescence meristem wild type Parcy et al
0.15670726.12835390.html.plaintext.txt	316	2000 lateral movement would required efficient protein exchange two tissues
0.15670726.12835390.html.plaintext.txt	317	The inflorescence meristem may even form symplasmic domain insulated emerging floral primordia Rinne van der Schoot 1998 thus restricting movement macromolecules
0.15670726.12835390.html.plaintext.txt	318	Alternatively may selective gating movement certain macromolecules floral primordia inflorescence meristem vice versa permitted
0.15670726.12835390.html.plaintext.txt	319	A similar mechanism may also responsible maintaining discrete whorl boundaries within flower
0.15670726.12835390.html.plaintext.txt	320	In context noteworthy floral homeotic proteins expressed distinct whorls developing Arabidopsis flower AP1 AP3 move whereas LFY expressed throughout flower Jenik Irish 2001 Sessions et al
0.15670726.12835390.html.plaintext.txt	321	Movement subcellular localization LFY LFY GFP fusions move inner tissue layers L1
0.15670726.12835390.html.plaintext.txt	322	By contrast AP1GFP move tissue layers
0.15670726.12835390.html.plaintext.txt	323	This cannot simply due size N terminal fusion GFPAP1 could move well
0.15670726.12835390.html.plaintext.txt	324	Furthermore GFPAP1 55 kDa smaller either NLS2xGFP 57 kDa LFY GFP fusions 74 kDa
0.15670726.12835390.html.plaintext.txt	325	Therefore LFY moving diffusion AP1 AP1GFP must actively retained cells expressed
0.15670726.12835390.html.plaintext.txt	326	One way achieve retention may subcellular localization nuclear ER localization
0.15670726.12835390.html.plaintext.txt	327	From study found good correlation nuclear localization movement 2xGFP highly cytoplasmic move considerable distance L1 true predominantly cytoplasmic GFPAP1 fusion
0.15670726.12835390.html.plaintext.txt	328	AP1GFP appeared exclusively nuclear move
0.15670726.12835390.html.plaintext.txt	329	Between two extremes NLS2xGFP showed little cytoplasmic localization moved one cell layer
0.15670726.12835390.html.plaintext.txt	330	The GFP LFY fusions showed cytoplasmic localization NLS2xGFP moved farther NLS2xGFP less 2xGFP
0.15670726.12835390.html.plaintext.txt	331	Among three GFP LFY fusions LFYGFP cytoplasmic localization moved farthest
0.15670726.12835390.html.plaintext.txt	332	Another possible mechanism retaining protein could formation large protein complexes exclusive subcellular localization simply sizes SEL plasmodesmata
0.15670726.12835390.html.plaintext.txt	333	This may contribute retention MADS domain proteins AP1 several including AP1 known form heteromultimers absence DNA Egea Cortines et al
0.15670726.12835390.html.plaintext.txt	334	In addition shown AP3 MADS domain transcription factor move tissue layers needs heterodimerize another MADS domain protein PISTILLATA PI order localize nucleus McGonigle et al
0.15670726.12835390.html.plaintext.txt	335	It possible GFPAP1 fusion disrupts interactions thereby interfering biological activity nuclear localization well retention cells produced
0.15670726.12835390.html.plaintext.txt	336	In context noteworthy SHR found nucleus cytoplasm stele produced
0.15670726.12835390.html.plaintext.txt	337	From SHR moves exactly one cell diameter adjacent endodermis located entirely nucleus Nakajima et al
0.15670726.12835390.html.plaintext.txt	338	This observation consistent model SHR gets trapped nuclei endodermis interaction partner causes translocation nucleus similar AP3PI interaction McGonigle et al
0.15670726.12835390.html.plaintext.txt	339	Mechanisms movement Our results compatible view LFY movement driven diffusion
0.15670726.12835390.html.plaintext.txt	340	However remains unclear whether conclusion drawn regarding intercellular movement transcription factors
0.15670726.12835390.html.plaintext.txt	341	Another well studied example trafficking transcription factor KN1 maize Kim et al
0.15670726.12835390.html.plaintext.txt	342	As LFY KN1 GFP fusions detected nucleus cytoplasm punctate pattern associated cell wall Kim et al
0.15670726.12835390.html.plaintext.txt	343	In contrast LFY various deletions prevent movement simple mutation homeodomain potential NLS KN1 abolished movement
0.15670726.12835390.html.plaintext.txt	344	Furthermore experiments tobacco indicated presence cellular component limiting KN1 movement suggested mode KN1 trafficking may related targeted movement viral movement proteins Kragler et al
0.15670726.12835390.html.plaintext.txt	345	However results consistent KN1 moving non targeted fashion
0.15670726.12835390.html.plaintext.txt	346	In bombardment assays KN1 GFP moved considerably less well fusion GFP movement protein TVCV Kim et al
0.15670726.12835390.html.plaintext.txt	347	Furthermore movement KN1 expressed SCR promoter shoot apex transgenic Arabidopsis plants rather limited Kim et al
0.15670726.12835390.html.plaintext.txt	348	2002 similar NLS2xGFP GFPLFY expressed ML1 promoter work
0.15670726.12835390.html.plaintext.txt	349	Further studies nonheterologous system required clarify mechanisms behind KN1 movement
0.15670726.12835390.html.plaintext.txt	350	A complex relationship targeted non targeted movement also indicated recent study dominant negative form tobacco NON CELL AUTONOMOUS PATHWAY PROTEIN 1 NtNCAPP1 overexpressed
0.15670726.12835390.html.plaintext.txt	351	In transgenic plants trafficking viral movement protein KN1 affected Lee et al
0.15670726.12835390.html.plaintext.txt	352	Interestingly tobacco LFY protein appears uniform transgenic plants also phenotypes reminiscent LFY overexpressing plants
0.15670726.12835390.html.plaintext.txt	353	The causal relationship observations needs investigation interesting combine dominant negative NtCAPP1 overexpressing plants tools presented
0.15670726.12835390.html.plaintext.txt	354	It also worth noting determinants underlying transcription factor movement may species dependent
0.15670726.12835390.html.plaintext.txt	355	Like LFY Antirrhinum ortholog FLORICAULA FLO non cell autonomous effects mosaic studies Carpenter Coen 1995
0.15670726.12835390.html.plaintext.txt	356	In contrast LFY extent FLO rescue mutant flowers varies depending layer FLO expressed Hantke et al
0.15670726.12835390.html.plaintext.txt	357	As FLO protein examined mosaics unknown whether differential rescue ability caused differences FLO movement result downstream effects documented abnormalities target gene expression mosaics Hantke et al
0.15670726.12835390.html.plaintext.txt	358	Another example interspecific differences provided DEF Antirrhinum found move L2 L1 stage organ dependent manner Perbal et al
0.15670726.12835390.html.plaintext.txt	359	However DEF ortholog AP3 Arabidopsis move layers Jenik Irish 2001 indicates subtle differences sequence interspecific differences translocation machinery affect transcription factor movement latter consistent interspecific differences reported GFP movement Crawford Zambryski 2001
0.15670726.12835390.html.plaintext.txt	360	These observations highlight care must taken extrapolating one transcription factor assayed single species single tissue
0.15670726.12835390.html.plaintext.txt	361	In conclusion presented evidence transcription factor LFY moves non targeted fashion
0.15670726.12835390.html.plaintext.txt	362	We proposing testable hypothesis movement default mechanism many proteins Arabidopsis shoot apex unless either efficiently targeted specific subcellular locations retained formation protein complexes
0.15670726.12835390.html.plaintext.txt	363	More case studies needed determine whether results indeed generalized include proteins tissues species
0.15670726.12835390.html.plaintext.txt	364	ACKNOWLEDGMENTS We thank Steve Barlow help confocal microscopy Virginia Butel generating GLFY Ji Hoon Ahn Marty Yanofsky gifts material Ray Hong Jan Lohmann Alexis Maizel Javier Palatnik Markus Schmid Jon Werner Philip Wigge discussions critical reading manuscript
0.15670726.12835390.html.plaintext.txt	365	We especially acknowledge comrade plasmodesmatis Bill Lucas spirited discussions exchange ideas intercellular protein movement
0.15670726.12835390.html.plaintext.txt	366	This work supported fellowships Life Sciences Research FoundationUS Department Energy X
0.15670726.12835390.html.plaintext.txt	367	Howard Hughes Medical Institute J
0.15670726.12835390.html.plaintext.txt	368	grant NIH GM45244 P
0.15670726.12835390.html.plaintext.txt	369	grants NIH GM50224 NSF 9975717 0210992 USDA 00 35304 9333 BSF 0100476 BARD 334702 V
0.15670726.12835390.html.plaintext.txt	370	grant NIH GM62932 funding Max Planck Society D
0.15670726.12835390.html.plaintext.txt	371	Director Max Planck Institute
0.15670726.12835390.html.plaintext.txt	372	REFERENCES TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES
0.15670726.12835390.html.plaintext.txt	373	LEAFY expression flower initiation Arabidopsis
0.15670726.12835390.html.plaintext.txt	374	Activation floral homeotic gene Arabidopsis
0.15670726.12835390.html.plaintext.txt	375	Transposon induced chimeras show floricaula meristem identity gene acts non autonomously cell layers
0.15670726.12835390.html.plaintext.txt	376	Tobacco mosaic virus pioneer cell cell movement
0.15670726.12835390.html.plaintext.txt	377	Plasmodesmata signaling many roles sophisticated statutes
0.15670726.12835390.html.plaintext.txt	378	Subcellular localization determines availability non targeted proteins plasmodesmatal transport
0.15670726.12835390.html.plaintext.txt	379	Non targeted targeted protein movement plasmodesmata leaves different developmental physiological states
0.15670726.12835390.html.plaintext.txt	380	Ternary complex formation MADS box proteins SQUAMOSA DEFICIENS GLOBOSA involved control floral architecture Antirrhinum majus
0.15670726.12835390.html.plaintext.txt	381	PKS1 substrate phosphorylated phytochrome modulates light signaling Arabidopsis
0.15670726.12835390.html.plaintext.txt	382	Signaling cell fate decisions CLAVATA3 Arabidopsis shoot meristems
0.15670726.12835390.html.plaintext.txt	383	Temporal spatial regulation symplastic trafficking development Arabidopsis thaliana apices
0.15670726.12835390.html.plaintext.txt	384	Leaf shoot apex movement symplastic tracer restricted coincident flowering Arabidopsis
0.15670726.12835390.html.plaintext.txt	385	Expression floricaula single cell layers periclinal chimeras activates downstream homeotic genes layers floral meristems
0.15670726.12835390.html.plaintext.txt	386	Removal cryptic intron subcellular localization green fluorescent protein required mark transgenic Arabidopsis plants brightly
0.15670726.12835390.html.plaintext.txt	387	Plasmodesmata pathways protein ribonucleoprotein signaling
0.15670726.12835390.html.plaintext.txt	388	Changing patterns localization tobacco mosaic virus movement protein replicase endoplasmic reticulum microtubules infection
0.15670726.12835390.html.plaintext.txt	389	The SHORT ROOT gene controls radial patterning Arabidopsis root radial signaling
0.15670726.12835390.html.plaintext.txt	390	Floral determination expression floral regulatory genes Arabidopsis
0.15670726.12835390.html.plaintext.txt	391	Regulatory elements floral homeotic gene AGAMOUS identified phylogenetic footprinting shadowing
0.15670726.12835390.html.plaintext.txt	392	Complexes MADS box proteins sufficient convert leaves floral organs
0.15670726.12835390.html.plaintext.txt	393	LEAFY interacts floral homeotic genes regulate Arabidopsis floral development
0.15670726.12835390.html.plaintext.txt	394	Cell cell long distance trafficking green fluorescent protein phloem symplastic unloading protein sink tissues
0.15670726.12835390.html.plaintext.txt	395	Expression maize KNOTTED1 related homeobox genes shoot apical meristem predicts patterns morphogenesis vegetative shoot
0.15670726.12835390.html.plaintext.txt	396	The Arabidopsis floral homeotic gene APETALA3 differentially regulates intercellular signaling required petal stamen development
0.15670726.12835390.html.plaintext.txt	397	Intercellular trafficking KNOTTED1 green fluorescent protein fusion leaf shoot meristem Arabidopsis
0.15670726.12835390.html.plaintext.txt	398	Developmental changes due long distance movement homeobox fusion transcript tomato
0.15670726.12835390.html.plaintext.txt	399	Peptide antagonists plasmodesmal macromolecular trafficking pathway
0.15670726.12835390.html.plaintext.txt	400	Macromolecular trafficking indicated localization turnover sucrose transporters enucleate sieve elements
0.15670726.12835390.html.plaintext.txt	401	Selective trafficking non cell autonomous proteins mediated NtNCAPP1
0.15670726.12835390.html.plaintext.txt	402	Plasmodesmata intercellular channels macromolecular transport plants
0.15670726.12835390.html.plaintext.txt	403	Selective trafficking KNOTTED1 homeodomain protein mRNA plasmodesmata
0.15670726.12835390.html.plaintext.txt	404	Peptide signals receptors higher plants
0.15670726.12835390.html.plaintext.txt	405	Conservation innovation plant signaling pathways
0.15670726.12835390.html.plaintext.txt	406	Nuclear localization Arabidopsis APETALA3 PISTILLATA homeotic gene products depends simultaneous expression
0.15670726.12835390.html.plaintext.txt	407	Intercellular movement putative transcription factor SHR root patterning
0.15670726.12835390.html.plaintext.txt	408	Activation Arabidopsis B class homeotic genes APETALA1
0.15670726.12835390.html.plaintext.txt	409	Simple branched plasmodesmata allow nonspecific trafficking proteins developing tobacco leaves
0.15670726.12835390.html.plaintext.txt	410	A genetic framework floral patterning
0.15670726.12835390.html.plaintext.txt	411	Non cell autonomous function Antirrhinum floral homeotic proteins DEFICIENS GLOBOSA exerted polar cell cell trafficking
0.15670726.12835390.html.plaintext.txt	412	Symplasmic fields tunica shoot apical meristem coordinate morphogenetic events
0.15670726.12835390.html.plaintext.txt	413	From gradients stripes Drosophila embryogenesis filling gaps
0.15670726.12835390.html.plaintext.txt	414	Phloem long distance transport CmNACP mRNA implications supracellular regulation plants
0.15670726.12835390.html.plaintext.txt	415	The Arabidopsis thaliana MERISTEM LAYER 1 promoter specifies epidermal expression meristems young primordia
0.15670726.12835390.html.plaintext.txt	416	Cell cell signaling movement floral transcription factors LEAFY APETALA1
0.15670726.12835390.html.plaintext.txt	417	A dominant mutation maize homeobox gene Knotted 1 causes ectopic expression leaf cells altered fates
0.15670726.12835390.html.plaintext.txt	418	A developmental switch sufficient flower initiation diverse plants
0.15670726.12835390.html.plaintext.txt	419	Arabidopsis A Laboratory Manual
0.15670726.12835390.html.plaintext.txt	420	Cold Spring Harbor NY Cold Spring Harbor Laboratory Press
0.15670726.12835390.html.plaintext.txt	421	LEAFY controls floral meristem identity Arabidopsis
0.15670726.12835390.html.plaintext.txt	422	Signaling plants intercellular RNA protein movement
0.15670726.12835390.html.plaintext.txt	423	Plasmodesmata gatekeepers cell cell transport developmental signals plants
0.15670726.12835390.html.plaintext.txt	424	Related articles Development
0.15670726.12835390.html.plaintext.txt	425	Plant transcription factors move Development 2003 130 1601
0.15123306.11222739.html.plaintext.txt	0	Three Dimensional Structure Human Follicle Stimulating Hormone Kristin M
0.15123306.11222739.html.plaintext.txt	1	Union College Schenectady New York 12308 Division Molecular Medicine K
0.15123306.11222739.html.plaintext.txt	2	Wadsworth Center Albany New York 12201 0509
0.15123306.11222739.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS AND DISCUSSION MATERIALS AND METHODS REFERENCES The crystal structure ssThr26Ala mutant human follicle stimulating hormone hFSH determined 3
0.15123306.11222739.html.plaintext.txt	4	The hFSH mutant expressed baculovirus infected Hi5 insect cells purified affinity chromatography using sshFSH specific monoclonal antibody
0.15123306.11222739.html.plaintext.txt	5	The ssThr26Ala mutation results elimination ssAsn24 glycosylation site yielding protein suitable crystallization without affecting receptor binding signal transduction activity glycohormone
0.15123306.11222739.html.plaintext.txt	6	The crystal structure two independent hFSH molecules asymmetric unit solvent content 80
0.15123306.11222739.html.plaintext.txt	7	The sssubunits hFSH similar folds consisting central cystine knot motifs three ss hairpins extend
0.15123306.11222739.html.plaintext.txt	8	The two subunits associate tightly head tail arrangement forming elongated slightly curved structure similar human chorionic gonadotropin hCG
0.15123306.11222739.html.plaintext.txt	9	The hFSH heterodimers differ conformations amino carboxy termini second loop ss subunit L2ss
0.15123306.11222739.html.plaintext.txt	10	Detailed comparison structures hFSH hCG reveals several differences ss subunits may important respect receptor binding specificity signal transduction
0.15123306.11222739.html.plaintext.txt	11	These differences include conformational changes andor differential distributions polar charged residues loops L3ss hFSH residues 62 73 cystine noose determinant loop residues 87 94 carboxy terminal loop residues 94 104
0.15123306.11222739.html.plaintext.txt	12	An additional interesting feature hFSH structure extensive hydrophobic patch area formed loops L1 L3 ssL2
0.15123306.11222739.html.plaintext.txt	13	Glycosylation Asn52 well known required full signal transduction activity heterodimer stability
0.15123306.11222739.html.plaintext.txt	14	The structure reveals intersubunit hydrogen bonding interaction carbohydrate ssTyr58 indication mechanism carbohydrate may stabilize heterodimer
0.15123306.11222739.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS AND DISCUSSION MATERIALS AND METHODS REFERENCES FSH member family pituitary glycoprotein hormones GPH play key roles human fertility
0.15123306.11222739.html.plaintext.txt	16	The GPH also include CG LH TSH heterodimers consisting common subunit 92 amino acids unique ss subunit 111 amino acids FSH 1 2 3 4
0.15123306.11222739.html.plaintext.txt	17	FSH acts binding G protein coupled receptors signal part protein kinase A pathway 5 6
0.15123306.11222739.html.plaintext.txt	18	FSH enables ovarian folliculogenesis antral follicle stage essential Sertoli cell proliferation maintenance sperm quality testis
0.15123306.11222739.html.plaintext.txt	19	The amino acids GPH identified critical receptor binding striking similarity yet residues essential signal transduction 7
0.15123306.11222739.html.plaintext.txt	20	Identification GPH residues key signal transduction could provide development molecular mimetics antagonists GPH action clinical applications fertility management 8 treatment thyroid disorders 9
0.15123306.11222739.html.plaintext.txt	21	Glycosylation GPH shown important circulatory persistence clearance bioactivity 10 11 12 13 14
0.15123306.11222739.html.plaintext.txt	22	Each subunit contains two glycosylation sites Asn52 Asn78 subunit conserved sites ss subunit Asn7 Asn24 human FSH hFSH
0.15123306.11222739.html.plaintext.txt	23	ss Subunit glycosylation reported affect disulfide bond formation rate secretion site 2 greater effect site 1 especially secretion 15
0.15123306.11222739.html.plaintext.txt	24	Glycosylation Asn78 appears important thermal stability 16
0.15123306.11222739.html.plaintext.txt	25	Deglycosylation hFSH hCG Asn52 long accepted impair signal transduction allowing full binding activity suggesting receptor binding signal transduction two separate functions involving different residues carbohydrate key signal transduction
0.15123306.11222739.html.plaintext.txt	26	Recent evidence suggests deglycosylation Asn52 causes hCG metastable dissociation subunits occurs 37 C 17
0.15123306.11222739.html.plaintext.txt	27	In study disulfide bonds engineered subunits could overcome effect deglycosylation signal transduction
0.15123306.11222739.html.plaintext.txt	28	Although studies performed hFSH obscure previous results deglycosylated GPH demonstrate carbohydrate Asn52 essential full signal transduction subunit association otherwise stabilized
0.15123306.11222739.html.plaintext.txt	29	It remains unclear whether carbohydrate lack affects structure GPH whether formation intersubunit disulfide bonds stabilizes hCG conformation signal transduction competent
0.15123306.11222739.html.plaintext.txt	30	Previous structural studies GPH heteroolimers limited two independent reports crystal structure human CG hCG partially deglycosylated hydrogen fluoride treatment 3 4 recent report low resolution structure ternary complex fully glycosylated hCG two Fv fragments 18
0.15123306.11222739.html.plaintext.txt	31	With goal determining structure fully active glycosylated hFSH achieved high level expression hFSH Hi5 insect cells established method purification produces biologically active hFSH
0.15123306.11222739.html.plaintext.txt	32	As part studies glycosylation hFSH observed glycosylation Asn24 ss subunit detectable half molecules 7
0.15123306.11222739.html.plaintext.txt	33	To reduce glycoform heterogeneity anticipation would facilitate crystallization glycosylation ssAsn24 eliminated site directed mutagenesis converting Thr26 Ala
0.15123306.11222739.html.plaintext.txt	34	This isoform hFSH fully active yielded crystals suitable x ray diffraction
0.15123306.11222739.html.plaintext.txt	35	Here report structure ssT26A hFSH compare hCG
0.15123306.11222739.html.plaintext.txt	36	RESULTS AND DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS AND DISCUSSION MATERIALS AND METHODS REFERENCES Characterization Recombinant hFSH ssT26A Amino acid sequencing purified Hi5 insect cell expressed hFSH ssT26A revealed N termini APDVQDCPEC ss CELTNITIAI indicating subunit signal peptide cleaved mammalian cells ss subunit lacked two amino terminal residues Asn Ser
0.15123306.11222739.html.plaintext.txt	37	Purified hFSH ssT26A similar activity hFSH expressed insect cells stable 16 h incubation period room temperature bound receptor effectively competing labeled pituitary hFSH binding hFSH receptors expressed Chinese hamster ovary CHO cells Fig
0.15123306.11222739.html.plaintext.txt	38	As expected biological activity hFSH ssT26A indistinguishable wild type hFSH showing dose response related stimulation progesterone production Fig
0.15123306.11222739.html.plaintext.txt	39	1C Y1 cells stably transfected hFSHR
0.15123306.11222739.html.plaintext.txt	40	View larger version 21K Figure 1
0.15123306.11222739.html.plaintext.txt	41	Characterization Vitro Bioactivity ssT26A hFSH Wild Type Wt hFSH
0.15123306.11222739.html.plaintext.txt	42	The data representative experiments repeated least twice
0.15123306.11222739.html.plaintext.txt	43	Error bars represent sample error
0.15123306.11222739.html.plaintext.txt	44	A Competition recombinant wild type hFSH iFSH ssT26A hFSH 125I hFSH pituitary hFSH receptors expressed CHO cells
0.15123306.11222739.html.plaintext.txt	45	B Progesterone production induced wild type hFSH ssT26A hFSH measured vitro bioassay
0.15123306.11222739.html.plaintext.txt	46	C cAMP production induced treatment either wild type hFSH ssT26A hFSH
0.15123306.11222739.html.plaintext.txt	47	Crystallization The first hFSH crystals obtained glycohormone extracted human pituitary glands purified previously described 19 desialylated neuraminidase treatment
0.15123306.11222739.html.plaintext.txt	48	4 M NH42SO4 phosphate buffer pH 7
0.15123306.11222739.html.plaintext.txt	49	5 mm three dimensions required 6 months grow full size diffracted inconsistently crystals diffracting 3
0.15123306.11222739.html.plaintext.txt	50	8 A resolution diffracting less 5
0.15123306.11222739.html.plaintext.txt	51	Next crystals insect cell expressed wild type hFSH grown initially starting cross seeding crystals pituitary hFSH
0.15123306.11222739.html.plaintext.txt	52	These crystals consistent quality diffracting 4
0.15123306.11222739.html.plaintext.txt	53	0 A resolution still required several months grow
0.15123306.11222739.html.plaintext.txt	54	The crystals ssT26A mutant grown macroseeding methods similar conditions initial crystals obtained cross seeding recombinant wild type hFSH
0.15123306.11222739.html.plaintext.txt	55	The final crystallization conditions similar initial pituitary protein conditions except crystals grew consistently pH 9
0.15123306.11222739.html.plaintext.txt	56	Crystals grew full size less 1 month similar diffraction quality
0.15123306.11222739.html.plaintext.txt	57	Structure Determination The crystals belong space group P41212 cell parameters 128
0.15123306.11222739.html.plaintext.txt	58	Structure determination revealed presence two hFSH molecules asymmetric unit solvent content 80
0.15123306.11222739.html.plaintext.txt	59	The structure determined multiple isomorphous replacement anomalous scattering using four heavy atom derivatives followed solvent flattening
0.15123306.11222739.html.plaintext.txt	60	Continuous electron density 95 main chain observed initial 3
0.15123306.11222739.html.plaintext.txt	61	The model refined R value 0
0.15123306.11222739.html.plaintext.txt	62	7 total data set data 30 3
0.15123306.11222739.html.plaintext.txt	63	The final model contains residues 5 90 ss3 ss109 hFSH molecule 1 hFSH1 residues 5 90 ss3 ss108 hFSH molecule 2 hFSH2 addition 14 sugar residues 2 sulfate ions
0.15123306.11222739.html.plaintext.txt	64	No attempt made include solvent molecules relatively low resolution structure uncertainty location disordered protein carbohydrate moieties
0.15123306.11222739.html.plaintext.txt	65	Thermal parameter refinement performed blocked mode main chain atoms side chain atoms residue represented separate blocks
0.15123306.11222739.html.plaintext.txt	66	The thermal parameters high due combination high solvent content high flexibility molecule average protein atoms 58 A2 ranging 28 A2 residues core molecule 100 A2 loops
0.15123306.11222739.html.plaintext.txt	67	Figure 2 shows initial experimental electron density maps representative loop residues ss87 94
0.15123306.11222739.html.plaintext.txt	68	The atomic coordinates structure factors deposited Protein Data Bank RCSB entry number 1FL7
0.15123306.11222739.html.plaintext.txt	69	View larger version 44K Figure 2
0.15123306.11222739.html.plaintext.txt	70	Electron Density Representative Loop hFSH
0.15123306.11222739.html.plaintext.txt	71	The model residues ss87 94 shown black sticks disulfide ss87 ss94 thicker line 3
0.15123306.11222739.html.plaintext.txt	72	5 A experimental electron density map displayed 1
0.15123306.11222739.html.plaintext.txt	73	The refined average temperature factors residues included figure 70A main chain atoms 85A side chain atoms
0.15123306.11222739.html.plaintext.txt	74	Figures 2 4 created using program Setor 46
0.15123306.11222739.html.plaintext.txt	75	Overall Structure As expected hFSH Fig
0.15123306.11222739.html.plaintext.txt	76	3 belongs family cystine knot growth factors 20 21 overall fold identical hCG
0.15123306.11222739.html.plaintext.txt	77	Both ss subunits similar topologies cystine knot central motif
0.15123306.11222739.html.plaintext.txt	78	In motif disulfide bond Cys 10 ss3 60 ss51 passes ring defined disulfide bonds Cys 28 82 Cys 32 84
0.15123306.11222739.html.plaintext.txt	79	Three ss hairpins extend cystine knot two end tight ss turns one end molecule loops L1 L3 one forms longer open loop L2 opposite end
0.15123306.11222739.html.plaintext.txt	80	The L2 loop subunit L2 includes helical segment molecule 1
0.15123306.11222739.html.plaintext.txt	81	5 turn helix runs nearly perpendicular ss strands
0.15123306.11222739.html.plaintext.txt	82	The ss hairpins stabilized associate disulfide bridges
0.15123306.11222739.html.plaintext.txt	83	The disulfide bond pairings hFSH 7 31 10 60 28 82 32 84 59 87 ss3 51 ss17 66 ss20 104 ss28 82 ss32 84 ss87 94 identical hCG contradict earlier biochemical assignments 22 23
0.15123306.11222739.html.plaintext.txt	84	The two subunits aligned head tail slightly wound around ssL2 L1 L3 form one end elongated curved heterodimer L2 ssL1 ssL3 form
0.15123306.11222739.html.plaintext.txt	85	The two subunits intimately associated via intermolecular contacts bury 32 total solvent accessible surface monomers
0.15123306.11222739.html.plaintext.txt	86	A loop C terminus ss subunit residues ss84 104 wraps around ss strands 2 3 subunit resulting subunit surrounded sides ss subunit
0.15123306.11222739.html.plaintext.txt	87	Consequently loop referred seat belt loop hCG 3
0.15123306.11222739.html.plaintext.txt	88	View larger version 38K Figure 3
0.15123306.11222739.html.plaintext.txt	89	Cartoon Illustrating Overall Fold hFSH
0.15123306.11222739.html.plaintext.txt	90	The fold typical cystine knot growth factors subunit light gray ribbon ss subunit dark gray ribbon similar topologies
0.15123306.11222739.html.plaintext.txt	91	The carbohydrate disulfide bonds subunits represented ball stick models
0.15123306.11222739.html.plaintext.txt	92	The N C termini subunit N glycosylated Asn residues ss7 Asn7 sssubunit loops discussed text labeled
0.15123306.11222739.html.plaintext.txt	93	Figures 3 6 7 8 drawn Molscript 47
0.15123306.11222739.html.plaintext.txt	94	Insect cell expressed glycoproteins glycosylated short high mannose type N linked oligosaccharides typically consisting core Man4 GlcNAc2
0.15123306.11222739.html.plaintext.txt	95	In ssT26A hFSH molecules interpretable electron density observed two GlcNAcs site 52 ss7 two GlcNAcs one Man site 78
0.15123306.11222739.html.plaintext.txt	96	Although additional density observed three sites hFSH molecules disorder prevents modeling remaining oligosaccharide
0.15123306.11222739.html.plaintext.txt	97	Crystal Packing The two molecules asymmetric unit sit close together concave surfaces associated clasped hands like fashion Fig
0.15123306.11222739.html.plaintext.txt	98	Residues loops L2 L3 ssL2 carboxy terminus subunit hFSH2 contact carboxy termini hFSH1 subunits well hFSH1 seatbelt
0.15123306.11222739.html.plaintext.txt	99	In total interactions render approximately 10 surface heterodimer solvent inaccessible
0.15123306.11222739.html.plaintext.txt	100	Intermolecular contacts symmetry related molecules limited loops ends molecules
0.15123306.11222739.html.plaintext.txt	101	This packing arrangement results open crystal lattice channels 70 A diameter
0.15123306.11222739.html.plaintext.txt	102	All carbohydrate chains extend open channel would expected crystals ultimately derived initial crystals produced extensively glycosylated pituitary protein
0.15123306.11222739.html.plaintext.txt	103	The average temperature factor hFSH2 49 A2 significantly lower hFSH1 59A2 possibly due slightly larger number crystal contacts hFSH2 involved
0.15123306.11222739.html.plaintext.txt	104	View larger version 46K Figure 4
0.15123306.11222739.html.plaintext.txt	105	Stereodiagram Showing Crystal Packing hFSH
0.15123306.11222739.html.plaintext.txt	106	Shown 16 hFSH heterodimers center mass within unit cell
0.15123306.11222739.html.plaintext.txt	107	The two dimers asymmetric unit associate tightly concave surfaces overlapping contacts symmetry related molecules mostly limited ends molecules
0.15123306.11222739.html.plaintext.txt	108	Comparison Two Molecules Asymmetric Unit The conformations two hFSH heterodimers asymmetric unit similar root mean square deviation r
0.15123306.11222739.html.plaintext.txt	109	9 A 180 carbon atoms Fig
0.15123306.11222739.html.plaintext.txt	110	Although subunits associate identical fashion heterodimers small difference angle subunits results r
0.15123306.11222739.html.plaintext.txt	111	6 A ss subunits subunits superimposed
0.15123306.11222739.html.plaintext.txt	112	This suggests flexibility association subunits
0.15123306.11222739.html.plaintext.txt	113	As expected core region protein cystine knot motifs surrounding ss strands conformation molecules major differences occur loops amino carboxy termini Fig
0.15123306.11222739.html.plaintext.txt	114	The C terminal end helix loop 2 subunit less helical hFSH2 resulting shift position carbon residue 48 2
0.15123306.11222739.html.plaintext.txt	115	ssL2 differs carboxy terminal end shifted 5
0.15123306.11222739.html.plaintext.txt	116	This shift appears correlated major difference conformation carboxy terminus subunit lies middle loop ssL2 hFSH2 positioned away molecule hFSH1
0.15123306.11222739.html.plaintext.txt	117	The final large difference L3 differs 3
0.15123306.11222739.html.plaintext.txt	118	7 A position residue 72
0.15123306.11222739.html.plaintext.txt	119	While conformational differences two independent observations hFSH structure indicative flexibility hFSH heterodimer small compared differences hFSH hCG many loops
0.15123306.11222739.html.plaintext.txt	120	View larger version 32K Figure 5
0.15123306.11222739.html.plaintext.txt	121	Difference Mapping hFSH hCG Structures
0.15123306.11222739.html.plaintext.txt	122	A Diagram showing variation temperature factor residue number two hFSH molecules asymmetric unit hFSH1 thin lines hFSH2 thick lines
0.15123306.11222739.html.plaintext.txt	123	The average temperature factor hFSH1 higher hFSH2
0.15123306.11222739.html.plaintext.txt	124	B Diagram showing carbon atom r
0.15123306.11222739.html.plaintext.txt	125	least squares superposition two hFSH molecules thin lines hFSH2 hCG thick lines
0.15123306.11222739.html.plaintext.txt	126	In subunit superpositions show largest deviations seen around residue 72 loop L3
0.15123306.11222739.html.plaintext.txt	127	The largest deviations hFSH hCG observed ss subunit loops ssL1 around residue 25 ssL2 around residue 50 ssL3 around residue 80 ss carboxy terminus
0.15123306.11222739.html.plaintext.txt	128	Large deviations also observed loop ssL2 comparison hFSH1 hFSH2
0.15123306.11222739.html.plaintext.txt	129	This suggests ssL2 quite flexible adopt variety conformations changes three regions protein may important receptor discrimination
0.15123306.11222739.html.plaintext.txt	130	C Alignment sequences ss subunits hFSH top hCG bottom important loops labeled
0.15123306.11222739.html.plaintext.txt	131	The cystine residues involved cystine knot highlighted filled diamonds different shades according disulfide pairings
0.15123306.11222739.html.plaintext.txt	132	The N glycosylated asparagines identified italicized N
0.15123306.11222739.html.plaintext.txt	133	Major sequence differences found ssL2 ssL3 cystine noose ss carboxy terminus
0.15123306.11222739.html.plaintext.txt	134	The carboxy terminus hCG sequence truncated residue 111 clarity
0.15123306.11222739.html.plaintext.txt	135	The hCG sequence numbering indicated parentheses
0.15123306.11222739.html.plaintext.txt	136	View larger version 29K Figure 6
0.15123306.11222739.html.plaintext.txt	137	Comparison Molecular Conformations hFSH hCG
0.15123306.11222739.html.plaintext.txt	138	A Superposition hFSH2 green ss light blue hFSH1 yellow ss dark blue shown two perpendicular views produced least squares fitting carbon atoms
0.15123306.11222739.html.plaintext.txt	139	B Similar figure superposition hFSH2 green ss light blue hCG orange ss magenta
0.15123306.11222739.html.plaintext.txt	140	Comparison hCG For comparisons conformations hFSH hCG hCG coordinates PDB code 1HCN 4 used structure determined somewhat higher resolution 1HRP structure 3
0.15123306.11222739.html.plaintext.txt	141	However two structures crystal form r
0.15123306.11222739.html.plaintext.txt	142	7 A maximum main chain differences approximately 1 A loops
0.15123306.11222739.html.plaintext.txt	143	In absence systematic differences two structures conformational analysis presented relevant structures
0.15123306.11222739.html.plaintext.txt	144	hFSH hCG identical folds significant differences occur amino carboxy termini several loops Figs
0.15123306.11222739.html.plaintext.txt	145	As expected subunits r
0.15123306.11222739.html.plaintext.txt	146	9 A least squares fit hCG hFSH1 hFSH2 respectively similar ss subunits r
0.15123306.11222739.html.plaintext.txt	147	The largest differences ss subunits occur three loops ssL1 ssL2 ssL3 cystine noose ss subunit carboxy terminal loop Fig
0.15123306.11222739.html.plaintext.txt	148	ssL1 ssL3 together L2 C terminus ss subunit form one end heterodimer extending beyond area two subunits interact Figs
0.15123306.11222739.html.plaintext.txt	149	Comparison structures reveals large differences conformations hFSH hCG area differences two independent molecules hFSH
0.15123306.11222739.html.plaintext.txt	150	The amino acid sequences hFSH hCG differ greatly ssL3 4 identical residues 13 residue span hFSH residues ss64 ss76
0.15123306.11222739.html.plaintext.txt	151	In addition loop includes three prolines hCG one hFSH
0.15123306.11222739.html.plaintext.txt	152	Consequently conformation ssL3 hFSH curved ss hairpin hCG resulting shift toward concave surface heterodimer nearer area ss subunit carboxy terminus Fig
0.15123306.11222739.html.plaintext.txt	153	The distances corresponding residues loop large 6
0.15123306.11222739.html.plaintext.txt	154	The amino acid sequences ssL1 hFSH hCG quite similar Fig
0.15123306.11222739.html.plaintext.txt	155	5C conformation loop also similar
0.15123306.11222739.html.plaintext.txt	156	However loop moves much 3
0.15123306.11222739.html.plaintext.txt	157	9 A toward concave side molecule hFSH concert ssL3 two loops tied together disulfide bridge ssCys17 ssCys66
0.15123306.11222739.html.plaintext.txt	158	These conformational changes also correlated conformational changes L2 C terminus ss subunit discussed
0.15123306.11222739.html.plaintext.txt	159	View larger version 19K Figure 7
0.15123306.11222739.html.plaintext.txt	160	Overlap Selected Areas hFSH2 green ss blue hCG orange ss magenta
0.15123306.11222739.html.plaintext.txt	161	The conformation adopted ssL3 different two hormones due significant sequence differences
0.15123306.11222739.html.plaintext.txt	162	Although overall sequence conformation ssL1 similar hFSH hCG tethering ssL1 ssL3 disulfide bridge results concerted movement two loops
0.15123306.11222739.html.plaintext.txt	163	Sequence variation respect charged residues area results negatively charged patch one side cystine noose hFSH several positively charged residues hCG
0.15123306.11222739.html.plaintext.txt	164	This loop may important receptor discrimination
0.15123306.11222739.html.plaintext.txt	165	c The solvent exposed hydrophobic patch area L1 L3 ssL2
0.15123306.11222739.html.plaintext.txt	166	The size shape patch differs hFSH hCG
0.15123306.11222739.html.plaintext.txt	167	The unusually large hydrophobic surface area suggests importance stabilizing intersubunit interaction possibly receptor binding
0.15123306.11222739.html.plaintext.txt	168	The conformation hCG loop ssL2 quite different either one conformations seen hFSH Fig
0.15123306.11222739.html.plaintext.txt	169	6B two hFSH molecules differ locus much conformation differ hCG Fig
0.15123306.11222739.html.plaintext.txt	170	While difference hFSH hCG part must result differences sequences loop including variation presence proline residues Fig
0.15123306.11222739.html.plaintext.txt	171	5C overall result suggests loop highly flexible GPH
0.15123306.11222739.html.plaintext.txt	172	The cystine noose determinant loop short loop two disulfide linked cysteines ss87 ss94 hFSH ss93 ss100 hCG 24 located toward center concave surface molecule adjacent L2
0.15123306.11222739.html.plaintext.txt	173	Residues cystine noose play role determining specificity hCG receptor 25 FSH receptor 26 binding
0.15123306.11222739.html.plaintext.txt	174	The main chain conformation loop similar hFSH hCG although entire loop shifted 3 A tip Fig
0.15123306.11222739.html.plaintext.txt	175	This shift part global conformational change end molecule also including ssL1 ssL3 L2
0.15123306.11222739.html.plaintext.txt	176	More important conformational differences cystine nooses strikingly different surface charge characteristics
0.15123306.11222739.html.plaintext.txt	177	There three negatively charged residues Asp 88 Asp 90 Asp 93 positively charged residues hFSH hCG two positively charged residues Arg 94 Arg 95 one negatively charged residue Asp 99
0.15123306.11222739.html.plaintext.txt	178	The conserved aspartic acid residues near C terminus cystine noose Asp 93 hFSH Asp 99 hCG similar conformations two hormones
0.15123306.11222739.html.plaintext.txt	179	The structure consistent biochemical data since residue shown essential hFSH activity 7 27 hCG activity
0.15123306.11222739.html.plaintext.txt	180	The three aspartic acid residues hFSH create negatively charged patch one side cystine noose
0.15123306.11222739.html.plaintext.txt	181	In contrast positively charged arginines hCG arranged form charged patch rather side chains directed opposite sides loop Fig
0.15123306.11222739.html.plaintext.txt	182	These observations consistent biochemical data showing neither hFSH Asp 88 Asp 90 essential hFSH binding receptor 27 play role discriminating hFSH hCGLH receptors 26
0.15123306.11222739.html.plaintext.txt	183	5C shows cystine noose ssL3 two areas significant charge differential hFSH hCG
0.15123306.11222739.html.plaintext.txt	184	The possibly significant area ssL2 change case generally charged surface hFSH generally uncharged surface hCG
0.15123306.11222739.html.plaintext.txt	185	The carboxy terminus hFSH ss subunit residues 95 108 adopts different conformation hCG maximum distances equivalent residues 7
0.15123306.11222739.html.plaintext.txt	186	5B 6B hFSH residue ss99
0.15123306.11222739.html.plaintext.txt	187	Specifically loop spanning residues 95 103 hFSH makes tighter turn equivalent loop 101 109 hCG
0.15123306.11222739.html.plaintext.txt	188	Both hFSH molecules identical conformations area despite fact loop hFSH1 involved intermolecular contacts hFSH2
0.15123306.11222739.html.plaintext.txt	189	Therefore differences hFSH hCG caused divergent sequences area Fig
0.15123306.11222739.html.plaintext.txt	190	Biochemical data indicate ss subunit carboxy terminus plays role hFSH receptor binding alanine substitution three residues Arg97 Gly98 Leu99 27 well replacement hFSH residues 95 100 corresponding residues human LH hLH 26 diminishes hFSH receptor binding
0.15123306.11222739.html.plaintext.txt	191	However swapping hLH residues hFSH residues locus allow LH receptor binding hFSH LH chimera 26
0.15123306.11222739.html.plaintext.txt	192	The biochemical data consistent structure residues clearly adopt different conformation allowing differential recognition appropriate receptor
0.15123306.11222739.html.plaintext.txt	193	However changes region alone sufficient change receptor specificity hormone
0.15123306.11222739.html.plaintext.txt	194	Comparison structures hFSH hCG indicate glycosylation global effect glycohormone conformations
0.15123306.11222739.html.plaintext.txt	195	Although conformation insect cell expressed fully active hFSH differs significantly extensively deglycosylated HF treated hCG several loops none differences directly correlated differences glycosylation
0.15123306.11222739.html.plaintext.txt	196	The structure hFSH reveals one likely mechanism oligosaccharide contributes heterodimer stability 17
0.15123306.11222739.html.plaintext.txt	197	The nitrogen atom acetamido group Asn proximal GlcNAc Asn52 forms hydrogen bond hydroxyl group ssTyr58 thereby adding additional intersubunit contact
0.15123306.11222739.html.plaintext.txt	198	In hCG equivalent residue Phe64 incapable forming similar hydrogen bond able make hydrophobic interaction hydrophobic side sugar ring
0.15123306.11222739.html.plaintext.txt	199	3 report contacts Asn52 carbohydrate residues ssTyr59 ssVal62 ssPhe64 ssAla83 ssThr97
0.15123306.11222739.html.plaintext.txt	200	While single additional hydrogen bond observed hFSH structure may adequate explain higher stability glycosylated heterodimer quite possible sugar groups fully defined electron density map make additional contacts
0.15123306.11222739.html.plaintext.txt	201	A propeller shaped triad aromatic residues Phe17 Phe74 ssTyr39 together Pro16 Phe18 Met71 forms solvent exposed hydrophobic patch end hFSH heterodimer composed loops L1 L3 ssL2 Fig
0.15123306.11222739.html.plaintext.txt	202	This region includes three charged residues Lys75 ssLys40 ssAsp41 directed away hydrophobic patch
0.15123306.11222739.html.plaintext.txt	203	In hCG ssLeu45 replaces hFSH ssTyr 39 patch smaller difference conformation ssL2 loop
0.15123306.11222739.html.plaintext.txt	204	This area may play major role receptor binding
0.15123306.11222739.html.plaintext.txt	205	Although relevance L1 loop hFSH residues 14 27 evaluated mutagenesis studies epitope mapping monoclonal antibodies revealed discontinuous immunoneutralizing epitope comprised residues 11 27 61 92 29 30
0.15123306.11222739.html.plaintext.txt	206	Mutational analysis Phe74 revealed modest decrease hFSH binding receptor
0.15123306.11222739.html.plaintext.txt	207	In contrast importance L1 L3 alanine scanning mutagenesis shown ssL2 residues 33 53 essential hFSH binding receptor 31
0.15123306.11222739.html.plaintext.txt	208	Rather ssL2 appears important stabilizing heterodimer association 32
0.15123306.11222739.html.plaintext.txt	209	The subunit carboxy terminus implicated receptor binding hCG 33 34 35 hFSH 36 TSH 37
0.15123306.11222739.html.plaintext.txt	210	Clearly region flexible hFSH adopts different conformations hFSH1 hFSH2 electron density lacking last two residues 91 92
0.15123306.11222739.html.plaintext.txt	211	This makes difficult draw conclusions region involved receptor binding
0.15123306.11222739.html.plaintext.txt	212	The clear difference hFSH hCG formation hydrogen bond side chain NH Arg95 cystine noose hCG carbonyl oxygen 89 constraining conformational flexibility hCG
0.15123306.11222739.html.plaintext.txt	213	This bond possible hFSH structure hFSH carboxy terminus close cystine noose
0.15123306.11222739.html.plaintext.txt	214	This difference conformation interesting context receptor interaction residues carboxy terminus subunit essential hFSH hCG binding 34 35 36
0.15123306.11222739.html.plaintext.txt	215	Conclusion The overall structures hFSH hCG similar several intriguing differences observed specific loops especially ss subunit
0.15123306.11222739.html.plaintext.txt	216	The largest difference one end molecule ssL1 ssL3 move together toward concave side molecule hFSH compared hCG
0.15123306.11222739.html.plaintext.txt	217	In addition ssL3 loop different conformation result major differences amino acid sequence
0.15123306.11222739.html.plaintext.txt	218	Currently biological data available regarding importance loops receptor binding signal transduction
0.15123306.11222739.html.plaintext.txt	219	The three areas different conformations ss carboxy terminal loop cystine noose hydrophobic patch area loops L1 L3 ssL2 also different surface characteristics
0.15123306.11222739.html.plaintext.txt	220	In addition several residues areas shown scanning alanine mutagenesis epitope mapping play role receptor binding Fig
0.15123306.11222739.html.plaintext.txt	221	Interestingly ss carboxy terminal loop cystine noose ssL1 ssL3 loops located concave side heterodimer Fig
0.15123306.11222739.html.plaintext.txt	222	8 resulting face different two gonadotropins
0.15123306.11222739.html.plaintext.txt	223	These differences therefore likely important discrimination hFSH hCG respective receptors
0.15123306.11222739.html.plaintext.txt	224	View larger version 29K Figure 8
0.15123306.11222739.html.plaintext.txt	225	Ribbon Image Structure hFSH Highlighting Areas Interest
0.15123306.11222739.html.plaintext.txt	226	Magenta areas known biological importance structural differences hCG blue areas biological significance defined conformational difference hCG yellow areas conformational differences hFSH hCG without known biological relevance
0.15123306.11222739.html.plaintext.txt	227	Residues known important hFSH receptor binding shown Lys51 L2 Ser85 Thr86 Tyr88 Tyr89 carboxy terminus subunit blue Asp93 red ss carboxy terminal loop
0.15123306.11222739.html.plaintext.txt	228	The residues forming exposed hydrophobic patch shown green
0.15123306.11222739.html.plaintext.txt	229	All areas interest except hydrophobic patch located concave surface molecule
0.15123306.11222739.html.plaintext.txt	230	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS AND DISCUSSION MATERIALS AND METHODS REFERENCES Preparation hFSH Isoform ssT26A Site directed mutagenesis experiments aimed elimination hFSHss glycosylation site 2 performed previously described hFSH mutants 36
0.15123306.11222739.html.plaintext.txt	231	The oligonucleotide used create mutation 5 A AGC ATC AAC ACC GCT TGG TGT GCT GGC 3
0.15123306.11222739.html.plaintext.txt	232	Production Recombinant hFSH Production recombinant hFSH insect cells carried using procedures previously described 26 31
0.15123306.11222739.html.plaintext.txt	233	Each production run consisted 30 roller bottles seeded 1 x 108 Hi5 cells kept 27 C 48 h
0.15123306.11222739.html.plaintext.txt	234	At time virus added directly flask 1
0.15123306.11222739.html.plaintext.txt	235	0 MOI multiplicity infection hFSHssT26A virus 3
0.15123306.11222739.html.plaintext.txt	236	5 MOI hFSH virus flasks rotated additional 4 5 days
0.15123306.11222739.html.plaintext.txt	237	Next media collected centrifugation 1 liter bottles 2500 x g 10 min
0.15123306.11222739.html.plaintext.txt	238	The clarified media pooled made 1
0.15123306.11222739.html.plaintext.txt	239	0 mM phenylmethylsulfonyl fluoride 0
0.15123306.11222739.html.plaintext.txt	240	Typically recombinant hFSH ssT26A expressed levels 2
0.15123306.11222739.html.plaintext.txt	241	7 mgliter n 9 determined enzyme linked immunosorbent assay ELISA 32
0.15123306.11222739.html.plaintext.txt	242	Media typically 4 liters concentrated 4 C utilizing Amicon Waltham MA radial flow cartridge 10000 mwc volume 200 ml frozen processed
0.15123306.11222739.html.plaintext.txt	243	The concentrate thawed clarified centrifugation 16000 x g 30 min applied affinity column without processing
0.15123306.11222739.html.plaintext.txt	244	Preparation Affinity Support An affinity column prepared using monoclonal antibody mAb 46
0.15123306.11222739.html.plaintext.txt	245	This antibody binds monomeric ss subunit native hFSH heterodimeric hormone measurable cross reactivity subunit hLH 19 38
0.15123306.11222739.html.plaintext.txt	246	B7 expanded ascites tumors mice Animal Welfare Committee Approval obtained studies
0.15123306.11222739.html.plaintext.txt	247	B7 ascitic fluid diluted 13 PBS subjected ammonium sulfate precipitation follows
0.15123306.11222739.html.plaintext.txt	248	Saturated ammonium sulfate pH 7
0.15123306.11222739.html.plaintext.txt	249	2 added diluted ascitic fluid ratio 4
0.15123306.11222739.html.plaintext.txt	250	5 volumes ammonium sulfate solution 5
0.15123306.11222739.html.plaintext.txt	251	The mixture stirred 4 C 30 min antibody precipitate collected centrifugation 5 858 x g 15 min
0.15123306.11222739.html.plaintext.txt	252	Each precipitate dissolved PBS reprecipitated twice
0.15123306.11222739.html.plaintext.txt	253	Wet pellets dissolved dialyzed 0
0.15123306.11222739.html.plaintext.txt	254	Dialyzed samples clarified centrifugation pH conductivity adjusted buffer values sample applied 1
0.15123306.11222739.html.plaintext.txt	255	9 x 18 cm diethylaminoethyl DEAE Sephacel column
0.15123306.11222739.html.plaintext.txt	256	Antibody eluted gradient 0
0.15123306.11222739.html.plaintext.txt	257	The procedure used coupling DEAE Sephacel purified antibody 100 mg CNBr activated Sepharose exactly described manufacturer Pharmacia Biotech Piscataway NJ
0.15123306.11222739.html.plaintext.txt	258	Purification hFSH ssT26A Concentrates conditioned media collected cells producing hFSH ssT26A applied directly affinity support
0.15123306.11222739.html.plaintext.txt	259	The sample buffer column buffer 0
0.15123306.11222739.html.plaintext.txt	260	1 M potassium phosphate made 0
0.15123306.11222739.html.plaintext.txt	261	The absorbance 275 nm fractions determined procedure
0.15123306.11222739.html.plaintext.txt	262	After decrease absorbance baseline elution buffer 0
0.15123306.11222739.html.plaintext.txt	263	5 M NaCl pumped column
0.15123306.11222739.html.plaintext.txt	264	Fractions collected tubes containing 2
0.15123306.11222739.html.plaintext.txt	265	0 M Tris base mixed neutralize fraction
0.15123306.11222739.html.plaintext.txt	266	Biological Characterization hFSH ssT26A Heterodimer Recombinant hFSH ssT26A compared wild type hFSH RRA using CHO cells stably expressing hFSH receptors 36 39
0.15123306.11222739.html.plaintext.txt	267	Signal transduction induced hFSH ssT26A determined measuring progesterone 36 cAMP 38 production Y1 cells stably express hFSH receptors 39
0.15123306.11222739.html.plaintext.txt	268	Protein Crystallization Crystals ssT26A hFSH grown macroseeding drops containing 3 microl protein 9 mgml 10 mM Tris pH 7 1 microl reservoir solution
0.15123306.11222739.html.plaintext.txt	269	The reservoir solution 100 mM glycine pH 9
0.15123306.11222739.html.plaintext.txt	270	Data Collection Structure Determination The crystals transferred solution consisting crystallization buffer enriched 25 wtvol sucrose flash cooling liquid nitrogen
0.15123306.11222739.html.plaintext.txt	271	The crystals highly sensitive addition heavy atom compounds
0.15123306.11222739.html.plaintext.txt	272	Crystals tolerated soaking heavy atom solutions 10 h heavy atom compounds especially platinum mercury compounds resulting significant degradation diffraction quality little 2 h
0.15123306.11222739.html.plaintext.txt	273	Data collected Stanford Synchrotron Radiation Laboratory SSRL Beamline B9
0.15123306.11222739.html.plaintext.txt	274	1 processed MOSFLM 40 scaled merged SCALA 40 Table 1
0.15123306.11222739.html.plaintext.txt	275	Initial MIRAS phases calculated using SOLVE 41 Table 1
0.15123306.11222739.html.plaintext.txt	276	The correct space group enantiomer determining examining figure merit FOM space groups hand
0.15123306.11222739.html.plaintext.txt	277	This clearly indicated P41212 correct space group FOM 0
0.15123306.11222739.html.plaintext.txt	278	43 positive hand correct
0.15123306.11222739.html.plaintext.txt	279	All four derivatives relatively weak phasing power due low occupancy sites platinum osmium derivatives similar
0.15123306.11222739.html.plaintext.txt	280	However solvent flattening CCP4 program DM 40 greatly improved quality phases high solvent content crystals 80
0.15123306.11222739.html.plaintext.txt	281	MIRAS phasing program SOLVE resulted overall FOM 0
0.15123306.11222739.html.plaintext.txt	282	After solvent flattening electron density clearly showed two molecules asymmetric unit
0.15123306.11222739.html.plaintext.txt	283	Structure Refinement An initial model built MIRASsolvent flattened electron density map
0.15123306.11222739.html.plaintext.txt	284	Rounds simulated annealing refinement using torsion angle dynamics option CNS 42 followed phase combination SIGMAA 40 rebuilding O 43 early stages refinement
0.15123306.11222739.html.plaintext.txt	285	Once majority sequence placed model composite omit maps CNS used rebuilding effort reduce model bias
0.15123306.11222739.html.plaintext.txt	286	The quality model monitored throughout PROCHECK 44
0.15123306.11222739.html.plaintext.txt	287	Grouped temperature factor refinement main chain atoms residue formed one group side chain atoms formed second group used later stages refinement
0.15123306.11222739.html.plaintext.txt	288	Thermal parameters exceeded 100 A2 reset value refinement
0.15123306.11222739.html.plaintext.txt	289	Experiments done using NCS constraints restraints tether two molecules asymmetric unit cases caused Rfree increase
0.15123306.11222739.html.plaintext.txt	290	The final hFSH structure R value 25
0.15123306.11222739.html.plaintext.txt	291	The model contains 2992 protein atoms 14 carbohydrate residues 2 sulfate ions
0.15123306.11222739.html.plaintext.txt	292	3 residues favored regions Ramachandran plot three residues 0
0.15123306.11222739.html.plaintext.txt	293	9 loops disallowed regions
0.15123306.11222739.html.plaintext.txt	294	values ideality protein follows bonds 0
0.15123306.11222739.html.plaintext.txt	295	Structure ComparisonsSurface Area Calculations Protein structures compared using LSQMAN 45 values quoted text results comparing regions structure entire structure superimposed least squares fitting carbon atoms
0.15123306.11222739.html.plaintext.txt	296	Solvent accessible surface area calculated using CNS 1
0.15123306.11222739.html.plaintext.txt	297	ACKNOWLEDGMENTS We thank Carrie Arnold Smita D
0.15123306.11222739.html.plaintext.txt	298	Mahale Maria Patrascu Barbara Sheppard Yiqiu Zhang assistance hFSH ssT26A hFSH expression purification characterization Xiaochun Ding assistance crystallization experiments Jeffrey A
0.15123306.11222739.html.plaintext.txt	299	Waddling assistance data collection SSRL
0.15123306.11222739.html.plaintext.txt	300	The authors gratefully acknowledge support Wadsworth Center Core Facilities including Molecular Genetics Amino Acid Analysis Sequencing Facilities well Wadsworth Center Tissue Culture Facility
0.15123306.11222739.html.plaintext.txt	301	FOOTNOTES Address requests reprints Patrick Van Roey James Dias Wadsworth Center P
0.15123306.11222739.html.plaintext.txt	302	Box 509 Albany New York 12201 0509
0.15123306.11222739.html.plaintext.txt	303	org u d james
0.15123306.11222739.html.plaintext.txt	304	This research supported NIH Grants HD 18407 J
0.15123306.11222739.html.plaintext.txt	305	grant ARES Advanced TechnologiesSerono
0.15123306.11222739.html.plaintext.txt	306	The x ray crystallography facilities SSRL funded Department Energy National Institutes Health
0.15123306.11222739.html.plaintext.txt	307	Received publication June 30 2000
0.15123306.11222739.html.plaintext.txt	308	Revision received August 29 2000
0.15123306.11222739.html.plaintext.txt	309	Accepted publication September 19 2000
0.15123306.11222739.html.plaintext.txt	310	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS AND DISCUSSION MATERIALS AND METHODS REFERENCES Pierce JG Parsons TF 1981 Glycoprotein hormones structure function
0.15123306.11222739.html.plaintext.txt	311	Annu Rev Biochem 50465 495CrossRefMedline Parsons TF Strickland TW Pierce JG 1985 Disassembly assembly glycoprotein hormones
0.15123306.11222739.html.plaintext.txt	312	Methods Enzymol 109736 749Medline Lapthorn AP Harris DC Littlejohn A Lustbader JW Canfield RE Machin KJ Morgan FJ Isaacs NW 1994 Crystal structure human chorionic gonadotropin
0.15123306.11222739.html.plaintext.txt	313	Nature 369455 461CrossRefMedline Wu H Lustbader JW Liu Y Canfield RE Hendrickson WA 1994 Structure human chorionic gonadotropin 2
0.15123306.11222739.html.plaintext.txt	314	6 A resolution MAD analysis selenomethionyl protein
0.15123306.11222739.html.plaintext.txt	315	Structure 2545 558Medline Simoni M Gromoll J Nieschlag E 1997 The follicle stimulating hormone receptor biochemistry molecular biology physiology pathophysiology
0.15123306.11222739.html.plaintext.txt	316	Endocr Rev 18739 773AbstractFree Full Text Milgrom E de Roux N Ghinea N Beau I Loosfelt H Vannier B Savouret JF Misrahi M 1997 Gonadotrophin thyrotrophin receptors
0.15123306.11222739.html.plaintext.txt	317	Horm Res 48Suppl 433 37 Dias JA Lindau Shepard B Hauer C Auger I 1998 Human follicle stimulating hormone structure activity relationships
0.15123306.11222739.html.plaintext.txt	318	Biol Reprod 581331 1336Medline Chappel S Buckler D Kelton C Tayar NE 1998 Follicle stimulating hormone receptor future perspectives
0.15123306.11222739.html.plaintext.txt	319	Hum Reprod 13Suppl 318 35 discussion 47 51 Grossmann M Leitolf H Weintraub BD Szkudlinski MW 1998 A rational design strategy protein hormone superagonists
0.15123306.11222739.html.plaintext.txt	320	Nat Biotechnol 16871 875Medline Baenzinger JU 1994 Glycosylation glycoprotein hormone function
0.15123306.11222739.html.plaintext.txt	321	In Lustbader JW Puett D Ruddon RW eds Glycoprotein Hormones Structure Function Clinical Implications
0.15123306.11222739.html.plaintext.txt	322	Springer Verlag New York pp 167 174 Ulloa Aguirre A Midgley Jr AR Beitins IZ Padmanabhan V 1995 Follicle stimulating isohormones characterization physiological relevance
0.15123306.11222739.html.plaintext.txt	323	Endocr Rev 16765 787Medline Ulloa Aguirre A Timossi C 1998 Structure function relationship follicle stimulating hormone receptor
0.15123306.11222739.html.plaintext.txt	324	Hum Reprod Update 4260 283AbstractFree Full Text Szkudlinski MW Thotakura NR Tropea JE Grossmann M Weintraub BD 1995 Asparagine linked oligosaccharide structures determine clearance organ distribution pituitary recombinant thyrotropin
0.15123306.11222739.html.plaintext.txt	325	Endocrinology 1363325 3330Abstract Ulloa Aguirre A Timossi C Damian Matsumura P Dias JA 1999 Role glycosylation function follicle stimulating hormone
0.15123306.11222739.html.plaintext.txt	326	Endocrine 11205 215CrossRefMedline Feng W Matzuk MM Mountjoy K Bedows E Ruddon RW Boime I 1995 The asparagine linked oligosaccharides human chorionic gonadotropin ss subunit facilitate correct disulfide bond pairing
0.15123306.11222739.html.plaintext.txt	327	J Biol Chem 27011851 11859AbstractFree Full Text van Zuylen CW Kamerling JP Vliegenthart JF 1997 Glycosylation beyond Asn78 linked GlcNAc residue significant enhancing effect stability subunit human chorionic gonadotropin
0.15123306.11222739.html.plaintext.txt	328	Biochem Biophys Res Commun 232117 120CrossRefMedline Heikoop JC van den Boogaart P de Leeuw R Mulders JW Grootenhuis PD 1998 Partially deglycosylated human choriogonadotropin stabilized intersubunit disulfide bonds shows full bioactivity
0.15123306.11222739.html.plaintext.txt	329	Eur J Biochem 253354 356Abstract Tegoni M Spinelli S Verhoeyen M Davis P Cambillau C 1999 Crystal structure ternary complex human corionic gonadotropin hCG two Fv fragments specific ss subunits
0.15123306.11222739.html.plaintext.txt	330	J Mol Biol 2891375 1385CrossRefMedline Weiner RS Dias JA Andersen TT 1991 Epitope mapping human follicle stimulating hormone using monoclonal antibody 3A identifies potential receptor binding sequence
0.15123306.11222739.html.plaintext.txt	331	Endocrinology 1281485 1495Abstract Isaacs NW 1995 Cystine knots
0.15123306.11222739.html.plaintext.txt	332	Curr Opin Struct Biol 5391 395CrossRefMedline Sun PD Davies DR 1995 The cystine knot growth factor superfamily
0.15123306.11222739.html.plaintext.txt	333	Annu Rev Biophys Biomol Struct 24269 291CrossRefMedline Rathnam P Tolvo A Saxena BB 1982 Elucidation disulfide bond positions ss subunit human follicle stimulating hormone
0.15123306.11222739.html.plaintext.txt	334	Biochim Biophys Acta 708160 166Medline Fujiki Y Rathnam P Saxena BB 1980 Studies disulfide bonds human pituitary follicle stimulating hormone
0.15123306.11222739.html.plaintext.txt	335	Biochim Biophys Acta 624428 435Medline Lapthorn AJ Janes RW Isaacs NW Wallace BA 1995 Cystine nooses protein specificity
0.15123306.11222739.html.plaintext.txt	336	Nat Struct Biol 2266 268Medline Campbell RK Dean Emig DM Moyle WR 1991 Conversion human choriogonadotropin follitropin protein engineering
0.15123306.11222739.html.plaintext.txt	337	Proc Natl Acad Sci USA 88760 764Abstract Dias JA Zhang Y Liu X 1994 Receptor binding functional properties chimeric human follitropin prepared exchange small hydrophilic intercysteine loop human follitropin human lutropin
0.15123306.11222739.html.plaintext.txt	338	J Biol Chem 26925289 25294AbstractFree Full Text Lindau Shepard B Roth KE Dias JA 1994 Identification amino acids C terminal region human follicle stimulating hormone FSH ss subunit involved binding human FSH receptor
0.15123306.11222739.html.plaintext.txt	339	Endocrinology 1351235 1240Abstract Chen F Wang Y Puett D 1991 Role invariant aspartic acid 99 human choriogonadotropin ss receptor binding biological activity
0.15123306.11222739.html.plaintext.txt	340	J Biol Chem 26619357 19361AbstractFree Full Text Szkudlinski MW Teh NG Grossmann M Tropea JE Weintraub BD 1996 Engineering human glycoprotein hormone superactive analogs
0.15123306.11222739.html.plaintext.txt	341	Nat Biotechnol 141257 1263Medline Weiner RS Dias JA 1992 Identification assembled epitopes subunit human follicle stimulating hormone
0.15123306.11222739.html.plaintext.txt	342	Mol Cell Endocrinol 8541 52CrossRefMedline Roth KE Dias JA 1995 Scanning alanine mutagenesis long loop residues 33 53 follicle stimulating hormone ss subunit
0.15123306.11222739.html.plaintext.txt	343	Mol Cell Endocrinol 109143 149CrossRefMedline Roth KE Dias JA 1996 Follitropin conformational stability mediated loop 2 ss effects follitropin receptor interaction
0.15123306.11222739.html.plaintext.txt	344	Biochemistry 357928 7935CrossRefMedline Chen F Wang Y Puett D 1992 The carboxy terminal region glycoprotein hormone subunit contributions receptor binding signaling human chorionic gonadotropin
0.15123306.11222739.html.plaintext.txt	345	Mol Endocrinol 6914 919Abstract Yoo J Zeng H Ji I Murdoch WJ Ji TH 1993 COOH terminal amino acids subunit play common different roles human choriogonadotropin follitropin
0.15123306.11222739.html.plaintext.txt	346	J Biol Chem 26813034 13042AbstractFree Full Text Zeng H Ji I Ji TH 1995 Lys91 His90 subunit crucial receptor binding hormone action follicle stimulating hormone FSH play hormone specific roles FSH human chorionic gonadotropin
0.15123306.11222739.html.plaintext.txt	347	Endocrinology 1362948 2953Abstract Arnold CJ Liu C Lindau Shepard B Losavio ML Patrascu MT Dias JA 1998 The human follitropin subunit C terminus collaborates ss subunit cystine noose subunit loop assemble receptor binding domain competent signal transduction
0.15123306.11222739.html.plaintext.txt	348	Biochemistry 371762 1768CrossRefMedline Grossmann M Szkudlinski MW Zeng H Kraiem Z Ji I Tropea JE Ji TH Weintraub BD 1995 Role carboxy terminal residues subunit expression bioactivity human thyroid stimulating hormone
0.15123306.11222739.html.plaintext.txt	349	Mol Endocrinol 9948 958Abstract Roth KE Liu C Shepard BA Shaffer JB Dias JA 1993 The flanking amino acids human follitropin ss subunit 33 53 region involved assembly follitropin heterodimer
0.15123306.11222739.html.plaintext.txt	350	Endocrinology 1322571 2577Abstract Kelton CA Cheng SV Nugent NP Schweickhardt RL Rosenthal JL Overton SA Wands GD Kuzeja JB Luchette CA Chappel SC 1992 The cloning human follicle stimulating hormone receptor expression COS 7 CHO Y 1 cells
0.15123306.11222739.html.plaintext.txt	351	Mol Cell Endocrinol 89141 151CrossRefMedline CCP4 1994 Collaborative Computing Project No
0.15123306.11222739.html.plaintext.txt	352	The CCP4 suite programs protein crystallography
0.15123306.11222739.html.plaintext.txt	353	Acta Crystallogr D 50760 763CrossRef Terwilliger TC Berendzen J 1999 Automated MAD MIR structure solution
0.15123306.11222739.html.plaintext.txt	354	Acta Crystallogr D 55849 861CrossRefMedline Brunger A Adams P Clore G DeLano W Gros P Grosse Kunstleve R Jiang J Kuszewski J Nilges M Pannu N Read R Rice L Simonson T Warren G 1998 Crystallography NMR system new software suite macromolecular structure determination
0.15123306.11222739.html.plaintext.txt	355	Acta Crystallogr D 54905 921CrossRefMedline Jones TA Zou JY Cowan SW Kjeldgaard M 1991 Improved methods building protein models electron density maps location errors maps
0.15123306.11222739.html.plaintext.txt	356	Acta Crystallogr A 47110 119CrossRefMedline Laskowski RA McArthur MW Moss DS Thornton JM 1993 PROCHECK program check stereochemical quality protein structures
0.15123306.11222739.html.plaintext.txt	357	J Appl Crystallogr 26282 291CrossRef Kleywegt G 1999 Experimental assessment differences related protein crystal structures
0.15123306.11222739.html.plaintext.txt	358	Acta Crystallogr D 551878 84CrossRefMedline Evans SV 1993 SETOR hardware highlighted three dimensional solid model representation macromolecules
0.15123306.11222739.html.plaintext.txt	359	J Mol Graph 11134 138CrossRefMedline Kraulis PJ 1991 MOLSCRIPT program produce detailed schematic plots protein structures
0.15123306.11222739.html.plaintext.txt	360	J Appl Crystallogr 24946 950CrossRef
0.15107806.9024688.html.plaintext.txt	0	A Multistep ATP dependent Pathway Assembly Human Immunodeficiency Virus Capsids Cell free System
0.15107806.9024688.html.plaintext.txt	1	Hill Mei Lie Wong Ramanujan S
0.15107806.9024688.html.plaintext.txt	2	Department Physiology Department Medicine Department Biochemistry HHMI University California San Francisco California 94143 0444 Abstract Materials Methods Results Discussion Footnotes Acknowledgements Abbreviations used paper References
0.15107806.9024688.html.plaintext.txt	3	To understand mechanism human immunodeficiency virus type 1 HIV capsids formed reconstituted assembly immature HIV capsids de novo cell free system
0.15107806.9024688.html.plaintext.txt	4	Capsid authenticity established multiple biochemical morphologic criteria
0.15107806.9024688.html.plaintext.txt	5	Known features assembly process closely reproduced indicating fidelity cell free reaction
0.15107806.9024688.html.plaintext.txt	6	Assembly separated co posttranslational phases three independent posttranslational requirements demonstrated ATP b detergent sensitive host factor c detergent insensitive host subcellular fraction depleted reconstituted
0.15107806.9024688.html.plaintext.txt	7	Assembly appears proceed way multiple intermediates whose conversion completed capsids blocked either ATP depletion treatment nondenaturing detergent
0.15107806.9024688.html.plaintext.txt	8	Specific subsets intermediates accumulate upon expression various assembly defective Gag mutants cell free system suggesting mutant blocked particular step assembly
0.15107806.9024688.html.plaintext.txt	9	Furthermore accumulation complexes similar sizes cells expressing corresponding mutants suggests comparable intermediates may exist vivo
0.15107806.9024688.html.plaintext.txt	10	From data propose multi step pathway biogenesis HIV capsids assembly process disrupted number discrete points
0.15107806.9024688.html.plaintext.txt	11	The protein shell human immunodeficiency virus type 1 HIV1 virion termed HIV capsid core composed 1500 copies Pr55 Gag structural protein precursor review see Gelderblom 1991
0.15107806.9024688.html.plaintext.txt	12	For proper assembly capsid occur Pr55 chains must undergo myristoylation Gheysen et al
0.15107806.9024688.html.plaintext.txt	13	1989 NH2 terminal modification thought occur co translationally Towler et al
0.15107806.9024688.html.plaintext.txt	14	The myristoylated chains targeted host plasma membrane assembly takes place concomitant RNA encapsidation
0.15107806.9024688.html.plaintext.txt	15	As capsids formed bud plasma membrane results envelopment subsequent release viral particles cell
0.15107806.9024688.html.plaintext.txt	16	Coincident events immature viral particles undergo maturation process involving proteolytic processing precursor structural proteins condensation capsids collapsed electron dense cores review see Gelderblom 1991 Wills Craven 1991
0.15107806.9024688.html.plaintext.txt	17	Much knowledge HIV capsid assembly comes studies viral particle formation cultured cells transfected viral genes
0.15107806.9024688.html.plaintext.txt	18	EM studies cells indicated plasma membrane site capsid assembly Gelderblom 1991 Wills Craven 1991
0.15107806.9024688.html.plaintext.txt	19	Analysis various mutants Pr55 revealed key domains required efficient capsid assembly targeting plasma membrane Gheysen et al
0.15107806.9024688.html.plaintext.txt	20	1993 Wang Barklis 1993 Hockley et al
0.15107806.9024688.html.plaintext.txt	21	However actual mechanisms involved coordinating formation HIV capsid 1500 Gag monomers elucidated
0.15107806.9024688.html.plaintext.txt	22	Many important questions HIV capsid assembly remain unanswered including whether assembly energy dependent process whether host proteins required assembly take place whether assembly proceeds way discrete intermediates
0.15107806.9024688.html.plaintext.txt	23	A major obstacle addressing questions experimentally inherent difficulty studying capsid assembly cellular systems
0.15107806.9024688.html.plaintext.txt	24	In cells many events question proceed extremely rapidly readily amenable manipulation making difficult identify trans acting factors energy substrates may required assembly
0.15107806.9024688.html.plaintext.txt	25	Development cell free system recreates capsid biogenesis would greatly facilitate biochemical dissection mechanistic understanding capsid formation
0.15107806.9024688.html.plaintext.txt	26	In study report development cell free system assembly immature HIV capsids appears reproduce known features capsid structure biogenesis including phenotypes variety assembly competent assembly defective Gag mutants
0.15107806.9024688.html.plaintext.txt	27	We use system demonstrate capsid formation dissociated co posttranslational phases distinct requirements
0.15107806.9024688.html.plaintext.txt	28	The reactions occur posttranslational phase dependent ATP least two independent host factors distinguished sensitivity detergent
0.15107806.9024688.html.plaintext.txt	29	In addition posttranslational phase appears proceed way previously unrecognized assembly intermediates
0.15107806.9024688.html.plaintext.txt	30	Expression Gag mutants defective assembly results accumulation assembly intermediates cell free system
0.15107806.9024688.html.plaintext.txt	31	Similar findings obtained cellular systems
0.15107806.9024688.html.plaintext.txt	32	Together data indicate HIV capsid formation regulated energy dependent multi step process involving trans acting host factors
0.15107806.9024688.html.plaintext.txt	33	Materials Methods Plasmid Constructions
0.15107806.9024688.html.plaintext.txt	34	All plasmid constructions cell free transcription made using PCR standard nucleic acid techniques Sambrook et al
0.15107806.9024688.html.plaintext.txt	35	Plasmid vectors derived SP64 Promega Heidelberg Germany 5 untranslated region Xenopus laevis globin inserted HindIII site Melton et al
0.15107806.9024688.html.plaintext.txt	36	The gag ORF HIV genomic DNA kind gift Jay Levy University California San Francisco CA introduced downstream SP6 promoter globin untranslated region
0.15107806.9024688.html.plaintext.txt	37	The GA mutation made changing glycine position 2 Gag alanine using PCR
0.15107806.9024688.html.plaintext.txt	38	The Pr46 mutant made introducing stop codon gly 435 removes p6 Pr41 stop codon arg 363 COOH terminal region p24
0.15107806.9024688.html.plaintext.txt	39	These truncation mutants comparable described Jowett et al
0.15107806.9024688.html.plaintext.txt	40	To make D2 mutant amino acids gly 250 val 260 deleted Hockley et al
0.15107806.9024688.html.plaintext.txt	41	All changes engineered PCR verified DNA sequencing
0.15107806.9024688.html.plaintext.txt	42	Transcription SP6 polymerase translation transcription products wheat germ extract containing 35Smethionine ICN Biochemicals Irvine CA performed previously described Lingappa et al
0.15107806.9024688.html.plaintext.txt	43	1994 except modifications noted
0.15107806.9024688.html.plaintext.txt	44	Improved assembly obtained wheat germ extract prepared described Erickson Blobel 1983 Lingappa et al
0.15107806.9024688.html.plaintext.txt	45	1994 subjected ultracentrifugation 50000 rpm TLA 100 rotor Beckman Instruments Palo Alto CA 15 min 4 degrees C supernatant used vitro translation Lingappa J
0.15107806.9024688.html.plaintext.txt	46	10 microM myristol CoA MCoA Sigma Chemical Co
0.15107806.9024688.html.plaintext.txt	47	Louis MO added start translation indicated
0.15107806.9024688.html.plaintext.txt	48	Translation reactions ranged volume 20 100 microl incubated 25 degrees C 150 min
0.15107806.9024688.html.plaintext.txt	49	Some reactions adjusted final concentration following agents times indicated figure legends 0
0.15107806.9024688.html.plaintext.txt	50	2 microM emetine Sigma Chemical Co 1
0.15107806.9024688.html.plaintext.txt	51	Results cell free translation assembly reactions repeated using rabbit reticulocyte lysate prepared described previously Merrick 1983
0.15107806.9024688.html.plaintext.txt	52	In pulse chase experiments translation reactions contained 35Scysteine Amersham Corp
0.15107806.9024688.html.plaintext.txt	53	Arlington Heights IL radiolabeling
0.15107806.9024688.html.plaintext.txt	54	4 min translation 3 mM unlabeled cysteine added reaction continued 25 degrees C variable chase times indicated
0.15107806.9024688.html.plaintext.txt	55	A standard curve quantity translation product established immunoblotting cell free translation product standards known concentration Lingappa J
0.15107806.9024688.html.plaintext.txt	56	The amount Pr55 determined interpolation curve
0.15107806.9024688.html.plaintext.txt	57	Cell free reactions diluted ice cold NP40 buffer containing 10 mM TrisAc pH 7
0.15107806.9024688.html.plaintext.txt	58	4 100 mM NaCl 4 mM MgAc 50 mM KAc 1 NP 40 layered onto following gradients
0.15107806.9024688.html.plaintext.txt	59	All sucrose solutions made using buffer
0.15107806.9024688.html.plaintext.txt	60	After centrifugation TLS55 rotor Beckman Instruments 200 microl fractions collected serially top
0.15107806.9024688.html.plaintext.txt	61	Sucrose step gradients batch separation soluble particulate material used Figs
0.15107806.9024688.html.plaintext.txt	62	1 2 4 contained 600 microl 66 sucrose 900 microl 40 sucrose 500 microl 20 sucrose centrifuged 30000 rpm 35 min 4 degrees C
0.15107806.9024688.html.plaintext.txt	63	Particles 500 750 S partition fractions 4 6 collected analysis
0.15107806.9024688.html.plaintext.txt	64	Linear 10 50 sucrose gradients used Fig
0.15107806.9024688.html.plaintext.txt	65	1 centrifuged 30000 rpm 35 min 4 degrees C
0.15107806.9024688.html.plaintext.txt	66	Immature HIV capsids synthesized cell free system resemble authentic capsids biochemical morphologic criteria
0.15107806.9024688.html.plaintext.txt	67	A B Migration capsids velocity sedimentation gradients
0.15107806.9024688.html.plaintext.txt	68	A Cell free translation assembly reactions containing 10 microM MCoA 35S methionine programmed HIV Gag transcript performed described Materials Methods
0.15107806.9024688.html.plaintext.txt	69	At end reaction samples diluted buffer containing 1 NP 40 separated soluble particulate fractions sucrose step gradients
0.15107806.9024688.html.plaintext.txt	70	Material particulate fraction 500 S analyzed variety methods
0.15107806.9024688.html.plaintext.txt	71	Shown analysis particulate fraction velocity sedimentation linear sucrose gradient
0.15107806.9024688.html.plaintext.txt	72	Radiolabeled Pr55 protein gradient fractions visualized SDSPAGE autoradiography
0.15107806.9024688.html.plaintext.txt	73	The autoradiograph shows 10 consecutive fractions gradient top gradient left side
0.15107806.9024688.html.plaintext.txt	74	B Cell culture medium collected transfected Cos cells releasing immature HIV particles
0.15107806.9024688.html.plaintext.txt	75	Virus particles harvested ultracentrifugation 20 sucrose cushion described Materials Methods
0.15107806.9024688.html.plaintext.txt	76	Authentic immature capsids generated treating harvested particles detergent remove envelopes
0.15107806.9024688.html.plaintext.txt	77	These authentic capsids sedimented velocity sedimentation gradient parallel particulate fraction cell free reaction shown A
0.15107806.9024688.html.plaintext.txt	78	Pr55 present fractions visualized immunoblotting
0.15107806.9024688.html.plaintext.txt	79	Fractions displayed order described A
0.15107806.9024688.html.plaintext.txt	80	C D Examination buoyant density
0.15107806.9024688.html.plaintext.txt	81	The particulate fraction cell free reaction C authentic immature capsids D analyzed parallel equilibrium centrifugation CsCl
0.15107806.9024688.html.plaintext.txt	82	Particle density obtained measuring refractive index fraction plotted right ordinate open circles
0.15107806.9024688.html.plaintext.txt	83	Gag polypeptide fractions visualized amount protein determined densitometry bands plotted left ordinate closed circles
0.15107806.9024688.html.plaintext.txt	84	E Examination electron microscopic appearance
0.15107806.9024688.html.plaintext.txt	85	The particulate fraction cell free reaction 1 4 authentic capsids 5 6 incubated EM grids coated antibody HIV Gag
0.15107806.9024688.html.plaintext.txt	86	100 nm particles visualized negative staining
0.15107806.9024688.html.plaintext.txt	87	View Larger Versions Images 28 27 19 18 121K GIF file
0.15107806.9024688.html.plaintext.txt	88	Characteristics HIV capsid assembly reproduced cell free system
0.15107806.9024688.html.plaintext.txt	89	A Co translational myristoylation required capsid assembly
0.15107806.9024688.html.plaintext.txt	90	Cell free translation assembly reactions programmed Gag transcript absence added MCoA 10 microM MCoA added either start reaction 0 90 min reaction translation completed 90
0.15107806.9024688.html.plaintext.txt	91	The detergent treated products cell free reactions separated soluble particulate fractions centrifugation step gradients radiolabeled protein fraction visualized SDS PAGE autoradiography
0.15107806.9024688.html.plaintext.txt	92	The amount radiolabeled Pr55 particulate fraction contains assembled capsids determined densitometry bands expressed percentage total Gag protein synthesized
0.15107806.9024688.html.plaintext.txt	93	The presence MCoA effect total amount Pr55 synthesized
0.15107806.9024688.html.plaintext.txt	94	Values shown average three independent experiments error bars indicate standard error
0.15107806.9024688.html.plaintext.txt	95	B Effect detergent capsid assembly
0.15107806.9024688.html.plaintext.txt	96	Cell free translation assembly reactions containing 10 microM MCoA programmed Gag transcript
0.15107806.9024688.html.plaintext.txt	97	Nikkol nonionic detergent affect protein synthesis added start translation reaction final concentration 0
0.15107806.9024688.html.plaintext.txt	98	At end incubation reactions analyzed amount assembly Fig
0.15107806.9024688.html.plaintext.txt	99	Addition detergent effect total amount Pr55 synthesized
0.15107806.9024688.html.plaintext.txt	100	Values shown average three independent experiments error bars indicate standard error
0.15107806.9024688.html.plaintext.txt	101	View Larger Version Image 32K GIF file
0.15107806.9024688.html.plaintext.txt	102	Both ATP subcellular fraction cell lysate required capsid assembly
0.15107806.9024688.html.plaintext.txt	103	A Effect ATP hydrolysis posttranslational phase capsid assembly
0.15107806.9024688.html.plaintext.txt	104	2 B cell free translation assembly reactions programmed Pr55 presence 10 microM MCoA
0.15107806.9024688.html.plaintext.txt	105	2 microM emetine protein synthesis inhibitor added reactions indicated
0.15107806.9024688.html.plaintext.txt	106	Immediately emetine treatment apyrase enzyme hydrolyzes ATP added concentration 1 U microl one emetine treated reactions
0.15107806.9024688.html.plaintext.txt	107	At end incubation 150 min 1 microl reaction analyzed directly SDS PAGE autoradiographs shown bar graph
0.15107806.9024688.html.plaintext.txt	108	The remainder products analyzed amount assembly described Fig
0.15107806.9024688.html.plaintext.txt	109	Shown bar graph amount Pr55 assembled percentage total Pr55 synthesized reaction
0.15107806.9024688.html.plaintext.txt	110	Values bar graph average three independent experiments error bars indicate standard error
0.15107806.9024688.html.plaintext.txt	111	B Effect assembly depletion reconstitution subcellular fraction
0.15107806.9024688.html.plaintext.txt	112	Wheat germ extract subjected ultracentrifugation described Materials Methods generate HSS HSP HSPd
0.15107806.9024688.html.plaintext.txt	113	The HSS used program cell free translation assembly reactions presence absence 10 microM MCoA indicated
0.15107806.9024688.html.plaintext.txt	114	Each reactions treated protein synthesis inhibitor emetine 50 min
0.15107806.9024688.html.plaintext.txt	115	After HSP HSPd added aliquots reaction indicated bar graph
0.15107806.9024688.html.plaintext.txt	116	All reactions incubated total 150 min
0.15107806.9024688.html.plaintext.txt	117	A 1 microl aliquot removed analyzed directly SDS PAGE shown bar graph
0.15107806.9024688.html.plaintext.txt	118	The remainder reaction analyzed amount assembly described Fig
0.15107806.9024688.html.plaintext.txt	119	2 plotted percentage total Pr55 present reaction
0.15107806.9024688.html.plaintext.txt	120	The values shown bar graph average three independent experiments error bars indicate standard error
0.15107806.9024688.html.plaintext.txt	121	View Larger Version Image 26K GIF file
0.15107806.9024688.html.plaintext.txt	122	Equilibrium centrifugation performed using 2 ml isopycnic CsCl gradients used Fig
0.15107806.9024688.html.plaintext.txt	123	6 microgml centrifuged 50000 rpm 26 h 25 degrees C 200 microl fractions collected
0.15107806.9024688.html.plaintext.txt	124	13 ml 15 60 linear sucrose gradients centrifuged SW40 Ti rotor Beckman Instruments 75 Fig
0.15107806.9024688.html.plaintext.txt	125	3 6 7 35000 rpm 5 degrees C
0.15107806.9024688.html.plaintext.txt	126	Fractions 350 microl collected top gradients using Haake Buchler gradient fractionator processed immediately
0.15107806.9024688.html.plaintext.txt	127	Either aliquots fractions loaded directly SDS PAGE buffer entire fraction precipitated TCA washed ethanol ether previously described Lingappa et al
0.15107806.9024688.html.plaintext.txt	128	1994 SDS PAGE analysis
0.15107806.9024688.html.plaintext.txt	129	SDS PAGE performed using 15 gels gels fluorographed using Enhance Dupont Co
0.15107806.9024688.html.plaintext.txt	130	Radiolabeled products cell free translations visualized autoradiography
0.15107806.9024688.html.plaintext.txt	131	Pulse chase analysis HIV capsid assembly
0.15107806.9024688.html.plaintext.txt	132	A Analysis continuously labeled cell free reaction velocity sedimentation
0.15107806.9024688.html.plaintext.txt	133	Cell free translation assembly Pr55 performed previously described
0.15107806.9024688.html.plaintext.txt	134	Upon completion cell free reaction products diluted 1 NP 40 sample buffer ice analyzed velocity sedimentation 13 ml 15 60 sucrose gradients
0.15107806.9024688.html.plaintext.txt	135	Fractions collected top gradient described Materials Methods amount radiolabeled Pr55 protein fraction determined expressed percentage total Pr55 protein present reaction
0.15107806.9024688.html.plaintext.txt	136	The calculated positions 10 80 150 500 750 S complexes indicated markers see Materials Methods
0.15107806.9024688.html.plaintext.txt	137	750 S represents position authentic immature de enveloped HIV capsids
0.15107806.9024688.html.plaintext.txt	138	B D Analysis pulse chase cell free reaction velocity sedimentation
0.15107806.9024688.html.plaintext.txt	139	Cell free translation assembly Pr55 performed previously described except 35Scysteine used radiolabeling
0.15107806.9024688.html.plaintext.txt	140	At 4 min translation excess unlabeled cysteine added reaction radiolabeling would occur
0.15107806.9024688.html.plaintext.txt	141	Aliquots reaction collected 25 C 150 min D reaction
0.15107806.9024688.html.plaintext.txt	142	1 microl aliquot analyzed SDS PAGE autoradiography reveal total amount radiolabeled Pr55 translation product B arrow present chase time
0.15107806.9024688.html.plaintext.txt	143	The remainder aliquots diluted 1 NP 40 sample buffer ice analyzed velocity sedimentation 13 ml 15 60 sucrose gradients 5 C D respectively manner described 5 A
0.15107806.9024688.html.plaintext.txt	144	View Larger Versions Images 24 15 15 15K GIF file
0.15107806.9024688.html.plaintext.txt	145	Phenotypes known mutations Gag appear reproduced cell free system
0.15107806.9024688.html.plaintext.txt	146	A Diagram mutations within Gag
0.15107806.9024688.html.plaintext.txt	147	Gag polyprotein precursor consists four domains referred p17 p24 p7 p6
0.15107806.9024688.html.plaintext.txt	148	The Pr46 Pr41 mutants constructed introducing stop codon truncation amino acid 435 amino acid 363 respectively
0.15107806.9024688.html.plaintext.txt	149	In D2 mutation amino acids 250 260 deleted
0.15107806.9024688.html.plaintext.txt	150	In GA mutation glycine amino acid 2 substituted alanine thereby blocking myristoylation
0.15107806.9024688.html.plaintext.txt	151	The known phenotypes respect particle release cells expressing mutants indicated right
0.15107806.9024688.html.plaintext.txt	152	B Capsid assembly cell free reactions programmed Gag mutants
0.15107806.9024688.html.plaintext.txt	153	Cell free translation assembly reactions programmed transcript coding Gag mutants described well transcript coding wild type Gag presence absence MCoA labeled WT MCoA respectively
0.15107806.9024688.html.plaintext.txt	154	At end reaction period sample detergent treated fractionated velocity sedimentation 13 ml sucrose gradients analyzed SDS PAGE autoradiography
0.15107806.9024688.html.plaintext.txt	155	The amount radiolabeled translation product position completed 750 S capsids quantitated densitometry expressed reaction percentage total synthesis
0.15107806.9024688.html.plaintext.txt	156	The total amount translation approximately equal reactions
0.15107806.9024688.html.plaintext.txt	157	View Larger Version Image 22K GIF file
0.15107806.9024688.html.plaintext.txt	158	Estimates S values Gag containing complexes seen 13 ml sucrose gradients determined method McEwen 1967 using following formula S I 2t S sedimentation coefficient particle Svedberg units I time integral sucrose separated zone minus time integral sucrose meniscus gradient rotor speed radianssec time sec
0.15107806.9024688.html.plaintext.txt	159	Values I determined particles density 1
0.15107806.9024688.html.plaintext.txt	160	3 gcm3 temperature 5 degrees C according tables published McEwen 1967
0.15107806.9024688.html.plaintext.txt	161	Calculated S values different fractions gradients labeled markers gradient tracing Figs
0.15107806.9024688.html.plaintext.txt	162	Markers BSA 5 S macroglobulin 20 S Hepatitis B Virus capsids 100 S ribosomal subunits 40 S 60 S polysomes 100 S used calibrate gradients confirm calculated S values
0.15107806.9024688.html.plaintext.txt	163	However noted S value assignments Gag containing complex meant approximate estimates allow general description complex interpreted constituting detailed biophysical analysis
0.15107806.9024688.html.plaintext.txt	164	Different assembly defective mutants Gag accumulate different assembly intermediates
0.15107806.9024688.html.plaintext.txt	165	Cell free translation assembly reactions programmed wild type Gag A assembly competent Pr46 truncation mutant B assembly defective Pr41 truncation mutant C assembly defective GA mutant D assemblydefective D2 mutant E
0.15107806.9024688.html.plaintext.txt	166	At end incubation reaction products detergent treated analyzed velocity sedimentation 13 ml sucrose gradients Fig
0.15107806.9024688.html.plaintext.txt	167	The amount radiolabeled translation product fraction determined expressed percentage total synthesis reaction
0.15107806.9024688.html.plaintext.txt	168	View Larger Versions Images 11 11K GIF file
0.15107806.9024688.html.plaintext.txt	169	Gag containing complexes cells transfected wild type Gag assembly defective Gag mutants
0.15107806.9024688.html.plaintext.txt	170	A Cos 1 cells transfected transfection vector encoding Pr55 cDNA described Materials Methods
0.15107806.9024688.html.plaintext.txt	171	4 d later medium cells collected
0.15107806.9024688.html.plaintext.txt	172	Viral particles medium harvested ultracentrifugation 20 sucrose cushion treated detergent remove envelopes
0.15107806.9024688.html.plaintext.txt	173	The transfected cells solubilized detergent generate cell lysate see Materials Methods
0.15107806.9024688.html.plaintext.txt	174	The particles medium right ordinate open circles detergent lysate cells left ordinate closed circles analyzed parallel velocity sedimentation 13 ml 15 60 sucrose gradients Fig
0.15107806.9024688.html.plaintext.txt	175	The amount Pr55 protein fraction gradients determined immunoblotting expressed percentage total Pr55 protein present
0.15107806.9024688.html.plaintext.txt	176	The calculated positions 10 80 150 500 750 S complexes indicated markers see Materials Methods
0.15107806.9024688.html.plaintext.txt	177	750 S represents position authentic immature de enveloped HIV capsids
0.15107806.9024688.html.plaintext.txt	178	B C Cos 1 cells transfected transfection vector encoding Pr41 mutant B D2 mutant C
0.15107806.9024688.html.plaintext.txt	179	Transfected cells lysed detergent lysate analyzed velocity sedimentation 13 ml sucrose gradients A
0.15107806.9024688.html.plaintext.txt	180	The amount capsid protein fraction gradients determined immunoblotting anti Gag antibody expressed percentage total immunoreactive protein present reaction
0.15107806.9024688.html.plaintext.txt	181	View Larger Version Image 14K GIF file
0.15107806.9024688.html.plaintext.txt	182	Preparation HSS HSP HSPd
0.15107806.9024688.html.plaintext.txt	183	Where indicated wheat germ extract centrifuged either 50000 rpm 21 min 100000 rpm 30 min TLA 100 rotor Beckman Instruments
0.15107806.9024688.html.plaintext.txt	184	The supernatant HSS 50000 rpm spin used cellfree translation assembly reactions
0.15107806.9024688.html.plaintext.txt	185	The pellet 100000 rpm spin HSP resuspended 5 x concentration buffer 25 mM Hepes pH 7
0.15107806.9024688.html.plaintext.txt	186	Wheat germ extract adjusted 0
0.15107806.9024688.html.plaintext.txt	187	5 Nikkol subjected ultracentrifugation parallel generate detergent treated high speed pellet HSPd
0.15107806.9024688.html.plaintext.txt	188	This pellet washed twice 200 microl nondetergent buffer remove traces detergent resuspended
0.15107806.9024688.html.plaintext.txt	189	After treatment emetine 50 min 1
0.15107806.9024688.html.plaintext.txt	190	8 microl HSP HSPd added 18 microl cell free reactions programmed HSS
0.15107806.9024688.html.plaintext.txt	191	Control reactions treated volume buffer time
0.15107806.9024688.html.plaintext.txt	192	At end 150 min incubation reactions separated soluble particulate fractions analyzed described
0.15107806.9024688.html.plaintext.txt	193	Transfections Production Authentic Capsids
0.15107806.9024688.html.plaintext.txt	194	Cos 1 cells transfected method Forsayeth Garcia 1994 using plasmids pSVGagRRE R pSVRev Smith et al
0.15107806.9024688.html.plaintext.txt	195	1993 kind gift D
0.15107806.9024688.html.plaintext.txt	196	Rekosh University Virginia Charlottesville VA
0.15107806.9024688.html.plaintext.txt	197	4 d transfection immature HIV particles purified culture medium sedimentation 4 ml 20 sucrose cushion SW 40 rotor 29000 rpm 120 min Mergener et al
0.15107806.9024688.html.plaintext.txt	198	The pellet harvested stored aliquots 80 degrees C treated 1 NP 40 buffer use remove envelopes
0.15107806.9024688.html.plaintext.txt	199	These de enveloped authentic immature HIV capsids used standards analyzed parallel products cell free reactions variety methods including velocity sedimentation equilibrium centrifugation electron microscopy
0.15107806.9024688.html.plaintext.txt	200	Lysate transfected Cos cells prepared solubilizing transfected cells 60 mm plates 700 microl 1 NP 40 buffer
0.15107806.9024688.html.plaintext.txt	201	This detergent lysate passaged 20 times 20 gauge needle clarified centrifugation 10 min 2000 g 150 microl supernatent loaded onto 13 ml gradients analysis described
0.15107806.9024688.html.plaintext.txt	202	Gag polypeptide present fractions visualized immunoblotting monoclonal antibody Gag Dako Santa Barbara CA
0.15107806.9024688.html.plaintext.txt	203	Bound antibody detected using enhanced chemiluminescence system Amersham Intl
0.15107806.9024688.html.plaintext.txt	204	Band density determined described image analysis relative band densities confirmed quantitating films representing different exposure times
0.15107806.9024688.html.plaintext.txt	205	Cell free reactions well authentic capsid standards rapidly separated soluble particulate fractions 2 ml 20 80 linear sucrose gradients centrifugation 10 min 30000 rpm
0.15107806.9024688.html.plaintext.txt	206	Under conditions authentic capsids partition fractions 3 5 determined advance immunoblotting standards Gag antibody
0.15107806.9024688.html.plaintext.txt	207	EM grids glow discharged drop Gag antibody placed grid allowed air dry
0.15107806.9024688.html.plaintext.txt	208	Grids inserted eppendorf tubes containing particulate material sucrose gradients incubated 10 min 4 degrees C allow antibodies bind Gag containing particles
0.15107806.9024688.html.plaintext.txt	209	Grids rinsed water negative staining uranyl acetate performed described Dubochet et al
0.15107806.9024688.html.plaintext.txt	210	The following negative controls analyzed parallel control transfections Cos cells transfected lac Z containing plasmids mock cell free reactions generated programming vitro transcriptions buffer instead gag cDNA using mock transcript cell free translation assembly reactions
0.15107806.9024688.html.plaintext.txt	211	Experiments repeated three additional times single blind fashion
0.15107806.9024688.html.plaintext.txt	212	In experiments microscopist able correctly assign identity sample based presence absence particles
0.15107806.9024688.html.plaintext.txt	213	Autoradiographs digitized using AGFA Focus Color Plus scanner Adobe Photoshop software Adobe Systems Incorporated Mountain View CA
0.15107806.9024688.html.plaintext.txt	214	Mean band densities determined adjusted band size background
0.15107806.9024688.html.plaintext.txt	215	Results Reconstitution Immature HIV Capsid Assembly Cell free System
0.15107806.9024688.html.plaintext.txt	216	Since interested dissecting early steps capsid assembly rather better understood late stage capsid maturation chose study formation immature HIV capsids undergo steps capsid assembly except final protease dependent maturation event
0.15107806.9024688.html.plaintext.txt	217	Assembly immature capsids cells requires expression HIV Pr55 protein Gheysen et al
0.15107806.9024688.html.plaintext.txt	218	However others Sakalian et al
0.15107806.9024688.html.plaintext.txt	219	1996 found standard vitro translation systems consisting cytosolic extract amino acids ATP regenerating system vitro synthesized transcript coding Pr55 Gag fail support assembly HIV capsids data shown
0.15107806.9024688.html.plaintext.txt	220	Since assembly HIV capsids well assembly retroviral capsids known require myristoylation Gag Gheysen et al
0.15107806.9024688.html.plaintext.txt	221	1989 well targeting Gag membranes Jacobs et al
0.15107806.9024688.html.plaintext.txt	222	1989 Bryant Ratner 1990 Rhee Hunter 1990 Wang Barklis 1993 Platt Haffar 1994 Hockley et al
0.15107806.9024688.html.plaintext.txt	223	1994 modified standard system ensure events take place
0.15107806.9024688.html.plaintext.txt	224	MCoA added reaction cellular extracts fractionated optimize capsid assembly
0.15107806.9024688.html.plaintext.txt	225	Translation transcript encoding Gag cell free system resulted synthesis 2 ng Pr55 protein microl translation reaction data shown
0.15107806.9024688.html.plaintext.txt	226	We expected newly synthesized Pr55 chains become myristoylated target membrane vesicles present cellular extract assemble stable capsids
0.15107806.9024688.html.plaintext.txt	227	Other Pr55 chains might achieve steps capsid assembly would therefore detectable heterogeneous assembly intermediates
0.15107806.9024688.html.plaintext.txt	228	To quantify amount assembly efficient method separating assembled capsids remainder translation reaction required
0.15107806.9024688.html.plaintext.txt	229	This achieved two steps
0.15107806.9024688.html.plaintext.txt	230	First completion assembly reaction membrane vesicles solubilized using nonionic detergent NP 40
0.15107806.9024688.html.plaintext.txt	231	This treatment removes membranes enveloping capsids affect integrity fully assembled capsids Yu et al
0.15107806.9024688.html.plaintext.txt	232	1994 solubilize unassembled Pr55 chains may anchored membranes
0.15107806.9024688.html.plaintext.txt	233	Secondly detergent treated completed reaction size fractionated sucrose step gradient soluble fraction containing material 500 S particulate fraction containing material 500 1000 S would expected contain completed immature capsids Royer et al
0.15107806.9024688.html.plaintext.txt	234	Thus standard translation assembly reaction carried absence detergent allow association membrane vesicles analysis reaction product performed presence detergent allowing assembly status naked proteinacious capsid assessed
0.15107806.9024688.html.plaintext.txt	235	We found particulate fraction typical translation assembly reaction contained 15 40 total Pr55 synthesized see Fig
0.15107806.9024688.html.plaintext.txt	236	To assess whether fraction contained properly assembled immature capsids analyzed velocity sedimentation linear sucrose gradients equilibrium centrifugation CsCl EM
0.15107806.9024688.html.plaintext.txt	237	For comparison authentic immature HIV capsids produced transfected cultured COS 1 cells analyzed parallel
0.15107806.9024688.html.plaintext.txt	238	We found detergent treated capsids generated cell free system detergent treated de enveloped authentic capsids behaved relatively homogenous population particles 750 S Fig
0.15107806.9024688.html.plaintext.txt	239	1 A B buoyant density 1
0.15107806.9024688.html.plaintext.txt	240	Additionally cell free assembled capsids authentic standard identical size judged gel filtration data shown
0.15107806.9024688.html.plaintext.txt	241	When examined EM found capsids made cellfree system Fig
0.15107806.9024688.html.plaintext.txt	242	1 E 1 4 morphologically similar authentic capsids released transfected cells Fig
0.15107806.9024688.html.plaintext.txt	243	1 E 5 6 expected diameter 100 nm Gelderblom 1991
0.15107806.9024688.html.plaintext.txt	244	Thus average 25 radiolabeled Pr55 protein synthesized cell free system assembles particles closely resemble authentic immature HIV capsids generated transfected cells judged EM appearance well biochemical criteria size sedimentation coefficient buoyant density
0.15107806.9024688.html.plaintext.txt	245	Fidelity Cell free HIV Capsid Assembly
0.15107806.9024688.html.plaintext.txt	246	To determine whether process capsid assembly cell free system occurs cells examined whether known characteristics capsid assembly also reconstituted
0.15107806.9024688.html.plaintext.txt	247	Studies cellular systems demonstrated myristoylation Gag required proper capsid assembly Gheysen 1989 Gottlinger 1989
0.15107806.9024688.html.plaintext.txt	248	This NH2 terminal modification thought occur co translationally Wilcox et al
0.15107806.9024688.html.plaintext.txt	249	To assess role myristoylation cell free system omitted MCoA assembly reaction added posttranslationally 90 min reaction 90 Pr55 chains finished synthesis data shown
0.15107806.9024688.html.plaintext.txt	250	In cases dramatic decrease capsid assembly observed Fig
0.15107806.9024688.html.plaintext.txt	251	Consistent data found Gag mutant fails become myristoylated GA also assemble cell free system see Fig
0.15107806.9024688.html.plaintext.txt	252	In cells assembly HIV capsids takes place inner surface host cell plasma membrane Gelderblom 1991 Wills Craven 1991
0.15107806.9024688.html.plaintext.txt	253	Membrane targeting Pr55 chains directed NH2 terminal myristate moiety internal domains Pr55 polypeptide Jacobs et al
0.15107806.9024688.html.plaintext.txt	254	1989 Bryant Ratner 1990 Wang Barklis 1993 Platt Haffar 1994 Hockley et al
0.15107806.9024688.html.plaintext.txt	255	Studies using Pr55 mutations shown abolishing membrane targeting results inefficient capsid assembly failure capsid release Jacobs et al
0.15107806.9024688.html.plaintext.txt	256	1989 Bryant Ratner 1990
0.15107806.9024688.html.plaintext.txt	257	For reason targeting plasma membranes thought facilitate nucleation Gag chains site within cell assembly envelopment budding newly formed capsids occur
0.15107806.9024688.html.plaintext.txt	258	If immature HIV capsid assembly cell free system requires membrane fragments present wheat germ extracts used sensitive addition detergent concentrations solubilize membranes
0.15107806.9024688.html.plaintext.txt	259	Thus final criterion authenticity cell free capsid assembly reaction investigated sensitivity cell free capsid assembly presence detergent translation assembly reaction
0.15107806.9024688.html.plaintext.txt	260	We treated assembly reaction gentle nonionic detergent inhibit enzymatic reactions involved protein synthesis Walter Blobel 1980 thus would likely affect protein interactions involved assembly
0.15107806.9024688.html.plaintext.txt	261	As expected detergent Nikkol added concentration 0
0.15107806.9024688.html.plaintext.txt	262	1 beginning translation reaction effect Gag polypeptide synthesis data shown
0.15107806.9024688.html.plaintext.txt	263	2 B Nikkol concentration largely abolished capsid assembly
0.15107806.9024688.html.plaintext.txt	264	This effect observed Nikkol used concentration 0
0.15107806.9024688.html.plaintext.txt	265	002 required disrupt lipid bilayers Walter Blobel 1980
0.15107806.9024688.html.plaintext.txt	266	Furthermore found Nikkol added completion 150 min assembly reaction diminish amount assembly even added concentration 1
0.15107806.9024688.html.plaintext.txt	267	Thus appears whereas completed capsid particle sensitive Nikkol even high concentrations assembly structure inhibited concentrations Nikkol sufficient solubilize membranes
0.15107806.9024688.html.plaintext.txt	268	These data consistent idea membranes required newly synthesized Pr55 efficiently assembled capsids cell free system
0.15107806.9024688.html.plaintext.txt	269	Thus dependence assembly cotranslational myristoylation apparent requirement membranes indicate capsid assembly cell free system faithfully reproduces characteristics capsid assembly described cellular systems
0.15107806.9024688.html.plaintext.txt	270	Studies capsid assembly cell culture model systems revealed certain mutations within Gag coding region disrupt immature HIV capsid assembly
0.15107806.9024688.html.plaintext.txt	271	As third criterion fidelity examined assembly phenotypes cell free system four previously described mutations Gag Fig
0.15107806.9024688.html.plaintext.txt	272	3 A Pr46 mutant COOH terminal p6 domain Gag deleted Royer et al
0.15107806.9024688.html.plaintext.txt	273	1994 b Pr41 mutant deleted domains include p6 p7 distal end p24 containing p24 p7 protease cleavage site Gheysen et al
0.15107806.9024688.html.plaintext.txt	274	1994 c D2 mutation 10 amino acids p24 domain Gag upstream p24 p7 protease cleavage site deleted Hockley et al
0.15107806.9024688.html.plaintext.txt	275	1994 d GA mutation NH2 terminal single amino acid substitution abolishes myristoylation Gag Gottlinger et al
0.15107806.9024688.html.plaintext.txt	276	1989 Bryant Ratner 1990
0.15107806.9024688.html.plaintext.txt	277	Upon expression cells Pr46 mutant capable producing viral particles indistinguishable produced expression wild type Gag Royer et al
0.15107806.9024688.html.plaintext.txt	278	Each three mutants fails result proper viral particle production release Gheysen et al
0.15107806.9024688.html.plaintext.txt	279	1989 Bryant Ratner 1990 Jowett et al
0.15107806.9024688.html.plaintext.txt	280	Assembly reactions programmed transcript encoding mutations amount immature capsid produced quantitated described legend Fig
0.15107806.9024688.html.plaintext.txt	281	3 B Pr41 GA mutants failed assemble completed capsids 40 total translation product assembly competent Pr46 mutant wild type Gag assembled completed capsids
0.15107806.9024688.html.plaintext.txt	282	The D2 mutant appeared generated small amount material region completed capsids analysis material revealed trail large Gag complex 400 500 S comigrate completed capsid see Fig
0.15107806.9024688.html.plaintext.txt	283	Thus like Pr41 GA D2 assemble 750 S completed capsid
0.15107806.9024688.html.plaintext.txt	284	Together data indicate cell free system appears faithfully reproduce phenotypes variety assembly defective competent mutations Gag
0.15107806.9024688.html.plaintext.txt	285	Posttranslational Requirements Capsid Assembly
0.15107806.9024688.html.plaintext.txt	286	For optimum assembly occur cell free reaction must incubated 25 degrees C least 150 min data shown
0.15107806.9024688.html.plaintext.txt	287	We observed whereas majority Pr55 synthesis occurs first hour incubation significant capsid formation take place final 90 min reaction
0.15107806.9024688.html.plaintext.txt	288	Thus aliquot reaction incubated 50 min contains 60 full length Pr55 chains present aliquot incubated standard 150 min data shown
0.15107806.9024688.html.plaintext.txt	289	However essentially none chains present 50 min time point assembled capsids data shown 150 min 25 completed assembly process Fig
0.15107806.9024688.html.plaintext.txt	290	This indicated us might possible completely separate translation assembly phases reaction
0.15107806.9024688.html.plaintext.txt	291	To confirm reaction split two aliquots 50 min incubation
0.15107806.9024688.html.plaintext.txt	292	To one aliquot added emetine blocks translation inhibiting chain elongation aliquots incubated 150 min
0.15107806.9024688.html.plaintext.txt	293	While total Pr55 synthesis emetine treated reaction 60 control Fig
0.15107806.9024688.html.plaintext.txt	294	4 A compare gel lanes 1 2 proportion capsid assembly treated reaction comparable untreated control Fig
0.15107806.9024688.html.plaintext.txt	295	4 A bar graph indicating assembly takes place even translation halted
0.15107806.9024688.html.plaintext.txt	296	Based data one would expect manipulations performed emetine treatment would effects posttranslational phase assembly affect Pr55 synthesis already completed
0.15107806.9024688.html.plaintext.txt	297	Having established means analyzing events specific assembly examined whether previously described detergent sensitivity HIV capsid assembly Fig
0.15107806.9024688.html.plaintext.txt	298	2 B due effect co posttranslational events
0.15107806.9024688.html.plaintext.txt	299	We treated Pr55 reactions emetine 0
0.15107806.9024688.html.plaintext.txt	300	1 Nikkol 50 min reaction continued incubation 150 min determined amount assembly previously described
0.15107806.9024688.html.plaintext.txt	301	Under conditions assembly dramatically reduced data shown Nikkol added start translation Fig
0.15107806.9024688.html.plaintext.txt	302	Therefore conclude detergent sensitive steps HIV capsid assembly occurs posttranslationally
0.15107806.9024688.html.plaintext.txt	303	Next examined whether posttranslational events capsid assembly dependent presence ATP
0.15107806.9024688.html.plaintext.txt	304	Translation Gag allowed proceed 50 min point protein synthesis inhibited emetine
0.15107806.9024688.html.plaintext.txt	305	The sample divided one aliquot depleted ATP addition apyrase enzyme hydrolyzes free ATP
0.15107806.9024688.html.plaintext.txt	306	After completion assembly reaction samples analyzed previously described amount assembly occurred
0.15107806.9024688.html.plaintext.txt	307	We found depletion free ATP assembly reaction resulted dramatic reduction capsid assembly Fig
0.15107806.9024688.html.plaintext.txt	308	The effect ATP depletion reversed addition nonhydrolyzable analogues AMP PNP GTP S data shown suggesting ATP hydrolysis ATP binding required
0.15107806.9024688.html.plaintext.txt	309	As expected addition apyrase change total amount Pr55 synthesis Fig
0.15107806.9024688.html.plaintext.txt	310	4 A compare gel lanes 2 3
0.15107806.9024688.html.plaintext.txt	311	Furthermore adding apyrase reaction capsid assembly completed effect amount assembly data shown ruling possibility effect apyrase ATP depletion capsid stability
0.15107806.9024688.html.plaintext.txt	312	These data indicate requirement ATP capsid assembly process ATP dependence distinct energy requirements protein synthesis
0.15107806.9024688.html.plaintext.txt	313	A Subcellular Fraction Is Required Capsid Assembly
0.15107806.9024688.html.plaintext.txt	314	Given Gag protein known bind hydrolyze ATP requirement energy substrate suggests host protein proteins involved assembly reaction
0.15107806.9024688.html.plaintext.txt	315	Demonstrating host factor required would involve showing assembly fails occur factor depleted cellular extracts used assembly reaction
0.15107806.9024688.html.plaintext.txt	316	Furthermore adding back depleted fraction reaction restore assembly
0.15107806.9024688.html.plaintext.txt	317	Thus sought fractionate translation extract manner would leave intact components needed translation remove least one component required assembly
0.15107806.9024688.html.plaintext.txt	318	The cellular extract used translation assembly subfractionated ultracentrifugation two portions HSS HSP
0.15107806.9024688.html.plaintext.txt	319	The HSS depleted components 90 S greater supported Pr55 translation assembly Fig
0.15107806.9024688.html.plaintext.txt	320	This indicates HSP likely contains assembly specific host factors
0.15107806.9024688.html.plaintext.txt	321	This demonstrated directly showing addition HSP posttranslationally emetine treatment unassembled Gag chains synthesized HSS resulted considerable restoration particle assembly Fig
0.15107806.9024688.html.plaintext.txt	322	As expected total synthesis Pr55 unaltered addition HSP Fig
0.15107806.9024688.html.plaintext.txt	323	Together data indicate subcellular fraction eukaryotic cell lysate required posttranslational events capsid assembly take place
0.15107806.9024688.html.plaintext.txt	324	We previously observed detergent also disrupts posttranslational phase capsid assembly data shown
0.15107806.9024688.html.plaintext.txt	325	We examined therefore whether HSP contained detergent sensitive component required capsid formation
0.15107806.9024688.html.plaintext.txt	326	HSP prepared cell extract treated detergent 0
0.15107806.9024688.html.plaintext.txt	327	The resulting HSP washed detergent free buffer added posttranslationally assembly reaction
0.15107806.9024688.html.plaintext.txt	328	We found HSP detergent treated extract active promoting posttranslational capsid formation control HSP Fig
0.15107806.9024688.html.plaintext.txt	329	Thus separate detergent sensitive insensitive host factors appear involved posttranslational phase HIV capsid assembly
0.15107806.9024688.html.plaintext.txt	330	Furthermore detergent insensitive host factor depleted ultracentrifugation reconstituted posttranslational addition
0.15107806.9024688.html.plaintext.txt	331	Intermediates Assembly HIV Capsids
0.15107806.9024688.html.plaintext.txt	332	The existence multiple specific requirements HIV capsid biogenesis including host factors ATP suggests discrete biochemical intermediates may exist assembly process
0.15107806.9024688.html.plaintext.txt	333	To date intermediates capsid assembly described likely due difficulty detection cellular systems would present transiently minute quantities
0.15107806.9024688.html.plaintext.txt	334	Since cell free system less efficient forming completed capsids cellular systems might constitute better system detecting assembly intermediates
0.15107806.9024688.html.plaintext.txt	335	Consistent possibility found conditions small amount 750 S capsid assembly occurs cell free reaction analysis reaction products 13 ml velocity sedimentation gradients revealed presence series Gag containing complexes addition 750 S completed capsids Fig
0.15107806.9024688.html.plaintext.txt	336	These complexes calculated sedimentation coefficients 10 S 80 S 150 S henceforth referred complexes A B C respectively
0.15107806.9024688.html.plaintext.txt	337	If complexes represent assembly intermediates would expected present large quantities early time points diminished later times reaction
0.15107806.9024688.html.plaintext.txt	338	To assess whether complexes displayed behavior used pulse chase analysis follow small cohort radiolabeled Pr55 chains time
0.15107806.9024688.html.plaintext.txt	339	The cell free reaction performed radiolabeled cysteine
0.15107806.9024688.html.plaintext.txt	340	After first 4 min translation excess unlabeled cysteine added abolish labeling subsequently synthesized Pr55 chains
0.15107806.9024688.html.plaintext.txt	341	We observed total amount radiolabeled Pr55 25 150 min pulse chase reaction Fig
0.15107806.9024688.html.plaintext.txt	342	5 B indicating neither radiolabeling degradation Pr55 occurred 25 min confirming population Pr55 chains analyzed times
0.15107806.9024688.html.plaintext.txt	343	Aliquots cell free reactions removed times indicated treated detergent analyzed 13 ml velocity sedimentation gradients
0.15107806.9024688.html.plaintext.txt	344	At 25 min reaction radiolabeled Pr55 found complexes A B C Fig
0.15107806.9024688.html.plaintext.txt	345	5 C radiolabeled Pr55 present region completed 750 S capsids
0.15107806.9024688.html.plaintext.txt	346	While complexes A B appear peaks 10 S 80 S positions gradient complex C appears less distinct shoulder approximately 150 S position
0.15107806.9024688.html.plaintext.txt	347	In marked contrast examination assembly reaction 150 min showed significant amount radiolabeled Pr55 assembled completed capsids migrated 750 S position Fig
0.15107806.9024688.html.plaintext.txt	348	Correspondingly amount Pr55 complexes A B C diminished precisely amount found assembled demonstrating least material complexes A B C constitutes intermediates biogenesis completed 750 S capsids
0.15107806.9024688.html.plaintext.txt	349	At extremely short chase times
0.15107806.9024688.html.plaintext.txt	350	13 min radiolabeled chains completed synthesis full length Pr55 chains found exclusively complex A 13 ml sucrose gradients nascent chains yet completed form polysomes greater 100 S data shown
0.15107806.9024688.html.plaintext.txt	351	Thus polysome associated nascent chains Gag constitute starting material pathway 10 S complex A contains completed Gag chains likely first intermediate formation immature capsids
0.15107806.9024688.html.plaintext.txt	352	It possible therefore complexes B C represent later assembly intermediates pathway capsid formation
0.15107806.9024688.html.plaintext.txt	353	If complexes A B C fact constitute intermediates assembly one would predict blockade assembly would result accumulation Gag chains form complexes S values
0.15107806.9024688.html.plaintext.txt	354	Furthermore one would expect blockade different points along pathway would result accumulation complexes A B C various combinations determined order appearance along assembly pathway
0.15107806.9024688.html.plaintext.txt	355	For example ordered pathway intermediates exists blockade early points pathway result accumulation one two Gag containing complexes corresponding early putative assembly intermediates blockade late point pathway would result accumulation putative assembly intermediates final completed capsid product
0.15107806.9024688.html.plaintext.txt	356	To test predictions blocked assembly variety ways pharmacologically use mutations examined Gag containing complexes formed
0.15107806.9024688.html.plaintext.txt	357	Pharmacological Blockade Results Accumulation Assembly Intermediates
0.15107806.9024688.html.plaintext.txt	358	Capsid assembly disrupted adding either apyrase posttranslationally Fig
0.15107806.9024688.html.plaintext.txt	359	3 detergent co translationally Fig
0.15107806.9024688.html.plaintext.txt	360	2 reaction products analyzed velocity sedimentation described Fig
0.15107806.9024688.html.plaintext.txt	361	Material fractions corresponding assembly intermediates completed capsid quantified presented Table I
0.15107806.9024688.html.plaintext.txt	362	The untreated reaction contained Pr55 complexes A B C well peak final 750 S capsid position treated reactions expected contained peak position final capsid product Table I
0.15107806.9024688.html.plaintext.txt	363	Treatment either apyrase detergent resulted accumulation additional material complexes B C result accumulation additional material complex A
0.15107806.9024688.html.plaintext.txt	364	This consistent idea complexes B C immediate precursors 750 S completed capsids interventions block conversion complexes B C fully assembled capsid end product
0.15107806.9024688.html.plaintext.txt	365	Effect ATP Hydrolysis Detergent Treatment Assembly Intermediates
0.15107806.9024688.html.plaintext.txt	366	Assembly defective Mutants Are Arrested Specific Points Assembly Pathway
0.15107806.9024688.html.plaintext.txt	367	To determine whether putative assembly intermediates accumulate capsid assembly blocked specific mutations Gag cell free reactions programmed previously described assembly competent defective Gag mutants Fig
0.15107806.9024688.html.plaintext.txt	368	3 incubated 150 min analyzed velocity sedimentation
0.15107806.9024688.html.plaintext.txt	369	Reactions programmed wild type Gag Fig
0.15107806.9024688.html.plaintext.txt	370	6 A assembly competent Pr46 mutant Fig
0.15107806.9024688.html.plaintext.txt	371	6 B found nearly identical profiles 30 radiolabeled Gag chains synthesized formed completed immature capsids migrate 750 S remainder form residual putative assembly intermediates A B
0.15107806.9024688.html.plaintext.txt	372	Thus two assembly competent forms Gag appear indistinguishable cell free system expressed cells Royer et al
0.15107806.9024688.html.plaintext.txt	373	6 C shows analysis assembly defective Pr41 mutant
0.15107806.9024688.html.plaintext.txt	374	We found radiolabeled chains end Pr41 cell free reaction contained single complex peaks 10 S corresponds complex A
0.15107806.9024688.html.plaintext.txt	375	Since 10 S peak large led irregular trail could masking 80 150 S peaks reanalyzed products Pr41 reaction gradient allowed high resolution 1 200 S size range data shown confirmed Pr41 translation product present complex A 10 S size
0.15107806.9024688.html.plaintext.txt	376	Thus cell free system appears Pr41 fails progress beyond complex A likely represent first intermediate assembly pathway
0.15107806.9024688.html.plaintext.txt	377	Like Pr41 myristoylation incompetent GA mutant failed assemble 750 S capsids Fig
0.15107806.9024688.html.plaintext.txt	378	6 D unlike Pr41 GA distinct peaks 10 80 S regions gradient Fig
0.15107806.9024688.html.plaintext.txt	379	These data indicate GA mutant contains entire Gag coding region except myristoylation signal capable forming complex A appeared first assembly intermediate pulse chase experiment well complex B progress towards forming completed capsids
0.15107806.9024688.html.plaintext.txt	380	These data suggest complex B likely second assembly intermediate formed biogenesis immature HIV capsids
0.15107806.9024688.html.plaintext.txt	381	Previously shown absence exogenously added MCoA wild type Gag failed assemble cell free system Fig
0.15107806.9024688.html.plaintext.txt	382	2 A consistent previous observations myristoylation required proper capsid assembly occur
0.15107806.9024688.html.plaintext.txt	383	Thus cell free reaction programmed wild type Gag performed absence MCoA would expected blocked point assembly pathway GA mutant
0.15107806.9024688.html.plaintext.txt	384	Consistent found assembly performed absence MCoA resulted formation complexes A B data shown therefore closely resembled GA mutant shown Fig
0.15107806.9024688.html.plaintext.txt	385	Analysis cell free reaction programmed D2 mutant shown Fig
0.15107806.9024688.html.plaintext.txt	386	Unlike previously described assembly defective mutants D2 found form spectrum Gag containing complexes including peaks corresponding complexes A B 10 80 S shoulder corresponding complex C 150 S region additional peak 400 500 S henceforth referred complex D
0.15107806.9024688.html.plaintext.txt	387	Note complex D trails 750 S region accounting appearance small amount assembly simpler analysis presented Fig
0.15107806.9024688.html.plaintext.txt	388	However detailed analysis presented makes clear fact discrete peak region completed capsid 750 S
0.15107806.9024688.html.plaintext.txt	389	Thus D2 mutant appears form series complexes corresponding size assembly intermediates seen pulse chase experiment Fig
0.15107806.9024688.html.plaintext.txt	390	5 well additional complex larger size fails produce completed 750 S product
0.15107806.9024688.html.plaintext.txt	391	Gag containing Complexes within Mammalian Cells
0.15107806.9024688.html.plaintext.txt	392	Having demonstrated pulse chase analysis pharmacologic blockade analysis mutants assembly intermediates appear exist cell free system examined whether complexes sizes present mammalian cells expressing wild type Gag Gag mutants
0.15107806.9024688.html.plaintext.txt	393	The finding complexes would consistent existence similar transient intermediates vivo
0.15107806.9024688.html.plaintext.txt	394	Cos cells transfected wild type Gag lysed detergent lysate analyzed 13 ml velocity sedimentation gradients Figs
0.15107806.9024688.html.plaintext.txt	395	Gradient fractions immunoblotted Gag antibody relative amount Gag polypeptide present fraction quantitated described Materials Methods Fig
0.15107806.9024688.html.plaintext.txt	396	The cell lysate contained Pr55 spectrum complexes ranging 10 200 S
0.15107806.9024688.html.plaintext.txt	397	Since cells efficiently release completed HIV capsids completed capsid would expected medium steady state
0.15107806.9024688.html.plaintext.txt	398	This confirmed finding substantial amount fully assembled 750 S capsid present medium Fig
0.15107806.9024688.html.plaintext.txt	399	7 A open circles cell lysate contained 750 S capsids Fig
0.15107806.9024688.html.plaintext.txt	400	We conclude therefore within cells Pr55 present heterogeneous mixture complexes S values similar complexes A B C assembly intermediates found cell free system
0.15107806.9024688.html.plaintext.txt	401	If complexes correspond assembly intermediates seen cell free system one would expect different assembly defective mutants would result accumulation sized complexes cellular systems cell free system
0.15107806.9024688.html.plaintext.txt	402	Thus examined whether Pr41 mutant appears blocked first assembly intermediate cell free system D2 mutant appears blocked end assembly pathway cell free system resulted corresponding patterns Gag containing complexes within cells
0.15107806.9024688.html.plaintext.txt	403	Cos cells transfected mutants medium well lysate examined immunoblotting
0.15107806.9024688.html.plaintext.txt	404	As expected medium cells transfected assembly defective Pr41 D2 contain 750 S completed capsids data shown
0.15107806.9024688.html.plaintext.txt	405	The cell lysate Cos cells transfected Pr41 mutant contained material peaked 10 S region velocity gradient Fig
0.15107806.9024688.html.plaintext.txt	406	7 B resembling found Pr41 mutant expressed cell free system Fig
0.15107806.9024688.html.plaintext.txt	407	The observation Pr41 reaction product migrated single complex peaked 10 S region confirmed analysis variety different velocity sedimentation gradients allowed higher resolution 1 200 S size range data shown
0.15107806.9024688.html.plaintext.txt	408	In contrast cell lysate Cos cells transfected D2 mutant contained spectrum immunoreactive complexes ranged size 10 500 S Fig
0.15107806.9024688.html.plaintext.txt	409	7 C resembling found D2 expressed cell free system Fig
0.15107806.9024688.html.plaintext.txt	410	Thus data transfected cells suggests behavior Gag mutants cell free system reflects events capsid assembly occur living cells
0.15107806.9024688.html.plaintext.txt	411	In paper first demonstrate immature HIV capsids assembled cell free system
0.15107806.9024688.html.plaintext.txt	412	We establish capsids produced closely resemble immature HIV capsids produced cellular systems Fig
0.15107806.9024688.html.plaintext.txt	413	1 key known features capsid assembly faithfully reproduced cell free system Figs
0.15107806.9024688.html.plaintext.txt	414	We use dissect assembly number steps
0.15107806.9024688.html.plaintext.txt	415	First use inhibitor protein synthesis demonstrate assembly resolved co translational phase Pr55 polypeptides synthesized followed posttranslational phase additional events necessary assembly take place
0.15107806.9024688.html.plaintext.txt	416	Being able separate two phases allows us analyze reactions specific assembly process independent events protein synthesis
0.15107806.9024688.html.plaintext.txt	417	By manipulating posttranslational phase assembly demonstrate least three specific requirements Fig
0.15107806.9024688.html.plaintext.txt	418	First ATP necessary since enzyme apyrase able effectively block posttranslational progression completed Pr55 chains fully assembled capsids
0.15107806.9024688.html.plaintext.txt	419	Second phase sensitive nonionic detergent implying membrane fragments likely involved
0.15107806.9024688.html.plaintext.txt	420	Third using depletion reconstitution approach demonstrate subcellular fraction eukaryotic cell lysate required posttranslational assembly events take place
0.15107806.9024688.html.plaintext.txt	421	In addition multiple criteria used demonstrate posttranslational phase assembly proceeds way series Gag containing complexes appear constitute intermediates cell free capsid assembly reaction Figs
0.15107806.9024688.html.plaintext.txt	422	Finally show complexes resembling assembly intermediates may also present cellular systems producing immature HIV particles mutants Gag similar behavior cellular cell free systems Fig
0.15107806.9024688.html.plaintext.txt	423	Novel Requirements HIV Capsid Assembly
0.15107806.9024688.html.plaintext.txt	424	To date studies revealed whether HIV capsid assembly occurs way passive process Gag polypeptide multimerization whether assembly active regulated process requiring Gag associations proteins well Gag Gag interactions
0.15107806.9024688.html.plaintext.txt	425	By demonstrating posttranslational phase assembly requires ATP detergent insensitive host cell component data indicate fact HIV capsid assembly energydependent coordinated process host proteins play crucial role
0.15107806.9024688.html.plaintext.txt	426	Thus model HIV capsid assembly supported data conceptually different view many viral capsids formed capsid monomers way passive process self assembly requiring components besides individual capsid protein subunits Klug 1980
0.15107806.9024688.html.plaintext.txt	427	Indeed host factors previously documented play role assembly HIV capsids possibility existence raised data demonstrating yeast expressing Gag support HIV capsid assembly Jacobs et al
0.15107806.9024688.html.plaintext.txt	428	1989 baculovirus mammalian systems expression review see Boulanger Jones 1996
0.15107806.9024688.html.plaintext.txt	429	Such studies imply yeast either contain factor inhibits HIV capsid assembly absent higher eukaryotes lack factor necessary assembly present higher eukaryotes
0.15107806.9024688.html.plaintext.txt	430	Our data support latter possibility
0.15107806.9024688.html.plaintext.txt	431	Consistent notion previously unrecognized host factors may important various points HIV life cycle recent demonstration cyclophilins associated HIV virus particle required infectivity Luban et al
0.15107806.9024688.html.plaintext.txt	432	The finding HIV capsid assembly requires ATP well host cell components suggests posttranslational phase assembly may occur via step wise pathway previously unrecognized assembly intermediates
0.15107806.9024688.html.plaintext.txt	433	We present three lines evidence support view
0.15107806.9024688.html.plaintext.txt	434	First using pulse chase analysis demonstrate population lower molecular weight Gag containing complexes referred complexes A B C present early time points capsid assembly Gag polypeptides population converted final capsid product time
0.15107806.9024688.html.plaintext.txt	435	Note possibility complexes represent polyribosomes ruled demonstration sensitive RNase A used concentrations result complete digestion messenger RNA Lingappa J
0.15107806.9024688.html.plaintext.txt	436	At short chase times radiolabeled Pr55 pulse chase reaction present complex A suggesting may first intermediate assembly reaction appearing completed Gag chains released ribosomes
0.15107806.9024688.html.plaintext.txt	437	It remains determined whether complex A constitutes either monomer dimer Gag whether composed Gag chain associated host protein
0.15107806.9024688.html.plaintext.txt	438	Secondly show blocking assembly pharmacologically using either apyrase detergent material two complexes complexes B C accumulates indicating likely precursors completed 750 S capsid end product
0.15107806.9024688.html.plaintext.txt	439	Note data exclude existence intermediates might occur later pathway
0.15107806.9024688.html.plaintext.txt	440	Such intermediates would seen apyrase detergent blockade since agents appear block assembly preventing progression beyond 150 S complex
0.15107806.9024688.html.plaintext.txt	441	The demonstration detergent ATP depletion appear result accumulation assembly intermediates raises possibility point assembly pathway may critical one variety events necessary assembly must take place coordinated fashion
0.15107806.9024688.html.plaintext.txt	442	Further work required determine whether represents important point regulation assembly pathway
0.15107806.9024688.html.plaintext.txt	443	Finally analysis three different Gag mutants known assembly defective lends support presence assembly intermediates
0.15107806.9024688.html.plaintext.txt	444	We find mutant results accumulation different subsets assembly intermediates
0.15107806.9024688.html.plaintext.txt	445	Thus mutant appears blocked first step assembly pathway results accumulation complex A alone Fig
0.15107806.9024688.html.plaintext.txt	446	6 C one appears blocked second step pathway results accumulation complex A complex B Fig
0.15107806.9024688.html.plaintext.txt	447	A spectrum complexes including complexes A B C well larger complex D seen upon expression mutant appears blocked late step assembly pathway Fig
0.15107806.9024688.html.plaintext.txt	448	Thus analysis mutants supports existence intermediates assembly HIV capsids also suggests order appearance intermediates process capsid assembly
0.15107806.9024688.html.plaintext.txt	449	There number caveats demonstration assembly intermediates
0.15107806.9024688.html.plaintext.txt	450	First one putative intermediates could fact constitute side reaction dead end byproduct main pathway capsid assembly
0.15107806.9024688.html.plaintext.txt	451	The likely candidate dead end byproduct complex D clearly apparent analysis assembly defective D2 mutant Fig
0.15107806.9024688.html.plaintext.txt	452	Arguing possibility complexes A B C simply nonproductive side reactions finding amount complexes varies inversely amount completed immature capsid formed
0.15107806.9024688.html.plaintext.txt	453	Such behavior would expected assembly intermediates dead end byproducts side reactions
0.15107806.9024688.html.plaintext.txt	454	For example quantity complexes decreases time pulse chase experiment period completed capsids appearing total number radiolabeled Gag chains present constant Fig
0.15107806.9024688.html.plaintext.txt	455	Likewise complexes B C increase quantity formation capsids blocked Table I
0.15107806.9024688.html.plaintext.txt	456	Additionally analysis mutant efficient capsid production wild type cells find amount complex A drops low levels large amounts capsid made Hill R
0.15107806.9024688.html.plaintext.txt	457	Lingappa unpublished observation
0.15107806.9024688.html.plaintext.txt	458	Thus simplest interpretation data Gag complexes A B C constitute true assembly intermediates although definitive proof must await functional examination intermediates isolation
0.15107806.9024688.html.plaintext.txt	459	A second caveat analysis could complicated instability Gag containing complexes
0.15107806.9024688.html.plaintext.txt	460	Thus lower molecular weight complexes could actually result disassembly higher order complex
0.15107806.9024688.html.plaintext.txt	461	This seems unlikely significant problem system given observed Gag containing complexes labile studies
0.15107806.9024688.html.plaintext.txt	462	For example pulse chase experiments Fig
0.15107806.9024688.html.plaintext.txt	463	5 clear cut progression time complexes A B C completed immature capsids
0.15107806.9024688.html.plaintext.txt	464	Residual amounts complexes A B present end incubation likely due incomplete conversion resulting depletion inactivation necessary factors time
0.15107806.9024688.html.plaintext.txt	465	A third caveat noted may exist additional intermediates HIV capsid assembly obvious current analysis
0.15107806.9024688.html.plaintext.txt	466	Finally wish point S values assigned complexes described approximate S values calculated migration complexes velocity sedimentation gradients see Materials Methods
0.15107806.9024688.html.plaintext.txt	467	While one complexes may appear distinct particular experiment particular gradient
0.15107806.9024688.html.plaintext.txt	468	5 C specific complexes described seen repeatedly many different experiments variety gradient conditions therefore likely represent discrete complexes difficult resolve perfectly every experiment given transient dynamic nature
0.15107806.9024688.html.plaintext.txt	469	A Multi step Pathway Assembly HIV Capsids
0.15107806.9024688.html.plaintext.txt	470	Together results support model capsid assembly stepwise process consisting discrete biochemical events specific requirements ATP least one detergent insensitive component eukaryotic cell lysate
0.15107806.9024688.html.plaintext.txt	471	8 presents simplest scenario unifies data presented
0.15107806.9024688.html.plaintext.txt	472	While analysis system may reveal additional complexities scheme presents biochemical framework hypotheses tested
0.15107806.9024688.html.plaintext.txt	473	A model assembly immature HIV capsids
0.15107806.9024688.html.plaintext.txt	474	This model based simplest interpretation data presented
0.15107806.9024688.html.plaintext.txt	475	Newly synthesized Gag proteins myristoylated cotranslationally
0.15107806.9024688.html.plaintext.txt	476	Nascent Gag polypeptides appear chase completed immature capsids way series Gag containing complexes complexes A B C D
0.15107806.9024688.html.plaintext.txt	477	Evidence presented text suggests complexes A B C may constitute assembly intermediates
0.15107806.9024688.html.plaintext.txt	478	It less clear whether complex D constitutes assembly intermediate side reaction
0.15107806.9024688.html.plaintext.txt	479	Both ATP subcellular fraction eukaryotic cell extract required assembly take place detergent apyrase proposed disrupt assembly indicated position
0.15107806.9024688.html.plaintext.txt	480	The points along pathway various mutants Gag arrested indicated model
0.15107806.9024688.html.plaintext.txt	481	View Larger Version Image 11K GIF file
0.15107806.9024688.html.plaintext.txt	482	While intermediates along pathway demonstrated previously within cells could consequence transient nature difficulties involved manipulating cellular systems
0.15107806.9024688.html.plaintext.txt	483	Further work required determine extent mechanism cell free HIV capsid assembly reflects biochemical events occur vivo
0.15107806.9024688.html.plaintext.txt	484	Here show steady state conditions cells releasing immature HIV capsids contain Pr55 complexes correspond approximate size complexes A B C assembly intermediates observed cell free system
0.15107806.9024688.html.plaintext.txt	485	In addition assembly defective mutants arrested specific complexes cell free system appear arrested form similar sized complexes expressed cells Fig
0.15107806.9024688.html.plaintext.txt	486	While data constitute proof assembly intermediates exist cells lend support idea process HIV capsid assembly cell free system closely correlated capsid assembly process cells
0.15107806.9024688.html.plaintext.txt	487	It noted biological systems transient intermediates well documented cell free reactions yet identified cells
0.15107806.9024688.html.plaintext.txt	488	For example case targeting nascent secretory proteins endoplasmic reticulum signal recognition particle bound nascent chains demonstrated biochemically cell free systems Walter Blobel 1983 even though genetic evidence confirms importance signal recognition particles vivo Hann Walter 1991
0.15107806.9024688.html.plaintext.txt	489	A Mechanistic View HIV Capsid Assembly
0.15107806.9024688.html.plaintext.txt	490	In addition allowing us identify novel steps HIV capsid assembly cell free system also allows us mechanistic insights known aspects capsid assembly
0.15107806.9024688.html.plaintext.txt	491	For example data suggest reason certain Gag mutants fail assemble lack domains Gag polypeptide may required either directly indirectly progression one assembly intermediate next along proposed pathway HIV capsid assembly
0.15107806.9024688.html.plaintext.txt	492	Similarly results indicate absence myristate moiety absence intact membranes capsid assembly fails progress beyond specific stages assembly process
0.15107806.9024688.html.plaintext.txt	493	Altogether demonstrate capsid assembly disrupted different points proposed assembly pathway five different means omitting MCoA co translational phase reaction b depleting ATP posttranslational phase c treating detergent either start translation posttranslationally d removing detergent insensitive subcellular components eukaryotic cell lysate used assembly reaction e programming reaction assembly defective Gag mutants
0.15107806.9024688.html.plaintext.txt	494	While details mechanisms underlying forms blockade remain determined analysis data reveal power approach elucidating biochemical events underlie capsid assembly
0.15107806.9024688.html.plaintext.txt	495	Cell free Assembly Other Viral Capsids
0.15107806.9024688.html.plaintext.txt	496	Cell free systems used past assemble simple viral particles whose formation dependent cytosolic components host cells Molla et al
0.15107806.9024688.html.plaintext.txt	497	In current study demonstrate systems also used reconstitute assembly much complex viral capsids HIV capsids require co translational modifications well membrane targeting biogenesis
0.15107806.9024688.html.plaintext.txt	498	These data suggest cell free system used examine capsid assembly mechanisms many different types viruses
0.15107806.9024688.html.plaintext.txt	499	Previously used cell free system study mechanism assembly Hepatitis B Virus HBV completely unrelated virus Lingappa et al
0.15107806.9024688.html.plaintext.txt	500	Unlike HIV capsids HBV capsids formed free cytoplasm host cell review see Ganem 1991
0.15107806.9024688.html.plaintext.txt	501	We found capsids assemble way intermediate associated least one host protein
0.15107806.9024688.html.plaintext.txt	502	When intermediate isolated manipulation energy substrates resulted release completed capsid end product
0.15107806.9024688.html.plaintext.txt	503	Thus cell free HIV HBV capsid assembly differ greatly many details complexity share general mechanistic themes
0.15107806.9024688.html.plaintext.txt	504	Capsid formation systems involves assembly intermediates use energy substrates association host proteins
0.15107806.9024688.html.plaintext.txt	505	Thus propose viruses different types may assemble capsids via step wise pathway using host cell machinery
0.15107806.9024688.html.plaintext.txt	506	Whether different host machinery recruited various viruses remains determined
0.15107806.9024688.html.plaintext.txt	507	Implications Cell free System Viral Assembly
0.15107806.9024688.html.plaintext.txt	508	To allow analysis earliest events capsid biogenesis designed cell free system assemble simplest version HIV capsid one undergo maturation lacks HIV genomic RNA HIVspecific proteins except Gag
0.15107806.9024688.html.plaintext.txt	509	Now method established possible supplement system additional components manner extend reconstitution allow roles components capsid assembly determined
0.15107806.9024688.html.plaintext.txt	510	For example using modified version system possible determine requirements encapsidation viral RNA viral specific enzymes
0.15107806.9024688.html.plaintext.txt	511	Note although HIV specific RNA besides gag transcript included cell free reactions described study entirely possible nonspecific RNA cellular extract becomes incorporated capsids made
0.15107806.9024688.html.plaintext.txt	512	Recent studies demonstrating highly dynamic nature HIV Ho et al
0.15107806.9024688.html.plaintext.txt	513	1995 indicate successful approach combating infection simultaneous multi drug therapy
0.15107806.9024688.html.plaintext.txt	514	Antiretroviral agents currently use target two aspects HIV life cycle namely reverse transcription protease dependent virion maturation
0.15107806.9024688.html.plaintext.txt	515	In order develop novel targets future antiretroviral therapy mechanistic analysis aspects HIV life cycle capsid assembly must aggressively pursued
0.15107806.9024688.html.plaintext.txt	516	The work presented establishes means carrying biochemical analysis assembly HIV capsid
0.15107806.9024688.html.plaintext.txt	517	Furthermore data indicate existence novel steps viral assembly appear amenable blockade
0.15107806.9024688.html.plaintext.txt	518	Received publication 20 August 1996 revised form 4 November 1996
0.15107806.9024688.html.plaintext.txt	519	Lingappa supported National Institutes Health grant K08AI01292 R
0.15107806.9024688.html.plaintext.txt	520	Hegde supported Medical Scientist Training Program grant GM 07618
0.15107806.9024688.html.plaintext.txt	521	Please address correspondence Jaisri Lingappa Department Physiology Department Medicine University California San Francisco CA 94143 0444
0.15107806.9024688.html.plaintext.txt	522	We would like thank Jay Levy genomic HIV cDNA David Rekosh plasmids used transfections John Forsayeth transfection reagents advice David Chu cultured cells advice Concepcion Zimmerman excellent cell culture work Alfredo Calayag technical assistance
0.15107806.9024688.html.plaintext.txt	523	We would also like thank Vishwanath Lingappa support advice helpful discussions assistance manuscript David Andrews William Welch Mike McCune John Forsayeth helpful discussions Joel Ernst encouragement
0.15107806.9024688.html.plaintext.txt	524	Abbreviations used paper
0.15107806.9024688.html.plaintext.txt	525	HBV Hepatitis B Virus HIV human immunodeficiency virus type 1 HSP high speed pellet HSS high speed supernatant HSPd detergent treated high speed pellet MCoA myristoyl CoA
0.15107806.9024688.html.plaintext.txt	526	Use heterologous expression systems study Retroviral morphogenesis
0.15107806.9024688.html.plaintext.txt	527	Myristoylation dependent replication assembly human immunodeficiency virus 1
0.15107806.9024688.html.plaintext.txt	528	A new preparation method dark field electron microscopy biomacromolecules
0.15107806.9024688.html.plaintext.txt	529	Cell free translation messenger RNA wheat germ system
0.15107806.9024688.html.plaintext.txt	530	A large deletion matrix domain human immunodeficiency virus gag gene redirects virus particle assembly plasma membrane endoplasmic reticulum
0.15107806.9024688.html.plaintext.txt	531	Adenovirus mediated transfection cultured cells
0.15107806.9024688.html.plaintext.txt	532	Specific incorporation cyclophilin A HIV 1 virions
0.15107806.9024688.html.plaintext.txt	533	Assembly hepadnaviral virions subviral particles
0.15107806.9024688.html.plaintext.txt	534	Assembly morphology HIV potential effect structure viral function
0.15107806.9024688.html.plaintext.txt	535	Assembly release HIV 1 precursor Pr55gag viruslike particles recombinant Baculovirus infected insect cells
0.15107806.9024688.html.plaintext.txt	536	Role capsid precursor processing myristoylation morphogenesis infectivity human immunodeficiency virus type 1
0.15107806.9024688.html.plaintext.txt	537	The signal recognition particle S
0.15107806.9024688.html.plaintext.txt	538	Rapid turnover plasma virions CD4 lymphocytes HIV 1 infection
0.15107806.9024688.html.plaintext.txt	539	Comparative morphology Gag protein structures produced mutants gag gene human immunodeficiency virus type 1
0.15107806.9024688.html.plaintext.txt	540	The HIV 1 Gag precursor Pr55 gag synthesized yeast myristoylated targeted plasma membrane
0.15107806.9024688.html.plaintext.txt	541	Distinct signals human immunodeficiency virus type 1 Pr55 necessary RNA binding particle formation
0.15107806.9024688.html.plaintext.txt	542	The assembly Tobacco Mosaic Virus structure specificity
0.15107806.9024688.html.plaintext.txt	543	A eukaryotic cytosolic chaperonin associated high molecular weight intermediate assembly Hepatitis B Virus capsid multimeric particle
0.15107806.9024688.html.plaintext.txt	544	Human immunodeficiency virus type 1 Gag protein binds cyclophilins A B
0.15107806.9024688.html.plaintext.txt	545	Tables estimating sedimentation linear concentration gradients sucrose solution
0.15107806.9024688.html.plaintext.txt	546	Efficient vitro synthesis biologically active RNA RNA hybridization probes plasmids containing bacteriophage SP6 promoter
0.15107806.9024688.html.plaintext.txt	547	Analysis HIV particle formation using transient expression subviral constructs mammalian cells
0.15107806.9024688.html.plaintext.txt	548	Translation exogenous mRNA reticulocyte lysates
0.15107806.9024688.html.plaintext.txt	549	Cell free de novo synthesis poliovirus
0.15107806.9024688.html.plaintext.txt	550	Characterization human immunodeficiency virus type 1 pr55gag membrane association cell free system requirement COOH terminal domain
0.15107806.9024688.html.plaintext.txt	551	A single amino acid substitution within matrix protein type D retrovirus converts morphogenesis type C retrovirus
0.15107806.9024688.html.plaintext.txt	552	Functional domains HIV 1 gag polyproteins expressed baculovirus infected cells
0.15107806.9024688.html.plaintext.txt	553	Synthesis assembly retrovirus Gag precursors immature capsids vitro
0.15107806.9024688.html.plaintext.txt	554	Molecular Cloning A Laboratory Manual
0.15107806.9024688.html.plaintext.txt	555	Cold Spring Harbor Laboratory Cold Spring Harbor NY
0.15107806.9024688.html.plaintext.txt	556	Requirements incorporation Pr 160 gag pol human immunodeficiency virus type 1 virus like particles
0.15107806.9024688.html.plaintext.txt	557	Identification human immunodeficiency virus type 1 Gag protein domains essential membrane binding particle assembly
0.15107806.9024688.html.plaintext.txt	558	Functional association cyclophilin A HIV 1 virions
0.15107806.9024688.html.plaintext.txt	559	The biology enzymology eukaryotic protein acylation
0.15107806.9024688.html.plaintext.txt	560	HIV 1 Gag mutants dominantly interfere replication wild type virus
0.15107806.9024688.html.plaintext.txt	561	Purification membrane associated protein complex required protein translocation across endoplasmic reticulum
0.15107806.9024688.html.plaintext.txt	562	Disassembly reconstitution signal recognition particle
0.15107806.9024688.html.plaintext.txt	563	Assembly processing infectivity Human Immunodeficiency Virus type 1 Gag mutants
0.15107806.9024688.html.plaintext.txt	564	Viral dynamics human immunodeficiency virus type 1 infection
0.15107806.9024688.html.plaintext.txt	565	Acylation proteins myristic acid occurs co translationally
0.15107806.9024688.html.plaintext.txt	566	Form function use retroviral Gag proteins
0.15107806.9024688.html.plaintext.txt	567	Vpx Simian Immunodeficiency Virus localized primarily outside virus core mature virions
0.15107806.9024688.html.plaintext.txt	568	Complementation Human Immunodeficiency Virus HIV 1 Gag Particle Formation
0.15107806.9024688.html.plaintext.txt	569	199 403 408 Copyright 1997 The Rockefeller University Press
0.16015147.12867639.html.plaintext.txt	0	Human papillomavirus type 16 E2 L1 specific serological T cell responses women vulval intraepithelial neoplasia Emma J
0.16015147.12867639.html.plaintext.txt	1	Davidson12 Peter Sehr3 Rebecca L
0.16015147.12867639.html.plaintext.txt	2	Parish4 Kevin Gaston4 Richard A
0.16015147.12867639.html.plaintext.txt	3	Moore5 Michael Pawlita3 Henry C
0.16015147.12867639.html.plaintext.txt	4	1 Immunology Group Paterson Institute Cancer Research Christie Hospital NHS Trust Wilmslow Road Manchester M20 4BX UK 2 Academic Unit Obstetrics Gynaecology St Marys Hospital Whitworth Park Manchester M13 0JH UK 3 Applied Tumorvirology Deutsches Krebsforschungszentrum Heidelberg Germany 4 Department Biochemistry University Bristol Bristol UK 5 Department Pathology University Cambridge Tennis Court Road Cambridge CB2 1QP UK
0.16015147.12867639.html.plaintext.txt	5	Correspondence Peter Stern psternatpicr
0.16015147.12867639.html.plaintext.txt	6	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Human papillomavirus type 16 HPV 16 associated vulval intraepithelial neoplasia VIN frequently chronic multifocal high grade condition appreciable risk progression vulval cancer
0.16015147.12867639.html.plaintext.txt	7	The requirement treat women VIN recently stimulated use immunotherapy E6E7 oncogene vaccines
0.16015147.12867639.html.plaintext.txt	8	Animal models shown E2 may also useful vaccine target HPV associated disease however little known E2 immunity humans
0.16015147.12867639.html.plaintext.txt	9	This study investigated prevalence HPV 16 E2 specific serological T cell responses 18 women HPV 16 associated VIN 17 healthy volunteers
0.16015147.12867639.html.plaintext.txt	10	E2 responses determined full length E2 GST ELISA ELISPOT proliferation assays using E2 C terminal protein
0.16015147.12867639.html.plaintext.txt	11	As positive controls HPV 16 L1 responses measured using virus like particles VLPs L1 GST ELISA ELISPOT proliferation using VLPs antigen
0.16015147.12867639.html.plaintext.txt	12	The VIN patients showed strong serological response L1 compared healthy volunteers VLP 1518 vs 117 P 0 001 L1 GST ELISA 1818 vs 117 P 0 001
0.16015147.12867639.html.plaintext.txt	13	In contrast L1 specific cellular immune responses detected significant proportion controls prevalent VIN patients proliferation assay 917 vs 1718 P 0 02 interferon ELISPOT 917 vs 1318 Pnot significant
0.16015147.12867639.html.plaintext.txt	14	Similar low numbers patients controls seropositive E2 specific Ig 218 vs 117
0.16015147.12867639.html.plaintext.txt	15	In spite previous studies showing immunogenicity E2 eliciting primary T cell responses vitro low prevalence E2 responses VIN patients controls 218 vs 017
0.16015147.12867639.html.plaintext.txt	16	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Genital human papillomavirus HPV infections extremely common young sexually active women Ho et al
0.16015147.12867639.html.plaintext.txt	17	While majority infections inconsequential short lived virus persistence associated anogenital disease especially cervical carcinogenesis Rozendaal et al
0.16015147.12867639.html.plaintext.txt	18	Several observations indicated host immunity plays important role effecting viral clearance provided impetus development vaccines prevent andor treat cancer cervix precursor lesions
0.16015147.12867639.html.plaintext.txt	19	Most approaches concentrated eliciting specific immunity HPV E6 E7 oncoproteins expressed throughout spectrum HPV associated disease development Borysiewicz et al
0.16015147.12867639.html.plaintext.txt	20	E2 recently proposed potential immune target vaccines aimed treating pre malignant disease Schiller Hildesheim 2000
0.16015147.12867639.html.plaintext.txt	21	This supported data cotton tail rabbit papillomavirus CRPV model vaccination rabbits DNA encoding CRPV E2 found protect development papillomas following subsequent tumour challenge Han et al
0.16015147.12867639.html.plaintext.txt	22	There limited data responses E2 patients HPV associated disease
0.16015147.12867639.html.plaintext.txt	23	Serology studies provided conflicting results IgA IgG responses cryptic peptide correlating antigen exposure cervical cancer patients Dillner et al
0.16015147.12867639.html.plaintext.txt	24	1995 IgA IgG responses detected using baculovirus produced E2 protein associated low rather high grade cervical intraepithelial neoplasia CIN cervical cancer Rocha Zavaleta et al
0.16015147.12867639.html.plaintext.txt	25	These assays variously detect linear conformational epitopes respectively lack concordance may surprising
0.16015147.12867639.html.plaintext.txt	26	A single study investigated naturally occurring E2 specific T cell responses women HPV associated CIN helper T cell responses E2 C terminus N terminus occurred time viral clearance Bontkes et al
0.16015147.12867639.html.plaintext.txt	27	Clearly need baseline investigations naturally occurring E2 specific immune responses patients HPV associated disease
0.16015147.12867639.html.plaintext.txt	28	VIN associated high risk HPV 16 infection 90 cases shown significant increase incidence recent decades particularly younger women van Beurden et al
0.16015147.12867639.html.plaintext.txt	29	It chronic disease characterized recurrence following standard treatment Herod et al
0.16015147.12867639.html.plaintext.txt	30	It therefore provides excellent opportunity study naturally occurring HPV specific immune responses women persistent high risk HPV infections
0.16015147.12867639.html.plaintext.txt	31	This immunity likely arisen consequence chronic exposure virus may insufficient effect disease regression virus clearance
0.16015147.12867639.html.plaintext.txt	32	The relapsing recurring nature VIN likely represent ongoing battle viral immune factors natural control disease
0.16015147.12867639.html.plaintext.txt	33	Thus comparison HPV specific immunity women chronic HPV infections without may provide insight immunological responses play important role natural history HPV associated disease
0.16015147.12867639.html.plaintext.txt	34	We previously described interferon IFN ELISPOT assay facilitates detection HPV 16 E2 specific memory T cell responses E2 C terminus protein following processing presentation autologous dendritic cells DCs Davidson et al
0.16015147.12867639.html.plaintext.txt	35	The advantage system limited use HLA restricted peptides rather allows study full range T cell responses may arisen consequence natural antigen presentation vivo
0.16015147.12867639.html.plaintext.txt	36	In present study measured 86 amino acid C terminal E2 virus like particle VLP L1 specific T cell responses women HPV 16 associated VIN healthy female volunteers using methodology proliferation
0.16015147.12867639.html.plaintext.txt	37	HPV 16 L1 VLP specific T cell responses measured positive control since previous studies found high proportions healthy volunteers patients HPV 16 associated high grade CIN respond antigen
0.16015147.12867639.html.plaintext.txt	38	In addition measured full length GST E2 GST L1 VLP L1 specific serological responses VIN control subjects
0.16015147.12867639.html.plaintext.txt	39	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Patient volunteer materials
0.16015147.12867639.html.plaintext.txt	40	Eighteen women HPV 16 positive VIN 3 recruited Vulva Clinic St Marys Hospital Manchester UK
0.16015147.12867639.html.plaintext.txt	41	Seventeen female age matched healthy volunteers recruited staff Paterson Institute Cancer Research Manchester UK
0.16015147.12867639.html.plaintext.txt	42	These healthy volunteers recruited basis medically fit lifetime history normal cervical cytology previous history cervical vulval pathology
0.16015147.12867639.html.plaintext.txt	43	The Central Manchester Local Research Ethics Committee approved study subjects gave written informed consent
0.16015147.12867639.html.plaintext.txt	44	A vulval biopsy taken patients histological grading HPV analysis
0.16015147.12867639.html.plaintext.txt	45	Histological grading tissue specimens performed two independent consultant histopathologists special interest gynaecological oncology
0.16015147.12867639.html.plaintext.txt	46	HPV analysis performed DNA extracted vulval biopsies proteinase K digestion amplified globulin primers Bauer et al
0.16015147.12867639.html.plaintext.txt	47	HPV DNA detected using GP5GP6 consensus primers De Roda Husman et al
0.16015147.12867639.html.plaintext.txt	48	1995 genotyped using type specific primers Soler et al
0.16015147.12867639.html.plaintext.txt	49	Amplification products resolved 2 agarose gels visualized ethidium bromide staining
0.16015147.12867639.html.plaintext.txt	50	Forty ml blood subject heparinized 6000 iU heparin per 20 ml blood layered Lymphoprep lymphocyte separation medium LSM Nycomed Amersham centrifuged 900 g 20 min 20 degrees C
0.16015147.12867639.html.plaintext.txt	51	Aliquots plasma 250 microl stored 20 degrees C required
0.16015147.12867639.html.plaintext.txt	52	PBMCs collected LSM interface washed centrifuging 400 g PBS three times 10 min
0.16015147.12867639.html.plaintext.txt	53	PBMCs frozen concentration 5x106 cells ml 1 10 DMSO foetal calf serum stored liquid nitrogen required
0.16015147.12867639.html.plaintext.txt	54	HPV 16 E2 L1 specific Ig detected patient plasma ELISA
0.16015147.12867639.html.plaintext.txt	55	L1 antibodies measured using recombinant GST tagged L1 fusion protein HPV 16 VLP protein antigen
0.16015147.12867639.html.plaintext.txt	56	The HPV 16 L1 gene cloned baculovirus transfer vector pAcGHLT Pharmingen co transfected baculovirus DNA Sf9 cells obtained Wei Zhang Dept Pathology University Cambridge
0.16015147.12867639.html.plaintext.txt	57	The resultant supernatant titrated used infection
0.16015147.12867639.html.plaintext.txt	58	Flasks 80 90 confluent Sf9 cells infected baculovirus expressing HPV 16 L1 protein 72 h constant agitation 27 degrees C
0.16015147.12867639.html.plaintext.txt	59	Cells pelleted centrifugation 200 g processed similar manner previously described Kirnbauer et al
0.16015147.12867639.html.plaintext.txt	60	In summary cells homogenized using Dounce homogenizer centrifuged 7500 r
0.16015147.12867639.html.plaintext.txt	61	The pellet resuspended sonicated 22 microm using probe sonicator
0.16015147.12867639.html.plaintext.txt	62	This loaded 40 sucrose centrifuged high speed 45 000 r
0.16015147.12867639.html.plaintext.txt	63	The pellet resuspended sonicated briefly mixing caesium chloride solution final density 1 33 g cm 3
0.16015147.12867639.html.plaintext.txt	64	This mixture centrifuged overnight 45 000 r
0.16015147.12867639.html.plaintext.txt	65	SW50 Ti rotor resultant VLP band density 1 29 g cm 3 collected
0.16015147.12867639.html.plaintext.txt	66	This dialysed PBS remove caesium chloride preparation quality checked Western blot Coomassie staining visualization electron microscopy
0.16015147.12867639.html.plaintext.txt	67	Protein immobilizer microwell plates Exiqon coated baculovirus HPV 16 VLP 2 microg ml 1 PBS antigen PBS control 37 degrees C 1 h
0.16015147.12867639.html.plaintext.txt	68	The plate washed thoroughly 0 05 Tween PBS PBST Sigma subsequent step
0.16015147.12867639.html.plaintext.txt	69	Plasma dilutions 1 100 1 400 1 1600 prepared 3 BSA highly purified 97 Sigma added plate duplicate wells 1 h room temperature
0.16015147.12867639.html.plaintext.txt	70	One plasma sample high HPV 16 L1 VLP absorbance included positive control every plate
0.16015147.12867639.html.plaintext.txt	71	Bound antibodies detected incubation goat anti human IgG heavy light chain Jackson ImmunoResearch Laboratories 1 2400 1 BSA followed biotinylated rabbit anti goat 1 5000 1 BSA Dako 1 h streptavidin HRP 1 5000 1 BSA Dako 30 min
0.16015147.12867639.html.plaintext.txt	72	The plates developed 3355 tetramethylbenzidine TMB Sigma hydrogen peroxide H2O2 phosphatecitrate buffer pH 5
0.16015147.12867639.html.plaintext.txt	73	The reaction stopped addition 1 M H2SO4 plates read automatic plate reader
0.16015147.12867639.html.plaintext.txt	74	The sample total VLP specific absorbance determined subtracting mean absorbance control coated wells plasma dilution 1 400 mean absorbance antigen coated wells plasma dilution 1 400
0.16015147.12867639.html.plaintext.txt	75	This normalized across plates dividing sample total VLP specific absorbance positive control total VLP specific absorbance particular plate
0.16015147.12867639.html.plaintext.txt	76	GST capture ELISA HPV 16 L1 E2
0.16015147.12867639.html.plaintext.txt	77	These ELISAs performed described Sehr et al
0.16015147.12867639.html.plaintext.txt	78	Briefly 96 well Polysorb plates Nunc coated glutathione cross linked casein
0.16015147.12867639.html.plaintext.txt	79	Thereafter wells blocked casein 0 2 wv PBST blocking buffer followed incubation cleared lysates E
0.16015147.12867639.html.plaintext.txt	80	coli overexpressing either L1 lacking 10 N terminal amino acids full length E2 HPV 16 GST X tag proteins diluted blocking buffer 0 25 microg total lysate protein microl 1
0.16015147.12867639.html.plaintext.txt	81	Human sera diluted 1 50 blocking buffer containing 0 25 microg total lysate protein microl 1 parental E
0.16015147.12867639.html.plaintext.txt	82	coli strain BL21 incubated 1 h 4 degrees C block reactivities sera contaminating E
0.16015147.12867639.html.plaintext.txt	83	Coated ELISA plates incubated diluted pre incubated sera
0.16015147.12867639.html.plaintext.txt	84	Bound human antibodies detected donkey anti human IgG HL polyclonal antibody conjugated HRP 1 10 000 dilution blocking buffer Dianova also reacts human IgA IgM IgE
0.16015147.12867639.html.plaintext.txt	85	TMB 10 microg ml 1 0 1 M sodium acetate pH 6 0 0 003 H2O2 used substrate
0.16015147.12867639.html.plaintext.txt	86	After 8 min enzyme reaction stopped adding 50 microl 1 M sulphuric acid per well absorbance 450 nm measured
0.16015147.12867639.html.plaintext.txt	87	The absorbance wells GST tag antigen defined background reactivity serum subtracted absorbance GST X tag proteins calculate specific reactivity serum antigen X
0.16015147.12867639.html.plaintext.txt	88	T cell assays E2 C terminal protein
0.16015147.12867639.html.plaintext.txt	89	The plasmid pWEB E2Ct expresses truncated 86 amino acid E2 protein lacks N terminal amino acids E2 1 279 dimerizes binds DNA normally
0.16015147.12867639.html.plaintext.txt	90	HPV 16 E2 C terminus protein prepared purified homogeneity described Webster et al
0.16015147.12867639.html.plaintext.txt	91	PBMCs quick thawed washed X VIVO 10 medium BioWhittaker UK
0.16015147.12867639.html.plaintext.txt	92	PBMCs concentration 4x106 cells ml 1 X VIVO 10 supplemented 2 mM glutamine transferred tissue culture plates incubated 37 degrees C 2 h
0.16015147.12867639.html.plaintext.txt	93	The non adherent peripheral blood lymphocytes PBLs collected 3 ml X VIVO 10 supplemented 2 mM glutamine Life Technologies 100 ng GM CSF ml 1 50 ng IL 4 ml 1 R D systems added well adherent cells plates incubated 37 degrees C 5 CO2
0.16015147.12867639.html.plaintext.txt	94	Fresh medium supplemented GM CSF IL 4 added cultures day 4
0.16015147.12867639.html.plaintext.txt	95	On day 6 DCs incubated 10 microg purified HPV 16 E2 C terminal protein ml 1 10 microg HPV 16 VLP ml 1 35 000 U tuberculin purified protein derivative PPD Evans Vaccines Ltd ml 1 4 h 37 degrees C
0.16015147.12867639.html.plaintext.txt	96	After time DCs washed twice resuspended 1 ml X VIVO 10 supplemented 100 ng GM CSF ml 1 50 ng IL 4 ml 1 10 ng LPS Sigma ml 1 incubated 37 degrees C 24 h
0.16015147.12867639.html.plaintext.txt	97	Mature DCs harvested washed twice resuspended 100 microl RPMI 1640 Life Technologies
0.16015147.12867639.html.plaintext.txt	98	Autologous PBLs concentration 3x106 ml 1 RPMI 1640 supplemented 10 human AB serum Quest Biomedical 100 microg streptomycin ml 1 100 iU penicillin Life Technologies ml 1 added E2 VLP PPD protein loaded DCs cultured 4 days
0.16015147.12867639.html.plaintext.txt	99	DCs without added antigen also cultured autologous PBLs 4 days negative control
0.16015147.12867639.html.plaintext.txt	100	The PBL cultures harvested washed seeded three replicate wells three doubling dilutions 1x105 cells per well multiscreen 96 well Immobilon P filtration plate Millipore coated anti IFN antibody capture mAb 1 D1K ELISPOT assay kit Mabtech
0.16015147.12867639.html.plaintext.txt	101	In addition PBMCs seeded duplicate wells concentration 2x105 cells per well medium alone negative control 10 microg E2 C terminus protein ml 1 10 microg HPV 16 VLP ml 1 35 000 U PPD ml 1 0 5 microg phytohaemagglutinin PHA Murex Diagnostics ml 1 positive control plate
0.16015147.12867639.html.plaintext.txt	102	The plates incubated overnight 37 degrees C assay developed according manufacturers instructions
0.16015147.12867639.html.plaintext.txt	103	Spots counted cell density using dissecting microscope scores normalized mean standard errors calculated
0.16015147.12867639.html.plaintext.txt	104	Results plotted number IFN producing cells per 2x104 cells DC stimulated T cells 2x105 cells PBMCs subtracting background medium control responses
0.16015147.12867639.html.plaintext.txt	105	A positive ELISPOT defined 20 spots per 2x104 2x105 cells respectively
0.16015147.12867639.html.plaintext.txt	106	PBMCs seeded triplicate wells 96 well round bottomed microtitre plate Alpha Laboratories 2x105 cells per well RPMI supplemented 10 AB serum 100 microg streptomycin ml 1 100 iU penicillin ml 1
0.16015147.12867639.html.plaintext.txt	107	PBMCs alone medium control PBMCs 5 microg E2 protein ml 1 2 5 microg HPV 16 VLP ml 1 35 000 U PPD ml 1 0 5 microg PHA ml 1 incubated 5 days 37 degrees C
0.16015147.12867639.html.plaintext.txt	108	During final 18 h culture 1 microCi per well 3Hthymidine NEN Life Science Products added
0.16015147.12867639.html.plaintext.txt	109	The cells harvested using Packard 96 well vacuum cell harvester Unifilter plates Packard BioSciences left dry overnight 30 microl per well Microscint 20 scintillation fluid Packard BioSciences added
0.16015147.12867639.html.plaintext.txt	110	3HThymidine incorporation measured using Topcount scintillation counter Packard
0.16015147.12867639.html.plaintext.txt	111	Results plotted mean number counts antigen stimulated PBMCs divided mean number counts medium negative control PBMCs give stimulation index
0.16015147.12867639.html.plaintext.txt	112	A stimulation index 2 scored positive
0.16015147.12867639.html.plaintext.txt	113	Cut values define antibody positive sera calculated separately antigen assay mean specific absorbance values control sera3SD excluding positive outliers
0.16015147.12867639.html.plaintext.txt	114	The 2 test used compare serological T cell responses patient control groups
0.16015147.12867639.html.plaintext.txt	115	Students test used compare mean ages two groups
0.16015147.12867639.html.plaintext.txt	116	A value P 0 05 considered statistically significant values P 0 05 considered significant NS
0.16015147.12867639.html.plaintext.txt	117	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Patient control group characteristics The mean age VIN patients healthy volunteers 41 1 years range 28 61 years 39 5 years range 27 58 respectively PNS
0.16015147.12867639.html.plaintext.txt	118	The healthy volunteers comprised women lifetime history normal cervical cytology previous history cervical vulval pathology
0.16015147.12867639.html.plaintext.txt	119	The VIN patient group comprised women HPV 16 positive high grade VIN
0.16015147.12867639.html.plaintext.txt	120	A histological diagnosis VIN 3 made average 6 4 years range 6 months 17 years prior recruitment study
0.16015147.12867639.html.plaintext.txt	121	Fourteen women undergone least one previous treatment nine women undergone three previous treatments VIN 3 surgical excision laser therapy trial entry
0.16015147.12867639.html.plaintext.txt	122	Thirteen patients also previously treated high grade CIN either laser cone biopsy large loop excision transformation zone hysterectomy
0.16015147.12867639.html.plaintext.txt	123	L1 E2 specific serological responses Serological responses HPV 16 L1 measured VIN patients controls ELISA using recombinant GST tagged L1 fusion protein HPV 16 VLP antigen
0.16015147.12867639.html.plaintext.txt	124	L1 specific serological responses prevalent VIN group compared controls using L1 fusion protein 1818 patients vs 117 controls P 0 0005 VLP ELISA 1518 patients vs 117 controls P 0 0005 Fig
0.16015147.12867639.html.plaintext.txt	125	Linear regression analysis revealed statistically significant correlation two ELISAs r0 85 P 0 001
0.16015147.12867639.html.plaintext.txt	126	Small similar numbers women groups seropositive HPV 16 E2 specific Ig 218 VIN patients vs 117 controls Fig
0.16015147.12867639.html.plaintext.txt	127	View larger version 12K Fig
0.16015147.12867639.html.plaintext.txt	128	HPV 16 L1 E2 specific serological responses VIN patients healthy volunteers
0.16015147.12867639.html.plaintext.txt	129	L1 E2 Ig levels measured ELISA using HPV 16 L1 virus like particles VLPs recombinant GST tagged fusion proteins b
0.16015147.12867639.html.plaintext.txt	130	A positive response defined mean specific corrected absorbance 206 mUnits VLP ELISA mean specific absorbance 82 mUnits GST L1 264 mUnits GST E2 fusion protein ELISAs mean score healthy volunteer group3SD minus positive outliers
0.16015147.12867639.html.plaintext.txt	131	Positive thresholds indicated horizontal lines
0.16015147.12867639.html.plaintext.txt	132	L1 E2 specific T cells L1 E2 specific T cell responses measured patient control groups proliferation assay IFN ELISPOT
0.16015147.12867639.html.plaintext.txt	133	PHA tuberculin PPD included positive control antigens assays
0.16015147.12867639.html.plaintext.txt	134	All donors showed strong proliferative responses PHA PPD
0.16015147.12867639.html.plaintext.txt	135	Two different ELISPOT assays used first PBMCs incubated protein antigens 24 h testing IFN release
0.16015147.12867639.html.plaintext.txt	136	In second protein loaded DCs used stimulate autologous T cells 4 days testing latter IFN release
0.16015147.12867639.html.plaintext.txt	137	In ELISPOT assays strong PHA PPD responses observed although frequency responding cells much greater DC stimulated T cell assays full PBMC assays
0.16015147.12867639.html.plaintext.txt	138	In contrast L1 E2 specific T cell responses observed DC stimulated T cell assays PBMC assays Fig
0.16015147.12867639.html.plaintext.txt	139	View larger version 39K Fig
0.16015147.12867639.html.plaintext.txt	140	ELISPOT data two individual VIN patients
0.16015147.12867639.html.plaintext.txt	141	c ELISPOT data two individual VIN patients following 24 h stimulation bulk PBMC cultures antigen
0.16015147.12867639.html.plaintext.txt	142	A positive response defined 20 spots per 2x105 cells
0.16015147.12867639.html.plaintext.txt	143	A 24 h stimulation PBMCs antigen sufficient reveal memory response PPD patients
0.16015147.12867639.html.plaintext.txt	144	b d ELISPOT data two VIN patients following 4 day stimulation T cells protein pulsed DCs
0.16015147.12867639.html.plaintext.txt	145	A positive response defined 20 spots per 104 cells
0.16015147.12867639.html.plaintext.txt	146	Positive E2 VLP responses demonstrated patient 8 b patient 2 d following 4 day stimulation procedure
0.16015147.12867639.html.plaintext.txt	147	L1 specific T cell responses prevalent VIN group healthy volunteers proliferation assay 1718 patients vs 917 controls P 0 02 IFN ELISPOT 1318 patients vs 917 controls PNS Table 1 although latter reach statistical significance
0.16015147.12867639.html.plaintext.txt	148	Of 35 women tested L1 specific T cell responses seven showed proliferative responses 19 showed proliferative responses IFN release three showed IFN release
0.16015147.12867639.html.plaintext.txt	149	All patients showed L1 specific serological responses also demonstrated L1 specific T cell responses either proliferation assay alone 517 proliferation assay IFN ELISPOT 1217 IFN ELISPOT alone 117
0.16015147.12867639.html.plaintext.txt	150	E2 specific T cell responses detected two VIN patients none controls
0.16015147.12867639.html.plaintext.txt	151	These responses observed IFN ELISPOT proliferation assay one patients also seropositive E2 specific Ig Table 1
0.16015147.12867639.html.plaintext.txt	152	In addition showed L1 specific serological T cell responses T cell assays
0.16015147.12867639.html.plaintext.txt	153	E2 L1 specific Ig T cell responses VIN patients healthy volunteers
0.16015147.12867639.html.plaintext.txt	154	Results serological assays based E2 L1 GST tagged fusion protein ELISAs
0.16015147.12867639.html.plaintext.txt	155	A positive serological response HPV 16 E2 L1 GST tagged fusion proteins defined mean specific absorbancethe mean control group3SD minus positive outliers
0.16015147.12867639.html.plaintext.txt	156	A positive ELISPOT response defined 20 spots per 104 cells subtracting background DCs0 responses
0.16015147.12867639.html.plaintext.txt	157	Note background responses subtracted table
0.16015147.12867639.html.plaintext.txt	158	A positive proliferative response defined stimulation index 2
0.16015147.12867639.html.plaintext.txt	159	Positive responses shown bold
0.16015147.12867639.html.plaintext.txt	160	View table b Healthy volunteers
0.16015147.12867639.html.plaintext.txt	161	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES In study investigated HPV 16 E2 L1 specific serological T cell responses women HPV 16 positive high grade VIN female age matched healthy volunteers negative history previous current cervical vulval pathology
0.16015147.12867639.html.plaintext.txt	162	Studies cervical neoplasia shown antibodies viral capsids seen concomitantly within months following acquisition HPV 16 DNA 70 infected Carter et al
0.16015147.12867639.html.plaintext.txt	163	1995 stable time Carter et al
0.16015147.12867639.html.plaintext.txt	164	1996 even 15 years follow Shah et al
0.16015147.12867639.html.plaintext.txt	165	There therefore little evidence exposure HPV 16 cohort healthy volunteers
0.16015147.12867639.html.plaintext.txt	166	This may partly explained lifetime history normal cervical cytology although genital high risk HPV infections frequent always associated abnormal smears
0.16015147.12867639.html.plaintext.txt	167	The cut values defined study assays consistent absorbance values measured sera virgins data shown suggesting normal sera generally representative population previously exposed HPV 16
0.16015147.12867639.html.plaintext.txt	168	In contrast VLP L1 specific antibodies associated majority HPV 16 positive high grade VIN patients 1518 1718 respectively compared one healthy volunteers demonstrating seropositivity
0.16015147.12867639.html.plaintext.txt	169	A dominant antibody response humans HPV 16 capsids involves type specific epitope present assembled capsids individual pentavalent capsomeres Heino et al
0.16015147.12867639.html.plaintext.txt	170	The L1 forms pentamers N terminus fused GST allow detection L1 reactive antibodies
0.16015147.12867639.html.plaintext.txt	171	Thus GST L1 assay may allow epitopes ordinarily hidden within fully assembled capsid phenotype become available serological reactivity may explain responses seen using assay VLP assay
0.16015147.12867639.html.plaintext.txt	172	Previous studies HPV 16 VLP specific antibodies women high grade VIN found approximately 60 patients seropositive studies determine HPV status lesions therefore may identified HPV 16 negative disease Hildesheim et al
0.16015147.12867639.html.plaintext.txt	173	We found HPV 16 E2 specific Ig one healthy volunteers consistent populations lack exposure HPV 16 218 HPV 16 positive high grade VIN patients seropositive
0.16015147.12867639.html.plaintext.txt	174	From previous studies serological responses E2 protein appear correlate antigen exposure Lehtinen et al
0.16015147.12867639.html.plaintext.txt	175	However clear different assays baculoviral protein peptide GST fusion E2 antibodies directly compared
0.16015147.12867639.html.plaintext.txt	176	In particular know whether GST E2 fusion protein native conformation ELISA
0.16015147.12867639.html.plaintext.txt	177	Nevertheless relatively infrequent detection E2 specific Ig responses VIN patient cohort may indicate lack E2 expression high grade VIN lesions
0.16015147.12867639.html.plaintext.txt	178	The E2 open reading frame typically disrupted following virus integration host cell genome process shown occur malignant transformation HPV infected cells Graham Herrington 2000 Peitsaro et al
0.16015147.12867639.html.plaintext.txt	179	Cell mediated immunity likely play pivotal role eradicating established HPV infection effecting disease regression
0.16015147.12867639.html.plaintext.txt	180	IFN ELISPOT potentially allows detection low frequency memory CD8 cytotoxic T lymphocytes CTLs CD4 T helper 1 Th1 cells since release IFN following re exposure specific antigens Sallusto et al
0.16015147.12867639.html.plaintext.txt	181	Multiple restimulation normal donor T cell cultures autologous E2 C terminus protein pulsed DCs shown induce CTLs capable E2 specific lysis autologous lymphoblastoid cell lines infected recombinant vaccinia virus encoding HPV 16 E2 Davidson et al
0.16015147.12867639.html.plaintext.txt	182	Thus E2 specific CTL repertoire available normal individuals
0.16015147.12867639.html.plaintext.txt	183	Other studies using overlapping peptides HPV 16 E2 protein revealed broad E2 specific T helper cell repertoire healthy volunteers de Jong et al
0.16015147.12867639.html.plaintext.txt	184	DCs pulsed HPV 16 VLP also shown stimulate primarily type 1 dominated T helper cell responses Lenz et al
0.16015147.12867639.html.plaintext.txt	185	2001 MHC class I restricted CTL responses Rudolf et al
0.16015147.12867639.html.plaintext.txt	186	The specific release IFN CD4 Th1 cells CD8 CTLs following stimulation E2 VLP protein antigens may therefore provide useful measure cell mediated immune responses likely important natural clearance HPV infections
0.16015147.12867639.html.plaintext.txt	187	In present study ELISPOT responses C terminal E2 L1 required 4 day stimulation T cells autologous protein pulsed DCs 24 h stimulation bulk PBMC cultures antigen sufficient reveal responses
0.16015147.12867639.html.plaintext.txt	188	This suggests appropriate antigen processing presentation necessary demonstrate low frequency memory responses
0.16015147.12867639.html.plaintext.txt	189	VLP L1 specific T cell responses prevalent VIN group compared controls IFN ELISPOT 72 vs 53 PNS proliferation assay 94 vs 53 P 0 02
0.16015147.12867639.html.plaintext.txt	190	All one patients seropositive L1 specific Ig also demonstrated L1 specific proliferative T cell responses
0.16015147.12867639.html.plaintext.txt	191	Twelve patients additionally showed L1 specific IFN release ELISPOT
0.16015147.12867639.html.plaintext.txt	192	All one healthy volunteers seronegative HPV 16 L1 specific Ig significant proportion group L1 specific proliferative IFN releasing T cell responders
0.16015147.12867639.html.plaintext.txt	193	In absence HPV 16 L1 specific antibodies T cells measured assays likely reflect cross reactivity shared epitopes following exposure HPV types
0.16015147.12867639.html.plaintext.txt	194	There evidence studies Williams et al
0.16015147.12867639.html.plaintext.txt	195	2002 HPV 11 Steele et al
0.16015147.12867639.html.plaintext.txt	196	Overall HPV 16 positive VIN patients high levels antibodies viral capsid proteins likely capable neutralizing virus
0.16015147.12867639.html.plaintext.txt	197	This antibody production presumably also reflected high prevalence T helper responses measured either proliferation ELISPOT
0.16015147.12867639.html.plaintext.txt	198	E2 seropositivity prevalent disease T helper responses de Jong et al
0.16015147.12867639.html.plaintext.txt	199	2002 may reflect exposure different HPV types shared epitopes
0.16015147.12867639.html.plaintext.txt	200	However appear subgroup patients specific T cell responses E2 measured proliferation ELISPOT
0.16015147.12867639.html.plaintext.txt	201	These two patients clinical responders trial HPV vaccine E
0.16015147.12867639.html.plaintext.txt	202	The clinical outcome may result shift immune factors clear lesions may heterogeneous concomitant reduction local virus immune suppression Tindle 2002
0.16015147.12867639.html.plaintext.txt	203	None healthy volunteers showed evidence E2 specific T cell responses either proliferation assay ELISPOT
0.16015147.12867639.html.plaintext.txt	204	This consistent results Bontkes et al
0.16015147.12867639.html.plaintext.txt	205	1999 found E2 specific T helper cell responses healthy control subjects using IL 2 release assay Bontkes et al
0.16015147.12867639.html.plaintext.txt	206	1999 contradictory findings de Jong et al
0.16015147.12867639.html.plaintext.txt	207	2002 found frequent strong T helper cell responses HPV 16 E2 peptides four eight normal donors
0.16015147.12867639.html.plaintext.txt	208	There several explanations discrepancies noted studies
0.16015147.12867639.html.plaintext.txt	209	Firstly evidence exposure HPV 16 one healthy volunteers recruited study
0.16015147.12867639.html.plaintext.txt	210	2002 tested anonymous donors E2 specific T helper cell responses details regarding age sex cervical smear history HPV 16 VLP antibody status subjects
0.16015147.12867639.html.plaintext.txt	211	Secondly methodology used different
0.16015147.12867639.html.plaintext.txt	212	used 30 mer overlapping peptides full HPV 16 E2 sequence
0.16015147.12867639.html.plaintext.txt	213	Significant cross reactivity seen particular HPV 16 E2 specific T cell responses homologous peptides HPV types
0.16015147.12867639.html.plaintext.txt	214	Thus measured responses may reflect priming HPV types HPV 16
0.16015147.12867639.html.plaintext.txt	215	Furthermore clear whether peptides investigated study naturally processed antigen presenting cells vivo
0.16015147.12867639.html.plaintext.txt	216	In contrast since intact E2 C terminus protein used measure T cell responses study measured E2 specific immunity must reflect stimulation naturally processed peptides
0.16015147.12867639.html.plaintext.txt	217	This also true study Bontkes et al
0.16015147.12867639.html.plaintext.txt	218	1999 E2 C terminus N terminus proteins used stimulate PBMCs 7 days testing supernatant IL 2 concentration
0.16015147.12867639.html.plaintext.txt	219	However assays used present study also test responses HPV 16 E2 N terminus since possible missing significant response evident IL 2 release assays Bontkes et al
0.16015147.12867639.html.plaintext.txt	220	It appears exposure HPV 16 positive VIN stimulates antibody T cell responses L1 protein may always sufficient clear lesions
0.16015147.12867639.html.plaintext.txt	221	In contrast E2 specific T cell responses rare although repertoire exists possible absence may facilitate persistence VIN lesions
0.16015147.12867639.html.plaintext.txt	222	Without clear proof E2 specific T cell responses associated lesion resolution unclear whether lack responsiveness indicates inappropriateness assay true absence E2 specific T cells
0.16015147.12867639.html.plaintext.txt	223	Nevertheless studies immunity early late HPV 16 protein VIN provide baseline comparison responses vaccines chimeric VLPs including L1 E7 E2 Schiller Hildesheim 2000
0.16015147.12867639.html.plaintext.txt	224	The challenge demonstrate immune responses patients time virus clearance systemic local analyses long term follow studies large numbers young women required
0.16015147.12867639.html.plaintext.txt	225	This resolve whether E2 simply non immunogenic whether absence immunogenicity specifically associated persistence HPV 16 infection
0.16015147.12867639.html.plaintext.txt	226	ACKNOWLEDGEMENTS The research P
0.16015147.12867639.html.plaintext.txt	227	S supported Cancer Research UK
0.16015147.12867639.html.plaintext.txt	228	supported PhD studentship BBSRC Enact Pharma PLC
0.16015147.12867639.html.plaintext.txt	229	supported research grant Royal Society
0.16015147.12867639.html.plaintext.txt	230	The Joseph Starkey Fellowship Wigan Cancer Research Fund Cancer Research UK supported E
0.16015147.12867639.html.plaintext.txt	231	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Bauer H
0.16015147.12867639.html.plaintext.txt	232	Determination genital human papillomavirus infection consensus PCR amplification
0.16015147.12867639.html.plaintext.txt	233	In Diagnostic Molecular Pathology Practical Approach vol
0.16015147.12867639.html.plaintext.txt	234	Oxford Oxford University Press
0.16015147.12867639.html.plaintext.txt	235	Human papillomavirus type 16 E2 specific T helper lymphocyte responses patients cervical intraepithelial neoplasia
0.16015147.12867639.html.plaintext.txt	236	A recombinant vaccinia virus encoding human papillomavirus types 16 18 E6 E7 proteins immunotherapy cervical cancer
0.16015147.12867639.html.plaintext.txt	237	The natural history human papillomavirus type 16 capsid antibodies among cohort university women
0.16015147.12867639.html.plaintext.txt	238	Human T cell responses HPV 16 E2 generated monocyte derived dendritic cells
0.16015147.12867639.html.plaintext.txt	239	Frequent detection human papillomavirus 16 E2 specific T helper immunity healthy subjects
0.16015147.12867639.html.plaintext.txt	240	The use general primers Gp5 Gp6 elongated 3 ends adjacent highly conserved sequences improves papillomavirus detection PCR
0.16015147.12867639.html.plaintext.txt	241	A population based seroepidemiological study cervical cancer
0.16015147.12867639.html.plaintext.txt	242	HPV 16 E2 gene disruption sequence variation CIN 3 lesions invasive squamous cell carcinomas cervix relation numerical chromosome abnormalities
0.16015147.12867639.html.plaintext.txt	243	Presence antibodies seven human papillomavirus type 16 derived peptides cervical cancer patients healthy controls
0.16015147.12867639.html.plaintext.txt	244	J Infect Dis 170 1424 1431
0.16015147.12867639.html.plaintext.txt	245	DNA vaccination prevents andor delays carcinoma development papillomavirus induced skin papillomas rabbits
0.16015147.12867639.html.plaintext.txt	246	Immunization rabbits cottontail rabbit papillomavirus E1 E2 genes protective immunity induced gene gun mediated intracutaneous delivery intramuscular injection
0.16015147.12867639.html.plaintext.txt	247	Human papillomavirus type 16 capsid proteins produced recombinant Semliki Forest virus assemble virus like particles
0.16015147.12867639.html.plaintext.txt	248	Vulvar intraepithelial neoplasia long term follow treated untreated women
0.16015147.12867639.html.plaintext.txt	249	Br J Obstet Gynaecol 103 446 452
0.16015147.12867639.html.plaintext.txt	250	Human papillomavirus type 16 risk preinvasive invasive vulvar cancer results seroepidemiological case control study
0.16015147.12867639.html.plaintext.txt	251	Natural history cervicovaginal papillomavirus infection young women
0.16015147.12867639.html.plaintext.txt	252	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.16015147.12867639.html.plaintext.txt	253	Encapsulated plasmid DNA treatment human papillomavirus 16 associated anal dysplasia phase I study ZYC101
0.16015147.12867639.html.plaintext.txt	254	Clin Cancer Res 8 1028 1037
0.16015147.12867639.html.plaintext.txt	255	Pre post treatment serum antibody responses HPV 16 E2 HSV 2 ICP8 proteins women cervical carcinoma
0.16015147.12867639.html.plaintext.txt	256	Serum antibody responses human papillomavirus relation tumor characteristics response treatment survival carcinoma uterine cervix
0.16015147.12867639.html.plaintext.txt	257	Cancer Immunol Immunother 40 201 205
0.16015147.12867639.html.plaintext.txt	258	Papillomavirus like particles induce acute activation dendritic cells
0.16015147.12867639.html.plaintext.txt	259	A phase I trial human papillomavirus HPV peptide vaccine women high grade cervical vulvar intraepithelial neoplasia HPV 16 positive
0.16015147.12867639.html.plaintext.txt	260	Clin Cancer Res 6 3406 3416
0.16015147.12867639.html.plaintext.txt	261	Integrated human papillomavirus type 16 frequently found cervical cancer precursors demonstrated novel quantitative real time PCR technique
0.16015147.12867639.html.plaintext.txt	262	J Clin Microbiol 40 886 891
0.16015147.12867639.html.plaintext.txt	263	Differences serological IgA responses recombinant baculovirus derived human papillomavirus E2 protein natural history cervical neoplasia
0.16015147.12867639.html.plaintext.txt	264	Brit J Cancer 75 1144 1150
0.16015147.12867639.html.plaintext.txt	265	High risk human papillomavirus cytomorphological normal smears high predictive value development severe dysplasia
0.16015147.12867639.html.plaintext.txt	266	CO2 ZlinktypeDOI CrossRefMedline
0.16015147.12867639.html.plaintext.txt	267	Human dendritic cells activated chimeric human papillomavirus type 16 virus like particles induce epitope specific human T cell responses vitro
0.16015147.12867639.html.plaintext.txt	268	Two subsets memory T lymphocytes distinct homing potentials effector functions see comments
0.16015147.12867639.html.plaintext.txt	269	Vaccination HPV 18 E7 pulsed dendritic cells patient metastatic cervical cancer
0.16015147.12867639.html.plaintext.txt	270	N Engl J Med 346 1752 1753
0.16015147.12867639.html.plaintext.txt	271	Developing HPV virus like particle vaccines prevent cervical cancer progress report
0.16015147.12867639.html.plaintext.txt	272	A generic capture ELISA recombinant proteins fused glutathione S transferase validation HPV serology
0.16015147.12867639.html.plaintext.txt	273	J Immunol Methods 253 153 162
0.16015147.12867639.html.plaintext.txt	274	HPV antibody detection ELISA capsid protein L1 fused glutathione S transferase
0.16015147.12867639.html.plaintext.txt	275	Antibodies human papillomavirus 16 subsequent situ invasive cancer cervix
0.16015147.12867639.html.plaintext.txt	276	Cancer Epidemiol Biomark Prev 6 233 237
0.16015147.12867639.html.plaintext.txt	277	Detection human papillomavirus types 6 11 16 18 mucosal cutaneous lesions multiplex polymerase chain reaction
0.16015147.12867639.html.plaintext.txt	278	J Virol Methods 35 143 157
0.16015147.12867639.html.plaintext.txt	279	Detection CD4 CD8 T cell responses human papillomavirus type 1 antigens expressed various stages virus life cycle using enzyme linked immunospot assay gamma interferon release
0.16015147.12867639.html.plaintext.txt	280	Inverse relationship expression human papillomavirus type 16 transcription factor E2 virus DNA copy number progression cervical intraepithelial neoplasia
0.16015147.12867639.html.plaintext.txt	281	Human papillomavirus specific serologic response vulvar neoplasia
0.16015147.12867639.html.plaintext.txt	282	Immune evasion human papillomavirus associated cervical cancer
0.16015147.12867639.html.plaintext.txt	283	Physical status E2 human papillomavirus 16 viral gene cervical preneoplastic neoplastic lesions
0.16015147.12867639.html.plaintext.txt	284	Multifocal vulvar intraepithelial neoplasia grade III multicentric lower genital tract neoplasia associated transcriptionally active human papillomavirus
0.16015147.12867639.html.plaintext.txt	285	Natural T helper immunity human papillomavirus type 16 HPV 16 E7 derived peptide epitopes patients HPV 16 positive cervical lesions identification 3 human leukocyte antigen class II restricted epitopes
0.16015147.12867639.html.plaintext.txt	286	CO2 ClinktypeDOI CrossRefMedline
0.16015147.12867639.html.plaintext.txt	287	A monoclonal antibody intact human papillomavirus type 16 capsids blocks serological reactivity human sera
0.16015147.12867639.html.plaintext.txt	288	The human papillomavirus HPV 16 E2 protein induces apoptosis absence HPV proteins via p53 dependent pathway
0.16015147.12867639.html.plaintext.txt	289	Identification human papillomavirus seroconversions
0.16015147.12867639.html.plaintext.txt	290	Analysis CD4 T cell responses human papillomavirus HPV type 11 L1 healthy adults reveals high degree responsiveness cross reactivity HPV types
0.16015147.12867639.html.plaintext.txt	291	Definition linear antigenic regions HPV 16 L1 capsid protein using synthetic virion like particles
0.16015147.12867639.html.plaintext.txt	292	Received 13 January 2003 accepted 13 May 2003
0.25418594.11181775.html.plaintext.txt	0	Safety Immunogenicity Trial Adult Volunteers Human Papillomavirus 16 L1 Virus Like Particle Vaccine
0.25418594.11181775.html.plaintext.txt	1	Harro Yuk Ying Susana Pang Richard B
0.25418594.11181775.html.plaintext.txt	2	Roden Allan Hildesheim Zhaohui Wang Mary Jane Reynolds T
0.25418594.11181775.html.plaintext.txt	3	Christopher Mast Robin Robinson Brian R
0.25418594.11181775.html.plaintext.txt	4	Karron Joakim Dillner John T
0.25418594.11181775.html.plaintext.txt	5	Karron Center Immunization Research Department International Medicine School Hygiene Public Health R
0.25418594.11181775.html.plaintext.txt	6	Roden Department Pathology School Medicine The Johns Hopkins University Baltimore MD Y
0.25418594.11181775.html.plaintext.txt	7	Lowy Laboratory Cellular Oncology Division Basic Sciences A
0.25418594.11181775.html.plaintext.txt	8	Hildesheim Environmental Epidemiology Branch Division Cancer Epidemiology Genetics National Cancer Institute Bethesda MD Z
0.25418594.11181775.html.plaintext.txt	9	Dillner Microbiology Tumor Biology Centre Karolinska Institute Stockholm Sweden R
0.25418594.11181775.html.plaintext.txt	10	Murphy Laboratory Infectious Diseases National Institute Allergy Infectious Diseases Bethesda
0.25418594.11181775.html.plaintext.txt	11	National Institutes Health Bldg
0.25418594.11181775.html.plaintext.txt	12	1D 32 Bethesda MD 20892 e mail drlathelix
0.25418594.11181775.html.plaintext.txt	13	ABSTRACT Top Notes Abstract Introduction Subjects Methods Results Discussion References Background Studies animal models shown systemic immunization papillomavirus virus like particle VLP vaccine composed L1 major structural viral protein confer protection subsequent experimental challenge homologous virus
0.25418594.11181775.html.plaintext.txt	14	Here report results double blind placebo controlled dose escalation trial evaluate safety immunogenicity human papillomavirus HPV type 16 HPV16 L1 VLP vaccine healthy adults
0.25418594.11181775.html.plaintext.txt	15	Methods Volunteers given intramuscular injections placebo 10 50 microg doses HPV16 L1 VLP vaccine given without adjuvant alum MF59 adjuvants 0 1 4 months
0.25418594.11181775.html.plaintext.txt	16	All vaccine recipients monitored clinical signs symptoms 7 days inoculation
0.25418594.11181775.html.plaintext.txt	17	Immune responses measured HPV16 L1 VLP based enzyme linked immunosorbent assay ELISA HPV16 pseudovirion neutralization assay
0.25418594.11181775.html.plaintext.txt	18	The antibody titers given reciprocals highest dilution showing positive reactivity assay
0.25418594.11181775.html.plaintext.txt	19	All statistical tests two sided
0.25418594.11181775.html.plaintext.txt	20	Results The prevaccination geometric mean ELISA titer six seropositive individuals 202 range 40 640
0.25418594.11181775.html.plaintext.txt	21	All vaccine formulations well tolerated subjects receiving vaccine seroconverted
0.25418594.11181775.html.plaintext.txt	22	Serum antibody responses 1 month third injection dose dependent recipients vaccine without adjuvant MF59 similar doses alum adjuvant
0.25418594.11181775.html.plaintext.txt	23	With higher dose geometric means serum ELISA antibody titers 95 confidence intervals purified VLP 1 month third injection follows 10 240 1499 69 938 without adjuvant 10 240 1114 94 145 MF59 2190 838 5723 alum
0.25418594.11181775.html.plaintext.txt	24	Responses subjects within group similar
0.25418594.11181775.html.plaintext.txt	25	Neutralizing ELISA antibody titers highly correlated Spearman correlation
0.25418594.11181775.html.plaintext.txt	26	85 confirming ELISA titers valid proxies neutralizing antibodies
0.25418594.11181775.html.plaintext.txt	27	Conclusions The HPV16 L1 VLP vaccine well tolerated highly immunogenic even without adjuvant majority recipients achieving serum antibody titers approximately 40 fold higher observed natural infection
0.25418594.11181775.html.plaintext.txt	28	INTRODUCTION Top Notes Abstract Introduction Subjects Methods Results Discussion References Invasive cervical cancer develops approximately 400 000 women per year worldwide results approximately 200 000 deaths per year 12
0.25418594.11181775.html.plaintext.txt	29	The greatest burden disease developing countries cervical cancer often frequent female malignancy may constitute one quarter female cancers
0.25418594.11181775.html.plaintext.txt	30	Early detection premalignant cervical neoplasia possible Pap smears difficult establish screening programs developing countries
0.25418594.11181775.html.plaintext.txt	31	In United States Pap smear screening follow estimated cost 5 billion dollars annually widespread availability screening associated 75 reduction incidence cervical cancer 3
0.25418594.11181775.html.plaintext.txt	32	However United States cancer still accounts 7 female malignancies 5000 deaths per year 4
0.25418594.11181775.html.plaintext.txt	33	Clinical molecular epidemiologic investigations identified human papillomavirus HPV major cause cervical cancer cervical dysplasia 56
0.25418594.11181775.html.plaintext.txt	34	Virtually cervical cancers contain genes high risk HPVs commonly types 16 18 31 45 relative frequency types found remarkably similar regions world 67
0.25418594.11181775.html.plaintext.txt	35	HPV16 found approximately 50 cervical cancers types 18 31 45 account additional 25 30 HPV positive tumors
0.25418594.11181775.html.plaintext.txt	36	Identification HPV causal factor virtually cervical cancers implies development effective vaccine high risk HPV could prevent premalignant malignant disease associated HPV infection
0.25418594.11181775.html.plaintext.txt	37	Since prophylactic viral vaccines long record cost effective approach prevent infection modify disease vaccine might also lower cost screening treating premalignant cervical disease
0.25418594.11181775.html.plaintext.txt	38	HPVs DNA tumor viruses contain oncogenes
0.25418594.11181775.html.plaintext.txt	39	There might theoretic arguments presence genes disrupt normal growth controls vaccine destined normal individuals
0.25418594.11181775.html.plaintext.txt	40	To develop prophylactic vaccine HPV infection others 8 therefore taken subunit vaccine approach analogous used successfully hepatitis B induced disease including hepatocarcinoma 9
0.25418594.11181775.html.plaintext.txt	41	Papillomaviruses encode major capsid protein L1 intrinsic capacity self assemble virus like particles VLPs absence viral gene products 10 13
0.25418594.11181775.html.plaintext.txt	42	Recombinant L1 VLPs morphologically indistinguishable authentic virions contain immunodominant conformationally dependent neutralization epitopes present authentic virions ability generate high titers type specific neutralizing antibodies 8
0.25418594.11181775.html.plaintext.txt	43	Several trials preventive papillomavirus vaccine candidates using L1 VLPs purified insect cells conducted use cutaneous cottontail rabbit papillomavirus CRPV oral mucosal bovine papillomavirus 4 BPV4 canine oral papillomavirus COPV disease model natural host
0.25418594.11181775.html.plaintext.txt	44	Three subcutaneous injections CRPV L1 VLPs given without adjuvant combined alum Freunds adjuvant protected rabbits persistent infection subsequent carcinoma high dose CRPV challenge 1415
0.25418594.11181775.html.plaintext.txt	45	Protection lasted least 1 year 15
0.25418594.11181775.html.plaintext.txt	46	Similarly dogs calves given two intramuscular injections COPV L1 VLPs without adjuvant BPV4 L1 VLPs alum respectively protected subsequent oral mucosal challenge 1617
0.25418594.11181775.html.plaintext.txt	47	In CRPV COPV models passive transfer serum immunoglobulin Ig G animals immunized L1 VLPs protected naive animals challenged homologous virus indicating neutralizing antibodies sufficient confer protection 1416
0.25418594.11181775.html.plaintext.txt	48	Since papillomaviruses species specific HPVs induce disease animals 4 HPV vaccine development evaluation require studies humans
0.25418594.11181775.html.plaintext.txt	49	Therefore initial step demonstrating proof principle developed prophylactic recombinant HPV16 L1 VLP vaccine candidate produced insect cells recombinant baculovirus testing humans
0.25418594.11181775.html.plaintext.txt	50	This study designed evaluate safety immunogenicity healthy young adults two dose levels 10 50 microg HPV16 L1 VLP vaccine given aqueous solution without adjuvant mixed alum MF59 adjuvant
0.25418594.11181775.html.plaintext.txt	51	SUBJECTS AND METHODS Top Notes Abstract Introduction Subjects Methods Results Discussion References Vaccine
0.25418594.11181775.html.plaintext.txt	52	Recombinant baculovirus expressing full length L1 capsid gene HPV16 strain 114K 11 VLPs constructed use bacmid system 18
0.25418594.11181775.html.plaintext.txt	53	5 kilobase BglII DNA fragment pEVnod KL1 11 containing HPV16 L1 gene cloned BamHI site downstream polyhedrin promoter within polh locus baculovirus donor plasmid pFASTBAC 1 Life Technologies Inc
0.25418594.11181775.html.plaintext.txt	54	GIBCO BRL Rockville MD site specific recombination Escherichia coli DH10Bac1
0.25418594.11181775.html.plaintext.txt	55	Recombinant baculovirus containing HPV16 L1 DNA isolated Sf 9 insect cells transfected recombinant bacmid DNA use cationic lipid Cellfectin Life Technologies Inc
0.25418594.11181775.html.plaintext.txt	56	Recombinant baculovirus plaque purified three times screened insert integrity DNA sequencing L1 capsid antigen expression insect cells sodium dodecyl sulfate polyacrylamide gel electrophoresis western blot analyses
0.25418594.11181775.html.plaintext.txt	57	One recombinant baculovirus isolate expressed high levels L1 protein intracellularly extracellularly amplified Sf 9 cells tested microbial contaminants adventitious agents designated master virus seed stock bHPV16 L1 R 212
0.25418594.11181775.html.plaintext.txt	58	Working virus seed stocks bHPV16 L1 virus produced Sf 9 cells infected 3 days multiplicity infection moi 0
0.25418594.11181775.html.plaintext.txt	59	01 plaque forming unit pfucell
0.25418594.11181775.html.plaintext.txt	60	Production clinical lots recombinant HPV16 L1 VLP vaccines performed accordance good manufacturing practice guidelines well characterized biologicals Vaccine Production Facility Novavax Inc
0.25418594.11181775.html.plaintext.txt	61	formerly DynCorp Columbia MD
0.25418594.11181775.html.plaintext.txt	62	Production lots recombinant HPV16 L1 VLPs manufactured Sf 9 cells 2 3 x 106 cellsmL 16
0.25418594.11181775.html.plaintext.txt	63	8 L size batches infected bHPV 16 L1 virus moi 3 5 pfuscell 4 5 days 28 degrees C described previously 19
0.25418594.11181775.html.plaintext.txt	64	Sf 9 cells cultivated suspension cultures use Sf 900 II serum free medium Life Technologies Inc
0.25418594.11181775.html.plaintext.txt	65	Extracellular HPV16 L1 VLPs recovered infected cell suspension low speed centrifugation 1000g 10 minutes 4 degrees C supernatants clarified centrifugation 10 000g 30 minutes 4 degrees C
0.25418594.11181775.html.plaintext.txt	66	Clarified supernatants concentrated 15 fold ultrafiltration use hollow fiber membranes UFP 5 C 6A MWCO 500 000 AG Technologies diafiltered 20 volumes phosphate buffered saline PBS pH 7
0.25418594.11181775.html.plaintext.txt	67	The dialysate clarified centrifugation described clarified supernatant loaded onto 30 sucrose cushions PBS recombinant VLPs baculovirus pelleted sucrose cushions ultracentrifugation 26 000g 3 hours 4 degrees C use swinging bucket rotors
0.25418594.11181775.html.plaintext.txt	68	Pellets solubilized PBS loaded onto 25 65 sucrose step gradients
0.25418594.11181775.html.plaintext.txt	69	VLPs resolved bluish bands gradients ultracentrifugation 25 000g 1 hour 4 degrees C use swinging bucket rotors
0.25418594.11181775.html.plaintext.txt	70	Successive rounds ultracentrifugation sucrose gradients used obtain VLPs purity 95
0.25418594.11181775.html.plaintext.txt	71	VLPs recovered banded VLPs ultracentrifugation 26 000g 3 hours 4 degrees C
0.25418594.11181775.html.plaintext.txt	72	Sucrose removed pelleted VLPs dialysis PBS
0.25418594.11181775.html.plaintext.txt	73	The VLPs diluted 0
0.25418594.11181775.html.plaintext.txt	74	3 mgmL filtered aseptically 0
0.25418594.11181775.html.plaintext.txt	75	The filtered VLPs designated final bulk product stored 20 degrees C
0.25418594.11181775.html.plaintext.txt	76	The final bulk product underwent safety analytic testing batch records audited quality assurance release final bulk product formulation final container vaccine product
0.25418594.11181775.html.plaintext.txt	77	The integrity VLPs monitored morphology electron microscope ability hemagglutinate mouse red blood cells efficiently 20 strong reactivity HPV16 conformational neutralizing monoclonal antibodies H16
0.25418594.11181775.html.plaintext.txt	78	U4 2122 nonreactivity HPV11 neutralizing monoclonal antibody H11
0.25418594.11181775.html.plaintext.txt	79	The final bulk product recombinant HPV16 L1 VLPs formulated final volume 0
0.25418594.11181775.html.plaintext.txt	80	5 mL nonadjuvanted vaccine 10 50 microg dose final volume 0
0.25418594.11181775.html.plaintext.txt	81	25 mL mixed MF 59 adjuvant Chiron Corporation Emeryville CA microfluidized oil water emulsion consisting 1
0.25418594.11181775.html.plaintext.txt	82	25 mg sorbitan amonoleate Tween 80 1
0.25418594.11181775.html.plaintext.txt	83	25 mg sorbitan trioleate Span 85 10
0.25418594.11181775.html.plaintext.txt	84	At time vaccine administration 0
0.25418594.11181775.html.plaintext.txt	85	25 mL MF59 emulsion combined 0
0.25418594.11181775.html.plaintext.txt	86	25 mL vaccine yield vaccine dose 10 50 microg
0.25418594.11181775.html.plaintext.txt	87	Alternatively final bulk product formulated alum aluminum potassium sulfate 10 EM Merck Darmstadt Germany 120 mg alum per mg VLP antigen
0.25418594.11181775.html.plaintext.txt	88	The final volume VLP alum vaccine 0
0.25418594.11181775.html.plaintext.txt	89	5 mL 10 50 microg doses
0.25418594.11181775.html.plaintext.txt	90	Sterile saline served placebo vaccine
0.25418594.11181775.html.plaintext.txt	91	Formulated VLPs dispensed aseptically sterile vials 3
0.25418594.11181775.html.plaintext.txt	92	0 mL size type 1 borosilicate glass silanized depyrogenated Wheaton Glass Wheaton MD single unit dose designated final container vials
0.25418594.11181775.html.plaintext.txt	93	Vials containing VLP antigen stored 20 degrees C administration whereas vials containing VLP antigen adsorbed alum stored 4 degrees C stability concerns
0.25418594.11181775.html.plaintext.txt	94	This double blind randomized placebo controlled phase I safety immunogenicity trial conducted The Johns Hopkins University Center Immunization Research Baltimore MD
0.25418594.11181775.html.plaintext.txt	95	Guidelines human experimentation Joint Committee Clinical Investigation The Johns Hopkins University School Medicine institutional review board followed conduct study
0.25418594.11181775.html.plaintext.txt	96	Seventy two healthy human immunodeficiency virus HIV 1 seronegative 18 29 year old volunteers 58 females 14 males recruited study
0.25418594.11181775.html.plaintext.txt	97	Subjects determined history low risk HPV16 exposure
0.25418594.11181775.html.plaintext.txt	98	Individuals eligible participate history four lifetime sexual partners two sexual partners within preceding 6 months
0.25418594.11181775.html.plaintext.txt	99	Additional exclusion criteria included history abnormal cervical cytology immunodeficiency anaphylaxis medicines vaccines receipt blood products within 3 months enrollment current pregnancy lactation condition might interfere study objectives
0.25418594.11181775.html.plaintext.txt	100	All aspects protocol explained subjects met eligibility criteria informed witnessed written consent obtained
0.25418594.11181775.html.plaintext.txt	101	Preimmune HPV16 serostatus criterion eligibility since expected 10 volunteers would seropositve study six 72 volunteers found seropositive study entry omission simplified recruitment enrollment initiation vaccination presence seropositive vaccine recipients would enable us monitor response individuals
0.25418594.11181775.html.plaintext.txt	102	Before enrollment medical history obtained subject physical examination performed following laboratory tests done Quest Diagnostics Baltimore MD complete blood cell count CBC platelet count alanine aminotransferase ALT serum creatinine hepatitis B surface antigen HIV antibody test urine dipstick hemoglobin protein
0.25418594.11181775.html.plaintext.txt	103	Volunteers eligible enroll medical history physical examination laboratory tests without clinically significant abnormalities
0.25418594.11181775.html.plaintext.txt	104	Individuals clinically significant abnormalities enrolled counseled referred medical consultation appropriate
0.25418594.11181775.html.plaintext.txt	105	To qualify enrollment subsequent vaccination female subjects required negative urine pregnancy test day vaccination use acceptable method birth control completion study
0.25418594.11181775.html.plaintext.txt	106	To determine whether dose HPV16 L1 VLP vaccine andor addition alum MF59 adjuvant would influence reactogenicity immune response trial conducted dose escalation manner starting 10 microg HPV16 L1 VLP vaccine given alone alum MF59 adjuvants
0.25418594.11181775.html.plaintext.txt	107	When dose determined safe evaluated 50 microg dose HPV16 L1 VLP vaccine given alone alum MF59 adjuvant Table 1
0.25418594.11181775.html.plaintext.txt	108	For doseadjuvant group 10 subjects randomly assigned receive investigational vaccine two randomly assigned receive placebo sterile physiologic saline
0.25418594.11181775.html.plaintext.txt	109	Subjects received vaccine placebo intramuscular injection 0
0.25418594.11181775.html.plaintext.txt	110	5 mL deltoid region months 0 1 4
0.25418594.11181775.html.plaintext.txt	111	To maintain blinding individual prepared administered vaccine involved data collection clinical evaluation volunteers
0.25418594.11181775.html.plaintext.txt	112	Immunization scheme safety immunogenicity trial human papillomavirus 16 L1 virus like particle vaccine without alum MF59 adjuvant Subjects evaluated clinically blood collected clinical immunologic tests injection months 0 1 4 1 month injection
0.25418594.11181775.html.plaintext.txt	113	Clinical laboratory tests done visits included following CBC platelet count serum ALT serum creatinine urine protein urine hemoglobin measurements
0.25418594.11181775.html.plaintext.txt	114	After injection oral temperatures recorded 30 minutes 6 hours daily 6 days
0.25418594.11181775.html.plaintext.txt	115	Adverse reactions monitored study staff clinic 30 minutes 2 days injection telephone following 6 days
0.25418594.11181775.html.plaintext.txt	116	Clinical signs symptoms scored follows none reaction mild transient mild discomfort moderate mild moderate limitation activity severe marked limitation activity
0.25418594.11181775.html.plaintext.txt	117	IgG specific HPV16 L1 VLP based enzyme linked immunosorbent assays ELISAs performed 96 well plate format described previously 24 except 200 ng VLPs used per well end point dilution titers determined
0.25418594.11181775.html.plaintext.txt	118	VLPs ELISAs purified nuclei HPV16 L1 recombinant baculovirus infected Sf 9 cells described previously 11
0.25418594.11181775.html.plaintext.txt	119	Fourfold dilutions serum assayed starting dilution 10
0.25418594.11181775.html.plaintext.txt	120	Sera designated ELISA positive given dilution absolute optical density OD greater equal 0
0.25418594.11181775.html.plaintext.txt	121	2 least double reactivity serum dilution well containing blocking buffer VLPs
0.25418594.11181775.html.plaintext.txt	122	Seroconversion defined fourfold greater rise titer
0.25418594.11181775.html.plaintext.txt	123	Vaccine recipients considered HPV16 seropositive enrollment prevaccination serum demonstrated ELISA antibody titer greater equal reactivity standard pooled serum assayed plate generally OD 0
0.25418594.11181775.html.plaintext.txt	124	Reactivity standard serum validated cut point seropositivity previous seroepidemiologic study 24
0.25418594.11181775.html.plaintext.txt	125	The detailed procedure IgM IgA IgG isotyping determining IgG subclass subclass specific second antibodies reported elsewhere 25
0.25418594.11181775.html.plaintext.txt	126	Sera individuals receiving vaccine without adjuvant alum tested triplicate dilution 1 50 IgG IgG1 dilution 1 20 IgG2 IgG3 IgG4 use corresponding isotype subclass specific second antibody
0.25418594.11181775.html.plaintext.txt	127	A sample considered positive subtraction reactivity denatured BPV1 VLPs OD greater mean OD plus three standard deviations mean panel sera virgin women least 0
0.25418594.11181775.html.plaintext.txt	128	In vitro HPV16 pseudovirion neutralization assays performed described previously 26
0.25418594.11181775.html.plaintext.txt	129	Briefly infectious virions composed HPV16 L1 L2 capsid proteins BPV1 genome generated infection BPHE 1 hamster cells contain autonomously replicating BPV genomes replication defective Semliki Forest Virus vectors expressing HPV16 L1 L2 genes
0.25418594.11181775.html.plaintext.txt	130	Individual infections pseudotype virions detected transformed foci monolayer mouse C127 cells
0.25418594.11181775.html.plaintext.txt	131	Fourfold dilutions sera starting dilution 1 10 mixed approximately 50 100 focus forming units pseudotype virions assayed inhibition focal transformation
0.25418594.11181775.html.plaintext.txt	132	Neutralization defined least 50 reduction number foci compared number obtained absence human serum
0.25418594.11181775.html.plaintext.txt	133	The ELISA neutralizing antibody titers given reciprocal highest positive dilution assay
0.25418594.11181775.html.plaintext.txt	134	The data local systemic reactions grouped vaccine dose adjuvant
0.25418594.11181775.html.plaintext.txt	135	Data placebo recipients pooled analysis
0.25418594.11181775.html.plaintext.txt	136	We compared proportions reactions among different categories volunteers use continuity corrected test proportions two independent groups 27
0.25418594.11181775.html.plaintext.txt	137	Nonparametric statistics Kruskal Wallis test used make comparisons across groups given time
0.25418594.11181775.html.plaintext.txt	138	The Kruskal Wallis test also used compare distribution antibody titers different groups time 28
0.25418594.11181775.html.plaintext.txt	139	The Spearman correlation coefficient used comparing ELISA results obtained using neutralization test 28
0.25418594.11181775.html.plaintext.txt	140	Categorized ELISA neutralization results compared use Kappa statistic overall agreement percentages also computed 29
0.25418594.11181775.html.plaintext.txt	141	All statistical tests two sided
0.25418594.11181775.html.plaintext.txt	142	RESULTS Top Notes Abstract Introduction Subjects Methods Results Discussion References This double blind randomized placebo controlled safety immunogenicity dose escalation trial HPV16 L1 VLPs made insect cells recombinant baculovirus
0.25418594.11181775.html.plaintext.txt	143	An electron micrograph VLP preparation given Fig
0.25418594.11181775.html.plaintext.txt	144	When VLP preparation denatured subjected gel electrophoresis L1 band seen gel Fig
0.25418594.11181775.html.plaintext.txt	145	The trial tested two vaccine doses 10 50 microg without adjuvant alum MF59 adjuvant Table 1
0.25418594.11181775.html.plaintext.txt	146	Each vaccine preparation given 0 1 4 months
0.25418594.11181775.html.plaintext.txt	147	The demographic characteristics study population shown Table 2
0.25418594.11181775.html.plaintext.txt	148	In first part study 35 36 subjects randomly assigned received three injections either 10 microg HPV16 L1 VLP vaccine without adjuvant placebo
0.25418594.11181775.html.plaintext.txt	149	One placebo recipient moved away receiving third injection
0.25418594.11181775.html.plaintext.txt	150	In second part study 33 36 subjects randomly assigned received three injections either 50 microg HPV16 L1 VLP vaccine without adjuvant placebo
0.25418594.11181775.html.plaintext.txt	151	Two subjects complete scheduled series injections group received 50 microg HPV16 L1 VLP alum
0.25418594.11181775.html.plaintext.txt	152	One subjects received two immunizations return follow visits thereafter
0.25418594.11181775.html.plaintext.txt	153	The subject received first two immunizations third given 1 hemoglobin urine determined standard dipstick measurement calibrated 0 neg 4 noted day third vaccination scheduled
0.25418594.11181775.html.plaintext.txt	154	Subsequent urologic evaluation volunteer revealed abnormality
0.25418594.11181775.html.plaintext.txt	155	The third subject complete full series injections placebo recipient lost follow second injection
0.25418594.11181775.html.plaintext.txt	156	View larger version 67K Fig
0.25418594.11181775.html.plaintext.txt	157	Human papillomavirus type 16 L1 virus like particles HPV16 L1 VLPs used vaccine trial
0.25418594.11181775.html.plaintext.txt	158	A transmission electron micrograph showing morphology HPV16 L1 VLPs vaccine preparation original magnification x36 000
0.25418594.11181775.html.plaintext.txt	159	B Coomassie Blue stained gradient polyacrylamide gel electrophoresis vaccine preparation showing L1 detectable band
0.25418594.11181775.html.plaintext.txt	160	Demographics study population human papillomavirus type 16 L1 virus like particle HPV16 L1 VLP vaccine dose group Clinical Responses
0.25418594.11181775.html.plaintext.txt	161	Administration three injections HPV16 L1 VLP vaccine given alone alum MF59 adjuvant well tolerated dose levels Table 3
0.25418594.11181775.html.plaintext.txt	162	For group frequency severity reactions following three doses similar reactions three vaccinations therefore grouped together
0.25418594.11181775.html.plaintext.txt	163	Most local systemic reactions classified mild
0.25418594.11181775.html.plaintext.txt	164	Clinical responses subjects received 10 microg vaccine without adjuvant almost identical placebo group
0.25418594.11181775.html.plaintext.txt	165	Subjects received 50 microg vaccine without adjuvant reported local side effects twice frequently placebo recipients
0.25418594.11181775.html.plaintext.txt	166	Recipients either 10 50 microg vaccine MF59 reported pain injection site frequently recipients vaccine alum without adjuvant 10 microg 24 80 30 versus 11 36
0.25418594.11181775.html.plaintext.txt	167	0001 respectively 50 microg 28 93
0.25418594.11181775.html.plaintext.txt	168	However pain mild moderate intensity resolved spontaneously within 48 72 hours subjects
0.25418594.11181775.html.plaintext.txt	169	Similarly recipients 50 microg vaccine MF59 reported local induration andor erythema frequently recipients 50 microg vaccine alum without adjuvant
0.25418594.11181775.html.plaintext.txt	170	Of note one recipient 50 microg vaccine MF59 reported erythema peaked 60 mm diameter day third vaccination resolved day 2 vaccination
0.25418594.11181775.html.plaintext.txt	171	A second recipient 50 microg vaccine MF59 reported 45 mm erythema induration began day second vaccination resolved day 4 vaccination
0.25418594.11181775.html.plaintext.txt	172	Neither subjects required medication clinical intervention
0.25418594.11181775.html.plaintext.txt	173	There notable difference clinical responses five vaccine recipients seropositive entry compared seronegative vaccine recipients group frequency severity reactions greater third vaccination initial vaccinations
0.25418594.11181775.html.plaintext.txt	174	Cumulative percent reactions subjects within 1 week vaccination Two subjects clinically significant laboratory abnormalities
0.25418594.11181775.html.plaintext.txt	175	As described one subject group received 50 microg vaccine alum transient idiopathic microscopic hematuria
0.25418594.11181775.html.plaintext.txt	176	A second subject noted asymptomatic ALT elevation 1 month receiving second vaccine dose ALT 356 U normal range 0 48 U resolved subsequent month
0.25418594.11181775.html.plaintext.txt	177	Clinical evaluation including laboratory studies hepatitis unrevealing except subject recalled similar asymptomatic episode reported enrollment vaccine study ALT elevation discovered 2 years earlier donating blood
0.25418594.11181775.html.plaintext.txt	178	The clinical evaluation time also negative
0.25418594.11181775.html.plaintext.txt	179	After resolution ALT abnormality subject received third vaccine dose elevation ALT level
0.25418594.11181775.html.plaintext.txt	180	Clinical laboratory results subjects unremarkable
0.25418594.11181775.html.plaintext.txt	181	HPV16 Specific Antibody Responses
0.25418594.11181775.html.plaintext.txt	182	The volunteers evaluated serum IgG responses vaccine use HPV16 VLP ELISA 24 Table 4
0.25418594.11181775.html.plaintext.txt	183	Overall sexual history screening tool used study effective predictor baseline HPV16 seronegativity ELISA
0.25418594.11181775.html.plaintext.txt	184	A total six 72 subjects IgG seropositive ELISA study entry
0.25418594.11181775.html.plaintext.txt	185	The geometric mean ELISA titer GMT prevaccination sera six individuals 202 range 40 640
0.25418594.11181775.html.plaintext.txt	186	Four subjects received 10 microg HPV16 L1 VLP vaccine one without adjuvant two alum one MF59 one received 50 microg HPV16 L1 VLP vaccine without adjuvant one received placebo
0.25418594.11181775.html.plaintext.txt	187	The final serum ELISA titers five vaccine recipients seropositive vaccination one fourfold dilution final serum GMT prevaccination seronegative vaccinees group
0.25418594.11181775.html.plaintext.txt	188	Geometric mean titers human papillomavirus type 16 HPV16 specific antibodies enzyme linked immunosorbent assay ELISA neutralization assay Excluding initial seropositive subjects GMT ELISA titers entry less equal 20 group statistically significant difference baseline antibody titers groups P
0.25418594.11181775.html.plaintext.txt	189	None placebo recipients seroconverted
0.25418594.11181775.html.plaintext.txt	190	By contrast vaccine recipients seroconverted within 1 month second vaccination data shown group mean
0.25418594.11181775.html.plaintext.txt	191	In groups receiving investigational vaccine titers 3 months second injection month 4 waned compared achieved 1 month injection month 2 P values comparisons
0.25418594.11181775.html.plaintext.txt	192	1 exception comparison group received 10 microg vaccine MF59 P
0.25418594.11181775.html.plaintext.txt	193	Conversely clear boost titers seen 1 month third injection month 5 P values ranging
0.25418594.11181775.html.plaintext.txt	194	04 except group received 50 microg VLP alum whose titers showed small increase P
0.25418594.11181775.html.plaintext.txt	195	In group received vaccine alone adjuvant peak titers observed month 5 1 month third injection
0.25418594.11181775.html.plaintext.txt	196	The month 5 antibody titers groups received 10 microg vaccine alum 10 microg vaccine MF59 similar P
0.25418594.11181775.html.plaintext.txt	197	76 significantly higher P
0.25418594.11181775.html.plaintext.txt	198	01 respectively month 5 antibody titers group received 10 microg HPV16 L1 VLP alone
0.25418594.11181775.html.plaintext.txt	199	Thus within low dose group addition alum MF59 adjuvant enhanced immune response
0.25418594.11181775.html.plaintext.txt	200	Compared month 5 titers 10 microg dose titers 50 microg groups markedly higher recipients vaccine without adjuvant modestly higher recipients vaccine MF59 slightly lower recipients vaccine alum
0.25418594.11181775.html.plaintext.txt	201	In contrast results obtained 10 microg vaccine dose ELISA antibody titers achieved group received 50 microg vaccine without adjuvant equivalent group received 50 microg vaccine MF59 P
0.25418594.11181775.html.plaintext.txt	202	Month 5 antibody titers two groups significantly higher P
0.25418594.11181775.html.plaintext.txt	203	001 respectively antibody titers group received vaccine alum
0.25418594.11181775.html.plaintext.txt	204	The sera subjects vaccinated without adjuvant alum also analyzed HPV16 VLP ELISAs specific IgM IgA IgG subclasses Table 5
0.25418594.11181775.html.plaintext.txt	205	The majority antibody response VLP vaccination IgG1 subclass
0.25418594.11181775.html.plaintext.txt	206	As expected vaccine recipients became transiently seropositive HPV16 IgM antibodies usually detected sample taken 1 month initial vaccination
0.25418594.11181775.html.plaintext.txt	207	Most vaccine recipients also became seropositive serum IgA however relative IgG responses responses varied considerably generally weaker
0.25418594.11181775.html.plaintext.txt	208	All vaccine recipients became strongly seropositive IgG1 responses closely paralleled response total IgG
0.25418594.11181775.html.plaintext.txt	209	In contrast one subject became weakly although consistently seropositive IgG2 assay
0.25418594.11181775.html.plaintext.txt	210	Responses IgG3 IgG4 weak variable
0.25418594.11181775.html.plaintext.txt	211	Number vaccine recipients became ELISA seropositive human papillomavirus type 16 virus like particle specific immunoglobulin Ig isotype subclass The VLP ELISAs may measure combination neutralizing non neutralizing HPV virion antibodies well antibodies immunogenic insect cell baculovirus proteins common vaccine ELISA antigen
0.25418594.11181775.html.plaintext.txt	212	Therefore important determine directly whether HPV L1 VLP vaccine able induce virion neutralizing antibodies expected correlate closely potential protection
0.25418594.11181775.html.plaintext.txt	213	For analysis employed HPV16 pseudovirion neutralization assay developed previously 26
0.25418594.11181775.html.plaintext.txt	214	On basis studies animals assay approximately 20 30 fold less sensitive HPV16 ELISA 30
0.25418594.11181775.html.plaintext.txt	215	For analysis current trial month 5 sera recipients 50 microg dose without adjuvant studied neutralization assay Table 4 Fig
0.25418594.11181775.html.plaintext.txt	216	View larger version 66K Fig
0.25418594.11181775.html.plaintext.txt	217	Month 5 serum enzyme linked immunosorbent assay ELISA titers neutralization antibody titers individuals vaccinated three doses 50 microg human papillomavirus type 16 L1 virus like particles HPV16 L1 VLPs
0.25418594.11181775.html.plaintext.txt	218	HPV16 L1 VLP ELISA titers indicated hatched bars HPV16 pseudovirion neutralizing titers indicated black bars
0.25418594.11181775.html.plaintext.txt	219	The individuals vaccinated without adjuvant alum MF59 grouped left right
0.25418594.11181775.html.plaintext.txt	220	indicates individual whose preinoculation serum ELISA positive
0.25418594.11181775.html.plaintext.txt	221	indicates individual received first two immunizations
0.25418594.11181775.html.plaintext.txt	222	As expected neutralization titers much lower obtained ELISA Fig
0.25418594.11181775.html.plaintext.txt	223	However sera vaccine recipients detectable neutralizing antibodies
0.25418594.11181775.html.plaintext.txt	224	In contrast none placebo recipients developed detectable neutralizing antibody response data shown
0.25418594.11181775.html.plaintext.txt	225	There remarkable consistency neutralizing titer within vaccineadjuvant group
0.25418594.11181775.html.plaintext.txt	226	With exception one individual MF59 group unusually strong response neutralizing titers varied one fourfold dilution median Fig
0.25418594.11181775.html.plaintext.txt	227	In addition neutralizing antibody titers highly correlated ELISA antibody titers Spearman correlation
0.25418594.11181775.html.plaintext.txt	228	Similarly neutralization assay ELISA results categorized low medium high titers ELISA low 160 medium 640 2450 high 2450 neutralization assay low 10 medium 40 160 high 160 compared kappa coefficient
0.25418594.11181775.html.plaintext.txt	229	80 95 confidence interval 0
0.25418594.11181775.html.plaintext.txt	230	99 percent agreement 87
0.25418594.11181775.html.plaintext.txt	231	These data suggest ELISA titers effective surrogates neutralizing antibody titers
0.25418594.11181775.html.plaintext.txt	232	The GMT neutralizing antibody titers group received 50 microg vaccine MF59 greater titers recipients 50 microg vaccine without adjuvant difference statistically significant P
0.25418594.11181775.html.plaintext.txt	233	However neutralizing antibody titers achieved groups receiving VLPs MF59 adjuvant significantly higher titers group receiving VLPs alum P
0.25418594.11181775.html.plaintext.txt	234	Thus relative hierarchy GMT neutralization resembled GMT ELISA titers
0.25418594.11181775.html.plaintext.txt	235	DISCUSSION Top Notes Abstract Introduction Subjects Methods Results Discussion References The results presented indicate three intramuscular doses 10 50 microg HPV16 L1 VLP vaccine adjuvant alum MF59 well tolerated highly immunogenic normal human volunteers
0.25418594.11181775.html.plaintext.txt	236	Regardless dose whether adjuvant present vaccine volunteers received vaccine demonstrated serum immune response 1 month second immunization
0.25418594.11181775.html.plaintext.txt	237	The third immunization induced elevation end point serum antibody titers instances
0.25418594.11181775.html.plaintext.txt	238	These results complement high risk HPV type recent report HPV VLP vaccination therapeutic setting 31
0.25418594.11181775.html.plaintext.txt	239	In study multiple injections 1 5 10 microg HPV6 VLPs without adjuvant well tolerated genital wart patients HPV6 infections vaccination induced increase VLP ELISA titers patients
0.25418594.11181775.html.plaintext.txt	240	The commonly reported side effect study pain site injection
0.25418594.11181775.html.plaintext.txt	241	Most pain mild short lived consistent intramuscularly administered recombinant subunit vaccines licensed hepatitis B vaccines 3233
0.25418594.11181775.html.plaintext.txt	242	Side effects similar recipients placebo recipients 10 microg vaccine without adjuvant
0.25418594.11181775.html.plaintext.txt	243	However recipients higher vaccine dose 50 microg without adjuvant report side effects placebo recipients
0.25418594.11181775.html.plaintext.txt	244	As expected greater proportion recipients HPV16 L1 VLP MF59 reported moderate pain injection site recipients HPV16 L1 VLP vaccine given alone alum
0.25418594.11181775.html.plaintext.txt	245	The proportion subjects experiencing injection site reactogenicity injection HPV16 L1 VLP MF59 comparable reported investigational vaccine antigens given MF59 hepatitis B surface antigen herpes simplex type II gD glycoprotein 3435
0.25418594.11181775.html.plaintext.txt	246	In study adjuvant effects alum MF59 evident recipients lower vaccine dose 10 microg
0.25418594.11181775.html.plaintext.txt	247	In addition dose dependent response groups receiving vaccine without adjuvant MF59 although groups receiving vaccine alum
0.25418594.11181775.html.plaintext.txt	248	Specifically determined GMT ELISA titers marked increase immune response 50 microg without adjuvant compared 10 microg without adjuvant 10 240 versus 640 modest increase MF59 10 240 versus 3480 increase ELISA titers seen alum 3040 versus 2190
0.25418594.11181775.html.plaintext.txt	249	Since 50 microg dose ELISA titers recipients vaccine without adjuvant comparable titers group received vaccine MF59 even higher group received vaccine alum apparent benefit using adjuvant dose serum antibody titers measured shortly immunizations
0.25418594.11181775.html.plaintext.txt	250	It unknown whether properties would continue true following longer interval third vaccine dose
0.25418594.11181775.html.plaintext.txt	251	Since addition MF59 adjuvant associated increased pain induration injection site optimal immunogenicity reactogenicity profile current study obtained 50 microg HPV16 L1 VLP vaccine without adjuvant
0.25418594.11181775.html.plaintext.txt	252	It encouraging note higher dose without adjuvant MF59 final serum titers 40 times higher detected systemically natural infection subjects seropositive vaccination
0.25418594.11181775.html.plaintext.txt	253	The similar titers seen 50 microg dose adjuvant MF59 combined modest increase seen MF59 higher dose suggest even higher doses vaccine would probably induce substantially higher antibody titers
0.25418594.11181775.html.plaintext.txt	254	For alum 10 microg vaccine dose induced maximum ELISA titers
0.25418594.11181775.html.plaintext.txt	255	A similar plateau effect reported alum used HPV11 L1 VLP vaccination macaques 36
0.25418594.11181775.html.plaintext.txt	256	Although understand basis phenomenon two factors substantial impact immune response antigens delivered alum degree antigen adsorption onto alum dose alum used 37
0.25418594.11181775.html.plaintext.txt	257	It unlikely degree antigen adsorption adversely affected immunogenicity formulation containing 50 microg HPV16 L1 VLP alum 95 VLPs complexed aluminum hydroxide
0.25418594.11181775.html.plaintext.txt	258	However even high levels antigen adsorption possible concentration alum insufficient induce maximal adjuvant effect
0.25418594.11181775.html.plaintext.txt	259	It also possible VLPs alum stored 4 degrees C might less stable
0.25418594.11181775.html.plaintext.txt	260	Such instability would presumably affected 50 microg dose given 10 microg dose
0.25418594.11181775.html.plaintext.txt	261	A predominantly IgG1 response also unexpected
0.25418594.11181775.html.plaintext.txt	262	We found recently IgG1 also IgG isotype predominates seroconversion natural infection 25
0.25418594.11181775.html.plaintext.txt	263	Predominantly IgG1 responses also commonly seen microbial infections 38
0.25418594.11181775.html.plaintext.txt	264	In C57BL6 mice HPV16 L1 VLPs induce varied IgG response substantial amounts specific IgG1 IgG2b IgG3 detected Heather Greenstone Ph
0.25418594.11181775.html.plaintext.txt	265	Thesis The Johns Hopkins University
0.25418594.11181775.html.plaintext.txt	266	Whether reflects stronger Th1 type response HPV VLPs humans mice remains determined
0.25418594.11181775.html.plaintext.txt	267	The inability detect IgG2 response vaccine recipients unlikely due poor sensitivity specificity IgG2 assay
0.25418594.11181775.html.plaintext.txt	268	In fact sensitivityspecificity IgG2 assay superior IgG1 assay isotype specific human Ig control subjects 25
0.25418594.11181775.html.plaintext.txt	269	Neutralization assays often considered gold standard assessing immunogenicity prophylactic vaccine one tested
0.25418594.11181775.html.plaintext.txt	270	When month 5 sera groups received 50 microg dose vaccine analyzed HPV16 peudovirion neutralizing activity excellent quantitative correlation ELISA titers
0.25418594.11181775.html.plaintext.txt	271	This correlation held individuals well groups implying ELISA appears represent appropriate surrogate assay cumbersome expensive neutralization assay
0.25418594.11181775.html.plaintext.txt	272	For assays remarkable consistency response within vaccine group
0.25418594.11181775.html.plaintext.txt	273	The immunogenicity results seen human volunteers parallel obtained animals consistently statistically significant immunogenicity protection experimental disease observed even adjuvant given
0.25418594.11181775.html.plaintext.txt	274	It likely particulate nature regular array L1 VLPs contribute high immunogenicity
0.25418594.11181775.html.plaintext.txt	275	Perhaps efficient immune recognition promoted interaction VLPs cell surface pattern recognition receptors bind ordered external structure icosahedral virions 39
0.25418594.11181775.html.plaintext.txt	276	It possible know studies whether systemic administration vaccine protect cervical infection natural conditions
0.25418594.11181775.html.plaintext.txt	277	However magnitude antibody responses human volunteers compares favorably seen animal studies VLP vaccination alum without adjuvant induced protection high dose virus challenge Table 6
0.25418594.11181775.html.plaintext.txt	278	Although caution must taken comparing studies different vaccination protocols ELISAs used overall impression humans experimental animals respond similarly VLP vaccination
0.25418594.11181775.html.plaintext.txt	279	Animal studies demonstrating ability virus like particles protect experimental papillomavirus challenge The animal models used experimental inoculation abraded epithelium tested cutaneous oral mucosal infection rather genital infection
0.25418594.11181775.html.plaintext.txt	280	However reasons suspect anticapsid antibodies generated systemically could least partially neutralize natural HPV16 infection even though HPV infection replication occur epidermis genital tract
0.25418594.11181775.html.plaintext.txt	281	First likely HPV infection basal cell layer requires microtrauma abrasion epidermis 4
0.25418594.11181775.html.plaintext.txt	282	Such disruption epidermis could expose virus serous exudate containing neutralizing IgG antibodies
0.25418594.11181775.html.plaintext.txt	283	Second immune mediated dermatologic diseases pemphigus vulgaris circulating antiepidermal antibody traverses dermal epidermal junction suggesting basement membrane impermeable barrier immunoglobulins 40
0.25418594.11181775.html.plaintext.txt	284	Third statistically significant levels IgG reported cervicovaginal secretions
0.25418594.11181775.html.plaintext.txt	285	Much IgG likely result transudation circulation 41
0.25418594.11181775.html.plaintext.txt	286	36 demonstrated African green monkeys parenteral immunization little 10 microg HPV11 L1 VLPs induced detectable IgG antibody titers cervicovaginal secretions
0.25418594.11181775.html.plaintext.txt	287	Although lower magnitude titers closely paralleled serum responses
0.25418594.11181775.html.plaintext.txt	288	In addition IgG present cervicovaginal secretions sufficient neutralize HPV11 virus
0.25418594.11181775.html.plaintext.txt	289	It therefore plausible parenteral immunization HPV16 L1 VLPs could result appearance HPV16 specific IgG cervicovaginal secretions humans
0.25418594.11181775.html.plaintext.txt	290	Even VLP vaccination achieve sterilizing immunity might nevertheless substantially modify incidence duration HPV16 induced genital neoplasia restricting virus replication extent primary infection
0.25418594.11181775.html.plaintext.txt	291	It likely reduction viral load would also diminish transmission sex partners
0.25418594.11181775.html.plaintext.txt	292	The safety immunogenicity profile obtained study encourages clinical investigation HPV VLP based immunoprophylactic vaccines
0.25418594.11181775.html.plaintext.txt	293	On basis results initiated phase II trial 50 microg L1 VLP without adjuvant
0.25418594.11181775.html.plaintext.txt	294	The key question whether systemic administration VLP vaccine confer protection natural conditions must await outcome controlled efficacy trials
0.25418594.11181775.html.plaintext.txt	295	If vaccine eventually shown effective type specificity neutralizing activity induced VLPs implies protection would type specific
0.25418594.11181775.html.plaintext.txt	296	Since multiple HPV types implicated cervical cancer multivalent vaccine would needed
0.25418594.11181775.html.plaintext.txt	297	A vaccine composed four HPV types seen frequently cervical cancer types 16 18 31 45 would theoretically able protect approximately 80 cervical cancers 6
0.25418594.11181775.html.plaintext.txt	298	NOTES Supported National Institutes Health NIH Office Womens Health NIH Office Research Minority Health intramural research programs National Institute Allergy Infectious Diseases National Cancer Institute Bethesda MD
0.25418594.11181775.html.plaintext.txt	299	We thank Catherine Greer Lori Hansen Chiron Emeryville CA providing MF59 Dr
0.25418594.11181775.html.plaintext.txt	300	Robert Chanock National Institute Allergy Infectious Diseases National Institutes Health Bethesda MD critical reading manuscript Dr
0.25418594.11181775.html.plaintext.txt	301	Richard Leapman colleagues Division Bioengineering Physical Science National Institute Arthritis Musculoskeletal Skin Diseases National Institutes Health providing electron microscopic facilities assistance
0.25418594.11181775.html.plaintext.txt	302	We also acknowledge expert assistance Gwen Hammer Sabrina Drayton Arlene Bloom Nancy Frazier Martin Blair Denos Harris The Johns Hopkins University Baltimore MD
0.25418594.11181775.html.plaintext.txt	303	REFERENCES Top Notes Abstract Introduction Subjects Methods Results Discussion References
0.25418594.11181775.html.plaintext.txt	304	1 Parkin DM Pisani P Ferlay J
0.25418594.11181775.html.plaintext.txt	305	Estimates worldwide incidence 25 major cancers 1990
0.25418594.11181775.html.plaintext.txt	306	Int J Cancer 199980827 41
0.25418594.11181775.html.plaintext.txt	307	2 Pisani P Parkin DM Bray F Ferlay J
0.25418594.11181775.html.plaintext.txt	308	Estimates worldwide mortality 25 cancers 1990
0.25418594.11181775.html.plaintext.txt	309	3 Kurman RJ Henson DE Herbst AL Noller KL Schiffman MH
0.25418594.11181775.html.plaintext.txt	310	Interim guidelines management abnormal cervical cytology
0.25418594.11181775.html.plaintext.txt	311	The 1992 National Cancer Institute Workshop
0.25418594.11181775.html.plaintext.txt	312	In Fields B Knipe DM Howley PM editors
0.25418594.11181775.html.plaintext.txt	313	Philadelphia PA Lippincott Raven 1996
0.25418594.11181775.html.plaintext.txt	314	5 International Agency Research Cancer IARC
0.25418594.11181775.html.plaintext.txt	315	IARC monographs evaluation carcinogenic risks humans
0.25418594.11181775.html.plaintext.txt	316	Geneva Switzerland World Health Organization 1995
0.25418594.11181775.html.plaintext.txt	317	6 Bosch FX Manos MM Munoz N Sherman M Jansen AM Peto J et al
0.25418594.11181775.html.plaintext.txt	318	Prevalence human papillomavirus cervical cancer worldwide perspective
0.25418594.11181775.html.plaintext.txt	319	International Biological Study Cervical Cancer IBSCC Study Group
0.25418594.11181775.html.plaintext.txt	320	J Natl Cancer Inst 199587796 802
0.25418594.11181775.html.plaintext.txt	321	7 Walboomers JM Jacobs MC Manos MM Bosch FX Kummer JA Shah KV et al
0.25418594.11181775.html.plaintext.txt	322	Human papillomavirus necessary cause invasive cervical cancer worldwide
0.25418594.11181775.html.plaintext.txt	323	Papillomavirus like particles HPV vaccine development
0.25418594.11181775.html.plaintext.txt	324	Semin Cancer Biol 19967373 82
0.25418594.11181775.html.plaintext.txt	325	9 Chang MH Chen CJ Lai MS Hsu HM Wu TC Kong MS et al
0.25418594.11181775.html.plaintext.txt	326	Universal hepatitis B vaccination Taiwan incidence hepatocellular carcinoma children
0.25418594.11181775.html.plaintext.txt	327	Taiwan Childhood Hepatoma Study Group
0.25418594.11181775.html.plaintext.txt	328	N Engl J Med 19973361855 9
0.25418594.11181775.html.plaintext.txt	329	10 Kirnbauer R Booy F Cheng N Lowy DR Schiller JT
0.25418594.11181775.html.plaintext.txt	330	Papillomavirus L1 major capsid protein self assembles virus like particles highly immunogenic
0.25418594.11181775.html.plaintext.txt	331	Proc Natl Acad Sci U S A 19928912180 4
0.25418594.11181775.html.plaintext.txt	332	11 Kirnbauer R Taub J Greenstone H Roden R Durst M Gissmann L et al
0.25418594.11181775.html.plaintext.txt	333	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.25418594.11181775.html.plaintext.txt	334	Growing human papillomaviruses virus like particles laboratory
0.25418594.11181775.html.plaintext.txt	335	Papillomavirus Rep 19934121 4
0.25418594.11181775.html.plaintext.txt	336	13 Rose RC Bonnez W Reichman RC Garcea RL
0.25418594.11181775.html.plaintext.txt	337	Expression human papillomavirus type 11 L1 protein insect cells vivo vitro assembly viruslike particles
0.25418594.11181775.html.plaintext.txt	338	14 Breitburd F Kirnbauer R Hubbert NL Nonnenmacher B Trin Dinh Desmarquet C Orth G et al
0.25418594.11181775.html.plaintext.txt	339	Immunization viruslike particles cottontail rabbit papillomavirus CRPV protect experimental CRPV infection
0.25418594.11181775.html.plaintext.txt	340	15 Christensen ND Reed CA Cladel NM Han R Kreider HW
0.25418594.11181775.html.plaintext.txt	341	Immunization viruslike particles induces long term protection rabbits challenge cottontail rabbit papillomaviruses
0.25418594.11181775.html.plaintext.txt	342	16 Suzich JA Ghim SJ Palmer Hill FJ White WI Tamura JK Bell A et al
0.25418594.11181775.html.plaintext.txt	343	Systemic immunization papillomavirus L1 protein completely prevents development viral mucosal papillomas
0.25418594.11181775.html.plaintext.txt	344	Proc Natl Acad Sci U S A 19959211553 7
0.25418594.11181775.html.plaintext.txt	345	17 Kirnbauer R Chandrachud LM ONeil BW Wagner ER Grindlay GJ Armstrong A et al
0.25418594.11181775.html.plaintext.txt	346	Virus like particles bovine papillomavirus type 4 prophylactic therapeutic immunization
0.25418594.11181775.html.plaintext.txt	347	18 Luckow V Lee SC Barry GF Olins PO
0.25418594.11181775.html.plaintext.txt	348	Efficient generation infectious recombinant baculoviruses site specific transposon mediated insertion foreign genes baculovirus genome propagated Escherichia coli
0.25418594.11181775.html.plaintext.txt	349	19 Robinson RA Burgess WH Emerson SU Leibowitz RS Sosnovtseva S Tsarev S et al
0.25418594.11181775.html.plaintext.txt	350	Structural characterization recombinant hepatitis E virus ORF2 proteins baculovirus infected insect cells
0.25418594.11181775.html.plaintext.txt	351	Protein Expr Purif 19981275 84
0.25418594.11181775.html.plaintext.txt	352	20 Roden RB Hubbert NL Kirnbauer R Breitburd F Lowy DR Schiller JT
0.25418594.11181775.html.plaintext.txt	353	Papillomavirus L1 capsids agglutinate mouse erythrocytes proteinaceous receptor
0.25418594.11181775.html.plaintext.txt	354	21 Christensen ND Dillner J Eklund C Carter JJ Wipf GC Reed CA et al
0.25418594.11181775.html.plaintext.txt	355	Surface conformational linear epitopes HPV 16 HPV 18 L1 virus like particles defined monoclonal antibodies
0.25418594.11181775.html.plaintext.txt	356	22 Roden RB Armstrong A Haderer P Christensen ND Hubbert NL Lowy DR et al
0.25418594.11181775.html.plaintext.txt	357	Characterization human papillomavirus type 16 variant dependent neutralizing epitope
0.25418594.11181775.html.plaintext.txt	358	23 Christensen ND Kirnbauer R Schiller JT Ghim SJ Schlegel R Jenson AB et al
0.25418594.11181775.html.plaintext.txt	359	Human papillomavirus types 6 11 antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
0.25418594.11181775.html.plaintext.txt	360	24 Wideroff L Schiffman MH Nonnemacher B Hubbert N Kirnbauer R Greer CE et al
0.25418594.11181775.html.plaintext.txt	361	Evaluation seroreactivity HPV16 virus like particle incident case control study cervical neoplasia
0.25418594.11181775.html.plaintext.txt	362	J Infect Dis 19951721425 30
0.25418594.11181775.html.plaintext.txt	363	25 Wang ZH Kjellberg L Abdalla H Wiklund F Eklund C Knekt P et al
0.25418594.11181775.html.plaintext.txt	364	Type specificity significance different isotypes serum antibodies human papillomavirus capsids
0.25418594.11181775.html.plaintext.txt	365	J Infect Dis 2000181456 62
0.25418594.11181775.html.plaintext.txt	366	26 Roden RB Greenstone HL Kirnbauer R Booy FP Jessie J Lowy DR et al
0.25418594.11181775.html.plaintext.txt	367	In vitro generation type specific neutralization human papillomavirus type 16 virion pseudotype
0.25418594.11181775.html.plaintext.txt	368	Practical statistics medical research
0.25418594.11181775.html.plaintext.txt	369	Englewood Cliffs NJ Prentice Hall 1984
0.25418594.11181775.html.plaintext.txt	370	Statistical methods rates proportions
0.25418594.11181775.html.plaintext.txt	371	New York NY John Wiley Sons 1981
0.25418594.11181775.html.plaintext.txt	372	30 Nardelli Haefliger D Roden R Balmelli C Potts A Schiller J De Grandi P
0.25418594.11181775.html.plaintext.txt	373	Mucosal parenteral immunization purified human papillomavirus type 16 virus like particles induces neutralizing titers antibodies throughout estrous cycle mice
0.25418594.11181775.html.plaintext.txt	374	31 Zhang LF Zhou J Chen S Cai LL Bao QY Zheng FY et al
0.25418594.11181775.html.plaintext.txt	375	HPV6b virus like particles potent immunogens without adjuvant man
0.25418594.11181775.html.plaintext.txt	376	32 Scolnick EM McLean AA West DJ McAleer WJ Miller WJ Buynak EB
0.25418594.11181775.html.plaintext.txt	377	Clinical evaluation healthy adults hepatitis B vaccine made recombinant DNA
0.25418594.11181775.html.plaintext.txt	378	33 Wiedermann G Scheiermann N Goubau P Ambrosch F Gesemann M De Bel C et al
0.25418594.11181775.html.plaintext.txt	379	Multicentre dose range study yeast derived hepatitis B vaccine
0.25418594.11181775.html.plaintext.txt	380	34 Langenberg AG Burke RL Adair SF Sekulovich R Tigges M Dekker CL et al
0.25418594.11181775.html.plaintext.txt	381	A recombinant glycoprotein vaccine herpes simplex virus type 2 safety immunogenicity
0.25418594.11181775.html.plaintext.txt	382	Ann Intern Med 1995122889 98
0.25418594.11181775.html.plaintext.txt	383	35 Heineman TC Clements Mann ML Poland GA Jacobson RM Izu AE Sakamoto D et al
0.25418594.11181775.html.plaintext.txt	384	A randomized controlled study adults immunogenicity novel hepatitis B vaccine containing MF59 adjuvant
0.25418594.11181775.html.plaintext.txt	385	36 Lowe RS Brown DR Bryan JT Cook JC George HA Hofmann KJ et al
0.25418594.11181775.html.plaintext.txt	386	Human papillomavirus type 11 HPV 11 neutralizing antibodies serum genital mucosal secretions African green monkeys immunized HPV 11 virus like particles expressed yeast
0.25418594.11181775.html.plaintext.txt	387	J Infect Dis 19971761141 5
0.25418594.11181775.html.plaintext.txt	388	37 Gupta RK Rost BE Relyveld E Siber GR
0.25418594.11181775.html.plaintext.txt	389	Adjuvant properties aluminum calcium compounds
0.25418594.11181775.html.plaintext.txt	390	In Powells MF Newman MJ Burdman JR editors
0.25418594.11181775.html.plaintext.txt	391	New York NY Plenum Press 1995
0.25418594.11181775.html.plaintext.txt	392	Selective IgG subclass expression biologic clinical functional aspects
0.25418594.11181775.html.plaintext.txt	393	New York NY Pergamon Press 1990
0.25418594.11181775.html.plaintext.txt	394	The influence virus structure antibody responses virus serotype formation
0.25418594.11181775.html.plaintext.txt	395	Immunol Today 199617553 8
0.25418594.11181775.html.plaintext.txt	396	Correlation antibodies skin serum disease severity pemphigus
0.25418594.11181775.html.plaintext.txt	397	Arch Dermatol 1979115428 32
0.25418594.11181775.html.plaintext.txt	398	41 van Ginkel FW VanCott JL Kiyono H McGhee JR
0.25418594.11181775.html.plaintext.txt	399	Mucosal immunity human papillomavirus female reproductive tract
0.25418594.11181775.html.plaintext.txt	400	Papillomavirus Rep 199781 10
0.25418594.11181775.html.plaintext.txt	401	Manuscript received June 5 2000 revised December 12 2000 accepted December 21 2000
0.25418594.11181775.html.plaintext.txt	402	This article cited articles HighWire Press hosted journals
0.25418594.11181775.html.plaintext.txt	403	Intranasal Vaccination Recombinant Adeno Associated Virus Type 5 Human Papillomavirus Type 16 L1
0.25418594.11181775.html.plaintext.txt	404	80 2621 2630 Abstract Full Text Ko Y
0.25418594.11181775.html.plaintext.txt	405	Noninfectious Virus Like Particle Antigen Detection Swine Vesicular Disease Virus Antibodies Pigs Enzyme Linked Immunosorbent Assay
0.25418594.11181775.html.plaintext.txt	406	CVI 12 922 929 Abstract Full Text Orozco J
0.25418594.11181775.html.plaintext.txt	407	Humoral Immune Response Recognizes Complex Set Epitopes Human Papillomavirus Type 6 L1 Capsomers
0.25418594.11181775.html.plaintext.txt	408	79 9503 9514 Abstract Full Text Warfield K
0.25418594.11181775.html.plaintext.txt	409	Induction Humoral CD8 T Cell Responses Are Required Protection Lethal Ebola Virus Infection
0.25418594.11181775.html.plaintext.txt	410	J Immunol 175 1184 1191 Abstract Full Text Yang R
0.25418594.11181775.html.plaintext.txt	411	Papillomavirus Capsid Mutation To Escape Dendritic Cell Dependent Innate Immunity Cervical Cancer
0.25418594.11181775.html.plaintext.txt	412	79 6741 6750 Abstract Full Text Bousarghin L
0.25418594.11181775.html.plaintext.txt	413	Human papillomavirus 16 virus like particles use heparan sulfates bind dendritic cells colocalize langerin Langerhans cells
0.25418594.11181775.html.plaintext.txt	414	J Gen Virol 86 1297 1305 Abstract Full Text Berg M
0.25418594.11181775.html.plaintext.txt	415	Viable adenovirus vaccine prototypes High level production papillomavirus capsid antigen major late transcriptional unit
0.25418594.11181775.html.plaintext.txt	416	102 4590 4595 Abstract Full Text Buck C
0.25418594.11181775.html.plaintext.txt	417	Maturation Papillomavirus Capsids
0.25418594.11181775.html.plaintext.txt	418	79 2839 2846 Abstract Full Text Viscidi R
0.25418594.11181775.html.plaintext.txt	419	Human Papillomavirus Capsid Antibody Response Natural Infection Risk Subsequent HPV Infection HIV Positive HIV Negative Women
0.25418594.11181775.html.plaintext.txt	420	Cancer Epidemiol Biomarkers Prev 14 283 288 Abstract Full Text Yang R
0.25418594.11181775.html.plaintext.txt	421	Papillomavirus Like Particles Stimulate Murine Bone Marrow Derived Dendritic Cells To Produce Alpha Interferon Th1 Immune Responses via MyD88
0.25418594.11181775.html.plaintext.txt	422	78 11152 11160 Abstract Full Text Zhang H
0.25418594.11181775.html.plaintext.txt	423	Human Immunodeficiency Virus Type 1 Gag Specific Mucosal Immunity Oral Immunization Papillomavirus Pseudoviruses Encoding Gag
0.25418594.11181775.html.plaintext.txt	424	78 10249 10257 Abstract Full Text Berzofsky J
0.25418594.11181775.html.plaintext.txt	425	Progress new vaccine strategies chronic viral infections
0.25418594.11181775.html.plaintext.txt	426	114 450 462 Abstract Full Text Yang R
0.25418594.11181775.html.plaintext.txt	427	Human Papillomavirus Type 16 Virus Like Particles Activate Complementary Defense Responses Key Dendritic Cell Subpopulations
0.25418594.11181775.html.plaintext.txt	428	J Immunol 173 2624 2631 Abstract Full Text Castle P
0.25418594.11181775.html.plaintext.txt	429	Comparison Ophthalmic Sponges Measurements Immune Markers Cervical Secretions
0.25418594.11181775.html.plaintext.txt	430	CVI 11 399 405 Abstract Full Text Lowy D
0.25418594.11181775.html.plaintext.txt	431	RESPONSE Re Specific Antibody Levels Cervix During Menstrual Cycle Women Vaccinated With Human Papillomavirus 16 Virus Like Particles
0.25418594.11181775.html.plaintext.txt	432	J Natl Cancer Inst 96 413 414 Full Text Viscidi R
0.25418594.11181775.html.plaintext.txt	433	Seroreactivity Human Papillomavirus HPV Types 16 18 31 Risk Subsequent HPV Infection Results Population Based Study Costa Rica
0.25418594.11181775.html.plaintext.txt	434	Cancer Epidemiol Biomarkers Prev 13 324 327 Abstract Full Text Mandic A
0.25418594.11181775.html.plaintext.txt	435	Human papillomavirus vaccine new way preventing cervical cancer dream future
0.25418594.11181775.html.plaintext.txt	436	Ann Oncol 15 197 200 Abstract Full Text Ho G
0.25418594.11181775.html.plaintext.txt	437	Natural History Human Papillomavirus Type 16 Virus Like Particle Antibodies Young Women
0.25418594.11181775.html.plaintext.txt	438	Cancer Epidemiol Biomarkers Prev 13 110 116 Abstract Full Text Baud D
0.25418594.11181775.html.plaintext.txt	439	Immunogenicity Human Papillomavirus Type 16 Virus Like Particles Is Strongly Enhanced PhoPc Phenotype Salmonella enterica Serovar Typhimurium
0.25418594.11181775.html.plaintext.txt	440	72 750 756 Abstract Full Text Shafti Keramat S
0.25418594.11181775.html.plaintext.txt	441	Different Heparan Sulfate Proteoglycans Serve Cellular Receptors Human Papillomaviruses
0.25418594.11181775.html.plaintext.txt	442	77 13125 13135 Abstract Full Text Rousseau M
0.25418594.11181775.html.plaintext.txt	443	Predictors Cervical Coinfection Multiple Human Papillomavirus Types
0.25418594.11181775.html.plaintext.txt	444	Cancer Epidemiol Biomarkers Prev 12 1029 1037 Abstract Full Text Le Q
0.25418594.11181775.html.plaintext.txt	445	Therapeutic Exploitation Physiological Molecular Genetic Alterations Head Neck Cancer
0.25418594.11181775.html.plaintext.txt	446	Clin Cancer Res 9 4287 4295 Abstract Full Text Devaraj K
0.25418594.11181775.html.plaintext.txt	447	DEVELOPMENT OF HPV VACCINES FOR HPV ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
0.25418594.11181775.html.plaintext.txt	448	Crit Rev Oral Biol Med 14 345 362 Abstract Full Text Nardelli Haefliger D
0.25418594.11181775.html.plaintext.txt	449	Specific Antibody Levels Cervix During Menstrual Cycle Women Vaccinated With Human Papillomavirus 16 Virus Like Particles
0.25418594.11181775.html.plaintext.txt	450	J Natl Cancer Inst 95 1128 1137 Abstract Full Text Warzecha H
0.25418594.11181775.html.plaintext.txt	451	Oral Immunogenicity Human Papillomavirus Like Particles Expressed Potato
0.25418594.11181775.html.plaintext.txt	452	77 8702 8711 Abstract Full Text Varsani A
0.25418594.11181775.html.plaintext.txt	453	Chimeric Human Papillomavirus Type 16 HPV 16 L1 Particles Presenting Common Neutralizing Epitope L2 Minor Capsid Protein HPV 6 HPV 16
0.25418594.11181775.html.plaintext.txt	454	77 8386 8393 Abstract Full Text Reid T W Dushku N 2003
0.25418594.11181775.html.plaintext.txt	455	Does human papillomavirus cause pterygium
0.25418594.11181775.html.plaintext.txt	456	87 806 808 Full Text Parmiani G
0.25418594.11181775.html.plaintext.txt	457	Vaccination patients solid tumours
0.25418594.11181775.html.plaintext.txt	458	Ann Oncol 14 817 824 Abstract Full Text Lowy D
0.25418594.11181775.html.plaintext.txt	459	Chapter 16 Prophylactic Human Papillomavirus Vaccines
0.25418594.11181775.html.plaintext.txt	460	J Natl Cancer I Monographs 2003 111 116 Abstract Full Text Wang X
0.25418594.11181775.html.plaintext.txt	461	Human papillomavirus type 6 virus like particles present overlapping yet distinct conformational epitopes
0.25418594.11181775.html.plaintext.txt	462	J Gen Virol 84 1493 1497 Abstract Full Text Crum C
0.25418594.11181775.html.plaintext.txt	463	Cervical Cancer Screening From Papanicolaou Smear Vaccine Era
0.25418594.11181775.html.plaintext.txt	464	J Clin Oncol 21 224s 230 Abstract Full Text Finnen R
0.25418594.11181775.html.plaintext.txt	465	Interactions Papillomavirus L1 L2 Capsid Proteins
0.25418594.11181775.html.plaintext.txt	466	77 4818 4826 Abstract Full Text Ohlschlager P
0.25418594.11181775.html.plaintext.txt	467	Human Papillomavirus Type 16 L1 Capsomeres Induce L1 Specific Cytotoxic T Lymphocytes Tumor Regression C57BL6 Mice
0.25418594.11181775.html.plaintext.txt	468	77 4635 4645 Abstract Full Text Schiffman M
0.25418594.11181775.html.plaintext.txt	469	Epidemiologic Studies Necessary Causal Risk Factor Human Papillomavirus Infection Cervical Neoplasia
0.25418594.11181775.html.plaintext.txt	470	J Natl Cancer Inst 95 E2 2 Full Text Burd E
0.25418594.11181775.html.plaintext.txt	471	Human Papillomavirus Cervical Cancer
0.25418594.11181775.html.plaintext.txt	472	16 1 17 Abstract Full Text Chackerian B
0.25418594.11181775.html.plaintext.txt	473	Determinants Autoantibody Induction Conjugated Papillomavirus Virus Like Particles
0.25418594.11181775.html.plaintext.txt	474	J Immunol 169 6120 6126 Abstract Full Text Crum C
0.25418594.11181775.html.plaintext.txt	475	The Beginning End Cervical Cancer
0.25418594.11181775.html.plaintext.txt	476	NEJM 347 1703 1705 Full Text Koutsky L
0.25418594.11181775.html.plaintext.txt	477	Proof Principle Study Investigators 2002
0.25418594.11181775.html.plaintext.txt	478	A Controlled Trial Human Papillomavirus Type 16 Vaccine
0.25418594.11181775.html.plaintext.txt	479	NEJM 347 1645 1651 Abstract Full Text Greenwald P
0.25418594.11181775.html.plaintext.txt	480	Cancer Prevention Clinical Trials
0.25418594.11181775.html.plaintext.txt	481	J Clin Oncol 20 14s 22 Abstract Full Text Embers M
0.25418594.11181775.html.plaintext.txt	482	Protective Immunity Rabbit Oral Cutaneous Papillomaviruses Immunization Short Peptides L2 Minor Capsid Protein
0.25418594.11181775.html.plaintext.txt	483	76 9798 9805 Abstract Full Text Emeny R
0.25418594.11181775.html.plaintext.txt	484	Priming Human Papillomavirus Type 11 Specific Humoral Cellular Immune Responses College Aged Women Virus Like Particle Vaccine
0.25418594.11181775.html.plaintext.txt	485	76 7832 7842 Abstract Full Text Nakagawa M
0.25418594.11181775.html.plaintext.txt	486	Time Course Humoral Cell Mediated Immune Responses Human Papillomavirus Type 16 Infected Women
0.25418594.11181775.html.plaintext.txt	487	CVI 9 877 882 Abstract Full Text Combita A
0.25418594.11181775.html.plaintext.txt	488	Identification Two Cross Neutralizing Linear Epitopes within L1 Major Capsid Protein Human Papillomaviruses
0.25418594.11181775.html.plaintext.txt	489	76 6480 6486 Abstract Full Text Bosch F X Lorincz A Munoz N Meijer C J L M Shah K V 2002
0.25418594.11181775.html.plaintext.txt	490	The causal relation human papillomavirus cervical cancer
0.25418594.11181775.html.plaintext.txt	491	J Clin Pathol 55 244 265 Abstract Full Text Lehtinen M Dillner J 2002
0.25418594.11181775.html.plaintext.txt	492	Preventive human papillomavirus vaccination
0.25418594.11181775.html.plaintext.txt	493	Sex Transm Infect 78 4 6 Abstract Full Text Giuliano A
0.25418594.11181775.html.plaintext.txt	494	Human Papillomavirus Infection United States Mexico Border Implications Cervical Cancer Prevention Control
0.25418594.11181775.html.plaintext.txt	495	Cancer Epidemiol Biomarkers Prev 10 1129 1136 Abstract Full Text Chackerian B
0.25418594.11181775.html.plaintext.txt	496	Conjugation self antigen papillomavirus like particles allows efficient induction protective autoantibodies
0.25418594.11181775.html.plaintext.txt	497	108 415 423 Abstract Full Text Hausen H
0.25418594.11181775.html.plaintext.txt	498	Cervical Carcinoma Human Papillomavirus On Road Preventing Major Human Cancer
0.25418594.11181775.html.plaintext.txt	499	J Natl Cancer Inst 93 252 253 Full Text Copyright 2001 Oxford University Press unless otherwise stated Oxford University Press Privacy Policy Legal Statement Search All Search JNCI Search Journals Search Cancer Statistics Search PDQ Search PDR Search Calendar
0.19826251.15319446.html.plaintext.txt	0	tRNASerCGA differentially regulates expression wild type codon modified papillomavirus L1 genes Wenyi Gu Mengrong Li Wei Ming Zhao Ning Xia Fang Shurui Bu Ian H
0.19826251.15319446.html.plaintext.txt	1	Centre Immunology Cancer Research University Queensland Princess Alexandra Hospital Woolloongabba Queensland 4102 Australia
0.19826251.15319446.html.plaintext.txt	2	To correspondence addressed
0.19826251.15319446.html.plaintext.txt	3	Tel 61 7 3240 5282 Fax 61 7 3240 5946 Email knzhaoatcicr
0.19826251.15319446.html.plaintext.txt	4	au u d Present addresses Mengrong Li Wenzhou Medical College PR China Wei Ming Zhao School Medicine Shandong University PR China The authors wish known opinion first three authors regarded joint First Authors
0.19826251.15319446.html.plaintext.txt	5	Received May 27 2004 Revised Accepted July 20 2004
0.19826251.15319446.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Exogenous transfer RNAs tRNAs favor translation bovine papillomavirus 1 wild type wt L1 mRNA vitro translation systems Zhou et al
0.19826251.15319446.html.plaintext.txt	7	We therefore investigated whether papillomavirus PV wt L1 protein expression could enhanced eukaryotic cells following exogenous tRNA supplementation
0.19826251.15319446.html.plaintext.txt	8	Both Chinese hamster ovary CHO Cos1 cells transfected PV1 wt L1 genes effectively transcribed genes translate
0.19826251.15319446.html.plaintext.txt	9	However L1 protein translation demonstrated following co transfection L1 gene gene expressing tRNASerCGA
0.19826251.15319446.html.plaintext.txt	10	Cell lines stably transfected bovine papillomavirus 1 BPV1 wt L1 expression construct produced L1 protein transfection tRNASerCGA gene following transfection basal vectors suggesting tRNASerCGA gene enhanced wt L1 translation result endogenous tRNA alterations phosphorylation translation initiation factors elF4E elF2 tRNASerCGA transfected L1 cell lines
0.19826251.15319446.html.plaintext.txt	11	The tRNASerCGA gene expression significantly reduced translation L1 proteins expressed codon modified HB PV L1 genes utilizing mammalian preferred codons variable effects translation green fluorescent proteins GFPs expressed six serine GFP variants
0.19826251.15319446.html.plaintext.txt	12	The changes tRNA pools appear match codon composition PV wt HB L1 genes serine GFP variants regulate translation mRNAs
0.19826251.15319446.html.plaintext.txt	13	These findings demonstrate first time eukaryotic cells translation target genes differentially influenced provision single tRNA expression construct
0.19826251.15319446.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Translation key facet central dogma molecular biology 1 uses genetic information mRNA synthesize protein
0.19826251.15319446.html.plaintext.txt	15	Transfer RNAs tRNAs play central role translation acting carrier monomeric units proteins amino acids growing polypeptide chains 2
0.19826251.15319446.html.plaintext.txt	16	Both tRNA mRNA eventually pair ribosome determine amino acid inserted particular point nascent polypeptide chain
0.19826251.15319446.html.plaintext.txt	17	To ensure protein synthesis correct base pairing three bases codons mRNAs anticodons cognate aminoacyl aa tRNAs dictates sequence polypeptide chain
0.19826251.15319446.html.plaintext.txt	18	In addition cellular content tRNA isoaccepting species clearly determinant rates amounts protein synthesis 3
0.19826251.15319446.html.plaintext.txt	19	In unicellular organisms correlation tRNA content constraint gene expression level demonstrated using concept optimal codons 4
0.19826251.15319446.html.plaintext.txt	20	A shortage critical tRNAs could result slowed elongation nascent peptide premature termination translation 56
0.19826251.15319446.html.plaintext.txt	21	The tRNAs uninfected cells rescue translation global proteins Autographa california nucleopolyhedrovirus infected Ld652Y cells 7
0.19826251.15319446.html.plaintext.txt	22	Stimulated expression GTase tRNAAGA tRNAAGG resulted 5 fold increase GTase production Escherichia coli codon usage highly biased tRNAs specific codons AGAarg AGGarg extremely rare 8
0.19826251.15319446.html.plaintext.txt	23	Expression single tRNA gene enhanced expression heterologous genes especially genes containing rare codons bacterial expression systems 910
0.19826251.15319446.html.plaintext.txt	24	The data support argument variable copy number individual isoacceptor tRNAs primary determinant translation 11
0.19826251.15319446.html.plaintext.txt	25	However clear whether provision single tRNA gene expression mediate expression target genes either transcriptional translational levels eukaryotic cells
0.19826251.15319446.html.plaintext.txt	26	The tRNA molecules tRNA like structures identified crucial elements replication diverse group viruses including plant viruses 1213 mammalian retroviruses 14
0.19826251.15319446.html.plaintext.txt	27	Recently human tRNASerCGA gene cloned expressed mammalian cells 1516
0.19826251.15319446.html.plaintext.txt	28	The cloned human tRNASerCGA gene containing 400 bp previously verified integrity functionality 1516 via ability act reverse transcription retroviral vector harboring complementary primer binding site sequence 16
0.19826251.15319446.html.plaintext.txt	29	The human tRNASerCGA molecule originally identified via screening human BOSC23 retroviral packaging cell line 17 tRNA molecules functionable primers murine leukemia virus MLV replication 16
0.19826251.15319446.html.plaintext.txt	30	But clear whether tRNASerCGA molecule could functional protein translation MLV viruses
0.19826251.15319446.html.plaintext.txt	31	More recently tRNA like structure turnip yellow mosaic virus reported 3 translational enhancer enhanced expression firefly luciferase LUC reporter gene 25 fold 18
0.19826251.15319446.html.plaintext.txt	32	Therefore interested investigate whether expression human tRNASerCGA gene would affect expression wild type wt codon modified HB papillomavirus PV L1 genes cultured mammalian cells
0.19826251.15319446.html.plaintext.txt	33	Both wt HB PV L1 genes chosen target genes throughout experiments initially considered choice three reasons
0.19826251.15319446.html.plaintext.txt	34	First PVs exclusively epitheliotropic viruses
0.19826251.15319446.html.plaintext.txt	35	The PV life cycle tightly linked epithelial cell differentiation
0.19826251.15319446.html.plaintext.txt	36	Production viral capsid proteins L1 L2 expressed late gene L1 L2 restricted terminally differentiated keratinocytes upper layers epithelium
0.19826251.15319446.html.plaintext.txt	37	Expression L1 L2 proteins wt PV L1 L2 genes observed proliferating transfected keratinocytes 19 replicating mammalian cells 20
0.19826251.15319446.html.plaintext.txt	38	However mRNAs encoding capsid proteins detected less differentiated keratinocytes replicating mammalian cells suggesting expression late genes post transcriptionally regulated 21
0.19826251.15319446.html.plaintext.txt	39	When L1 L2 genes cloned cytomegalovirus CMV simian virus 40 SV40 promoters continuously growing transformed cell lines transient transfection assays large amounts PV L1 L2 mRNAs made proteins detected 20
0.19826251.15319446.html.plaintext.txt	40	Second blockage translation PV L1 mRNAs overcome two means point mutation 19 codon modification 2022 24
0.19826251.15319446.html.plaintext.txt	41	Introduction point mutations 5 end L1 gene altered RNA sequence without affecting protein sequence resulted production high levels HPV 16 L1 mRNA protein HeLa cells 19
0.19826251.15319446.html.plaintext.txt	42	Codon modification PV L1 L2 genes utilizing mammalian preferred codons without changing protein sequence express L1 L2 proteins large amounts replicating mammalian cells 2022 24
0.19826251.15319446.html.plaintext.txt	43	The argument proposed codon modification studies codon usage PV L1 L2 genes may major determinant PV capsid protein expression
0.19826251.15319446.html.plaintext.txt	44	The observation made recently bovine papillomavirus BPV 1 undergo life cycle BPV1 virus infected Saccharomyces cerevisiae 2526 supports argument codon usage BPV1 genes closely resembles yeast genes mammalian consensus 20
0.19826251.15319446.html.plaintext.txt	45	The low expression efficiency several viral proteins HIV due unfavorable codon usage reported various groups 27 29
0.19826251.15319446.html.plaintext.txt	46	Third provision exogenous tRNAs either bovine liver yeast could greatly assist translation BPV1 L1 gene human PV 16 HPV16 E7 translation different vitro translation systems 2030
0.19826251.15319446.html.plaintext.txt	47	These observations support argument codon usage mRNAs tends matched population tRNAs cells regulate translational efficiency
0.19826251.15319446.html.plaintext.txt	48	Previous studies indicated codon usage highly expressed genes biased toward optimal codons corresponding tRNAs tissue cell environments 31
0.19826251.15319446.html.plaintext.txt	49	31 reported synthesis number colicins linked difference tRNA availability various codons
0.19826251.15319446.html.plaintext.txt	50	However clear whether tRNA abundance cells matches corresponding codons mRNAs target genes regulate expression translational levels specific mammalian cell lines
0.19826251.15319446.html.plaintext.txt	51	In report first examined whether expression tRNASerCGA gene construct could enhance translation wt PV L1 mRNAs two replicating eukaryotic cell lines Chinese hamster ovary CHO cell system closely mimics living cells 32 Cos1 cells effectively transcribe wt PV L1 genes produce L1 proteins 20
0.19826251.15319446.html.plaintext.txt	52	We established two cell lines CHO L1 Cos1 L1 transfected wt BPV1 L1 expression construct determine whether tRNASerCGA gene could assist translation BPV1 L1 mRNA
0.19826251.15319446.html.plaintext.txt	53	At time examined whether supplement exogenous tRNAs would enhance translation wt PV L1 mRNAs cell culture systems
0.19826251.15319446.html.plaintext.txt	54	We examined whether expression tRNASerCGA gene affected tRNA populations phosphorylation translation initiation factors elF4E elF2 expression cellular proteins two L1 cell lines
0.19826251.15319446.html.plaintext.txt	55	We studied whether tRNASerCGA gene affected expression L1 proteins encoded two HB PV L1 genes BPV1 HPV6b L1 genes CGA rarely used codon two cell lines
0.19826251.15319446.html.plaintext.txt	56	Finally investigated whether tRNASerCGA gene affected expression green fluorescent proteins GFPs expressed hm gfp gene six serine GFP variants leader sequence six consecutive identical codons one six serine codons AGC AGU UCA UCC UCG UCU introduced hm gfp gene downstream AUG codon CHO cells
0.19826251.15319446.html.plaintext.txt	57	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Plasmid constructions The tRNASerCGA gene construction The tRNASerCGA DNA 400 bp cut pGEM T tRNASerCGA kindly provided Lund et al
0.19826251.15319446.html.plaintext.txt	58	15 ligated pSVneo vector EcoRI site construct pSV2tRNASerCGA plasmid tRNASerCGA hereafter
0.19826251.15319446.html.plaintext.txt	59	Construction wild type codon modified papillomavirus L1 genes Plasmids pCDNA3BPV1 L1 pCDNA3BPV1 HB L1 pCDNA3HPV6b L1 pCDNA3HPV6b HB L1 used experiments described previously 20
0.19826251.15319446.html.plaintext.txt	60	Briefly BPV1 HPV6b wt L1 open reading frames ORFs 1
0.19826251.15319446.html.plaintext.txt	61	5 kb length encoding 500 amino acids
0.19826251.15319446.html.plaintext.txt	62	The PV wt L1 genes show strong codon usage bias amongst degenerately encoded amino acids toward 18 codons mainly T third position rarely used mammalian genes 2033
0.19826251.15319446.html.plaintext.txt	63	We artificially modified BPV1 HPV6b L1 genes L1 ORFs substituted codons preferentially used mammalian genome
0.19826251.15319446.html.plaintext.txt	64	We made 250 base substitutions 250 codons rarely used mammalian cells produce unmodified L1 proteins encoded L1 ORFs consensus codon usage using strategy previously reported 20
0.19826251.15319446.html.plaintext.txt	65	All wt codon modified PV L1 sequences sequenced found error free cloned mammalian expression vector pCDNA3 containing SV40 ori Invitrogen Australia giving four expression plasmids pCDNA3BPV1 L1 pCDNA3BPV1 HB L1 pCDNA3HPV6b L1 pCDNA3HPV6b HB L1
0.19826251.15319446.html.plaintext.txt	66	Construction hm gfp gene serine GFP variants As described previously Zhao et al
0.19826251.15319446.html.plaintext.txt	67	35 leader sequence six consecutive identical codons one six serine codons AGC AGU UCA UCC UCG UCU introduced hm gfp gene Invitrogen Australia downstream AUG produce six serine GFP variants
0.19826251.15319446.html.plaintext.txt	68	All serine GFP variant hm gfp cDNAs produced hm gfp PCR using two flanking primers described previously 35 ligated EcoRI KpnI sites pCDNA3 vector construct seven GFP plasmids hm gfp AGC GFP AGU GFP UCA GFP UCC GFP UCG GFP UCU GFP
0.19826251.15319446.html.plaintext.txt	69	All constructs sequenced ensure PCR induced mutations introduced
0.19826251.15319446.html.plaintext.txt	70	The correct orientations plasmids used confirmed enzyme restriction analysis used transfection
0.19826251.15319446.html.plaintext.txt	71	Cell culture DNA transfection CHO cells grown Hams F12 medium supplemented 10 fetal bovine serum FBS CSL Australia brought 70 confluence monolayer transfected plasmid DNA using lipofectamine following instructions provided manufacturer Invitrogen Australia
0.19826251.15319446.html.plaintext.txt	72	After transfection cells continued grow Hams F12 medium supplemented 10 FBS
0.19826251.15319446.html.plaintext.txt	73	Cos1 cells grown Dulbeccos modified Eagles medium DMEM supplemented 10 FBS
0.19826251.15319446.html.plaintext.txt	74	Cells transfected plasmid DNA using Effectene reagent following instructions provided manufacturer Qiagen Australia
0.19826251.15319446.html.plaintext.txt	75	After transfection cells continued grow DMEM medium supplemented 10 FBS
0.19826251.15319446.html.plaintext.txt	76	Establishment BPV1 L1 expression cell lines CHO Cos1 cells transfected pCDNA3 BPV1 L1
0.19826251.15319446.html.plaintext.txt	77	G418 Invitrogen Australia supplemented medium used select cells establish two cell lines CHO L1 Cos1 L1
0.19826251.15319446.html.plaintext.txt	78	Expression BPV1 L1 confirmed PCR two three passages cell lines transfected pSV tRNASerCGA control expression constructs
0.19826251.15319446.html.plaintext.txt	79	Cells collected 40 h transfection pelleted centrifugation Hirt total genomic DNA preparation according methods described Zhao et al
0.19826251.15319446.html.plaintext.txt	80	The DNA samples digested overnight DpnIBamHIEcoRI remove residual input DNA
0.19826251.15319446.html.plaintext.txt	81	Digested DNA electrophoresed 1 agarose blotted nylon membrane
0.19826251.15319446.html.plaintext.txt	82	The membrane hybridized 32P labeled mixed probes BPV L1 tRNASerCGA genes
0.19826251.15319446.html.plaintext.txt	83	Protein sample preparation western blotting Both DNA transfected CHO Cos1 cells collected protein preparation 42 h post transfection
0.19826251.15319446.html.plaintext.txt	84	Cell pellets resuspended phosphate buffered 0
0.19826251.15319446.html.plaintext.txt	85	4 containing 2 mM phenylmethylsulpfnyl fluoride PMSF sonicated 40
0.19826251.15319446.html.plaintext.txt	86	An aliquot 30 microg total protein samples resuspended 40 microl 1x Laemmli buffer 37 boiled 8 min loaded onto 10 wv polyacrylamide gel SDS PAGE electrophoresis
0.19826251.15319446.html.plaintext.txt	87	After electrophoresis gel electrotransferred onto PVDF membrane Bio Rad
0.19826251.15319446.html.plaintext.txt	88	The blot washed PBS 10 min blocked PBS containing 5 skim milk 1 h room temperature labeled monoclonal antibody BPV1 L1 protein 26 overnight 4 degrees C
0.19826251.15319446.html.plaintext.txt	89	The blot incubated secondary antibody goat anti mouse immunoglobulin G IgG Silenus Australia conjugated horseradish peroxidase HRP room temperature 4 h developed using enhanced chemiluminescence ECL kit Amersham Australia
0.19826251.15319446.html.plaintext.txt	90	The L1 probed blots stripped relabeled monoclonal antibody ss tubulin Sigma Australia confirm equal loading proteins samples
0.19826251.15319446.html.plaintext.txt	91	Total RNA sample preparation northern blot analysis Total RNA extracted cells transfected various plasmids using Machery Nagel RNAII Kit Integrated Sciences Australia
0.19826251.15319446.html.plaintext.txt	92	An aliquot 15 microg total RNA sample digested DNase I electrophoresed 1
0.19826251.15319446.html.plaintext.txt	93	2 denatured agarose gels blotted onto Nylon N membrane Amersham Australia hybridized either 32P labeled L1 gene actin gene probe
0.19826251.15319446.html.plaintext.txt	94	Immunofluorescence labeling Cells grown 8 well chamber slides transfected different plasmids fixed permeabilized 85 ethanol 42 h post transfection
0.19826251.15319446.html.plaintext.txt	95	The fixed cells blocked 5 skim milk PBS probed monoclonal antibody BPV1 L1 protein followed fluorescein isothiocyanate conjugated FITC anti mouse IgG Sigma Australia
0.19826251.15319446.html.plaintext.txt	96	Nuclei countstained DAPI
0.19826251.15319446.html.plaintext.txt	97	Cells examined immunofluorescent microscopy
0.19826251.15319446.html.plaintext.txt	98	tRNA preparation northern blot hybridization Total tRNAs extracted purified using Qiagen kit instructed supplier CHO L1 Cos1 L1 cell lines without transfection tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	99	An aliquot 2 microg tRNA fractioned 10 denaturing PAGE containing 8 M Urea 0
0.19826251.15319446.html.plaintext.txt	100	Electrophoresis carried 0
0.19826251.15319446.html.plaintext.txt	101	After electrophoresis tRNA gel electroblotted onto Nytran Plus membrane 40 mM Tris acetate pH 4
0.19826251.15319446.html.plaintext.txt	102	2 2 mM EDTA 20 V 90 min 4 degrees C
0.19826251.15319446.html.plaintext.txt	103	The membrane crosslinked 254 nm irradiation
0.19826251.15319446.html.plaintext.txt	104	The blot prehybridized hybridization buffer containing 6x SSC 10x DEN 0
0.19826251.15319446.html.plaintext.txt	105	2 SDS 1 mM EDTA 37 degrees C least 4 h
0.19826251.15319446.html.plaintext.txt	106	The blot hybridized DNA oligonucleotide probes complementary tRNASerCGA three tRNAs tRNALysAAA tRNALysAAG tRNAMetinitiator 4x SET buffer 1x SET 0
0.19826251.15319446.html.plaintext.txt	107	03 M Tris HCl 2 mM Na2EDTA pH 8
0.19826251.15319446.html.plaintext.txt	108	The DNA oligonucleotide probes complementary tRNASerCGA 5 CCTGAGCTTTAGGTTACC 3 tRNALysAAA 5 TCACTATGGAGATTTTA 3 tRNALysAAG 5 CGCCCAACGTGGGGCTC 3 tRNAMetinitiator 5 TAGCAGAGGATGGTTTC 3
0.19826251.15319446.html.plaintext.txt	109	The DNA oligomers labeled T4 polynucleotide kinase 32PATP 3000 Cimmol Amersham first 5 end
0.19826251.15319446.html.plaintext.txt	110	Specific activities 108 109 c
0.19826251.15319446.html.plaintext.txt	111	microg generally reached
0.19826251.15319446.html.plaintext.txt	112	oligomers used per blot hybridization reactions
0.19826251.15319446.html.plaintext.txt	113	Blots washed 1x SET buffer 37 degrees C autoradiographed
0.19826251.15319446.html.plaintext.txt	114	Aminoacyl methionine tRNA determination The tRNA samples used direct analysis aminoacyl methionine tRNA aminoacyl Met tRNA
0.19826251.15319446.html.plaintext.txt	115	An aliquot 2 microg tRNA sample treated Tris base strip aminoacyl tRNAs 0
0.19826251.15319446.html.plaintext.txt	116	0 37 degrees C 30 min 2 microg tRNA sample left untreated control
0.19826251.15319446.html.plaintext.txt	117	Both Tris treated untreated tRNAs fractioned denaturing PAGE blotted onto Nytran Plus membrane described
0.19826251.15319446.html.plaintext.txt	118	The blot probed DNA probes complementary either tRNASer CGA tRNAMet initiator
0.19826251.15319446.html.plaintext.txt	119	Synthesis cellular proteins Synthesis cellular proteins CHO L1 Cos1 L1 cell lines without transient transfection tRNASerCGA gene pSVneo vector studied labeling 35Smethionine
0.19826251.15319446.html.plaintext.txt	120	Cells 32 h transfection incubated 2 ml medium supplemented 10 microCi L 35SMet 370 kBq 4 h
0.19826251.15319446.html.plaintext.txt	121	This extended labeling time required incorporate sufficient radioactivity newly synthesized proteins consequence relatively slow growth rates G418 treated cells
0.19826251.15319446.html.plaintext.txt	122	An aliquot 10 microg protein sample separated 10 SDS PAGE
0.19826251.15319446.html.plaintext.txt	123	Gels stained Coomassie blue dried autoradiographed
0.19826251.15319446.html.plaintext.txt	124	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Co transfection tRNASerCGA assists protein expression PV wt L1 genes Expression BPV1 L1 gene cell free translation systems enhanced addition exogenous tRNAs 20
0.19826251.15319446.html.plaintext.txt	125	To study whether provision single tRNA species similarly affected L1 expression examined BPV1 L1 transcription translation CHO Cos1 cells transfected BPV1 L1 gene constructs either unmodified codon modified match eukaryotic consensus codon usage co transfected tRNASerCGA expression construct
0.19826251.15319446.html.plaintext.txt	126	Northern blot hybridization revealed cell lines effectively transcribed BPV1 L1 whether codon modified Figure 1A confirming previous results obtained laboratory 20
0.19826251.15319446.html.plaintext.txt	127	Co transfection tRNASerCGA expression construct affect transcription BPV1 L1 gene two cell lines Figure 1A
0.19826251.15319446.html.plaintext.txt	128	We examined whether L1 protein expressed Figure 1B
0.19826251.15319446.html.plaintext.txt	129	Neither cell line produced detectable L1 protein transfected BPV1 wt L1 gene Figure 1B though previously shown 20 codon modified L1 gene expressed
0.19826251.15319446.html.plaintext.txt	130	The L1 protein expressed BPV1 wt L1 gene cells co transfected tRNASer CGA expression construct Figure 1B
0.19826251.15319446.html.plaintext.txt	131	Immunofluorescent labeling confirmed L1 protein expressed CHO Cos1 cells following co transfection BPV1 wt L1 tRNASerCGA expression constructs Figure 1C
0.19826251.15319446.html.plaintext.txt	132	We also tested whether tRNASerCGA gene could affect expression L1 gene HPV 6b two cell lines similar results obtained data shown
0.19826251.15319446.html.plaintext.txt	133	Thus tRNASerCGA gene product appeared assist expression L1 protein encoded PV wt L1 genes replicating mammalian cells
0.19826251.15319446.html.plaintext.txt	134	View larger version 32K Figure 1
0.19826251.15319446.html.plaintext.txt	135	Translation BPV1 L1 mRNA enhanced provision tRNASerCGA
0.19826251.15319446.html.plaintext.txt	136	CHO Cos1 cells transiently transfected pCDNA3 ii pCDNA3 pSVtRNASerCGA iii pCDNA3BPV1 L1 iv pCDNA3BPV1 L1 pSVtRNASerCGA v pCDNA3BPV1 HBL1 codon modified
0.19826251.15319446.html.plaintext.txt	137	Northern blot hybridization L1 mRNA transcription
0.19826251.15319446.html.plaintext.txt	138	RNA samples prepared 42 h post transfection
0.19826251.15319446.html.plaintext.txt	139	Of sample DNase I digested total RNA 10 microg electrophoresed 1
0.19826251.15319446.html.plaintext.txt	140	2 denatured agarose gel blotted onto nylon membrane
0.19826251.15319446.html.plaintext.txt	141	The northern blots hybridized 32P labeled wt HB L1 probe mixture
0.19826251.15319446.html.plaintext.txt	142	As controls northern blots hybridized 32P labeled actin gene probe
0.19826251.15319446.html.plaintext.txt	143	B Immunoblotting analysis L1 protein
0.19826251.15319446.html.plaintext.txt	144	Monoclonal antibody BPV L1 protein used probe blots
0.19826251.15319446.html.plaintext.txt	145	Upper panels show results L1 immunoblotting assay lower panels show results ss tubulin immunoblotting assay indicating equal loading protein samples
0.19826251.15319446.html.plaintext.txt	146	C L1 expression CHO Cos1 cells co transfected pCDNA3BPV1 L1 pSVtRNASerCGA demonstrated indirect immunofluorescence microscopy
0.19826251.15319446.html.plaintext.txt	147	Upper panels show L1 labeling lower panels show nuclear staining DAPI
0.19826251.15319446.html.plaintext.txt	148	To confirm enhanced translation L1 mRNA specifically related expression tRNASerCGA gene examined effects translation cells pSVNeo basal vector exogenous supplementation yeast tRNAs
0.19826251.15319446.html.plaintext.txt	149	L1 effectively transcribed BPV1 L1 transfected cells whether cells co transfected pSVNeo basal plasmid exposed exogenous yeast tRNAs Figure 2A
0.19826251.15319446.html.plaintext.txt	150	However L1 protein detected cell lines co transfected BPV1 L1 tRNASerCGA expression constructs Figure 2B
0.19826251.15319446.html.plaintext.txt	151	Results indicate expression tRNASerCGA gene thus assist translation BPV1 L1 protein non differentiated mammalian cells
0.19826251.15319446.html.plaintext.txt	152	View larger version 48K Figure 2
0.19826251.15319446.html.plaintext.txt	153	Enhancement translation BPV1 wt L1 mRNA tRNASerCGA specific
0.19826251.15319446.html.plaintext.txt	154	CHO Cos1 cells transiently transfected pCDNA3 mock 1 ii pCDNA3BPV1 L1 mock 2 iii pCDNA3BPV1 L1 plus exogenous supplement yeast tRNAs culture medium commercial bake yeast tRNAs Sigma Australia added CHO Cos1 cell cultures 1 microgml following transfection BPV1 wt L1 expression construct iv pCDNA3BPV1 L1 plus pSVneo basal vector v pCDNA3BPV1 L1 plus pSVtRNASerCGA
0.19826251.15319446.html.plaintext.txt	155	Northern blot hybridization L1 mRNA transcription
0.19826251.15319446.html.plaintext.txt	156	RNA samples prepared 42 h post transfection
0.19826251.15319446.html.plaintext.txt	157	Of sample DNase I digested total RNA 10 microg electrophoresed 1
0.19826251.15319446.html.plaintext.txt	158	2 denatured agarose gel blotted onto nylon membrane
0.19826251.15319446.html.plaintext.txt	159	Northern blots hybridized 32P labeled BPV1 wt L1 probe upper panel
0.19826251.15319446.html.plaintext.txt	160	As controls northern blots also hybridized 32P labeled actin gene probe lower panel
0.19826251.15319446.html.plaintext.txt	161	B Western blotting analysis L1 protein
0.19826251.15319446.html.plaintext.txt	162	Monoclonal antibody BPV L1 protein used probe blot
0.19826251.15319446.html.plaintext.txt	163	Upper panels show results L1 immunoblotting assay lower panels show results ss tubulin immunoblotting assay indicating equal loading protein samples
0.19826251.15319446.html.plaintext.txt	164	tRNASerCGA induces L1 protein expression cell lines stably transfected L1 gene To examine whether enhanced translation BPV1 L1 gene co transfected tRNASerCGA expression construct due consequence co transfection expression tRNASerCGA gene established cell lines CHO L1 Cos1 L1 stably transfected BPV1 L1 expression construct Figure 3A
0.19826251.15319446.html.plaintext.txt	165	Multiple replication forms revealed Southern blot hybridization using total genomic DNA samples confirmed presence integrated BPV1 L1 genes data shown
0.19826251.15319446.html.plaintext.txt	166	However episomal format BPV1 L1 gene also observed Hirt DNA samples presumably passage number cell lines Figure 3B
0.19826251.15319446.html.plaintext.txt	167	The tRNASerCGA gene detected two L1 cell lines following transfection tRNASerCGA expression construct Figure 3B
0.19826251.15319446.html.plaintext.txt	168	View larger version 56K Figure 3
0.19826251.15319446.html.plaintext.txt	169	Replication BPV1 L1 tRNASerCGA genes CHO L1 Cos1 L1 cells
0.19826251.15319446.html.plaintext.txt	170	A PCR analysis DNA prepared CHO L1 Cos1 L1 cells confirming cell lines retained BPV1 L1 expression construct
0.19826251.15319446.html.plaintext.txt	171	B Southern blot analysis Hirt DNA BPV1 L1 tRNASerCGA gene replication CHO L1 Cos1 L1 cells
0.19826251.15319446.html.plaintext.txt	172	20 microg Hirt DNA samples prepared CHO L1 Cos1 L1 cells either untransfected transfected tRNASerCGA expression plasmid restricted BamHI EcoRI plus DpnI least 4 h electrophoresed 1
0.19826251.15319446.html.plaintext.txt	173	0 agarose gel blotted onto nylon membrane
0.19826251.15319446.html.plaintext.txt	174	The Southern blot hybridized mixture 32P labeled BPV1 L1 tRNASerCGA gene probes
0.19826251.15319446.html.plaintext.txt	175	The two L1 cell lines transcribed BPV1 L1 gene equally whether transfected tRNASerCGA gene basal plasmid also exposed culture exogenous yeast tRNAs Figure 4A
0.19826251.15319446.html.plaintext.txt	176	However L1 protein produced cell lines transfected tRNASerCGA expression construct control plasmids andor supplemented exogenous yeast tRNAs
0.19826251.15319446.html.plaintext.txt	177	Again immunofluorescent labeling confirmed L1 protein produced two L1 cell lines transfection tRNASerCGA gene Figure 4C
0.19826251.15319446.html.plaintext.txt	178	The results confirm L1 protein produced due presence tRNASerCGA gene product
0.19826251.15319446.html.plaintext.txt	179	View larger version 33K Figure 4
0.19826251.15319446.html.plaintext.txt	180	Expression BPV1 L1 gene cell lines carrying L1 expression construct influenced transfection pSV tRNASerCGA
0.19826251.15319446.html.plaintext.txt	181	CHO cos1 cells mock 1
0.19826251.15319446.html.plaintext.txt	182	The CHO L1 Cos1 L1 cell lines transiently transfected ii pCDNA3 iii plasmid exogenous supplement yeast tRNAs culture medium described Figure 2 iv pSVneo basal vector v pSV tRNASerCGA
0.19826251.15319446.html.plaintext.txt	183	A Northern blot hybridization L1 mRNA transcription
0.19826251.15319446.html.plaintext.txt	184	RNA samples prepared 42 h post transfection
0.19826251.15319446.html.plaintext.txt	185	Of sample DNase I digested total RNA 10 microg electrophoresed 1
0.19826251.15319446.html.plaintext.txt	186	2 denatured agarose gel blotted onto nylon membrane
0.19826251.15319446.html.plaintext.txt	187	The northern blots hybridized 32P labeled BPV1 L1 probe upper panel
0.19826251.15319446.html.plaintext.txt	188	As controls northern blots hybridized 32P labeled actin gene probe lower panel
0.19826251.15319446.html.plaintext.txt	189	B Western blotting analysis L1 protein
0.19826251.15319446.html.plaintext.txt	190	Monoclonal antibody BPV1 L1 protein used probe blots
0.19826251.15319446.html.plaintext.txt	191	Upper panels show results L1 immunoblotting assay lower panels show results ss tubulin immunoblotting assay indicating equal loading protein samples
0.19826251.15319446.html.plaintext.txt	192	C Immunofluorescence labeling L1 expression CHO Cos1 L1 cells transfection tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	193	Upper panels show L1 labeling lower panels show nuclear staining DAPI
0.19826251.15319446.html.plaintext.txt	194	Action tRNASerCGA expression BPV1 wt L1 protein specific To examine whether transfection might induce expression BPV1 L1 protein transfected CHO L1 cell lines tRNASerCGA expression construct also several vectors including pIBT100 pUC19 pcDNA3 pSVneo
0.19826251.15319446.html.plaintext.txt	195	No L1 protein expression detected following transfection control vectors CHO L1 cells Figure 5 suggesting expression BPV1 L1 protein due tRNASerCGA gene product
0.19826251.15319446.html.plaintext.txt	196	View larger version 54K Figure 5
0.19826251.15319446.html.plaintext.txt	197	Expression BPV1 L1 protein CHO L1 cell line requires provision tRNASerCGA
0.19826251.15319446.html.plaintext.txt	198	Immunoblotting L1 protein CHO L1 cells transfected various plasmids shown upper panel using monoclonal antibody L1 protein ss tubulin shown lower panel indicating equal loading protein samples
0.19826251.15319446.html.plaintext.txt	199	tRNASerCGA results enhanced expression tRNA species It unexpected expression single tRNA gene would induce translation wt PV L1 mRNAs block translation might expected consequence shortages many tRNA species critical optimal translation gene
0.19826251.15319446.html.plaintext.txt	200	Thus determine might occur examined whether transduced tRNASerCGA gene affected expression tRNAs tRNASerCGA two L1 cell lines
0.19826251.15319446.html.plaintext.txt	201	We first used polyacrylamide gel electrophoresis fractionate total tRNAs prepared CHO L1 Cos1 L1 cell lines either untransfected following transfection tRNASerCGA expression construct
0.19826251.15319446.html.plaintext.txt	202	As shown Figure 6A total tRNA populations prepared two L1 cell lines differed according whether transfected tRNASerCGA gene Figure 6A
0.19826251.15319446.html.plaintext.txt	203	Several extra tRNA bands relative low molecular weights observed L1 cell lines transfection tRNASerCGA gene Figure 6A suggesting expression tRNASerCGA gene may result enhanced production new tRNA species
0.19826251.15319446.html.plaintext.txt	204	View larger version 45K Figure 6
0.19826251.15319446.html.plaintext.txt	205	Fractionation total tRNAs isolated CHO L1 Cos1 L1 cells without transfection tRNASerCGA gene northern blot analysis aminoacyl aa forms methionine tRNA
0.19826251.15319446.html.plaintext.txt	206	A Total tRNAs 10 denatured PAGE extra tRNA bands induced tRNASerCGA expression construct marked solid arrows right side
0.19826251.15319446.html.plaintext.txt	207	B Analysis uncharged aa forms methionine tRNA
0.19826251.15319446.html.plaintext.txt	208	Parts tRNA samples denoted asterisk treated 0
0.19826251.15319446.html.plaintext.txt	209	0 strip aa tRNAs fractionated denaturing PAGE described Materials methods
0.19826251.15319446.html.plaintext.txt	210	tRNA blots probed 32P lableled oligonucleotide complementary specific regions tRNAMetATG
0.19826251.15319446.html.plaintext.txt	211	Uncharged aminoacyl forms methionine tRNA marked left position
0.19826251.15319446.html.plaintext.txt	212	The relative levels uncharged aminoacyl methionine tRNA shown arbitrary units number measured blots densitometry
0.19826251.15319446.html.plaintext.txt	213	The aa methionine tRNA signals shown arbitrary units parentheses
0.19826251.15319446.html.plaintext.txt	214	We arbitrarily chose four oligonucleotide probes complementary specific regions four tRNA species tRNASerCGA tRNALysAAA tRNALysAAG tRNAMetAUG northern blot analysis
0.19826251.15319446.html.plaintext.txt	215	The four probes mixed detect tRNA blot revealed expression tRNASerCGA gene slightly increased signals four tRNAs two L1 cell lines based densitometric analysis data shown
0.19826251.15319446.html.plaintext.txt	216	To examine whether tRNASerCGA gene affected aminoacylation tRNA species two L1 cell lines detected different forms uncharged aminoacyl tRNAs tRNASerCGA initiator tRNAMetAUG northern blot hybridization
0.19826251.15319446.html.plaintext.txt	217	The tRNASerCGA gene increased slightly levels aminoacylation tRNASerCGA L1 cell lines data shown
0.19826251.15319446.html.plaintext.txt	218	In contrast two forms uncharged aminoacyl tRNAMetAUG well separated Cos1 L1 cells Figure 6B although CHO L1 cells
0.19826251.15319446.html.plaintext.txt	219	A high percentage tRNAMetAUG aminoacylated Figure 6B tRNASerCGA gene significantly increased levels aminoacylation tRNAMetAUG Cos1 L1 cell line Figure 6B suggesting expression tRNASerCGA gene may affect translation initiation
0.19826251.15319446.html.plaintext.txt	220	tRNASerCGA induces phosphorylation translation initiation factors We examined phosphorylation status two translation initiation factors elF4E elF2 L1 cell lines without transfection tRNASerCGA gene investigate whether tRNASerCGA gene product affects phosphorylation translation initiation factors Figure 7
0.19826251.15319446.html.plaintext.txt	221	By performing western blotting analysis antibodies specifically recognize phosphorylation forms elF4E elF2 phosphorylation elF4E elF2 observed CHO L1 Cos1 L1 cells Figure 7 contrast phosphorylated elF4E elF2 detected CHO L1 Cos1 L1 cells transfected tRNASerCGA gene Figure 7
0.19826251.15319446.html.plaintext.txt	222	At time phosphorylation levels elF4E elF2 much higher CHO L1 cells Cos1 L1 cells
0.19826251.15319446.html.plaintext.txt	223	Consistent L1 protein detected CHO L1 Cos1 L1 cells transfected tRNASer CGA gene Figure 7 results suggest phosphorylation two translation initiation factors elF4E elF2 induced tRNASerCGA gene product may involved enhancing translation L1 protein two cell lines examined
0.19826251.15319446.html.plaintext.txt	224	View larger version 76K Figure 7
0.19826251.15319446.html.plaintext.txt	225	Effects tRNASerCGA gene product phosphorylation two translation initiation factors elF4e elF2 CHO L1 Cos1 L1 cell lines
0.19826251.15319446.html.plaintext.txt	226	Protein samples 40 microg prepared two L1 cell lines without transfection tRNASerCGA gene resolved SDS PAGE transferred PVDF membrane analyzed western blotting antibodies L1 top panel eIF4E P phosphorylated serine 209 eIF4E P Ser 209 middle panel eIF2 P phosphorylated serine 51eIF2 P Ser 51 bottom panel
0.19826251.15319446.html.plaintext.txt	227	tRNASerCGA increases yields total cellular proteins As alteration tRNA populations increased aminoacylation initiator tRNAMetATG together phosphorylation elF4e elF2 might impact synthesis cellular proteins examined whether expression tRNASerCGA gene affected production cellular proteins two L1 cell lines
0.19826251.15319446.html.plaintext.txt	228	Cells 1 x 106well either untransfected following transfection basal pSVneo vector tRNASerCGA gene cultured 48 h collected total protein analysis
0.19826251.15319446.html.plaintext.txt	229	Untransfected CHO L1 cells CHO L1 cells following transfection basal pSVneo vector produced significantly less proteins 0
0.19826251.15319446.html.plaintext.txt	230	014 mg respectively CHO L1 cells following transfection tRNASerCGA gene 0
0.19826251.15319446.html.plaintext.txt	231	Cos1 L1 cells following transfection tRNASerCGA gene produced 0
0.19826251.15319446.html.plaintext.txt	232	009 mg protein slightly untransfected Cos1 L1 cells 0
0.19826251.15319446.html.plaintext.txt	233	008 mg pSVneo transfected Cos1 L1 cells 0
0.19826251.15319446.html.plaintext.txt	234	SDS PAGE used fractionate equal amounts cellular proteins two L1 cell lines either untransfected following transfection basal pSVneo vector tRNASerCGA gene stained Commasie blue Figure 8B
0.19826251.15319446.html.plaintext.txt	235	The SDS PAGE profiles total cellular proteins two L1 cell lines without transfection tRNASerCGA gene different Figure 8B
0.19826251.15319446.html.plaintext.txt	236	But transfection basal pSVneo vector appeared affect SDS PAGE profiles total cellular proteins two L1 cell lines Figure 8B
0.19826251.15319446.html.plaintext.txt	237	The levels cellular proteins significantly enhanced tRNASerCGA gene Figure 8B
0.19826251.15319446.html.plaintext.txt	238	At time proteins seemed reduced amounts L1 cells transfection tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	239	These observations confirmed 35Smethionine labeling experiments Figure 8B suggesting tRNASerCGA gene product negative effects synthesis cellular proteins although increased yields total cellular proteins two L1 cell lines
0.19826251.15319446.html.plaintext.txt	240	View larger version 59K Figure 8
0.19826251.15319446.html.plaintext.txt	241	Effects tRNASerCGA gene product cellular proteins CHO L1 Cos1 L1 cell lines
0.19826251.15319446.html.plaintext.txt	242	A Yields total cellular proteins
0.19826251.15319446.html.plaintext.txt	243	CHO L1 Cos1 L1 cells 1 x 106 transfected either tRNASerCGA gene vector pSVneo transfected analyzed total cellular proteins 48 h
0.19826251.15319446.html.plaintext.txt	244	The yields total cellular proteins shown milligrams mgs histograms means triplicates
0.19826251.15319446.html.plaintext.txt	245	Vertical bars indicate standard errors n 3
0.19826251.15319446.html.plaintext.txt	246	P values shown top corner left side
0.19826251.15319446.html.plaintext.txt	247	Double asterisks indicate difference total proteins CHO L1 cell lines without tRNASerCGA gene transfection tRNASerCGA gene vector pSVneo transfection significant different P 0
0.19826251.15319446.html.plaintext.txt	248	B Synthesis cellular proteins
0.19826251.15319446.html.plaintext.txt	249	An aliquot 10 microg protein samples separated 10 SDS PAGE duplicates
0.19826251.15319446.html.plaintext.txt	250	Left panels show PAGE gels stained Coomassie blue
0.19826251.15319446.html.plaintext.txt	251	Right panels show newly synthesized proteins labeled 35Smethionine PAGE gels dried 3 M paper exposed X ray film
0.19826251.15319446.html.plaintext.txt	252	Solid arrows right indicate relative levels proteins increased L1 cell lines transfection tRNASerCGA gene empty arrows left indicate relative levels proteins reduced L1 cell lines transfection tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	253	tRNASerCGA reduces expression L1 proteins encoded codon modified PV L1 genes To explain tRNASerCGA gene overexpression variable effects expression different cellular proteins hypothesize matching tRNAs codon usage genes regulates expression cellular proteins cells
0.19826251.15319446.html.plaintext.txt	254	To test hypothesis examined whether tRNASerCGA gene could affect expression L1 protein encoded codon modified BPV1 L1 gene BPV1 HB L1 demonstrated translate L1 protein large amounts replicating mammalian cells previous studies 2030 current one Figure 1B
0.19826251.15319446.html.plaintext.txt	255	Both CHO Cos1 cells transfected solely BPV1 HB L1 gene co transfected BPV1 HB L1 tRNASerCGA genes incubated 42 h collected L1 mRNA protein expression analysis Figure 9
0.19826251.15319446.html.plaintext.txt	256	Northern blot hybridization confirmed BPV1 HB L1 gene effectively transcribed Figure 9A
0.19826251.15319446.html.plaintext.txt	257	No significant differences levels L1 mRNA transfection solely BPV1 HB L1 gene co transfection BPV1 HB L1 tRNASer genes observed Figure 9A confirmed quantitative RT PCR analysis using L1 mRNAs data shown
0.19826251.15319446.html.plaintext.txt	258	However western blot analysis shows tRNASerCGA gene resulted reduction levels L1 protein expressed BPV1 HB L1 gene 50 Figure 9B two cell lines whereas ss tubulin expression remained unaffected Figure 9B
0.19826251.15319446.html.plaintext.txt	259	To confirm observations examined whether expression another codon modified PV L1 gene HPV6b HB L1 also affected expression tRNASerCGA gene Figure 9B
0.19826251.15319446.html.plaintext.txt	260	The results Figure 9 agreement obtained experiments using BPV1 HB L1 gene supporting idea tRNAs may complement codon composition genes regulate gene translation mammalian cells
0.19826251.15319446.html.plaintext.txt	261	View larger version 37K Figure 9
0.19826251.15319446.html.plaintext.txt	262	Effects tRNASerCGA expression construct expression L1 proteins encoded codon modified PV L1 genes BPV1 HB L1 HPV6b HB L1 CHO Cos1 cells
0.19826251.15319446.html.plaintext.txt	263	CHO Cos1 cells transiently transfected PV HB L1 gene construct PV HB L1 gene construct tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	264	Four dilutions protein samples cells either transfected PV HB L1 gene construct co transfected PV HBL1 gene construct tRNASerCGA gene loaded onto SDS PAGE gel protein fractionation blotted PVDF membranes immunoblotting assay
0.19826251.15319446.html.plaintext.txt	265	Monoclonal antibody BPV L1 protein used probe blots
0.19826251.15319446.html.plaintext.txt	266	Upper panels show results L1 immunoblotting assay lower panels show results ss tubulin immunoblotting assay indicating equal loading protein samples two treatments
0.19826251.15319446.html.plaintext.txt	267	tRNASerCGA differentially regulates expression serine GFP variants Based results Figure 9 hypothesize tRNASerCGA gene may favor expression target genes UCG codons six serine codons used frequently
0.19826251.15319446.html.plaintext.txt	268	To test hypothesis studied transcription translation hm gfp gene six serine GFP variants CHO Cos1 cells either transfected solely hm gfp six serine GFP variants co transfected GFP expression constructs tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	269	The serine GFP variants express protein sequences six additional serines N terminal GFP molecules following AUG codon encoded one six serine codons AGC AGU UCA UCC UCG UCU respectively
0.19826251.15319446.html.plaintext.txt	270	Northern blot hybridization revealed hm gfp gene six serine GFP variants transcribed effectively two cell lines co transfection tRNASerCGA gene affect significantly levels transcripts data shown
0.19826251.15319446.html.plaintext.txt	271	Western blot analysis first shows six serine GFP variants exhibited levels immunoreactive GFPs significantly higher hm gfp gene Figure 10A confirming previous study addition serine codons hm gfp gene downstream AUG increased significantly steady state levels GFP 35
0.19826251.15319446.html.plaintext.txt	272	Then western blot analysis shows co transfection tRNASerCGA gene barely affected levels immunoreactive GFPs produced hm gfp gene two serine AGC UCU GFP variants Figure 10B
0.19826251.15319446.html.plaintext.txt	273	However tRNASerCGA increased significantly levels immunoreactive GFPs produced AGU UCG GFP variants Figure 10B contrast significant reduction level immunoreactive GFPs produced UCA GFP variant followed co transfection tRNASerCGA gene Figure 10B
0.19826251.15319446.html.plaintext.txt	274	Moreover tRNASerCGA slightly increased level immunoreactive GFP produced UCC GFP variants Figure 10B
0.19826251.15319446.html.plaintext.txt	275	In parallel experiments used flow cytometry analysis FAC examine fluorescence intensity CHO Cos1 cells either transfected solely hm gfp six serine GFP variants co transfected GFP expression constructs tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	276	Results obtained FAC analysis data shown confirmed western blotting analysis immunoreactive GFPs produced hm gfp gene six serine GFP variants two cell lines proving hypothesis
0.19826251.15319446.html.plaintext.txt	277	View larger version 46K Figure 10
0.19826251.15319446.html.plaintext.txt	278	Variable effects tRNASerCGA expression construct expression GFPs encoded hm gfp six serine GFP variants CHO cells
0.19826251.15319446.html.plaintext.txt	279	A Protein expression hm gfp six serine GFP variants CHO cells transiently transfected solely seven GFP plasmid DNAs 42 h post transfection
0.19826251.15319446.html.plaintext.txt	280	Protein sample 4 microg separated SDS PAGE blotted PVDF membrane
0.19826251.15319446.html.plaintext.txt	281	Signals GFPs produced GFP expression constructs ss tubulin detected monoclonal antibodies GFP ss tubulin
0.19826251.15319446.html.plaintext.txt	282	B Effects tRNASerCGA expression construct expression GFPs produced hm gfp gene six serine GFP variants CHO cells
0.19826251.15319446.html.plaintext.txt	283	Two dilutions protein samples CHO cells either transfected solely hm gfp six Serine GFP variants co transfected GFP gene construct tRNASerCGA gene 42 h post transfection loaded onto SDS PAGE gel protein fractionation blotted PVDF membranes immunoblotting assay
0.19826251.15319446.html.plaintext.txt	284	Upper panels show results GFP immunoblotting assay lower panels show results ss tubulin immunoblotting assay indicating equal loading protein samples two treatments
0.19826251.15319446.html.plaintext.txt	285	The relative levels GFPs tubulin produced six serine GFP variants without co transfection tRNASerCGA gene shown arbitrary units means SDx 103 measured four blots densitometry two independent experiments
0.19826251.15319446.html.plaintext.txt	286	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In present study supplementation exogenous tRNAs enhance translation PV wt L1 genes two cell lines
0.19826251.15319446.html.plaintext.txt	287	The results cannot confirm previous observations supplementation exogenous tRNAs enhanced translation PV L1 E7 genes vitro translation systems 2030 consistent studies carried researchers exogenous tRNAs effect protein synthesis permeabilized cells 3238
0.19826251.15319446.html.plaintext.txt	288	The major reason different translation machinery used vitro translation systems cell culture systems
0.19826251.15319446.html.plaintext.txt	289	Using CHO cell system previous work provided strong evidence translation apparatus highly organized cultured cells 32
0.19826251.15319446.html.plaintext.txt	290	Exogenous tRNAs cannot enter translation machinery cultured cells despite fact exogenous tRNA rapidly distribute throughout cells aminoacylated minor portion cellular aminoacyl tRNA synthetases aaRS permeabilized cells 38
0.19826251.15319446.html.plaintext.txt	291	Moreover exogenous aminoacyl tRNA permeable cells sequestered protected RNase treatment contrast endogenous tRNA molecules 39 translation endogenous tRNAs never state mix competed exogenous tRNA molecules 38
0.19826251.15319446.html.plaintext.txt	292	All observations may explain exogenous tRNAs play role enhancing translation PV L1 mRNA CHO Cos1 cells examined present study efficiently taken two cell lines
0.19826251.15319446.html.plaintext.txt	293	It also possible exogenous tRNAs taken cells functional roles could identified
0.19826251.15319446.html.plaintext.txt	294	Previous studies indicated changes physiological factors resulted alteration populations specific total tRNAs mammalian tissues cells 40 44
0.19826251.15319446.html.plaintext.txt	295	For example ovariectomy resulted alterations population uterine serine tRNA 40
0.19826251.15319446.html.plaintext.txt	296	Due carcinogenesis cellular tRNA distribution shifted tRNA population increased level initiator tRNAMet malignant tissues 44
0.19826251.15319446.html.plaintext.txt	297	Selenium essential trace element functions proteins selenocysteine Sec critical variety cellular processes influences level Sec tRNAsersec population distribution Sec tRNAsersec isoacceptors mammalian cells grown culture 45 mammalian tissues 46 turnover Sec tRNAsersec CHO cells 43
0.19826251.15319446.html.plaintext.txt	298	The present data indicate expression tRNASerCGA gene increased relative levels tRNASerCGA initiator tRNAMet also probably resulted new tRNA species produced two cell lines
0.19826251.15319446.html.plaintext.txt	299	Consequently expression tRNASerCGA gene altered gel profiles total tRNAs two cell lines
0.19826251.15319446.html.plaintext.txt	300	Our results agreement previous studies 47 52 genes expressing tRNA species introduced cells change tRNA contents targeted cells
0.19826251.15319446.html.plaintext.txt	301	Thus observations suggest mammalian cells may sensitive mechanism sense respond changes physiological factors introduction foreign tRNA genes altering tRNA populations
0.19826251.15319446.html.plaintext.txt	302	Here expression tRNASerCGA gene identified enhance expression L1 proteins encoded PV wt L1 genes GFPs encoded two UCG AGU serine variants two cell lines examined
0.19826251.15319446.html.plaintext.txt	303	Previously examples synthesis specialized protein associated expression single tRNA gene due modification tRNA population different expression systems 910
0.19826251.15319446.html.plaintext.txt	304	Expression tRNASerCGA gene found increases synthesis cellular proteins present study
0.19826251.15319446.html.plaintext.txt	305	As result expression 5 10 total cellular proteins increased L1 cells following transfection tRNASerCGA gene compared control L1 cells
0.19826251.15319446.html.plaintext.txt	306	Our results support previous studies tRNAs even single tRNA affect protein expression encoded heterologous genes different expression systems 91020304041
0.19826251.15319446.html.plaintext.txt	307	For example tRNAs oviducts estrogen stimulated chicks oviducts laying hens produced enhanced stimulation ovalbumin synthesis vitro 40
0.19826251.15319446.html.plaintext.txt	308	The use tRNA AGAAGG increased human interferon HUIFN a2 HCV core protein expression 910 barely affected human IFN 8 expression E
0.19826251.15319446.html.plaintext.txt	309	However expression tRNASerCGA gene reduced expression L1 proteins encoded PV HB L1 genes GFP encoded UCA serine variant cellular proteins
0.19826251.15319446.html.plaintext.txt	310	The result consistent studies
0.19826251.15319446.html.plaintext.txt	311	A tRNASerUCN gene flanked deafness associated mitochondrial DNA mtDNA T7445C mutation 3 end causes average reduction 70 levels tested proteins decrease 45 protein synthesis rate cell lines analyzed 53
0.19826251.15319446.html.plaintext.txt	312	Recently Akama Beier 54 reported co transfection Arabidopsis hypocotyls amber suppressor tRNASerCGA gene GUS reporter gene resulted 10 GUS activity found tissue transformed solely GUS gene
0.19826251.15319446.html.plaintext.txt	313	Therefore speculate contents modifications endogenous tRNAs effects expression large number foreign host genes tRNA function translation mammalian cells
0.19826251.15319446.html.plaintext.txt	314	Our findings consistent conclusion host cell tRNAs affect synthesis gene products quantitatively qualitatively translating heterologous genes 5556
0.19826251.15319446.html.plaintext.txt	315	The interesting finding present study tRNASerCGA gene variable effects expression PV wt HB L1 genes hm gfp gene serine GFP variants protein translational levels two cell lines examined
0.19826251.15319446.html.plaintext.txt	316	Previous studies reported expression PV capsid genes L1 L2 controlled several means late viral promoters depend differentiation status cells polyadenylation signals terminate transcription reaching late regions 57 60 mRNAs encoding capsid proteins contain inhibitory elements prevent nuclear export destabilize message 1961 66
0.19826251.15319446.html.plaintext.txt	317	However none studies produced PV L1 L2 proteins expressed wt L1 L2 genes replicating mammalian cells
0.19826251.15319446.html.plaintext.txt	318	In contrast previous findings laboratory indicated strong bias codon usage apparent papillomavirus host blocks BPV1 capsid genes expressing proteins non differentiated mammalian cells 2033
0.19826251.15319446.html.plaintext.txt	319	On basis hypothesis match codon usage tRNA contents regulates gene expression protein levels 20 limitation PV capsid protein expression overcome modifying codon usage genes toward mammalian consensus without changing protein sequence demonstrating codon usage one determinants rate HPV gene expression non differentiated mammalian cells 2022 2467
0.19826251.15319446.html.plaintext.txt	320	In present study take different approach test hypothesis match codon usage tRNAs regulate PV L1 genes express proteins
0.19826251.15319446.html.plaintext.txt	321	We expressed tRNASerCGA gene two non differentiated cell lines
0.19826251.15319446.html.plaintext.txt	322	Expression tRNASerCGA gene resulted alterations tRNA patterns two cell lines examined enhanced translation two PV wt L1 mRNAs contain large numbers codons rarely used mammalian genes 2033
0.19826251.15319446.html.plaintext.txt	323	Meanwhile enhanced expression serine UCG GFP variant probably corresponding expression tRNASerCGA gene according previous statement correct translation UCG codon depends tRNASerCGA molecule 68
0.19826251.15319446.html.plaintext.txt	324	Although reported tRNA1SerG34 anticodon GGA recognize UCC UCU codons also UCA UCG codons 69 enhanced expression serine AGU GFP variant expression tRNASerCGA gene presently understood
0.19826251.15319446.html.plaintext.txt	325	Moreover observed expression tRNASerCGA gene resulted dramatic reduction translation PV HB L1 UCA serine GFP variant mRNAs two cell lines
0.19826251.15319446.html.plaintext.txt	326	Thus phenomena observed present study may well explained two previous statements Del Tito et al
0.19826251.15319446.html.plaintext.txt	327	These statements described tRNAs cells related gene expression translation levels level certain tRNAs low one would predict translational difficulties decoding mRNA species containing large numbers rare codons 55 ii cellular content tRNA species often correlates positively codon bias mRNAs major homologous protein products 70
0.19826251.15319446.html.plaintext.txt	328	Taken together statements 55 previous studies 20 current data strengthen support hypothesis codon usage matches tRNAs regulate expression target genes non differentiated differentiated epithelium
0.19826251.15319446.html.plaintext.txt	329	Recently Walsh Mohr 71 provided first evidence phosphorylation translation initiation factor elF4E elF4E kinase mnk 1 crucial viral protein synthesis replication herpes simplex virus 1 HSV 1 quiescent cells
0.19826251.15319446.html.plaintext.txt	330	Consistent report phosphorylation two translation initiation factors elF4E elF2 induced tRNASerCGA gene appears required translation PV wt L1 mRNAs two cell lines examined present study
0.19826251.15319446.html.plaintext.txt	331	In contrast expectation however phosphorylation elF4E elF2 may selective effects even reducing translation PV HB L1 serine UCA GFP mRNAs
0.19826251.15319446.html.plaintext.txt	332	Thus expression tRNASerCGA gene able regulate phosphorylation levels elF4E elF2 suggesting another possible mechanism involved PV L1 genes serine GFP variants may differentially regulate cap dependent cap independent translation initiation
0.19826251.15319446.html.plaintext.txt	333	Based observations conclude alterations tRNAs phosphorylation elF4E elF2 caused expression tRNASerCGA gene important modulating expression PV L1 genes different codon usage serine GFP variants protein translational levels two cell lines
0.19826251.15319446.html.plaintext.txt	334	However tRNAs must associate cognate aaRSs catalyze attachment particular amino acid 3 end appropriate tRNAs containing anticodon corresponding amino acid generate aminoacyl tRNAs necessary protein synthesis
0.19826251.15319446.html.plaintext.txt	335	But clear whether expression activities aaRSs affected tRNASerCGA gene
0.19826251.15319446.html.plaintext.txt	336	Detailed studies therefore necessary examine expression tRNASerCGA gene affects components protein synthesizing machinery including aaRSs elongator factors two cell lines
0.19826251.15319446.html.plaintext.txt	337	ACKNOWLEDGEMENTS We thank Rebecca Brown Nigel McMillan reading manuscript
0.19826251.15319446.html.plaintext.txt	338	This work funded part Queensland Cancer Fund Q52 K
0.19826251.15319446.html.plaintext.txt	339	National Health Medical Research Council Australia Industry Research Fellowship 301256 K
0.19826251.15319446.html.plaintext.txt	340	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES CrickF
0.19826251.15319446.html.plaintext.txt	341	1970 Central dogma molecular biology
0.19826251.15319446.html.plaintext.txt	342	1991 Translational control mammalian cells
0.19826251.15319446.html.plaintext.txt	343	1975 Reticulocyte transfer RNA hemoglobin synthesis
0.19826251.15319446.html.plaintext.txt	344	1990 Suppression negative effect minor arginine codons gene expression preferential usage minor codons within first 25 codons Escherichia coli genes
0.19826251.15319446.html.plaintext.txt	345	1997 Codon anticodon assignment detection codon usage trends seven microbial genomes
0.19826251.15319446.html.plaintext.txt	346	1991 Translation vitro codon UGA tryptophan Mycoplasma capricolum
0.19826251.15319446.html.plaintext.txt	347	Biochimie 73 1109 1112
0.19826251.15319446.html.plaintext.txt	348	1999 Global protein synthesis shutdown Autographa californica nucleopolyhedrovirus infected Ld652Y cells rescued tRNA uninfected cells
0.19826251.15319446.html.plaintext.txt	349	1999 High level expression Thermococcus litoralis 4 alpha glucanotransferase soluble form Escherichia coli novel expression system involving minor arginine tRNAs GroELS
0.19826251.15319446.html.plaintext.txt	350	2002 Improvement human interferon HUIFNalpha2 HCV core protein expression levels Escherichia coli HUIFNalpha8 using tRNAAGAAGG
0.19826251.15319446.html.plaintext.txt	351	2000 tRNA assisted overproduction eukaryotic ribosomal proteins
0.19826251.15319446.html.plaintext.txt	352	1999 Relationships transcriptional translational control gene expression Saccharomyces cerevisiae multiple regression analysis
0.19826251.15319446.html.plaintext.txt	353	1983 tRNA like structures plant viral RNAs conformational requirements adenylation aminoacylation
0.19826251.15319446.html.plaintext.txt	354	1983 Involvement reverse transcription replication cauliflower mosaic virus detailed model test aspects
0.19826251.15319446.html.plaintext.txt	355	Cold Spring Harbor Laboratory Press Cold Spring Harbor NY
0.19826251.15319446.html.plaintext.txt	356	2000 Selection functional tRNA primers primer binding site sequences retroviral combinatorial library identification new functional tRNA primers murine leukemia virus replication
0.19826251.15319446.html.plaintext.txt	357	2000 Identification novel human tRNASerCGA functional murine leukemia virus replication
0.19826251.15319446.html.plaintext.txt	358	1993 Production high titer helper free retroviruses transient transfection
0.19826251.15319446.html.plaintext.txt	359	2004 The tRNA like structure Turnip yellow mosaic virus RNA 3 translational enhancer
0.19826251.15319446.html.plaintext.txt	360	2002 Specific inactivation inhibitory sequences 5 end human papillomavirus type 16 L1 open reading frame results production high levels L1 protein human epithelial cells
0.19826251.15319446.html.plaintext.txt	361	1999 Papillomavirus capsid protein expression level depends match codon usage tRNA availability
0.19826251.15319446.html.plaintext.txt	362	2002 The human papillomavirus type 31 late 3 untranslated region contains complex bipartite negative regulatory element
0.19826251.15319446.html.plaintext.txt	363	2001 Enhancement capsid gene expression preparing human papillomavirus type 16 major structural gene L1 DNA vaccination purposes
0.19826251.15319446.html.plaintext.txt	364	2002 Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T lymphocyte induction anti tumour activity
0.19826251.15319446.html.plaintext.txt	365	2001 Polynucleotide viral vaccines codon optimisation ubiquitin conjugation enhances prophylactic therapeutic efficacy
0.19826251.15319446.html.plaintext.txt	366	2002 Replication bovine papillomavirus type 1 BPV 1 DNA Saccharomyces cerevisiae following infection BPV 1 virions
0.19826251.15319446.html.plaintext.txt	367	2002 Saccharomyces cerevisiae permissive replication bovine papillomavirus type 1
0.19826251.15319446.html.plaintext.txt	368	1996 Codon usage limitation expression HIV 1 envelope glycoprotein
0.19826251.15319446.html.plaintext.txt	369	2000 Increased expression immunogenicity sequence modified human immunodeficiency virus type 1 gag gene
0.19826251.15319446.html.plaintext.txt	370	2003 Codon usage mediated inhibition HIV 1 gag expression mammalian cells occurs independently translation
0.19826251.15319446.html.plaintext.txt	371	Tsitologiia 45 94 100
0.19826251.15319446.html.plaintext.txt	372	1998 Modulation HPV16 E7 translation tRNAs eukaryotic cell free translation systems
0.19826251.15319446.html.plaintext.txt	373	1984 Translation non uniform process
0.19826251.15319446.html.plaintext.txt	374	Effect tRNA availability rate elongation nascent polypeptide chains
0.19826251.15319446.html.plaintext.txt	375	1994 Supramolecular organization mammalian translation system
0.19826251.15319446.html.plaintext.txt	376	2003 Codon usage bias A T content variation human papillomavirus genomes
0.19826251.15319446.html.plaintext.txt	377	1998 DNA packaging L1 L2 capsid proteins bovine papillomavirus type 1
0.19826251.15319446.html.plaintext.txt	378	2003 Effects additional sequences directly downstream AUG expression GFP gene
0.19826251.15319446.html.plaintext.txt	379	1999 Human papillomavirus type 31 oncoproteins E6 E7 required maintenance episomes viral life cycle normal human keratinocytes
0.19826251.15319446.html.plaintext.txt	380	1970 Cleavage structural proteins assembly head bacteriophage T4
0.19826251.15319446.html.plaintext.txt	381	1995 A channeled tRNA cycle mammalian protein synthesis
0.19826251.15319446.html.plaintext.txt	382	1992 A sequestered pool aminoacyl tRNA mammalian cells
0.19826251.15319446.html.plaintext.txt	383	1976 A mechanism estrogen action gene expression level translation
0.19826251.15319446.html.plaintext.txt	384	1977 Infidelity translation encephalomyocarditis viral RNA tRNA human malignant trophoblastic cells
0.19826251.15319446.html.plaintext.txt	385	1997 Changes tRNA population compensatory cell proliferation differential expression methionine tRNA species
0.19826251.15319446.html.plaintext.txt	386	2002 Selenium influences turnover selenocysteine tRNASerSec Chinese hamster ovary cells
0.19826251.15319446.html.plaintext.txt	387	1997 Enhanced expression initiator TRNAMet human gastric colorectal carcinoma
0.19826251.15319446.html.plaintext.txt	388	1991 Selenium induces changes selenocysteine tRNASerSec population mammalian cells
0.19826251.15319446.html.plaintext.txt	389	1993 Dietary selenium affects methylation wobble nucleoside anticodon selenocysteine tRNASerSec
0.19826251.15319446.html.plaintext.txt	390	1987 Codon replacement PGK1 gene Saccharomyces cerevisiae experimental approach study role biased codon usage gene expression
0.19826251.15319446.html.plaintext.txt	391	1994 Analysis acceptor stem base pairing tRNATrp aminoacylation function vivo
0.19826251.15319446.html.plaintext.txt	392	1993 In vivo overexpression purification Escherichia coli tRNAser
0.19826251.15319446.html.plaintext.txt	393	1989 Effect variation charged uncharged tRNATrp levels ppGpp synthesis Escherichia coli
0.19826251.15319446.html.plaintext.txt	394	1990 Relationship protein synthesis concentrations charged uncharged tRNATrp Escherichia coli
0.19826251.15319446.html.plaintext.txt	395	1989 Analysis regions coding transfer RNAs Kluyveromyces lactis mitochondrial DNA
0.19826251.15319446.html.plaintext.txt	396	1998 The deafness associated mitochondrial DNA mutation position 7445 affects tRNASerUCN precursor processing long range effects NADH dehydrogenase subunit ND6 gene expression
0.19826251.15319446.html.plaintext.txt	397	2003 Translational nonsense codon suppression indicator functional pre tRNA splicing transformed Arabidopsis hypocotyl derived calli
0.19826251.15319446.html.plaintext.txt	398	1995 Effects minor isoleucyl tRNA heterologous protein translation Escherichia coli
0.19826251.15319446.html.plaintext.txt	399	1996 Problems translating heterologous genes expression systems role tRNA
0.19826251.15319446.html.plaintext.txt	400	1996 Functional characterization naturally occurring mutants human papillomavirus type 16 large deletions non coding region
0.19826251.15319446.html.plaintext.txt	401	CO2 8linktypeDOI CrossRefISIMedline
0.19826251.15319446.html.plaintext.txt	402	1996 HPV6 variants malignant tumors sequence alterations regulatory region reveal differences activities oncogene promoters contain amino acid exchanges E6 E7 proteins
0.19826251.15319446.html.plaintext.txt	403	1987 Differential promoter utilization bovine papillomavirus transformed cells productively infected wart tissues
0.19826251.15319446.html.plaintext.txt	404	1987 Structural transcriptional analysis human papillomavirus type 16 sequences cervical carcinoma cell lines
0.19826251.15319446.html.plaintext.txt	405	1998 Translational inhibition vitro human papillomavirus type 16 L2 mRNA mediated interaction heterogenous ribonucleoprotein K polyrC binding proteins 1 2
0.19826251.15319446.html.plaintext.txt	406	1995 In vitro vivo inhibition human papillomavirus type 16 E6 E7 genes
0.19826251.15319446.html.plaintext.txt	407	1995 Efficient expression human papillomavirus type 16 L1 protein epithelial cells using Rev Rev responsive element human immunodeficiency virus cis acting transactivation element simian retrovirus type 1
0.19826251.15319446.html.plaintext.txt	408	1998 mRNA instability elements human papillomavirus type 16 L2 coding region
0.19826251.15319446.html.plaintext.txt	409	1990 Analysis human papillomavirus type 16 late mRNA 3 processing signals vitro vivo
0.19826251.15319446.html.plaintext.txt	410	1991 A negative regulatory element human papillomavirus type 16 genome acts level late mRNA stability
0.19826251.15319446.html.plaintext.txt	411	2003 A synthetic E7 gene human papillomavirus type 16 yields enhanced expression protein mammalian cells useful DNA immunization studies
0.19826251.15319446.html.plaintext.txt	412	1985 Amber ochre opal suppressor tRNA genes derived human serine tRNA gene
0.19826251.15319446.html.plaintext.txt	413	2003 tRNA1SerG34 anticodon GGA recognize UCC UCU codons also UCA UCG codons
0.19826251.15319446.html.plaintext.txt	414	1992 Selenocysteyl tRNAs recognize UGA Beta vulgaris higher plant Gliocladium virens filamentous fungus
0.19826251.15319446.html.plaintext.txt	415	2004 Phosphorylation eIF4E Mnk 1 enhances HSV 1 translation replication quiescent cells
0.28238976.15914847.html.plaintext.txt	0	Human papillomavirus viral load proliferation rate recurrent respiratory papillomatosis response alpha interferon treatment Michael Szeps1 Liselotte Dahlgren1 Leena Maija Aaltonen2 John Ohd1 Lena Kanter Lewenshon1 Hanna Dahlstrand1 Eva Munck Wikland3 Dan Grander1 Tina Dalianis1
0.28238976.15914847.html.plaintext.txt	1	1 Department Oncology Pathology CancerCenterKarolinska R8 01 Karolinska Institutet Karolinska University Hospital 171 76 Stockholm Sweden 2 Department Oto Rhino Laryngology Helsinki University Hospital Helsinki Finland 3 Department Oto Rhino Laryngology Head Neck Surgery CancerCenterKarolinska R8 01 Karolinska Institutet Karolinska University Hospital 171 76 Stockholm Sweden
0.28238976.15914847.html.plaintext.txt	2	Correspondence Liselotte Dahlgren Liselotte
0.28238976.15914847.html.plaintext.txt	3	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES The aim study identify recurrent respiratory papillomatosis patients may benefit interferon IFN treatment determine means IFN action
0.28238976.15914847.html.plaintext.txt	4	The presence human papillomavirus HPV viral load proliferation rate pre ongoing post treatment respiratory papillomatosis biopsies examined retrospectively 25 patients 18 IFN treated seven IFN non treated
0.28238976.15914847.html.plaintext.txt	5	Using PCR HPV found present 2025 respiratory papillomatosis patients HPV type determined 1825 patients 12 HPV6 six HPV11
0.28238976.15914847.html.plaintext.txt	6	Eighteen patients treated IFN 14 HPV positive eight HPV6 five HPV11 one undefined HPV
0.28238976.15914847.html.plaintext.txt	7	Response IFN therapy observed 12 patients 78 HPV6 35 HPV11 11 undefined HPV 14 HPV negative six patients 18 HPV6 25 HPV11 34 HPV negative respond therapy
0.28238976.15914847.html.plaintext.txt	8	Viral load determined quantitative real time PCR 0 03 533 HPV copies per cell proliferation rate determined percentage Ki 67 positive cells 8 54 similar IFN treated non treated patients generally unaffected IFN treatment
0.28238976.15914847.html.plaintext.txt	9	In summary 1218 IFN treated patients responded therapy
0.28238976.15914847.html.plaintext.txt	10	Moreover tendency patients HPV6 positive 78 respiratory papillomatosis respond frequently IFN therapy patients HPV11 35 HPV negative 14 respiratory papillomatosis
0.28238976.15914847.html.plaintext.txt	11	Finally presence HPV viral load proliferation respiratory papillomatosis biopsies similar patients treated IFN general unaffected IFN treatment
0.28238976.15914847.html.plaintext.txt	12	These authors contributed equally work
0.28238976.15914847.html.plaintext.txt	13	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Recurrent respiratory papillomatosis RRP epithelial exophytic benign neoplastic growth rarely turns malignant Aaltonen et al
0.28238976.15914847.html.plaintext.txt	14	It frequently 90 located vocal cords Kimberlin Malis 2000
0.28238976.15914847.html.plaintext.txt	15	The common age onset early childhood juvenile RRP age onset 13 years age disease also seen adults adult RRP Abramson et al
0.28238976.15914847.html.plaintext.txt	16	RRP regarded induced human papillomavirus HPV particularly HPV type 6 HPV6 HPV11 shows variable clinical course Abramson et al
0.28238976.15914847.html.plaintext.txt	17	The primary therapeutic method endoscopic surgery approximately one tenth patients cured first surgical intervention
0.28238976.15914847.html.plaintext.txt	18	Spontaneous remissions also seen majority patients disease recurrent thereby demands treatment methods
0.28238976.15914847.html.plaintext.txt	19	In addition surgery well documented treatment laryngeal papillomatosis interferon IFN widely used 20 years proposed decrease number recurrences considerably Deunas et al
0.28238976.15914847.html.plaintext.txt	20	Although IFN used clinically decades proven anti tumour agent variety malignant non malignant neoplastic disorders underlying mechanisms action remain elucidated
0.28238976.15914847.html.plaintext.txt	21	Furthermore since IFN treatment burdened side effects patients cost considerable markers predict patients may responsive treatment remains challenge future studies
0.28238976.15914847.html.plaintext.txt	22	New substances treatment patients respiratory papillomatosis cidofovir acyclovir ribavirin Kimberlin 2004 currently evaluated role controlling disease still uncertain
0.28238976.15914847.html.plaintext.txt	23	The aim study examine presence HPV determine viral load proliferation rate respiratory papillomatosis response IFN therapy order determine possible mechanisms IFN action identify patients respond IFN treatment
0.28238976.15914847.html.plaintext.txt	24	Twenty five respiratory papillomatosis patients 18 subjected IFN treatment included study
0.28238976.15914847.html.plaintext.txt	25	From patients 54 papillomatosis biopsies including pre ongoing post treatment biopsies examined
0.28238976.15914847.html.plaintext.txt	26	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Patients
0.28238976.15914847.html.plaintext.txt	27	Twenty five RRP patients treated 1977 1994 Karolinska University Hospital Stockholm Sweden 1989 2002 Helsinki University Hospital Helsinki Finland included study conducted accordance local ethical committees
0.28238976.15914847.html.plaintext.txt	28	During selected time period 18 25 patients subjected IFN treatment
0.28238976.15914847.html.plaintext.txt	29	A total 25 pre treatment 17 ongoing treatment 12 post treatment samples obtained
0.28238976.15914847.html.plaintext.txt	30	The diagnosis respiratory papillomatosis confirmed histopathology haematoxylineosin stained sections
0.28238976.15914847.html.plaintext.txt	31	The specimens coded analyses performed double blind set
0.28238976.15914847.html.plaintext.txt	32	Therapy response evaluation
0.28238976.15914847.html.plaintext.txt	33	The clinical charts patients carefully reviewed
0.28238976.15914847.html.plaintext.txt	34	All patients examined indirect direct laryngoscopy lesion extirpation pathologicalanatomical confirmation laryngeal papillomatosis diagnosis
0.28238976.15914847.html.plaintext.txt	35	In one patient treated primarily IFN response defined absence recurrence
0.28238976.15914847.html.plaintext.txt	36	All patients treated recurrence considered responders one relapse occurred 1 year period IFN treatment period
0.28238976.15914847.html.plaintext.txt	37	DNA extracted 5x5 microm formalin fixed paraffin embedded archival tumour sections taken 1 24 years prior DNA extraction
0.28238976.15914847.html.plaintext.txt	38	Before section additional section taken tumour tissue verification haematoxylineosin staining
0.28238976.15914847.html.plaintext.txt	39	To check HPV contamination tissue blocks empty block cut empty sections collected every tumour block subsequently treated tissue sections
0.28238976.15914847.html.plaintext.txt	40	The paraffin removed xylene treatment followed ethanol washing
0.28238976.15914847.html.plaintext.txt	41	The pellet air dried incubated proteinase K 1x PCR buffer II Applied Biosystems 60 degrees C followed inactivation proteinase K 98 degrees C 8 min
0.28238976.15914847.html.plaintext.txt	42	For 21 samples DNA instead extracted using High Pure RNA Paraffin kit Roche Diagnostics according manufacturers instructions exclusion DNase treatment
0.28238976.15914847.html.plaintext.txt	43	Before running real time quantitative PCR see samples extracted High Pure method cleaned cellular debris using DNA binding columns High Pure RNA Paraffin kit Roche Diagnostics
0.28238976.15914847.html.plaintext.txt	44	Verification amplifiable DNA HLA andor S14 PCR
0.28238976.15914847.html.plaintext.txt	45	All tumour samples run HLA andor S14 PCR verification amplifiable DNA described previously Dahlgren et al
0.28238976.15914847.html.plaintext.txt	46	Water used negative control DNA extracted human fibroblasts used positive control
0.28238976.15914847.html.plaintext.txt	47	PCR products run 2 5 agarose gel stained ethidium bromide visualized UV light
0.28238976.15914847.html.plaintext.txt	48	Samples showing band 250 bp HLA 127 bp S14 considered amplifiable DNA
0.28238976.15914847.html.plaintext.txt	49	Only HLA S14 positive samples used assays study
0.28238976.15914847.html.plaintext.txt	50	The presence HPV analysed using general primers GP56 de Roda Husman et al
0.28238976.15914847.html.plaintext.txt	51	As positive controls cloned plasmids either HPV6 16 used water negative control
0.28238976.15914847.html.plaintext.txt	52	The products detected samples band 130 150 bp considered positive run HPV type specific PCR andor sequenced previously described Mellin et al
0.28238976.15914847.html.plaintext.txt	53	Samples negative GP56 PCR run another general PCR CPICPIIG primer pair Tieben et al
0.28238976.15914847.html.plaintext.txt	54	1993 exclude false negatives result disrupted L1
0.28238976.15914847.html.plaintext.txt	55	The products detected samples band 187 bp considered HPV positive run HPV type specific PCR andor sequenced previously described Mellin et al
0.28238976.15914847.html.plaintext.txt	56	Samples considered HPV positive general HPV PCR run HPV type specific PCR primers specific HPV6 11 16 18 33 Karlsen et al
0.28238976.15914847.html.plaintext.txt	57	1996 described previously Mellin et al
0.28238976.15914847.html.plaintext.txt	58	The positive controls consisted plasmids containing cloned HPV6 16 18 33
0.28238976.15914847.html.plaintext.txt	59	The products detected samples band 154 bp HPV6 89 bp HPV11 120 bp HPV16 172 bp HPV18 211 bp HPV33 considered positive
0.28238976.15914847.html.plaintext.txt	60	HPV quantification real time PCR specific HPV6 HPV11
0.28238976.15914847.html.plaintext.txt	61	Three nanograms HPV6 positive samples run triplicate type specific quantitative PCR SybrGreen protocol iCycler iQ iCycler iQ Real time PCR Detection System Bio Rad HPV6 type specific primers used
0.28238976.15914847.html.plaintext.txt	62	The reaction mixture total volume 25 microl consisted 12 5 microl iQ SYBR Green Supermix Bio Rad 1 25 microl 10 pmol microl 1 HPV6 primers
0.28238976.15914847.html.plaintext.txt	63	The programme consisted 50 degrees C 2 min 95 degrees C 10 min followed 40 cycles denaturation 95 degrees C 15 annealing 60 degrees C 30 elongation 74 degrees C 30
0.28238976.15914847.html.plaintext.txt	64	Finally melting curve starting 40 degrees C increasing 0 5 degrees C every 10 120 degrees C reached run order verify specificity obtained amplicons
0.28238976.15914847.html.plaintext.txt	65	Cloned HPV6 diluted contain 1x102 5x105 copies HPV6 per test tube used triplicate standard series
0.28238976.15914847.html.plaintext.txt	66	For estimation number viral copies per cell 1 ng DNA considered approximately equivalent 200 cells
0.28238976.15914847.html.plaintext.txt	67	For quantification HPV11 GP56 protocol adjusted SybrGreen system described 3 ng sample run triplicates
0.28238976.15914847.html.plaintext.txt	68	The reaction mixture total volume 25 microl consisted 12 5 microl iQ SYBR Green Supermix Bio Rad 1 25 microl 10 pmol microl 1 GP5 GP6 primers
0.28238976.15914847.html.plaintext.txt	69	The program consisted 50 degrees C 2 min 95 degrees C 10 min followed 40 cycles denaturation 95 degrees C 15 annealing 50 degrees C 30 elongation 71 degrees C 30
0.28238976.15914847.html.plaintext.txt	70	Melting curve analysis carried HPV6
0.28238976.15914847.html.plaintext.txt	71	Cloned HPV11 diluted contain 10 1x106 copies HPV11 per test tube used triplicate standard series
0.28238976.15914847.html.plaintext.txt	72	For estimation number viral copies per cell 1 ng DNA considered approximately equivalent 200 cells
0.28238976.15914847.html.plaintext.txt	73	For quantitative HPV6 HPV11 PCR assays sample values concordant triplicate duplicate accepted
0.28238976.15914847.html.plaintext.txt	74	All samples rerun acceptable concordant triplicate duplicate values obtained
0.28238976.15914847.html.plaintext.txt	75	When following individual patient samples time variation viral load 0 5 log difference considered significant quantitative increase decrease Yun et al
0.28238976.15914847.html.plaintext.txt	76	Immunostaining performed according standard avidin biotin peroxidase complex ABC technique Elite Standard ABC kit Vector Laboratories
0.28238976.15914847.html.plaintext.txt	77	Paraffin sections deparaffinized rehydrated pre treated citrate buffer pH 6 microwave oven 20 min 700 W
0.28238976.15914847.html.plaintext.txt	78	After rinsing endogenous peroxidase activity blocked 0 5 hydrogen peroxide 30 min
0.28238976.15914847.html.plaintext.txt	79	The sections rinsed incubated blocking serum 1 BSA 20 min subsequently incubated overnight moist chamber 8 degrees C primary antibody MIB 1 diluted 1 160 Dakopatts AB detect Ki 67 antigen specific proliferating cells
0.28238976.15914847.html.plaintext.txt	80	A secondary biotinylated anti mouse IgG antibody Dakopatts AB added slides 30 min incubation followed rinsing ABC complex added 30 min
0.28238976.15914847.html.plaintext.txt	81	The peroxidase reaction developed using 33 diaminobenzidine 6 min
0.28238976.15914847.html.plaintext.txt	82	Nuclear counterstaining performed Mayers haematoxylin
0.28238976.15914847.html.plaintext.txt	83	Tris buffered saline pH 7 4 used rinsing step
0.28238976.15914847.html.plaintext.txt	84	Staining checked positive controls intestinal mucosa lymph node
0.28238976.15914847.html.plaintext.txt	85	The Ki 67 labelling index determined light microscopy x40 objective randomly counting cells positive nuclear staining expressing results number immunoreactive cells among 200 nuclei respiratory papilloma cells
0.28238976.15914847.html.plaintext.txt	86	A 2 exact test used statistical analysis
0.28238976.15914847.html.plaintext.txt	87	A 95 confidence interval used P0 05 considered significant
0.28238976.15914847.html.plaintext.txt	88	Non categorical variables tested Students two tailed test performing Levenes test normality P0 05 considered significant
0.28238976.15914847.html.plaintext.txt	89	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Clinical outcome Detailed information age gender patients well available biopsies treatment shown Table 1
0.28238976.15914847.html.plaintext.txt	90	Most patients males presented equal distribution juvenile RRP adult RRP female patients juvenile RRP
0.28238976.15914847.html.plaintext.txt	91	The dominance male patients maintained IFN treated group Table 1
0.28238976.15914847.html.plaintext.txt	92	Respiratory papillomatosis patients age onset gender HPV status treatment duration response IFN treatment number available biopsies
0.28238976.15914847.html.plaintext.txt	93	F Female M male R response NR response
0.28238976.15914847.html.plaintext.txt	94	Twenty five patients 18 IFN treated seven IFN treated included study study could carried blind well allowing us analyse whether two groups similar details see Table 1
0.28238976.15914847.html.plaintext.txt	95	Of 18 IFN treated patients 16 started first IFN therapy three recurrences 1 year period prior IFN treatment one patient two recurrences 1 year period final patient introduced IFN treatment within 1 month diagnosis
0.28238976.15914847.html.plaintext.txt	96	For one patients RP 14 biopsies available second round IFN treatment
0.28238976.15914847.html.plaintext.txt	97	Furthermore one patients RP 2 received IFN treatment two separate periods samples available IFN treatment periods
0.28238976.15914847.html.plaintext.txt	98	The duration IFN treatment ranged 1 5 months 10 years
0.28238976.15914847.html.plaintext.txt	99	Twelve treated patients aged 0 5 40 years showed clinical response defined
0.28238976.15914847.html.plaintext.txt	100	absence recurrence primary IFN treatment one relapse occurring 1 year treatment exception RP 3 see response definition footnote Table 1
0.28238976.15914847.html.plaintext.txt	101	The remaining six judged non responders Table 1
0.28238976.15914847.html.plaintext.txt	102	Of seven patients subjected IFN treatment three cured first surgical intervention four recurrent disease Table 1 data shown
0.28238976.15914847.html.plaintext.txt	103	Detection HPV PCR general HPV primers respiratory papillomatosis response IFN therapy The presence HPV DNA found PCR 2025 80 patients possible establish HPV type 18 20 patients Table 1
0.28238976.15914847.html.plaintext.txt	104	Furthermore frequency HPV determined PCR similar patients subjected 1418 77 8 subjected 67 85 7 IFN treatment Table 1
0.28238976.15914847.html.plaintext.txt	105	The number HPV positive respiratory papillomas IFN responders general higher respiratory papillomas IFN non responders
0.28238976.15914847.html.plaintext.txt	106	1114 14 respectively Table 1 difference statistically significant P0 083 2 exact test
0.28238976.15914847.html.plaintext.txt	107	Of available pre treatment respiratory papillomas 912 75 IFN treated responders HPV positive 24 50 available pre treatment papillomas IFN non responders HPV positive Table 2
0.28238976.15914847.html.plaintext.txt	108	Furthermore 88 100 available ongoing 55 100 available post treatment IFN responsive respiratory papillomatosis HPV positive 13 33 available ongoing 23 67 post treatment IFN non responsive papillomas HPV positive Table 2
0.28238976.15914847.html.plaintext.txt	109	However none differences statistically significant
0.28238976.15914847.html.plaintext.txt	110	Human papillomavirus viral load proliferation respiratory papillomatosis response IFN treatment
0.28238976.15914847.html.plaintext.txt	111	R Response NR response Neg negative result NA available ND done
0.28238976.15914847.html.plaintext.txt	112	Determination HPV type type specific PCR sequencing respiratory papillomatosis response IFN therapy HPV type specific PCR sequencing showed 12 patients harboured HPV6 six patients harboured HPV11 respiratory papillomas two patients HPV type could determined due limited material Table 1
0.28238976.15914847.html.plaintext.txt	113	The frequency HPV6 similar IFN treated 818 44 non treated 47 57 presence HPV11 higher IFN treated 518 28 non treated 17 14 patients Table 1
0.28238976.15914847.html.plaintext.txt	114	However 78 87 5 patients HPV6 positive papillomas responded IFN therapy 35 60 patients HPV11 responded difference statistically significant P0 5105 2 exact test
0.28238976.15914847.html.plaintext.txt	115	There also significant statistical difference 78 patients HPV6 positive papillomas 35 patients HPV11 positive papillomas compared patient 14 HPV negative papilloma responded IFN therapy P0 067 P0 524 respectively 2 exact test
0.28238976.15914847.html.plaintext.txt	116	Viral load estimation real time quantitative PCR HPV6 HPV11 respiratory papillomatosis response IFN therapy The viral load HPV6 HPV11 positive samples estimated real time quantitative PCR ranged 0 25 533 copies per cell HPV6 0 03 87 copies per cell HPV11 Table 2
0.28238976.15914847.html.plaintext.txt	117	Patients different pre treatment viral loads 6 2 126 HPV6 copies per cell 0 07 0 1 HPV11 copies per cell responded IFN therapy major changes viral load biopsies individual patients HPV positive tumours generally observed IFN treatment Table 2
0.28238976.15914847.html.plaintext.txt	118	Furthermore three patients HPV positive respiratory papillomas still respond IFN treatment viral load differ significantly patients responded therapy Table 2
0.28238976.15914847.html.plaintext.txt	119	HPV6 viral load could compared treatment four IFN responding patients Table 2
0.28238976.15914847.html.plaintext.txt	120	The viral load somewhat lower patients treatment decrease significant 0 5 log one patient RP 2 showing drop 6 2 0 65 HPV6 copies per cell remaining three patients RP 3 RP 6 RP 7 Table 2
0.28238976.15914847.html.plaintext.txt	121	HPV6 viral load available two patients post treatment cases clear increase viral load observed Table 2
0.28238976.15914847.html.plaintext.txt	122	HPV11 viral load could compared treatment two IFN responding patients one non responding patient Table 2
0.28238976.15914847.html.plaintext.txt	123	The viral load somewhat higher patients treatment increase significant 0 5 log two IFN responsive patients RP 9 RP 11 Table 2
0.28238976.15914847.html.plaintext.txt	124	For remaining IFN non responsive patient RP 12 significant increase viral load seen initially treatment dropped 0 55 6 04 0 08 HPV11 copies per cell viral load increased 87 6 HPV11 copies per cell termination IFN treatment Table 2
0.28238976.15914847.html.plaintext.txt	125	Proliferation IFN treatment Ki 67 staining mainly observed basal layer respiratory tract epithelium although occasional staining also detected superficial layers epithelium
0.28238976.15914847.html.plaintext.txt	126	A high proliferation rate generally seen samples Ki 67 indexes ranging 8 54 median 35 Table 2
0.28238976.15914847.html.plaintext.txt	127	There major differences proliferation rate pre treatment samples IFN responders 8 50 median 35 non responders 22 35 median 35 10 54 median 28 19 47 median 37 5 IFN treatment Table 2
0.28238976.15914847.html.plaintext.txt	128	More specifically IFN treated group available samples eight responding patients Ki 67 index increased half decreased half patients treatment Table 2
0.28238976.15914847.html.plaintext.txt	129	In available samples 34 IFN non responding patients could analysed Ki 67 index increased one decreased remaining two patients treatment Table 2
0.28238976.15914847.html.plaintext.txt	130	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES With clinical characteristics early onset frequent recurrences therapeutic resistance respiratory papillomatosis constitutes challenge clinicians improve therapeutic results also decrease impairment life quality due disease related symptoms side effects therapy
0.28238976.15914847.html.plaintext.txt	131	Since surgery alone commonly sufficient disease control RRP need adjuvant treatment
0.28238976.15914847.html.plaintext.txt	132	IFN several decades drug choice Kimberlin Malis 2000
0.28238976.15914847.html.plaintext.txt	133	To achieve remission long term treatment many cases associated severe side effects necessary
0.28238976.15914847.html.plaintext.txt	134	In order prevent unnecessary treatment patients resistant IFN therapy low risk relapse surgery extended investigation potentially predictive factors desirable
0.28238976.15914847.html.plaintext.txt	135	In study biopsies 25 respiratory papillomatosis patients 18 subjected IFN treatment examined presence HPV determine viral load proliferation rate order find possible means IFN action identify patients might benefit therapy
0.28238976.15914847.html.plaintext.txt	136	Of respiratory papillomatosis biopsies investigated majority determined HPV positive similar previous observations Lie et al
0.28238976.15914847.html.plaintext.txt	137	Furthermore also similar previous studies HPV6 HPV11 found predominant HPV types Kimberlin Malis 2000 Rabah et al
0.28238976.15914847.html.plaintext.txt	138	We also noted dominance HPV6 among Swedish cases HPV11 dominated among Finnish cases data shown showing variation described previously populations Rabah et al
0.28238976.15914847.html.plaintext.txt	139	Of patients subjected IFN therapy majority 67 responded successfully similar previously published results Deunas et al
0.28238976.15914847.html.plaintext.txt	140	There evident difference age presence HPV patients subjected IFN treatment responded
0.28238976.15914847.html.plaintext.txt	141	However males dominant whole IFN treated group Table 1
0.28238976.15914847.html.plaintext.txt	142	Biopsies taken prior IFN treatment available majority treated patients presence HPV demonstrated PCR 1116 cases 73 HPV positive cases responded therapy
0.28238976.15914847.html.plaintext.txt	143	It remarkable HPV could detected biopsies treatment could due part low viral load
0.28238976.15914847.html.plaintext.txt	144	In fact among five pre treatment respiratory papillomatosis cases originally determined HPV negative two biopsies taken later IFN treatment HPV6 positive two patients also responded IFN treatment
0.28238976.15914847.html.plaintext.txt	145	Summarizing data HPV HPV type tendency observed HPV6 cases respond readily therapy HPV11 HPV negative cases difference statistically significant although close borderline P0 067 HPV6 HPV negative groups
0.28238976.15914847.html.plaintext.txt	146	We explanation tendency HPV6 positive papillomas respond readily IFN treatment HPV11 positive cases however suggested HPV11 associated papillomatosis aggressive HPV6 associated disease Rabah et al
0.28238976.15914847.html.plaintext.txt	147	Furthermore correlation virus genotype response IFN treatment noted viruses hepatitis C virus Tan Katze 2001
0.28238976.15914847.html.plaintext.txt	148	The viral load varied considerably among biopsies patients various pre treatment loads responded IFN therapy indicating patients low well high viral load respond IFN
0.28238976.15914847.html.plaintext.txt	149	In addition viral load generally significantly affected IFN treatment although HPV6 cases viral load tendency decrease opposite tendency observed HPV11 cases
0.28238976.15914847.html.plaintext.txt	150	Nevertheless significant increase viral load could observed IFN withdrawal four cases Table 2 indicating risk rebound phenomena observed clinical practice increase numbers papillomas Kimberlin Malis 2000
0.28238976.15914847.html.plaintext.txt	151	The absence influence IFN viral load treatment anticipated could possibly due limited number patients included study
0.28238976.15914847.html.plaintext.txt	152	However reported previously although quantitative PCR Steinberg et al
0.28238976.15914847.html.plaintext.txt	153	It possible IFN exerts mechanisms means
0.28238976.15914847.html.plaintext.txt	154	One possibility enhancement immunological response HPV infected cells example increasing major histocompatibility complex MHC expression Grander Einhorn 1998
0.28238976.15914847.html.plaintext.txt	155	An increase MHC expression would consequently increase ability immune system respond combat HPV positive respiratory papillomatosis without directly influencing viral load extensively remaining respiratory papillomatosis cells treatment
0.28238976.15914847.html.plaintext.txt	156	This mechanism could also explain cell proliferation affected IFN treatment discussed
0.28238976.15914847.html.plaintext.txt	157	Another possibility could IFN increases rate apoptosis virus infected cells
0.28238976.15914847.html.plaintext.txt	158	This could also lead decreased amount papilloma cells maintained levels virus
0.28238976.15914847.html.plaintext.txt	159	IFN shown act pro apoptotically neoplastic cells recently found expression HPV16 E7 oncogene may sensitize tumour cells IFN induced apoptosis Thyrell et al
0.28238976.15914847.html.plaintext.txt	160	Whether induction apoptosis explains clinical effects IFN respiratory papillomatosis however remains investigated
0.28238976.15914847.html.plaintext.txt	161	IFN also known exert anti proliferative effects many cell types suggested also importance anti neoplastic activities Grander Einhorn 1998
0.28238976.15914847.html.plaintext.txt	162	Cell proliferation determined percentage Ki 67 positive cells immunohistochemistry significant difference cell proliferation observed patients treated treated IFN
0.28238976.15914847.html.plaintext.txt	163	Moreover Ki 67 index significantly affected IFN treatment differ significantly patients responded respond IFN therapy unexpected
0.28238976.15914847.html.plaintext.txt	164	To knowledge reports comparison effect IFN proliferation rate respiratory papillomatosis
0.28238976.15914847.html.plaintext.txt	165	HPV clearly induces perturbed regulation cell cycle manifested relatively high percentage cycling cells papillomas
0.28238976.15914847.html.plaintext.txt	166	IFN seems act anti proliferative agent alterations impinging G1 cyclin dependent kinase complexes HPV induced alteration cell cycle machinery may responsible lack IFN induced anti proliferative effects Sangfelt et al
0.28238976.15914847.html.plaintext.txt	167	IFN may also exert anti tumour function means inhibition angiogenesis well induction differentiation Grander Einhorn 1998 could play role papillomatosis setting although needs studied detail
0.28238976.15914847.html.plaintext.txt	168	In conclusion one studies investigating putative anti tumour effects IFN vivo treatment aimed defining mechanism action IFN well defining predictive markers IFN therapy
0.28238976.15914847.html.plaintext.txt	169	One reason limited number similar studies IFN treatment used standard therapy RRP
0.28238976.15914847.html.plaintext.txt	170	Nevertheless even though RRP patient group study heterogeneous age clinical course treatment strategy IFN treated patients responded therapy
0.28238976.15914847.html.plaintext.txt	171	Furthermore tendency HPV6 positive cases respond better HPV 11 positive HPV negative cases IFN therapy
0.28238976.15914847.html.plaintext.txt	172	Interestingly highly IFN responsive disease prominent anti tumour effects reflected IFN induced changes fundamental disease related parameters viral load hyperproliferative state HPV affected epithelium
0.28238976.15914847.html.plaintext.txt	173	Finally although study conclusively pinpoint mechanism successful IFN treatment suggests analysed factors ruled possible markers response prediction
0.28238976.15914847.html.plaintext.txt	174	The study also indicates areas future investigation aimed selecting patients may benefit IFN treatment
0.28238976.15914847.html.plaintext.txt	175	ACKNOWLEDGEMENTS We thank Swedish Cancer Foundation Stockholm Cancer Society Swedish Research Council VR Stockholm City Council Karolinska Institute financial support
0.28238976.15914847.html.plaintext.txt	176	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Aaltonen L
0.28238976.15914847.html.plaintext.txt	177	Human papillomavirus larynx
0.28238976.15914847.html.plaintext.txt	178	Laryngeal papillomatosis clinical histopathologic molecular studies
0.28238976.15914847.html.plaintext.txt	179	HLA alleles IFN responses HPV 11 E6 disease severity patients recurrent respiratory papillomatosis
0.28238976.15914847.html.plaintext.txt	180	Human papillomavirus HPV genotypes associated laryngeal papilloma
0.28238976.15914847.html.plaintext.txt	181	Comparative genomic hybridization analysis tonsillar cancer reveals different pattern genomic imbalances human papillomavirus positive negative tumors
0.28238976.15914847.html.plaintext.txt	182	The use general primers GP5 GP6 elongated 3 ends adjacent highly conserved sequences improves human papillomavirus detection PCR
0.28238976.15914847.html.plaintext.txt	183	Use interferon alpha laryngeal papillomatosis eight years Cuban national programme
0.28238976.15914847.html.plaintext.txt	184	J Laryngol Otol 111 134 140
0.28238976.15914847.html.plaintext.txt	185	Molecular transformation recurrent respiratory papillomatosis viral typing p53 overexpression
0.28238976.15914847.html.plaintext.txt	186	Ann Otol Rhinol Laryngol 112 298 302
0.28238976.15914847.html.plaintext.txt	187	Interferon malignant disease work doesnt always Acta Oncol 37 331 338
0.28238976.15914847.html.plaintext.txt	188	Use multiple PCR primer sets optimal detection human papillomavirus
0.28238976.15914847.html.plaintext.txt	189	J Clin Microbiol 34 2095 2100
0.28238976.15914847.html.plaintext.txt	190	Current status antiviral therapy juvenile onset recurrent respiratory papillomatosis
0.28238976.15914847.html.plaintext.txt	191	Juvenile onset recurrent respiratory papillomatosis possibilities successful antiviral therapy
0.28238976.15914847.html.plaintext.txt	192	Detection human papillomavirus routinely processed biopsy specimens laryngeal papillomas evaluation reproducibility polymerase chain reaction DNA situ hybridization procedures
0.28238976.15914847.html.plaintext.txt	193	Acta Otolaryngol 116 627 632
0.28238976.15914847.html.plaintext.txt	194	Human papillomavirus HPV DNA tonsillar cancer clinical correlates risk relapse survival
0.28238976.15914847.html.plaintext.txt	195	CO2 7linktypeDOI CrossRefMedline
0.28238976.15914847.html.plaintext.txt	196	Human papillomavirus type 16 episomal high viral load may correlated better prognosis tonsillar cancer
0.28238976.15914847.html.plaintext.txt	197	Adult respiratory papillomatosis human papillomavirus type viral coinfections predictors prognosis
0.28238976.15914847.html.plaintext.txt	198	Ann Otol Rhinol Laryngol 104 758 762
0.28238976.15914847.html.plaintext.txt	199	Human papillomavirus 11 associated recurrent respiratory papillomatosis aggressive human papillomavirus 6 associated disease
0.28238976.15914847.html.plaintext.txt	200	Pediatr Dev Pathol 4 68 72
0.28238976.15914847.html.plaintext.txt	201	Mechanisms interferon induced cell cycle arrest
0.28238976.15914847.html.plaintext.txt	202	Persistence expression human papillomavirus interferon therapy
0.28238976.15914847.html.plaintext.txt	203	Arch Otolaryngol Head Neck Surg 114 27 32
0.28238976.15914847.html.plaintext.txt	204	How hepatitis C virus counteracts interferon response jury still NS5A
0.28238976.15914847.html.plaintext.txt	205	Human papillomavirus 16 E7 oncogene sensitizes malignant cells interferon alpha induced apoptosis
0.28238976.15914847.html.plaintext.txt	206	Detection cutaneous genital HPV types clinical samples PCR using consensus primers
0.28238976.15914847.html.plaintext.txt	207	J Virol Methods 42 265 279
0.28238976.15914847.html.plaintext.txt	208	A real time TaqMan PCR routine quantitation cytomegalovirus DNA crude leukocyte lysates stem cell transplant patients
0.28238976.15914847.html.plaintext.txt	209	Received 21 December 2004 accepted 25 February 2005
0.28238976.15914847.html.plaintext.txt	210	This Article Abstract Full Text PDF Alert article cited Alert correction posted Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles Szeps M
0.28238976.15914847.html.plaintext.txt	211	Articles citing Article PubMed PubMed Citation Articles Szeps M
0.28238976.15914847.html.plaintext.txt	212	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL J MED MICROBIOL ALL SGM JOURNALS
0.21141487.10788482.html.plaintext.txt	0	Specificity Determinants Pyruvate Dehydrogenase Component Reaction Mapped Mutated Prosthetic Group Modified Lipoyl Domains Xiaoming Gong Tao Peng Alexander Yakhnin Michal Zolkiewski Janet Quinn Stephen J
0.21141487.10788482.html.plaintext.txt	1	From Department Biochemistry Kansas State University Manhattan Kansas 66506 Department Biochemistry Genetics The Medical School University Newcastle Newcastle Upon Tyne NE2 4HH United Kingdom
0.21141487.10788482.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.21141487.10788482.html.plaintext.txt	3	Efficient catalysis second step pyruvate dehydrogenase E1 component reaction requires lipoyl group attached lipoyl domain displays appropriately positioned specificity residues
0.21141487.10788482.html.plaintext.txt	4	As substrates human dihydrolipoyl acetyltransferase provides N terminal L1 inner L2 lipoyl domain
0.21141487.10788482.html.plaintext.txt	5	We evaluated specificity requirements E1 reaction 27 mutant L2 including four substitutions lipoylated lysine Lys173 three analogs substituted lipoyl group Lys173 selected L1 mutants
0.21141487.10788482.html.plaintext.txt	6	Besides Lys173 mutants E170Q mutation prevented lipoylation
0.21141487.10788482.html.plaintext.txt	7	Based analysis structural stability mutants differential scanning calorimetry alanine substitutions residues aromatic side chains terminal regions outside folded portion L2 domain significantly decreased stability mutant L2 suggesting specific interactions terminal regions folded domain
0.21141487.10788482.html.plaintext.txt	8	E1 reaction rates markedly reduced following substitutions L2 domain equivalent site L1 L140A S141A S14A L1 T143A E162A D172N E179A E52A L1
0.21141487.10788482.html.plaintext.txt	9	These mutants gave diverse changes kinetic parameters
0.21141487.10788482.html.plaintext.txt	10	These residues spread 24 A one side L2 structure supporting extensive contact E1 L2 domain
0.21141487.10788482.html.plaintext.txt	11	Alignment 40 lipoyl domain sequences supports Ser141 Thr143 Glu179 serving specificity residues use E1 eukaryotic sources
0.21141487.10788482.html.plaintext.txt	12	Extensive interactions lipoyl lysine prosthetic group within active site supported limited inhibition E1 acetylation native L2 L2 domains altered either mutation Lys173 enzymatic addition lipoate analogs Lys173
0.21141487.10788482.html.plaintext.txt	13	Thus efficient use mammalian E1 cognate lipoyl domains derives unique surface residues critical interactions contributed universal lipoyl lysine prosthetic group key specificity residues conserved residues particularly Asp172 adjacent Lys173
0.21141487.10788482.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.21141487.10788482.html.plaintext.txt	15	The pyruvate dehydrogenase complex PDC1 oxidatively decarboxylates pyruvate production acetyl CoA NADH
0.21141487.10788482.html.plaintext.txt	16	The PDC reaction results sequential catalysis pyruvate dehydrogenase E1 dihydrolipoyl acetyltransferase E2 dihydrolipoyl dehydrogenase E3 components
0.21141487.10788482.html.plaintext.txt	17	In intermediate steps lipoyl groups mobile lipoyl domains E2 reductively acetylated E1 de acetylated E2 re oxidized E3
0.21141487.10788482.html.plaintext.txt	18	Thus lipoyl domains play vital role connecting sequential series reaction catalyzed three components
0.21141487.10788482.html.plaintext.txt	19	In mammalian PDC two lipoyl domains L1 L2 E1 binding domain provided outer structure E2 1 2
0.21141487.10788482.html.plaintext.txt	20	These flexibly held domains surround pentagonal dodecahedron shaped inner core formed association 60 C terminal catalytic domains E2
0.21141487.10788482.html.plaintext.txt	21	The capacity lipoyl domains rapidly move active sites provided highly flexible inter domain linker segments located globular domains E2
0.21141487.10788482.html.plaintext.txt	22	In mammalian PDC E2 linker regions 20 30 amino acids length high alanine proline residues prolines introduce stiffness interdomain segments 3
0.21141487.10788482.html.plaintext.txt	23	Mammalian PDC third lipoyl domain E3 binding protein E3BP similar segmented structure 1
0.21141487.10788482.html.plaintext.txt	24	In first step E1 reaction bound thiamin diphosphate TPP forms adduct pyruvate rapidly decarboxylated generate 2 1 hydroxyethylidene TPP HE TPP 4
0.21141487.10788482.html.plaintext.txt	25	In second step reductive acetylation lipoyl group achieved linking oxidation hydroxyethylidene group reduction disulfide dithiolane ring lipoyl group
0.21141487.10788482.html.plaintext.txt	26	By either concerted sequential mechanism acetyl group introduced onto thiol formed 8 position lipoyl group
0.21141487.10788482.html.plaintext.txt	27	The E1 reaction proceeds high efficiency lipoyl domain substrate
0.21141487.10788482.html.plaintext.txt	28	Known model reactions coupled coupled artificial electron acceptors proceed slowly free lipoate lipoamide lipoyl lysine particularly poor acceptors 3
0.21141487.10788482.html.plaintext.txt	29	2 Consistent standard two step mechanism described Liu et al
0.21141487.10788482.html.plaintext.txt	30	2 established steady state kinetic analyses rapid E1 catalysis using natural lipoyl domain substrates proceeds ping pong reaction sequence
0.21141487.10788482.html.plaintext.txt	31	Thus lipoyl domain makes critical contributions rapid E1 catalysis
0.21141487.10788482.html.plaintext.txt	32	Furthermore set specificity residues lipoyl domain structure required allow E1 source use cognate lipoyl domains use lipoyl domains complexes
0.21141487.10788482.html.plaintext.txt	33	In case mammalian PDC specific molecular recognition E1 component must exclude using lipoyl domains provided mitochondrial systems ketoglutarate dehydrogenase complex branched chain keto acid dehydrogenase complex glycine cleavage enzyme
0.21141487.10788482.html.plaintext.txt	34	In marked contrast lipoyl domains multienzyme systems substrates common E3 component catalyzes reversible conversion reduced lipoyl groups disulfide form coupled reduction NAD 1 5 6
0.21141487.10788482.html.plaintext.txt	35	Studies using bacterial PDC E1 various lipoyl domain sources delineated structural features lipoyl domains contribute specific recognition 7 8
0.21141487.10788482.html.plaintext.txt	36	The first loop lipoyl domain structures located adjacent lipoyl prosthetic group shown contribute reaction specificity 8 10
0.21141487.10788482.html.plaintext.txt	37	These studies focused residues fairly close lipoyl group provided limited insights relative importance interactions prosthetic group lipoyl domain
0.21141487.10788482.html.plaintext.txt	38	Despite high specificity E1 cognate lipoyl domain weak interactions E1 lipoyl domain substrate detected 11
0.21141487.10788482.html.plaintext.txt	39	2 Indeed dissociation constants E1 lipoyl domain interactions appear much higher Km E1 lipoyl domain substrates
0.21141487.10788482.html.plaintext.txt	40	A weak interaction probably desirable feature sustaining high efficiency since flexibly held lipoyl domains concentrated mammalian PDC 1
0.21141487.10788482.html.plaintext.txt	41	0 mM 12 13 next E1 therefore efficiently ferry lipoyl groups active site E1
0.21141487.10788482.html.plaintext.txt	42	The recent crystal structure Pseudomonas putida branched chain keto acid dehydrogenase also 22 tetramer show active site long funnel requiring full reach lipoyl lysine prosthetic group 14
0.21141487.10788482.html.plaintext.txt	43	Consistent specificity determining interactions provided specific interactions E1 cognate lipoyl domains particular complex predicted lipoyl domain would need positioned close surface E1 reaction proceed
0.21141487.10788482.html.plaintext.txt	44	Similar requirements lipoyl lysine cofactor use length reaching deep active sites also formed subunit interfaces E2 15 16 E3 17 oligomers indicate extended length cofactor needed directly support three catalytic reactions connecting linker regions provide capacity movement lipoyl domains active sites 14 18
0.21141487.10788482.html.plaintext.txt	45	We used two approaches evaluate structural features lipoyl domain human PDC E2 contribute specificity efficiency reductive acetylation reaction catalyzed mammalian E1
0.21141487.10788482.html.plaintext.txt	46	First compared capacity mutated human E2 lipoyl domains serve substrates E1 reaction determine key specificity residues residues important catalysis
0.21141487.10788482.html.plaintext.txt	47	Mutation putative specificity residues L2 domain guided three dimensional structure domain determined NMR spectroscopy 19
0.21141487.10788482.html.plaintext.txt	48	Second evaluate contribution lipoyl prosthetic group interactions E1 evaluated competitive inhibition versus native domain lipoyl domains modified lysyl lipoyl prosthetic group either replacing lysine amino acids substituting nonreactive lipoyl analogs onto lysine side chain
0.21141487.10788482.html.plaintext.txt	49	Our studies support extensive interactions E1 lipoyl domain lipoyl lysine prosthetic group
0.21141487.10788482.html.plaintext.txt	50	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.21141487.10788482.html.plaintext.txt	51	Materials Bovine kidney E1 prepared described previously purified kidney PDC 20 21
0.21141487.10788482.html.plaintext.txt	52	As described detail elsewhere3 human E1 prepared restructuring preparation Korotchkina et al
0.21141487.10788482.html.plaintext.txt	53	22 His tag could removed treatment Precision Protease changing purification procedure eliminate contaminant
0.21141487.10788482.html.plaintext.txt	54	The sodium salt 2 14Cpyruvate purchased NEN Life Science Products Inc
0.21141487.10788482.html.plaintext.txt	55	quantified measuring extent NADH formed pyruvate limiting using overall PDC reaction liquid scintillation counting analyzed separation AMINEX ion exclusion HPX87H column Bio Rad isocratic elution using 5 mM H2SO4 continuous monitoring radioactivity using PACKARD TRACE 7140
0.21141487.10788482.html.plaintext.txt	56	2 14CPyruvate preparations gave single peak different preparations specific radioactivities 20
0.21141487.10788482.html.plaintext.txt	57	Oligonucleotides purchased Oligos Etc
0.21141487.10788482.html.plaintext.txt	58	synthesized Applied Biosystems 381A DNA synthesizer
0.21141487.10788482.html.plaintext.txt	59	Pfu polymerase Stratagene
0.21141487.10788482.html.plaintext.txt	60	Preparation Evaluation Lipoyl Domain Constructs Expression conditions 23 24 compared modified described Results
0.21141487.10788482.html.plaintext.txt	61	Optimal expression GST lipoyl domain constructs obtained host Escherichia coli BL21 grown 37 degrees C 0
0.21141487.10788482.html.plaintext.txt	62	9 absorbance 600 nm followed induction 1 mM isopropyl 1 thio D galactopyranoside expression 22 24 degrees C 6 h
0.21141487.10788482.html.plaintext.txt	63	Prior preparation mutated L11 1284 L2120 233 structures silent mutations introduced flanking lipoyl domains produce restriction sites corresponding changes introduced coding sequence native E2 mutated lipoyl domains could substituted produce modified E2 oligomers 25
0.21141487.10788482.html.plaintext.txt	64	3 All mutations introduced pGEX 2T plasmids produce single amino acid substitutions GST L11 128 GST L2120 233 introduced using offset oligonucleotide primers containing appropriate base changes design allowed replication parental strands
0.21141487.10788482.html.plaintext.txt	65	Replication performed using Pfu polymerase 10 one base change 12 two base change replication cycles
0.21141487.10788482.html.plaintext.txt	66	This followed digestion methylated parent strands DpnI endonuclease target sequence 5 GmATC 3
0.21141487.10788482.html.plaintext.txt	67	Mutations L2128 229 introduced using Altered Sites mutagenesis kit Promega Corp
0.21141487.10788482.html.plaintext.txt	68	properties previously described 26
0.21141487.10788482.html.plaintext.txt	69	All mutations confirmed dideoxy sequencing
0.21141487.10788482.html.plaintext.txt	70	In L2120 233 alanine substituted Tyr129 Leu140 Ser141 Thr143 Thr145 Val156 Lys173 site lipoylation Glu179 Leu190 Asp197 Phe217 Thr220
0.21141487.10788482.html.plaintext.txt	71	The basic residues Lys188 Arg196 substituted glutamine selected acidic residues extended C terminal tail converted corresponding amides e
0.21141487.10788482.html.plaintext.txt	72	The site lipoylation Lys173 also mutated Met Leu L2120 233 Gln using L2128 229 structure
0.21141487.10788482.html.plaintext.txt	73	Neighboring lipoylation site L2128 229 mutations included E170Q D172N A174S
0.21141487.10788482.html.plaintext.txt	74	The positions mutated amino acids L2 structure shown Fig
0.21141487.10788482.html.plaintext.txt	75	L11 128 mutated alanine substitution Ser14 Lys46 site lipoylation Glu52 Asp70 correspond Ser141 Lys173 Glu179 Asp197 L2 domain
0.21141487.10788482.html.plaintext.txt	76	Lipoyl domain sequences obtained GenBank aligned Genetics Corporation Group Pileup program Wisconsin Package version 9
0.21141487.10788482.html.plaintext.txt	77	Native mutated lipoyl domains purified described previously 23 evaluated native gel electrophoresis readily detects degree lipoylation 23 24 26
0.21141487.10788482.html.plaintext.txt	78	The effective use lipoyl group tested use lipoyl domains substrates E3 reaction described previously 23
0.21141487.10788482.html.plaintext.txt	79	Compact mobility native gel electrophoresis requires well folded domains
0.21141487.10788482.html.plaintext.txt	80	As reported changes forms tend aggregate also detected native gel electrophoresis
0.21141487.10788482.html.plaintext.txt	81	In cases masses also evaluated matrix assisted laser desorption ionization mass spectrometry using Lasermat 2000
0.21141487.10788482.html.plaintext.txt	82	Melting transitions cooperative unfolding domains determined DSC using MicroCal VP DSC 27 scanning rate 1 degrees Cmin unless otherwise indicated
0.21141487.10788482.html.plaintext.txt	83	7 2 mgml dialyzed 20 mM potassium phosphate buffer pH 7
0.21141487.10788482.html.plaintext.txt	84	0 scans buffer alone subtracted lipoyl domains
0.21141487.10788482.html.plaintext.txt	85	After first scan sample solution cooled re scanned test reversiblity unfolding
0.21141487.10788482.html.plaintext.txt	86	Tm values reported transition mid point temperatures
0.21141487.10788482.html.plaintext.txt	87	For estimation H values base line corrections made using smooth transition pre post melting transition baselines
0.21141487.10788482.html.plaintext.txt	88	Protein concentrations determined measurements absorbance 280 nm standardized based amino acid composition
0.21141487.10788482.html.plaintext.txt	89	For wild type L2s gives predicted 280 9650 M1 cm1 constructs wild type L2 share aromatic residues therefore molar extinction coefficient
0.21141487.10788482.html.plaintext.txt	90	On per mg basis 280 translates L2120 233 0
0.21141487.10788482.html.plaintext.txt	91	74 A280mgml cm L2128 229 0
0.21141487.10788482.html.plaintext.txt	92	Protein concentrations obtained BCA method using bovine serum albumin standard 23 generally gave protein values 55 65 high values determined 280 nm absorbance domains exhaustively dialyzed 20 mM phosphate buffer
0.21141487.10788482.html.plaintext.txt	93	Circular dichroism CD spectra obtained lipoyl domain structures using quartz cell 1 mm light path 20 mM potassium phosphate pH 7
0.21141487.10788482.html.plaintext.txt	94	0 maintained water jacketed holder 20 degrees C using Jasco J720 spectrometer averaging least 16 scans accumulated 50 nmmin
0.21141487.10788482.html.plaintext.txt	95	Spectra 300 180 nm collected 0
0.21141487.10788482.html.plaintext.txt	96	Protein concentrations based 280 nm absorbance
0.21141487.10788482.html.plaintext.txt	97	The instrument calibrated using D 10 camphorsulfonic acid standard
0.21141487.10788482.html.plaintext.txt	98	E1 Activity Assays The rate acetylation lipoyl domain constructs measured minor modification procedure Liu et al
0.21141487.10788482.html.plaintext.txt	99	2 E1 diluted 50 mM potassium phosphate pH 7
0.21141487.10788482.html.plaintext.txt	100	5 mgml bovine serum albumin 0
0.21141487.10788482.html.plaintext.txt	101	In duplicate triplicate lipoyl domain construct equilibrated 30 degrees C small conical tubes 20 microl followed addition 5 microl E1 6 15 ng 60 5 microl 2 14Cpyruvate initiate reaction
0.21141487.10788482.html.plaintext.txt	102	In assays volume reduced 15 microl final volume E1 pyruvate added 2 3 microl
0.21141487.10788482.html.plaintext.txt	103	In assays final reaction mixture contained 50 mM potassium phosphate final pH 7
0.21141487.10788482.html.plaintext.txt	104	5 mgml bovine serum albumin indicated levels pyruvate lipoyl domain
0.21141487.10788482.html.plaintext.txt	105	After 40 reactions terminated spotting two thirds reaction mixture P81 filter paper discs pretreated 1 M acetic acid
0.21141487.10788482.html.plaintext.txt	106	Discs washed 5 6 changes 1 M acetic acid 10 mldisc least 1 h period wash followed 5 min treatments ethanol ethyl ether
0.21141487.10788482.html.plaintext.txt	107	Radioactivity retained discs counted measure level acetylation lipoyl domain substrates
0.21141487.10788482.html.plaintext.txt	108	Kinetic data analyzed least square analysis double reciprocal plots 1v versus 1S Cricket graph version 1
0.21141487.10788482.html.plaintext.txt	109	Lipoate Substitution 8 Thioloctanoate synthesized reacting 0
0.21141487.10788482.html.plaintext.txt	110	65 M 8 bromooctanoic acid thiol urea 11
0.21141487.10788482.html.plaintext.txt	111	1 dry ethanol refluxing 8 h
0.21141487.10788482.html.plaintext.txt	112	This followed addition 3 ml 5 N NaOH per 10 ml reaction mixture bring pH 7
0.21141487.10788482.html.plaintext.txt	113	After stirred 0 degrees C 1 h reaction mixture clear HCl added acidify solution pH 3
0.21141487.10788482.html.plaintext.txt	114	The product extracted three times 10 ml CHCl3
0.21141487.10788482.html.plaintext.txt	115	The combined CHCl3 fraction washed three times water dried MgSO4
0.21141487.10788482.html.plaintext.txt	116	The solution filtered solvent removed vacuum evaporation
0.21141487.10788482.html.plaintext.txt	117	This 8 thioloctanoic acid adequate studies studies product purified silica gel column remove small amounts disulfide ethanol esterified forms product
0.21141487.10788482.html.plaintext.txt	118	Nonlipoylated L2 isolated preparation purified L2 made cells grown without lipoate supplementation separation lipoylated L2 using 5 ml Econo Pac Methyl HIC cartridge Bio Rad using linear decreasing salt gradient starting 2
0.21141487.10788482.html.plaintext.txt	119	4 M NH42SO4 100 mM potassium phosphate pH 7
0.21141487.10788482.html.plaintext.txt	120	0 developed versus 100 mM potassium phosphate buffer pH 7
0.21141487.10788482.html.plaintext.txt	121	The nonlipoylated L2 elutes first well separated lipoylated L2 salt removed dialysis versus 20 mM potassium phosphate pH 7
0.21141487.10788482.html.plaintext.txt	122	8 Thioloctanoate octanoate heptanoate 0
0.21141487.10788482.html.plaintext.txt	123	5 mM ligated onto L2 using E
0.21141487.10788482.html.plaintext.txt	124	coli lipoyl protein ligase 28 presence 0
0.21141487.10788482.html.plaintext.txt	125	Native gel electrophoresis used follow ligation reaction since modified domain changed mobile L2 described previously addition lipoate 23 34 26
0.21141487.10788482.html.plaintext.txt	126	Modified L2 dialyzed remove ATP
0.21141487.10788482.html.plaintext.txt	127	RESULTS AND DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.21141487.10788482.html.plaintext.txt	128	Mutation Sites Lipoyl Domains Fig
0.21141487.10788482.html.plaintext.txt	129	1 shows ribbon diagram space filled views two sides barrel structure L2 19 labeling amino acids substituted
0.21141487.10788482.html.plaintext.txt	130	Panel A shows location loop arrow containing Lys173 lipoyl group attached location specificity loop panel B approximately orientation
0.21141487.10788482.html.plaintext.txt	131	This side folded domain includes high proportion acidic residues upper side located away basic residues lower side generally located near basic residues
0.21141487.10788482.html.plaintext.txt	132	The opposing side folded domain hydrophobic face yellow residues Fig
0.21141487.10788482.html.plaintext.txt	133	1 panel C centered around Leu190 one acidic residue Asp197 prominent basic residues
0.21141487.10788482.html.plaintext.txt	134	Besides prominent hydrophilic groups substitutions made hydrophobic side chains well exposed solvent surface folded portion L2 domain Leu140 Val156 Leu190 terminal regions e
0.21141487.10788482.html.plaintext.txt	135	At lipoylated end molecule alanine substitutions made solvent exposed residues specificity loop L140A S141A T143A around lipoyl domain next interior Lys173 T145A E170Q D172Q A174S R196Q D197A
0.21141487.10788482.html.plaintext.txt	136	To rear folded domain substitutions well exposed hydrophilic residues included Q134A E162A E179A Q181A K188Q
0.21141487.10788482.html.plaintext.txt	137	Substitutions also made residues potential functional importance N terminal Y129A C terminal D213N F217A D219N Y220A R221Q E224Q regions
0.21141487.10788482.html.plaintext.txt	138	View larger version 50K Fig
0.21141487.10788482.html.plaintext.txt	139	Ribbon diagram space filled presentations human L2 domain
0.21141487.10788482.html.plaintext.txt	140	These models based structure Howard et al
0.21141487.10788482.html.plaintext.txt	141	19 extra amino acids N terminus part L2 structure removed
0.21141487.10788482.html.plaintext.txt	142	The ribbon diagram panel A shows L2 flattened barrel structure made two antiparallel sheet regions
0.21141487.10788482.html.plaintext.txt	143	The position Lys173 marked arrow specificity loop loop 1 star
0.21141487.10788482.html.plaintext.txt	144	Panel B shows space filled model positioned similar orientation ribbon diagram Panel A panel C shows opposing side lipoyl domain
0.21141487.10788482.html.plaintext.txt	145	The positions mutated amino acids location specificity loop L2 structure indicated
0.21141487.10788482.html.plaintext.txt	146	Residues numbered according sequence mature E2 123 higher numbering used Ref
0.21141487.10788482.html.plaintext.txt	147	Each asterisk panels B C indicates residue different amino acid aligned sequence L1 domain
0.21141487.10788482.html.plaintext.txt	148	Colors used Asp red Glu orange Lys Arg blue except Lys magenta Gln Asn burgundy Ser Thr green Pro Met Gly white Leu Ile Val yellow Phe Tyr gray
0.21141487.10788482.html.plaintext.txt	149	Ala residues white panel A yellow panel B
0.21141487.10788482.html.plaintext.txt	150	Cys Trp significant exposure surface L2 left white
0.21141487.10788482.html.plaintext.txt	151	Corresponding Ser141 Glu179 Asp197 L2 Ser14 Glu52 Asp70 substituted L1 based residues seldom found aligned sequences bacterial PDC lipoyl domains domains keto acid dehydrogenase complexes
0.21141487.10788482.html.plaintext.txt	152	Thus seemed high likelihood specificity residues
0.21141487.10788482.html.plaintext.txt	153	Beyond pursuit full range E1 interactions L2 mutants also used determine basis specific interactions certain kinase phosphatase isoforms pyruvate dehydrogenase complex L2 domain
0.21141487.10788482.html.plaintext.txt	154	5 Indeed Tyr129 Gln134 Thr145 Gln181 Val156 would expected major specificity residues E1 function since residues differ L1 good E1 substrate2 however residues may contribute specificities different regulatory enzymes
0.21141487.10788482.html.plaintext.txt	155	The testing mutants E1 use important since effective use E1 reaction constitutes strong evidence mutant domain retains near native folding allow correct presentation residues interact E1
0.21141487.10788482.html.plaintext.txt	156	Lipoyl Domain Properties Besides substitutions Lys undergoes lipoylation Lys46 Lys173 L1 L2 respectively substitution E170Q prevented lipoylation L2 bacterial lipoyl protein ligase
0.21141487.10788482.html.plaintext.txt	157	Besides used E1 E3 reactions lack lipoylation confirmed mass determined matrix assisted laser desorption ionization MS
0.21141487.10788482.html.plaintext.txt	158	The E170Q L2 well folded
0.21141487.10788482.html.plaintext.txt	159	29 demonstrated importance Glu residues corresponding position 3 residues N terminal side lipoylation site lipoylation various lipoyl domain sources mammalian lipoyl AMPN lysine lipoyl transferase
0.21141487.10788482.html.plaintext.txt	160	coli lipoyl protein ligase mammalian enzyme apparently share need residue
0.21141487.10788482.html.plaintext.txt	161	With many mutated L1 L2 native gel electrophoresis detected small portions nonlipoylated domain upper band level 1 5 expression 23 25 degrees C 3 30 expression 37 degrees C wild type mutant L1 L2
0.21141487.10788482.html.plaintext.txt	162	Like wild type construct lane 1 upper panel Fig
0.21141487.10788482.html.plaintext.txt	163	2 mutant L2120 233 structures expressed 37 degrees C lanes 2 6 upper panel generally contained low levels nonlipoylated domain although level upper band rose high 30 T145A mutant L2128 229 constructs lane 8 wild type
0.21141487.10788482.html.plaintext.txt	164	Expression 23 25 degrees C greatly reduced eliminated nonlipoylated constructs lanes 3 5 10 upper panel lanes 1 4 lower panel even case T145A construct lane 5 A174S lane 4 D172N shown L2128 229 structures mutated sites adjacent lipoylated Lys173
0.21141487.10788482.html.plaintext.txt	165	The latter finding consistent mutations Bacillus stearothermophilus PDC E2 lipoyl domain Met residues introduced either side lipoylated lysine without affecting relative extent lipoylation 30
0.21141487.10788482.html.plaintext.txt	166	However wild type form bacterial domain partially lipoylated 30 E
0.21141487.10788482.html.plaintext.txt	167	Lipoylation probably limited high expression small domain hindered contains glutamate position aligned Glu170 glutamine substitution prevented lipoylation L2
0.21141487.10788482.html.plaintext.txt	168	coli pyruvate ketoglutarate dehydrogenase complexes glutamate position 31 32
0.21141487.10788482.html.plaintext.txt	169	The successful removal nonlipoylated domain chromatography small HIC column established native gel electrophoresis e
0.21141487.10788482.html.plaintext.txt	170	2 L2128 229 upper panel lane 9 prepared mixture lane 8 lipoylated nonlipoylated domain
0.21141487.10788482.html.plaintext.txt	171	For introduction lipoate analogs lanes 6 8 lower panel nonlipoylated L2120 233 prepared HIC lower panel lane 5 L2 preparation containing 80 nonlipoylated L2 made expressing cells media supplemented lipoate 37 degrees C
0.21141487.10788482.html.plaintext.txt	172	View larger version 54K Fig
0.21141487.10788482.html.plaintext.txt	173	Characterization lipoyl domain preparations native gel electrophoresis
0.21141487.10788482.html.plaintext.txt	174	Native gel electrophoresis staining Coomassie Brilliant Blue R 250 conducted indicated L2 constructs conditions previously described 28 except 0
0.21141487.10788482.html.plaintext.txt	175	1 Pluronic F 68 included buffers used produce gel shown lanes 10 12 upper panel
0.21141487.10788482.html.plaintext.txt	176	L2 structures lanes 1 3 5 8 upper panel lane 5 lower panel expressed 37 degrees C lanes 4 5 7 10 12 upper panel lanes 1 4 lower panel expressed 23 24 degrees C
0.21141487.10788482.html.plaintext.txt	177	HIC chromatography used prepare lipoylated L2128 229 lane 8 preparation lane 9 separate nonlipoylated L2120 233 shown lane 5 lower panel lipoylated L2
0.21141487.10788482.html.plaintext.txt	178	This nonlipoylated L2 turn used prepare octanoyl L2 oct
0.21141487.10788482.html.plaintext.txt	179	8 thiol octanoyl L2 8 SH oct
0.21141487.10788482.html.plaintext.txt	180	lipoyl protein ligase reaction 32
0.21141487.10788482.html.plaintext.txt	181	Protein amounts loaded 2 microg lanes 1 6 lane 10 upper panel lanes lower panel 6 microg lanes 7 8 8 microg lane 9 1
0.21141487.10788482.html.plaintext.txt	182	L190A F217A well lipoylated based masses determined matrix assisted laser desorption ionization MS native gel electrophoresis Fig
0.21141487.10788482.html.plaintext.txt	183	2 revealed tendency aggregate
0.21141487.10788482.html.plaintext.txt	184	Primarily dimer observed L190A lane 11 combination dimer monomer F217A lane 12
0.21141487.10788482.html.plaintext.txt	185	Leu190 exposed center hydrophobic face L2 Phe217 located unfolded C terminal region Fig
0.21141487.10788482.html.plaintext.txt	186	It would appear Leu190 Phe217 must participate interactions prevent aggregation elicited individual alanine substitutions
0.21141487.10788482.html.plaintext.txt	187	Consistent deletion C terminal regions L1 L2 also led aggregation
0.21141487.10788482.html.plaintext.txt	188	An interaction C terminal lobe surface L2 detected NMR studies 19 suggesting interaction either weak condition dependent
0.21141487.10788482.html.plaintext.txt	189	An interesting prospect hydrophobic face centered around Leu190 interacts hydrophobic residues C terminus
0.21141487.10788482.html.plaintext.txt	190	With large number charged residues C terminus next hydrophobic face reversible positioning C terminal lobe folded domain might also aided favorable electrostatic interactions
0.21141487.10788482.html.plaintext.txt	191	The finding high lipoylation mutated domains constitutes strong evidence lipoylated domains folded appropriate barrel structure since E
0.21141487.10788482.html.plaintext.txt	192	coli lipoyl protein ligase requires folded lipoyl domain lipoylated Lys residue located tip sharp turn onto lipoate added 28 30
0.21141487.10788482.html.plaintext.txt	193	Additionally domains tested effectiveness substrates E3 reaction cyclic activity measured 23
0.21141487.10788482.html.plaintext.txt	194	2 All mutant lipoyl domains lipoylated functioned effective substrates E3 reaction
0.21141487.10788482.html.plaintext.txt	195	Using 10 microM levels lipoyl domains rates within plus minus 15 26
0.21141487.10788482.html.plaintext.txt	196	7 micromolminmg E3 observed L2 mutants
0.21141487.10788482.html.plaintext.txt	197	This rate 5 times faster rate 10 microM lipoamide lipoylated peptide substrate L2 domain residues 163 177 also used higher rate
0.21141487.10788482.html.plaintext.txt	198	Mutant lipoyl domains CD patterns similar found native L1 L2 structures2 positive peak 227 nm deep trough 198 200 nm Fig
0.21141487.10788482.html.plaintext.txt	199	The trough depth decreased L2128 229 structures comparison L2120 233 structures2 supporting major contribution terminal regions feature CD spectra
0.21141487.10788482.html.plaintext.txt	200	Some variation observed spectra mutant lipoyl domains
0.21141487.10788482.html.plaintext.txt	201	However CD spectra give good insight presence expected barrel fold spectra typical domain containing primarily antiparallel structure dominated contributions terminal regions particularly large C terminal lobe
0.21141487.10788482.html.plaintext.txt	202	2 This marked contrast B
0.21141487.10788482.html.plaintext.txt	203	stearothermophilus PDC E2 lipoyl domain 30 33 gave typical CD pattern structure dominated antiparallel structure
0.21141487.10788482.html.plaintext.txt	204	Similar spectra found K173A mutant native L2 indicating absence lipoyl group greatly change CD pattern also found nonlipoylated Lys173
0.21141487.10788482.html.plaintext.txt	205	View larger version 21K Fig
0.21141487.10788482.html.plaintext.txt	206	Circular dichroism pattern native mutated L2120 233
0.21141487.10788482.html.plaintext.txt	207	CD spectra collected described Experimental Procedures L2 domains indicated L2120 233 construct added 1 mm cuvette 0
0.21141487.10788482.html.plaintext.txt	208	To establish lipoyl domains form stably folded structures differential scanning calorimetry studies conducted
0.21141487.10788482.html.plaintext.txt	209	Table I data columns 1 2 summarizes Tm H values determined scans Fig
0.21141487.10788482.html.plaintext.txt	210	4 shows representative Cp profiles highly cooperative melting transitions
0.21141487.10788482.html.plaintext.txt	211	All two transitions nearly symmetric Tm values unchanged multiple cycles heating cooling performed consistent unfolding transitions representing two state reversible equilibrium process
0.21141487.10788482.html.plaintext.txt	212	Tm values reproduced considerable accuracy repeat determinations invariably within plus minus 0
0.21141487.10788482.html.plaintext.txt	213	Although Tm values unchanged repeated melting cycles area second third scans typically reduced 4 10
0.21141487.10788482.html.plaintext.txt	214	The likely cause lack refolding due aggregation unfolded domain prior lowering temperature
0.21141487.10788482.html.plaintext.txt	215	The combination base line corrections small deviations protein determinations limit accuracy H estimates two constructs considered significantly different H values difference 5 kcalmol
0.21141487.10788482.html.plaintext.txt	216	View table Table I Tm H values thermal unfolding various L2 domain structures comparison E1 activity using wild type various mutant L2 domains 20 50 microM Values determined differential scanning calorimetry determined Experimental Procedures
0.21141487.10788482.html.plaintext.txt	217	E1 activity assays conducted 15 microl reaction mixtures using 8 ng E1 40 reaction time
0.21141487.10788482.html.plaintext.txt	218	Data several experiments combined normalized rates wild type L2 range rates 50 microM wild type L2 5
0.21141487.10788482.html.plaintext.txt	219	7 micromolminmg E1 assigned value 100 lipoyl domain concentration
0.21141487.10788482.html.plaintext.txt	220	The average ratio rates using wild type L2 20 microM rates 50 microM L2 different experiments 0
0.21141487.10788482.html.plaintext.txt	221	Other conditions described Experimental Procedures
0.21141487.10788482.html.plaintext.txt	222	View larger version 20K Fig
0.21141487.10788482.html.plaintext.txt	223	Thermal unfolding L2 domains measured differential scanning calorimetry
0.21141487.10788482.html.plaintext.txt	224	A comparison made thermal melting profiles occur range 13 degrees C centered around wild type L2120 233 domain
0.21141487.10788482.html.plaintext.txt	225	The 22 mutant L2 fell within range similarly shaped profiles thermal unfolding appear involve entropy based Boltzman distribution
0.21141487.10788482.html.plaintext.txt	226	Twenty three mutants Tm values within plus minus 4 degrees C native L2 Table I
0.21141487.10788482.html.plaintext.txt	227	NMR studies indicate specificity loop somewhat flexible side chains tend extend outward folded structure 19
0.21141487.10788482.html.plaintext.txt	228	Substitution alanine mutation exposed side chains loop Leu140 Ser141 Thr143 lowered Tm Leu140 mutation causing 11 degrees C decrease
0.21141487.10788482.html.plaintext.txt	229	In case H values also significantly reduced apparent S S HTm S entropy difference unfolded folded domain Tm K values therefore also reduced relative native L2 largest S decrease 36 occurring S141A mutation
0.21141487.10788482.html.plaintext.txt	230	One possibility alanine substitution enhances flexibility specificity loop leading smaller gain entropy upon unfolding S141A L2 also reducing specific interactions contribute stability folded domain also reduces H difference
0.21141487.10788482.html.plaintext.txt	231	This suggests significant organization contributed specificity loop native structure even though region somewhat flexible 19
0.21141487.10788482.html.plaintext.txt	232	Marked decreases Tm also observed L190A F217A L2 mutants
0.21141487.10788482.html.plaintext.txt	233	This consistent loss stabilizing interaction involving C terminal lobe results tendency mutant L2 aggregate described
0.21141487.10788482.html.plaintext.txt	234	With L190A F217A second transition observed main cooperative melting transition
0.21141487.10788482.html.plaintext.txt	235	The area second first transition greatly reduced increasing scan rate 1 degrees Cmin 1
0.21141487.10788482.html.plaintext.txt	236	That consistent second phase arising aggregation unfolded domain
0.21141487.10788482.html.plaintext.txt	237	Besides F217A substitution D213N Fig
0.21141487.10788482.html.plaintext.txt	238	5 Y220A mutations C terminal lobe caused significant reductions Tms
0.21141487.10788482.html.plaintext.txt	239	The combination reduced Tm maintenance high H indicates S gain D213N L2 mutation
0.21141487.10788482.html.plaintext.txt	240	This suggests C terminal lobe reduced flexibility upon converting Asp Asn larger gain entropy upon unfolding structure
0.21141487.10788482.html.plaintext.txt	241	Given large number C terminal residues separating Asp219 folded domain surprising mutation reduces H value estimated melting transitions
0.21141487.10788482.html.plaintext.txt	242	Since D219N mutation lowered H 20 plus minus 6 kcalmol without significantly affecting Tm indicates S significantly decreased suggesting decrease organization within C terminal lobe due mutation
0.21141487.10788482.html.plaintext.txt	243	Asp219 likely forms electrostatic interaction reduces flexibility C terminal lobe native domain
0.21141487.10788482.html.plaintext.txt	244	Smaller decreases H estimated substitutions C terminal residues Y220A R221A suggesting Tyr220 Arg221 contribute structure within lobe
0.21141487.10788482.html.plaintext.txt	245	View larger version 30K Fig
0.21141487.10788482.html.plaintext.txt	246	Comparison E1 reaction rates using wild type mutant L1 domains
0.21141487.10788482.html.plaintext.txt	247	Lipoyl domains added indicated concentrations
0.21141487.10788482.html.plaintext.txt	248	Other conditions described Table II Experimental Procedures
0.21141487.10788482.html.plaintext.txt	249	Similarly mutation N terminal Tyr129 mounted folded domain two intervening Pro residues reduced Tm 63
0.21141487.10788482.html.plaintext.txt	250	6 degrees C outcome suggests Tyr129 interacts stabilize folded domain possibly H bond
0.21141487.10788482.html.plaintext.txt	251	Conversion Glu162 alanine produced domain significantly increased Tm value Fig
0.21141487.10788482.html.plaintext.txt	252	Tm values also increased E179A K173Q substitutions
0.21141487.10788482.html.plaintext.txt	253	Removal charge repulsion Glu162 Glu179 concomitant gain flexibility remaining acidic residue favorable H bonding Gln173 side chain likely sources increased stability mutant L2
0.21141487.10788482.html.plaintext.txt	254	Overall DSC results support mutant L2 cooperatively folded
0.21141487.10788482.html.plaintext.txt	255	Differences stability mutants seem reflect changes interaction surface L2 pronounced case F217A L190A mutant L2 domains
0.21141487.10788482.html.plaintext.txt	256	Both structures well lipoylated described used substrates E1 reaction
0.21141487.10788482.html.plaintext.txt	257	As noted E1 reductively acetylate folded lipoyl domain structures 10
0.21141487.10788482.html.plaintext.txt	258	Mapping Specificity Residues Lipoyl Domains E1 Catalysis Table I data columns 3 4 compares use wild type lipoylated mutant L2 bovine E1 using 20 50 microM L2 construct concentrations Km E1 wild type L2
0.21141487.10788482.html.plaintext.txt	259	The L2 mutants L140A S141A T143A E162A D172N E179A reductively acetylated E1 greatly reduced rates
0.21141487.10788482.html.plaintext.txt	260	Much smaller rate reductions observed A174S L190A F217A mutants
0.21141487.10788482.html.plaintext.txt	261	The reduced rates L190A F217A may part due tendency aggregate
0.21141487.10788482.html.plaintext.txt	262	In comparison wild type L2 small decreases change E1 activity observed Y129A T145A V156A K188Q R196Q D197A D213N D219N Y220A R221Q E224Q mutant L2 domains
0.21141487.10788482.html.plaintext.txt	263	This indicates residues directly contribute interaction L2 E1 mutations greatly alter L2 structure regions required E1 binding
0.21141487.10788482.html.plaintext.txt	264	The D172N mutant gave greatest reduction E1 activity whereas A174S mutation side lipoylated K173 used rate modestly reduced Table I
0.21141487.10788482.html.plaintext.txt	265	The effects substitutions corresponding Asp Ala residues preceding following respectively lipoylated Lys B
0.21141487.10788482.html.plaintext.txt	266	stearothermophilus PDC E2 lipoyl domain characterized 30
0.21141487.10788482.html.plaintext.txt	267	The D42A mutation smaller effect rate bacterial E1 reaction D172N substitution mammalian E1
0.21141487.10788482.html.plaintext.txt	268	It would appear Asp172 plays important role reaction catalyzed mammalian E1
0.21141487.10788482.html.plaintext.txt	269	Introduction charged residue Glu Ala44 greatly reduced activity B
0.21141487.10788482.html.plaintext.txt	270	stearothermophilus E1 substitution Met even less effect corresponding A174S substitution reducing activity bovine E1
0.21141487.10788482.html.plaintext.txt	271	The substantial effects Leu140 Ser141 Thr143 mutations add support studies bacterial domains 8 10 indicated loop formed following first run N terminal structure Fig
0.21141487.10788482.html.plaintext.txt	272	1 key specificity loop E1 reaction
0.21141487.10788482.html.plaintext.txt	273	The size sequence loop region varies different lipoyl domain sources
0.21141487.10788482.html.plaintext.txt	274	Substitution alanine L1 domain Ser14 aligns Ser141 L2 Glu52 position aligns Glu179 L2 gave similar decreases E1 activity corresponding substitutions L2 Fig
0.21141487.10788482.html.plaintext.txt	275	As case D197A mutation L2 corresponding D70A mutation L1 affect E1 activity
0.21141487.10788482.html.plaintext.txt	276	Most kinetic studies performed bovine E1 prior developing human E1 preparations nearly equivalent specific activities reconstituted PDC assays
0.21141487.10788482.html.plaintext.txt	277	Human E1 use lipoyl domain substrates characterization human E1 E2 E3BP native mutant forms along use human E3 described elsewhere
0.21141487.10788482.html.plaintext.txt	278	25 Human E1 similar activity reconstitution assays bovine E1 human E2 E3BP3 similar Km free lipoyl domain substrates nevertheless lower kcat using free L1 L2 substrates E1 reaction
0.21141487.10788482.html.plaintext.txt	279	5 fold lower Vmapp bovine E1 using free L2 domain substrates 120 microM pyruvate
0.21141487.10788482.html.plaintext.txt	280	All mutant L2 constructs greatly reduced catalysis bovine E1 also reduced activity human E1 similar relative changes activity 20 50 microM shown Table I
0.21141487.10788482.html.plaintext.txt	281	Because discrepancy nearly equivalent activities human E1 bovine E1 reconstituted PDC assays using either human E2 E3BP bovine E2 E3BP human E3 porcine E3 lower activities utilizing free lipoyl domain substrates human E1 studies conducted evaluate whether improved assay conditions elevate activity human E1
0.21141487.10788482.html.plaintext.txt	282	Nevertheless results support common set key residues lipoyl domain substrates required efficient reductive acetylation bovine human E1
0.21141487.10788482.html.plaintext.txt	283	Changes Kinetic Parameters Key Residues Mutations sites greatly reduced E1 activity produced folded domains underwent highly cooperative melting transitions
0.21141487.10788482.html.plaintext.txt	284	Thus substantial effects mutations favor direct involvement residues interactions E1 component
0.21141487.10788482.html.plaintext.txt	285	Apparent Km Vmax values obtained mutant L2 domains greatly lowered E1 activity Table II
0.21141487.10788482.html.plaintext.txt	286	The apparent Km bovine E1 pyruvate fixed 120 microM 35 microM L2 true Km determined full steady state study pyruvate level also varied 49 plus minus 6 microM L2
0.21141487.10788482.html.plaintext.txt	287	2 The changes E1 kinetic parameters different different mutants
0.21141487.10788482.html.plaintext.txt	288	The L140A mutation actually gave reduced Km conjunction decreasing Vmax kcatKm ratio E1 reaction significantly changed Table II
0.21141487.10788482.html.plaintext.txt	289	In native L2 Leu140 may aid E1 catalysis favoring dissociation reductively acetylated lipoyl domain
0.21141487.10788482.html.plaintext.txt	290	With S141A Km E1 L2 mutant increased along decrease maximal velocity produce overall 26
0.21141487.10788482.html.plaintext.txt	291	8 fold change catalytic efficiency E1 reaction
0.21141487.10788482.html.plaintext.txt	292	Thus seems likely Ser141 contributes specific binding lipoyl domain E1
0.21141487.10788482.html.plaintext.txt	293	With T143A mutant kcat E1 reaction markedly decreased little change apparent Km mutant Table II suggesting Thr143 contributes E1 specificity enhancing rate acetylation native substrate
0.21141487.10788482.html.plaintext.txt	294	View table Table II Variation kinetic parameters E1 mutant lipoyl domains markedly supported markedly reduced activities Table I Pyruvate fixed 120 microM initial velocities measured duplicate six lipoyl domain concentrations
0.21141487.10788482.html.plaintext.txt	295	The kinetic parameters estimated double reciprocal plots 1v versus llipoyl domain concentration
0.21141487.10788482.html.plaintext.txt	296	The E179A mutation caused marked reduction E1 catalysis Table I result 5 fold increase Km 2
0.21141487.10788482.html.plaintext.txt	297	5 fold decrease kcat Table II
0.21141487.10788482.html.plaintext.txt	298	The change apparent Km E52A mutant nearly large Glu179 data shown
0.21141487.10788482.html.plaintext.txt	299	This distinction suggests E1 interacts somewhat differently L1 domain interacts L2 domain
0.21141487.10788482.html.plaintext.txt	300	Glu162 located behind Glu179 Fig
0.21141487.10788482.html.plaintext.txt	301	Alanine substitution position primarily reduced Vm also modestly elevating Km E1 substrate Table II
0.21141487.10788482.html.plaintext.txt	302	The strong effects mutations Glu179 Glu162 indicate E1 interaction extends well beyond specificity loop
0.21141487.10788482.html.plaintext.txt	303	However E1 activity significantly affected substitutions Thr145 Arg196 Asp197 located almost directly opposite Thr143 Ser141 respectively lipoylated end L2
0.21141487.10788482.html.plaintext.txt	304	Asp197 acidic residue side folded domain panel C Fig
0.21141487.10788482.html.plaintext.txt	305	1 selected potential specificity residue based sequence alignments
0.21141487.10788482.html.plaintext.txt	306	Substitutions corresponding amides three acidic residues C terminal tail Asp213 Asp219 Glu214 also failed significantly affect E1 reaction
0.21141487.10788482.html.plaintext.txt	307	The marked decrease activity due D172N mutation consequence largest increase among L2 mutants apparent Km E1 reduction Vmax Table II
0.21141487.10788482.html.plaintext.txt	308	The catalytic efficiency kcatKm decreased 75 fold
0.21141487.10788482.html.plaintext.txt	309	Replacing acid side chain corresponding amide affect E3 catalysis alter lipoylation change parameters scanning calorimetry native L2 Table II greatly change CD spectra Fig
0.21141487.10788482.html.plaintext.txt	310	It would therefore seem likely presentation adjacent lipoyl group probably substantially modified D172N mutation
0.21141487.10788482.html.plaintext.txt	311	Thus residue found virtually lipoyl domains makes important contribution catalysis mammalian E1
0.21141487.10788482.html.plaintext.txt	312	Key Specificity Residues Lipoyl Domain Alignment Residues particularly important role providing high specificity mammalian PDC E1s cognate lipoyl domain substrates would expected found aligned positions bacterial PDC lipoyl domain sequences lipoyl domains E2 components various sources including mammalian ketoglutarate branched chain keto acid dehydrogenase complexes
0.21141487.10788482.html.plaintext.txt	313	Leu140 similar amino acid particularly Ile commonly found aligned position wide range keto acid dehydrogenase complexes
0.21141487.10788482.html.plaintext.txt	314	However Ser141 Thr143 Glu179 found even aligned positions 19 known sequences bacterial PDC lipoyl domains one instance Ser residue found aligned Ser141 sequences non PDC lipoyl domains
0.21141487.10788482.html.plaintext.txt	315	These residues present aligned position L1 domain mammalian E2 also known lipoyl domain sequences eukaryotic PDC E2
0.21141487.10788482.html.plaintext.txt	316	In lipoyl domain human E3BP component Glu179 conservatively substituted Asp50
0.21141487.10788482.html.plaintext.txt	317	This residue E3BP lipoyl domain preceded leucine substantial change phenylalanine located aligned position L1 L2
0.21141487.10788482.html.plaintext.txt	318	Further studies needed evaluate importance Glu occupying position L1 L2 Asp residue occupying position E3BP
0.21141487.10788482.html.plaintext.txt	319	Competitive Inhibition Lipoyl Domains Modified Site Lipoylation Graham Perham 11 observed weak interaction E
0.21141487.10788482.html.plaintext.txt	320	coli PDC E1 cognate lipoyl domain despite high specificity substrate
0.21141487.10788482.html.plaintext.txt	321	Using GST H1 L2 laboratory able detect weak binding L2 E1 containing transition state analogs HE TPP even turnover conditions inner domain E2 E3 supported slow catalysis overall reaction
0.21141487.10788482.html.plaintext.txt	322	2 A potential explanation capacity E1 highly selective lipoyl domain substrate weak affinity binding energy required protein protein interactions E1 lipoyl domain used move lipoyl group active site
0.21141487.10788482.html.plaintext.txt	323	This would predict L2 mutant K173A would good competitive inhibitor
0.21141487.10788482.html.plaintext.txt	324	Alternatively long lysyl octanoyl chain specific interactions dithiolane ring lipoyl group may make important contribution specific binding catalysis
0.21141487.10788482.html.plaintext.txt	325	To evaluate L2 modified site lipoylation either substitution amino acids alanine methionine leucine glutamine Lys173 introduction lipoyl substitutes octanoate 8 thioloctanoate heptanoate nonlipoylated L2
0.21141487.10788482.html.plaintext.txt	326	Although 8 thioloctanoyl L2 efficient substrate transacetylation reaction catalyzed E2 component3 used E1 significant rate 2 nmolminmg E1
0.21141487.10788482.html.plaintext.txt	327	Using driven NADH regenerating system ketoglutarate dehydrogenase complex reaction convert maintain lipoyl groups via E3 reaction reduced form rates acetylation E1 reduced lipoyl groups using pyruvate least 100 fold faster rate obtained using 8 thioloctanoyl L2
0.21141487.10788482.html.plaintext.txt	328	6 In cases O2 presumably serves electron acceptor required oxidation HE TPP acetyl TPP 4
0.21141487.10788482.html.plaintext.txt	329	Assuming low levels oxidized lipoyl groups contributing higher rates dihydrolipoyl containing substrate6 finding suggests presence thiol 6 position important reductive acetylation reaction proceed even though acetylation 8 position 4
0.21141487.10788482.html.plaintext.txt	330	6 left panel substitution Leu Gln Lys173 yielded L2 inhibitory 11 ratio versus native L2 whereas Ala Met substituted L2 gave much less inhibition
0.21141487.10788482.html.plaintext.txt	331	Introduction heptanoate gave weak inhibition 8 thioloctanoate gave stronger inhibition Fig
0.21141487.10788482.html.plaintext.txt	332	However octanoyl L2 weak inhibitor
0.21141487.10788482.html.plaintext.txt	333	It possible substitutions like Leu Gln Lys173 heptanoate lipoate produce L2 interact E1 artificial ways mimic prosthetic group native domain
0.21141487.10788482.html.plaintext.txt	334	However substantial inhibition 8 thioloctanoyl L2 probably involves specific interactions thiol group since octanoyl L2 much weaker inhibitor
0.21141487.10788482.html.plaintext.txt	335	The poor inhibition due substitutions like K173A octanoyl L2 supports lipoyl lysine group interacting via specific structure
0.21141487.10788482.html.plaintext.txt	336	Specifically dithiolane ring lipoate may contribute binding forming favorable interactions increasing probability cofactor conformation accommodates active site
0.21141487.10788482.html.plaintext.txt	337	In combination results Lys173 substitutions lipoate substitutions support significant interactions E1 occur throughout lipoyl lysine prosthetic group support lipoate forced active site
0.21141487.10788482.html.plaintext.txt	338	This consistent active site channel P
0.21141487.10788482.html.plaintext.txt	339	putida branched chain E1 lined hydrophobic groups could interact favorably mostly aliphatic lipoyl lysine prosthectic group 14
0.21141487.10788482.html.plaintext.txt	340	View larger version 40K Fig
0.21141487.10788482.html.plaintext.txt	341	Inhibition E1 activity L2 structures modified within site lipoylation
0.21141487.10788482.html.plaintext.txt	342	L2 modified either substitution Lys173 left panel ligation onto Lys173 lipoate analogs right panel lipoyl protein ligase described Experimental Procedures
0.21141487.10788482.html.plaintext.txt	343	The E1 assays conducted modified nonsubstrate L2 structures wild type L2 included levels indicated insets
0.21141487.10788482.html.plaintext.txt	344	L2 Structure Relation E1 Reaction We prepared versatile set mutant lipoyl domains well folded
0.21141487.10788482.html.plaintext.txt	345	All mutant domains major effects E1 activity well behaved native gel electrophoresis exception L140A L2 mutant unfolded Tm values excess 64 degrees C
0.21141487.10788482.html.plaintext.txt	346	We would emphasize D170Q L2 lipoylated gave near wild type values DSC CD studies indicating near native structure
0.21141487.10788482.html.plaintext.txt	347	Thus studies support concept lipoylation requires proper folding presentation essential residues
0.21141487.10788482.html.plaintext.txt	348	Since lipoyl domains used test E1 function well lipoylated supports retaining well folded structure properly presented tight turn bearing Lys173 lipoylation reaction
0.21141487.10788482.html.plaintext.txt	349	The specificity loop 1 Leu140 Ser141 Thr143 conserved Asp172 anterior residues Glu179 Glu162 located one side L2 domain panel B Fig
0.21141487.10788482.html.plaintext.txt	350	1 region abundant acidic residues 10 folded part domain
0.21141487.10788482.html.plaintext.txt	351	Glu179 located long strand leading away Lys173 C 16 A Ser141 C amino acids separated 19 A 11 A respectively C Lys173
0.21141487.10788482.html.plaintext.txt	352	Glu162 located additional 6 A behind Glu179
0.21141487.10788482.html.plaintext.txt	353	These acidic residues well separated basic residues contrast acidic residues line bottom edge panel B structure
0.21141487.10788482.html.plaintext.txt	354	Electrostatic interactions Glu162 Glu179 basic residues surface E1 predicted contribute E1 L2 complex
0.21141487.10788482.html.plaintext.txt	355	Thus E1 interacts substantial region surface lipoyl domain
0.21141487.10788482.html.plaintext.txt	356	The opposite side lipoyl domain hydrophobic face Fig
0.21141487.10788482.html.plaintext.txt	357	1 panel C Leu190 center prominent residues Arg196 Asp197 Thr145 important E1 catalysis
0.21141487.10788482.html.plaintext.txt	358	Apparently limited interaction E1 side lipoyl domain structure although mutation Val156 Leu190 reduced activity
0.21141487.10788482.html.plaintext.txt	359	The mutants developed used establish specificity residues specific kinase phosphatase isoforms
0.21141487.10788482.html.plaintext.txt	360	5 Those studies revealed overlapping pattern supporting function regulatory enzymes E1 also established involvement many distinct residues large differences relative importance overlapping residues
0.21141487.10788482.html.plaintext.txt	361	This indicates established mutations propagate extended changes structure lipoyl domain thereby interfere normal lipoyl domain roles
0.21141487.10788482.html.plaintext.txt	362	Now initial mapping achieved substitutions key specificity sites greatly add understanding roles relative importance key specificity residues L2 domain E1 function
0.21141487.10788482.html.plaintext.txt	363	Based capacity lipoylated L2 compete effectively versus analogs lacking structural features lipoyl lysine prosthetic group structural requirements interaction lipoyl prosthetic group include distinct structural features probably including active site complementarity favoring binding dithiolane ring lipoate prosthetic group
0.21141487.10788482.html.plaintext.txt	364	The stronger inhibition substituting Gln rather Ala Met Lys173 probably results Gln participating H bonding E1 cannot formed Met Ala side chains
0.21141487.10788482.html.plaintext.txt	365	However alternative explanation Gln participates relatively stable internal H bond within lipoyl domain enhances binding E1 cannot eliminated
0.21141487.10788482.html.plaintext.txt	366	Since extensive interactions E1 L2 supported yet date binding lipoyl domains E1 appear weak Kd well Km values 112 suggests intrinsic interaction energy used facilitate catalysis
0.21141487.10788482.html.plaintext.txt	367	That consistent high specificity cognate lipoyl domains E1 source keto acid dehydrogenase complex extraordinarily slow use free lipoamide substrate 3
0.21141487.10788482.html.plaintext.txt	368	Thus seems likely productive E1 lipoyl domain interactions facilitate structural changes within E1 aid catalytic turnover facilitating slight repositioning HE TPP intermediate formed decarboxylation aid efficient reductive acetylation
0.21141487.10788482.html.plaintext.txt	369	Overall conclude second step ping pong reaction catalyzed mammalian E1 reaction specificity reductive acetylation cognate lipoyl domain governed unique surface residues spread primarily along upper edge folded L2 structure shown Fig
0.21141487.10788482.html.plaintext.txt	370	Additional critical interactions universal lipoyl lysine prosthetic group preceding Asp residue Asp172 L2 contribute catalysis
0.21141487.10788482.html.plaintext.txt	371	Although E1 function affected mutations terminal regions substitutions particularly C terminal lobe shown DSC studies contribute ordered structure L2
0.21141487.10788482.html.plaintext.txt	372	Further structural studies required determine lobe structured degree interacts barrel structure within domain
0.21141487.10788482.html.plaintext.txt	373	We thank Xiaohua Yan Jason C
0.21141487.10788482.html.plaintext.txt	374	Baker help preparing PDC E1 Shane Kasten help preparing wild type mutant lipoyl domains
0.21141487.10788482.html.plaintext.txt	375	This work supported National Institutes Health Grant DK18320 Kansas Agriculture Experiment Station
0.21141487.10788482.html.plaintext.txt	376	This contribution 00 237 J Kansas Agriculture Experiment Station
0.21141487.10788482.html.plaintext.txt	377	The costs publication article defrayed part payment page charges
0.21141487.10788482.html.plaintext.txt	378	The article must therefore hereby marked advertisement accordance 18 U
0.21141487.10788482.html.plaintext.txt	379	Section 1734 solely indicate fact
0.21141487.10788482.html.plaintext.txt	380	Supported Studentship Biotechnology Biological Sciences Research Council United Kingdom
0.21141487.10788482.html.plaintext.txt	381	To correspondence addressed Dept
0.21141487.10788482.html.plaintext.txt	382	Biochemistry Willard Hall Kansas State University Manhattan KS 66506
0.21141487.10788482.html.plaintext.txt	383	785 532 6116 Fax 785 532 7278 E mail bchterksu
0.21141487.10788482.html.plaintext.txt	384	Roche submitted publication
0.21141487.10788482.html.plaintext.txt	385	Roche manuscript preparation
0.21141487.10788482.html.plaintext.txt	386	4 The numbers parentheses lipoyl domain designations correspond amino acid sequence human E2 included construct
0.21141487.10788482.html.plaintext.txt	387	Roche manuscript preparation
0.21141487.10788482.html.plaintext.txt	388	6 Using ketoglutarate dehydrogenase prepared free PDC activity measured M
0.21141487.10788482.html.plaintext.txt	389	Roche unpublished data using bilipoyl domain fragment derived bovine E2 substrate
0.21141487.10788482.html.plaintext.txt	390	Reaction re neutralized acid quenched sample 55 dithiobis2 nitrobenzoate supported full reduction lipoyl domain substrate however complete absence oxidized lipoyl groups uncertain presence NADH NAD tends cause E3 converted four electron reduced state allows oxygen react E3 active site form H2O2 turn may serve oxidize small portion dihydrolipoyl groups
0.21141487.10788482.html.plaintext.txt	391	The abbreviations used PDC pyruvate dehydrogenase complex E1 pyruvate dehydrogenase component TPP thiamin pyrophosphate E2 dihydrolipoyl acetyltransferase component L1 NH2 lipoyl domain E2 L2 interior lipoyl domain E2 E3 dihydrolipoyl dehydrogenase E3BP E3 binding protein GST glutathione S transferase
0.21141487.10788482.html.plaintext.txt	392	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES 1
0.21141487.10788482.html.plaintext.txt	393	240 45 48CrossRefMedline Order article via Infotrieve 3
0.21141487.10788482.html.plaintext.txt	394	1991 Biochemistry 30 8501 8512Medline Order article via Infotrieve 4
0.21141487.10788482.html.plaintext.txt	395	573 21 35Medline Order article via Infotrieve 5
0.21141487.10788482.html.plaintext.txt	396	268 409 425Medline Order article via Infotrieve 6
0.21141487.10788482.html.plaintext.txt	397	14 411 414Medline Order article via Infotrieve 7
0.21141487.10788482.html.plaintext.txt	398	1989 Biochemistry 28 1574 1581Medline Order article via Infotrieve 8
0.21141487.10788482.html.plaintext.txt	399	262 241 244CrossRefMedline Order article via Infotrieve 12
0.21141487.10788482.html.plaintext.txt	400	266 24650 24656AbstractFree Full Text 13
0.21141487.10788482.html.plaintext.txt	401	1993 Biochemistry 32 5629 5637Medline Order article via Infotrieve 14
0.21141487.10788482.html.plaintext.txt	402	6 785 792CrossRefMedline Order article via Infotrieve 15
0.21141487.10788482.html.plaintext.txt	403	1992 Science 225 1544 1550 16
0.21141487.10788482.html.plaintext.txt	404	1993 Biochemistry 32 3887 3901Medline Order article via Infotrieve 17
0.21141487.10788482.html.plaintext.txt	405	206 365 379Medline Order article via Infotrieve 18
0.21141487.10788482.html.plaintext.txt	406	1996 Channeling Intermediary Metabolism Agius L
0.21141487.10788482.html.plaintext.txt	407	1998 Gastroenterology 115 139 146Medline Order article via Infotrieve 20
0.21141487.10788482.html.plaintext.txt	408	183 664 677Medline Order article via Infotrieve 21
0.21141487.10788482.html.plaintext.txt	409	148 327 342Medline Order article via Infotrieve 22
0.21141487.10788482.html.plaintext.txt	410	1995 Protein Expression Purif
0.21141487.10788482.html.plaintext.txt	411	6 79 90CrossRefMedline Order article via Infotrieve 23
0.21141487.10788482.html.plaintext.txt	412	316 926 940CrossRefMedline Order article via Infotrieve 24
0.21141487.10788482.html.plaintext.txt	413	289 81 85Medline Order article via Infotrieve 25
0.21141487.10788482.html.plaintext.txt	414	273 14130 14137AbstractFree Full Text 26
0.21141487.10788482.html.plaintext.txt	415	279 193 239Medline Order article via Infotrieve 27
0.21141487.10788482.html.plaintext.txt	416	250 237 244CrossRefMedline Order article via Infotrieve 28
0.21141487.10788482.html.plaintext.txt	417	271 653 662AbstractFree Full Text 29
0.21141487.10788482.html.plaintext.txt	418	236 209 216CrossRefMedline Order article via Infotrieve 31
0.21141487.10788482.html.plaintext.txt	419	229 1037 1048CrossRefMedline Order article via Infotrieve
0.21141487.10788482.html.plaintext.txt	420	Copyright 2000 The American Society Biochemistry Molecular Biology Inc
0.2088173.12601013.html.plaintext.txt	0	Xanthophyll Binding Sites CP29 Lhcb4 Subunit Higher Plant Photosystem II Investigated Domain Swapping Mutation Analysis Mirko Gastaldelli Giusy Canino Roberta Croce Roberto Bassi
0.2088173.12601013.html.plaintext.txt	1	From Dipartimento Scientifico e Tecnologico Universita di Verona Strada Le Grazie15 37134 Verona Italy Istituto di Biofisica Consiglio Nazionale delle Ricerche sezione di Milano
0.2088173.12601013.html.plaintext.txt	2	Via Celoria 26 20133 Milano Italy Universite Aix Marseille II LGBP Laboratoire de Genetique et Biophysique des Plantes Faculte des Sciences de Luminy Departement de Biologie Case 901 163 Avenue de Luminy 13288 Marseille Cedex 09 France
0.2088173.12601013.html.plaintext.txt	3	Received publication November 27 2002 revised form February 21 2003
0.2088173.12601013.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The binding sites xanthophylls CP29 antenna protein higher plant Photosystem II investigated using recombinant proteins refolded vitro
0.2088173.12601013.html.plaintext.txt	5	Despite presence three xanthophyll species CP29 binds two carotenoids per polypeptide
0.2088173.12601013.html.plaintext.txt	6	The localization neoxanthin studied producing chimeric protein constructed swapping C helix domain CP29 LHCII
0.2088173.12601013.html.plaintext.txt	7	The resulting holoprotein bind neoxanthin confirming N1 site present CP29
0.2088173.12601013.html.plaintext.txt	8	Neoxanthin CP29 instead bound L2 site thus shown wider specificity respect homologous site L2 LHCII
0.2088173.12601013.html.plaintext.txt	9	Lutein found L1 site CP29
0.2088173.12601013.html.plaintext.txt	10	For site selectivity individual xanthophyll species studied well role protein stabilization energy transfer photoprotection
0.2088173.12601013.html.plaintext.txt	11	Putative xanthophyll binding sequences identified primary structure analysis stretch hydrophobic residues including acidic term analyzed site directed mutagenesis one case deleting entire sequence
0.2088173.12601013.html.plaintext.txt	12	The mutant proteins unaffected xanthophyll composition thus suggesting target motifs little influence determining xanthophyll binding whereas hydrophobic sequences membrane spanning helices important
0.2088173.12601013.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Carotenoids involved many aspects higher plants photosynthesis
0.2088173.12601013.html.plaintext.txt	14	Reaction center complexes bind carotene light harvesting chlorophyll Chl a1 triplet quenching electron transport cytochrome b559 P680 1 2
0.2088173.12601013.html.plaintext.txt	15	In peripheral antenna Lhc proteins bind number xanthophyll species namely lutein neoxanthin violaxanthin acting harvesting light transfer excitation energy Chls 3 4 5 6
0.2088173.12601013.html.plaintext.txt	16	The photoprotection function xanthophylls accomplished multiple mechanisms including quenching Chl triplet states scavenging singlet oxygen produced reaction Chl triplets O2 participation non photochemical quenching mechanism violaxanthin de epoxidated zeaxanthin excess energy dissipated heat 7
0.2088173.12601013.html.plaintext.txt	17	In addition xanthophylls essential Lhc protein folding 8 whereas binding specific allosteric site controls transition dissipative conservative protein conformations 9 10
0.2088173.12601013.html.plaintext.txt	18	The reason Lhc proteins require number xanthophyll species reaction center proteins require carotene completely understood carotenoid species similar physico chemical properties enabling case efficient light harvesting triplet quenching singlet oxygen scavenging 11
0.2088173.12601013.html.plaintext.txt	19	Nonetheless pigment composition one conserved traits higher plants suggesting specific function carotenoid species
0.2088173.12601013.html.plaintext.txt	20	The best known xanthophyll binding protein major light harvesting complex Photosystem II LHCII four distinct binding sites reported bound distinct domains protein
0.2088173.12601013.html.plaintext.txt	21	Sites L1 L2 intersect helix Ahelix B cross domain center Lhc structure 12
0.2088173.12601013.html.plaintext.txt	22	L1 selective lutein whereas L2 also bind violaxanthin 13
0.2088173.12601013.html.plaintext.txt	23	Site N1 highly selective neoxanthin located within C helix domain LHCII 14
0.2088173.12601013.html.plaintext.txt	24	Finally low affinity binding site named V1 major ligand violaxanthin low light conditions 15 16
0.2088173.12601013.html.plaintext.txt	25	Each binding site shown play distinct functional role structure stabilization Chl triplet quenching provided lutein site L1 10 17
0.2088173.12601013.html.plaintext.txt	26	Site V1 involved singlet triplet energy transfer suggested accommodate pool readily available substrate molecules violaxanthin deepoxydase enzyme 16 whose product zeaxanthin bound allosteric site L2 18
0.2088173.12601013.html.plaintext.txt	27	Site N1 active light harvesting singlet oxygen scavenging 13 stabilizes long lifetime conformation LHCII 19
0.2088173.12601013.html.plaintext.txt	28	Despite high homology transmembrane regions suggests similar folding number xanthophyll binding sites selectivity occupancy structure seem different Lhc gene product
0.2088173.12601013.html.plaintext.txt	29	Considering different roles individual sites complexity Lhc multigene protein family possible function individual Lhc gene products largely determined presenceabsence individual xanthophyll sites selectivity strength
0.2088173.12601013.html.plaintext.txt	30	Primary sequence analysis structural determinants xanthophyll binding sites less successful case Chl binding sites possibly due contribution neighbor Chls rather amino acid side chains formation binding pocket xanthophylls 13 14
0.2088173.12601013.html.plaintext.txt	31	Nevertheless four short sequences located hydrophilic domains consisting four hydrophobic amino acids charged residue could involved binding forming hydrophobic pocket hosting xanthophylls end rings whereas charged side chain supposed interact oxygenated ring substituents 20
0.2088173.12601013.html.plaintext.txt	32	Alternatively binding might performed interactions hydrophobic residues polyene chain located deeply membrane observed bacterial LH2 complex 21
0.2088173.12601013.html.plaintext.txt	33	In study report results detailed analysis chlorophyll abxanthophyll protein CP29 Lhcb4 respect xanthophyll stoichiometry location function well sequence determinants involved interaction polypeptide chain
0.2088173.12601013.html.plaintext.txt	34	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES DNA Construction Mutation CP29 CP29 WT mutants obtained reported Bassi et al
0.2088173.12601013.html.plaintext.txt	35	The chimeric complex build using two restriction sites BsshII SalI present nucleotide sequence Lhcb1 gene Zea mays
0.2088173.12601013.html.plaintext.txt	36	These sites respectively upstream downstream region coding helix C portion LHCII apoprotein
0.2088173.12601013.html.plaintext.txt	37	The region sites changed corresponding sequence CP29 cloned using two primers GGGGCGCGCGCCTCGGCGCCCTCTCCGTCGAG GGGGGGTCGACCGGGTCGAGCTCGGCGTTGCG restriction sites
0.2088173.12601013.html.plaintext.txt	38	1 sequence chimeric complex presented together sequences LHCII CP29
0.2088173.12601013.html.plaintext.txt	39	The apoproteins overexpressed isolated reported Bassi et al
0.2088173.12601013.html.plaintext.txt	40	View larger version 34K FIG
0.2088173.12601013.html.plaintext.txt	41	Sequence comparison chimeric complex LHCII CP29
0.2088173.12601013.html.plaintext.txt	42	The bold indicates region LHCII CP29 present chimera
0.2088173.12601013.html.plaintext.txt	43	In CP29 sequence putative carotenoid binding sequences underlined
0.2088173.12601013.html.plaintext.txt	44	Reconstitution Purification CP29 WT Mutants Chimera Pigment Complexes Complex reconstitution purification procedures performed described Giuffra et al
0.2088173.12601013.html.plaintext.txt	45	22 using CP29 chlorophyll ab ratio 4
0.2088173.12601013.html.plaintext.txt	46	The chimera reconstituted conditions using chlorophyll ab ratio 4
0.2088173.12601013.html.plaintext.txt	47	3 LHCII full carotenoid complement present thylakoid membrane
0.2088173.12601013.html.plaintext.txt	48	Samples different carotenoid complement reconstituted way changed xanthophyll composition pigment mixture
0.2088173.12601013.html.plaintext.txt	49	Native CP29 purified Z
0.2088173.12601013.html.plaintext.txt	50	mays reported Croce et al
0.2088173.12601013.html.plaintext.txt	51	Pigment Analysis The pigment complement holoprotein analyzed HPLC 24 fitting acetone extract spectra individual pigments 25
0.2088173.12601013.html.plaintext.txt	52	Spectroscopy Absorption spectra measured SLM Aminco DW 2000 spectrophotometer room temperature
0.2088173.12601013.html.plaintext.txt	53	Fluorescence excitation emission spectra obtained using Jasco FP 777 spectrofluorimeter
0.2088173.12601013.html.plaintext.txt	54	Circular dichroism CD spectra recorded 10 degrees C Jasco 600
0.2088173.12601013.html.plaintext.txt	55	Samples 10 mM Hepes pH 7
0.2088173.12601013.html.plaintext.txt	56	06 D dodecylmaltoside 20 glycerol
0.2088173.12601013.html.plaintext.txt	57	Chlorophyll concentration 10 microgml CD absorption measurements 0
0.2088173.12601013.html.plaintext.txt	58	01 microgml fluorescence measurements
0.2088173.12601013.html.plaintext.txt	59	LD spectra reported Simonetto et al
0.2088173.12601013.html.plaintext.txt	60	Photobleaching kinetic measured described Formaggio et al
0.2088173.12601013.html.plaintext.txt	61	Stability Measurements The stability complexes determined decrease CD signal 490 nm induced temperature
0.2088173.12601013.html.plaintext.txt	62	A temperature range 20 80 degrees C used
0.2088173.12601013.html.plaintext.txt	63	The temperature changed continuously 1 degrees Cmin
0.2088173.12601013.html.plaintext.txt	64	The thermal stability protein determined finding signal decay
0.2088173.12601013.html.plaintext.txt	65	Data Analysis Deconvolution spectra Soret 350 550 nm wavelength range performed previously described 27 using homemade program
0.2088173.12601013.html.plaintext.txt	66	Energy transfer efficiency Cars Chls estimated ratio contributions fluorescence excitation respect absorption individual pigment pools
0.2088173.12601013.html.plaintext.txt	67	In samples energy transfer Chl normalized 100
0.2088173.12601013.html.plaintext.txt	68	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES The first step work consisted determination number carotenoids bound CP29 polypeptide
0.2088173.12601013.html.plaintext.txt	69	To end complex purified preparative isoelectrofocalization Z
0.2088173.12601013.html.plaintext.txt	70	mays grana membrane previously reported 28
0.2088173.12601013.html.plaintext.txt	71	The pigments extracted 80 acetone absorption spectrum shown Fig
0.2088173.12601013.html.plaintext.txt	72	The spectra individual pigments used reconstructing spectrum acetone extract two hypothetical CP29 complexes binding 8 Chls 6 Chl plus 2 Chl b 17 29 either 2 3 xanthophylls ratio shown HPLC analysis 0
0.2088173.12601013.html.plaintext.txt	73	The synthetic spectra shown Fig
0.2088173.12601013.html.plaintext.txt	74	2 together experimental spectrum
0.2088173.12601013.html.plaintext.txt	75	An almost perfect fit obtained considering two Cars per polypeptide whereas hypothesis three Cars discarded
0.2088173.12601013.html.plaintext.txt	76	View larger version 23K FIG
0.2088173.12601013.html.plaintext.txt	77	Number carotenoids present CP29
0.2088173.12601013.html.plaintext.txt	78	Comparison absorption spectrum acetone extract CP29 WT solid reconstituted spectra 2 dotted 3 dashed carotenoids
0.2088173.12601013.html.plaintext.txt	79	Reconstitution Recombinant CP29 Different Xanthophyll Species Although Car polypeptide stoichiometry CP29 21 three xanthophyll species found pigment protein complex indicating promiscuity least one binding sites
0.2088173.12601013.html.plaintext.txt	80	To investigate affinity binding sites different xanthophylls recombinant CP29 apoprotein overexpressed Escherichia coli reconstituted presence individual carotenoids combination two
0.2088173.12601013.html.plaintext.txt	81	Stable complexes obtained xanthophylls alone except neoxanthin similar observed LHCII CP26 13 25 31
0.2088173.12601013.html.plaintext.txt	82	The pigment composition reconstituted products analyzed HPLC fitting acetone extracts
0.2088173.12601013.html.plaintext.txt	83	The results reported Table I
0.2088173.12601013.html.plaintext.txt	84	All samples showed ChlCar ratio around 4
0.2088173.12601013.html.plaintext.txt	85	0 implying two xanthophylls per polypeptide
0.2088173.12601013.html.plaintext.txt	86	The complex reconstituted zeaxanthin exception although complex two zeaxanthin molecules per polypeptide obtained CP29 Zb experiments preparations single Zea molecule found CP29 Za
0.2088173.12601013.html.plaintext.txt	87	Neoxanthin complex never exceeded one molecule per polypeptide suggesting one site accommodate xanthophyll
0.2088173.12601013.html.plaintext.txt	88	Clearly occupancy site alone could sustain folding pigment protein complex
0.2088173.12601013.html.plaintext.txt	89	View table TABLE I Pigment composition denaturation temperature complexes reconstituted presence different carotenoids
0.2088173.12601013.html.plaintext.txt	90	Stability It previously shown reconstitution absence carotenoid yield folded Chl protein complex 8 implying carotenoids play primary role stabilizing Lhc holoproteins
0.2088173.12601013.html.plaintext.txt	91	To study influence two Car binding sites individual xanthophyll species therein stabilization structure denaturation experiments performed
0.2088173.12601013.html.plaintext.txt	92	The data reported Table I
0.2088173.12601013.html.plaintext.txt	93	The control CP29 complex containing lutein violaxanthin neoxanthin denaturation temperature 64 degrees C
0.2088173.12601013.html.plaintext.txt	94	Among complexes reconstituted presence two xanthophyll species CP29 LV CP29 VN slightly less stable whereas CP29 LN somewhat stable CP29 control thus showing neoxanthin stabilizing effect respect violaxanthin
0.2088173.12601013.html.plaintext.txt	95	Complexes containing one carotenoid species less stable denaturation temperature ranging 53 49 degrees C
0.2088173.12601013.html.plaintext.txt	96	Light Harvesting The absorption spectra complexes recorded room temperature
0.2088173.12601013.html.plaintext.txt	97	The spectra almost identical Qy region indicating binding different xanthophyll species strongly influence Chl absorption data shown
0.2088173.12601013.html.plaintext.txt	98	Major differences observed 400 520 nm region Cars directly absorb S0 S2 transition Fig
0.2088173.12601013.html.plaintext.txt	99	View larger version 37K FIG
0.2088173.12601013.html.plaintext.txt	100	Fitting absorption excitation spectra Soret region samples different carotenoid composition
0.2088173.12601013.html.plaintext.txt	101	A CP29 L B CP29 V C CP29 Z D CP29 NV E CP29 LN F CP29 LV
0.2088173.12601013.html.plaintext.txt	102	Black lines correspond experimental absorption left excitation right
0.2088173.12601013.html.plaintext.txt	103	The dark yellow line represents fitting
0.2088173.12601013.html.plaintext.txt	104	The spectra fitted spectra individual pigments protein environment blue Chl green Chl b red lutein magenta violaxanthin yellow zeaxanthin orange neoxanthin
0.2088173.12601013.html.plaintext.txt	105	In antenna complexes higher plants carotenoids light harvesting function
0.2088173.12601013.html.plaintext.txt	106	To determine energy transfer efficiency individual Cars two sites absorption spectra complexes described terms absorption individual pigments using two Chl forms two Chl b forms two Cars forms
0.2088173.12601013.html.plaintext.txt	107	Once best fit chosen absorption spectrum set data used describe correspondent fluorescence excitation spectrum Fig
0.2088173.12601013.html.plaintext.txt	108	The integrated areas pigment bands absorption excitation spectra used calculate efficiencies energy transfer complex
0.2088173.12601013.html.plaintext.txt	109	The error around 5 assuming Chl 100 transfer efficiency
0.2088173.12601013.html.plaintext.txt	110	The data reported Table II
0.2088173.12601013.html.plaintext.txt	111	View table TABLE II Energy transfer efficiency individual Cars different sites
0.2088173.12601013.html.plaintext.txt	112	The overall Car Chl energy transfer depends xanthophyll composition
0.2088173.12601013.html.plaintext.txt	113	Among complexes single xanthophyll species CP29 L complex lowest transfer efficiency 60 whereas CP29 V highest 73
0.2088173.12601013.html.plaintext.txt	114	The two samples reconstituted zeaxanthin different energy transfer efficiency CP29 Za single xanthophyll showed efficiency 62 whereas CP29 Zb two xanthophylls value dropped 37 thus indicating additional zeaxanthin molecule unable transfer energy Chl significant extent 5
0.2088173.12601013.html.plaintext.txt	115	When two xanthophyll species allowed highest efficiency obtained case CP29 VN 81 lowest CP29 LN 69
0.2088173.12601013.html.plaintext.txt	116	In control CP29 sample three xanthophyll species present lutein transferring 75 efficiency violaxanthin neoxanthin 60 65 6
0.2088173.12601013.html.plaintext.txt	117	Photoprotection Xanthophylls Lhc complexes act quenching 3Chl scavenging 1O2 thus providing photoprotection
0.2088173.12601013.html.plaintext.txt	118	Photoprotection measured ability preventing Chl photobleaching strong white light illumination presence oxygen 13
0.2088173.12601013.html.plaintext.txt	119	The results measurement recombinant CP29 complexes shown Fig
0.2088173.12601013.html.plaintext.txt	120	CP29 control complexes two xanthophyll species show high resistance photooxidation whereas complexes one xanthophyll species sensitive thus yielding behavior according following series CTR LN LV V L Z
0.2088173.12601013.html.plaintext.txt	121	It interesting note violaxanthin effective photoprotection lutein also noted CP29 Za contains single carotenoid molecule per polypeptide whereas CP29 V sample two
0.2088173.12601013.html.plaintext.txt	122	View larger version 29K FIG
0.2088173.12601013.html.plaintext.txt	123	Photobleaching recombinant CP29 proteins altered xanthophyll content
0.2088173.12601013.html.plaintext.txt	124	The decay curves show total Qy absorption relative 100 initial value
0.2088173.12601013.html.plaintext.txt	125	Points refer experimental data
0.2088173.12601013.html.plaintext.txt	126	Error lower 3 values assessed three independent measurements
0.2088173.12601013.html.plaintext.txt	127	Occupancy Xanthophyll Binding Sites CP29 Versus LHCII Three tightly bound xanthophyll binding sites described LHCII sites L1 L2 12 accommodating mostly lutein native complex N1 selective neoxanthin 13 14
0.2088173.12601013.html.plaintext.txt	128	The data presented show two sites conserved CP29
0.2088173.12601013.html.plaintext.txt	129	Previous work showed site L1 conserved CP29 17
0.2088173.12601013.html.plaintext.txt	130	However clear either site N1 L2 conserved
0.2088173.12601013.html.plaintext.txt	131	Alternatively sites could present partially occupied
0.2088173.12601013.html.plaintext.txt	132	To discriminate hypotheses chimeric complex produced including central domain helices A B LHCII C helix domain CP29
0.2088173.12601013.html.plaintext.txt	133	The helix A helix C lumenal loop part helix C helix B stromal loop also included swapped domain since loops affect Lhc protein folding 32 Fig
0.2088173.12601013.html.plaintext.txt	134	The apoprotein overexpressed E
0.2088173.12601013.html.plaintext.txt	135	coli complex reconstituted vitro pigments
0.2088173.12601013.html.plaintext.txt	136	A pigment protein complex obtained mobility sucrose gradient CP29 LHCII monomeric complexes denaturation temperature 66 degrees C intermediate CP29 64 degrees C LHCII 73 degrees C
0.2088173.12601013.html.plaintext.txt	137	The absorption spectrum complex along second derivative presented Fig
0.2088173.12601013.html.plaintext.txt	138	The maximum Qy region 676 nm whereas strong Chl contribution detected 666 nm
0.2088173.12601013.html.plaintext.txt	139	In blue region minima 495 468
0.2088173.12601013.html.plaintext.txt	140	2 nm derivative spectrum attributed respectively Car Chl b Chl
0.2088173.12601013.html.plaintext.txt	141	HPLC pigment analysis showed chimeric complex Chl ab ratio 2
0.2088173.12601013.html.plaintext.txt	142	7 reconstituted condition LHCII WT Chl ab 2
0.2088173.12601013.html.plaintext.txt	143	0 reconstituted condition CP29 WT Chl ab 4
0.2088173.12601013.html.plaintext.txt	144	0 xanthophyll species bound lutein small amount violaxanthin
0.2088173.12601013.html.plaintext.txt	145	The chimeric LHCII CP29 complex never binds neoxanthin irrespective xanthophyll availability pigment mixture reconstitution conditions Table III
0.2088173.12601013.html.plaintext.txt	146	View larger version 17K FIG
0.2088173.12601013.html.plaintext.txt	147	Absorption spectrum chimeric complex
0.2088173.12601013.html.plaintext.txt	148	Absorption spectrum second derivative room temperature LHCII CP29 chimeric complex reconstituted Chl ab 4
0.2088173.12601013.html.plaintext.txt	149	View table TABLE III Pigment composition chimeric complex reconstituted two different conditions
0.2088173.12601013.html.plaintext.txt	150	Orientation Xanthophyll Transition Moments CP29 Xanthophylls bound L1 L2 sites LHCII polyene chain forming angle respectively 56
0.2088173.12601013.html.plaintext.txt	151	4 degrees respect normal thylakoid membrane plane 12
0.2088173.12601013.html.plaintext.txt	152	We used LD determine orientation xanthophyll transition moments lying within degrees plane polyene chain 33 CP29
0.2088173.12601013.html.plaintext.txt	153	To distinguish contribution xanthophylls sites L1 L2 LD signal used CP29 mutants E166V E174V previously shown either complete partial emptiness site L2 17
0.2088173.12601013.html.plaintext.txt	154	The major contribution xanthophylls CP29 WT LD spectrum Fig
0.2088173.12601013.html.plaintext.txt	155	6 appears positive signal 495 nm whose amplitude reduced E174V mutant becomes negative E166V mutant
0.2088173.12601013.html.plaintext.txt	156	This suggests xanthophyll bound site L1 dipole moment transition forming angle smaller 54
0.2088173.12601013.html.plaintext.txt	157	7 degrees normal membrane plane
0.2088173.12601013.html.plaintext.txt	158	View larger version 24K FIG
0.2088173.12601013.html.plaintext.txt	159	LD spectra 100K CP29 control dash CP29 E166V solid CP29 E174V dotted
0.2088173.12601013.html.plaintext.txt	160	The decreased intensity positive signal CP29 E174V complex confirms positive contribution related carotenoid L2 site
0.2088173.12601013.html.plaintext.txt	161	In case angle dipole moment transition axis normal membrane plane larger 54
0.2088173.12601013.html.plaintext.txt	162	Using internal standard possible determine exact values angles
0.2088173.12601013.html.plaintext.txt	163	In CP29 orientation Chls determined LD signal normalization
0.2088173.12601013.html.plaintext.txt	164	We therefore analyzed spectra previously presented Simonetto et al
0.2088173.12601013.html.plaintext.txt	165	26 calculated orientation Cars transition moments
0.2088173.12601013.html.plaintext.txt	166	The orientation xanthophyll located L1 site calculated spectrum E166V mutant xanthophyll present located site L1
0.2088173.12601013.html.plaintext.txt	167	The analysis L2 performed WT E166V difference spectrum
0.2088173.12601013.html.plaintext.txt	168	The spectra fitted absorption spectra Cars calculate carotenoid LD signal reported Croce et al
0.2088173.12601013.html.plaintext.txt	169	Then using factor normalization value obtained analysis Chls transition moments 26 values L1 L2 calculated
0.2088173.12601013.html.plaintext.txt	170	These values respectively 50 70 degrees
0.2088173.12601013.html.plaintext.txt	171	L1 L2 Putative Binding Sequences By primary structure analysis within Lhc family four consensus sequences identified hydrophilic domains adjacent trans membrane helix regions A B two stromal loops two lumenal loops could involved xanthophyll binding 20 Fig
0.2088173.12601013.html.plaintext.txt	172	These sequences characterized hydrophobic stretch four residues polar residue insertion thus allowing formation hydrophobic pocket hosting end rings xanthophylls whereas interaction polar residue oxygenated ring substituents could stabilizing effect 20
0.2088173.12601013.html.plaintext.txt	173	To check involvement consensus sequences xanthophyll binding mutation analysis performed
0.2088173.12601013.html.plaintext.txt	174	In three cases charged amino acids center hydrophobic sequence either substituted non charged one residue opposite charge one case putative binding sequence deleted together whole N terminal domain
0.2088173.12601013.html.plaintext.txt	175	In case putative lumenal ligand carotenoid L1 site mutation central AA Gln 230 ligand Chl A3 17 previously performed effect xanthophyll binding
0.2088173.12601013.html.plaintext.txt	176	Close inspection LHCII structure Kuhlbrandt et al
0.2088173.12601013.html.plaintext.txt	177	12 indicates end ring xanthophyll L2 site appears closely spaced respect carbonyl proline 238
0.2088173.12601013.html.plaintext.txt	178	This residue could interact OH xanthophyll ring substituents
0.2088173.12601013.html.plaintext.txt	179	This residue mutated arginine
0.2088173.12601013.html.plaintext.txt	180	7A scheme representing structure CP29 indication putative carotenoid binding sequences mutations performed shown
0.2088173.12601013.html.plaintext.txt	181	The mutant sequences expressed E
0.2088173.12601013.html.plaintext.txt	182	coli apoproteins reconstituted complexes using pigment mixture xanthophylls available together Chl Chl b
0.2088173.12601013.html.plaintext.txt	183	The mutant Lhc complexes purified characterized biochemical spectroscopic methods
0.2088173.12601013.html.plaintext.txt	184	All complexes showed high yield reconstitution similar WT complex
0.2088173.12601013.html.plaintext.txt	185	Heat denaturation experiments accordingly show mutant proteins stability WT 64 plus minus 1 degrees C
0.2088173.12601013.html.plaintext.txt	186	The exception CP29 P238R mutant denaturation temperature 57 degrees C see Discussion
0.2088173.12601013.html.plaintext.txt	187	View larger version 29K FIG
0.2088173.12601013.html.plaintext.txt	188	Schematic representation structure CP29 chimera
0.2088173.12601013.html.plaintext.txt	189	A scheme structure CP29
0.2088173.12601013.html.plaintext.txt	190	The putative carotenoid binding sequences indicated red
0.2088173.12601013.html.plaintext.txt	191	The mutated amino acid indicated blue circle substituted amino acids indicated blue
0.2088173.12601013.html.plaintext.txt	192	In scheme Chls indicated blue Chl b green lutein orange violaxanthin magenta neoxanthin yellow
0.2088173.12601013.html.plaintext.txt	193	Two colors pigment indicates mixed occupancy
0.2088173.12601013.html.plaintext.txt	194	B schematic representation chimerical complex black domain LHCII red domain CP29
0.2088173.12601013.html.plaintext.txt	195	In Table IV pigment analysis reconstituted complexes presented
0.2088173.12601013.html.plaintext.txt	196	The differences pigment binding mutants respect WT rather small CP29 D50L CP29 N term showed Chl ab Chlcarotenoid ratios identical CP29 WT reconstituted conditions whereas small decrease neoxanthin violaxanthin compensated increase lutein content
0.2088173.12601013.html.plaintext.txt	197	CP29 D138L identical WT
0.2088173.12601013.html.plaintext.txt	198	CP29 D195L CP29 P238R complexes showed lower Chl ab ratio CP29 WT especially case P238R mutant variation carotenoid composition suggesting changes due loss Chl binding site
0.2088173.12601013.html.plaintext.txt	199	These data clearly indicate protein motifs including mutations performed play major role xanthophyll binding
0.2088173.12601013.html.plaintext.txt	200	View table TABLE IV Pigment composition mutants putative carotenoid binding sites relative WT composition
0.2088173.12601013.html.plaintext.txt	201	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES CP29 simplest chlorophyll binding protein Lhc superfamily since binds eight Chls per polypeptide 29 coordinated specific amino acid residue 17
0.2088173.12601013.html.plaintext.txt	202	The binding xanthophylls CP29 however still matter discussion
0.2088173.12601013.html.plaintext.txt	203	Consensus results obtained binding three xanthophyll species violaxanthin lutein neoxanthin 34 different hypotheses proposed location species particular binding site
0.2088173.12601013.html.plaintext.txt	204	Although consensus binding lutein site L1 violaxanthin neoxanthin either proposed bind different sites LHCII 15 compete site L2 thus implying site N1 absent empty CP29 17
0.2088173.12601013.html.plaintext.txt	205	In work performed extensive analysis xanthophyll binding CP29
0.2088173.12601013.html.plaintext.txt	206	In particular address four questions many carotenoids tightly bound complex ii sites located iii role individual sites individual xanthophylls iv putative binding sequences influence binding
0.2088173.12601013.html.plaintext.txt	207	We approached problem using recombinant pigment protein complexes either carotenoid complement biochemically modified apoprotein engineered putative carotenoid binding sites
0.2088173.12601013.html.plaintext.txt	208	How Many Carotenoids Are Bound CP29 The data presented clearly indicate native recombinant CP29 tightly bind two carotenoids per polypeptide
0.2088173.12601013.html.plaintext.txt	209	One mole lutein substoichiometric amounts neoxanthin violaxanthin together summing one per polypeptide found preparations thus suggesting low selectivity least one binding sites
0.2088173.12601013.html.plaintext.txt	210	This also supported analysis CP29 purified different plant sources showing variations ratio xanthophylls 5 35 36
0.2088173.12601013.html.plaintext.txt	211	Reconstitution experiments presence either one xanthophyll species combination two xanthophyll species indicate lutein violaxanthin zeaxanthin enter binding sites although different affinity binding strength
0.2088173.12601013.html.plaintext.txt	212	The neoxanthin instead accommodated one two sites inability drive folding process alone testifies occupancy site sufficient stabilize pigment protein complex
0.2088173.12601013.html.plaintext.txt	213	Which Binding Sites Are Present CP29 Four xanthophyll binding sites described LHCII three tightly bound L1 L2 N1 loose one V1
0.2088173.12601013.html.plaintext.txt	214	In CP29 two three tight sites conserved
0.2088173.12601013.html.plaintext.txt	215	Previous results show L1 site present CP29 accommodates mainly lutein 17
0.2088173.12601013.html.plaintext.txt	216	The second carotenoid binding site present CP29 shows high affinity neoxanthin participate protein stability either L2 N1 site
0.2088173.12601013.html.plaintext.txt	217	To discriminate two sites constructed chimeric LHCII CP29 protein two central helices A B derive LHCII whereas C helix domain previously shown host N1 binding site derives CP29 Fig
0.2088173.12601013.html.plaintext.txt	218	7B schematic representation complex presented
0.2088173.12601013.html.plaintext.txt	219	The chimeric complex stable spectral pigment binding properties intermediate CP29 LHCII
0.2088173.12601013.html.plaintext.txt	220	However neoxanthin found complex despite high amounts carotenoid used reconstitution
0.2088173.12601013.html.plaintext.txt	221	We conclude N1 site present CP29 second carotenoid binding site complex homologous L2 site LHCII
0.2088173.12601013.html.plaintext.txt	222	The LD analysis indicates dipole moment transition axis L1 L2 forms respectively angle 50 70 degrees normal membrane plane
0.2088173.12601013.html.plaintext.txt	223	Although possible data determine exact orientation polyene chain seems quite clear xanthophylls oriented differently compared LHCII perfect symmetry observed
0.2088173.12601013.html.plaintext.txt	224	Although models CP29 structure proposed based LHCII available Lhc structure 12 appears Lhc proteins may carry significant structural differences
0.2088173.12601013.html.plaintext.txt	225	New structural data critical interest understanding Lhc protein structure function
0.2088173.12601013.html.plaintext.txt	226	Stability The results presented indicate neoxanthin enter L2 site whereas Cars accommodated sites
0.2088173.12601013.html.plaintext.txt	227	This implies complex contains one molecule neoxanthin one molecule another xanthophyll latter located site L1
0.2088173.12601013.html.plaintext.txt	228	This allows studying role played individual xanthophylls two sites
0.2088173.12601013.html.plaintext.txt	229	We applied model stability measurements determine influence different xanthophylls L1 L2 sites
0.2088173.12601013.html.plaintext.txt	230	We considered denaturation temperature CP29 L CP29 V CP29 NV CP29 NL CP29 VL resolved system five equations five variables
0.2088173.12601013.html.plaintext.txt	231	This calculation take account contribution Chls stability since Chl content samples identical
0.2088173.12601013.html.plaintext.txt	232	The calculation yields value 50
0.2088173.12601013.html.plaintext.txt	233	3 degrees C contribution lutein site L1 stability protein whereas xanthophyll contributed 3
0.2088173.12601013.html.plaintext.txt	234	2 degrees C located site L2
0.2088173.12601013.html.plaintext.txt	235	For violaxanthin corresponding values respectively 42
0.2088173.12601013.html.plaintext.txt	236	2 degrees C L2 whereas neoxanthin site L2 contributes 14
0.2088173.12601013.html.plaintext.txt	237	As example calculate stability CP29 control 62
0.2088173.12601013.html.plaintext.txt	238	33 degrees C verify matches measured denaturation temperature 64 degrees C CP29 control complex
0.2088173.12601013.html.plaintext.txt	239	The good match indicates independence variables e
0.2088173.12601013.html.plaintext.txt	240	lutein L1 site stabilizes complex way independently xanthophyll present site L2
0.2088173.12601013.html.plaintext.txt	241	The results confirm site L1 important Lhc protein stabilization previously assessed Lhcb1 10 lutein site seems confer highest stability complex
0.2088173.12601013.html.plaintext.txt	242	Lutein L2 site almost effect stability whereas occupancy site violaxanthin even better neoxanthin increases temperature denaturation
0.2088173.12601013.html.plaintext.txt	243	Energy Transfer The excitation energy transfer efficiency individual binding sites determined analyzing absorption excitation spectra terms spectral contribution individual pigments
0.2088173.12601013.html.plaintext.txt	244	The possibility comparing samples differ carotenoid composition allowed quantitative information obtained analysis
0.2088173.12601013.html.plaintext.txt	245	It worth mentioning samples fully equilibrated partial exception CP29 Za CP29 Zb showed small emission contribution Chl b fluorescence 660 nm complex excited 475 nm
0.2088173.12601013.html.plaintext.txt	246	Again applied model used stability analysis see Stability
0.2088173.12601013.html.plaintext.txt	247	It demonstrated binding either one two sites yields different modulation S2 energy level xanthophylls 4
0.2088173.12601013.html.plaintext.txt	248	This indicates xanthophyll two sites spectroscopically different
0.2088173.12601013.html.plaintext.txt	249	In agreement two distinct values red peak found lutein violaxanthin corresponding absorption L1 L2 sites
0.2088173.12601013.html.plaintext.txt	250	In contrast single neoxanthin spectral form needed best fit absorption fluorescence excitation spectra consisting exclusive binding L2 site
0.2088173.12601013.html.plaintext.txt	251	Considering samples containing neoxanthin violaxanthin lutein located L1 site possible associate two absorptions site L1 L2 based pigment composition samples
0.2088173.12601013.html.plaintext.txt	252	Thus lutein L1 site absorbs 494 nm whereas site violaxanthin absorbs 496 nm
0.2088173.12601013.html.plaintext.txt	253	The description found absorption spectra applied analysis excitation spectra thus allowing discrimination transfer Car L1 L2
0.2088173.12601013.html.plaintext.txt	254	It therefore possible read data Table II understanding notations 1 2 actually correspond xanthophyll binding sites L1 L2
0.2088173.12601013.html.plaintext.txt	255	We conclude lutein transfers high efficiency 91 site L1 efficiency exciting Chl fluorescence low 28 located L2 site
0.2088173.12601013.html.plaintext.txt	256	Violaxanthin transfers efficiently L1 site efficiency around 60 violaxanthin neoxanthin L2 site
0.2088173.12601013.html.plaintext.txt	257	Both violaxanthin lutein show high 80 90 efficiency L1 site decrease transfer efficiency L2 site different lutein decreases efficiency factor 3
0.2088173.12601013.html.plaintext.txt	258	2 whereas viola decreases efficiency factor 1
0.2088173.12601013.html.plaintext.txt	259	This suggests arrangement two xanthophylls L2 site different
0.2088173.12601013.html.plaintext.txt	260	The case zeaxanthin even extreme energy transfer efficiency L1 site around 60 whereas L2 site low
0.2088173.12601013.html.plaintext.txt	261	These results suggest energy transfer single site dependent site occupancy
0.2088173.12601013.html.plaintext.txt	262	In general L2 site seems less active energy transfer compared L1 site
0.2088173.12601013.html.plaintext.txt	263	Moreover efficiency excitation energy transfer Chl modulated xanthophyll species bound following gradient V N L Z
0.2088173.12601013.html.plaintext.txt	264	The lower transfer efficiency L2 site common xanthophyll species indicates site distanceorientation pigments optimal excitation energy transfer
0.2088173.12601013.html.plaintext.txt	265	It recently observed transfer Car Chl occurs via S2 Car state less 100 fs
0.2088173.12601013.html.plaintext.txt	266	Considering short carotenoid S2 lifetime perfect geometry donor acceptor required highly efficient energy transfer 3 4 6 small changes geometry strongly influence process
0.2088173.12601013.html.plaintext.txt	267	Moreover finding xanthophylls behave differently bound L2 site suggests protein domain may change folding presence different xanthophylls supporting proposal L2 site allosteric nature 10
0.2088173.12601013.html.plaintext.txt	268	It thus possible suggest example lutein enters site usually occupied neoxanthin violaxanthin conformational change occurs changing relative chromophore orientation thus decreasing transfer efficiency
0.2088173.12601013.html.plaintext.txt	269	The picture CP29 thus different compared case LHCII L1 L2 sites showed high efficiency excitation energy transfer Chl 4
0.2088173.12601013.html.plaintext.txt	270	This suggests L2 site different function two proteins
0.2088173.12601013.html.plaintext.txt	271	In case CP29 Ca2 dicyclohexylcarbodiimide binding site loop helix B C suggested work sensor pH changes lumen 37 38
0.2088173.12601013.html.plaintext.txt	272	Dicyclohexylcarbodiimide binding sites also found CP26 39
0.2088173.12601013.html.plaintext.txt	273	At low lumenal pH substitution Ca2 H would open structure allowing violaxanthin exit zeaxanthin enter site 18
0.2088173.12601013.html.plaintext.txt	274	The high flexibility required process thus explain low energy transfer efficiency site
0.2088173.12601013.html.plaintext.txt	275	In case LHCII zeaxanthin never enters central sites thus structure could optimized function excitation energy transfer
0.2088173.12601013.html.plaintext.txt	276	Photoprotection The photobleaching measurements show samples two xanthophyll species resistant photooxidation
0.2088173.12601013.html.plaintext.txt	277	Among samples containing one xanthophyll species CP29 L CP29 Z sensitive photo oxidation
0.2088173.12601013.html.plaintext.txt	278	It proposed lutein site L2 organized differently compared xanthophylls effect transfer energy efficiently
0.2088173.12601013.html.plaintext.txt	279	CP29 Z one xanthophyll molecule located L1 site
0.2088173.12601013.html.plaintext.txt	280	The results thus indicate L2 site CP29 play important role photoprotection role modulated site occupancy
0.2088173.12601013.html.plaintext.txt	281	In respect CP29 differs strongly LHCII clearly shown L1 site active preventing photooxidation 10
0.2088173.12601013.html.plaintext.txt	282	Do Putative Carotenoid Binding Sequences Participate Actual Xanthophyll Binding In last part work putative binding sequences carotenoids L1 L2 sites studied mutation analysis
0.2088173.12601013.html.plaintext.txt	283	Comparison primary structures Lhc multigenic family members shown loops conserved sequences composed one charged amino acid hydrophobic residues four
0.2088173.12601013.html.plaintext.txt	284	Considering Lhc proteins cannot bind carotene argued sequences involved xanthophyll binding establishing H bond polar residue polypeptide stretch ring OH substituent 20
0.2088173.12601013.html.plaintext.txt	285	However mutation four putative binding sequences decrease pigment protein stability also change affinity binding sites different xanthophyll species
0.2088173.12601013.html.plaintext.txt	286	The changes Chl composition observed P238R mutant probably due changes D helix domain loss Chl A3 site suggested similar effects mutation P238R work Q230L 17 detected pigment analysis CD spectroscopy data shown heat denaturation kinetics
0.2088173.12601013.html.plaintext.txt	287	The two mutations affect putative stromal binding sequences xanthophylls L2 site CP29 D50L CP29 N term support view pigment protein stabilization xanthophyll binding provided hydrophilic sequences
0.2088173.12601013.html.plaintext.txt	288	A small reproducible decrease violaxanthin neoxanthin balanced increase lutein however consistently found
0.2088173.12601013.html.plaintext.txt	289	This result may indicate sequence encompassing Asp 50 residue plays minor role determining selectivity L2 site
0.2088173.12601013.html.plaintext.txt	290	The pigment binding properties chimeric LHCII CP29 complex support conclusion lumenal sequences little effect site selectivity despite presence CP29 sequence lumenal region B C helices still accommodates mostly lutein L2 site case LHCII 13 rather violaxanthin neoxanthin CP29
0.2088173.12601013.html.plaintext.txt	291	Nevertheless absence clear phenotype chimeric complex useful search structural determinants affinity Car binding sites individual xanthophyll
0.2088173.12601013.html.plaintext.txt	292	In fact effect xanthophyll composition observed either deleting N terminal domain residue 96 CP29 substituting half B helix lumenal loop
0.2088173.12601013.html.plaintext.txt	293	We conclude structural determinant selectivity L2 site located two regions namely within 28 amino acid sequence e
0.2088173.12601013.html.plaintext.txt	294	residue 50 residue 77 LHCII sequence
0.2088173.12601013.html.plaintext.txt	295	It recently demonstrated CP26 L2 occupancy CP29 25 means determinant conserved CP29 CP26 LHCII
0.2088173.12601013.html.plaintext.txt	296	The three sequences reported Fig
0.2088173.12601013.html.plaintext.txt	297	The candidate N 61 LHCII
0.2088173.12601013.html.plaintext.txt	298	An aromatic amino acid CP29 CP26 occupies position
0.2088173.12601013.html.plaintext.txt	299	In structure LHCII asparagine within 5 A carotenoid L2
0.2088173.12601013.html.plaintext.txt	300	The presence position Phe Tyr may change steric interaction pigments possibly favoring binding violaxanthin neoxanthin respect lutein
0.2088173.12601013.html.plaintext.txt	301	This may due difference ring orientation lutein violaxanthin neoxanthin lutein low energy conformation cycle oriented parallel polyene chain whereas cycles violaxanthin neoxanthin oriented perpendicularly
0.2088173.12601013.html.plaintext.txt	302	This difference play role selectivity binding site aromatic group site higher steric hindrance select lutein
0.2088173.12601013.html.plaintext.txt	303	However stringency cannot high lutein able enter L2 site reconstitution performed absence violaxanthin neoxanthin
0.2088173.12601013.html.plaintext.txt	304	Consistent hypothesis finding CP29 L sample less stable control CP29 lutein site L2 differently oriented complex proposed
0.2088173.12601013.html.plaintext.txt	305	View larger version 7K FIG
0.2088173.12601013.html.plaintext.txt	306	Sequence comparison CP29 CP26 LHCII B helix
0.2088173.12601013.html.plaintext.txt	307	Although putative carotenoid binding sequences stroma exposed side protein somehow involved selectivity sites different xanthophylls quite clear stabilization carotenoid binding cannot attributed sequences
0.2088173.12601013.html.plaintext.txt	308	Similar results obtained major light harvesting complex LHCII deletion N terminal domain contains putative binding sequence L1 site influence carotenoid composition complex
0.2088173.12601013.html.plaintext.txt	309	The dragging force carotenoid binding probably found hydrophobic interaction portion complex inside membrane similar way observed bacteria 40
0.2088173.12601013.html.plaintext.txt	310	Aromatic residues present A B helices involved binding
0.2088173.12601013.html.plaintext.txt	311	The position residues conserved different members Lhc family maintained gene products different species
0.2088173.12601013.html.plaintext.txt	312	Mutation analysis Chl binding residues CP29 LHCII shown interactions Chls carotenoids play major role xanthophylls binding
0.2088173.12601013.html.plaintext.txt	313	In particular binding neoxanthin N1 site LHCII stabilized interaction Chls 14
0.2088173.12601013.html.plaintext.txt	314	This consistent CP29 lacking N1 site number Chls domain helices A C lower LHCII critical Chl neoxanthin interactions might lacking
0.2088173.12601013.html.plaintext.txt	315	The loop helix A helix C CP29 shorter respect corresponding domain LHCII may bring helix C closer helix A thus prevent Chl A6 A7 B1 binding CP29 chimeric LHCII CP29 complex
0.2088173.12601013.html.plaintext.txt	316	CP29 member Lhc family conserved higher plants green algae involved light harvesting protection abiotic stress
0.2088173.12601013.html.plaintext.txt	317	Knowledge biochemical functional properties isolated proteins contribute understanding physiological roles individual gene products providing stress resistance
0.2088173.12601013.html.plaintext.txt	318	Recent work showed light stress xanthophyll ligand site L2 violaxanthin changed zeaxanthin 18 thus inducing conformational change leading fluorescence quenching whereas binding neoxanthin site N1 stabilizes unquenched conformation 9 19
0.2088173.12601013.html.plaintext.txt	319	The absence site N1 CP29 qualifies antenna subunit prompt response light induced photoprotective conformational change
0.2088173.12601013.html.plaintext.txt	320	FOOTNOTES This work supported Ministero dellIstruzione dellUniversita e della Ricerca progetto FIRB Grant RBAu01ECX Consiglio Nazionale delle Ricerche Agenzia 2000
0.2088173.12601013.html.plaintext.txt	321	The costs publication article defrayed part payment page charges
0.2088173.12601013.html.plaintext.txt	322	This article must therefore hereby marked advertisement accordance 18 U
0.2088173.12601013.html.plaintext.txt	323	Section 1734 solely indicate fact
0.2088173.12601013.html.plaintext.txt	324	To correspondence addressed Universite Aix Marseille II LGBP Faculte des Sciences de Luminy Departement de Biologie Case 901 163 Avenue de Luminy 13288 Marseille Cedex 09 France
0.2088173.12601013.html.plaintext.txt	325	1 The abbreviations used Chl chlorophyll Car carotenoid Lhc light harvesting complex L lutein LD linear dichroism N neoxanthin V violaxanthin WT wild type PSII Photosystem II HPLC high performance liquid chromatography CTL control
0.2088173.12601013.html.plaintext.txt	326	ACKNOWLEDGMENTS We thank Stefano Caffarri University Verona preparing Fig
0.2088173.12601013.html.plaintext.txt	327	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Tracewell C
0.2088173.12601013.html.plaintext.txt	328	2001 Biochemistry 40 193 203CrossRefMedline Order article via Infotrieve Faller P
0.2088173.12601013.html.plaintext.txt	329	2001 Biochemistry 40 6431 6440CrossRefMedline Order article via Infotrieve Gradinaru C
0.2088173.12601013.html.plaintext.txt	330	B 104 9330 9342CrossRef Croce R
0.2088173.12601013.html.plaintext.txt	331	80 901 915AbstractFree Full Text Das S
0.2088173.12601013.html.plaintext.txt	332	2002 Biochemisty 41 13087 13095CrossRefMedline Order article via Infotrieve Croce R
0.2088173.12601013.html.plaintext.txt	333	84 2517 2532AbstractFree Full Text Demmig B
0.2088173.12601013.html.plaintext.txt	334	84 146 150Abstract Moya I
0.2088173.12601013.html.plaintext.txt	335	2001 Biochemistry 40 12552 12561CrossRefMedline Order article via Infotrieve Formaggio E
0.2088173.12601013.html.plaintext.txt	336	314 1157 1166CrossRefMedline Order article via Infotrieve Bassi R
0.2088173.12601013.html.plaintext.txt	337	64 243 256CrossRef Kuhlbrandt W
0.2088173.12601013.html.plaintext.txt	338	1994 Nature 367 614 621CrossRefMedline Order article via Infotrieve Croce R
0.2088173.12601013.html.plaintext.txt	339	274 29613 29623AbstractFree Full Text Croce R
0.2088173.12601013.html.plaintext.txt	340	456 1 6CrossRefMedline Order article via Infotrieve Ruban A
0.2088173.12601013.html.plaintext.txt	341	274 10458 10465AbstractFree Full Text Caffarri S
0.2088173.12601013.html.plaintext.txt	342	276 35924 35933AbstractFree Full Text Bassi R
0.2088173.12601013.html.plaintext.txt	343	96 10056 10061AbstractFree Full Text Morosinotto T
0.2088173.12601013.html.plaintext.txt	344	277 36913 36920AbstractFree Full Text Polivka T
0.2088173.12601013.html.plaintext.txt	345	2002 Biochemistry 41 439 450CrossRefMedline Order article via Infotrieve Pichersky E
0.2088173.12601013.html.plaintext.txt	346	1996 Oxygenic Photosynthesis The Light Reactions Ort D
0.2088173.12601013.html.plaintext.txt	347	507 521 Kluwer Academic Publishers Group Dordrecht Netherlands McDermott G
0.2088173.12601013.html.plaintext.txt	348	1995 Nature 374 517 521CrossRef Giuffra E
0.2088173.12601013.html.plaintext.txt	349	238 112 120Abstract Croce R
0.2088173.12601013.html.plaintext.txt	350	1996 Biochemistry 35 11142 11148CrossRefMedline Order article via Infotrieve Gilmore A
0.2088173.12601013.html.plaintext.txt	351	2002 Biochemistry 38 7334 7343CrossRef Simonetto R
0.2088173.12601013.html.plaintext.txt	352	1999 Biochemistry 38 12974 12983CrossRefMedline Order article via Infotrieve Croce R
0.2088173.12601013.html.plaintext.txt	353	266 8136 8142AbstractFree Full Text Giuffra E
0.2088173.12601013.html.plaintext.txt	354	1997 Biochemistry 36 12984 12993CrossRefMedline Order article via Infotrieve Frank H
0.2088173.12601013.html.plaintext.txt	355	2001 Biochemistry 40 1220 1225CrossRefMedline Order article via Infotrieve Heinemann B
0.2088173.12601013.html.plaintext.txt	356	1999 Biochemistry 38 14088 14093CrossRefMedline Order article via Infotrieve Dolan P
0.2088173.12601013.html.plaintext.txt	357	B 105 12134 12142CrossRef Bassi R
0.2088173.12601013.html.plaintext.txt	358	212 297 303Abstract Sandona D
0.2088173.12601013.html.plaintext.txt	359	Acta 1365 207 214Medline Order article via Infotrieve Pascal A
0.2088173.12601013.html.plaintext.txt	360	262 817 823AbstractFree Full Text Jegerschold C
0.2088173.12601013.html.plaintext.txt	361	275 12781 12788AbstractFree Full Text Pesaresi P
0.2088173.12601013.html.plaintext.txt	362	402 151 156CrossRefMedline Order article via Infotrieve Walters R
0.2088173.12601013.html.plaintext.txt	363	226 1063 1069Abstract Prince S
0.2088173.12601013.html.plaintext.txt	364	268 412 423CrossRefMedline Order article via Infotrieve
0.2730276.16135518.html.plaintext.txt	0	Nucleo cytoplasmic Shuttling High Risk Human Papillomavirus E2 Proteins Induces Apoptosis Stephanie Blachon1 Sophie Bellanger2 Caroline Demeret Francoise Thierry3
0.2730276.16135518.html.plaintext.txt	1	From Unite Expression Genetique et Maladies CNRS FRE 2850 Institut Pasteur 25 rue du Dr
0.2730276.16135518.html.plaintext.txt	2	Roux 75724 Paris cedex 15 France
0.2730276.16135518.html.plaintext.txt	3	Received publication May 10 2005 revised form August 31 2005
0.2730276.16135518.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Human Papillomavirus HPV E2 proteins major viral regulators transcription replication viral life cycle
0.2730276.16135518.html.plaintext.txt	5	In addition conserved functions show E2 proteins high risk HPV types 16 18 associated cervical cancer induce apoptosis
0.2730276.16135518.html.plaintext.txt	6	In contrast E2 proteins low risk HPV types 6 11 associated benign lesions cause cell death
0.2730276.16135518.html.plaintext.txt	7	We show ability induce apoptosis linked intracellular localization respective E2 proteins rather inherent properties proteins
0.2730276.16135518.html.plaintext.txt	8	Although low risk HPV E2 proteins remain strictly nuclear high risk HPV E2 proteins present nucleus cytoplasm expressing cells due exportin 1 receptor CRM1 dependent nucleo cytoplasmic shuttling
0.2730276.16135518.html.plaintext.txt	9	Induction apoptosis caused accumulation E2 cytoplasm involves caspase 8 activation
0.2730276.16135518.html.plaintext.txt	10	We speculate disruption E2 gene viral genome integration cervical carcinoma provides means avoid E2 induced apoptosis allow initiation carcinogenesis
0.2730276.16135518.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Human papillomaviruses etiologic agents cervical cancer found associated 90 type cancer
0.2730276.16135518.html.plaintext.txt	12	Viruses infecting anogenital tract divided two distinct classes associated either benign lesions HPV4 types 6 11 cancer HPV types 16 18
0.2730276.16135518.html.plaintext.txt	13	The class high risk HPVs associated cervical carcinoma expresses two oncogenes E6 E7 transform cells negatively interfering p53 pRB pathways 1 2
0.2730276.16135518.html.plaintext.txt	14	In contrast E6 E7 proteins low risk HPVs shown unable induce cellular transformation vitro review see Ref
0.2730276.16135518.html.plaintext.txt	15	The HPV E2 protein plays crucial role viral life cycle
0.2730276.16135518.html.plaintext.txt	16	E2 proteins transcription factors repress transcription E6 E7 genes genital papillomaviruses independently oncogenic potential 4 8
0.2730276.16135518.html.plaintext.txt	17	Transcriptional repression shown result binding E2 sequences within E6 E7 early promoters high risk well low risk HPVs 5 9 12
0.2730276.16135518.html.plaintext.txt	18	Other properties E2 proteins also conserved ability activate transcription heterologous promoters containing least two E2 binding sites specific configuration activate viral DNA replication concert E1 helicase 13
0.2730276.16135518.html.plaintext.txt	19	Comparative analyses E2 proteins high risk low risk HPV viruses suggested high degree conservation three dimensional structure compatible conserved functions viral DNA replication transcription 14 17
0.2730276.16135518.html.plaintext.txt	20	E2 proteins also shown directly influence host cell biology
0.2730276.16135518.html.plaintext.txt	21	In particular proapoptotic activity demonstrated HPV18 E2 protein 18 19 well HPV16 E2 protein 20 shown intrinsic property independent transcription 18 19
0.2730276.16135518.html.plaintext.txt	22	More recently interaction E2 mitotic chromosomes described direct interaction Brd4 bromodomain protein associated acetylated chromatin 21
0.2730276.16135518.html.plaintext.txt	23	E2 also associated mitotic spindles via tubulin interactions proposed take part segregation viral genomes cell division 22
0.2730276.16135518.html.plaintext.txt	24	Finally also recently described novel interaction high risk HPV E2 proteins activators mitotic ubiquitin ligase anaphase promoting complex APCC inhibiting degradation various APCC substrates results strong genomic instability 23
0.2730276.16135518.html.plaintext.txt	25	These additional functions E2 proteins mediated direct interactions cellular proteins rather transcriptional control shown independent viral functions
0.2730276.16135518.html.plaintext.txt	26	The E2 proteins composed three distinct domains expressed separately retain function 24
0.2730276.16135518.html.plaintext.txt	27	The carboxyl terminal domain forms small barrel dimer binds specific recognition sequences DNA 25
0.2730276.16135518.html.plaintext.txt	28	A hinge domain specific structure mainly serves flexible linker two functional domains
0.2730276.16135518.html.plaintext.txt	29	The amino terminal domain composed two sub domains separated fulcrum one contains three helices amino terminal end composed succession sheets carboxyl terminal end 15 16
0.2730276.16135518.html.plaintext.txt	30	The amino terminal domain retains functions E2 involved regulating transcription replication
0.2730276.16135518.html.plaintext.txt	31	Above shown interact cellular proteins involved transactivation well E1 helicase activates viral DNA replication 15 26 Brd4 involved episomal segregation mitosis 21
0.2730276.16135518.html.plaintext.txt	32	Other characteristics ubiquitination degradation proteasome 24 well induction apoptosis 19 involve domain
0.2730276.16135518.html.plaintext.txt	33	The proapoptotic property HPV18 E2 shown depend induction extrinsic pathway activation caspase 8 19
0.2730276.16135518.html.plaintext.txt	34	The exact mechanism activation yet understood appears E2 activates caspase 8 direct protein protein interaction
0.2730276.16135518.html.plaintext.txt	35	5 Induction apoptosis also shown occur HPV16 E2 protein although mechanism fully understood 20
0.2730276.16135518.html.plaintext.txt	36	In present work sought examine whether autonomous properties HPV E2 proteins could differ among virus types shown E6 E7 proteins
0.2730276.16135518.html.plaintext.txt	37	We examined whether proapoptotic property HPV18 E2 protein conserved among E2 proteins genital HPV subtypes
0.2730276.16135518.html.plaintext.txt	38	We fused GFP amino terminus HPV16 HPV11 HPV6 E2 proteins used recombinant adenoviruses express previously described HPV18 E2 19
0.2730276.16135518.html.plaintext.txt	39	Subcellular localization E2 proteins appeared strikingly different E2 proteins low risk viruses HPV6 HPV11 exclusively nuclear whereas proteins high risk viruses located nucleus cytoplasm
0.2730276.16135518.html.plaintext.txt	40	We show HPV18 E2 protein actively shuttles nucleus cytoplasm infected cells partial cytoplasmic localization high risk E2 proteins correlates induction apoptosis caspase 8 activation
0.2730276.16135518.html.plaintext.txt	41	In contrast E2 proteins low risk HPVs induce apoptosis due exclusive nuclear localization
0.2730276.16135518.html.plaintext.txt	42	These experiments point important differences biological functions E2 proteins high low risk papillomaviruses infecting anogenital tract
0.2730276.16135518.html.plaintext.txt	43	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Construction Plasmids Recombinant Adenoviruses E2 ORFs wild type HPV16 HPV6 HPV11 viruses different mutants cloned pEGFP C1 expression plasmid Clontech previously done HPV18 E2 ORF 24
0.2730276.16135518.html.plaintext.txt	44	The E2 open reading frames HPV6 11 cloned PCR PCR3 E2 kind gift J
0.2730276.16135518.html.plaintext.txt	45	Archambault frame carboxyl terminus GFP
0.2730276.16135518.html.plaintext.txt	46	Expression cassettes various GFP fusion proteins introduced place E1A E1B region replication deficient recombinant adenoviruses two step procedure bacteria described previously 19 27
0.2730276.16135518.html.plaintext.txt	47	Recombinant adenoviruses produced amplified 293 cells
0.2730276.16135518.html.plaintext.txt	48	Viruses subsequently purified CsCl gradients titrated
0.2730276.16135518.html.plaintext.txt	49	Adenovirus expressing GFP alone purchased Quantum
0.2730276.16135518.html.plaintext.txt	50	Conventional PCR based mutagenesis used introduce point mutations AT RK position 246 247 insertion arginine position 250 amino acids sequence HPV18 E2 ORF well mutations KR TH position 107 108 RK AT position 238 239 amino acid sequence HPV11 E2 ORF
0.2730276.16135518.html.plaintext.txt	51	The deleted mutant GFP E2 del 26 prepared exchanging XhoI StuI fragment digested pXLGFP E2 previously described 19 XhoI StuI fragment prepared PCR amplification specific primer containing XhoI site 5 end 5 AAAACTCGAGCTAGTAAAGACATAGACAGC 3 3 primer 5 CGCGGATCCACTGCACATAGAGTCATTAC 3
0.2730276.16135518.html.plaintext.txt	52	The deleted mutant GFP E2 del53 cloned PCR amplification position 53 amino acid sequence end HPV18 E2 open reading frame specific primers containing EcoRI BamHI restriction sites cloning frame carboxyl terminus GFP 5 CGAATTCCGGCATACAGACATTAAACCAC 3 5 AAAGGATCCTTACATTGTCATGTATCCC 3 restriction site indicated boldface
0.2730276.16135518.html.plaintext.txt	53	The putative nuclear export sequence NES amplified PCR HPV18 E2 specific primers containing BamHI XbaI restriction sites cloning frame carboxyl terminus GFP nuclear localization signals NLS expression plasmid previously described 24
0.2730276.16135518.html.plaintext.txt	54	The primers used 5 CGCGGATCCGACATAGACAGCCAAATACAG 3 5 CTAGTCTAGATTAAAAGAATATTGCATTTTCCC 3
0.2730276.16135518.html.plaintext.txt	55	Cell Cultures Transient Transfections Infections MCF7 HeLa cells grown 6 10 cm Petri dishes Dulbeccos modified Eagles medium supplemented 7 fetal calf serum
0.2730276.16135518.html.plaintext.txt	56	Saos 2 cells grown Dulbeccos modified Eagles medium supplemented 10 fetal calf serum
0.2730276.16135518.html.plaintext.txt	57	Transient transfections HeLa cells done standard calcium phosphate co precipitation technique previously described 5 5 10 microg GFP expression plasmids 6 cm Petri dishes
0.2730276.16135518.html.plaintext.txt	58	Infections done multiplicity infection m
0.2730276.16135518.html.plaintext.txt	59	varying 200 1000 various recombinant adenoviruses
0.2730276.16135518.html.plaintext.txt	60	Cells incubated 1 ml Dulbeccos modified Eagles medium without serum containing adenovirus dilutions complemented 4 microM Polybrene Saos 2 MCF7 cells 1 h 37 degrees C
0.2730276.16135518.html.plaintext.txt	61	When indicated cells treated pan caspase inhibitor benzyloxycarbonyl Val Ala Asp fluoromethyl ketone Z VAD FMK 40 microM Biomol equivalent volume Me2SO added medium infection
0.2730276.16135518.html.plaintext.txt	62	24 h post infection cells treated 10 ngml leptomycin B Sigma
0.2730276.16135518.html.plaintext.txt	63	Inhibition proteasome obtained treating cells 10 microM lactacystin Calbiochem 6h
0.2730276.16135518.html.plaintext.txt	64	For video microscopy treated cells transferred thermostatted chamber 7 CO2 37 degrees C objective microscope maintained 4 h
0.2730276.16135518.html.plaintext.txt	65	Images captured every 5 min phase contrast fluorescence using 20x objective Axiovert Zeiss microscope
0.2730276.16135518.html.plaintext.txt	66	Images processed Metamorph software converted Adobe Photoshop
0.2730276.16135518.html.plaintext.txt	67	Immunofluorescence HeLa cells grown cover slips rinsed phosphate buffered saline PBS 24 h infection transfection fixed 2 paraformaldehydePBS 1 h 4 degrees C
0.2730276.16135518.html.plaintext.txt	68	After rehydration cells permeabilized saturated PBS containing 2 serum 0
0.2730276.16135518.html.plaintext.txt	69	They incubated primary antibodies anti p53 Santa Cruz PAB1801 anti HPV18 E2 24 anti HPV16 E2 Ab261 anti HPV11 6 E2 kind gifts J
0.2730276.16135518.html.plaintext.txt	70	Archambault 1 h followed incubation appropriate secondary antibody coupled Texas Red
0.2730276.16135518.html.plaintext.txt	71	Nuclei stained 46 diamidino 2 phenylindole 0
0.2730276.16135518.html.plaintext.txt	72	Annexin labeling done according manufacturer annexin V PE BD Pharmingen
0.2730276.16135518.html.plaintext.txt	73	Pictures taken Zeiss Axiophot microscope coupled CCD camera processed Metaview software converted Adobe Photoshop
0.2730276.16135518.html.plaintext.txt	74	In Vitro Caspase Cleavage HeLa cells expressing GFP E2 proteins harvested cell lysates prepared p300 buffer 20 mM NaH2PO4 250 mM NaCl 30 mM Na4P2O7 10 H2O 0
0.2730276.16135518.html.plaintext.txt	75	1 Nonidet P 40 5 mM EDTA 5 mM dithiothreitol protease inhibitor Roche Applied Science 30 min 4 degrees C followed centrifugation
0.2730276.16135518.html.plaintext.txt	76	Protein G PLUS agarose Santa Cruz sc 2002 used preclear extracts
0.2730276.16135518.html.plaintext.txt	77	Immunoprecipitation done monoclonal anti GFP antibody Roche Applied Science 1814460
0.2730276.16135518.html.plaintext.txt	78	Immune complexes collected protein G PLUS agarose washed 3 times p300 buffer
0.2730276.16135518.html.plaintext.txt	79	One tenth immunoprecipitate used perform vitro cleavage recombinant caspase 3 BD Pharmingen 556472 according manufacturers instructions
0.2730276.16135518.html.plaintext.txt	80	Results visualized Western blot anti GFP antibody
0.2730276.16135518.html.plaintext.txt	81	Western Blot Experiments Cells either resuspended directly Laemmli sample buffer extracted p300 buffer 20 mM NaH2PO4 250 mM NaCl 30 mM NaPPi 0
0.2730276.16135518.html.plaintext.txt	82	1 Nonidet P 40 5 mM EDTA 5 mM dithiothreitol 30 min 4 degrees C followed centrifugation
0.2730276.16135518.html.plaintext.txt	83	Equal amounts total cells cellular extracts denatured Laemmli sample buffer boiled separated 12 SDS PAGE acrylamide gels
0.2730276.16135518.html.plaintext.txt	84	After overnight transfer nitrocellulose membranes saturated PBS Tween plus 10 milk incubated appropriate first antibodies anti GFP Torrey Pines Biolab TP401 anti caspase 8 BD biosciences 559932 anti actin Sigma A2066 1 h washed PBS Tween
0.2730276.16135518.html.plaintext.txt	85	Incubations secondary antibodies coupled peroxidase done 1 h followed washing PBS Tween
0.2730276.16135518.html.plaintext.txt	86	Membranes revealed using ECL plus Western blot detection system Amersham Biosciences
0.2730276.16135518.html.plaintext.txt	87	Pulse Chase Experiments HeLa cells incubated medium deficient methionine cysteine supplemented 5 dialyzed fetal calf serum 30 min
0.2730276.16135518.html.plaintext.txt	88	Radiolabeling Tran35S label 0
0.2730276.16135518.html.plaintext.txt	89	25 mCiml ICN done 30 min followed chase complete medium indicated time points
0.2730276.16135518.html.plaintext.txt	90	Cell lysates prepared p300 buffer 20 mM NaH2PO4 250 mM NaCl 30 mM Na4P2O7 10 H2O 0
0.2730276.16135518.html.plaintext.txt	91	1 Nonidet P 40 5 mM EDTA 5 mM dithiothreitol protease inhibitor Roche Applied Science
0.2730276.16135518.html.plaintext.txt	92	Immunoprecipitation GFP E2 proteins done vitro cleavage experiments
0.2730276.16135518.html.plaintext.txt	93	Proteins eluted SDS PAGE sample buffer boiled separated SDS PAGE 12 gel
0.2730276.16135518.html.plaintext.txt	94	Gels fixed dried autoradiographed
0.2730276.16135518.html.plaintext.txt	95	Quantification performed using PhosphorImager ImageQuant software Molecular Dynamics
0.2730276.16135518.html.plaintext.txt	96	Flow Cytometry Analyses Cells harvested 24 48 h post infection washed PBS fixed ice cold 100 ethanol
0.2730276.16135518.html.plaintext.txt	97	Cells rehydrated PBS 2 serum
0.2730276.16135518.html.plaintext.txt	98	In cases cells treated 0
0.2730276.16135518.html.plaintext.txt	99	2 M Na2HPO4 40 mM citric acid 15 min favor extraction low molecular weight DNA
0.2730276.16135518.html.plaintext.txt	100	DNA stained propidium iodide 20 microgml plus 10 microgml RNase 30 min analyzed epics XL fluorescence activated cell sorter Coulter
0.2730276.16135518.html.plaintext.txt	101	For annexin detection cells harvested binding buffer labeled annexin V PE analysis according manufacturer instructions BD Bioscience
0.2730276.16135518.html.plaintext.txt	102	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Comparison High Risk Low Risk HPV E2 Expression E2 induced G1 Arrest HeLa Cells We prepared recombinant adenoviruses expressing four different amino terminal GFP E2 fusion proteins originating human genital papillomaviruses either high risk 16 18 low risk 6 11 types
0.2730276.16135518.html.plaintext.txt	103	We infected HeLa cells comparable m
0.2730276.16135518.html.plaintext.txt	104	get GFP fluorescence virtually cells present plates
0.2730276.16135518.html.plaintext.txt	105	As expected GFP observed nuclei cells infected four recombinant adenoviruses expressing E2 however cytoplasmic fluorescence also clearly visible high risk HPV16 HPV18 E2 Fig
0.2730276.16135518.html.plaintext.txt	106	Western blots analysis indicated differences subcellular localization depend differences levels expression
0.2730276.16135518.html.plaintext.txt	107	Notably cytoplasmic localization high risk HPV E2 proteins necessarily associated higher levels protein expression shown HPV16 E2 protein Fig
0.2730276.16135518.html.plaintext.txt	108	In contrast even expressed high levels low risk HPV11 HPV6 E2 proteins remain strictly nuclear Fig
0.2730276.16135518.html.plaintext.txt	109	Because HPV18 E2 shown particularly unstable 24 compared stability four E2 proteins pulse chase experiments Fig
0.2730276.16135518.html.plaintext.txt	110	These experiments showed HPV16 HPV18 E2 proteins exhibit similar half life 50 min exactly matches half life reported previously HPV18 E2 24
0.2730276.16135518.html.plaintext.txt	111	In contrast HPV6 HPV11 E2 proteins appeared stable although half life times increased 1
0.2730276.16135518.html.plaintext.txt	112	5 fold HPV11 E2 75 min 2
0.2730276.16135518.html.plaintext.txt	113	We concluded experiments exclusive nuclear localization E2 proteins low risk viruses correlate strong stabilization proteins
0.2730276.16135518.html.plaintext.txt	114	We also checked whether E2 proteins able repress transcription viral oncogenes HeLa cells previously reported 28 30
0.2730276.16135518.html.plaintext.txt	115	It shown transcriptional repression induces p53 stabilization HeLa cells due E6 repression consequently inducing strong G1 growth arrest 28 31
0.2730276.16135518.html.plaintext.txt	116	The presence p53 cells expressing E2 control cells clearly indicated four proteins equally able stabilize nuclear p53 infected cells Fig
0.2730276.16135518.html.plaintext.txt	117	1A induce G1 growth arrest Fig
0.2730276.16135518.html.plaintext.txt	118	We also checked transactivation DNA binding properties four proteins detected significant differences data shown
0.2730276.16135518.html.plaintext.txt	119	These experiments show GFP fusion proteins retain biological activity native proteins reported HPV18 E2 24
0.2730276.16135518.html.plaintext.txt	120	High Risk HPV E2 Proteins Induce Apoptosis Because four GFP E2 fusion proteins appear maintain biological activity decided compare proapoptotic activities infecting HeLa cells increasing m
0.2730276.16135518.html.plaintext.txt	121	respective recombinant adenoviruses
0.2730276.16135518.html.plaintext.txt	122	We previously showed induction apoptosis requires threshold expression level HPV18 E2 protein 19
0.2730276.16135518.html.plaintext.txt	123	Indeed apoptosis clearly detectable cells infected higher m
0.2730276.16135518.html.plaintext.txt	124	HPV18 HPV16 GFP E2 expressing recombinant adenoviruses shown direct microscopic observation black arrows Fig
0.2730276.16135518.html.plaintext.txt	125	Under similar conditions cells infected recombinant adenoviruses expressing HPV6 HPV11 E2 proteins die even high m
0.2730276.16135518.html.plaintext.txt	126	correlating accumulation fluorescence nuclei infected cells Fig
0.2730276.16135518.html.plaintext.txt	127	The infected cells subjected flow cytometry detected presence sub 2N populations 70 highest m
0.2730276.16135518.html.plaintext.txt	128	HPV18 HPV16 E2 expressing cells contrast HPV6 HPV11 E2 expressing cells population remained 10 Fig
0.2730276.16135518.html.plaintext.txt	129	Accumulation E2 proteins infected cells confirmed Western blot analysis Fig
0.2730276.16135518.html.plaintext.txt	130	These experiments indicated full length HPV18 HPV16 E2 proteins accumulate high levels partly due emergence specific cleavage products degradation increasing m
0.2730276.16135518.html.plaintext.txt	131	The cleavage products inhibited pan caspase inhibitor Z VAD vivo Fig
0.2730276.16135518.html.plaintext.txt	132	2D result caspase 3 cleavages HPV18 HPV16 GFP fusion proteins cryptic sites shown vitro cleavage experiments Fig
0.2730276.16135518.html.plaintext.txt	133	These cleaved products thus indicators caspase activation apoptosis infected cells
0.2730276.16135518.html.plaintext.txt	134	In contrast full length HPV6 HPV11 E2 proteins accumulated levels higher two E2 proteins due absence caspase cleavage Fig
0.2730276.16135518.html.plaintext.txt	135	We checked whether stabilization GFP E2 proteins HPV18 HPV11 would change levels apoptosis Fig
0.2730276.16135518.html.plaintext.txt	136	Inhibition proteasome lactacystin induces accumulation GFP E2 proteins shown lower panel Fig
0.2730276.16135518.html.plaintext.txt	137	2E modulate apoptosis upper panel Fig
0.2730276.16135518.html.plaintext.txt	138	Thus conclude experiment stabilization E2 seem change apoptotic phenotype whether E2 protein proapoptotic like high risk HPV18 E2 like low risk HPV11 E2 protein
0.2730276.16135518.html.plaintext.txt	139	High Risk HPV E2 Proteins Induce Apoptosis via Common Mechanism Involving Caspase 8 Activation Different Cell Lines Clear differences behavior E2 proteins high risk HPVs compared low risk HPVs inducing apoptosis also demonstrated cell lines breast cancer MCF7 cells containing wild type p53 osteosarcoma Saos cells lack p53 Fig
0.2730276.16135518.html.plaintext.txt	140	We deduced experiments E2 proteins low risk viruses unable induce high levels apoptosis conditions E2 proteins high risk viruses efficient apoptotic inducers
0.2730276.16135518.html.plaintext.txt	141	We tested whether pan caspase inhibitor Z VAD could inhibit HPV16 well HPV18 E2 induced apoptosis demonstrated 19
0.2730276.16135518.html.plaintext.txt	142	The addition Z VAD totally abolished appearance sub 2N population Fig
0.2730276.16135518.html.plaintext.txt	143	These results suggested two viral proteins induced apoptosis caspase 8 activation previously shown HPV18 E2 19
0.2730276.16135518.html.plaintext.txt	144	In living cells caspase 8 exists full length proform protein 5055 kDa doublet
0.2730276.16135518.html.plaintext.txt	145	This form caspase inactive activated autocleavage give rise active heterodimers able induce apoptosis
0.2730276.16135518.html.plaintext.txt	146	We examined cleaved products caspase 8 dead cells infected recombinant adenoviruses expressing HPV18 HPV16 HPV11 HPV6 GFP E2 proteins Fig
0.2730276.16135518.html.plaintext.txt	147	As expected previous data HPV18 E2 expressing dead cells lost almost caspase 8 proform exhibited intermediate cleaved product 4036 kDa doublet
0.2730276.16135518.html.plaintext.txt	148	Interestingly exactly pattern seen HPV16 E2 expressing cells indicating unambiguously two high risk HPV proteins induce apoptosis pathway Fig
0.2730276.16135518.html.plaintext.txt	149	In experiment cleaved product caspase 8 could detected low risk viruses GFP E2 expressing cells
0.2730276.16135518.html.plaintext.txt	150	View larger version 51K FIGURE 1
0.2730276.16135518.html.plaintext.txt	151	Characterization recombinant adenoviruses
0.2730276.16135518.html.plaintext.txt	152	A stabilization p53 E2 proteins HPV types 18 16 6 11
0.2730276.16135518.html.plaintext.txt	153	HeLa cells either non infected NI infected m
0.2730276.16135518.html.plaintext.txt	154	500 recombinant adenoviruses expressing GFP four GFP E2 indicated
0.2730276.16135518.html.plaintext.txt	155	Direct GFP fluorescence well detection p53 immunofluorescence using anti p53 antibody followed Texas Red coupled secondary antibodies shown
0.2730276.16135518.html.plaintext.txt	156	Dapi46 diamidino 2 phenylindole
0.2730276.16135518.html.plaintext.txt	157	B levels expression E2 proteins detected Western blots WB done equivalent quantities protein extracts
0.2730276.16135518.html.plaintext.txt	158	C pulse chase experiments done four E2 proteins
0.2730276.16135518.html.plaintext.txt	159	200 labeled 30 min Tran35 S labeled methionine cysteine chased 4 h
0.2730276.16135518.html.plaintext.txt	160	At indicated time points cells extracted equal amounts proteins migrated SDS PAGE exposed
0.2730276.16135518.html.plaintext.txt	161	Radioactivity counted half lives calculated 50 min HPV18 previously described 24 HPV16 E2 proteins 125 min HPV6 E2 75 min HPV11 E2
0.2730276.16135518.html.plaintext.txt	162	DG1 arrest HeLa cells infected four recombinant adenoviruses expressing E2
0.2730276.16135518.html.plaintext.txt	163	250 cell cycles analyzed flow cytometry 24 h post infection
0.2730276.16135518.html.plaintext.txt	164	View larger version 58K FIGURE 2
0.2730276.16135518.html.plaintext.txt	165	Apoptosis induced high risk low risk viruses E2 proteins
0.2730276.16135518.html.plaintext.txt	166	A apoptosis infected HeLa cells visualized direct microscopy
0.2730276.16135518.html.plaintext.txt	167	HeLa cells infected increasing m
0.2730276.16135518.html.plaintext.txt	168	500 2000 plaque forming units per cell images taken 40 h infection Axiovert microscope phase contrast fluorescence
0.2730276.16135518.html.plaintext.txt	169	Several dead cells indicated arrows
0.2730276.16135518.html.plaintext.txt	170	B analyses sub 2N populations flow cytometry
0.2730276.16135518.html.plaintext.txt	171	Cells infected conditions analyzed flow cytometry sub 2N populations marked black
0.2730276.16135518.html.plaintext.txt	172	The sub 2N populations represented 2 10 total population cells infected HPV6 HPV11 E2 recombinant viruses increasing m
0.2730276.16135518.html.plaintext.txt	173	whereas 6 70 HPV18 HPV16 E2 recombinant viruses
0.2730276.16135518.html.plaintext.txt	174	C Western blot WB analysis proteins expressed infected cells presented panels A B
0.2730276.16135518.html.plaintext.txt	175	The quantity cells extracted analyzed SDS PAGE blotted revealed anti GFP antibody
0.2730276.16135518.html.plaintext.txt	176	Stars indicate caspase 3 cleavage products E2 proteins cryptic sites HPV18 HPV16 E2 proteins
0.2730276.16135518.html.plaintext.txt	177	D addition pan caspase inhibitor Z VAD vivo inhibits appearance cleaved products left panel
0.2730276.16135518.html.plaintext.txt	178	Cleavage experiments recombinant caspase 3 vitro show products result caspase 3 cleavage high risk E2 proteins low risk E2 proteins right panel
0.2730276.16135518.html.plaintext.txt	179	E stabilization GFP E2 proteins influence apoptotic induction
0.2730276.16135518.html.plaintext.txt	180	Saos cells infected increasing m
0.2730276.16135518.html.plaintext.txt	181	treated either Me2SO proteasome inhibitor lactacystin Lacta
0.2730276.16135518.html.plaintext.txt	182	Inhibition proteasome leads stabilization two E2 proteins HPV18 HPV11 seen increase percentage fluorescent cells among living cells lower graph
0.2730276.16135518.html.plaintext.txt	183	Levels apoptosis deduced sub 2N populations fluorescence activated cell sorter analysis samples affected upper graph
0.2730276.16135518.html.plaintext.txt	184	View larger version 19K FIGURE 3
0.2730276.16135518.html.plaintext.txt	185	Apoptosis high risk viruses E2 proteins involves caspase activation extrinsic pathway
0.2730276.16135518.html.plaintext.txt	186	A high risk low risk E2 proteins induce apoptosis cell lines
0.2730276.16135518.html.plaintext.txt	187	MCF7 Saos cells contain respectively wild type p53 disrupted p53 infected m
0.2730276.16135518.html.plaintext.txt	188	1000 four recombinant adenoviruses
0.2730276.16135518.html.plaintext.txt	189	The cells subjected flow cytometry analyses sub 2N populations black
0.2730276.16135518.html.plaintext.txt	190	In MCF7 sub 2N population corresponded 12 cells infected recombinant viruses expressing low risk E2 proteins whereas represented 25 population high risk E2 recombinant adenovirus infected cells
0.2730276.16135518.html.plaintext.txt	191	In Saos cells sub 2N populations 17 21 HPV18 HPV16 respectively 4 HPV6 HPV11 E2 proteins
0.2730276.16135518.html.plaintext.txt	192	B sub 2N populations disappeared treatment pan caspase inhibitor Z VAD HeLa cells infected HPV18 HPV16 E2 recombinant adenoviruses m
0.2730276.16135518.html.plaintext.txt	193	C detection caspase 8 cells expressing HPV18 HPV16 HPV6 HPV11 E2 proteins
0.2730276.16135518.html.plaintext.txt	194	750 HPV GFP E2 recombinant adenoviruses dead living cells separated dead cells supernatants immunoblotted wb anti caspase 8 antibodies
0.2730276.16135518.html.plaintext.txt	195	The cleaved forms caspase 8 detected specifically dead cell populations HPV18 HPV16 E2 infected cells
0.2730276.16135518.html.plaintext.txt	196	Different NLS Regulate Subcellular Localization E2 Proteins High Risk Low Risk Viruses As previously shown localization four GFP E2 proteins clearly different detected GFP fluorescence
0.2730276.16135518.html.plaintext.txt	197	We checked whether GFP fluorescence reflected localization fusion proteins immunofluorescence using specific antibodies E2 protein
0.2730276.16135518.html.plaintext.txt	198	We observed good superposition direct GFP fluorescence Texas Red images except nucleolar GFP fluorescence indicating E2 proteins high risk viruses expressed nuclei cytoplasm infected cells whereas HPV6 11 E2 proteins exclusively nuclear Fig
0.2730276.16135518.html.plaintext.txt	199	NLSs described E2 protein BPV1 32 HPV11 33
0.2730276.16135518.html.plaintext.txt	200	Careful examination E2 proteins sequences revealed conserved NLS four HPV E2 proteins within DNA binding domain Fig
0.2730276.16135518.html.plaintext.txt	201	In contrast NLS found hinge HPV11 HPV 6 E2 proteins 33 seem conserved high risk HPV 18 HPV16 E2 proteins
0.2730276.16135518.html.plaintext.txt	202	Another NLS amino terminal domain could found sequence homology BPV1 E2 32 HPV6 HPV11 E2 proteins HPV18 HPV16 E2 proteins Fig
0.2730276.16135518.html.plaintext.txt	203	Based comparative sequence data made three different mutants E2 proteins try modify subcellular localization
0.2730276.16135518.html.plaintext.txt	204	Our goal render GFP HPV18 E2 exclusively nuclear contrast make GFP HPV11 E2 partly cytoplasmic
0.2730276.16135518.html.plaintext.txt	205	For purpose first added NLS hinge domain HPV18 E2 protein 18E2 insNLS2 substituting two amino acids inserting arginine position 250 mimic HPV11 E2 hinge NLS Fig
0.2730276.16135518.html.plaintext.txt	206	Second mutated putative NLS amino terminal domain GFP HPV11 E2 protein 11E2 mutNLS1 changing two basic amino acids corresponding amino acids present HPV18 E2 protein
0.2730276.16135518.html.plaintext.txt	207	A third mutant generated changing two amino acids NLS hinge HPV11 E2 11E2 mutNLS2 Fig
0.2730276.16135518.html.plaintext.txt	208	These mutants transfected HeLa cells localization checked directly living cells GFP fluorescence immunofluorescence specific anti E2 antibodies
0.2730276.16135518.html.plaintext.txt	209	4A mutations amino terminal NLS1 HPV11 protein modify exclusive nuclear localization whereas striking contrast mutation NLS2 hinge induced nuclear exclusion previously shown 33
0.2730276.16135518.html.plaintext.txt	210	The reverse experiment adding strong NLS hinge HPV18 E2 protein rendered protein nuclear expected Fig
0.2730276.16135518.html.plaintext.txt	211	These experiments indicated presence absence functional NLS hinge domain HPV18 E2 protein dictate subcellular localization protein
0.2730276.16135518.html.plaintext.txt	212	View larger version 50K FIGURE 4
0.2730276.16135518.html.plaintext.txt	213	Subcellular localization E2 proteins high risk low risk viruses different
0.2730276.16135518.html.plaintext.txt	214	A high risk E2 proteins nuclear cytoplasmic whereas low risk E2 proteins essentially nuclear
0.2730276.16135518.html.plaintext.txt	215	GFP fluorescence HeLa cells infected m
0.2730276.16135518.html.plaintext.txt	216	100 adenoviruses expressing wild type GFP E2 fusion proteins shown well cells transfected point mutants indicated top figure
0.2730276.16135518.html.plaintext.txt	217	The corresponding Texas Red immunofluorescence obtained specific anti E2 antibodies shown indicated
0.2730276.16135518.html.plaintext.txt	218	Dapi46 diamidino 2 phenylindole
0.2730276.16135518.html.plaintext.txt	219	B comparison sequences NLSs four E2 proteins
0.2730276.16135518.html.plaintext.txt	220	The point mutations add new NLS hinge HPV18 E2 shown 18 insNLS2 well destroy NLS amino terminal domain HPV11 E2 protein 11 mutNLS1 point mutations destroy NLS hinge HPV11 E2 protein 11 mutNLS2
0.2730276.16135518.html.plaintext.txt	221	The HPV18 E2 Protein Contains NES Its Amino terminal Domain Previous unpublished data indicated deletion amino terminal domain HPV 18 E2 resulted protein increased nuclear accumulation
0.2730276.16135518.html.plaintext.txt	222	These observations suggested HPV18 E2 protein could possess NES amino terminal domain 34 35
0.2730276.16135518.html.plaintext.txt	223	To address generated deletions amino terminal domain HPV18 E2 protein fused resultant polypeptides GFP study subcellular localization
0.2730276.16135518.html.plaintext.txt	224	The E2 del53 lacking first 53 aminoacids corresponding two first helices according published crystal structure 15 16 clearly localizes differently full length E2 protein
0.2730276.16135518.html.plaintext.txt	225	E2 del53 accumulates high levels nucleus displaying localization similar low risk HPV E2 proteins HPV18 E2 protein lacking entire amino terminal domain
0.2730276.16135518.html.plaintext.txt	226	Interestingly deletion one helix amino terminal domain E2 del26 extensive cytoplasmic localization similar even greater full length protein Fig
0.2730276.16135518.html.plaintext.txt	227	We thus speculated NES could lie within second helix residues 26 53 HPV18 E2 protein
0.2730276.16135518.html.plaintext.txt	228	Examining sequences region found cluster 20 amino acids contains putative consensus NES sequence 35 37 Fig
0.2730276.16135518.html.plaintext.txt	229	View larger version 47K FIGURE 5
0.2730276.16135518.html.plaintext.txt	230	The HPV18 E2 protein contains NES amino terminal domain
0.2730276.16135518.html.plaintext.txt	231	A deletion first amino terminal helix E2 del26 alter HPV18 E2 localization whereas deletion first two helices E2 del53 rendered exclusively nuclear
0.2730276.16135518.html.plaintext.txt	232	Shown localization deleted HPV18 E2 proteins direct GFP fluorescence upper panels immunofluorescence specific anti E2 antibodies lower panels
0.2730276.16135518.html.plaintext.txt	233	Dapi46 diamidino 2 phenylindole
0.2730276.16135518.html.plaintext.txt	234	B second helix contains putative NES sequence characterized sequential incidence large hydrophobic amino acids
0.2730276.16135518.html.plaintext.txt	235	C sequences amino acids 29 47 sufficient delocalize GFP NLS fusion protein cytoplasm
0.2730276.16135518.html.plaintext.txt	236	HeLa cells transfected two plasmids expressing fusion proteins GFP NLS GFP NLS NES indicated
0.2730276.16135518.html.plaintext.txt	237	Direct GFP fluorescence shown well 46 diamidino 2 phenylindole staining nuclei
0.2730276.16135518.html.plaintext.txt	238	D cytoplasmic localization E2 due CRM1 dependent shuttling
0.2730276.16135518.html.plaintext.txt	239	HeLa cells infected recombinant adenovirus expressing HPV18 GFP E2 treated leptomycin B LMB 24 h post infection subjected video microscopy
0.2730276.16135518.html.plaintext.txt	240	We fused potential E2 NES GFP containing NLS HPV18 E2 DNA binding domain 24
0.2730276.16135518.html.plaintext.txt	241	The addition putative NES sequence caused strong delocalization nuclear GFP cytoplasm transfected cells Fig
0.2730276.16135518.html.plaintext.txt	242	5C clearly indicating sequence sufficient promote nuclear export fused protein
0.2730276.16135518.html.plaintext.txt	243	To investigate process E2 nuclear export used leptomycin B inhibitor CRM1 one main exportins responsible protein export nucleus cytoplasm
0.2730276.16135518.html.plaintext.txt	244	By time lapse microscopy found GFP E2 18 protein accumulated nuclei infected cells almost completely disappeared cytoplasm 4 h treatment leptomycin B Fig
0.2730276.16135518.html.plaintext.txt	245	These experiments strongly suggest HPV18 E2 able shuttle nucleus cytoplasm via CRM1 dependent mechanism
0.2730276.16135518.html.plaintext.txt	246	Thus subcellular localization E2 proteins seems result complex interplay signals nuclear import export
0.2730276.16135518.html.plaintext.txt	247	View larger version 22K FIGURE 6
0.2730276.16135518.html.plaintext.txt	248	Subcellular localization E2 determines apoptotic phenotype
0.2730276.16135518.html.plaintext.txt	249	A HeLa cells transfected HPV18 full length two deleted GFP E2 fused proteins indicated
0.2730276.16135518.html.plaintext.txt	250	Green fluorescent cells labeled annexin V coupled phycoerythrin counted reported graph
0.2730276.16135518.html.plaintext.txt	251	B HeLa cells transfected HPV11 GFP E2 proteins either wild type mutated NLS visualized phase contrast pc fluorescence upper panels dead cells indicated arrows
0.2730276.16135518.html.plaintext.txt	252	The cells labeled annexin V quantified fluorescence activated cell sorter analysis lower panels
0.2730276.16135518.html.plaintext.txt	253	Subcellular Localization E2 Correlated Its Proapoptotic Activity Apoptosis high risk HPV E2 proteins coincides presence E2 proteins cytoplasm
0.2730276.16135518.html.plaintext.txt	254	We thus examined apoptotic properties different E2 mutants vary subcellular localization
0.2730276.16135518.html.plaintext.txt	255	The two amino terminal deleted HPV18 E2 proteins strikingly differ proapoptotic abilities E2 del53 exclusively nuclear induce apoptosis background whereas E2 del26 partly cytoplasmic strong inducer apoptosis Fig
0.2730276.16135518.html.plaintext.txt	256	These results led us examine behavior NLS point mutants described
0.2730276.16135518.html.plaintext.txt	257	We examined level apoptosis induced HPV18 E2 mutant rendered nuclear addition hinge NLS HPV11 E2
0.2730276.16135518.html.plaintext.txt	258	Our experiments indicated intermediate phenotype wild type E2 amino terminal deleted E2 protein difficult quantify precisely transfection experiments
0.2730276.16135518.html.plaintext.txt	259	In contrast cytoplasmic NLS mutant HPV11 E2 protein could induce apoptosis measured direct observation annexin labeling higher levels compared HPV11 E2 wild type protein Fig
0.2730276.16135518.html.plaintext.txt	260	We deduced experiments differences induction apoptosis two types E2 proteins due inherent differences effector functions rather different subcellular localization
0.2730276.16135518.html.plaintext.txt	261	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES The roles Papillomavirus E2 proteins viral life cycle studied extensively
0.2730276.16135518.html.plaintext.txt	262	Human Papillomavirus E2 proteins exhibit transactivation function whose role yet understood course viral life cycle
0.2730276.16135518.html.plaintext.txt	263	In contrast E2 function transcriptional repressor viral oncogenes specific disruption E2 gene establishment HPV induced cervical carcinogenesis well documented
0.2730276.16135518.html.plaintext.txt	264	E2 also activates viral DNA replication interacting cooperatively viral helicase E1 origin replication viral genome
0.2730276.16135518.html.plaintext.txt	265	Apart functions regulating transcription viral DNA replication E2 proteins also appear able interact physically cellular proteins directly influence host cell biology
0.2730276.16135518.html.plaintext.txt	266	One functions linked transactivation induction apoptosis shown occur induction extrinsic death pathway activation caspase 8 19
0.2730276.16135518.html.plaintext.txt	267	We also shown apoptosis independent p53 occur many different cell types provided viral protein expressed certain threshold
0.2730276.16135518.html.plaintext.txt	268	This activity also described HPV16 E2 protein although reported induction apoptosis required p53 activation 20
0.2730276.16135518.html.plaintext.txt	269	Nothing known propapoptotic functions E2 proteins particularly E2 proteins human papillomaviruses involved benign infections anogenital tract low risk HPV types 6 11
0.2730276.16135518.html.plaintext.txt	270	One notable differences E2 proteins two types HPV viruses subcellular localization
0.2730276.16135518.html.plaintext.txt	271	Although HPV11 HPV6 E2 proteins exclusively nuclear many cell types tested HPV16 HPV18 proteins also found cytoplasm
0.2730276.16135518.html.plaintext.txt	272	We could show differences behavior due fact dominant functional NLS present hinge domain HPV11 E2 protein 33 absent HPV18 HPV16 E2 proteins
0.2730276.16135518.html.plaintext.txt	273	In addition showed HPV18 E2 contains NES amino terminal domain responsible active export protein nucleus cytoplasm repressed leptomycin B
0.2730276.16135518.html.plaintext.txt	274	Furthermore inactivating point mutations strong NLS HPV11 E2 protein lead clear delocalization protein cytoplasm transfected cells indicating NLS sufficient explain strict nuclear localization full length proteins
0.2730276.16135518.html.plaintext.txt	275	In contrast complex phenomena probably dictate localization HPV18 E2 none NLSs appeared sufficient induce nuclear retention
0.2730276.16135518.html.plaintext.txt	276	In contrast NES able delocalize protein cytoplasm subcellular localization protein seems tightly regulated complex interplay signals active nucleo cytoplasmic shuttling
0.2730276.16135518.html.plaintext.txt	277	As transcription replication factors E2 proteins primarily expressed nuclei infected cells normal viral life cycle
0.2730276.16135518.html.plaintext.txt	278	Other functions high risk virus E2 proteins could account cytoplasmic localization shown proapoptotic activity could one
0.2730276.16135518.html.plaintext.txt	279	There clear differences E2 proteins high risk low risk viruses inducing apoptosis
0.2730276.16135518.html.plaintext.txt	280	Although E2 proteins high risk viruses able induce apoptosis equivalent rates different cell types E2 proteins low risk viruses unable
0.2730276.16135518.html.plaintext.txt	281	Caspase 8 activation could detected HPV16 HPV18 E2 expressing cells indicating mechanism apoptotic cell death probably conserved two viruses
0.2730276.16135518.html.plaintext.txt	282	In addition using mutants E2 proteins could show apoptosis linked cytoplasmic expression E2 linking apoptosis nucleo cytoplasmic shuttling rather inherent properties E2 protein
0.2730276.16135518.html.plaintext.txt	283	There several viral proteins shown activate apoptosis infected cells various mechanisms review see Refs
0.2730276.16135518.html.plaintext.txt	284	38 40 although exact role specific function viral life cycle generally fully understood
0.2730276.16135518.html.plaintext.txt	285	Among viral proteins shown induce apoptosis caspase 8 activation lyssavirus matrix protein 41 NS3 protein hepatitis C 42 HBx hepatitis B
0.2730276.16135518.html.plaintext.txt	286	HBx among various pleiotropic functions transcription factor expressed nucleus cytoplasm infected cells
0.2730276.16135518.html.plaintext.txt	287	The cytoplasmic HBx protein activate caspase 8 repressing c FLIP direct protein interaction rendering cells hypersensitive tumor necrosis apoptotic activation 43
0.2730276.16135518.html.plaintext.txt	288	Nucleo cytoplasmic shuttling proteins frequent event accompanying induction apoptosis
0.2730276.16135518.html.plaintext.txt	289	Many apoptotic proteins expressed specific cellular compartment efficient probably allow direct protein protein interactions
0.2730276.16135518.html.plaintext.txt	290	Examples viral proapototic proteins expressed cytoplasm nucleus infected cells apoptin viral protein associated chicken anemia E4orf4 adenovirus
0.2730276.16135518.html.plaintext.txt	291	Contrary E2 apoptin expressed nucleus exert proapoptotic function 44
0.2730276.16135518.html.plaintext.txt	292	In contrast E4orf4 exerted proapoptotic activity two distinct pathways one nucleus cytoplasm 45
0.2730276.16135518.html.plaintext.txt	293	Caspase 8 activation occurs via extrinsic death pathway consequence activation death inducing signal complex death receptors cytoplasmic membrane 46
0.2730276.16135518.html.plaintext.txt	294	Because E2 intracellular protein caspase activation might occur within cytoplasm direct action proteins death inducing signal complex directly caspase 8
0.2730276.16135518.html.plaintext.txt	295	We yet know exact mechanism E2 activates apoptosis clearly due direct interactions E2 cytoplasmic substructures containing activated caspase 8 results shown
0.2730276.16135518.html.plaintext.txt	296	Why might viruses induce apoptosis infected cells A plethora viral proteins inducing apoptosis described indicating proapoptotic functions play universal role viral life cycle review see Refs
0.2730276.16135518.html.plaintext.txt	297	One possibility apoptosis might help newly created particles end viral life cycle escape host cell spread
0.2730276.16135518.html.plaintext.txt	298	This hypothesis however raises question function conserved low risk HPVs
0.2730276.16135518.html.plaintext.txt	299	There least two possibilities
0.2730276.16135518.html.plaintext.txt	300	First low risk E2 proteins could efficient inducing apoptosis physiological situation co expression viral proteins instance could help E2 shuttle cytoplasm
0.2730276.16135518.html.plaintext.txt	301	This particularly attractive hypothesis since shown low risk HPV E2 proteins induce apoptosis artificially directed cytoplasm infected cells
0.2730276.16135518.html.plaintext.txt	302	Another possibility function expressed another viral protein E4 instance viral protein expressed later time points viral cycle shown induce apoptosis 48
0.2730276.16135518.html.plaintext.txt	303	An alternative hypothesis E6 E7 proteins high risk HPVs modify cell cycle block cellular differentiation
0.2730276.16135518.html.plaintext.txt	304	These modifications host cell biology might induce greater resistance apoptosis specifically reduction p53 expression 49
0.2730276.16135518.html.plaintext.txt	305	The proapoptotic activity high risk E2 proteins would required overcome effects contrary low risk infected cells many E6 E7 functions conserved
0.2730276.16135518.html.plaintext.txt	306	The proapoptotic activity high risk E2 proteins however could explain high risk viral genomes integrated cellular DNA preferentially disruption E2 ORF disruption leading higher transcription E6 E7 oncogenes carcinogenic progression
0.2730276.16135518.html.plaintext.txt	307	FOOTNOTES This work supported Association pour la Recherche sur le Cancer Ligue Contre le Cancer comite de Paris
0.2730276.16135518.html.plaintext.txt	308	The costs publication article defrayed part payment page charges
0.2730276.16135518.html.plaintext.txt	309	This article must therefore hereby marked advertisement accordance 18 U
0.2730276.16135518.html.plaintext.txt	310	Section 1734 solely indicate fact
0.2730276.16135518.html.plaintext.txt	311	1 Supported Ministere de lEducation Nationale de la Recherche et de la Technologie fellowship fellowship Association pour la Recherche sur le Cancer
0.2730276.16135518.html.plaintext.txt	312	2 Supported Association pour la Recherche sur le Cancer fellowship
0.2730276.16135518.html.plaintext.txt	313	3 To correspondence addressed
0.2730276.16135518.html.plaintext.txt	314	33 1 45688526 Fax 33 1 40613033 E mail fthierryatpasteur
0.2730276.16135518.html.plaintext.txt	315	4 The abbreviations used HPV human Papillomavirus GFP green fluorescent protein ORF open reading frame NES nuclear export sequence Z VAD benzyloxycarbonyl Val Ala Asp PBS phosphate buffered saline NLS nuclear localization signals sub 2N less 2N chromosomes
0.2730276.16135518.html.plaintext.txt	316	ACKNOWLEDGMENTS We thank Jacques Archambault gift HPV6 HPV11 E2 expression vectors antibodies
0.2730276.16135518.html.plaintext.txt	317	We thank Peter Beard gift HPV16 E2 antibodies
0.2730276.16135518.html.plaintext.txt	318	We thank Jonathan Weitzman Moshe Yaniv critical reading manuscript
0.2730276.16135518.html.plaintext.txt	319	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Werness B
0.2730276.16135518.html.plaintext.txt	320	1990 Science 248 76 79Medline Order article via Infotrieve Scheffner M
0.2730276.16135518.html.plaintext.txt	321	1990 Cell 63 1129 1136CrossRefMedline Order article via Infotrieve Munger K
0.2730276.16135518.html.plaintext.txt	322	89 213 228CrossRefMedline Order article via Infotrieve Thierry F
0.2730276.16135518.html.plaintext.txt	323	6 3391 3397Abstract Demeret C
0.2730276.16135518.html.plaintext.txt	324	68 7075 7082Abstract Dong G
0.2730276.16135518.html.plaintext.txt	325	68 1115 1127Abstract Tan S
0.2730276.16135518.html.plaintext.txt	326	68 6411 6420Abstract Chin M
0.2730276.16135518.html.plaintext.txt	327	62 2994 3002Medline Order article via Infotrieve Dostatni N
0.2730276.16135518.html.plaintext.txt	328	5 1657 1671Abstract Thierry F
0.2730276.16135518.html.plaintext.txt	329	3 90 100Medline Order article via Infotrieve Romanczuk H
0.2730276.16135518.html.plaintext.txt	330	64 2849 2859Medline Order article via Infotrieve Tan S
0.2730276.16135518.html.plaintext.txt	331	20 251 256Abstract Desaintes C
0.2730276.16135518.html.plaintext.txt	332	7 339 347CrossRefMedline Order article via Infotrieve Hegde R
0.2730276.16135518.html.plaintext.txt	333	31 343 360CrossRefMedline Order article via Infotrieve Abbate E
0.2730276.16135518.html.plaintext.txt	334	18 1981 1996AbstractFree Full Text Antson A
0.2730276.16135518.html.plaintext.txt	335	2000 Nature 403 805 809CrossRefMedline Order article via Infotrieve Wang Y
0.2730276.16135518.html.plaintext.txt	336	279 6976 6985AbstractFree Full Text Desaintes C
0.2730276.16135518.html.plaintext.txt	337	1999 Oncogene 18 4538 4546CrossRefMedline Order article via Infotrieve Demeret C
0.2730276.16135518.html.plaintext.txt	338	2003 Oncogene 22 168 175CrossRefMedline Order article via Infotrieve Webster K
0.2730276.16135518.html.plaintext.txt	339	275 87 94AbstractFree Full Text You J
0.2730276.16135518.html.plaintext.txt	340	2004 Cell 117 349 360CrossRefMedline Order article via Infotrieve Van Tine B
0.2730276.16135518.html.plaintext.txt	341	101 4030 4035AbstractFree Full Text Bellanger S
0.2730276.16135518.html.plaintext.txt	342	2005 Cell Cycle 4 press Bellanger S
0.2730276.16135518.html.plaintext.txt	343	75 7244 7251AbstractFree Full Text Hegde R
0.2730276.16135518.html.plaintext.txt	344	284 1479 1489CrossRefMedline Order article via Infotrieve Yasugi T
0.2730276.16135518.html.plaintext.txt	345	71 891 899Abstract Crouzet J
0.2730276.16135518.html.plaintext.txt	346	94 1414 1419AbstractFree Full Text Desaintes C
0.2730276.16135518.html.plaintext.txt	347	16 504 514AbstractFree Full Text Dowhanick J
0.2730276.16135518.html.plaintext.txt	348	69 7791 7799Abstract Hwang E
0.2730276.16135518.html.plaintext.txt	349	67 3720 3729Abstract Hwang E
0.2730276.16135518.html.plaintext.txt	350	1996 Oncogene 12 795 803Medline Order article via Infotrieve Skiadopoulos M
0.2730276.16135518.html.plaintext.txt	351	70 1117 1124Abstract Zou N
0.2730276.16135518.html.plaintext.txt	352	74 3761 3770AbstractFree Full Text Bogerd H
0.2730276.16135518.html.plaintext.txt	353	16 4207 4214Abstract Otero G
0.2730276.16135518.html.plaintext.txt	354	72 7593 7597AbstractFree Full Text Henderson B
0.2730276.16135518.html.plaintext.txt	355	256 213 224CrossRefMedline Order article via Infotrieve Rowland R
0.2730276.16135518.html.plaintext.txt	356	95 23 33CrossRefMedline Order article via Infotrieve Boya P
0.2730276.16135518.html.plaintext.txt	357	Acta 1659 178 189Medline Order article via Infotrieve Irusta P
0.2730276.16135518.html.plaintext.txt	358	15 700 705CrossRefMedline Order article via Infotrieve Roulston A
0.2730276.16135518.html.plaintext.txt	359	53 577 628CrossRefMedline Order article via Infotrieve Kassis R
0.2730276.16135518.html.plaintext.txt	360	78 6543 6555AbstractFree Full Text Prikhodko E
0.2730276.16135518.html.plaintext.txt	361	2004 Virology 329 53 67CrossRefMedline Order article via Infotrieve Kim K
0.2730276.16135518.html.plaintext.txt	362	22 2104 2116AbstractFree Full Text Teodoro J
0.2730276.16135518.html.plaintext.txt	363	18 1952 1957AbstractFree Full Text Robert A
0.2730276.16135518.html.plaintext.txt	364	158 519 528AbstractFree Full Text Kischkel F
0.2730276.16135518.html.plaintext.txt	365	14 5579 5588Abstract Ameisen J
0.2730276.16135518.html.plaintext.txt	366	78 7199 7207AbstractFree Full Text Finzer P
0.2730276.16135518.html.plaintext.txt	367	188 15 24CrossRefMedline Order article via Infotrieve This Article Abstract Full Text PDF All Versions Article 2804336088 recent M505138200v1 Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Copyright Permissions Google Scholar Articles Blachon S
0.2730276.16135518.html.plaintext.txt	368	PubMed PubMed Citation Articles Blachon S
0.2730276.16135518.html.plaintext.txt	369	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS All ASBMB Journals Molecular Cellular Proteomics Journal Lipid Research Biochemistry Molecular Biology Education Copyright 2005 American Society Biochemistry Molecular Biology
0.26717928.9060466.html.plaintext.txt	0	Microtubule mediated Transport Incoming Herpes Simplex Virus 1 Capsids Nucleus
0.26717928.9060466.html.plaintext.txt	1	Yale University School Medicine Department Cell Biology New Haven Connecticut 06520 8002 Abstract Materials Methods Results Discussion Footnotes Abbreviations used paper References
0.26717928.9060466.html.plaintext.txt	2	Herpes simplex virus 1 fuses plasma membrane host cell incoming capsids efficiently rapidly transported across cytosol nuclear pore complexes viral DNA genomes released nucleoplasm
0.26717928.9060466.html.plaintext.txt	3	Using biochemical assays immunofluorescence immunoelectron microscopy presence absence microtubule depolymerizing agents shown cytosolic capsid transport Vero cells mediated microtubules
0.26717928.9060466.html.plaintext.txt	4	Antibody labeling revealed attachment dynein minus end directed microtubule dependent motor viral capsids
0.26717928.9060466.html.plaintext.txt	5	We propose incoming capsids bind microtubules use dynein propel cell periphery nucleus
0.26717928.9060466.html.plaintext.txt	6	The entry animal viruses host cells involves adsorption cell surface receptors penetration cytosol uncoating viral genome
0.26717928.9060466.html.plaintext.txt	7	For viruses replicate nucleus entry also entails extensive movement viruses viral capsids cytoplasm
0.26717928.9060466.html.plaintext.txt	8	Transport long distances particularly critical viruses infect neurons site entry located far cell body nucleus
0.26717928.9060466.html.plaintext.txt	9	Since movement virus sized particles cytosol likely occur free diffusion due high viscosity steric obstacles Bray 1992 Luby Phelps 1994 viruses likely exploit cells motile functions transport
0.26717928.9060466.html.plaintext.txt	10	The limited information available suggests viruses make use microtubules MT1 actin filaments
0.26717928.9060466.html.plaintext.txt	11	EM analysis shown MT binding certain viral capsids adenovirus reovirus vivo vitro review see Luftig 1982 well herpes simplex virus 1 HSV 1 neurons Lycke et al
0.26717928.9060466.html.plaintext.txt	12	Way co workers described actin filament dependent intra intercellular transport vaccinia virus egress cells Cudmore et al
0.26717928.9060466.html.plaintext.txt	13	Moreover many viruses take advantage retrograde movement endocytic organelles entry
0.26717928.9060466.html.plaintext.txt	14	They internalized receptor mediated endocytosis carried within coated vesicles endosomes cell periphery toward perinuclear area cell see Greber et al
0.26717928.9060466.html.plaintext.txt	15	1994 Marsh Helenius 1989
0.26717928.9060466.html.plaintext.txt	16	In study focused intracytosolic transport incoming HSV 1 capsids Vero cells
0.26717928.9060466.html.plaintext.txt	17	HSV 1 three structural components capsid tegument envelope
0.26717928.9060466.html.plaintext.txt	18	The capsid consists viral DNA 152 kbp proteinaceous shell comprising six different proteins diameter 125 nm proteins arranged icosahedron formed 12 pentons 150 hexons Booy et al
0.26717928.9060466.html.plaintext.txt	19	1974 Spear Roizman 1972
0.26717928.9060466.html.plaintext.txt	20	VP5 constitutes major protein component hexons pentons Newcomb et al
0.26717928.9060466.html.plaintext.txt	21	The tegument protein layer envelope capsid contains 12 different viral polypeptides Roizman Furlong 1974 Roizman Sears 1996
0.26717928.9060466.html.plaintext.txt	22	While functions remain identified one protein kinase LeMaster Roizman 1980 one induces shut host cell protein synthesis Read Frenkel 1983 known activators modulators viral gene expression Batterson Roizman 1983 Campbell et al
0.26717928.9060466.html.plaintext.txt	23	The viral envelope contains least 12 different membrane proteins involved receptor binding fusion
0.26717928.9060466.html.plaintext.txt	24	The infectious cycle begins virus binding heparan sulfate receptors cell surface followed glycoprotein mediated fusion envelope plasma membrane review see Spear 1993
0.26717928.9060466.html.plaintext.txt	25	After release cytosol dissociation tegument components capsids move cytosol nucleus bind nuclear pores Batterson et al
0.26717928.9060466.html.plaintext.txt	26	1988 whereafter genome released nucleus
0.26717928.9060466.html.plaintext.txt	27	Transcription replication viral DNA assembly progeny capsids take place within host nucleus review see Roizman Sears 1996 Steven Spear 1996
0.26717928.9060466.html.plaintext.txt	28	The synthesis early viral proteins peaks 4 6 h virus entry first progeny viruses produced 8 h Honess Roizman 1973
0.26717928.9060466.html.plaintext.txt	29	We analyzed transport incoming HSV 1 capsids nucleus fibroblasts found occurs rapidly efficiently MT mediated mechanism
0.26717928.9060466.html.plaintext.txt	30	The incoming capsids shed associated tegument proteins bind dynein MT dependent minus end directed motor peripheral cytosol whereafter transported along MT toward cell center
0.26717928.9060466.html.plaintext.txt	31	The viral capsids thus make use machinery responsible retrograde organelle transport animal cells
0.26717928.9060466.html.plaintext.txt	32	Materials Methods Cells Antibodies
0.26717928.9060466.html.plaintext.txt	33	BHK 21 cells grown Glasgows MEM 5 FCS 10 tryptose phosphate broth Vero cells grown MEM 7
0.26717928.9060466.html.plaintext.txt	34	5 FCS nonessential amino acids
0.26717928.9060466.html.plaintext.txt	35	Both media contained 100 Uml penicillin 100 microgml streptomycin 2 mM glutamine
0.26717928.9060466.html.plaintext.txt	36	All tissue culture reagents obtained GIBCO BRL Gaithersburg MD
0.26717928.9060466.html.plaintext.txt	37	Both cell lines maintained adherent cultures 5 CO2 humid incubator 37 degrees C passaged twice week
0.26717928.9060466.html.plaintext.txt	38	We used rabbit polyclonal antibodies VP 5 NC 1 VP 19c NC 2 DNA containing capsids anti HC empty capsids anti LC provided Roselyn Eisenberg Gary Cohen University Pennsylvania Philadelphia mouse mAb 8F5 VP5 provided William Newcomb Jay Brown University Virginia Charlottesville
0.26717928.9060466.html.plaintext.txt	39	All rabbit polyclonal antibodies viral proteins preadsorbed paraformaldehyde PFA fixed Triton X 100 TX 100 permeabilized Vero cells
0.26717928.9060466.html.plaintext.txt	40	They used highest possible concentration giving signal noninfected cells
0.26717928.9060466.html.plaintext.txt	41	An mAb ICP4 early herpes protein obtained Advanced Biotechnologies Inc
0.26717928.9060466.html.plaintext.txt	42	We used mouse monoclonal anti tubulin 1A2 provided Dr
0.26717928.9060466.html.plaintext.txt	43	Thomas Kreis University Geneva Switzerland Kreis 1987 rabbit antipeptide anti calnexin Hammond Helenius 1994 rabbit polyclonal affinity purified antibody directed bacterially expressed fragment dynein heavy chain provided Dr
0.26717928.9060466.html.plaintext.txt	44	Eugeni Vaisberg University Colorado Boulder Vaisberg et al
0.26717928.9060466.html.plaintext.txt	45	Fluorescently labeled secondary antibodies Texas red fluorescein conjugated goat anti rabbit goat anti mouse obtained Jackson ImmunoResearch Laboratories West Grove PA rabbit anti mouse obtained Organon Teknika Cappel Durham NC
0.26717928.9060466.html.plaintext.txt	46	HSV 1 strain F designated passage 1 obtained American Type Culture Collection Rockville MD
0.26717928.9060466.html.plaintext.txt	47	BHK 21 cells grown confluency 37 degrees C 3 d infected 8 ml175 cm2 flask MEM containing 0
0.26717928.9060466.html.plaintext.txt	48	01 plaque forming units PFU per cell
0.26717928.9060466.html.plaintext.txt	49	After 2 h 25 ml per flask normal medium added cells 3 d medium containing secreted extracellular virus collected
0.26717928.9060466.html.plaintext.txt	50	All following steps performed 4 degrees C
0.26717928.9060466.html.plaintext.txt	51	Cells debris removed spinning 2000 rpm 10 min virus collected centrifugation medium using JA 14 rotor Beckman Instruments Inc
0.26717928.9060466.html.plaintext.txt	52	Palo Alto CA 12000 rpm 90 min
0.26717928.9060466.html.plaintext.txt	53	The resulting pellets resuspended gentle shaking overnight MNT buffer 30 mM MES 100 mM NaCl 20 mM Tris pH 7
0.26717928.9060466.html.plaintext.txt	54	After waterbath sonification 4 degrees C three times 30 suspension derived 30 flasks layered top one linear 10 40 wtvol sucrose gradient MNT buffer centrifuged Beckman SW28 15000 rpm 45 min
0.26717928.9060466.html.plaintext.txt	55	The virus containing band middle gradient detected light scattering collected 3 ml per gradient aliquoted snap frozen liquid nitrogen stored 80 degrees C
0.26717928.9060466.html.plaintext.txt	56	All experiments described carried gradient purified virus passage three
0.26717928.9060466.html.plaintext.txt	57	Virus diluted 10 fold steps MEM 0
0.26717928.9060466.html.plaintext.txt	58	2 BSA incubated 24 well dishes confluent Vero cells 1 2 h 37 degrees C humidified 5 CO2 incubator
0.26717928.9060466.html.plaintext.txt	59	Unbound virus removed three washes MEM BSA cells incubated normal medium 30 h
0.26717928.9060466.html.plaintext.txt	60	Plaques counted using dissecting microscope fixation absolute methanol 20 degrees C Giemsa staining
0.26717928.9060466.html.plaintext.txt	61	Titers 109 1010 PFUml protein concentrations 0
0.26717928.9060466.html.plaintext.txt	62	5 2 mgml obtained using protocol
0.26717928.9060466.html.plaintext.txt	63	Preparation 3HThymidine labeled virus
0.26717928.9060466.html.plaintext.txt	64	BHK cells grown 850cm2 roller bottle 70 confluency infected multiplicity infection MOI 0
0.26717928.9060466.html.plaintext.txt	65	2 wtvol containing 20 mM Hepes pH 7
0.26717928.9060466.html.plaintext.txt	66	At 2 h postinfection PI inoculum removed normal growth medium containing 5 mCi methyl 3Hthymidine Amersham Lifescience Amersham UK added
0.26717928.9060466.html.plaintext.txt	67	After 2 d cells medium collected transferred 4 degrees C cells pelleted low speed spin resulting supernatant spun Beckman SW40Ti 13700 rpm 2 h
0.26717928.9060466.html.plaintext.txt	68	The pellet resuspended gentle shaking overnight MNT buffer layered onto linear 10 40 wtvol sucrose gradient MNT buffer spun Beckman SW40Ti 15800 rpm 1 h
0.26717928.9060466.html.plaintext.txt	69	The gradient fractionated 1 ml fractions radioactivity fraction determined scintillation counting
0.26717928.9060466.html.plaintext.txt	70	The peak fractions pooled aliquoted snap frozen stored 80 degrees C
0.26717928.9060466.html.plaintext.txt	71	This preparation titer 1 x 107 PFUml contained 0
0.26717928.9060466.html.plaintext.txt	72	Cells inoculated virus 2 h 4 degrees C constant rocking RPMI medium containing 0
0.26717928.9060466.html.plaintext.txt	73	2 wtvol BSA 20 mM Hepes pH 6
0.26717928.9060466.html.plaintext.txt	74	Viral infection initiated shifting cells growth medium 37 degrees C humidified 5 CO2 incubator
0.26717928.9060466.html.plaintext.txt	75	In experiments analyzing incoming viral particles 0
0.26717928.9060466.html.plaintext.txt	76	5 mM cycloheximide added medium prevent synthesis new viral proteins progeny virus
0.26717928.9060466.html.plaintext.txt	77	In experiments cells incubated 1 h infection normal medium containing 2 microM nocodazole 10 microM vinblastine 2 microM colchicine 20 microM taxol 0
0.26717928.9060466.html.plaintext.txt	78	5 microM cytochalasin D maintained drugs infection
0.26717928.9060466.html.plaintext.txt	79	Nocodazole stored stock 20 mM vinblastine 10 mM colchicine 20 mM taxol 20 mM cytochalasin D 10 mM DMSO 20 degrees C
0.26717928.9060466.html.plaintext.txt	80	Vero cells grown culture dishes glass coverslips flat embedding 1 d confluency infected HSV 1 MOI 500 PFU per cell 150 PFUcell nocodazole experiment presence cycloheximide
0.26717928.9060466.html.plaintext.txt	81	The virus dialyzed infection RPMI containing 0
0.26717928.9060466.html.plaintext.txt	82	2 BSA 2 h 75 kD cut remove sucrose
0.26717928.9060466.html.plaintext.txt	83	The infected cells analyzed three different protocols
0.26717928.9060466.html.plaintext.txt	84	The cells fixed 1 glutaraldehyde GA 200 mM cacodylate pH 7
0.26717928.9060466.html.plaintext.txt	85	4 2 GA PBS containing 0
0.26717928.9060466.html.plaintext.txt	86	5 mM CaCl2 1 mM MgCl2 30 min room temperature MT analysis treated 1 OsO4 1 h 30 min MT treated 2 uranyl acetate 50 mM maleate buffer pH 5
0.26717928.9060466.html.plaintext.txt	87	2 1 h dehydrated using graded ethanol series propylenoxid pelleted embedding Epon cutting flat embedded Epon cut parallel substrate MT
0.26717928.9060466.html.plaintext.txt	88	Flat Embedding Extracted Immunolabeled Cells
0.26717928.9060466.html.plaintext.txt	89	5 Triton X 100 MT stabilizing buffer MT buffer 80 mM Pipes KOH pH 6
0.26717928.9060466.html.plaintext.txt	90	8 5 mM EDTA 1 mM MgSO4 10 microM taxol 2 min 37 degrees C 4 degrees C 0 min time point addition twofold fixative 2 GA MT buffer Baas Ahmad 1992
0.26717928.9060466.html.plaintext.txt	91	The cells fixed 20 min room temperature rinsed PBS remaining fixative inactivated three rounds freshly prepared 2 mgml sodium borohydride PBS pH 7
0.26717928.9060466.html.plaintext.txt	92	After blocking 10 FCS PBS cells incubated primary antibody secondary rabbit anti mouse antibody primary rabbit antibody 9 nm protein A gold University Utrecht The Netherlands 10 FCS PBS 30 min room temperature extensive washings PBS
0.26717928.9060466.html.plaintext.txt	93	After second fixation 1 GA 2 mgml tannic acid 100 mM cacodylate buffer pH 7
0.26717928.9060466.html.plaintext.txt	94	4 10 min cells contrasted using 2 OsO4 10 min 2 uranyl acetate 50 mM maleate buffer pH 5
0.26717928.9060466.html.plaintext.txt	95	They embedded Epon ultrathin sections parallel substrate prepared
0.26717928.9060466.html.plaintext.txt	96	All Epon sections first second protocols contrasted using lead citrate uranyl acetate
0.26717928.9060466.html.plaintext.txt	97	The cells transferred 4 degrees C removed culture dish either proteinase K treatment 25 microgml 2 3 min ice fixed 4 paraformaldehyde 0
0.26717928.9060466.html.plaintext.txt	98	4 fixed first 20 min collected scraping
0.26717928.9060466.html.plaintext.txt	99	After pelleting cells fixed overnight
0.26717928.9060466.html.plaintext.txt	100	The pellets infiltrated 20 wtvol polyvinyl pyrolidone 2
0.26717928.9060466.html.plaintext.txt	101	0 M sucrose PBS frozen liquid nitrogen ultrathin sections cut 100 degrees 120 degrees C immunolabeled previously described Griffiths 1993a Sodeik et al
0.26717928.9060466.html.plaintext.txt	102	To analyze efficiency capsid transport nucleus see Fig
0.26717928.9060466.html.plaintext.txt	103	5 25 EM negatives infected flat embedded cells taken magnification 5800 systematic random fashion time point Griffiths 1993b
0.26717928.9060466.html.plaintext.txt	104	The negatives analyzed dissecting microscope number localization cytosolic capsids determined
0.26717928.9060466.html.plaintext.txt	105	Capsids within 100 nm plasma membrane scored plasma membrane within 50 nm MT nuclear pore complex
0.26717928.9060466.html.plaintext.txt	106	The remaining capsids scored apparently free cytosol
0.26717928.9060466.html.plaintext.txt	107	Virions present endosomes also counted
0.26717928.9060466.html.plaintext.txt	108	To quantify effect nocodazole see Fig
0.26717928.9060466.html.plaintext.txt	109	7 50 negatives conventionally embedded cells infected presence absence nocodazole 10 microM taken systematic random fashion
0.26717928.9060466.html.plaintext.txt	110	Cytosolic capsids scored plasma membrane cytosol nuclear pore complex
0.26717928.9060466.html.plaintext.txt	111	To quantify dynein labeling 25 micrographs cryosections taken magnification 16900
0.26717928.9060466.html.plaintext.txt	112	Since incoming herpes capsids rare structures specimen systematically translated defined direction micrograph taken every time cytosolic capsid came view
0.26717928.9060466.html.plaintext.txt	113	7 area structure outlined virions capsids mitochondria nuclei cytoplasm
0.26717928.9060466.html.plaintext.txt	114	A lattice grid placed prints number points gold particles falling structure counted
0.26717928.9060466.html.plaintext.txt	115	The formula GPd2 gives labeling density gold particles per microm2 G number gold particles P number points lattice grid structure d distance points Griffiths 1993b
0.26717928.9060466.html.plaintext.txt	116	Vero cells infected MOI 500 presence CH fixed various times postinfection 2 glutaraldehyde PBS embedded Epon EM analysis
0.26717928.9060466.html.plaintext.txt	117	Schematic cross section perpendicular substrate adherent Vero cell
0.26717928.9060466.html.plaintext.txt	118	For quantitation 25 random electron micrographs obtained sections cut parallel substrate basal part cells taken systematic fashion time point
0.26717928.9060466.html.plaintext.txt	119	Basal defined within 2 microm distance substrate 30 sections 50 70 nm
0.26717928.9060466.html.plaintext.txt	120	b The total numbers cytosolic capsids full empty cytosolic empty capsids virions endosomes determined time point
0.26717928.9060466.html.plaintext.txt	121	The number cytosolic capsids increased rapidly 1 h postinfection
0.26717928.9060466.html.plaintext.txt	122	At later time points less cytosolic capsids detected suggesting ultimately disassembled
0.26717928.9060466.html.plaintext.txt	123	In addition subcellular localization capsid determined numbers expressed percentage total c g
0.26717928.9060466.html.plaintext.txt	124	c At earliest time point 15 min majority cytosolic capsids localized close plasma membrane disappeared rapidly later
0.26717928.9060466.html.plaintext.txt	125	d Several capsids could localized particular organelle
0.26717928.9060466.html.plaintext.txt	126	At 1 h postinfection highest amount capsids apparently free cytosol
0.26717928.9060466.html.plaintext.txt	127	e A significant portion cytosolic capsids namely 10 1 h postinfection colocalized transiently microtubules
0.26717928.9060466.html.plaintext.txt	128	f Capsids began appear nuclear pores 2 h postinfection 4 h 60 cytosolic capsid reached nucleus
0.26717928.9060466.html.plaintext.txt	129	g The appearance empty cytosolic capsids coincided arrival nucleus
0.26717928.9060466.html.plaintext.txt	130	Only 4 h postinfection small portion empty cytosolic capsids
0.26717928.9060466.html.plaintext.txt	131	N nucleus PM plasma membrane
0.26717928.9060466.html.plaintext.txt	132	View Larger Version Image 21K GIF file
0.26717928.9060466.html.plaintext.txt	133	Quantitation capsid transport viral protein synthesis absence MTs
0.26717928.9060466.html.plaintext.txt	134	Vero cells infected MOI 170 presence CH absence presence nocodazole depolymerize microtubules
0.26717928.9060466.html.plaintext.txt	135	They fixed 2 4 b h postinfection 1 GA collected scraping pelleting Epon sections prepared
0.26717928.9060466.html.plaintext.txt	136	For quantitation 50 random electron micrographs obtained systematic fashion time point treatments
0.26717928.9060466.html.plaintext.txt	137	The subcellular localization cytosolic capsid determined
0.26717928.9060466.html.plaintext.txt	138	At 2 h postinfection presence microtubules majority cytosolic capsids localized cytosol significant fraction reached nucleus
0.26717928.9060466.html.plaintext.txt	139	In absence microtubules majority capsids remained plasma membrane PM cytosol none reached nucleus
0.26717928.9060466.html.plaintext.txt	140	b At 4 h 70 capsids reached nucleus
0.26717928.9060466.html.plaintext.txt	141	In presence nocodazole much smaller fraction transported nucleus capsids remained plasma membrane cytosol
0.26717928.9060466.html.plaintext.txt	142	Vero cells infected MOI 0
0.26717928.9060466.html.plaintext.txt	143	5 without CH absence presence 5 microM nocodazole various times
0.26717928.9060466.html.plaintext.txt	144	The cells harvested lysed 0
0.26717928.9060466.html.plaintext.txt	145	5 TX 100 buffer nuclei pelleted supernatants analyzed immunoblotting
0.26717928.9060466.html.plaintext.txt	146	To monitor viral protein synthesis antibodies ICP4 early viral protein VP5 late viral protein used
0.26717928.9060466.html.plaintext.txt	147	Calnexin membrane bound ER protein used cellular marker protein
0.26717928.9060466.html.plaintext.txt	148	Equal amounts protein loaded per lane amount ICP4 VP5 normalized amount calnexin
0.26717928.9060466.html.plaintext.txt	149	ICP4 synthesis commences 2 h PI whereas VP5 first detectable 5 h PI
0.26717928.9060466.html.plaintext.txt	150	The amount ICP4 maximal 6 h PI
0.26717928.9060466.html.plaintext.txt	151	In contrast VP5 synthesis increases whole time course experiment
0.26717928.9060466.html.plaintext.txt	152	At time points lower amounts ICP4 VP5 synthesized absence microtubules
0.26717928.9060466.html.plaintext.txt	153	View Larger Version Image 12K GIF file
0.26717928.9060466.html.plaintext.txt	154	Quantitation Virus Binding Internalization
0.26717928.9060466.html.plaintext.txt	155	We assayed virus binding internalization described previously Helenius et al
0.26717928.9060466.html.plaintext.txt	156	To quantify binding 6 well dishes containing Vero cells grown 2 d confluency set metal plate ice box washed three times ice cold RPMI BSA 3Hthymidinelabeled virus added 1 ml per dish
0.26717928.9060466.html.plaintext.txt	157	After incubation ice various amounts time intensive washings cells scraped 1 ml RPMI BSA pelleted cell associated radioactivity determined scintillation counting
0.26717928.9060466.html.plaintext.txt	158	The data expressed mean values duplicates
0.26717928.9060466.html.plaintext.txt	159	To assay virus internalization 3Hthymidine labeled virus bound cells 4 degrees C 2 h
0.26717928.9060466.html.plaintext.txt	160	The cells washed remove unbound virus shifted normal medium 37 degrees C 5 CO2 various lengths time
0.26717928.9060466.html.plaintext.txt	161	The cells transferred back ice washed stored 4 degrees C last time point
0.26717928.9060466.html.plaintext.txt	162	All following treatments performed 4 degrees C
0.26717928.9060466.html.plaintext.txt	163	The cells washed cold protein free PBS incubated 1 ml per well proteinase K 2 mgml PBS Boehringer Mannheim GmbH Mannheim Germany
0.26717928.9060466.html.plaintext.txt	164	After 1 h 1 ml PBS containing 1
0.26717928.9060466.html.plaintext.txt	165	25 mM PMSF 3 wtvol BSA added stop proteolysis
0.26717928.9060466.html.plaintext.txt	166	The cells collected wells rinsed wash buffer PBS containing 0
0.26717928.9060466.html.plaintext.txt	167	2 BSA cells along wash buffer spun 1500 rpm 10 min
0.26717928.9060466.html.plaintext.txt	168	The pellet resuspended pelleted scintillation liquid added resuspended pellet 0
0.26717928.9060466.html.plaintext.txt	169	5 ml counted liquid scintillation counter
0.26717928.9060466.html.plaintext.txt	170	The amount internalized virus expressed cell associated 3Hthymidine counts mean value triplicates
0.26717928.9060466.html.plaintext.txt	171	Control cells warmed virus binding showed proteinase K treatment removed 90 95 cell bound virus
0.26717928.9060466.html.plaintext.txt	172	Vero cells grown coverslips 1 2 d 70 confluency infected HSV 1 MOI 50 PFU per cell presence cycloheximide
0.26717928.9060466.html.plaintext.txt	173	In one protocol cells fixed 3 wtvol paraformaldehyde 20 min followed quenching remaining fixative using 50 mM NH4Cl 10 min permeabilization 0
0.26717928.9060466.html.plaintext.txt	174	Here incubations carried PBS pH 7
0.26717928.9060466.html.plaintext.txt	175	In alternative protocol cells preextracted 0
0.26717928.9060466.html.plaintext.txt	176	5 TX100 10 37 degrees C MT stabilizing buffer 80 mM Pipes 2 mM MgSO4 pH 6
0.26717928.9060466.html.plaintext.txt	177	8 10 microM taxol fixed 100 methanol 20 degrees C 4 min
0.26717928.9060466.html.plaintext.txt	178	Before immunolabeling room temperature cells protocols washed PBS transferred 10 normal goat serum 30 min labeled primary antibody 10 goat serum 20 min
0.26717928.9060466.html.plaintext.txt	179	The coverslips rinsed three times 5 min incubated fluorescently labeled secondary antibodies 10 goat serum 20 min
0.26717928.9060466.html.plaintext.txt	180	For double labeling experiments two primary two secondary antibodies applied simultaneously
0.26717928.9060466.html.plaintext.txt	181	After extensive washing one short wash water coverslips mounted Mowiol containing 2
0.26717928.9060466.html.plaintext.txt	182	5 wtvol 14 diazabicyclo 2
0.26717928.9060466.html.plaintext.txt	183	2octane glass slides examined Axiophot fluorescence microscope Carl Zeiss Inc
0.26717928.9060466.html.plaintext.txt	184	Thornwood NY confocal fluorescence microscope Bio Rad Laboratories Hercules CA
0.26717928.9060466.html.plaintext.txt	185	Image processing performed using Adobe Photoshop Adobe Systems Inc
0.26717928.9060466.html.plaintext.txt	186	Assay Viral Protein Synthesis
0.26717928.9060466.html.plaintext.txt	187	Confluent Vero cells grown 6 cm tissue culture dishes infected HSV 1 MOI 0
0.26717928.9060466.html.plaintext.txt	188	5 PFU per cell 30 min 37 degrees C 5 CO2 MEM containing 0
0.26717928.9060466.html.plaintext.txt	189	2 wtvol BSA incubated normal growth medium
0.26717928.9060466.html.plaintext.txt	190	At various time points transferred 4 degrees C washed three times ice cold PBS scraped pelleted resuspended 0
0.26717928.9060466.html.plaintext.txt	191	3 ml per dish lysis buffer MNT 0
0.26717928.9060466.html.plaintext.txt	192	5 TX 100 2 mM DTT 2 mM EDTA 10 microgml chymostatin leupeptin antipain pepstatin
0.26717928.9060466.html.plaintext.txt	193	The nuclei removed centrifugation 5000 rpm 5 min
0.26717928.9060466.html.plaintext.txt	194	A 50 microl aliquot resulting supernatant used protein assays bicinchoninic assay Pierce Chemical Co
0.26717928.9060466.html.plaintext.txt	195	2 ml solubilized 5 x Laemmli sample buffer
0.26717928.9060466.html.plaintext.txt	196	Equal amounts protein loaded onto 7
0.26717928.9060466.html.plaintext.txt	197	5 SDS polyacrylamide gel electrophoresis separated proteins blotted onto nitrocellulose membranes using semidry blotter
0.26717928.9060466.html.plaintext.txt	198	After blocking 5 lowfat milk PBS 0
0.26717928.9060466.html.plaintext.txt	199	1 Tween 20 membranes incubated either anti NC 1 calnexin anti ICP4 calnexin followed HRP conjugated anti rabbit anti mouse secondary antibody Pierce Chemical Co
0.26717928.9060466.html.plaintext.txt	200	The secondary antibodies visualized enhanced chemiluminescence detection Amersham Corp
0.26717928.9060466.html.plaintext.txt	201	Kodak film Eastman Kodak Co
0.26717928.9060466.html.plaintext.txt	202	The bands quantified densitometry using Visage 200 digital gel scanner Bioimage Ann Arbor MI
0.26717928.9060466.html.plaintext.txt	203	The amount viral protein ICP4 VP5 normalized amount cellular protein calnexin
0.26717928.9060466.html.plaintext.txt	204	Results Early Events HSV 1 Entry
0.26717928.9060466.html.plaintext.txt	205	Due large size HSV 1 virions capsids early virus cell interactions readily visualized EM Campadelli Fiume et al
0.26717928.9060466.html.plaintext.txt	206	We followed incoming capsids different stages entry Vero cells Fig
0.26717928.9060466.html.plaintext.txt	207	The extracellular surface bound virus particles familiar features herpes virus membrane envelope spikes capsid electron dense DNA core tegument layer capsid envelope Fig
0.26717928.9060466.html.plaintext.txt	208	Images fusion viral envelope plasma membrane readily obtained Fig
0.26717928.9060466.html.plaintext.txt	209	After fusion capsids appeared separate bulk tegument since electron dense mass remained associated cytoplasmic surface plasma membrane Fig
0.26717928.9060466.html.plaintext.txt	210	1 e f arrowheads see also CampadelliFiume et al
0.26717928.9060466.html.plaintext.txt	211	Ultrathin Epon sections Vero cells infected HSV 1 MOI 500 presence cycloheximide CH
0.26717928.9060466.html.plaintext.txt	212	After 2 h virus binding 4 degrees C cells either fixed immediately b warmed 30 c f 60 min g h
0.26717928.9060466.html.plaintext.txt	213	The main morphological features intact virus bound plasma membrane PM viral envelope b arrowhead viral spikes arrowhead viral capsid arrow electron dense viral DNA genome within capsid
0.26717928.9060466.html.plaintext.txt	214	Upon warming viral envelope fuses plasma membrane capsid arrow tegument proteins released cytosol
0.26717928.9060466.html.plaintext.txt	215	e f Release capsid
0.26717928.9060466.html.plaintext.txt	216	Preparations display prominent contrast tegument show tegument arrowheads stays behind PM
0.26717928.9060466.html.plaintext.txt	217	g h Binding nuclear pore
0.26717928.9060466.html.plaintext.txt	218	At later time points capsids arrows arrived nuclear envelope NE exclusively located close apposition nuclear pore complexes
0.26717928.9060466.html.plaintext.txt	219	Occasionally fibers emanating pores arrowheads visible capsids seem bind
0.26717928.9060466.html.plaintext.txt	220	Almost capsids nuclear pores appear empty lost electron dense DNA core
0.26717928.9060466.html.plaintext.txt	221	View Larger Version Image 91K GIF file
0.26717928.9060466.html.plaintext.txt	222	After 1 h first capsids reached nucleus attached nuclear pore complexes Fig
0.26717928.9060466.html.plaintext.txt	223	1 g h see also Batterson et al
0.26717928.9060466.html.plaintext.txt	224	They seemed bind cytsosolic fibers emerging pores see arrowheads Fig
0.26717928.9060466.html.plaintext.txt	225	Since capsids nuclear envelope lacked electron dense central mass DNA release apparently occurred
0.26717928.9060466.html.plaintext.txt	226	At later time points empty capsids also seen free cytosol without connection nucleus
0.26717928.9060466.html.plaintext.txt	227	Occasionally 1 h postinfection later intact partially degraded virions also seen endosomes lysosomes indicating fraction inoculum taken endocytosis
0.26717928.9060466.html.plaintext.txt	228	The rate efficiency cell surface binding subsequent internalization assayed quantitatively using 3Hthymidine labeled HSV 1
0.26717928.9060466.html.plaintext.txt	229	To monitor binding cells incubated labeled virus MOI 10 50 100 4 degrees C cell associated radioactivity measured different times
0.26717928.9060466.html.plaintext.txt	230	As previously reported continuous increase virus binding observed 4 h signs saturation Fig
0.26717928.9060466.html.plaintext.txt	231	2 McClain Fuller 1994 Shieh et al
0.26717928.9060466.html.plaintext.txt	232	At 2 hthe adsorption period used subsequent experiments 40 added virus bound
0.26717928.9060466.html.plaintext.txt	233	Efficiency kinetics HSV 1 binding internalization
0.26717928.9060466.html.plaintext.txt	234	Using 3Hthymidine labeled virus different multiplicities infection MOI amount virus bound cells 4 degrees C quantified various time points
0.26717928.9060466.html.plaintext.txt	235	There apparent saturation virus binding Vero cells
0.26717928.9060466.html.plaintext.txt	236	After 2 h 40 virus added bound
0.26717928.9060466.html.plaintext.txt	237	b Using 3Hthymidine labeled virus different MOIs amount virus internalized cells quantified various time points
0.26717928.9060466.html.plaintext.txt	238	At time 0 min equals 2 h virus binding 4 degrees C proteinase K treatment removes 95 virus bound plasma membrane
0.26717928.9060466.html.plaintext.txt	239	Upon warming 37 degrees C viral fusion virus protected within cells protease treatment
0.26717928.9060466.html.plaintext.txt	240	After 30 min maximal amount virus 70 bound virus internalized
0.26717928.9060466.html.plaintext.txt	241	The half time t12 internalization 8 min
0.26717928.9060466.html.plaintext.txt	242	Depolymerization microtubules nocodazole ND effect kinetics amount internalization
0.26717928.9060466.html.plaintext.txt	243	View Larger Version Image 17K GIF file
0.26717928.9060466.html.plaintext.txt	244	To follow internalization biochemically protease protection assay used Helenius et al
0.26717928.9060466.html.plaintext.txt	245	After 2 h binding period cold cells warmed 37 degrees C different periods time initiate penetration
0.26717928.9060466.html.plaintext.txt	246	Thereafter chilled 4 degrees C treated proteinase K detach remaining cell surface viruses
0.26717928.9060466.html.plaintext.txt	247	The fraction virus protected protease increased rapidly warming Fig
0.26717928.9060466.html.plaintext.txt	248	2 b half time internalization 8 min
0.26717928.9060466.html.plaintext.txt	249	The overall protease resistance reached level 70 within 30 min
0.26717928.9060466.html.plaintext.txt	250	The efficiency rate internalization identical multiplicity range 3 x 104 10 MOI
0.26717928.9060466.html.plaintext.txt	251	Treatment cells nocodazole drug depolymerizes MT Fig
0.26717928.9060466.html.plaintext.txt	252	2 b ND cytochalasin D depolymerizes actin filaments shown effect either efficiency binding internalization kinetics internalization
0.26717928.9060466.html.plaintext.txt	253	Consistent previous reports using acid inactivation plaque assays assess virus internalization Huang Wagner 1964 results showed HSV 1 penetration occurs rapidly efficiently
0.26717928.9060466.html.plaintext.txt	254	Transport Capsids Plasma Membrane Nucleus
0.26717928.9060466.html.plaintext.txt	255	Indirect immunofluorescence microscopy next used analyze transport individual capsids cell periphery nucleus
0.26717928.9060466.html.plaintext.txt	256	The antibodies used either VP 5 anti NC 1 VP19c anti NC 2 two major capsid proteins purified whole capsids anti HC anti LC
0.26717928.9060466.html.plaintext.txt	257	All antibodies gave similar results common stained capsids cytosol Fig
0.26717928.9060466.html.plaintext.txt	258	3 1 h capsids present surface bound intact viruses Fig
0.26717928.9060466.html.plaintext.txt	259	Presumably useful selectivity caused antigen accessibility relevant capsid epitopes intact virus particles probably obscured envelope andor tegument components
0.26717928.9060466.html.plaintext.txt	260	In contrast anti capsid antibodies labeled viral capsids thawed cryosections Sodeik B
0.26717928.9060466.html.plaintext.txt	261	Helenius unpublished observations
0.26717928.9060466.html.plaintext.txt	262	Subcellular distribution incoming HSV 1 capsids
0.26717928.9060466.html.plaintext.txt	263	Conventional immunofluorescence microscopy Vero cells infected HSV 1 MOI 50 presence CH
0.26717928.9060466.html.plaintext.txt	264	The cells fixed 3 PFA permeabilized 0
0.26717928.9060466.html.plaintext.txt	265	1 TX 100 labeled anti HC antibody generated purified capsids
0.26717928.9060466.html.plaintext.txt	266	After 2 h virus binding 4 degrees C 0 h signal
0.26717928.9060466.html.plaintext.txt	267	At 1 h PI numerous cytoplasmic capsids arrows distributed within entire cytoplasm detectable
0.26717928.9060466.html.plaintext.txt	268	At 2 h PI capsids begin accumulate nucleus
0.26717928.9060466.html.plaintext.txt	269	At 4 h PI capsids decorate nuclei
0.26717928.9060466.html.plaintext.txt	270	Note 1 h focus close coverslip whereas 2 4 h nuclear membrane
0.26717928.9060466.html.plaintext.txt	271	View Larger Version Image 74K GIF file
0.26717928.9060466.html.plaintext.txt	272	The capsids cytoplasm appeared small intensely labeled spots Fig
0.26717928.9060466.html.plaintext.txt	273	Using immunoelectron microscopy thawed ultrathin cryosections confirmed spots represented single capsids shown
0.26717928.9060466.html.plaintext.txt	274	All structures labeled cytosol nuclear membrane antibodies directed capsid VP5 represented single viral capsids shown
0.26717928.9060466.html.plaintext.txt	275	The number fluorescently labeled spots increased continuously first hour warming
0.26717928.9060466.html.plaintext.txt	276	In addition distribution within cell changed increasing time cell periphery toward nucleus accumulated nuclear rim Fig
0.26717928.9060466.html.plaintext.txt	277	After 4 h virtually spots localized nuclear membrane Fig
0.26717928.9060466.html.plaintext.txt	278	3 4 h several hundred capsids could seen
0.26717928.9060466.html.plaintext.txt	279	Thus incoming cytosolic capsids transported efficiently periphery host nucleus
0.26717928.9060466.html.plaintext.txt	280	Double immunofluorescence microscopy using anti capsid anti tubulin antibodies showed capsids bound nucleus associated MT Fig
0.26717928.9060466.html.plaintext.txt	281	Moreover many cells capsids seen concentrate around MT organizing center MTOC Fig
0.26717928.9060466.html.plaintext.txt	282	The close association capsids MT confirmed EM Fig
0.26717928.9060466.html.plaintext.txt	283	Numerous cytoplasmic capsids seen close proximity cytoplasmic filaments expected 24 nm width MT like morphology
0.26717928.9060466.html.plaintext.txt	284	Typically distance capsid surface tubules 50 nm suggesting presence additional tethering components
0.26717928.9060466.html.plaintext.txt	285	The viral DNA inside MT associated capsids could seen darkly stained material
0.26717928.9060466.html.plaintext.txt	286	Incoming HSV 1 capsids colocalize MTs
0.26717928.9060466.html.plaintext.txt	287	Conventional immunofluorescence microscopy
0.26717928.9060466.html.plaintext.txt	288	Vero cells infected MOI 50 presence CH fixed methanol 2 h PI double labeled anti VP5 NC 1 FITC anti rabbit antitubulin antibodies IA2 rhodamine anti mouse
0.26717928.9060466.html.plaintext.txt	289	The FITC rhodamine signals documented simultaneously using FITC filter set
0.26717928.9060466.html.plaintext.txt	290	Almost capsids arrows localized nucleus N colocalize microtubules
0.26717928.9060466.html.plaintext.txt	291	b Confocal immunofluorescence microscopy
0.26717928.9060466.html.plaintext.txt	292	Vero cells infected MOI 50 presence CH fixed methanol 2 h PI double labeled anti capsid HC white anti tubulin antibodies IA2 gray
0.26717928.9060466.html.plaintext.txt	293	Almost capsids localized nucleus N colocalize microtubules
0.26717928.9060466.html.plaintext.txt	294	Note cells viral capsids accumulate microtubule organizing center MTOC
0.26717928.9060466.html.plaintext.txt	295	At 1 h postinfection Vero cells infected MOI 500 presence CH fixed 2 glutaraldehyde PBS
0.26717928.9060466.html.plaintext.txt	296	Epon sections cut parallel substrate
0.26717928.9060466.html.plaintext.txt	297	Numerous incoming viral capsids localized microtubules MT identified typical morphology localization 24 nm diameter
0.26717928.9060466.html.plaintext.txt	298	f h Immunoelectron microscopy
0.26717928.9060466.html.plaintext.txt	299	Vero cells infected MOI 500 presence CH extracted 1 h f 4 h PI g h 0
0.26717928.9060466.html.plaintext.txt	300	5 TX 100 MT buffer fixation
0.26717928.9060466.html.plaintext.txt	301	They labeled rabbit anti tubulin followed protein A 9 nm gold Epon sections cut parallel substrate
0.26717928.9060466.html.plaintext.txt	302	The cytoskeleton nucleus nuclear pore complexes NPC well cytoplasmic capsids preserved excellently whereas membranous organelles extracted
0.26717928.9060466.html.plaintext.txt	303	The microtubules MT easily identified since heavily decorated antibody protein A gold
0.26717928.9060466.html.plaintext.txt	304	In rather thick sections f microtubules traced long distances many capsids filled arrows localized
0.26717928.9060466.html.plaintext.txt	305	These capsids still contain electron dense DNA core
0.26717928.9060466.html.plaintext.txt	306	At later time points g h capsids lost electron dense core h open arrow mostly located close proximity nucleus
0.26717928.9060466.html.plaintext.txt	307	Very often capsids bound directly outer ring nuclear pore complex g NPC
0.26717928.9060466.html.plaintext.txt	308	Virions bound plasma membrane h curved arrowhead lost trilaminar appearance membrane apparently lot glycoprotein tegument remains attached causing distinct morphology easily distinguished cytoplasmic capsids g
0.26717928.9060466.html.plaintext.txt	309	View Larger Version Image 135K GIF file
0.26717928.9060466.html.plaintext.txt	310	The tubules unambiguously identified MT antitubulin labeling specimen preextracted TX 100 fixation
0.26717928.9060466.html.plaintext.txt	311	After extraction thicker sections could viewed allowing analysis MT longer distances
0.26717928.9060466.html.plaintext.txt	312	The MT associated capsids generally contained viral DNA Fig
0.26717928.9060466.html.plaintext.txt	313	At later time points capsids empty typically located nuclear pores nuclear envelope membrane Fig
0.26717928.9060466.html.plaintext.txt	314	Most capsids contain DNA Fig
0.26717928.9060466.html.plaintext.txt	315	At 4 h postinfection occasionally empty capsids localized MT close proximity nucleus shown
0.26717928.9060466.html.plaintext.txt	316	Whenever extracellular viruses observed TX 100 extracted samples surrounded electron dense material probably represented viral glycoproteins tegument proteins apparently removed extraction Fig
0.26717928.9060466.html.plaintext.txt	317	Quantitation HSV 1 Entry Capsid Transport
0.26717928.9060466.html.plaintext.txt	318	To quantify kinetics cytosolic capsid transport determined subcellular localization incoming virus EM various time points postinfection MOI 500 Fig
0.26717928.9060466.html.plaintext.txt	319	To compare experiment immunofluorescence microscopy ultrathin sections cut parallel substrate basal region cells see Fig
0.26717928.9060466.html.plaintext.txt	320	For time point 25 electron micrographs taken systematic random fashion number localization cytosolic capsids determined
0.26717928.9060466.html.plaintext.txt	321	5 b localized plasma membrane Fig
0.26717928.9060466.html.plaintext.txt	322	5 c cytosol without obvious connection organelle Fig
0.26717928.9060466.html.plaintext.txt	323	After warming total number cytosolic capsids increased rapidly reaching peak 60 min Fig
0.26717928.9060466.html.plaintext.txt	324	At later times number cytosolic capsids declined suggesting capsids ultimately disassembled
0.26717928.9060466.html.plaintext.txt	325	We also scored whether cytosolic capsids contained electron dense viral DNA core whether appeared empty see Fig
0.26717928.9060466.html.plaintext.txt	326	Up 60 min internalization empty capsids detected whereas 2 h 20 4 h 64 lost electron dense DNA core Fig
0.26717928.9060466.html.plaintext.txt	327	Virions endosomes peaked 1 h sharply declined thereafter
0.26717928.9060466.html.plaintext.txt	328	They may degraded recycled back cell surface capsids could released fusion cytosol
0.26717928.9060466.html.plaintext.txt	329	At 15 min postinfection almost 70 cytosolic capsids localized within 100 nm plasma membrane see Figs
0.26717928.9060466.html.plaintext.txt	330	All capsids close plasma membrane contained viral DNA core
0.26717928.9060466.html.plaintext.txt	331	At 1 h postinfection cytosolic capsids almost 80 intermediate location neither close plasma membrane nucleus Fig
0.26717928.9060466.html.plaintext.txt	332	A significant fraction 10 cytosolic capsids colocalized MT see Figs
0.26717928.9060466.html.plaintext.txt	333	Since capsids 125 nm considerably larger section thickness 60 70 nm figure colocalization MT likely underestimation
0.26717928.9060466.html.plaintext.txt	334	Of cytosolic capsids one capsid 0
0.26717928.9060466.html.plaintext.txt	335	9 capsids 4 h postinfection seen colocalize intermediate filaments shown
0.26717928.9060466.html.plaintext.txt	336	Cytosolic capsids arrived nucleus 2 h postinfection 4 h majority cytosolic capsids 60 localized nucleus Fig
0.26717928.9060466.html.plaintext.txt	337	At ealier time points 1 h 4 cytosolic capsids located nucleus
0.26717928.9060466.html.plaintext.txt	338	Of nuclear capsids 68 2 h 87 4 h empty suggesting DNA release occurred arrival nucleus
0.26717928.9060466.html.plaintext.txt	339	The vast majority empty capsids localized nucleus Fig
0.26717928.9060466.html.plaintext.txt	340	All capsids nucleus localized nuclear pore complexes see Fig
0.26717928.9060466.html.plaintext.txt	341	In summary electron microscopic experiment confirmed immunofluorescence microscopy data
0.26717928.9060466.html.plaintext.txt	342	Cytosolic capsids efficiently transported plasma membrane via cytosol nuclear pore complexes
0.26717928.9060466.html.plaintext.txt	343	During transit significant fraction attached MT
0.26717928.9060466.html.plaintext.txt	344	Empty capsids appeared soon arrival nucleus released cytosol
0.26717928.9060466.html.plaintext.txt	345	Ultimately capsids seemed disassemble disappear overall number cytosolic capsids decreased late infection
0.26717928.9060466.html.plaintext.txt	346	Interestingly appearance cytosolic capsids plasma membrane peaked transport virions endosomes strongly suggesting early cytosolic capsids indeed derived fusion virus plasma membrane rather fusion endosomes
0.26717928.9060466.html.plaintext.txt	347	Reduced Capsid Transport Nucleus without Microtubules
0.26717928.9060466.html.plaintext.txt	348	To determine whether efficient capsid transport via cytosol depended intact cytoskeleton cells infected MOI 50 2 h presence drugs affect MT actin filaments
0.26717928.9060466.html.plaintext.txt	349	Immunofluorescence microscopy showed neither taxol drug prevents disassembly MT Wilson Jordan 1994 cytochalasin D drug causes depolymerization actin filaments Cooper 1987 affected capsid transport nucleus Fig
0.26717928.9060466.html.plaintext.txt	350	In contrast capsid accumulation nuclear membrane significantly reduced colchicine vinblastine nocodazole Fig
0.26717928.9060466.html.plaintext.txt	351	These drugs interact tubulin different molecular mechanisms Wilson Jordan 1994
0.26717928.9060466.html.plaintext.txt	352	Labeling anti tubulin confirmed colchicine nocodazole depolymerized MT whereas vinblastine caused tubulin paracrystal formation shown
0.26717928.9060466.html.plaintext.txt	353	In presence drugs majority capsids remained scattered throughout cytosol
0.26717928.9060466.html.plaintext.txt	354	To test whether effect nocodazole reversible cells analyzed 2 h drug removal
0.26717928.9060466.html.plaintext.txt	355	At time MT repolymerized previously dispersed capsids concentrated nuclear rim Fig
0.26717928.9060466.html.plaintext.txt	356	Reduced transport capsids nucleus absence MTs
0.26717928.9060466.html.plaintext.txt	357	Immunofluorescence microscopy Vero cells infected HSV 1 2 h MOI 50 presence CH drugs affecting cytoskeleton
0.26717928.9060466.html.plaintext.txt	358	Under control conditions almost capsids accumulate around nucleus
0.26717928.9060466.html.plaintext.txt	359	If cells infected presence nocodazole colchicine vinblastine respectively lower panel accumulation viral capsids nucleus instead capsids scattered throughout entire cytoplasm
0.26717928.9060466.html.plaintext.txt	360	In cells infected presence taxol cytochalasin D capsids accumulate nucleus upper panel
0.26717928.9060466.html.plaintext.txt	361	The cells fixed 3 PFA permeabilized 0
0.26717928.9060466.html.plaintext.txt	362	1 TX 100 labeled antibody directed purified capsids HC
0.26717928.9060466.html.plaintext.txt	363	In presence nocodazole amount viral capsids localized nucleus drastically reduced whereas 2 h chase nocodazole free medium capsids accumulate around cell nuclei
0.26717928.9060466.html.plaintext.txt	364	Cells infected presence nocodazole 2 h fixed immediately left panels washed incubated normal medium additional 2 h fixation right panels
0.26717928.9060466.html.plaintext.txt	365	5 TX 100 MT buffer fixation methanol cells double labeled anti tubulin left panels anti capsid HC right panels
0.26717928.9060466.html.plaintext.txt	366	View Larger Versions Images 76 86K GIF file
0.26717928.9060466.html.plaintext.txt	367	Since unable quantify localization fluorescent spots representing cytosolic capsids reliably infected Vero cells MOI 150 presence absence nocodazole analyzed embedded cell pellets quantitative EM
0.26717928.9060466.html.plaintext.txt	368	For experimental condition 50 electron negatives taken systematic random fashion localization cytosolic capsids determined Fig
0.26717928.9060466.html.plaintext.txt	369	After 2 h infection 31 cytosolic capsids reached nucleus 25 still close proximity plasma membrane
0.26717928.9060466.html.plaintext.txt	370	In contrast absence MT none reached nucleus 58 still region close plasma membrane
0.26717928.9060466.html.plaintext.txt	371	After 4 h postinfection 75 cytosolic capsids reached nucleus 14 plasma membrane remaining 11 present cytosol
0.26717928.9060466.html.plaintext.txt	372	In presence nocodazole 47 cytosolic capsids reached nucleus 18 still plasma membrane 36 cytosol distant plasma membrane nucleus
0.26717928.9060466.html.plaintext.txt	373	As nocodazole vinblastine colchicine affect network MT Wilson Jordan 1994 concluded MT directly indirectly involved rapid transport capsids cell periphery nucleus Vero cells
0.26717928.9060466.html.plaintext.txt	374	In cells devoid functional MT arrival capsids nucleus significantly delayed
0.26717928.9060466.html.plaintext.txt	375	Viral Infection Absence Microtubules
0.26717928.9060466.html.plaintext.txt	376	Whether nocodazole would effect productive infection determined monitoring onset viral protein synthesis presence absence drug
0.26717928.9060466.html.plaintext.txt	377	Cell extracts prepared different periods infection subjected immunoblotting using antibodies early HSV 1 protein ICP4 late structural protein VP5
0.26717928.9060466.html.plaintext.txt	378	7 c show synthesis viral proteins delayed reduced absence MT
0.26717928.9060466.html.plaintext.txt	379	Calnexin integral membrane protein ER Hammond Helenius 1994 used control remained constant
0.26717928.9060466.html.plaintext.txt	380	Labeling 35Smethionine demonstrated nocodazole overall effect protein synthesis uninfected HSV 1 infected Vero cells shown
0.26717928.9060466.html.plaintext.txt	381	When immunofluorescence microscopy using ICP4 performed found control conditions viral protein synthesis commenced many cells already 2 h postinfection
0.26717928.9060466.html.plaintext.txt	382	In contrast presence nocodazole cells showed ICP4 labeling
0.26717928.9060466.html.plaintext.txt	383	At 4 h postinfection control cells strongly labeled ICP4 whereas absence MT significantly less cells show strong labeling ICP4 data shown
0.26717928.9060466.html.plaintext.txt	384	However later time points cells synthezised ICP4 presence absence MT
0.26717928.9060466.html.plaintext.txt	385	Thus depolymerization MT delayed onset viral protein synthesis cultured fibroblasts prevent viral infection per se
0.26717928.9060466.html.plaintext.txt	386	Dynein Colocalizes Incoming Capsids
0.26717928.9060466.html.plaintext.txt	387	Our results strongly suggested incoming herpes capsids move along MT toward nucleus
0.26717928.9060466.html.plaintext.txt	388	Therefore ask whether would use host MT dependent motors transport
0.26717928.9060466.html.plaintext.txt	389	Since antibody tubulin often obscured morphology putative tethering factors located viral capsids MT see Fig
0.26717928.9060466.html.plaintext.txt	390	4 repeated experiments without immunolabeling
0.26717928.9060466.html.plaintext.txt	391	Electron dense material usually attached vertices capsids associated MT Fig
0.26717928.9060466.html.plaintext.txt	392	The morphology appendages variable cases Fig
0.26717928.9060466.html.plaintext.txt	393	8 d arrow dimensions shape cytoplasmic dynein minus end directed MT dependent motor
0.26717928.9060466.html.plaintext.txt	394	Dynein Y shaped protein complex length 50 nm
0.26717928.9060466.html.plaintext.txt	395	It connected cargo via stalk MT two 14 nm globular domains Gilbert Sloboda 1989 Vale 1990 Vallee et al
0.26717928.9060466.html.plaintext.txt	396	Incoming HSV 1 capsids display appendices vertices
0.26717928.9060466.html.plaintext.txt	397	At 1 h PI Vero cells infected MOI 500 presence CH extracted 0
0.26717928.9060466.html.plaintext.txt	398	5 TX 100 MT buffer 2 min 37 degrees C fixed 1 GA MT buffer
0.26717928.9060466.html.plaintext.txt	399	They labeled anti tubulin followed protein A 9 nm gold embedded directly b d Epon sections cut parallel substrate
0.26717928.9060466.html.plaintext.txt	400	All viral capsids display appendages outside arrowheads
0.26717928.9060466.html.plaintext.txt	401	The appendages visible three four five six corners visible section represent pentons viral capsid
0.26717928.9060466.html.plaintext.txt	402	Some appendices morphology similar purified cytoplasmic dynein large arrow d large globular stalk two smaller globular head domains
0.26717928.9060466.html.plaintext.txt	403	The capsid size 100 110 nm dynein like appendices 50 nm
0.26717928.9060466.html.plaintext.txt	404	In thick sections golden color appendices often buried cytoskeletal material b d whereas thin sections grey color c prominent
0.26717928.9060466.html.plaintext.txt	405	The appendices kinds different morphology varying sizes electron density always located pentons
0.26717928.9060466.html.plaintext.txt	406	View Larger Version Image 172K GIF file
0.26717928.9060466.html.plaintext.txt	407	To test whether cytoplasmic dynein indeed associated capsids used affinity purified antibody directed heavy chain cytoplasmic dynein Vaisberg et al
0.26717928.9060466.html.plaintext.txt	408	Immunoelectron microscopy anti dynein antibody performed ultrathin cryosections situ fixed cells 1 2 h initiation virus entry
0.26717928.9060466.html.plaintext.txt	409	In addition low level labeling cytoplasm dynein found localized surface endosomes Fig
0.26717928.9060466.html.plaintext.txt	410	9 Golgi apparatus Fig
0.26717928.9060466.html.plaintext.txt	411	Very gold particles seen nucleus mitochondrial matrix Fig
0.26717928.9060466.html.plaintext.txt	412	The mitochondria contain dynein served background control
0.26717928.9060466.html.plaintext.txt	413	Compared mitochondrial matrix slightly higher labeling nuclei cytoplasm labeled 2
0.26717928.9060466.html.plaintext.txt	414	3 fold higher background Table I
0.26717928.9060466.html.plaintext.txt	415	Anti dynein antibodies label incoming viral HSV 1 capsids
0.26717928.9060466.html.plaintext.txt	416	Thawed cryosections Vero cells infected 1 c 2 h b d h presence CH MOI 500 labeled rabbit antibodies followed protein A 5 nm d g 10 nm gold e g h
0.26717928.9060466.html.plaintext.txt	417	About 5 incoming viral capsids f h labeled anti dynein arrows affinity purified antibody made recombinant fragment dynein heavy
0.26717928.9060466.html.plaintext.txt	418	Labeled capsids localized close plasma membrane g PM nuclear envelope c d within cytoplasm without obvious connection either one b
0.26717928.9060466.html.plaintext.txt	419	Note capsids within extracellular virions f within endosomes g h E labeled
0.26717928.9060466.html.plaintext.txt	420	Anti dynein also labels membranes mitochondria M endosomes h E Golgi complex G diffusely entire cytoplasm whereas mitochondrial matrix b d nucleus d N show labeling dynein
0.26717928.9060466.html.plaintext.txt	421	View Larger Version Image 168K GIF file
0.26717928.9060466.html.plaintext.txt	422	Quantitation Dynein Immunolabeling
0.26717928.9060466.html.plaintext.txt	423	In cells containing incoming HSV 1 capsids dynein addition found associated many capsids Fig
0.26717928.9060466.html.plaintext.txt	424	Capsids directly underneath plasma membrane Fig
0.26717928.9060466.html.plaintext.txt	425	9 g within cytoplasm Fig
0.26717928.9060466.html.plaintext.txt	426	9 b well capsids close proximity nucleus Fig
0.26717928.9060466.html.plaintext.txt	427	9 c d labeled anti dynein
0.26717928.9060466.html.plaintext.txt	428	On average 13 cytoplasmic capsids labeled Table I
0.26717928.9060466.html.plaintext.txt	429	Capsids intact virions either extracellular Fig
0.26717928.9060466.html.plaintext.txt	430	5 capsids present virions colloidal gold particles close proximity Table I
0.26717928.9060466.html.plaintext.txt	431	Thus labeling density eightfold higher cytosolic capsids compared capsids within virions ruling possibility antidynein antibody showed cross reactivity capsid proteins
0.26717928.9060466.html.plaintext.txt	432	Given labeling efficiency using technique exceed 10 e
0.26717928.9060466.html.plaintext.txt	433	10 primary antibody present sections detected protein A gold Griffiths 1993a results showed incoming cytosolic viral capsids associated cytoplasmic dynein
0.26717928.9060466.html.plaintext.txt	434	HSV 1 causes range diseases benign common cold sores life threatening encephalitis
0.26717928.9060466.html.plaintext.txt	435	It infects epithelial cells mucocutaneous membranes herpesviridae establishes latent infections sensory ganglia Whitley Gnann 1993
0.26717928.9060466.html.plaintext.txt	436	It thought enter neurons fusion presynaptic membrane capsid transported along axon nucleus Hill et al
0.26717928.9060466.html.plaintext.txt	437	1988 Roizman Sears 1989 Topp et al
0.26717928.9060466.html.plaintext.txt	438	The efficient infection neurons terminally differentiated cells made HSV 1 useful vehicle gene delivery potential gene therapy human brain Glorioso et al
0.26717928.9060466.html.plaintext.txt	439	The biochemical morphological assays used study showed HSV 1 entry Vero cells rapid efficient
0.26717928.9060466.html.plaintext.txt	440	Over broad range multiplicities found 70 bound virus penetrated half time 8 min
0.26717928.9060466.html.plaintext.txt	441	More 60 capsids delivered cytosol transported nucleus within 4 h uptake binding fibers extending nuclear pore complexes seemed occur
0.26717928.9060466.html.plaintext.txt	442	The ratio particles plaque forming units HSV 1 10 50 Frenkel et al
0.26717928.9060466.html.plaintext.txt	443	1992 Smith 1964 Watson et al
0.26717928.9060466.html.plaintext.txt	444	Thus cells infected MOI 50 40 bound number particles entering cells 140 700 according proteinase K assay
0.26717928.9060466.html.plaintext.txt	445	We determined 60 internalized virus namely 80 420 particles uncoat viral genome within 4 h postinfection measured DNase protection assay Ojala P
0.26717928.9060466.html.plaintext.txt	446	Helenius manuscript preparation
0.26717928.9060466.html.plaintext.txt	447	A majority capsids remained associated nuclear pores releasing DNA see also Batterson et al
0.26717928.9060466.html.plaintext.txt	448	The apparent transient stability empty capsids contrasts adenovirus another virus delivers DNA nucleus nuclear pore complexes empty capsids could detected nuclear pore complexes Greber et al
0.26717928.9060466.html.plaintext.txt	449	We cannot formally rule even though herpes capsids appeared empty nuclear membrane viral DNA release completed yet
0.26717928.9060466.html.plaintext.txt	450	Our results demonstrate MT involved capsid transport cell surface nucleus
0.26717928.9060466.html.plaintext.txt	451	Since distance plasma membrane nucleus Vero cells large neurons MT assisted transport essential infection accelerated transfer capsids nucleus onset viral protein synthesis
0.26717928.9060466.html.plaintext.txt	452	Having first detached tegument proteins plasma membrane capsids moved minus end direction along MT MTOC
0.26717928.9060466.html.plaintext.txt	453	From transferred nuclear pores unknown mechanisms
0.26717928.9060466.html.plaintext.txt	454	At early times 1 2 h PI majority capsids associated nuclear membrane proximal MTOC later distribution became homogenous around nucleus
0.26717928.9060466.html.plaintext.txt	455	Nocodazole colchicine depolymerize MT vinblastine causes MT paracrystal formation reduced capsid accumulation nuclear envelope
0.26717928.9060466.html.plaintext.txt	456	These drugs also reported reduce amount infectious HSV 1 recovered rat dorsal root ganglia infected vitro Kristensson et al
0.26717928.9060466.html.plaintext.txt	457	1986 trigeminal ganglia inoculation murine cornea Topp et al
0.26717928.9060466.html.plaintext.txt	458	We think likely capsids derived virions bound apical plasma membrane system see Fig
0.26717928.9060466.html.plaintext.txt	459	5 reached nucleus independent MT since distance apical plasma membrane nuclear membrane 200 300 nm
0.26717928.9060466.html.plaintext.txt	460	Thus larger distance plasma membrane virion bound nucleus transport nucleus depended MT
0.26717928.9060466.html.plaintext.txt	461	In contrast results obtained neurons Kristensson et al
0.26717928.9060466.html.plaintext.txt	462	1986 taxol stabilizes MT reduce efficiency capsid transport suggesting dynamic turnover treadmilling MT required capsid transport Vero cells
0.26717928.9060466.html.plaintext.txt	463	Depolymerization actin filaments cytochalasin D effect either HSV 1 internalization transport nucleus
0.26717928.9060466.html.plaintext.txt	464	The presence dynein heavy chains material attached cytosolic capsids indicated MT mediated transport powered cytoplasmic dynein
0.26717928.9060466.html.plaintext.txt	465	Cytoplasmic dynein multisubunit protein complex 1270 kD consisting two heavy chains two three intermediate chains variable number small subunits Holzbaur Vallee 1994 Schroer 1994
0.26717928.9060466.html.plaintext.txt	466	It length 40 50 nm shape reminiscent letter Y
0.26717928.9060466.html.plaintext.txt	467	The two head domains contain MT binding ATPase sites base interacts cargo Gilbert Sloboda 1989 Vale 1990 Vallee et al
0.26717928.9060466.html.plaintext.txt	468	Dynein responsible minus end directed movement chromosomes membrane organelles along MT Cole LippincottSchwartz 1995 Mitchison 1988
0.26717928.9060466.html.plaintext.txt	469	Since plus ends MT localized periphery Vero cells close plasma membrane minus ends anchored perinuclear MTOC dynein seems logical choice motor transport incoming viral capsids nucleus
0.26717928.9060466.html.plaintext.txt	470	The applies axons neurons MT plus ends toward synapse minus end anchored MTOC cell body Black Baas 1989
0.26717928.9060466.html.plaintext.txt	471	Although kinesin like MT minus end directed motors implicated play role mitosis meiosis none demonstrated involved interphase transport processes Barton Goldstein 1996 Hirokawa 1996
0.26717928.9060466.html.plaintext.txt	472	Since MT mediated transport crucial infection neurons also operates cultured fibroblasts analysis greatly facilitated
0.26717928.9060466.html.plaintext.txt	473	It believed dynein attachment vesicles kinetochores requires another large multimeric complex called dynactin contains 10 different proteins Holzbaur Vallee 1994 Schroer 1994 Vallee Sheetz 1996
0.26717928.9060466.html.plaintext.txt	474	So far receptor molecules dynein dynactin identified cargo structures several studies indicate activity dynein binding cargo may regulated phosphorylation Allen 1995 Dillman Pfister 1994 Lin et al
0.26717928.9060466.html.plaintext.txt	475	Whether binding dynein HSV 1 capsids involves dynactin cellular components whether regulated phosphorylation remains unclear point
0.26717928.9060466.html.plaintext.txt	476	The viral proteins serve dynein receptors also remain identified
0.26717928.9060466.html.plaintext.txt	477	Since polypeptide composition capsids tegument known potential candidates however singled
0.26717928.9060466.html.plaintext.txt	478	The capsid contains six different proteins
0.26717928.9060466.html.plaintext.txt	479	Of VP5 known located pentons Trus et al
0.26717928.9060466.html.plaintext.txt	480	1992 sites preferential attachment proteinaceous material onto cytosolic capsids shown
0.26717928.9060466.html.plaintext.txt	481	In addition bona fide capsid polypeptides components derived tegument also likely present
0.26717928.9060466.html.plaintext.txt	482	For example VP1 2 270 kD protein particularly tightly associated capsids Roizman Furlong 1974 may constitute part material seen attached pentons electron micrographs
0.26717928.9060466.html.plaintext.txt	483	Taking advantage relative simplicity capsids existing virus mutants complete genomic sequence virus work progress identify characterize dynein receptor HSV 1 capsids
0.26717928.9060466.html.plaintext.txt	484	Received publication 4 October 1996 revised form 13 December 1996
0.26717928.9060466.html.plaintext.txt	485	Gary Cohen Roselyn Eisenberg generous hospitality labs many helpful suggestions
0.26717928.9060466.html.plaintext.txt	486	Victor Stolc acknowledged contribution immunofluorescence studies
0.26717928.9060466.html.plaintext.txt	487	We also thank Lisa Hartnell Linda Iadarola Philippe Male Paul Webster Center Cell Imaging Cell Biology Department Yale University teaching many aspects EM Henry Tan superb photographic work
0.26717928.9060466.html.plaintext.txt	488	Gary Whittaker Jani Simons Paivi Ojala Philippe Pierre Urs Greber many stimulating discussions critical reading manuscript
0.26717928.9060466.html.plaintext.txt	489	The work supported National Institutes Health grant A
0.26717928.9060466.html.plaintext.txt	490	Helenius AI18599 long term postdoctoral EMBO fellowship B
0.26717928.9060466.html.plaintext.txt	491	Address correspondence Beate Sodeik Department Cell Biology Yale University School Medicine 333 Cedar Street New Haven CT 06520 8002
0.26717928.9060466.html.plaintext.txt	492	edu u d Abbreviations used paper
0.26717928.9060466.html.plaintext.txt	493	CH cycloheximide GA glutaraldehyde HSV 1 herpes simplex virus 1 MOI multiplicity infection MT microtubule MTOC microtubule organizing center PFA paraformaldehyde PFU plaque forming unit PI postinfection TX 100 Triton X 100
0.26717928.9060466.html.plaintext.txt	494	Protein phosphatase 1 regulates cytoplasmic dynein driven formation endoplasmic reticulum networks vitro
0.26717928.9060466.html.plaintext.txt	495	The plus ends microtubules exclusive nucleating structures microtubules axon
0.26717928.9060466.html.plaintext.txt	496	Going mobile microtubule motors chromosome segregation
0.26717928.9060466.html.plaintext.txt	497	93 1735 1742 AbstractFree Full Text
0.26717928.9060466.html.plaintext.txt	498	Characterization HSV associated factor responsible induction genes
0.26717928.9060466.html.plaintext.txt	499	Further characterization temperature sensitive mutant defective release viral DNA stages viral reproductive cycle
0.26717928.9060466.html.plaintext.txt	500	The basis polarity neurons
0.26717928.9060466.html.plaintext.txt	501	Liquid crystalline phage like packing encapsidated DNA herpes simplex virus
0.26717928.9060466.html.plaintext.txt	502	Internal movements changes shape
0.26717928.9060466.html.plaintext.txt	503	Entry HSV 1 BJ cells constituitively express viral gD endocytosis results degradation virus
0.26717928.9060466.html.plaintext.txt	504	Identification herpes simplex virus DNA sequence encodes trans acting polypeptide responsible stimulation immediate early transcription
0.26717928.9060466.html.plaintext.txt	505	Structural analysis capsid polypeptides herpes simplex virus types 1 2
0.26717928.9060466.html.plaintext.txt	506	Organization organelles membrane traffic microtubules
0.26717928.9060466.html.plaintext.txt	507	Effects cytochalasin phalloidin actin
0.26717928.9060466.html.plaintext.txt	508	Actin based motility vaccinia virus
0.26717928.9060466.html.plaintext.txt	509	Differential phosphorylation vivo cytoplasmic dynein associated anterogradely moving organelles
0.26717928.9060466.html.plaintext.txt	510	Characterization defective DNA molecules biological properties virus populations containing
0.26717928.9060466.html.plaintext.txt	511	Neutralizing antibodies specific glycoprotein H herpes simplex virus permit viral attachment cells prevent penetration
0.26717928.9060466.html.plaintext.txt	512	A squid dynein isoform promotes axoplasmic vesicle translocation
0.26717928.9060466.html.plaintext.txt	513	Herpes simplex virus gene delivery vector central nervous system
0.26717928.9060466.html.plaintext.txt	514	In Viral vectorsGene Therapy Neuroscience Applications
0.26717928.9060466.html.plaintext.txt	515	Academic Press San DiegoNew YorkBostonLondonSydneyTokyoToronto
0.26717928.9060466.html.plaintext.txt	516	Stepwise dismantling adenovirus 2 entry cells
0.26717928.9060466.html.plaintext.txt	517	Labeling reactions immunocytochemistry
0.26717928.9060466.html.plaintext.txt	518	In Fine Structure Immunocytochemistry
0.26717928.9060466.html.plaintext.txt	519	Springer Verlag BerlinHeidelbergNew York
0.26717928.9060466.html.plaintext.txt	520	Quantitative aspects immunocytochemistry
0.26717928.9060466.html.plaintext.txt	521	In Fine Structure Immunocytochemistry
0.26717928.9060466.html.plaintext.txt	522	Springer Verlag BerlinHeidelbergNew York
0.26717928.9060466.html.plaintext.txt	523	Quality control secretory pathway retention misfolded viral membrane glycoprotein involves cycling ER intermediate compartment Golgi apparatus
0.26717928.9060466.html.plaintext.txt	524	The virion polypeptides type 1 strains
0.26717928.9060466.html.plaintext.txt	525	On entry Semliki Forest virus BHK 21 cells
0.26717928.9060466.html.plaintext.txt	526	84 404 420 AbstractFree Full Text
0.26717928.9060466.html.plaintext.txt	527	Intra axonal location HSV particles
0.26717928.9060466.html.plaintext.txt	528	Organelle transport along microtubulesthe role KIFs
0.26717928.9060466.html.plaintext.txt	529	Dyneins molecular structure cellular function
0.26717928.9060466.html.plaintext.txt	530	Identification relative molar rates synthesis structural nonstructural herpes virus polypeptides infected cells
0.26717928.9060466.html.plaintext.txt	531	Penetration HSV human epidermoid cells
0.26717928.9060466.html.plaintext.txt	532	The principles gene therapy nervous system
0.26717928.9060466.html.plaintext.txt	533	Microtubules containing detyrosinated tubulin less dynamic
0.26717928.9060466.html.plaintext.txt	534	Neuritic transport HSV rat sensory neurons vitro
0.26717928.9060466.html.plaintext.txt	535	Effects substances interacting microtubular function axonal flow nocodazole taxol erythro 9 3 2 hydroxynonyladenine
0.26717928.9060466.html.plaintext.txt	536	Characterization virion protein kinase polypeptides phosphorylated virion
0.26717928.9060466.html.plaintext.txt	537	Cytoplasmic dynein undergoes intracellular redistribution concomitant phosphorylation heavy chain response serum starvation okadeic acid
0.26717928.9060466.html.plaintext.txt	538	Physical properties cytoplasm
0.26717928.9060466.html.plaintext.txt	539	Does cytoskeleton play significant role animal virus replication J
0.26717928.9060466.html.plaintext.txt	540	Herpes simplex infection human sensory neuron
0.26717928.9060466.html.plaintext.txt	541	Uptake transport herpes simplex virus neurites rat dorsal root ganglia cells culture
0.26717928.9060466.html.plaintext.txt	542	Cell specific kinetics efficiency HSV 1 entry determined two distinct phases attachment
0.26717928.9060466.html.plaintext.txt	543	Noninfectious L particles supply functions facilitate infection HSV 1
0.26717928.9060466.html.plaintext.txt	544	Identification characterization virion protein products HSV 1 UL47
0.26717928.9060466.html.plaintext.txt	545	Microtubule dynamics kinetochore function mitosis
0.26717928.9060466.html.plaintext.txt	546	Structure HSV capsid molecular composition pentons triplexes
0.26717928.9060466.html.plaintext.txt	547	Cell cycle regulation dynein association membranes modulates microtubule based organelle transport
0.26717928.9060466.html.plaintext.txt	548	Axonal transport herpes simplex virions epidermal cells evidence specialized mode virus transport assembly
0.26717928.9060466.html.plaintext.txt	549	HSV mutants defective virion associated shutoff host polypeptide synthesis exhibiting abnormal synthesis alpha immediate early viral polypeptides
0.26717928.9060466.html.plaintext.txt	550	The replication herpes viruses
0.26717928.9060466.html.plaintext.txt	551	An inquiry mechanisms herpes simplex virus latency
0.26717928.9060466.html.plaintext.txt	552	Herpes simplex viruses replication
0.26717928.9060466.html.plaintext.txt	553	Lippincott Raven Publishers Philadelphia
0.26717928.9060466.html.plaintext.txt	554	Structure function regulation cytoplasmic dynein
0.26717928.9060466.html.plaintext.txt	555	Cell surface receptors herpes simplex virus heparan sulfate proteoglycans
0.26717928.9060466.html.plaintext.txt	556	Relationship envelope infectivity herpes simplex virus
0.26717928.9060466.html.plaintext.txt	557	Assembly vaccinia virus role intermediate region endoplasmic reticulum Golgi complex
0.26717928.9060466.html.plaintext.txt	558	Membrane fusion induced HSV
0.26717928.9060466.html.plaintext.txt	559	CRC Press Boca RatonAnn ArborLondonTokyo
0.26717928.9060466.html.plaintext.txt	560	Purification structural proteins herpes virion
0.26717928.9060466.html.plaintext.txt	561	Herpes virus capsid assembly envelopment
0.26717928.9060466.html.plaintext.txt	562	In Structural Biology Viruses
0.26717928.9060466.html.plaintext.txt	563	Oxford University Press New York
0.26717928.9060466.html.plaintext.txt	564	Microtubule polarity peripheral processes trigeminal ganglion cells relevance retrograde transport herpes simplex virus
0.26717928.9060466.html.plaintext.txt	565	Distinct monoclonal antibodies separately label hexons pentons herpes simplex virus capsid
0.26717928.9060466.html.plaintext.txt	566	Cytoplasmic dynein plays role mammalian mitotic spindle formation
0.26717928.9060466.html.plaintext.txt	567	Microtubule based motor proteins
0.26717928.9060466.html.plaintext.txt	568	Microtubule associated protein 1C brain two headed cytosolic dynein
0.26717928.9060466.html.plaintext.txt	569	Electron microscopic particle counts Herpes virus using phosphotungstate negative staining technique
0.26717928.9060466.html.plaintext.txt	570	The epidemiology clinical manifestations herpes simplex virus infections
0.26717928.9060466.html.plaintext.txt	571	Pharmacological probes microtubule function
0.26717928.9060466.html.plaintext.txt	572	Copyright 1997 The Rockefeller University Press
0.18210748.11815585.html.plaintext.txt	0	Differential regulation L1 L2 ss lactamase expression Stenotrophomonas maltophilia
0.18210748.11815585.html.plaintext.txt	1	Bristol Centre Antimicrobial Research Evaluation Department Pathology Microbiology School Medical Sciences University Bristol Bristol BS8 1TD UK
0.18210748.11815585.html.plaintext.txt	2	Abstract Top Abstract Introduction Materials methods Results Discussion Acknowledgements References It reported Stenotrophomonas maltophilia L1 L2 ss lactamase expression coordinated
0.18210748.11815585.html.plaintext.txt	3	maltophilia mutants L1 constitutively hyper expressed L2 inducible ii L2 hyper expressed L1 inducible iii L1 L2 constitutively hyper expressed
0.18210748.11815585.html.plaintext.txt	4	The frequency isolating type 1 2 mutants c
0.18210748.11815585.html.plaintext.txt	5	10 7 indicating promoter mutations probably involved providing strong evidence L1 L2 expression coordinated
0.18210748.11815585.html.plaintext.txt	6	The frequency isolating type 3 mutants c
0.18210748.11815585.html.plaintext.txt	7	10 9 however implying significant overlap regulatory mechanisms
0.18210748.11815585.html.plaintext.txt	8	Introduction Top Abstract Introduction Materials methods Results Discussion Acknowledgements References In recent survey British medical microbiologists Stenotrophomonas maltophilia voted one important emergent multidrug resistant pathogens
0.18210748.11815585.html.plaintext.txt	9	1 As well causing bacteraemias S
0.18210748.11815585.html.plaintext.txt	10	maltophilia reported responsible many different organ specific infections important cause respiratory tract colonization young adults cystic fibrosis
0.18210748.11815585.html.plaintext.txt	11	maltophilia isolates resistant many clinically useful antibiotics ss lactam resistance mediated two ss lactamases L1 L2 whose expression induced cells exposed ss lactam antibiotics
0.18210748.11815585.html.plaintext.txt	12	23 Little known mechanisms used regulate L1 L2 expression experiments presented report designed investigate regulation L1 L2 expression S
0.18210748.11815585.html.plaintext.txt	13	maltophilia isolating mutants L1 L2 expression altered
0.18210748.11815585.html.plaintext.txt	14	Materials methods Top Abstract Introduction Materials methods Results Discussion Acknowledgements References Bacterial strains materials
0.18210748.11815585.html.plaintext.txt	15	maltophilia isolates used study described previously
0.18210748.11815585.html.plaintext.txt	16	3 They divided groups A B C according 16S rRNA gene sequence
0.18210748.11815585.html.plaintext.txt	17	Group A strains K279a H33b J530b J675Ib group B strains N531 P567II group C strains J675a J675b O132II O133
0.18210748.11815585.html.plaintext.txt	18	3 All materials used study described elsewhere
0.18210748.11815585.html.plaintext.txt	19	Induction preparation crude cell extracts ss lactamase assay
0.18210748.11815585.html.plaintext.txt	20	Induction ss lactamase activity attempted appropriate crude cell extracts made ss lactamase assays carried specific ss lactamase activity calculated using methods described previously
0.18210748.11815585.html.plaintext.txt	21	4 One unit ss lactamase activity defined required hydrolyse 1 micromole substrate per minute 25 degrees C
0.18210748.11815585.html.plaintext.txt	22	Isolation total RNA RT PCR analysis
0.18210748.11815585.html.plaintext.txt	23	Isolation RNA RT PCR carried described previously
0.18210748.11815585.html.plaintext.txt	24	5 The RT PCR primers used L1 MID forward 5 CTGGCCGTCGCTCTTCCG 3 reverse 5 TCCAGGCGGTGCTGCCC 3 L2 MID forward 5 CGATGATCACCAGCGACA 3 reverse 5 CGGTTACCTCATCCGATC 3
0.18210748.11815585.html.plaintext.txt	25	Although primers designed L1c L2b gene sequences located S
0.18210748.11815585.html.plaintext.txt	26	maltophilia group A isolates known amplify equivalent regions L1 L2 isoforms carried group B C S
0.18210748.11815585.html.plaintext.txt	27	Selection ss lactamase hyper producing mutants
0.18210748.11815585.html.plaintext.txt	28	Etest MIC determinations carried IsoSensitest agar inoculum 0
0.18210748.11815585.html.plaintext.txt	29	Following incubation 37 degrees C 24 h colonies grew within zone clearing selected
0.18210748.11815585.html.plaintext.txt	30	Results Top Abstract Introduction Materials methods Results Discussion Acknowledgements References Using crude cell extracts uninduced cefoxitin induced group A B C S
0.18210748.11815585.html.plaintext.txt	31	maltophilia isolates see Materials methods activities L1 L2 ss lactamases determined meropenem specific L1 substrate ceftazidime L2 substrate Figure 1a
0.18210748.11815585.html.plaintext.txt	32	In latter case EDTA 100 mM added inhibit L1 also hydrolyses ceftazidime
0.18210748.11815585.html.plaintext.txt	33	6 RT PCR analysis used determine L1 L2 transcript levels similarly incubated cells Figure 1b
0.18210748.11815585.html.plaintext.txt	34	The data reveal L2 expressed higher levels following induction group A strains little L2 expression detected group B C strains even following induction
0.18210748.11815585.html.plaintext.txt	35	The level L1 induction seen group A B strains detectable L1 expression group C strains Figure 1
0.18210748.11815585.html.plaintext.txt	36	View larger version 41K Figure 1
0.18210748.11815585.html.plaintext.txt	37	maltophilia L1 L2 transcription
0.18210748.11815585.html.plaintext.txt	38	maltophilia isolates group A B C strains represented figure isolates K279a N531 J675a respectively
0.18210748.11815585.html.plaintext.txt	39	Crude extracts cefoxitin induced labelled A In B In C In uninduced labelled A B C cultures prepared described Materials methods
0.18210748.11815585.html.plaintext.txt	40	ss Lactamase activities extracts measured meropenem white bar ceftazidime presence 100 mM EDTA black bar
0.18210748.11815585.html.plaintext.txt	41	b From cultures used total RNA prepared assayed abundance L1 L2 transcripts RT PCR see Materials methods
0.18210748.11815585.html.plaintext.txt	42	The figure represents ethidium bromide stained 1
0.18210748.11815585.html.plaintext.txt	43	2 wv agarose gel UV illumination following resolution L1 mid L2 mid PCR amplicons
0.18210748.11815585.html.plaintext.txt	44	maltophilia K279a group A inducible L1 L2 ss lactamases Figure 1
0.18210748.11815585.html.plaintext.txt	45	K279a mutants display high level resistance meropenem ceftazidime ampicillin isolated see Materials methods
0.18210748.11815585.html.plaintext.txt	46	Of 50 hyper resistant mutants examined eight showed increased levels ss lactamase expression
0.18210748.11815585.html.plaintext.txt	47	Three classes ss lactamase hyper producing mutants isolated denoted K279a M1 K279a M2 K279a M3
0.18210748.11815585.html.plaintext.txt	48	Using crude cell extracts uninduced K279a M1 K279a M2 K279a M3 activities L1 L2 ss lactamases Figure 2a levels L1 L2 transcripts Figure 2b determined
0.18210748.11815585.html.plaintext.txt	49	Compared K279a K279a M1 increased expression L1 L2 K279a M2 increased expression L2 L1 K279a M3 increased expression L1 L2 Figure 2
0.18210748.11815585.html.plaintext.txt	50	The ss lactamases expressed uninduced K279a M1 K279a M2 inducible upon cefoxitin challenge data shown
0.18210748.11815585.html.plaintext.txt	51	View larger version 49K Figure 2
0.18210748.11815585.html.plaintext.txt	52	maltophilia isolate K279a used produce mutants denoted M1 M2 M3 described text
0.18210748.11815585.html.plaintext.txt	53	Crude extracts uninduced cultures parent strain three mutants prepared described Materials methods
0.18210748.11815585.html.plaintext.txt	54	ss Lactamase activities extracts measured using meropenem white bar ceftazidime presence 100 mM EDTA black bar
0.18210748.11815585.html.plaintext.txt	55	b The cultures used prepare total RNA assayed abundance L1 L2 transcripts RT PCR see Materials methods
0.18210748.11815585.html.plaintext.txt	56	The figure represents ethidium bromide stained 1
0.18210748.11815585.html.plaintext.txt	57	2 wv agarose gel UV illumination following resolution L1 mid L2 mid PCR amplicons
0.18210748.11815585.html.plaintext.txt	58	Discussion Top Abstract Introduction Materials methods Results Discussion Acknowledgements References Both sets data indicate expression L1 L2 genes S
0.18210748.11815585.html.plaintext.txt	59	maltophilia differential conclusion contrasts previous studies
0.18210748.11815585.html.plaintext.txt	60	2 It clear several reports challenging S
0.18210748.11815585.html.plaintext.txt	61	maltophilia isolates ss lactams induces L1 L2 expression simultaneously
0.18210748.11815585.html.plaintext.txt	62	From concluded mechanism used control expression enzymes
0.18210748.11815585.html.plaintext.txt	63	maltophilia mutant L1 constitutively repressed L2 remained inducible Bonfiglio et al
0.18210748.11815585.html.plaintext.txt	64	8 found clinical isolate identical properties found clinical isolates L2 repressed L1 inducible Figure 1
0.18210748.11815585.html.plaintext.txt	65	Promoter mutations could explain findings however uncoupling one gene case induction machinery
0.18210748.11815585.html.plaintext.txt	66	We also report isolation S
0.18210748.11815585.html.plaintext.txt	67	maltophilia K279a mutants either L1 L2 constitutively hyper expressed partner enzyme remains inducible Figure 2
0.18210748.11815585.html.plaintext.txt	68	Again promoter mutations could explain frequency differentially hyper expressing mutations arise argues theory
0.18210748.11815585.html.plaintext.txt	69	Promoter mutations lead expression ss lactamases rare events
0.18210748.11815585.html.plaintext.txt	70	For example promoter mutation frequency resulting ampC expression Escherichia coli c
0.18210748.11815585.html.plaintext.txt	71	9 Although Etest method used allow determination accurate mutation frequencies frequency L1 expression c
0.18210748.11815585.html.plaintext.txt	72	10 7 L2 expression similar
0.18210748.11815585.html.plaintext.txt	73	Hence mutation L1 L2 expression two orders magnitude greater ampC expression E
0.18210748.11815585.html.plaintext.txt	74	coli due promoter mutation
0.18210748.11815585.html.plaintext.txt	75	9 A similar high mutation frequency c
0.18210748.11815585.html.plaintext.txt	76	10 7 leading ss lactamase expression ampC Citrobacter freundii Enterobacter cloacae primarily reflection non specific loss function mutations ampD
0.18210748.11815585.html.plaintext.txt	77	10 Hence think likely non specific mutations cause ss lactamase hyper production S
0.18210748.11815585.html.plaintext.txt	78	maltophilia mutants isolated promoter mutations
0.18210748.11815585.html.plaintext.txt	79	Whereas predicted frequency isolating L1 L2 double expressing mutants would 10 14 10 7 L2 multiplied 10 7 L1 systems entirely independent observed frequency c
0.18210748.11815585.html.plaintext.txt	80	This frequency indicates single site mutations result expression genes implying common components control L1 L2 gene expression
0.18210748.11815585.html.plaintext.txt	81	Acknowledgements Top Abstract Introduction Materials methods Results Discussion Acknowledgements References This work funded grants British Society Antimicrobial Chemotherapy M
0.18210748.11815585.html.plaintext.txt	82	receipt Biotechnology Biological Sciences Research Council CASE studentship collaboration GlaxoSmithKline pharmaceuticals
0.18210748.11815585.html.plaintext.txt	83	Notes Correspondence address
0.18210748.11815585.html.plaintext.txt	84	Department Biochemistry School Medical Sciences University Bristol University Walk Bristol BS8 1TD UK
0.18210748.11815585.html.plaintext.txt	85	Tel 44 117 9287439 Fax 44 117 9287896 E mail matthewb
0.18210748.11815585.html.plaintext.txt	86	References Top Abstract Introduction Materials methods Results Discussion Acknowledgements References 1
0.18210748.11815585.html.plaintext.txt	87	An assessment impact antibiotic resistance different bacterial species contribution animal sources resistance human infections
0.18210748.11815585.html.plaintext.txt	88	Journal Antimicrobial Chemotherapy 46 643 5
0.18210748.11815585.html.plaintext.txt	89	Microbial clinical aspects infection associated Stenotrophomonas maltophilia
0.18210748.11815585.html.plaintext.txt	90	Clinical Microbiology Reviews 11 57 80
0.18210748.11815585.html.plaintext.txt	91	Plasmid location molecular heterogeneity L1 L2 ss lactamase genes Stenotrophomonas maltophilia
0.18210748.11815585.html.plaintext.txt	92	Antimicrobial Agents Chemotherapy 45 413 9
0.18210748.11815585.html.plaintext.txt	93	Aeromonas hydrophila AmpH CepH ss lactamases derepressed expression Escherichia coli mutants lacking creB
0.18210748.11815585.html.plaintext.txt	94	Journal Antimicrobial Chemotherapy 46 695 702
0.18210748.11815585.html.plaintext.txt	95	Escherichia coli CreBC global regulator gene expression responds growth minimal media
0.18210748.11815585.html.plaintext.txt	96	Journal Biological Chemistry 276 26955 61
0.18210748.11815585.html.plaintext.txt	97	Over expression purification characterization cloned metallo ss lactamase L1 Stenotrophomonas maltophilia
0.18210748.11815585.html.plaintext.txt	98	Antimicrobial Agents Chemotherapy 42 921 6
0.18210748.11815585.html.plaintext.txt	99	Susceptibility ss lactam antibiotics mutant strains Xanthomonas maltophilia high low level constitutive expression L1 L2 ss lactamases
0.18210748.11815585.html.plaintext.txt	100	Journal Medical Microbiology 35 208 13
0.18210748.11815585.html.plaintext.txt	101	Clinical isolates Xanthomonas maltophilia producing L1 deficient L2 inducible ss lactamases
0.18210748.11815585.html.plaintext.txt	102	Sequence elements determining ampC promoter strength E
0.18210748.11815585.html.plaintext.txt	103	Induction ss lactamases Enterobacter cloacae
0.18210748.11815585.html.plaintext.txt	104	Clinical Infectious Diseases 27 S42 7
0.18210748.11815585.html.plaintext.txt	105	Received 15 May 2001 returned 26 October 2001 revised 5 November 2001 accepted 8 November 2001
0.33389336.14634007.html.plaintext.txt	0	Crystal Structure E2 Transactivation Domain Human Papillomavirus Type 11 Bound Protein Interaction Inhibitor Yong Wang Rene Coulombe Dale R
0.33389336.14634007.html.plaintext.txt	1	Cameron Louise Thauvette Marie Josee Massariol Lynn M
0.33389336.14634007.html.plaintext.txt	2	Amon Dominique Fink Steve Titolo Ewald Welchner Christiane Yoakim Jacques Archambault Peter W
0.33389336.14634007.html.plaintext.txt	3	From Department Biological Sciences Department Chemistry Boehringer Ingelheim Canada Ltd
0.33389336.14634007.html.plaintext.txt	4	Laval Quebec H7S 2G5 Canada Department Medicinal Chemistry Boehringer Ingelheim Pharmaceuticals Inc
0.33389336.14634007.html.plaintext.txt	5	Ridgefield Connecticut 06877
0.33389336.14634007.html.plaintext.txt	6	Received publication October 16 2003 revised form November 21 2003
0.33389336.14634007.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Interaction E2 protein E1 helicase human papillomaviruses HPVs essential initiation viral DNA replication
0.33389336.14634007.html.plaintext.txt	8	We recently described series small molecules bind N terminal transactivation domain TAD HPV type 11 E2 inhibits interaction E1 vitro cellular assays
0.33389336.14634007.html.plaintext.txt	9	Here report crystal structures HPV11 TAD complex domain inhibitor 2
0.33389336.14634007.html.plaintext.txt	10	The HPV11 TAD structure similar analogous domain HPV16
0.33389336.14634007.html.plaintext.txt	11	Inhibitor binding caused significant alteration protein backbone movements several amino acid side chains binding site particular Tyr 19 His 32 Leu 94 Glu 100 resulted formation deep hydrophobic pocket accommodates indandione moiety inhibitor
0.33389336.14634007.html.plaintext.txt	12	Mutational analysis provides functional evidence specific interactions Tyr 19 E1 His 32 inhibitor
0.33389336.14634007.html.plaintext.txt	13	A second inhibitor molecule also present binding pocket
0.33389336.14634007.html.plaintext.txt	14	Although evidence presented second molecule makes weak interactions protein likely artifact crystallization presence defines additional regions binding pocket could exploited design potent inhibitors
0.33389336.14634007.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Human papillomaviruses HPVs1 etiological agents malignant benign lesions differentiating squamous mucosal epithelium notably cervical cancer
0.33389336.14634007.html.plaintext.txt	16	Approximately 25 HPV types replicate mucosal tissues anogenital tract
0.33389336.14634007.html.plaintext.txt	17	HPV16 18 31 prevalent high risk types found pre cancerous malignant lesions cervix
0.33389336.14634007.html.plaintext.txt	18	HPV6 11 common low risk types cause benign genital warts condyloma acuminata less serious condition one common sexually transmitted diseases 1
0.33389336.14634007.html.plaintext.txt	19	Currently specific antivirals available treatment HPV infections
0.33389336.14634007.html.plaintext.txt	20	The small circular double stranded DNA genome papillomavirus actively maintained multicopy episome nucleus infected epithelial cells
0.33389336.14634007.html.plaintext.txt	21	This process dependent replication viral genome viral E1 E2 proteins conjunction host DNA replication machinery
0.33389336.14634007.html.plaintext.txt	22	E2 sequence specific DNA binding protein number functions viral lifecycle
0.33389336.14634007.html.plaintext.txt	23	In addition role initiation viral DNA replication E2 involved regulating transcription viral genes 2 7 segregation viral genome cell division 8 9
0.33389336.14634007.html.plaintext.txt	24	As replication initiation factor E2 binds high affinity specific sites located within viral origin ori help recruit E1 helicase 10 13
0.33389336.14634007.html.plaintext.txt	25	Formation ternary complex E1 E2 origin relies interaction E1 E2 specific DNA sequences origin also critically dependent direct interaction two proteins 14 18
0.33389336.14634007.html.plaintext.txt	26	The 40 kDa E2 protein exists solution dimer consists N terminal transactivation domain TAD 200 residues C terminal DNA bindingdimerization domain 100 residues connecting hinge region 70 amino acids 19
0.33389336.14634007.html.plaintext.txt	27	The N terminal TAD region E2 binds E1 14 15 18
0.33389336.14634007.html.plaintext.txt	28	Crystal structures reported TAD HPV16 amino acids 1 201 20 truncated TAD HPV18 amino acids 66 215 lacking two N terminal helices 21
0.33389336.14634007.html.plaintext.txt	29	The HPV16 18 TADs share 45 sequence identity see Fig
0.33389336.14634007.html.plaintext.txt	30	1 similar L shaped structure composed three helix bundle partly missing structure truncated HPV18 TAD followed antiparallel sheet
0.33389336.14634007.html.plaintext.txt	31	View larger version 71K FIG
0.33389336.14634007.html.plaintext.txt	32	Sequences E2 transactivation domains prevalent anogenital HPV types
0.33389336.14634007.html.plaintext.txt	33	Sequence alignment N terminal 201 amino acids E2 proteins two low risk HPV11 6a three high risk HPV16 31 18 HPV types
0.33389336.14634007.html.plaintext.txt	34	The two pairs HPV11 6 well HPV16 31 80 identical
0.33389336.14634007.html.plaintext.txt	35	For possible pairwise combinations sequence identity 45
0.33389336.14634007.html.plaintext.txt	36	The position every 10th amino acid HPV11 numbering marked numbering individual sequences given beginning every line
0.33389336.14634007.html.plaintext.txt	37	Conserved residues colored red 12 residues within 4
0.33389336.14634007.html.plaintext.txt	38	5 A inhibitor A highlighted asterisks
0.33389336.14634007.html.plaintext.txt	39	Secondary structural elements helices orange strands blue indicated according position HPV11 structures
0.33389336.14634007.html.plaintext.txt	40	We recently described series small molecules antagonize E1 E2 protein protein interaction binding reversibly E2 TAD 22 23
0.33389336.14634007.html.plaintext.txt	41	This class inhibitors termed indandiones feature indandione system spirofused onto substituted tetrahydrofuran ring blocks assembly HPV11 E1 E2 ori ternary complex submicromolar concentrations vitro abrogates viral DNA replication transient transfection assay
0.33389336.14634007.html.plaintext.txt	42	To knowledge small molecule inhibitors HPV DNA replication cellular activity
0.33389336.14634007.html.plaintext.txt	43	Here report three dimensional structure HPV11 TAD TAD indandione inhibitor complex
0.33389336.14634007.html.plaintext.txt	44	The HPV11 TAD structure similar analogous domains HPV16 18
0.33389336.14634007.html.plaintext.txt	45	Inhibitor binding significantly affect protein backbone results formation deep pocket makes several well defined interactions inhibitor
0.33389336.14634007.html.plaintext.txt	46	Residues previously implicated binding E1 indandione inhibitors including Gln 12 24 Glu 39 25 27 Glu 100 23 near pocket
0.33389336.14634007.html.plaintext.txt	47	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Proteins Wild type WT HPV11 E2 TAD N terminal polyhistidine tag His TAD sequence MGHHHHHH followed E2 amino acids 2 201 purified bacteria described 23
0.33389336.14634007.html.plaintext.txt	48	To incorporate selenomethionine protein expressed Escherichia coli strain B834 28 methionine auxotroph grown DL30 medium 29 lacking methionine supplemented 2 microgml biotin thiamin 50 microgml seleno DL methionine Se Met
0.33389336.14634007.html.plaintext.txt	49	Purification performed described WT protein except buffers sparged helium purification steps completed within 1 day
0.33389336.14634007.html.plaintext.txt	50	Addition 4 lysine tail C terminus His TAD performed PCR using primer encoding four lysines followed ligation PCR product plasmid pET15b Novagen
0.33389336.14634007.html.plaintext.txt	51	The encoded His Lys TAD protein purified described His TAD
0.33389336.14634007.html.plaintext.txt	52	Electrospray mass spectrometry used verify molecular weights three proteins determine lacked N terminal methionine
0.33389336.14634007.html.plaintext.txt	53	Complete incorporation Se Met also verified amino acid analysis
0.33389336.14634007.html.plaintext.txt	54	Purified proteins 95 pure SDS PAGE
0.33389336.14634007.html.plaintext.txt	55	Protein concentrations determined absorbance 280 nm using molar extinction coefficient 49060 M 1 cm 1
0.33389336.14634007.html.plaintext.txt	56	Site directed mutagenesis HPV11 HPV6 HPV31 E2 His Lys TAD performed using QuikChange kit Stratagene according instructions supplied manufacturer
0.33389336.14634007.html.plaintext.txt	57	E2 proteins synthesized vitro coupled transcriptiontranslation using TNT reticulocyte lysate system Promega
0.33389336.14634007.html.plaintext.txt	58	Inhibitors Inhibitors synthesized procedures described compounds series 22
0.33389336.14634007.html.plaintext.txt	59	Single enantiomers isolated chiral chromatography
0.33389336.14634007.html.plaintext.txt	60	Radiolabeled inhibitor 3 synthesized enantiomerically pure Boc protected amine precursor
0.33389336.14634007.html.plaintext.txt	61	The acetate moiety tritiated methyl group incorporated using 3HN acetoxyphthalimide American Radiolabeled Chemicals Inc
0.33389336.14634007.html.plaintext.txt	62	Specific activity product 9
0.33389336.14634007.html.plaintext.txt	63	Size exclusion Chromatography Size exclusion chromatography performed using SMART System Pharmacia Superdex 75 PC 3
0.33389336.14634007.html.plaintext.txt	64	230 column buffer composed 25 mM Tris HCl pH 8
0.33389336.14634007.html.plaintext.txt	65	1 mM EDTA flow rate 40 microlm
0.33389336.14634007.html.plaintext.txt	66	All buffers adjusted room temperature stated pH
0.33389336.14634007.html.plaintext.txt	67	Analytical Ultracentrifugation Sedimentation velocity equilibrium experiments performed 20 degrees C using XL A analytical ultracentrifuge Beckman Spinco An 60 Ti rotor 1
0.33389336.14634007.html.plaintext.txt	68	2 cm charcoal filled Epon centerpieces double sector velocity six sector equilibrium quartz windows
0.33389336.14634007.html.plaintext.txt	69	TAD proteins exchanged buffer composed 20 mM Tris pH 8
0.33389336.14634007.html.plaintext.txt	70	Velocity data collected 60000 rpm 0
0.33389336.14634007.html.plaintext.txt	71	005 cm intervals 5 replicate readings per point
0.33389336.14634007.html.plaintext.txt	72	Protein concentrations 16 microM
0.33389336.14634007.html.plaintext.txt	73	Scans spaced closely absorbance optics would allow
0.33389336.14634007.html.plaintext.txt	74	Equilibrium data collected successively 26000 30000 38000 rpm using TAD concentrations 2 8 microM
0.33389336.14634007.html.plaintext.txt	75	5 replicate readings taken 0
0.33389336.14634007.html.plaintext.txt	76	Scans taken every hour speed system judged reached equilibrium difference observed successive scans determined subtraction using Origin software Microcal
0.33389336.14634007.html.plaintext.txt	77	01922 gml protein partial specific volumes 20 degrees C 0
0.33389336.14634007.html.plaintext.txt	78	7311 cm3g HPV11 His TAD HPV11 His Lys TAD respectively calculated using program SEDNTERP 30
0.33389336.14634007.html.plaintext.txt	79	Velocity data analyzed using program SVEDBERG 6
0.33389336.14634007.html.plaintext.txt	80	38 31 equilibrium data analyzed using WinNonlin 1
0.33389336.14634007.html.plaintext.txt	81	For equilibrium experiments data truncated absorbance 1
0.33389336.14634007.html.plaintext.txt	82	0 corresponds TAD concentration 17 microM
0.33389336.14634007.html.plaintext.txt	83	Very similar molecular weight estimates obtained data absorbance 1
0.33389336.14634007.html.plaintext.txt	84	2 retained variances higher residuals nonrandom
0.33389336.14634007.html.plaintext.txt	85	Isothermal Titration Calorimetry Titration inhibitor 1 solution HPV11 His Lys TAD performed using VP isothermal titration calorimetry instrument MicroCal Inc
0.33389336.14634007.html.plaintext.txt	86	buffer composed 20 mM Tris pH 7
0.33389336.14634007.html.plaintext.txt	87	1 mM EDTA 1 vv Me2SO 20 degrees C analyzed described previously 23
0.33389336.14634007.html.plaintext.txt	88	Data blank run using solution compound 1 injected buffer without His Lys TAD subtracted inhibitor protein run prior fitting data one site binding model
0.33389336.14634007.html.plaintext.txt	89	Crystallization Data Collection Final crystals apo HPV11 His TAD containing either Met Se Met obtained 4 degrees C using micro seeding hanging drop vapor diffusion plate
0.33389336.14634007.html.plaintext.txt	90	The precipitant solution composed 0
0.33389336.14634007.html.plaintext.txt	91	0 18 PEG 5000 monomethyl ether 0
0.33389336.14634007.html.plaintext.txt	92	Diffraction data Se Met E2 TAD collected ADSC Q4 CCD National Synchrotron Light Source beamline X4a Brookhaven National Laboratory NY
0.33389336.14634007.html.plaintext.txt	93	Four datasets collected single crystal cooled 100 K four different wavelengths near selenium absorption edge 0
0.33389336.14634007.html.plaintext.txt	94	The first dataset selected structure refinement data collection statistics dataset listed Table I
0.33389336.14634007.html.plaintext.txt	95	View table TABLE I Crystallographic data HPV11 E2 TAD structures
0.33389336.14634007.html.plaintext.txt	96	The complex His Lys TAD inhibitor 1 formed adding 1 microl 60 mM solution 1 BILH 434 Me2SO 74 microl His Lys TAD 10 mgml purification buffer incubating mixture ice 2 3 h
0.33389336.14634007.html.plaintext.txt	97	Crystals obtained vapor diffusion using precipitant solution composed 0
0.33389336.14634007.html.plaintext.txt	98	5 35 methyl 24 pentanediol
0.33389336.14634007.html.plaintext.txt	99	Diffraction data collected National Synchrotron Light Source beamline X25 Brookhaven National Laboratory NY
0.33389336.14634007.html.plaintext.txt	100	Data single crystal cooled 100 K recorded Brandeis B4 detector Brandeis University mounted axis goniometer Enraf Nonius The Netherlands
0.33389336.14634007.html.plaintext.txt	101	Data collection statistics listed Table I
0.33389336.14634007.html.plaintext.txt	102	Structure Determination Refinement All data processed HKL software Denzo Scalepack Table I
0.33389336.14634007.html.plaintext.txt	103	Initial phasing Se Met HPV11 His TAD Multiwavelength Anomalous Dispersion data done using software SHARP 33 selenium sites located SHELX 34
0.33389336.14634007.html.plaintext.txt	104	Model building initial electron density maps carried using software O Alwyn Jones Uppsala University Sweden model refinement done software CNX Accelrys
0.33389336.14634007.html.plaintext.txt	105	At later stage model building also helped molecular replacement phasing CNX using published HPV16 coordinates Protein Data Bank code 1DTO PDB 20
0.33389336.14634007.html.plaintext.txt	106	10 data used test set Rfree calculation
0.33389336.14634007.html.plaintext.txt	107	The final model includes residues 3 121 128 195 Table I 15 residues modeled alanines inadequate electron density side chains Lys 6 Asp 9 Glu 17 Gln 48 Glu 66 Lys 107 Lys 120 Val 128 Lys 173 Ser 180 Thr 181 Asn 182 His 183 Ser 190 Ser 195
0.33389336.14634007.html.plaintext.txt	108	The structure His Lys TAD 1 complex solved molecular replacement using refined HPV11 His TAD model
0.33389336.14634007.html.plaintext.txt	109	This final model includes residues 2 196 side chains modeled correct residue two molecules inhibitor 1 27 water molecules one molecule Me2SO one partially defined buffer molecule statistics Table I
0.33389336.14634007.html.plaintext.txt	110	The refined atomic coordinates structure factors deposited Protein Data Bank accession codes 1R6K 1R6N TAD TADinhibitor 1 structures respectively
0.33389336.14634007.html.plaintext.txt	111	Computational Studies The atoms making binding pocket identified applying Site Finder application within MOE software package Chemical Computing Group Inc
0.33389336.14634007.html.plaintext.txt	112	Montreal Canada crystal structure complex inhibitors well solvent atoms removed
0.33389336.14634007.html.plaintext.txt	113	The isolated donor acceptor radius 3
0.33389336.14634007.html.plaintext.txt	114	0 A connection distance 2
0.33389336.14634007.html.plaintext.txt	115	Inhibitor protein binding affinities evaluated using empirical scoring functions PMF 35 PLP 36 LUDI 37
0.33389336.14634007.html.plaintext.txt	116	Each inhibitor protein interaction evaluated removal inhibitor well solvent atoms except one water molecule His 29 His 32 appears hydrogen bonded residues
0.33389336.14634007.html.plaintext.txt	117	For calculations hydrogen atoms added residues molecules
0.33389336.14634007.html.plaintext.txt	118	E1 E2 Ori Complex Formation Assay This assay performed using vitro translated E2 proteins described previously 23
0.33389336.14634007.html.plaintext.txt	119	Briefly binding reactions 80 microl consisted HPV11 E1 containing insect cell nuclear extract titrated give 70 maximal activity purified WT HPV11 E2 2 microl vitro translated E2 0
0.33389336.14634007.html.plaintext.txt	120	4 ng ori probe generated PCR using 33PdCTP
0.33389336.14634007.html.plaintext.txt	121	Negative controls contained E2 protein E1 extract
0.33389336.14634007.html.plaintext.txt	122	Signals detected capturing E1 E2 ori complexes using anti E1 coated scintillation proximity beads
0.33389336.14634007.html.plaintext.txt	123	Circular Dichroism CD Spectroscopy Far UV CD spectra acquired 260 187 nm using J 715 spectropolarimeter Jasco 0
0.33389336.14634007.html.plaintext.txt	124	05 cm cell room temperature approximately 23 degrees C
0.33389336.14634007.html.plaintext.txt	125	Proteins diluted 5 microM buffer composed 20 mM sodium phosphate pH 7
0.33389336.14634007.html.plaintext.txt	126	A total 5 accumulations taken sample speed 20 nmm resolution 0
0.33389336.14634007.html.plaintext.txt	127	2 nm response 2 bandwidth 1
0.33389336.14634007.html.plaintext.txt	128	Differential Scanning Calorimetry Melting temperatures TAD proteins determined using VP DSC MicroCal Inc
0.33389336.14634007.html.plaintext.txt	129	TAD proteins exchanged buffer composed 50 mM Tris pH 7
0.33389336.14634007.html.plaintext.txt	130	5 mM TCEP adjusted 5 microM filtered degassed
0.33389336.14634007.html.plaintext.txt	131	Temperature scanned 10 65 degrees C 1
0.33389336.14634007.html.plaintext.txt	132	Unfolding conditions irreversible TAD proteins relative denaturation temperatures estimated buffer subtraction fitting Cp versus temperature curves modified two state model 38 using Origin software supplied instrument
0.33389336.14634007.html.plaintext.txt	133	It acceptable use equations equilibrium thermodynamics analyze unfolding events practice irreversible irreversibility typically results secondary slower events aggregation 39
0.33389336.14634007.html.plaintext.txt	134	Binding Tritiated 3 TAD Proteins Titrations performed 96 well nickel chelate Flashplates PerkinElmer Life Sciences using 50 nM His Lys TAD protein 4 500 nM tritiated inhibitor 3 buffer composed 25 mM MOPS pH 7
0.33389336.14634007.html.plaintext.txt	135	0025 vv Tween 20 2 Me2SO
0.33389336.14634007.html.plaintext.txt	136	After 3 h incubation allow equilibration interactions His Lys TAD nickel plate inhibitor 3 signals bound 3 detected scintillation counting using TopCount NXT PerkinElmer Life Sciences
0.33389336.14634007.html.plaintext.txt	137	Blank titrations compound 3 wells lacking His Lys TAD performed parallel signals nonspecific binding compound subtracted prior data analysis
0.33389336.14634007.html.plaintext.txt	138	Signals ranged 30 4000 cpm negative controls 120 7000 WT TAD prior blank subtraction
0.33389336.14634007.html.plaintext.txt	139	Binding data analyzed non linear regression GraFit 3
0.33389336.14634007.html.plaintext.txt	140	using quadratic equation
0.33389336.14634007.html.plaintext.txt	141	Max denotes countsmin observed saturation
0.33389336.14634007.html.plaintext.txt	142	ATPase Assays ATPase activity purified recombinant E1 40 measured using scintillation proximity assay described previously 40 41
0.33389336.14634007.html.plaintext.txt	143	The concentration HPV11 E1 3 nM ATP magnesium acetate used 20 500 microM respectively
0.33389336.14634007.html.plaintext.txt	144	After subtraction background measured reactions lacking E1 inhibition data fit three parameter logistic using SAS release 6
0.33389336.14634007.html.plaintext.txt	145	TAD mutants Y19A E39A inhibited weakly IC50 Imax parameters could estimated
0.33389336.14634007.html.plaintext.txt	146	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Expression Purification Characterization HPV11 E2 TAD The HPV11 E2 TAD amino acids 1 201 Fig
0.33389336.14634007.html.plaintext.txt	147	coli N terminal polyhistidine tagged protein
0.33389336.14634007.html.plaintext.txt	148	The purified protein eluted sharp peak analyzed analytical size exclusion chromatography Fig
0.33389336.14634007.html.plaintext.txt	149	2A comparison elution time molecular mass standards gave estimated mass 24
0.33389336.14634007.html.plaintext.txt	150	7 kDa close expected monomer based sequence 23
0.33389336.14634007.html.plaintext.txt	151	View larger version 24K FIG
0.33389336.14634007.html.plaintext.txt	152	Biophysical characterization HPV11 TAD
0.33389336.14634007.html.plaintext.txt	153	A analytical size exclusion chromatography
0.33389336.14634007.html.plaintext.txt	154	15 mg HPV11 His TAD injected onto SMART Superdex 75 column elution volume 1
0.33389336.14634007.html.plaintext.txt	155	The elution volumes standards analyzed using buffer indicated diamonds ovalbumin 44 kDa 1
0.33389336.14634007.html.plaintext.txt	156	The apparent TAD molecular weight estimated plot log Mr versus elution volume three molecular weight standards
0.33389336.14634007.html.plaintext.txt	157	B equilibrium sedimentation data HPV11 His TAD
0.33389336.14634007.html.plaintext.txt	158	The data shown absorbance 280 nm versus radius r22 cm2 obtained 30000 rpm 20 degrees C
0.33389336.14634007.html.plaintext.txt	159	The initial TAD concentration 4 microM
0.33389336.14634007.html.plaintext.txt	160	The line corresponds fit obtained data runs Table II using model assumes presence monomeric TAD
0.33389336.14634007.html.plaintext.txt	161	The deviations experimental data fit also plotted
0.33389336.14634007.html.plaintext.txt	162	C isothermal titration calorimetry
0.33389336.14634007.html.plaintext.txt	163	Top raw data obtained 20 degrees C 16 microl injections inhibitor 1 120 microM sample cell containing HPV11 E2 TAD 1
0.33389336.14634007.html.plaintext.txt	164	Bottom calculated enthalpies subtraction background described Experimental Procedures
0.33389336.14634007.html.plaintext.txt	165	Data fit simple one binding site model give Ka 2
0.33389336.14634007.html.plaintext.txt	166	07 kcalmol stoichiometry 0
0.33389336.14634007.html.plaintext.txt	167	Based values Ka H entropy binding TS 3
0.33389336.14634007.html.plaintext.txt	168	The HPV11 TAD also appeared monomeric analytical ultracentrifugation
0.33389336.14634007.html.plaintext.txt	169	In equilibrium sedimentation experiment significant trends apparent mass observed increasing rotor speed loading concentration Table II
0.33389336.14634007.html.plaintext.txt	170	Such trend would observed protein formed mixture monomers dimers experimental conditions 42
0.33389336.14634007.html.plaintext.txt	171	Data centrifugation velocity experiment best fit estimated average molecular mass 22
0.33389336.14634007.html.plaintext.txt	172	5 kDa single species based individual parameters S 1
0.33389336.14634007.html.plaintext.txt	173	Collectively results indicate HPV11 E2 TAD fully monomeric solution concentration range studied 20 microM
0.33389336.14634007.html.plaintext.txt	174	View table TABLE II Analytical ultracentrifugation data HPV11 His TAD
0.33389336.14634007.html.plaintext.txt	175	Equilibrium centrifugation parameters obtained 20 degrees C using three HPV11 TAD concentrations spun three speeds
0.33389336.14634007.html.plaintext.txt	176	Absorbance 280 nm versus radius r22 data see example Fig
0.33389336.14634007.html.plaintext.txt	177	2B analyzed individually using program WinNonlin
0.33389336.14634007.html.plaintext.txt	178	Global analysis runs assuming monomer present gave 1
0.33389336.14634007.html.plaintext.txt	179	An even soluble version HPV11 TAD containing 4 lysines C terminus also purified also found monomeric size exclusion chromatography analytical ultracentrifugation data shown
0.33389336.14634007.html.plaintext.txt	180	3 Lys tailed TAD analyzed isothermal titration calorimetry
0.33389336.14634007.html.plaintext.txt	181	Formation 11 complex observed Kd value 40 nM Fig
0.33389336.14634007.html.plaintext.txt	182	View larger version 14K FIG
0.33389336.14634007.html.plaintext.txt	183	Inhibitor 1 BILH 434 used calorimetry crystallization studies IC50 180 nM E1 E2 ori complex formation assay
0.33389336.14634007.html.plaintext.txt	184	Inhibitor 2 used obtain results Table IV
0.33389336.14634007.html.plaintext.txt	185	Inhibitor 3 carrying tritiated methyl group used obtain results Fig
0.33389336.14634007.html.plaintext.txt	186	The unlabeled analogue compound IC50 100 nM E1 E2 ori complex formation assay Kd TAD binding 40 nM determined isothermal titration calorimetry
0.33389336.14634007.html.plaintext.txt	187	All three inhibitors single enantiomers absolute configuration shown
0.33389336.14634007.html.plaintext.txt	188	Crystal Structure Apo HPV11 E2 TAD The structure HPV11 TAD determined Multiwavelength Anomalous Dispersion diffraction data obtained using crystals protein labeled Se Met see Experimental Procedures
0.33389336.14634007.html.plaintext.txt	189	Overall structure HPV11 TAD shown Fig
0.33389336.14634007.html.plaintext.txt	190	4 similar previously reported analogous domain HPV16
0.33389336.14634007.html.plaintext.txt	191	The C superposition HPV11 16 structures 187 residues yielded r
0.33389336.14634007.html.plaintext.txt	192	54 A secondary structural elements conserved
0.33389336.14634007.html.plaintext.txt	193	The major differences slight twist 1 degrees relative orientation helical sheet subdomains variations position loops particular comprised residues 140 143 160 165 involved crystal packing HPV16 HPV11 structures respectively
0.33389336.14634007.html.plaintext.txt	194	The N terminal amino acids 3 94 C terminal amino acids 95 195 subdomains individually superimposed r
0.33389336.14634007.html.plaintext.txt	195	Interestingly HPV11 protein crystal lattice distinct reported HPV16 different monomer monomer interface observed HPV11 crystal structure
0.33389336.14634007.html.plaintext.txt	196	View larger version 51K FIG
0.33389336.14634007.html.plaintext.txt	197	Comparison HPV11 HPV16 TAD structures
0.33389336.14634007.html.plaintext.txt	198	All C superposition HPV11 His TAD 1R6K HPV16 His TAD Protein Data Bank code 1DTO PDB 20 proteins
0.33389336.14634007.html.plaintext.txt	199	The HPV11 structure shown red HPV16 shown blue
0.33389336.14634007.html.plaintext.txt	200	The location loops amino acids 122 127 modeled HPV11 structure 140 143 160 165 well superimposed crystal packing differences also indicated
0.33389336.14634007.html.plaintext.txt	201	Crystal Structure HPV11 E2 TAD Inhibitor Complex We obtained crystals soluble Lys tailed TAD complex compound 1 albeit using different conditions used crystallize apo His TAD
0.33389336.14634007.html.plaintext.txt	202	The space group crystals also different previous TAD structures Table I
0.33389336.14634007.html.plaintext.txt	203	The conformation HPV11 TAD within complex Fig
0.33389336.14634007.html.plaintext.txt	204	5A similar observed apoprotein backbone C could superimposed r
0.33389336.14634007.html.plaintext.txt	205	The two inhibitor 1 molecules free carboxylate form drawn Fig
0.33389336.14634007.html.plaintext.txt	206	3 one two distinct forms class inhibitors adopts solution 43
0.33389336.14634007.html.plaintext.txt	207	The presence crystal structure free carboxylate form confirms prediction form one inhibitory activity 43
0.33389336.14634007.html.plaintext.txt	208	View larger version 61K FIG
0.33389336.14634007.html.plaintext.txt	209	Structure HPV11 TAD inhibitor 1 complex
0.33389336.14634007.html.plaintext.txt	210	A stereo view complex two inhibitor molecules bound HPV11 TAD 1R6N
0.33389336.14634007.html.plaintext.txt	211	Inhibitor molecule B molecule A
0.33389336.14634007.html.plaintext.txt	212	B stereo view molecular surface HPV11 TAD inhibitor molecules A bottom B top
0.33389336.14634007.html.plaintext.txt	213	Spheres corresponding locations within binding site ligand atoms predicted make particularly favorable interactions protein shown yellow amino acids comprise small molecule binding pocket shown magenta
0.33389336.14634007.html.plaintext.txt	214	The indandione moiety inhibitor B left portion view shown well protein surface 7 A nearest residue binding pocket
0.33389336.14634007.html.plaintext.txt	215	C stereo view selected amino acids within 4 A inhibitor A shown appear apo structure magenta inhibitor TAD complex green
0.33389336.14634007.html.plaintext.txt	216	Inhibitor A shown orange
0.33389336.14634007.html.plaintext.txt	217	The relative positions residues based C superposition two structures
0.33389336.14634007.html.plaintext.txt	218	Thin green lines indicate hydrogen bonds inhibitor carboxylate main chain amide nitrogens residues 99 100
0.33389336.14634007.html.plaintext.txt	219	Because demonstrated TAD inhibitor 1 form 11 complex solution surprised find two molecules inhibitor bound per protein monomer Fig
0.33389336.14634007.html.plaintext.txt	220	We believe molecule referred inhibitor A one binds tightly biological assays see
0.33389336.14634007.html.plaintext.txt	221	In contrast inhibitor B appears interact weakly secondary binding pocket formed TAD protein alone also part one surface inhibitor A well residues adjacent protein monomer crystal lattice
0.33389336.14634007.html.plaintext.txt	222	In fact inhibitor B approximately equal surface area contact two TAD molecules well inhibitor A data shown
0.33389336.14634007.html.plaintext.txt	223	The close contact two inhibitor molecules may distort observed interaction TAD dichlorophenyl ring inhibitor A see
0.33389336.14634007.html.plaintext.txt	224	The TAD TAD interface incorporates inhibitor B distinct apo structure fact result formation dimer rather infinite array along 41 screw axis crystal unlikely exist solution except high protein inhibitor concentrations
0.33389336.14634007.html.plaintext.txt	225	To demonstrate region TAD near inhibitor A constitutes better binding pocket one near B computational analysis protein surface performed using Site Finder application within MOE software package see Experimental Procedures
0.33389336.14634007.html.plaintext.txt	226	This program uses shape based algorithm 44 identify concave regions protein surface
0.33389336.14634007.html.plaintext.txt	227	Furthermore evaluates whether cavities appropriate composition hydrophobic hydrophilic atoms hydrophilic cavities likely highly solvated thus interact weakly organic molecules aqueous solution
0.33389336.14634007.html.plaintext.txt	228	The TAD surface evaluated removal two inhibitors residues comprised best small molecule binding pocket highlighted Fig
0.33389336.14634007.html.plaintext.txt	229	Inhibitor A makes number close contacts highlighted residues described
0.33389336.14634007.html.plaintext.txt	230	Inhibitor B located periphery pocket make well defined hydrogen bonding Van der Waals interactions
0.33389336.14634007.html.plaintext.txt	231	The dichlorophenyl ring inhibitor B 4 A nearest pocket atoms portions molecule protein surface indandione moiety make closest contact non pocket atoms thiadiazoylphenyl moiety
0.33389336.14634007.html.plaintext.txt	232	In separate computational study binding energies inhibitor molecule TAD absence predicted using three different empirical protein binding scoring functions Table III
0.33389336.14634007.html.plaintext.txt	233	As expected results significantly favored binding inhibitor A relative B predicted binding energies 2 fold higher inhibitor A
0.33389336.14634007.html.plaintext.txt	234	Taken together different methods suggest inhibitor A solely responsible inhibition low concentrations used biological assays presence inhibitor B might artifact crystallization
0.33389336.14634007.html.plaintext.txt	235	This suggestion supported mutational analysis inhibitor binding pocket presented
0.33389336.14634007.html.plaintext.txt	236	Although artifact possible fortuitous presence second molecule aided crystallization complex
0.33389336.14634007.html.plaintext.txt	237	View table TABLE III Estimated binding affinities inhibitors A B
0.33389336.14634007.html.plaintext.txt	238	Three empirical scoring functions applied compound 1 bound location either inhibitor A B
0.33389336.14634007.html.plaintext.txt	239	For PMF 35 PLP 36 lower negative score indicates better affinity whereas LUDI 37 higher score predicts better affinity
0.33389336.14634007.html.plaintext.txt	240	For program scores proportional predicted binding energies
0.33389336.14634007.html.plaintext.txt	241	5 A 12 residues marked asterisks Fig
0.33389336.14634007.html.plaintext.txt	242	1 backbone superposition apo complex structures gives r
0.33389336.14634007.html.plaintext.txt	243	However binding inhibitor induces significant movement several amino acid side chains
0.33389336.14634007.html.plaintext.txt	244	The indandione moiety inhibitor buried pocket present apo structure results rotations side chains Tyr 19 1 85 degrees 2 40 degrees His 32 2 90 degrees Fig
0.33389336.14634007.html.plaintext.txt	245	In apo structure aromatic rings His 32 Trp 33 form T shaped edge face structure hydroxyl group Tyr 19 close enough form hydrogen bond nitrogen His 32
0.33389336.14634007.html.plaintext.txt	246	In complex structure interaction lost rings His 32 Trp 33 become parallel
0.33389336.14634007.html.plaintext.txt	247	Two side chains Leu 94 Glu 100 also adjust conformations accommodate inhibitor Fig
0.33389336.14634007.html.plaintext.txt	248	Together changes side chain conformation result formation observed binding pocket Fig
0.33389336.14634007.html.plaintext.txt	249	View larger version 121K FIG
0.33389336.14634007.html.plaintext.txt	250	Amino acids form inhibitor binding pocket
0.33389336.14634007.html.plaintext.txt	251	Residues discussed text colored follows Tyr 19 His 32 magenta Leu 94 Glu 100 yellow left right respectively Trp 33 blue Met 101 cyan
0.33389336.14634007.html.plaintext.txt	252	Residues surrounding shallow end binding pocket colored red
0.33389336.14634007.html.plaintext.txt	253	The new positions Tyr 19 His 32 open pocket also allow indandione moiety inhibitor become middle layer three tier stacking interaction His 32 Trp 33
0.33389336.14634007.html.plaintext.txt	254	Additional Van der Waals contacts Leu 94 side chain result highly complementary shape deepest part pocket
0.33389336.14634007.html.plaintext.txt	255	Two important interactions made backbone nitrogen atoms Tyr 99 Glu 100 distance 2
0.33389336.14634007.html.plaintext.txt	256	77 A angle atoms inhibitor carboxylate oxygens suggests formation strong hydrogen bonds Fig
0.33389336.14634007.html.plaintext.txt	257	Remaining contacts inhibitor A pocket less well defined hydrophobic interactions
0.33389336.14634007.html.plaintext.txt	258	The dichlorophenyl ring lies wider shallower portion pocket without making obvious specific interactions
0.33389336.14634007.html.plaintext.txt	259	Although found previous studies 22 chlorine atoms contribute significantly binding neither atom close protein closest one 4 A Tyr 19 side chain
0.33389336.14634007.html.plaintext.txt	260	The observed position dichlorophenyl ring may due part distortions induced crystal packing presence second inhibitor molecule discussed
0.33389336.14634007.html.plaintext.txt	261	The thiadiazolylphenyl group lies along protein surface outside pocket
0.33389336.14634007.html.plaintext.txt	262	Notably phenyl thiadiazole bond close side chain Met 101
0.33389336.14634007.html.plaintext.txt	263	This finding consistent recent photoaffinity labeling experiments2 carbon atom para amide bond analogue found covalently linked terminal carbon Met 101 see Fig
0.33389336.14634007.html.plaintext.txt	264	Mutational Analysis Inhibitor Binding Pocket Several residues near inhibitor binding pocket mutated examine roles specific side chains binding indandione well gain insight possible overlap E1 inhibitor binding sites
0.33389336.14634007.html.plaintext.txt	265	Most residues mutated Ala residues replaced amino acids found HPV types His 32 changed Tyr found HPV16 E2 whereas Ile 30 Met 31 Ile 36 changed Val Leu Met respectively found HPV6 E2
0.33389336.14634007.html.plaintext.txt	266	These last three residues ones vicinity inhibitor A different HPV11 6 E2
0.33389336.14634007.html.plaintext.txt	267	Also included study amino acid substitution I73A located opposite face protein previously shown specifically affect transactivation activity E2 rather replication E1 binding activity 25
0.33389336.14634007.html.plaintext.txt	268	Each mutant protein produced vitro translation tested previously described E1 E2 ori complex formation assay using radiolabeled origin DNA Table IV
0.33389336.14634007.html.plaintext.txt	269	The ability protein interact E1 scored qualitatively control variations level protein produced vitro transcription translation reaction case could assess proper folding stability proteins
0.33389336.14634007.html.plaintext.txt	270	Most mutant proteins retained least ability productively interact E1 origin
0.33389336.14634007.html.plaintext.txt	271	View table TABLE IV Effect amino acid substitutions E2 TAD E1 E2 ori complex formation
0.33389336.14634007.html.plaintext.txt	272	E1 E2 ori complex assembly reactions carried using vitro translated HPV11 E2 E1 containing extract 33P labeled origin DNA see Experimental Procedures
0.33389336.14634007.html.plaintext.txt	273	A signal 3100 cpm signal background SB ratio 21 observed assays performed wild type E2
0.33389336.14634007.html.plaintext.txt	274	For mutant E2 proteins E1 E2 ori complex formation scored qualitatively follows 1000 cpm SB 8 500 1000 cpm SB 3 8 150 500 cpm SB 2 3
0.33389336.14634007.html.plaintext.txt	275	IC50 values compound 2 Fig
0.33389336.14634007.html.plaintext.txt	276	3 determined measuring complex assembly presence compound concentrations ranging 2 nM 40 microM
0.33389336.14634007.html.plaintext.txt	277	Values shown average duplicate determinations cases differed 30 less
0.33389336.14634007.html.plaintext.txt	278	We also determined sensitivity mutant proteins inhibitor 2 Fig
0.33389336.14634007.html.plaintext.txt	279	3 analogue compound 1 described previously 23
0.33389336.14634007.html.plaintext.txt	280	A number substitutions little effect interaction E1 inhibitor binding
0.33389336.14634007.html.plaintext.txt	281	These included V64A K68A interact inhibitor molecule B inhibitor TAD complex thereby providing evidence binding second molecule relevant inhibition
0.33389336.14634007.html.plaintext.txt	282	Substitutions I30VM31L I36M make HPV11 TAD similar HPV6 E2 also little effect inhibition
0.33389336.14634007.html.plaintext.txt	283	These results suggest none three residues responsible 30 fold weaker affinity HPV6 E2 compound 2 23
0.33389336.14634007.html.plaintext.txt	284	In support residues play major role type selectivity indandione inhibitors found corresponding mutations V30IL31M M36I HPV6 E2 also little effect inhibition data shown
0.33389336.14634007.html.plaintext.txt	285	Other substitutions L15A Y19A E39A S98A produced inactive weakly active proteins
0.33389336.14634007.html.plaintext.txt	286	In principle could indicate either side chains directly involved interaction E1 mutant proteins properly folded
0.33389336.14634007.html.plaintext.txt	287	The low signals obtained Y19A E39A E2 proteins E1 E2 ori complex formation assay insufficient assess inhibition
0.33389336.14634007.html.plaintext.txt	288	Substitution Gln 12 His 32 Leu 43 Ser 65 Ile 73 deleterious effect compound binding IC50 values interaction E1 suggesting residues may specific role binding inhibitor
0.33389336.14634007.html.plaintext.txt	289	However three substitutions periphery inhibitor binding site Gln 12 Leu 43 Ser 65 Ile 73 opposite face protein
0.33389336.14634007.html.plaintext.txt	290	A possible rationale observations discussed
0.33389336.14634007.html.plaintext.txt	291	In contrast His 32 direct contact biologically relevant inhibitor A
0.33389336.14634007.html.plaintext.txt	292	The presence tyrosine instead histidine position 32 E2 proteins HPV16 18 31 Fig
0.33389336.14634007.html.plaintext.txt	293	1 may contribute insensitivity proteins indandione class inhibitors
0.33389336.14634007.html.plaintext.txt	294	Consistent proposal found studies3 HPV31 E2 carrying double amino acid substitution D31MY32H significantly sensitive compound 2 IC50 6 microM WT counterpart IC50 70 microM tested assay format similar used generate results reported Table IV
0.33389336.14634007.html.plaintext.txt	295	Finally particularly interesting result noted previously 23 improved affinity E100A E2 class inhibitors
0.33389336.14634007.html.plaintext.txt	296	Biophysical Functional Characterization Purified Mutant E2 TADs Because roles Tyr 19 Glu 39 binding E1 inhibitors could assessed using E1 E2 ori complex formation assay produced corresponding mutant TAD proteins E
0.33389336.14634007.html.plaintext.txt	297	coli carry additional assays biophysical studies
0.33389336.14634007.html.plaintext.txt	298	We also expressed L15A TAD moderately reduced affinity E1 inhibitor 2 observed well I73A E100A proteins better understand significant effects two mutations inhibitor binding
0.33389336.14634007.html.plaintext.txt	299	Analysis proteins circular dichroism indicated significant change secondary structure compared WT data shown
0.33389336.14634007.html.plaintext.txt	300	The thermal stability mutant protein determined differential scanning calorimetry found comparable WT TAD L15A protein reproducibly least stable Table V
0.33389336.14634007.html.plaintext.txt	301	View table TABLE V Effect selected amino acid substitutions properties E2 TAD proteins
0.33389336.14634007.html.plaintext.txt	302	Melting temperatures determined differential scanning calorimetry
0.33389336.14634007.html.plaintext.txt	303	Values shown averages two determinations differed less 0
0.33389336.14634007.html.plaintext.txt	304	Dissociation constants compound 3 determined using tight binding equation see data Fig
0.33389336.14634007.html.plaintext.txt	305	Parameters inhibition E1 ATPase activity determined using three parameter logistic WT L15A I73A E100A possible estimation Y19A E39A see data Fig
0.33389336.14634007.html.plaintext.txt	306	For experiments values shown averages triplicate quadruplicate experiments plus minus SD
0.33389336.14634007.html.plaintext.txt	307	Next measured affinity TAD protein compound 3 Fig
0.33389336.14634007.html.plaintext.txt	308	3 using equilibrium binding assay
0.33389336.14634007.html.plaintext.txt	309	The Kd values binding 3 WT Y19A TADs similar Fig
0.33389336.14634007.html.plaintext.txt	310	Because side chain Tyr 19 undergoes substantial change position upon inhibitor binding lack effect Y19A mutation affinity inhibitor 3 may actually due combination two offsetting effects loss Tyr 19 inhibitor interactions partially compensated reduction conformational change entropic cost necessary form inhibitor binding pocket
0.33389336.14634007.html.plaintext.txt	311	Further mutagenesis residue would necessary address possibility
0.33389336.14634007.html.plaintext.txt	312	The Kd value 3 binding E100A roughly 10 fold lower could precisely determined part value Kd well protein concentration used experiment 5 versus 50 nM
0.33389336.14634007.html.plaintext.txt	313	I73A L15A especially E39A significantly reduced affinities compound
0.33389336.14634007.html.plaintext.txt	314	Where direct comparison made results Table V qualitative agreement E1 E2 ori complex formation assay shown Table IV
0.33389336.14634007.html.plaintext.txt	315	View larger version 21K FIG
0.33389336.14634007.html.plaintext.txt	316	Interaction mutant TAD proteins inhibitor 3 E1
0.33389336.14634007.html.plaintext.txt	317	For panels data points shown WT TAD solid circles derivatives carrying substitutions L15A open squares Y19A black triangles E39A open triangles I73A open circles E100A solid squares
0.33389336.14634007.html.plaintext.txt	318	A dissociation constants inhibitor 3 determined titrating inhibitor 4 500 nM 96 well Ni chelate Flashplates containing 50 nM TAD
0.33389336.14634007.html.plaintext.txt	319	Lines determined non linear regression using tight binding equation based triplicate measurements
0.33389336.14634007.html.plaintext.txt	320	B E1 binding evaluated ability different proteins inhibit HPV11 E1 ATPase activity
0.33389336.14634007.html.plaintext.txt	321	ATPase activity measured scintillation proximity assay described previously 40 41 using 3 nM E1 20 microM ATP
0.33389336.14634007.html.plaintext.txt	322	Inhibition measured TAD protein concentrations 2 1000 nM points based averages three separate experiments
0.33389336.14634007.html.plaintext.txt	323	Lines connecting points ease visualization
0.33389336.14634007.html.plaintext.txt	324	We assessed relative affinity TAD proteins E1 taking advantage earlier finding ATPase activity E1 inhibited addition transactivation domain
0.33389336.14634007.html.plaintext.txt	325	TAD binding significantly increases apparent Km E1 ATP
0.33389336.14634007.html.plaintext.txt	326	However observed TAD saturated E1 retained ATPase activity
0.33389336.14634007.html.plaintext.txt	327	We also reported corresponding weakening E2 binding presence high ATP concentrations might play role dissociation E2 assembly E1 hexamers origin 40
0.33389336.14634007.html.plaintext.txt	328	Although direct binding assay monitoring ATPase activity presence E2 TAD provides DNA independent solution phase method assessing E1 E2 interaction
0.33389336.14634007.html.plaintext.txt	329	Titration WT TAD E1 ATPase assays inhibited activity maximum 86 Imax 86 IC50 4 nM Fig
0.33389336.14634007.html.plaintext.txt	330	Similar results obtained I73A E100A confirming mutations affect E1 binding substantially
0.33389336.14634007.html.plaintext.txt	331	It noted however IC50 values reported I73A E100A WT TAD close E1 concentration used assays 3 nM hence IC50 values likely underestimate affinity proteins E1
0.33389336.14634007.html.plaintext.txt	332	The remaining three mutant E2 proteins L15A Y19A E39A differed WT counterpart two ways
0.33389336.14634007.html.plaintext.txt	333	First maximal degree E1 ATPase inhibition obtained saturating concentrations TAD lower mutants WT E2
0.33389336.14634007.html.plaintext.txt	334	This prominent Y19A E39A E2 achieved maximum inhibition 32 38 respectively
0.33389336.14634007.html.plaintext.txt	335	Although completely understand mutant E2 TADs achieve lower maximum level inhibition suggests geometry TAD E1 complexes form two proteins complexes retain greater residual ATPase activity
0.33389336.14634007.html.plaintext.txt	336	The second way three mutant proteins differed WT E2 lower affinity E1 measured IC50 values required reach respective maximal level ATPase inhibition
0.33389336.14634007.html.plaintext.txt	337	By measure L15A found reduce slightly affinity E2 E1 whereas Y19A E39A larger effect
0.33389336.14634007.html.plaintext.txt	338	Qualitatively results good agreement obtained E1 E2 ori complex formation assay Table IV E1 E2 interaction little affected I73A E100A moderately affected L15A significantly reduced Y19A anticipated E39A
0.33389336.14634007.html.plaintext.txt	339	Notably mutant proteins retained ability interact E1
0.33389336.14634007.html.plaintext.txt	340	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Structure HPV11 E2 TAD The tertiary structure HPV11 E2 TAD nearly identical analogous domain HPV16 20
0.33389336.14634007.html.plaintext.txt	341	In particular orientations two subdomains similar TADs suggesting relative position subdomains fundamental characteristic fold overall structure fairly rigid even though far globular
0.33389336.14634007.html.plaintext.txt	342	This idea supported fact neither binding indandione inhibitor differing crystal packing arrangements three structures significantly altered observed tertiary structure
0.33389336.14634007.html.plaintext.txt	343	Based structure HPV16 E2 TAD Antson et al
0.33389336.14634007.html.plaintext.txt	344	20 proposed existence additional E2 dimerization interface within TAD comprised second third helices notably involving cluster conserved residues Arg 37 Ala 69 Ile 73 Gln 76 Leu 77 Glu 80 Thr 81
0.33389336.14634007.html.plaintext.txt	345	Although area interface relatively large 2000 A2 contains number water mediated interactions relatively hydrophobic residue contacts contrast protein interfaces typically less hydrophilic solvent exposed surfaces 45 46
0.33389336.14634007.html.plaintext.txt	346	Our observation quite distinct monomer monomer interactions found HPV11 TAD structures together results chromatography ultracentrifugation experiments HPV11 TAD fully monomeric concentrations 20 microM calls question generality TAD dimerization interface thus likelihood plays fundamental role function E2 least case HPV11
0.33389336.14634007.html.plaintext.txt	347	Nature Inhibitor Binding Site The inhibitor binding pocket Fig
0.33389336.14634007.html.plaintext.txt	348	7 present E2 apo structure rather appears induced upon inhibitor binding
0.33389336.14634007.html.plaintext.txt	349	This pocket comprised large shallow end approximately defined residues Gln 12 Glu 39 Lys 68 Gln 71 smaller deep end defined His 32 Trp 33 Leu 94
0.33389336.14634007.html.plaintext.txt	350	The indandione moiety inhibitor A complementary deep end resulting Van der Waals interactions together hydrogen bonds carboxylate backbone amides account strongly exothermic binding compounds series Fig
0.33389336.14634007.html.plaintext.txt	351	Additional interactions made thiadiazoylphenyl moiety extends pocket near Met 101
0.33389336.14634007.html.plaintext.txt	352	Conclusions Based Studies Mutant E2 Proteins The Side Chain Glu 100 May Impede Inhibitor Binding Mutation Glu 100 Ala affect substantially interaction E2 E1 specifically enhanced inhibitor binding reported previously 23
0.33389336.14634007.html.plaintext.txt	353	The structure inhibitor TAD complex provides explanation gain affinity namely entropic cost associated conformational change Glu 100 side chain necessary compound binding Fig
0.33389336.14634007.html.plaintext.txt	354	5C likely reduced case Ala 100
0.33389336.14634007.html.plaintext.txt	355	Amino Acids Outside Pocket Can Reduce Inhibitor Binding A number substitutions Q12A L15A L43A S65A I73A clearly affected binding inhibitor although changed residues directly contact inhibitor structure
0.33389336.14634007.html.plaintext.txt	356	Further structural information would required fully understand effects five substitutions residues located helices three helix bundle defines N terminal subdomain TAD
0.33389336.14634007.html.plaintext.txt	357	The residues form deep pocket binds tightly indandione moiety also located within three helix bundle given close fit inhibitor pocket possible substitutions subtly affect packing three helices way slightly alters binding pocket
0.33389336.14634007.html.plaintext.txt	358	Perhaps similar subtle conformational changes explain indandione class inhibitors binds HPV6 E2 10 30 fold less tightly HPV11 E2 amino acid differences near binding pocket account type differential activity
0.33389336.14634007.html.plaintext.txt	359	The effects non binding site residue differences conceptually similar HIV protease resistance mutations occur well outside active site 47
0.33389336.14634007.html.plaintext.txt	360	Importance His 32 Inhibitor Binding We found specificity inhibitor binding low risk rather high risk HPV types part residue forming pocket His 32 tyrosine high risk types Fig
0.33389336.14634007.html.plaintext.txt	361	Substitution His 32 tyrosine HPV11 E2 abrogated inhibitor binding although significantly affect interaction E1
0.33389336.14634007.html.plaintext.txt	362	Based structure inhibitor TAD complex substitution predicted prevent formation deep end inhibitor binding pocket
0.33389336.14634007.html.plaintext.txt	363	Furthermore converse experiment inserting His 32 HPV31 E2 generated mutant protein could interact compound 2 albeit extent HPV11 HPV6 E2
0.33389336.14634007.html.plaintext.txt	364	A Role Tyrosine 19 Binding E1 Tyr 19 highly conserved among HPV types although Ile bovine papillomaviruses
0.33389336.14634007.html.plaintext.txt	365	Substitution residue Ala resulted HPV11 E2 protein still capable binding inhibitor whose melting temperature CD spectrum similar wild type E2 indicating mutation affect overall structure TAD
0.33389336.14634007.html.plaintext.txt	366	However Y19A mutant protein defective binding E1 E1 E2 ori complex formation assay E1 ATPase inhibition assay
0.33389336.14634007.html.plaintext.txt	367	Thus mutation appears specifically affect E1 binding
0.33389336.14634007.html.plaintext.txt	368	The proximity TAD surface Tyr 19 Glu 39 residue specifically implicated binding E1 suggests surface E2 might form part E1 E2 protein protein interface
0.33389336.14634007.html.plaintext.txt	369	If results would imply interaction Tyr 19 E1 energetically important formation interface indandione class inhibitors antagonizes E1 binding competing directly overlapping binding surface E2
0.33389336.14634007.html.plaintext.txt	370	In fact structure HPV18 E1 E2 TAD complex recently determined Tyr 19 appear make important interaction E1
0.33389336.14634007.html.plaintext.txt	371	Analysis two crystal structures presented provided detailed understanding mechanism indandione inhibitors bind E2 disrupt E1 E2 protein protein interaction
0.33389336.14634007.html.plaintext.txt	372	Comparison two structures revealed induced fit mechanism inhibitor binding pocket formed illustrates difficult accurately identify binding pockets model protein ligand interactions using structure unliganded protein 48
0.33389336.14634007.html.plaintext.txt	373	The binding pocket includes deep narrow cavity filled indandione moiety well wider shallow region makes contacts inhibitor
0.33389336.14634007.html.plaintext.txt	374	The finding second inhibitor molecule bind shallow region pocket raises possibility molecules could found would retain specific interactions deep cavity gain additional binding energy interaction larger shallow region
0.33389336.14634007.html.plaintext.txt	375	The characterization well defined small molecule binding pocket E2 TAD represents important step toward design HPV antivirals
0.33389336.14634007.html.plaintext.txt	376	FOOTNOTES The atomic coordinates structure factors code 1R6K 1R6N deposited Protein Data Bank Research Collaboratory Structural Bioinformatics Rutgers University New Brunswick NJ httpwww
0.33389336.14634007.html.plaintext.txt	377	The costs publication article defrayed part payment page charges
0.33389336.14634007.html.plaintext.txt	378	This article must therefore hereby marked advertisement accordance 18 U
0.33389336.14634007.html.plaintext.txt	379	Section 1734 solely indicate fact
0.33389336.14634007.html.plaintext.txt	380	To correspondence addressed Dept
0.33389336.14634007.html.plaintext.txt	381	Biological Sciences Boehringer Ingelheim Canada Ltd
0.33389336.14634007.html.plaintext.txt	382	Laval Quebec H7S 2G5 Canada
0.33389336.14634007.html.plaintext.txt	383	4269 Fax 450 682 4642 E mail pwhiteatlav
0.33389336.14634007.html.plaintext.txt	384	1 The abbreviations used HPV human papillomavirus His TAD TAD N terminal polyhistidine tag His Lys TAD His TAD C terminal four lysine tail Me2SO dimethyl sulfoxide MOPS 3 N morpholinopropanesulfonic acid ori origin replication r
0.33389336.14634007.html.plaintext.txt	385	root mean squared Se Met selenomethionine TAD E2 transactivation domain TCEP tris2 carboxyethylphosphine WT wild type
0.33389336.14634007.html.plaintext.txt	386	Botchan personal communication
0.33389336.14634007.html.plaintext.txt	387	ACKNOWLEDGMENTS We thank Dr
0.33389336.14634007.html.plaintext.txt	388	Michael Cordingley stimulating discussions Drs
0.33389336.14634007.html.plaintext.txt	389	Nathalie Goudreau Christopher Lemke Steven Mason Boehringer Ingelheim Canada Ltd
0.33389336.14634007.html.plaintext.txt	390	Liang Tong Columbia University critical reading manuscript
0.33389336.14634007.html.plaintext.txt	391	We also thank Eric Abbate Prof
0.33389336.14634007.html.plaintext.txt	392	Michael Botchan communicating results prior publication
0.33389336.14634007.html.plaintext.txt	393	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Shah K
0.33389336.14634007.html.plaintext.txt	394	1996 Fields Virology Fields B
0.33389336.14634007.html.plaintext.txt	395	2077 2109 Lippincott Raven Publishers Philadelphia PA Yao J
0.33389336.14634007.html.plaintext.txt	396	72 1013 1019AbstractFree Full Text Benson J
0.33389336.14634007.html.plaintext.txt	397	71 8041 8047Abstract Rank N
0.33389336.14634007.html.plaintext.txt	398	1991 Cell 65 493 505Medline Order article via Infotrieve Spalholz B
0.33389336.14634007.html.plaintext.txt	399	65 743 753Medline Order article via Infotrieve Breiding D
0.33389336.14634007.html.plaintext.txt	400	17 7208 7219Abstract Piirsoo M
0.33389336.14634007.html.plaintext.txt	401	95 4338 4343AbstractFree Full Text Yang L
0.33389336.14634007.html.plaintext.txt	402	1991 Nature 353 628 632CrossRefMedline Order article via Infotrieve Seo Y
0.33389336.14634007.html.plaintext.txt	403	90 2865 2869Abstract Sedman J
0.33389336.14634007.html.plaintext.txt	404	14 6218 6228Abstract Sedman T
0.33389336.14634007.html.plaintext.txt	405	71 2887 2896Abstract Benson J
0.33389336.14634007.html.plaintext.txt	406	69 4364 4372Abstract Berg M
0.33389336.14634007.html.plaintext.txt	407	71 3853 3863Abstract Mohr I
0.33389336.14634007.html.plaintext.txt	408	1990 Science 250 1694 1699Medline Order article via Infotrieve Titolo S
0.33389336.14634007.html.plaintext.txt	409	73 5282 5293AbstractFree Full Text Yasugi T
0.33389336.14634007.html.plaintext.txt	410	7 2823 2829Abstract Antson A
0.33389336.14634007.html.plaintext.txt	411	2000 Nature 403 805 809CrossRefMedline Order article via Infotrieve Harris S
0.33389336.14634007.html.plaintext.txt	412	1999 Science 284 1673 1677AbstractFree Full Text Yoakim C
0.33389336.14634007.html.plaintext.txt	413	13 2539 2541CrossRefMedline Order article via Infotrieve White P
0.33389336.14634007.html.plaintext.txt	414	278 26765 26772AbstractFree Full Text Brokaw J
0.33389336.14634007.html.plaintext.txt	415	70 1602 1611Abstract Ferguson M
0.33389336.14634007.html.plaintext.txt	416	70 4193 4199Abstract Cooper C
0.33389336.14634007.html.plaintext.txt	417	1998 Virology 241 312 322CrossRefMedline Order article via Infotrieve Wood W
0.33389336.14634007.html.plaintext.txt	418	16 118 133Medline Order article via Infotrieve LeMaster D
0.33389336.14634007.html.plaintext.txt	419	1985 Biochemistry 24 7263 7268Medline Order article via Infotrieve Laue T
0.33389336.14634007.html.plaintext.txt	420	1992 Analytical Ultracentrifugation Biochemistry Polymer Science Harding S
0.33389336.14634007.html.plaintext.txt	421	72 435 444Abstract Johnson M
0.33389336.14634007.html.plaintext.txt	422	36 575 588Abstract de La Fortelle E
0.33389336.14634007.html.plaintext.txt	423	A 46 467 473CrossRef Muegge I
0.33389336.14634007.html.plaintext.txt	424	42 791 804CrossRefMedline Order article via Infotrieve Gehlhaar D
0.33389336.14634007.html.plaintext.txt	425	2 317 324Medline Order article via Infotrieve Bohm H
0.33389336.14634007.html.plaintext.txt	426	38 463 488CrossRef Privalov P
0.33389336.14634007.html.plaintext.txt	427	35 1 104Medline Order article via Infotrieve White P
0.33389336.14634007.html.plaintext.txt	428	276 22426 22438AbstractFree Full Text Jeffery J
0.33389336.14634007.html.plaintext.txt	429	304 55 62CrossRefMedline Order article via Infotrieve Laue T
0.33389336.14634007.html.plaintext.txt	430	259 427 452Medline Order article via Infotrieve Yoakim C
0.33389336.14634007.html.plaintext.txt	431	CO2 9linktypeDOI CrossRefMedline Order article via Infotrieve Tsai C
0.33389336.14634007.html.plaintext.txt	432	6 53 64AbstractFree Full Text Janin J
0.33389336.14634007.html.plaintext.txt	433	204 155 164Medline Order article via Infotrieve Muzammil S
0.33389336.14634007.html.plaintext.txt	434	2003 Biochemistry 42 631 638CrossRefMedline Order article via Infotrieve Teague S
0.33389336.14634007.html.plaintext.txt	435	2 527 541CrossRefMedline Order article via Infotrieve Yphantis D
0.15854263.12900451.html.plaintext.txt	0	Developmental regulation significance KNOX protein trafficking Arabidopsis Jae Yean Kim Zhuang Yuan David Jackson
0.15854263.12900451.html.plaintext.txt	1	Cold Spring Harbor Laboratory 1 Bungtown Road Cold Spring Harbor NY 11724 USA
0.15854263.12900451.html.plaintext.txt	2	Author correspondence e mail jacksondatcshl
0.15854263.12900451.html.plaintext.txt	3	SUMMARY TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Intercellular communication delivers critical information position dependent specification cell fate
0.15854263.12900451.html.plaintext.txt	4	In plants novel mechanism cell cell communication involves intercellular trafficking regulatory proteins mRNAs
0.15854263.12900451.html.plaintext.txt	5	The maize KNOTTED1 KN1 gene acts non cell autonomously maize leaf KN1 first plant protein shown traffic cell cell presumably plasmodesmata
0.15854263.12900451.html.plaintext.txt	6	We compared intercellular trafficking green fluorescent protein GFP fusions KN1 Arabidopsis KN1 related homeobox proteins viral movement protein turnip vein clearing tobamovirus
0.15854263.12900451.html.plaintext.txt	7	We show specific developmental regulation GFPKN1 trafficking
0.15854263.12900451.html.plaintext.txt	8	GFPKN1 able traffic inner layers leaf epidermis opposite direction epidermis mesophyll
0.15854263.12900451.html.plaintext.txt	9	However GFP GFPmovement protein fusion moved readily epidermis
0.15854263.12900451.html.plaintext.txt	10	GFPKN1 however able traffic epidermal L1 layer shoot apical meristem indicating KN1 movement L1 developmentally regulated
0.15854263.12900451.html.plaintext.txt	11	GFPKNAT1BREVIPEDICELLUS GFPSHOOTMERISTEMLESS fusions could also traffic L1 L2L3 layers meristem
0.15854263.12900451.html.plaintext.txt	12	In test functional significance trafficking showed L1 specific expression KN1 KNAT1 able partially complement strong shootmeristemless 11 stm 11 mutant
0.15854263.12900451.html.plaintext.txt	13	However cell autonomous GUS fusion KN1 showed neither trafficking ability complementation stm 11 expressed L1
0.15854263.12900451.html.plaintext.txt	14	These results suggest activity KN1 related homeobox proteins maintained following intercellular trafficking trafficking may required normal developmental function
0.15854263.12900451.html.plaintext.txt	15	Key words Homeodomain KNOX Shoot meristem knotted1 GFP Plasmodesmata Protein trafficking Arabidopsis thaliana
0.15854263.12900451.html.plaintext.txt	16	INTRODUCTION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In last years intercellular trafficking regulatory proteins mRNAs emerged novel mechanism cell cell communication plant development Ding 1998 Zambryski Crawford 2000 Jackson 2001 Haywood et al
0.15854263.12900451.html.plaintext.txt	17	Many studies trafficking macromolecules relate virus infection plant viruses move cell cell plasmodesmata PD
0.15854263.12900451.html.plaintext.txt	18	However smallest viruses viral nucleic acids estimated larger channel size PDs Ding et al
0.15854263.12900451.html.plaintext.txt	19	1992b viruses traffic via active pathway requires virus encoded movement proteins MPs Gibbs 1976 Wang et al
0.15854263.12900451.html.plaintext.txt	20	For example tobacco mosaic virus TMV encodes 30 kDa MP interacts PDs increase size exclusion limit SEL traffics facilitates spread virus Deom et al
0.15854263.12900451.html.plaintext.txt	21	The observation viral MP trafficking prompted speculation endogenous macromolecules might also traffic PD Lucas Wolf 1993 Lucas et al
0.15854263.12900451.html.plaintext.txt	22	The use green fluorescent protein GFP greatly facilitated development vivo trafficking assays
0.15854263.12900451.html.plaintext.txt	23	Tissue specific GFP expression studies also revealed dynamic regulation PD SEL
0.15854263.12900451.html.plaintext.txt	24	Estimates PD SEL mesophyll trichome cells mature leaves obtained microinjection experiments range one kDa Wolf et al
0.15854263.12900451.html.plaintext.txt	25	1989 Waigmann Zambryski 1995
0.15854263.12900451.html.plaintext.txt	26	However immature sink tissues observation GFP diffusion suggests PD SEL may high 30 50 kDa tissues Imlau et al
0.15854263.12900451.html.plaintext.txt	27	Developmental changes GFP diffusion correlated changes PD structure leaf development simple linear channels complex branched forms Oparka et al
0.15854263.12900451.html.plaintext.txt	28	It also evident GFP diffuse cell cell mature tissues depending tissue type species Crawford Zambryski 2000 Itaya et al
0.15854263.12900451.html.plaintext.txt	29	Developmental modifications PDs also relevant MP localization trafficking
0.15854263.12900451.html.plaintext.txt	30	For example TMV cucumber mosaic virus MP shown targeted plasmodesmata trafficked cells leaf reached certain developmental stage Ding et al
0.15854263.12900451.html.plaintext.txt	31	These observations GFP diffusion MP trafficking reveal developmental regulation PD function suggesting signaling PDs important plant development
0.15854263.12900451.html.plaintext.txt	32	The idea MP trafficking related endogenous proteins also supported fact trafficking extremely rapid Ding 1998 plant MP related protein CmPP16 traffic mRNA PDs Xoconostle Cazares et al
0.15854263.12900451.html.plaintext.txt	33	However extent trafficking endogenous proteins developmentally regulated unclear
0.15854263.12900451.html.plaintext.txt	34	Endogenous trafficking proteins include phloem proteins Balachandran et al
0.15854263.12900451.html.plaintext.txt	35	1997 well several developmental transcription factors LEAFY LFY SHORTROOT SHR KNOTTED1 KN1
0.15854263.12900451.html.plaintext.txt	36	The LFY meristem identity protein acts non autonomously able traffic L1 layer L2 L3 meristem cells complement lfy mutant Sessions et al
0.15854263.12900451.html.plaintext.txt	37	In root SHR protein traffics stele endodermal cell layer trafficking appears required function cell fate specification Nakajima et al
0.15854263.12900451.html.plaintext.txt	38	The influence tissue specific developmental signals trafficking proteins largely unknown
0.15854263.12900451.html.plaintext.txt	39	The first endogenous protein shown traffic cell cell maize homeodomain protein KN1
0.15854263.12900451.html.plaintext.txt	40	Mosaic analysis dominant Kn1 allele showed acts non autonomously maize leaf development Hake Freeling 1986
0.15854263.12900451.html.plaintext.txt	41	Later situ hybridization immunolocalization experiments showed KN1 protein detected outside domain mRNA expression suggesting possibility KN1 trafficking Jackson et al
0.15854263.12900451.html.plaintext.txt	42	Microinjection studies fluorescently labeled KN1 protein showed directly KN1 ability traffic mesophyll cells increase PD SEL specifically transport mRNA Lucas et al
0.15854263.12900451.html.plaintext.txt	43	These studies suggested KN1 protein could cell non autonomous signal support hypothesis showed GFP tagged KN1 fusion able traffic leaf shoot apical meristem SAM Arabidopsis Kim et al
0.15854263.12900451.html.plaintext.txt	44	Arabidopsis encodes four class I KN1 related homeobox KNOX genes Bharathan et al
0.15854263.12900451.html.plaintext.txt	45	The closely related KN1 KNOTTED 1 like homeobox protein 1BREVIPEDICELLUS KNAT1BP SHOOTMERISTEMLESS STM KNAT1 thought Arabidopsis ortholog KN1 Bharathan et al
0.15854263.12900451.html.plaintext.txt	46	2000 STM closer functional similarity KN1 basis similar null mutant phenotypes expression patterns Long et al
0.15854263.12900451.html.plaintext.txt	47	STM KN1 function SAM initiation andor maintenance KNAT1BP involved regulation inflorescence architecture Byrne et al
0.15854263.12900451.html.plaintext.txt	48	The possible involvement trafficking function Arabidopsis KNOX proteins investigated
0.15854263.12900451.html.plaintext.txt	49	In report show specific difference inter layer trafficking Arabidopsis leaf GFPMP GFPKN1
0.15854263.12900451.html.plaintext.txt	50	Our observations suggest different mechanisms involved trafficking proteins
0.15854263.12900451.html.plaintext.txt	51	We also show GFPKN1 trafficking tissue specific regulation influenced developmental stage
0.15854263.12900451.html.plaintext.txt	52	In support biological function KNOX protein trafficking KN1 related Arabidopsis proteins STM KNAT1 could traffic L1 layer shoot apical meristem movement correlated complementation stm 11 mutant phenotypes
0.15854263.12900451.html.plaintext.txt	53	Based findings discuss potential roles trafficking KNOX gene products development
0.15854263.12900451.html.plaintext.txt	54	MATERIALS AND METHODS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Plant material growth conditions plant transformation The Arabidopsis thaliana line used UASGAL4 system Nossen 0 No 0 except J2111 GAL4 enhancer line C24 ecotype
0.15854263.12900451.html.plaintext.txt	55	The stm 11 mutant Landsberg erecta Ler ecotype kind gift Dr Kathy Barton
0.15854263.12900451.html.plaintext.txt	56	Plants grown greenhouse premixed soil 75 sphagnum peat moss 15 vermiculite 10 perlite pH 5
0.15854263.12900451.html.plaintext.txt	57	0 Scotts Customblend Low Plus 1 Scotts Co
0.15854263.12900451.html.plaintext.txt	58	controlled release fertilizer 12 12 12 Scotts Co
0.15854263.12900451.html.plaintext.txt	59	18 hours light provided fluorescent lamps 150 250 micromole quanta m 2 1 20 24 degrees C
0.15854263.12900451.html.plaintext.txt	60	About 4 week old Arabidopsis plants floral buds dipped Agrobacterium strain GV3101 suspension culture YEP medium yeast extract 10 gl peptone 10 gl NaCl 5 gl pH 7
0.15854263.12900451.html.plaintext.txt	61	04 Silwet 77 modified method Clough Bent Clough Bent 1998
0.15854263.12900451.html.plaintext.txt	62	Transgenic seedlings screened MS medium 0
0.15854263.12900451.html.plaintext.txt	63	43 Murashige Skoog salt mixture 2
0.15854263.12900451.html.plaintext.txt	64	5 mM 2 N morpholinoethanesulfonic acid 1x Gamborgs vitamin solution 0
0.15854263.12900451.html.plaintext.txt	65	9 containing 50 microgml kanamycin andor hygromycin incubator 22 degrees C 100 micromole quanta m 2 1 transferred soil greenhouse
0.15854263.12900451.html.plaintext.txt	66	DNA constructs The pUAS GFPKN1 construct described previously Kim et al
0.15854263.12900451.html.plaintext.txt	67	We used 10 alanine linker represented GFP KN1 improve stability folding Doyle Botstein 1996 Kim et al
0.15854263.12900451.html.plaintext.txt	68	The MP coding region GenBank accession
0.15854263.12900451.html.plaintext.txt	69	U03357 turnip vein clearing tobamovirus TVCV capable viral movementinfection Arabidopsis Lartey et al
0.15854263.12900451.html.plaintext.txt	70	1997 amplified using proofreading PCR insert restriction enzyme sites allowing replacement KN1 produce pUAS GFPMP
0.15854263.12900451.html.plaintext.txt	71	The RbcS2b LTP1 AtML1 gene promoters amplified PCR Ler genomic DNA inserted upstream GAL4 gene vector pCambia2300
0.15854263.12900451.html.plaintext.txt	72	The primers used pRbcS2b 5 primer GCTGCTAGCTTTACCCTAACTACTCCTTT3 primer GTCGTCGACCCCGGGTTGTTGTTTCTCTTCTTCTTTT pLTP1 5 primer GGGAAGCTTGACCAAAATGATTAACTTGCATTAC3 primer GGGGGATCCATTGATCTCTTAGGTAGTGTTTTATGT pAtML1 5 primer GAGGAATTCTTAATTAACATTGATTCTGAACTGTACCC3 primer CATGGATCCGGCGCGCCAACCGGTGGATTCAGGGAG
0.15854263.12900451.html.plaintext.txt	73	All constructs including pAtML1 GFPKN1 pAtML1 GFPSTM pAtML GFPKNAT1 pAtML1 GUSGFP pAtML1 GUSKN1 35S GUSKN1 prepared sequential modification replacement PCR fragments original GFPKN1 construct
0.15854263.12900451.html.plaintext.txt	74	The PCR fragments verified sequencing
0.15854263.12900451.html.plaintext.txt	75	pAtML GFPKNAT1 pAtML1 GUSGFP pAtML1 GUSKN1 35S GUSKN1 prepared sequential modification replacement PCR fragments original GFPKN1 construct
0.15854263.12900451.html.plaintext.txt	76	The PCR fragments verified sequencing
0.15854263.12900451.html.plaintext.txt	77	Imaging T1 T2 Arabidopsis plants grown long day conditions incubator greenhouse
0.15854263.12900451.html.plaintext.txt	78	Unless noted otherwise leaf images taken fully expanded leaves
0.15854263.12900451.html.plaintext.txt	79	Confocal microscopy performed described previously Kim et al
0.15854263.12900451.html.plaintext.txt	80	For free hand cut cross sections tissues embedded 4 agarose cut using double sided razor blade mounted water
0.15854263.12900451.html.plaintext.txt	81	The confocal pinhole set 3
0.15854263.12900451.html.plaintext.txt	82	0 Airy units AU leaf tissues 2
0.15854263.12900451.html.plaintext.txt	83	Two photon microscopy scanning electron microscopy conducted described Oertner et al
0.15854263.12900451.html.plaintext.txt	84	2002 Taguchi Shiobara et al
0.15854263.12900451.html.plaintext.txt	85	2001 respectively whole plants photographed using digital camera Sony
0.15854263.12900451.html.plaintext.txt	86	ss glucuronidase staining immunolocalization ss glucuronidase GUS staining performed described previously Jefferson 1987
0.15854263.12900451.html.plaintext.txt	87	The stained tissues fixed FAA 50 ethanol 10 formaldehyde 5 acetic acid 1 hour dehydrated cleared embedded Paraplast X tra Fisher Scientific Jackson et al
0.15854263.12900451.html.plaintext.txt	88	Tissue sections 10 microm dewaxed mounted Cytoseal 60 Stephens Scientific mounting medium
0.15854263.12900451.html.plaintext.txt	89	Immunolocalization KN1 performed described previously Lucas et al
0.15854263.12900451.html.plaintext.txt	90	stm 11 genotyping Genotyping The stm 11 allele genotyped using CAPS marker M
0.15854263.12900451.html.plaintext.txt	91	Barton personal communication
0.15854263.12900451.html.plaintext.txt	92	Two stm primers 5 primer GGGCTTGATCAATTCATGGAAGCTTACTGTGAAATGCTCGTGCAGTATGAG 3 primer CCCTAGTAACAACCATCAAAG used produce 350 bp fragment genomic DNA
0.15854263.12900451.html.plaintext.txt	93	PCR performed follows 95 degrees C 3 minutes 35 cycles 94 degrees C 45 seconds 60 degrees C 45 seconds 72 degrees C 1 minute followed 72 degrees C 6 minutes
0.15854263.12900451.html.plaintext.txt	94	The MwoI restriction enzyme cuts 50 bp 5 end amplified wild type fragment cut stm 11 fragment
0.15854263.12900451.html.plaintext.txt	95	The enzyme digestion visualized running 2 agarose gel containing ethidium bromide
0.15854263.12900451.html.plaintext.txt	96	RESULTS TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Expression KN1 different cell layers leaf leads distinct phenotypes To determine whether intercellular protein trafficking might developmentally regulated example different tissue types used tissue specific promoters express GFPKN1 fusion leaf development
0.15854263.12900451.html.plaintext.txt	97	For green tissue primarily mesophyll guard cells used rubisco small subunit gene RbcS2b promoter Kim et al
0.15854263.12900451.html.plaintext.txt	98	In practical terms trafficking assays pRbcS2b serves mesophyll specific promoter guard cells symplastically isolated epidermal cells early stage development Wille Lucas 1984 Ding et al
0.15854263.12900451.html.plaintext.txt	99	For epidermis specific expression used LIPID TRANSFER PROTEIN 1 LTP1 MERISTEM LAYER 1 AtML1 promoters Thoma et al
0.15854263.12900451.html.plaintext.txt	100	These promoters used two component GAL4 system drive expression four reporters endoplasmic reticulum ER localized cell autonomous GFP mGFP5 ER free cytoplasmic GFP fusions GFP TVCV MP KN1 Haseloff et al
0.15854263.12900451.html.plaintext.txt	101	The GAL4 driver UAS reporter constructs sequentially transformed Arabidopsis Kim et al
0.15854263.12900451.html.plaintext.txt	102	In cases plants expressing GFP mGFP5 ER Fig
0.15854263.12900451.html.plaintext.txt	103	1A GFPTVCV MP indistinguishable normal plants example leaf shape plant stature
0.15854263.12900451.html.plaintext.txt	104	Plants expressing GFPKN1 however showed distinctive developmental phenotypes
0.15854263.12900451.html.plaintext.txt	105	When expressing GFPKN1 epidermis using LTP1 AtML1 promoters plants relatively mild phenotype leaves reduced size rumpled sometimes mildly lobed Fig
0.15854263.12900451.html.plaintext.txt	106	The pAtML1 GFPKN1 plants stronger phenotypes pLTP1 GFPKN1 plants
0.15854263.12900451.html.plaintext.txt	107	The overall stature plants upon flowering normal
0.15854263.12900451.html.plaintext.txt	108	In contrast plants expressing GFPKN1 RbcS2b promoter severe phenotype reminiscent plants overexpressing KNOX genes using strong constitutive 35S promoter Lincoln et al
0.15854263.12900451.html.plaintext.txt	109	These plants stunted reduced severely lobed leaves Fig
0.15854263.12900451.html.plaintext.txt	110	Some seedlings severe phenotype whole shoot comprising multiple organs smaller single cotyledon Fig
0.15854263.12900451.html.plaintext.txt	111	1F seedlings also developed ectopic shoots leaves reminiscent 35S KNOX expressors Lincoln et al
0.15854263.12900451.html.plaintext.txt	112	In summary plants developed distinct phenotypes depending whether expressed GFPKN1 epidermis green predominantly mesophyll tissues
0.15854263.12900451.html.plaintext.txt	113	View larger version 54K Fig
0.15854263.12900451.html.plaintext.txt	114	Tissue specific expression GFPKN1 fusion produces transgenic plants carrying distinct phenotypes
0.15854263.12900451.html.plaintext.txt	115	A Plants expressing mGFP5 ER mesophyll normal phenotype
0.15854263.12900451.html.plaintext.txt	116	BC Epidermis specific expression GFPKN1 using pLTP1 B pAtML1 C resulted mildly rumpled leaf phenotype
0.15854263.12900451.html.plaintext.txt	117	E Mesophyll specific GFPKN1 expression resulted lobed leaf phenotypes D reminiscent plants overexpressing KNOX genes using 35S promoter
0.15854263.12900451.html.plaintext.txt	118	E Representative leaves plants shown A D displayed order
0.15854263.12900451.html.plaintext.txt	119	FG Severe pRbcS2b GFPKN1 seedlings F SEM G confocal image showing ectopic shoot adaxial side leaf G
0.15854263.12900451.html.plaintext.txt	120	Scale bars 1 cm A E 1 mm F 50 microm G
0.15854263.12900451.html.plaintext.txt	121	To confirm tissue specificity LTP1 AtML1 RbcS2b promoters imaged GFP fluorescence seedlings carrying promoters driving expression cell autonomous mGFP5 ER reporter
0.15854263.12900451.html.plaintext.txt	122	Fidelity promoters tested least 10 independent plant lines representative results shown Figs 2 3
0.15854263.12900451.html.plaintext.txt	123	The RbcS2b promoter drove expression expected leaf mesophyll guard cells epidermis Fig
0.15854263.12900451.html.plaintext.txt	124	In contrast LTP1 AtML1 promoters drove epidermis specific expression unexpanded leaves fully expanded leaves hypocotyls Fig
0.15854263.12900451.html.plaintext.txt	125	3A C green fluorescence background detected sub epidermal tissues
0.15854263.12900451.html.plaintext.txt	126	The AtML1 promoter stronger cotyledons young leaves LTP1 promoter drove stronger expression mature leaves
0.15854263.12900451.html.plaintext.txt	127	View larger version 75K Fig
0.15854263.12900451.html.plaintext.txt	128	Protein trafficking mesophyll epidermal cells Arabidopsis leaf
0.15854263.12900451.html.plaintext.txt	129	GFP fusion reporters expressed using mesophyll specific pRbcS2b GAL4UAS reporter system
0.15854263.12900451.html.plaintext.txt	130	The tissue specificity promoter shown expression cell autonomous mGFP5 ER reporter
0.15854263.12900451.html.plaintext.txt	131	A C Expanded leaves transgenic plants expressing mGFP5 ER showed GFP fluorescence mesophyll epidermal guard cells epidermal pavement cells
0.15854263.12900451.html.plaintext.txt	132	D L In contrast presence GFPKN1 D F GFPTVCV MP G I free GFP J L promoter detected epidermal subepidermal cells
0.15854263.12900451.html.plaintext.txt	133	F GFPKN1 I GFPTVCV MP localized puncta arrowheads observed plants expressing free GFP L
0.15854263.12900451.html.plaintext.txt	134	Hand made cross sections A BD EG HJ K imaged using red green channels left column green channel middle column confocal microscope
0.15854263.12900451.html.plaintext.txt	135	Paradermal images shown CFIL
0.15854263.12900451.html.plaintext.txt	136	Left panels A D show bright field images mGFP5 ER GFPKN1 plant sections respectively
0.15854263.12900451.html.plaintext.txt	137	M O Immunolocalization using anti KN1 antiserum performed leaf sections wild type M red box magnified upper panel O GFPKN1 expressing plants N red box magnified lower panel O
0.15854263.12900451.html.plaintext.txt	138	GFPKN1 protein detected nuclei epidermal cells mesophyll cells
0.15854263.12900451.html.plaintext.txt	139	Arrows indicate nuclear localization GFP GFP fusions F I L KN1 protein O
0.15854263.12900451.html.plaintext.txt	140	Scale bars 50 microm ABDEGHJKM 25 microm CFILNO
0.15854263.12900451.html.plaintext.txt	141	View larger version 102K Fig
0.15854263.12900451.html.plaintext.txt	142	GFPKN1 traffic epidermal sub epidermal cells leaf
0.15854263.12900451.html.plaintext.txt	143	GFP fusion reporters expressed using epidermis specific pLTP1 pAtML1 promoters GAL4UAS reporter system
0.15854263.12900451.html.plaintext.txt	144	Expression cell autonomous mGFP5 ER reporter A C control pLTP1 showed epidermal specificity pLTP1 expanded leaf AC hypocotyl B
0.15854263.12900451.html.plaintext.txt	145	Similarly GFPKN1 restricted epidermal cells expanded leaf D hypocotyl E
0.15854263.12900451.html.plaintext.txt	146	Note weak fluorescence mesophyll cell layers A D autofluorescence inevitable sectioned plant tissues
0.15854263.12900451.html.plaintext.txt	147	F Epidermally expressed GFPKN1 show punctate cell wall spots green fluorescence
0.15854263.12900451.html.plaintext.txt	148	pAtML1 expression similarly resulted epidermis specific localization GFPKN1 young leaf primordia GH lower panel mGFP5 ER H upper panel
0.15854263.12900451.html.plaintext.txt	149	I K In contrast GFP I GFPTVCV MP J expressed control pLTP1 showed extensive movement GFPTVCV MP localized PDs K
0.15854263.12900451.html.plaintext.txt	150	L A control root expressing mGFP5 ER control pAtML1 show green fluorescence background levels L upper panel
0.15854263.12900451.html.plaintext.txt	151	In contrast GFPTVCV MP fusion produced shoot epidermal cells could also detected root vascular cortical tissues lower panel indicating long distant trafficking
0.15854263.12900451.html.plaintext.txt	152	CFK paradermal AB inset D E inset G J cross sections
0.15854263.12900451.html.plaintext.txt	153	Inset images paradermal images redgreen channel images
0.15854263.12900451.html.plaintext.txt	154	Yellow arrows indicate nuclei arrowheads show punctate cell wall spots
0.15854263.12900451.html.plaintext.txt	155	Scale bars 25 microm CFKH 50 microm ABDEIJL 100 microm G
0.15854263.12900451.html.plaintext.txt	156	Free GFP GFPKN1 GFPMP traffic mesophyll epidermal cells leaf To determine whether GFP GFPKN1 GFPTVCV MP could traffic mesophyll epidermal cells shoot imaged hand cut cross sections respective UAS transgene seedlings carrying pRbcS2b GAL4 driver Fig
0.15854263.12900451.html.plaintext.txt	157	The term driver means promoter GAL4UAS two component system
0.15854263.12900451.html.plaintext.txt	158	We observed movement GFPKN1 Fig
0.15854263.12900451.html.plaintext.txt	159	In case level fluorescence epidermal cells approximately equal mesophyll
0.15854263.12900451.html.plaintext.txt	160	We assessed sub cellular localization fusion proteins higher magnification paradermal confocal sections
0.15854263.12900451.html.plaintext.txt	161	Both GFPKN1 GFPTVCV MP localized nuclei cytoplasm punctate spots cells Fig
0.15854263.12900451.html.plaintext.txt	162	Similar spots seen plants expressing mGFP5 ER free GFP Fig
0.15854263.12900451.html.plaintext.txt	163	The GFPKN1 fusion protein also detected epidermal cell nuclei using anti KN1 antibody Fig
0.15854263.12900451.html.plaintext.txt	164	2NO lower panel Smith et al
0.15854263.12900451.html.plaintext.txt	165	1992 suggesting epidermal GFP fluorescence lines represented intact GFPKN1 fusion protein free GFP degradation product
0.15854263.12900451.html.plaintext.txt	166	This observation GFPKN1 trafficking consistent results using enhancer trap line express fusion perivascular cells Kim et al
0.15854263.12900451.html.plaintext.txt	167	2002 showed free GFP GFPTVCV MP also able move mesophyll epidermal cells
0.15854263.12900451.html.plaintext.txt	168	GFPKN1 traffic epidermis leaf primordia fully expanded leaves GFPKN1 could traffic leaf mesophyll epidermal cell layer accumulated nuclei punctate cell wall spots
0.15854263.12900451.html.plaintext.txt	169	To investigate whether trafficking could also occur opposite direction epidermis mesophyll expressed GFPKN1 fusion proteins epidermal layer shoot using pLTP1 pAtML1 GAL4 drivers
0.15854263.12900451.html.plaintext.txt	170	In leaves hypocotyls pLTP1 pAtML1 GAL4 drivers induced mGFP5 ER expression specifically epidermal cells green fluorescence background levels detected tissues shoot Fig
0.15854263.12900451.html.plaintext.txt	171	We next imaged fluorescence GFPKN1 control L1 specific GAL4 drivers
0.15854263.12900451.html.plaintext.txt	172	GFPKN1 fluorescence restricted epidermal tissues mature leaf hypocotyl detect movement mesophyll cells Fig
0.15854263.12900451.html.plaintext.txt	173	Therefore contrast result mesophyll specific expression expressed specifically epidermal cells GFPKN1 unable traffic cells adjacent cell layers
0.15854263.12900451.html.plaintext.txt	174	To determine whether absence trafficking GFPKN1 epidermal cells also occurred early stages leaf development imaged GFP fluorescence young leaf primordia approximately 2 mm long
0.15854263.12900451.html.plaintext.txt	175	Expression mGFP5 ER showed pAtML1 also epidermis specific young leaf primordia Fig
0.15854263.12900451.html.plaintext.txt	176	GFPKN1 expressed control pAtML1 also restricted epidermal layer Fig
0.15854263.12900451.html.plaintext.txt	177	Plants expressing GFPKN1 control mesophyll perivascular tissue specific GAL4 driver showed punctate localization cell wall investigated whether plants expressing GFPKN1 epidermis also phenotype
0.15854263.12900451.html.plaintext.txt	178	We could detect spots GFP fluorescence cell walls plants expressing GFPKN1 epidermis Fig
0.15854263.12900451.html.plaintext.txt	179	3F although epidermally expressed GFPMP show putative plasmodesmal localization Fig
0.15854263.12900451.html.plaintext.txt	180	To test whether restriction protein trafficking epidermal cells general phenomenon expressed free GFP GFPTVCV MP using L1 specific GAL4 drivers
0.15854263.12900451.html.plaintext.txt	181	Previous reports Oparka et al
0.15854263.12900451.html.plaintext.txt	182	1999 unpublished results suggested free GFP could move freely epidermal mesophyll cells bombardment assays observed similar results stable transgenic lines Fig
0.15854263.12900451.html.plaintext.txt	183	We also detected extensive trafficking GFPTVCV MP epidermis mesophyll vascular tissues Fig
0.15854263.12900451.html.plaintext.txt	184	In cases green fluorescence intensity mesophyll vascular tissues approximately equal epidermal cells suggesting GFP GFPTVCV MP moved readily epidermal mesophyll cells
0.15854263.12900451.html.plaintext.txt	185	Therefore PDs epidermal mesophyll cells open non selective selective movement
0.15854263.12900451.html.plaintext.txt	186	Previous studies underline importance viral MPs play long distance viral movement infection Deom et al
0.15854263.12900451.html.plaintext.txt	187	Since saw high level GFP fluorescence GFPTVCV MP fusion mesophyll vascular tissues shoot investigated far GFPTVCV MP could traffic plant imaging roots pAtML1 GFPTVCV MP plants
0.15854263.12900451.html.plaintext.txt	188	AtML1 mRNA detectable root Lu et al
0.15854263.12900451.html.plaintext.txt	189	1996 mGFP5 ER expression detected mature region pAtML1 mGFP5 ER roots Fig
0.15854263.12900451.html.plaintext.txt	190	However seedlings carrying UAS GFPTVCV MP construct green fluorescence detected vascular cortical tissue throughout length root Fig
0.15854263.12900451.html.plaintext.txt	191	3L lower panel indicating MP trafficking occurred long distance shoot epidermis root presumably phloem
0.15854263.12900451.html.plaintext.txt	192	Since MP binds MP RNA facilitates cell cell trafficking Nguyen et al
0.15854263.12900451.html.plaintext.txt	193	1996 possible RNA trafficking responsible non autonomous effects
0.15854263.12900451.html.plaintext.txt	194	In summary whereas GFPKN1 could traffic freely mesophyll epidermal cells could traffic opposite direction
0.15854263.12900451.html.plaintext.txt	195	The epidermalmesophyll interface blocked either free diffusion mediated selective movement since free GFP GFPTVCV MP moved readily epidermis mesophyll vascular tissues
0.15854263.12900451.html.plaintext.txt	196	GFP fusions KN1 STM KNAT1 trafficked epidermal L1 layer shoot apical meristem
0.15854263.12900451.html.plaintext.txt	197	To investigate whether restriction trafficking GFPKN1 epidermal layer occurred throughout stages shoot development imaged SAM pAtML1 GFPKN1 plants
0.15854263.12900451.html.plaintext.txt	198	Our previous results indicated GFPKN1 could traffic L3 layers inflorescence meristem expressed L1 L2 using SCARECROW promoter Kim et al
0.15854263.12900451.html.plaintext.txt	199	However study determine specifically whether GFPKN1 could traffic L1
0.15854263.12900451.html.plaintext.txt	200	In SAM pAtML1 induced expression mGFP5 ER reporter specifically L1 Fig
0.15854263.12900451.html.plaintext.txt	201	4A showing strong perinuclear fluorescence Fig
0.15854263.12900451.html.plaintext.txt	202	A GUSGFP fusion similarly restricted L1 Fig
0.15854263.12900451.html.plaintext.txt	203	In contrast situation leaf found GFPKN1 could traffic L1 L2 L3 layers Fig
0.15854263.12900451.html.plaintext.txt	204	We also tested cell cell trafficking property KN1 conserved Arabidopsis homologs
0.15854263.12900451.html.plaintext.txt	205	GFPKNAT1 GFPSTM expressed using pAtML1 traffic SAM showed strong L1 weaker L2 fluorescence Fig
0.15854263.12900451.html.plaintext.txt	206	L3 GFP fluorescence GFPKNAT1 GFPSTM evident confocal images GFPKNAT1 detected using two photon microscope Fig
0.15854263.12900451.html.plaintext.txt	207	Quantification two photon signal indicated photon number outer cell layer L3 least two fold higher background levels Fig
0.15854263.12900451.html.plaintext.txt	208	The nuclear accumulation GFP tagged protein less evident two photon image confocal image two photon microscope collects light narrower Z section 1 microm
0.15854263.12900451.html.plaintext.txt	209	However nuclear signal evident cells two photon image arrowed Fig
0.15854263.12900451.html.plaintext.txt	210	We also expressed GFPMP GFP L1 layer proteins could also traffic L1
0.15854263.12900451.html.plaintext.txt	211	The fluorescence patterns apices expressing GFP GFPMP demonstrated extensive movement GFPKNOX fusions least 6 cell layers Fig
0.15854263.12900451.html.plaintext.txt	212	Two three apices 4 independent transgenic lines showed similar patterns GFP GFPMP localization
0.15854263.12900451.html.plaintext.txt	213	View larger version 96K Fig
0.15854263.12900451.html.plaintext.txt	214	GFP fusions KNAT1 STM KN1 able traffic inflorescence SAM
0.15854263.12900451.html.plaintext.txt	215	All reporter constructs expressed control pAtML1
0.15854263.12900451.html.plaintext.txt	216	AB Cell autonomous mGFP5 ER A GUSGFP B reporter expression demonstrates L1 specificity pAtML1
0.15854263.12900451.html.plaintext.txt	217	The high magnification views A B insets show predominant perinuclear cytoplasmic green fluorescence mGFP5 ER GUSGFP
0.15854263.12900451.html.plaintext.txt	218	C E The GFP fusions KN1 C STM D KNAT1 E showed strong L1 weaker L2 green fluorescence suggesting short range movement
0.15854263.12900451.html.plaintext.txt	219	FG GFPKNAT1 detected L3 well L1 L2 two photon microscope image F quantified G region corresponding red box F
0.15854263.12900451.html.plaintext.txt	220	Nuclear localization GFP fusions KNOX proteins also evident cross section images L1 L2 cells C F arrowheads
0.15854263.12900451.html.plaintext.txt	221	L1 expression GFPTVCV MP H GFP I resulted extensive movement SAM GFPKNOX fusions
0.15854263.12900451.html.plaintext.txt	222	Scale bars 25 microm A 50 microm B I 10 microm insets
0.15854263.12900451.html.plaintext.txt	223	GFPKN1 trafficking L1 L2L3 occurred SAM indicating aspect KN1 trafficking developmental control
0.15854263.12900451.html.plaintext.txt	224	KNAT1 STM could also traffic SAM trafficking KNOX proteins restricted GFP GFPMP
0.15854263.12900451.html.plaintext.txt	225	The conservation trafficking ability functionally related KNOX proteins different species suggests trafficking may associated innate functions
0.15854263.12900451.html.plaintext.txt	226	L1 specific expression KN1 GFPKN1 partially complement stm 11
0.15854263.12900451.html.plaintext.txt	227	What potential functions KN1 trafficking development As first step answer question investigated whether KN1 continues function SAM maintenance cell cell trafficking
0.15854263.12900451.html.plaintext.txt	228	We first tested complementation stm mutants KN1 GFPKN1
0.15854263.12900451.html.plaintext.txt	229	STM expressed central peripheral regions SAM L1 L2 L3 layers Long et al
0.15854263.12900451.html.plaintext.txt	230	However STM promoter used study drove strong GUS expression peripheral region Fig
0.15854263.12900451.html.plaintext.txt	231	Barton personal communication
0.15854263.12900451.html.plaintext.txt	232	View larger version 119K Fig
0.15854263.12900451.html.plaintext.txt	233	L1 specific expression KN1 STM KNAT1 sufficient partially complement stm 11
0.15854263.12900451.html.plaintext.txt	234	A GUS expression STM promoter pSTM detected mainly peripheral region SAM
0.15854263.12900451.html.plaintext.txt	235	B pSTM driven GFPKN1 expression shows similar pattern GUS GFP fluorescence also central region arrowhead
0.15854263.12900451.html.plaintext.txt	236	C The pSTM GFPKN1 transgene complemented stm 11 producing stm homozygous plants shoots showing relatively normal phyllotaxy flower morphology inset stm 11 seedling fused cotyledons true leaves shown M upper left
0.15854263.12900451.html.plaintext.txt	237	D L1 specific expression KN1 left GFPKN1 right control pAtML1 partially rescued stm 11
0.15854263.12900451.html.plaintext.txt	238	E pAtML1 GFPSTM STM expression resulted severe phenotype plants although partially rescued stm 11 homozygous plants bushy phenotype F
0.15854263.12900451.html.plaintext.txt	239	G L1 specific GFPKNAT1 expression could also partially rescue stm 11
0.15854263.12900451.html.plaintext.txt	240	H K The GUSKN1 fusion protein cell autonomous leaf H J SAM K
0.15854263.12900451.html.plaintext.txt	241	Perivascular specific GUS staining leaf J2111UAS GUSKN1 plant seen top H cross section view I
0.15854263.12900451.html.plaintext.txt	242	JK In pAtML1 GUS KN1 plants GUS activity epidermis specific leaf J shoot apex K
0.15854263.12900451.html.plaintext.txt	243	The inset K shows epidermal GUSKN1 expression whole mount stm 11 seedling
0.15854263.12900451.html.plaintext.txt	244	LM In 35S GUSKN1 plants GUS activity detected SAM layers L 35S GUSKN1 could partially rescue stm 11 two rescued stm 11 seedlings right stm 11 seedling top left wild type seedling bottom left shown M
0.15854263.12900451.html.plaintext.txt	245	However expression GUSKN1 leaf lead expression phenotypes
0.15854263.12900451.html.plaintext.txt	246	NO A J2111UAS GFPKN1 plant shows KN1 expression phenotypes N J2111UAS GUSKN1 plants wild type morphology O
0.15854263.12900451.html.plaintext.txt	247	P Similarly 35S GUSKN1 overexpressing plants stm 11STM genotype show KN1 expression phenotypes despite showing high GUS activity inset
0.15854263.12900451.html.plaintext.txt	248	Scale bars 50 microm ABH L 0
0.15854263.12900451.html.plaintext.txt	249	5 cm F insets KP 1 cm EGM P 3 cm CD
0.15854263.12900451.html.plaintext.txt	250	As stm 11 mutants seedling lethal transformed stm 11 heterozygotes pSTM GFPKN1 construct
0.15854263.12900451.html.plaintext.txt	251	In transgenic seedlings GFPKN1 expression pattern similar pSTM GUS except fluorescence also evident central region Fig
0.15854263.12900451.html.plaintext.txt	252	5B arrow suggesting GFPKN1 trafficking peripheral central region
0.15854263.12900451.html.plaintext.txt	253	To determine whether stm 11 mutants complemented KN1 GFPKN1 genotyped transgenic plants using CAPS assay A
0.15854263.12900451.html.plaintext.txt	254	Barton personal communication
0.15854263.12900451.html.plaintext.txt	255	We observed shoot rescue stm 11 homozygotes carrying pSTM GFPKN1 transgene representative plant shown Fig
0.15854263.12900451.html.plaintext.txt	256	Similar rescue phenotypes observed 50 independent transgenic lines 4 lines total
0.15854263.12900451.html.plaintext.txt	257	The complemented plants showed relatively normal phyllotaxy leaf flower morphology Fig
0.15854263.12900451.html.plaintext.txt	258	5C inset shorter additional axillary shoots sterile
0.15854263.12900451.html.plaintext.txt	259	In contrast transgenic lines carrying pSTM KN1 showed full complementation stm 11 shown including normal stature flower morphology fertile seeds
0.15854263.12900451.html.plaintext.txt	260	Therefore KN1 could fully complement stm expressed STM promoter fusion GFP KN1 slightly impaired function
0.15854263.12900451.html.plaintext.txt	261	To address whether KN1 expression L1 subsequent trafficking L2 L3 layers sufficient rescue stm next transformed stm 11 heterozygotes pAtML1 GFPKN1 construct
0.15854263.12900451.html.plaintext.txt	262	In T1 generation 2132 66 stm 11 homozygotes showed partial complementation stm 11 phenotype Fig
0.15854263.12900451.html.plaintext.txt	263	All complemented plants showed abnormal phyllotaxy lacked flowers abnormal sterile flowers Fig
0.15854263.12900451.html.plaintext.txt	264	5D right similar weak stm 2 mutant Clark et al
0.15854263.12900451.html.plaintext.txt	265	Therefore L1 expression GFPKN1 gave partial complementation stm 11 less complete complementation observed using pSTM GFPKN1
0.15854263.12900451.html.plaintext.txt	266	To identify whether partial complementation L1 expression GFPKN1 GFP fusion KN1 also transformed stm 11 heterozygotes pAtML1 KN1 construct
0.15854263.12900451.html.plaintext.txt	267	The T1 stm 11 seedlings 20 independent lines carrying pAtML1 KN1 construct showed similar phenotypes pAtML1 GFPKN1
0.15854263.12900451.html.plaintext.txt	268	also showed partial complementation Fig
0.15854263.12900451.html.plaintext.txt	269	We also analyzed T2 generation stm 11 heterozygous T1 plants carrying pAtML1 KN1
0.15854263.12900451.html.plaintext.txt	270	About 32 74229 stm homozygous seedlings 3 independent lines showed partial complementation phenotypes similar observed T1 shown
0.15854263.12900451.html.plaintext.txt	271	Since STM KNAT1 could also traffic L1 determined whether L1 expression proteins could complement stm 11
0.15854263.12900451.html.plaintext.txt	272	Plants expressing STM GFPSTM pAtML1 showed severe phenotype stunted growth small lobed leaves cauline leaves flowers defective sepal petal stamen development Fig
0.15854263.12900451.html.plaintext.txt	273	This phenotypes presumably partly due ectopic expression STM leaves floral organs
0.15854263.12900451.html.plaintext.txt	274	A plants showed milder bushy phenotypes Fig
0.15854263.12900451.html.plaintext.txt	275	These bushy plants homozygous stm 11 shown suggesting therefore partial complementation L1 specific expression STM
0.15854263.12900451.html.plaintext.txt	276	L1 expression KNAT1 also resulted partial complementation 30 7 24 T1 plants expressing GFPKNAT1 L1 showed partial rescue stm 11
0.15854263.12900451.html.plaintext.txt	277	The stm 11pAtML1 GFPKNAT1 seedlings developed rosette shoots Fig
0.15854263.12900451.html.plaintext.txt	278	5G later became bushy similar stm 2 plants shown
0.15854263.12900451.html.plaintext.txt	279	In summary L1 expression KN1 STM KNAT1 sufficient give partial rescue stm 11
0.15854263.12900451.html.plaintext.txt	280	We assume rescue part due KNOX protein traffics L2 L3 layers SAM
0.15854263.12900451.html.plaintext.txt	281	The partial complementation stm 11 KNAT1 expression agrees previous findings KNAT1 partially redundant function STM Byrne et al
0.15854263.12900451.html.plaintext.txt	282	To test KN1 trafficking essential complementation stm 11 assay made non trafficking GUSKN1 fusion
0.15854263.12900451.html.plaintext.txt	283	We fused GUS 68 kDa N terminus KN1 intervening alanine linker previous studies showed optimal configuration KN1 fusions Kim et al
0.15854263.12900451.html.plaintext.txt	284	The GUSKN1 fusion protein behaved cell autonomously leaf GUS activity detected perivascular cells J2111UAS GUSKN1 lines Fig
0.15854263.12900451.html.plaintext.txt	285	5HI epidermis pAtML1 GUSKN1 lines Fig
0.15854263.12900451.html.plaintext.txt	286	The GUSKN1 fusion also cell autonomous SAM pAtML1 GUSKN1 plants showed GUS activity L1 layer Fig
0.15854263.12900451.html.plaintext.txt	287	We next asked L1 restricted expression GUSKN1 could rescue stm 11
0.15854263.12900451.html.plaintext.txt	288	We observed rescue stm 11 phenotype 16 independent T1 stm 11 seedlings 200 stm 11 seedlings 4 independent T2 lines expressed GUSKN1 strongly L1 Fig
0.15854263.12900451.html.plaintext.txt	289	This failure complement could GUSKN1 unable traffic L2 L3 layers GUS fusion blocked KN1 function independently inhibition KN1 trafficking
0.15854263.12900451.html.plaintext.txt	290	To distinguish possibilities asked expression GUSKN1 cell layers SAM sufficient rescue stm 11
0.15854263.12900451.html.plaintext.txt	291	To end 35S GUSKN1 construct transformed stm 11 heterozygotes
0.15854263.12900451.html.plaintext.txt	292	As expected transgenic plants showed constitutive GUS activity SAM layers Fig
0.15854263.12900451.html.plaintext.txt	293	We confirmed GUSKN1 expression western blotting using anti KN1 antibody Smith et al
0.15854263.12900451.html.plaintext.txt	294	We observed shoot rescue five 15 independent T2 lines 33 segregated stm 11 indicating GUSKN1 fusion indeed functional shoot rescue assay Fig
0.15854263.12900451.html.plaintext.txt	295	The rescue phenotypes generally weaker GFPKN1 lines though 35S GUSKN1 rescued seedlings developed inflorescence shoots similar stm 11 plants rescued L1 specific expression KNOX proteins shown
0.15854263.12900451.html.plaintext.txt	296	Therefore GUSKN1 expression SAM layers could partially complement stm 11 whereas L1 specific expression gave complementation
0.15854263.12900451.html.plaintext.txt	297	We previously showed 35S GFPKN1 plants develop KNOX expression phenotypes Kim et al
0.15854263.12900451.html.plaintext.txt	298	To surprise 35S GUSKN1 transgenic plants 40 wild type stm show KN1 expression phenotypes Fig
0.15854263.12900451.html.plaintext.txt	299	5P despite strong expression GUSKN1 throughout leaves Fig
0.15854263.12900451.html.plaintext.txt	300	In summary GUSKN1 cell autonomous partially complemented stm 11 expressed meristem layers expressed specifically L1
0.15854263.12900451.html.plaintext.txt	301	These data support hypothesis trafficking L1 required shoot rescue pAtML1 KNOX expression lines
0.15854263.12900451.html.plaintext.txt	302	Over expression GUSKN1 fusion produce KNOX expression phenotypes suggesting either expression phenotypes require trafficking function KN1 GUS fusion interrupts function KN1 involved specifically generating expression phenotypes
0.15854263.12900451.html.plaintext.txt	303	DISCUSSION TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES The intercellular trafficking regulatory proteins likely transmits important developmental signals plants
0.15854263.12900451.html.plaintext.txt	304	Protein trafficking thought occur plasmodesmata developmentally significant strict temporal andor tissue specific control
0.15854263.12900451.html.plaintext.txt	305	Developmental modifications PDs indeed affect free GFP diffusion selective MP trafficking Itaya et al
0.15854263.12900451.html.plaintext.txt	306	1999 however almost nothing known whether regulation occurs plant proteins
0.15854263.12900451.html.plaintext.txt	307	Here showed KN1 trafficking developmental control also KNOX protein trafficking regulates fate target cells meristem indicating trafficking homeodomain proteins potential developmental significance
0.15854263.12900451.html.plaintext.txt	308	Developmental tissue specific control KN1 trafficking In plants simple leaves KNOX genes usually expressed SAM though developmental consequences ectopic leaf expression expression KNOX genes compound leaves indicate function leaf development Bharathan et al
0.15854263.12900451.html.plaintext.txt	309	We found GFPKN1 trafficking regulated tissue specifically leaf
0.15854263.12900451.html.plaintext.txt	310	Whereas could traffic mesophyll epidermis trafficking occur epidermis mesophyll either leaf primordia fully expanded leaves
0.15854263.12900451.html.plaintext.txt	311	Consistent observations distinctive phenotypes arose layer specific expression KN1
0.15854263.12900451.html.plaintext.txt	312	As expected mesophyll specific expression GFPKN1 resulted strong KNOX expression phenotypes similar constitutive 35S promoter driven expression Lincoln et al
0.15854263.12900451.html.plaintext.txt	313	However epidermal specific expression GFPKN1 produced relatively mild rumpled phenotype
0.15854263.12900451.html.plaintext.txt	314	This mild phenotype probably due restriction KN1 epidermis though fact epidermal expression able alter leaf shape indicate non autonomous effect KN1 presumably due trafficking
0.15854263.12900451.html.plaintext.txt	315	Similar unidirectional signaling observed periclinal chimeras floral organ identity genes GLOBOSA GLO DEFICIENS DEF Antirrhinum
0.15854263.12900451.html.plaintext.txt	316	Some effects DEF GLO expression non cell autonomous however effects partially explained movement DEF also moves L2 L1 opposite direction Perbal et al
0.15854263.12900451.html.plaintext.txt	317	In study showed lack protein movement epidermis however general phenomenon
0.15854263.12900451.html.plaintext.txt	318	Both GFP GFPTVCV MP moved freely epidermis mesophyll demonstrating PDs epidermal mesophyll cells open diffusion mediated selective protein movement
0.15854263.12900451.html.plaintext.txt	319	Uni directional trafficking KN1 leaf suggests KN1 normally traffics inner outer layers may reveal directional signaling pathway
0.15854263.12900451.html.plaintext.txt	320	Although class I KNOX genes normally expressed simple leaves maize rice Arabidopsis expressed compound leaves Bharathan et al
0.15854263.12900451.html.plaintext.txt	321	For example LeT6 expressed tomato leaf primordia well SAM Chen et al
0.15854263.12900451.html.plaintext.txt	322	showed LeT6 mRNA expression strong L2L3 layers reduced absent L1 layer SAM note expression pattern continues young leaf primordia Chen et al
0.15854263.12900451.html.plaintext.txt	323	It would interesting therefore test whether KNOX proteins traffic directionally tomato compound leaf process could provide mechanism regulation leaf morphology signaling inner outer layers development
0.15854263.12900451.html.plaintext.txt	324	Classic studies involving inter specific periclinal leaf chimeras indeed indicate potential direction signaling leaf morphogenesis reviewed Tilney Bassett 1986
0.15854263.12900451.html.plaintext.txt	325	In support hypothesis KN1 traffics PDs showed punctate pattern resembling seen GFPMP linked plasmodesmata studies using electron microscope level immunolocalization Ding et al
0.15854263.12900451.html.plaintext.txt	326	Our results imply however mechanism KN1 trafficking differs viral MP
0.15854263.12900451.html.plaintext.txt	327	This could tissue specific receptors recognize distinct trafficking motifs different proteins
0.15854263.12900451.html.plaintext.txt	328	This idea supported recent report non cell autonomous pathway protein NCAPP1 putative PD receptor interacts CmPP16 TMV MP KN1 Lee et al
0.15854263.12900451.html.plaintext.txt	329	Alternatively tissue specific post translational modifications KN1 might affect ability traffic
0.15854263.12900451.html.plaintext.txt	330	For example phosphorylation regulates trafficking TMV MP Citovsky et al
0.15854263.12900451.html.plaintext.txt	331	2000 perhaps similar mechanism controls KN1 trafficking
0.15854263.12900451.html.plaintext.txt	332	KN1 related Arabidopsis KNOX proteins STM KNAT1 traffic SAM Whereas KN1 unable traffic epidermal mesophyll cells leaf could traffic epidermal L1 cells underlying cells inflorescence SAM
0.15854263.12900451.html.plaintext.txt	333	Two Arabidopsis homologs KN1 KNAT1 STM could also traffic SAM suggesting hypothetical signals trafficking KN1 conserved KNOX proteins
0.15854263.12900451.html.plaintext.txt	334	These signals could made simple short sequence andor complex structural motifs
0.15854263.12900451.html.plaintext.txt	335	So far studies using viral MPs rice phloem proteins suggest recognition PD trafficking machinery involves structural motifs Haywood et al
0.15854263.12900451.html.plaintext.txt	336	1998 though short sequence motif appears control trafficking heat shock cognate 70 chaperone Aoki et al
0.15854263.12900451.html.plaintext.txt	337	In case KN1 short peptide homologous region near N terminus protein interfere trafficking though known whether sequence motif sufficient trafficking Kragler et al
0.15854263.12900451.html.plaintext.txt	338	We observed relatively short range GFPKNOX protein trafficking Arabidopsis SAM generated steep gradient GFP fluorescence spanning approximately 23 cell layers
0.15854263.12900451.html.plaintext.txt	339	In contrast GFPKN1 traffic least 3 5 cell layers leaf Kim et al
0.15854263.12900451.html.plaintext.txt	340	GFPTVCV MP free GFP moved GFPKNOX SAM six cell layers
0.15854263.12900451.html.plaintext.txt	341	This suggests KNOX protein trafficking meristem relatively restricted may used short range signaling
0.15854263.12900451.html.plaintext.txt	342	The pronounced nuclear localization GFPKN1 meristem leaf may cause shorter range trafficking nuclear localization probably restricts chance interact PD
0.15854263.12900451.html.plaintext.txt	343	A similar mechanism proposed restriction SHR trafficking Nakajima et al
0.15854263.12900451.html.plaintext.txt	344	2001 GFP diffusion Crawford Zambryski 2000
0.15854263.12900451.html.plaintext.txt	345	In maize shoot apex KN1 protein gradient also evident SAM leaf primordia Jackson 2002
0.15854263.12900451.html.plaintext.txt	346	Although biological significance KNOX protein gradients yet clear possible used activate target genes different positions along gradient Jackson 2002
0.15854263.12900451.html.plaintext.txt	347	Caution required interpreting trafficking GFP fusion proteins
0.15854263.12900451.html.plaintext.txt	348	The GFP tag increases size protein may affect trafficking efficiency
0.15854263.12900451.html.plaintext.txt	349	However GFPKN1 fusion used study produced normal KN1 overexpression phenotypes also complemented stm mutation suggesting retained normal biological functions
0.15854263.12900451.html.plaintext.txt	350	In addition low quantum yield GFP relative fluorophores may well result significant underestimation range tagged protein traffic
0.15854263.12900451.html.plaintext.txt	351	Biological function KNOX homeodomain protein trafficking The critical question function KNOX protein trafficking intercellular signaling The conservation trafficking ability KNOX proteins different species suggests function requires trafficking nuclear localization GFPKNOX proteins following trafficking SAM suggests function transcription target cells
0.15854263.12900451.html.plaintext.txt	352	Cell cell trafficking KNAT1 could explain non cell autonomous regulation epidermal cell fate KNAT1 reported Venglat et al
0.15854263.12900451.html.plaintext.txt	353	GFPKNOX expression L1 rescued shoot formation stm 11 mutants trafficking probably required rescue cell autonomous GUSKN1 fusion result rescue
0.15854263.12900451.html.plaintext.txt	354	Whereas failure rescue could GUSKN1 inactive case since could partially rescue stm 11 expressed meristem cell layers using 35S promoter
0.15854263.12900451.html.plaintext.txt	355	However rescue stm 11 35S GUSKN1 partial speculate full KN1 function SAM might require intercellular trafficking
0.15854263.12900451.html.plaintext.txt	356	A functional requirement KN1 trafficking wild type situation remains tested determining expression non trafficking version KN1 faithful STM promoter complement stm mutant
0.15854263.12900451.html.plaintext.txt	357	Our results suggest correct spatial temporal expression pattern andor level KN1STM SAM required full complementation stm 11
0.15854263.12900451.html.plaintext.txt	358	In contrast AtML1 promoter use STM promoter resulted GFPKN1 expression relatively homogeneous level different SAM layers
0.15854263.12900451.html.plaintext.txt	359	These expression differences probably reason two constructs resulted different complementation phenotypes pAtML1 GFPKN1 KN1 expression always resulted partial complementation stm abnormal phyllotaxy complementation using pSTM GFPKN1 KN1 complete produced seedlings normal phyllotaxy
0.15854263.12900451.html.plaintext.txt	360	In regard intercellular protein trafficking might provide way regulate distribution concentration key developmental regulators across cellular domain like SAM
0.15854263.12900451.html.plaintext.txt	361	Intercellular KN1STM trafficking may redundant fail safe mechanism ensure cells adopt SAM fate analogous mechanism originally proposed Mezitt Lucas Mezitt Lucas 1996 non autonomous action FLORICAULA supported demonstration LFY trafficking Sessions et al
0.15854263.12900451.html.plaintext.txt	362	Plants expressing non trafficking 35S GUSKN1 fusion usual KN1 expression phenotypes
0.15854263.12900451.html.plaintext.txt	363	We therefore hypothesize KN1 trafficking might required generate expression phenotypes movement per se important function rather simply cells contain KN1
0.15854263.12900451.html.plaintext.txt	364	One possible mechanism would KN1 modified gained novel function intercellular movement
0.15854263.12900451.html.plaintext.txt	365	Partial unfolding KN1 required passage PDs Kragler et al
0.15854263.12900451.html.plaintext.txt	366	1998 could expose KN1 post translational modifications
0.15854263.12900451.html.plaintext.txt	367	Alternatively lack KNOX overexpression phenotype 35S GUSKN1 plants could fusion GUS inhibits ability KN1 interact partner proteins Arabidopsis homologs KN1 interacting protein KIP BEL1 like TALE homeodomain protein Smith et al
0.15854263.12900451.html.plaintext.txt	368	Such interacting proteins may differentially expressed differentially required expression SAM functions KN1
0.15854263.12900451.html.plaintext.txt	369	Lastly nuclear localization STM required activity Gallois et al
0.15854263.12900451.html.plaintext.txt	370	2002 fusion GUS interfered KN1 nuclear localization specifically leaf could also affect ability generate expression phenotypes
0.15854263.12900451.html.plaintext.txt	371	In conclusion KN1 trafficking temporal tissue specific developmental control trafficking ability conserved STM KNAT1
0.15854263.12900451.html.plaintext.txt	372	Our results suggest trafficking KNOX homeodomain proteins functionally significant may coordinate development source target cells provide redundant fail safe mechanism control fate cells SAM
0.15854263.12900451.html.plaintext.txt	373	ACKNOWLEDGMENTS We thank Anita Fernandez University Wisconsin M
0.15854263.12900451.html.plaintext.txt	374	Kathryn Barton Carnegie Institution Washington stm 11 mutant seeds STM promoter Jim Haseloff University Cambridge GFP GAL4 constructs
0.15854263.12900451.html.plaintext.txt	375	We thank Julie Thomas making pAtML1 constructs Ryohei Yasuda assistance two photon microscopy Tim Mulligan greenhouse management
0.15854263.12900451.html.plaintext.txt	376	Funding provided National Science Foundation Integrative Plant Biology Grant 9727959 Cold Spring Harbor Laboratory institutional funds
0.15854263.12900451.html.plaintext.txt	377	Footnotes Present address Scully Scott Murphy Presser 400 Garden City Plaza Garden City New York NY 11530 USA
0.15854263.12900451.html.plaintext.txt	378	REFERENCES TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES
0.15854263.12900451.html.plaintext.txt	379	A subclass plant heat shock cognate 70 chaperones carries motif facilitates trafficking plasmodesmata
0.15854263.12900451.html.plaintext.txt	380	Phloem sap proteins cucurbita maxima ricinus communis capacity traffic cell cell plasmodesmata
0.15854263.12900451.html.plaintext.txt	381	Phylogenetic relationships evolution KNOTTED class plant homeodomain proteins
0.15854263.12900451.html.plaintext.txt	382	Homologies leaf form inferred KNOXI gene expression development
0.15854263.12900451.html.plaintext.txt	383	ASYMMETRIC LEAVES1 reveals knox gene redundancy Arabidopsis
0.15854263.12900451.html.plaintext.txt	384	A gene fusion homeobox locus alterations leaf shape implications morphological evolution
0.15854263.12900451.html.plaintext.txt	385	KNAT1 induces lobed leaves ectopic meristems overexpressed Arabidopsis
0.15854263.12900451.html.plaintext.txt	386	Phosphorylation tobacco mosaic virus cell cell movement protein developmentally regulated plant cell wall associated protein kinase
0.15854263.12900451.html.plaintext.txt	387	The CLAVATA SHOOT MERISTEMLESS loci competitively regulate meristem activity Arabidopsis
0.15854263.12900451.html.plaintext.txt	388	Floral dip simplified method Agrobacterium mediated transformation Arabidopsis thaliana
0.15854263.12900451.html.plaintext.txt	389	Subcellular localization determines availability non targeted proteins plasmodesmatal transport
0.15854263.12900451.html.plaintext.txt	390	The 30 kilodalton gene product tobacco mosaic virus potentiates virus movement
0.15854263.12900451.html.plaintext.txt	391	Influence heterologous tobamovirus movement protein chimeric movement protein genes cell cell long distance movement
0.15854263.12900451.html.plaintext.txt	392	Intercellular protein trafficking plasmodesmata
0.15854263.12900451.html.plaintext.txt	393	Secondary plasmodesmata specific sites localization tobacco mosaic virus movement protein transgenic tobacco plants
0.15854263.12900451.html.plaintext.txt	394	Substructure freeze substituted plasmodesmata
0.15854263.12900451.html.plaintext.txt	395	Cell cell movement potato spindle tuber viroid
0.15854263.12900451.html.plaintext.txt	396	KNAT1 ERECTA regulate inflorescence architecture Arabidopsis
0.15854263.12900451.html.plaintext.txt	397	Movement yeast cortical actin cytoskeleton visualized vivo
0.15854263.12900451.html.plaintext.txt	398	The SHOOT MERISTEMLESS gene required maintenance undifferentiated cells Arabidopsis shoot floral meristems acts different regulatory level meristem genes WUSCHEL ZWILLE
0.15854263.12900451.html.plaintext.txt	399	Combined SHOOT MERISTEMLESS WUSCHEL trigger ectopic organogenesis Arabidopsis
0.15854263.12900451.html.plaintext.txt	400	In Intercellular Communication Plants Studies Plasmodesmata ed
0.15854263.12900451.html.plaintext.txt	401	BerlinHeidelbergNew York Springer Verlag
0.15854263.12900451.html.plaintext.txt	402	Analysis genetic mosaics shows extraepidermal cell divisions Knotted1 mutant maize plants induced adjacent mesophyll cells
0.15854263.12900451.html.plaintext.txt	403	Removal cryptic intron subcellular localization green fluorescent protein required mark transgenic Arabidopsis plants brightly
0.15854263.12900451.html.plaintext.txt	404	Plasmodesmata pathways protein ribonucleoprotein signaling
0.15854263.12900451.html.plaintext.txt	405	Cell cell long distance trafficking green fluorescent protein phloem symplastic unloading protein sink tissues
0.15854263.12900451.html.plaintext.txt	406	Rice phloem thioredoxin h capacity mediate cell cell transport plasmodesmata
0.15854263.12900451.html.plaintext.txt	407	Developmental regulation intercellular protein trafficking plasmodesmata tobacco leaf epidermis
0.15854263.12900451.html.plaintext.txt	408	Nonspecific intercellular protein trafficking probed green fluorescent protein
0.15854263.12900451.html.plaintext.txt	409	Plasmodesma mediated selective protein traffic symplasmically isolated cells probed viral movement protein
0.15854263.12900451.html.plaintext.txt	410	The long short signaling development plasmodesmata
0.15854263.12900451.html.plaintext.txt	411	Double labeling KNOTTED1 mRNA protein reveals multiple potential sites protein trafficking shoot apex
0.15854263.12900451.html.plaintext.txt	412	Expression maize KNOTTED1 related homeobox genes shoot apical meristem predicts patterns morphogenesis vegetative shoot
0.15854263.12900451.html.plaintext.txt	413	GUS fusions beta glucuronidase sensitive versatile gene fusion marker higher plants
0.15854263.12900451.html.plaintext.txt	414	Developmental changes due long distance movement homeobox fusion transcript tomato
0.15854263.12900451.html.plaintext.txt	415	Intercellular trafficking KNOTTED1 green fluorescent protein fusion leaf shoot meristem Arabidopsis
0.15854263.12900451.html.plaintext.txt	416	Cell cell transport proteins requirement unfolding characterization binding putative plasmodesmal receptor
0.15854263.12900451.html.plaintext.txt	417	Movement subcellular localization tobamovirus Arabidopsis
0.15854263.12900451.html.plaintext.txt	418	Selective trafficking non cell autonomous proteins mediated NtNCAPP1
0.15854263.12900451.html.plaintext.txt	419	A knotted1 like homeobox gene Arabidopsis expressed vegetative meristem dramatically alters leaf morphology overexpressed transgenic plants
0.15854263.12900451.html.plaintext.txt	420	A member KNOTTED class homeodomain proteins encoded STM gene Arabidopsis
0.15854263.12900451.html.plaintext.txt	421	Identification meristem L1 layer specific gene Arabidopsis expressed embryonic pattern formation defines new class homeobox genes
0.15854263.12900451.html.plaintext.txt	422	Plasmodesmata supracellular nature plants
0.15854263.12900451.html.plaintext.txt	423	Plasmodesmata intercellular organelles green plants
0.15854263.12900451.html.plaintext.txt	424	Selective trafficking KNOTTED1 homeodomain protein mRNA plasmodesmata
0.15854263.12900451.html.plaintext.txt	425	Plant virus movement de novo process redeployed machinery Trends Microbiol
0.15854263.12900451.html.plaintext.txt	426	Plasmodesmal cell cell transport proteins nucleic acids
0.15854263.12900451.html.plaintext.txt	427	Developmental changes plasmodesmata transgenic tobacco expressing movement protein tobacco mosaic virus
0.15854263.12900451.html.plaintext.txt	428	Intercellular movement putative transcription factor SHR root patterning
0.15854263.12900451.html.plaintext.txt	429	Viral RNA trafficking inhibited replicase mediated resistant transgenic tobacco plants
0.15854263.12900451.html.plaintext.txt	430	Facilitation single synapses probed optical quantal analysis
0.15854263.12900451.html.plaintext.txt	431	Simple branched plasmodesmata allow nonspecific trafficking proteins developing tobacco leaves
0.15854263.12900451.html.plaintext.txt	432	Non cell autonomous function Antirrhinum floral homeotic proteins DEFICIENS GLOBOSA exerted polar cell cell trafficking
0.15854263.12900451.html.plaintext.txt	433	Knots family tree evolutionary relationships functions knox homeobox genes
0.15854263.12900451.html.plaintext.txt	434	The ASYMMETRIC LEAVES2 gene Arabidopsis thaliana regulates formation symmetric lamina establishment venation repression meristem related homeobox genes leaves
0.15854263.12900451.html.plaintext.txt	435	The Arabidopsis thaliana MERISTEM LAYER 1 promoter specifies epidermal expression meristems young primordia
0.15854263.12900451.html.plaintext.txt	436	Cell cell signaling movement floral transcription factors LEAFY APETALA1
0.15854263.12900451.html.plaintext.txt	437	A dominant mutation maize homeobox gene Knotted 1 causes ectopic expression leaf cells altered fates
0.15854263.12900451.html.plaintext.txt	438	Selective interaction plant homeodomain proteins mediates high DNA binding affinity
0.15854263.12900451.html.plaintext.txt	439	The fasciated ear2 gene encodes leucine rich repeat receptor like protein regulates shoot meristem proliferation maize
0.15854263.12900451.html.plaintext.txt	440	Tissue specific expression gene encoding cell wall localized lipid transfer protein Arabidopsis
0.15854263.12900451.html.plaintext.txt	441	The homeobox gene BREVIPEDICELLUS key regulator inflorescence architecture Arabidopsis
0.15854263.12900451.html.plaintext.txt	442	Shoot meristem size dependent inbred background presence maize homeobox gene knotted1
0.15854263.12900451.html.plaintext.txt	443	Direct functional assay tobacco mosaic virus cell cell movement protein identification domain involved increasing plasmodesmal permeability
0.15854263.12900451.html.plaintext.txt	444	Tobacco mosaic virus movement protein mediated protein transport trichome cells
0.15854263.12900451.html.plaintext.txt	445	Regulation plasmodesmal transport phosphorylation tobacco mosaic virus cell cell movement protein
0.15854263.12900451.html.plaintext.txt	446	Mutations viral movement protein alter systemic infection identify intercellular barrier entry phloem long distance transport system
0.15854263.12900451.html.plaintext.txt	447	Ultrastructural histochemical studies guard cells
0.15854263.12900451.html.plaintext.txt	448	Movement protein tobacco mosaic virus modifies plasmodesmatal size exclusion limit
0.15854263.12900451.html.plaintext.txt	449	Signaling plants intercellular RNA protein movement
0.15854263.12900451.html.plaintext.txt	450	Plant paralog viral movement protein potentiates transport mRNA phloem
0.15854263.12900451.html.plaintext.txt	451	Plasmodesmata gatekeepers cell cell transport developmental signals plants
0.17798969.9281577.html.plaintext.txt	0	Structure L A Virus A Specialized Compartment Transcription Replication Double stranded RNA
0.17798969.9281577.html.plaintext.txt	1	Laboratory Structural Biology National Institute Arthritis Musculoskeletal Skin Diseases Computational Bioscience Engineering Laboratory Division Computer Research Technology Laboratory Biochemistry Genetics National Institute Diabetes Digestive Kidney Diseases National Institutes Health Bethesda Maryland 20892 Department Biology Brookhaven National Laboratory Upton New York 11973 Abstract Materials Methods Results Discussion Footnotes Acknowledgements Abbreviations used paper References
0.17798969.9281577.html.plaintext.txt	2	The genomes double stranded dsRNA viruses never exposed cytoplasm confined replicated specialized protein bound compartmentthe viral capsid
0.17798969.9281577.html.plaintext.txt	3	We used cryoelectron microscopy three dimensional image reconstruction study compartment case L A yeast virus whose capsid consists 60 asymmetric dimers Gag protein 76 kD
0.17798969.9281577.html.plaintext.txt	4	At 16 A resolution distinguish multiple domains elongated Gag subunits whose nonequivalent packing reflected subtly different morphologies two protomers
0.17798969.9281577.html.plaintext.txt	5	Small holes 10 15 A across perforate capsid wall functions molecular sieve allowing exit transcripts influx metabolites retaining dsRNA excluding degradative enzymes
0.17798969.9281577.html.plaintext.txt	6	Scanning transmission electron microscope measurements mass per unit length suggest L A RNA A form duplex RNA filaments emanating disrupted virions often consist two closely associated duplexes
0.17798969.9281577.html.plaintext.txt	7	Nuclease protection experiments confirm genome entirely sequestered inside full capsids packed relatively loosely L A center center spacing duplexes 40 45 A compared 25 30 A double stranded viruses
0.17798969.9281577.html.plaintext.txt	8	The looser packing L A RNA allows maneuverability crowded capsid interior genome replication transcription must translocated sequentially past polymerase immobilized inner capsid wall
0.17798969.9281577.html.plaintext.txt	9	IN eukaryotic prokaryotic cells alike medium genetic information stored double stranded ds1 DNA
0.17798969.9281577.html.plaintext.txt	10	From repository genes copied medium replication different media transcription translation
0.17798969.9281577.html.plaintext.txt	11	Viruses limited less constrained genetic entities cells exhibit greater diversity replication cycles
0.17798969.9281577.html.plaintext.txt	12	All four alternative media single stranded ssRNA ssDNA dsDNA dsRNA used different virus families encode genomes review see Roizman Palese 1996
0.17798969.9281577.html.plaintext.txt	13	Whereas dsDNA ssRNA molecules abundant cellular components dsRNA ssDNA molecules
0.17798969.9281577.html.plaintext.txt	14	In circumstances one might expect viruses latter kinds developed special strategies interfacing metabolic resources host cells
0.17798969.9281577.html.plaintext.txt	15	One strategy widespread universal among dsRNA viruses use capsids specialized cytoplasmic compartments genomes confined replicated expressed Dryden et al
0.17798969.9281577.html.plaintext.txt	16	Such capsids selectively porous protein shells genome replicase reside within nucleotides infuse nascent strands positive sense extruded
0.17798969.9281577.html.plaintext.txt	17	The present study addresses capsid structure organization encapsidated RNA L A virus yeast excellent model system relative simplicity well known molecular biology
0.17798969.9281577.html.plaintext.txt	18	6 kbp single segment molecule encodes major capsid protein Gag 680 residues 76 kD minor capsid protein
0.17798969.9281577.html.plaintext.txt	19	The latter molecule fusion Gag Pol RNA dependent RNA polymerase Pol 868 residues 100 kD Fujimura Wickner 1988a Icho Wickner 1989 generated ribosomal frameshifting Dinman et al
0.17798969.9281577.html.plaintext.txt	20	The L A capsid spherical particle 430 A diam composed 120 copies Gag Esteban Wickner 1986 Cheng et al
0.17798969.9281577.html.plaintext.txt	21	1994 approximately two carry Pol moiety Dinman Wickner 1992 Ribas J
0.17798969.9281577.html.plaintext.txt	22	Its surface lattice unusual property composed 60 asymmetric dimers Cheng et al
0.17798969.9281577.html.plaintext.txt	23	1994 configured otherwise conventional icosahedron triangulation class T 1 Caspar Klug 1962
0.17798969.9281577.html.plaintext.txt	24	Interestingly 120 subunit capsids detected several dsRNA viruses including bacteriophage 6 Mindich Bamford 1988 reovirus Dryden et al
0.17798969.9281577.html.plaintext.txt	25	1993 orbivirus Burroughs et al
0.17798969.9281577.html.plaintext.txt	26	1995 aquareovirus Shaw et al
0.17798969.9281577.html.plaintext.txt	27	1996 rotavirus Estes 1996 thus far kind virus
0.17798969.9281577.html.plaintext.txt	28	Motivated expanding generality unusual capsid stoichiometry architecture prospect gaining insight features commend compartment sequestration replication dsRNA pursued cryoelectron microscopic studies L A capsid extending resolution 16 A
0.17798969.9281577.html.plaintext.txt	29	Using data also examined structural organization viral genome encapsidated state released virions
0.17798969.9281577.html.plaintext.txt	30	Complementary information obtained using dark field scanning transmission electron microscopy STEM Wall Hainfeld 1986 Thomas et al
0.17798969.9281577.html.plaintext.txt	31	1994 measure mass per unit length L A chromosomes extruding directly capsids isolation
0.17798969.9281577.html.plaintext.txt	32	Materials Methods Virus Particle Preparation
0.17798969.9281577.html.plaintext.txt	33	L A virus extracted stationary phase cells Saccharomyces cerevisiae strain TF229 MATa His34 Leu2 ski2 2 L A HN grown 1 liter rich medium purified CsCl equilibrium gradient centrifugation described Fujimura Wickner 1988b except 12
0.17798969.9281577.html.plaintext.txt	34	5 ml CsCl gradients run 157000 g 44000 rpm Beckman NVT65 rotor Beckman Instruments Inc
0.17798969.9281577.html.plaintext.txt	35	Fullerton CA 15 h 4 degrees C
0.17798969.9281577.html.plaintext.txt	36	The virus containing fractions dialyzed buffer A 50 mM Tris HCl 150 mM NaCl 5 mM EDTA 1 mM DTT pH 7
0.17798969.9281577.html.plaintext.txt	37	8 6 h stored 20 mgml 4 degrees C
0.17798969.9281577.html.plaintext.txt	38	All samples used within 7 d purification L A virions tend lose dsRNA upon protracted storage
0.17798969.9281577.html.plaintext.txt	39	Virions examined cryoelectron microscopy dialyzed buffer A 8 12 h remove CsCl
0.17798969.9281577.html.plaintext.txt	40	They diluted buffer A examined negative staining uniform dense continuous distribution particles observed
0.17798969.9281577.html.plaintext.txt	41	5 microl drops virus concentration typically 2 5 mgml applied holey carbon films 400 mesh copper grids observed cryoelectron microscopy essentially described Booy et al
0.17798969.9281577.html.plaintext.txt	42	Micrographs recorded minimal exposure conditions nominal magnifications x 36000 x 46000 8 eA2 Kodak SO 163 films using electron microscope EM400RT Philips Technologies Eindhoven The Netherlands equipped modified Gatan anticontaminator blades Gatan 626 cryoholder Gatan Warrendale PA
0.17798969.9281577.html.plaintext.txt	43	In experiments bacteriophage T4 mixed L A 40
0.17798969.9281577.html.plaintext.txt	44	5 A axial spacing tail sheath Moody Makowski 1981 used internal magnification standard
0.17798969.9281577.html.plaintext.txt	45	Micrographs assessed resolution stigmation optical diffraction large areas defocus values estimated positions first zero contrast transfer function CTF
0.17798969.9281577.html.plaintext.txt	46	For micrographs chosen analysis first zero range 15 A1 27 A1 Table I
0.17798969.9281577.html.plaintext.txt	47	Underfocus values calculated according 1k2 wavelength 100 keV electrons 0
0.17798969.9281577.html.plaintext.txt	48	037 A k spatial frequency first zero Lepault Leonard 1985
0.17798969.9281577.html.plaintext.txt	49	Spectra calculated powder patterns genome revealing difference images L A virions
0.17798969.9281577.html.plaintext.txt	50	The positions spread peaks spectra give statistically representative estimates predominant spacings RNA filaments packed L A virus capsids
0.17798969.9281577.html.plaintext.txt	51	Because shape spectrum depends defocus micrographs calculated analysis repeated micrographs covering range defocus values
0.17798969.9281577.html.plaintext.txt	52	In case difference images calculated shown Fig
0.17798969.9281577.html.plaintext.txt	53	4 diffraction patterns calculated azimuthally averaged powder pattern obtained summing many particles
0.17798969.9281577.html.plaintext.txt	54	The various spectra indexed according serial numbers micrographs used
0.17798969.9281577.html.plaintext.txt	55	The closest focus spectrum top furthest focus one bottom Table I
0.17798969.9281577.html.plaintext.txt	56	Each spectrum shows broad peak range 47 A1 31 A1 gray vertical band
0.17798969.9281577.html.plaintext.txt	57	Also shown control spectrum calculated empty particles micrograph 7261
0.17798969.9281577.html.plaintext.txt	58	It shows much weaker peak frequency range indicative defocus value micrograph recorded confirms strong peak full particle spectrum reflects scattering viral RNA
0.17798969.9281577.html.plaintext.txt	59	For reference line shown 26 A1 average interduplex spacing many dsDNA dsRNA viruses
0.17798969.9281577.html.plaintext.txt	60	View Larger Version Image 29K GIF file
0.17798969.9281577.html.plaintext.txt	61	Computer filtered images encapsidated L A genomes
0.17798969.9281577.html.plaintext.txt	62	Typical full empty particles shown e respectively
0.17798969.9281577.html.plaintext.txt	63	b f show particles low pass filtering 28 A1
0.17798969.9281577.html.plaintext.txt	64	c g obtained reprojecting corresponding density maps appropriate viewing orientations reproduce micrographs well particularly terms peripheral detail
0.17798969.9281577.html.plaintext.txt	65	d h difference images calculated subtracting c nullifying internal density full map g b respectively
0.17798969.9281577.html.plaintext.txt	66	d reveals encapsidated genome
0.17798969.9281577.html.plaintext.txt	67	The control h simply represents background noise confirms shell cleanly removed procedure
0.17798969.9281577.html.plaintext.txt	68	The two particles shown highest defocus micrograph analyzed 2 microm defocus first CTF zero 27 A1
0.17798969.9281577.html.plaintext.txt	69	l show two examples exposed genomes four micrographs different defocus values
0.17798969.9281577.html.plaintext.txt	70	Their first CTF zeros spacings 15
0.17798969.9281577.html.plaintext.txt	71	In case density map used calculate shell contribution virion image calculated micrograph question
0.17798969.9281577.html.plaintext.txt	72	These images illustrate variable appearance encapsidated genomes demonstrate variability arise differences defocus
0.17798969.9281577.html.plaintext.txt	73	View Larger Version Image 182K GIF file
0.17798969.9281577.html.plaintext.txt	74	Micrographs digitized Perkin Elmer 1010MG microdensitometer Norwalk CT 12 microm intervals x 36000 negatives 16 microm intervals x 46000 negatives corresponding 3
0.17798969.9281577.html.plaintext.txt	75	General image processing operations carried using PIC Software system Trus et al
0.17798969.9281577.html.plaintext.txt	76	1996 running Alpha workstations Digital Equipment Co
0.17798969.9281577.html.plaintext.txt	77	Particles extracted preprocessed using automated procedure Conway et al
0.17798969.9281577.html.plaintext.txt	78	Particle orientations determined means Polar Fourier Transform algorithm iterative model based procedure Baker Cheng 1996
0.17798969.9281577.html.plaintext.txt	79	As starting model used earlier 26A resolution three dimensional 3 D map empty L A particles Cheng et al
0.17798969.9281577.html.plaintext.txt	80	In micrographs analyzed reconstructions empty full particles calculated separately using Fourier Bessel techniques Crowther 1971 Fuller 1987 Baker et al
0.17798969.9281577.html.plaintext.txt	81	Complete icosahedral 532 symmetry imposed final density map
0.17798969.9281577.html.plaintext.txt	82	The contour level imposed surface rendering based 100 expected volume assuming protein density 1
0.17798969.9281577.html.plaintext.txt	83	Resolution three dimensional maps estimated terms Fourier shell correlation procedure Saxton Baumeister 1982 Conway et al
0.17798969.9281577.html.plaintext.txt	84	1993 case close first zero CTF
0.17798969.9281577.html.plaintext.txt	85	Data quality also assessed eigenvalue spectra Fuller et al
0.17798969.9281577.html.plaintext.txt	86	To obtain distribution particle orientations uniformly cover asymmetric unit Baker et al
0.17798969.9281577.html.plaintext.txt	87	1989 data three micrographs combined
0.17798969.9281577.html.plaintext.txt	88	All three micrographs well stigmated first zeros 15 A1
0.17798969.9281577.html.plaintext.txt	89	Three independent reconstructions first calculated mutually scaled magnification density matching spherically averaged radial density profiles Booy et al
0.17798969.9281577.html.plaintext.txt	90	A composite reconstruction including 80 particles Table I calculated orientation alignment parameters particle refined final map calculated
0.17798969.9281577.html.plaintext.txt	91	The resolution 16 A criterion
0.17798969.9281577.html.plaintext.txt	92	To visualize internal contents full particles first calculated reconstructions micrographs recorded several different defocus values
0.17798969.9281577.html.plaintext.txt	93	The contribution capsid shell image obtained reprojecting three dimensional map corresponding orientation setting internal densities background solvent level
0.17798969.9281577.html.plaintext.txt	94	Finally projected capsid shell subtracted raw image Baker et al
0.17798969.9281577.html.plaintext.txt	95	1991 thus providing unobstructed view encapsidated dsRNA
0.17798969.9281577.html.plaintext.txt	96	As control procedure applied images empty particles
0.17798969.9281577.html.plaintext.txt	97	Diffraction patterns calculated difference images data set
0.17798969.9281577.html.plaintext.txt	98	These added together equal weighting combining empty full particles separately azimuthally averaged obtain respective one dimensional powder patterns
0.17798969.9281577.html.plaintext.txt	99	Scanning Transmission Electron Microscopy STEM
0.17798969.9281577.html.plaintext.txt	100	STEM performed Brookhaven Biotechnology Resource Upton NY Wall 1979 Wall Hainfeld 1986
0.17798969.9281577.html.plaintext.txt	101	Full particles purified described stored briefly concentration 20 mgml diluted 40 fold buffer A 5 microl drop applied thin carbon film
0.17798969.9281577.html.plaintext.txt	102	The grid washed 10 times 100 mM ammonium acetate pH 6
0.17798969.9281577.html.plaintext.txt	103	5 frozen dried Wall 1979
0.17798969.9281577.html.plaintext.txt	104	To visualize isolated dsRNA material purified phenol extraction Wickner 1994 2
0.17798969.9281577.html.plaintext.txt	105	4 mgml diethyl pyrocarbonate treated water diluted 100 times 100 mM ammonium acetate applied polylysine coated carbon film washed 20 mM ammonium acetate freeze dried
0.17798969.9281577.html.plaintext.txt	106	Tobacco mosaic virus TMV 50 100 microgml included preparations internal mass standard
0.17798969.9281577.html.plaintext.txt	107	Digital micrographs 512 x 512 pixels recorded using sampling steps 20 10 Apixel
0.17798969.9281577.html.plaintext.txt	108	Mass determinations carried described Newcomb et al
0.17798969.9281577.html.plaintext.txt	109	RNase protection assays performed three different samples dsRNA purified full viral particles freshly prepared full particles viral particles disrupted dilution low ionic strength 25 mM NaCl incubated 45 min room temperature
0.17798969.9281577.html.plaintext.txt	110	RNase III exclusive specificity dsRNA Crouch 1974 conditions active presence 10 mM MgCl2
0.17798969.9281577.html.plaintext.txt	111	The reaction mixture 25 microl containing 0
0.17798969.9281577.html.plaintext.txt	112	5 microg dsRNA 1 microg RNase III 50 mM Tris HCl pH 7
0.17798969.9281577.html.plaintext.txt	113	1 mM DTT 0 10 mM MgCl2 incubated 45 min 37 degrees C
0.17798969.9281577.html.plaintext.txt	114	The resulting products phenol extracted ethanol precipitated separated 1
0.17798969.9281577.html.plaintext.txt	115	5 agarose gel detected ethidium bromide staining
0.17798969.9281577.html.plaintext.txt	116	Results Cryoelectron Microscopy Full Empty Capsids
0.17798969.9281577.html.plaintext.txt	117	Fields purified L A particles shown Fig
0.17798969.9281577.html.plaintext.txt	118	1 micrographs recorded several different defocus values
0.17798969.9281577.html.plaintext.txt	119	As expected image contrast increases defocus however L A exhibits conspicuous surface relief even quite high defocus Fig
0.17798969.9281577.html.plaintext.txt	120	Empty particles clearly distinguished full ones almost capsids appear intact see
0.17798969.9281577.html.plaintext.txt	121	We observed small percentage distinctive polymorphic variant dimeric capsid e
0.17798969.9281577.html.plaintext.txt	122	1 d large arrowhead seems fusion two capsids lacking one icosahedral cap
0.17798969.9281577.html.plaintext.txt	123	Whether arise pairing two partially dissociated capsids simply aberrant assembly products known
0.17798969.9281577.html.plaintext.txt	124	Filamentous material presumably RNA released virions usually visible e
0.17798969.9281577.html.plaintext.txt	125	Some full particles exhibit swirl patterns curved striations e
0.17798969.9281577.html.plaintext.txt	126	1 c large arrowhead attribute encapsidated RNA never seen empty capsids
0.17798969.9281577.html.plaintext.txt	127	The spacing striations 35 40 A
0.17798969.9281577.html.plaintext.txt	128	More often full particles present punctate nonsymmetric motifs
0.17798969.9281577.html.plaintext.txt	129	Cryoelectron micrographs purified L A virions different defocus values
0.17798969.9281577.html.plaintext.txt	130	One full particles exhibits ringlike swirl pattern c large arrowhead
0.17798969.9281577.html.plaintext.txt	131	d At 2 microm underfocus dimeric capsid shown large arrowhead
0.17798969.9281577.html.plaintext.txt	132	Filamentous material presumably RNA observed four micrographs small arrowheads
0.17798969.9281577.html.plaintext.txt	133	View Larger Version Image 129K GIF file
0.17798969.9281577.html.plaintext.txt	134	In typical experiment full empty particles observed ratio 32
0.17798969.9281577.html.plaintext.txt	135	Since sample collected compact band one third way CsCl gradient originally contained full particles
0.17798969.9281577.html.plaintext.txt	136	We infer empty particles generated either dialysis see Materials Methods grid preparation
0.17798969.9281577.html.plaintext.txt	137	Three dimensional Structures Full Empty Capsids 16 A Resolution
0.17798969.9281577.html.plaintext.txt	138	The presence kinds particles micrographs allowed us calculate reconstructions may compared directly without concern extraneous factors differences defocus ice thickness radiation damage etc
0.17798969.9281577.html.plaintext.txt	139	The resolution achieved 16 A cases
0.17798969.9281577.html.plaintext.txt	140	The outer diameter average thickness capsid shell measured spherically averaged radial density profiles shown maps whose magnification carefully calibrated 430 46 A respectively
0.17798969.9281577.html.plaintext.txt	141	However reconstructions reveal local variations shell thickness maximally 54 A compare Fig
0.17798969.9281577.html.plaintext.txt	142	Three dimensional density maps L A capsids 16 A resolution
0.17798969.9281577.html.plaintext.txt	143	Stereo views outer upper panels inner lower panels surfaces full capsid viewed along fivefold axis symmetry
0.17798969.9281577.html.plaintext.txt	144	The internal contents computationally removed expose inner surface
0.17798969.9281577.html.plaintext.txt	145	b Transverse central sections taken maps empty left full right capsids viewed along twofold axis
0.17798969.9281577.html.plaintext.txt	146	Darker shades represent higher densities corresponding protein andor RNA
0.17798969.9281577.html.plaintext.txt	147	Black arrowheads fivefold symmetry axes black lollipops threefold axes white arrowheads twofold axes
0.17798969.9281577.html.plaintext.txt	148	The two shells virtually identical
0.17798969.9281577.html.plaintext.txt	149	In full capsid right closest contacts inner surface protein shell underlying RNA appear take place around lateral twofolds
0.17798969.9281577.html.plaintext.txt	150	The white rings inside outside shell represent interference fringes arising phase contrast
0.17798969.9281577.html.plaintext.txt	151	Since holes capsid wall small admit A form duplex see Discussion seems likely empty capsids lost RNA hole created dislodging one Gag subunits
0.17798969.9281577.html.plaintext.txt	152	With averaging takes place calculating density map loss would significantly affect average density lattice site thus may reconciled essentially identical structures visualized full empty capsids
0.17798969.9281577.html.plaintext.txt	153	View Larger Version Image 121K GIF file
0.17798969.9281577.html.plaintext.txt	154	The molecular topography capsid shown stereo Fig
0.17798969.9281577.html.plaintext.txt	155	2 viewed along fivefold axis
0.17798969.9281577.html.plaintext.txt	156	The structure shown calculated images full capsids internal contents erased computationally expose inner surface Fig
0.17798969.9281577.html.plaintext.txt	157	The placement subunits surface lattice indexed Fig
0.17798969.9281577.html.plaintext.txt	158	The penton constructed inner ring five elongated subunits A subunits surrounded outer ring five similar partially intercalated B subunits
0.17798969.9281577.html.plaintext.txt	159	The nonequivalent bonding environments A B subunits reflected subtly different morphologies see
0.17798969.9281577.html.plaintext.txt	160	Structural organization two nonequivalent Gag monomers L A capsid
0.17798969.9281577.html.plaintext.txt	161	Spherical sections density map L A capsid viewed along twofold axis
0.17798969.9281577.html.plaintext.txt	162	These sections correspond radii 214 207 201 194 188 181 175 168 A respectively left right top bottom
0.17798969.9281577.html.plaintext.txt	163	Here white tones correspond high density denoting protein andor RNA
0.17798969.9281577.html.plaintext.txt	164	contrast reversed relative Fig
0.17798969.9281577.html.plaintext.txt	165	b Schematic diagram showing arrangement Gag subunits L A surface lattice viewed along fivefold axis compare Fig
0.17798969.9281577.html.plaintext.txt	166	The A subunits green B subunits orange
0.17798969.9281577.html.plaintext.txt	167	c Diagram showing three pentons Gag decamer clustered around threefold axis
0.17798969.9281577.html.plaintext.txt	168	Five twofold axes also marked
0.17798969.9281577.html.plaintext.txt	169	d The outer crests subunits may subdivided three domains B1 B2 B3 A1 A2 A3 respectively
0.17798969.9281577.html.plaintext.txt	170	Two possible modes association neighboring A B subunits dimers shown lower part panel
0.17798969.9281577.html.plaintext.txt	171	The one left appears extensive intersubunit contacts therefore may favored
0.17798969.9281577.html.plaintext.txt	172	e Closeup views twofold axis outside left inside right
0.17798969.9281577.html.plaintext.txt	173	A B subunits marked cases A B respectively
0.17798969.9281577.html.plaintext.txt	174	On left panel largest five kinds holes traverse capsid wall marked arrows
0.17798969.9281577.html.plaintext.txt	175	On right panel Y shaped motifs seen subunits undersides apparent
0.17798969.9281577.html.plaintext.txt	176	For one A subunit motif tinged green B subunit orange
0.17798969.9281577.html.plaintext.txt	177	View Larger Version Image 80K GIF file
0.17798969.9281577.html.plaintext.txt	178	The empty capsid essentially identical structure particularly outer surface data shown
0.17798969.9281577.html.plaintext.txt	179	On inner surface match full empty capsids less perfect differences slight
0.17798969.9281577.html.plaintext.txt	180	Of prominent thin arms density near twofold axes full capsid Fig
0.17798969.9281577.html.plaintext.txt	181	2 b right white arrows connect protein underlying genome associated density
0.17798969.9281577.html.plaintext.txt	182	These features imply likely close contact RNA capsid wall sites comparison elsewhere
0.17798969.9281577.html.plaintext.txt	183	Unlike impression given 26 A resolution Cheng et al
0.17798969.9281577.html.plaintext.txt	184	1994 capsid wall seen quite porous perforated many small holes Figs
0.17798969.9281577.html.plaintext.txt	185	There five classes holes fivefold axes area 107 A2 surrounding fivefold axes 165 A2 threefold axes 118 A2 relatively large Y shaped holes surrounding threefold axes 244 A2 oblong holes A B subunits 110 A2
0.17798969.9281577.html.plaintext.txt	186	In maps capsids interiors icosahedrally symmetric although reason suppose material regions actually conforms symmetry imposed reconstruction procedure
0.17798969.9281577.html.plaintext.txt	187	In empty capsid internal density expected level solvent outside
0.17798969.9281577.html.plaintext.txt	188	In full capsid map internal density gives impression three concentric shells 35 40 A apart Fig
0.17798969.9281577.html.plaintext.txt	189	We interpret mean viral RNA strictly confined three spherical shells
0.17798969.9281577.html.plaintext.txt	190	Rather micrographs contain strong signal spacings arising distances nearest neighbor RNA filaments icosahedral density map calculated also contains strong features spacings
0.17798969.9281577.html.plaintext.txt	191	The density shells diminishes progressively towards center probably valid indication proportionately RNA resides higher radii
0.17798969.9281577.html.plaintext.txt	192	Structures Interactions Nonequivalent A B Subunits
0.17798969.9281577.html.plaintext.txt	193	The A B subunits similar morphology
0.17798969.9281577.html.plaintext.txt	194	On outer capsid surface subunit shaped like boomerang subdivides three domains called A1 A2 A3 B1 B2 B3 respectively Fig
0.17798969.9281577.html.plaintext.txt	195	On inner surface two kinds subunit less alike although present Y shaped motif Fig
0.17798969.9281577.html.plaintext.txt	196	This motif clearly visible spherical sections inner radii shown Fig
0.17798969.9281577.html.plaintext.txt	197	3 especially bottom row third left
0.17798969.9281577.html.plaintext.txt	198	In middle capsid wall hollow cavity Fig
0.17798969.9281577.html.plaintext.txt	199	2 b separates inner outer surface domains
0.17798969.9281577.html.plaintext.txt	200	Within given penton Gag decamer neighboring A B subunits aligned rotation 15 degrees see Fig
0.17798969.9281577.html.plaintext.txt	201	3 e left whence conclude oriented parallel
0.17798969.9281577.html.plaintext.txt	202	3 e right supports conclusion
0.17798969.9281577.html.plaintext.txt	203	The internal features Gag subunits conveniently viewed spherical sections density map Fig
0.17798969.9281577.html.plaintext.txt	204	The protomer Gag dimer
0.17798969.9281577.html.plaintext.txt	205	In principle three possible pairings neighboring A B subunits
0.17798969.9281577.html.plaintext.txt	206	The pairing subunits interact across twofold axis A3 B3 involves small contact surface
0.17798969.9281577.html.plaintext.txt	207	Consequently favor two compact arrangements Fig
0.17798969.9281577.html.plaintext.txt	208	3 d bottom extensive interactions stabilize dimer
0.17798969.9281577.html.plaintext.txt	209	From spherical sections Fig
0.17798969.9281577.html.plaintext.txt	210	3 discern likely boundaries subunits pattern interactions consolidates surface lattice
0.17798969.9281577.html.plaintext.txt	211	A subunits cluster around fivefold axis via A1 A1 interactions
0.17798969.9281577.html.plaintext.txt	212	The corresponding region B subunit B1 makes contacts A1 A2 fivefold axis
0.17798969.9281577.html.plaintext.txt	213	Three B3 domains meet around threefold axis whereas across twofold axis contacts head head A3 B3
0.17798969.9281577.html.plaintext.txt	214	Interactions twofold threefold axes take place deep lattice radii 184 197 A whereas protein shell extends radii 171 217 A via arclike densities Fig
0.17798969.9281577.html.plaintext.txt	215	The thin arms density linking capsid underlying RNA see also visualized Fig
0.17798969.9281577.html.plaintext.txt	216	3 bottom far right twofold axes extend A subunits
0.17798969.9281577.html.plaintext.txt	217	Packing dsRNA Inside L A Capsid
0.17798969.9281577.html.plaintext.txt	218	The protein shell accounting 73 virion mass tends dominate images full particles coprojected RNA
0.17798969.9281577.html.plaintext.txt	219	To obtain unimpeded views encapsidated genomes erased shell contributions virion images computationally Booy et al
0.17798969.9281577.html.plaintext.txt	220	The resulting difference images show punctate motifs swirls examples shown Fig
0.17798969.9281577.html.plaintext.txt	221	To estimate interstrand spacings measured positions diffraction peaks powder patterns calculated many images Fig
0.17798969.9281577.html.plaintext.txt	222	Because phase contrast imaging accentuates particular spatial frequencies depending defocus analysis performed micrographs cover range defocus values
0.17798969.9281577.html.plaintext.txt	223	All patterns exhibited broad peaks extending 31 A1 47 A1
0.17798969.9281577.html.plaintext.txt	224	The position peak varied slightly defocus invariably 36 A1 40 A1
0.17798969.9281577.html.plaintext.txt	225	As control procedure applied empty capsids
0.17798969.9281577.html.plaintext.txt	226	5 dashes small peak range probably reflects noise amplified phase contrast defocus value
0.17798969.9281577.html.plaintext.txt	227	It however much weaker corresponding peak full particle powder pattern confirming peak primarily reflects scattering RNA
0.17798969.9281577.html.plaintext.txt	228	Resistance Encapsidated RNA RNase Digestion
0.17798969.9281577.html.plaintext.txt	229	The interstrand spacings measured considerably larger values obtained dsDNA dsRNA viruses Lepault et al
0.17798969.9281577.html.plaintext.txt	230	Accordingly one might wonder whether RNA partly extruded concomitant loosening portion remaining inside capsid
0.17798969.9281577.html.plaintext.txt	231	The presence empty capsids free RNA electron micrographs consistent hypothesis
0.17798969.9281577.html.plaintext.txt	232	To test conducted accessibility experiments RNase III nuclease specific dsRNA
0.17798969.9281577.html.plaintext.txt	233	The genomes freshly prepared virions proved entirely resistant enzyme Fig
0.17798969.9281577.html.plaintext.txt	234	6 whereas positive control isolated L A RNA extensively digested Fig
0.17798969.9281577.html.plaintext.txt	235	When virions preincubated low salt buffer known destabilize Esteban Wickner 1986 RNA partially degraded Fig
0.17798969.9281577.html.plaintext.txt	236	These results imply dsRNA entirely sequestered inside freshly prepared virions
0.17798969.9281577.html.plaintext.txt	237	This conclusion consistent earlier STEM mass measurements yielded masses full L A virions consistent containing whole genomes Cheng et al
0.17798969.9281577.html.plaintext.txt	238	RNA gradually lost storage release given particle started appears proceed quite rapidly
0.17798969.9281577.html.plaintext.txt	239	The conclusion L A genome indeed packed loosely viruses supported calculations packing density see Discussion
0.17798969.9281577.html.plaintext.txt	240	RNase III accessibility L A dsRNA
0.17798969.9281577.html.plaintext.txt	241	Purified RNA lanes 1 3 dsRNA intact full particles lanes 4 6 dsRNA disrupted full particles lanes 7 8 treated RNase III described Material Methods absence lanes 2 5 7 presence lanes 3 6 8 10 mM MgCl2
0.17798969.9281577.html.plaintext.txt	242	Lanes 1 4 controls purified dsRNA dsRNA intact full particles without RNase III treatment respectively
0.17798969.9281577.html.plaintext.txt	243	On left molecular weight markers
0.17798969.9281577.html.plaintext.txt	244	After RNase treatment RNA separated 1
0.17798969.9281577.html.plaintext.txt	245	5 agarose gel detected ethidium bromide staining
0.17798969.9281577.html.plaintext.txt	246	The digestion products diffusely spread lane 8 whereas lanes genome band either present appropriate position absent digested small fragments
0.17798969.9281577.html.plaintext.txt	247	View Larger Version Image 85K GIF file
0.17798969.9281577.html.plaintext.txt	248	We used dark field electron microscopy measure mass per unit length L A chromosomes purification e
0.17798969.9281577.html.plaintext.txt	249	7 released still connected disrupted capsids e
0.17798969.9281577.html.plaintext.txt	250	The data obtained purified RNA molecules observe quasi Gaussian distribution mean 2
0.17798969.9281577.html.plaintext.txt	251	For RNA filaments emanating capsids distribution Fig
0.17798969.9281577.html.plaintext.txt	252	7 b broader displaced higher values suggestive multiple components
0.17798969.9281577.html.plaintext.txt	253	The lower values 30 40 data match obtained purified molecules
0.17798969.9281577.html.plaintext.txt	254	The measurements higher appear represent structures two duplexes associate laterally form multistranded filaments
0.17798969.9281577.html.plaintext.txt	255	We think unlikely higher density reflects coating RNA protein since preparations contain protein Gag detectable amounts
0.17798969.9281577.html.plaintext.txt	256	When similar experiment carried particles stored days 4 degrees C L A virions gradually lose dsRNA upon storage see measurements matched obtained purified molecules
0.17798969.9281577.html.plaintext.txt	257	STEM dark field images unstained L A RNA molecules
0.17798969.9281577.html.plaintext.txt	258	Freeze dried preparation purified dsRNA tobacco mosaic virions rodlike particles included internal mass standards
0.17798969.9281577.html.plaintext.txt	259	At right histogram mass per unit length measurements made micrographs n 53
0.17798969.9281577.html.plaintext.txt	260	b Purified L A virions free RNA right histogram mass per unit length data n 275
0.17798969.9281577.html.plaintext.txt	261	These measurements restricted RNA segments visibly connected capsids
0.17798969.9281577.html.plaintext.txt	262	The arrows indicate densities corresponding integral numbers strands per filament assuming 2
0.17798969.9281577.html.plaintext.txt	263	8 kDnm A form RNA duplex Results
0.17798969.9281577.html.plaintext.txt	264	Black arrows mark even numbers strands
0.17798969.9281577.html.plaintext.txt	265	The precision measurements insufficient resolve distribution set well defined peaks
0.17798969.9281577.html.plaintext.txt	266	In principle densities could biased higher values residual salt deposits consequence insufficient grid washing
0.17798969.9281577.html.plaintext.txt	267	However case one would expect greater variability data standard deviation measurements made TMV particles considerably higher
0.17798969.9281577.html.plaintext.txt	268	In fact SDs similar 3
0.17798969.9281577.html.plaintext.txt	269	81 TMV experiments purified RNA molecules 4
0.17798969.9281577.html.plaintext.txt	270	48 capsid connected RNA filaments
0.17798969.9281577.html.plaintext.txt	271	View Larger Version Image 86K GIF file
0.17798969.9281577.html.plaintext.txt	272	The replication cycles known dsRNA viruses follow pattern Roizman Palese 1996
0.17798969.9281577.html.plaintext.txt	273	First dsRNA transcribed polymerase resident within virion
0.17798969.9281577.html.plaintext.txt	274	Next strand transcripts extruded serve mRNA synthesis viral proteins b species becomes encapsidated progeny virions c used template synthesis complementary strands replication
0.17798969.9281577.html.plaintext.txt	275	Both transcription replication take place inside nucleocapsid complete virion fungal dsRNA viruses inner core higher eukaryotic viruses like Reoviridae family e
0.17798969.9281577.html.plaintext.txt	276	1993 rotavirus Mansell Patton 1990 Labbe et al
0.17798969.9281577.html.plaintext.txt	277	1991 orbivirus Huismans et al
0.17798969.9281577.html.plaintext.txt	278	This model also applies prokaryotic dsRNA virus bacteriophage 6 Mindich Bamford 1988
0.17798969.9281577.html.plaintext.txt	279	What features various transcription cum replication chambers common
0.17798969.9281577.html.plaintext.txt	280	As noted Introduction stoichiometry data indicate many dsRNA virus capsids contain 120 copies least one protein
0.17798969.9281577.html.plaintext.txt	281	So far kind virus capsid stoichiometry corresponds forbidden T number two Caspar Klug 1962
0.17798969.9281577.html.plaintext.txt	282	It interest know whether commonality extends detailed aspects capsid architecture
0.17798969.9281577.html.plaintext.txt	283	Here fewer data available note definite morphological similarity L A capsid core Bluetongue virus Hewat et al
0.17798969.9281577.html.plaintext.txt	284	1992 virus also composed 120 subunits Burroughs et al
0.17798969.9281577.html.plaintext.txt	285	Aquareovirus cores also show 120 morphological subunits surface Shaw et al
0.17798969.9281577.html.plaintext.txt	286	Although reovirus cores complex L A capsid presence Y shaped domains inner surface Dryden et al
0.17798969.9281577.html.plaintext.txt	287	Birnaviruses whose genomes consist two segments dsRNA seem exception since single shelled T13 particles internal core Bottcher et al
0.17798969.9281577.html.plaintext.txt	288	Capsid Structure Control Assembly
0.17798969.9281577.html.plaintext.txt	289	Our current three dimensional map 16 A resolution depicts 76 kD Gag monomer elongated molecule multiple domains coiled around central cavity
0.17798969.9281577.html.plaintext.txt	290	The structural differences seen nonequivalent A B subunits minor bonding environments entirely different Fig
0.17798969.9281577.html.plaintext.txt	291	As shown expression studies Fujimura et al
0.17798969.9281577.html.plaintext.txt	292	1992 Gag selfassemble correctly sized capsids
0.17798969.9281577.html.plaintext.txt	293	This reaction controlled switching event specifies A B conformations Johnson 1996
0.17798969.9281577.html.plaintext.txt	294	This switch may operate level dimer formation yielding protomers 60 equivalent copies would self assemble conventional T 1 icosahedron
0.17798969.9281577.html.plaintext.txt	295	The plausibility model supported indirectly observations systems e
0.17798969.9281577.html.plaintext.txt	296	human growth hormone receptor de Vos et al
0.17798969.9281577.html.plaintext.txt	297	1992 attest asymmetric homodimer stable state assembly
0.17798969.9281577.html.plaintext.txt	298	Alternatively A subunits might associate homo pentamers switch accompanying accretion B subunits convert decamers capable forming capsid pentons
0.17798969.9281577.html.plaintext.txt	299	The fact Gag Pol appears nucleate assembly L A vivo Fujimura Wickner 1988b 1 2 copies protein per capsid argues pentamer based model
0.17798969.9281577.html.plaintext.txt	300	Mass per unit length Measurements Suggest L A dsRNA Is A form
0.17798969.9281577.html.plaintext.txt	301	Our STEM data mass per unit length purified L A dsRNA yield mean value 2
0.17798969.9281577.html.plaintext.txt	302	Acknowledging spread data suggest A type duplex2
0.17798969.9281577.html.plaintext.txt	303	81 A rise per base pair Arnott et al
0.17798969.9281577.html.plaintext.txt	304	1972 682 D bpand less consistent B form duplex2
0.17798969.9281577.html.plaintext.txt	305	It previously demonstrated spectroscopy packaged 6 dsRNA A form structure Bamford et al
0.17798969.9281577.html.plaintext.txt	306	However x ray diffraction studies crystallized reovirus dsRNA review see Nibert et al
0.17798969.9281577.html.plaintext.txt	307	1996 indicative double helix 10 11 bp per turn 3 A pitch corresponds structure intermediate A form 2
0.17798969.9281577.html.plaintext.txt	308	81 A rise per bp B form 3
0.17798969.9281577.html.plaintext.txt	309	The L A Capsid Molecular Sieve
0.17798969.9281577.html.plaintext.txt	310	One striking feature revealed capsid model porosity capsid wall perforated many small holes
0.17798969.9281577.html.plaintext.txt	311	While sizes may revised somewhat higher resolution data become available current estimates suggest strategically useful property
0.17798969.9281577.html.plaintext.txt	312	None holes large enough pass A form duplex 23 A diam largest holes triangular average distance apex base 15 A Fig
0.17798969.9281577.html.plaintext.txt	313	3 e readily allow passage ssRNA molecule
0.17798969.9281577.html.plaintext.txt	314	Thus capsid appears configured function molecular sieve duplex RNA retained inside transcripts may exit
0.17798969.9281577.html.plaintext.txt	315	It would expedient freshly synthesized transcript fed directly exit port Fig
0.17798969.9281577.html.plaintext.txt	316	8 would forestall formation secondary structure might impede export
0.17798969.9281577.html.plaintext.txt	317	Since one two copies Pol per capsid presumably two transcripts per capsid exported one time
0.17798969.9281577.html.plaintext.txt	318	However holes facilitate infusion nucleotides steady supply required sustain synthesis transcription replication
0.17798969.9281577.html.plaintext.txt	319	A filtering property holes presumably small enough exclude potentially degradative enzymes
0.17798969.9281577.html.plaintext.txt	320	Hypothetical model transcriptionally active L A virion
0.17798969.9281577.html.plaintext.txt	321	The polymerase Pol covalently attached Gag subunit assume integrated icosahedral surface lattice thus immobilizing Pol Icho Wickner 1989
0.17798969.9281577.html.plaintext.txt	322	Pol COOH terminus Gag assumed reside inner surface shell facilitate access substrate dsRNA
0.17798969.9281577.html.plaintext.txt	323	The shape assigned Pol diagram arbitrary
0.17798969.9281577.html.plaintext.txt	324	In scenario necessary genome propelled sequentially past Pol transcription proceeds
0.17798969.9281577.html.plaintext.txt	325	Transcripts hypothesized extruded directly largest holes capsid shell Discussion
0.17798969.9281577.html.plaintext.txt	326	View Larger Version Image 159K GIF file
0.17798969.9281577.html.plaintext.txt	327	Unusually Low Density dsRNA Packing L A
0.17798969.9281577.html.plaintext.txt	328	In projection encapsidated L A genomes exhibit punctate andor swirl motifs Fig
0.17798969.9281577.html.plaintext.txt	329	Presumably two classes motifs represent distinct views although clear genome packed way particle
0.17798969.9281577.html.plaintext.txt	330	We infer genomes loosely coiled variable spacing adjacent filaments
0.17798969.9281577.html.plaintext.txt	331	5 average Bragg spacings 36 40 A corresponding center center spacing 41 46 A filaments
0.17798969.9281577.html.plaintext.txt	332	The L A motifs differ dsDNA viruses phages T4 Lepault et al
0.17798969.9281577.html.plaintext.txt	333	1992 herpes simplex virus Booy et al
0.17798969.9281577.html.plaintext.txt	334	1991 dsRNA viruses reovirus Dryden et al
0.17798969.9281577.html.plaintext.txt	335	1993 relatively highly ordered tightly packed center center spacings 25 30 A
0.17798969.9281577.html.plaintext.txt	336	In part larger spacing L A reflects fact A form duplexes wider B form duplexes
0.17798969.9281577.html.plaintext.txt	337	However average interduplex spacing may calculated independently volume available average internal capsid diam 348 A genome length 1
0.17798969.9281577.html.plaintext.txt	338	Assuming quasi hexagonal close packing uniform density spacing 40 A obtained
0.17798969.9281577.html.plaintext.txt	339	There flexibility figure arising center less populated RNA packing perfectly crystalline possibly also local compaction multistranded filaments see
0.17798969.9281577.html.plaintext.txt	340	Nevertheless figure good agreement spacings measured directly powder patterns Fig
0.17798969.9281577.html.plaintext.txt	341	Its consistency supports inferences dsRNA genome fully internalized b packing much looser double stranded viruses
0.17798969.9281577.html.plaintext.txt	342	RNA extending capsids often uniform mass per unit length significantly higher single A form duplex Fig
0.17798969.9281577.html.plaintext.txt	343	7 appears represent sort higher order filament formed two duplexes
0.17798969.9281577.html.plaintext.txt	344	We observed thicker filaments preparations isolated dsRNA see obvious way might arise artifact specimen preparation
0.17798969.9281577.html.plaintext.txt	345	It may within confines capsid
0.17798969.9281577.html.plaintext.txt	346	conditions high packing density piecewise condensation duplexes higher order filaments takes place
0.17798969.9281577.html.plaintext.txt	347	much lower density RNA gradually relaxes single duplexes
0.17798969.9281577.html.plaintext.txt	348	Headful Replication Churning Model Transcription
0.17798969.9281577.html.plaintext.txt	349	L A also helper virus dsRNA segments Saccharomyces cerevisiae Wickner 1996a
0.17798969.9281577.html.plaintext.txt	350	These satellite viruses M1 M2 etc
0.17798969.9281577.html.plaintext.txt	351	deletion mutants L A X contain dsRNA segments L A approximately number base pairs per particle
0.17798969.9281577.html.plaintext.txt	352	This occurs headful replication whereby one viral strand packaged replicates inside particle full
0.17798969.9281577.html.plaintext.txt	353	Subsequently synthesized strands extruded particle Esteban Wickner 1986 Fujimura et al
0.17798969.9281577.html.plaintext.txt	354	As noted much room remains available packaged L A capsid double stranded viruses
0.17798969.9281577.html.plaintext.txt	355	We think two explanations
0.17798969.9281577.html.plaintext.txt	356	In one Gag gene evolved recently provide capacious capsid genome whole yet evolved fully exploit opportunity expansion
0.17798969.9281577.html.plaintext.txt	357	The fact multisegmented satellites package RNA densely L A appears argue hypothesis
0.17798969.9281577.html.plaintext.txt	358	In second explanation speculate maximum viable packing density may dictated requirement long range mobility dsRNA transcriptionally active particle
0.17798969.9281577.html.plaintext.txt	359	The polymerase thought reside inner surface anchored integration Gag moiety surface lattice Wickner 1996ab
0.17798969.9281577.html.plaintext.txt	360	8 large tracts dsRNA must propelled sequentially past fixed point
0.17798969.9281577.html.plaintext.txt	361	In organization entire packaged genome must undergo constant revision churning motion
0.17798969.9281577.html.plaintext.txt	362	In contrast tightly compressed genomes dsDNA phages thought static vegetative state
0.17798969.9281577.html.plaintext.txt	363	RNA polymerases known powerful translocases capable generating forces range 14 piconewtons Yin et al
0.17798969.9281577.html.plaintext.txt	364	The ability L A Pol function replication transcription depends capable overcoming frictional drag imposed packaged genome
0.17798969.9281577.html.plaintext.txt	365	We infer resistance increases higher packing density whence observed packing density may represent highest level frictional resistance enzyme function effectively
0.17798969.9281577.html.plaintext.txt	366	This idea testable generating insertions L A genome
0.17798969.9281577.html.plaintext.txt	367	Is similar mechanism operative dsRNA viruses The consideration dsRNA appears packed densely cores reovirus Dryden et al
0.17798969.9281577.html.plaintext.txt	368	1993 rotavirus Prasad et al
0.17798969.9281577.html.plaintext.txt	369	1996 L A might suggest otherwise
0.17798969.9281577.html.plaintext.txt	370	However systems transcriptionally active particles visualized Yeager M
0.17798969.9281577.html.plaintext.txt	371	1997 considerably complex proteins many RNA segments involved precisely calibrated spacings packaged genomes yet reported
0.17798969.9281577.html.plaintext.txt	372	Transcription reovirions thought require activation proteases concomitant conformational changes Powell et al
0.17798969.9281577.html.plaintext.txt	373	1993 conjecture may rearrange core structure facilitate motion dsRNA transcription
0.17798969.9281577.html.plaintext.txt	374	Nevertheless overall requirements apply
0.17798969.9281577.html.plaintext.txt	375	It fascinating learn possible solutions problem properties protein shells closed containers also active metabolic compartments
0.17798969.9281577.html.plaintext.txt	376	Received publication 5 March 1997 revised form 30 June 1997
0.17798969.9281577.html.plaintext.txt	377	Please address correspondence A
0.17798969.9281577.html.plaintext.txt	378	Steven Building 6 Room B2 34 6 Center Drive MSC 2717 National Institutes Health Bethesda MD 20892 2717
0.17798969.9281577.html.plaintext.txt	379	Castons present address Centro Nacional de Biotecnologia Consejo Superior de Investigaciones Cientificas Universidad Autonoma de Madrid 28049 Madrid Spain
0.17798969.9281577.html.plaintext.txt	380	Simon Brookhaven Upton NY help STEM T
0.17798969.9281577.html.plaintext.txt	381	Baker Purdue University West Lafayette IN reconstruction software Dr
0.17798969.9281577.html.plaintext.txt	382	Crouch National Institute Child Health Human Development gift RNase III D
0.17798969.9281577.html.plaintext.txt	383	Zlotnick National Institute Arthritis Musculoskeletal Skin Diseases D
0.17798969.9281577.html.plaintext.txt	384	Furlong Harvard Cambridge MA stimulating discussions helpful input
0.17798969.9281577.html.plaintext.txt	385	Abbreviations used paper
0.17798969.9281577.html.plaintext.txt	386	CTF contrast transfer function ds double stranded ss single stranded STEM scanning transmission electron microscopy TMV tobacco mosaic virus
0.17798969.9281577.html.plaintext.txt	387	Optimised parameters RNA double helices
0.17798969.9281577.html.plaintext.txt	388	A model based approach determining orientations biological macromolecules imaged cryoelectron microscopy
0.17798969.9281577.html.plaintext.txt	389	Reconstruction three dimensional structure simian virus 40 visualization chromatin core
0.17798969.9281577.html.plaintext.txt	390	The capsid small papovaviruses contains 72 pentameric capsomers Direct evidence cryo electron microscopy simian virus 40
0.17798969.9281577.html.plaintext.txt	391	Three dimensional structures maturable abortive capsids equine herpes virus 1 cryoelectron microscopy
0.17798969.9281577.html.plaintext.txt	392	Structural studies enveloped dsRNA bacteriophage 6 Pseudomonas syringae Raman spectroscopy
0.17798969.9281577.html.plaintext.txt	393	Nucleocapsid structure thermostability virion nucleocapsid polymerase complex
0.17798969.9281577.html.plaintext.txt	394	Liquid crystalline phage like packing encapsidated DNA herpes simplex virus
0.17798969.9281577.html.plaintext.txt	395	Organization dsDNA icosahedral virus capsids
0.17798969.9281577.html.plaintext.txt	396	Electron Microscopy Society America Boston MA Vol
0.17798969.9281577.html.plaintext.txt	397	San Francisco Press San Francisco
0.17798969.9281577.html.plaintext.txt	398	Finding needle haystack detection small protein 12 kDa VP26 large complex 200 MDa capsid herpes simplex virus
0.17798969.9281577.html.plaintext.txt	399	Three dimensional structure infectious bursal disease virus determined electron cryomicroscopy
0.17798969.9281577.html.plaintext.txt	400	Crystallization preliminary X ray analysis core particle Bluetongue virus
0.17798969.9281577.html.plaintext.txt	401	Physical principles construction regular viruses
0.17798969.9281577.html.plaintext.txt	402	Fungal virus capsids cytoplasmic compartments replication double stranded RNA formed icosahedral shells asymmetric Gag dimers
0.17798969.9281577.html.plaintext.txt	403	The effects radiation damage structure frozen hydrated HSV 1 capsids
0.17798969.9281577.html.plaintext.txt	404	Ribonuclease III degrade deoxyribonucleic acid ribonucleic acid hybrids
0.17798969.9281577.html.plaintext.txt	405	249 1314 1316 AbstractFree Full Text
0.17798969.9281577.html.plaintext.txt	406	Procedures three dimensional reconstruction spherical viruses Fourier synthesis electron micrographs
0.17798969.9281577.html.plaintext.txt	407	Human growth hormone extracellular domain receptor crystal structure complex
0.17798969.9281577.html.plaintext.txt	408	Ribosomal frameshifting efficiency gaggag pol ratio critical yeast M1 double stranded RNA virus propagation
0.17798969.9281577.html.plaintext.txt	409	A 1 ribosomal frameshift double stranded RNA virus yeast forms gag pol fusion protein
0.17798969.9281577.html.plaintext.txt	410	Early steps reovirus infection associated dramatic changes supramolecular structure protein conformation analysis virions subviral particles cryoelectron microscopy image reconstruction
0.17798969.9281577.html.plaintext.txt	411	Three different M1 RNA containing virus like particle types Saccharomyces cerevisiae vitro M1 double stranded RNA synthesis
0.17798969.9281577.html.plaintext.txt	412	Rotavirus replication
0.17798969.9281577.html.plaintext.txt	413	Lippincott Raven Publishers Philadelphia
0.17798969.9281577.html.plaintext.txt	414	Replicase L A viruslike particles Saccharomyces cerevisiae
0.17798969.9281577.html.plaintext.txt	415	In vitro conversion exogenous L A M1 single stranded RNAs double stranded form
0.17798969.9281577.html.plaintext.txt	416	263 454 460 AbstractFree Full Text
0.17798969.9281577.html.plaintext.txt	417	Gene overlap results viral protein RNA binding domain major coat protein domain
0.17798969.9281577.html.plaintext.txt	418	Portable encapsidation signal L A double stranded RNA virus Saccharomyces cerevisiae
0.17798969.9281577.html.plaintext.txt	419	Pol gag pol fusion protein required encapsidation viral RNA yeast L A virus
0.17798969.9281577.html.plaintext.txt	420	The T4 envelope Sindbis virus organized interactions complementary T3 capsid
0.17798969.9281577.html.plaintext.txt	421	Three dimensional reconstruction icosahedral particlesthe uncommon line
0.17798969.9281577.html.plaintext.txt	422	Biophysical studies reovirus type 3
0.17798969.9281577.html.plaintext.txt	423	Three dimensional reconstruction baculovirus expressed Bluetongue Virus core like particles cryo electron microscopy
0.17798969.9281577.html.plaintext.txt	424	Uncoating parental bluetongue virus core subcore particles infected L cells
0.17798969.9281577.html.plaintext.txt	425	The double stranded RNA genome yeast virus L A encodes putative RNA polymerase fusing two open reading frames
0.17798969.9281577.html.plaintext.txt	426	264 6716 6723 AbstractFree Full Text
0.17798969.9281577.html.plaintext.txt	427	Functional implications protein protein interactions icosahedral viruses
0.17798969.9281577.html.plaintext.txt	428	93 27 33 AbstractFree Full Text
0.17798969.9281577.html.plaintext.txt	429	Expression rotavirus VP2 produces empty core like particles
0.17798969.9281577.html.plaintext.txt	430	Three dimensional visualization mRNA release actively transcribing rotavirus particles
0.17798969.9281577.html.plaintext.txt	431	Three dimensional structure unstained frozen hydrated extended tails bacteriophage T4
0.17798969.9281577.html.plaintext.txt	432	Organization double stranded DNA bacteriophages study cryo electron microscopy vitrified samples
0.17798969.9281577.html.plaintext.txt	433	Oxford University Press Oxford
0.17798969.9281577.html.plaintext.txt	434	Rotavirus RNA replication VP2 VP6 necessary viral replicase activity
0.17798969.9281577.html.plaintext.txt	435	Lipid containing bacteriophages
0.17798969.9281577.html.plaintext.txt	436	X ray diffraction study tail tubes bacteriophage T21
0.17798969.9281577.html.plaintext.txt	437	Structure herpes simplex virus capsid
0.17798969.9281577.html.plaintext.txt	438	Molecular composition pentons triplexes
0.17798969.9281577.html.plaintext.txt	439	Reovirus replication
0.17798969.9281577.html.plaintext.txt	440	Lippincott Raven Publishers Philadelphia
0.17798969.9281577.html.plaintext.txt	441	Reovirus RNA transcriptase evidence conformational change activation core particle
0.17798969.9281577.html.plaintext.txt	442	Visualization ordered genomic RNA localization transcriptional complexes rotavirus
0.17798969.9281577.html.plaintext.txt	443	Multiplication viruses overview
0.17798969.9281577.html.plaintext.txt	444	Lippincott Raven Publishers Philadelphia
0.17798969.9281577.html.plaintext.txt	445	The correlation averaging regularly arranged bacterial envelope protein
0.17798969.9281577.html.plaintext.txt	446	The structure aquareovirus shows different geometries two layers capsid reconciled provide symmetrical interactions stabilization
0.17798969.9281577.html.plaintext.txt	447	Mass analysis biological macromolecular complexes STEM
0.17798969.9281577.html.plaintext.txt	448	Digital image processing electron micrographs PIC system III
0.17798969.9281577.html.plaintext.txt	449	Ribosomal movement impeded pseudoknot required ribosomal frameshifting
0.17798969.9281577.html.plaintext.txt	450	Mass measurements electron microscope
0.17798969.9281577.html.plaintext.txt	451	In Introduction Analytical Electron Microscopy
0.17798969.9281577.html.plaintext.txt	452	Mass mapping scanning electron microscope
0.17798969.9281577.html.plaintext.txt	453	Yeast double stranded RNA viruses genetic biochemical molecular methods
0.17798969.9281577.html.plaintext.txt	454	In Methods Molecular Genetics
0.17798969.9281577.html.plaintext.txt	455	Double stranded RNA viruses Saccharomyces cerevisiae
0.17798969.9281577.html.plaintext.txt	456	Viruses yeasts fungi parasitic microorganisms
0.17798969.9281577.html.plaintext.txt	457	Lippincott Raven Publishers Philadelphia
0.17798969.9281577.html.plaintext.txt	458	Transcription applied force
0.17798969.9281577.html.plaintext.txt	459	Copyright 1997 The Rockefeller University Press
0.15668444.15994312.html.plaintext.txt	0	Focal Adhesion Kinase Plays Pivotal Role Herpes Simplex Virus Entry Natalia Cheshenko Wen Liu Lisa M
0.15668444.15994312.html.plaintext.txt	1	From Departments Pediatrics Microbiology Mount Sinai School Medicine New York New York 10029
0.15668444.15994312.html.plaintext.txt	2	Received publication March 31 2005 revised form June 29 2005
0.15668444.15994312.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Development strategies prevent herpes simplex virus HSV infection requires knowledge cellular pathways harnessed virus invasion
0.15668444.15994312.html.plaintext.txt	4	This study demonstrates HSV induces rapid phosphorylation focal adhesion kinase FAK several human target cells phosphorylation important entry post binding
0.15668444.15994312.html.plaintext.txt	5	Nuclear transport viral tegument protein VP16 transport viral capsids nuclear pore downstream events including expression immediate early genes viral plaque formation substantially reduced cells transfected dominant negative mutants FAK small interfering RNA designed inhibit FAK expression
0.15668444.15994312.html.plaintext.txt	6	These observations substantiated using mouse embryonic fibroblast cells derived embryonic FAK deficient mice
0.15668444.15994312.html.plaintext.txt	7	Infection reduced 90 knockout cells relative control cells reduced knockout cells transfected small interfering RNA targeting proline rich tyrosine kinase 2 also phosphorylated response HSV
0.15668444.15994312.html.plaintext.txt	8	The knockout cells permissive viral binding virus triggered intracellular calcium response nuclear transport inhibited
0.15668444.15994312.html.plaintext.txt	9	Together results support novel model invasion implicates FAK phosphorylation important delivery viral capsids nuclear pore
0.15668444.15994312.html.plaintext.txt	10	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Herpes simplex virus HSV1 type 2 major global health problem leading cause genital herpes neonatal herpes encephalitis major cofactor human immunodeficiency virus HIV infection
0.15668444.15994312.html.plaintext.txt	11	Novel strategies prevent HSV 2 sexually transmitted infections urgently needed
0.15668444.15994312.html.plaintext.txt	12	Development new approaches requires understanding molecular cellular events critical establishment infection
0.15668444.15994312.html.plaintext.txt	13	Previous work demonstrates HSV entry complex process requiring following steps binding heparan sulfate receptors ii engagement glycoprotein D coreceptors iii penetration human epithelial cells mediated primarily fusion viral envelope cell membrane iv transport viral tegument protein VP16 trans inducing factor TIF nucleus v transport viral capsids nuclear pore release viral DNA nucleoplasm 1 2
0.15668444.15994312.html.plaintext.txt	14	Glycoprotein B plays major role mediating binding HSV 2 heparan sulfate receptors whereas glycoprotein C plays dominant role mediating binding HSV 1 3 4
0.15668444.15994312.html.plaintext.txt	15	For serotypes glycoproteins B D H L required penetration precise role cellular pathways important viral invasion fully elucidated
0.15668444.15994312.html.plaintext.txt	16	The observations heparan sulfate major attachment receptor HSV heparan sulfate moieties also interact gp120 HIV fostered development sulfated sulfonated polymers candidate topical microbicides prevent viral transmission
0.15668444.15994312.html.plaintext.txt	17	These compounds prevent genital herpes mouse simian immunodeficiency virus macaque currently evaluated Phase IIIII clinical trials 5 6
0.15668444.15994312.html.plaintext.txt	18	However competitive antagonists viral binding likely sufficient fully protect sexual transmission
0.15668444.15994312.html.plaintext.txt	19	Experience systemic therapy indicates combination therapies target one step viral life cycle optimal
0.15668444.15994312.html.plaintext.txt	20	Thus elucidating cellular pathways required viral entry may provide novel targets microbicide development
0.15668444.15994312.html.plaintext.txt	21	We reported previously serotypes HSV trigger inositol triphosphate mediated release endoplasmic reticulum ER Ca2 stores Ca2 signaling plays critical role viral entry 7
0.15668444.15994312.html.plaintext.txt	22	Pharmacological inhibition ER Ca2 release chelation intracellular Ca2 reduces nuclear transport viral tegument protein VP16 surrogate marker capsid transport downstream events viral life cycle including expression viral immediate early genes viral plaque formation
0.15668444.15994312.html.plaintext.txt	23	Activation Ca2 signaling associated triggering phosphorylation signaling pathways
0.15668444.15994312.html.plaintext.txt	24	Specifically observed previously HSV 1 HSV 2 trigger phosphorylation focal adhesion kinase FAK within 5 10 min following exposure Vero monkey kidney CaSki human cervical epithelial cells virus
0.15668444.15994312.html.plaintext.txt	25	FAK phosphorylation appears occur downstream release ER Ca2 stores treatment cells 2 aminoethoxydiphenyl borate inositol triphosphate receptor antagonist prevents release ER Ca2 chelation intracellular Ca2 blocks virus induced phosphorylation FAK
0.15668444.15994312.html.plaintext.txt	26	Activation pathways Ca2 FAK phosphorylation requires exposure entry competent virus HSV 1 deleted glycoproteins essential penetration glycoproteins B D H L fails induce Ca2 release trigger FAK phosphorylation whereas Ca2 release phosphorylation preserved following exposure repaired viruses inactivated virus retain ability penetrate cells
0.15668444.15994312.html.plaintext.txt	27	These findings led proposal new paradigm HSV entry HSV triggers inositol triphosphate mediated release ER Ca2 stores may facilitate fusion viral envelope cell membrane allowing delivery capsids cytoplasm 7
0.15668444.15994312.html.plaintext.txt	28	In response activation Ca2 pathways hypothesize FAK related signaling pathways activated may promote transport viral capsids nuclear pores
0.15668444.15994312.html.plaintext.txt	29	This study designed test hypothesis evaluate whether HSV exploits FAK signaling pathways promote nuclear transport
0.15668444.15994312.html.plaintext.txt	30	We used complementary molecular techniques including dominant negative variants small interfering RNA siRNA knockout cells explore role played FAK HSV invasion
0.15668444.15994312.html.plaintext.txt	31	We tested hypothesis serotypes using human murine cells
0.15668444.15994312.html.plaintext.txt	32	Our findings indicate FAK phosphorylation plays central role promoting transport viral capsids
0.15668444.15994312.html.plaintext.txt	33	View larger version 71K FIG
0.15668444.15994312.html.plaintext.txt	34	HSV induces phosphorylation FAK multiple human target cells
0.15668444.15994312.html.plaintext.txt	35	Cells mock infected infected HSV 2G m
0.15668444.15994312.html.plaintext.txt	36	At indicated times post infection minutes cell lysates prepared proteins separated transferred Western blotting incubated anti phospho Tyr397 FAK antibody FAKpY397
0.15668444.15994312.html.plaintext.txt	37	Blots stripped reprobed mAb total FAK
0.15668444.15994312.html.plaintext.txt	38	The blots representative results obtained three independent experiments
0.15668444.15994312.html.plaintext.txt	39	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Cells Viruses CaSki human cervical epithelial CaCo 2 human colonic epithelial SK N SH human neuroblastoma cells obtained American Type Culture Collection passaged Dulbeccos modified Eagles medium supplemented 10 fetal bovine serum
0.15668444.15994312.html.plaintext.txt	40	Immortalized human endocervical ectocervical cells generous gift R
0.15668444.15994312.html.plaintext.txt	41	Mouse embryonic fibroblast MEF cells derived embryonic FAK deficient mice FAK control MEF cells FAK originally described Ilic et al
0.15668444.15994312.html.plaintext.txt	42	9 generous gift I
0.15668444.15994312.html.plaintext.txt	43	Gelman Mount Sinai School Medicine
0.15668444.15994312.html.plaintext.txt	44	The FAK cells derived age embryos day 8
0.15668444.15994312.html.plaintext.txt	45	Cells cultured overnight serum free medium minimize background tyrosine phosphorylation due growth factors serum
0.15668444.15994312.html.plaintext.txt	46	Roizman University Chicago Chicago IL vesicular stomatitis virus Indiana provided P
0.15668444.15994312.html.plaintext.txt	47	Palese Mount Sinai School Medicine grown Vero cells
0.15668444.15994312.html.plaintext.txt	48	HSV 1 containing green fluorescent protein GFP VP26 fusion protein designated K26GFP generous gift P
0.15668444.15994312.html.plaintext.txt	49	Desai The Johns Hopkins University 10
0.15668444.15994312.html.plaintext.txt	50	Heat inactivated virus prepared heating 56 degrees C 30 min
0.15668444.15994312.html.plaintext.txt	51	Purification Quantification Viruses For binding Ca2 studies dextran purified viruses used described previously 4 11
0.15668444.15994312.html.plaintext.txt	52	Titers purified virus determined plaque assays
0.15668444.15994312.html.plaintext.txt	53	Relative viral particle numbers determined comparing amounts glycoprotein D optical densitometry Western blotting anti glycoprotein D monoclonal antibody mAb 1103 Rumbaugh Goodwin Institute Plantation FL described previously 3 12
0.15668444.15994312.html.plaintext.txt	54	Reagents EGTA ionomycin purchased Calbiochem diluted Me2SO phosphate buffered saline PBS following manufacturers instructions
0.15668444.15994312.html.plaintext.txt	55	Fura 2 acetoxymethyl ester purchased Molecular Probes Inc
0.15668444.15994312.html.plaintext.txt	56	Heparin cycloheximide purchased Sigma
0.15668444.15994312.html.plaintext.txt	57	Plasmids Transfections pKH3 FAK carrying gene wild type FAK pKH3 Y397 carrying FAK gene Y397F mutation gifts J
0.15668444.15994312.html.plaintext.txt	58	Guan Cornell University Ithaca NY
0.15668444.15994312.html.plaintext.txt	59	All transfections done Effectene transfection reagent Qiagen Inc
0.15668444.15994312.html.plaintext.txt	60	following manufacturers protocol
0.15668444.15994312.html.plaintext.txt	61	CaSki FAK FAK cells grown 12 well plates transfected siRNA FAK Pyk2 control nonspecific siRNA using siRNA siABTM assay kits Upstate20BiotechnologyUpstate Biotechnology Inc
0.15668444.15994312.html.plaintext.txt	62	concentration 100 pmolwell
0.15668444.15994312.html.plaintext.txt	63	24 h post transfection cells infected virus analyzed expression phosphorylated FAKFAK phosphorylated Pyk2Pyk2 preparing cell lysates performing Western blotting detailed
0.15668444.15994312.html.plaintext.txt	64	Measurement Ca2i Cells loaded 25 mM fura 2 acetoxymethyl ester prepared PBS 30 60 min rinsed PBS 30 min 37 degrees C exposed sequentially PBS buffer HSV diluted PBS 37 degrees C
0.15668444.15994312.html.plaintext.txt	65	The viral inoculum equivalent multiplicity infection m
0.15668444.15994312.html.plaintext.txt	66	equal 1 5 plaque forming units pfucell
0.15668444.15994312.html.plaintext.txt	67	Using Nikon Eclipse TE300 inverted epifluorescence microscope linked cooled Pentamax CCD camera Princeton Instruments interfaced digital imaging system MetaFluor Molecular Devices Downingtown PA Ca2i measured individually identified fura 2 loaded cells visualized using Nikon S Fluor x40 objective numerical aperture 0
0.15668444.15994312.html.plaintext.txt	68	Cells alternately excited 340 380 nm images digitized subsequent analysis
0.15668444.15994312.html.plaintext.txt	69	Images acquired every 2 10
0.15668444.15994312.html.plaintext.txt	70	An intracellular calibration performed conclusion experiment described previously 7
0.15668444.15994312.html.plaintext.txt	71	8 15 cells monitored experiment
0.15668444.15994312.html.plaintext.txt	72	Plaque Assays Briefly cells 6 well dishes exposed virus 2 h 37 degrees C inoculum removed cells washed three times PBS
0.15668444.15994312.html.plaintext.txt	73	The cells overlaid medium containing 0
0.15668444.15994312.html.plaintext.txt	74	For HSV 1KOS HSV 2G plaques counted immunoassay black plaque 4
0.15668444.15994312.html.plaintext.txt	75	For vesicular stomatitis virus cells overlaid 1 methylcellulose fixed 24 h methanol stained Giemsa stain
0.15668444.15994312.html.plaintext.txt	76	Unless indicated otherwise m
0.15668444.15994312.html.plaintext.txt	77	selected yield 200 500 pfuwell e
0.15668444.15994312.html.plaintext.txt	78	Viral Binding VP16 Time Course Assays To examine steps HSV infection blocked transfected knockout cells viral binding VP16 transport nucleus compared
0.15668444.15994312.html.plaintext.txt	79	For binding studies cells exposed serial 2 fold dilutions purified HSV 2G 5 h 4 degrees C
0.15668444.15994312.html.plaintext.txt	80	Unbound virus removed washing cell bound virus analyzed preparing Western blots cell lysates probing anti glycoprotein D mAb 1103
0.15668444.15994312.html.plaintext.txt	81	To examine transport VP16 nucleus synchronized infection assays conducted described previously 7
0.15668444.15994312.html.plaintext.txt	82	Cells precooled exposed HSV 4 degrees C 2 h m
0.15668444.15994312.html.plaintext.txt	83	1 1 10 pfucell allow binding
0.15668444.15994312.html.plaintext.txt	84	Unbound virus removed cells washed three times PBS transferred 37 degrees C 15 min allow penetration
0.15668444.15994312.html.plaintext.txt	85	Unpenetrated virus inactivated washing cell monolayer low pH citrate buffer adjusted pH 3
0.15668444.15994312.html.plaintext.txt	86	0 2 min washing three times PBS
0.15668444.15994312.html.plaintext.txt	87	The cells overlaid fresh medium nuclear extracts prepared 1 h citrate treatment
0.15668444.15994312.html.plaintext.txt	88	The nuclear proteins separated 10 SDS polyacrylamide gel transferred polyvinylidene difluoride membrane PerkinElmer Life Sciences using Trans Blot system Bio Rad blocked overnight 5 milk containing Tris buffered saline
0.15668444.15994312.html.plaintext.txt	89	Membranes incubated mouse anti VP16 antibody 1500 dilution Santa Cruz Biotechnology Inc
0.15668444.15994312.html.plaintext.txt	90	diluted 5 milk containing Tris buffered saline 2 h rinsed extensively 50 mM Tris Cl pH 7
0.15668444.15994312.html.plaintext.txt	91	The membranes incubated horseradish peroxidase conjugated goat anti mouse IgG 11000 dilution Calbiochem 5 milk containing PBS 2 h
0.15668444.15994312.html.plaintext.txt	92	After rinsing membranes developed using Immuno Star AP chemiluminescent kit Bio Rad
0.15668444.15994312.html.plaintext.txt	93	Blots scanned analyzed using GelDoc 2000 system
0.15668444.15994312.html.plaintext.txt	94	View larger version 27K FIG
0.15668444.15994312.html.plaintext.txt	95	FAK cells exhibit reduced susceptibility HSV infection
0.15668444.15994312.html.plaintext.txt	96	A FAK FAK cells infected HSV 2G m
0.15668444.15994312.html.plaintext.txt	97	At indicated times post infection cell lysates prepared proteins separated transferred Western blotting incubated anti phospho Tyr397 FAK antibody FAKpY397
0.15668444.15994312.html.plaintext.txt	98	Blots stripped reprobed mAb total FAK antibody actin
0.15668444.15994312.html.plaintext.txt	99	Representative blots FAK left panel FAK right panel cells shown
0.15668444.15994312.html.plaintext.txt	100	B compare susceptibility HSV infection cells exposed serial dilutions HSV 1KOS VP26 GFP HSV 2G vesicular stomatitis virus VSV
0.15668444.15994312.html.plaintext.txt	101	Plaques counted 48 h post infection viral titer plaque forming unitsml determined
0.15668444.15994312.html.plaintext.txt	102	The results means plus minus S
0.15668444.15994312.html.plaintext.txt	103	two independent experiments conducted duplicate
0.15668444.15994312.html.plaintext.txt	104	Detection FAK Pyk2 Phosphorylation Immunoblotting Nearly confluent cell monolayers preincubated serum free medium 12 h infection exposed HSVs m
0.15668444.15994312.html.plaintext.txt	105	1 pfucell indicated times 5 120 min
0.15668444.15994312.html.plaintext.txt	106	Cell lysates prepared described proteins separated SDS PAGE immunoblotting
0.15668444.15994312.html.plaintext.txt	107	Membranes incubated 1500 dilution rabbit anti phospho Tyr397 FAK antibody recognizes tyrosine autophosphorylation site position 397 FAK catalog
0.15668444.15994312.html.plaintext.txt	108	44 624G BIOSOURCE Camarillo CA 1500 dilution rabbit anti phospho Tyr402 Pyk2 recognizes tyrosine autophosphorylation site position 402 catalog
0.15668444.15994312.html.plaintext.txt	109	The membranes stripped reincubated 11000 dilution mouse anti FAK mAb catalog
0.15668444.15994312.html.plaintext.txt	110	F15020 GenBank Transduction Laboratories recognizes total FAK 1500 dilution rabbit anti Pyk2 antibody recognizes total Pyk2 catalog
0.15668444.15994312.html.plaintext.txt	111	07 437 Upstate20BiotechnologyUpstate Biotechnology Inc
0.15668444.15994312.html.plaintext.txt	112	View larger version 41K FIG
0.15668444.15994312.html.plaintext.txt	113	FAK required steps post binding
0.15668444.15994312.html.plaintext.txt	114	A FAK FAK cells exposed serial dilutions purified HSV 2G m
0.15668444.15994312.html.plaintext.txt	115	indicated 5 h 4 degrees C
0.15668444.15994312.html.plaintext.txt	116	The input cell bound viral particles detected analyzing Western blots cell lysates glycoprotein gD
0.15668444.15994312.html.plaintext.txt	117	Blots also probed mAb actin control cell loading
0.15668444.15994312.html.plaintext.txt	118	B alternatively cells exposed indicated m
0.15668444.15994312.html.plaintext.txt	119	HSV 2G synchronized infection assay 1 h post citrate treatment nuclear extracts prepared analyzed presence viral tegument protein VP16 Western blotting
0.15668444.15994312.html.plaintext.txt	120	The results shown representative three independent experiments
0.15668444.15994312.html.plaintext.txt	121	C confirm nuclear VP16 represents transported synthesized protein experiments conducted absence presence cycloheximide indicated
0.15668444.15994312.html.plaintext.txt	122	Nuclear extracts Nucl cell lysates Cell separating nuclear pellets analyzed VP16 Western blotting
0.15668444.15994312.html.plaintext.txt	123	The results representative two independent experiments
0.15668444.15994312.html.plaintext.txt	124	Confocal Microscopy CaSki FAK FAK cells grown glass coverslips 12 well plates indicated transfected siRNA described infected 24 h post transfection K26GFP indicated m
0.15668444.15994312.html.plaintext.txt	125	At indicated times post infection infected cell monolayers washed three times PBS
0.15668444.15994312.html.plaintext.txt	126	To label plasma membranes cells stained 30 min EZ Link sulfosuccinimidobiotin reagent 11000 dilution Pierce reacts primary amines cell surface proteins prior fixation 13 biotinylated cells reacted Alexa Fluor 647 conjugated streptavidin antibody 11000 dilution Molecular Probes Inc
0.15668444.15994312.html.plaintext.txt	127	Microtubules labeled anti tubulin mAb 1200 dilution catalog
0.15668444.15994312.html.plaintext.txt	128	Alexa Fluor 647 conjugated goat anti mouse secondary antibody 1200 dilution Molecular Probes Inc
0.15668444.15994312.html.plaintext.txt	129	Nuclei detected staining 46 diamidino 2 phenylindole nucleic acid stain Molecular Probes Inc
0.15668444.15994312.html.plaintext.txt	130	Images examined using Zeiss LSM 510 Meta confocal microscope fitted x100 objective
0.15668444.15994312.html.plaintext.txt	131	Image analysis subcellular co localization generated analyzed using LSM confocal software package
0.15668444.15994312.html.plaintext.txt	132	Quantification amounts cell associated GFP performed NIH Image densitometric software
0.15668444.15994312.html.plaintext.txt	133	In addition determine fraction cells expressing nuclear GFP 8 h post infection 100 cells analyzed counted
0.15668444.15994312.html.plaintext.txt	134	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES We previously showed HSV induces FAK phosphorylation CaSki Vero cells phosphorylation requires fusion competent virus 7
0.15668444.15994312.html.plaintext.txt	135	This study expanded include multiple cell types known susceptible HSV 2
0.15668444.15994312.html.plaintext.txt	136	Cells serum starved overnight exposed HSV 2 mock infected
0.15668444.15994312.html.plaintext.txt	137	At indicated times post infection cell lysates prepared examined expression total phosphorylated FAKs Western blotting
0.15668444.15994312.html.plaintext.txt	138	HSV 2 induced increase phosphorylated FAK within 5 min CaSki cells Fig
0.15668444.15994312.html.plaintext.txt	139	Similar results obtained immortalized human ectocervical cells Ecto1E6E7 colonic cells CaCo 2 neuronal cells SH N SK macrophages Fig
0.15668444.15994312.html.plaintext.txt	140	View larger version 34K FIG
0.15668444.15994312.html.plaintext.txt	141	Transfection CaSki cells FAK specific siRNA dominant negative variant Y397F reduces susceptibility HSV
0.15668444.15994312.html.plaintext.txt	142	A CaSki cells transfected FAK specific control siRNA 24 h later mock infected infected HSV 2G m
0.15668444.15994312.html.plaintext.txt	143	5 min post infection cell lysates prepared proteins separated transferred Western blotting incubated anti phospho Tyr397 FAK antibody FAKpY397
0.15668444.15994312.html.plaintext.txt	144	Blots stripped reprobed mAb total FAK antibody actin control
0.15668444.15994312.html.plaintext.txt	145	B alternatively CaSki cells mock transfected transfected empty vector wild type FAK Y397F variant 24 h later infected HSV 2 m
0.15668444.15994312.html.plaintext.txt	146	Cell lysates prepared 5 min post infection analyzed total phosphorylated FAKs immunoblotting
0.15668444.15994312.html.plaintext.txt	147	C assess impact transfections susceptibility HSV cells transfected 24 h later infected 150 pfu HSV 2G well
0.15668444.15994312.html.plaintext.txt	148	Plaques counted immunostaining 48 h post infection results means plus minus S
0.15668444.15994312.html.plaintext.txt	149	three independent experiments
0.15668444.15994312.html.plaintext.txt	150	To determine whether phosphorylated FAK contributes HSV infection used several different strategies
0.15668444.15994312.html.plaintext.txt	151	First exposed MEF cells derived embryonic FAK deficient mice FAK 9 control MEF cells FAK HSV 2 examined FAK response susceptibility infection
0.15668444.15994312.html.plaintext.txt	152	HSV 2 induced 3 fold increase level phosphorylated FAK percentage total FAK compared mock infected cells Fig
0.15668444.15994312.html.plaintext.txt	153	2A left panel response persisted 1 h
0.15668444.15994312.html.plaintext.txt	154	In contrast FAK phosphorylated FAK detected FAK cells Fig
0.15668444.15994312.html.plaintext.txt	155	Moreover FAK cells showed reduced susceptibility infection either serotype Fig
0.15668444.15994312.html.plaintext.txt	156	Viral titers reduced 93 96 FAK cells relative FAK cells HSV 1 HSV 2 respectively
0.15668444.15994312.html.plaintext.txt	157	Notably reduction susceptibility vesicular stomatitis virus observed FAK cells relative FAK cells
0.15668444.15994312.html.plaintext.txt	158	Susceptibility HSV infection partially restored cells transfected wild type FAK gene data shown
0.15668444.15994312.html.plaintext.txt	159	To carefully explore steps viral infection impaired FAK cells compared viral binding nuclear transport viral tegument protein VP16 FAK FAK cells
0.15668444.15994312.html.plaintext.txt	160	The results demonstrate reduction binding virus cells FAK cells relative FAK cells Fig
0.15668444.15994312.html.plaintext.txt	161	However nuclear transport VP16 1 h citrate treatment substantially reduced FAK cells compared FAK cells Fig
0.15668444.15994312.html.plaintext.txt	162	The blots scanned optical densitometry corrected differences loading
0.15668444.15994312.html.plaintext.txt	163	10 pfucell 93 reduction relative amounts VP16 detected nuclei FAK cells compared FAK cells
0.15668444.15994312.html.plaintext.txt	164	The amount nuclear VP16 detected comparable observed FAK cells infected 10 fold less virus m
0.15668444.15994312.html.plaintext.txt	165	To ensure nuclear VP16 reflects transported newly synthesized protein experiments also conducted presence cycloheximide inhibitor protein synthesis Fig
0.15668444.15994312.html.plaintext.txt	166	Comparable amounts nuclear VP16 detected 1 h citrate treatment FAK cells independent cycloheximide treatment accounted 73 total cell associated VP16
0.15668444.15994312.html.plaintext.txt	167	As anticipated substantial reduction viral ICP4 expression also observed FAK cells compared FAK cells consistent impaired delivery viral DNA cell nucleus thus viral gene expression data shown
0.15668444.15994312.html.plaintext.txt	168	Taken together results suggest absence FAK viral invasion blocked step post binding leading reduced nuclear transport VP16 inhibition downstream events including expression immediate early gene products plaque formation
0.15668444.15994312.html.plaintext.txt	169	Because embryonic knockout cells murine goal identify signaling pathways required HSV infection human target cells adopted complementary strategy assess role FAK phosphorylation human cervical epithelial cells
0.15668444.15994312.html.plaintext.txt	170	CaSki cells transfected siRNA specific FAK dominant negative variant FAK Y397F major autophosphorylation site mutated gift J
0.15668444.15994312.html.plaintext.txt	171	Guan 14 appropriate controls impact HSV infection examined
0.15668444.15994312.html.plaintext.txt	172	Transfection FAK sequence specific siRNA control nonspecific siRNA reduced FAK protein expression 85 based optical densitometry scanning blots prevented HSV induced FAK phosphorylation Fig
0.15668444.15994312.html.plaintext.txt	173	Similarly substantial reduction 70 virus triggered phosphorylated FAK also observed CaSki cells transfected Y397F compared cells transfected wild type FAK Fig
0.15668444.15994312.html.plaintext.txt	174	Transfection FAK specific siRNA Y397F FAK variant also reduced HSV 2 infection Fig
0.15668444.15994312.html.plaintext.txt	175	4C supporting results obtained FAK cells showing FAK phosphorylation play important roles HSV infection
0.15668444.15994312.html.plaintext.txt	176	View larger version 111K FIG
0.15668444.15994312.html.plaintext.txt	177	Delivery viral capsids cytoplasm newly synthesized GFP readily detected confocal microscopy following infection cells HSV 1KOS GFP VP26 m
0.15668444.15994312.html.plaintext.txt	178	A CaSki cells infected m
0.15668444.15994312.html.plaintext.txt	179	1 upper panels 1 middle panels 10 lower panels pfucell indicated times post infection fixed stained described Materials Methods
0.15668444.15994312.html.plaintext.txt	180	Red plasma membrane blue 46 diamidino 2 phenylindole staining delineating nuclei green viral capsid GFP fusion protein
0.15668444.15994312.html.plaintext.txt	181	B cells infected absence upper panels presence lower panels cycloheximide Cyclohex 10 microgml
0.15668444.15994312.html.plaintext.txt	182	The results representative three independent experiments
0.15668444.15994312.html.plaintext.txt	183	To determine whether FAK inactivation prevents viral capsid transport confocal microscopy studies conducted
0.15668444.15994312.html.plaintext.txt	184	For studies took advantage viral variant K26GFP HSV 1 expresses GFP VP26 fusion protein VP26 major viral capsid protein
0.15668444.15994312.html.plaintext.txt	185	K26GFP grows comparably wild type virus cell culture 10 infection FAK cells impaired similar extent K26GFP compared HSV 2G Fig
0.15668444.15994312.html.plaintext.txt	186	confocal experiments CaSki cells first infected K26GFP m
0.15668444.15994312.html.plaintext.txt	187	1 1 10 pfucell indicated times post infection fixed stained EZ Link sulfosuccinimidobiotin detect cellular plasma membranes 46 diamidino 2 phenylindole detect nuclei viewed confocal microscopy
0.15668444.15994312.html.plaintext.txt	188	Viral GFP detected cytoplasm cells infected 10 pfucell early 1 h post infection cells infected 1 pfucell Fig
0.15668444.15994312.html.plaintext.txt	189	1 pfucell GFP visible
0.15668444.15994312.html.plaintext.txt	190	Notably 4 h post infection newly synthesized GFP appeared accumulate nucleus cells infected 1 10 pfucell
0.15668444.15994312.html.plaintext.txt	191	To confirm observed nuclear GFP reflects newly synthesized protein experiments conducted presence absence cycloheximide m
0.15668444.15994312.html.plaintext.txt	192	Cycloheximide effect delivery viral capsids cytoplasm transport nuclear pore 1 2 h post infection blocked synthesis GFP 4 8 h post infection Fig
0.15668444.15994312.html.plaintext.txt	193	Next explore role played FAK HSV entry CaSki cells transfected nonspecific siRNA Fig
0.15668444.15994312.html.plaintext.txt	194	6A upper panels FAK specific siRNA middle panels infected K26GFP m
0.15668444.15994312.html.plaintext.txt	195	10 pfucell fixed stained 1 2 4 8 h post infection described
0.15668444.15994312.html.plaintext.txt	196	Viral GFP detected plasma membrane cytoplasm CaSki cells early 1 h post infection independent transfection
0.15668444.15994312.html.plaintext.txt	197	However transport viral capsids nuclear pore newly synthesized GFP rarely detected cells transfected FAK specific siRNA 4 8 h post infection
0.15668444.15994312.html.plaintext.txt	198	Parallel experiments conducted MEF cells Fig
0.15668444.15994312.html.plaintext.txt	199	As reported previously 15 knockout FAK alters morphology fibroblast cells loss typical elongated morphology
0.15668444.15994312.html.plaintext.txt	200	Intracellular GFP VP26 detected 1 h post infection FAK FAK cells newly synthesized GFP observed FAK cells
0.15668444.15994312.html.plaintext.txt	201	The relative amounts intracellular nuclear GFPs 1 8 h post infection respectively determined scanning 100 cells using NIH Image densitometric software Fig
0.15668444.15994312.html.plaintext.txt	202	No measurable reduction intracellular GFP detected 1 h post infection absence FAK FAK cells CaSki cells transfected FAK specific siRNA suggesting impediment viral entry
0.15668444.15994312.html.plaintext.txt	203	In contrast substantial reduction newly synthesized GFP detected consistent block level capsid transport nuclear pore
0.15668444.15994312.html.plaintext.txt	204	To explore role FAK capsid transport confocal experiments modified instead staining plasma membrane microtubules immunostained using anti tubulin mAb
0.15668444.15994312.html.plaintext.txt	205	In CaSki FAK cells viral capsids readily detected associated microtubule structures 1 2 h post infection Fig
0.15668444.15994312.html.plaintext.txt	206	7 upper middle panels respectively
0.15668444.15994312.html.plaintext.txt	207	In contrast GFP detected microtubules FAK cells Fig
0.15668444.15994312.html.plaintext.txt	208	Taken together results indicate absence FAK restriction capsid transport leading reduction delivery viral DNA nucleus subsequent viral gene expression
0.15668444.15994312.html.plaintext.txt	209	View larger version 74K FIG
0.15668444.15994312.html.plaintext.txt	210	Transport capsids nuclear pore subsequent synthesis new viral proteins impaired absence FAK
0.15668444.15994312.html.plaintext.txt	211	A CaSki cells transfected nonspecific NS upper panels FAK specific middle panels Pyk2 specific lower panels siRNA 24 h later infected HSV 1KOS GFP VP26 m
0.15668444.15994312.html.plaintext.txt	212	10 pfucell indicated times fixed stained described Materials Methods
0.15668444.15994312.html.plaintext.txt	213	B confocal microscopy studies also conducted following infection FAK upper panels FAK lower panels cells HSV 1KOS GFP VP26 m
0.15668444.15994312.html.plaintext.txt	214	C experiment relative amount intracellular GFP nuclear GFP detected 1 8 h post infection respectively compared collecting data 100 cells different fields using NIH Image densitometric software
0.15668444.15994312.html.plaintext.txt	215	The results expressed intensitycell relative units
0.15668444.15994312.html.plaintext.txt	216	siNS nonspecific siRNA siFAK FAK specific siRNA siPyk2 Pyk2 specific siRNA
0.15668444.15994312.html.plaintext.txt	217	Our previous study suggested phosphorylation FAK triggered downstream Ca2 signaling pharmacological agents block release ER Ca2 chelation intracellular Ca2 prevent virus induced phosphorylation FAK 7
0.15668444.15994312.html.plaintext.txt	218	These observations suggest Ca2 signaling preserved FAK cells
0.15668444.15994312.html.plaintext.txt	219	To test directly examined virus induced Ca2 signaling response excitation ratio fluorometry cells loaded Ca2 indicator fura 2
0.15668444.15994312.html.plaintext.txt	220	FAK FAK cells exposed sequentially PBS HSV 2G m
0.15668444.15994312.html.plaintext.txt	221	A rapid increase superfusate flow rate PBS alone simulating conditions elicited addition virus bathing medium effect resting Ca2i
0.15668444.15994312.html.plaintext.txt	222	The resting Ca2i FAK FAK cells comparable 100 nM Fig
0.15668444.15994312.html.plaintext.txt	223	Exposure FAK FAK cells HSV resulted significant rapid increase Ca2i peaked within 1 min returned base line within 3 min p 0
0.15668444.15994312.html.plaintext.txt	224	001 analysis variance Fig
0.15668444.15994312.html.plaintext.txt	225	8 although mean change peak Ca2i greater FAK cells compared FAK cells 181
0.15668444.15994312.html.plaintext.txt	226	1 versus 70 plus minus 45 nM respectively mean plus minus S
0.15668444.15994312.html.plaintext.txt	227	n 20 cells possibly reflecting reduction virus induced Ca2 signaling absence FAK perturbations signal transduction pathways knockout cells
0.15668444.15994312.html.plaintext.txt	228	The ability HSV induce significant Ca2 response FAK cells supports notion FAK phosphorylation occurs downstream virus induced release ER Ca2
0.15668444.15994312.html.plaintext.txt	229	View larger version 114K FIG
0.15668444.15994312.html.plaintext.txt	230	Viral capsid incorporated GFP co localizes microtubules following infection CaSki FAK cells FAK cells
0.15668444.15994312.html.plaintext.txt	231	Cells infected HSV 1KOS GFP VP26 m
0.15668444.15994312.html.plaintext.txt	232	50 pfucell indicated times post infection fixed stained
0.15668444.15994312.html.plaintext.txt	233	Microtubules labeled anti tubulin antibody red nuclei stained 46 diamidino 2 phenylindole blue
0.15668444.15994312.html.plaintext.txt	234	The results representative obtained three independent experiments
0.15668444.15994312.html.plaintext.txt	235	Pyk2 non receptor tyrosine kinase related FAK activated various extracellular signals including increase Ca2i overexpressed embryonic FAK cells 15 16
0.15668444.15994312.html.plaintext.txt	236	We hypothesized HSV may also trigger phosphorylation Pyk2 could contribute signaling pathways required capsid transport
0.15668444.15994312.html.plaintext.txt	237	CaSki FAK FAK cells serum starved exposed HSV 2G 1 pfucell mock infected
0.15668444.15994312.html.plaintext.txt	238	Cell lysates prepared different times post infection analyzed phosphorylated total Pyk2 proteins
0.15668444.15994312.html.plaintext.txt	239	HSV 2 triggered Pyk2 phosphorylation within 5 min following inoculation cells Fig
0.15668444.15994312.html.plaintext.txt	240	The response substantially greater FAK cells presumably reflecting increase total Pyk2 cells absence FAK Fig
0.15668444.15994312.html.plaintext.txt	241	The observation Pyk2 phosphorylation occurs absence FAK suggests Pyk2 phosphorylated independent FAK phosphorylation
0.15668444.15994312.html.plaintext.txt	242	To address independence Pyk2 FAK phosphorylation took advantage siRNA strategy
0.15668444.15994312.html.plaintext.txt	243	CaSki cells transfected control nonspecific siRNA Pyk2 FAK specific siRNA mock infected infected HSV 2G
0.15668444.15994312.html.plaintext.txt	244	Transfection Pyk2 specific siRNA led 70 reduction Pyk2 expression virus induced Pyk2 phosphorylation Fig
0.15668444.15994312.html.plaintext.txt	245	In contrast virus induced Pyk2 phosphorylation preserved cells transfected FAK specific siRNA Fig
0.15668444.15994312.html.plaintext.txt	246	9B middle panels virus induced FAK phosphorylation preserved cells transfected Pyk2 specific siRNA lower panels show results FAK cells similar results obtained CaSki cells
0.15668444.15994312.html.plaintext.txt	247	To evaluate whether Pyk2 phosphorylation contributes HSV infection plaque assays conducted cells transfected siRNA specific FAK Pyk2 alone combination
0.15668444.15994312.html.plaintext.txt	248	Compared cells transfected control nonspecific siRNA HSV 2 infection inhibited 74 plus minus 6 60 plus minus 5 94 plus minus 7 CaSki cells transfected siRNA FAK Pyk2 respectively Fig
0.15668444.15994312.html.plaintext.txt	249	Consistent low level Pyk2 phosphorylation observed FAK cells Fig
0.15668444.15994312.html.plaintext.txt	250	9A transfection cells Pyk2 specific siRNA little inhibitory effect 22 whereas transfection FAK specific siRNA reduced viral infection 71
0.15668444.15994312.html.plaintext.txt	251	In contrast transfection FAK cells Pyk2 specific siRNA reduced viral infection 99
0.15668444.15994312.html.plaintext.txt	252	To directly evaluate whether Pyk2 phosphorylation also contributes nuclear transport CaSki cells transfected nonspecific Pyk2 specific siRNA effects viral binding VP16 transport nucleus evaluated
0.15668444.15994312.html.plaintext.txt	253	Transfection Pyk2 specific siRNA effect viral binding Fig
0.15668444.15994312.html.plaintext.txt	254	10B modest inhibitory effect nuclear transport VP16 Fig
0.15668444.15994312.html.plaintext.txt	255	Optical densitometry scanning gels demonstrated 40 reduction nuclear VP16 following Pyk2 specific siRNA transfection consistent modest inhibition viral plaque formation Fig
0.15668444.15994312.html.plaintext.txt	256	Similarly transfection Pyk2 specific siRNA also moderate effect delivery GFP nuclear pore detected confocal microscopy Fig
0.15668444.15994312.html.plaintext.txt	257	Together results suggest HSV induces phosphorylation Pyk2 independent phosphorylation FAK although FAK plays predominant role activation kinases contributes viral infection
0.15668444.15994312.html.plaintext.txt	258	View larger version 10K FIG
0.15668444.15994312.html.plaintext.txt	259	Effect exposure cells HSV 2 Ca2i
0.15668444.15994312.html.plaintext.txt	260	FAK A FAK B cells loaded Ca2 indicator dye fura 2 exposed HSV 2 m
0.15668444.15994312.html.plaintext.txt	261	0 changes Ca2i monitored
0.15668444.15994312.html.plaintext.txt	262	Shown representative recordings two cells showing Ca2 exposure virus
0.15668444.15994312.html.plaintext.txt	263	The base line peak Ca2 achieved response HSV 2 shown n 20 cells C
0.15668444.15994312.html.plaintext.txt	264	The asterisk indicates peak change Ca2i compared base line cell types significant p 0
0.15668444.15994312.html.plaintext.txt	265	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES The dependence viruses host cell machinery transcription translation genome replication well established
0.15668444.15994312.html.plaintext.txt	266	However viruses presumably also must harness host cell pathways entry egress 16
0.15668444.15994312.html.plaintext.txt	267	The results obtained study demonstrate first time HSV triggers phosphorylation cellular kinases FAK Pyk2 promote successful invasion
0.15668444.15994312.html.plaintext.txt	268	HSV independently induces phosphorylation FAK Pyk2 disruption pathways impedes delivery tegument protein VP16 nucleus delivery capsids nuclear pore leading reduction downstream events viral gene expression plaque formation
0.15668444.15994312.html.plaintext.txt	269	View larger version 46K FIG
0.15668444.15994312.html.plaintext.txt	270	HSV induces Pyk2 phosphorylation
0.15668444.15994312.html.plaintext.txt	271	A CaSki FAK FAK cells serum starved overnight challenged HSV 2G m
0.15668444.15994312.html.plaintext.txt	272	At indicated times post infection cell lysates prepared analyzed Western blotting phosphorylated total Pyk2 proteins
0.15668444.15994312.html.plaintext.txt	273	B additionally CaSki cells transfected control Pyk2 specific FAK specific siRNA 24 h later mock infected infected HSV 2G
0.15668444.15994312.html.plaintext.txt	274	5 min post infection cell lysates prepared analyzed indicated tyrosine phosphorylated protein Pyk2 phosphorylated Tyr402 Pyk2pY402 FAK Pyk2
0.15668444.15994312.html.plaintext.txt	275	The results representative three independent experiments
0.15668444.15994312.html.plaintext.txt	276	Several studies suggest HSV uses microtubule based transport delivery viral capsids nuclear pore viral DNA released nucleus 1 17 19
0.15668444.15994312.html.plaintext.txt	277	Immunofluorescence studies demonstrate HSV 1 capsids co localize dynein dynactin
0.15668444.15994312.html.plaintext.txt	278	Microtubule depolymerizing agents nocodazole block HSV infection culture animal models 1
0.15668444.15994312.html.plaintext.txt	279	Moreover nuclear transport capsids reduced dynein inhibitors 19
0.15668444.15994312.html.plaintext.txt	280	Precisely HSV viruses engages regulates microtubule complexes known
0.15668444.15994312.html.plaintext.txt	281	It suggested cellular kinases triggered viral infection perhaps encoded viruses may play regulatory role
0.15668444.15994312.html.plaintext.txt	282	The results obtained study support notion suggest cellular FAK related tyrosine kinase Pyk2 activated HSV promote transport along microtubules
0.15668444.15994312.html.plaintext.txt	283	View larger version 37K FIG
0.15668444.15994312.html.plaintext.txt	284	Pyk2 also contributes HSV infection
0.15668444.15994312.html.plaintext.txt	285	A CaSki FAK FAK cells transfected FAK specific siRNA Pyk2 specific siRNA siRNAs 24 h later challenged serial dilutions HSV 2G
0.15668444.15994312.html.plaintext.txt	286	Plaques counted 48 h post infection viral titer plaque forming unitsml determined
0.15668444.15994312.html.plaintext.txt	287	The results means plus minus S
0.15668444.15994312.html.plaintext.txt	288	two independent experiments conducted duplicate
0.15668444.15994312.html.plaintext.txt	289	B CaSki cells transfected nonspecific NS Pyk2 specific siPyk2 siRNA 24 h later exposed serial dilutions purified HSV 2G m
0.15668444.15994312.html.plaintext.txt	290	indicated 5 h 4 degrees C
0.15668444.15994312.html.plaintext.txt	291	The input cell bound viral particles detected analyzing Western blots cell lysates glycoprotein D gD
0.15668444.15994312.html.plaintext.txt	292	Blots also probed mAb actin control cell lysate loading
0.15668444.15994312.html.plaintext.txt	293	C transfected cells Cell exposed HSV 2G m
0.15668444.15994312.html.plaintext.txt	294	10 pfucell synchronized infection assay 1 h post entry nuclear extracts Nucl prepared analyzed presence viral tegument protein VP16 Western blotting
0.15668444.15994312.html.plaintext.txt	295	FAK originally identified tyrosine kinase localized focal adhesions multiprotein structures link extracellular matrix actin cytoskeleton integrin receptors
0.15668444.15994312.html.plaintext.txt	296	More recent studies indicate FAK also participates regulation microtubule function
0.15668444.15994312.html.plaintext.txt	297	For example integrin mediated activation FAK required microtubule stabilization mouse fibroblasts 20
0.15668444.15994312.html.plaintext.txt	298	Additionally FAK phosphorylation Ser732 important microtubule organization nuclear movement neuronal migration 21
0.15668444.15994312.html.plaintext.txt	299	The latter study suggests FAK phosphorylation regulates microtubule based nuclear translocation neuronal migration
0.15668444.15994312.html.plaintext.txt	300	Pyk2 also called FAK2 belongs family non receptor tyrosine kinases FAK
0.15668444.15994312.html.plaintext.txt	301	In contrast FAK expressed ubiquitously Pyk2 expression restricted found hematopoietic neuronal epithelial cells
0.15668444.15994312.html.plaintext.txt	302	Pyk2 shares substantial homology FAK interacts intracellular signaling molecules activate variety cellular pathways including regulation microtubules 15
0.15668444.15994312.html.plaintext.txt	303	Notably increases intracellular Ca2 levels associated Pyk2 phosphorylation
0.15668444.15994312.html.plaintext.txt	304	We found HSV also induces Pyk2 phosphorylation independent FAK
0.15668444.15994312.html.plaintext.txt	305	Pyk2 phosphorylation evident FAK fibroblasts known overexpress Pyk2 15 also contributed viral infection post binding
0.15668444.15994312.html.plaintext.txt	306	Thus observation HSV capsid nuclear transport occurs via microtubules association FAK Pyk2 microtubule regulation suggest HSV triggers cellular kinases harness microtubule machinery nuclear transport
0.15668444.15994312.html.plaintext.txt	307	Several viruses activate FAK related signaling pathways precise role played pathways viral invasion pathogenicity delineated previously
0.15668444.15994312.html.plaintext.txt	308	FAK activated integrin binding aggregation
0.15668444.15994312.html.plaintext.txt	309	Thus viruses bind integrin receptors adenovirus human herpesvirus 8 HHV 8 trigger FAK phosphorylation
0.15668444.15994312.html.plaintext.txt	310	Adenovirus induces tyrosine phosphorylation FAK within 15 min following infection human corneal fibroblasts role viral pathogenicity known 22
0.15668444.15994312.html.plaintext.txt	311	HHV 8 glycoprotein B possesses RGD motif binds integrin receptors target cells triggers rapid phosphorylation FAK related signaling pathways
0.15668444.15994312.html.plaintext.txt	312	The finding HHV 8 infection FAK null cells substantially reduced suggests FAK may also required HHV 8 entry yet experimentally demonstrated 23 25
0.15668444.15994312.html.plaintext.txt	313	Additionally binding HIV gp120 T cells also triggers tyrosine phosphorylation FAK 26 may promote apoptosis 27 yet demonstrated play role HIV entry nuclear transport
0.15668444.15994312.html.plaintext.txt	314	It clear yet HSV activates FAK cell signaling pathway
0.15668444.15994312.html.plaintext.txt	315	Although glycoprotein B highly conserved among herpesviruses HHV 8 glycoprotein B possesses RGD motif interacts integrin molecules receptor 28
0.15668444.15994312.html.plaintext.txt	316	Recent studies demonstrate HSV 1 glycoprotein H binds v3 integrins however functional significance interaction unclear 29
0.15668444.15994312.html.plaintext.txt	317	A recombinant virus RGD motif glycoprotein H mutated RGE shows impairment entry infectivity vitro 30 also induces FAK phosphorylation
0.15668444.15994312.html.plaintext.txt	318	The results study suggest FAK phosphorylation occurs downstream Ca2 signaling triggered either directly increase Ca2i response Ca2 dependent viral penetration
0.15668444.15994312.html.plaintext.txt	319	This notion supported findings HSV induces increase Ca2i FAK cells Fig
0.15668444.15994312.html.plaintext.txt	320	9 treatment cells pharmacological agents block release ER Ca2 stores chelation intracellular Ca2 prevents virus induced phosphorylation FAK 7
0.15668444.15994312.html.plaintext.txt	321	In contrast observed HHV 8 glycoprotein B HIV gp120 single HSV glycoprotein cell interaction appears sufficient activate requisite cell signaling pathways
0.15668444.15994312.html.plaintext.txt	322	Our studies deletion viruses indicate penetration competent virus required induce signaling
0.15668444.15994312.html.plaintext.txt	323	This follows observations HSV 1 deleted glycoprotein L glycoprotein D bind penetrate fails induce signaling responses whereas heat inactivated virus induces phosphorylated FAK 7
0.15668444.15994312.html.plaintext.txt	324	Possibly one HSV envelope glycoproteins interacts cell surface receptor trigger signaling cascade interaction dependent glycoproteins present viral envelope
0.15668444.15994312.html.plaintext.txt	325	This could occur example glycoproteins induce conformational change andor recruit requisite glycoproteins specific site membrane
0.15668444.15994312.html.plaintext.txt	326	Defining precisely HSV triggers signaling pathways critical viral proteins involved excellent candidate targets antiviral therapies
0.15668444.15994312.html.plaintext.txt	327	Although targeting critical cellular pathways FAK phosphorylation undoubtedly pleiotropic potentially deleterious effects suggested reduction magnitude virus induced Ca2 transients FAK cells observed changes morphology FAK knockout cells 15 targeting viral proteins activate requisite signaling pathways lead development novel specific antiviral therapies
0.15668444.15994312.html.plaintext.txt	328	The results study provide important piece puzzle suggest blockade HSV triggered phosphorylation FAK lesser extent Pyk2 prevent nuclear transport critical step establishment HSV infection
0.15668444.15994312.html.plaintext.txt	329	FOOTNOTES This work supported part National Institutes Health Grants AI061679 HD43733 B
0.15668444.15994312.html.plaintext.txt	330	Grants DK38470 DK64104 L
0.15668444.15994312.html.plaintext.txt	331	The costs publication article defrayed part payment page charges
0.15668444.15994312.html.plaintext.txt	332	This article must therefore hereby marked advertisement accordance 18 U
0.15668444.15994312.html.plaintext.txt	333	Section 1734 solely indicate fact
0.15668444.15994312.html.plaintext.txt	334	Supported Polycystic Kidney Research Foundation fellowship grant Revson Foundation fellowship
0.15668444.15994312.html.plaintext.txt	335	To correspondence addressed Pediatric Infectious Diseases Mount Sinai School Medicine One Gustave L
0.15668444.15994312.html.plaintext.txt	336	212 241 5272 Fax 212 426 4813 E mail betsy
0.15668444.15994312.html.plaintext.txt	337	1 The abbreviations used HSV herpes simplex virus HIV human immunodeficiency virus ER endoplasmic reticulum FAK focal adhesion kinase siRNA small interfering RNA MEF mouse embryonic fibroblast GFP green fluorescent protein mAb monoclonal antibody PBS phosphate buffered saline m
0.15668444.15994312.html.plaintext.txt	338	multiplicity infection pfu plaque forming units HHV 8 human herpesvirus 8
0.15668444.15994312.html.plaintext.txt	339	ACKNOWLEDGMENTS We thank Prashant Desai generous gift K26GFP virus Robert F
0.15668444.15994312.html.plaintext.txt	340	Hennigan Paul Carman Mount Sinai School Medicine Microscopy Shared Research Facility advice assistance
0.15668444.15994312.html.plaintext.txt	341	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Sodeik B
0.15668444.15994312.html.plaintext.txt	342	136 1007 1021AbstractFree Full Text Spear P
0.15668444.15994312.html.plaintext.txt	343	77 10179 10185Free Full Text Cheshenko N
0.15668444.15994312.html.plaintext.txt	344	83 2247 2255AbstractFree Full Text Herold B
0.15668444.15994312.html.plaintext.txt	345	65 1090 1098Medline Order article via Infotrieve Keller M
0.15668444.15994312.html.plaintext.txt	346	51 1099 1102Free Full Text Keller M
0.15668444.15994312.html.plaintext.txt	347	55 420 423AbstractFree Full Text Cheshenko N
0.15668444.15994312.html.plaintext.txt	348	163 283 293AbstractFree Full Text Fichorova R
0.15668444.15994312.html.plaintext.txt	349	1995 Nature 377 539 544CrossRefMedline Order article via Infotrieve Desai P
0.15668444.15994312.html.plaintext.txt	350	72 7563 7568AbstractFree Full Text Herold B
0.15668444.15994312.html.plaintext.txt	351	75 1211 1222Abstract Qie L
0.15668444.15994312.html.plaintext.txt	352	1999 Virology 256 220 227CrossRefMedline Order article via Infotrieve Foster T
0.15668444.15994312.html.plaintext.txt	353	78 13262 13277AbstractFree Full Text Zhao J
0.15668444.15994312.html.plaintext.txt	354	Cell 12 4066 4077AbstractFree Full Text Gelman I
0.15668444.15994312.html.plaintext.txt	355	27 507 510CrossRefMedline Order article via Infotrieve Smith G
0.15668444.15994312.html.plaintext.txt	356	18 135 161CrossRefMedline Order article via Infotrieve Kristensson K
0.15668444.15994312.html.plaintext.txt	357	67 2023 2028Abstract Topp K
0.15668444.15994312.html.plaintext.txt	358	64 343 354CrossRefMedline Order article via Infotrieve Dohner K
0.15668444.15994312.html.plaintext.txt	359	Cell 13 2795 2809AbstractFree Full Text Palazzo A
0.15668444.15994312.html.plaintext.txt	360	2004 Science 303 836 839AbstractFree Full Text Xie Z
0.15668444.15994312.html.plaintext.txt	361	2003 Cell 114 469 482CrossRefMedline Order article via Infotrieve Natarajan K
0.15668444.15994312.html.plaintext.txt	362	43 2685 2690AbstractFree Full Text Sharma Walia N
0.15668444.15994312.html.plaintext.txt	363	78 4207 4223AbstractFree Full Text Naranatt P
0.15668444.15994312.html.plaintext.txt	364	79 1191 1206AbstractFree Full Text Naranatt P
0.15668444.15994312.html.plaintext.txt	365	77 1524 1539CrossRefMedline Order article via Infotrieve Cicala C
0.15668444.15994312.html.plaintext.txt	366	97 1178 1183AbstractFree Full Text Wang F
0.15668444.15994312.html.plaintext.txt	367	77 3131 3147AbstractFree Full Text Parry C
0.15668444.15994312.html.plaintext.txt	368	86 7 10AbstractFree Full Text Galdiero M
0.15876892.9469840.html.plaintext.txt	0	Transcriptional interference perturbs binding Sp1 HIV 1 promoter
0.15876892.9469840.html.plaintext.txt	1	Greger Francesca Demarchi1 Mauro Giacca1 Nick J
0.15876892.9469840.html.plaintext.txt	2	Sir William Dunn School Pathology University Oxford South Parks Road Oxford OX1 3RE UK 1International Centre Genetic Engineering Biotechnology AREA Science Park Padriciano 99 34012 Trieste Italy
0.15876892.9469840.html.plaintext.txt	3	Received October 24 1997 Revised Accepted January 8 1998
0.15876892.9469840.html.plaintext.txt	4	Transcriptional interference adjacent genes demonstrated variety biological systems
0.15876892.9469840.html.plaintext.txt	5	To study process RNA polymerase II pol II transcribed genes analysed effect transcription tandem HIV 1 promoters integrated genome HeLa cells
0.15876892.9469840.html.plaintext.txt	6	We show transcriptional activation upstream promoter reduces transcription downstream promoter compared basal transcription conditions absence activator
0.15876892.9469840.html.plaintext.txt	7	Furthermore insertion strong transcriptional termination element two promoters alleviates transcriptional interference resulting elevated levels transcription downstream promoter
0.15876892.9469840.html.plaintext.txt	8	Actual protein interactions downstream occluded promoter analysed vivo footprinting
0.15876892.9469840.html.plaintext.txt	9	Binding Sp1 transcription factors occluded promoter reduced compared footprint pattern promoter protected terminator
0.15876892.9469840.html.plaintext.txt	10	This suggests promoter occlusion due disruption certain transcription factors blocked intervening transcriptional terminator
0.15876892.9469840.html.plaintext.txt	11	Chromatin mapping DNase I indicates factor binds termination element basal induced conditions
0.15876892.9469840.html.plaintext.txt	12	Termination transcription may defined arrest elongating polymerase followed release transcription complex nascent RNA DNA template
0.15876892.9469840.html.plaintext.txt	13	It known eukaryotes functional polyA signals required efficient transcriptional termination RNA polymerase II pol II since mutations disrupt polyadenylation also result loss termination 1 3
0.15876892.9469840.html.plaintext.txt	14	Furthermore strength polyA signal correlates termination efficiency since stronger processing signal effective directing termination 4
0.15876892.9469840.html.plaintext.txt	15	Actual termination sites remain ill defined cases studied far transcription continues well beyond polyA site 5 downstream element encountered forces elongating polymerase pause arrest 67
0.15876892.9469840.html.plaintext.txt	16	Pause sites take various forms DNA bound protein complexes intrinsic DNA sequence elements either capable causing polyA site dependent termination transcription 68 11
0.15876892.9469840.html.plaintext.txt	17	It reported inefficient transcriptional termination cause interference DNA replication transcription adjacent downstream gene leading impairment central cellular processes 12 16
0.15876892.9469840.html.plaintext.txt	18	This emphasizes need efficient termination process cases
0.15876892.9469840.html.plaintext.txt	19	Transcriptional interference promoter occlusion observed various eukaryotic systems including genes transcribed pol I II prokaryotic operons certain viruses 12
0.15876892.9469840.html.plaintext.txt	20	In vitro experiments pol I system suggested mechanism promoter occlusion transcription promoter may cause displacement bound transcription factor
0.15876892.9469840.html.plaintext.txt	21	Interference prevented terminator elements reside upstream pol I promoter 1718
0.15876892.9469840.html.plaintext.txt	22	In contrast less complex pol I promoter transcription pol II depends multiple protein protein protein DNA interactions promoter enhancer regions form stable initiation complexes 19
0.15876892.9469840.html.plaintext.txt	23	In present work studied tandem pol II promoters derived HIV 1 long terminal repeat LTR stably integrated chromosome
0.15876892.9469840.html.plaintext.txt	24	We investigated importance intervening transcriptional terminator context furthermore also investigated DNA protein interactions downstream promoter
0.15876892.9469840.html.plaintext.txt	25	Analysis cytoplasmic RNA revealed upon transactivation viral Tat protein transcription downstream promoter reduced compared already high basal transcriptional conditions
0.15876892.9469840.html.plaintext.txt	26	A transcriptional terminator placed two LTR promoters allowed increased transcription promoters upon transactivation Tat
0.15876892.9469840.html.plaintext.txt	27	Actual DNA protein interactions downstream promoter analysed DMS vivo footprinting
0.15876892.9469840.html.plaintext.txt	28	While consistently observed footprints promoter preceded terminator reduced protective intervening terminator absent suggesting reduced binding transcription factors occluded promoter
0.15876892.9469840.html.plaintext.txt	29	The footprint pattern changed mainly across binding sites transcription factor Sp1
0.15876892.9469840.html.plaintext.txt	30	Furthermore DNase I footprinting vivo indicated binding protein 5prime end pause site corresponding position termination factor MAZ shown bind vitro 11
0.15876892.9469840.html.plaintext.txt	31	This binding activity stable induced conditions
0.15876892.9469840.html.plaintext.txt	32	Taken together results demonstrate pol II termination element located strong pol II promoters plays critical role preventing transcriptional interference chromosomal context
0.15876892.9469840.html.plaintext.txt	33	We suggest transcriptional interference may result destabilization specific transcription factors occluded promoter
0.15876892.9469840.html.plaintext.txt	34	Schematic diagram two constructs CI CII used study
0.15876892.9469840.html.plaintext.txt	35	Both contain two minimal HIV 1 LTR promoters tandem L1 L2
0.15876892.9469840.html.plaintext.txt	36	CII contains termination element placed LTR promoters SpA polyA site followed C2 pause site allowing termination L1 transcripts upstream L2 promoter
0.15876892.9469840.html.plaintext.txt	37	L1 transcripts derived CI construct read L2 promoter use HIV polyA site HpA
0.15876892.9469840.html.plaintext.txt	38	The transcriptional start sites indicated arrows transcripts initiated L1 indicated dashed lines major upstream promoter elements shown boxes NF kappaB black SP1 white
0.15876892.9469840.html.plaintext.txt	39	MATERIALS AND METHODS Plasmid constructs
0.15876892.9469840.html.plaintext.txt	40	The interference constructs L1alphaL2alpha L1alpha SPAC L2alpha previously described 20
0.15876892.9469840.html.plaintext.txt	41	For stable transfection HeLa cells 2404 bp SfiI BamHI fragment containing SV40 early promoter driving neo gene inserted SfiI EagI sites constructs generate CI CII
0.15876892.9469840.html.plaintext.txt	42	The Tat gene derived Tat expression plasmid 21 cloned pBabe hygro plasmid containing hygromycin resistance gene driven SV40 early promoter 22
0.15876892.9469840.html.plaintext.txt	43	HeLa cells transfected calcium phosphate precipitation technique 5 microg plasmid
0.15876892.9469840.html.plaintext.txt	44	The medium changed 12 h transfection selective medium MEM Gibco containing 400 microgml G418 Gibco 300 microgml hygromycin Boehringer Mannheim 10 fetal bovine calf serum added 48 h transfection
0.15876892.9469840.html.plaintext.txt	45	Single colonies picked expanded cell pools consisted 100 individual colonies
0.15876892.9469840.html.plaintext.txt	46	Cells maintained medium containing 200 microgml G418
0.15876892.9469840.html.plaintext.txt	47	Tat expressing HeLa cells established transfecting CI CII clonally derived cell lines Tat expressing plasmid propagated selective medium containing additionally 200 microgml hygromycin
0.15876892.9469840.html.plaintext.txt	48	RNA extraction RNase protections carried described previously 20
0.15876892.9469840.html.plaintext.txt	49	Riboprobe L complementary PvuII SmaI region L2 Figs 2 3 20
0.15876892.9469840.html.plaintext.txt	50	Riboprobe S internal standard constructed inserting restriction fragment AvaI HindIII CI spanning neo gene AvaIHindIII cut pGEM 3 Promega
0.15876892.9469840.html.plaintext.txt	51	The plasmid linearized NcoI vitro transcription
0.15876892.9469840.html.plaintext.txt	52	Riboprobes purified 5 sequencing gels 5 x 105 c
0.15876892.9469840.html.plaintext.txt	53	probe hybridized 10 microg cytoplasmic RNA
0.15876892.9469840.html.plaintext.txt	54	Gels scanned phosphorimager quantified using appropriate software Molecular Dynamics
0.15876892.9469840.html.plaintext.txt	55	HeLa cells 106 grown 10 cm dishes incubated DMS 1 microlml Aldrich 5 min
0.15876892.9469840.html.plaintext.txt	56	DNA extraction linker mediated PCR reactions performed described Current Protocols 1996
0.15876892.9469840.html.plaintext.txt	57	All primers purified 20 sequencing gels
0.15876892.9469840.html.plaintext.txt	58	HeLa cells 2 x 106 trypsinized washed PBS physiological buffer 23 taken 200 microl physiological buffer 1 NP 40 treated 175 U DNase I Boehringer Mannheim 5 min 4 degrees C
0.15876892.9469840.html.plaintext.txt	59	After DNase I treatment 5 ml lysis buffer 50 mM Tris HCl pH 8 20 mM EDTA 1 SDS added DNA phenol extracted analysed linker mediated PCR 24
0.15876892.9469840.html.plaintext.txt	60	It previously shown strong transcriptional termination signal block interference two HIV 1 LTR promoters plasmids transiently transfected HeLa cells 20
0.15876892.9469840.html.plaintext.txt	61	To study promoter interference chromosomal context stably integrated tandem promoter constructs HeLa cells
0.15876892.9469840.html.plaintext.txt	62	Two constructs CI CII Fig
0.15876892.9469840.html.plaintext.txt	63	1 transfected one containing intervening termination signal SPAC consisting strong polyA site SPA downstream C2 pause element two LTRs CII 25 without intervening termination signal CI
0.15876892.9469840.html.plaintext.txt	64	Individual cell clones containing CI CII transgenes respectively expanded maintained selective G418 containing medium
0.15876892.9469840.html.plaintext.txt	65	Since HIV 1 promoter inducible viral transactivator Tat able detect transcriptional interference enhancing transcription Tat
0.15876892.9469840.html.plaintext.txt	66	This achieved stably transfecting clonally derived CI CII cells lines Tat expressing vector allowing direct comparison basal Tat trans activated transcription one particular clone
0.15876892.9469840.html.plaintext.txt	67	Tat expression monitored RNA level S1 nuclease mapping Tat transcript data shown
0.15876892.9469840.html.plaintext.txt	68	In experiments described analysed individual clones derived stable transfections checked integrity copy number Southern blotting data shown
0.15876892.9469840.html.plaintext.txt	69	Clones containing single copy integrants employed
0.15876892.9469840.html.plaintext.txt	70	Furthermore obtain position independent values also analysed complex cell pools consisiting 100 positive clones
0.15876892.9469840.html.plaintext.txt	71	Trans activation Tat leads reduced transcription L2 promoter CI cell lines
0.15876892.9469840.html.plaintext.txt	72	RNase protection assay cytoplasmic RNA HeLa cells stably transfected CI
0.15876892.9469840.html.plaintext.txt	73	Lanes 1 2 undigested riboprobes S L lanes 3 5 7 three different CI clones basal transcription conditions lanes 4 6 8 clones transactivated Tat
0.15876892.9469840.html.plaintext.txt	74	The gel quantified phosphorimager
0.15876892.9469840.html.plaintext.txt	75	Bars represent RNA levels L1 L2 promoters basal Tat trans activated conditions Tat normalized neo control
0.15876892.9469840.html.plaintext.txt	76	Also shown values complex CI cell pool note lower scale
0.15876892.9469840.html.plaintext.txt	77	The diagram bottom shows origin protected RNA species
0.15876892.9469840.html.plaintext.txt	78	The tandem promoters L1 L2 white boxes driving alpha2 globin reporter fragments grey bars SV40 promoter driving neo gene shown HIV 1 polyA site 80 relative start site 1 empty triangles alpha2 globin polyA site grey triangle LTR specific antisense riboprobe L protects transcripts initiated LTR promoters simultaneously
0.15876892.9469840.html.plaintext.txt	79	The intervening terminator SPAC allows increased transcription L2 promoters presence Tat
0.15876892.9469840.html.plaintext.txt	80	RNase protection assay cytoplasmic RNA HeLa cells stably transfected CII
0.15876892.9469840.html.plaintext.txt	81	Lanes 1 3 two different CII clones trans activated conditions Tat lanes 2 4 clones basal conditions Tat lanes 5 6 undigested riboprobes L S
0.15876892.9469840.html.plaintext.txt	82	Trans activation allows increase transcription promoters L1 L2 presence terminator
0.15876892.9469840.html.plaintext.txt	83	Values normalized internal neo standard
0.15876892.9469840.html.plaintext.txt	84	Also shown values complex CII cell pool
0.15876892.9469840.html.plaintext.txt	85	Diagram Figure 2 except intervening terminator SPAC containing synthetic polyA site shown filled triangle
0.15876892.9469840.html.plaintext.txt	86	It noted CI CII constructs contain adjacent SV40 promoter enhancer element used drive expression neo gene
0.15876892.9469840.html.plaintext.txt	87	Consequently HIV LTR promoters significantly active absence Tat presumably due proximity SV40 enhancer 2627
0.15876892.9469840.html.plaintext.txt	88	Even presence Tat activated LTR promoters allowed detection transcriptional interference effects adjacent LTR promoters
0.15876892.9469840.html.plaintext.txt	89	Transcriptional activity two promoters L1 L2 assessed RNase protection assays Figs 2 3
0.15876892.9469840.html.plaintext.txt	90	Cytoplasmic RNA extracted various individual clones pools analysed using mixture two riboprobes probe L LTR specific riboprobe recognizes LTR transcripts simultaneously distinguishes L1 read L2 initiating transcripts derived PvuII SmaI fragment L2 probe S hybridizes transcripts initiated SV40 promoter drives transcription neo gene contained within transfected plasmid
0.15876892.9469840.html.plaintext.txt	91	Probe S included internal control assay allowed direct comparison single clone basal trans activated conditions normalized internal standard
0.15876892.9469840.html.plaintext.txt	92	Transcriptional interference occurs stably integrated tandem HIV 1 LTR promoters
0.15876892.9469840.html.plaintext.txt	93	As shown Figure 2 RNase protection analysis transcripts derived three CI clones yields two major products 134 230 nt corresponding transcripts initiating L1 L2 promoters respectively
0.15876892.9469840.html.plaintext.txt	94	Figure 2 also shows quantitative analysis data well comparable data CI pool
0.15876892.9469840.html.plaintext.txt	95	These results demonstrate relatively small change L1 L2 promoter activity following trans activation Tat presumably due already high basal levels
0.15876892.9469840.html.plaintext.txt	96	Using SV40 RNA internal standard responsive Tat direct assessment change LTR promoter activity induced conditions determined
0.15876892.9469840.html.plaintext.txt	97	Under basal conditions Tat L2L1 ratio calculated 3 varying 2
0.15876892.9469840.html.plaintext.txt	98	5 three clonal pool RNAs taking number labeled residues account
0.15876892.9469840.html.plaintext.txt	99	However presence Tat activity L1 increased L2 activity actually decreased relative basal transcription conditions indicating trans activated upstream promoter may reducing transcription downstream promoter
0.15876892.9469840.html.plaintext.txt	100	The LTR fragment comprising L2 contains additional 20 bp LTR 3prime end might explain consistently higher L2 promoter activity
0.15876892.9469840.html.plaintext.txt	101	As mentioned using chromosomally integrated constructs transcription HIV 1 promoters rather high even absence Tat
0.15876892.9469840.html.plaintext.txt	102	In contrast transcription constructs lacking SV40 driven neo gene could hardly detected without Tat transient expression assays 20
0.15876892.9469840.html.plaintext.txt	103	The likely explanation difference presence SV40 regulatory region containing enhancer 380 bp SfiI PvuII shown influence expression HIV 1 human globin gene promoters 28
0.15876892.9469840.html.plaintext.txt	104	The proximity potent enhancer could affect basal transcription rates thereby leading relatively muted Tat enhancement 2728
0.15876892.9469840.html.plaintext.txt	105	However since tandem promoters differently affected Tat infer activated L1 promoter Tat reduces transcription downstream L2 promoter
0.15876892.9469840.html.plaintext.txt	106	Additional minor bands visible Figure 2 derive L1 transcripts reading L2 region construct
0.15876892.9469840.html.plaintext.txt	107	In particular L1 transcript polyadenylated downstream L2 HIV polyA site HpA Fig
0.15876892.9469840.html.plaintext.txt	108	1 giving rise 116 nt 3prime doublet
0.15876892.9469840.html.plaintext.txt	109	A small fraction transcripts read polyA site generating bands 150 248 nt
0.15876892.9469840.html.plaintext.txt	110	The 248 nt species arises read HpA L2 5prime splice site alpha globin reporter gene
0.15876892.9469840.html.plaintext.txt	111	The origin 150 nt species may derive cryptic splice site
0.15876892.9469840.html.plaintext.txt	112	Both L1 species well major 134 nt fragment increase upon trans activation
0.15876892.9469840.html.plaintext.txt	113	The constant band 200 nt change upon trans activation derives incompletely digested riboprobe
0.15876892.9469840.html.plaintext.txt	114	Overall 3prime end products transcription initiated L1 promoter clearly present much lower levels 134 nt 5prime product using probe L
0.15876892.9469840.html.plaintext.txt	115	Presumably significant fraction L1 transcripts spliced L2 region
0.15876892.9469840.html.plaintext.txt	116	Identification various minor L1 derived bands confirmed S1 nuclease mapping data shown
0.15876892.9469840.html.plaintext.txt	117	An intervening transcriptional terminator alleviates interference restores L2 promoter activity upon Tat transactivation
0.15876892.9469840.html.plaintext.txt	118	To examine role strong transcriptional termination element placed two pol II promoters chromosomal context cytoplasmic RNA extracted clones pools stably transfected CII construct analysed RNase protection Fig
0.15876892.9469840.html.plaintext.txt	119	CII contains strong synthetic polyA site SPA followed C2 transcriptional pause site 112529 two LTR promoters
0.15876892.9469840.html.plaintext.txt	120	As mentioned transcriptional termination signals previously shown relieve interference transient transfection assays 30
0.15876892.9469840.html.plaintext.txt	121	Since promoters may regulated differently part higher order chromatin wished examine role termination element LTR promoters stable integrants
0.15876892.9469840.html.plaintext.txt	122	As shown Figure 3 read transcripts detected L1 promoter suggesting 100 SPA use
0.15876892.9469840.html.plaintext.txt	123	Secondly whereas trans activaton led relative decrease L2 CI clones consistently observed increase promoters L1 L2 CII transcription enhanced Tat
0.15876892.9469840.html.plaintext.txt	124	These results suggest transcription downstream promoter upon trans activation increase preceded termination element
0.15876892.9469840.html.plaintext.txt	125	The data presented Figures 2 3 indicate interference occurs stably integrated tandem LTR promoter constructs detected upon transcriptional enhancement Tat
0.15876892.9469840.html.plaintext.txt	126	Inhibition downstream promoter overcome presence intervening termination signal
0.15876892.9469840.html.plaintext.txt	127	In vivo footprinting indicates reduced binding transcription factors occluded L2 promoter
0.15876892.9469840.html.plaintext.txt	128	Promoter occlusion incoming polymerase complex may caused impeding transcription factor access promoter alternatively actual displacement factors already bound promoter 17
0.15876892.9469840.html.plaintext.txt	129	We therefore analysed actual DNA protein interactions downstream L2 promoter vivo footprinting 31
0.15876892.9469840.html.plaintext.txt	130	It noted neither restricted access displacement factors likely nothing effect resolution vivo therefore limited
0.15876892.9469840.html.plaintext.txt	131	Footprinting carried using dimethylsulfate DMS modifying agent
0.15876892.9469840.html.plaintext.txt	132	DMS methylates freely accessible guanosine residues DNA living cells unless protected DNA bound factors
0.15876892.9469840.html.plaintext.txt	133	Cells derived lines CI CII incubated DMS 5 min qualitatively similar results obtained 2 10 min incubations genomic DNA purified cleaved piperidine analysed linker mediated PCR 6 sequencing gels
0.15876892.9469840.html.plaintext.txt	134	As control phenol extracted chromosomal DNA treated DMS vitro analysed parallel
0.15876892.9469840.html.plaintext.txt	135	DMS vivo footprinting across L2 promoter
0.15876892.9469840.html.plaintext.txt	136	Footprinting performed coding strand various clones pools
0.15876892.9469840.html.plaintext.txt	137	The promoter region 15 relative start site 1 distal NF kappaB sites shown
0.15876892.9469840.html.plaintext.txt	138	The left half figure CI shows reduced footprints across upstream elements indicated left side CI integrants
0.15876892.9469840.html.plaintext.txt	139	Lanes 1 2 DNA CI cell pool lanes 3 6 DNA two CI clones Tat Tat lane 7 vitro treated control DNA co right half showing footprints upstream elements lanes 8 9 DNA CII cell pool lanes 10 11 DNA CII clone
0.15876892.9469840.html.plaintext.txt	140	Three G residues indicated right side filled arrowheads 47 60 79 relative start site 1
0.15876892.9469840.html.plaintext.txt	141	A typical analysis shown Figure 4 panel CII represents samples CII clone pool
0.15876892.9469840.html.plaintext.txt	142	Binding sites transcription factor Sp1 clearly visible compared control co lane 7
0.15876892.9469840.html.plaintext.txt	143	As expected sites engaged protein interactions active HIV 1 promoter 32
0.15876892.9469840.html.plaintext.txt	144	In detail CII profiles compared control DNA lane 7 indicate partial protection G residues Sp1 sites 1 2 particular positions 54 55 respect transcriptional start site hypersensitive site proximal Sp1 sites 1 2 position 60 strong protections Sp1 site 3 hypersensitive site 79
0.15876892.9469840.html.plaintext.txt	145	The distal Sp1 site 3 known highest affinity Sp1 vitro 33
0.15876892.9469840.html.plaintext.txt	146	Whereas footprints clearly apparent CII clones pools significantly reduced CI clones pools lacking intervening terminator
0.15876892.9469840.html.plaintext.txt	147	The clearest differences seen distal high affinity Sp1 site 3 G residues less protected CI integrants
0.15876892.9469840.html.plaintext.txt	148	Also G residues 54 55 markedly less protected CI clones G residues SP1 site 1 also slightly less protected
0.15876892.9469840.html.plaintext.txt	149	A reduction hypersensity NF kappaB sites also noted mainly CI clones although less consistency
0.15876892.9469840.html.plaintext.txt	150	Overall results indicate protein interactions downstream promoter especially Sp1 sites CI clones reduced compared corresponding promoter preceded terminator
0.15876892.9469840.html.plaintext.txt	151	We also observed minor differences protein interactions CI clones trans activated Tat compared basal conditions
0.15876892.9469840.html.plaintext.txt	152	In particular two NF kappaB sites position 79 evident c11 c12 less hypersensitive presence Tat indicate perturbed protein interactions trans activated conditions
0.15876892.9469840.html.plaintext.txt	153	Taken together genomic footprinting data presented Figure 4 reveal reduced binding Sp1 lesser extent NF kappaB downstream promoter absence upstream terminator indicating effect interference protein interactions promoter
0.15876892.9469840.html.plaintext.txt	154	Since Sp1 activates transcription synergistically 34 proteins Sp1 NF kappaB known contact components basal transcription factor TFIID 35 displacement factors would explain reduced transcription occluded promoter
0.15876892.9469840.html.plaintext.txt	155	A factor binds C2 pause site vivo
0.15876892.9469840.html.plaintext.txt	156	The C2 pause element originates 420 bp intergenic region human complement genes C2 factor B located MHC class III region
0.15876892.9469840.html.plaintext.txt	157	A region 156 bp downstream C2 polyA site contains protein binding site towards 5prime end implicated pol II termination Fig
0.15876892.9469840.html.plaintext.txt	158	The zinc finger protein MAZ Myc associated zinc finger protein originally identified factor binds c myc P2 promoter 36 correlated termination efficiency pause sites various assays 29
0.15876892.9469840.html.plaintext.txt	159	DNase I vivo footprinting C2 pause site
0.15876892.9469840.html.plaintext.txt	160	The 5prime end C2 pause site containing MAZ binding site shown
0.15876892.9469840.html.plaintext.txt	161	All samples lanes 1 5 probed set primers
0.15876892.9469840.html.plaintext.txt	162	Lane 1 G ladder CII DNA treated DMS piperidine marker lanes 2 3 DNA CII clone Tat Tat lane 4 DNA CII pool Tat lane 5 naked DNA treated DNase I
0.15876892.9469840.html.plaintext.txt	163	The white box left hand side corresponds vitro MAZ binding site
0.15876892.9469840.html.plaintext.txt	164	Arrowheads show protected empty hypersensitive sites filled degree indicated size arrowhead
0.15876892.9469840.html.plaintext.txt	165	The diagram bottom shows position pause site MAZ binding site
0.15876892.9469840.html.plaintext.txt	166	To see whether protein binds MAZ site integrated construct vivo analysed chromatin structure region DNase I vivo footprinting
0.15876892.9469840.html.plaintext.txt	167	Footprinting carried isolated nuclei taken physiological buffer 23 partially digested DNase I 24
0.15876892.9469840.html.plaintext.txt	168	The cleavage pattern non coding strand analysed linker mediated PCR compared naked DNA partially digested vitro specific primers could designed analyse coding strand
0.15876892.9469840.html.plaintext.txt	169	Figure 5 shows hypersensitive site 5prime border protein binding site slight protection centre compare lane 2 5 strongly protected residue towards 3prime end hypersensitive site 3prime border
0.15876892.9469840.html.plaintext.txt	170	The vivo footprinting pattern agreement previous vitro footprinting data 27 bp region position protected DNase I using HeLa cell extract 29
0.15876892.9469840.html.plaintext.txt	171	The data also indicated pattern change upon Tat induction Fig
0.15876892.9469840.html.plaintext.txt	172	5 lanes 2 3 suggesting stable binding protein site basal induced conditions
0.15876892.9469840.html.plaintext.txt	173	The pattern obtained analysing DNA cell pool presence Tat lane 4
0.15876892.9469840.html.plaintext.txt	174	These results indicate protein binds C2 pause site vivo binding abolished Tat actived transcription upstream
0.15876892.9469840.html.plaintext.txt	175	It would therefore seem likely binding factor terminator sequence disrupted transcriptional interference
0.15876892.9469840.html.plaintext.txt	176	Transcriptional interference adjacent transcription units observed various systems
0.15876892.9469840.html.plaintext.txt	177	Initially experiments Escherichia coli showed transcription strong prophage lambda promoter Pl inhibits adjacent gal promoter 12
0.15876892.9469840.html.plaintext.txt	178	Interference promoters also detected plasmids transiently transfected mammalian cells 30
0.15876892.9469840.html.plaintext.txt	179	In vitro experiments pol I systems led suggestion possible mechanism phenomenon
0.15876892.9469840.html.plaintext.txt	180	Template competition experiments mouse pol I system indicated actual displacement transcription factor D incoming polymerase allowed transcription competitor templates displaced factor 17
0.15876892.9469840.html.plaintext.txt	181	A similar observation made pol I promoter lower eukaryote Acanthamoeba single initiation factor TIF Acanthamoeba analogue mouse factor D required pre initiation complex assembly polymerase recruitment promoter
0.15876892.9469840.html.plaintext.txt	182	In vitro footprinting analysis revealed displacement TIF dimeric pol I promoter construct pol I passage promoter 18
0.15876892.9469840.html.plaintext.txt	183	Earlier work emphasized role transcriptional termination elements relieve interference transcription units plasmids transiently transfected mammalian cells
0.15876892.9469840.html.plaintext.txt	184	To examine importance terminators transcription units genome used HIV 1 LTR driven reporter constructs stably integrated HeLa cells
0.15876892.9469840.html.plaintext.txt	185	Since HIV promoter trans activated Tat could directly compare individual clones basal trans activated conditions effect trans activated promoter downstream transcription unit
0.15876892.9469840.html.plaintext.txt	186	As mentioned high basic transcription rates transgenes ascribed proximity SV40 regulatory region strong enhancer
0.15876892.9469840.html.plaintext.txt	187	Therefore relative increase transcription presence Tat system drastic 27
0.15876892.9469840.html.plaintext.txt	188	Nevertheless upon trans activation transcription upstream promoter L1 increased 5 fold transcription downstream L2 promoter increased preceded terminator
0.15876892.9469840.html.plaintext.txt	189	Mapping 3prime end upstream L1 transcript revealed extension L2 promoter CI terminator cell lines whereas CII lines processed intervening terminator
0.15876892.9469840.html.plaintext.txt	190	The terminator consisting strong synthetic polyA site SPA linked C2 pause site SPAC shown prevent promoter interference MLV LTR promoter keratin 10 gene recent study 22
0.15876892.9469840.html.plaintext.txt	191	Stable cell lines transfected MLV expression vector containing whole keratin 10 gene downstream MLV promoter followed hygromycin B resistance gene selected tested keratin expression western blotting
0.15876892.9469840.html.plaintext.txt	192	No keratin 10 detected clones unless SPAC positioned MLV keratin promoters
0.15876892.9469840.html.plaintext.txt	193	Eighteen 22 hygromycin B resistant clones synthesized keratin 10 SPAC present 22
0.15876892.9469840.html.plaintext.txt	194	Since interference might caused disruption transcription factor binding promoter upstream elongation competent polymerase complex mapped DNA protein interactions L2 promoter vivo
0.15876892.9469840.html.plaintext.txt	195	Comparison occluded versus protected L2 promoter DMS vivo footprinting revealed reduced footprints occluded promoter
0.15876892.9469840.html.plaintext.txt	196	Differences protein binding pattern CI CII mainly evident across three Sp1 binding sites lesser degree tandem NF kappaB binding sites
0.15876892.9469840.html.plaintext.txt	197	Reduction Sp1 binding consistent several experiments 3 fold whereas changes NF kappaB sites varied
0.15876892.9469840.html.plaintext.txt	198	Since Sp1 activates transcription synergistically 34 partly interacting TAF 110 component basal transcription factor TFIID 37 loss Sp1 would expected result reduction transcriptional activity
0.15876892.9469840.html.plaintext.txt	199	Interestingly Sp1 sites shown effect transcriptional termination 10 whereas bound CAAT box binding protein effective termination
0.15876892.9469840.html.plaintext.txt	200	It seems possible depending nature DNA protein interaction binding factors disrupted transcription whereas others remain stably bound
0.15876892.9469840.html.plaintext.txt	201	The ability DNA bound proteins impede polymerase elongation previously demonstrated 38
0.15876892.9469840.html.plaintext.txt	202	DNase I vivo footprinting across C2 pause site terminator indicated binding factor 5prime part pause element
0.15876892.9469840.html.plaintext.txt	203	This binding pattern change Tat trans activation suggesting stable contact despite increased transcription upstream
0.15876892.9469840.html.plaintext.txt	204	This region pause site particular sequence G5AG5 shown bind zinc finger protein MAZ vitro implicated termination various assays
0.15876892.9469840.html.plaintext.txt	205	Insertion C2 pause site two polyA sites greatly increased use weak upstream site probably pausing polymerase
0.15876892.9469840.html.plaintext.txt	206	Binding factor pause site might necessary halt polymerase Fig
0.15876892.9469840.html.plaintext.txt	207	The role MAZ termination process currently investigated vitro
0.15876892.9469840.html.plaintext.txt	208	Model interference stably integrated HIV 1 promoters
0.15876892.9469840.html.plaintext.txt	209	Shown L2 promoter regions CI CII constructs
0.15876892.9469840.html.plaintext.txt	210	Sp1 transcription factors filled grey circles displaced incoming polymerase pol II CI
0.15876892.9469840.html.plaintext.txt	211	In CII polymerase stalled terminator possibly MAZ black oval bound pause site terminator allowing stable binding Sp1 downstream promoter
0.15876892.9469840.html.plaintext.txt	212	Our data suggest transcriptional termination elements play important role regulation gene expression allow individual expression adjacent transcription units
0.15876892.9469840.html.plaintext.txt	213	The absence terminator lead reduction impairment adjacent gene expression probably resulting disruption DNA bound regulatory proteins processive polymerase complex
0.15876892.9469840.html.plaintext.txt	214	We currently testing model transcriptional interference Fig
0.15876892.9469840.html.plaintext.txt	215	6 yeast transcription units densely packed therefore efficient transcriptional termination significance
0.15876892.9469840.html.plaintext.txt	216	Murphy critical reading manuscript S
0.15876892.9469840.html.plaintext.txt	217	Grange providing us DNase I footprinting protocol
0.15876892.9469840.html.plaintext.txt	218	supported Oesterreichisches Bundesministerium fuer Wissenschaft und Forschung
0.15876892.9469840.html.plaintext.txt	219	This work supported Wellcome Trust Programme Grant
0.15876892.9469840.html.plaintext.txt	220	1992 New Biologist 4 369 381
0.15876892.9469840.html.plaintext.txt	221	To correspondence addressed
0.15876892.9469840.html.plaintext.txt	222	Tel 44 1865 275566 Fax 44 1865 275556 Email nicholas
0.15876892.9469840.html.plaintext.txt	223	uk This page run Oxford University Press Great Clarendon Street Oxford OX2 6DP part OUP Journals Comments feedback www adminatoup
0.15876892.9469840.html.plaintext.txt	224	uk u d Last modification 19 Feb 1998 Copyright Oxford University Press 1998
0.19470528.10777613.html.plaintext.txt	0	An NF Y Binding Site Is Important Basal Not Gonadotropin releasing Hormone stimulated Expression Luteinizing Hormone Subunit Gene Ruth A
0.19470528.10777613.html.plaintext.txt	1	Bachmann Alireza Behrooz Brian D
0.19470528.10777613.html.plaintext.txt	2	From Department Pharmacology Case Western Reserve University Cleveland Ohio 44106
0.19470528.10777613.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.19470528.10777613.html.plaintext.txt	4	Regulated synthesis luteinizing hormone LH requires coordinated transcriptional control LH subunits pituitary gonadotropes
0.19470528.10777613.html.plaintext.txt	5	Several cis acting elements trans acting factors defined control LH promoter heterologous cell culture models
0.19470528.10777613.html.plaintext.txt	6	In report describe identification bipartite NF Y CBFCP1 binding sites within proximal bovine LH promoter
0.19470528.10777613.html.plaintext.txt	7	When multimerized one sites activates heterologous minimal HSV thymidine kinase promoter gonadotrope derived cell line T3 1
0.19470528.10777613.html.plaintext.txt	8	The functional role promoter distal site regulating full length bovine LH promoter assessed vivo using transgenic mice harboring mutant promoter linked chloramphenicol acetyltransferase reporter gene
0.19470528.10777613.html.plaintext.txt	9	While element important conferring high level activity LH promoter pituitary appear essential mediating gonadotropin releasing hormone GnRH regulation
0.19470528.10777613.html.plaintext.txt	10	This first characterization cis acting element within GnRH dependent promoter restricted regulating basal expression GnRH induced activity
0.19470528.10777613.html.plaintext.txt	11	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.19470528.10777613.html.plaintext.txt	12	Stimulation gametogenesis synthesis sex steroids luteinizing hormone LH1 essential reproduction mammalian species
0.19470528.10777613.html.plaintext.txt	13	Thus understanding regulated synthesis secretion hormone gonadotropes pituitary paramount understanding reproductive process
0.19470528.10777613.html.plaintext.txt	14	LH member glycoprotein hormone family whose members composed shared subunit combines unique hormone defining subunits
0.19470528.10777613.html.plaintext.txt	15	Synthesis secretion LH requires coordinated gonadotrope specific expression genes encoding LH subunits 1
0.19470528.10777613.html.plaintext.txt	16	Gonadotrope specific expression subunit gene requires number cis acting elements located within promoter proximal 400 bp 5 flanking region gene 2 7
0.19470528.10777613.html.plaintext.txt	17	Discernment essential cis acting elements involved expression LH subunit lagged behind made subunit due lack readily accessible appropriate model systems
0.19470528.10777613.html.plaintext.txt	18	Five models used uncover regulatory elements within LH promoter
0.19470528.10777613.html.plaintext.txt	19	These include cell lines corresponding kidney fibroblasts CV 1 8 9 modified somatotropes GGH3 1 10 11 primordial gonadotropes T3 1 12 14 differentiated gonadotropes LT2 15 16 well transgenic mice 17 21
0.19470528.10777613.html.plaintext.txt	20	Using approaches four transcription factors identified regulate expression LH subunit gene direct binding promoter see Fig
0.19470528.10777613.html.plaintext.txt	21	These include orphan nuclear receptor SF 1 8 15 21 early growth response protein Egr 1 22 23 bicoid related homeodomain protein Pitx1 9 ubiquitous transcription factor Sp1 11
0.19470528.10777613.html.plaintext.txt	22	There two Egr 1 SF 1 binding sites exist pairwise conformation interrupted Pitx1 binding site within promoter proximal 150 bp 24
0.19470528.10777613.html.plaintext.txt	23	This configuration conserved across many mammalian LH promoters
0.19470528.10777613.html.plaintext.txt	24	Numerous recent studies shown SF 1 Egr 1 functionally cooperate activate transcription 16 24 25 LH subunit gene
0.19470528.10777613.html.plaintext.txt	25	In addition Pitx1 potentiates activation mediated two proteins however appear require direct binding Pitx1 DNA 25
0.19470528.10777613.html.plaintext.txt	26	Rather Pitx1 interact directly SF 1 Egr 1 induce expression 25
0.19470528.10777613.html.plaintext.txt	27	Sp1 regulates rat LH promoter binding two elements reside upstream promoter 451428 411386 11
0.19470528.10777613.html.plaintext.txt	28	This region less conserved across species promoter proximal sequences importance species remains determined
0.19470528.10777613.html.plaintext.txt	29	The relative importance Egr 1 SF 1 Pitx1 regulating LH gene expression confirmed targeted disruption gene mice
0.19470528.10777613.html.plaintext.txt	30	Mice deficient Egr 1 exhibit specific loss LH gene expression follicle stimulating hormone genes remain functional 22 23
0.19470528.10777613.html.plaintext.txt	31	This suggests Egr 1 selective transcriptional regulator LH gene may mediate differential regulation LH follicle stimulating hormone within cell
0.19470528.10777613.html.plaintext.txt	32	In contrast mice deficient SF 1 reduced gonadotrope population accompanied attenuated expression three gonadotropin genes 26
0.19470528.10777613.html.plaintext.txt	33	Whether due solely defect within gonadotrope 21 additional impact hypothalamus 27 remains determined
0.19470528.10777613.html.plaintext.txt	34	Targeted disruption Pitx1 gene leads gross defects limb development 28 29 well multiple pituitary effects 28
0.19470528.10777613.html.plaintext.txt	35	Although gonadotrope number expression gonadotropin genes significantly reduced animals ablation either 28
0.19470528.10777613.html.plaintext.txt	36	Thus Pitx1 important LH gene expression gonadotrope development appear essential
0.19470528.10777613.html.plaintext.txt	37	While earlier work focused evaluating basal expression LH subunit gene rapidly evolved analyses effects gonadotropin releasing hormone GnRH
0.19470528.10777613.html.plaintext.txt	38	This reflects exquisite dependence transcriptional activity LH gene pulsatile release GnRH hypothalamus exemplified hpghpg mouse 30 harbors spontaneous deletion gene 31
0.19470528.10777613.html.plaintext.txt	39	Mice harboring mutation express LH subunit gene 5 10 normal levels 32 suggesting basal activity gene requires activation GnRH induced signaling cascades
0.19470528.10777613.html.plaintext.txt	40	Indeed factors described date important LH gene expression also contribute GnRH induction 11 13 14 16 21 24 25
0.19470528.10777613.html.plaintext.txt	41	In current manuscript report identification additional pairwise cis acting element binds NF Y CBFCP1
0.19470528.10777613.html.plaintext.txt	42	In contrast previously described cis acting elements cognate factors characterized gene sites first described solely affect basal expression gene
0.19470528.10777613.html.plaintext.txt	43	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.19470528.10777613.html.plaintext.txt	44	Materials Radiolabeled nucleotides chloramphenicol obtained NEN Life Science Products
0.19470528.10777613.html.plaintext.txt	45	Acetyl coenzyme A GnRH antagonist antide Sigma
0.19470528.10777613.html.plaintext.txt	46	DNA modifying enzymes either Roche Molecular Biochemicals Life Technologies Inc
0.19470528.10777613.html.plaintext.txt	47	0 Amersham Pharmacia Biotech
0.19470528.10777613.html.plaintext.txt	48	PolydI dC purchased Roche Molecular Biochemicals
0.19470528.10777613.html.plaintext.txt	49	Sp1 antibody obtained Santa Cruz Biotechnology Inc
0.19470528.10777613.html.plaintext.txt	50	NF Y A subunit specific antibody Rockland Immunochemicals
0.19470528.10777613.html.plaintext.txt	51	Plasmid Constructs The HSVtk luc vector constructed inserting XhoISalI fragment containing HSVtk minimal promoter 1055 BLCAT2 33 XhoI site pGL2 Basic Promega
0.19470528.10777613.html.plaintext.txt	52	Kinased double stranded oligodeoxynucleotides corresponding L1 L2 see ligated SacI site 5 thymidine kinase promoter
0.19470528.10777613.html.plaintext.txt	53	The number orientation elements determined dideoxynucleotide sequencing
0.19470528.10777613.html.plaintext.txt	54	A transversion mutation L1 site within context full length 77610bLH promoter accomplished using oligodeoxynucleotide replacement approach previously described 77610bLHCAT vector 18
0.19470528.10777613.html.plaintext.txt	55	Oligodeoxynucleotides corresponding region mutated 5 CCGGGAACCGACAACGATTCCCCGGTTCAGAGGGGCGGTGCTGCA 3 5 GCACCGCCCCTCTGAACCGGGGAATCGTTGTCGGTTCCCGG 3 mutant sequence indicated boldface letters
0.19470528.10777613.html.plaintext.txt	56	The annealed oligodeoxynucleotide 5 blunt end 3 PstI overhang
0.19470528.10777613.html.plaintext.txt	57	The annealed double stranded oligodeoxynucleotide inserted PstI sites 397 355 relative start site transcription flank L1 consensus site
0.19470528.10777613.html.plaintext.txt	58	This required conversion 5 PstI site blunt end prior ligation mutant oligonucleotide
0.19470528.10777613.html.plaintext.txt	59	The composition resultant clone confirmed sequencing region containing mutation restriction digests confirming remainder expression cassette
0.19470528.10777613.html.plaintext.txt	60	Isolation transgene accomplished restriction digestion SalI BamHI
0.19470528.10777613.html.plaintext.txt	61	Cell CultureTransient Transfections Transient transfection assays T3 1 MCF 7 cells performed essentially described 7 using 1
0.19470528.10777613.html.plaintext.txt	62	42 microg RSV gal per 35 mm2 well containing 110000 170000 cells
0.19470528.10777613.html.plaintext.txt	63	Cells harvested 48 h post transfection 150 microl reporter lysis buffer Promega
0.19470528.10777613.html.plaintext.txt	64	Luciferase galactosidase assays performed previously reported 7
0.19470528.10777613.html.plaintext.txt	65	Electrophoretic Mobility Shift Assays EMSAs Nuclear extracts T3 1 MCF 7 BeWo cells prepared described previously 7
0.19470528.10777613.html.plaintext.txt	66	EMSAs performed essentially described 21 except 5 10 microg nuclear protein
0.19470528.10777613.html.plaintext.txt	67	The following oligodeoxynucleotides used lowercase type indicates SacI sites added cloning purposes L1 5 cTGCAGCCAATCACCATCGGAAAATTGagct 3 L1 5 CAATTTTCCGATGGTGATTGGCTGCAgagct 3 L1 micro610 5 cTGCAGTCAACACCATCGGAAAATTGagct 3 L1 micro610 5 CAATTTTCCGATGGTGTTGACTGCAgagct 3 L110 micro18 5 cTGCAGCCAACACCATCTGAAAATTGagct 3 L110 micro18 5 CAATTTTCAGATGGTGTTGGCTGCAgagct 3 L1 micro1825 5 cTGCAGCCAATCACCATCTGAAAATGGagct 3 L1 micro1825 5 CCATTTTCAGATGGTGATTGGCTGCAgagct 3 L1 micro6 5 cTGCAGTCAATCACCATCGGAAAATTGagct 3 L1 micro6 5 CAATTTTCGATGGTGATTGACTGCAgagct 3 L2 5 cTGTGAAGTCACCTTCTCCTGGGTGagct 3 L2 5 CACCCAAGGAGAAGGTGACTTCACAgagct 3 B1 5 CTGCAGTCAACACCATCTGAAAATGGA 3 B1 5 CCATTTTCAGATGGTGTTGACTGCAGA 3 Sp1 consensus oligodeoxynucleotide obtained Promega Corp
0.19470528.10777613.html.plaintext.txt	68	Double stranded oligodeoxynucleotides end labeled 32PATP using polynucleotide kinase
0.19470528.10777613.html.plaintext.txt	69	For antibody supershift experiments binding reactions performed 5 10 microg T3 1 nuclear extract 1 microg polydI dC 10 mM Tris HCl pH 7
0.19470528.10777613.html.plaintext.txt	70	5 mM dithiothreitol 4 glycerol total volume 15 microl
0.19470528.10777613.html.plaintext.txt	71	After 30 min incubation ice 5 x 104 cpm labeled probe added additional 30 min incubation ice
0.19470528.10777613.html.plaintext.txt	72	For reactions containing antibody 1 microl anti Sp1 anti NF Y added initial 30 min incubation
0.19470528.10777613.html.plaintext.txt	73	Transgenic Mice All mice housed microisolator plus units pathogen free conditions
0.19470528.10777613.html.plaintext.txt	74	Food water given ad libitum animals subjected 12 h lightdark cycle
0.19470528.10777613.html.plaintext.txt	75	Mice harboring 77610bLHCAT construct previously described 18
0.19470528.10777613.html.plaintext.txt	76	For work regenerated transgenic strain utilize mice generations founder animals possible direct comparison mice harboring microL1 construct
0.19470528.10777613.html.plaintext.txt	77	To generate mice 77610 microL1bLHCAT construct 2
0.19470528.10777613.html.plaintext.txt	78	4 kilobase pair expression cassette liberated SalI plus BamHI
0.19470528.10777613.html.plaintext.txt	79	Transgenic mouse production identification characterization tissue specific expression done reported 18
0.19470528.10777613.html.plaintext.txt	80	Chloramphenicol acetyltransferase CAT assays performed described 18 10 25 microg cellular lysate 1 4 h
0.19470528.10777613.html.plaintext.txt	81	Each assay contained control tissues mice containing wild type promoter
0.19470528.10777613.html.plaintext.txt	82	The amount lysate used CAT assay identical sample within assay
0.19470528.10777613.html.plaintext.txt	83	The ovariectomyantide treatment paradigm performed follows
0.19470528.10777613.html.plaintext.txt	84	Female mice harboring either wild type mutant promoter ovariectomized avertin anesthesia
0.19470528.10777613.html.plaintext.txt	85	Following surgery randomized mice separated two groups receiving vehicle 20 propylene glycol saline injections receiving antide injections
0.19470528.10777613.html.plaintext.txt	86	60 microg antide given subcutaneous injection every 48 h 10 days
0.19470528.10777613.html.plaintext.txt	87	On day 10 mice killed asphyxiation CO2 chamber cardiac blood pituitaries livers collected
0.19470528.10777613.html.plaintext.txt	88	All animals used adults age matched within 1 month within individual experiments
0.19470528.10777613.html.plaintext.txt	89	All animal studies approved Case Western Reserve University Institutional Animal Care Use Committee
0.19470528.10777613.html.plaintext.txt	90	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.19470528.10777613.html.plaintext.txt	91	Alignment Bovine LH Promoters Reveals Three Conserved Regions Production LH requires coordinated expression LH genes
0.19470528.10777613.html.plaintext.txt	92	These genes must expressed concurrently temporal spatial pattern form intact heterodimer
0.19470528.10777613.html.plaintext.txt	93	In addition regulation expression GnRH gonadal steroids may involve similar mechanisms two genes
0.19470528.10777613.html.plaintext.txt	94	Thus speculated specific cis acting elements may shared two gonadotropin subunit genes means confer similar signals regulated expression
0.19470528.10777613.html.plaintext.txt	95	To begin identify targets functional analysis LH promoter transgenic animals examined bovine gonadotropin promoters regions apparent conservation
0.19470528.10777613.html.plaintext.txt	96	Three regions greater 80 homology identified Fig
0.19470528.10777613.html.plaintext.txt	97	One GSE previously shown important activity 5 LH 8 21 genes
0.19470528.10777613.html.plaintext.txt	98	The two elements located positions 399372 element L1 228204 element L2 relative start site transcription bovine LH gene subject analyses determine role activating LH promoter
0.19470528.10777613.html.plaintext.txt	99	A diagrammatic sketch positions elements well others identified bovine rat genes shown Fig
0.19470528.10777613.html.plaintext.txt	100	View larger version 30K Fig
0.19470528.10777613.html.plaintext.txt	101	Alignment bovine LH promoters reveals three conserved regions
0.19470528.10777613.html.plaintext.txt	102	A schematic diagram bovine LH promoter position L1 L2 shown
0.19470528.10777613.html.plaintext.txt	103	Binding sites SF 1 GSE Egr 1 Pitx1 indicated
0.19470528.10777613.html.plaintext.txt	104	The positions Sp1 binding sites present within rat LH promoter also shown
0.19470528.10777613.html.plaintext.txt	105	L4 harbors sequence binds protein L1
0.19470528.10777613.html.plaintext.txt	106	The Sp1 site 5 L1 site outlined gray reflect lack Sp1 consensus site bovine promoter
0.19470528.10777613.html.plaintext.txt	107	B bovine LH subunits scanned regions conservation two promoters
0.19470528.10777613.html.plaintext.txt	108	The sequences three conserved elements indicated
0.19470528.10777613.html.plaintext.txt	109	The GSE previously described 5 8 21
0.19470528.10777613.html.plaintext.txt	110	Element 1 element 2 designated L1 L2 referring elements within LH promoter
0.19470528.10777613.html.plaintext.txt	111	L1 Not L2 Stimulates Transcriptional Activity Minimal Thymidine Kinase Promoter In absence GnRH bovine LH promoter low activity transiently transfected cells 18 precludes functional analyses L1 L2 elements context full length promoter
0.19470528.10777613.html.plaintext.txt	112	Therefore functional activity initially assessed determining whether multimerized L1 L2 elements could stimulate expression HSVtk minimal promoter linked luciferase
0.19470528.10777613.html.plaintext.txt	113	The resulting constructs transiently transfected T3 1 cells
0.19470528.10777613.html.plaintext.txt	114	2 L1 element capable activating HSVtk promoter 2 3 fold inverted repeats sequence resulting greatest induction
0.19470528.10777613.html.plaintext.txt	115	In contrast L2 incapable activating heterologous promoter
0.19470528.10777613.html.plaintext.txt	116	Similar results obtained breast cancer cell line MCF 7 data shown
0.19470528.10777613.html.plaintext.txt	117	The ability L1 function independently cell lineage suggested might bind factor gonadotrope specific
0.19470528.10777613.html.plaintext.txt	118	View larger version 42K Fig
0.19470528.10777613.html.plaintext.txt	119	L1 L2 stimulates transcriptional activity minimal thymidine kinase promoter
0.19470528.10777613.html.plaintext.txt	120	Oligodeoxynucleotides corresponding L1 L2 multimerized ligated upstream HSVtk minimal promoter linked luciferase
0.19470528.10777613.html.plaintext.txt	121	A shaded L1 black L2 box indicates presence orientation arrowheads element
0.19470528.10777613.html.plaintext.txt	122	T3 1 cells transiently transfected construct
0.19470528.10777613.html.plaintext.txt	123	Values expressed relative HSVtk luc activity represent mean plus minus S
0.19470528.10777613.html.plaintext.txt	124	three independent experiments three replicates
0.19470528.10777613.html.plaintext.txt	125	L1 Not L2 Binds Nuclear Factor That Is Common Variety Cell Lines To determine L1 L2 elements bind nuclear proteins EMSAs performed T3 1 nuclear extracts
0.19470528.10777613.html.plaintext.txt	126	This assay revealed L1 could bind single complex high specificity affinity Fig
0.19470528.10777613.html.plaintext.txt	127	While 50 100 fold molar excess homologous competitor necessary eliminate binding factor probe 100 fold molar excess heterologous competitor LH GSE 21 impact protein binding
0.19470528.10777613.html.plaintext.txt	128	A monophasic Scatchard analysis revealed high affinity interaction nuclear protein L1 site KD 1
0.19470528.10777613.html.plaintext.txt	129	2 x 1010 M data shown well within known range eukaryotic transcription factors bind DNA 34
0.19470528.10777613.html.plaintext.txt	130	In contrast L1 incubation L2 probe T3 1 nuclear extract failed reveal high affinity complexes Fig
0.19470528.10777613.html.plaintext.txt	131	This supports data obtained transient transfection studies suggests L2 nonfunctional cells
0.19470528.10777613.html.plaintext.txt	132	Given transcriptional activity protein binding function L1 chose focus characterization element
0.19470528.10777613.html.plaintext.txt	133	Whether L2 transcriptional function mature gonadotropes remains determined
0.19470528.10777613.html.plaintext.txt	134	Studies aimed addressing issue probably involve complex experimental paradigms transgenic mice preparation nuclear extracts mature gonadotrope cells
0.19470528.10777613.html.plaintext.txt	135	View larger version 57K Fig
0.19470528.10777613.html.plaintext.txt	136	L1 binds nuclear factor common variety cell lines
0.19470528.10777613.html.plaintext.txt	137	A EMSA performed either L1 L2 probes T3 1 nuclear extracts
0.19470528.10777613.html.plaintext.txt	138	A single complex observed L1 probe
0.19470528.10777613.html.plaintext.txt	139	To assess binding specificity competition analyses performed adding 10 50 100 fold molar excess unlabeled homologous L1 L2 indicated heterologous GSE 21
0.19470528.10777613.html.plaintext.txt	140	Increasing concentrations added oligodeoxynucleotides indicated triangles
0.19470528.10777613.html.plaintext.txt	141	B EMSA accomplished nuclear extracts obtained cell lines derived gonadotrope T3 1 choriocarcinoma BeWo mammary epithelium MCF 7
0.19470528.10777613.html.plaintext.txt	142	The L1 band indicated arrow
0.19470528.10777613.html.plaintext.txt	143	Competition analyses performed unlabeled homologous L1 L1 mutant harboring CT transition position 6 see Fig
0.19470528.10777613.html.plaintext.txt	144	4A L1 mutant sequence
0.19470528.10777613.html.plaintext.txt	145	To address whether L1 protein binding complex unique gonadotrope origin cell lines performed additional EMSA studies using nuclear extracts MCF 7 BeWo cells
0.19470528.10777613.html.plaintext.txt	146	Both extracts exhibited complex mobility competition profile observed T3 1 nuclear extracts Fig
0.19470528.10777613.html.plaintext.txt	147	An additional complex displaying faster migration pattern also observed heterologous extracts
0.19470528.10777613.html.plaintext.txt	148	This interaction considered nonspecific due increase intensity corresponded increasing concentrations unlabeled competitors
0.19470528.10777613.html.plaintext.txt	149	From results conclude proteins bind LB1 cell specific likely ubiquitous given distribution gonadotrope mammary choriocarcinoma derived cell lines
0.19470528.10777613.html.plaintext.txt	150	The L1 Element Contains CCAAT Motif That Is Essential Protein Binding To begin discern whether L1 element functionally conserved bovine subunit promoter performed EMSA L1 homolog designated B1
0.19470528.10777613.html.plaintext.txt	151	Interestingly although homology analysis utilized originally identify L1 B1 element bind proteins high affinity EMSA T3 1 nuclear extracts data shown
0.19470528.10777613.html.plaintext.txt	152	While function B1 element within context full length subunit promoter addressed lack protein binding gonadotrope derived cells suggests region important transcriptional function bovine subunit gene promoter
0.19470528.10777613.html.plaintext.txt	153	Only four nucleotide differences exist L1 B1 elements
0.19470528.10777613.html.plaintext.txt	154	Thus lack high affinity binding nuclear protein B1 could used rapidly discern specific nucleotides required protein binding L1
0.19470528.10777613.html.plaintext.txt	155	Mutations L1 element made mimic nucleotide differences observed B1
0.19470528.10777613.html.plaintext.txt	156	4A outlines mutant oligodeoxynucleotides utilized EMSA
0.19470528.10777613.html.plaintext.txt	157	Two nucleotide changes within CCAAT motif two additional differences external motif
0.19470528.10777613.html.plaintext.txt	158	The importance particular nucleotides protein binding addressed using pairwise mutations competition analysis EMSA utilizing wild type L1 probe
0.19470528.10777613.html.plaintext.txt	159	4B mutation nucleotides positions 6 10 within L1 eliminated ability oligonucleotide compete binding wild type L1 probe
0.19470528.10777613.html.plaintext.txt	160	Similar 610 mutation mutation nucleotides 10 18 also resulted loss L1 protein binding
0.19470528.10777613.html.plaintext.txt	161	In contrast pairwise mutation two nucleotides outside CCAAT motif positions 18 24 resulted change affinity
0.19470528.10777613.html.plaintext.txt	162	These results implicate position 10 nucleotide T CCAAT protein binding minimized likelihood binding involved specific sequences eight nucleotides downstream CCAAT motif
0.19470528.10777613.html.plaintext.txt	163	To directly assess importance C position 6 L1 additional point mutant used EMSA
0.19470528.10777613.html.plaintext.txt	164	This mutant incapable competing protein binding wild type L1 probe Fig
0.19470528.10777613.html.plaintext.txt	165	Thus initial C T CCAAT motif essential protein binding L1
0.19470528.10777613.html.plaintext.txt	166	View larger version 83K Fig
0.19470528.10777613.html.plaintext.txt	167	The L1 element contains CCAAT motif essential protein binding
0.19470528.10777613.html.plaintext.txt	168	A alignment element 1 sequences bovine B1 LH L1 promoters reveals four nucleotide differences two must dictate binding activity
0.19470528.10777613.html.plaintext.txt	169	These differences indicated boldface letters position denoted
0.19470528.10777613.html.plaintext.txt	170	B EMSA T3 1 nuclear extracts L1 probe
0.19470528.10777613.html.plaintext.txt	171	wild type added 10 50 fold molar excess
0.19470528.10777613.html.plaintext.txt	172	Unlabeled mutant L1 oligonucleotide competitors added 50 100 300 fold molar excess
0.19470528.10777613.html.plaintext.txt	173	The mutations within L1 oligodeoxynucleotides indicated position mutation
0.19470528.10777613.html.plaintext.txt	174	At positions sequence converted LH promoter sequence present within promoter
0.19470528.10777613.html.plaintext.txt	175	NF Y Is L1 binding Protein The requirement sequences corresponding CCAAT motif suggested L1 element might bind known CCAAT box binding factor
0.19470528.10777613.html.plaintext.txt	176	To begin determine nature CCAAT binding protein interacts L1 performed variety competition EMSA studies consensus oligodeoxynucleotides antisera known CCAAT box binding factors
0.19470528.10777613.html.plaintext.txt	177	Antiserum directed NF Y capable supershifting L1 protein band Fig
0.19470528.10777613.html.plaintext.txt	178	NF Y ubiquitous transcription factor binds CCAAT motifs
0.19470528.10777613.html.plaintext.txt	179	Thus protein interacts L1 either NF Y highly related protein
0.19470528.10777613.html.plaintext.txt	180	Within rat LH promoter Sp1 site resides 5 NF Y binding site shown important mediating GnRH regulation
0.19470528.10777613.html.plaintext.txt	181	No Sp1 consensus binding sequence exists bovine promoter site however determine Sp1 could also bind L1 element performed additional EMSA
0.19470528.10777613.html.plaintext.txt	182	Antiserum transcription factor Sp1 affect binding nuclear factors L1 element retard mobility complex formed oligodeoxynucleotide corresponding consensus Sp1 element Fig
0.19470528.10777613.html.plaintext.txt	183	Thus conclude NF Y Sp1 binds site bovine LH promoter
0.19470528.10777613.html.plaintext.txt	184	View larger version 63K Fig
0.19470528.10777613.html.plaintext.txt	185	NF Y L1 L4 binding protein
0.19470528.10777613.html.plaintext.txt	186	A EMSA performed T3 1 nuclear extracts either L1 L4 Sp1 labeled probes
0.19470528.10777613.html.plaintext.txt	187	Supershift assays performed antisera directed NF Y Sp1 assess nature protein complexes associated oligodeoxynucleotide probes
0.19470528.10777613.html.plaintext.txt	188	Supershifted complexes containing either NF Y Sp1 indicated arrows
0.19470528.10777613.html.plaintext.txt	189	B L1 L2 core CCAAT elements aligned NF Y consensus sequence 36
0.19470528.10777613.html.plaintext.txt	190	The L1 site harbors exact consensus sequence NF Y
0.19470528.10777613.html.plaintext.txt	191	Lowercase letters indicates mismatches consensus
0.19470528.10777613.html.plaintext.txt	192	The full sequences probes used EMSA delineated Experimental Procedures
0.19470528.10777613.html.plaintext.txt	193	The L1 Element Exists Inverted Repeat Bovine LH Promoter Subsequent analysis bovine LH promoter additional CCAAT motifs surprisingly indicated motif present region surrounding 80 bp relative start site transcription
0.19470528.10777613.html.plaintext.txt	194	5B additional imperfect motif CCTAT observed opposing orientation LH promoter positions 332 328
0.19470528.10777613.html.plaintext.txt	195	This sequence within context larger oligodeoxynucleotide designated L4 analyzed ability bind nuclear protein EMSA Fig
0.19470528.10777613.html.plaintext.txt	196	Interestingly L4 bound protein L1 shown complete cross competition antibody supershift experiments
0.19470528.10777613.html.plaintext.txt	197	However L4 bound protein significantly lower affinity
0.19470528.10777613.html.plaintext.txt	198	While 100 fold molar excess unlabeled L1 required compete binding L1 probe 500 fold molar excess unlabeled L4 required similar level competition data shown
0.19470528.10777613.html.plaintext.txt	199	It intriguing inverted orientation L4 L1 elements within LH promoter identical active multimerized L1 elements transient transfection Fig
0.19470528.10777613.html.plaintext.txt	200	Inverted repeats NF Y sites identified multiple genes suggesting sequences may cooperate lead full expression LH promoter 35
0.19470528.10777613.html.plaintext.txt	201	The L1 Element Regulates Pituitary specific Expression Bovine LH Promoter To determine functional importance L1 element context full length promoter appropriate physiological context transgenic mice made
0.19470528.10777613.html.plaintext.txt	202	These mice harbored 776 bp bovine LH promoter containing transversion mutation throughout entire 26 bp region L1 element linked CAT
0.19470528.10777613.html.plaintext.txt	203	Pituitary CAT activity mice compared observed mice harboring wild type promoter linked CAT
0.19470528.10777613.html.plaintext.txt	204	Previous studies shown full length wild type promoter highly active gonadotropes transgenic mice 18
0.19470528.10777613.html.plaintext.txt	205	In addition promoter responds appropriately GnRH gonadal steroids 18
0.19470528.10777613.html.plaintext.txt	206	Pituitary CAT activity six independent lines mice harboring mutant LH promoter compared activity observed three independent lines mice harboring wild type promoter
0.19470528.10777613.html.plaintext.txt	207	Mutation L1 element reduced activity LH promoter approximately 14 wild type promoters activity Fig
0.19470528.10777613.html.plaintext.txt	208	While reduction substantial important note L1 mutant promoter detectable activity number mice
0.19470528.10777613.html.plaintext.txt	209	In particular mutant lines 1 3 4 displayed higher activity lines mice harboring mutation
0.19470528.10777613.html.plaintext.txt	210	This suggests L1 important high level expression LH promoter integration sites permit low level expression attenuated promoter
0.19470528.10777613.html.plaintext.txt	211	Thus remaining cis acting elements must compensate degree loss distal NF Y binding site
0.19470528.10777613.html.plaintext.txt	212	View larger version 26K Fig
0.19470528.10777613.html.plaintext.txt	213	The L1 element regulates pituitary specific expression bovine LH promoter
0.19470528.10777613.html.plaintext.txt	214	Transgenic mice harboring either wild type wt gray bars L1 mutant micro black bars LH promoter linked CAT made
0.19470528.10777613.html.plaintext.txt	215	Pituitary CAT activity measured three lines mice wild type promoter six lines mice harboring mutant promoter
0.19470528.10777613.html.plaintext.txt	216	Values mean plus minus S
0.19470528.10777613.html.plaintext.txt	217	The following numbers animals used 29 wt1 44 wt2 11 wt3 12 micro1 5 micro2 8 micro3 6 micro4 1 micro5 1 micro6
0.19470528.10777613.html.plaintext.txt	218	The micro5 micro6 animals founder transgenics
0.19470528.10777613.html.plaintext.txt	219	In animals liver activity examined detection similar levels activity observed micro3 micro5 micro6 animals
0.19470528.10777613.html.plaintext.txt	220	Expression wild type transgene versus mutant transgene significantly different p 0
0.19470528.10777613.html.plaintext.txt	221	0001 two tailed Students test assuming unequal variances
0.19470528.10777613.html.plaintext.txt	222	L1 Is Unnecessary GnRH Regulation LH Promoter Numerous cis acting elements described LH promoter mediate GnRH stimulation 11 14 16 21 24 25
0.19470528.10777613.html.plaintext.txt	223	To determine role L1 element conveying GnRH regulation female transgenic mice harboring either wild type promoter L1 mutant promoter subjected ovariectomyantide treatment paradigm
0.19470528.10777613.html.plaintext.txt	224	Ovariectomy removes negative feedback ovarian steroids causes increase GnRH synthesis secretion hypothalamus results increased LH gene expression 1
0.19470528.10777613.html.plaintext.txt	225	Treatment GnRH specific antagonist antide block increase 18
0.19470528.10777613.html.plaintext.txt	226	Thus degree repression transgene activity following antide administration indicator degree promoter responsiveness GnRH
0.19470528.10777613.html.plaintext.txt	227	To assess impact L1 mutation mice ovariectomized treated either vehicle antide 10 days
0.19470528.10777613.html.plaintext.txt	228	As previously shown 18 21 antide treatment lead 38 63 reduction wild type promoter activity two independent lines mice Fig
0.19470528.10777613.html.plaintext.txt	229	Similarly antide treatment ovariectomized mice harboring L1 mutation resulted 50 reduction promoter function
0.19470528.10777613.html.plaintext.txt	230	This indicates basal function LH promoter significantly attenuated mutation L1 element element necessary mediating GnRH regulated expression
0.19470528.10777613.html.plaintext.txt	231	Whether NF Y mediate GnRH regulation intact L4 site additional uncharacterized binding sites unknown warrants study
0.19470528.10777613.html.plaintext.txt	232	View larger version 33K Fig
0.19470528.10777613.html.plaintext.txt	233	L1 unnecessary GnRH regulation LH promoter
0.19470528.10777613.html.plaintext.txt	234	Transgenic mice harboring either wild type wt mutant microL1 77610 LH promoter subjected GnRH regulation assay
0.19470528.10777613.html.plaintext.txt	235	The mutant line used study corresponds micro1 Fig
0.19470528.10777613.html.plaintext.txt	236	Mice ovariectomized treated either vehicle OVX gray bars 60 microg antide OVX antide black bars every 48 h
0.19470528.10777613.html.plaintext.txt	237	Pituitaries collected CAT enzymatic activity measured
0.19470528.10777613.html.plaintext.txt	238	Values expressed relative OVX control line mice represent mean plus minus S
0.19470528.10777613.html.plaintext.txt	239	In case antide treatment resulted CAT activity significantly different OVX animals p 0
0.19470528.10777613.html.plaintext.txt	240	05 one tailed Students test assuming unequal variances
0.19470528.10777613.html.plaintext.txt	241	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.19470528.10777613.html.plaintext.txt	242	Expression luteinizing hormone gonadotrope pituitary requires coordinated expression LH subunits
0.19470528.10777613.html.plaintext.txt	243	Both subunit genes respond GnRH sex steroids promote synthesis secretion appropriate levels intact heterodimer 1
0.19470528.10777613.html.plaintext.txt	244	Several elements defined transcriptional control LH subunit genes
0.19470528.10777613.html.plaintext.txt	245	However complete picture LH gene regulation resolved
0.19470528.10777613.html.plaintext.txt	246	This largely due lack appropriate cell culture models study expression gene
0.19470528.10777613.html.plaintext.txt	247	Using transgenic mice others shown LH promoter proximal region confers high level expression confined gonadotropes responds appropriately GnRH gonadal steroids 17 20
0.19470528.10777613.html.plaintext.txt	248	In report describe inverted repeat element binds NF Y important full activity LH promoter transgenic mice
0.19470528.10777613.html.plaintext.txt	249	In contrast elements described thus far promoter distal NF Y binding site required mediating GnRH responsiveness
0.19470528.10777613.html.plaintext.txt	250	Thus two different classes cis active elements exist LH promoter
0.19470528.10777613.html.plaintext.txt	251	These include basal GnRH responsive sites contribute transcriptional tone
0.19470528.10777613.html.plaintext.txt	252	Since expression LH gene low absence GnRH 32 called basal elements may play role amplifying signal must initiated GnRH acting promoter proximal SF 1 Pitx1 Egr 1 binding sites well potential Sp1 sites
0.19470528.10777613.html.plaintext.txt	253	NF Y ubiquitous CCAAT box binding factor composed three subunits 36
0.19470528.10777613.html.plaintext.txt	254	It regulates TATA containing TATA less promoters 35
0.19470528.10777613.html.plaintext.txt	255	Functional NF Y sites within promoters usually closely associated start site transcription occurring within promoter proximal 100 bp 36
0.19470528.10777613.html.plaintext.txt	256	However several genes contain NF Y binding sites 1 kilobase pairs 5 promoter 35
0.19470528.10777613.html.plaintext.txt	257	Both L1 L4 sites located distally typical NF Y site
0.19470528.10777613.html.plaintext.txt	258	In addition factor displays almost strict requirement pentanucleotide CCAAT motif occur either coding noncoding strand 35 36
0.19470528.10777613.html.plaintext.txt	259	While L1 harbors exact consensus NF Y L4 site CCTAT motif opposite strand L1
0.19470528.10777613.html.plaintext.txt	260	Although L4 site also binds NF Y lower affinity L1 data shown
0.19470528.10777613.html.plaintext.txt	261	The L4 motif observed cdc25 gene 37 well MHC Class II DPA gene 38
0.19470528.10777613.html.plaintext.txt	262	Interestingly sequences like L4 occurred reverse orientation coding strand
0.19470528.10777613.html.plaintext.txt	263	Unlike LH subunit gene however genes TATA less
0.19470528.10777613.html.plaintext.txt	264	There numerous examples NF Y cooperativity transcription factors 39 41
0.19470528.10777613.html.plaintext.txt	265	It particularly interesting note NF Y synergize transcription factor Sp1 39 41
0.19470528.10777613.html.plaintext.txt	266	An Sp1 site characterized within rat LH promoter immediately adjacent conserved NF Y sequence 11
0.19470528.10777613.html.plaintext.txt	267	Whether two proteins synergize activate rat promoter remains determined
0.19470528.10777613.html.plaintext.txt	268	With regard LH promoters species Sp1 sequence conserved site although adjacent NF Y sequence
0.19470528.10777613.html.plaintext.txt	269	Within bovine LH promoter shown oligodeoxynucleotide encompasses NF Y site fails bind Sp1
0.19470528.10777613.html.plaintext.txt	270	Thus transcriptional regulation occurs cis acting element cannot attributed Sp1
0.19470528.10777613.html.plaintext.txt	271	It important determine Sp1 consensus sequences located within regions promoter bind Sp1 potentially synergize NF Y binding sites activate transcription
0.19470528.10777613.html.plaintext.txt	272	Sp1 factors define transcriptional activity LH promoter largely characterized using heterologous cell culture systems
0.19470528.10777613.html.plaintext.txt	273	These include use kidney fibroblasts CV 1 8 9 22 somatotropes GH3 GGH3 1 10 11 24 immature gonadotropes T3 1 13 15
0.19470528.10777613.html.plaintext.txt	274	None cell lines express endogenous LH subunit gene probably devoid essential factors activating transcription
0.19470528.10777613.html.plaintext.txt	275	While models allowed ascertainment ability specific transcription factors induce LH promoter depended upon overexpression factors
0.19470528.10777613.html.plaintext.txt	276	Thus relative importance factors defining transcriptional tone LH promoter within mature gonadotrope unknown
0.19470528.10777613.html.plaintext.txt	277	The recently derived LT2 cell line express endogenous LH subunit gene 42 probably present ideal avenue confirm studies previously performed alternative models
0.19470528.10777613.html.plaintext.txt	278	Prior development cell line however mature gonadotrope model effectively used analyses LH promoter pituitary transgenic mice
0.19470528.10777613.html.plaintext.txt	279	Even cell line transgenic mouse presents physiologically relevant system assess important factors regulating expression LH gene
0.19470528.10777613.html.plaintext.txt	280	In regard characterized new site important basal expression gene GnRH induction
0.19470528.10777613.html.plaintext.txt	281	The function element contrasts previously defined GSE shown essential pituitary activity well GnRH activation promoter transgenic mice 21
0.19470528.10777613.html.plaintext.txt	282	While previous vivo vitro studies focused specifically promoter proximal 150 bp studies presented herein indicate additional sequences involved regulation promoter activity reside upstream region
0.19470528.10777613.html.plaintext.txt	283	Thus attempts study proximal promoter isolation probably result limited picture transcription control gene
0.19470528.10777613.html.plaintext.txt	284	We acknowledge Pharmacological Sciences Consortium Core Transgenic Facility Case Western Reserve University production transgenic mice
0.19470528.10777613.html.plaintext.txt	285	We also thank David Peck excellent technical assistance Paul MacDonald helpful discussions preparation manuscript
0.19470528.10777613.html.plaintext.txt	286	This work supported National Institutes Health Grants DK28559 J
0.19470528.10777613.html.plaintext.txt	287	Endocrine Society fellowship B
0.19470528.10777613.html.plaintext.txt	288	The costs publication article defrayed part payment page charges
0.19470528.10777613.html.plaintext.txt	289	The article must therefore hereby marked advertisement accordance 18 U
0.19470528.10777613.html.plaintext.txt	290	Section 1734 solely indicate fact
0.19470528.10777613.html.plaintext.txt	291	To correspondence addressed Dept
0.19470528.10777613.html.plaintext.txt	292	Pharmacology Case Western Reserve University School Medicine 2109 Adelbert Rd
0.19470528.10777613.html.plaintext.txt	293	216 368 4497 Fax 216 368 3395 E mail jhnpo
0.19470528.10777613.html.plaintext.txt	294	The abbreviations used LH luteinizing hormone SF 1 steroidogenic factor 1 GnRH gonadotropin releasing hormone CAT chloramphenicol acetyltransferase HSVtk herpes simplex virus thymidine kinase EMSA electrophoretic mobility shift assay GSE gonadotrope specific element bp base pairs
0.19470528.10777613.html.plaintext.txt	295	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.19470528.10777613.html.plaintext.txt	296	11 177 199Medline Order article via Infotrieve 2
0.19470528.10777613.html.plaintext.txt	297	9 5113 5122Medline Order article via Infotrieve 3
0.19470528.10777613.html.plaintext.txt	298	268 3903 3910AbstractFree Full Text 5
0.19470528.10777613.html.plaintext.txt	299	270 26497 26504AbstractFree Full Text 8
0.19470528.10777613.html.plaintext.txt	300	271 6645 6650AbstractFree Full Text 9
0.19470528.10777613.html.plaintext.txt	301	12 428 441AbstractFree Full Text 10
0.19470528.10777613.html.plaintext.txt	302	1998 Endocrinology 139 2443 2451AbstractFree Full Text 11
0.19470528.10777613.html.plaintext.txt	303	273 12943 12951AbstractFree Full Text 12
0.19470528.10777613.html.plaintext.txt	304	12 451 457AbstractFree Full Text 13
0.19470528.10777613.html.plaintext.txt	305	13 106 116AbstractFree Full Text 14
0.19470528.10777613.html.plaintext.txt	306	13 752 763AbstractFree Full Text 15
0.19470528.10777613.html.plaintext.txt	307	13 1497 1510AbstractFree Full Text 16
0.19470528.10777613.html.plaintext.txt	308	274 13870 13876AbstractFree Full Text 17
0.19470528.10777613.html.plaintext.txt	309	93 157 165CrossRefMedline Order article via Infotrieve 18
0.19470528.10777613.html.plaintext.txt	310	271 10782 10785AbstractFree Full Text 22
0.19470528.10777613.html.plaintext.txt	311	1996 Science 273 1219 1221Abstract 23
0.19470528.10777613.html.plaintext.txt	312	12 107 122AbstractFree Full Text 24
0.19470528.10777613.html.plaintext.txt	313	273 14712 14720AbstractFree Full Text 25
0.19470528.10777613.html.plaintext.txt	314	19 2567 2576AbstractFree Full Text 26
0.19470528.10777613.html.plaintext.txt	315	13 484 494AbstractFree Full Text 29
0.19470528.10777613.html.plaintext.txt	316	1999 Development 126 1805 1810AbstractFree Full Text 30
0.19470528.10777613.html.plaintext.txt	317	1977 Nature 269 338 340Medline Order article via Infotrieve 31
0.19470528.10777613.html.plaintext.txt	318	1986 Science 234 1366 1371Medline Order article via Infotrieve 32
0.19470528.10777613.html.plaintext.txt	319	268 16999 17009AbstractFree Full Text 34
0.19470528.10777613.html.plaintext.txt	320	1995 DNA Protein Structural Interactions pp
0.19470528.10777613.html.plaintext.txt	321	26 1135 1143AbstractFree Full Text 36
0.19470528.10777613.html.plaintext.txt	322	23 174 178CrossRefMedline Order article via Infotrieve 37
0.19470528.10777613.html.plaintext.txt	323	1990 Immunogenetics 32 117 128Medline Order article via Infotrieve 39
0.19470528.10777613.html.plaintext.txt	324	270 20978 20986AbstractFree Full Text 40
0.19470528.10777613.html.plaintext.txt	325	271 22271 22279AbstractFree Full Text 41
0.19470528.10777613.html.plaintext.txt	326	Acta 1352 311 324Medline Order article via Infotrieve 42
0.19470528.10777613.html.plaintext.txt	327	Copyright 2000 The American Society Biochemistry Molecular Biology Inc
0.25950646.12533712.html.plaintext.txt	0	Positively charged sequences human papillomavirus type 16 capsid proteins sufficient mediate gene transfer target cells via heparan sulfate receptor Latifa Bousarghin Antoine Touze Alba Lucia Combita Rojas Pierre Coursaget
0.25950646.12533712.html.plaintext.txt	1	Laboratoire de Virologie Moleculaire INSERM EMIU 00 10 USC INRA Faculte des Sciences Pharmaceutiques Philippe Maupas 31 avenue Monge 37200 Tours France
0.25950646.12533712.html.plaintext.txt	2	Correspondence Pierre Coursaget coursagetatuniv tours
0.25950646.12533712.html.plaintext.txt	3	ABSTRACT Top ABSTRACT Introduction Methods Results discussion REFERENCES Using synthetic peptides shown positively charged sequences present C terminus L1 protein N C termini L2 protein human papillomavirus type 16 HPV 16 bind DNA heparan sulfate receptors
0.25950646.12533712.html.plaintext.txt	4	Moreover short amino acid sequences sufficient mediate gene transfer COS 7 cells
0.25950646.12533712.html.plaintext.txt	5	The L1 proteins HPVs shown contain one two DNA heparin binding sequences capacity transfer genes
0.25950646.12533712.html.plaintext.txt	6	These DNA binding sequences also recognized enhancing packaging sequence bovine papillomavirus type 1
0.25950646.12533712.html.plaintext.txt	7	The results suggest L2 protein could participate DNA packaging maturation virions
0.25950646.12533712.html.plaintext.txt	8	Introduction Top ABSTRACT Introduction Methods Results discussion REFERENCES Papillomaviruses non enveloped DNA tumour viruses persistently infect squamous epithelia
0.25950646.12533712.html.plaintext.txt	9	Their viral capsids 50 55 nm diameter contain 72 pentamers major structural L1 protein capsomers centred vertices T7 icosahedral lattice Baker et al
0.25950646.12533712.html.plaintext.txt	10	The minor structural protein L2 present ratio 130 L1 Kirnbauer et al
0.25950646.12533712.html.plaintext.txt	11	The L1 protein self assemble virus like particles VLPs presence absence L2 protein review see Schiller Roden 1995
0.25950646.12533712.html.plaintext.txt	12	The use artificial virus vectors consisting DNA packaged vitro associated recombinant papillomavirus VLPs recently described Kawana et al
0.25950646.12533712.html.plaintext.txt	13	1998 Touze Coursaget 1998 Rossi et al
0.25950646.12533712.html.plaintext.txt	14	Papillomaviruses difficult propagate vitro thus production pseudovirions offers model study human papillomavirus HPV cell entry
0.25950646.12533712.html.plaintext.txt	15	The pseudovirions obtained ability transfer plasmid DNA cells reporter gene expressed
0.25950646.12533712.html.plaintext.txt	16	Entry artificial gene delivery vehicles cells dependent interaction VLPs cell surface
0.25950646.12533712.html.plaintext.txt	17	Two putative cell receptors identified HPVs
0.25950646.12533712.html.plaintext.txt	18	The first 6 integrin Evander et al
0.25950646.12533712.html.plaintext.txt	19	1999 second comprises cell surface glycosaminoglycans GAGs Joyce et al
0.25950646.12533712.html.plaintext.txt	20	2001 interact C terminal portion HPV L1 Joyce et al
0.25950646.12533712.html.plaintext.txt	21	Translocation L1 L2 proteins nucleus mediated nuclear localization signals NLS containing majority NLS high proportion positively charged residues K R
0.25950646.12533712.html.plaintext.txt	22	The prototype NLS SV40 large T antigen NLS KKKRK
0.25950646.12533712.html.plaintext.txt	23	One six basic amino acids aa 499 504
0.25950646.12533712.html.plaintext.txt	24	The bipartite NLS aa 484 486 499 500 Zhou et al
0.25950646.12533712.html.plaintext.txt	25	The L2 protein contains two NLS corresponding arginine lysine rich sequences located N C termini protein Sun et al
0.25950646.12533712.html.plaintext.txt	26	Two DNA binding sequences identified L1 L2 proteins HPV 16
0.25950646.12533712.html.plaintext.txt	27	The first DNA binding sequence identified N terminal end L2 Zhou et al
0.25950646.12533712.html.plaintext.txt	28	The second identified C terminus L1 protein HPV 11 HPV 16 Li et al
0.25950646.12533712.html.plaintext.txt	29	In addition nine C terminal amino acids L2 protein shown necessary infection bovine papillomavirus type 1 BPV 1 pseudovirions Roden et al
0.25950646.12533712.html.plaintext.txt	30	The DNA binding activity two domains sequence independent
0.25950646.12533712.html.plaintext.txt	31	However recently shown DNA binding BPV 1 HPV 6 HPV 16 VLPs enhanced presence 120 bp DNA sequence located BPV 1 E1 gene Zhao et al
0.25950646.12533712.html.plaintext.txt	32	We previously demonstrated HPV L1 VLPs obtained self assembly L1 protein lacking last nine C terminal amino acids lost capacity bind DNA transfer genes target cells Touze et al
0.25950646.12533712.html.plaintext.txt	33	Moreover addition sequence N terminus major capsid protein RNA virus rabbit haemorrhagic disease virus RHDV allowed production chimeric VLPs could encapsidate DNA transfer reporter genes cells El Mehdaoui et al
0.25950646.12533712.html.plaintext.txt	34	These experiments suggest central role short sequence DNA binding interacting cell surface target cells facilitating nuclear import complexes owing presence NLS
0.25950646.12533712.html.plaintext.txt	35	In order verify role positively charged sequence investigated possibility using synthetic peptide corresponding 14 C terminal amino acids HPV 16 L1 protein DNA transfection experiments
0.25950646.12533712.html.plaintext.txt	36	The study extended positively charged sequences HPV 16 L2 protein L1 protein four HPVs
0.25950646.12533712.html.plaintext.txt	37	Methods Top ABSTRACT Introduction Methods Results discussion REFERENCES Plasmids peptides VLPs
0.25950646.12533712.html.plaintext.txt	38	Three different plasmids used 7 2 kbp plasmid encoding galactosidase pCMV Ozyme 7 3 kbp plasmid pCMV PES El Medhaoui et al
0.25950646.12533712.html.plaintext.txt	39	2000 obtained insertion 120 bp BPV 1 packaging enhancing sequence PES described Zhao et al
0.25950646.12533712.html.plaintext.txt	40	1999 7 1 kbp plasmid encoding luciferase pCMV Luc Ozyme
0.25950646.12533712.html.plaintext.txt	41	The peptides synthesized Sigma Genosys Neosystem
0.25950646.12533712.html.plaintext.txt	42	HPV 16 31 VLPs expressed Sf21 cells infected recombinant baculoviruses encoding HPV 16 31 L1 open reading frames respectively purified according previously described procedures El Medhaoui et al
0.25950646.12533712.html.plaintext.txt	43	In addition HPV 16 L19 VLPs composed L1 protein lacking nine C terminal amino acids used Touze et al
0.25950646.12533712.html.plaintext.txt	44	VLPDNA peptideDNA complex formation
0.25950646.12533712.html.plaintext.txt	45	VLPDNA complexes obtained according previously described method Combita et al
0.25950646.12533712.html.plaintext.txt	46	Ten microg VLPs 1 microg DNA mixed 40 microl 50 mM NaCl pH 5 incubated 30 min room temperature transfection
0.25950646.12533712.html.plaintext.txt	47	PeptideDNA complexes obtained according method
0.25950646.12533712.html.plaintext.txt	48	One microg plasmid DNA amount peptide corresponding DNA peptide charge ratio 110 mixed 40 microl 50 mM NaCl pH 5 incubated 30 min room temperature
0.25950646.12533712.html.plaintext.txt	49	This charge ratio corresponded peptideDNA mass ratios ranging 8 6 15 6 L1 peptides except peptide HPV 16 L1 Cta peptideDNA mass ratio 20 6 2 6 4 L2 peptides SV40 large T NLS 17 4 100 peptides
0.25950646.12533712.html.plaintext.txt	50	Charge ratios take account histidines since DNApeptide complexes obtained pH 5
0.25950646.12533712.html.plaintext.txt	51	DNA retardation assay protection DNA DNase
0.25950646.12533712.html.plaintext.txt	52	DNA binding investigated agarose gel retardation assays
0.25950646.12533712.html.plaintext.txt	53	One microg plasmid incubated 30 min 25 degrees C 50 mM NaCl pH 5 amount peptide corresponding DNApeptide charge ratios ranging 11 110
0.25950646.12533712.html.plaintext.txt	54	Complexes electrophoresed 1 agarose gel 1xTAE buffer
0.25950646.12533712.html.plaintext.txt	55	To evaluate amount protected plasmid DNA complexes treated Benzonase Merck previously described Touze Coursaget 1998 El Mehdaoui et al
0.25950646.12533712.html.plaintext.txt	56	The amount DNA quantified using Molecular Analyst Software Bio Rad results expressed percentage Benzonase protected DNA
0.25950646.12533712.html.plaintext.txt	57	Detection DNA binding ELISA
0.25950646.12533712.html.plaintext.txt	58	The DNA binding activity peptides detected ELISA previously described Touze et al
0.25950646.12533712.html.plaintext.txt	59	2000 modifications
0.25950646.12533712.html.plaintext.txt	60	The digoxigenin labelled PES probe 120 bp obtained PCR amplification PES sequence plasmid pBPV CMV El Mehdaoui et al
0.25950646.12533712.html.plaintext.txt	61	2000 presence digoxigenin labelled dUTP Roche Diagnostics
0.25950646.12533712.html.plaintext.txt	62	PCR performed using following oligonucleotide primers upper 5 CCGGAATTCAAGCTTATGCAAAAAAGATCTCATGAAGGAGGA 3 lower 5 CCGGAATTCCTCTTCTCTTACATTTAGCGTGTTTGC 3
0.25950646.12533712.html.plaintext.txt	63	A PES negative DNA probe obtained PCR amplification 290 bp fragment corresponding cDNA E1E4 HPV 16 mRNA presence digoxigenin dUTP using following primers upper 5 CTTAAGATGGCTGATCCTGCATATTATGTCCTACATCTGTG 3 lower 5 CTTAAGTGGGTGTAGTGTTACTATTACAGTTAATCC 3
0.25950646.12533712.html.plaintext.txt	64	A 96 well plate Maxisorp Nunc seeded 1 microg peptide per well diluted PBS pH 7 6 incubated overnight 4 degrees C
0.25950646.12533712.html.plaintext.txt	65	BSA used negative control
0.25950646.12533712.html.plaintext.txt	66	After blocking step 5 BSA PBS 1 5 h 37 degrees C equimolar amounts digoxigenin labelled DNA probes 0 5 ng PES probe 0 2 ng PESprobe diluted PBS added
0.25950646.12533712.html.plaintext.txt	67	After 1 h incubation room temperature four washes bound DNA revealed anti digoxigenin antibodies covalently linked horseradish peroxidase Roche Diagnostics diluted 1 1000 PBS
0.25950646.12533712.html.plaintext.txt	68	After 1 h 37 degrees C four washes bound antibodies revealed using 22 azino bis3 ethylbenzthiazoline sulfonic acid H2O2
0.25950646.12533712.html.plaintext.txt	69	Absorbance read 405 nm results shown means four determinations
0.25950646.12533712.html.plaintext.txt	70	COS 7 cells grown monolayers Dulbeccos Minimal Essential Medium D MEMGlutamax Invitrogen supplemented 10 foetal calf serum FCS 100 IU penicillin ml 1 100 microg streptomycin ml 1 seeded 96 well plates Nunc
0.25950646.12533712.html.plaintext.txt	71	After washing serum free medium pCMV Lucpeptides pCMV LucVLP complexes diluted 50 microl culture medium added well
0.25950646.12533712.html.plaintext.txt	72	After 1 h incubation 37 degrees C complexes removed 50 microl D MEMGlutamax supplemented 10 FCS added
0.25950646.12533712.html.plaintext.txt	73	Cells incubated 48 h 37 degrees C
0.25950646.12533712.html.plaintext.txt	74	Luciferase gene expression measured luminescence assay luciferase reporter gene assay constant light signal Roche Molecular Biochemical
0.25950646.12533712.html.plaintext.txt	75	The luminescence integrated 10 Victor2 Wallac Perkin Elmer results expressed counts per second c
0.25950646.12533712.html.plaintext.txt	76	At time well contained approximately 6x104 cells
0.25950646.12533712.html.plaintext.txt	77	For experiments using pCMV peptide complexes situ galactosidase activity determined according previously described procedure Muller et al
0.25950646.12533712.html.plaintext.txt	78	To evaluate effects GAGs transfection L1 L2 peptides peptideDNA complexes 5 microg heparin ml 1 added simultaneously cells according protocol described Mislick Baldeschweiler 1996
0.25950646.12533712.html.plaintext.txt	79	After 48 h incubation 37 degrees C luciferase gene expression measured results expressed percentages inhibition gene transfer compared gene transfer peptideDNA complexes alone
0.25950646.12533712.html.plaintext.txt	80	The role GAGs also investigated desulfation cells
0.25950646.12533712.html.plaintext.txt	81	COS 7 cells seeded 96 well plates medium supplemented 50 mM sodium chlorate 12 h incubation 37 degrees C
0.25950646.12533712.html.plaintext.txt	82	After additional 48 h incubation period cells washed twice 200 microl PBS 200 microl D MEMGlutamax medium added
0.25950646.12533712.html.plaintext.txt	83	PeptideDNA complexes added cells luciferase gene expression measured 48 h incubation 37 degrees C
0.25950646.12533712.html.plaintext.txt	84	Results expressed percentage inhibition gene transfer compared gene transfer obtained untreated cells
0.25950646.12533712.html.plaintext.txt	85	The interaction peptides heparin tested using competition assay derived heparin binding assays described Giroglou et al
0.25950646.12533712.html.plaintext.txt	86	Microtitre plates Maxisorp Nunc coated 20 ng per well either heparin BSA Sigma BSA
0.25950646.12533712.html.plaintext.txt	87	The plates incubated 4 degrees C overnight
0.25950646.12533712.html.plaintext.txt	88	After four washings PBS containing 0 1 Tween 20 non specific binding sites blocked incubation 1 h 37 degrees C PBS plus 1 FCS
0.25950646.12533712.html.plaintext.txt	89	After washing 200 ng peptides BSA diluted PBS per well added
0.25950646.12533712.html.plaintext.txt	90	Following incubation 37 degrees C 60 min four washes HPV 31 VLPs 200 ng per well PBS added incubated 37 degrees C 60 min
0.25950646.12533712.html.plaintext.txt	91	After washing mouse anti HPV 31 VLP antibodies diluted 1 1000 PBS 0 1 Tween 20 10 FCS added incubated 45 degrees C 60 min
0.25950646.12533712.html.plaintext.txt	92	Bound antibodies detected mouse anti IgG antibodies covalently linked horseradish peroxidase
0.25950646.12533712.html.plaintext.txt	93	After 1 h incubation 45 degrees C four washings 100 microl substrate solution containing o phenylene diamine H2O2 added
0.25950646.12533712.html.plaintext.txt	94	The reaction stopped 30 min addition 100 microl 2 M H2SO4 absorbance read 492 nm automated plate reader
0.25950646.12533712.html.plaintext.txt	95	The absorbance control well subtracted values test wells
0.25950646.12533712.html.plaintext.txt	96	Results expressed percentage reduction HPV 31 VLP binding heparin
0.25950646.12533712.html.plaintext.txt	97	Results discussion Top ABSTRACT Introduction Methods Results discussion REFERENCES DNA binding gene transfer HPV 16 C terminal synthetic peptide HPV 16 L1 Ctb synthetic peptide SSTSTTAKRKKRKL nt 492 505 mixed pCMV DNA 7 2 kbp DNApeptide interaction measured determining amount peptide required retard migration plasmid DNA agarose gel electrophoresis
0.25950646.12533712.html.plaintext.txt	98	1A electrophoretic mobility DNA reduced charge ratios 13 15 completely abolished charge ratio 110
0.25950646.12533712.html.plaintext.txt	99	Retardation observed using positively charged SV40 large T NLS peptide PPKKKRKVA charge ratios
0.25950646.12533712.html.plaintext.txt	100	We hypothesized formation complexes might prevent DNA degradation nuclease
0.25950646.12533712.html.plaintext.txt	101	L1 peptidepCMV DNA complexes therefore treated 1 h 37 degrees C Benzonase
0.25950646.12533712.html.plaintext.txt	102	Two antigenic peptides HPV 16 E4 Ag KPSPWAPKKHRRLS HPV 16 L1 Ag cVGENVPDDLYIKGSG charge ratio 110 corresponding mass ratio DNApeptide 1100 SV40 large T NLS peptide used control peptides varying proportions positively charged amino acids
0.25950646.12533712.html.plaintext.txt	103	Seventy two per cent DNA protection observed HPV 16 L1 Ctb peptide Fig
0.25950646.12533712.html.plaintext.txt	104	2 compared 55 HPV 16 VLPs
0.25950646.12533712.html.plaintext.txt	105	No protection observed HPV 16 E4 Ag peptide Fig
0.25950646.12533712.html.plaintext.txt	106	2 lane 6 23 SV40 large T NLS peptide shown
0.25950646.12533712.html.plaintext.txt	107	The ability HPV 16 L1 Ctb peptide deliver DNA cells investigated galactosidase reporter plasmid COS 7 cells Fig
0.25950646.12533712.html.plaintext.txt	108	Transfections performed 1 microg DNA per well
0.25950646.12533712.html.plaintext.txt	109	The highest level galactosidase expression observed DNApeptide charge ratio 110
0.25950646.12533712.html.plaintext.txt	110	This peptide one examples natural peptide capable interacting plasmid DNA carrying across cellular barriers observed HIV 1 VpR C terminal sequence Kichler et al
0.25950646.12533712.html.plaintext.txt	111	Moreover pre incubation COS 7 cells HPV 16 L1 Ctb peptide induced 60 inhibition gene transfer obtained HPV 31 pseudovirions compared absence inhibition 0 observed pre incubation SV40 large T NLS peptide
0.25950646.12533712.html.plaintext.txt	112	This result suggests peptide binds HPV 31 cell surface receptor
0.25950646.12533712.html.plaintext.txt	113	An alternative explanation could excess peptide binds DNA associated VLPs resulting decrease gene transfer due lower capacity peptide transfer gene compared obtained VLPs
0.25950646.12533712.html.plaintext.txt	114	In order rule hypothesis COS 7 cells pre incubated HPV 16 L1 Ctb peptide followed addition plasmid DNA cell culture medium
0.25950646.12533712.html.plaintext.txt	115	The absence gene transfer shown thus supports hypothesis peptide binds cell receptor HPV 31
0.25950646.12533712.html.plaintext.txt	116	View larger version 38K Fig
0.25950646.12533712.html.plaintext.txt	117	Formation peptideDNA complexes
0.25950646.12533712.html.plaintext.txt	118	The charge ratios pCMV HPV 16 L1 peptide 11 12 13 15 110 120
0.25950646.12533712.html.plaintext.txt	119	BSA used negative control
0.25950646.12533712.html.plaintext.txt	120	View larger version 39K Fig
0.25950646.12533712.html.plaintext.txt	121	Benzonase protection plasmid DNA complexed positively charged synthetic peptides
0.25950646.12533712.html.plaintext.txt	122	Lane 1 DNA Benzonase positive control lane 2 DNA alone negative control lane 3 HPV 16 L2 Nt lane 4 HPV 16 L2 Ct lane 5 HPV 16 L1 Ctb lane 6 HPV 16 E4 Ag
0.25950646.12533712.html.plaintext.txt	123	Gene transfer COS 7 cells using pCMV Luc DNA also investigated varying conditions pH molarity used binding DNA peptides
0.25950646.12533712.html.plaintext.txt	124	A gene transfer 500 plus minus 52 c
0.25950646.12533712.html.plaintext.txt	125	observed DNApeptide complexes prepared pH 5 presence 50 mM NaCl
0.25950646.12533712.html.plaintext.txt	126	Gene transfer decreased 235 plus minus 63 c
0.25950646.12533712.html.plaintext.txt	127	pH 7 5 50 mM NaCl 225 plus minus 49 c
0.25950646.12533712.html.plaintext.txt	128	At pH 7 2 50 mM TrisHCl 100 mM NaCl gene transfer 210 plus minus 35 c
0.25950646.12533712.html.plaintext.txt	129	The results obtained indicate HPV 16 L1 Ctb peptide binds DNA conditions resembling inside cell
0.25950646.12533712.html.plaintext.txt	130	DNA binding gene transfer positively charged peptides derived L1 L2 proteins HPVs There two positively charged sequences C terminus HPV L1 proteins one sequence N C terminal ends HPV L2 proteins
0.25950646.12533712.html.plaintext.txt	131	In order investigate whether gene transfer properties observed HPV 16 L1 Ctb peptide features shared similar sequences observed HPV L1 L2 various synthetic peptides corresponding positively charged sequences derived L1 protein HPV 16 31 33 45 58 HPV 16 L2 protein investigated Table 1
0.25950646.12533712.html.plaintext.txt	132	DNA heparin binding HPV L1 L2 positively charge peptides
0.25950646.12533712.html.plaintext.txt	133	These peptides tested DNA binding gel retardation assay gene delivery COS 7 cells using pCMV Luc DNA reporter plasmid 7 1 kbp
0.25950646.12533712.html.plaintext.txt	134	The results indicated peptides bound DNA 110 charge ratio Table 1 exception control peptides HPV 16 E4 Ag SV40 large T NLS HPV 16 L1 Cta HPV 31 L1 Ctb HPV 58 L1 Ctb peptides
0.25950646.12533712.html.plaintext.txt	135	A mobility shift observed 140 ratio five peptides
0.25950646.12533712.html.plaintext.txt	136	The complexes formed DNA binding peptides pCMV Luc plasmid DNA used transfect COS 7 cells gene transfer measured luciferase activity determined 2 days transfection Fig
0.25950646.12533712.html.plaintext.txt	137	The cut value gene transfer positivity set 25 c
0.25950646.12533712.html.plaintext.txt	138	mean value observed DNA alone plus minus 3 SD
0.25950646.12533712.html.plaintext.txt	139	No gene transfer observed two control peptides HPV 16 L1 Ag HPV 16 E4 Ag positively charged peptide corresponding SV40 large T NLS
0.25950646.12533712.html.plaintext.txt	140	Using HPV 16 L1 Ctb scramble peptide HPV 16 L1 CtbSc gene transfer 118 c
0.25950646.12533712.html.plaintext.txt	141	observed compared 413 c
0.25950646.12533712.html.plaintext.txt	142	The reduction gene transfer scramble peptide suggested gene transfer sequence specific dependent phenomenon
0.25950646.12533712.html.plaintext.txt	143	The residual capacity scramble peptide transfer gene could attributed generic charge effect
0.25950646.12533712.html.plaintext.txt	144	This agreement fact similarly charged peptides HPV 31 Ctb HPV 58 Ctb peptides low capacity transfer genes
0.25950646.12533712.html.plaintext.txt	145	View larger version 12K Fig
0.25950646.12533712.html.plaintext.txt	146	Gene transfer HPV L1 L2 derived synthetic peptides
0.25950646.12533712.html.plaintext.txt	147	HPV 16 VLPs used positive controls data mean three experiments
0.25950646.12533712.html.plaintext.txt	148	Error bars represent mean plus minus SD
0.25950646.12533712.html.plaintext.txt	149	Using L1 positively charged peptides highest level gene transfer observed sequence located C terminal end L1 protein L1 Ctb peptides compared level observed sequence located upstream L1 Cta types 16 45
0.25950646.12533712.html.plaintext.txt	150	Among efficient peptides highest level transfer observed upstream sequence types 31 33 58
0.25950646.12533712.html.plaintext.txt	151	It noted gene transfer observed HPV 16 L1 Cta peptide 22 c
0.25950646.12533712.html.plaintext.txt	152	low levels HPV 31 L1 Ctb HPV 58 L1 Ctb peptides 89 27 c
0.25950646.12533712.html.plaintext.txt	153	These results indicate presence two L1 sequences bind DNA play role gene transfer HPV 33 45 L1 VLPs show properties linked last amino acids L1 protein HPV 16 first C terminal sequence HPV 31 58
0.25950646.12533712.html.plaintext.txt	154	Gene transfer HPV 16 L1 Ctb peptide 574 c
0.25950646.12533712.html.plaintext.txt	155	3 gene transfer HPV 31 L1 Cta peptide 1048 c
0.25950646.12533712.html.plaintext.txt	156	Thus level gene transfer obtained L1 peptides 24 26 observed corresponding VLPs
0.25950646.12533712.html.plaintext.txt	157	L2 derived peptides also tested verify role L2 DNA binding gene transfer
0.25950646.12533712.html.plaintext.txt	158	The results showed N C terminal L2 peptides bound protected DNA Benzonase degradation 65 88 respectively Fig
0.25950646.12533712.html.plaintext.txt	159	COS 7 transfection observed peptides luciferase activity 860 1115 c
0.25950646.12533712.html.plaintext.txt	160	respectively Table 1 Fig
0.25950646.12533712.html.plaintext.txt	161	These findings indicate presence two DNA binding sequences HPV 16 L2 protein contrary findings Zhou et al
0.25950646.12533712.html.plaintext.txt	162	2001 recently observed nine C terminal amino acids L2 necessary BPV infection
0.25950646.12533712.html.plaintext.txt	163	Our findings suggest could due presence strong DNA binding sequence C terminus protein
0.25950646.12533712.html.plaintext.txt	164	This raises question DNA binding sequence detected within L1 L2 proteins interacts PES identified BPV 1 genome nucleotides 1506 1625 Zhao et al
0.25950646.12533712.html.plaintext.txt	165	This PES also recognized HPV 6b VLPs despite phylogenic distance two papillomavirus types
0.25950646.12533712.html.plaintext.txt	166	1999 therefore suggested papillomaviruses may use packaging sequence confirmed using HPV 16 VLPs El Mehdaoui et al
0.25950646.12533712.html.plaintext.txt	167	It shown presence L2 HPV VLPs dramatically increase gene transfer efficiency Roden et al
0.25950646.12533712.html.plaintext.txt	168	1998 packaging BPV 1 L1L2 VLPs increased presence papillomavirus DNA sequence Zhao et al
0.25950646.12533712.html.plaintext.txt	169	1999 suggesting specific DNA binding L2 necessary obtain efficient packaging
0.25950646.12533712.html.plaintext.txt	170	We therefore investigated gene transfer COS 7 cells using L1 L2 synthetic peptides complexed pCMV plasmid pPES CMV plasmid El Mehdaoui et al
0.25950646.12533712.html.plaintext.txt	171	No transfection observed HPV 16 L1 Cta HPV 31 L1 Ctb peptides whichever plasmid used
0.25950646.12533712.html.plaintext.txt	172	However using two HPV 16 L2 peptides HPV 16 L1 Ctb HPV 31 L1 Cta HPV 45 L1 Cta peptides two threefold significant increase level gene transfer observed Table 2 plasmid contained BPV PES comparison levels obtained pCMV plasmid P10 5 10 2 10 5 7x10 5and 2x10 4 respectively
0.25950646.12533712.html.plaintext.txt	173	No increase gene transfer observed using Lipofectamine pCMV PES 438 plus minus 3 cells per well compared use pCMV 470 plus minus 2 cells per well
0.25950646.12533712.html.plaintext.txt	174	This suggested increase observed gene transfer L1 L2 peptides due differences gene transfer efficiency two plasmids used post entry effect PES luciferase expression
0.25950646.12533712.html.plaintext.txt	175	Gene transfer L1 L2 peptides presence absence BPV 1 packaging enhancing sequence PES
0.25950646.12533712.html.plaintext.txt	176	Data means three experiments
0.25950646.12533712.html.plaintext.txt	177	To confirm higher binding positively charged sequences L1 L2 proteins PES sequences compared random DNA suggested transfection experiments binding HPV 16 L1 Ctb HPV 16 L2 Ct SV40 large T peptides probes containing PES also investigated ELISA
0.25950646.12533712.html.plaintext.txt	178	Absence DNA binding PES positive PES negative DNA sequences observed SV40 Large T peptide A0 007 plus minus 0 001 0 014 plus minus 0 007 respectively
0.25950646.12533712.html.plaintext.txt	179	Increased DNA binding activity DNA sequences containing PES sequence BPV1 observed HPV 16 L1 Ctb peptide 0 390 plus minus 0 040 versus 0 030 plus minus 0 020 HPV 16 L2 Ct peptide 0 440 plus minus 0 040 versus 0 030 plus minus 0 020
0.25950646.12533712.html.plaintext.txt	180	These findings indicated gene transfer enhanced presence BPV PES peptides capacity bind DNA
0.25950646.12533712.html.plaintext.txt	181	This confirmed PES papillomavirus type specific suggested L1 L2 proteins recognized BPV PES
0.25950646.12533712.html.plaintext.txt	182	In addition results suggested low level gene transfer observed HPV 16 L1 Cta HPV 31 L1 Ctb peptides presence pCMV Luc plasmid consequence fact peptides higher affinity papillomavirus DNA
0.25950646.12533712.html.plaintext.txt	183	Binding positively charged peptides derived HPV L1 L2 proteins heparin cell GAGs As L1 L2 positively charged sequences able transfer genes could hypothesized peptides bind DNA cells NLS activity peptides sends plasmid DNA nucleus reporter gene expressed
0.25950646.12533712.html.plaintext.txt	184	GAGs proposed cell receptors HPVs Joyce et al
0.25950646.12533712.html.plaintext.txt	185	2001 sequence identified C terminus HPV 11 L1 protein interacts cell receptor Joyce et al
0.25950646.12533712.html.plaintext.txt	186	This sequence included HPV 16 L1 Ctb peptide
0.25950646.12533712.html.plaintext.txt	187	The interaction peptides heparin tested using competition assay measuring binding HPV 31 VLPs heparin coated plates
0.25950646.12533712.html.plaintext.txt	188	The results expressed percentage inhibition HPV 31 VLP binding heparin
0.25950646.12533712.html.plaintext.txt	189	Inhibition greater 50 considered indicate binding peptide heparin
0.25950646.12533712.html.plaintext.txt	190	To rule hypothesis findings due binding peptides VLPs interaction HPV 31 VLPs HPV 16 L1 Ctb HPV 31 L1 Cta HPV 45 L1 Ctb HPV16 E4 Ag peptides investigated ELISA
0.25950646.12533712.html.plaintext.txt	191	No binding A 0 050 HPV 31 VLPs peptides investigated observed
0.25950646.12533712.html.plaintext.txt	192	These results indicated peptides inhibited binding VLPs heparin exception HPV 16 E4 Ag HPV 16 L1 Cta HPV 31 L1 Ctb HPV 58 L1 Ctb Table 1
0.25950646.12533712.html.plaintext.txt	193	It noted peptides deliver genes cells bind heparin bind efficiently DNA
0.25950646.12533712.html.plaintext.txt	194	In addition absence binding HPV 16 L19 VLPs heparin data shown confirmed extended results Joyce et al
0.25950646.12533712.html.plaintext.txt	195	1999 HPV 11 suggesting binding heparin mediated L1 protein 15 C terminal amino acids
0.25950646.12533712.html.plaintext.txt	196	To test whether GAGs could competitively inhibit gene delivery COS 7 cells transfected DNApeptide complexes transferred genes presence heparin
0.25950646.12533712.html.plaintext.txt	197	Following exposure DNApeptide complexes heparin cells washed incubated fresh culture medium assayed luciferase expression 48 h later
0.25950646.12533712.html.plaintext.txt	198	Gene transfer inhibited 67 90 heparin added DNApeptide complexes depending peptide used Fig
0.25950646.12533712.html.plaintext.txt	199	Inhibition gene transfer observed pre incubation complexes BSA place heparin
0.25950646.12533712.html.plaintext.txt	200	The role proteoglycans binding HPV cells also assessed inhibition sulfation sodium chlorate
0.25950646.12533712.html.plaintext.txt	201	For purpose COS 7 cells grown presence sodium chlorate 12 h transfected HPV 16 L1 Ctb HPV 33 L1 Ctb HPV 45 L1 Ctb L2 N C terminal peptides
0.25950646.12533712.html.plaintext.txt	202	Luciferase gene expression inhibited pretreatment sodium chlorate dose dependent manner data shown
0.25950646.12533712.html.plaintext.txt	203	Gene transfer dramatically decreased compared untreated cells decrease 69 HPV 16 L1 Ctb peptide 70 HPV 45 L1 Ctb Fig
0.25950646.12533712.html.plaintext.txt	204	These findings suggested L1 derived peptides use heparan sulfate enter cells deliver genes cells VLPs
0.25950646.12533712.html.plaintext.txt	205	View larger version 21K Fig
0.25950646.12533712.html.plaintext.txt	206	Inhibition luciferase gene transfer heparin black bars pretreatment cells sodium chlorate grey bars
0.25950646.12533712.html.plaintext.txt	207	Data mean three experiments
0.25950646.12533712.html.plaintext.txt	208	Error bars represent mean plus minus SD
0.25950646.12533712.html.plaintext.txt	209	The results obtained agreement gene transfer using HPV 16 L19 VLPs made L1 protein lacking last nine amino acids Touze et al
0.25950646.12533712.html.plaintext.txt	210	2000 indicating amino acids essential DNA binding gene transfer
0.25950646.12533712.html.plaintext.txt	211	These findings agreement Giroglou et al
0.25950646.12533712.html.plaintext.txt	212	2001 indicating HPV 33 VLPs made L1 protein lacking last seven amino acids still bind target cells since identified second positively charged sequence able bind heparan sulfate positions 472 481 C terminus HPV 33 L1 protein
0.25950646.12533712.html.plaintext.txt	213	However agreement fact HPV 33 VLPs made L1 protein lacking 22 last amino acids still bind target cells since deletion partially deletes second DNA heparin binding sequence
0.25950646.12533712.html.plaintext.txt	214	However noted VLPs used Giroglou et al
0.25950646.12533712.html.plaintext.txt	215	2001 composed L1 L2 proteins binding heparin could due presence two DNA heparin binding sequences identified N C termini L2
0.25950646.12533712.html.plaintext.txt	216	Structural data available concerning L1 protein Chen et al
0.25950646.12533712.html.plaintext.txt	217	2000 immunological DNA binding data concerning L2 protein Zhou et al
0.25950646.12533712.html.plaintext.txt	218	2002 suggest peptides tested study inside virions would expected unavailable heparin cell GAG binding
0.25950646.12533712.html.plaintext.txt	219	However gene transfer experiments using VLPs indicated VLP binding DNA cells heparin linked last C terminal amino acids L1 protein Joyce et al
0.25950646.12533712.html.plaintext.txt	220	2000 suggesting presence surface VLPs
0.25950646.12533712.html.plaintext.txt	221	The absence heparin binding observed HPV 16 L19 VLPs clearly suggests involvement sequence cell binding binding GAGs
0.25950646.12533712.html.plaintext.txt	222	The role positively charged termini L2 protein viral encapsidation fully established Zhou et al
0.25950646.12533712.html.plaintext.txt	223	The results heparin binding obtained L2 positively charged peptides raise possibility sequences could also involved VLP virion binding cell GAGs
0.25950646.12533712.html.plaintext.txt	224	L1L2 VLPs lacking either N C terminus L2 protein shown immunoflurescence studies bind cells way wild type VLPs Roden et al
0.25950646.12533712.html.plaintext.txt	225	2001 suggesting sequences play central role binding cells
0.25950646.12533712.html.plaintext.txt	226	However absence data obtained pseudovirions composed L1 C terminal mutants L2 proteins wild type N terminal mutants difficult conclude whether N terminal positively charged sequences L2 protein present virion surface play role binding cell
0.25950646.12533712.html.plaintext.txt	227	In conclusion using synthetic peptides confirmed DNA binding HPV 16 L1 protein due last C terminal amino acids
0.25950646.12533712.html.plaintext.txt	228	We also confirmed binding properties N C terminal amino acids HPV 16 L2 protein
0.25950646.12533712.html.plaintext.txt	229	In addition determined second positively charged sequence located upstream previous L1 sequence able bind DNA HPV types HPV 33 45 significantly types HPV 16 31 58
0.25950646.12533712.html.plaintext.txt	230	The interaction DNA binding peptides DNA induced protection DNase degradation sufficient obtain gene transfer COS 7 cells
0.25950646.12533712.html.plaintext.txt	231	However level gene transfer peptide around 150 times less efficient observed corresponding sequence within VLPs
0.25950646.12533712.html.plaintext.txt	232	It also shown gene transfer mediated binding DNApeptide complexes heparan sulfate receptors VLPs confirming positively charged DNA complexes enter cells binding membrane associated sulfated proteoglycans Mislick Baldeschweiler 1996 Mounkes et al
0.25950646.12533712.html.plaintext.txt	233	In addition findings agreement reports inclusion L2 protein constitution HPV VLPs increases gene transfer capacity Roden et al
0.25950646.12533712.html.plaintext.txt	234	2001 thus suggests L2 participates DNA encapsidation could play role binding cells
0.25950646.12533712.html.plaintext.txt	235	ACKNOWLEDGEMENTS This study supported grants Association pour la Recherche sur le Cancer grant No
0.25950646.12533712.html.plaintext.txt	236	5836 Association Vaincre la Mucoviscidose Biotechnocentre
0.25950646.12533712.html.plaintext.txt	237	recipient fellowship Region Centre A
0.25950646.12533712.html.plaintext.txt	238	REFERENCES Top ABSTRACT Introduction Methods Results discussion REFERENCES Baker T
0.25950646.12533712.html.plaintext.txt	239	Structures bovine human papillomaviruses
0.25950646.12533712.html.plaintext.txt	240	Analysis cryoelectron microscopy three dimensional image reconstruction
0.25950646.12533712.html.plaintext.txt	241	Detection neutralizing antibodies human papillomaviruses HPV inhibition gene transfer mediated HPV pseudovirions
0.25950646.12533712.html.plaintext.txt	242	J Clin Microbiol 40 926 932
0.25950646.12533712.html.plaintext.txt	243	Structure small virus like particles assembled L1 protein human papillomavirus 16
0.25950646.12533712.html.plaintext.txt	244	Gene transfer using human papillomavirus pseudovirions varies according virus genotype requires cell surface heparan sulfate
0.25950646.12533712.html.plaintext.txt	245	FEMS Microbiol Lett 204 183 188
0.25950646.12533712.html.plaintext.txt	246	Gene transfer using recombinant rabbit hemorrhagic disease virus capsids genetically modified DNA encapsidation capacity addition packaging sequences L1 L2 protein human papillomavirus type 16
0.25950646.12533712.html.plaintext.txt	247	Identification 6 integrin candidate receptor papillomaviruses
0.25950646.12533712.html.plaintext.txt	248	Human papillomavirus infection requires cell surface heparan sulfate
0.25950646.12533712.html.plaintext.txt	249	The L1 major capsid protein human papillomavirus type 11 recombinant virus like particles interacts heparin cell surface glycosaminoglycans human keratinocytes
0.25950646.12533712.html.plaintext.txt	250	In vitro construction pseudovirions human papillomavirus type 16 incorporation plasmid DNA reassembled L1L2 capsids
0.25950646.12533712.html.plaintext.txt	251	Efficient DNA transfection mediated C terminal domain human immunodeficiency virus type 1 viral protein R
0.25950646.12533712.html.plaintext.txt	252	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.25950646.12533712.html.plaintext.txt	253	Expression human papillomavirus type 11 L1 capsid protein Escherichia coli characterization protein domains involved DNA binding capsid assembly
0.25950646.12533712.html.plaintext.txt	254	Sequence close N terminus L2 protein displayed surface bovine papillomavirus type 1 virions
0.25950646.12533712.html.plaintext.txt	255	Expression alpha 6 integrin confers papillomavirus binding upon receptor negative B cell
0.25950646.12533712.html.plaintext.txt	256	Evidence role proteoglycans cation mediated gene transfer
0.25950646.12533712.html.plaintext.txt	257	Proc Natl Acad Sci US A 93 12349 12354
0.25950646.12533712.html.plaintext.txt	258	Proteoglycans mediate cationic liposome DNA complexes based gene delivery vitro vivo
0.25950646.12533712.html.plaintext.txt	259	J Biol Chem 273 26164 26170
0.25950646.12533712.html.plaintext.txt	260	Papillomavirus binding uptake cells different tissues species
0.25950646.12533712.html.plaintext.txt	261	In vitro generation type specific neutralization human papillomavirus type 16 virion pseudotype
0.25950646.12533712.html.plaintext.txt	262	Positively charged termini L2 minor capsid protein necessary papillomavirus infection
0.25950646.12533712.html.plaintext.txt	263	Assembly human papillomavirus type 16 Saccharomyces cerevisiae
0.25950646.12533712.html.plaintext.txt	264	Hum Gene Ther 20 1165 1176
0.25950646.12533712.html.plaintext.txt	265	DNA binding L1 required human papillomavirus morphogenesis vivo
0.25950646.12533712.html.plaintext.txt	266	Papillomavirus Rep 6 121 128
0.25950646.12533712.html.plaintext.txt	267	Infectious human papillomavirus type 18 pseudovirions
0.25950646.12533712.html.plaintext.txt	268	Sequences required nuclear targeting accumulation human papillomavirus type 6B L2 protein
0.25950646.12533712.html.plaintext.txt	269	In vitro gene transfer using human papillomavirus like particles
0.25950646.12533712.html.plaintext.txt	270	Nucleic Acids Res 26 1317 1323
0.25950646.12533712.html.plaintext.txt	271	The 9 C terminal amino acids major capsid protein human papillomavirus type 16 essential DNA binding gene transfer capacity
0.25950646.12533712.html.plaintext.txt	272	FEMS Microbiol Lett 189 121 127
0.25950646.12533712.html.plaintext.txt	273	Gene transfer using human polyomavirus BK virus like particles expressed insect cells
0.25950646.12533712.html.plaintext.txt	274	Generation pseudovirions human papillomavirus type 33
0.25950646.12533712.html.plaintext.txt	275	Nucleotides 1506 1625 bovine papillomavirus type 1 genome enhance DNA packaging L1L2 capsids
0.25950646.12533712.html.plaintext.txt	276	Identification nuclear localization signal human papillomavirus type 16 L1 protein
0.25950646.12533712.html.plaintext.txt	277	Interaction human papillomavirus HPV type 16 capsid proteins HPV DNA requires intact L2 N terminal sequence
0.25950646.12533712.html.plaintext.txt	278	Received 1 May 2002 accepted 14 August 2002
0.22396544.14684736.html.plaintext.txt	0	Cyclin L2 Novel RNA Polymerase II associated Cyclin Is Involved Pre mRNA Splicing Induces Apoptosis Human Hepatocellular Carcinoma Cells Lianjun Yang Nan Li Chunmei Wang Yizhi Yu Liang Yuan Minghui Zhang Xuetao Cao
0.22396544.14684736.html.plaintext.txt	1	From Institute Immunology Second Military Medical University Shanghai 200433 Peoples Republic China
0.22396544.14684736.html.plaintext.txt	2	Received publication July 9 2003 revised form November 25 2003
0.22396544.14684736.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES We report cloning functional characterization human cyclin L2 novel member cyclin family
0.22396544.14684736.html.plaintext.txt	4	Human cyclin L2 shares significant homology cyclin L1 K T1 T2 C involved transcriptional regulation via phosphorylation C terminal domain RNA polymerase II
0.22396544.14684736.html.plaintext.txt	5	The cyclin L2 protein contains N terminal cyclin box C terminal dipeptide repeats alternating arginines serines hallmark SR family splicing factors
0.22396544.14684736.html.plaintext.txt	6	A new isoform mouse homologue human cyclin L2 also cloned study
0.22396544.14684736.html.plaintext.txt	7	Human cyclin L2 expressed ubiquitously normal human tissues tumor cells
0.22396544.14684736.html.plaintext.txt	8	We show cyclin L2 co localizes splicing factors SC 35 9G8 within nuclear speckles associates hyperphosphorylated hypophosphorylated RNA polymerase II CDK p110 PITSLRE kinase via N terminal cyclin domains
0.22396544.14684736.html.plaintext.txt	9	It also associate SC 35 9G8 RS repeat region
0.22396544.14684736.html.plaintext.txt	10	Recombinant cyclin L2 protein stimulate vitro mRNA splicing
0.22396544.14684736.html.plaintext.txt	11	Overexpression human cyclin L2 suppresses growth human hepatocellular carcinoma SMMC 7721 cells vitro vivo inducing cellular apoptosis
0.22396544.14684736.html.plaintext.txt	12	This process involves regulation p53 Bax decreased expression Bcl 2
0.22396544.14684736.html.plaintext.txt	13	The data suggest cyclin L2 represents new member cyclin family might regulate transcription RNA processing certain apoptosis related factors resulting tumor cell growth inhibition apoptosis
0.22396544.14684736.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Cyclins key regulatory proteins complex activate cyclin dependent kinase CDK1 subunits 1 4 playing pivotal roles regulation cell cycle progression 5
0.22396544.14684736.html.plaintext.txt	15	Cyclins may currently classified two major groups seemingly reflecting functions
0.22396544.14684736.html.plaintext.txt	16	The cell cycle regulator cyclins composed primarily cyclin A B D1 D2 D3 E F function CDK partners including CDK1 2 3 4 regulate promotion cell cycle
0.22396544.14684736.html.plaintext.txt	17	The transcription regulator cyclins include cyclin C H K L1 T1 T2 work together CDK7 8 9 tend play roles transcriptional regulation 6
0.22396544.14684736.html.plaintext.txt	18	The proposed functions cyclin G1 G2 seemingly distinct either cell cycle transcriptional regulation 7
0.22396544.14684736.html.plaintext.txt	19	Other cyclins also identified roles cell cycle control RNA transcription unclear remain studied
0.22396544.14684736.html.plaintext.txt	20	Transcription regulator cyclinCDK pairs associated initiation elongation processing RNA transcripts
0.22396544.14684736.html.plaintext.txt	21	During process cyclins interact large subunit RNA polymerase II phosphorylating C terminal domain CTD via partner CDKs
0.22396544.14684736.html.plaintext.txt	22	It widely accepted transcription RNA processing closely related
0.22396544.14684736.html.plaintext.txt	23	Capping enzymes polyadenylation factors splicing factors assemble CTD RNA polymerase II
0.22396544.14684736.html.plaintext.txt	24	Hyperphosphorylated RNA polymerase II RNAPIIo stimulates RNA splicing CTD observed target splicing factors RNA transcription sites vivo 8
0.22396544.14684736.html.plaintext.txt	25	Although direct evidence support critical role transcription regulator cyclins regulation cell cycle progression cellular apoptosis results implied one transcription regulator cyclin cyclin C may important regulation cell proliferation cooperation c Myc
0.22396544.14684736.html.plaintext.txt	26	Cyclin C reported regulate cell cycling cell adhesion suggesting cyclin may play part regulating G1S G2M phases cell cycle 9
0.22396544.14684736.html.plaintext.txt	27	It thus appears transcription regulator cyclins may also involved cell cycle progression apoptosis RNA transcription DNA repair although precise role phenomena remains elucidated
0.22396544.14684736.html.plaintext.txt	28	In addition small nuclear ribonucleoprotein particles spliceosome associated proteins SR proteins compose another group splicing factors
0.22396544.14684736.html.plaintext.txt	29	SR proteins characteristic C terminal ArgSer rich repeat variable length RS domain RNA binding domains N terminus constitute family highly conserved nuclear phosphoproteins function essential alternative pre mRNA splicing factors 10 11
0.22396544.14684736.html.plaintext.txt	30	SR related proteins proteins structurally functionally distinct SR family also identified
0.22396544.14684736.html.plaintext.txt	31	These proteins generally contain RS domains RNA binding domains associated transcriptional machinery mRNA 3 end formation implicated export
0.22396544.14684736.html.plaintext.txt	32	Cyclin L1 originally named cyclin L first known example cyclin containing RS domain addition typical cyclin box 12
0.22396544.14684736.html.plaintext.txt	33	We report novel candidate cyclin human cyclin L2 CCNL2 first identified large scale random sequencing cDNA library human bone marrow stromal cells BMSCs
0.22396544.14684736.html.plaintext.txt	34	Human cyclin L2 also cyclin box RS repeat region containing protein localizes within nuclear speckles co localizing splicing factors SC 35 9G8
0.22396544.14684736.html.plaintext.txt	35	We demonstrate human cyclin L2 associates RNAPIIo CDK p110 PITSLRE kinase CDK11 SC 35 9G8
0.22396544.14684736.html.plaintext.txt	36	In addition recombinant cyclin L2 protein stimulate vitro mRNA splicing
0.22396544.14684736.html.plaintext.txt	37	Furthermore overexpression exogenous cyclin L2 suppress growth human hepatocellular carcinoma SMMC 7721 cells vitro vivo inducing cellular apoptosis possibly regulating expression p53 Bax regulating Bcl 2
0.22396544.14684736.html.plaintext.txt	38	These results suggest cyclin L2 may functional cyclin associates transcriptional regulation participates regulating pre mRNA splicing process
0.22396544.14684736.html.plaintext.txt	39	The mechanism cyclin L2 suppresses growth induces apoptosis tumor cells requires investigation
0.22396544.14684736.html.plaintext.txt	40	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Mice Cell Lines Female BALBc nunu athymic mice BK Experimental Animal Co
0.22396544.14684736.html.plaintext.txt	41	Shanghai China 6 8 weeks age maintained specific pathogen free environment
0.22396544.14684736.html.plaintext.txt	42	All cell lines including HL 60 K 562 U 937 KG 1 Reh Daudi NAMALWA MOLT 4 Hut 78 Jurkat Raji HT 29 CaoV 3 HeLa PC 3 MCF 7 U251 mouse melanoma cell line B16 obtained ATCC except NB4 kind gift Prof
0.22396544.14684736.html.plaintext.txt	43	Guanli Sun Institute Hematology Ruijin Hospital Shanghai China human hepatocellular carcinoma cell line SMMC 7721 13
0.22396544.14684736.html.plaintext.txt	44	All cell lines maintained RPMI 1640 medium supplemented 2 mM glutamine penicillin 100 unitsml streptomycin 100 microgml 10 vv heat inactivated fetal calf serum Hyclone 5 CO2 incubator 37 degrees C
0.22396544.14684736.html.plaintext.txt	45	Molecular Cloning Full length Human Cyclin L2 Its Mouse Homologue The main EST human cyclin L2 directly isolated human BMSC cDNA library random sequencing described previously 14
0.22396544.14684736.html.plaintext.txt	46	Briefly BMSCs generated bone marrow aspirates adult patient
0.22396544.14684736.html.plaintext.txt	47	Red blood cells depleted monocytes plated 6 well plates 1 x 106 cellswell RPMI 1640 supplemented 10 fetal calf serum 10 horse serum 50 microM 2 mercaptoethanol 10 mM HEPES 2 mM glutamine 100 unitsml penicillin 100 microgml streptomycin
0.22396544.14684736.html.plaintext.txt	48	After 24 h floating cells removed adherent stromal cell layer established
0.22396544.14684736.html.plaintext.txt	49	On 14th day stromal cells activated 10 microgml lipopolysaccharide Sigma 100 ngml phorbol 12 myristate 13 acetate Sigma 8 h collected cDNA library construction
0.22396544.14684736.html.plaintext.txt	50	A plasmid cDNA library pCMV SPORT6
0.22396544.14684736.html.plaintext.txt	51	0 vector Invitrogen constructed using Superscript plasmid system Invitrogen cDNA synthesis
0.22396544.14684736.html.plaintext.txt	52	Plasmid cloning performed according manufacturers instructions
0.22396544.14684736.html.plaintext.txt	53	Random sequencing performed identify clone HNA6E9 contained insert sharing homology known transcription regulator cyclin proteins particular cyclin L1 CCNL1
0.22396544.14684736.html.plaintext.txt	54	This clone hence designated human cyclin L2 CCNL2 defined HUGO accordance nomenclature cyclin family members
0.22396544.14684736.html.plaintext.txt	55	The full length sequence human cyclin L2 isolated Raji human leukemia cells express high levels human cyclin L2 PCR primers 5 ATGAATTCGAAGGGGAGTCGGCGGCACAAAATGG 3 sense 5 CAGGATCCCACCTCCGATGCCTGCTGTGCCCAGGGTGGTC 3 antisense Advantage polymerase Clontech
0.22396544.14684736.html.plaintext.txt	56	The PCR product cloned frame myc 6His tagged expression vector pcDNA3
0.22396544.14684736.html.plaintext.txt	57	1Myc His B Invitrogen sequenced
0.22396544.14684736.html.plaintext.txt	58	The positive clone denoted pCCNL2 wt
0.22396544.14684736.html.plaintext.txt	59	The full length sequence human cyclin L2 available GenBankTM data base accession number AY037150 GenBank
0.22396544.14684736.html.plaintext.txt	60	Specific primers 5 ATGAATTCGAGTCGGCGGCACAAAATG 3 sense 5 TGCCCACTGTCTCATCAATCAAAT 3 antisense used amplify mouse homologue human cyclin L2 designated mouse cyclin L2 murine melanoma line B16 RT PCR
0.22396544.14684736.html.plaintext.txt	61	DNA sequencing showed encoded putative protein sharing high homology human cyclin L2
0.22396544.14684736.html.plaintext.txt	62	The full length sequence mouse cyclin L2 available GenBankTM data base accession number AY337018 GenBank
0.22396544.14684736.html.plaintext.txt	63	RT PCR Northern Blot Analysis Total cellular RNA isolated using Trizol reagent Invitrogen first strand cDNA prepared using Superscript II system oligodT15 primer Invitrogen
0.22396544.14684736.html.plaintext.txt	64	cDNA synthesis checked PCR human actin primers positive control
0.22396544.14684736.html.plaintext.txt	65	Human adult multiple tissue cDNA panels purchased Clontech
0.22396544.14684736.html.plaintext.txt	66	RT PCR performed primers specific human cyclin L2 5 CAGGCTGTACTCCGGGGTGCTCATCA 3 sense 5 CACGTGTCACCGGTCCCTCAGTTCCATTTC 3 antisense human cyclin L1 5 GGACGACGACCACGACGAC 3 sense 5 CGGAATCTGAAGTGCTCTAGC 3 antisense
0.22396544.14684736.html.plaintext.txt	67	The reaction subjected denaturing 95 degrees C 30 annealing 55 degrees C 30 extension 72 degrees C 30 30 cycles PCR products confirmed DNA sequencing
0.22396544.14684736.html.plaintext.txt	68	Human adult multiple tissue Northern blots Clontech used detect human cyclin L2 mRNA expression
0.22396544.14684736.html.plaintext.txt	69	A 324 bp XhoI fragment spanning positions 1181 1504 human cyclin L2 cDNA prepared probe labeled random priming 32PdCTP Amersham Biosciences
0.22396544.14684736.html.plaintext.txt	70	Molecular hybridization performed ExpressHyb hybridization solution Clontech according manufacturers instructions
0.22396544.14684736.html.plaintext.txt	71	After stringent washing filters exposed autoradiography 80 degrees C
0.22396544.14684736.html.plaintext.txt	72	RT PCR analysis apoptosis related factors p53 Bax Bcl 2 performed described
0.22396544.14684736.html.plaintext.txt	73	All PCR products resolved 1
0.22396544.14684736.html.plaintext.txt	74	The sequence primers available request
0.22396544.14684736.html.plaintext.txt	75	Expression GST Fusion Protein Generation Polyclonal Antibody The coding sequence cyclin L2 cDNA cloned frame pGEX 4T3 Amersham Biosciences GST fusion protein expression
0.22396544.14684736.html.plaintext.txt	76	GST CCNL2 fusion protein expressed Escherichia coli BL21 DE3 Stratagene affinity purified glutathione Sepharose 4B Amersham Biosciences eluted 10 mM reduced glutathione
0.22396544.14684736.html.plaintext.txt	77	Antibody recombinant human cyclin L2 anti CCNL2 raised rabbits purified GST CCNL2 fusion protein
0.22396544.14684736.html.plaintext.txt	78	Mammalian Expression Vector Construction Cell Transfection The construction pCCNL2 wt containing full length coding region human cyclin L2 tagged myc 6His described
0.22396544.14684736.html.plaintext.txt	79	Domain negative mutants human cyclin L2 including pCCNL2 CL deletion cyclin domains pCCNL2 RS deletion RS region generated PCR mutations
0.22396544.14684736.html.plaintext.txt	80	Full length cyclin L2 cloned pcDNA3
0.22396544.14684736.html.plaintext.txt	81	1Myc His B vector negative direction give antisense construct pCCNL2 AS
0.22396544.14684736.html.plaintext.txt	82	The myc 6His tag replaced FLAG sequence pCCNL2 wt vector generate pCCNL2 FLAG
0.22396544.14684736.html.plaintext.txt	83	pCCNL2 wt pCCNL2 CL pCCNL2 RS pCCNL2 AS pcDNA3
0.22396544.14684736.html.plaintext.txt	84	1Myc His B mock vectors transfected using liposome mediated LipofectAMINE reagent Invitrogen human hepatocellular carcinoma SMMC 7721 cells according manufacturers instructions screened 500 microgml G418 Calbiochem 3 5 weeks
0.22396544.14684736.html.plaintext.txt	85	Cell clones stably transected cells obtained limited dilution method
0.22396544.14684736.html.plaintext.txt	86	Immunoprecipitation Western Blot Cells lysed cell lysis buffer Cell Signaling
0.22396544.14684736.html.plaintext.txt	87	Anti Myc immunoprecipitations performed using mouse anti Myc monoclonal antibody Invitrogen cross linked protein G Sepharose beads Santa Cruz Biotechnology using dimethyl pimelimidate
0.22396544.14684736.html.plaintext.txt	88	Immunoprecipitation products cell extracts separated 12 SDS PAGE transferred onto nitrocellulose membranes subjected Western blot analysis
0.22396544.14684736.html.plaintext.txt	89	Relevant proteins visualized using anti PITSLRE kinase Santa Cruz Biotechnology anti RNAPIIo Covance anti hypophosphorylated RNA polymerase II RNAPIIa Biodesign anti splicing factors SC 35 Santa Cruz Biotechnology 9G8 Santa Cruz Biotechnology anti 53 Santa Cruz Biotechnology anti Bcl 2 Cell Signaling anti Bax Cell Signaling primary antibodies
0.22396544.14684736.html.plaintext.txt	90	Blots probed horseradish peroxidase conjugated secondary antibody Santa Cruz Biotechnology reactive protein bands visualized LumiGlo reagents Cell Signaling
0.22396544.14684736.html.plaintext.txt	91	Fluorescence Confocal Microscopy Analysis pCCNL2 FLAG transfected SMMC 7721 cells growing glass coverslips placed 6 well plates fixed incubated mouse biotin labeled anti FLAG antibody Sigma stained Avidin Texas Red BD Pharmingen
0.22396544.14684736.html.plaintext.txt	92	Endogenous splicing factors SC 35 9G8 detected mentioned primary antibodies fluorescent isothiocyanate coupled anti goat IgG antibody secondary antibody
0.22396544.14684736.html.plaintext.txt	93	Stained cells glass coverslips washed briefly phosphate buffered saline observed fluorescence confocal microscopy Carl Zeiss
0.22396544.14684736.html.plaintext.txt	94	In Vitro Splicing Assays Precursor RNA transcribed plasmid pCI pA102 kindly gifted Prof
0.22396544.14684736.html.plaintext.txt	95	Stein Saeboe Larssen University Oslo Norway containing globin precursor coding sequence 15 transcription reaction T7 Cap Scribe Roche Applied Science 32PUTP Amersham Biosciences described manufacturer
0.22396544.14684736.html.plaintext.txt	96	The labeled RNA run 6 denaturing polyacrylamide gel
0.22396544.14684736.html.plaintext.txt	97	The gel briefly exposed film band corresponding full length RNA excised gel
0.22396544.14684736.html.plaintext.txt	98	RNA eluted gel slice elution buffer 0
0.22396544.14684736.html.plaintext.txt	99	2 SDS overnight 37 degrees C
0.22396544.14684736.html.plaintext.txt	100	The eluted sample precipitated ethanol stored dry pellets 80 degrees C
0.22396544.14684736.html.plaintext.txt	101	Splicing reactions performed described 16 contained 80 mM potassium acetate 4 mM magnesium acetate 20 mM creatine phosphate 1 mM freshly prepared ATP 1 unitml RNasin Takara 2 ng labeled globin RNA precursor 50 microg HeLa nuclear extract Promega 25 microg HeLa nuclear extract plus 250 ng GST CCNL2 fusion protein total volume 20 microl
0.22396544.14684736.html.plaintext.txt	102	Reactions incubated 30 degrees C 3 h extracted phenolchloroform precipitated ethanol
0.22396544.14684736.html.plaintext.txt	103	The reaction products run 6 denaturing polyacrylamide gels visualized autoradiography
0.22396544.14684736.html.plaintext.txt	104	In Vitro Analysis Cell Growth Cell proliferation transiently stably transfected SMMC 7721 cells measured MTT dye reduction assay 17
0.22396544.14684736.html.plaintext.txt	105	Briefly cells seeded 96 well plates day harvest 100 microl spent medium replaced equal volume fresh medium containing 10 MTT 5 mgml stock
0.22396544.14684736.html.plaintext.txt	106	Plates incubated 37 degrees C 4 h 100 microl Me2SO Sigma added well plates shaken room temperature 10 min
0.22396544.14684736.html.plaintext.txt	107	Cellular viability determined measuring absorbance converted dye wavelength 570 nm
0.22396544.14684736.html.plaintext.txt	108	Colony Forming Assay Stably transfected SMMC 7721 parental SMMC 7721 cells 5 x 104ml mixed 1 ml MethoCult methylcellulose based medium StemCell British Columbia Canada plated 6 well plates according manufacturers instructions
0.22396544.14684736.html.plaintext.txt	109	After 7 10 days incubation 37 degrees C humidified atmosphere containing 5 CO2 air colonies 50 cells counted using inverted microscope
0.22396544.14684736.html.plaintext.txt	110	Apoptosis Assay Transiently transfected SMMC 7721 cells washed resuspended staining buffer examined ApoAlert Annexin V Apoptosis kit BD Biosciences PI according manufacturers instruction
0.22396544.14684736.html.plaintext.txt	111	Stained cells analyzed FACS FACS calibur BD Biosciences
0.22396544.14684736.html.plaintext.txt	112	In Vivo Gene Transfer Evaluation Tumor Growth nunu mice subcutaneously inoculated 3 x 106 SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	113	When tumors grown 2
0.22396544.14684736.html.plaintext.txt	114	5 mm diameter mice randomly divided three groups five tumor bearing mice
0.22396544.14684736.html.plaintext.txt	115	In vivo electroporation performed deliver naked DNA pre established tumors 18 19
0.22396544.14684736.html.plaintext.txt	116	Briefly 20 microg plasmid DNA 30 microl saline injected tumors tumor bearing mice
0.22396544.14684736.html.plaintext.txt	117	One minute injection site plasmid injected sandwiched electrode BTX 533 2 needle array electrode poles 5 mm diameter
0.22396544.14684736.html.plaintext.txt	118	Three electrical pulses 20 ms duration voltage 600 V delivered using ECM 830 Square Wave Electroporation System BTX
0.22396544.14684736.html.plaintext.txt	119	Following procedure tumor growth tumor bearing mice monitored every day
0.22396544.14684736.html.plaintext.txt	120	The tumor volume calculated follows V 0
0.22396544.14684736.html.plaintext.txt	121	4 x b2 V volume maximum tumor diameter b diameter 90 degrees 19
0.22396544.14684736.html.plaintext.txt	122	On 32nd day following treatment mice killed
0.22396544.14684736.html.plaintext.txt	123	The tissues inoculated site tumor bearing mice dissected fixed 4 paraformaldehyde embedded paraffin
0.22396544.14684736.html.plaintext.txt	124	Deparaffinized 5 microm thick specimens subjected hematoxylin eosin staining immunohistochemical ABC staining respectively
0.22396544.14684736.html.plaintext.txt	125	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Identification Sequence Analysis Human Cyclin L2 An EST novel cyclin like protein originally isolated human BMSC cDNA library large scale random sequencing
0.22396544.14684736.html.plaintext.txt	126	The full length sequence assembled silico searching NCBI GenBankTM data base finally obtained human leukemia Raji cells
0.22396544.14684736.html.plaintext.txt	127	The 2319 bp full length cDNA novel protein encoded single 520 amino acid open reading frame theoretic molecular mass 58
0.22396544.14684736.html.plaintext.txt	128	1 kDa isoelectric point 10
0.22396544.14684736.html.plaintext.txt	129	There two frame stop codons upstream open reading frame
0.22396544.14684736.html.plaintext.txt	130	A putative polyadenylation signal located 26 bases upstream polyA stretch
0.22396544.14684736.html.plaintext.txt	131	BLAST search protein data base indicated closely resembled human cyclin L1 CCNL1 65 identity 78 similarity overall protein sequences Fig
0.22396544.14684736.html.plaintext.txt	132	High homologies also found cyclins including cyclin K 31 identity 51 similarity cyclin T1 29 identity 50 similarity cyclin T2 25 identity 43 similarity cyclin C 30 identity 48 similarity Fig
0.22396544.14684736.html.plaintext.txt	133	The predicted phylogenetic tree showed similar human cyclin L1 origin Fig
0.22396544.14684736.html.plaintext.txt	134	Based sequence similarity known cyclins especially cyclin L1 conservation cyclin features capacity associating RNAPol II splicing factors see novel protein designated human cyclin L2 CCNL2 according cyclin family nomenclature system recommended HUGO
0.22396544.14684736.html.plaintext.txt	135	View larger version 105K FIG
0.22396544.14684736.html.plaintext.txt	136	Identification sequence analysis human cyclin L2
0.22396544.14684736.html.plaintext.txt	137	A multiple alignment human cyclin L2 hL2 mouse cyclin L2 mL2 closely related cyclin family members human cyclin L1 hL1 cyclin K hK cyclin T1 hT1 cyclin T2 hT2 cyclin C hC
0.22396544.14684736.html.plaintext.txt	138	Alignment performed GCG software minimally adjusted manually
0.22396544.14684736.html.plaintext.txt	139	Identical residues boxed black similar residues gray
0.22396544.14684736.html.plaintext.txt	140	Human mouse cyclin L2 sequences deposited GenBankTM data base accession numbers AY037150 GenBank AY337018 GenBank
0.22396544.14684736.html.plaintext.txt	141	Significant conservative cyclin domains labeled
0.22396544.14684736.html.plaintext.txt	142	Triangles residues indicate nuclear location signals asterisks indicate RS repeat regions C terminus
0.22396544.14684736.html.plaintext.txt	143	B phylogenetic tree showing relationship human cyclin L2 protein closely related cyclin family members
0.22396544.14684736.html.plaintext.txt	144	Alignment performed Lasergene 5
0.22396544.14684736.html.plaintext.txt	145	The putative human cyclin L2 protein contained two cyclin domains spanning amino acids 76 150 192 281
0.22396544.14684736.html.plaintext.txt	146	The cyclin domain helical domain present cyclin proteins twice similar folds
0.22396544.14684736.html.plaintext.txt	147	The predicted three dimensional structure human cyclin L2 generated Swiss model indeed indicate obvious helix N terminus data shown human cyclin L2 agreement common structural feature cyclin family
0.22396544.14684736.html.plaintext.txt	148	In addition highly conserved cyclin box region N terminus also conserved serinearginine rich RS repeat region C terminus human cyclin L2 protein Fig
0.22396544.14684736.html.plaintext.txt	149	1A similar cyclin L1 splicing factor proteins known SR protein
0.22396544.14684736.html.plaintext.txt	150	Although two transmembrane regions amino acids 10 24 224 228 predicted obvious signal peptide found suggesting human cyclin L2 may non secretory intracellular protein
0.22396544.14684736.html.plaintext.txt	151	A significant number nuclear location signals indicated human cyclin L2 might nuclear protein Fig
0.22396544.14684736.html.plaintext.txt	152	The strong hydrophilicity C terminus human cyclin L2 also consistent features cyclin L1 cyclin K important members transcriptional regulation cyclin family
0.22396544.14684736.html.plaintext.txt	153	Identification Isoform Mouse Homologue Human Cyclin L2 During cloning sequencing human cyclin L2 cDNA novel isoform found Raji cells
0.22396544.14684736.html.plaintext.txt	154	This new isoform human cyclin L2 designated human cyclin L2s CCNL2s submitted NCBI GenBankTM accession number AY116620 GenBank
0.22396544.14684736.html.plaintext.txt	155	The sequence human cyclin L2s identical 5 region human cyclin L2
0.22396544.14684736.html.plaintext.txt	156	The coding region cDNA cyclin L2s 684 bp length encoding theoretical protein 227 amino acids
0.22396544.14684736.html.plaintext.txt	157	There two conservative cyclin domains putative cyclin L2s protein lacking RS repeat region
0.22396544.14684736.html.plaintext.txt	158	A mouse homologue human cyclin L2 identified mouse melanoma B16 cells designated mouse cyclin L2
0.22396544.14684736.html.plaintext.txt	159	The mouse cyclin L2 cDNA 1617 bp length encoding putative protein 518 amino acids calculated molecular mass 58
0.22396544.14684736.html.plaintext.txt	160	0 kDa isoelectric point 10
0.22396544.14684736.html.plaintext.txt	161	Mouse cyclin L2 protein showed 90 identity 93 similarity human cyclin L2
0.22396544.14684736.html.plaintext.txt	162	There also two cyclin domains one SUA7 domain mouse cyclin L2 protein highly consistent human cyclin L2
0.22396544.14684736.html.plaintext.txt	163	A BLAST search NCBI genome data base indicated mouse cyclin L2 gene located low terminus mouse chromosome 4
0.22396544.14684736.html.plaintext.txt	164	A previous report 20 identified 224 amino acid protein mouse ANIA 6B N terminus mouse cyclin L2
0.22396544.14684736.html.plaintext.txt	165	Based protein genome structural analysis human mouse cyclin L2 mouse ANIA 6B might alternatively spliced isoform mouse cyclin L2
0.22396544.14684736.html.plaintext.txt	166	The sequence mouse cyclin L2 available GenBankTM data base accession number AY337018 GenBank
0.22396544.14684736.html.plaintext.txt	167	Expression Pattern Human Cyclin L2 mRNA The expression human cyclin L2 mRNA detected RT PCR Northern blot analysis
0.22396544.14684736.html.plaintext.txt	168	RT PCR detected expression human cyclin L2 human hematopoietic cell lines solid tumor cell lines examined Fig
0.22396544.14684736.html.plaintext.txt	169	2 A B including U 937 histiocytic lymphoma NB4 HL 60 promyelocytic leukemia KG 1 acute myelogenous leukemia K 562 chronic myelogenous leukemia MOLT 4 Jurkat Hut 78 T lymphoblastic leukemia Daudi B lymphoma NAMALWA Burkitts lymphoma Reh acute lymphocytic leukemia HeLa cervix epithelioid carcinoma U251 glioma CaoV 3 ovary adenocarcinoma PC 3 prostate adenocarcinoma HT 29 colon adenocarcinoma SMMC 7721 hepatocellular carcinoma MCF 7 breast adenocarcinoma
0.22396544.14684736.html.plaintext.txt	170	Relatively higher levels human cyclin L2 mRNA expression observed K 562 Reh CaoV 3 U251 HeLa cells
0.22396544.14684736.html.plaintext.txt	171	View larger version 52K FIG
0.22396544.14684736.html.plaintext.txt	172	Expression pattern human cyclin L2 mRNA
0.22396544.14684736.html.plaintext.txt	173	RT PCR human cyclin L2 cyclin L1 specific primers performed hematopoietic cell lines A solid tumor cell lines B
0.22396544.14684736.html.plaintext.txt	174	All cells similarly positive actin lower panel
0.22396544.14684736.html.plaintext.txt	175	C Northern blot analysis upper panel RT PCR lower panel multiple tissue Northern blots multiple tissue cDNA panels respectively tissue distribution human cyclin L2
0.22396544.14684736.html.plaintext.txt	176	Northern blots analyzed probe corresponding C terminal fragment human cyclin L2
0.22396544.14684736.html.plaintext.txt	177	On human adult multiple tissue Northern blots human cyclin L2 expressed message 5
0.22396544.14684736.html.plaintext.txt	178	0 kb normal human tissues assayed
0.22396544.14684736.html.plaintext.txt	179	Relatively higher expression levels seen ovary heart liver pancreas whereas much lower expression levels seen spleen colon peripheral blood leukocyte lung skeletal muscle Fig
0.22396544.14684736.html.plaintext.txt	180	We also examined expression human cyclin L1 cell tissue templates
0.22396544.14684736.html.plaintext.txt	181	Interestingly results revealed differential expression human cyclin L2 L1
0.22396544.14684736.html.plaintext.txt	182	Unlike cyclin L2 cyclin L1 expression restricted cultured cell lines
0.22396544.14684736.html.plaintext.txt	183	Cyclin L1 detected K 562 U 937 NAMALWA cells solid tumor cells except CaoV 3
0.22396544.14684736.html.plaintext.txt	184	Its expression much lower cyclin L2
0.22396544.14684736.html.plaintext.txt	185	On human multiple tissue cDNA panels expression patterns cyclins also dissimilar Fig
0.22396544.14684736.html.plaintext.txt	186	The differential distribution closely related cyclins belonging class may reflect functional diversity resulting existence finely tuned mechanism cell cycle transcriptional regulation different members multiple cyclin family
0.22396544.14684736.html.plaintext.txt	187	Nuclear Cytolocalization Human Cyclin L2 Because human cyclin L2 contained nuclear localization signals predicted nuclear protein examined subcellular localization FLAG tagged cyclin L2 determine whether localized within nucleus
0.22396544.14684736.html.plaintext.txt	188	pCCNL2 FLAG co transfected SMMC 7721 cells pEGFP Nuc encoding nuclear localized form GFP nuclear location signals
0.22396544.14684736.html.plaintext.txt	189	The expression CCNL2 FLAG protein assayed Western blot analysis anti FLAG antibody 59 kDa protein detected crude extract pCCNL2 FLAG transfected SMMC 7721 cells data shown consistent calculated molecular weight cyclin L2
0.22396544.14684736.html.plaintext.txt	190	In transfected SMMC 7721 cells observed generalized nucleoplasmic punctated nuclear staining speckled pattern expression CCNL2 FLAG protein Fig
0.22396544.14684736.html.plaintext.txt	191	3B preferentially co localized nuclear GFP signal Fig
0.22396544.14684736.html.plaintext.txt	192	The result confirmed structure prediction cyclin L2 typical nuclear protein
0.22396544.14684736.html.plaintext.txt	193	View larger version 44K FIG
0.22396544.14684736.html.plaintext.txt	194	Cytolocalization co localization human cyclin L2 protein human hepatocellular carcinoma SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	195	Cells transiently transfected pCCNL2 FLAG andor nuclear localizing GFP expression vectors double color confocal microscopy analysis human cyclin L2 anti FLAG red nuclear GFP signal green indirect immunofluorescence staining SC 35 9G8 green performed 72 h transfection
0.22396544.14684736.html.plaintext.txt	196	Confocal micrographs show SMMC 7721 cells expressing CCNL2 FLAG protein B E H nuclear GFP expression A SC 35 D 9G8 G stained vivo respective fluorescence signals overlaid C F I
0.22396544.14684736.html.plaintext.txt	197	Human Cyclin L2 Co localizes Splicing Factors SC 35 9G8 The speckled nuclear localization pattern characteristic proteins associated spliceosome complexes SC 35 21 22
0.22396544.14684736.html.plaintext.txt	198	The distinct RS repeat region human cyclin L2 suggested might found nuclear speckles co localized associated splicing components
0.22396544.14684736.html.plaintext.txt	199	pCCNL2 FLAG transfected SMMC 7721 cells splicing factors SC 35 9G8 detected indirect immunofluorescence
0.22396544.14684736.html.plaintext.txt	200	The FLAG tagged CNNL2 protein found similar punctated nuclear speckled regions Fig
0.22396544.14684736.html.plaintext.txt	201	3 E H SC 35 Fig
0.22396544.14684736.html.plaintext.txt	202	3G suggested cyclin L2 largely localized sub nuclear regions splicing factors Fig
0.22396544.14684736.html.plaintext.txt	203	Curiously cyclin L2 SC 35 signals appear overlap completely
0.22396544.14684736.html.plaintext.txt	204	The SC 35 protein appeared heavily concentrated CCNL2 FLAG although 9G8
0.22396544.14684736.html.plaintext.txt	205	The fluorescence dye staining CCNL2 FLAG indirect immunofluorescence staining SC 35 may superimpose one another perhaps indicating different functional association cyclin L2 SC 35 9G8
0.22396544.14684736.html.plaintext.txt	206	Human Cyclin L2 Associates RNA Polymerase II Splicing Factors SC 35 9G8 CDK p110 PITSLRE The cell nucleus particularly nuclear speckles believed contain compartments enriched nuclear proteins involved transcriptional regulation mRNA processing
0.22396544.14684736.html.plaintext.txt	207	Human cyclin C H K closest homologue cyclin L2 cyclin L1 proposed play roles regulation basal transcription association activation CDKs phosphorylate CTD large subunit RNA polymerase II
0.22396544.14684736.html.plaintext.txt	208	To explore possibility human cyclin L2 may associate RNA polymerase II CDKs splicing factors delineate domains cyclin L2 required interactions several domain negative constructs tagged myc 6His overexpressed SMMC 7721 cells immunoprecipitated anti Myc antibody cross linked protein G Sepharose beads
0.22396544.14684736.html.plaintext.txt	209	4A anti Myc antibody could detect expression Myc tagged CCNL2 wt 59 kDa CCNL2 CL 39 kDa cyclin domains deleted CCNL2 RS 51 kDa RS repeat region deleted
0.22396544.14684736.html.plaintext.txt	210	We examined association cyclin L2 RNA polymerases II CDKs splicing factors
0.22396544.14684736.html.plaintext.txt	211	View larger version 52K FIG
0.22396544.14684736.html.plaintext.txt	212	Selective interaction human cyclin L2 hyperphosphorylated RNA polymerase II CDK p110 PITSLRE splicing factors SC 35 9G8
0.22396544.14684736.html.plaintext.txt	213	SMMC 7721 cells transfected pCCNL2 wt pCCNL2 CL pCCNL2 RS pCCNL2 AS mock vector
0.22396544.14684736.html.plaintext.txt	214	Proteins immunoprecipitated cell lysates using anti Myc control mouse rabbit IgG detected using anti Myc antibody A antibodies B indicated left side panel
0.22396544.14684736.html.plaintext.txt	215	RNA polymerase II exists two major forms RNAPIIa RNAPIIo hyperphosphorylated CTD RNA polymerase II
0.22396544.14684736.html.plaintext.txt	216	Immunoprecipitation results showed human CCNL2 associated hyperphosphorylated form RNAPIIo RNAPIIa Fig
0.22396544.14684736.html.plaintext.txt	217	The hyperphosphorylation RNA polymerase II correlates association certain splicing factors involved mRNA processing
0.22396544.14684736.html.plaintext.txt	218	Here demonstrated cyclin L2 associates two splicing factors Fig
0.22396544.14684736.html.plaintext.txt	219	4B consistent co localization nuclear speckles
0.22396544.14684736.html.plaintext.txt	220	Cyclins together CDK partners regulate orderly progression cell cycle
0.22396544.14684736.html.plaintext.txt	221	We investigated whether human cyclin L2 could possibly interact known CDKs
0.22396544.14684736.html.plaintext.txt	222	Because CDK p110 PITSLRE also called CDK11 identified CDK partner human cyclin L1 12 mouse cyclin ANIA 6A 20 mouse homologue human cyclin L1 association human cyclin L2 PITSLRE assayed immunoprecipitation
0.22396544.14684736.html.plaintext.txt	223	4B human cyclin L2 could also associate p110 PITSLRE suggesting p110 PITSLRE might CDK partner human cyclin L2
0.22396544.14684736.html.plaintext.txt	224	It remains determined whether cyclin L2 partner CDKs
0.22396544.14684736.html.plaintext.txt	225	The results also showed association RNAPIIo p110 PITSLRE required presence N terminal cyclin domains human cyclin L2 cells overexpressing CCNL2 CL truncated protein lacking cyclin domains association cyclin L2 RNAPIIo p110 PITSLRE detected
0.22396544.14684736.html.plaintext.txt	226	In CCNL2 RS expressing cells levels RNAPIIo p110 PITSLRE precipitated approximately CCNL2 wt suggesting RS repeats might necessary RNAPIIo p110 PITSLRE interaction
0.22396544.14684736.html.plaintext.txt	227	Notably interactions SC 35 9G8 CCNL2 CL expressing cells similar CCNL2 wt whereas CCNL2 RS expressing cells interactions decreased
0.22396544.14684736.html.plaintext.txt	228	Although indicates requirement RS repeat region possibility cannot excluded indirect interactions cyclin L2 SC 35 9G8 may occur perhaps linked p110 PITSLRE via cyclin domains cyclin L2
0.22396544.14684736.html.plaintext.txt	229	Together nuclear distribution findings indicate human cyclin L2 might play active role cell nucleus involvement RNA processing complex via association hyperphosphorylated RNA polymerase II splicing factors SC 35 9G8 CDK p110 PITSLRE
0.22396544.14684736.html.plaintext.txt	230	Human Cyclin L2 Stimulates Pre mRNA Splicing Because cyclin L2 co localizes associates splicing factors SC 35 9G8 contribute splicing function We performed vitro splicing assays using HeLa cell nuclear extract 50 microg assaying effect anti CCNL2 polyclonal sera vitro splicing globin RNA precursor
0.22396544.14684736.html.plaintext.txt	231	5 presence preimmune sera anti GST antibody affect splicing whereas anti CCNL2 sera remarkably inhibited splicing activity suggesting human cyclin L2 involved pre mRNA splicing
0.22396544.14684736.html.plaintext.txt	232	We also performed vitro splicing assays using sub optimal amounts HeLa cell nuclear extract 25 microg addition GST GST CCNL2 recombinant protein
0.22396544.14684736.html.plaintext.txt	233	In absence additional protein GST added reaction splicing activity greatly reduced compared obtained 50 microg HeLa cell nuclear extract
0.22396544.14684736.html.plaintext.txt	234	Addition recombinant GST CCNL2 protein 250 ng strongly stimulated splicing activity Fig
0.22396544.14684736.html.plaintext.txt	235	Human cyclin L2 thus appears play positive role pre mRNA splicing
0.22396544.14684736.html.plaintext.txt	236	View larger version 51K FIG
0.22396544.14684736.html.plaintext.txt	237	Effect human cyclin L2 vitro splicing
0.22396544.14684736.html.plaintext.txt	238	GST CNNL2 fusion protein added splicing reactions globin precursor RNA optimal 50 microg suboptimal 25 microg amounts HeLa nuclear extract
0.22396544.14684736.html.plaintext.txt	239	The HeLa extract concentration required reduce yield splicing products determined empirically
0.22396544.14684736.html.plaintext.txt	240	Addition 250 ng GST CCNL2 restored splicing activity level comparable control
0.22396544.14684736.html.plaintext.txt	241	Overexpression Human Cyclin L2 Suppresses Growth Human Hepatocellular Carcinoma Cells Induces Cell Apoptosis Vitro Vivo Hepatocellular carcinoma accounts 80 90 liver cancers one prevalent carcinomas worldwide particularly Africa Asia
0.22396544.14684736.html.plaintext.txt	242	We wondered overexpression human cyclin L2 would affect growth human hepatocellular carcinoma SMMC 7721 cells may contribute understanding molecular mechanisms cellular malignancy phenotype invasion metastasis hepatocellular carcinoma
0.22396544.14684736.html.plaintext.txt	243	Proliferation SMMC 7721 cells transfected different cyclin L2 constructs analyzed MTT assay
0.22396544.14684736.html.plaintext.txt	244	6A proliferation pCCNL2 wt pCCNL2 RS transiently transfected SMMC 7721 cells inhibited compared mock vector transfected parental SMMC 7721 cells p 0
0.22396544.14684736.html.plaintext.txt	245	05 although transfection pCCNL2 AS pCCNL2 CL minor effects cell proliferation
0.22396544.14684736.html.plaintext.txt	246	The viability stably transfected SMMC 7721 cells analyzed colony formation assay
0.22396544.14684736.html.plaintext.txt	247	The colony formation rate CCNL2 wt transfected SMMC 7721 cells significantly reduced compared pCCNL2 AS transfected mock vector transfected parental SMMC 7721 cells p 0
0.22396544.14684736.html.plaintext.txt	248	The results suggested overexpression human cyclin L2 might inhibit vitro growth human hepatocellular carcinoma
0.22396544.14684736.html.plaintext.txt	249	View larger version 36K FIG
0.22396544.14684736.html.plaintext.txt	250	Effect human cyclin L2 growth apoptosis SMMC 7721 cells vitro
0.22396544.14684736.html.plaintext.txt	251	A cell proliferation transiently transfected SMMC 7721 cells determined MTT
0.22396544.14684736.html.plaintext.txt	252	B colony formation assay stably transfected SMMC 7721 cells n 200
0.22396544.14684736.html.plaintext.txt	253	C apoptosis SMMC 7721 cells determined annexin VPI staining 72 h transfection
0.22396544.14684736.html.plaintext.txt	254	MTT assay statistics analyzed Students test colony formation assay data 2 test
0.22396544.14684736.html.plaintext.txt	255	Columns represent means three independent experiments
0.22396544.14684736.html.plaintext.txt	256	The percentages apoptotic cells assessed annexin V positive including PI PI indicated
0.22396544.14684736.html.plaintext.txt	257	In order investigate mechanisms cyclin L2 inhibits tumor growth next performed fluorescent isothiocyanate conjugated annexin VPI staining followed FACS analysis detect cell apoptosis
0.22396544.14684736.html.plaintext.txt	258	6C percentages annexin V positive cells apoptotic cells including PI PI CCNL2 wt CCNL2 RS overexpressing SMMC 7721 cells much greater among pCCNL2 AS pCCNL2 CL mock vector transfected parental SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	259	Human cyclin L2 may thus involved induction cell apoptosis conserved cyclin domains playing vital role biological activity
0.22396544.14684736.html.plaintext.txt	260	In order determine whether overexpression cyclin L2 human hepatocellular carcinoma could mediate therapeutic effects vivo human hepatocellular carcinoma bearing nude mice used model
0.22396544.14684736.html.plaintext.txt	261	Purified human cyclin L2 expression plasmid delivered tumors vivo electroporation
0.22396544.14684736.html.plaintext.txt	262	Immunohistochemical analysis hepatocellular carcinoma tissue confirmed high expression Myc tagged human cyclin L2 protein tissues tumor bearing nude mice intratumorally transfected pCCNL2 wt Fig
0.22396544.14684736.html.plaintext.txt	263	7A panel indicating vivo electroporation effectively mediate human cyclin L2 gene transfer tumors
0.22396544.14684736.html.plaintext.txt	264	We next investigated whether intratumoral gene transfer human cyclin L2 could inhibit growth parental SMMC 7721 cells nude mice
0.22396544.14684736.html.plaintext.txt	265	We found compared mock DNA intratumoral gene transfer human cyclin L2 could significantly inhibit growth SMMC 7721 tumors nude mice Fig
0.22396544.14684736.html.plaintext.txt	266	These findings indicate intratumoral transfer human cyclin L2 gene inhibit tumor growth significantly vivo consistent results obtained vitro
0.22396544.14684736.html.plaintext.txt	267	View larger version 35K FIG
0.22396544.14684736.html.plaintext.txt	268	In vivo evaluation tumor growth pathological observations
0.22396544.14684736.html.plaintext.txt	269	A immunohistochemical detection Myc tagged human cyclin L2 protein hepatocellular carcinoma tissue nude mice intratumorally transfected pcDNA cyclinL2 x400
0.22396544.14684736.html.plaintext.txt	270	pCCNL2 wt transfected group b mock vector transfected group
0.22396544.14684736.html.plaintext.txt	271	B growth hepatocellular carcinoma SMMC 7721 cells nude mice inhibited intratumoral delivery human cyclin L2 naked DNA
0.22396544.14684736.html.plaintext.txt	272	Statistical analysis performed Students test assisted BioMedCalc software
0.22396544.14684736.html.plaintext.txt	273	05 versus pCCNL2 wt delivery group 2 p 0
0.22396544.14684736.html.plaintext.txt	274	05 versus mock vector delivery group
0.22396544.14684736.html.plaintext.txt	275	C pathological observation hematoxylin eosin staining human hepatocellular carcinoma tissue nude mice x400
0.22396544.14684736.html.plaintext.txt	276	On 32nd day following treatment mice killed dissected
0.22396544.14684736.html.plaintext.txt	277	Hematoxylin eosin staining performed tumor tissues
0.22396544.14684736.html.plaintext.txt	278	pCCNL2 wt transfected group b mock vector transfected group
0.22396544.14684736.html.plaintext.txt	279	Pathological observation revealed morphologically necrotic apoptotic changes pCCNL2 wt transfected group including pyknosis densely stained nuclei cytoplasm nucleus granularity ringing crescenting cytoplasm bubbling Fig
0.22396544.14684736.html.plaintext.txt	280	7C panel control groups
0.22396544.14684736.html.plaintext.txt	281	No obvious inflammatory infiltration found
0.22396544.14684736.html.plaintext.txt	282	This suggests delivery human cyclin L2 cDNA human hepatocellular hepatoma suppress tumor growth vivo
0.22396544.14684736.html.plaintext.txt	283	Overexpression Human Cyclin L2 Up regulates Expression p53 Bax Down regulates Expression Bcl 2 Overexpression human cyclin L2 induced apoptosis SMMC 7721 cells vitro
0.22396544.14684736.html.plaintext.txt	284	Cellular apoptosis involves complex molecular cascades dysfunction variety genes may lead onset progression apoptosis
0.22396544.14684736.html.plaintext.txt	285	We analyzed expression apoptosis related protein p53 anti apoptotic protein Bcl 2 pro apoptotic protein Bax Western blot RT PCR analysis
0.22396544.14684736.html.plaintext.txt	286	8A transient expression CCNL2 wt CCNL2 RS induced increase p53 Bax protein expression 3 4 fold respectively SMMC 7721 cells 72 h post transfection compared pCCNL2 AS pCCNL2 CL mock vector transfected parental SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	287	Significantly regulated p53 Bax mRNA expression also detected RT PCR Fig
0.22396544.14684736.html.plaintext.txt	288	Conversely Bcl 2 expression regulated SMMC 7721 cells overexpressing human cyclin L2
0.22396544.14684736.html.plaintext.txt	289	These results demonstrate overexpression human cyclin L2 modulates expression critical apoptotic factors leading cell apoptosis
0.22396544.14684736.html.plaintext.txt	290	It would interesting determine whether apoptotic factors may also relationship apoptosis induced overexpression human cyclin L2
0.22396544.14684736.html.plaintext.txt	291	View larger version 48K FIG
0.22396544.14684736.html.plaintext.txt	292	Effect human cyclin L2 overexpression expression apoptosis related proteins SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	293	A Western blot analysis protein expression p53 Bax Bcl 2
0.22396544.14684736.html.plaintext.txt	294	B RT PCR analysis mRNA expression p53 Bax Bcl 2
0.22396544.14684736.html.plaintext.txt	295	SMMC 7721 cells transfected indicated vectors harvested 72 h post transfection
0.22396544.14684736.html.plaintext.txt	296	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Known cyclins include 20 types A M T whose abundance oscillates different cell phases
0.22396544.14684736.html.plaintext.txt	297	The first cyclins identified named due critical function regulation cell cycle cyclins partner molecules CDKs recognized important functions beyond regulation cell cycle 23
0.22396544.14684736.html.plaintext.txt	298	These cyclins include cyclin C H T1 T2 K L1 proposed roles transcriptional regulation cyclin G1 G2 I appear distinct roles either cell cycle transcriptional regulation 24
0.22396544.14684736.html.plaintext.txt	299	In study describe identification characterization novel cyclin family member cyclin L2
0.22396544.14684736.html.plaintext.txt	300	Human cyclin L2 novel cyclin box RS repeat region containing protein localizes within nuclear speckles co localized splicing factors SC 35 9G8
0.22396544.14684736.html.plaintext.txt	301	Among known human cyclin proteins cyclin L2 closely related C type cyclins cyclins L1 K T1 T2 C particularly cyclin box region
0.22396544.14684736.html.plaintext.txt	302	C type cyclins CDK partners defined capacity phosphorylate CTD RNA polymerase II step required transcriptional elongation RNA processing
0.22396544.14684736.html.plaintext.txt	303	It reported cyclin HCDK7 25 26 cyclin CCDK8 27 cyclin KCDK9 28 30 promote transcriptional elongation affect RNA processing indirectly phosphorylation CTD
0.22396544.14684736.html.plaintext.txt	304	Phosphorylation CTD cyclin TCDK9 shown essential transition initiation transcription effective elongation nascent mRNA transcripts 31
0.22396544.14684736.html.plaintext.txt	305	Based sequence homology experimental observation human cyclin L2 immunoprecipitates associated hyperphosphorylated form RNA polymerase II likely CTD also target cyclin L2CDK vivo
0.22396544.14684736.html.plaintext.txt	306	The various aspects RNA elongation processing including capping splicing polyadenylation nascent transcripts tightly coupled protein factors physically associating CTD RNA polymerase II 32
0.22396544.14684736.html.plaintext.txt	307	Human cyclin L2 possesses RS repeat domains characteristic feature SR proteinspliceosome components associates co localizes known splicing factors SC 35 9G8
0.22396544.14684736.html.plaintext.txt	308	RS domains discovered several factors associated transcription components including SR like CTD associated factors 33 3 end cleavage factor cleavage factor I 68 kDa subunit 34 suggesting communication splicing transcription 3 end processing might cases mediated interactions involving RS domain proteins 35 36
0.22396544.14684736.html.plaintext.txt	309	We confirmed stimulatory effect cyclin L2 pre mRNA splicing
0.22396544.14684736.html.plaintext.txt	310	This activity may mediated interaction cyclin domains RNA polymerase II CDK p110 PITSLRE direct indirect interaction via cyclin domainRS repeat region SC 35 9G8 RNA elongationprocessing unit nuclear speckles
0.22396544.14684736.html.plaintext.txt	311	Of note manuscript revision de Graaf et al
0.22396544.14684736.html.plaintext.txt	312	37 reported cyclin L1 cyclin L2 interaction partners substrates DYRK1A dual specificity tyrosine phosphorylation regulated kinase 1A nuclear speckle locating protein kinase transcription factors splicing factors substrates
0.22396544.14684736.html.plaintext.txt	313	Because human cyclin L2 cyclin L1 expressed differentially different levels different cells tissues possible two closely related cyclins contribute tissue specific regulation splicing
0.22396544.14684736.html.plaintext.txt	314	The PITSLRE protein kinases parts large family p34cdc2 related kinases whose functions appear linked progression cell cycle signal transduction apoptosis oncogenesis
0.22396544.14684736.html.plaintext.txt	315	PITSLRE CDK also interacts selectively RNAPIIo RNAPIIa PITSLRE proteins also contain many serinearginine dipeptide repeats characteristic spliceosome components
0.22396544.14684736.html.plaintext.txt	316	The p110 PITSLRE shown participate signaling pathway may regulate processing RNA transcription
0.22396544.14684736.html.plaintext.txt	317	It interacts RNA binding protein RNPS1 activator mRNA splicing RNA polymerase II multiple transcriptional elongation factors regulating aspects RNA splicing andor transcription proliferating cells 38 40
0.22396544.14684736.html.plaintext.txt	318	Due identification partner human cyclin L1 12 mouse homologue cyclin ANIA 6A 20 referred CDK11
0.22396544.14684736.html.plaintext.txt	319	We show human cyclin L2 associate p110 PITSLRE cyclin domain dependent manner suggesting also likely partner CDK cyclin L2
0.22396544.14684736.html.plaintext.txt	320	Our work also revealed overexpression human cyclin L2 suppressed growth hepatocellular carcinoma SMMC 7721 cells vitro vivo induced cellular apoptosis vitro
0.22396544.14684736.html.plaintext.txt	321	Cyclin L2 ubiquitously expressed throughout body variety human cell lines including SMMC 7721 cells
0.22396544.14684736.html.plaintext.txt	322	Under normal conditions tumor cells SMMC 7721 cells may anti apoptotic mechanisms place antagonize apoptosis inducing effects cyclin L2
0.22396544.14684736.html.plaintext.txt	323	However cyclin L2 overexpressed apoptosis inducing effects cyclin L2 may counterattack anti apoptotic mechanisms resulting imbalance apoptosis cell survival cell cycle regulation
0.22396544.14684736.html.plaintext.txt	324	Previous studies implicated cyclins apoptosis growth inhibition tumor cells
0.22396544.14684736.html.plaintext.txt	325	A potential p53 binding site present intron 1 cyclin K gene colony formation assays indicate overexpression cyclin K suppresses growth glioblastoma cell lines U373MG T98G colon carcinoma SW480 cells 41
0.22396544.14684736.html.plaintext.txt	326	At high levels cyclin G1 p53 responsive gene induced alternative reading frame arrested cells also induces G1 phase arrest mammalian cells coincides p53 activation
0.22396544.14684736.html.plaintext.txt	327	Interestingly growth inhibition cyclin G1 require p53 instead exhibits partial retinoblastoma protein dependence 42
0.22396544.14684736.html.plaintext.txt	328	A recent study cDNA microarray RT PCR indicates cyclin L1 commonly overexpressed well differentiated poorly differentiated primary head neck tumors compared corresponding correlative normal tissues 43
0.22396544.14684736.html.plaintext.txt	329	Other RS repeat containing proteins Hs BTF 44 also act apoptosis promoting proteins interact Bcl 2 related proteins
0.22396544.14684736.html.plaintext.txt	330	To gain insight mechanism cyclin L2 induced apoptosis SMMC 7721 cells assessed expression apoptosis related proteins p53 Bax Bcl 2
0.22396544.14684736.html.plaintext.txt	331	In study following transient expression cyclin L2 SMMC 7721 cells p53 Bax expression observed increase significantly regulation Bcl 2 expression could also observed
0.22396544.14684736.html.plaintext.txt	332	Previous studies demonstrated overexpression p53 transactivate Bax expression inhibit Bcl 2 expression resulting apoptotic cell death 45
0.22396544.14684736.html.plaintext.txt	333	Combined observations including association RNAPII CDK p110 PITSLRE splicing factors stimulatory effect pre mRNA splicing results suggest overexpression cyclin L2 might regulate RNA transcription processing certain apoptosis related factors possibly p53 dependent increase Bax reduction Bcl 2 pathway signaling leading tumor cell growth inhibition
0.22396544.14684736.html.plaintext.txt	334	In conclusion report cloning human mouse cyclin L2 association human cyclin L2 p110 PITSLRE splicing factors SC 35 9G8 potential involvement human cyclin L2 stimulation pre mRNA splicing
0.22396544.14684736.html.plaintext.txt	335	Growth inhibition apoptosis inducing effects human cyclin L2 tumor cells also observed vitro vivo
0.22396544.14684736.html.plaintext.txt	336	Further experiments required elucidate roles novel molecule human cyclin L2 transcriptional regulation cell growth suppression related mechanisms
0.22396544.14684736.html.plaintext.txt	337	FOOTNOTES The nucleotide sequences reported paper submitted GenBankTMEBI Data Bank accession numbers AY037150 GenBank AY116620 GenBank AY337018 GenBank
0.22396544.14684736.html.plaintext.txt	338	This work supported National Natural Science Foundation China 30121002 National Key Basic Research Program China 2001CB510002 National High Biotechnology Development Program China 2002BA711A01
0.22396544.14684736.html.plaintext.txt	339	The costs publication article defrayed part payment page charges
0.22396544.14684736.html.plaintext.txt	340	This article must therefore hereby marked advertisement accordance 18 U
0.22396544.14684736.html.plaintext.txt	341	Section 1734 solely indicate fact
0.22396544.14684736.html.plaintext.txt	342	Both authors contributed equally work
0.22396544.14684736.html.plaintext.txt	343	To correspondence addressed Institute Immunology Second Military Medical University 800 Xiangyin Road Shanghai 200433 Peoples Republic China
0.22396544.14684736.html.plaintext.txt	344	Fax 86 21 6538 2502 E mail caoxtatpublic3
0.22396544.14684736.html.plaintext.txt	345	1 The abbreviations used CDK cyclin dependent kinase CTD C terminal domain RNAPIIo hyperphosphorylated RNA polymerase II RNAPIIa hypophosphorylated RNA polymerase IIa MTT 3 45 dimethylthiazol 2 yl 25 diphenyltetrazolium bromide GST glutathione S transferase GFP green fluorescent protein BMSCs bone marrow stromal cells RT reverse transcriptase PI propidium iodide
0.22396544.14684736.html.plaintext.txt	346	ACKNOWLEDGMENTS We thank Dr
0.22396544.14684736.html.plaintext.txt	347	Jin expert technical assistance
0.22396544.14684736.html.plaintext.txt	348	Jane Rayner critical reading manuscript
0.22396544.14684736.html.plaintext.txt	349	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Wasch R
0.22396544.14684736.html.plaintext.txt	350	2002 Nature 418 556 562CrossRefMedline Order article via Infotrieve Duman Scheel M
0.22396544.14684736.html.plaintext.txt	351	2002 Nature 417 299 304CrossRefMedline Order article via Infotrieve Koepp D
0.22396544.14684736.html.plaintext.txt	352	2001 Science 294 173 177AbstractFree Full Text Nguyen V
0.22396544.14684736.html.plaintext.txt	353	2001 Nature 414 322 325CrossRefMedline Order article via Infotrieve Miller M
0.22396544.14684736.html.plaintext.txt	354	114 1811 1820AbstractFree Full Text Bregman D
0.22396544.14684736.html.plaintext.txt	355	5 D244 D257Medline Order article via Infotrieve Chen X
0.22396544.14684736.html.plaintext.txt	356	Cell 2 518 519Medline Order article via Infotrieve Oelgeschlager T
0.22396544.14684736.html.plaintext.txt	357	190 160 169CrossRefMedline Order article via Infotrieve Liu Z
0.22396544.14684736.html.plaintext.txt	358	18 3445 3454AbstractFree Full Text Sanford J
0.22396544.14684736.html.plaintext.txt	359	98 10184 10189AbstractFree Full Text Tian H
0.22396544.14684736.html.plaintext.txt	360	276 33833 33839AbstractFree Full Text Dickinson L
0.22396544.14684736.html.plaintext.txt	361	277 25465 25473AbstractFree Full Text Yu Y
0.22396544.14684736.html.plaintext.txt	362	128 283 287CrossRefMedline Order article via Infotrieve Sun H
0.22396544.14684736.html.plaintext.txt	363	301 176 182CrossRefMedline Order article via Infotrieve Krainer A
0.22396544.14684736.html.plaintext.txt	364	1984 Cell 36 993 1005Medline Order article via Infotrieve Reichert V
0.22396544.14684736.html.plaintext.txt	365	28 416 423AbstractFree Full Text Alley M
0.22396544.14684736.html.plaintext.txt	366	8 1149 1156CrossRefMedline Order article via Infotrieve Li S
0.22396544.14684736.html.plaintext.txt	367	9 390 397Medline Order article via Infotrieve Berke J
0.22396544.14684736.html.plaintext.txt	368	2001 Neuron 32 277 287Medline Order article via Infotrieve Fu X
0.22396544.14684736.html.plaintext.txt	369	1990 Nature 343 437 441CrossRefMedline Order article via Infotrieve Spector D
0.22396544.14684736.html.plaintext.txt	370	9 265 315CrossRefMedline Order article via Infotrieve Murray A
0.22396544.14684736.html.plaintext.txt	371	2001 Nature 409 844 846CrossRefMedline Order article via Infotrieve Bates S
0.22396544.14684736.html.plaintext.txt	372	1996 Oncogene 13 1103 1109Medline Order article via Infotrieve Larochelle S
0.22396544.14684736.html.plaintext.txt	373	20 3749 3759AbstractFree Full Text Andersen G
0.22396544.14684736.html.plaintext.txt	374	16 958 967AbstractFree Full Text Tassan J
0.22396544.14684736.html.plaintext.txt	375	92 8871 8875Abstract Edwards M
0.22396544.14684736.html.plaintext.txt	376	18 4291 4300AbstractFree Full Text Lin X
0.22396544.14684736.html.plaintext.txt	377	277 16873 16878AbstractFree Full Text Fu T
0.22396544.14684736.html.plaintext.txt	378	274 34527 34530AbstractFree Full Text Peng J
0.22396544.14684736.html.plaintext.txt	379	12 755 762AbstractFree Full Text McCracken S
0.22396544.14684736.html.plaintext.txt	380	1997 Nature 385 357 361CrossRefMedline Order article via Infotrieve Corden J
0.22396544.14684736.html.plaintext.txt	381	22 413 416CrossRefMedline Order article via Infotrieve Ruegsegger U
0.22396544.14684736.html.plaintext.txt	382	Cell 1 243 253Medline Order article via Infotrieve Blencowe B
0.22396544.14684736.html.plaintext.txt	383	77 277 291CrossRefMedline Order article via Infotrieve Hirose Y
0.22396544.14684736.html.plaintext.txt	384	14 1415 1429Free Full Text de Graaf K
0.22396544.14684736.html.plaintext.txt	385	279 4612 4624AbstractFree Full Text Ariza M
0.22396544.14684736.html.plaintext.txt	386	274 28505 285013AbstractFree Full Text Lahti J
0.22396544.14684736.html.plaintext.txt	387	277 35314 35322AbstractFree Full Text Mori T
0.22396544.14684736.html.plaintext.txt	388	2002 Neoplasia 4 268 274CrossRefMedline Order article via Infotrieve Zhao L
0.22396544.14684736.html.plaintext.txt	389	1 195 206AbstractFree Full Text Redon R
0.22396544.14684736.html.plaintext.txt	390	62 6211 6217AbstractFree Full Text Kasof G
0.22396544.14684736.html.plaintext.txt	391	19 4390 4404AbstractFree Full Text Basu A
0.1763323.12857789.html.plaintext.txt	0	Targeting incoming retroviral Gag centrosome involves direct interaction dynein light chain 8 Coralie Petit1 Marie Lou Giron1 Joelle Tobaly Tapiero1 Patricia Bittoun1 Eleonore Real2 Yves Jacob2 Noel Tordo2 Hugues de The1 Ali Saib1
0.1763323.12857789.html.plaintext.txt	1	1 CNRS UPR9051 Hopital Saint Louis Conventionne par lUniversite Paris 7 1 avenue Claude Vellefaux 75475 Paris Cedex 10 France 2 Laboratoire des Lyssavirus Institut Pasteur 25 rue du Dr Roux 75724 Paris Cedex 15 France
0.1763323.12857789.html.plaintext.txt	2	Author correspondence e mail alisaibatinfobiogen
0.1763323.12857789.html.plaintext.txt	3	Summary Top Summary Introduction Materials Methods Results Discussion References The role cellular proteins replication retroviruses especially virus assembly partly unraveled recent studies
0.1763323.12857789.html.plaintext.txt	4	Paradoxically little known route taken retroviruses reach nucleus early stages infection
0.1763323.12857789.html.plaintext.txt	5	To get insight stage virus replication studied trafficking foamy retroviruses previously shown incoming viral proteins reach microtubule organizing center MTOC prior nuclear translocation viral genome
0.1763323.12857789.html.plaintext.txt	6	Here show incoming viruses concentrate around MTOC free structured capsids
0.1763323.12857789.html.plaintext.txt	7	Interestingly Gag protein scaffold component viral capsids targets pericentrosomal region transfected cells absence viral components microtubule dyneindynactin dependent manner
0.1763323.12857789.html.plaintext.txt	8	Trafficking Gag towards centrosome requires minimal 30 amino acid coiled coil motif N terminus molecule
0.1763323.12857789.html.plaintext.txt	9	Finally describe direct interaction Gag dynein light chain 8 probably accounts specific routing incoming capsids centrosome prior nuclear import viral genome
0.1763323.12857789.html.plaintext.txt	10	Key words Retrovirus Cytoskeleton Trafficking Spumavirus
0.1763323.12857789.html.plaintext.txt	11	Introduction Top Summary Introduction Materials Methods Results Discussion References After penetration host cell pathogens reach sites replication
0.1763323.12857789.html.plaintext.txt	12	To facilitate spread within infected cells viruses evolved many specific mechanisms hijack cellular cytoskeleton Ploubidou Way 2001
0.1763323.12857789.html.plaintext.txt	13	For example microtubules MTs essential herpes simplex virus HSV Sodeik et al
0.1763323.12857789.html.plaintext.txt	14	1997 adenovirus Suomalainen et al
0.1763323.12857789.html.plaintext.txt	15	1999 vaccinia virus VV Ploubidou et al
0.1763323.12857789.html.plaintext.txt	16	2000 reach nuclei infected cells
0.1763323.12857789.html.plaintext.txt	17	VV unique sequentially exploits MT network intracellular movement Rietdorf et al
0.1763323.12857789.html.plaintext.txt	18	2001 Ward Moss 2001 actin cytoskeleton enhance cell cell spread Geada et al
0.1763323.12857789.html.plaintext.txt	19	Intracellular VV particles propelled actin tails formation induced virus mimics cellular receptor tyrosine kinase signaling cascades normally occur actin polymerization plasma membrane Frischknecht et al
0.1763323.12857789.html.plaintext.txt	20	1999 Frischknecht Way 2001 Moreau et al
0.1763323.12857789.html.plaintext.txt	21	2000 situation already reported intracellular movements Listeria Shigella reviewed Frischknecht Way 2001
0.1763323.12857789.html.plaintext.txt	22	In case murine leukemia virus MuLV interaction Gag protein scaffold component retroviral capsids KIF4 microtubule plus end directed motor needed trafficking towards plasma membrane late step infection Tang et al
0.1763323.12857789.html.plaintext.txt	23	However despite growing knowledge host virus interactions little known retroviruses transported periphery center cell early stages infection
0.1763323.12857789.html.plaintext.txt	24	Gaining better insight mechanism retroviruses move within infected cells might improve retrovirus based gene therapy might allow design new therapeutic approaches retroviral pathogens
0.1763323.12857789.html.plaintext.txt	25	Spumaviruses also known foamy viruses FVs complex animal retroviruses encode structural Gag Env enzymatic Pol regulatory products Tas Bet
0.1763323.12857789.html.plaintext.txt	26	Although surface Env glycoproteins needed enter target cells interaction subsequent self multimerization Gag molecules lead capsid formation Eastman Linial 2001 Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	27	Several functional regions identified along scaffold Gag protein
0.1763323.12857789.html.plaintext.txt	28	There three glycineGarginineR rich sequences called GR boxes C terminus implicated viral nucleic acid binding harbor nuclear localization sequence NLS Schliephake Rethwilm 1994 Yu et al
0.1763323.12857789.html.plaintext.txt	29	1996 18 amino acid motif amino acids 43 60 resembling cytoplasmic targeting retention signal CTRS type D retroviruses allows cytoplasmic targeting Gag Eastman Linial 2001 finally coiled coil domain amino acids 130 160 necessary Gag Gag interaction Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	30	The last two motifs required capsid assembly
0.1763323.12857789.html.plaintext.txt	31	Although compelling studies demonstrated requirement Gag late steps infection
0.1763323.12857789.html.plaintext.txt	32	packaging genomic RNA virus egress little known role early steps virus cycle
0.1763323.12857789.html.plaintext.txt	33	We previously shown incoming human foamy virus HFV prototype FVs targets microtubule organizing center MTOC prior nuclear translocation
0.1763323.12857789.html.plaintext.txt	34	Centrosomal targeting incoming viral proteins subsequent viral replication inhibited treatment nocodazole demonstrating involvement MT network FV replication Saib et al
0.1763323.12857789.html.plaintext.txt	35	However precise status viral material MTOC mechanism transport towards organelle unknown
0.1763323.12857789.html.plaintext.txt	36	Here show incoming HFV reaches MTOC naked structured capsids
0.1763323.12857789.html.plaintext.txt	37	Remarkably Gag protein harbors determinant target MTOC requiring domain 30 amino acids predicted fold coiled coil
0.1763323.12857789.html.plaintext.txt	38	Transport Gag MTOC necessitates retrograde MT dependent dyneindynactin motor prevented overexpression central coiled coil domain CC1 p150Glued dynactin sidearm subunit
0.1763323.12857789.html.plaintext.txt	39	Finally direct interaction HFV Gag cytoplasmic light chain dynein LC8 described identifying molecular basis retroviral transport infected cells early steps infection
0.1763323.12857789.html.plaintext.txt	40	Materials Methods Top Summary Introduction Materials Methods Results Discussion References Recombinant DNA All HFV sequences initially derived pHFV13 infectious clone HFV
0.1763323.12857789.html.plaintext.txt	41	Gag expression plasmids generated insertion 2
0.1763323.12857789.html.plaintext.txt	42	54 kb Bsu36I full length Gag pSG Gag 1
0.1763323.12857789.html.plaintext.txt	43	77 kb AvrII pSG Gag575 fragments SmaI site eukaryotic expression vector pSG5M already described Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	44	The full length green fluorescent protein GFP Gag expression plasmid pGFP Gag generated inserting PCR product Gag open reading frame BamHIHindIII sites pEGFP C1 Clontech
0.1763323.12857789.html.plaintext.txt	45	Mutants M1 M8 except M7 derived pGFP Gag plasmid following either digestion appropriate restriction enzymes QuickChange Mutagenesis kit Stratagene
0.1763323.12857789.html.plaintext.txt	46	The sequence encoding first 200 amino acids Gag amplified PCR inserted EcoRI BamHI sites pEGFPN1 vector Clontech leading M7 mutant
0.1763323.12857789.html.plaintext.txt	47	The infectious clone harboring L171G mutation Gag open reading frame ORF obtained subcloning 2884 bp EagI SwaI fragment pHFV13 generated PCR pGEM T vector Promega
0.1763323.12857789.html.plaintext.txt	48	Following site directed mutagenesis EagI SwaI fragment harboring GagL171G mutation re inserted pHFV13 corresponding restriction sites producing pHFVGagL171G
0.1763323.12857789.html.plaintext.txt	49	The pCgp9 vector encoding HFV Gag Pol proteins kindly provided Axel Rethwilm
0.1763323.12857789.html.plaintext.txt	50	The DsRed CC1 expression vector kindly provided T
0.1763323.12857789.html.plaintext.txt	51	GFP LC8 generated inserting PCR amplified LC8 cDNA hDLC1 isoform pEGFP C1 Clontech BamHI site
0.1763323.12857789.html.plaintext.txt	52	LC8Flag already described Jacob et al
0.1763323.12857789.html.plaintext.txt	53	Primers used PCR amplification mutagenesis available request
0.1763323.12857789.html.plaintext.txt	54	Cell culture transfection Hamster BHK21 simian Cos6 cells maintained DMEM Gibco supplemented 5 fetal calf serum 100 microg ml 1 penicillin 50 microg ml 1 streptomycin 2 mM glutamine 240 mM Hepes
0.1763323.12857789.html.plaintext.txt	55	For transfection assays 2x105 Cos6 cells transfected 2 microg recombinant plasmid DNA Lipofectin reagent Gibco BRL specified manufacturer
0.1763323.12857789.html.plaintext.txt	56	20 hours transfection cells fixed permeabilized methanol 20 degrees C 5 minutes
0.1763323.12857789.html.plaintext.txt	57	HFV Gag detected rabbit polyclonal anti Gag antibodies 1400 dilution
0.1763323.12857789.html.plaintext.txt	58	Monoclonal antibodies mAbs vimentin clone V18 used 1100 dilution Sigma antibodies directed centriolar component provided M
0.1763323.12857789.html.plaintext.txt	59	Bornens Curie Institute clone CTR910 used 1100 dilution used experiments
0.1763323.12857789.html.plaintext.txt	60	Fluorescein FITC Texas red TR coupled antibodies used second fluorescent conjugates Biosys dilution 1800 PBS Tween 0
0.1763323.12857789.html.plaintext.txt	61	Cells nuclei stained DAPI
0.1763323.12857789.html.plaintext.txt	62	For confocal analysis cells mounted Mowiol Calbiochem examined using BioRad MRC 1024 confocal imaging system BioRad Microscience inverted Diaphot 300 Nikon microscope
0.1763323.12857789.html.plaintext.txt	63	For fluorescein kryptonargon laser Ion Laser Technology 488 nm filter used
0.1763323.12857789.html.plaintext.txt	64	For TR staining ion laser 568 nm filter used
0.1763323.12857789.html.plaintext.txt	65	Images FITC TR DAPI pseudocolored green red blue respectively
0.1763323.12857789.html.plaintext.txt	66	Virus titers determined using indicator FV activated GFP expression FAG cells harbor GFP ORF control HFV long terminal repeat LTR previously described Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	67	Thus titers measured fluorescent cell forming units FCFU per ml
0.1763323.12857789.html.plaintext.txt	68	Protein analysis 24 hours transfection pSG Gag575 pSG Gag575L171G pLC8Flag co transfection vectors 293T cells labeled 35Smethionine cysteine 200 microCi ml 1 1
0.1763323.12857789.html.plaintext.txt	69	175 Ci mmol 1 specific activity Dupont NEN 3 hours
0.1763323.12857789.html.plaintext.txt	70	Cells rinsed cold PBS lysed 10 mM Tris HCl pH 7
0.1763323.12857789.html.plaintext.txt	71	5 50 mM NaCl 1 mM CaCl2 3 mM MgCl2 anti protease cocktail Sigma followed centrifugation 20000 g 5 minutes 4 degrees C
0.1763323.12857789.html.plaintext.txt	72	Cytoplasmic proteins directly analysed western blot using rabbit anti Gag antibodies following denaturation Laemmli buffer immunoprecipitated anti Flag M2 mAb Sigma CHAPS buffer 10 mM Tris pH 7
0.1763323.12857789.html.plaintext.txt	73	5 150 mM NaCl 1 CHAPS 1 mM PMSF
0.1763323.12857789.html.plaintext.txt	74	For purpose pre cleared cell extracts incubated overnight 4 degrees C M2 anti Flag mAb CHAPS buffer absorbed protein ASepharose
0.1763323.12857789.html.plaintext.txt	75	Immune complexes centrifuged washed four times CHAPS buffer analysed western blot using anti Gag antibodies 1100
0.1763323.12857789.html.plaintext.txt	76	For western blot analyses proteins resolved using SDS 10 polyacrylamide gel electrophoresis
0.1763323.12857789.html.plaintext.txt	77	Culture supernatants Cos6 cells transfected pHFV13 pHFVGagL171G plasmid encoding Gag Pol proteins pCgp9 kindly provided A
0.1763323.12857789.html.plaintext.txt	78	Rethwilm first cleared cellular debris centrifuged 20 sucrose cushion solution containing 100 mM NaCl 10 mM Tris HCl pH 7
0.1763323.12857789.html.plaintext.txt	79	4 1 mM EDTA 80000 g 3 hours SW41 rotor 4 degrees C
0.1763323.12857789.html.plaintext.txt	80	The resulting pellets containing extracellular viruses cellular viral protein extracts parental cells visualized immunoblotting rabbit anti Gag antibodies 1100 peroxidase conjugated antibodies revealed enhanced chemiluminescence Amersham
0.1763323.12857789.html.plaintext.txt	81	GFP Gag fusions analyzed western blot using polyclonal anti GFP antibody sc 8334 TEBU 1100
0.1763323.12857789.html.plaintext.txt	82	Prediction coiled coil motifs performed COILS program httpwww
0.1763323.12857789.html.plaintext.txt	83	Electron microscopy Monolayers fixed situ 1
0.1763323.12857789.html.plaintext.txt	84	6 glutaraldehyde Taab Laboratory Equipment Reading UK 0
0.1763323.12857789.html.plaintext.txt	85	1 M Sorensen phosphate buffer pH 7
0.1763323.12857789.html.plaintext.txt	86	Cells scraped plastic substratum centrifuged
0.1763323.12857789.html.plaintext.txt	87	The resulting pellets successively post fixed 2 aqueous osmium tetroxide 1 hour room temperature dehydrated ethanol embedded Epon
0.1763323.12857789.html.plaintext.txt	88	Ultrathin sections collected 200 mesh copper grids coated Formvar carbon stained uranyl acetate lead citrate prior observation Philips 400 transmission electron microscope 80 kV 2800 36000 x magnification
0.1763323.12857789.html.plaintext.txt	89	Results Top Summary Introduction Materials Methods Results Discussion References HFV Gag targets centrosome transfected cells We previously shown prior nuclear import incoming HFV Gag proteins concentrate around MTOC Saib et al
0.1763323.12857789.html.plaintext.txt	90	This targeting subsequent virus production prevented treating cells nocodazole reflecting importance MTs viral replication
0.1763323.12857789.html.plaintext.txt	91	Moreover reported early 5 hours infection incoming Gag antigens concentrated around MTOC Saib et al
0.1763323.12857789.html.plaintext.txt	92	However unknown whether Gag transported centrosome free assembled capsids unstructured aggregates case retroviruses McDonald et al
0.1763323.12857789.html.plaintext.txt	93	To deal issue permissive BHK21 cells infected HFV low 1 high 10 multiplicity infection m
0.1763323.12857789.html.plaintext.txt	94	fixed 5 hours later analysed electron microscopy EM
0.1763323.12857789.html.plaintext.txt	95	1 incoming viruses mainly detected naked intact capsids 50 nm diameter near MTOC close MTs
0.1763323.12857789.html.plaintext.txt	96	Analysis dozen EM thin sections infected cells revealed average 20 capsids per section around MTOC low m
0.1763323.12857789.html.plaintext.txt	97	average 600 capsids per section high m
0.1763323.12857789.html.plaintext.txt	98	Viral capsids never observed nucleus close nuclear pores
0.1763323.12857789.html.plaintext.txt	99	View larger version 158K Fig
0.1763323.12857789.html.plaintext.txt	100	MTOC targeting incoming HFV early step infection
0.1763323.12857789.html.plaintext.txt	101	Five hours infection numerous free incoming viral capsids detected around centrosome low top high bottom m
0.1763323.12857789.html.plaintext.txt	102	Viral capsids close vicinity microtubules easily observed higher resolution picture centrosomal region
0.1763323.12857789.html.plaintext.txt	103	Scale bar 450 nm upper lower insets
0.1763323.12857789.html.plaintext.txt	104	Because Gag main component capsids next assessed whether Gag absence viral genome viral proteins could still reach centrosome
0.1763323.12857789.html.plaintext.txt	105	For purpose full length Gag expression vector pSG Gag transfected Cos6 cells Gag localization followed confocal microscopy using polyclonal anti Gag antibodies
0.1763323.12857789.html.plaintext.txt	106	20 hours transfection Gag mainly detected unique cytoplasmic dot close nucleus Fig
0.1763323.12857789.html.plaintext.txt	107	Double labeling using mAb clone CTR910 directed centriolar component confirmed staining corresponds accumulation Gag molecules around centrosome Fig
0.1763323.12857789.html.plaintext.txt	108	Expression structural Pol Env regulatory Tas Bet viral proteins never leads centrosomal staining data shown
0.1763323.12857789.html.plaintext.txt	109	View larger version 101K Fig
0.1763323.12857789.html.plaintext.txt	110	The structural Gag protein targets MTOC transfected Cos6 cells
0.1763323.12857789.html.plaintext.txt	111	Following transfection full length Gag expression vector confocal section reveals HFV Gag proteins mainly detected around MTOC revealed CTR910 antibody left
0.1763323.12857789.html.plaintext.txt	112	In Gag expressing cells vimentin network affected observed fluorescence microscopy right
0.1763323.12857789.html.plaintext.txt	113	It recently shown cytoplasm replicating large DNA viruses poxviruses African swine fever virus ASFV assemble aggresomes Heath et al
0.1763323.12857789.html.plaintext.txt	114	2001 structure located close MTOC generated response high levels misfolded proteins Johnston et al
0.1763323.12857789.html.plaintext.txt	115	Aggresome formation induces striking redistribution intermediate filament protein vimentin characteristic halo like cage around aggregates proteins Kopito 2000
0.1763323.12857789.html.plaintext.txt	116	To determine whether accumulation Gag around MTOC corresponded formation aggresome owing high level Gag expression transfected cells Cos6 cells transfected pSG Gag labeled anti Gag anti vimentin antibodies
0.1763323.12857789.html.plaintext.txt	117	As shown fluorescence microscopy Fig
0.1763323.12857789.html.plaintext.txt	118	2 right vimentin network affected Gag expressing cells demonstrating accumulation Gag around MTOC lead formation aggresome
0.1763323.12857789.html.plaintext.txt	119	Mapping minimal Gag sequence involved MTOC targeting Several functional domains already mapped along HFV Gag protein
0.1763323.12857789.html.plaintext.txt	120	To determine whether domains C terminal GR boxes two recently characterized N terminal regions responsible Gag self assembly involved MTOC targeting subcellular localization full length GFP Gag fusion protein deletion mutants investigated Fig
0.1763323.12857789.html.plaintext.txt	121	Cos6 cells transfected constructs GFP fluorescence directly observed 20 hours transfection following cell fixation
0.1763323.12857789.html.plaintext.txt	122	Although GFP alone diffusely localizes cytoplasm nucleus transfected cells never accumulates around MTOC data shown fusion GFP full length Gag targets fusion protein centrosome Fig
0.1763323.12857789.html.plaintext.txt	123	Serial deletions C terminus Gag residue 270 mutant M1 impair MTOC targeting corresponding GFP Gag fusions
0.1763323.12857789.html.plaintext.txt	124	Deletion amino acids 180 200 mutant M3 200 250 mutant M4 effect MTOC targeting whereas deletion amino acids 165 180 mutant M5 totally abolishes centrosomal targeting
0.1763323.12857789.html.plaintext.txt	125	Finally GFP Gag150 250 mutant M2 present around organelle
0.1763323.12857789.html.plaintext.txt	126	Taken together results suggest domain implicated MTOC targeting encompasses amino acids 150 180
0.1763323.12857789.html.plaintext.txt	127	This conclusion however clouded fact M6 mutant encoding GFP Gag1 201 longer detected centrosome
0.1763323.12857789.html.plaintext.txt	128	To assess whether absence MTOC targeting mutant M6 due inadequate positioning putative implicated domain regarding entire fusion protein first 200 amino acids Gag fused N terminus GFP transfected Cos6 cells
0.1763323.12857789.html.plaintext.txt	129	In case fusion protein Gag1 200 GFP mutant M7 detected centrosome suggesting domain involved MTOC targeting must flanked minimal amino acid sequences sides functional
0.1763323.12857789.html.plaintext.txt	130	Taken together results indicate proper centrosomal targeting require presence GR boxes domains involved capsid assembly necessitates sequence amino acids 150 180
0.1763323.12857789.html.plaintext.txt	131	All constructions controlled sequence analysis protein expression verified western blot Fig
0.1763323.12857789.html.plaintext.txt	132	View larger version 71K Fig
0.1763323.12857789.html.plaintext.txt	133	A Minimal Gag sequence requirement MTOC targeting
0.1763323.12857789.html.plaintext.txt	134	Schematic representation GFP Gag fusion proteins
0.1763323.12857789.html.plaintext.txt	135	The locations three glycinearginine rich motifs GR I II III Gag Gag interaction domain ID cytoplasmic targeting retention signal CTRS indicated black boxes
0.1763323.12857789.html.plaintext.txt	136	The numbers indicate percentage GFP positive cells harboring centrosomal staining values average three independent experiments
0.1763323.12857789.html.plaintext.txt	137	B Western blot analysis different GFP fusions revealed rabbit anti GFP antibodies
0.1763323.12857789.html.plaintext.txt	138	C Subcellular localization GFP Gag fusions observed fluorescence microscopy prediction coiled coil motifs first 270 amino acids HFV Gag revealed COILS program matrix MTIDK weight 2
0.1763323.12857789.html.plaintext.txt	139	It noteworthy N terminus HFV Gag harbors three putative coiled coil motifs revealed COILS program Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	140	We previously shown coiled coil motif located amino acids 130 160 crucial Gag Gag interaction Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	141	Interestingly second coiled coil encompassing amino acids 160 180 strikingly matches domain required MTOC targeting identified
0.1763323.12857789.html.plaintext.txt	142	To assess whether motif involved centriolar targeting generated GFP Gag fusion harboring mutation position 171 exchanging crucial leucine glycine disrupting coiled coil motif mutant M8
0.1763323.12857789.html.plaintext.txt	143	3C mutant longer able reach centrosome transfected Cos6 cells
0.1763323.12857789.html.plaintext.txt	144	Dynein dynactin required centrosomal targeting Gag Retrograde movements along MTs minus end directed MT transport require dynein motor complex assisted 20S dynactin cofactor Karki Holzbaur 1999
0.1763323.12857789.html.plaintext.txt	145	The motor activity dislodged cargo overexpression p50dynamitin component dynactin complex disrupting association Burkhardt et al
0.1763323.12857789.html.plaintext.txt	146	This approach widely used demonstrate involvement dynein dynactin complex movement viruses Alonso et al
0.1763323.12857789.html.plaintext.txt	147	However whereas dynamitin overexpression reported effect cytoskeleton HeLa cells Burkhardt et al
0.1763323.12857789.html.plaintext.txt	148	1997 might affect MT organization centrosome integrity Cos cells Quintyne et al
0.1763323.12857789.html.plaintext.txt	149	Interestingly shown overexpression central coiled coil domain CC1 p150Glued dynactin sidearm subunit specific inhibitory effect dynein based transport p50dynamitin Quintyne et al
0.1763323.12857789.html.plaintext.txt	150	Thus assays HeLa cells CC1 expressing vector used instead Cos6 cells p50dynamitin
0.1763323.12857789.html.plaintext.txt	151	4A overexpression DsRed CC1 affect MT network confirming previous studies
0.1763323.12857789.html.plaintext.txt	152	However presence CC1 prevented MTOC targeting Gag co transfected HeLa cells whereas Gag still associated organelle cells transfected empty DS Red vector
0.1763323.12857789.html.plaintext.txt	153	These observations demonstrate targeting Gag MTOC requires dynein dynactin retrograde motor
0.1763323.12857789.html.plaintext.txt	154	In experiments analysed cells contained evenly distributed recombinant proteins avoiding 10 transfected cells harbored large protein aggregates already reported using DsRed expressing vectors
0.1763323.12857789.html.plaintext.txt	155	View larger version 57K Fig
0.1763323.12857789.html.plaintext.txt	156	A Involvement dynein dynactin complex MTOC targeting Gag
0.1763323.12857789.html.plaintext.txt	157	In cells overexpressing CC1 central coiled coil domain p150Glued GFP Gag longer able reach centrosome top
0.1763323.12857789.html.plaintext.txt	158	By contrast expression CC1 disrupt MT network bottom
0.1763323.12857789.html.plaintext.txt	159	B Following nocodazole treatment GFP Gag longer linked pericentrosomal region dispersed within cytoplasm
0.1763323.12857789.html.plaintext.txt	160	Finally GFP Gag transfected Cos6 cells analysed immunofluorescence following treatment nocodazole 20 hours transfection
0.1763323.12857789.html.plaintext.txt	161	4B Gag remains diffuse punctate throughout cytoplasm treated cells never detected MTOC settings
0.1763323.12857789.html.plaintext.txt	162	This observation suggests MT network required target centrosome also stabilize Gag pericentrosomal region
0.1763323.12857789.html.plaintext.txt	163	HFV Gag directly interacts cytoplasmic light chain dynein Cytoplasmic dynein large multisubunit motor complex composed heavy intermediate light chains Karki Holzbaur 1999
0.1763323.12857789.html.plaintext.txt	164	For lyssaviruses specific interaction demonstrated dynein light chain 8 LC8 P phosphoprotein component viral ribonucleoprotein complex providing molecular basis axonal transport neurotropic viruses Jacob et al
0.1763323.12857789.html.plaintext.txt	165	To assess whether HFV Gag could interact LC8 first examined subcellular distribution co transfected cells
0.1763323.12857789.html.plaintext.txt	166	Confocal microscopy revealed 87 98 Gag localized GFP LC8 MTOC depending experiment analysed Fig
0.1763323.12857789.html.plaintext.txt	167	5A consistent possible interaction molecules whereas GFP LC8 distributed throughout cytoplasm expressed alone Fig
0.1763323.12857789.html.plaintext.txt	168	View larger version 50K Fig
0.1763323.12857789.html.plaintext.txt	169	Interaction structural Gag cytoplasmic light chain dynein LC8
0.1763323.12857789.html.plaintext.txt	170	A Cos6 cells co transfected pSG Gag pGFP LC8 analyzed 20 hours later
0.1763323.12857789.html.plaintext.txt	171	As shown confocal section 97 Gag co localizes GFP LC8 MTOC measured using Lasersharp software BioRad whereas GFP LC8 evenly distributed cytoplasm expressed alone
0.1763323.12857789.html.plaintext.txt	172	B A direct interaction LC8 Gag observed immunoprecipitation experiments followed western blotting 293T cells co transfected expression vectors whereas L171G mutation abolishes interaction
0.1763323.12857789.html.plaintext.txt	173	Anti Gag anti Flag antibodies precipitate LC8 HFV Gag respectively proteins expressed alone
0.1763323.12857789.html.plaintext.txt	174	A similar interaction observed M2 mutant GFP Gag150 250 M9 mutant lacks domain involved MTOC targeting
0.1763323.12857789.html.plaintext.txt	175	To investigate interaction co immunoprecipitation experiments performed following cell transfection
0.1763323.12857789.html.plaintext.txt	176	For purpose 293T cells transfected vector encoding Gag GagL171G LC8Flag combination vectors
0.1763323.12857789.html.plaintext.txt	177	A plasmid encoding first 575 amino acids Gag used rather full length molecule full length molecule hardly immunoprecipitated anti Gag antibodies Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	178	Direct analysis protein extracts transfected cells using rabbit anti Gag antibodies revealed presence Gag575 L171G mutant western blot Fig
0.1763323.12857789.html.plaintext.txt	179	By contrast LC8Flag detected immunoprecipitation anti Flag antibodies corresponding transfected cells following metabolic labeling
0.1763323.12857789.html.plaintext.txt	180	These immune complexes subsequently analysed western blot using anti Gag antibodies revealing presence Gag575 cells co transfected pLC8Flag pSG Gag575 whereas signal detected cells expressing Gag575L171G LC8Flag Fig
0.1763323.12857789.html.plaintext.txt	181	Similarly following procedure interaction LC8 detected using M2 mutant encoding GFP Gag150 250 whereas interaction observed cells co transfected vector encoding GFP Gag deleted amino acids 144 277 mutant M9 lacks domain required target MTOC
0.1763323.12857789.html.plaintext.txt	182	View larger version 40K Fig
0.1763323.12857789.html.plaintext.txt	183	Biological role coiled coil motif
0.1763323.12857789.html.plaintext.txt	184	Western blot analysis cell extracts virus pellets cells transfected infectious clone pHFV13 corresponding clone harboring GagL171G mutation pHFVGagL171G pSG Gag pCgp9 detected polyclonal anti Gag antibodies
0.1763323.12857789.html.plaintext.txt	185	The virus titer cells transfected pHFV13 corresponding 9x104 FCFU ml 1 arbitrarily set 100
0.1763323.12857789.html.plaintext.txt	186	The L171G point mutation affect particle release dramatically reduces infectivity corresponding virus 90 6
0.1763323.12857789.html.plaintext.txt	187	These results demonstrate direct interaction cytoplasmic light chain dynein LC8 structural HFV Gag protein
0.1763323.12857789.html.plaintext.txt	188	Effect GagL171G mutation viral cycle Finally assess biological role coiled coil motif amino acids 150 180 HFV Gag virus cycle full length viral clone harboring L171G helix breaking point mutation constructed behavior tissue culture compared parental infectious proviral clone
0.1763323.12857789.html.plaintext.txt	189	Cos6 transfected wild type pHFV13 pHFVGagL171G harboring L171G mutation Gag ORF pSG Gag pCgp9 vector encoding HFV Gag Pol viral proteins 72 hours later viral protein expression transfected cells virus production culture supernatants evaluated
0.1763323.12857789.html.plaintext.txt	190	7 cell extracts proviral clones express similar levels Gag molecules detected doublet 71 kDa 68 kDa polyclonal anti Gag antibodies demonstrating L171G point mutation effect Gag expression stability maturation
0.1763323.12857789.html.plaintext.txt	191	Indeed 71 kDa band corresponds full length Gag precursor p71 visualized pSG Gag transfected cells whereas 68 kDa product represents main cleavage product p68 mirroring presence active viral protease Giron et al
0.1763323.12857789.html.plaintext.txt	192	To assess whether Gag mutation affected virus egress supernatants transfected cells ultracentrifuged sucrose gradient resulting pellets contained extracellular virions analysed western blot using polyclonal anti Gag antibodies
0.1763323.12857789.html.plaintext.txt	193	In case major difference observed pHFV13 pHFVGagL171G demonstrating virus egress impaired helix breaking point mutation Gag
0.1763323.12857789.html.plaintext.txt	194	No viral particles produced neither pSG Gag pCgp9 transfected cells expected contrast retroviruses FV particle formation requires presence homologous envelope Pietschmann et al
0.1763323.12857789.html.plaintext.txt	195	Finally virus production culture supernatants evaluated following infection indicator cell line FAG cells harbor GFP ORF control HFV LTR already described Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	196	Direct fluorescence observed 48 hours infection reveals significant virus production pHFV13 transfected cells 9x104 FCFU ml 1 whereas Gag mutation dramatically reduced infectivity corresponding provirus totally abolished 6
0.1763323.12857789.html.plaintext.txt	197	Values averages three independent experiments
0.1763323.12857789.html.plaintext.txt	198	Altogether data demonstrate L171G mutation Gag ORF effect virus egress drastically reduces infectivity corresponding proviral clone
0.1763323.12857789.html.plaintext.txt	199	Discussion Top Summary Introduction Materials Methods Results Discussion References Several bacteria viruses shown subvert cytoskeleton intracellular trafficking Dramsi Cossart 1998 Frischknecht Way 2001 Ploubidou Way 2001 Sodeik 2000
0.1763323.12857789.html.plaintext.txt	200	However despite growing body knowledge accumulating field retroviruses reach nucleus newly infected cell still poorly understood
0.1763323.12857789.html.plaintext.txt	201	To shed new light stage viral replication studied route taken HFV animal retrovirus early steps infection
0.1763323.12857789.html.plaintext.txt	202	By EM show incoming HFV proteins concentrate pericentrosomal region free structured capsids close MTs
0.1763323.12857789.html.plaintext.txt	203	More viral capsids surround MTOC expected multiplicity infection used
0.1763323.12857789.html.plaintext.txt	204	Indeed extracellular retroviral particles produced infection harbor defective genome therefore unable transactivate viral LTR GFP indicator cells Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	205	In case HIV 1 reported infectivity particle ratio low 1 60000 Kimpton Emerman 1992 Piatak et al
0.1763323.12857789.html.plaintext.txt	206	1993 whereas recent study softened conclusion showing ratio 1 infectious particle 10 Andreadis et al
0.1763323.12857789.html.plaintext.txt	207	Furthermore demonstrate determinants required reach pericentrosomal area harbored scaffold component viral capsids structural Gag protein protein alone targets centrosome transfected cells absence viral partners
0.1763323.12857789.html.plaintext.txt	208	Because vimentin network affected Gag transfected cells accumulation Gag around MTOC trigger formation aggresome
0.1763323.12857789.html.plaintext.txt	209	However similar formation inclusion body Garcia Mata et al
0.1763323.12857789.html.plaintext.txt	210	1999 Gag transport towards MTOC involves retrograde dynein dynactin motor prevented overproduction CC1 central coiled coil domain p150Glued reported disrupt function retrograde motor
0.1763323.12857789.html.plaintext.txt	211	Other viruses shown use MT network intracellular transport
0.1763323.12857789.html.plaintext.txt	212	For instance adenovirus type 2 Ad2 HSV two nuclear replicative DNA viruses entering cell receptor mediated endocytosis direct membrane fusion respectively transported naked capsids towards nucleus via MT network Sodeik et al
0.1763323.12857789.html.plaintext.txt	213	For ASFV rabies viruses two viruses use MT network move within infected cell interaction LC8 forms molecular basis trafficking Alonso et al
0.1763323.12857789.html.plaintext.txt	214	The interaction LC8 HFV Gag described could play role case FVs
0.1763323.12857789.html.plaintext.txt	215	LC8 first identified integral component Chlamydomonas reinhardtii outer dynein arm Pfister et al
0.1763323.12857789.html.plaintext.txt	216	1982 Piperno Luck 1979
0.1763323.12857789.html.plaintext.txt	217	Since evolutionarily conserved molecule shown interact many cellular complexes nitric oxide synthase Jaffrey Snyder 1996 myosin V Goode et al
0.1763323.12857789.html.plaintext.txt	218	2000 actin based motor mainly located plasma membrane shuttles cell periphery MTOC along MT network Espreafico et al
0.1763323.12857789.html.plaintext.txt	219	LC8 encoded least two genes humans Naisbitt et al
0.1763323.12857789.html.plaintext.txt	220	2000 leading synthesis dynein light chain 2 DLC2 dynein light chain 1 DLC1 isoform used work
0.1763323.12857789.html.plaintext.txt	221	Interestingly myosin V shown interact DLC2 DLC1 Naisbitt et al
0.1763323.12857789.html.plaintext.txt	222	Thus migration HFV capsids towards centrosome microtubule network probably involves interaction dynein LC8 DLC1 rather myosin V LC8 DLC2
0.1763323.12857789.html.plaintext.txt	223	In sense HFV efficiently targets centrosomal region replicates myosin V deficient melanoma S91 6 cells E
0.1763323.12857789.html.plaintext.txt	224	However cannot exclude possibility HFV Gag also interacts DLC2 component myosin V favoring trafficking actin beneath plasma membrane devoid microtubules
0.1763323.12857789.html.plaintext.txt	225	Therefore interaction incoming FV capsids multifunctional LC8 could provide bridge shuttle actin based motor beneath plasma membrane MT network within cytoplasm
0.1763323.12857789.html.plaintext.txt	226	Remarkably similar MT dynein dependent trafficking towards centrosome recently described incoming HIV 1 although viral cellular protagonists involved retrograde transport determined McDonald et al
0.1763323.12857789.html.plaintext.txt	227	Nevertheless observations suggest distinct classes retroviruses might tether dynein dynactin complex motor MT network early stage infection reach nucleus opening new perspectives development anti retroviral drugs
0.1763323.12857789.html.plaintext.txt	228	Analysis subcellular distribution Gag deletion mutants reveals GR boxes well determinants involved capsid assembly Gag Gag interaction domain CTRS required target centrosome whereas amino acids 150 180 necessary reach organelle
0.1763323.12857789.html.plaintext.txt	229	This region harbor obvious similarities two previously described LC8 interacting motifs KRXTQT GIQVD Lo et al
0.1763323.12857789.html.plaintext.txt	230	2001 coiled coil motif conserved primate foamy viruses Tobaly Tapiero et al
0.1763323.12857789.html.plaintext.txt	231	2001 seems involved centriolar targeting Gag
0.1763323.12857789.html.plaintext.txt	232	In sense single point mutation L171G Gag ORF leading disruption coiled coil motif abolishes MTOC targeting corresponding GFP Gag fusion renders full length viral clone non infectious
0.1763323.12857789.html.plaintext.txt	233	Indeed whereas Gag assembly virus release affected helix breaking point mutation productive infection naive cells dramatically reduced
0.1763323.12857789.html.plaintext.txt	234	Because mutation shown prevent GagLC8 interaction tethering dynein retrograde motor following entry cytoplasm might impaired hypothesis currently exploring
0.1763323.12857789.html.plaintext.txt	235	The L171G point mutation totally abolish infectivity suggesting trafficking pathways might used FVs reach center cell
0.1763323.12857789.html.plaintext.txt	236	In sense intracellular trafficking involving actin cytoskeleton might account observation alternative route already put forward HIV 1 McDonald et al
0.1763323.12857789.html.plaintext.txt	237	2002 previously suggested FVs Gag also shown interact actin Giron et al
0.1763323.12857789.html.plaintext.txt	238	HFV Gag unique partner LC8 lacking two characterized LC8 interacting motifs
0.1763323.12857789.html.plaintext.txt	239	Interestingly proteins harbor helical coiled coil domain identified LC8 binding region
0.1763323.12857789.html.plaintext.txt	240	For example LC8 interacting domain myosin V predicted fold amphiphilic helix Naisbitt et al
0.1763323.12857789.html.plaintext.txt	241	2000 similarly signal response domain IB shown interact LC8 Crepieux et al
0.1763323.12857789.html.plaintext.txt	242	1997 folds coiled coil revealed COILS program data shown
0.1763323.12857789.html.plaintext.txt	243	Such hypothesis might also apply neuronal form nitric oxide synthase nNOS Benashski et al
0.1763323.12857789.html.plaintext.txt	244	Given LC8 harbors similar amphiphilic helix triggering multimerization Benashski et al
0.1763323.12857789.html.plaintext.txt	245	1997 interactions LC8 myosin V IB nNOS HFV Gag might occur via specific protein motif interface constituting new mode contact LC8
0.1763323.12857789.html.plaintext.txt	246	One remaining issue viral genome wrapped Gag molecules imported nucleus
0.1763323.12857789.html.plaintext.txt	247	Interestingly dynein dynactin complex recently shown associate nuclear envelope facilitating remodeling physical frontier Busson et al
0.1763323.12857789.html.plaintext.txt	248	Therefore interaction Gag dynein dynactin complex could drive incoming viral capsids towards centrosome also involved subsequent targeting nuclear envelope
0.1763323.12857789.html.plaintext.txt	249	Yet HFV capsids never detected within nucleus close nuclear pores even later replication cycle Fischer et al
0.1763323.12857789.html.plaintext.txt	250	1998 whereas unassembled Gag proteins viral genome detected nucleus early infection Saib et al
0.1763323.12857789.html.plaintext.txt	251	1997 Schliephake Rethwilm 1994
0.1763323.12857789.html.plaintext.txt	252	Therefore contrast Ad2 HSV capsids dock nuclear pore triggering nuclear translocation viral genome Greber et al
0.1763323.12857789.html.plaintext.txt	253	2001 nuclear import HFV Gag genome must accompanied disassembly significant deformation core particle MTOC
0.1763323.12857789.html.plaintext.txt	254	Acknowledgments We thank T
0.1763323.12857789.html.plaintext.txt	255	Schroer providing p50dynamitin DsRed CC1 vectors E
0.1763323.12857789.html.plaintext.txt	256	Espreafico providing S91 6 melanoma cells M
0.1763323.12857789.html.plaintext.txt	257	Bornens providing anti centriole antibodies F
0.1763323.12857789.html.plaintext.txt	258	Saumet help LPH F
0.1763323.12857789.html.plaintext.txt	259	Brau photographic work F
0.1763323.12857789.html.plaintext.txt	260	Lallemand critical reading manuscript kind help
0.1763323.12857789.html.plaintext.txt	261	This study supported ARC grant 5981 F
0.1763323.12857789.html.plaintext.txt	262	CP supported SIDACTIONEnsemble Contre le Sida grant AO12 2
0.1763323.12857789.html.plaintext.txt	263	References Top Summary Introduction Materials Methods Results Discussion References
0.1763323.12857789.html.plaintext.txt	264	African swine fever virus protein p54 interacts microtubular motor complex direct binding light chain dynein
0.1763323.12857789.html.plaintext.txt	265	Toward accurate quantitation activity recombinant retroviruses alternatives titer multiplicity infection
0.1763323.12857789.html.plaintext.txt	266	Dimerization highly conserved light chain shared dynein myosin V
0.1763323.12857789.html.plaintext.txt	267	Overexpression dynamitin p50 subunit dynactin complex disrupts dynein dependent maintenance membrane organelle distribution
0.1763323.12857789.html.plaintext.txt	268	Dynein dynactin localized astral microtubules cortical sites mitotic epithelial cells
0.1763323.12857789.html.plaintext.txt	269	I kappa B alpha physically interacts cytoskeleton associated protein signal response domain
0.1763323.12857789.html.plaintext.txt	270	Function dynein dynactin herpes simplex virus capsid transport
0.1763323.12857789.html.plaintext.txt	271	Intracellular pathogens actin cytoskeleton
0.1763323.12857789.html.plaintext.txt	272	Identification conserved residue foamy virus Gag required intracellular capsid assembly
0.1763323.12857789.html.plaintext.txt	273	Localization myosin V centrosome
0.1763323.12857789.html.plaintext.txt	274	Foamy virus particle formation
0.1763323.12857789.html.plaintext.txt	275	Surfing pathogens lessons learned actin polymerization
0.1763323.12857789.html.plaintext.txt	276	Actin based motility vaccinia virus mimics receptor tyrosine kinase signalling
0.1763323.12857789.html.plaintext.txt	277	Characterization dynamics aggresome formation cytosolic GFP chimera
0.1763323.12857789.html.plaintext.txt	278	Movements vaccinia virus intracellular enveloped virions GFP tagged F13L envelope protein
0.1763323.12857789.html.plaintext.txt	279	Expression maturation human foamy virus Gag precursor polypeptides
0.1763323.12857789.html.plaintext.txt	280	Functional cooperation microtubule actin cytoskeletons
0.1763323.12857789.html.plaintext.txt	281	The role nuclear pore complex adenovirus DNA entry
0.1763323.12857789.html.plaintext.txt	282	Aggresomes resemble sites specialized virus assembly
0.1763323.12857789.html.plaintext.txt	283	Vaccinia virus utilizes microtubules movement cell surface
0.1763323.12857789.html.plaintext.txt	284	Cytoplasmic dynein LC8 interacts lyssavirus phosphoprotein
0.1763323.12857789.html.plaintext.txt	285	PIN associated protein inhibitor neuronal nitric oxide synthase
0.1763323.12857789.html.plaintext.txt	286	Aggresomes cellular response misfolded proteins
0.1763323.12857789.html.plaintext.txt	287	Cytoplasmic dynein dynactin cell division intracellular transport
0.1763323.12857789.html.plaintext.txt	288	Detection replication competent pseudotyped human immunodeficiency virus sensitive cell line basis activation integrated beta galactosidase gene
0.1763323.12857789.html.plaintext.txt	289	Aggresomes inclusion bodies protein aggregation
0.1763323.12857789.html.plaintext.txt	290	The 8 kDa dynein light chain binds targets via conserved KRXTQT motif
0.1763323.12857789.html.plaintext.txt	291	Visualization intracellular behavior HIV living cells
0.1763323.12857789.html.plaintext.txt	292	A complex N WASP WIP integrates signalling cascades lead actin polymerization
0.1763323.12857789.html.plaintext.txt	293	Interaction postsynaptic density 95guanylate kinase domain associated protein complex light chain myosin V dynein
0.1763323.12857789.html.plaintext.txt	294	Herpes simplex virus type 1 entry host cells reconstitution capsid binding uncoating nuclear pore complex vitro
0.1763323.12857789.html.plaintext.txt	295	Purification polypeptide composition dynein ATPases Chlamydomonas flagella
0.1763323.12857789.html.plaintext.txt	296	High levels HIV 1 plasma stages infection determined competitive PCR
0.1763323.12857789.html.plaintext.txt	297	Foamy virus capsids require cognate envelope protein particle export
0.1763323.12857789.html.plaintext.txt	298	Axonemal adenosine triphosphatases flagella Chlamydomonas reinhardtii
0.1763323.12857789.html.plaintext.txt	299	Viral transport cytoskeleton
0.1763323.12857789.html.plaintext.txt	300	Vaccinia virus infection disrupts microtubule organization centrosome function
0.1763323.12857789.html.plaintext.txt	301	Bmf proapoptotic BH3 protein regulated interaction myosin V actin motor complex activated anoikis
0.1763323.12857789.html.plaintext.txt	302	Dynactin required microtubule anchoring centrosomes
0.1763323.12857789.html.plaintext.txt	303	Interaction rabies virus P protein LC8 dynein light chain
0.1763323.12857789.html.plaintext.txt	304	Kinesin dependent movement microtubules precedes actin based motility vaccinia virus
0.1763323.12857789.html.plaintext.txt	305	Identification novel cellular proteins bind LC8 dynein light chain using pepscan technique
0.1763323.12857789.html.plaintext.txt	306	Nuclear targeting incoming human foamy virus Gag proteins involves centriolar step
0.1763323.12857789.html.plaintext.txt	307	Cytoplasmic dynein facilitator nuclear envelope breakdown
0.1763323.12857789.html.plaintext.txt	308	Nuclear localization foamy virus Gag precursor protein
0.1763323.12857789.html.plaintext.txt	309	Mechanisms viral transport cytoplasm
0.1763323.12857789.html.plaintext.txt	310	Microtubule mediated transport incoming herpes simplex virus 1 capsids nucleus
0.1763323.12857789.html.plaintext.txt	311	Researchers cell motility cytoskeleton play major roles understanding AIDS
0.1763323.12857789.html.plaintext.txt	312	CO2 PlinktypeDOI CrossRefMedline
0.1763323.12857789.html.plaintext.txt	313	Microtubule dependent plus minus end directed motilities competing processes nuclear targeting adenovirus
0.1763323.12857789.html.plaintext.txt	314	Cellular motor protein KIF 4 associates retroviral Gag
0.1763323.12857789.html.plaintext.txt	315	Human foamy virus capsid formation requires interaction domain N terminus Gag
0.1763323.12857789.html.plaintext.txt	316	Import adenovirus DNA involves nuclear pore complex receptor CANNup214 histone H1
0.1763323.12857789.html.plaintext.txt	317	Subcellular localization GFP myosin V live mouse melanocytes
0.1763323.12857789.html.plaintext.txt	318	Vaccinia virus intracellular movement associated microtubules independent actin tails
0.1763323.12857789.html.plaintext.txt	319	The carboxyl terminus human foamy virus Gag protein contains separable nucleic acid binding nuclear transport domains
0.1763323.12857789.html.plaintext.txt	320	Retrovirus trafficking gagged dynein bound JCS 2003 116 1602
0.14963757.15831940.html.plaintext.txt	0	Human papillomavirus 16 virus like particles use heparan sulfates bind dendritic cells colocalize langerin Langerhans cells Latifa Bousarghin1 Pascale Hubert1 Elisabeth Franzen1 Nathalie Jacobs12 Jacques Boniver1 Philippe Delvenne1
0.14963757.15831940.html.plaintext.txt	1	1 University Hospital Liege Department Pathology Tour de Pathologie B35 B 4000 Liege Belgium 2 Department Virology Faculty Medicine Imperial College London St Marys Campus Norfolk Place London W2 1PG UK
0.14963757.15831940.html.plaintext.txt	2	Correspondence Latifa Bousarghin bousarghinatuniv tours
0.14963757.15831940.html.plaintext.txt	3	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Langerhans cells LC immature dendritic cells DC reside epithelial tissues among first immune cells encounter human papillomavirus HPV activated HPV virus like particles VLPs contrast DC
0.14963757.15831940.html.plaintext.txt	4	The notion differences response HPV VLPs LC DC associated different types cell binding intracellular trafficking addressed
0.14963757.15831940.html.plaintext.txt	5	Inhibition experiments heparin sodium chlorate showed heparan sulfates necessary HPV 16 VLPs bind DC LC
0.14963757.15831940.html.plaintext.txt	6	Electron microscopy analysis demonstrated colocalization HPV 16 VLPs langerin expressed LC
0.14963757.15831940.html.plaintext.txt	7	This colocalization observed cell surface also cytoplasmic vesicles
0.14963757.15831940.html.plaintext.txt	8	As anti langerin antibodies HPV 16 VLPs associated faster entry kinetics LC reflected fact VLPs observed near nuclear membrane LC within 10 min whereas 60 min needed DC
0.14963757.15831940.html.plaintext.txt	9	However difference LC DC observed endocytosis pathway
0.14963757.15831940.html.plaintext.txt	10	HPV 16 VLPs entered DC LC clathrin dependent pathway localized large cytoplasmic vesicles resembling endosomes
0.14963757.15831940.html.plaintext.txt	11	Present address Laboratoire de Virologie Moleculaire INSERM U618 Faculte de Pharmacie 31 Avenue Monge 37000 Tours France
0.14963757.15831940.html.plaintext.txt	12	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Cervical cancer second frequent cause death cancer amongst females worldwide associated human papillomavirus HPV infection represents one best examples human cancer preceded well characterized preneoplastic period Richart Barron 1967 Richart 1987
0.14963757.15831940.html.plaintext.txt	13	Despite evidence specific types HPV strongly implicated causative agents aetiology cervical cancer precursors designated squamous intraepithelial lesions SILs HPV alone sufficient cancer development Chen et al
0.14963757.15831940.html.plaintext.txt	14	The role intrinsic immunity controlling HPV infection subsequent development SILs shown indirectly increased frequency HPV associated lesions patients depressed cell mediated immunity Petry et al
0.14963757.15831940.html.plaintext.txt	15	Initiation progression HPV associated cancer uterine cervix shown related functional alterations Langerhans cells LC within cervical epithelium Giannini et al
0.14963757.15831940.html.plaintext.txt	16	LC immature dendritic cells DC myeloid origin resident squamous epithelia including skin genital mucosa
0.14963757.15831940.html.plaintext.txt	17	The normal function LC survey cell surfaces pathogens capture antigens micropinocytosis mannose receptor mediated uptake process captured proteins immunogenic peptides emigrate tissue lymph nodes present peptides context major histocompatibility complex MHC molecules T cells thereby initiating antigen specific immune responses
0.14963757.15831940.html.plaintext.txt	18	LC cells constitutively express MHC class II molecules CD1a Fithian et al
0.14963757.15831940.html.plaintext.txt	19	1981 langerin CD207 Valladeau et al
0.14963757.15831940.html.plaintext.txt	20	In addition LC differ ultrastructurally DC presence unique pentalamellar cytoplasmic organelle Birbeck granule
0.14963757.15831940.html.plaintext.txt	21	Because role initiating antiviral immune response DC LC represent ideal target immune evasion viruses
0.14963757.15831940.html.plaintext.txt	22	Several viruses interfere DC function especially measles virus Grosjean et al
0.14963757.15831940.html.plaintext.txt	23	1997 vaccinia virus Drillien et al
0.14963757.15831940.html.plaintext.txt	24	1999 dengue virus Tassaneetrithep et al
0.14963757.15831940.html.plaintext.txt	25	The study interactions HPV DC LC complicated fact native infectious HPV virions cannot isolated large enough quantities either vitro vivo
0.14963757.15831940.html.plaintext.txt	26	However HPV DC HPV LC interactions may studied using HPV virus like particles VLPs morphologically mimic native virions Lenz et al
0.14963757.15831940.html.plaintext.txt	27	HPV VLPs non enveloped icosahedral particles composed L1 major capsid protein form via self assembly nucleus high level expression L1 eukaryotic cells Kirnbauer et al
0.14963757.15831940.html.plaintext.txt	28	2002 reported DC LC able bind internalize HPV VLPs
0.14963757.15831940.html.plaintext.txt	29	However contrast DC LC incubated VLPs upregulate activation markers initiate immune response migrate vivo skin explants Fausch et al
0.14963757.15831940.html.plaintext.txt	30	In study showed HPV 16 VLPs bind similarly DC LC use different types cell binding intracellular trafficking
0.14963757.15831940.html.plaintext.txt	31	Heparan sulfates necessary VLPs bind DC LC
0.14963757.15831940.html.plaintext.txt	32	Electron microscopy analysis demonstrated colocalization HPV 16 VLPs langerin LC
0.14963757.15831940.html.plaintext.txt	33	However difference LC DC observed endocytosis pathway
0.14963757.15831940.html.plaintext.txt	34	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Production purification HPV 16 VLPs
0.14963757.15831940.html.plaintext.txt	35	HPV 16 VLPs expressed Sf9 cells infected recombinant baculovirus encoding HPV 16 L1 protein incubated 27 degrees C 72 h Touze et al
0.14963757.15831940.html.plaintext.txt	36	Cells harvested centrifugation resuspended PBS containing 0 5 NP40 allowed stand 4 degrees C 30 min
0.14963757.15831940.html.plaintext.txt	37	Cell lysates centrifuged 14 000 g 15 min 4 degrees C
0.14963757.15831940.html.plaintext.txt	38	The nuclear fraction resuspended PBS sonicated
0.14963757.15831940.html.plaintext.txt	39	This fraction loaded top preformed CsCl gradient centrifuged equilibrium Beckman SW28 rotor 24 h 27 000 r
0.14963757.15831940.html.plaintext.txt	40	L1 positive fractions pooled PBS centrifuged 3 h 28 000 r
0.14963757.15831940.html.plaintext.txt	41	VLPs resuspended 0 15 M NaCl
0.14963757.15831940.html.plaintext.txt	42	Carboxy fluorescein diacetate succinimyl ester CFDA SE labelling HPV 16 VLPs
0.14963757.15831940.html.plaintext.txt	43	Purified HPV 16 VLPs diluted PBS pH 8 5 0
0.14963757.15831940.html.plaintext.txt	44	CFDA SE Molecular Probes added final concentration 100 microM Drobni et al
0.14963757.15831940.html.plaintext.txt	45	Succinimyl ester group reacts primary amines VLPs forms stable conjugates
0.14963757.15831940.html.plaintext.txt	46	Inside cells acetate CFDA SE cleaved intracellular esterases yields highly fluorescent particles
0.14963757.15831940.html.plaintext.txt	47	After incubation 2 h room temperature reactions subjected centrifugation sucrose density gradient using 30 70 separate VLPs free CFDA SE
0.14963757.15831940.html.plaintext.txt	48	Fractions 1 ml collected L1 positive fractions pooled PBS sedimented ultracentrifugation
0.14963757.15831940.html.plaintext.txt	49	The pellet resuspended 0 15 M NaCl
0.14963757.15831940.html.plaintext.txt	50	To characterize integrity CFDA SE labelled VLP VLPs tested ELISA H16
0.14963757.15831940.html.plaintext.txt	51	V5 monoclonal antibody mAb Christensen et al
0.14963757.15831940.html.plaintext.txt	52	Plates coated VLP different dilutions stored overnight 4 degrees C washed four times PBS blocked 1 fetal calf serum FCS
0.14963757.15831940.html.plaintext.txt	53	The mAb diluted 1 5000 PBS FCS allowed bind HPV VLP 1 h room temperature
0.14963757.15831940.html.plaintext.txt	54	After four stringent washes bound primary antibody probed relevant streptavidin labelled secondary antibody absorbances ELISA plate read 450 nm
0.14963757.15831940.html.plaintext.txt	55	Generation human DC LC DC culture
0.14963757.15831940.html.plaintext.txt	56	Peripheral blood mononuclear cells PBMCs isolated heparinized leukocyte enriched buffy coats healthy adult donors Lymphoprep Lucron Bioproduct density gradient centrifugation applying 400 g room temperature
0.14963757.15831940.html.plaintext.txt	57	After two washes PBMCs plated tissue culture dishes density 1x107 cells ml 1 RPMI 1640 without serum incubated 24 h 37 degrees C select adherent cells
0.14963757.15831940.html.plaintext.txt	58	Non adherent cells washed away RPMI 1640 remaining adherent cells cultured 6 days medium containing 800 U granulocyte macrophage colony stimulating factor GM CSF Amoytop Biotech ml 1 20 U interleukin IL 4 Biosource ml 1
0.14963757.15831940.html.plaintext.txt	59	Routinely 70 DC displayed CD1a phenotype assessed flow cytometry
0.14963757.15831940.html.plaintext.txt	60	CD34 cells 1x105 isolated cord blood mononuclear cells using MACS Direct CD34 Progenitor Cell Isolation kit Miltenyi Biotec seeded T25 flasks Sarstedt 10 ml RPMI 1640 medium supplemented 10 FCS antibiotics 50 microM mercaptoethanol Gibco BRL
0.14963757.15831940.html.plaintext.txt	61	Cultures supplemented previously optimized concentrations following human molecules 20 ng stem cell factor ml 1 10 U thrombopoietin ml 1 25 ng Flt3 ligand ml 1 200 U GM CSF ml 1 50 U tumour necrosis factor TNF ml 1 100 U IL4 ml 1 5 ng transforming growth factor TGF ml 1
0.14963757.15831940.html.plaintext.txt	62	All agents purchased PeproTech except GM CSF IL4 obtained Amoytop Biotech Biosource respectively
0.14963757.15831940.html.plaintext.txt	63	The cells cultured 37 degrees C humidified atmosphere presence 5 CO2
0.14963757.15831940.html.plaintext.txt	64	At day 7 cellular density adjusted 2x104 per cm2 cells fed days 7 14 GM CSF IL4 TNF TGF
0.14963757.15831940.html.plaintext.txt	65	At day 18 cells collected cultures vigorous pipetting prepare single cell populations
0.14963757.15831940.html.plaintext.txt	66	To detect cell associated VLPs DC LC collected respectively day 6 18 transferred new 24 well plates density 2x105 cells ml 1
0.14963757.15831940.html.plaintext.txt	67	DC LC exposed CFDA SE labelled VLPs VLPs alone 10 microg ml 1 RPMI 1640 medium 1 h 37 degrees C
0.14963757.15831940.html.plaintext.txt	68	Unbound labelled VLPs removed extensive washing PBS
0.14963757.15831940.html.plaintext.txt	69	RPMI 1640 medium replaced RPMI 1640 containing 10 FCS cells incubated 37 degrees C 6 h
0.14963757.15831940.html.plaintext.txt	70	Flow cytometry measured fluorescence DC LC resulting uptake labelled VLPs
0.14963757.15831940.html.plaintext.txt	71	The relative fluorescent intensity measured using FACSVantage SE Cellquest software Becton Dickinson
0.14963757.15831940.html.plaintext.txt	72	Typically 20 000 events collected experiment
0.14963757.15831940.html.plaintext.txt	73	Transmission electron microscopy
0.14963757.15831940.html.plaintext.txt	74	DC LC incubated VLPs described different lengths time
0.14963757.15831940.html.plaintext.txt	75	Cells centrifuged room temperature prepared electron microscopy
0.14963757.15831940.html.plaintext.txt	76	They fixed room temperature 4 glutaraldehyde Laborimpex post fixed 1 osmium tetroxide Laborimpex 1 h 4 degrees C
0.14963757.15831940.html.plaintext.txt	77	Cells dehydrated graded 70 90 100 ethanol solutions VWR International
0.14963757.15831940.html.plaintext.txt	78	Fixed cells embedded Epon Serva propylene oxide Laborimpex hardened 60 degrees C
0.14963757.15831940.html.plaintext.txt	79	Ultrathin sections stained uranyl acetate Fluka lead citrate Leica
0.14963757.15831940.html.plaintext.txt	80	These sections examined using transmission electron microscope LEO 906E 60 kV Zeiss
0.14963757.15831940.html.plaintext.txt	81	DC LC incubated HPV 16 VLPs
0.14963757.15831940.html.plaintext.txt	82	After two washes PBS specimens incubated 1 h 4 degrees C anti langerin antibody Beckman
0.14963757.15831940.html.plaintext.txt	83	Other sections incubated unrelated antibody anti CD3 mAb anti 6 integrin antibody Sigma
0.14963757.15831940.html.plaintext.txt	84	Fixed antibodies revealed anti mouse IgG coupled 20 nm colloidal gold particles Tebu bio
0.14963757.15831940.html.plaintext.txt	85	Cells washed fixed treated electron microscopy analysis
0.14963757.15831940.html.plaintext.txt	86	DC LC incubated cell trafficking inhibitors following concentrations 25 microM chlorpromazine Sigma induces misassembly clathrin coated pits plasma membrane preventing clathrin recycling 2 microM cytochalasin D Sigma causes disruption actin filaments actin polymerization inhibition 25 microM nystatin 5 microg filipin ml 1 Sigma inhibit caveolae pathway
0.14963757.15831940.html.plaintext.txt	87	For blocking mannose type receptors LC also preincubated mannan Saccharomyces cerevisiae 5 mg ml 1 Sigma
0.14963757.15831940.html.plaintext.txt	88	Labelled VLPs incubated DC LC presence inhibitors 1 h
0.14963757.15831940.html.plaintext.txt	89	Washed cells incubated culture medium 6 h
0.14963757.15831940.html.plaintext.txt	90	Fluorescence DC LC resulting uptake CFDA SE labelled VLPs measured flow cytometry described earlier
0.14963757.15831940.html.plaintext.txt	91	Analysis VLP heparan sulfate interactions
0.14963757.15831940.html.plaintext.txt	92	Heparan sulfate expression LC DC detected anti syndecan 1 anti syndecan 4 mAb Santa Cruz Biotechnology followed goat anti mouse phycoerythrin PE antibody analysed flow cytometry
0.14963757.15831940.html.plaintext.txt	93	Labelled VLPs incubated heparin heparin leo Leo Pharma 37 degrees C 1 h adsorption DC LC
0.14963757.15831940.html.plaintext.txt	94	These cells washed PBS incubated appropriate medium 6 h 37 degrees C
0.14963757.15831940.html.plaintext.txt	95	Internalization efficiency assessed detecting cell fluorescence flow cytometry
0.14963757.15831940.html.plaintext.txt	96	To examine role heparan sulfates cell binding DC LC also incubated heparinase II 1 U ml 1 Sigma cleaves N acetyl D glucosaminidic linkage medium containing 20 mM TrisHCl 50 mM NaCl 4 mM CaCl2 0 01 BSA pH 6 8
0.14963757.15831940.html.plaintext.txt	97	After incubation 1 h 37 degrees C one wash PBS DC LC incubated labelled VLPs
0.14963757.15831940.html.plaintext.txt	98	To reduce sulfation heparan sulfate cell surface DC LC cultured 48 h presence sodium chlorate 100 microM described previously Bousarghin et al
0.14963757.15831940.html.plaintext.txt	99	Sodium chlorate acts competitive inhibitor sulfate recognition ATP sulfurylase first enzyme sulfate assimilation pathway Farley et al
0.14963757.15831940.html.plaintext.txt	100	Pretreated cells incubated labelled VLPs fluorescence measured flow cytometry
0.14963757.15831940.html.plaintext.txt	101	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Binding uptake labelled VLPs DC LC To investigate interactions viral particles antigen presenting cells studied binding HPV 16 VLPs DC LC generated vitro
0.14963757.15831940.html.plaintext.txt	102	In vitro generated LC exhibited morphological Birbeck granules immunohistochemical features LC observed FACS analysis surface phenotype CD1a CD207langerin E cadherin CCR6 Fig
0.14963757.15831940.html.plaintext.txt	103	The proportion cells expressing CD207 langerin entire population 57 plus minus 9 n8
0.14963757.15831940.html.plaintext.txt	104	DC generated adherent PBMC presence GM CSF IL4 also presented classical phenotypical markers DC CD1a HLA DR CD80 data shown
0.14963757.15831940.html.plaintext.txt	105	By electron microscopy HPV 16 VLPs shown bind DC LC Fig
0.14963757.15831940.html.plaintext.txt	106	HPV 16 VLPs internalization DC LC studied using CFDA SEVLPs flow cytometry
0.14963757.15831940.html.plaintext.txt	107	In order investigate integrity VLP CFDA SE labelling ELISA H16
0.14963757.15831940.html.plaintext.txt	108	V5 mAb specific conformational epitopes Christensen et al
0.14963757.15831940.html.plaintext.txt	109	This antibody reacted similarly VLP alone CFDA SEVLP suggesting labelling VLP CFDA SE induce VLP epitope conformation changes Fig
0.14963757.15831940.html.plaintext.txt	110	To determine suitable incubation time study VLPs cell internalization kinetics curve CFDA SE fluorescence studied
0.14963757.15831940.html.plaintext.txt	111	Mean fluorescence increased time incubation 6 h 80 cells fluorescent
0.14963757.15831940.html.plaintext.txt	112	To exclude possibility detected fluorescence caused non bound CFDA SE dye co migrating labelled VLPs DC LC incubated fraction control gradient loaded CFDA SE alone
0.14963757.15831940.html.plaintext.txt	113	No fluorescence detected DC LC incubated control gradient fraction data shown
0.14963757.15831940.html.plaintext.txt	114	View larger version 24K Fig
0.14963757.15831940.html.plaintext.txt	115	Phenotypical analysis LC generated vitro
0.14963757.15831940.html.plaintext.txt	116	CD34 cells cultivated 18 days presence TNF GM CSF IL4 TGF 1 amplification stem cell factor thrombopoietin Flt3 ligand display surface phenotype LC high expression CD1a CD207 E cadherin CCR6
0.14963757.15831940.html.plaintext.txt	117	The values correspond CD207 E cadherin CCR6 cells entire population
0.14963757.15831940.html.plaintext.txt	118	One representative result shown eight experiments
0.14963757.15831940.html.plaintext.txt	119	View larger version 35K Fig
0.14963757.15831940.html.plaintext.txt	120	Binding uptake HPV 16 VLPs DC LC
0.14963757.15831940.html.plaintext.txt	121	HPV 16 VLPs binding DC LC 4 degrees C BG Birbeck granules
0.14963757.15831940.html.plaintext.txt	122	b ELISA immunodetection CFDA SEVLP H16
0.14963757.15831940.html.plaintext.txt	123	c Entry kinetics CFDA SE labelled HPV 16 VLPs DC LC
0.14963757.15831940.html.plaintext.txt	124	Cells incubated labelled VLPs 4 degrees C 1 h washed incubated 37 degrees C different lengths time
0.14963757.15831940.html.plaintext.txt	125	They trypsinized incubated 6 h 37 degrees C
0.14963757.15831940.html.plaintext.txt	126	Fluorescence detected flow cytometry
0.14963757.15831940.html.plaintext.txt	127	To study cell entry kinetics DC LC first incubated labelled VLPs 4 degrees C washed incubated 37 degrees C 5 10 30 60 min 6 h Fig
0.14963757.15831940.html.plaintext.txt	128	After trypsin treatment remove uninternalized VLPs washings cells incubated 37 degrees C 6 h
0.14963757.15831940.html.plaintext.txt	129	Trypsin treatment reduced binding VLPs observed Evander et al
0.14963757.15831940.html.plaintext.txt	130	When cells incubated 5 min labelled VLPs 69 plus minus 7 LC fluorescent compared 27 plus minus 1 DC Fig
0.14963757.15831940.html.plaintext.txt	131	This difference also observed 1 h incubation fluorescence 84 plus minus 2 LC 35 plus minus 2 DC suggesting VLP entry DC slower LC
0.14963757.15831940.html.plaintext.txt	132	With increased incubation times differences two cell populations decreased 6 h incubation 84 plus minus 12 DC 94 plus minus 1 LC fluorescent
0.14963757.15831940.html.plaintext.txt	133	The faster VLPs entry LC compared DC confirmed electron microscopy see Fig
0.14963757.15831940.html.plaintext.txt	134	VLPs observed LC cytoplasm 5 min incubation see Fig
0.14963757.15831940.html.plaintext.txt	135	In contrast slower kinetic VLPs entry DC observed since VLPs detected cytoplasm 20 min incubation see Fig
0.14963757.15831940.html.plaintext.txt	136	In LC VLPs found near nuclear membrane incubation time 10 min see Fig
0.14963757.15831940.html.plaintext.txt	137	6c whereas 1 h needed VLPs reach nucleus DC data shown
0.14963757.15831940.html.plaintext.txt	138	View larger version 74K Fig
0.14963757.15831940.html.plaintext.txt	139	Clathrin dependent pathway HPV 16 VLPs LC c DC d f binding coated pits formation d clathrin vesicle formation e clathrin vesicle fusion b f VLPs near nuclear membrane c demonstration HPV 16 VLPs 0 2 microg ml 1 coated vesicles g clathrin vesicles h LC
0.14963757.15831940.html.plaintext.txt	140	HPV 16 VLPs use heparan sulfates bind DC Since difference observed entry kinetics DC LC could explained use different types cell binding investigated heparan sulfates used VLPs enter DC LC
0.14963757.15831940.html.plaintext.txt	141	We first examined ability heparin block binding cell entry
0.14963757.15831940.html.plaintext.txt	142	Labelled HPV 16 VLPs preincubated heparin 1 h 37 degrees C capacity enter DC LC investigated cell fluorescence Table 1
0.14963757.15831940.html.plaintext.txt	143	In presence heparin fluorescence inhibited 76 plus minus 5 DC whereas inhibition 12 plus minus 2 observed LC Table 1
0.14963757.15831940.html.plaintext.txt	144	To determine difference due origin cells used induce differentiation DC LC also generated DC CD34 cells showed entry VLPs inhibited presence heparin 51 plus minus 13 inhibition suggesting heparan sulfates receptors DC LC
0.14963757.15831940.html.plaintext.txt	145	We also investigated heparan sulfates expression immunostaining anti human syndecan 1 syndecan 4 antibodies
0.14963757.15831940.html.plaintext.txt	146	The results showed DC LC express similar levels syndecan 4 whereas syndecan 1 poorly expressed Fig
0.14963757.15831940.html.plaintext.txt	147	Effect heparin sodium chlorate labelled HPV 16 VLPs entry DC generated either PBMCs CD34 cells LC
0.14963757.15831940.html.plaintext.txt	148	Results expressed mean percentages cell fluorescence inhibition plus minus standard deviation
0.14963757.15831940.html.plaintext.txt	149	View larger version 31K Fig
0.14963757.15831940.html.plaintext.txt	150	Heparan sulfate expression DC LC
0.14963757.15831940.html.plaintext.txt	151	DC LC stained anti human syndecan 1 syndecan 4 analysed flow cytometry
0.14963757.15831940.html.plaintext.txt	152	The role proteoglycans binding HPV 16 VLPs DC LC also assessed inhibiting sulfation sodium chlorate
0.14963757.15831940.html.plaintext.txt	153	For purpose LC DC grown presence sodium chlorate 48 h addition labelled VLPs
0.14963757.15831940.html.plaintext.txt	154	As shown Table 1 HPV 16 VLPs entry reduced 71 plus minus 5 DC treated 100 microM sodium chlorate compared untreated cells
0.14963757.15831940.html.plaintext.txt	155	In contrast 13 plus minus 2 inhibition detected LC
0.14963757.15831940.html.plaintext.txt	156	To confirm role heparan sulfate DC entry VLPs DC incubated heparinase II induced 51 infection inhibition DC whereas LC affected data shown
0.14963757.15831940.html.plaintext.txt	157	Langerin colocalized HPV 16 VLPs Since VLPs enter LC heparan sulfates VLPs entry faster LC investigated VLPs use method langerin CD207 endocytic receptor LC enter quickly LC
0.14963757.15831940.html.plaintext.txt	158	Electron microscopy analysis showed incubation 37 degrees C 5 min anti langerin mAb present LC coated pits Fig
0.14963757.15831940.html.plaintext.txt	159	4a small vesicles clathrin morphology Fig
0.14963757.15831940.html.plaintext.txt	160	A proportion langerin also localized intracellularly large multivesicular compartments Fig
0.14963757.15831940.html.plaintext.txt	161	Electron microscopy also showed VLPs langerin colocalized Fig
0.14963757.15831940.html.plaintext.txt	162	We observed colocalization cell surface Fig
0.14963757.15831940.html.plaintext.txt	163	4e also coated pits Fig
0.14963757.15831940.html.plaintext.txt	164	4f lead formation vesicles clathrin morphology Fig
0.14963757.15831940.html.plaintext.txt	165	Langerin VLPs found inside large cytoplasmic vesicles LC Fig
0.14963757.15831940.html.plaintext.txt	166	4h whereas langerin detected DC
0.14963757.15831940.html.plaintext.txt	167	To exclude potential artefacts due high level VLP 10 microg ml 1 used VLP lower concentration 0 2 microg ml 1 showed electron microscopy langerin VLP also colocalize conditions Fig
0.14963757.15831940.html.plaintext.txt	168	View larger version 70K Fig
0.14963757.15831940.html.plaintext.txt	169	Colocalization HPV 16 VLPs langerin LC immunogold electron microscopy
0.14963757.15831940.html.plaintext.txt	170	LC incubated anti langerin alone d anti langerin HPV 16 VLPs e h
0.14963757.15831940.html.plaintext.txt	171	Langerin detected secondary antibody associated gold particles 20 nm found cell surface e clathrin vesicles b c f g large vesicles resembling endosome d h
0.14963757.15831940.html.plaintext.txt	172	Colocalization VLP 0 2 microg ml 1 langerin j LC
0.14963757.15831940.html.plaintext.txt	173	As negative control preincubated LC antibody specific LC anti CD3 mAb
0.14963757.15831940.html.plaintext.txt	174	In presence anti CD3 mAb gold particles detected data shown
0.14963757.15831940.html.plaintext.txt	175	We also tested ability anti 6 integrin mAb interact HPV 16 VLPs
0.14963757.15831940.html.plaintext.txt	176	The results revealed low expression integrin LC absence colocalization HPV16 VLPs data shown
0.14963757.15831940.html.plaintext.txt	177	To determine specificity VLPLC binding cells preincubated 5 mg mannan ml 1 adding labelled VLP
0.14963757.15831940.html.plaintext.txt	178	In presence mannan 40 inhibition fluorescence observed LC see Fig
0.14963757.15831940.html.plaintext.txt	179	View larger version 27K Fig
0.14963757.15831940.html.plaintext.txt	180	Cells pretreated chlorpromazine cytochalasin D b nystatin c filipin d mannan e
0.14963757.15831940.html.plaintext.txt	181	After 1 h incubation CFDA SE labelled VLPs added
0.14963757.15831940.html.plaintext.txt	182	Cells washed PBS incubated culture medium 6 h detecting fluorescence flow cytometry
0.14963757.15831940.html.plaintext.txt	183	Solid black line LCPBS solid grey line LCCFDA SEVLP dashed line LCCFDASEVLPdrug
0.14963757.15831940.html.plaintext.txt	184	HPV 16 VLPs endocytosis DC LC Since VLP could internalized different pathways Selinka et al
0.14963757.15831940.html.plaintext.txt	185	2003 examined role clathrin coated pit mediated endocytosis entry HPV 16 VLPs LC DC
0.14963757.15831940.html.plaintext.txt	186	These cells preincubated chlorpromazine inhibits clathrin mediated endocytosis
0.14963757.15831940.html.plaintext.txt	187	A 70 inhibition HPV 16 VLPs endocytosis observed DC LC populations chlorpromazine treatment Fig
0.14963757.15831940.html.plaintext.txt	188	We also tested effect cytochalasin D potent inhibitor actin dependent cellular processes
0.14963757.15831940.html.plaintext.txt	189	In presence drug VLP fluorescence shown decrease Fig
0.14963757.15831940.html.plaintext.txt	190	LC DC also treated nystatin filipin inhibit caveolae mediated endocytosis inhibition observed drugs Fig
0.14963757.15831940.html.plaintext.txt	191	To visually analyse uptake HPV VLPs DC LC transmission electron microscopy analysis also performed
0.14963757.15831940.html.plaintext.txt	192	In presence HPV 16 VLPs DC LC plasma membranes rich coated pits VLPs accumulated Fig
0.14963757.15831940.html.plaintext.txt	193	These coated pits budded yield coated vesicles clathrin morphology confirming HPV enter endocytosis clathrin coated pits DC Fig
0.14963757.15831940.html.plaintext.txt	194	VLPs contained cytoplasmic coated vesicles Fig
0.14963757.15831940.html.plaintext.txt	195	6b enlarged time fusion different coated vesicles Fig
0.14963757.15831940.html.plaintext.txt	196	The HPV 16 VLPs remained clustered large vesicles resembling endosome Fig
0.14963757.15831940.html.plaintext.txt	197	At step vesicles smooth rather coated
0.14963757.15831940.html.plaintext.txt	198	In LC vesicles containing VLPs located near nucleus incubation 10 min Fig
0.14963757.15831940.html.plaintext.txt	199	6c whereas time needed DC data shown
0.14963757.15831940.html.plaintext.txt	200	When using VLP low concentration 0 2 microg ml 1 also observed coated pits cytoplasmic vesicles LC clathrin morphology Fig
0.14963757.15831940.html.plaintext.txt	201	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES HPV 16 VLP based vaccine formulations shown induce strong humoral cell mediated immunity confer protection HPV 16 related SILs Koutsky et al
0.14963757.15831940.html.plaintext.txt	202	These data suggest vaccine antigens efficiently presented immune system may correlated ability HPV VLPs activate DC Rudolf et al
0.14963757.15831940.html.plaintext.txt	203	2002 demonstrated SILs deficient presenting antigens T cells suggesting function LC incapacitated HPV transformed epithelium
0.14963757.15831940.html.plaintext.txt	204	In agreement observations Fausch et al
0.14963757.15831940.html.plaintext.txt	205	2002 demonstrated LC presence HPV 16 VLPs unable activate T cells
0.14963757.15831940.html.plaintext.txt	206	The purpose present report investigate interactions HPV 16 VLPs DC LC
0.14963757.15831940.html.plaintext.txt	207	We showed antigen presenting cells differentially interact HPV 16 VLPs
0.14963757.15831940.html.plaintext.txt	208	Although DC LC able bind internalize HPV 16 VLPs difference entry kinetics observed cell types faster entry HPV 16 VLPs LC compared DC
0.14963757.15831940.html.plaintext.txt	209	As correlation entry kinetics cell receptors previously shown viruses Narayan et al
0.14963757.15831940.html.plaintext.txt	210	2003 looked potential different types HPV 16 VLPs binding DC LC
0.14963757.15831940.html.plaintext.txt	211	The described epithelial receptors HPV heparan sulfates integrin Evander et al
0.14963757.15831940.html.plaintext.txt	212	Our inhibition experiments heparin sodium chlorate confirm DC use heparan sulfates bind HPV 16 VLPs contrast LC agreement data Yan et al
0.14963757.15831940.html.plaintext.txt	213	2004 showing HPV 6b L1 VLPs uptake DC inhibited presence heparin
0.14963757.15831940.html.plaintext.txt	214	Other pathogens Chlamydia trachomatis also use heparan sulfates enter DC Matyszak et al
0.14963757.15831940.html.plaintext.txt	215	2002 suggested heparan sulfates moiety detected DC may also play immunoregulatory role
0.14963757.15831940.html.plaintext.txt	216	In fact heparan sulfates degradation products reported deliver costimulatory signals T cells maturation signals DC Wrenshall et al
0.14963757.15831940.html.plaintext.txt	217	1991 Kodaira Platt 2000 Johnson et al
0.14963757.15831940.html.plaintext.txt	218	This may explain HPV VLPs initiate DC LC maturation activation
0.14963757.15831940.html.plaintext.txt	219	HPV 6b genotype shown interact epithelial cells 6 integrin Evander et al
0.14963757.15831940.html.plaintext.txt	220	However receptor poorly expressed DC LC probably implicated differences HPV 16 VLPs uptake cell types
0.14963757.15831940.html.plaintext.txt	221	2004 also reported 6 integrin responsible initiation binding HPV 6b L1 VLPs LC
0.14963757.15831940.html.plaintext.txt	222	LC express several receptors facilitate antigen recognition uptake including Fc receptors DEC205 multilectin langerin
0.14963757.15831940.html.plaintext.txt	223	Langerin exclusively expressed LC Valladeau et al
0.14963757.15831940.html.plaintext.txt	224	1999 localized cell surface also intracellularly close association Birbeck granules
0.14963757.15831940.html.plaintext.txt	225	This molecule functions endocytic receptor Valladeau et al
0.14963757.15831940.html.plaintext.txt	226	Upon binding cell surface anti langerin antibodies rapidly internalized delivered Birbeck granules Valladeau et al
0.14963757.15831940.html.plaintext.txt	227	Electron microscopy analysis showed HPV 16 VLPs colocalize anti langerin antibodies
0.14963757.15831940.html.plaintext.txt	228	Indeed detected together coated pits large cytoplasmic vesicles
0.14963757.15831940.html.plaintext.txt	229	These data agreement recent studies showing processing pathway HPV 6b L1 VLPs LC associated langerin compartments Yan et al
0.14963757.15831940.html.plaintext.txt	230	2004 viruses HIV also use langerin lectin mannose enter LC DC respectively Turville et al
0.14963757.15831940.html.plaintext.txt	231	Our electron microscopy analysis showed colocalization HPV 16 VLPs langerin large cytoplasmic vesicles resembling endosome may related observation langerin associated CD1a recycling compartment McDermott et al
0.14963757.15831940.html.plaintext.txt	232	HPV 6 VLPs also shown colocalized CD1a endosome Yan et al
0.14963757.15831940.html.plaintext.txt	233	2004 loading mechanism determined
0.14963757.15831940.html.plaintext.txt	234	When mannan shown able inhibit HIV entry LC used 40 inhibition VLP entry observed suggesting proteins also involved VLP binding LC
0.14963757.15831940.html.plaintext.txt	235	It interesting determine direct effects langerin VLP binding experiments lectins also involved uptake VLPs LC
0.14963757.15831940.html.plaintext.txt	236	As cell surface binding HPV 16 VLPs differed DC LC wondered internalization also different suggested Fausch et al
0.14963757.15831940.html.plaintext.txt	237	2003 showed DC use clathrin mediated endocytosis whereas LC use different pathway associated clathrin caveolae
0.14963757.15831940.html.plaintext.txt	238	2004 show HPV 6 VLP enter LC caveolae dependent pathway
0.14963757.15831940.html.plaintext.txt	239	Entry pathways inhibited different stages specific inhibitors chlorpromazine cytochalasin D nystatin filipin
0.14963757.15831940.html.plaintext.txt	240	When using drugs HPV 16 VLP entry inhibited presence chlorpromazine cytochalasin D whereas inhibition observed caveolae inhibitors nystatin filipin
0.14963757.15831940.html.plaintext.txt	241	These results suggest VLP enter DC LC clathrin mediated pathway agreement direct demonstration HPV 16 VLPs coated pits cytoplasmic vesicles clathrin morphology LC DC preparations processed electron microscopy
0.14963757.15831940.html.plaintext.txt	242	The differences studies might related different methods used analyse HPV VLPs internalization although cannot exclude different endocytosis pathways according origin cells used generate LC
0.14963757.15831940.html.plaintext.txt	243	In agreement hypothesis LC used study poorly expressed syndecan 1 contrast LC generated Yan et al
0.14963757.15831940.html.plaintext.txt	244	The fact HPV 16 VLPs use different types cell binding DC LC might important functional consequences
0.14963757.15831940.html.plaintext.txt	245	It shown maturation DC LC depends receptors involved uptake pathogens also receptors directly acting DC activation Niedergang et al
0.14963757.15831940.html.plaintext.txt	246	Moreover cooperation two types receptors shown important diversity DC LC responses determine outcome immune response Gantner et al
0.14963757.15831940.html.plaintext.txt	247	As receptors implicated DC maturation activate nuclear factor kappa B mitogen activated protein kinase pathways Janeway Medzhitov 2002 interesting characterize cytoplasmic factors implicated DC LC maturation presence VLPs determine heparan sulfates able interact factors
0.14963757.15831940.html.plaintext.txt	248	Future research addressing recognition HPV VLP DC LC provide insight cell surface receptors regulate antigen presenting functions may contribute development novel strategies specifically prevent treat HPV infections associated preneoplasic lesions
0.14963757.15831940.html.plaintext.txt	249	ACKNOWLEDGEMENTS This work supported Belgian Fund Scientific Research FNRS Leon Fredericq Foundation Centre Anticancereux Pres lUniversite de Liege Centre de Recherche InterUniversitaire en Vaccinologie Convention 3073 GlaxoSmithKline Biologicals Walloon Region IAP InterUniversity Attraction Pole network P531
0.14963757.15831940.html.plaintext.txt	250	senior research associate FNRS
0.14963757.15831940.html.plaintext.txt	251	Christensen kindly providing anti L1 monoclonal antibodies H16
0.14963757.15831940.html.plaintext.txt	252	V5 Antoine Touze Pierre Coursaget generous donation HPV 16 recombinant baculovirus critical discussion manuscript
0.14963757.15831940.html.plaintext.txt	253	We also thank Renee Gathy Patrick Roncarati Josiane Renson Ludivine Herman help
0.14963757.15831940.html.plaintext.txt	254	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Bergsdorf C
0.14963757.15831940.html.plaintext.txt	255	Highly efficient transport carboxyfluorescein diacetate succinimidyl ester COS7 cells using human papillomavirus like particles
0.14963757.15831940.html.plaintext.txt	256	Detection neutralizing antibodies human papillomaviruses HPV inhibition gene transfer mediated HPV pseudovirions
0.14963757.15831940.html.plaintext.txt	257	J Clin Microbiol 40 926 932
0.14963757.15831940.html.plaintext.txt	258	Positively charged sequences human papillomavirus type 16 capsid proteins sufficient mediate gene transfer target cells via heparan sulfate receptor
0.14963757.15831940.html.plaintext.txt	259	Human papillomavirus types 16 31 58 use different endocytosis pathways enter cells
0.14963757.15831940.html.plaintext.txt	260	Squamous intraepithelial lesions cervical smears human immunodeficiency virus seropositive adolescents
0.14963757.15831940.html.plaintext.txt	261	CO2 WlinktypeDOI CrossRefMedline
0.14963757.15831940.html.plaintext.txt	262	Metastatic conversion cells expression human papillomavirus type 16 E6 E7 genes
0.14963757.15831940.html.plaintext.txt	263	Proc Natl Acad Sci U S A 90 6523 6527
0.14963757.15831940.html.plaintext.txt	264	Monoclonal antibodies HPV 6 L1 virus like particles identify conformational linear neutralizing epitopes HPV 11 addition type specific epitopes HPV 6
0.14963757.15831940.html.plaintext.txt	265	Papillomaviruses infect cells via clathrin dependent pathway
0.14963757.15831940.html.plaintext.txt	266	Vaccinia virus related events phenotypic changes infection dendritic cells derived human monocytes
0.14963757.15831940.html.plaintext.txt	267	Carboxy fluorescein diacetate succinimidyl ester labeled papillomavirus virus like particles fluoresce internalization interact heparan sulfate binding entry
0.14963757.15831940.html.plaintext.txt	268	Incidence cervical squamous intraepithelial lesions HIV infected women
0.14963757.15831940.html.plaintext.txt	269	Vaccinia virus inhibits maturation human dendritic cells novel mechanism immune evasion
0.14963757.15831940.html.plaintext.txt	270	Identification 6 integrin candidate receptor papillomaviruses
0.14963757.15831940.html.plaintext.txt	271	A phase 1 study recombinant viruslike particle vaccine human papillomavirus type 11 healthy adult volunteers
0.14963757.15831940.html.plaintext.txt	272	J Infect Dis 183 1485 1493
0.14963757.15831940.html.plaintext.txt	273	Adenosine triphosphate sulfurylase Penicillium chrysogenum equilibrium binding substrate hydrolysis isotope exchange studies
0.14963757.15831940.html.plaintext.txt	274	Arch Biochem Biophys 185 376 390
0.14963757.15831940.html.plaintext.txt	275	Human papillomavirus virus like particles activate Langerhans cells possible immune escape mechanism used human papillomaviruses
0.14963757.15831940.html.plaintext.txt	276	Differential uptake cross presentation human papillomavirus virus like particles dendritic cells Langerhans cells
0.14963757.15831940.html.plaintext.txt	277	Reactivity Langerhans cells hybridoma antibody
0.14963757.15831940.html.plaintext.txt	278	Proc Natl Acad Sci U S A 78 2541 2544
0.14963757.15831940.html.plaintext.txt	279	Collaborative induction inflammatory responses dectin 1 toll like receptor 2
0.14963757.15831940.html.plaintext.txt	280	Influence mucosal epithelium microenvironment Langerhans cells implications development squamous intraepithelial lesions cervix
0.14963757.15831940.html.plaintext.txt	281	Human papillomavirus infection requires cell surface heparan sulfate
0.14963757.15831940.html.plaintext.txt	282	Measles virus infects human dendritic cells blocks allostimulatory properties CD4 T cells
0.14963757.15831940.html.plaintext.txt	283	Self assembly human papillomavirus type 1 capsids expression L1 protein alone coexpression L1 L2 capsid proteins
0.14963757.15831940.html.plaintext.txt	284	Safety immunogenicity trial adult volunteers human papillomavirus 16 L1 virus like particle vaccine
0.14963757.15831940.html.plaintext.txt	285	J Natl Cancer Inst 93 284 292
0.14963757.15831940.html.plaintext.txt	286	Annu Rev Immunol 20 197 216
0.14963757.15831940.html.plaintext.txt	287	Receptor mediated monitoring tissue well via detection soluble heparan sulfate toll like receptor 4
0.14963757.15831940.html.plaintext.txt	288	The L1 major capsid protein human papillomavirus type 11 recombinant virus like particles interacts heparin cell surface glycosaminoglycans human keratinocytes
0.14963757.15831940.html.plaintext.txt	289	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.14963757.15831940.html.plaintext.txt	290	Modification antigen presenting cell functions heparan sulfate
0.14963757.15831940.html.plaintext.txt	291	A controlled trial human papillomavirus type 16 vaccine
0.14963757.15831940.html.plaintext.txt	292	N Engl J Med 347 1645 1651
0.14963757.15831940.html.plaintext.txt	293	Papillomavirus like particles induce acute activation dendritic cells
0.14963757.15831940.html.plaintext.txt	294	Uptake processing Chlamydia trachomatis human dendritic cells
0.14963757.15831940.html.plaintext.txt	295	CO2 9linktypeDOI CrossRefMedline
0.14963757.15831940.html.plaintext.txt	296	Birbeck granules subdomains endosomal recycling compartment human epidermal Langerhans cells form Langerin accumulates
0.14963757.15831940.html.plaintext.txt	297	Synthesis surface expression hyaluronan dendritic cells potential role antigen presentation
0.14963757.15831940.html.plaintext.txt	298	Two retroviral entry pathways distinguished lipid raft association viral receptor differences viral infectivity
0.14963757.15831940.html.plaintext.txt	299	Dendritic cells host Achilles heel mucosal pathogens Trends Microbiol 12 79 88
0.14963757.15831940.html.plaintext.txt	300	Cellular immunodeficiency enhances progression human papillomavirus associated cervical lesions
0.14963757.15831940.html.plaintext.txt	301	Causes management cervical intraepithelial neoplasia
0.14963757.15831940.html.plaintext.txt	302	The intrauterine device cervical neoplasia
0.14963757.15831940.html.plaintext.txt	303	A prospective study patients cervical dysplasia
0.14963757.15831940.html.plaintext.txt	304	Expression human papillomavirus type 11 L1 protein insect cells vivo vitro assembly viruslike particles
0.14963757.15831940.html.plaintext.txt	305	Human dendritic cells activated chimeric human papillomavirus type 16 virus like particles induce epitope specific human T cell responses vitro
0.14963757.15831940.html.plaintext.txt	306	Analysis infectious entry pathway human papillomavirus type 33 pseudovirions
0.14963757.15831940.html.plaintext.txt	307	DC SIGN CD209 mediates dengue virus infection human dendritic cells
0.14963757.15831940.html.plaintext.txt	308	The L1 major capsid protein human papillomavirus type 16 variants affects yield virus like particles produced insect cell expression system
0.14963757.15831940.html.plaintext.txt	309	J Clin Microbiol 36 2046 2051
0.14963757.15831940.html.plaintext.txt	310	Diversity receptors binding HIV dendritic cell subsets
0.14963757.15831940.html.plaintext.txt	311	The monoclonal antibody DCGM4 recognizes Langerin protein specific Langerhans cells rapidly internalized cell surface
0.14963757.15831940.html.plaintext.txt	312	Eur J Immunol 29 2695 2704
0.14963757.15831940.html.plaintext.txt	313	CO2 QlinktypeDOI CrossRefMedline
0.14963757.15831940.html.plaintext.txt	314	Langerin novel C type lectin specific Langerhans cells endocytic receptor induces formation Birbeck granules
0.14963757.15831940.html.plaintext.txt	315	Regulation murine splenocyte responses heparan sulfate
0.14963757.15831940.html.plaintext.txt	316	Despite differences dendritic cells Langerhans cells mechanism papillomavirus like particle antigen uptake cells cross prime T cells
0.14963757.15831940.html.plaintext.txt	317	Received 27 August 2004 accepted 8 February 2005
0.14963757.15831940.html.plaintext.txt	318	This Article Abstract Full Text PDF Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles Bousarghin L
0.14963757.15831940.html.plaintext.txt	319	Articles citing Article PubMed PubMed Citation Articles Bousarghin L
0.14963757.15831940.html.plaintext.txt	320	Agricola Articles Bousarghin L
0.14963757.15831940.html.plaintext.txt	321	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL J MED MICROBIOL ALL SGM JOURNALS
0.172249.15302958.html.plaintext.txt	0	Detection antibodies human papillomavirus HPV type 16 peptide differentiate high risk low risk HPV associated low grade squamous intraepithelial lesions Leticia Rocha Zavaleta1 Juana P
0.172249.15302958.html.plaintext.txt	1	Ambrosio1 Maria de Lourdes Mora Garcia2 Fernando Cruz Talonia3 Jorge Hernandez Montes2 Benny Weiss Steider2 Vianney Ortiz Navarrete4 Alberto Monroy Garcia2
0.172249.15302958.html.plaintext.txt	2	1 Department Molecular Biology Biotechnology Institute Biomedical Research National University Mexico Circuito Escolar SN Cd Universitaria Apdo Postal 70228 DF CP 04510 Mexico City Mexico 2 Laboratory Immunobiology L 326 Unit Research Cellular Differentiation Cancer FES Zaragoza National University Mexico Mexico City Mexico 3 National Center Clinics Dysplasias CENACLID General Hospital Mexico Mexico City Mexico 4 Unit Molecular Biomedicine CINVESTAV IPN Mexico City Mexico
0.172249.15302958.html.plaintext.txt	3	Correspondence Alberto Monroy Garcia albertomonatyahoo
0.172249.15302958.html.plaintext.txt	4	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES A nonapeptide 16L1 derived human papillomavirus type 16 HPV 16 major capsid protein tested detection potential cross reactive serum IgG cervical IgA antibodies low high risk HPV associated low grade squamous intraepithelial lesions LSIL cervical cancer patients ELISA
0.172249.15302958.html.plaintext.txt	5	The IgG response similar women low risk HPV associated LSIL controls P0 1
0.172249.15302958.html.plaintext.txt	6	In contrast 90 patients high risk HPV associated LSIL seropositive
0.172249.15302958.html.plaintext.txt	7	Although tumours cancer patients positive presence high risk HPV DNA level seropositivity decreased significantly group P 0 0001
0.172249.15302958.html.plaintext.txt	8	Cervical IgA antibodies also detected significantly high proportion women high risk HPV associated LSIL compared controls
0.172249.15302958.html.plaintext.txt	9	However proportion IgA positive patients lower proportion IgG seropositives
0.172249.15302958.html.plaintext.txt	10	In conclusion 16L1 peptide appears high risk type common epitope induces cross reactive antibodies high risk low risk HPV associated LSIL patients allowing differentiation high low risk infected women stage infection
0.172249.15302958.html.plaintext.txt	11	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Infection genital epithelium human papillomavirus HPV common sexually transmitted disease
0.172249.15302958.html.plaintext.txt	12	Epidemiological studies demonstrated low risk HPV genotypes mainly types 6 11 induce benign genital warts
0.172249.15302958.html.plaintext.txt	13	In contrast high risk genotypes including HPV 16 18 related types associated development cervical cancer Walboomers et al
0.172249.15302958.html.plaintext.txt	14	Cervical cancer still one prevalent cancers developing world Parkin et al
0.172249.15302958.html.plaintext.txt	15	HPV 16 related types 31 33 52 58 35 together HPV 18 related types 45 59 39 68 associated 91 cervical tumours Central South America Bosch et al
0.172249.15302958.html.plaintext.txt	16	Thus early detection genital infections high risk HPV types would value prevention cervical cancer
0.172249.15302958.html.plaintext.txt	17	Genital HPV infection frequently induces antibody mediated immune responses mostly directed viral capsid Wang et al
0.172249.15302958.html.plaintext.txt	18	The HPV capsid composed two structural proteins largely internal minor capsid protein L2 major protein L1 30 times abundant L2 Kirnbauer et al
0.172249.15302958.html.plaintext.txt	19	1993 represents 80 total viral protein
0.172249.15302958.html.plaintext.txt	20	L1 important target immune system
0.172249.15302958.html.plaintext.txt	21	Immunological assays based use HPV capsids known detect type restricted antibodies possibly due presentation type specific conformational epitopes
0.172249.15302958.html.plaintext.txt	22	Interestingly HPV 16 capsid exposes type restricted also type common antigenic epitopes Heino et al
0.172249.15302958.html.plaintext.txt	23	Thus addition specific antibodies Cason et al
0.172249.15302958.html.plaintext.txt	24	1992 widely cross reactive antibodies found react peptide sequences L1 protein high low risk HPV types LeCann et al
0.172249.15302958.html.plaintext.txt	25	We previously described peptide IHSMNSTIL derived HPV 16 L1 protein 16L1 peptide binds HLA class I allele B3901 elicits proliferative responses lymphocytes patients cervical cancer associated either HPV 16 18 Monroy Garcia et al
0.172249.15302958.html.plaintext.txt	26	Further analysis peptide using Lipman Pearsons ALIGN program showed sequence presented substantial amino acid identity corresponding sequence HPV 18 88 9 identity HPV 16 related types 77 8 66 7 identity HPV 18 related types 88 9 66 7 identity
0.172249.15302958.html.plaintext.txt	27	Interestingly comparison corresponding sequences HPV 6 11 demonstrated identity level 55 6
0.172249.15302958.html.plaintext.txt	28	This observation raised question whether antibodies generated sequences could cross react 16L1 peptide
0.172249.15302958.html.plaintext.txt	29	This study aimed evaluate anti peptide reactivity antibodies produced patients high risk HPV associated low grade squamous intraepithelial lesions LSIL cervical cancer compare reaction antibodies women low risk HPV associated LSIL assess potential cross reactivity
0.172249.15302958.html.plaintext.txt	30	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Study population human samples
0.172249.15302958.html.plaintext.txt	31	The study population selected patients attending National Center Clinics Dysplasias CENACLID General Hospital Mexico National Institute Cancerology INCAN Mexico City Mexico
0.172249.15302958.html.plaintext.txt	32	Samples collected 1997 2002
0.172249.15302958.html.plaintext.txt	33	Informed consent obtained participants
0.172249.15302958.html.plaintext.txt	34	Human material handled according institutional experimentation safety guidelines
0.172249.15302958.html.plaintext.txt	35	CENACLID provides gynaecological services women referred colposcopy abnormal cytology women without history cervical abnormalities ask routine examination
0.172249.15302958.html.plaintext.txt	36	In present study women groups analysed
0.172249.15302958.html.plaintext.txt	37	Women history previous high grade squamous intraepithelial lesions HSIL included study
0.172249.15302958.html.plaintext.txt	38	All women underwent cytological histopathological analysis colposcopy directed biopsies
0.172249.15302958.html.plaintext.txt	39	All Pap smears examined independently two experienced cytotechnologists
0.172249.15302958.html.plaintext.txt	40	Samples inconsistent diagnosis excluded study
0.172249.15302958.html.plaintext.txt	41	Cytology diagnoses classified according Bethesda system normal atypical squamous cells undetermined significance ASCUS LSIL HSIL cervical carcinoma
0.172249.15302958.html.plaintext.txt	42	Samples ASCUS HSIL excluded study
0.172249.15302958.html.plaintext.txt	43	Blood samples cervical washes colposcopy directed biopsies obtained patients
0.172249.15302958.html.plaintext.txt	44	Serum separated blood samples centrifugation 9000 g 15 min
0.172249.15302958.html.plaintext.txt	45	Cervical mucus collected washing uterine cervix 1 ml sterile PBS
0.172249.15302958.html.plaintext.txt	46	Cell debris eliminated centrifugation 9000 g 5 min
0.172249.15302958.html.plaintext.txt	47	Cervical washes containing blood contamination considered antibody detection
0.172249.15302958.html.plaintext.txt	48	Cervical mucus serum samples stored 70 degrees C tested
0.172249.15302958.html.plaintext.txt	49	Cervical biopsies placed immediately tubes containing sterile contaminant free PBS Roche Applied Science processed day
0.172249.15302958.html.plaintext.txt	50	Investigators performed molecular immunological assays aware clinical status samples
0.172249.15302958.html.plaintext.txt	51	To avoid contamination cases controls tested separate batches
0.172249.15302958.html.plaintext.txt	52	All samples underwent molecular analysis PCR hybrid capture
0.172249.15302958.html.plaintext.txt	53	Women consistently negative clinical molecular tests considered negative controls
0.172249.15302958.html.plaintext.txt	54	Only patients LSIL cervical carcinoma consistently positive results PCR hybrid capture tests included study
0.172249.15302958.html.plaintext.txt	55	All reagents used isolation amplification DNA purchased Gibco BRL
0.172249.15302958.html.plaintext.txt	56	Biopsies treated proteinase K described elsewhere Kaye et al
0.172249.15302958.html.plaintext.txt	57	DNA extracted phenolchloroform precipitated ethanol
0.172249.15302958.html.plaintext.txt	58	HPV DNA amplified using general primers MY09 5 CGTCCMARRGGAWACTGATC 3 MY11 5 GCMCAGGGWCATAAYAATGG 3 Manos et al
0.172249.15302958.html.plaintext.txt	59	1989 amplified conserved 450 bp fragment L1 gene
0.172249.15302958.html.plaintext.txt	60	Genomic DNA 100 ng denatured heating reaction 95 degrees C 30
0.172249.15302958.html.plaintext.txt	61	Annealing primers performed 45 degrees C 30 extension 72 degrees C 60
0.172249.15302958.html.plaintext.txt	62	The cycle repeated 30 times
0.172249.15302958.html.plaintext.txt	63	PCR products electrophoresed 2 agarose gels stained ethidium bromide visualized UV transilluminator
0.172249.15302958.html.plaintext.txt	64	Specific amplification HPV 16 achieved using primers Pr3 5 GTCAAAAGCCACTGTGTCCT 3 Pr4 5 CCATCCATTACATCCCGTAC 3 amplified 499 bp fragment covering HPV 16 E7 gene plus fragments E6 E1 genes
0.172249.15302958.html.plaintext.txt	65	Amplification HPV 18 performed using primers Pr1 5 CCGAGCACGACAGGAACGACT 3 Pr2 5 TCGTTTTCTTCCTCTGAGTCGCTT 3 amplified 172 bp fragment including parts HPV 18 E6 E7 genes described previously Karlsen et al
0.172249.15302958.html.plaintext.txt	66	An internal control ensure DNA integrity performed amplifying globin gene using primers PC03 PC04 described previously Saiki et al
0.172249.15302958.html.plaintext.txt	67	As positive control DNA SiHa cervical cancer derived cell line containing one two HPV 16 copies per cell HeLa cervical cancer derived cell line positive presence HPV 18 cells run concurrently reaction
0.172249.15302958.html.plaintext.txt	68	Additionally negative controls assess presence contaminants carried using purified water Gibco BRL PBS instead template DNA
0.172249.15302958.html.plaintext.txt	69	Patients whose DNA sample could amplified excluded study
0.172249.15302958.html.plaintext.txt	70	Detection high low risk HPV types hybrid capture
0.172249.15302958.html.plaintext.txt	71	The HPV Test Hybrid Capture II kit Digene detection high risk HPV types 16 18 31 33 35 39 45 51 52 56 58 59 68 low risk types 6 11 42 43 44 used
0.172249.15302958.html.plaintext.txt	72	DNA 250 500 ng 20 microl extracted cervical tissue placed tube containing 30 microl specimen transport medium
0.172249.15302958.html.plaintext.txt	73	NaOH based denaturation reagent 25 microl added sample tubes mixed vigorously incubated 65 degrees C 45 min
0.172249.15302958.html.plaintext.txt	74	Hybridization hybrid detection performed according manufacturers instructions
0.172249.15302958.html.plaintext.txt	75	Carrier DNA plasmid DNA containing HPV 16 HPV 11 genome used negative positive calibrators respectively run triplicate test
0.172249.15302958.html.plaintext.txt	76	An assay considered valid results negative positive calibrators showed coefficient variation 15 positive negative calibrator mean values ratio 2 0
0.172249.15302958.html.plaintext.txt	77	The cut value positivity calculated assay defined mean relative light units RLU value positive calibrator
0.172249.15302958.html.plaintext.txt	78	Patients positive low high risk types excluded study
0.172249.15302958.html.plaintext.txt	79	The nonamer peptide IHSMNSTIL generated solid phase synthesis multiple peptide automatic synthesizer Applied Biosystems Synergy Personal Peptide Synthesizer 432A Perkin Elmer
0.172249.15302958.html.plaintext.txt	80	Repeated cycles addition 9 fluorenylmethoxycarbonyl Fmoc protected amino acids polystyrene resin alternated Fmoc deprotection procedure Gausepohl et al
0.172249.15302958.html.plaintext.txt	81	After completion synthesis peptide cleaved resin side chain protective groups removed treatment trifluoroacetic acid containing 5 water
0.172249.15302958.html.plaintext.txt	82	Finally peptide analysed reverse phase HPLC amino acid composition purity
0.172249.15302958.html.plaintext.txt	83	A 75 pure peptide preparation lyophilized dissolved sterile PBS use
0.172249.15302958.html.plaintext.txt	84	Serum IgG mucosal IgA antibodies detected using 16L1 peptide target antigen standard ELISA
0.172249.15302958.html.plaintext.txt	85	ELISA plates Maxisorp Nalge Nunc coated 500 ng 16L1 peptide per well diluted sodium carbonatebicarbonate buffer 0 1 M sodium carbonate 0 1 M sodium bicarbonate pH 9 6 4 degrees C overnight
0.172249.15302958.html.plaintext.txt	86	Plates washed four times TBS containing 0 1 Tween 20 TBSTween 20
0.172249.15302958.html.plaintext.txt	87	Non specific binding sites blocked 200 microl 2 BSA TBSTween 20 2 h 37 degrees C
0.172249.15302958.html.plaintext.txt	88	After washing described 100 microl cervical mucus diluted 1 2 serum diluted 1 100 blocking buffer added plate incubated 2 h 37 degrees C
0.172249.15302958.html.plaintext.txt	89	After washing alkaline phosphatase conjugated rabbit anti human IgA secretory component Dako reacts specifically free human secretory component secretory component bound secretory IgA rabbit anti human IgG Dako diluted 1 500 blocking buffer 100 microl added well
0.172249.15302958.html.plaintext.txt	90	The plates incubated 1 5 h 37 degrees C
0.172249.15302958.html.plaintext.txt	91	After washing alkaline phosphatase substrate Sigma 104 Sigma diluted 10 diethanolamine solution pH 9 8 Sigma added plates
0.172249.15302958.html.plaintext.txt	92	The absorbance read 405 nm ELISA plate reader
0.172249.15302958.html.plaintext.txt	93	All samples tested triplicate antibody class
0.172249.15302958.html.plaintext.txt	94	The assay considered valid coefficient variation triplicates 10
0.172249.15302958.html.plaintext.txt	95	Additionally samples tested two wells coated peptide define non specific reactivity
0.172249.15302958.html.plaintext.txt	96	The final ELISA value calculated subtracting non specific reactivity mean absorbance triplicate mean absorbance
0.172249.15302958.html.plaintext.txt	97	To control inter assay variation positive IgG IgA controls selected previous study Rocha Zavaleta et al
0.172249.15302958.html.plaintext.txt	98	2003 included plate tested described
0.172249.15302958.html.plaintext.txt	99	Plates inter assay coefficient variation 10 considered valid
0.172249.15302958.html.plaintext.txt	100	The cut value positivity calculated basis distribution absorbance control group defined mean absorbance3 SD exclusion outliers
0.172249.15302958.html.plaintext.txt	101	The calculated cut value IgG seropositivity 0 440 IgA 0 237
0.172249.15302958.html.plaintext.txt	102	To evaluate differences proportions positive samples different groups data arranged form two two contingency tables analysed Fishers exact test calculate odds ratios OR 95 confidence intervals CI P values
0.172249.15302958.html.plaintext.txt	103	The Wilcoxon signed rank test Students test used compare mean signal strength absorbance various groups
0.172249.15302958.html.plaintext.txt	104	All tests two tailed basic significance level taken P0 05
0.172249.15302958.html.plaintext.txt	105	Sensitivity specificity predictive values efficiency ELISA calculated using standard medical biostatistical formulae
0.172249.15302958.html.plaintext.txt	106	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Detection IgG antibodies 16L1 peptide serum samples After clinical molecular diagnosis patients divided five groups A patients diagnosed LSIL infected low risk HPV types n122 B patients LSIL infected high risk HPV types n166 C patients high risk HPV associated cervical cancer n182 D patients diagnosis LSIL infected HPV 16 n119 E negative control women without clinical molecular evidence HPV infection n115 Table 1
0.172249.15302958.html.plaintext.txt	107	Groups A B C consisted independent groups patients
0.172249.15302958.html.plaintext.txt	108	Group A included patients infected low risk HPV types detected hybrid capture kit
0.172249.15302958.html.plaintext.txt	109	Groups B C comprised patients infected high risk HPV types detected hybrid capture test including HPV 16
0.172249.15302958.html.plaintext.txt	110	Group D contained samples tested positive high risk hybrid capture test subsequently proved positive presence HPV 16 PCR
0.172249.15302958.html.plaintext.txt	111	Characteristics groups patients included study
0.172249.15302958.html.plaintext.txt	112	The presence absence HPV DNA verified using general MY09MY11 primers PCR
0.172249.15302958.html.plaintext.txt	113	Low high risk types determined hybrid capture test
0.172249.15302958.html.plaintext.txt	114	HPV 16 detected using Pr3Pr4 type specific primers PCR
0.172249.15302958.html.plaintext.txt	115	Clinical diagnosis based cytological analysis corroborated histopathological analysis
0.172249.15302958.html.plaintext.txt	116	We first investigated presence IgG antibodies 16L1 peptide serum samples
0.172249.15302958.html.plaintext.txt	117	A small proportion patients low risk HPV associated LSIL 6 5 tested positive presence IgG antibodies
0.172249.15302958.html.plaintext.txt	118	This proportion similar proportion seropositive individuals normal population P0 1 Fig
0.172249.15302958.html.plaintext.txt	119	In contrast 90 patients infected high risk HPV positive presence IgG
0.172249.15302958.html.plaintext.txt	120	The difference group negative controls highly significant P 0 0001
0.172249.15302958.html.plaintext.txt	121	Moreover mean signal strength antibody response high risk HPV associated LSIL patients 3 7 fold higher mean signal strength control samples
0.172249.15302958.html.plaintext.txt	122	PCR analysis DNA high risk HPV associated LSIL samples indicated 60 8 patients infected HPV 16 17 4 infected HPV 18 21 6 high risk types
0.172249.15302958.html.plaintext.txt	123	However proportion seropositive subjects group similar P 0 1 Table 2
0.172249.15302958.html.plaintext.txt	124	This seemed indicate LSIL patients infected high risk HPV types produced antibodies reacted 16L1 peptide
0.172249.15302958.html.plaintext.txt	125	Thus next addressed question whether antibodies could also found patients developed high risk HPV associated cervical tumour
0.172249.15302958.html.plaintext.txt	126	Results showed 57 7 cervical cancer patients antibodies 16L1 peptide
0.172249.15302958.html.plaintext.txt	127	The proportion seropositive subjects cervical cancer group significantly higher observed negative controls P 0 0001
0.172249.15302958.html.plaintext.txt	128	However seropositivity cervical cancer patients significantly lower detected high risk HPV associated LSIL patients P 0 0001
0.172249.15302958.html.plaintext.txt	129	This suggested presence viral DNA cervical cancer patients correlate presence IgG antibodies peptide
0.172249.15302958.html.plaintext.txt	130	Furthermore statistical analysis revealed proportion seropositive patients whose tumours HPV 18 positive significantly lower proportion patients HPV 16 associated tumours P0 03 Table 2
0.172249.15302958.html.plaintext.txt	131	View larger version 30K Fig
0.172249.15302958.html.plaintext.txt	132	IgG antibody responses 16L1 peptide sera women without evidence HPV infection control patients LSIL infected low risk high risk HPV types patients cervical cancer CeCa also positive presence high risk HPV types
0.172249.15302958.html.plaintext.txt	133	The mean absorbance value group represented solid line
0.172249.15302958.html.plaintext.txt	134	The cut value positivity 0 440 indicated dotted line
0.172249.15302958.html.plaintext.txt	135	Statistical differences groups shown
0.172249.15302958.html.plaintext.txt	136	P values calculated using Fishers exact test
0.172249.15302958.html.plaintext.txt	137	Prevalence IgG serum antibodies 16L1 peptide patients LSIL cervical cancer infected different high risk HPV types
0.172249.15302958.html.plaintext.txt	138	Our results demonstrated difference anti peptide IgG response low high risk HPV infected women diagnosis LSIL
0.172249.15302958.html.plaintext.txt	139	Thus next addressed significance 16L1 peptide based ELISA detection high risk HPV infection LSIL cervical cancer patients
0.172249.15302958.html.plaintext.txt	140	As shown Table 3 16L1 peptide based ELISA able detect high proportion 91 6 LSIL patients actually infected high risk HPV types produced low levels false positive false negative results
0.172249.15302958.html.plaintext.txt	141	The probability LSIL patient infected high risk HPV types given positive ELISA value high positive predictive value97 7
0.172249.15302958.html.plaintext.txt	142	However probability infected high risk genotypes given negative ELISA result lower negative predictive value87 7
0.172249.15302958.html.plaintext.txt	143	The efficiency ELISA detect high risk HPV infection LSIL patients higher 90
0.172249.15302958.html.plaintext.txt	144	In comparison ELISA quite sensitive detection high risk viruses patients cervical cancer low negative predictive value 52 7 consequence reduced level efficiency 70 4
0.172249.15302958.html.plaintext.txt	145	Sensitivity specificity predictive values efficiency 16L1 peptide based ELISA serological detection high risk HPV infection LSIL cervical cancer
0.172249.15302958.html.plaintext.txt	146	Individuals tested positive ELISA high risk HPV type hybrid capture considered true positive individuals tested positive ELISA negative presence high risk HPV DNA hybrid capture considered false positive individuals tested negative ELISA high risk HPV type hybrid capture considered true negative individuals tested negative ELISA positive presence high risk HPV DNA hybrid capture considered false negative
0.172249.15302958.html.plaintext.txt	147	Detection IgA antibodies 16L1 peptide cervical secretions Since results showed IgG antibodies 16L1 peptide present sera high risk HPV infected LSIL patients next determined whether reactive IgA antibodies could also found cervical secretions women
0.172249.15302958.html.plaintext.txt	148	Once ELISAs revealed LSIL patients infected low risk HPV genotypes largely negative presence anti 16L1 peptide antibodies Fig
0.172249.15302958.html.plaintext.txt	149	In addition IgA reactivity high risk HPV associated LSIL population significantly higher observed negative control group low risk HPV group
0.172249.15302958.html.plaintext.txt	150	HPV 16 far frequent high risk HPV type infecting women Latin America Bosch et al
0.172249.15302958.html.plaintext.txt	151	Thus determine whether mucosal IgA antibodies 16L1 peptide prevalent women infected HPV 16 women infected high risk HPV type evaluated presence IgA cervical secretions HPV 16 associated LSIL patients
0.172249.15302958.html.plaintext.txt	152	2 proportion IgA positive subjects HPV 16 infected group significantly higher control group P 0 0001
0.172249.15302958.html.plaintext.txt	153	However statistical comparison IgA positivity high risk HPV HPV 16 associated LSIL groups indicated responses similar groups OR1 3 95 CI0 8 2 1 P0 09
0.172249.15302958.html.plaintext.txt	154	View larger version 27K Fig
0.172249.15302958.html.plaintext.txt	155	IgA antibody responses 16L1 peptide cervical secretions women without evidence HPV infection control patients LSIL infected low risk high risk HPV types patients evidence infection HPV 16
0.172249.15302958.html.plaintext.txt	156	The mean absorbance value group represented solid line
0.172249.15302958.html.plaintext.txt	157	The cut value positivity 0 237 indicated dotted line
0.172249.15302958.html.plaintext.txt	158	Statistical differences groups shown
0.172249.15302958.html.plaintext.txt	159	P values calculated using Fishers exact test
0.172249.15302958.html.plaintext.txt	160	To ascertain whether presence serum IgG correlated detection cervical IgA statistical analysis proportion positive subjects group performed
0.172249.15302958.html.plaintext.txt	161	As shown Table 4 difference proportion women positive presence IgG IgA non infected group P0 4
0.172249.15302958.html.plaintext.txt	162	Interestingly patients diagnosed LSIL analysed together difference detected IgG IgA responses P0 06
0.172249.15302958.html.plaintext.txt	163	However separate analysis LSIL patients infected low high risk HPV types showed proportion cervical IgA responders significantly higher proportion IgG seropositives group patients infected low risk HPV types
0.172249.15302958.html.plaintext.txt	164	In contrast patients infected high risk HPV proportion IgG seropositives significantly higher cervical IgA positives P 0 0001
0.172249.15302958.html.plaintext.txt	165	In group likelihood presenting circulating IgG antibodies 16L1 peptide six times higher presenting mucosal IgA antibodies peptide
0.172249.15302958.html.plaintext.txt	166	This suggested early infection high risk HPV genotypes antibody response mediated predominantly systemic IgG antibodies
0.172249.15302958.html.plaintext.txt	167	Statistical comparison serum IgG cervical IgA responses 16L1 peptide
0.172249.15302958.html.plaintext.txt	168	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES In present work shown IgG antibodies 16L1 peptide found sera LSIL patients infected high risk HPV types
0.172249.15302958.html.plaintext.txt	169	Antibodies HPV 16L1 derived peptides demonstrated previously Cason et al
0.172249.15302958.html.plaintext.txt	170	However knowledge first report peptide based serological assay capable differentiating low risk high risk HPV infections LSIL patients
0.172249.15302958.html.plaintext.txt	171	Previously conformation dependent HPV 16L1 epitope suggested immunodominant site recognized human sera following HPV infection Wang et al
0.172249.15302958.html.plaintext.txt	172	This site turned major neutralizing epitope HPV 16 White et al
0.172249.15302958.html.plaintext.txt	173	1999 seemed induce antibody response 75 infected patients
0.172249.15302958.html.plaintext.txt	174	Nevertheless epitope covers non contiguous regions capsid surface making use difficult detection reagent early HPV infection
0.172249.15302958.html.plaintext.txt	175	Serological studies using virus like particles VLPs antigenic targets demonstrated majority women infected HPV 16 produce IgG antibody response Kirnbauer et al
0.172249.15302958.html.plaintext.txt	176	Here found women high risk HPV type associated LSIL generated systemic IgG antibodies 16L1 peptide
0.172249.15302958.html.plaintext.txt	177	However antibodies detected VLP based assays mainly type restricted directed conformational epitopes Christensen et al
0.172249.15302958.html.plaintext.txt	178	Therefore might possible anti 16L1 anti VLP antibodies generated parallel response infection
0.172249.15302958.html.plaintext.txt	179	To ascertain whether antibodies co exist infected humans population studied herein currently tested VLP based ELISA
0.172249.15302958.html.plaintext.txt	180	It generally accepted IgG antibodies HPV capsid antigens long lasting Af Geijersstam et al
0.172249.15302958.html.plaintext.txt	181	2000 may marker past current infection
0.172249.15302958.html.plaintext.txt	182	From information presented Table 3 appears systemic IgG antibodies 16L1 peptide good indicators current infection
0.172249.15302958.html.plaintext.txt	183	Nevertheless cannot conclude analyse women previous history HPV infection number seropositive patients negative presence viral DNA small
0.172249.15302958.html.plaintext.txt	184	To ascertain whether antibodies 16L1 peptide markers prior infection necessary test groups currently non infected women previous infection either treated successfully cleared naturally
0.172249.15302958.html.plaintext.txt	185	On hand observed small proportion patients LSIL seronegative regardless presence HPV DNA
0.172249.15302958.html.plaintext.txt	186	With reference earlier study incident HPV infection demonstrated women persistent HPV infection never seroconverted Carter et al
0.172249.15302958.html.plaintext.txt	187	Thus possible seronegative patients detected work produce antibodies peptide
0.172249.15302958.html.plaintext.txt	188	Here demonstrated IgG antibodies 16L1 peptide detected sera LSIL patients infected high risk HPV types almost absent low risk HPV associated LSIL uninfected women
0.172249.15302958.html.plaintext.txt	189	In much HPV infection associated risk factors age sexual activity Giuliano et al
0.172249.15302958.html.plaintext.txt	190	1999 could postulated apparent cross reactivity high risk HPV types might reflect shared epidemiological risk factors
0.172249.15302958.html.plaintext.txt	191	This unlikely epidemiological data presented Table 1 showed mean values age number sexual partners pregnancies similar high low risk HPV associated LSIL even non infected women
0.172249.15302958.html.plaintext.txt	192	This suggests strongly antibodies detected associated risk factors
0.172249.15302958.html.plaintext.txt	193	Another possibility might patients included high risk HPV associated LSIL group previously infected HPV 16
0.172249.15302958.html.plaintext.txt	194	To determine whether previous HPV 16 infection occurred women study presence HPV 16 DNA archive tissue samples warranted
0.172249.15302958.html.plaintext.txt	195	A likely explanation might difference antibody responses associated level sequence conservation peptide region
0.172249.15302958.html.plaintext.txt	196	This hypothesis supported previous work antibodies raised peptide sequence containing 16L1 peptide reacted HPV 16 VLPs HPV 11 VLPs Heino et al
0.172249.15302958.html.plaintext.txt	197	The 16L1 peptide located within structure h2 h3 helices C terminal laterally projecting domain L1 Chen et al
0.172249.15302958.html.plaintext.txt	198	They form together h4 helix surface contact L1 monomers
0.172249.15302958.html.plaintext.txt	199	Consequently site important assembly viral capsids relatively conserved among different HPV types
0.172249.15302958.html.plaintext.txt	200	However comparison corresponding sequences high low risk types detected hybrid capture test used work showed interesting differences
0.172249.15302958.html.plaintext.txt	201	For instance five low risk types differed three amino acid positions 16L1 peptide sequence
0.172249.15302958.html.plaintext.txt	202	In contrast three 12 high risk types differed three amino acid positions 16L1 peptide
0.172249.15302958.html.plaintext.txt	203	Moreover changes positions 1 5 8 found four five low risk types four 12 high risk types changes
0.172249.15302958.html.plaintext.txt	204	We also observed high proportion patients cervical cancer positive presence systemic IgG antibodies 16L1 peptide
0.172249.15302958.html.plaintext.txt	205	In earlier study Dillner et al
0.172249.15302958.html.plaintext.txt	206	1990 IgG responses peptides covering complete amino acid sequence HPV 16 L1 protein examined sera patients cervical cancer
0.172249.15302958.html.plaintext.txt	207	Interestingly peptide region included 16L1 peptide sequence demonstrated largely unreactive
0.172249.15302958.html.plaintext.txt	208	This divergence might attributable differences amino acid sequences
0.172249.15302958.html.plaintext.txt	209	1990 16L1 peptide sequence included part 20 amino acid peptide meant extension nine amino acids N terminus one amino acid C terminus 16L1 peptide
0.172249.15302958.html.plaintext.txt	210	In respect evidence indicate recognition binding antibodies particular epitope highly influenced extension peptide sequence
0.172249.15302958.html.plaintext.txt	211	In fact extension single amino acid induce reduction monoclonal antibody recognition two three orders magnitude Uray et al
0.172249.15302958.html.plaintext.txt	212	2003 extension 13 amino acids result complete loss antibody binding Calderon Aranda et al
0.172249.15302958.html.plaintext.txt	213	Therefore extensions 16L1 peptide might account lack response observed former report
0.172249.15302958.html.plaintext.txt	214	Interestingly patients high risk HPV associated invasive cervical cancer showed reduced antibody response 16L1 peptide compared high risk HPV associated LSIL
0.172249.15302958.html.plaintext.txt	215	In agreement results previous studies shown IgG responses different L1 derived peptides significantly prevalent patients premalignant lesions Sharma et al
0.172249.15302958.html.plaintext.txt	216	1996 associated cervical cancer Dillner et al
0.172249.15302958.html.plaintext.txt	217	Reduction anti peptide IgG responses cervical cancer may due natural decline antibody titres occurs time infected individuals Andersson Ellstrom et al
0.172249.15302958.html.plaintext.txt	218	2000 may associated lack antigen expression
0.172249.15302958.html.plaintext.txt	219	It known transcription L1 gene restricted terminally differentiated keratinocytes level cellular differentiation decreases grade neoplasia increases Stoler et al
0.172249.15302958.html.plaintext.txt	220	Consequently expression L1 protein significantly reduced advanced lesions associated high risk HPV genotypes Melsheimer et al
0.172249.15302958.html.plaintext.txt	221	Furthermore integration HPV DNA cervical cancer may cause disruption L1 gene Walboomers Meijer 1997 affecting expression L1 protein
0.172249.15302958.html.plaintext.txt	222	Indeed integration viral DNA occurs frequently HPV 18 HPV 16 associated tumours
0.172249.15302958.html.plaintext.txt	223	This consistent observation prevalence antibodies lower patients HPV 18 patients HPV 16 associated cervical cancer
0.172249.15302958.html.plaintext.txt	224	In conclusion study indicates 16L1 peptide might high risk type common epitope capable inducing cross reactive antibodies high risk HPV associated LSIL patients
0.172249.15302958.html.plaintext.txt	225	Importantly antibodies LSIL patients infected low risk HPV types react peptide suggesting reaction restricted high risk virus types
0.172249.15302958.html.plaintext.txt	226	Although extensive studies investigate antibody responses 16L1 peptide still required primary results suggest 16L1 peptide might useful development serological assays study natural vaccine induced immune responses high risk HPV well early detection oncogenic HPV infections
0.172249.15302958.html.plaintext.txt	227	ACKNOWLEDGEMENTS We thank Mr Ranulfo Pedraza excellent technical assistance
0.172249.15302958.html.plaintext.txt	228	This study supported DGAPA PAPIIT UNAM grants IN210501 IN215703 2 CONACyT grant 34835 M
0.172249.15302958.html.plaintext.txt	229	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Af Geijersstam V
0.172249.15302958.html.plaintext.txt	230	Stability time serum antibody levels human papillomavirus type 16
0.172249.15302958.html.plaintext.txt	231	J Infect Dis 177 1710 1714
0.172249.15302958.html.plaintext.txt	232	Comparison development serum antibodies HPV16 HPV33 acquisition cervical HPV DNA among sexually experienced virginal young girls
0.172249.15302958.html.plaintext.txt	233	Prevalence human papillomavirus cervical cancer worldwide perspective
0.172249.15302958.html.plaintext.txt	234	International Biological Study Cervical Cancer IBSCC Study Group
0.172249.15302958.html.plaintext.txt	235	J Natl Cancer Inst 87 796 802
0.172249.15302958.html.plaintext.txt	236	Mapping epitope recognized neutralizing monoclonal antibody specific toxin Cn2 scorpion Centruroides noxius using discontinuous synthetic peptides
0.172249.15302958.html.plaintext.txt	237	Comparison human papillomavirus types 16 18 6 capsid antibody responses following incident infection
0.172249.15302958.html.plaintext.txt	238	J Infect Dis 181 1911 1919
0.172249.15302958.html.plaintext.txt	239	Detection antibodies linear epitope major coat protein L1 human papillomavirus type 16 HPV 16 sera patients cervical intraepithelial neoplasia children
0.172249.15302958.html.plaintext.txt	240	Structure small virus like particles assembled L1 protein human papillomavirus 16
0.172249.15302958.html.plaintext.txt	241	Human papillomavirus types 6 11 antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
0.172249.15302958.html.plaintext.txt	242	Surface conformational linear epitopes HPV 16 HPV 18 L1 virus like particles defined monoclonal antibodies
0.172249.15302958.html.plaintext.txt	243	Mapping linear epitopes human papillomavirus type 16 L1 L2 open reading frames
0.172249.15302958.html.plaintext.txt	244	Antibodies linear conformational epitopes human papillomavirus type 16 independently associate incident cervical cancer
0.172249.15302958.html.plaintext.txt	245	Automated multiple peptide synthesis
0.172249.15302958.html.plaintext.txt	246	Risk factors high risk type human papillomavirus infection among Mexican American women
0.172249.15302958.html.plaintext.txt	247	Cancer Epidemiol Biomarkers Prev 8 615 620
0.172249.15302958.html.plaintext.txt	248	Human papillomavirus type 16 capsids expose multiple type restricted type common antigenic epitopes
0.172249.15302958.html.plaintext.txt	249	Use multiple PCR primer sets optimal detection human papillomavirus
0.172249.15302958.html.plaintext.txt	250	J Clin Microbiol 34 2095 2100
0.172249.15302958.html.plaintext.txt	251	Viral load determinant transmission human papillomavirus type 16 mother child
0.172249.15302958.html.plaintext.txt	252	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.172249.15302958.html.plaintext.txt	253	A virus like particle enzyme linked immunosorbent assay detects serum antibodies majority women infected human papillomavirus type 16
0.172249.15302958.html.plaintext.txt	254	J Natl Cancer Inst 86 494 499
0.172249.15302958.html.plaintext.txt	255	Detection antibodies L1 L2 E4 proteins human papillomavirus types 6 11 16 ELISA using synthetic peptides
0.172249.15302958.html.plaintext.txt	256	Use polymerase chain reaction amplification detection genital human papillomaviruses
0.172249.15302958.html.plaintext.txt	257	Immunocytochemical detection HPV high risk type L1 capsid proteins LSIL HSIL compared detection HPV L1 DNA
0.172249.15302958.html.plaintext.txt	258	Identification two homologous antigenic peptides derived L1 HPV 16 18 proteins specific HLA B3901 allele
0.172249.15302958.html.plaintext.txt	259	Estimates worldwide incidence 25 major cancers 1990
0.172249.15302958.html.plaintext.txt	260	CO2 PlinktypeDOI CrossRefMedline
0.172249.15302958.html.plaintext.txt	261	Mucosal IgG IgA responses human papillomavirus type 16 capsid proteins HPV16 infected women without visible pathology
0.172249.15302958.html.plaintext.txt	262	Analysis enzymatically amplified globin HLA DQ alpha DNA allele specific oligonucleotide probes
0.172249.15302958.html.plaintext.txt	263	Antibodies human papillomavirus 16 subsequent situ invasive cancer cervix
0.172249.15302958.html.plaintext.txt	264	Cancer Epidemiol Biomarkers Prev 6 233 237
0.172249.15302958.html.plaintext.txt	265	Prevalence serum antibodies synthetic peptides HPV16 epitopes among Indian women cervical neoplasia
0.172249.15302958.html.plaintext.txt	266	Human papillomavirus type 16 18 gene expression cervical neoplasias
0.172249.15302958.html.plaintext.txt	267	Identification solution conformation multiple epitopes recognized MUC2 mucin specific monoclonal antibody
0.172249.15302958.html.plaintext.txt	268	Arch Biochem Biophys 410 254 260
0.172249.15302958.html.plaintext.txt	269	Do HPV negative cervical carcinomas exist J Pathol 181 253 254
0.172249.15302958.html.plaintext.txt	270	CO2 0linktypeDOI CrossRefMedline
0.172249.15302958.html.plaintext.txt	271	Human papillomavirus necessary cause invasive cervical cancer worldwide
0.172249.15302958.html.plaintext.txt	272	CO2 FlinktypeDOI CrossRefMedline
0.172249.15302958.html.plaintext.txt	273	Cervical mucus antibodies human papillomavirus type 16 18 33 capsids relation presence viral DNA
0.172249.15302958.html.plaintext.txt	274	J Clin Microbiol 34 3056 3062
0.172249.15302958.html.plaintext.txt	275	A monoclonal antibody intact human papillomavirus type 16 capsids blocks serological reactivity human sera
0.172249.15302958.html.plaintext.txt	276	Characterization major neutralizing epitope human papillomavirus type 16 L1
0.172249.15302958.html.plaintext.txt	277	Received 1 March 2004 accepted 12 May 2004
0.172249.15302958.html.plaintext.txt	278	This Article Abstract Full Text PDF Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles Rocha Zavaleta L
0.172249.15302958.html.plaintext.txt	279	Articles citing Article PubMed PubMed Citation Articles Rocha Zavaleta L
0.172249.15302958.html.plaintext.txt	280	Agricola Articles Rocha Zavaleta L
0.172249.15302958.html.plaintext.txt	281	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL J MED MICROBIOL ALL SGM JOURNALS
0.16214354.10767310.html.plaintext.txt	0	Neural cell recognition molecule L1 relating biological complexity human disease mutations Sue Kenwrick Alex Watkins Elena De Angelis
0.16214354.10767310.html.plaintext.txt	1	Wellcome Trust Centre Study Molecular Mechanisms Disease Department Medicine University Cambridge Addenbrooke Hospital Cambridge CB2 2XY UK
0.16214354.10767310.html.plaintext.txt	2	Received 5 February 2000 Accepted 11 February 2000
0.16214354.10767310.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	4	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	5	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	6	SUMMARY REFERENCES Human single gene disorders affect nervous system provide host natural mutations deployed quest understand development function
0.16214354.10767310.html.plaintext.txt	7	A paradigm approach study disorders caused mutations gene neural cell recognition molecule L1
0.16214354.10767310.html.plaintext.txt	8	L1 founder member subfamily cell adhesion molecules primarily expressed nervous system date one associated hereditary disease
0.16214354.10767310.html.plaintext.txt	9	In review summarize analysis pathological mutations L1 complementing study mouse models vitro analysis L1 function
0.16214354.10767310.html.plaintext.txt	10	INTRODUCTION TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	11	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	12	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	13	SUMMARY REFERENCES L1 one member subfamily four mammalian cell surface glycoproteins related structure sequence Fig
0.16214354.10767310.html.plaintext.txt	14	They belong large class immunoglobulin superfamily cell adhesion molecules CAMs mediate cell cell adhesion Ca2 independent homo heterophilic binding cell surface 12
0.16214354.10767310.html.plaintext.txt	15	Each member L1 subfamily contains six Ig like domains linked five fibronectin type III FNIII domains extracellular surface single pass transmembrane domain short highly conserved cytoplasmic tail
0.16214354.10767310.html.plaintext.txt	16	L1 L1 like molecules structure identified many species including rodent fish fruit fly nematode
0.16214354.10767310.html.plaintext.txt	17	In case proven important components ligand receptor network guidance forces influence axonal growth guidance reviews see refs 3 5
0.16214354.10767310.html.plaintext.txt	18	For reason L1 aptly called neural recognition molecule rather adhesion molecule
0.16214354.10767310.html.plaintext.txt	19	View larger version 30K Figure 1
0.16214354.10767310.html.plaintext.txt	20	The vertebrate L1 subfamily comprises four structurally related molecules containing six domains structural similarity constant domains immunoglobulins Ig four five domains similar type III repeats found fibronectins Fn
0.16214354.10767310.html.plaintext.txt	21	NrCAM Neurofascin ankyrin binding glycoproteinABGP rat known numerous isoforms dictated alternative splicing whereas L1 two isoforms neural isoform includes sequences encoded mini exons 2 27 peripheral form lacks residues
0.16214354.10767310.html.plaintext.txt	22	Neural L1 therefore contains five additional amino acids prior first Ig domain four residue insertion cytoplasmic domain
0.16214354.10767310.html.plaintext.txt	23	NgCAM thought chicken homologue L1 although sequence highly conserved L1 subfamily members
0.16214354.10767310.html.plaintext.txt	24	However functional studies using human rodent L1 usually corroborated findings conducted chick protein
0.16214354.10767310.html.plaintext.txt	25	In review NgCAM L1 considered functionally equivalent
0.16214354.10767310.html.plaintext.txt	26	In mammals L1 expressed throughout nervous system subsets developing differentiated neurons well Schwann cells peripheral nervous system
0.16214354.10767310.html.plaintext.txt	27	On differentiated neurons L1 found regions contact neighbouring axons growth cones structures leading tip axons responsible sensing extracellular growth guidance cues
0.16214354.10767310.html.plaintext.txt	28	This distribution supports suggestion vitro studies L1 adhesive inter actions may mediate axon bundling fasciculation 67 L1 acts growth cone receptor signals induce extension processes neurites neurons culture 8
0.16214354.10767310.html.plaintext.txt	29	Neurite outgrowth likened axon growth taken evidence L1 may involved axon growth development
0.16214354.10767310.html.plaintext.txt	30	L1 also involved interactions Schwann cells peripheral nervous system axons 910 neuronal cell migration 11 synaptogenesis myelination neuronal cell survival 12 even long term potentiation 13
0.16214354.10767310.html.plaintext.txt	31	Although primarily expressed nervous system L1 also found specialized sites including subclass leukocytes intestinal crypt cells kidney tubule epithelia 14 16 reviewed ref
0.16214354.10767310.html.plaintext.txt	32	As human disorder involving L1 essentially neurological focus role nervous system
0.16214354.10767310.html.plaintext.txt	33	MUTATIONS IN L1 AFFECT DEVELOPMENT OF THE NERVOUS SYSTEM IN MAN AND MOUSE TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	34	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	35	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	36	SUMMARY REFERENCES Mutations L1 gene responsible X linked recessive neurological disorder described X linked hydrocephalus MASA syndrome spastic paraplegia type I SPG1
0.16214354.10767310.html.plaintext.txt	37	The varying nomenclature reflection extremely variable presentation within families reviewed refs 18 20
0.16214354.10767310.html.plaintext.txt	38	The consistent features affected boys degrees lower limb spasticity mental retardation hydrocephalus flexion deformity thumbs
0.16214354.10767310.html.plaintext.txt	39	Those develop hydrocephalus water brain utero soon birth lower life expectancy many die neonatally
0.16214354.10767310.html.plaintext.txt	40	The excess cerebrospinal fluid CSF increased size cerebral ventricles may partly result stenosis thin channel called aqueduct Sylvius CSF circulates although inadequate cell migration loss neurons may also contribute increase cavity size
0.16214354.10767310.html.plaintext.txt	41	Perhaps striking pathological observation hypoplasia absence two long axonal tracts cortico spinal tract CST corpus callosum
0.16214354.10767310.html.plaintext.txt	42	The former involved control voluntary motor function disruption provides explanation spasticity observed patients
0.16214354.10767310.html.plaintext.txt	43	The corpus callosum large bundle nerve fibres connects two cerebral hemispheres underdevelopment may contribute mental retardation epilepsy observed patients abnormal L1
0.16214354.10767310.html.plaintext.txt	44	Other frequent malformations include underdevelopment anterior vermis cerebellum fused thalami 21 may indicate abnormal neuronal proliferation migration survival
0.16214354.10767310.html.plaintext.txt	45	The L1 protein mice similar sequence human L1 targeted disruption knockout mice produces interesting phenotypic similarities
0.16214354.10767310.html.plaintext.txt	46	As human condition central nervous system mice largely intact major malformation limited hypoplasia CST corpus callosum cerebellar vermis degree ventricular enlargement 22
0.16214354.10767310.html.plaintext.txt	47	L1 disruption mice also produces cognitive defect may relate mental retardation human condition 23
0.16214354.10767310.html.plaintext.txt	48	However real value mouse models detailed analysis nervous system malformations mechanism underlying possible
0.16214354.10767310.html.plaintext.txt	49	For example abnormalities hippocampus morphology individual neurons noted L1 knockout mice 24
0.16214354.10767310.html.plaintext.txt	50	Furthermore vivo confirmation involvement L1 Schwann cell function follows observation L1 deficient mice reduced interaction Schwann cells axons unmyelinated sensory nerves
0.16214354.10767310.html.plaintext.txt	51	The resulting degeneration sensory axons leads impaired sensory function 10
0.16214354.10767310.html.plaintext.txt	52	This observation un doubtedly lead assessment sensory function human subjects L1 mutations
0.16214354.10767310.html.plaintext.txt	53	The mechanism L1 mutation disrupts development CST knockout lines involves failure axonal pathfinding time axons required grow across midline 25
0.16214354.10767310.html.plaintext.txt	54	Presumably L1 required attractive repulsive cue substrate neuronal receptor point axon guidance
0.16214354.10767310.html.plaintext.txt	55	The underdeveloped CST observed mouse man could result degeneration neurons synapse correct targets
0.16214354.10767310.html.plaintext.txt	56	In keeping extreme interfamilial well intrafamilial variability seen condition man aspects knockout phenotype mouse vary markedly different genetic backgrounds 24 indicating epistatic influence genes penetrance L1 mutation
0.16214354.10767310.html.plaintext.txt	57	Overall phenotypes observed mouse man show L1 function clearly pivotal generation certain axonal tracts important correct cortical cerebellar morphology
0.16214354.10767310.html.plaintext.txt	58	HOW DOES L1 FUNCTION TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	59	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	60	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	61	SUMMARY REFERENCES It apparent L1 participates variety different cellular responses within outside nervous system
0.16214354.10767310.html.plaintext.txt	62	This flexibility function probably related multiplicity binding partners potential signalling routes post translational modifications
0.16214354.10767310.html.plaintext.txt	63	Cell surface ligands A bewildering array molecules found bind extracellular domains ECDs L1
0.16214354.10767310.html.plaintext.txt	64	These include L1 members Ig superfamily integrins extracellular matrix proteins laminin variety proteoglycans reviewed refs 172627 Fig
0.16214354.10767310.html.plaintext.txt	65	Where different interactions relevant challenging question
0.16214354.10767310.html.plaintext.txt	66	L1 acting ligand receptor promote cell adhesion neurite outgrowth explanted neurons indicating interaction may relevant fasciculation axon growth
0.16214354.10767310.html.plaintext.txt	67	Furthermore cerebellar neurons L1 knockout mice longer extend processes purified L1 22
0.16214354.10767310.html.plaintext.txt	68	However heterophilic ligands L1 may also influence L1 activity
0.16214354.10767310.html.plaintext.txt	69	In several cases influence exerted plane neuronal membrane cis
0.16214354.10767310.html.plaintext.txt	70	For example L1 binds cis TAG 1 member another subfamily Ig CAMs 28 interaction may even required L1 L1 mediated neurite outgrowth specific neurons 2930
0.16214354.10767310.html.plaintext.txt	71	DM GRASP another cell surface adhesion molecule may also cooperate L1 promote neurite outgrowth 31
0.16214354.10767310.html.plaintext.txt	72	Cis interaction NCAM shown enhance ability L1 bind homophilically 32 small cell surface glyco protein nectadrin CD24 may also recruited complex 33
0.16214354.10767310.html.plaintext.txt	73	View larger version 27K Figure 2
0.16214354.10767310.html.plaintext.txt	74	The complexity L1 interaction
0.16214354.10767310.html.plaintext.txt	75	L1 shown interacting homophilically neuronal cell surface L1 present another surface e
0.16214354.10767310.html.plaintext.txt	76	another cell membrane extracellular matrix
0.16214354.10767310.html.plaintext.txt	77	This interaction known initiate neurite outgrowth activation fibroblast growth factor receptors FGFR local increase intracellular calcium within neuronal growth cone least vitro systems
0.16214354.10767310.html.plaintext.txt	78	L1 likely part complex involves cis trans interactions cell surface
0.16214354.10767310.html.plaintext.txt	79	Some may modulate L1 binding activity
0.16214354.10767310.html.plaintext.txt	80	The biological consequences L1 interaction many potential heterophilic ligands largely unknown although interaction neurocan may negative effect adhesion axon growth
0.16214354.10767310.html.plaintext.txt	81	The cytoplasmic domain interacts cytoskeleton subject phosphorylation variety kinases
0.16214354.10767310.html.plaintext.txt	82	Ankyrin mobilized sites L1 L1 binding direct attachment L1 inside effect stabilizing homophilic interaction
0.16214354.10767310.html.plaintext.txt	83	Thin arrows represent binding potential thick arrows biological effect
0.16214354.10767310.html.plaintext.txt	84	F11 F3 axonin 1 TAG 1 homologous chick mammalian proteins respectively
0.16214354.10767310.html.plaintext.txt	85	Not L1 potential interactions result positive effect adhesion axon growth
0.16214354.10767310.html.plaintext.txt	86	For example L1 binds strong affinity neurocan neural extracellular matrix chondroitin sulfate proteoglycan inhibitory effect neuronal adhesion neurite outgrowth 34
0.16214354.10767310.html.plaintext.txt	87	Signalling Influences cell behaviour imply L1 ligand binding must linked intracellular signalling pathways
0.16214354.10767310.html.plaintext.txt	88	So cell surface glycoprotein self contained catalytic domains engage signalling pathway One obvious way binding molecules elicit signal trans duction
0.16214354.10767310.html.plaintext.txt	89	At least one mechanism L1 L1 recognition stimulate axonal growth activating tyrosine kinase linked receptors fibroblast growth factors FGFRs
0.16214354.10767310.html.plaintext.txt	90	The downstream signalling cascade involved worked considerable detail culminates transient influx calcium L N type channels localized sites growth cone 3536
0.16214354.10767310.html.plaintext.txt	91	Growth cone morphology behaviour known sensitive waves calcium increased concentration generally slowing neuritic growth 3738
0.16214354.10767310.html.plaintext.txt	92	How focal domains calcium conversely promote growth cone advance understood although one possibility action Ca2 dependent modifiers actin cytoskeleton
0.16214354.10767310.html.plaintext.txt	93	Dimerization TAG 1 offers yet another mechanism L1 may influence intracellular events chick homologue TAG 1 axonin 1 associated unknown linker non receptor tyrosine kinase 39
0.16214354.10767310.html.plaintext.txt	94	Components MAPK mitogen activated protein kinase signalling pathway 40 tyrosine kinase src pertussis toxin sensitive G proteins also implicated L1 mediated responses 4142
0.16214354.10767310.html.plaintext.txt	95	INTERACTIONS OF THE CYTOPLASMIC DOMAIN TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	96	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	97	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	98	SUMMARY REFERENCES The 100 amino acid stretch cytoplasmic domain conserved region L1 like molecules species functional importance highlighted finding deletions even single amino acid changes region cause neurological disease man
0.16214354.10767310.html.plaintext.txt	99	Members L1 subfamily share amino acid sequence high affinity ankyrin linker protein spectrin based cytoskeleton underlies plasma membrane 4344
0.16214354.10767310.html.plaintext.txt	100	Ankyrins multi domain proteins bind cytoskeletal integral membrane components two forms ankyrinB ankyrinG abundant nervous system 45
0.16214354.10767310.html.plaintext.txt	101	Mobilization ankyrin sites cell contact observed homophilic binding L1 formation TAG 1 L1 complex 28
0.16214354.10767310.html.plaintext.txt	102	Thus CAM adhesion translated mobilization cytoskeletal components potentially integral membrane proteins
0.16214354.10767310.html.plaintext.txt	103	The ability L1 like molecules bind ankyrin regulated phosphorylation highly conserved tyrosine residue within L1 cytoplasmic motif FIGQY 46
0.16214354.10767310.html.plaintext.txt	104	Interestingly deletion mutation phosphorylation motif inside effect ability L1 like CAMs bind homophilically 46 suggesting ankyrin recruitment may role stabilization intercellular contacts involve L1
0.16214354.10767310.html.plaintext.txt	105	A role ankyrin L1 function supported remarkable overlap phenotype ankyrinB mice L1 deficient mice human subjects L1 mutations 47
0.16214354.10767310.html.plaintext.txt	106	The cytoplasmic domain also associate actin stress fibres 48
0.16214354.10767310.html.plaintext.txt	107	The cytoplasmic domain also houses tyrosine based sorting motif YRSL generally Yxx amino acid bulky hydrophobic side chain required correct trafficking L1 along axons growth cone well L1 endocytosis 4950 see
0.16214354.10767310.html.plaintext.txt	108	The YRSL motif binds adaptor complex AP 2 pathway internalization via clathrin coated pits
0.16214354.10767310.html.plaintext.txt	109	L1 modification L1 subject glycosylation phosphorylation may affect function
0.16214354.10767310.html.plaintext.txt	110	Modulation L1 function NCAM example occurs recognition L1 carbohydrate 32
0.16214354.10767310.html.plaintext.txt	111	In addition tyrosine phosphorylation ankyrin binding domain serine phosphorylation specific kinases occurs several sites 4051 53
0.16214354.10767310.html.plaintext.txt	112	Interestingly sites next known binding domains either cytoskeletal components AP 2 complex Fig
0.16214354.10767310.html.plaintext.txt	113	3A suggesting serine phosphorylation may influence cytoplasmic inter actions L1 mobility internalization
0.16214354.10767310.html.plaintext.txt	114	Indeed phosphorylation ERK2 found dependent L1 endocytosis vitro 40
0.16214354.10767310.html.plaintext.txt	115	ERK2 p90rsk components MAPK pathway signalling cascade also activated FGFRs
0.16214354.10767310.html.plaintext.txt	116	The possibility cooperation pathways modulating L1 action intriguing
0.16214354.10767310.html.plaintext.txt	117	View larger version 51K Figure 3
0.16214354.10767310.html.plaintext.txt	118	A Cytoplasmic domain interactions mutations
0.16214354.10767310.html.plaintext.txt	119	L1 highly conserved cytoplasmic domain contains binding phosphorylation sites right
0.16214354.10767310.html.plaintext.txt	120	These shown relative pathological mutations left missense mutations boxed yellow
0.16214354.10767310.html.plaintext.txt	121	The YRSL motif L1 required correct targeting growth cone
0.16214354.10767310.html.plaintext.txt	122	It interacts AP 2 adapter complex facilitating endocytosis via clathrin coated pits
0.16214354.10767310.html.plaintext.txt	123	This may control ability L1 respond rapidly changes environment
0.16214354.10767310.html.plaintext.txt	124	This motif partly encoded alternatively spliced exon 27 RSLE
0.16214354.10767310.html.plaintext.txt	125	The rapid formation disassociation stable adhesion complexes L1 heterophilic ligands probably requires specific interaction two components cytoskeleton actin ankyrin
0.16214354.10767310.html.plaintext.txt	126	This may regulated phosphorylation serine tyrosine residues cytoplasmic domain
0.16214354.10767310.html.plaintext.txt	127	Phosphorylation Y1229 reduces binding ankyrin residue mutated one family
0.16214354.10767310.html.plaintext.txt	128	B Distribution missense mutations relative extracellular domain function
0.16214354.10767310.html.plaintext.txt	129	The sites missense mutations left shown relative L1 domains involved ligand binding proteolytic cleavage right
0.16214354.10767310.html.plaintext.txt	130	Each line represents results different study referenced parentheses solid lines covering regions definitely involved binding
0.16214354.10767310.html.plaintext.txt	131	The debate domains required homophilic binding continues
0.16214354.10767310.html.plaintext.txt	132	Analysis L1 fragments expressed E
0.16214354.10767310.html.plaintext.txt	133	coli highlights 14 amino acids Ig domain 2 key homophilic binding site 70
0.16214354.10767310.html.plaintext.txt	134	Studies based analysis pathological missense mutations support finding Ig domain 2 required homophilic binding indicate integrity several domains also required 69
0.16214354.10767310.html.plaintext.txt	135	Studies NgCAM chicken homologue L1 highlight Ig domains 2 4 key role homophilic binding 7
0.16214354.10767310.html.plaintext.txt	136	Interactions mutant L1 F11 axonin 1 indicate integrity number domains required 69 although effects individual mutations distinct effects L1 L1 interaction
0.16214354.10767310.html.plaintext.txt	137	Domain deletion studies using NgCAM axonin 1 suggest involvement least Ig domains 2 4 Fn domain 3 7
0.16214354.10767310.html.plaintext.txt	138	A site integrin binding 5ss1 vss3 localized two RGD motifs sixth Ig domain 7172
0.16214354.10767310.html.plaintext.txt	139	Neurocan inhibits neurite outgrowth bind Ig domain 1 domains may also involved 72
0.16214354.10767310.html.plaintext.txt	140	It known time addition full length 200 kDa protein fragments L1 polypeptide found tissue extracts matter debate whether L1 specifically cleaved
0.16214354.10767310.html.plaintext.txt	141	Recently however matrix metalloprotease TACE plasmin shown release L1 cell surface cleavage specific sites 5455 Fig
0.16214354.10767310.html.plaintext.txt	142	This raises interesting possibility well acting cell surface receptor L1 may released soluble form could act ligand distance source
0.16214354.10767310.html.plaintext.txt	143	Along regulated endocytosis may modulate spatial availability L1 response intra extracellular signals
0.16214354.10767310.html.plaintext.txt	144	Such regulation may important example growth cone polarity L1 mediated effects may influence axonal turning
0.16214354.10767310.html.plaintext.txt	145	L1 expression Further modification L1 activity localization afforded use specific splice variants
0.16214354.10767310.html.plaintext.txt	146	The L1 gene comprises 29 exons 28 coding 5657
0.16214354.10767310.html.plaintext.txt	147	Studies transcriptional regulation revealed neural expression least partly determined neuron restrictive silencing element NRSE contained within second intron homeobox paired domain containing region HPD first intron 5758
0.16214354.10767310.html.plaintext.txt	148	Neural expression also associated inclusion two mini exons exons 2 27 excluded non neural transcript 5960
0.16214354.10767310.html.plaintext.txt	149	Exon 27 encoding RSLE neuron specific function contributes YRSL motif required targeting growth cone
0.16214354.10767310.html.plaintext.txt	150	As sequence lacking outside nervous system AP 2 mediated endocytosis L1 presumably also restricted neural tissue
0.16214354.10767310.html.plaintext.txt	151	The function exon 2 unknown although preliminary results indicate may modulate homophilic heterophilic ligand binding E
0.16214354.10767310.html.plaintext.txt	152	MUTATIONS IN L1 INFERENCES FOR L1 FUNCTION TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	153	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	154	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	155	SUMMARY REFERENCES Since first description L1 mutation 61 91 different mutations identified 100 families 62 references therein
0.16214354.10767310.html.plaintext.txt	156	Most forms mutation reported distributed across domains 38 missense 10 nonsense 21 frameshift 17 splicing 5 intragenic deletion 1 intragenic duplication
0.16214354.10767310.html.plaintext.txt	157	Most nonsense frameshift mutations would eliminate cell surface expression L1 truncation prior transmembrane domain
0.16214354.10767310.html.plaintext.txt	158	Although mutations heterogeneous attempts relate position type disruption phenotype confounded intrafamilial variability presentation
0.16214354.10767310.html.plaintext.txt	159	Nevertheless mutations cytoplasmic domain less likely cause life threatening hydrocephalus disrupting extra cellular surface indicating qualitative difference effect two broad classes mutation 63
0.16214354.10767310.html.plaintext.txt	160	As homophilic binding may preserved absence cytoplasmic domain 6465 relative longevity patients cytoplasmic mutations may due preservation L1 adhesive functions
0.16214354.10767310.html.plaintext.txt	161	CYTOPLASMIC DOMAIN TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	162	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	163	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	164	SUMMARY REFERENCES Five mutations truncate cytoplasmic domain various points along length related known sites L1 binding modification intracellular trafficking Fig
0.16214354.10767310.html.plaintext.txt	165	Whereas delete additional functional sites eliminate least part conserved ankyrin binding domain well tyrosine residue position 1229 involved moderating ankyrin binding L1 subfamily 4666
0.16214354.10767310.html.plaintext.txt	166	Mutation Y1229 histidine one family confirms importance controlled ankyrin binding L1 function nervous system
0.16214354.10767310.html.plaintext.txt	167	No mutations found date mutate serines phosphorylated p90rsk S1152 casein kinase II S1181 ERK2 S1204 S1248
0.16214354.10767310.html.plaintext.txt	168	However mutation additional serine 1194 implicates residue potential substrate modification
0.16214354.10767310.html.plaintext.txt	169	Clearly mutations delete RSLE also disrupt trafficking L1 differentiated neurons allowing transport protein cell soma
0.16214354.10767310.html.plaintext.txt	170	MISSENSE MUTATIONS AFFECTING THE ECDS TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	171	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	172	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	173	SUMMARY REFERENCES The interesting mutations consider respect gene function missense mutations L1 represent largest single class
0.16214354.10767310.html.plaintext.txt	174	The majority distributed across 10 11 ECDs Fig
0.16214354.10767310.html.plaintext.txt	175	Outline structures ECDs based crystallographic resolution related proteins allow predictions made concerning structural outcome many changes 67
0.16214354.10767310.html.plaintext.txt	176	Over half mutations mapped onto structures found affect residues key structural integrity individual domains Table 1
0.16214354.10767310.html.plaintext.txt	177	A smaller proportion affect residues part core structure likely affect surface properties L1 domain integrity
0.16214354.10767310.html.plaintext.txt	178	Additional insight comes structural resolution hemolin insect protein composed four Ig domains similarity first four domains L1
0.16214354.10767310.html.plaintext.txt	179	In hemolin domains folded horseshoe structure interaction Ig domains 1 4 domains 2 3 68
0.16214354.10767310.html.plaintext.txt	180	Interestingly 50 human mutations affected Ig domains 1 4 lie contact regions required four domain conglomerate
0.16214354.10767310.html.plaintext.txt	181	Missense mutations L1 effect domain structure ligand binding Missense mutations theoretically number consequences L1 production function
0.16214354.10767310.html.plaintext.txt	182	Firstly may alter folding intracellular trafficking L1
0.16214354.10767310.html.plaintext.txt	183	A mutation signal peptide W9S example predictably found affect cell surface expression 69
0.16214354.10767310.html.plaintext.txt	184	Secondly mutations put cysteine surface molecule Y194C Y1070C could affecting protein function mobility promoting inappropriate intermolecular disulfides either folding cell surface
0.16214354.10767310.html.plaintext.txt	185	Thirdly intriguingly mutations may affect ligand binding therefore offer potential mutation based structure function studies
0.16214354.10767310.html.plaintext.txt	186	Through analysing 12 mutations shown missense changes ECDs variable effects binding L1 related CAMs TAG 1axonin 1 F3F11 69 Table 1
0.16214354.10767310.html.plaintext.txt	187	Whereas many mutations affect one binding activity several influence affect homo heterophilic binding selectively
0.16214354.10767310.html.plaintext.txt	188	As latter usually surface changes may highlight key binding sites specific ligands
0.16214354.10767310.html.plaintext.txt	189	For example E309K surface mutation affect homophilic binding severely compromises binding axonin 1 F11
0.16214354.10767310.html.plaintext.txt	190	Interestingly mutations affect TAG 1axonin 1 F3F11 binding similar way indicating two structurally related ligands interact L1 similar fashion
0.16214354.10767310.html.plaintext.txt	191	These studies indicate first time pathogenesis may result different effects L1 ligand binding
0.16214354.10767310.html.plaintext.txt	192	That several domains required correct homo heterophilic binding L1 also apparent
0.16214354.10767310.html.plaintext.txt	193	This contrast results previous study using isolated domains suggested Ig domain 2 required homophilic interaction 70
0.16214354.10767310.html.plaintext.txt	194	This difference may reconciled Ig domain 2 contains essential binding site interaction requires considerable antiparallel overlap L1 monomers
0.16214354.10767310.html.plaintext.txt	195	Figure 3B also shows distribution missense mutations alongside known binding regions several L1 ligands 769 72
0.16214354.10767310.html.plaintext.txt	196	It clear domains interaction overlap considerably human mutations may also affecting binding integrins proteo glycans
0.16214354.10767310.html.plaintext.txt	197	Further studies effects L1 mutations ligand binding intracellular processing allow much better understanding disease pathology functional requirements L1 domains influence design animal models test relevance disrupting specific aspects L1 interaction mobility
0.16214354.10767310.html.plaintext.txt	198	SUMMARY TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	199	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	200	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	201	SUMMARY REFERENCES L1 part dynamic complex interacting molecules associated signal transduction pathways cytoskeletal connections
0.16214354.10767310.html.plaintext.txt	202	How different pathways cross talk influence neurite outgrowth stabilize cell adhesion affect neuronal migration unclear although general principles emerge
0.16214354.10767310.html.plaintext.txt	203	Firstly L1 merely intercellular glue receptor capable transducing signals inside cell well responding signals inside
0.16214354.10767310.html.plaintext.txt	204	Secondly intimate plastic relationship cytoskeleton
0.16214354.10767310.html.plaintext.txt	205	Thirdly L1 activity mediated number different binding partners trans cis well post translational modification cleavage
0.16214354.10767310.html.plaintext.txt	206	Mutation L1 man mouse results developmental defects consistent role L1 axonal pathfinding well cell migration
0.16214354.10767310.html.plaintext.txt	207	Assessment effects disease causing mutations L1 function together analysis animal models proving valuable tool relating L1 function vivo activity
0.16214354.10767310.html.plaintext.txt	208	ACKNOWLEDGEMENTS We would like thank Wellcome Trust EC support
0.16214354.10767310.html.plaintext.txt	209	FOOTNOTES To correspondence addressed
0.16214354.10767310.html.plaintext.txt	210	Tel 44 1223 762616 Fax 44 1223 331206 Email sjk12mole
0.16214354.10767310.html.plaintext.txt	211	REFERENCES TOP ABSTRACT INTRODUCTION MUTATIONS IN L1 AFFECT
0.16214354.10767310.html.plaintext.txt	212	HOW DOES L1 FUNCTION INTERACTIONS OF THE CYTOPLASMIC
0.16214354.10767310.html.plaintext.txt	213	CYTOPLASMIC DOMAIN MISSENSE MUTATIONS AFFECTING THE
0.16214354.10767310.html.plaintext.txt	214	SUMMARY REFERENCES 1 Rathjen F
0.16214354.10767310.html.plaintext.txt	215	1984 Comparison two cell surface molecules involved neural cell adhesion
0.16214354.10767310.html.plaintext.txt	216	1991 Structure new nervous system glycoprotein Nr CAM relationship subgroups neural cell adhesion molecules
0.16214354.10767310.html.plaintext.txt	217	1996 Structurefunction relationships axon associated adhesion receptors immunoglobulin superfamily
0.16214354.10767310.html.plaintext.txt	218	1996 The L1 family neural cell adhesion molecules old proteins performing new tricks
0.16214354.10767310.html.plaintext.txt	219	1998 Molecular interactions involving immunoglobulin superfamily adhesion proteins
0.16214354.10767310.html.plaintext.txt	220	Ig Superfamily Molecules Nervous System
0.16214354.10767310.html.plaintext.txt	221	Harwood Academic Publishers Amsterdam The Netherlands pp
0.16214354.10767310.html.plaintext.txt	222	1998 In vitro studies growth cone behavior support role fasciculation mediated cell adhesion molecules sensory axon guidance development
0.16214354.10767310.html.plaintext.txt	223	1998 Neurite fasciculation mediated complexes axonin 1 Ng cell adhesion molecule
0.16214354.10767310.html.plaintext.txt	224	1989 L1 mediated axon growth occurs via homophilic binding mechanism
0.16214354.10767310.html.plaintext.txt	225	1988 Identification major proteins promote neuronal process outgrowth Schwann cells vitro
0.16214354.10767310.html.plaintext.txt	226	1999 Heterophilic binding L1 unmyelinated sensory axons mediates Schwann cell adhesion required axonal survival
0.16214354.10767310.html.plaintext.txt	227	1983 L1 mono poly clonal antibodies modify cell migration early postnatal mouse cerebellum
0.16214354.10767310.html.plaintext.txt	228	1999 Prevention neuronal cell death neural adhesion molecules L1 CHL1
0.16214354.10767310.html.plaintext.txt	229	1996 Neural cell adhesion molecules activity dependent development synaptic plasticity
0.16214354.10767310.html.plaintext.txt	230	1992 Expression function neural cell adhesion molecule L1 mouse leukocytes
0.16214354.10767310.html.plaintext.txt	231	1987 Characterization cell adhesion molecules L1 N CAM J1 mouse intestine
0.16214354.10767310.html.plaintext.txt	232	1998 The cell adhesion molecule L1 developmentally regulated renal epithelium involved kidney branching morphogenesis
0.16214354.10767310.html.plaintext.txt	233	1997 The cell adhesion molecule L1 species cell type dependent multiple binding mechanisms
0.16214354.10767310.html.plaintext.txt	234	Differentiation 61 143 150
0.16214354.10767310.html.plaintext.txt	235	1998 Congenital hydrocephalus nosology guidelines clinical approach genetic counselling
0.16214354.10767310.html.plaintext.txt	236	1996 X linked hydrocephalus MASA syndrome
0.16214354.10767310.html.plaintext.txt	237	1997 L1 associated diseases clinical geneticists divide molecular geneticists unite
0.16214354.10767310.html.plaintext.txt	238	1995 A clinical neuro radiological study X linked hydrocephalus Japan
0.16214354.10767310.html.plaintext.txt	239	1997 Disruption mouse L1 gene leads malformations nervous system
0.16214354.10767310.html.plaintext.txt	240	1998 L1 knockout mice show dilated ventricles vermis hypoplasia impaired exploration patterns
0.16214354.10767310.html.plaintext.txt	241	1999 Abnormalities neuronal process extension hippocampal development ventricular system L1 knockout mice
0.16214354.10767310.html.plaintext.txt	242	1998 Errors corticospinal axon guidance mice lacking neural cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	243	1997 Neural cell adhesion molecule L1 signaling pathways growth cone motility
0.16214354.10767310.html.plaintext.txt	244	1998 Neural cell recognition molecule L1 cell biology human hereditary brain malformations
0.16214354.10767310.html.plaintext.txt	245	1998 Cis activation L1 mediated ankyrin recruitment TAG 1 homophilic cell adhesion
0.16214354.10767310.html.plaintext.txt	246	1996 Cell adhesion molecules NgCAM axonin 1 form heterodimers neuronal membrane cooperate neurite outgrowth promotion
0.16214354.10767310.html.plaintext.txt	247	1996 Clustering functional cooperation Ng CAM axonin 1 substratum contact area growth cones
0.16214354.10767310.html.plaintext.txt	248	1996 Heterophilic interactions DM GRASP GRASP NgCAM interactions involved neurite extension
0.16214354.10767310.html.plaintext.txt	249	1993 The fourth immunoglobulin like domain NCAM contains carbohydrate recognition domain oligomannosidic glycans implicated association L1 neurite outgrowth
0.16214354.10767310.html.plaintext.txt	250	1995 Evidence cis interaction cooperative signalling heat stable antigen nectadrin murine CD24 cell adhesion molecule L1 neurons
0.16214354.10767310.html.plaintext.txt	251	1994 The neuronal chondroitin sulfate proteoglycan neurocan binds neural cell adhesion molecules Ng CAML1NILE N CAM inhibits neuronal adhesion neurite outgrowth
0.16214354.10767310.html.plaintext.txt	252	1996 CAM FGF receptor interactions model axonal growth
0.16214354.10767310.html.plaintext.txt	253	1999 CAMs FGF cause local submembrane calcium signal promoting axon outgrowth without rise bulk calcium concentration
0.16214354.10767310.html.plaintext.txt	254	1999 In vivo regulation axon extension pathfinding growth cone calcium transients
0.16214354.10767310.html.plaintext.txt	255	1999 Braking news calcium growth cone
0.16214354.10767310.html.plaintext.txt	256	1996 Intracellular signaling changed clustering neural cell adhesion molecules axonin 1 NgCAM neurite fasciculation
0.16214354.10767310.html.plaintext.txt	257	1999 Activation MAPK signal cascade neural cell adhesion molecule L1 requires L1 internalization
0.16214354.10767310.html.plaintext.txt	258	1989 Neural cell adhesion molecules influence second messenger systems
0.16214354.10767310.html.plaintext.txt	259	1994 Impaired neurite outgrowth src minus cerebellar neurons cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	260	1994 Ankyrin binding activity shared neurofascinL1NrCAM family nervous system cell adhesion molecules
0.16214354.10767310.html.plaintext.txt	261	1998 A conserved role L1 transmembrane link neuronal adhesion membrane cytoskeleton assembly
0.16214354.10767310.html.plaintext.txt	262	1998 Expression localization brain ankyrin isoforms related proteins early developmental stages rat nervous system
0.16214354.10767310.html.plaintext.txt	263	1997 The phosphorylation state FIGQY tyrosine neurofascin determines ankyrin binding activity patterns cell segregation
0.16214354.10767310.html.plaintext.txt	264	1998 Nervous system defects AnkyrinB mice suggest functional overlap cell adhesion molecule L1 440 kD AnkyrinB premyelinated axons
0.16214354.10767310.html.plaintext.txt	265	1997 Mutational analysis L1 neuronal cell adhesion molecule identifies membrane proximal amino acids cytoplasmic domain required cytoskeletal anchorage
0.16214354.10767310.html.plaintext.txt	266	1998 The neural cell adhesion molecule L1 interacts AP 2 adaptor endocytosed via clathrin mediated pathway
0.16214354.10767310.html.plaintext.txt	267	1998 A neuronal form cell adhesion molecule L1 contains tyrosine based signal required sorting axonal growth cone
0.16214354.10767310.html.plaintext.txt	268	1996 Involvement p90rsk neurite outgrowth mediated cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	269	1996 Casein kinase II phosphorylates neural cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	270	1997 Tyrosine phosphorylation L1 family adhesion molecules implication Eph kinase Cek5
0.16214354.10767310.html.plaintext.txt	271	1999 A potential role plasminogen system posttranslational cleavage neural cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	272	1999 Metalloproteinase mediated release ectodomain L1 adhesion molecule
0.16214354.10767310.html.plaintext.txt	273	1998 The neural cell adhesion molecule L1 genomic organisation differential splicing conserved man pufferfish Fugu
0.16214354.10767310.html.plaintext.txt	274	1997 Tissue specific expression L1 cell adhesion molecule modulated neural restrictive silencer element
0.16214354.10767310.html.plaintext.txt	275	1999 A binding site homeodomain Pax proteins necessary L1 cell adhesion molecule gene expression Pax 6 bone morphogenetic proteins
0.16214354.10767310.html.plaintext.txt	276	1992 Variants human L1 cell adhesion molecule arise alternate splicing RNA
0.16214354.10767310.html.plaintext.txt	277	1995 Exon 2 gene neural cell adhesion molecule L1 alternatively spliced B cells
0.16214354.10767310.html.plaintext.txt	278	1992 Aberrant splicing neural cell adhesion molecule L1 mRNA family X linked hydrocephalus
0.16214354.10767310.html.plaintext.txt	279	62 L1CAM Mutation Web Page httpdnalab www
0.16214354.10767310.html.plaintext.txt	280	1997 CRASH syndrome mutations L1CAM correlate severity disease
0.16214354.10767310.html.plaintext.txt	281	Neuropediatrics 28 175 178
0.16214354.10767310.html.plaintext.txt	282	1995 The cytoplasmic domain Drosophila cell adhesion molecule neuroglian essential homophilic adhesive properties S2 cells
0.16214354.10767310.html.plaintext.txt	283	1995 The cytoplasmic domain cell adhesion molecule L1 required homophilic adhesion
0.16214354.10767310.html.plaintext.txt	284	1997 Tyrosine phosphorylation site highly conserved L1 family cell adhesion molecules abolishes ankyrin binding increases lateral mobility neurofascin
0.16214354.10767310.html.plaintext.txt	285	1996 Outline structure human L1 cell adhesion molecule sites mutations cause neurological disorders
0.16214354.10767310.html.plaintext.txt	286	1998 Crystal structure hemolin horseshoe shape implications homophilic adhesion
0.16214354.10767310.html.plaintext.txt	287	1999 Pathological missense mutations neural cell adhesion molecule L1 affect homophilic heterophilic binding activities
0.16214354.10767310.html.plaintext.txt	288	1998 Identification homophilic binding site immunoglobulin like domain 2 cell adhesion molecule L1
0.16214354.10767310.html.plaintext.txt	289	1997 A single immunoglobulin like domain human neural cell adhesion molecule L1 supports adhesion multiple vascular platelet integrins
0.16214354.10767310.html.plaintext.txt	290	1999 Integrin neurocan binding L1 involves distinct Ig domains
0.2066687.8557670.html.plaintext.txt	0	1996 The American Society Biochemistry Molecular Biology Inc
0.2066687.8557670.html.plaintext.txt	1	Lipoyl Domain based Mechanism Integrated Feedback Control Pyruvate Dehydrogenase Complex Enhancement Pyruvate Dehydrogenase Kinase Activity
0.2066687.8557670.html.plaintext.txt	2	Received publication April 10 1995 revised form August 18 1995
0.2066687.8557670.html.plaintext.txt	3	From 1Department Biochemistry Kansas State University Manhattan Kansas 66506 2Department Molecular Biology Biotechnology University Sheffield Sheffield S102UH United Kingdom ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES ACKNOWLEDGEMENTS REFERENCES
0.2066687.8557670.html.plaintext.txt	4	To conserve carbohydrate reserves reaction pyruvate dehydrogenase complex PDC must regulated citric acid cycle provided sufficient acetyl CoA
0.2066687.8557670.html.plaintext.txt	5	PDC activity reduced primarily increased phosphorylation pyruvate dehydrogenase E1 component due E1 kinase activity markedly enhanced elevated intramitochondrial NADHNAD acetyl CoACoA ratios
0.2066687.8557670.html.plaintext.txt	6	A mechanism evaluated enhanced kinase activity facilitated build reduced acetylated forms lipoyl moieties dihydrolipoyl acetyltransferase E2 component using NADH acetyl CoA reverse downstream reactions complex
0.2066687.8557670.html.plaintext.txt	7	Using peptide substrate kinase activity stimulated products ruling possibility kinase activity increased due changes reaction state substrate E1 thiamin pyrophosphate
0.2066687.8557670.html.plaintext.txt	8	Each E2 subunit contains two lipoyl domains NH terminal L1 inward lipoyl domain L2 individually produced fully lipoylated forms recombinant techniques
0.2066687.8557670.html.plaintext.txt	9	Although reduction acetylation L1 domain free lipoamide increased kinase activity modifications lipoate kinase binding L2 domain gave much greater enhancements kinase activity
0.2066687.8557670.html.plaintext.txt	10	The large stimulation kinase generated acetyl CoA occurred upon addition transacetylase catalyzing lipoyl domain free inner core portion E2 plus reduced lipoate source affirming acetylation prosthetic group essential mechanistic step acetyl CoA enhancing kinase activity
0.2066687.8557670.html.plaintext.txt	11	Similarly lesser stimulation kinase activity NADH required lipoate source supporting need lipoate reduction E3 catalysis
0.2066687.8557670.html.plaintext.txt	12	Complete enzymatic delipoylation PDC E2 kinase subcomplex recombinant L2 abolished stimulatory effects NADH acetyl CoA
0.2066687.8557670.html.plaintext.txt	13	Retention small portion PDC lipoates lowered kinase activity allowed stimulation residual kinase activity products
0.2066687.8557670.html.plaintext.txt	14	Reintroduction lipoyl moieties using lipoyl protein ligase restored capacity E2 core support high kinase activity along stimulation activity 3 fold NADH acetyl CoA
0.2066687.8557670.html.plaintext.txt	15	As suggested results enhancement kinase activity responsive reductive acetylation half maximal stimulation achieved 20 free L2 acetylated analysis previous results acetylation 3 6 60 L2 domains intact PDC
0.2066687.8557670.html.plaintext.txt	16	Based findings suggest kinase stimulation results modification lipoate L2 domain becomes specifically engaged binding kinase
0.2066687.8557670.html.plaintext.txt	17	In conclusion kinase activity attenuated substantial range response modest changes proportion oxidized reduced acetylated lipoyl moieties L2 domain E2 produced fluctuations NADHNAD acetyl CoACoA ratios translated rapid reversible E3 E2 reactions
0.2066687.8557670.html.plaintext.txt	18	In mammalian cells pyruvate dehydrogenase complex PDC controls oxidative utilization glucose1
0.2066687.8557670.html.plaintext.txt	19	Flux reaction results net depletion body carbohydrate reserves
0.2066687.8557670.html.plaintext.txt	20	The activity PDC must reduced fatty acids ketone bodies preferentially used provide 2 carbon units oxidative energy production citric acid cycleoxidative phosphorylation systems routine situation many organs
0.2066687.8557670.html.plaintext.txt	21	Furthermore conditions starvation diabetes activity PDC reduced minimal level conserve carbohydrates essential brain specialized tissuesorgans
0.2066687.8557670.html.plaintext.txt	22	To achieve critical role cellular fuel conservation PDC reaction controlled primarily highly regulated phosphorylationdephosphorylation cycle carried dedicated kinase phosphatase components
0.2066687.8557670.html.plaintext.txt	23	Phosphorylation pyruvate dehydrogenase E1 component inactivates complex dephosphorylation reactivates complex
0.2066687.8557670.html.plaintext.txt	24	Shortly PDC shown regulated interconversion 2 capacity fatty acids ketone bodies promote inactivation PDC demonstrated intact tissues 3 4 studies intact mitochondria5 6
0.2066687.8557670.html.plaintext.txt	25	Studies purified complex 7 8 9 isolated mitochondria 10 11 12 found increases PDC reaction products promote increase proportion PDC phosphorylated inactive state
0.2066687.8557670.html.plaintext.txt	26	With purified complex activity kinase greatly enhanced upon elevation NADHNAD ratio acetyl CoACoA ratio along reciprocal reduction phosphatase activity NADHNAD ratio elevated7
0.2066687.8557670.html.plaintext.txt	27	Accordingly E1a kinase crucial role wherein throttles PDC activity response increases mitochondrial acetylation reduction potentials
0.2066687.8557670.html.plaintext.txt	28	Not NADH acetyl CoA produced mitochondrial oxidation fuels direct products PDC reaction
0.2066687.8557670.html.plaintext.txt	29	This laboratory presented evidence control kinase activity initially involves product substrate ratios translated competitive utilization downstream reactions complex turn adjusts fraction complexs lipoyl prosthetic groups oxidized versus reduced versus acetylated forms13 14 15 16 17
0.2066687.8557670.html.plaintext.txt	30	Specifically mechanism proposes kinase regulates PDC activity due NADH reacting reverse dihydrolipoyl dehydrogenase E3 reaction acetyl CoA reacting reverse dihydrolipoyl acetyltransferase E2 reaction
0.2066687.8557670.html.plaintext.txt	31	Typically 60 80 enhancement kinase activity occurs upon lipoate reduction 3 fold enhancement following lipoate acetylation
0.2066687.8557670.html.plaintext.txt	32	The potential understanding molecular basis control greatly improved new insights structure E2 subunits unusual nature association kinase E2
0.2066687.8557670.html.plaintext.txt	33	The E2 subunits mammalian PDC four domains connected relatively large 2 3 kDa highly mobile linker regions Fig
0.2066687.8557670.html.plaintext.txt	34	Sixty COOH terminal inner domains E2 associate form dodecahedral inner core catalyzes transacetylation reaction
0.2066687.8557670.html.plaintext.txt	35	Each inner domain connected 3 globular domains linker hinge regions
0.2066687.8557670.html.plaintext.txt	36	The globular domains consist two 10 kDa lipoyl domains E2 E2 L1 L2 E1 binding domain E2 located inner core lipoyl domain region
0.2066687.8557670.html.plaintext.txt	37	Figure 1 Domain structure dihydrolipoyl acetyltransferase E2 component interactions kinase E1 components
0.2066687.8557670.html.plaintext.txt	38	E2 four globular domains consisting NH terminal lipoyl domain L1 inner lipoyl domain L2 E1 binding domain core forming transacetylase catalyzing inner domain COOH terminal end18 19 20
0.2066687.8557670.html.plaintext.txt	39	The kinase binds L2 domain domain specific lipoyl prosthetic group requiring interaction26
0.2066687.8557670.html.plaintext.txt	40	E1 tetramer binds B domain E2 via subunit 18
0.2066687.8557670.html.plaintext.txt	41	The subunits E1a kinases PDC branched chain keto acid dehydrogenase complex related procaryotic histidine kinases extramitochondrial serine tyrosine kinases eukaryotes21 22 23
0.2066687.8557670.html.plaintext.txt	42	PDC kinase binds lipoyl domain region E2 association requires lipoyl prosthetic group24 25 26
0.2066687.8557670.html.plaintext.txt	43	Using lipoylated delipoylated forms recombinant L1 L2 human PDC E227 kinase shown bind preferentially lipoylated L2 Fig
0.2066687.8557670.html.plaintext.txt	44	The E1a kinase also shown interchange rapidly L2 structures26
0.2066687.8557670.html.plaintext.txt	45	To account tight binding rapid interchange dynamic hand hand mechanism proposed dimeric kinase alternates bound one two L2 domains
0.2066687.8557670.html.plaintext.txt	46	This interchange catalytic function kinase exert combined effects limited space surface complex kinase molecule many E1 components tightly bound mobile outer domains E2
0.2066687.8557670.html.plaintext.txt	47	The capacity continuously bound kinase phosphorylate bound E1 components rapidly free kinase phosphorylate free E1 termed E2 activated kinase function
0.2066687.8557670.html.plaintext.txt	48	The aim work determine compulsory components domains catalytic processes involved kinase stimulation NADH acetyl CoA evaluate relative capacities recombinant L1 L2 mediating stimulation kinase presence absence E2 activated kinase function
0.2066687.8557670.html.plaintext.txt	49	We found stimulation occurs peptide substrate kinase lipoyl source must available catalytic reduction E3 acetylation E2 L2 lipoyl domain much effective mediating kinase stimulation L1 domain kinase remarkably sensitive level acetylation L2
0.2066687.8557670.html.plaintext.txt	50	The Discussion integrates observations draws new mechanistic conclusions based previous results
0.2066687.8557670.html.plaintext.txt	51	MaterialsStandard procedures used prepare bovine kidney pyruvate dehydrogenase complex28 E2XK1K2 subcomplex29 E1 component bilipoyl domain region E2 fragment bovine E230
0.2066687.8557670.html.plaintext.txt	52	The inner core bovine E2 E2 prepared using trypsin treatment followed pelleting sucrose layer presence 5 microgml soybean trypsin inhibitor31
0.2066687.8557670.html.plaintext.txt	53	The individual lipoyl domains L11 98 L2120 233 human E2 expressed Escherichia coli fully lipoylated structures fused glutathione S transferase purified homogeneity fusion protein free domains described Liu et al
0.2066687.8557670.html.plaintext.txt	54	Lipoamidase Enterococcus faecalis prepared modification procedure Suzuki Reed32
0.2066687.8557670.html.plaintext.txt	55	coli strain TM202 contains expression plasmid pTM70 purified described33
0.2066687.8557670.html.plaintext.txt	56	The E3 component porcine heart Sigma
0.2066687.8557670.html.plaintext.txt	57	Kinase pentadecapeptide substrate YHGHSMSDPGVSYRT sequential sites phosphorylation designated S S prepared Biotechnology core facility Kansas State University shown give single symmetric peak reverse phase HPLC correct sequence automated Edman degradation correct mass FAB mass spectrometry
0.2066687.8557670.html.plaintext.txt	58	PATP 1 Cacetyl CoA 2 Cpyruvate obtained DuPont NEN
0.2066687.8557670.html.plaintext.txt	59	Kinase ActivityE1a kinase activity measured duplicate triplicate initial rate Pphosphate incorporation PATP 250 500 cpmpmol E1a tetramers PDC resolved E2 free component
0.2066687.8557670.html.plaintext.txt	60	Most assays conducted final volume 50 microl buffer A 50 mM MOPS K 20 mM potassium phosphate 60 mM KCl 2 mM MgCl 0
0.2066687.8557670.html.plaintext.txt	61	Unless otherwise indicated assays used 25 30 microg PDC 25 microg E1 1 microg E3
0.2066687.8557670.html.plaintext.txt	62	Some resolved E1 preparations E1a kinase preparation source stable E2 free kinase
0.2066687.8557670.html.plaintext.txt	63	The specific activity E1 kinase 0
0.2066687.8557670.html.plaintext.txt	64	44 nmolminmg assayed 20 mM potassium phosphate absence E2 indicates kinase represents 0
0.2066687.8557670.html.plaintext.txt	65	4 protein E1 fraction
0.2066687.8557670.html.plaintext.txt	66	Unless otherwise indicated levels following reactants NADH NAD 31 ratio final concentrations 0
0.2066687.8557670.html.plaintext.txt	67	2 mM NAD acetyl CoA pyruvate 50 microM L1 L2 16 microM dihydrolipoamide 20 200 microM E2 2 microg
0.2066687.8557670.html.plaintext.txt	68	Dihydrolipoamide dissolved HO containing 0
0.2066687.8557670.html.plaintext.txt	69	2 mM EDTA warming solution 60 degrees C critical stock solutions 0
0.2066687.8557670.html.plaintext.txt	70	0 mM maintained room temperature
0.2066687.8557670.html.plaintext.txt	71	placed ice retain ligand solution
0.2066687.8557670.html.plaintext.txt	72	The latter monitored E3 cycling reaction
0.2066687.8557670.html.plaintext.txt	73	ATP added last except one experiment concentrated fraction delipoylated E2XK1K2 subcomplex treated ATP lipoyl protein ligase subsequent kinase assays performed without removal residual ATP
0.2066687.8557670.html.plaintext.txt	74	In latter series assays including parallel samples untreated delipoylated subcomplex E1 kinase added last initiate kinase activity
0.2066687.8557670.html.plaintext.txt	75	For effective reductive acetylation E2 lipoyl domains E1 E1 preincubated 50 microM TPP diluted 10 20 fold kinase assays lacking additional TPP
0.2066687.8557670.html.plaintext.txt	76	Kinase acetylation assays conducted CoA removal performed using conditions described acetylation studies
0.2066687.8557670.html.plaintext.txt	77	All control assays conducted triplicate quadruplicate assays least duplicate
0.2066687.8557670.html.plaintext.txt	78	In assays absolute deviations shown
0.2066687.8557670.html.plaintext.txt	79	Reactions terminated spotting samples dry trichloroacetic acid containing Whatmann No
0.2066687.8557670.html.plaintext.txt	80	3MM E1 substrate Whatmann P81 phosphocellulose paper disks peptide substrate followed steps previously described16 25
0.2066687.8557670.html.plaintext.txt	81	Extent AcetylationThe degree acetylation lipoyl prosthetic groups various sources E2 lipoyl domains measured using either E1 reaction 2 Cpyruvate substrate 15 17 E3NADH reduction followed acetylation 1 Cacetyl CoA15 16 17
0.2066687.8557670.html.plaintext.txt	82	For acetylation pyruvate concentrate E1 50 microM TPP prepared used described
0.2066687.8557670.html.plaintext.txt	83	In experiments acetylation E2 lipoyl domains using acetyl CoA driven completion converting CoA product succinyl CoA ketoglutarate dehydrogenase complex reaction mixtures containing 0
0.2066687.8557670.html.plaintext.txt	84	4 mM ketoglutarate 50 microM Ca16
0.2066687.8557670.html.plaintext.txt	85	This gave maximal acetylation 16 microM L1 L2 high acetyl CoA e
0.2066687.8557670.html.plaintext.txt	86	24 microM whereas lower levels acetyl CoA e
0.2066687.8557670.html.plaintext.txt	87	5 16 microM acetyl CoA completely used producing extent acetylation lipoyl domains equivalent added acetyl CoA
0.2066687.8557670.html.plaintext.txt	88	The acetylation intact E2 subunits measured spotting samples dry trichloroacetic acid containing paper disks P81 phosphocellulose disks kinase assays P81 disks always used measure acetylation L1 L2 domains
0.2066687.8557670.html.plaintext.txt	89	The washing counting procedures described previously16 27
0.2066687.8557670.html.plaintext.txt	90	E3 Cyclic AssayLipoyl domain levels routinely assessed assay coupling conversion E3NADH dependent reduction lipoates reoxidation reaction 55 dithiobis2 nitrobenzoate produce two 5 thio2 nitrobenzoates27
0.2066687.8557670.html.plaintext.txt	91	Reactions conducted mixtures containing 50 mM sodium phosphate buffer pH 7
0.2066687.8557670.html.plaintext.txt	92	1 mM 55 dithiobis2 nitrobenzoate
0.2066687.8557670.html.plaintext.txt	93	Reactions started adding 0
0.2066687.8557670.html.plaintext.txt	94	5 microg E3 final volume 200 microl
0.2066687.8557670.html.plaintext.txt	95	The change absorbance 27
0.2066687.8557670.html.plaintext.txt	96	2 ODmMcm 405 nm measured time using UV Max microplate reader
0.2066687.8557670.html.plaintext.txt	97	Lipoamidase TreatmentLipoyl groups released PDC E2XK1K2 isolated lipoyl domains incubation E
0.2066687.8557670.html.plaintext.txt	98	faecalis lipoamidase 90 210 min 30 degrees C overnight room temperature24 25 26 27
0.2066687.8557670.html.plaintext.txt	99	The incubation mixture contained 50 mM potassium phosphate pH 7
0.2066687.8557670.html.plaintext.txt	100	5 1 mM EGTA ratios lipoyl bearing structure lipoamidase ww 3451 PDC 1801 E2XK1K2 1001 human L2 domain
0.2066687.8557670.html.plaintext.txt	101	The extent delipoylation monitored measuring either residual PDC activity reconstituted PDC activity
0.2066687.8557670.html.plaintext.txt	102	A steep decline occurred final 40 lipoyl groups removed E2 protein X
0.2066687.8557670.html.plaintext.txt	103	Final products evaluated content lipoyl groups measuring extents acetylation CoA removal approach described
0.2066687.8557670.html.plaintext.txt	104	Delipoylation isolated lipoyl domains estimated loss activity E3 cyclic assay
0.2066687.8557670.html.plaintext.txt	105	Free lipoate caused minor interference latter assay since lipoyl domains much efficient substrates full delipoylation judged occurred rate dropped produced equivalent concentration free lipoate
0.2066687.8557670.html.plaintext.txt	106	Delipoylation L1 L2 also evaluated characteristic shift mobility decrease observed delipoylated domains native gel electrophoresis27
0.2066687.8557670.html.plaintext.txt	107	All delipoylated preparations examined SDS PAGE ensure subunit degradation occurred
0.2066687.8557670.html.plaintext.txt	108	In experiments delipoylation followed ligase treatment delipoylated preparations treated 0
0.2066687.8557670.html.plaintext.txt	109	4 mM PMSF 15 min 30 degrees C terminate lipoamidase activity residual PMSF quenched 0
0.2066687.8557670.html.plaintext.txt	110	Ligase ProcedureRelipoylation conducted incubating delipoylated samples 25 mM potassium phosphate buffer pH 7
0.2066687.8557670.html.plaintext.txt	111	5 containing lipoyl protein ligase 50 microM lipoic acid 0
0.2066687.8557670.html.plaintext.txt	112	The acetylation E3 assays described used show lipoyl moieties incorporated
0.2066687.8557670.html.plaintext.txt	113	Usually excess ATP removed dialysis versus 20 mM potassium phosphate buffer pH 7
0.2066687.8557670.html.plaintext.txt	114	PDC Activity StudiesThe effects delipoylation relipoylation PDC E2XK1K2 samples deduced PDC activities34
0.2066687.8557670.html.plaintext.txt	115	For E2XK1K2 subcomplex 4 microg subcomplex combined 8 microg E1 4 microg E3 10 microl incubated 60 30 degrees C 6 microl sample added standard PDC assay
0.2066687.8557670.html.plaintext.txt	116	Since removal lipoyl groups disproportionately low effect PDC activity early stages delipoylation analyzed accurately determining changes acetylation capacity
0.2066687.8557670.html.plaintext.txt	117	The fractional binding TPP E1 evaluated PDC activity assays bound TPP continuously converted tightly bound hydroxyethylidene thiamin pyrophosphate intermediate substrate rate limiting reductive acetylation step35 36
0.2066687.8557670.html.plaintext.txt	118	The levels TPP bound E1 evaluated comparing rates PDC reaction obtained diluting enzyme 200 fold last addition assay mixtures lacking containing TPP
0.2066687.8557670.html.plaintext.txt	119	Reconstituted PDC activity measured resolved E1 excess E2XK1K2 subcomplex 10 microg E3 4 microg limiting E1 4 microg
0.2066687.8557670.html.plaintext.txt	120	The fractional E1 TPP defined ratio highest activity observed absence TPP observed presence TPP
0.2066687.8557670.html.plaintext.txt	121	The effects changes NADHNAD acetyl CoACoA ratios PDC activity analyzed absence ATP high K buffer buffer A used evaluate regulation kinase activities rather standard 40 mM potassium phosphate buffer used routine PDC activity assays
0.2066687.8557670.html.plaintext.txt	122	Pyruvate TPP introduced saturating levels 1
0.2066687.8557670.html.plaintext.txt	123	When relative amount NADH NAD varied retaining total concentration constant 0
0.2066687.8557670.html.plaintext.txt	124	5 mM PDC activity measured 365 nm 4
0.2066687.8557670.html.plaintext.txt	125	Other conditions described legend Fig
0.2066687.8557670.html.plaintext.txt	126	Figure 8 Effects changes product substrate ratios PDC reaction measured buffer A
0.2066687.8557670.html.plaintext.txt	127	Reaction mixtures modified follows
0.2066687.8557670.html.plaintext.txt	128	The acetyl CoACoA ratio varied constant total pool 0
0.2066687.8557670.html.plaintext.txt	129	1 mM total pyridine nucleotides NADHNAD ratio varied constant total pool 0
0.2066687.8557670.html.plaintext.txt	130	2 mM CoA acetyl CoACoA ratio 1 using 0
0.2066687.8557670.html.plaintext.txt	131	In case 100 rates rate observed product substrate ratio zero varied ratio
0.2066687.8557670.html.plaintext.txt	132	Other conditions assay procedures described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	133	E1 E1 TPP Peptide SubstratesThe requirements NADH acetyl CoA stimulation E1 kinase activity evaluated via phosphorylating various substrates using E2XK1K2 subcomplex source kinase activity
0.2066687.8557670.html.plaintext.txt	134	As assays NAD NADH used 13 ratio prevent inhibition E3 conversion 4 e reduced state
0.2066687.8557670.html.plaintext.txt	135	At ratio kinase activity near maximally stimulated NADH maximally stimulated combination NADH acetyl CoA
0.2066687.8557670.html.plaintext.txt	136	We used E1 preparation gave 1 activity PDC reaction mixture lacking TPP
0.2066687.8557670.html.plaintext.txt	137	As shown Table 1 kinase activity stimulated 50 NADH nearly 2 fold combination NADH acetyl CoA phosphorylation E1 whether E1 contained TPP cofactor
0.2066687.8557670.html.plaintext.txt	138	As expected37 kinase activity reduced TPP
0.2066687.8557670.html.plaintext.txt	139	However stimulation due reversing inhibitory effect TPP activation via formation reaction intermediate E1 e
0.2066687.8557670.html.plaintext.txt	140	hydroxyethylidenethiamin pyrophosphate formed acetyl lipoate E2
0.2066687.8557670.html.plaintext.txt	141	Table 1also shows E1 replaced peptide substrate stimulations dependent changes E138
0.2066687.8557670.html.plaintext.txt	142	This consistent observation Reed et al
0.2066687.8557670.html.plaintext.txt	143	40 kinase stimulation occurs tryptic digestion PDC
0.2066687.8557670.html.plaintext.txt	144	Such PDC digestion produces complex mixture lipoyl domains catalytic inner core E2 trypsin resistant E3 required kinase stimulation see
0.2066687.8557670.html.plaintext.txt	145	Because stimulation acetyl CoA detected absence NADH level incorporation covalently attached acetyl groups 1 Cacetyl CoA determined presence absence unlabeled ATP conditions kinase assays Table 1
0.2066687.8557670.html.plaintext.txt	146	Without NADH exposure submillimolar levels dithiothreitol allows acetylation small portion lipoyl groups acetyl CoA
0.2066687.8557670.html.plaintext.txt	147	The low stimulation kinase occurs conjunction low level acetylation absence NADH agrees previous studies 15 16 17 cf
0.2066687.8557670.html.plaintext.txt	148	Thus results eliminate possibility kinase stimulation due changes form TPP interacting E1 substrate consistent participation lipoyl prosthetic groups
0.2066687.8557670.html.plaintext.txt	149	Pyruvate StimulationStimulation pyruvate first reported Cooper et al
0.2066687.8557670.html.plaintext.txt	150	Support stimulation occurring via reductive acetylation lipoyl moieties stems findings adding low levels pyruvate TPP containing PDC generates increased kinase activity equivalent NADH plus acetyl CoA pyruvate principally used reductive acetylation oxidized lipoyl groups13 14 15
0.2066687.8557670.html.plaintext.txt	151	This mechanism kinase stimulation predicts TPP bound E1 lipoyl domain source required
0.2066687.8557670.html.plaintext.txt	152	Using resolved TPP dependent E1 preparation containing low levels kinase activity completely free E2 kinase activity significantly enhanced pyruvate andor lipoyl domain absence TPP Table 2
0.2066687.8557670.html.plaintext.txt	153	Even presence TPP pyruvate failed stimulate kinase activity E1 unless lipoyl domains added
0.2066687.8557670.html.plaintext.txt	154	Furthermore fragment bovine E2 contains lipoyl domains designated E2 effective
0.2066687.8557670.html.plaintext.txt	155	The results thus consistent view enhancement kinase activity mediated E1TPP catalyzed acetylation E2 fragment
0.2066687.8557670.html.plaintext.txt	156	Furthermore low level E2 fragment 1 microM effective
0.2066687.8557670.html.plaintext.txt	157	This level gave small enhancement kinase 4025 suggesting specific possibly stronger interaction kinase acetylated E2
0.2066687.8557670.html.plaintext.txt	158	Lipoamidase Treatment PDCThe proposed mechanism lipoyl mediated enhancement kinase activity predicts complete removal lipoyl groups would abolish kinase stimulation
0.2066687.8557670.html.plaintext.txt	159	Lipoyl groups removed treatment PDC E2XK1K2 subcomplex isolated lipoyl domains E
0.2066687.8557670.html.plaintext.txt	160	The enhancement kinase activity E2 component absence effectors declines rapidly last portion lipoyl groups removed kinase tends dissociate E224
0.2066687.8557670.html.plaintext.txt	161	Treating PDC 150 min lipoamidase 1 microg345 microg complex produced preparation complex PDCD lacking 96 lipoyl groups based maximal acetylation assay see Experimental Procedures
0.2066687.8557670.html.plaintext.txt	162	Delipoylation reduced kinase activity 6
0.2066687.8557670.html.plaintext.txt	163	removed E2 enhancement kinase function Fig
0.2066687.8557670.html.plaintext.txt	164	Surprisingly PDCD could still stimulated nearly 2 fold NADH plus acetyl CoA activity remained well fully lipoylated PDC control Fig
0.2066687.8557670.html.plaintext.txt	165	The delipoylated PDCD incorporated 5 acetyl groups per molecule complex M 7
0.2066687.8557670.html.plaintext.txt	166	5 10 conditions
0.2066687.8557670.html.plaintext.txt	167	The retention lipoyl groups allowing effector stimulation explained lipoyl prosthetic group critical part high affinity binding site kinase kinase moving lipoyl domains25 26
0.2066687.8557670.html.plaintext.txt	168	This would allow kinase relocate E2 subunits retaining lipoyl groups residual activity localized kinase still enhanced reductive acetylation remaining lipoyl groups cf
0.2066687.8557670.html.plaintext.txt	169	Figure 2 Effect lipoamidase treatment activity effector stimulation E1a kinase associated intact PDC
0.2066687.8557670.html.plaintext.txt	170	Lipoamidase treatments PDC 150 min second series bar graphs PDC D 210 min fourth set bar graphs PDC D
0.2066687.8557670.html.plaintext.txt	171	The interested preparations PDC PDC incubated times lipoamidase
0.2066687.8557670.html.plaintext.txt	172	No changes SDS PAGE profiles detected incubated samples
0.2066687.8557670.html.plaintext.txt	173	Kinase assays conducted described Experimental Procedures addition indicated bar graph key legend NADH NAD mixture final concentration 0
0.2066687.8557670.html.plaintext.txt	174	2 mM respectively acetyl CoA 50 microM
0.2066687.8557670.html.plaintext.txt	175	Pyridine nucleotides added 60 acetyl CoA 20 prior PATP reactions terminated 60
0.2066687.8557670.html.plaintext.txt	176	Using 210 min lipoamidase treatment PDC lowered level acetylation 1
0.2066687.8557670.html.plaintext.txt	177	8 untreated PDC control abolished stimulations kinase activity NADH andor acetyl CoA relative control Fig
0.2066687.8557670.html.plaintext.txt	178	The low stimulation control kinase PDC PDC acetyl CoA absence NADH associated low level acetylation lipoates reduced storage complex 0
0.2066687.8557670.html.plaintext.txt	179	SDS PAGE analysis lipoamidase treated PDC PDC showed changes protein pattern indicating proteolysis lipoamidase treatments
0.2066687.8557670.html.plaintext.txt	180	Lipoamidase Lipoyl Protein Ligase Treatment EXK1K2The requirement lipoate could confirmed reattaching cofactor E1 must absent avoid phosphorylation ATP dependent lipoyl protein ligase reaction
0.2066687.8557670.html.plaintext.txt	181	E2XK1K2 incubated without lipoamidase 210 min lipoamidase inactivated PMSF described Experimental Procedures legend Fig
0.2066687.8557670.html.plaintext.txt	182	Acetylation per subcomplex reduced 165
0.2066687.8557670.html.plaintext.txt	183	89 per subcomplex using acetyl CoA CoA removal approach reconstituted pyruvate dehydrogenase complex activity decreased 99
0.2066687.8557670.html.plaintext.txt	184	Portions delipoylated control subcomplexes treated lipoate ATP lipoate protein ligase described Experimental Procedures dialyzed remove ATP lipoate
0.2066687.8557670.html.plaintext.txt	185	The acetylation capacity increased 117
0.2066687.8557670.html.plaintext.txt	186	3 per subcomplex 60 min declined slightly thereafter remained untreated subcomplex 160 acetyl incorporatedsubcomplex
0.2066687.8557670.html.plaintext.txt	187	In parallel study lipoamidase lipoate protein ligase treatments E2XK1K2 subcomplex gave reconstituted PDC activity 30
0.2066687.8557670.html.plaintext.txt	188	6 micromolminmg nearly high untreated control 31
0.2066687.8557670.html.plaintext.txt	189	SDS PAGE analysis detect change profile subunits subcomplex
0.2066687.8557670.html.plaintext.txt	190	Delipoylation subcomplex reduced kinase activity abolished rate enhancing effects NADH acetyl CoA Fig
0.2066687.8557670.html.plaintext.txt	191	3 large extent restored following ligase treatment
0.2066687.8557670.html.plaintext.txt	192	Figure 3 Effects kinase activity regulation enzymatic removal restoration lipoyl groups E2Xkinase subcomplex
0.2066687.8557670.html.plaintext.txt	193	The E2Xkinase subcomplex treated lipoamidase 210 min lipoamidase inactivated PMSF described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	194	Lipoyl groups restored portion preparation using E
0.2066687.8557670.html.plaintext.txt	195	coli lipoyl protein ligase substrates removed described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	196	The control sample subcomplex given parallel incubations
0.2066687.8557670.html.plaintext.txt	197	Kinase assays included 25 microg E1 pyridine nucleotides added 60 acetyl CoA 20 prior PATP reactions terminated 60
0.2066687.8557670.html.plaintext.txt	198	Lipoyl Domain Role Requirement Acetyltransferase ReactionTo investigate relative effectiveness E2s lipoyl domains capacity recombinant human lipoyl domains L1 L2 mediating kinase stimulation evaluated resolved E1 presence E3 presence absence lipoyl domain free E2 Fig
0.2066687.8557670.html.plaintext.txt	199	Kinase activity increased slightly NADH L1 domain much larger extent L2 domain
0.2066687.8557670.html.plaintext.txt	200	In absence E2 acetyl CoA effect alone enhance effect NADH alone
0.2066687.8557670.html.plaintext.txt	201	In presence acetyltransferase catalyzing E2 kinase activity stimulated combination NADH acetyl CoA L1 domain extent achieved NADH L2 domain Fig
0.2066687.8557670.html.plaintext.txt	202	An even larger nearly 3 fold enhancement kinase activity observed combination effectors added L2 presence E2
0.2066687.8557670.html.plaintext.txt	203	Since seems possible role E2 catalyzing transacetylation reaction results provide definitive support view stimulating effects acetyl CoA mediated lipoate acetylation
0.2066687.8557670.html.plaintext.txt	204	4 enhancement acetyl CoA alone occurred acetylation L2
0.2066687.8557670.html.plaintext.txt	205	The results establish preferential role L2 mediating kinase stimulation keeping preferential binding kinase L2 domain 26 cf
0.2066687.8557670.html.plaintext.txt	206	Figure 4 Capacity L1 L2 domains E2 support effector stimulation kinase activity
0.2066687.8557670.html.plaintext.txt	207	Kinase assays conducted 25 microg E1 containing low kinase indicated human recombinant L1 L2 domains included 16 microM
0.2066687.8557670.html.plaintext.txt	208	Effectors added levels times given Fig
0.2066687.8557670.html.plaintext.txt	209	The solid bar shows kinase activity absence L1 L2
0.2066687.8557670.html.plaintext.txt	210	Other conditions described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	211	In parallel experiments levels acetylation lipoyl domains conditions used studying kinase stimulation evaluated
0.2066687.8557670.html.plaintext.txt	212	With L2 domain 20 time ATP addition acetyl CoA addition 80 time kinase reactions terminated 0
0.2066687.8557670.html.plaintext.txt	213	25 acetyl groups incorporated per L2 presence E2 absence NADH
0.2066687.8557670.html.plaintext.txt	214	Whereas presence NADHNAD slightly one acetyl group per L2 incorporated 20 80
0.2066687.8557670.html.plaintext.txt	215	Similar levels acetylation occurred L1
0.2066687.8557670.html.plaintext.txt	216	This indicates low level biacetylation
0.2066687.8557670.html.plaintext.txt	217	6 8 positions lipoate previously observed recombinant L1 L2 constructs27
0.2066687.8557670.html.plaintext.txt	218	Degree Acetylation L2 Versus Extent Stimulation KinaseThe results suggest progression kinase stimulation L2 acetylation
0.2066687.8557670.html.plaintext.txt	219	This relationship evaluated studying kinase activity acetylation parallel conditions controlled acetylation acetyl CoA completely consumed Fig
0.2066687.8557670.html.plaintext.txt	220	Low concentrations acetyl CoA incubated L2 domain presence E2 E3 11 ratio NADHNAD along ketoglutarate dehydrogenase complex plus ketoglutarate convert CoA produced succinyl CoA
0.2066687.8557670.html.plaintext.txt	221	The measured extents acetylation confirmed highest level 24 microM 1 Cacetyl CoA consumed acetylating L2 domain 16 microM
0.2066687.8557670.html.plaintext.txt	222	The enhancement kinase activity increased level acetylation half maximal stimulation observed 20 L2 acetylated Fig
0.2066687.8557670.html.plaintext.txt	223	Though low proportion free L2 higher proportion L2 acetylated required intact complex explained Discussion
0.2066687.8557670.html.plaintext.txt	224	The decline stimulation high levels acetylation also consistent latter studies intact complex15 16 17
0.2066687.8557670.html.plaintext.txt	225	Figure 5 Relationship degree acetylation L2 domain stimulation kinase activity
0.2066687.8557670.html.plaintext.txt	226	In kinase acetylation assays acetylation 16 microM L2 catalyzed E2 oligomer carried removal CoA formed ketoglutarate dehydrogenase complex reaction conditions described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	227	Acetyl CoA included levels 1
0.2066687.8557670.html.plaintext.txt	228	5 30 microM completely consumed acetylating L2 two highest concentrations based measured extents acetylation
0.2066687.8557670.html.plaintext.txt	229	NADH NAD present 0
0.2066687.8557670.html.plaintext.txt	230	Other conditions described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	231	Effects Dihydrolipoamide Acetyl dihydrolipoamide Requirement Lipoyl Source NADH Stimulation Kinase ActivityPreviously reported stimulation PDC kinase dihydrolipoamide 13 14 could involve reduction lipoyl moieties complex E3 catalysis disulfide exchange
0.2066687.8557670.html.plaintext.txt	232	We unable experiments absence E3 trace E3 E1 resolved kinase preparations
0.2066687.8557670.html.plaintext.txt	233	E3 active enzyme one round turnover needed reduce lipoate L1 L2
0.2066687.8557670.html.plaintext.txt	234	With lipoyl domain source present E1 kinase increased dihydrolipoamide maximal stimulation 50 microM 40 55
0.2066687.8557670.html.plaintext.txt	235	26 found L1 L2 inhibited kinase activity levels greater 20 microM
0.2066687.8557670.html.plaintext.txt	236	For direct comparison effects lipoate sources dihydrolipoamide L1 L2 20 microM alone combination determined evaluate direct supportive roles dihydrolipoamide
0.2066687.8557670.html.plaintext.txt	237	Addition 20 microM dihydrolipoamide E1 kinase without lipoyl domain source L1 L2 gave small reproducible enhancements 15 40 plus minus L1 30 60 L2 kinase activity Fig
0.2066687.8557670.html.plaintext.txt	238	NADH stimulate absence lipoate source first series solid bar indeed mixture NADH NAD 31 ratio seemed inhibit kinase activity
0.2066687.8557670.html.plaintext.txt	239	This strongly supports conclusion E3 catalyzed reduction lipoate source required
0.2066687.8557670.html.plaintext.txt	240	Only L2 NADH increase kinase activity beyond dihydrolipoamide
0.2066687.8557670.html.plaintext.txt	241	6 third series larger effects observed NADH dihydrolipoamide combination effect beyond NADH alone
0.2066687.8557670.html.plaintext.txt	242	These results indicate higher stimulation dihydrolipoamide presence L2 results reduction lipoyl group L2
0.2066687.8557670.html.plaintext.txt	243	Figure 6 Relative effects dihydrolipoamide acetylated dihydrolipoamide L1 L2 kinase activity capacity dihydrolipoamide support lipoyl domain effects
0.2066687.8557670.html.plaintext.txt	244	Where indicated key bar legends dihydrolipoamide L1 L2 added assays 20 microM
0.2066687.8557670.html.plaintext.txt	245	E1 kinase added reaction mixtures containing 1 microg E3 reactants except dihydrolipoamide acetyl CoA ATP
0.2066687.8557670.html.plaintext.txt	246	Dihydrolipoamide added 40 acetyl CoA 20 ATP additions made described legend Fig
0.2066687.8557670.html.plaintext.txt	247	4and Experimental Procedures
0.2066687.8557670.html.plaintext.txt	248	Dihydrolipoamide alone effective supporting acetyl CoA stimulation
0.2066687.8557670.html.plaintext.txt	249	It important acetylation dihydrolipoamide immediately precede kinase assay since stimulation detected stored preparations acetyl groups transfer L isomer incorrect D isomer 8 position 6 position dihydrolipoamide
0.2066687.8557670.html.plaintext.txt	250	Dihydrolipoamide replaced NADH supporting higher acetyl CoA stimulation L1 particularly L2 diagonally cross hatched bars
0.2066687.8557670.html.plaintext.txt	251	Acetyl CoA stimulation required E2 minus E2 results shown
0.2066687.8557670.html.plaintext.txt	252	For marked stimulation acetyl CoA plus L2 dihydrolipoamide likely reduced enough L2 lipoates presence E3 allow L2 acetylation extent giving near maximal stimulation
0.2066687.8557670.html.plaintext.txt	253	7 fold enhancement greater NADH probably due extent acetylation somewhat lower resulting less diacetyl L2
0.2066687.8557670.html.plaintext.txt	254	Although reduction acetylation lipoate L2 clearly effective direct stimulation kinase activity observable dihydrolipoamide acetyl dihydrolipoamide limits mechanistic possibilities cf
0.2066687.8557670.html.plaintext.txt	255	Effect Delipoylation Relipoylation L2 DomainTo test importance L2s lipoate exposing kinase lipoamidase lipoate protein ligase delipoylated relipoylated preparations L2 made
0.2066687.8557670.html.plaintext.txt	256	Delipoylation L2 domain abolished capacity potentiate acetyl CoA stimulation kinase ligase treatment restored full capacity stimulation Fig
0.2066687.8557670.html.plaintext.txt	257	The previous lack full recovery ligase treatment delipoylated E2XK1K2 Fig
0.2066687.8557670.html.plaintext.txt	258	3 probably due loss modification kinase treatments
0.2066687.8557670.html.plaintext.txt	259	The requirement L2s lipoyl group E2 catalysis seem constitute incontrovertible evidence kinase stimulation mediated acetylation effectively via L2 domain E2
0.2066687.8557670.html.plaintext.txt	260	Figure 7 Effects removal restoration lipoyl groups L2 kinase stimulation NADH acetyl CoA
0.2066687.8557670.html.plaintext.txt	261	The L2 domain delipoylated lipoamidase relipoylated lipoyl protein ligase using conditions described Experimental Procedures
0.2066687.8557670.html.plaintext.txt	262	Kinase assays conducted described legend Fig
0.2066687.8557670.html.plaintext.txt	263	4and Experimental Procedures except L2 unchanged delipoylated relipoylated indicated
0.2066687.8557670.html.plaintext.txt	264	Direct Product Inhibition PDC ReactionThe mechanism product inhibition PDC low salt conditions 43 effects higher ionic strengths PDC reaction characterized44
0.2066687.8557670.html.plaintext.txt	265	However physiological K levels effects varying NADHNAD acetyl CoACoA ratios characterized kinase reaction 27 PDC reaction
0.2066687.8557670.html.plaintext.txt	266	8show half maximal inhibition PDC observed NADHNAD ratio 0
0.2066687.8557670.html.plaintext.txt	267	42 absence acetyl CoA acetyl CoACoA ratio 11
0.2066687.8557670.html.plaintext.txt	268	2 absence NADH 3
0.2066687.8557670.html.plaintext.txt	269	55 combination fixed NADHNAD ratio 0
0.2066687.8557670.html.plaintext.txt	270	The strongest direct product inhibition PDC found half maximal effect low NADHNAD ratio 0
0.2066687.8557670.html.plaintext.txt	271	125 acetyl CoACoA ratio held 1 Fig
0.2066687.8557670.html.plaintext.txt	272	However near maximal stimulation kinase switch bovine kidney PDC occurs NADHNAD ratio 0
0.2066687.8557670.html.plaintext.txt	273	1 10 fold lower acetyl CoACoA ratio
0.2066687.8557670.html.plaintext.txt	274	We conclude much higher ratios products substrates required direct product inhibition bovine kidney PDC speeding PDC inactivation enhancing kinase activity cf
0.2066687.8557670.html.plaintext.txt	275	Randle co workers 45 46 pointed importance feedback control PDC satisfying metabolic needs presented evidence direct product inhibition PDC reaction
0.2066687.8557670.html.plaintext.txt	276	After regulatory interconversion PDC active inactive forms 2 became known Randles laboratory contributed evidence cf
0.2066687.8557670.html.plaintext.txt	277	Introduction products PDC reaction influence proportion PDC active form diverse studies purified complex isolated mitochondria intact tissues 1 8 9 47
0.2066687.8557670.html.plaintext.txt	278	In studies purified porcine heart PDC stimulation acetyl CoA beyond NADH detected speculated enhanced kinase activity might due removal inhibition kinase activity caused absence interaction oxidized lipoate E1 substrate 8 9
0.2066687.8557670.html.plaintext.txt	279	Although correct mechanism detection effect acetyl CoA required use higher K concentration see suggestion role changes intermediate status lipoyl groups insightful linking stimulatory effect pyruvate 41 effect products9
0.2066687.8557670.html.plaintext.txt	280	This laboratory presented initial much subsequent evidence reduction acetylation lipoyl prosthetic groups PDC constituted essential steps operation sensitive signal translation process whereby increases NADHNAD acetyl CoACoA ratios markedly enhance kinase activity13 14 15 16 17
0.2066687.8557670.html.plaintext.txt	281	However elucidation minimal requirements operation control could accomplished following greatly enhanced understanding organization complex preparation individual lipoyl domains PDC E2 availability lipoamidase lipoyl protein ligase combined selective use peptide substrate free forms lipoamide
0.2066687.8557670.html.plaintext.txt	282	Using tools found marked enhancement kinase activity acetyl CoA requires lipoate source reduction catalytic domain E2 peptide substrate
0.2066687.8557670.html.plaintext.txt	283	These requirements conclusively support change kinase mediated catalytically forming acetyl dihydrolipoate
0.2066687.8557670.html.plaintext.txt	284	Accumulation intermediate explains similarly strong stimulation kinase activity low pyruvate via E1TPP catalysis
0.2066687.8557670.html.plaintext.txt	285	The direct stimulation dihydrolipoamide capacity replace NADH potentiating acetyl CoA stimulation complete lack effect NADH kinase activity absence lipoate source strongly favor NADH boosting kinase activity use E3 reaction
0.2066687.8557670.html.plaintext.txt	286	We established intervention abolished complete removal lipoates intact E2 subunits lipoyl domains
0.2066687.8557670.html.plaintext.txt	287	Of particular importance understanding operation regulation kinase finding kinase binding L2 domain much effective E2s L1 domain lipoamide mediating kinase stimulation
0.2066687.8557670.html.plaintext.txt	288	The 3 fold increase kinase activity generated reductive acetylation recombinant L2 comparable change kinase activity produced acetylation lipoyl moieties intact complex
0.2066687.8557670.html.plaintext.txt	289	Reduced L1 slightly effective free dihydrolipoamide compared 20 microM 50 microM dihydrolipoamide gave least equivalent stimulation suggesting structure L1 contribute significantly effects
0.2066687.8557670.html.plaintext.txt	290	At higher levels L1 inhibits kinase activity26
0.2066687.8557670.html.plaintext.txt	291	Thus L2 domain must structural features facilitate dedicated roles binding kinase producing enhanced E1 phosphorylation within confines complex increasing kinase activity upon reduction acetylation lipoyl group
0.2066687.8557670.html.plaintext.txt	292	This raises question linkage L2 supported actions kinase
0.2066687.8557670.html.plaintext.txt	293	Detaching lipoates E2 core removes capacity E2 core give severalfold increase E1 phosphorylation24
0.2066687.8557670.html.plaintext.txt	294	Via lipoyl dependent binding L2 domain rapid hand hand interchange kinase dimer lipoyl domains apparently eliminates constraints normally associated binding tight exists E2 kinase25 26
0.2066687.8557670.html.plaintext.txt	295	It significant lipoamidase treatment PDC left lipoates caused close full loss E2 enhanced kinase function still allowed marked stimulation residual kinase activity upon acetylation domains retaining lipoyl groups PDC series Fig
0.2066687.8557670.html.plaintext.txt	296	This result forcefully suggests kinase moved limited number lipoylated L2 domains furthermore acetylation short lived dissociation reassociation kinase facilitated kinase stimulation
0.2066687.8557670.html.plaintext.txt	297	Based continued stimulation E2 subunits retain lipoate hypothesize maximal effector stimulation mediated allosteric effect induced reductively acetylated L2 domain becomes engaged binding kinase
0.2066687.8557670.html.plaintext.txt	298	interaction acetylated prosthetic group neighboring lipoyl domain engaged binding kinase
0.2066687.8557670.html.plaintext.txt	299	Such highly specific interaction supported
0.2066687.8557670.html.plaintext.txt	300	Beside E1 catalyzed reductive acetylation giving nearly equivalent stimulation acetyl CoA13 14 15 ketobutyrate 38 gives lesser stimulation similar propionyl CoA low levels propionylation16
0.2066687.8557670.html.plaintext.txt	301	In absence lipoyl domain source kinase phosphorylation E1 stimulated low pyruvate 17 miniprint section show TPP lipoyl domain source needed achieve pyruvate stimulation
0.2066687.8557670.html.plaintext.txt	302	These findings raise question whether E1 reaction downstream E2E3 reactions determine relative proportion lipoates oxidized reduced acetylated forms complex
0.2066687.8557670.html.plaintext.txt	303	Since E1 catalyzes rate limiting step35 36 metabolic conditions distribution determined NADHNAD acetyl CoACoA ratios kinase activity primarily respond fluctuation
0.2066687.8557670.html.plaintext.txt	304	With purified porcine liver bovine kidney PDC half maximal stimulations kinase activities occur ratios NADHNAD 0
0.2066687.8557670.html.plaintext.txt	305	05 respectively 2 mM dithiothreitol reducing agent ratios acetyl CoACoA 0
0.2066687.8557670.html.plaintext.txt	306	Even lower acetyl CoACoA 0
0.2066687.8557670.html.plaintext.txt	307	1 give half maximal stimulation NADHNAD ratio 0
0.2066687.8557670.html.plaintext.txt	308	1 provided reduce lipoates data shown
0.2066687.8557670.html.plaintext.txt	309	At low ratios minimal product inhibition PDC reaction NADH plus acetyl CoA cf
0.2066687.8557670.html.plaintext.txt	310	Significant direct product inhibition occurs low NADHNAD ratio acetyl CoACoA ratio held relatively high level 1 Fig
0.2066687.8557670.html.plaintext.txt	311	Acetyl CoACoA ratios generated range isolated mitochondria proposed contribute direct PDC inhibition 48 depletion CoA may also inhibit PDC due buildup fatty acyl CoAs49
0.2066687.8557670.html.plaintext.txt	312	While probably contribute fine tuning role small portion active PDC enhanced phosphorylation effectively throttle PDC activity onset extremes
0.2066687.8557670.html.plaintext.txt	313	A priori lesser enhancement kinase activity conversion lipoates oxidized reduced form could involve either removal inhibitory interaction oxidized lipoates enhancement kinase activity gain positive allosteric interaction reduced form change thiol disulfide state kinase subunit
0.2066687.8557670.html.plaintext.txt	314	Studies E2 bound kinase found kinase sensitive thiol reagents13 52 effects probably due changes oxidation reduction state lipoate L2 domains
0.2066687.8557670.html.plaintext.txt	315	Although small increase alkylation cysteines K1 subunit following treatment E2Xkinase E3 NADH rapidly reversed excess NAD opposes kinase stimulation
0.2066687.8557670.html.plaintext.txt	316	Thus mediator role changes thiol disulfide status kinase indicated
0.2066687.8557670.html.plaintext.txt	317	Furthermore finding free dihydrolipoamide greater extent acetylated dihydrolipoamide directly stimulated kinase activity absence lipoyl domain source eliminating prospect stimulation results removal inhibitory effect oxidized form lipoate
0.2066687.8557670.html.plaintext.txt	318	9 conclude kinase activity enhanced direct positive allosteric interactions reduced acetylated form L2 lipoate suggest L2 specificity derives L2 domain engaged binding kinase
0.2066687.8557670.html.plaintext.txt	319	Figure 9 Model proposed steps kinase stimulation
0.2066687.8557670.html.plaintext.txt	320	The proportion L2 domains E core oxidized reduced acetylated lipoates responds changes NADHNAD ratio acetyl CoACoA ratio via rapid reversible reactions catalyzed E3 E2 respectively
0.2066687.8557670.html.plaintext.txt	321	Our model proposes change kinase binding one two L2 containing oxidized lipoate nonstimulated K state interacting L2 containing reduced acetylated lipoate results modified lipoates allosterically inducing conformational changes generate progressively active K K states respectively
0.2066687.8557670.html.plaintext.txt	322	Consistent stimulation occurring low ratios acetyl CoA CoA half maximal near maximal stimulation kinase associated intact bovine kidney PDC achieved 7 10 22 26 acetyl groups incorporated respectively per PDC15 16 17
0.2066687.8557670.html.plaintext.txt	323	With recent knowledge 3 lipoyl domains two E2 one E3 binding protein giving total least 126 lipoates per E2 seems likely 12 possibly 7 acetyl groups incorporated per PDC kinase binding L2 domain near maximal stimulation 3 6 incorporated half maximal stimulation
0.2066687.8557670.html.plaintext.txt	324	This constitutes highly responsive regulatory mechanism kinase must preferentially interact acetylated L2 suggests full stimulation may result one subunit kinase dimer interacting reductively acetylated L2 domain
0.2066687.8557670.html.plaintext.txt	325	Consistent prospect half maximal stimulation occurred free L2 20 L2 acetylated
0.2066687.8557670.html.plaintext.txt	326	Although much higher portion found estimated intact complex different conditions operative outer surface complex lipoyl domains concentrated 1 mM making localized L2 level least 50 fold higher highest level free L2 used present work
0.2066687.8557670.html.plaintext.txt	327	Interaction kinase acetylated L2 would aided steady state turnover overall PDC reaction rapidly changing location acetyl groups within multienzyme cluster
0.2066687.8557670.html.plaintext.txt	328	Kinase shuffling L2 domains may also contribute needed regardless since acetylation acetyl CoA requires unhindered lipoate50 51 kinase must interact L2 acetylation
0.2066687.8557670.html.plaintext.txt	329	We conclude increased reductive acetylation effective activating kinase due preferred interaction acetylated L2 altering structure kinase thereby increasing kinase activity Fig
0.2066687.8557670.html.plaintext.txt	330	In stimulated kinase kinetic properties must fundamentally change since stimulation occurs wide range rates e
0.2066687.8557670.html.plaintext.txt	331	even peptide substrate slowly phosphorylated absence kinase movement surface E2 core
0.2066687.8557670.html.plaintext.txt	332	Previous studies demonstrated stimulation kinase requires physiological levels potassium salts7 14 53
0.2066687.8557670.html.plaintext.txt	333	Increasing K low 0 10 mM higher levels 90 120 mM leads marked inhibition kinase activity gain capacity NADH acetyl CoA stimulation
0.2066687.8557670.html.plaintext.txt	334	Another property kinase changes increasing K ion ADP inhibition markedly increases55
0.2066687.8557670.html.plaintext.txt	335	A potential mechanism interaction kinase L2 domain containing acetyl dihydrolipoate leads conformational change kinase speeds ADP dissociation probably rate limiting step kinase reaction elevated physiological K levels
0.2066687.8557670.html.plaintext.txt	336	Consistent prospect observation acetylation causes greater stimulation ADP inhibited kinase 13 evidence kinase ADP prominent reaction intermediate since pyruvate effectively inhibits binding kinase ADP absence free ADP56
0.2066687.8557670.html.plaintext.txt	337	For mechanism correct must operate conjunction slow rate phosphorylation peptide substrate particularly useful system testing mechanism
0.2066687.8557670.html.plaintext.txt	338	Further studies needed define structural changes attenuate kinase changes L2s lipoyl group determine K1 K2 subunits kinase vary regulatory control
0.2066687.8557670.html.plaintext.txt	339	In conclusion results strongly support E3 catalyzed reduction E2 catalyzed acetylation lipoyl moiety kinase binding inner L2 domain E2 mediating marked enhancement kinase activity
0.2066687.8557670.html.plaintext.txt	340	The effectiveness intact PDC acetylating low proportion L2 domains enhancing phosphorylation many bound E1 single tightly bound kinase molecule probably accomplished inter L2 domain movement kinase combined stronger interaction kinase acetylated L2 domains
0.2066687.8557670.html.plaintext.txt	341	Several studies kinase function regulation consistent change K requiring process ultimately occurring kinase stimulation
0.2066687.8557670.html.plaintext.txt	342	A candidate mechanism involves counteracting K strengthened ADP binding kinase speed slow dissociation product active site kinase
0.2066687.8557670.html.plaintext.txt	343	This work supported part National Institutes Health Grant DK18320 grant Kansas Affiliate American Heart Association Agriculture Experiment Station contribution 95 476 J T
0.2066687.8557670.html.plaintext.txt	344	grant The Wellcome Trust J
0.2066687.8557670.html.plaintext.txt	345	The costs publication article defrayed part payment page charges
0.2066687.8557670.html.plaintext.txt	346	This article must therefore hereby marked advertisement accordance 18 U
0.2066687.8557670.html.plaintext.txt	347	Section 1734 solely indicate fact
0.2066687.8557670.html.plaintext.txt	348	To correspondence addressed Dept
0.2066687.8557670.html.plaintext.txt	349	Biochemistry Willard Hall Kansas State University Manhattan KS 66506
0.2066687.8557670.html.plaintext.txt	350	913 532 6121 Fax 913 532 7278
0.2066687.8557670.html.plaintext.txt	351	The abbreviations used PDC pyruvate dehydrogenase complex E1 pyruvate dehydrogenase component E1a active nonphosphorylated form E1 E2 dihydrolipoyl acetyltransferase component E2 L1 NH terminal lipoyl domain E2 E2 L2 interior lipoyl domain E2 E2 E1 binding domain E2 oligomer forming transacetylase catalyzing COOH terminal domain E2 PDK1 K1 major bovine kidney catalytic subunit pyruvate dehydrogenase kinase formerly designated K PDK2 K2 minor catalytic subunit pyruvate dehydrogenase kinase formerly designated K E3 dihydrolipoyl dehydrogenase E3BP X E3 binding protein protein X TPP thiamin pyrophosphate PAGE polyacrylamide gel electrophoresis PMSF phenylmethylsulfonyl fluoride MOPS 4 morpholinepropanesulfonic acid
0.2066687.8557670.html.plaintext.txt	352	The E1 fraction free E2 based SDS PAGE separation silver staining Western blot analysis using monoclonal antibodies specific L2 domain E2
0.2066687.8557670.html.plaintext.txt	353	Silver staining 2 microg sample E1 demonstrated band migrated position K1 subunit kinase
0.2066687.8557670.html.plaintext.txt	354	However comigration subunit E1 K2 subunit kinase unable determine whether kinase subunit also present preparation
0.2066687.8557670.html.plaintext.txt	355	A low level E3 also present E1 preparation
0.2066687.8557670.html.plaintext.txt	356	The E3 component uses lipoyl domain attached lipoate much effectively free lipoate cyclic E3 assay accordingly little interference lipoates released lipoamidase lipoyl domains J
0.2066687.8557670.html.plaintext.txt	357	Roche manuscript preparation
0.2066687.8557670.html.plaintext.txt	358	The binding E1 TPP 37 thiaminthiazalone pyrophosphate analog transition state intermediate hydroxyethylidene TPP14 inhibits phosphorylation E1 kinase
0.2066687.8557670.html.plaintext.txt	359	To evaluate effect hydroxyethylidene TPP intermediate kinase activity Cary 39 tested effect addition TPP PDC presence low pyruvate plus level acetyl CoA NADH give high acetylation lipoyl moieties high stimulation kinase
0.2066687.8557670.html.plaintext.txt	360	Addition 50 microM TPP reduced kinase activity 60 due formation hydroxyethylidene TPP due short reaction time 40 low pyruvate used 50 microM used minimally converted acetoin acetolactate
0.2066687.8557670.html.plaintext.txt	361	This inhibition tightly bound intermediate similar saturating level TPP binding E1 37 indicates stimulation kinase activity result relieving kinase inhibition E1 bound TPP
0.2066687.8557670.html.plaintext.txt	362	This level acetylation requires biacetylation lipoates
0.2066687.8557670.html.plaintext.txt	363	This tends occur conditions acetyl CoA lipoyl domains complex particularly CoA removal approach used prevent deacetylation
0.2066687.8557670.html.plaintext.txt	364	As acetylation increased level expected give primarily monoacetylated lipoates reduced biacetylated level expected give much higher proportion biacetylated lipoates concomitant decrease number sites alkylated N Cethylmaleimide supporting formation biacetyl lipoates S
0.2066687.8557670.html.plaintext.txt	365	54 presented evidence 12 protein X E3BP yeast PDC using area densiometric analysis approach
0.2066687.8557670.html.plaintext.txt	366	Using less accurate densiometric approach Jilka et al
0.2066687.8557670.html.plaintext.txt	367	42 determined 6 E3BP mammalian PDC reinvestigated
0.2066687.8557670.html.plaintext.txt	368	Even fairly low levels acetylation E2 E3BP acetylated42
0.2066687.8557670.html.plaintext.txt	369	Furthermore analysis autoradiography acetylation elastase generated polypeptides L1 L2 identified blots L1 L2 specific monoclonal antibodies27 demonstrated lipoyl domains E2 acetylated well low levels acetylation S
0.2066687.8557670.html.plaintext.txt	370	There appeared somewhat higher acetylation L2 complex distribution L1 L2 derived polypeptides made judgment uncertain
0.2066687.8557670.html.plaintext.txt	371	We thankful Jason Baker preparing lipoyl domain constructs helping figure preparation Connie Schmidt helping preparation manuscript
0.2066687.8557670.html.plaintext.txt	372	14 799 806 Medline Order article via Infotrieve Linn T
0.2066687.8557670.html.plaintext.txt	373	62 234 241 Abstract Wieland O
0.2066687.8557670.html.plaintext.txt	374	15 295 298 CrossRefMedline Order article via Infotrieve Taylor S
0.2066687.8557670.html.plaintext.txt	375	248 73 81 AbstractFree Full Text Wieland O
0.2066687.8557670.html.plaintext.txt	376	45 577 588 Medline Order article via Infotrieve Taylor S
0.2066687.8557670.html.plaintext.txt	377	250 2028 2035 Abstract Pettit F
0.2066687.8557670.html.plaintext.txt	378	65 575 582 Medline Order article via Infotrieve Cooper H
0.2066687.8557670.html.plaintext.txt	379	1975 Nature 257 808 809 Medline Order article via Infotrieve Kerbey A
0.2066687.8557670.html.plaintext.txt	380	154 327 348 Medline Order article via Infotrieve Batenburg J
0.2066687.8557670.html.plaintext.txt	381	66 533 540 Medline Order article via Infotrieve Batenburg J
0.2066687.8557670.html.plaintext.txt	382	251 1364 1370 Abstract Hansford R
0.2066687.8557670.html.plaintext.txt	383	251 5483 5489 Abstract Roche T
0.2066687.8557670.html.plaintext.txt	384	72 1375 1383 Medline Order article via Infotrieve Cate R
0.2066687.8557670.html.plaintext.txt	385	253 496 503 Medline Order article via Infotrieve Cate R
0.2066687.8557670.html.plaintext.txt	386	254 1659 1665 Medline Order article via Infotrieve Rahmatullah M
0.2066687.8557670.html.plaintext.txt	387	260 10146 10152 AbstractFree Full Text Rahmatullah M
0.2066687.8557670.html.plaintext.txt	388	262 10265 10271 AbstractFree Full Text Patel M
0.2066687.8557670.html.plaintext.txt	389	4 3224 3233 Abstract Reed L
0.2066687.8557670.html.plaintext.txt	390	265 8971 8974 Free Full Text Perham R
0.2066687.8557670.html.plaintext.txt	391	1991 Biochemistry 30 8501 8512 Medline Order article via Infotrieve Popov K
0.2066687.8557670.html.plaintext.txt	392	268 26602 26606 AbstractFree Full Text Popov K
0.2066687.8557670.html.plaintext.txt	393	269 29720 29724 AbstractFree Full Text Radke G
0.2066687.8557670.html.plaintext.txt	394	190 982 991 CrossRefMedline Order article via Infotrieve Ono K
0.2066687.8557670.html.plaintext.txt	395	268 26135 26143 AbstractFree Full Text Liu S
0.2066687.8557670.html.plaintext.txt	396	270 793 800 AbstractFree Full Text Liu S
0.2066687.8557670.html.plaintext.txt	397	316 926 940 CrossRefMedline Order article via Infotrieve Roche T
0.2066687.8557670.html.plaintext.txt	398	183 664 677 Medline Order article via Infotrieve Linn T
0.2066687.8557670.html.plaintext.txt	399	148 327 342 Medline Order article via Infotrieve Rahmatullah M
0.2066687.8557670.html.plaintext.txt	400	265 14512 14517 AbstractFree Full Text Rahmatullah M
0.2066687.8557670.html.plaintext.txt	401	264 1245 1251 AbstractFree Full Text Suzuki K
0.2066687.8557670.html.plaintext.txt	402	238 4021 4025 Free Full Text Green D
0.2066687.8557670.html.plaintext.txt	403	309 853 862 Medline Order article via Infotrieve Hucho F
0.2066687.8557670.html.plaintext.txt	404	151 328 340 Medline Order article via Infotrieve Cate R
0.2066687.8557670.html.plaintext.txt	405	255 7556 7562 Free Full Text Sumegi B
0.2066687.8557670.html.plaintext.txt	406	136 347 353 Abstract Roche T
0.2066687.8557670.html.plaintext.txt	407	48 840 846 Medline Order article via Infotrieve Robertson J
0.2066687.8557670.html.plaintext.txt	408	264 11626 11631 AbstractFree Full Text Cary M
0.2066687.8557670.html.plaintext.txt	409	1984 Regulation Pyruvate Dehydrogenase Kinase Conditions Concomitant Turnover Pyruvate Dehydrogenase Complex
0.2066687.8557670.html.plaintext.txt	410	thesis Kansas State University Reed L
0.2066687.8557670.html.plaintext.txt	411	1980 Enzyme Regulation Mechanism Action Mildner P
0.2066687.8557670.html.plaintext.txt	412	47 56 Pergamon Press New York Cooper H
0.2066687.8557670.html.plaintext.txt	413	1975 Nature 257 808 809 Medline Order article via Infotrieve Jilka J
0.2066687.8557670.html.plaintext.txt	414	261 1858 1867 AbstractFree Full Text Tsai C
0.2066687.8557670.html.plaintext.txt	415	248 8348 8352 AbstractFree Full Text Pawelczyk T
0.2066687.8557670.html.plaintext.txt	416	294 44 49 Medline Order article via Infotrieve Garland P
0.2066687.8557670.html.plaintext.txt	417	93 665 678 Medline Order article via Infotrieve Denton R
0.2066687.8557670.html.plaintext.txt	418	9 27 53 Medline Order article via Infotrieve Hansford R
0.2066687.8557670.html.plaintext.txt	419	191 65 81 Medline Order article via Infotrieve Olson M
0.2066687.8557670.html.plaintext.txt	420	187 121 131 Medline Order article via Infotrieve Mattevi A
0.2066687.8557670.html.plaintext.txt	421	1992 Science 255 1544 1550 Medline Order article via Infotrieve Mattevi A
0.2066687.8557670.html.plaintext.txt	422	1993 Biochemistry 32 3887 3901 Medline Order article via Infotrieve Pettit F
0.2066687.8557670.html.plaintext.txt	423	79 3945 3948 Abstract Robertson J
0.2066687.8557670.html.plaintext.txt	424	265 16814 16820 AbstractFree Full Text Maeng C Y
0.2066687.8557670.html.plaintext.txt	425	1994 Biochemistry 33 13801 13807 Medline Order article via Infotrieve Roche T
0.2066687.8557670.html.plaintext.txt	426	59 1341 1348 Medline Order article via Infotrieve Pratt M
0.2066687.8557670.html.plaintext.txt	427	254 7191 7196 Medline Order article via Infotrieve 1996 The American Society Biochemistry Molecular Biology Inc
0.2416355.10725437.html.plaintext.txt	0	DNA containing empty hepatitis B virus core particles bind similarly envelope protein domains Christophe Hourioux1 Antoine Touze2 Pierre Coursaget2 Philippe Roingeard1
0.2416355.10725437.html.plaintext.txt	1	Laboratoires de Biologie Cellulaire et Virologie EA 2639 Analyse Structurale des Antigenes Faculte de Medecine Institut Federatif de Recherche Transposons et Virus Universite Francois Rabelais 2 bis Boulevard Tonnelle F 37032 Tours Cedex France1 Laboratoire de Virologie Moleculaire EA 2637 Processus Infectieux et Tumoraux Faculte des Sciences Pharmaceutiques Philippe Maupas Institut Federatif de Recherche Transposons et Virus Universite Francois Rabelais Tours France2
0.2416355.10725437.html.plaintext.txt	2	Author correspondence Philippe Roingeard
0.2416355.10725437.html.plaintext.txt	3	Abstract Top Abstract Main text References DNA synthesis within hepatitis B virus HBV nucleocapsid appears coupled nucleocapsid envelopment
0.2416355.10725437.html.plaintext.txt	4	The nature envelopment signal unknown thought involve conformational change surface capsid facilitates interaction HBV envelope proteins
0.2416355.10725437.html.plaintext.txt	5	In binding assays vitro found empty HBV core particles bound synthetic peptides corresponding HBV envelope protein domains affinity HBV DNA containing core particles
0.2416355.10725437.html.plaintext.txt	6	This suggests selection replication competent nucleocapsids envelopment related capacity DNA containing core particles bind specifically HBV envelope proteins must alternative mechanism
0.2416355.10725437.html.plaintext.txt	7	Main text Top Abstract Main text References Human hepatitis B virus HBV member hepadnaviruses family small enveloped viruses partially double stranded circular DNA genomes replicate reverse transcription Ganem Varmus 1987
0.2416355.10725437.html.plaintext.txt	8	During initiation infection virus particles deliver DNA nucleus converted covalently closed circular DNA molecule acts transcriptional template production RNA genome pregenome Tuttleman et al
0.2416355.10725437.html.plaintext.txt	9	The RNA pregenome viral polymerase encapsidated cytoplasm viral capsid proteins form immature nucleocapsid particles within viral DNA synthesis occurs
0.2416355.10725437.html.plaintext.txt	10	Initially minus strand DNA synthesized reverse transcription pregenome
0.2416355.10725437.html.plaintext.txt	11	This minus strand DNA used template plus strand synthesis reviewed Nassal 1996
0.2416355.10725437.html.plaintext.txt	12	Thereafter nucleocapsids interact surface proteins embedded lipid bilayer post endoplasmic reticulum pre Golgi compartment bud lumen compartment form mature virions Roingeard et al
0.2416355.10725437.html.plaintext.txt	13	1990 Bruss Ganem 1991 Huovila et al
0.2416355.10725437.html.plaintext.txt	14	Previous studies shown immature nucleocapsids containing pregenomic RNA incompetent envelopment minus strand DNA synthesis must completed core particle envelopment occur Wei et al
0.2416355.10725437.html.plaintext.txt	15	This suggests DNA synthesis within capsid coupled appearance signal exterior nucleocapsid essential nucleocapsid envelopment
0.2416355.10725437.html.plaintext.txt	16	The molecular nature envelopment signal unknown thought involve specific binding DNA containing core particles RNA containing core particles HBV envelope proteins Hui et al
0.2416355.10725437.html.plaintext.txt	17	We recently investigated core envelope interactions involved maturation HBV using vitro assays determine capacity HBV core particles bind panel synthetic peptides map HBV envelope proteins Poisson et al
0.2416355.10725437.html.plaintext.txt	18	A short domain large L envelope protein aa 96 116 ayw subtype short domain cytosolic loop small S envelope protein aa 56 80 found bind HBV core particles efficiently
0.2416355.10725437.html.plaintext.txt	19	The L envelope domain found interact HBV core particles subsequently shown essential virion morphogenesis two independent studies envelope mutants domain substituted random sequence Bruss 1997 deleted Le Seyec et al
0.2416355.10725437.html.plaintext.txt	20	A recent study S domain confirmed deletions andor amino acid substitutions within domain hinder subviral particle morphogenesis therefore provide information role domain virion packaging Jenna Sureau 1998
0.2416355.10725437.html.plaintext.txt	21	Our previous assays binding HBV core particles HBV envelope peptides performed purified liver derived core particles containing HBV DNA Poisson et al
0.2416355.10725437.html.plaintext.txt	22	In study used similar assays compare binding DNA containing core particles empty HBV core particles obtained using baculovirus expression system
0.2416355.10725437.html.plaintext.txt	23	These particles called HBV core particles obtained expression sequence encoding first 144 amino acids HBV core gene excluding arginine rich C terminal stretch 39 amino acids responsible pregenome binding described elsewhere Touze et al
0.2416355.10725437.html.plaintext.txt	24	1 binding assays described previously Poisson et al
0.2416355.10725437.html.plaintext.txt	25	We used two 25 residue peptides S1 S2 together covered cytosolic loop HBV S protein
0.2416355.10725437.html.plaintext.txt	26	To cover cytosolic domain HBV L protein used five peptides 28 28 29 23 55 residues named L1 L2 L3 L4 L5 respectively L1 L4 corresponded pre S1 domain L5 corresponded pre S2 domain
0.2416355.10725437.html.plaintext.txt	27	Two additional peptides overlapping peptide L4 used peptide L4a last 10 residues peptide L3 plus first eight residues peptide L4 peptide L4b last 13 residues peptide L4 plus first eight residues peptide L5
0.2416355.10725437.html.plaintext.txt	28	View larger version 11K Fig
0.2416355.10725437.html.plaintext.txt	29	Synthetic peptides map cytoplasmic domains HBV S L envelope proteins
0.2416355.10725437.html.plaintext.txt	30	The S protein 226 residues spans membrane N terminal type I central type II signals open boxes probably twice hydrophobic C terminal region
0.2416355.10725437.html.plaintext.txt	31	The S protein exposes loop 50 residues covered peptides S1 S2
0.2416355.10725437.html.plaintext.txt	32	The L protein contains S plus 55 residues pre S2 domain covered peptide L5 108 residues ayw subtype pre S1 domain covered peptides L1 L2 L3 L4
0.2416355.10725437.html.plaintext.txt	33	Two overlapping peptides L4a L4b complete mapping
0.2416355.10725437.html.plaintext.txt	34	Dynatech ELISA plates coated various peptides coupled BSA BSA alone concentration 20 microgml 0 05 M bicarbonate buffer pH 9 6 24 h 4 degrees C 200 microl per well
0.2416355.10725437.html.plaintext.txt	35	Plates washed three times 0 01 M PBS containing 0 15 M NaCl pH 7 4 0 5 Tween 20 blocked adding 300 microl PBS containing 2 newborn calf serum NBCS incubating 45 min 37 degrees C
0.2416355.10725437.html.plaintext.txt	36	The plates washed HBV core preparations adjusted concentration estimated immunocapture ELISA electron microscopy around 105 core particlesml 1 mM PBS plus 15 mM NaCl pH 7 4 incubated 24 h 4 degrees C peptides
0.2416355.10725437.html.plaintext.txt	37	The plates washed three times 100 microl anti HBc monoclonal antibody 6C6A1 diluted 110000 0 05 M PBS 0 75 M NaCl pH 7 4 containing 5 NBCS 5 BSA 0 5 Tween 20 added
0.2416355.10725437.html.plaintext.txt	38	The plates incubated 1 h room temperature washed three times 100 microl horseradish peroxidase conjugated goat anti mouse Fab2 Tago diluted 110000 buffer added
0.2416355.10725437.html.plaintext.txt	39	Plates incubated 30 min 37 degrees C washed three times
0.2416355.10725437.html.plaintext.txt	40	A mixture hydrogen peroxide o phenylenediamine added plates left 30 min dark room temperature
0.2416355.10725437.html.plaintext.txt	41	Colour development stopped 1 M H2SO4 absorbance read 492 nm
0.2416355.10725437.html.plaintext.txt	42	The cut value chosen twice mean value obtained eight control wells containing BSA alone 2x0 035 representative experiment
0.2416355.10725437.html.plaintext.txt	43	Binding activity given peptide expressed absorbancecut value
0.2416355.10725437.html.plaintext.txt	44	We found HBV core particles bound L S HBV envelope peptide domains affinity liver derived HBV DNA containing capsids Table 1
0.2416355.10725437.html.plaintext.txt	45	We cannot rule hypothesis absence C terminal part truncated capsids could adopt structure resembles DNA containing capsids thus explaining binding envelope peptides
0.2416355.10725437.html.plaintext.txt	46	This unlikely however others demonstrated ability full length E
0.2416355.10725437.html.plaintext.txt	47	coli derived HBV capsids bind HBV L envelope protein expressed rabbit reticulocyte lysates Tan et al
0.2416355.10725437.html.plaintext.txt	48	Therefore results suggest selection replication competent nucleocapsids envelopment related particular capacity DNA containing nucleocapsids bind HBV envelope proteins
0.2416355.10725437.html.plaintext.txt	49	Binding BSA coupled HBV envelope peptides HBV DNA containing liver derived HBV core particles empty baculovirus derived HBV core particles
0.2416355.10725437.html.plaintext.txt	50	Alternatively HBV DNA containing capsids may interact cellular factor molecular chaperone element cytoskeleton involved cell trafficking
0.2416355.10725437.html.plaintext.txt	51	We recently analysed HBV morphogenesis HepG2 cells transfected HBV DNA showed nucleocapsids seems regroup bud specific areas dilated host cell compartments Roingeard Sureau 1998
0.2416355.10725437.html.plaintext.txt	52	This suggests may specific transport DNA containing core particles towards cellular compartments
0.2416355.10725437.html.plaintext.txt	53	Such mechanism may depend host cell factors binding specifically DNA containing core particles resulting selection core particles envelopment
0.2416355.10725437.html.plaintext.txt	54	In vitro binding assays value identifying host factors potentially bind HBV core particles
0.2416355.10725437.html.plaintext.txt	55	Such studies may reveal novel targets specific antiviral strategies
0.2416355.10725437.html.plaintext.txt	56	supported fellowship Association pour la Recherche contre le Cancer ARC France
0.2416355.10725437.html.plaintext.txt	57	References Top Abstract Main text References Bruss V
0.2416355.10725437.html.plaintext.txt	58	A short linear sequence pre S domain large hepatitis B virus envelope protein required virion formation
0.2416355.10725437.html.plaintext.txt	59	Journal Virology 71 9350 9357
0.2416355.10725437.html.plaintext.txt	60	The role envelope proteins hepatitis B virus assembly
0.2416355.10725437.html.plaintext.txt	61	Proceedings National Academy Sciences USA 88 1059 1063
0.2416355.10725437.html.plaintext.txt	62	The molecular biology hepatitis B viruses
0.2416355.10725437.html.plaintext.txt	63	Annual Review Biochemistry 56 651 693
0.2416355.10725437.html.plaintext.txt	64	Hepatitis B virus nucleocapsid envelopment occur without genomic DNA synthesis
0.2416355.10725437.html.plaintext.txt	65	Journal Virology 70 4269 4274
0.2416355.10725437.html.plaintext.txt	66	Interaction hepatitis delta virus encoded proteins hepatitis B virus envelope protein domains
0.2416355.10725437.html.plaintext.txt	67	Journal General Virology 79 1115 1119
0.2416355.10725437.html.plaintext.txt	68	Hepatitis B viral core proteins N terminal extension assemble core like particles cannot enveloped
0.2416355.10725437.html.plaintext.txt	69	Journal General Virology 80 2647 2659
0.2416355.10725437.html.plaintext.txt	70	Hepatitis B surface antigen assembles post ER pre Golgi compartment
0.2416355.10725437.html.plaintext.txt	71	Journal Cell Biology 118 1305 1320
0.2416355.10725437.html.plaintext.txt	72	Effect mutations small envelope protein hepatitis B virus assembly secretion hepatitis delta virus
0.2416355.10725437.html.plaintext.txt	73	Role pre S2 domain large envelope protein hepatitis B virus assembly infectivity
0.2416355.10725437.html.plaintext.txt	74	Journal Virology 72 5573 5578
0.2416355.10725437.html.plaintext.txt	75	Hepatitis B virus morphogenesis
0.2416355.10725437.html.plaintext.txt	76	Current Topics Microbiology Immunology 214 297 337
0.2416355.10725437.html.plaintext.txt	77	Hepatitis B virus replication novel roles virus host interactions
0.2416355.10725437.html.plaintext.txt	78	Both pre S1 S domains hepatitis B virus envelope proteins interact core particle
0.2416355.10725437.html.plaintext.txt	79	Ultrastructural analysis hepatitis B virus HepG2 transfected cells special emphasis subviral filament morphogenesis
0.2416355.10725437.html.plaintext.txt	80	Immunocytochemical electron microscopic study hepatitis B virus antigen complete particle production hepatitis B virus DNA transfected HepG2 cells
0.2416355.10725437.html.plaintext.txt	81	Two distinct segments hepatitis B virus surface antigen contribute synergistically association viral core particles
0.2416355.10725437.html.plaintext.txt	82	Journal Molecular Biology 286 797 808
0.2416355.10725437.html.plaintext.txt	83	Baculovirus expression chimeric hepatitis B virus core particles hepatitis E virus epitopes use hepatitis E immunoassay
0.2416355.10725437.html.plaintext.txt	84	Journal Clinical Microbiology 37 438 441
0.2416355.10725437.html.plaintext.txt	85	In vitro experimental infection primary duck hepatocyte cultures duck hepatitis B virus
0.2416355.10725437.html.plaintext.txt	86	Relationship viral DNA synthesis virion envelopment hepatitis B viruses
0.2416355.10725437.html.plaintext.txt	87	Journal Virology 70 6455 6458
0.2416355.10725437.html.plaintext.txt	88	Received 29 November 1999 accepted 13 January 2000
0.2416355.10725437.html.plaintext.txt	89	This Article Abstract Full Text PDF Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles Hourioux C
0.2416355.10725437.html.plaintext.txt	90	Articles citing Article PubMed PubMed Citation Articles Hourioux C
0.2416355.10725437.html.plaintext.txt	91	Agricola Articles Hourioux C
0.2416355.10725437.html.plaintext.txt	92	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL J MED MICROBIOL ALL SGM JOURNALS
0.41806388.11304544.html.plaintext.txt	0	Characterization Recombinant HPV6 11 E1 Helicases EFFECT OF ATP ON THE INTERACTION OF E1 WITH E2 AND MAPPING OF A MINIMAL HELICASE DOMAIN Peter W
0.41806388.11304544.html.plaintext.txt	1	White Alex Pelletier Karine Brault Steve Titolo Ewald Welchner Louise Thauvette Monika Fazekas Michael G
0.41806388.11304544.html.plaintext.txt	2	Cordingley Jacques Archambault
0.41806388.11304544.html.plaintext.txt	3	From Department Biological Sciences Boehringer Ingelheim Canada Ltd
0.41806388.11304544.html.plaintext.txt	4	Laval Quebec H7S 2G5 Canada
0.41806388.11304544.html.plaintext.txt	5	Received publication March 2 2001 revised form April 12 2001
0.41806388.11304544.html.plaintext.txt	6	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.41806388.11304544.html.plaintext.txt	7	To better characterize enzymatic activities required human papillomavirus HPV DNA replication E1 helicases HPV types 6 11 produced using baculovirus expression system
0.41806388.11304544.html.plaintext.txt	8	The purified wild type proteins version HPV11 E1 lacking N terminal 71 amino acids better expressed found hexameric wide range concentrations helicase ATPase activities relatively low values KmATP 12 microM HPV6 E1 6 microM HPV11 E1
0.41806388.11304544.html.plaintext.txt	9	Interestingly value KmATP increased 7 fold presence E2 transactivation domain
0.41806388.11304544.html.plaintext.txt	10	In turn ATP found perturb co operative binding E1 E2 DNA
0.41806388.11304544.html.plaintext.txt	11	Mutant truncated versions vitro translated E1 used identify minimal ATPase domain composed C terminal 297 amino acids
0.41806388.11304544.html.plaintext.txt	12	This fragment expressed purified found fully active ATP hydrolysis single stranded DNA binding unwinding assays despite lacking minimal origin binding domain
0.41806388.11304544.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.41806388.11304544.html.plaintext.txt	14	The papillomaviruses PVs1 small nonenveloped DNA viruses infect replicate cutaneous mucosal epithelia humans mammals
0.41806388.11304544.html.plaintext.txt	15	There 100 types human papillomavirus HPV cause conditions ranging plantar warts HPV1 genital warts HPV6 11 cervical cancer HPV16 18 31
0.41806388.11304544.html.plaintext.txt	16	HPV6 11 also responsible laryngeal papillomatosis rare serious infection respiratory tract 1
0.41806388.11304544.html.plaintext.txt	17	Antiviral agents capable specifically inhibiting PV replication could play important role treatment diseases none exist time
0.41806388.11304544.html.plaintext.txt	18	Despite host tissue specificity PV types share common genomic organization
0.41806388.11304544.html.plaintext.txt	19	The closed circular genome 8000 base pairs codes 10 proteins eight early proteins termed E1 E8 two late proteins L1 L2 make viral coat 2
0.41806388.11304544.html.plaintext.txt	20	E1 E2 viral proteins required HPV DNA replication 3 4
0.41806388.11304544.html.plaintext.txt	21	E2 sequence specific DNA binding protein serves regulate transcription DNA replication
0.41806388.11304544.html.plaintext.txt	22	E1 DNA helicase PV protein possesses enzymatic activity 5 also highly conserved PV proteins
0.41806388.11304544.html.plaintext.txt	23	For reasons E1 considered attractive molecular target development antiviral agents 6
0.41806388.11304544.html.plaintext.txt	24	During initiation PV DNA replication E2 serves specificity factor enhance binding E1 monomers origin bind double stranded DNA little sequence specificity 4 7 11
0.41806388.11304544.html.plaintext.txt	25	E2 dimers bind high specificity DNA sequences within origin recruit E1 monomers direct protein protein interactions 12 13
0.41806388.11304544.html.plaintext.txt	26	Upon binding DNA E1 monomers assemble hexamers 14 15 E1 E2 interaction maintained 16 17
0.41806388.11304544.html.plaintext.txt	27	Thus role E2 catalyze assembly hexameric E1 complexes specifically origin
0.41806388.11304544.html.plaintext.txt	28	ATP hydrolysis also required E1 hexamers distort origin encircle single strands DNA 18
0.41806388.11304544.html.plaintext.txt	29	Using vitro translated HPV11 proteins previously shown ATP binding stimulates E2 dependent association E1 origin 19
0.41806388.11304544.html.plaintext.txt	30	ATP binding affect E2 binding step E1 E2 interaction rather subsequent process either oligomerization binding E1 DNA stability assembled E1 origin DNA complex 19 20
0.41806388.11304544.html.plaintext.txt	31	ATP hydrolysis required case since nonhydrolyzable analog ATPS ADP similar effects
0.41806388.11304544.html.plaintext.txt	32	For BPV demonstrated ATP hydrolysis required displacement E2 origin assembly E1 multimeric complexes 17
0.41806388.11304544.html.plaintext.txt	33	Either concurrent formation E1 oligomers host polymerase primase 21 25 possibly also replication protein A 22 26 bind E1 replication complex formed together additional host factors
0.41806388.11304544.html.plaintext.txt	34	We others identified subdomains E1 well conserved amino acids required number DNA replication activities
0.41806388.11304544.html.plaintext.txt	35	We recently shown amino acids 166 649 E1 efficiently support DNA replication cell free system thus must encode necessary binding enzymatic activities required vitro 25
0.41806388.11304544.html.plaintext.txt	36	In vivo additional sequences spanning amino acids 82 128 HPV11 E1 required contain extended nuclear localization sequence 27 28 well cyclin binding motif cyclin dependent kinase phosphorylation sites 29 31
0.41806388.11304544.html.plaintext.txt	37	A minimal DNA bindingorigin recognition sequence mapped approximately amino acids 140 300 BPV E1 32 35 amino acids 185 345 HPV11 E1 although entire C terminus protein amino acids 186 649 required observe stable binding HPV11 E1 origin 20 36
0.41806388.11304544.html.plaintext.txt	38	An HPV11 E1 truncation consisting C terminal amino acids 353 649 retains ability bind E2 p70 subunit polymerase primase oligomerize hexamers 19 20 25
0.41806388.11304544.html.plaintext.txt	39	Within C terminal fragment E1 four conserved regions termed A B C D see Fig
0.41806388.11304544.html.plaintext.txt	40	1 highly similar functionally related T antigens SV40 polyomaviruses 37
0.41806388.11304544.html.plaintext.txt	41	The conserved region A lies minimal E1 oligomerization sequence located within amino acids 353 416 see Fig
0.41806388.11304544.html.plaintext.txt	42	Three motifs characteristic superfamily 3 NTP binding proteins located amino acids 478 525 HPV11 E1 see Fig
0.41806388.11304544.html.plaintext.txt	43	Two motifs motifs b correspond Walker A B boxes involved binding substrate nucleotide triphosphate magnesium complex 39 exact function third motif motif c remains unclear
0.41806388.11304544.html.plaintext.txt	44	Mutations conserved residues three motifs shown significantly decrease ATPase activity superfamily 3 helicase Rep68 encoded adeno associated virus 40
0.41806388.11304544.html.plaintext.txt	45	Mutation highly conserved lysine motif Lys484 HPV11 E1 shown abrogate ATPase activity BPV E1 41 HPV11 E1 42 also observed many ATPases 43
0.41806388.11304544.html.plaintext.txt	46	View larger version 16K Fig
0.41806388.11304544.html.plaintext.txt	47	Domain structure HPV11 E1 helicase
0.41806388.11304544.html.plaintext.txt	48	The 649 amino acid long HPV11 E1 helicase diagrammed rectangle black boxes labeled A B C D indicating regions E1 conserved large T antigens SV40 polyomaviruses 37
0.41806388.11304544.html.plaintext.txt	49	The region HPV11 E1 corresponds minimal DNA binding domain mapped BPV E1 32 35 also indicated black box
0.41806388.11304544.html.plaintext.txt	50	The locations conserved motifs b c common members superfamily 3 NTP binding proteins 38 indicated arrows
0.41806388.11304544.html.plaintext.txt	51	Indicated E1 truncated constructs protein found previous studies sufficient catalyzing DNA replication cell free system stable binding origin interaction transactivation domain E2 19 p70 subunit polymerase primase 25 oligomerization protein 20
0.41806388.11304544.html.plaintext.txt	52	The position minimal E1 E1 interaction domain mapped amino acids 353 416 using yeast two hybrid system 20 indicated hatched box
0.41806388.11304544.html.plaintext.txt	53	Most studies enzymatic activities purified E1 carried using BPV enzyme purified baculovirus infected insect cells 5 41 44 45 Escherichia coli 15 46
0.41806388.11304544.html.plaintext.txt	54	Although HPV E1 proteins 40 50 identical primary sequence BPV E1 presumably similar structures mechanisms action proven difficult isolate sufficient quantities purified HPV enzymes characterize enzymatic activities
0.41806388.11304544.html.plaintext.txt	55	Very low levels expression compounded proteolysis contamination proteins commonly observed
0.41806388.11304544.html.plaintext.txt	56	Of reports isolation HPV E1 42 47 49 one case sufficient material obtained basic characterization helicase activity biophysical properties 42
0.41806388.11304544.html.plaintext.txt	57	50 reported isolation epitope tagged HPV11 E1 functional vitro DNA replication assays enzymatic activities E1 preparations described
0.41806388.11304544.html.plaintext.txt	58	In report present characterization enzymatic activities HPV11 6 E1 helicases
0.41806388.11304544.html.plaintext.txt	59	We made extensive use N terminal truncated form E1 composed amino acids 72 649 shown previously active wild type E1 supporting HPV DNA replication vitro
0.41806388.11304544.html.plaintext.txt	60	We report truncated E1 expressed significantly greater yield full length E1 improved biophysical properties
0.41806388.11304544.html.plaintext.txt	61	We show contrast previous reports 41 42 45 49 purified E1 preparations relatively low value KmATP well physiological concentration ATP
0.41806388.11304544.html.plaintext.txt	62	We show high concentrations E2 transactivation domain raise apparent value KmATP also demonstrate binding ATP Mg E1 weakens interaction E2
0.41806388.11304544.html.plaintext.txt	63	The perturbation E1 E2 binding physiological concentrations ATP suggests mechanism energy gained tight binding ATP used destabilize E1 E2 complex forms transiently initiation viral DNA replication
0.41806388.11304544.html.plaintext.txt	64	We also show E1 353 649 encodes motifs enzymatic activity lacks previously identified minimal origin DNA binding region fully active ATPase helicase ssDNA binding assays
0.41806388.11304544.html.plaintext.txt	65	Thus N terminal half E1 necessary replication HPV origin sequences necessary proper folding oligomerization enzymatic catalysis within C terminus
0.41806388.11304544.html.plaintext.txt	66	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.41806388.11304544.html.plaintext.txt	67	Construction Recombinant Baculoviruses The complete E1 open reading frame HPV11 amplified plasmid pCR3 E1 19
0.41806388.11304544.html.plaintext.txt	68	The forward primer 5 CGC GGA TCC AGG ATG CAT CAC CAT CAC CAT CAC GCG GAC GAT TCA CGT ACA GAA AAT GAG 3 reverse GG CTG AAT TCA TAA AGT TCT AAC AAC T 3 inserting 6 histidines immediately initial methionine
0.41806388.11304544.html.plaintext.txt	69	Similarly E1 72 649 E1 353 649 amplified plasmid pTM1 E1 19 reverse primer following forward primers respectively 5 CGC GGA TCC AGG ATG CAT CAC CAT CAC CAT CAC GCG GAT GCT CAT TAT GCG ACT GTG CAG GAC 3 5 CGC GGA TCC AGG ATG CAT CAC CAT CAC CAT CAC GAC AGT CAA TTT AAA TTA ACT GAA ATG GTG C 3
0.41806388.11304544.html.plaintext.txt	70	To express corresponding catalytically inactive mutant E1 proteins similar PCR amplifications performed appropriate mutant E1 template 19
0.41806388.11304544.html.plaintext.txt	71	The PCR products cut BamHI EcoRI subcloned BamHI EcoRI sites pFASTBAC1 Life Technologies Inc
0.41806388.11304544.html.plaintext.txt	72	transposed baculovirus genome according manufacturers instructions
0.41806388.11304544.html.plaintext.txt	73	E1 containing recombinant baculovirus genomes transfected SF9 insect cells baculovirus containing supernatants amplified large scale protein production
0.41806388.11304544.html.plaintext.txt	74	The gene HPV6 E1 amplified PCR clinical condyloma sample subcloned pCR3
0.41806388.11304544.html.plaintext.txt	75	PCR primers used 5 CAA CGA TGG CGG ACG ATT CAG GTA CAG 3 forward nt 827 853 5 TGC TTC GGA CAC CT 3 reverse nt 2923 2910
0.41806388.11304544.html.plaintext.txt	76	The baculovirus expression construct made procedure HPV11 E1 using forward reverse primers PCR
0.41806388.11304544.html.plaintext.txt	77	The DNA sequence matched reported HPV6a E1 GenBankTM accession number L41216 except eight silent mutations nt 1297 C A nt 1495 T A nt 1540 C T nt 2170 C T nt 2363 T C nt 2396 T C nt 2530 G A nt 2548 T C two mutations encoding conservative changes nt 1670 G T changing Val280 Leu nt 1741 C A changing Asp303 Glu
0.41806388.11304544.html.plaintext.txt	78	2 The amino acid sequence HPV6a E1 88 identical HPV11 E1
0.41806388.11304544.html.plaintext.txt	79	E1 Expression SF21 cells maintained SFM 900 medium Life Technologies cell densities 1 2 x 106ml
0.41806388.11304544.html.plaintext.txt	80	Infections carried 48 72 h using multiplicity infection 5
0.41806388.11304544.html.plaintext.txt	81	Cells harvested frozen rapidly liquid nitrogen stored 80 degrees C
0.41806388.11304544.html.plaintext.txt	82	All subsequent steps performed 0 4 degrees C
0.41806388.11304544.html.plaintext.txt	83	For nuclear extraction frozen cell pellets thawed resuspended one volume cell lysis buffer 20 mM Tris pH 8 5 mM mercaptoethanol 5 mM KCl 1 mM MgCl2 1 mM Pefabloc Pentapharm Ltd
0.41806388.11304544.html.plaintext.txt	84	1 microgml pepstatin 1 microgml leupeptin 1 microgml antipain 15 min broken Dounce homogenizer 20 strokes 40 ml pestle B followed centrifugation 2500 x g 20 min
0.41806388.11304544.html.plaintext.txt	85	Supernatant cytosol discarded nuclei resuspended 1
0.41806388.11304544.html.plaintext.txt	86	4 volumes extraction buffer A 20 mM Tris pH 8 5 mM mercaptoethanol 2 mM Pefabloc 2 microgml pepstatin 2 microgml leupeptin 2 microgml antipain followed addition equal volume extraction buffer B 20 mM Tris pH 8 5 mM mercaptoethanol 0
0.41806388.11304544.html.plaintext.txt	87	02 Triton X 100 full length E1 buffer supplemented NaCl final concentration 450 mM truncated proteins
0.41806388.11304544.html.plaintext.txt	88	The nuclei incubated rocking 30 min ultracentrifugation 148000 x g 45 min
0.41806388.11304544.html.plaintext.txt	89	Glycerol added supernatant final concentration 10 extract frozen rapidly dry ice stored 80 degrees C
0.41806388.11304544.html.plaintext.txt	90	His E1 Purification All steps performed 4 degrees C
0.41806388.11304544.html.plaintext.txt	91	A 5 ml Hi Trap chelating column charged NiSO4 according manufacturers instructions Amersham Pharmacia Biotech washed equilibration buffer 20 mM Tris pH 8 5 mM mercaptoethanol 500 mM NaCl 10 mM imidazole 10 glycerol
0.41806388.11304544.html.plaintext.txt	92	Nuclear extracts 5 liters culture thawed rapidly NaCl concentration adjusted 500 mM full length E1 initially extracted low salt material loaded onto Hi Trap column
0.41806388.11304544.html.plaintext.txt	93	The column washed 50 ml equilibration buffer followed 10 volumes washing buffer equilibration buffer 50 mM imidazole
0.41806388.11304544.html.plaintext.txt	94	His tagged E1 eluted 1 ml fractions equilibration buffer containing 180 mM imidazole dialyzed 20 mM MES pH 7
0.41806388.11304544.html.plaintext.txt	95	05 mM EDTA 10 glycerol frozen dry ice stored 80 degrees C
0.41806388.11304544.html.plaintext.txt	96	E1 truncations eluted 250 mM E1 72 649 350 mM E1 353 649 imidazole dialyzed prior freezing since dilution protein assay buffers found give insignificant residual imidazole concentrations
0.41806388.11304544.html.plaintext.txt	97	E1 preparations tested presence DNA using fluorescent dye PicoGreen Molecular Probes Inc
0.41806388.11304544.html.plaintext.txt	98	Eugene OR according published procedures 51
0.41806388.11304544.html.plaintext.txt	99	The concentrations purified proteins determined using Coomassie Plus reagent Pierce bovine serum albumin serving standard
0.41806388.11304544.html.plaintext.txt	100	Cross linking Bismaleimidohexane cross linking purified HPV11 E1 72 649 subsequent analysis Weber Osborn polyacrylamide gels 52 performed described previously vitro translated protein 20
0.41806388.11304544.html.plaintext.txt	101	Analytical Ultracentrifugation A velocity run HPV11 E1 72 649 carried using XL A analytical ultracentrifuge Beckman Coulter An 60 Ti rotor 40000 rpm 11 degrees C
0.41806388.11304544.html.plaintext.txt	102	E1 72 649 exchanged buffer composed 20 mM Tris 500 mM NaCl 10 glycerol 1 mM DTT 0
0.41806388.11304544.html.plaintext.txt	103	0 using NAP 5 column Amersham Pharmacia Biotech
0.41806388.11304544.html.plaintext.txt	104	The protein diluted 40 microgml 600 nM analyzed using 1
0.41806388.11304544.html.plaintext.txt	105	2 cm double sector charcoal filled Epon centerpiece quartz windows pretreated Sigmacoat silconizing agent Sigma
0.41806388.11304544.html.plaintext.txt	106	Data acquired 230 nm 0
0.41806388.11304544.html.plaintext.txt	107	005 cm intervals five replicate readings taken point
0.41806388.11304544.html.plaintext.txt	108	Scans spaced closely absorbance optics would allow approximately every 2 min
0.41806388.11304544.html.plaintext.txt	109	E1 72 649 found stable time required acquire velocity data although began lose activity several hours 4 11 degrees C
0.41806388.11304544.html.plaintext.txt	110	Buffer density determined 1
0.41806388.11304544.html.plaintext.txt	111	00007 gml 22 degrees C using pyknometer corrected value 1
0.41806388.11304544.html.plaintext.txt	112	05851 gml 11 degrees C 53
0.41806388.11304544.html.plaintext.txt	113	The partial specific volume E1 72 649 0
0.41806388.11304544.html.plaintext.txt	114	7285 cm3g solvent viscosity 1
0.41806388.11304544.html.plaintext.txt	115	810 centipoise 11 degrees C calculated using program Sednterp 53
0.41806388.11304544.html.plaintext.txt	116	Data analyzed programs DCDT 1
0.41806388.11304544.html.plaintext.txt	117	38 56 gave similar results
0.41806388.11304544.html.plaintext.txt	118	E2 dependent E1 DNA Binding E2 dependent binding E1 HPV11 origin measured using modification procedure previously used vitro translated proteins 19
0.41806388.11304544.html.plaintext.txt	119	Binding reactions 80 microl contained 0
0.41806388.11304544.html.plaintext.txt	120	4 ng probe DNA 2 microg salmon sperm DNA indicated amounts E1 E2
0.41806388.11304544.html.plaintext.txt	121	Radiolabeled probe DNA obtained PCR amplification HPV11 origin plasmid pN9
0.41806388.11304544.html.plaintext.txt	122	HPV11 E2 expressed SF21 insect cells infected baculovirus Ac11E2 obtained R
0.41806388.11304544.html.plaintext.txt	123	Rose University Rochester purified DNA affinity chromatography procedure similar Seo et al
0.41806388.11304544.html.plaintext.txt	124	After 1 h binding reactions detection performed modification previously described procedure protein A scintillation proximity assay beads SPA beads used place protein A Sepharose
0.41806388.11304544.html.plaintext.txt	125	Anti E1 coated SPA beads added binding reactions additional 1 h plates spun briefly pellet beads counted using TopCount NXT microplate scintillation counter Packard Instruments
0.41806388.11304544.html.plaintext.txt	126	Blanks subtracted calculating relative activities
0.41806388.11304544.html.plaintext.txt	127	Synthesis Helicase Substrates M13mp18 ssDNA obtained infection E
0.41806388.11304544.html.plaintext.txt	128	coli according standard procedures 58
0.41806388.11304544.html.plaintext.txt	129	Substrate oligonucleotides synthesized trityl Applied Biosystems 394 DNARNA synthesizer purified gel electrophoresis 58
0.41806388.11304544.html.plaintext.txt	130	To synthesize substrate used work report 125 pmol purified oligonucleotide 5 TTC CCA GTC ACG TTG T 3 mixed equimolar amount M13mp18 500 microl TEN buffer 10 mM Tris 80 mM NaCl 1 mM EDTA heated water bath 95 degrees C allowed cool slowly overnight
0.41806388.11304544.html.plaintext.txt	131	dCTP added give 230 microM together 33PdATP 125 pmol 250 microCi unlabeled dATP 400 pmol give final volume 700 microl oligonucleotide sequence extended Klenow fragment 30 degrees C give final sequence 5 TTC CCA GTC ACG ACG TTG TAA AAC 3 radiolabeled residues boldface
0.41806388.11304544.html.plaintext.txt	132	The labeled partial duplex purified using freshly packed 50 ml column Sepharose 4B equilibrated TEN buffer
0.41806388.11304544.html.plaintext.txt	133	Pooled partial duplex fractions 10 ml concentrated 2 ml using Centriprep 50 filters Millipore Corp
0.41806388.11304544.html.plaintext.txt	134	The typical yield 80 pmol purified product specific activity 107 cpmpmol
0.41806388.11304544.html.plaintext.txt	135	To synthesize substrates testing effect 3 5 unannealed tails 125 pmol oligonucleotide 5 labeled using 30 units polynucleotide kinase 125 pmol 33PATP
0.41806388.11304544.html.plaintext.txt	136	The reaction stopped addition EDTA 70 mM labeled oligonucleotide separated remaining 33PATP using Chromaspin 10 column CLONTECH
0.41806388.11304544.html.plaintext.txt	137	Radiolabeled oligonucleotides annealed M13mp18 purified Sepharose 4B chromatography
0.41806388.11304544.html.plaintext.txt	138	Oligonucleotides used follows GTA AAA CGA CGG CCA GTG CCA AGC nontailed GTA AAA CGA CGG CCA GTG CCA AGC AAT GTA AGA TAG CAT CTC CGT 3 tailed substrate AAG AAG AAG AAG AAG AAG GTA AAA CGA CGG CCA GTG CCA AGC 5 tailed substrate
0.41806388.11304544.html.plaintext.txt	139	The sequence complementary M13 underlined
0.41806388.11304544.html.plaintext.txt	140	Helicase Assays Unless stated otherwise reactions run 90 min incubator maintained 37 degrees C 70 humidity Microfluor 2 96 well plates Dynex buffer consisting 20 mM HEPES pH 7
0.41806388.11304544.html.plaintext.txt	141	01 IGEPAL CA630 Sigma equivalent Nonidet P40
0.41806388.11304544.html.plaintext.txt	142	M13 partial duplex substrates used 0
0.41806388.11304544.html.plaintext.txt	143	Reaction products analyzed using either gel electrophoresis streptavidin coated SPA beads two methods gave equivalent results
0.41806388.11304544.html.plaintext.txt	144	For detection gel electrophoresis aliquot reaction mixed one half volume gel loading buffer 60 mM EDTA pH 8 0
0.41806388.11304544.html.plaintext.txt	145	09 nonintercalating dye Orange G Sigma
0.41806388.11304544.html.plaintext.txt	146	Samples 10 microl loaded onto 20 acrylamide gels electrophoresed 100 V orange band migrated two thirds way gel
0.41806388.11304544.html.plaintext.txt	147	Gels dried onto DE 81 paper Whatman exposed storage phosphor screen
0.41806388.11304544.html.plaintext.txt	148	Unwinding quantified using STORM 860 imaging system Molecular Dynamics Inc
0.41806388.11304544.html.plaintext.txt	149	Results calculated percentage substrate unwound value measured relative intensity oligonucleotide band reaction blank sample boiled 15 min prior electrophoresis
0.41806388.11304544.html.plaintext.txt	150	Blank reactions containing enzyme run parallel helicase reactions resulting blank value typically 2 3 boiled sample subtracted enzyme reactions
0.41806388.11304544.html.plaintext.txt	151	For detection SPA beads Amersham Pharmacia Biotech 45 microl helicase reaction mixed 20 microl stop solution 100 mM HEPES pH 7
0.41806388.11304544.html.plaintext.txt	152	5 300 mM NaCl 20 mM EDTA 1 SDS containing biotinylated oligonucleotide complementary substrate oligonucleotide 20 nM
0.41806388.11304544.html.plaintext.txt	153	After 30 min 20 microl streptavidin SPA beads suspended 3
0.41806388.11304544.html.plaintext.txt	154	After brief mixing 30 min incubation plates centrifuged 1300 x g 5 min counted using TopCount NXT Packard Instruments
0.41806388.11304544.html.plaintext.txt	155	SPA detected reactions quantified way using boiled reaction mixture 100 reference subtracting value reaction blanks
0.41806388.11304544.html.plaintext.txt	156	ATPase Assays Purified Proteins Reactions performed using buffer used helicase reactions either Dynex Microfluor 2 plates Packard Optiplates
0.41806388.11304544.html.plaintext.txt	157	Unless stated otherwise reactions typically performed using 0
0.41806388.11304544.html.plaintext.txt	158	0 mM MgOAc 1 microM ATP 0
0.41806388.11304544.html.plaintext.txt	159	Reactions higher ATP concentrations carried 37 degrees C phosphate product quantified using ammonium molybdatemalachite green colorimetric assay 59
0.41806388.11304544.html.plaintext.txt	160	The procedure used assays seven nucleotide triphosphates manganese magnesium chloride
0.41806388.11304544.html.plaintext.txt	161	We found practical limit sensitivity method 25 microM phosphate product
0.41806388.11304544.html.plaintext.txt	162	Reactions low ATP concentrations supplemented 33PATP Amersham Pharmacia Biotech PerkinElmer Life Sciences least 1 nCi45 microl reaction unless stated otherwise carried room temperature
0.41806388.11304544.html.plaintext.txt	163	For reactions run determine value KmATP ATP radiolabeled ATP maintained constant ratio magnesium concentration adjusted give constant excess usually 500 microM since ATP magnesium complex true substrate reaction Kd ATP chelation magnesium 50 microM 60
0.41806388.11304544.html.plaintext.txt	164	Radiolabeled phosphate product detected either thin layer chromatography binding phosphate molybdate complex streptavidin SPA beads
0.41806388.11304544.html.plaintext.txt	165	For TLC detection reactions stopped addition one half volume cold EDTA 500 mM 1 microl aliquots spotted onto polyethyleneimine cellulose TLC plates Sigma
0.41806388.11304544.html.plaintext.txt	166	Spots allowed dry samples eluted running buffer 1 M formic acid plus 1 M LiCl
0.41806388.11304544.html.plaintext.txt	167	Plates dried exposed storage phosphor screen resulting signal quantified using STORM 860 imaging system Molecular Dynamics
0.41806388.11304544.html.plaintext.txt	168	Blank reactions containing E1 run parallel background signal typically 3 5 subtracted
0.41806388.11304544.html.plaintext.txt	169	The TLC procedure used reactions using 33PGTP UTP dATP since nucleoside diphosphates found Rf values similar orthophosphate
0.41806388.11304544.html.plaintext.txt	170	The SPA based detection procedure described detail elsewhere3 briefly involves quenching reactions mixture polyvinyl toluene SPA beads ammonium molybdate HCl
0.41806388.11304544.html.plaintext.txt	171	The resulting phosphomolybdate complex binds SPA beads hydrophobic forces binding enhanced subsequent addition cesium chloride citric acid
0.41806388.11304544.html.plaintext.txt	172	Signals detected scintillation counting using TopCount NXT Packard Instruments values enzyme blank reactions run parallel typically 2 4 subtracted
0.41806388.11304544.html.plaintext.txt	173	To correlate detected signal absolute amount phosphate product produced time point assay reactions detected TLC SPA procedures
0.41806388.11304544.html.plaintext.txt	174	Plots cpm SPA versus nM phosphate TLC linear least 100 microM phosphate slope line used conversion factor reactions assay
0.41806388.11304544.html.plaintext.txt	175	Data Analysis IC50 inhibition curves fit logistic using SAS kinetic data analyzed using appropriate equations program GraFit 3
0.41806388.11304544.html.plaintext.txt	176	For kinetic experiments reaction aliquots taken triplicate multiple time points 20 120 min
0.41806388.11304544.html.plaintext.txt	177	Observed rates calculated using data 20 conversion lower maintain initial rate conditions
0.41806388.11304544.html.plaintext.txt	178	ATPase Assay Using Vitro Translated E1 Truncated E1 proteins synthesized labeled vitro 35Smethionine coupled transcriptiontranslation using TNT reticulocyte lysate system Promega described previously 19
0.41806388.11304544.html.plaintext.txt	179	150 microl transcriptiontranslation reactions programmed deletion constructs E1 open reading frame cloned plasmid pTM1 described previously 19 20
0.41806388.11304544.html.plaintext.txt	180	In vitro synthesized E1 proteins immunoprecipitated using either K72 polyclonal antibody indicated anti FLAG M2 monoclonal antibody Sigma coupled protein A protein G Sepharose beads Amersham Pharmacia Biotech respectively
0.41806388.11304544.html.plaintext.txt	181	Immunoprecipitations carried 90 min binding buffer 20 mM Tris HCl pH 7
0.41806388.11304544.html.plaintext.txt	182	6 100 mM NaCl 3 mM MgCl2 1 mM EDTA 1 mM DTT
0.41806388.11304544.html.plaintext.txt	183	The immunoprecipitated proteins bound beads washed three times 1 ml ATPase wash buffer 50 mM HEPES pH 7
0.41806388.11304544.html.plaintext.txt	184	1 Triton X 100 1 mM DTT followed two times 1 ml ATPase buffer 50 mM HEPES pH 7
0.41806388.11304544.html.plaintext.txt	185	ATPase reactions performed resuspending bead bound E1 immunocomplexes 30 microl ATPase buffer supplemented 1 mM ATP followed incubation 37 degrees C 2 h
0.41806388.11304544.html.plaintext.txt	186	Inorganic phosphate generated reaction quantified using ammonium molybdatemalachite green colorimetric microassay 59
0.41806388.11304544.html.plaintext.txt	187	ATPase activities background levels normalized amount 35S labeled E1 protein present immunoprecipitate determined SDS PAGE analysis autoradiography
0.41806388.11304544.html.plaintext.txt	188	Quantification 35S labeled E1 performed STORM 860 imaging system Molecular Dynamics correction number methionine residues present E1 truncation
0.41806388.11304544.html.plaintext.txt	189	DNA binding Assay 75 microl binding reactions performed triplicate 96 well plates Dynex indicated concentrations purified HPV11 E1 protein either E1 353 649 E1 72 649 binding buffer 20 mM Tris pH 7
0.41806388.11304544.html.plaintext.txt	190	6 100 mM NaCl 5 mM ATP 3 mM MgCl2 1 mM EDTA 1 mM DTT 0
0.41806388.11304544.html.plaintext.txt	191	Binding reactions started adding mixture probe competitor DNA
0.41806388.11304544.html.plaintext.txt	192	The probe consisted either 1
0.41806388.11304544.html.plaintext.txt	193	25 ng 63 mer oligonucleotide end labeled phosphorylation 33PATP ssDNA probe 370 base pair 33P labeled PCR fragment dsDNA probe identical probe used E2 dependent E1 DNA binding assay described
0.41806388.11304544.html.plaintext.txt	194	Binding reactions performed 23 degrees C 1 h
0.41806388.11304544.html.plaintext.txt	195	E1 DNA complexes immunoprecipitated using anti E1 K72 polyclonal antibody coupled protein A Sepharose beads washed three times 200 microl binding buffer filtered 96 well 0
0.41806388.11304544.html.plaintext.txt	196	45 microm Durapore membrane filter plate Millipore
0.41806388.11304544.html.plaintext.txt	197	The amount radiolabeled DNA probe present retained E1 DNA complexes quantified TopCount NXT Packard Instruments
0.41806388.11304544.html.plaintext.txt	198	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.41806388.11304544.html.plaintext.txt	199	Expression Purification HPV11 HPV6 E1 We initially attempted purify E1 overexpression E
0.41806388.11304544.html.plaintext.txt	200	However consistently found HPV E1 expressed bacteria largely insoluble soluble protein partially degraded
0.41806388.11304544.html.plaintext.txt	201	Preparations E1 proteins amino acid substitutions essential Lys484 Walker A phosphate binding motif retained helicase ATPase activities demonstrating bacterially produced E1 copurified contaminating helicases ATPases data shown
0.41806388.11304544.html.plaintext.txt	202	As result experiences decided express HPV E1 insect cells using baculovirus expression system
0.41806388.11304544.html.plaintext.txt	203	Recombinant baculoviruses constructed express full length HPV11 HPV6 E1 well slightly shorter version HPV11 E1 encompassing amino acids 72 649
0.41806388.11304544.html.plaintext.txt	204	A similar truncation HPV33 E1 reported expressed higher levels full length protein E
0.41806388.11304544.html.plaintext.txt	205	Furthermore shown previously truncated E1 made vitro translation retains ability support cell free DNA replication 25
0.41806388.11304544.html.plaintext.txt	206	These three E1 proteins expressed fusions N terminal 6 histidine tag facilitate rapid purification metal affinity chromatography hence minimize losses activity course procedure
0.41806388.11304544.html.plaintext.txt	207	Finally order rule possibility enzymatic activities associated E1 preparations due contaminating proteins also expressed several catalytically inactive HPV11 E1 proteins containing single amino acid substitutions lysine 484
0.41806388.11304544.html.plaintext.txt	208	We showed previously using vitro translated proteins HPV11 E1 Lys484 substituted alanine histidine isoleucine arginine retains ability form specific complex E2 HPV origin 19
0.41806388.11304544.html.plaintext.txt	209	These substitutions made context full length HPV11 E1 protein alanine arginine changes also made E1 72 649
0.41806388.11304544.html.plaintext.txt	210	In agreement previous work found expression baculovirus infected SF21 cells E1 accumulated nuclei small proportion cytosolic fraction
0.41806388.11304544.html.plaintext.txt	211	E1 extracted nuclei buffer containing 500 mM NaCl experiments found full length HPV6 HPV11 E1 could extracted nuclei using buffer added salt
0.41806388.11304544.html.plaintext.txt	212	This unusual low salt extraction efficient standard high salt procedure extracting soluble wild type E1 advantage significantly fewer contaminating proteins present low salt extracts final product obtained chromatography pure data shown
0.41806388.11304544.html.plaintext.txt	213	Due higher expression level obtained E1 72 649 pure E1 could isolated relatively good yield high salt extraction
0.41806388.11304544.html.plaintext.txt	214	Following extraction three E1 proteins purified single nickel affinity chromatography step
0.41806388.11304544.html.plaintext.txt	215	The E1 isolated procedure 80 pure estimated SDS PAGE Fig
0.41806388.11304544.html.plaintext.txt	216	We routinely obtained 200 microg full length E1 800 microg E1 72 649 per liter insect cell culture
0.41806388.11304544.html.plaintext.txt	217	View larger version 51K Fig
0.41806388.11304544.html.plaintext.txt	218	Elution profiles HPV11 E1 proteins nickel chelating columns activity purified WT mutant proteins
0.41806388.11304544.html.plaintext.txt	219	A full length E1 protein eluted buffer containing imidazole collected 1 ml fractions
0.41806388.11304544.html.plaintext.txt	220	4 indicated column fractions analyzed 10 SDS PAGE along aliquots corresponding 0
0.41806388.11304544.html.plaintext.txt	221	0025 input nuclear extract 0
0.41806388.11304544.html.plaintext.txt	222	0025 flow fraction 0
0.41806388.11304544.html.plaintext.txt	223	The gel stained Coomassie Blue
0.41806388.11304544.html.plaintext.txt	224	Sizes molecular weight markers MWM indicated left gel
0.41806388.11304544.html.plaintext.txt	225	B composite SDS PAGE showing fraction 7 purification indicated mutant E1 proteins
0.41806388.11304544.html.plaintext.txt	226	The sample HPV6 E1 taken pooled peak fractions multiple purifications
0.41806388.11304544.html.plaintext.txt	227	C SDS PAGE analysis E1 72 649 elution profile
0.41806388.11304544.html.plaintext.txt	228	4 indicated column fractions analyzed along 0
0.41806388.11304544.html.plaintext.txt	229	003 input nuclear extract 0
0.41806388.11304544.html.plaintext.txt	230	003 flow fraction 0
0.41806388.11304544.html.plaintext.txt	231	D composite SDS PAGE showing peak fraction eluted indicated mutant E1 72 649 proteins
0.41806388.11304544.html.plaintext.txt	232	E purified wild type Lys484 mutant E1 proteins 200 ng able form complex E2 10 ng origin shown binding assay complex E1 E2 33P labeled origin fragment detected binding anti E1 antibody bound protein A SPA beads black
0.41806388.11304544.html.plaintext.txt	233	Results proteins helicase dark grayATPase light gray assays show mutant preparations lack enzymatic activity
0.41806388.11304544.html.plaintext.txt	234	Enzymatic assays run 37 degrees C using E1 270 nM buffer containing 25 mM MES 0
0.41806388.11304544.html.plaintext.txt	235	1 mM EDTA 10 glycerol pH 7
0.41806388.11304544.html.plaintext.txt	236	0 1 mM ATP 2 mM MgCl2 0
0.41806388.11304544.html.plaintext.txt	237	1 nM helicase substrate nontailed substrate Fig
0.41806388.11304544.html.plaintext.txt	238	After 2 h separate samples used analysis helicase ATPase activities using SPA colorimetric procedures described Experimental Procedures
0.41806388.11304544.html.plaintext.txt	239	In reaction WT E1 36 substrate unwound 20 ATP hydrolyzed
0.41806388.11304544.html.plaintext.txt	240	The purified HPV11 E1 mutant proteins active WT E1 binding cooperatively E2 origin indicating folded properly
0.41806388.11304544.html.plaintext.txt	241	However detectable helicase ATPase activity Fig
0.41806388.11304544.html.plaintext.txt	242	Collectively results demonstrate E1 responsible activity detected WT E1 preparations
0.41806388.11304544.html.plaintext.txt	243	Similar results obtained mutant HPV11 E1 72 649 proteins data shown
0.41806388.11304544.html.plaintext.txt	244	HPV6 E1 preparations validated way given complete lack activity HPV11 mutant proteins purified procedure similarity HPV6 E1 HPV11 E1 terms sequence behavior purification enzymatic properties reported unlikely contaminating proteins responsible activity HPV6 preparations
0.41806388.11304544.html.plaintext.txt	245	It reported HPV11 E1 preparations obtained nuclear extracts contain significant concentrations contaminating DNA 42
0.41806388.11304544.html.plaintext.txt	246	We used sensitive assay fluorescent intercalating dye PicoGreen 51 determine purified E1 contains trace amounts DNA 1 ng microg protein data shown
0.41806388.11304544.html.plaintext.txt	247	Quaternary Structure Purified HPV11 E1 72 649 HPV11 E1 expressed insect cells Glu Glu epitope tag native form purified immunoaffinity shown previously consist mixture oligomers monomers hexamers predominating depending E1 concentration 14
0.41806388.11304544.html.plaintext.txt	248	Similar results reported BPV E1 expressed insect cells 15 although studies BPV E1 also purified essentially monomeric form insect cells 44 expressed bacteria 11 15
0.41806388.11304544.html.plaintext.txt	249	Preliminary investigations oligomeric state preparations polyhistidine tagged HPV11 E1 analytical size exclusion chromatography suggested full length protein mixture hexamers much larger species whereas E1 72 649 existed solution predominately hexamers
0.41806388.11304544.html.plaintext.txt	250	Further biophysical characterization therefore focused homogenous E1 72 649
0.41806388.11304544.html.plaintext.txt	251	We previously shown chemical cross linking experiments HPV11 E1 produced vitro translation exists solution predominately monomers form hexamers upon addition single stranded DNA 20
0.41806388.11304544.html.plaintext.txt	252	Similar cross linking experiments performed purified HPV11 E1 72 649 revealed exists predominately entirely hexamer solution concentration range 0
0.41806388.11304544.html.plaintext.txt	253	5 microM even absence ssDNA Fig
0.41806388.11304544.html.plaintext.txt	254	These experiments carried buffer containing 500 mM NaCl since high salt concentrations found reduce tendency E1 aggregate high concentration
0.41806388.11304544.html.plaintext.txt	255	View larger version 23K Fig
0.41806388.11304544.html.plaintext.txt	256	Chemical cross linking sedimentation velocity analysis demonstrate purified HPV11 E1 72 649 isolated hexamer
0.41806388.11304544.html.plaintext.txt	257	A HPV11 E1 72 649 samples ranging concentration 20 nM 2
0.41806388.11304544.html.plaintext.txt	258	5 microM cross linked using bismaleimidohexane BMH
0.41806388.11304544.html.plaintext.txt	259	Denatured samples equal final concentration analyzed 3 Weber Osborn gel 52 followed silver staining
0.41806388.11304544.html.plaintext.txt	260	At concentrations E1 existed predominantly hexamer
0.41806388.11304544.html.plaintext.txt	261	At higher E1 concentrations faint bands visible correspond dimers trimers tetramers pentamers possibly due incomplete cross linking
0.41806388.11304544.html.plaintext.txt	262	B sedimentation velocity results HPV11 E1 72 649
0.41806388.11304544.html.plaintext.txt	263	Shown graph versus dcdt showing transformed data points theoretical best fit
0.41806388.11304544.html.plaintext.txt	264	Data obtained 230 nm 11 degrees C using Beckman XL A analytical ultracentrifuge
0.41806388.11304544.html.plaintext.txt	265	The dcdt data analyzed using DCDT 54 55 fit well model assuming single species sedimentation coefficient 4
0.41806388.11304544.html.plaintext.txt	266	5 S diffusion coefficient 1
0.41806388.11304544.html.plaintext.txt	267	04 Ficks estimated mass 355000 Da
0.41806388.11304544.html.plaintext.txt	268	The rms residual fit 7
0.41806388.11304544.html.plaintext.txt	269	The loading concentration 40 microgml 600 nM 0
0.41806388.11304544.html.plaintext.txt	270	Sedimentation velocity analytical ultracentrifugation also performed assess oligomeric state purified HPV E1 72 649 Fig
0.41806388.11304544.html.plaintext.txt	271	Data well fit model assuming single thermodynamic species estimated molecular mass 355000
0.41806388.11304544.html.plaintext.txt	272	This close value expected hexamer 399000 kDa cannot rule possibility low concentration E1 monomers lower order species also present equilibrium hexamer
0.41806388.11304544.html.plaintext.txt	273	Hence results cross linking sedimentation experiments demonstrate purified E1 72 649 predominantly hexameric
0.41806388.11304544.html.plaintext.txt	274	Helicase ATPase Activities Purified E1 Proteins Characterization helicase activity purified E1 proteins performed DNA substrates made short 33P radiolabeled oligonucleotides annealed bacteriophage M13 single stranded DNA
0.41806388.11304544.html.plaintext.txt	275	Similar reaction conditions reports found activity optimal pH 7
0.41806388.11304544.html.plaintext.txt	276	Low concentrations bovine serum albumin found stimulate activity data shown used experiments reported
0.41806388.11304544.html.plaintext.txt	277	As illustrated HPV11 E1 200 microM ATP Mg sufficient maximal unwinding
0.41806388.11304544.html.plaintext.txt	278	The addition excess magnesium significant effect activity except possibly low levels ATP Fig
0.41806388.11304544.html.plaintext.txt	279	At low ATP concentrations also found significant proportion ATP consumed 90 min incubation data shown
0.41806388.11304544.html.plaintext.txt	280	The linearity unwinding ATPase activities time 90 min helicase 120 min ATPase illustrated Fig
0.41806388.11304544.html.plaintext.txt	281	At concentrations used Fig
0.41806388.11304544.html.plaintext.txt	282	4 HPV6 11 E1 similar helicase activity E1 72 649 tested lower concentration approximately 5 fold greater specific activity see also Fig
0.41806388.11304544.html.plaintext.txt	283	In contrast HPV11 proteins similar ATPase activities HPV6 E1 less active
0.41806388.11304544.html.plaintext.txt	284	View larger version 18K Fig
0.41806388.11304544.html.plaintext.txt	285	Basic characterization HPV E1 enzymatic activity
0.41806388.11304544.html.plaintext.txt	286	Except noted assays used 300 microM ATP 1 mM MgOAc 0
0.41806388.11304544.html.plaintext.txt	287	05 nM Klenow labeled partial duplex helicase substrate described Experimental Procedures
0.41806388.11304544.html.plaintext.txt	288	Reactions run 90 min 37 degrees C HEPES buffer 20 mM pH 7
0.41806388.11304544.html.plaintext.txt	289	Reaction products detected gel electrophoresis helicase colorimetric assay using malachite green ammonium molybdate ATPase see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	290	A helicase activity HPV11 E1 25 nM presence increasing concentrations ATP Mg 0 0
0.41806388.11304544.html.plaintext.txt	291	0 mM excess MgOAc ATP concentration
0.41806388.11304544.html.plaintext.txt	292	B C time course helicase B ATPase C activities HPV6 E1 30 nM HPV11 E1 25 nM HPV11 E1 72 649 10 nM
0.41806388.11304544.html.plaintext.txt	293	At time two aliquots removed reaction mixture measure helicase ATPase activity
0.41806388.11304544.html.plaintext.txt	294	D effect M13 ssDNA helicase ATPase activity
0.41806388.11304544.html.plaintext.txt	295	Shown data HPV11 E1 helicase ATPase E1 72 649 helicase ATPase
0.41806388.11304544.html.plaintext.txt	296	E1 concentrations A
0.41806388.11304544.html.plaintext.txt	297	We found M13 DNA could inhibit HPV11 helicase activity IC50 2 microgml 7 microM nucleotides Fig
0.41806388.11304544.html.plaintext.txt	298	Interestingly however little inhibition observed M13 DNA added shortly mixing E1 substrate data shown demonstrating binding hexameric E1 circular single stranded DNA rapid dissociation slow
0.41806388.11304544.html.plaintext.txt	299	Furthermore M13 found much potent inhibitor E1 72 649 wild type E1 IC50 0
0.41806388.11304544.html.plaintext.txt	300	2 microgml suggesting truncated form enzyme may bind tightly ssDNA
0.41806388.11304544.html.plaintext.txt	301	We also examined DNA substrate specificity purified E1
0.41806388.11304544.html.plaintext.txt	302	As shown previously BPV E1 44 helicases 62 63 unwinding often efficiently initiated tailed substrates possess DNA fork formed junction dsDNA noncomplementary single strands
0.41806388.11304544.html.plaintext.txt	303	To test case HPV E1 unwinding reactions performed three substrates shown Fig
0.41806388.11304544.html.plaintext.txt	304	HPV11 E1 HPV6 E1 HPV11 E1 72 649 show significant preference forked versus nonforked substrates
0.41806388.11304544.html.plaintext.txt	305	View larger version 33K Fig
0.41806388.11304544.html.plaintext.txt	306	Unwinding HPV6 11 E1 stimulated using forked substrate
0.41806388.11304544.html.plaintext.txt	307	E1 helicase reactions run using three substrates different radiolabeled oligonucleotides annealed region M13 containing either tail 21 nucleotide 3 tail 18 nucleotide 5 tail
0.41806388.11304544.html.plaintext.txt	308	For composite gel lanes shown boiled substrate reaction blank followed reactions HPV6 E1 HPV11 E1 HPV11 E1 72 649
0.41806388.11304544.html.plaintext.txt	309	Unwinding percentages shown values obtained relative boiled substrate subtraction blank value
0.41806388.11304544.html.plaintext.txt	310	Reaction conditions described Fig
0.41806388.11304544.html.plaintext.txt	311	4A except ATP concentration 1 mM
0.41806388.11304544.html.plaintext.txt	312	Although expect ATP Mg complex natural substrate E1 nucleotide hydrolysis helicase activities could observed WT HPV11 E1 using eight natural nucleoside triphosphates Table I
0.41806388.11304544.html.plaintext.txt	313	CTP dCTP poorest substrates tested still hydrolyzed 20 30 rate ATP
0.41806388.11304544.html.plaintext.txt	314	Manganese could substituted magnesium approximately 50 loss activity
0.41806388.11304544.html.plaintext.txt	315	View table Table I HPV E1 helicase NTPase activity eight natural NTPs Reactions run using 1 mM MgOAc 0
0.41806388.11304544.html.plaintext.txt	316	3 mM nucleoside triphosphate except two conditions using 1 mM MgCl2 MnCl2 0
0.41806388.11304544.html.plaintext.txt	317	The HPV11 E1 concentration 25 nM helicase reactions 50 nM NTPase reactions
0.41806388.11304544.html.plaintext.txt	318	Products detected gel electrophoresis helicase colorimetric assay NTPase see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	319	Values reported percentage activity relative ATP MgOAc averaged 48 DNA substrate unwound 140 microM ATP hydrolyzed averages three experiments plus minus S
0.41806388.11304544.html.plaintext.txt	320	4B helicase activity slightly affected decreasing concentration ATP 1 0
0.41806388.11304544.html.plaintext.txt	321	This suggested value KmATP might significantly lower 100 microM contrast much higher values reported previously 41 42 45 49
0.41806388.11304544.html.plaintext.txt	322	The colorimetric assay used initially characterize ATPase activity HPV6 11 E1 sensitive enough measure ATP hydrolysis low micromolar concentrations ATP turned sensitive assays using radiolabeled ATP
0.41806388.11304544.html.plaintext.txt	323	Two different formats assay used
0.41806388.11304544.html.plaintext.txt	324	In one released radiolabeled phosphate detected thin layer chromatography complexed ammonium molybdate selectively bound scintillation proximity beads see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	325	These two assays gave equivalent results found bead procedure suitable kinetic time courses require large number data points
0.41806388.11304544.html.plaintext.txt	326	We determined values KmATP 6 12 microM HPV11 HPV6 E1 respectively Table II
0.41806388.11304544.html.plaintext.txt	327	HPV6 E1 consistently higher values Km lower values kcat
0.41806388.11304544.html.plaintext.txt	328	Similar values obtained HPV11 E1 72 649
0.41806388.11304544.html.plaintext.txt	329	We obtained similar values alternate nucleoside triphosphate substrates GTP UTP dATP also found higher levels free magnesium affect kinetic parameters data shown
0.41806388.11304544.html.plaintext.txt	330	Plots observed rate versus substrate concentration hyperbolic suggesting individual active sites E1 hexamer hydrolyze ATP independently see Fig
0.41806388.11304544.html.plaintext.txt	331	View table Table II Kinetic parameters E1 ATPase activity
0.41806388.11304544.html.plaintext.txt	332	View larger version 22K Fig
0.41806388.11304544.html.plaintext.txt	333	Binding E2 inhibits E1 ATPase activity productive binding ATP perturbs interaction E1 E2
0.41806388.11304544.html.plaintext.txt	334	A ATPase reactions 1 nM HPV11 E1 presence proteins
0.41806388.11304544.html.plaintext.txt	335	Each protein used 1 nM black 10 nM dark gray 100 nM light gray 1000 nM white
0.41806388.11304544.html.plaintext.txt	336	All values shown relative activity absence added protein 23 plus minus 2 hydrolysis
0.41806388.11304544.html.plaintext.txt	337	Reactions run 120 min 23 degrees C using 1 microM ATP 500 microM magnesium acetate
0.41806388.11304544.html.plaintext.txt	338	B plots observed rate versus ATP concentration HPV11 E1 absence presence 1 microM GST TAD
0.41806388.11304544.html.plaintext.txt	339	Reactions carried using 2 nM HPV11 E1 indicated concentration ATP sufficient magnesium acetate give constant excess 500 microM
0.41806388.11304544.html.plaintext.txt	340	Observed rates determined time course described Data Analysis Experimental Procedures
0.41806388.11304544.html.plaintext.txt	341	Lines represent best fits Michaelis Menten equation data set KmATP 5
0.41806388.11304544.html.plaintext.txt	342	9 microM 49 plus minus 9 microM presence GST TAD parameters given Table II averages multiple experiments
0.41806388.11304544.html.plaintext.txt	343	C E2 dependent E1 DNA binding
0.41806388.11304544.html.plaintext.txt	344	Observed complex formation shown cpm HPV11 E2 2 nM different E1 proteins 2 nM presence 0 mM black 0
0.41806388.11304544.html.plaintext.txt	345	3 mM dark gray 3 mM light gray ATP MgOAc
0.41806388.11304544.html.plaintext.txt	346	The ATP analog ATPS inhibited ATPase activity HPV11 E1 IC50 6 microM 1 microM ATP consistent value KmATP shown Table II
0.41806388.11304544.html.plaintext.txt	347	As anticipated ATPS much weaker inhibitor ATPase helicase activity 300 microM ATP IC50 120 microM data shown consistent binding competition ATP
0.41806388.11304544.html.plaintext.txt	348	In experiments using 1 microM ATP found ADP inhibited HPV 11 E1 ATPase activity IC50 40 microM whereas inhibition observed 600 microM AMP data shown
0.41806388.11304544.html.plaintext.txt	349	For many helicases ATPase activity stimulated severalfold ssDNA 62 63 BPV E1 shown stimulation correlates ability ssDNA stimulate E1 oligomerization 46
0.41806388.11304544.html.plaintext.txt	350	The experiments described done absence ssDNA
0.41806388.11304544.html.plaintext.txt	351	The addition M13 ssDNA HPV11 E1 E1 72 649 ATPase reactions containing 0
0.41806388.11304544.html.plaintext.txt	352	3 mM ATP modest effect activity Fig
0.41806388.11304544.html.plaintext.txt	353	Effect E2 Transactivation Domain ATPase Activity The finding others ATP hydrolysis somehow promotes dissociation BPV E1 E2 origin 17 prompted us examine whether complex formation HPV E1 E2 would turn affect E1 ATPase activity
0.41806388.11304544.html.plaintext.txt	354	To GST fusion HPV11 E2 transactivation domain GST TAD amino acids 1 209 portion protein binds E1 19 64 66 purified expression E
0.41806388.11304544.html.plaintext.txt	355	Titration GST TAD ATPase assays using HPV11 E1 1 microM ATP resulted inhibition nanomolar concentrations Fig
0.41806388.11304544.html.plaintext.txt	356	Inhibition much weaker reactions using 5 20 microM ATP GST TAD effect helicase assays performed 300 microM ATP data shown
0.41806388.11304544.html.plaintext.txt	357	Several control experiments performed verify specificity inhibition
0.41806388.11304544.html.plaintext.txt	358	GST effect ATPase activity
0.41806388.11304544.html.plaintext.txt	359	Most importantly GST TAD protein containing amino acid substitution E39A known weaken E1 E2 binding transactivation 67 68 affect ATP hydrolysis
0.41806388.11304544.html.plaintext.txt	360	As expected full length E2 protein also inhibited ATPase activity
0.41806388.11304544.html.plaintext.txt	361	In case however observe complete inhibition ATPase activity
0.41806388.11304544.html.plaintext.txt	362	This lack complete inhibition ATP concentration dependence observed TAD inhibition suggested TAD E1 complex might still possess ATPase activity altered kinetic parameters
0.41806388.11304544.html.plaintext.txt	363	In fact determined apparent value KmATP presence saturating 1 microM HPV11 GST TAD 7 fold higher value obtained absence GST TAD apparent value kcat altered Fig
0.41806388.11304544.html.plaintext.txt	364	Since ATP binds weakly E1 E2 TAD complex expected ATP Mg would turn weaken interaction E1 E2 affect cooperative binding origin vitro
0.41806388.11304544.html.plaintext.txt	365	We fact found true Fig
0.41806388.11304544.html.plaintext.txt	366	6C HPV11 E1 HPV11 E1 72 649
0.41806388.11304544.html.plaintext.txt	367	Inhibition ATP Mg detected low concentrations E1 E2 higher saturating concentrations little effect observed data shown
0.41806388.11304544.html.plaintext.txt	368	Interestingly ATP Mg effect interaction two catalytically inactive mutants E1 72 649 Fig
0.41806388.11304544.html.plaintext.txt	369	6C confirming observed effects due productive binding substrate
0.41806388.11304544.html.plaintext.txt	370	We observed similar results using ATPS data shown also affected binding full length E1 E1 72 649 much greater degree two inactive mutants
0.41806388.11304544.html.plaintext.txt	371	Identification Mutational Analysis Minimal ATPase Domain As part characterization ATPase activity E1 wished identify smallest domain protein retains ATPase activity
0.41806388.11304544.html.plaintext.txt	372	To achieve made use fact ATPase activity vitro translated E1 protein assayed qualitatively following immunoprecipitation protein rabbit reticulocyte lysate see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	373	By performing assay series truncated HPV11 E1 proteins determined C terminal half E1 comprising amino acids 353 649 necessary sufficient ATPase activity Fig
0.41806388.11304544.html.plaintext.txt	374	View larger version 19K Fig
0.41806388.11304544.html.plaintext.txt	375	ATPase activity truncated E1 proteins made vitro translation
0.41806388.11304544.html.plaintext.txt	376	A left side panel shows diagram various N terminally truncated HPV11 E1 proteins synthesized 35S labeled coupled vitro transcriptiontranslation
0.41806388.11304544.html.plaintext.txt	377	Proteins immunoprecipitated polyclonal antibody directed C terminal 14 amino acids E1
0.41806388.11304544.html.plaintext.txt	378	An autoradiogram SDS polyacrylamide gels used quantify amount immunoprecipitated E1 protein shown right
0.41806388.11304544.html.plaintext.txt	379	For protein amount ATPase activity normalized amount radiolabeled protein contained E1 immunoprecipitate see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	380	The relative ATPase activity percent truncated protein indicated relative E1 1 649 set arbitrarily 100
0.41806388.11304544.html.plaintext.txt	381	B A using C terminally truncated E1 proteins containing FLAG epitope indicated hatched box
0.41806388.11304544.html.plaintext.txt	382	Proteins immunoprecipitated anti FLAG monoclonal antibody
0.41806388.11304544.html.plaintext.txt	383	ATPase activity normalized relative amount immunoprecipitated protein A indicated relative FLAG tagged E1 72 649 set arbitrarily 100
0.41806388.11304544.html.plaintext.txt	384	As mentioned Introduction portion protein encompasses four highly conserved regions termed A B C D shared E1 large T antigens SV40 polyomaviruses Fig
0.41806388.11304544.html.plaintext.txt	385	To confirm importance regions ATPase activity mutant HPV11 E1 72 649 proteins containing amino acid substitutions highly conserved residues region A D three conserved NTP binding motifs synthesized vitro tested ATPase activity Table III
0.41806388.11304544.html.plaintext.txt	386	Amino acid substitutions NTP binding domain lysine 484 motif P loop two aspartate residues positions 522 523 motif b dramatically affected ATPase activity anticipated
0.41806388.11304544.html.plaintext.txt	387	Another substitution P loop P479S also reduced completely abolish ATPase activity contrast observed E1 BPV1 41 HPV6b 49 agreement previous report full length HPV11 E1 42
0.41806388.11304544.html.plaintext.txt	388	This result also consistent earlier observation P479S substitution completely abolish ability HPV11 E1 support transient HPV DNA replication vivo 19
0.41806388.11304544.html.plaintext.txt	389	Substitutions T566A N568A motif c also reduced ATPase activity
0.41806388.11304544.html.plaintext.txt	390	Although exact function motif c yet clear results support importance ATPase activity
0.41806388.11304544.html.plaintext.txt	391	Altogether results confirm importance motifs b c ATPase activity
0.41806388.11304544.html.plaintext.txt	392	View table Table III Effect amino acid substitutions HPV11 E1 72 649 ATPase activity ATPase activity measured described Experimental Procedures legend Fig
0.41806388.11304544.html.plaintext.txt	393	Activity E1 72 649 set arbitrarily 100
0.41806388.11304544.html.plaintext.txt	394	The amino acid sequence region motif indicated substituted amino acids boldface type
0.41806388.11304544.html.plaintext.txt	395	The ATPase activity E1 also proved affected amino acid substitutions conserved region A minimal E1 oligomerization region
0.41806388.11304544.html.plaintext.txt	396	Three substitutions Y380A N389A F393A severely hampered activity two others A390G Q399A reduced activity slightly
0.41806388.11304544.html.plaintext.txt	397	Only F378A mutant protein activity comparable wild type E1
0.41806388.11304544.html.plaintext.txt	398	These substitutions NTP binding motifs shown slight effect interaction E1 E2 19 20 also affect interaction p70 subunit polymerase primase4 indicating deleterious effect ATPase activity related dramatic change structure E1
0.41806388.11304544.html.plaintext.txt	399	Hence results support notion region A needed ATPase activity
0.41806388.11304544.html.plaintext.txt	400	Similarly fact one two region D substitutions N609A negative effect ATPase activity consistent role region ATP binding andor hydrolysis either directly indirectly
0.41806388.11304544.html.plaintext.txt	401	Enzymatic Activities Purified E1 Minimal ATPase Domain To characterize enzymatic activities minimal E1 ATPase domain expressed insect cells polyhistidine fusion protein using baculovirus expression system
0.41806388.11304544.html.plaintext.txt	402	For validation purposes two catalytically inactive mutant derivatives K484A K484R also expressed parallel
0.41806388.11304544.html.plaintext.txt	403	All three proteins purified near homogeneity Fig
0.41806388.11304544.html.plaintext.txt	404	8A nickel affinity chromatography see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	405	The purified wild type E1 353 649 found active ATPase assays activity comparable full length E1 Table II
0.41806388.11304544.html.plaintext.txt	406	As expected mutant derivatives inactive confirming ATPase activity observed wild type E1 subdomain due contaminating polypeptides
0.41806388.11304544.html.plaintext.txt	407	View larger version 24K Fig
0.41806388.11304544.html.plaintext.txt	408	Helicase DNA binding activities purified E1 353 649
0.41806388.11304544.html.plaintext.txt	409	A purified E1 353 649 analogous mutant proteins bearing amino acid substitutions K484A K484R analyzed along purified E1 72 649 10 SDS polyacrylamide gel stained Coomassie Blue
0.41806388.11304544.html.plaintext.txt	410	Sizes molecular weight markers MWM indicated right gel
0.41806388.11304544.html.plaintext.txt	411	B helicase activity full length HPV11 E1 x E1 72 649 E1 353 649 conditions described legend Fig
0.41806388.11304544.html.plaintext.txt	412	4 measured scintillation proximity assay described Experimental Procedures
0.41806388.11304544.html.plaintext.txt	413	The K484A K484R mutants detectable helicase activity conditions
0.41806388.11304544.html.plaintext.txt	414	C D complexes formed radiolabeled DNA increasing amounts purified E1 proteins E1 72 649 E1 353 649 E1 353 649 K484A E1 353 649 K484R
0.41806388.11304544.html.plaintext.txt	415	Complexes immunoprecipitated anti E1 antibody
0.41806388.11304544.html.plaintext.txt	416	C shows results 840 pM 1
0.41806388.11304544.html.plaintext.txt	417	25 ng single stranded 60 mer oligonucleotide D shows results 68
0.41806388.11304544.html.plaintext.txt	418	25 ng 370 base pair double stranded DNA probe containing minimal HPV11 origin DNA replication
0.41806388.11304544.html.plaintext.txt	419	Given C terminal domain E1 ATPase activity previously showed domain able assemble hexamers 20 wished determine sufficient helicase activity
0.41806388.11304544.html.plaintext.txt	420	The purified C terminal domain indeed able unwind M13 based substrates efficiency similar full length HPV11 E1 one half E1 72 649 Fig
0.41806388.11304544.html.plaintext.txt	421	Improved activity observed E1 353 649 relative full length E1 higher enzyme concentrations suggesting preparations protein contain lower levels residual nuclease activity
0.41806388.11304544.html.plaintext.txt	422	As anticipated two ATPase defective mutant proteins also inactive data shown
0.41806388.11304544.html.plaintext.txt	423	These results indicate two known enzymatic activities E1 helicase ATPase encoded within C terminal 297 amino acids
0.41806388.11304544.html.plaintext.txt	424	Binding Purified E1 Single stranded Double stranded DNA The finding E1 353 649 able unwind partial duplex DNA substrates suggested domain protein able bind single stranded DNA
0.41806388.11304544.html.plaintext.txt	425	This significance since ssDNA binding domain E1 mapped previously
0.41806388.11304544.html.plaintext.txt	426	To examine directly binding E1 353 649 DNA measured binding radiolabeled ssDNA dsDNA probes Fig
0.41806388.11304544.html.plaintext.txt	427	In parallel also examined DNA binding ability E1 72 649 two mutant forms E1 353 649
0.41806388.11304544.html.plaintext.txt	428	In assays E1 DNA complexes immunoprecipitated using anti E1 antibodies coupled beads amount co precipitated DNA detected scintillation counting see Experimental Procedures
0.41806388.11304544.html.plaintext.txt	429	All four purified proteins displayed similar ssDNA binding activity concentration range tested Fig
0.41806388.11304544.html.plaintext.txt	430	These results suggest ssDNA binding activity E1 indeed associated C terminal domain protein affected two amino acid substitutions P loop
0.41806388.11304544.html.plaintext.txt	431	The C terminal domain E1 also able bind dsDNA Fig
0.41806388.11304544.html.plaintext.txt	432	8D contrast observed ssDNA showed 75 reduction activity compared measured E1 72 649
0.41806388.11304544.html.plaintext.txt	433	Hence sequences located amino acids 72 353 contribute dsDNA binding anticipated fact also needed origin binding see Introduction
0.41806388.11304544.html.plaintext.txt	434	Collectively results suggest ssDNA binding domain E1 distinct origin binding domain
0.41806388.11304544.html.plaintext.txt	435	Since C terminal helicase domain E1 able bind ss dsDNA performed competition experiments determine binding E1 mutually exclusive
0.41806388.11304544.html.plaintext.txt	436	In assays 4 ng 8 nM unlabeled 20 mer oligonucleotide 30 ng 20 nM longer 60 mer oligonucleotide required inhibit binding E1 ssDNA probe 50 data shown
0.41806388.11304544.html.plaintext.txt	437	In contrast 1300 ng double stranded linearized plasmid DNA necessary achieve similar percentage inhibition suggesting E1 353 649 binds preferentially ssDNA dsDNA binds forms DNA mutually exclusive manner
0.41806388.11304544.html.plaintext.txt	438	Finally competition plasmid DNA regardless whether plasmid linearized cut 23 different fragments indicating weak binding E1 353 649 dsDNAs occur ends dsDNA molecules data shown
0.41806388.11304544.html.plaintext.txt	439	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.41806388.11304544.html.plaintext.txt	440	E1 plays key role replication human papillomavirus thus understanding activities protein important step search improved antiviral therapies
0.41806388.11304544.html.plaintext.txt	441	The expression purification conditions outlined report allowed us produce sufficient quantities full length truncated HPV E1 proteins study ATP hydrolysis nonspecific helicase activities detail
0.41806388.11304544.html.plaintext.txt	442	Unlike vitro translated HPV E1 proteins used previous studies protein expressed baculovirus infected insect cells isolated preformed hexamers rather monomers
0.41806388.11304544.html.plaintext.txt	443	These preformed HPV E1 hexamers could easily converted monomers vitro similar observed Rocque et al
0.41806388.11304544.html.plaintext.txt	444	42 preparations HPV11 E1 isolated cytosolic fraction baculovirus infected insect cells
0.41806388.11304544.html.plaintext.txt	445	As result unable compare enzymatic activities monomeric hexameric E1
0.41806388.11304544.html.plaintext.txt	446	However case SV40 T antigen direct comparison monomeric protein preformed hexamers indicated equal ATPase activity similar helicase activity partial duplex DNA substrates
0.41806388.11304544.html.plaintext.txt	447	In agreement earlier studies BPV E1 46 SV40 T antigen 69 observed preformed HPV11 E1 hexamers nonspecific helicase activity inactive catalyzing cell free viral DNA replication
0.41806388.11304544.html.plaintext.txt	448	These results suggest HPV11 E1 like BPV E1 SV40 T antigen must isolated monomeric form active cell free DNA replication assays
0.41806388.11304544.html.plaintext.txt	449	In support suggestion observed previously HPV11 E1 expressed monomers vitro translation 25 active cell free DNA replication assay
0.41806388.11304544.html.plaintext.txt	450	The oligomeric nature purified E1 also likely reason ATPase nonspecific helicase activities could stimulated ssDNA forked DNA substrate respectively
0.41806388.11304544.html.plaintext.txt	451	Indeed previous studies BPV E1 indicated ssDNA enhances ATPase helicase activity promoting oligomerization monomeric protein rather affecting activity preformed oligomers 46
0.41806388.11304544.html.plaintext.txt	452	The unwinding activity HPV11 E1 preparations appears similar reported previously BPV E1 SV40 T antigen recently HPV11 E1
0.41806388.11304544.html.plaintext.txt	453	BPV E1 reported unwind 0
0.41806388.11304544.html.plaintext.txt	454	7 pM substratehnM E1 monomer 5
0.41806388.11304544.html.plaintext.txt	455	By comparison SV40 T antigen found one study unwind 3 pM substratehnM enzyme 70 another somewhat lower value 0
0.41806388.11304544.html.plaintext.txt	456	69 reported values either 1 0
0.41806388.11304544.html.plaintext.txt	457	6 pMhnM depending whether assays initiated monomeric hexameric protein respectively
0.41806388.11304544.html.plaintext.txt	458	4B calculated comparable value 0
0.41806388.11304544.html.plaintext.txt	459	3 pMhnM purified HPV11 E1
0.41806388.11304544.html.plaintext.txt	460	This rate unwinding appears similar observed Rocque et al
0.41806388.11304544.html.plaintext.txt	461	42 preparations HPV11 E1 reported approximately 4 fold less unwinding activity T antigen
0.41806388.11304544.html.plaintext.txt	462	The helicase activity measured E1 72 649 1
0.41806388.11304544.html.plaintext.txt	463	6 pMhnM enzyme approximately 5 fold greater wild type E1 despite fact enzymes similar ATPase activity shown Fig
0.41806388.11304544.html.plaintext.txt	464	4C values kcat KmATP
0.41806388.11304544.html.plaintext.txt	465	The first 71 amino acids E1 contain high proportion acidic residues removal region may account improved helicase activity well improved affinity truncated E1 ssDNA Fig
0.41806388.11304544.html.plaintext.txt	466	We found truncated E1 less prone aggregation may account part improved activities
0.41806388.11304544.html.plaintext.txt	467	Our characterization NTPase activity purified E1 revealed eight different nucleoside deoxynucleoside triphosphates could serve substrates NTP hydrolysis helicase assays
0.41806388.11304544.html.plaintext.txt	468	These results extend reported Rocque et al
0.41806388.11304544.html.plaintext.txt	469	42 consistent previous findings NTPs also able stimulate E1 DNA binding oligomerization 20
0.41806388.11304544.html.plaintext.txt	470	We also found ATPS ADP AMP shown previously stimulate E1 DNA binding oligomerization inhibit ATPase activity
0.41806388.11304544.html.plaintext.txt	471	Collectively findings reinforce earlier suggestion E1 catalytic site accommodate wide variety substrates
0.41806388.11304544.html.plaintext.txt	472	However reproducibly lower activity obtained CTP dCTP TTP suggests nevertheless constraints substrate binding
0.41806388.11304544.html.plaintext.txt	473	Surprisingly using TLC scintillation proximity procedures obtained much lower values KmATP nucleoside triphosphates reported previously HPV E1 230 380 microM 42 49 BPV E1 750 1100 microM 41 45
0.41806388.11304544.html.plaintext.txt	474	A similar value 600 microM also reported SV40 T antigen 72 later report much lower value 4 microM given 73
0.41806388.11304544.html.plaintext.txt	475	This latter value consistent another finding fluorescent analog ATP Kd 0
0.41806388.11304544.html.plaintext.txt	476	4 microM 74 well finding absence DNA T antigen monomers oligomerize half maximal efficiency upon addition 10 microM ATP 69
0.41806388.11304544.html.plaintext.txt	477	Our values E1 consistent value 4 microM T antigen
0.41806388.11304544.html.plaintext.txt	478	Although difficult explain differences possible previously reported values obtained true initial velocity conditions
0.41806388.11304544.html.plaintext.txt	479	Furthermore one report BPV E1 Santucci et al
0.41806388.11304544.html.plaintext.txt	480	45 observed biphasic rate versus ATP curves suggest could due contaminating ATPase preparations
0.41806388.11304544.html.plaintext.txt	481	It also noteworthy value 230 microM reported HPV6 E1 obtained preparation purified E1 E2 complex 49 presence E2 may affected reported value see
0.41806388.11304544.html.plaintext.txt	482	42 report turnover value HPV11 E1 ATPase reaction 8 min1 saturating ATP quite similar value kcat 16 min1
0.41806388.11304544.html.plaintext.txt	483	We observed transactivation domain E2 either context full length E2 fusion GST significant effect E1 ATPase activity low ATP concentrations
0.41806388.11304544.html.plaintext.txt	484	Even high concentrations TAD effect higher ATP concentrations despite fact E2 still bind E1 conditions 19
0.41806388.11304544.html.plaintext.txt	485	In apparent contrast results previous study found presence BPV E2 significant effect ATPase activity BPV E1 wide range ATP concentrations 45
0.41806388.11304544.html.plaintext.txt	486	In study however activity partially purified E1 compared partially purified E1 E2 complex obtained coinfection insect cells baculoviruses expressing E1 E2
0.41806388.11304544.html.plaintext.txt	487	E2 titrated ATPase reaction possible estimate percentage E1 remained associated E2 assay conditions
0.41806388.11304544.html.plaintext.txt	488	The inhibition observed specific since neither GST alone GST TAD change Glu39 Ala known weaken E1 binding 67 inhibitory
0.41806388.11304544.html.plaintext.txt	489	GST TAD appeared modulate ATPase activity saturating concentrations E2 increased apparent value Km ATP 7 fold value kcat unchanged
0.41806388.11304544.html.plaintext.txt	490	A simple thermodynamic consequence saturating concentrations ATP weaken binding E2 E1 similar degree 75 provided evidence using E2 dependent E1 DNA binding assay requires interaction E1 E2
0.41806388.11304544.html.plaintext.txt	491	In assay observed inhibition low protein concentrations consistent modest 7 fold decrease affinity expected ATPase experiments
0.41806388.11304544.html.plaintext.txt	492	Binding E2 catalytically inactive E1 proteins significantly affected ATP Mg suggesting productive substrate binding weakens E1 E2 protein protein interaction
0.41806388.11304544.html.plaintext.txt	493	Since E2 affects ATP binding Km rather hydrolysis kcat would expect ATP binding suffices weaken interaction E1 E2 75 probably inducing conformational changes E1
0.41806388.11304544.html.plaintext.txt	494	In virus infected cells E2 present low concentrations ATP large excess perturbation E2 binding could promote efficient viral DNA replication since previous work us 25 others 23 24 suggested E2 must dissociate E1 prior association polymerase primase
0.41806388.11304544.html.plaintext.txt	495	Hence saturation E1 ATP subsequent E1 oligomerization may help release E1 E2 allow interaction pol primase
0.41806388.11304544.html.plaintext.txt	496	It proposed ATP hydrolysis required displacement E2 origin concomitantly conversion initial E1 E2 origin complex enzymatically active multimeric E1 origin complex 17
0.41806388.11304544.html.plaintext.txt	497	While results suggest ATP binding plays direct role weakening E1 E2 interaction displacement E2 DNA may addition require ATP hydrolysis example drive distortion opening origin E1 hexamers
0.41806388.11304544.html.plaintext.txt	498	Additional work ideally purified monomeric E1 necessary fully understand sequence binding enzymatic events involved initiation HPV DNA replication
0.41806388.11304544.html.plaintext.txt	499	We determined deletion analysis C terminal domain E1 comprising amino acids 353 649 necessary sufficient ATPase activity
0.41806388.11304544.html.plaintext.txt	500	Shorter E1 fragments still retain three ATPase motifs characteristic superfamily 3 helicases 38 inactive indicating sequences encompassing conserved regions A D Fig
0.41806388.11304544.html.plaintext.txt	501	1 also necessary activity
0.41806388.11304544.html.plaintext.txt	502	The requirement two conserved regions three NTP binding motifs demonstrated site directed mutagenesis highly conserved residues
0.41806388.11304544.html.plaintext.txt	503	Region A part minimal E1 E1 interaction domain effect region A substitutions E1 ATPase activity remarkably paralleled effect oligomerization protein reported previously 20
0.41806388.11304544.html.plaintext.txt	504	The vitro synthesized E1 72 649 used ATPase assays either WT mutant sequences probably monomeric based previous chemical cross linking studies 20 although cannot rule protein may oligomerized assay conditions andor immunocapture E1 beads
0.41806388.11304544.html.plaintext.txt	505	Further studies required address issue
0.41806388.11304544.html.plaintext.txt	506	Nevertheless results point functional relationship minimal E1 E1 interaction domain ATPase activity perhaps underlying fact oligomerization enhances ATPase activity
0.41806388.11304544.html.plaintext.txt	507	Contrary expectation found minimal E1 ATPase domain amino acids 353 649 also sufficient nonspecific helicase activity binding ssDNA despite fact lacks minimal origin binding domain
0.41806388.11304544.html.plaintext.txt	508	A recent report indicated analogous C terminal domain SV40 T antigen also lacking origin binding domain sufficient binding ssDNA probably hexamer 76
0.41806388.11304544.html.plaintext.txt	509	It determined domain T antigen enzymatic activity basis findings E1 seems likely possibility
0.41806388.11304544.html.plaintext.txt	510	Despite encoding sequences needed nonspecific helicase activity C terminal domain E1 made vitro translation unable support cell free DNA replication 25 presumably lacks upstream sequences amino acids 166 353 required binding double stranded DNA
0.41806388.11304544.html.plaintext.txt	511	It suggested previously initiation viral DNA replication E1 must first function sequence specific DNA binding protein albeit low sequence specificity prior assembling enzymatically active hexamers 9 16 77 78
0.41806388.11304544.html.plaintext.txt	512	Our results suggest two activities E1 sequence specific DNA binding helicase activity require different domains protein N terminal half E1 required primarily function dsDNA binding protein C terminal half sufficient unwinding
0.41806388.11304544.html.plaintext.txt	513	One could speculate two main activities E1 may arisen fusion two independent functional domains course evolution
0.41806388.11304544.html.plaintext.txt	514	A similar domain organization also likely apply origin binding replicative helicases particular related large T antigens SV40 polyomaviruses
0.41806388.11304544.html.plaintext.txt	515	Recent electron microscopic images T antigen double hexamers bound SV40 origin indeed revealed protein composed two structurally distinct domains corresponding origin binding C terminal domains respectively 79
0.41806388.11304544.html.plaintext.txt	516	More generally note 34 kDa C terminal helicase domain E1 similar size smallest naturally occurring hexameric helicase identified date RepA protein 30 kDa autonomously replicating RSF1010 plasmid 80
0.41806388.11304544.html.plaintext.txt	517	Furthermore enzymatically active C terminal domains similar size identified E
0.41806388.11304544.html.plaintext.txt	518	coli DnaB 81 83 phage T7 gene 4 protein 84 hexameric helicases F4 family RepA 85
0.41806388.11304544.html.plaintext.txt	519	Interestingly catalytic C terminal domains possess organization E1 353 649 oligomerization region N terminal portion followed additional motifs required ATPase helicase activities
0.41806388.11304544.html.plaintext.txt	520	This striking similarity E1 T antigen distantly related helicases suggests many hexameric replicative helicases may similar architecture C terminal domain 30 40 kDa sufficient support oligomerization around single stranded DNA well ATP hydrolysis DNA unwinding
0.41806388.11304544.html.plaintext.txt	521	We thank Lyne Lamarre providing antibodies
0.41806388.11304544.html.plaintext.txt	522	Craig Fenwick Steve Mason critical reading manuscript
0.41806388.11304544.html.plaintext.txt	523	The costs publication article defrayed part payment page charges
0.41806388.11304544.html.plaintext.txt	524	The article must therefore hereby marked advertisement accordance 18 U
0.41806388.11304544.html.plaintext.txt	525	Section 1734 solely indicate fact
0.41806388.11304544.html.plaintext.txt	526	To correspondence addressed Dept
0.41806388.11304544.html.plaintext.txt	527	Biological Sciences Boehringer Ingelheim Canada Ltd
0.41806388.11304544.html.plaintext.txt	528	Laval Quebec H7S 2G5 Canada
0.41806388.11304544.html.plaintext.txt	529	4269 Fax 450 682 4642 E mail pwhitelav
0.41806388.11304544.html.plaintext.txt	530	Published JBC Papers Press April 13 2001 DOI 10
0.41806388.11304544.html.plaintext.txt	531	White manuscript preparation
0.41806388.11304544.html.plaintext.txt	532	The abbreviations used PV papillomavirus ATPS adenosine 5 O 3 thiotriphosphate BPV bovine papillomavirus dsDNA double stranded DNA DTT dithiothreitol GST glutathione S transferase HPV human papillomavirus MES 2 N morpholinoethanesulfonic acid PAGE polyacrylamide gel electrophoresis PCR polymerase chain reaction SPA scintillation proximity assay ssDNA single stranded DNA TAD E2 transactivation domain WT wild type nt nucleotides
0.41806388.11304544.html.plaintext.txt	533	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.41806388.11304544.html.plaintext.txt	534	1996 Fields Virology Fields B
0.41806388.11304544.html.plaintext.txt	535	2077 2109 Lippincott Raven Publishers Philadelphia 2
0.41806388.11304544.html.plaintext.txt	536	1996 Fields Virology Fields B
0.41806388.11304544.html.plaintext.txt	537	2045 2076 Lippincott Raven Publishers Philadelphia 3
0.41806388.11304544.html.plaintext.txt	538	1991 Nature 353 628 632CrossRefMedline Order article via Infotrieve 5
0.41806388.11304544.html.plaintext.txt	539	9 359 377Medline Order article via Infotrieve 7
0.41806388.11304544.html.plaintext.txt	540	91 12398 12402AbstractFree Full Text 8
0.41806388.11304544.html.plaintext.txt	541	268 15795 15803AbstractFree Full Text 9
0.41806388.11304544.html.plaintext.txt	542	1990 Science 250 1694 1699Medline Order article via Infotrieve 10
0.41806388.11304544.html.plaintext.txt	543	65 649 656Medline Order article via Infotrieve 13
0.41806388.11304544.html.plaintext.txt	544	273 30704 30712AbstractFree Full Text 15
0.41806388.11304544.html.plaintext.txt	545	274 4447 4458AbstractFree Full Text 16
0.41806388.11304544.html.plaintext.txt	546	17 7044 7055AbstractFree Full Text 18
0.41806388.11304544.html.plaintext.txt	547	73 5282 5293AbstractFree Full Text 20
0.41806388.11304544.html.plaintext.txt	548	74 7349 7361AbstractFree Full Text 21
0.41806388.11304544.html.plaintext.txt	549	72 7407 7419AbstractFree Full Text 24
0.41806388.11304544.html.plaintext.txt	550	274 2696 2705AbstractFree Full Text 25
0.41806388.11304544.html.plaintext.txt	551	2000 Virology 272 137 150CrossRefMedline Order article via Infotrieve 26
0.41806388.11304544.html.plaintext.txt	552	73 4899 4907AbstractFree Full Text 27
0.41806388.11304544.html.plaintext.txt	553	72 7255 7262AbstractFree Full Text 31
0.41806388.11304544.html.plaintext.txt	554	96 382 387AbstractFree Full Text 32
0.41806388.11304544.html.plaintext.txt	555	1995 Virology 211 385 396CrossRefMedline Order article via Infotrieve 34
0.41806388.11304544.html.plaintext.txt	556	72 2567 2576AbstractFree Full Text 36
0.41806388.11304544.html.plaintext.txt	557	1984 Nature 311 276 279Medline Order article via Infotrieve 38
0.41806388.11304544.html.plaintext.txt	558	262 145 148CrossRefMedline Order article via Infotrieve 39
0.41806388.11304544.html.plaintext.txt	559	1 945 951Medline Order article via Infotrieve 40
0.41806388.11304544.html.plaintext.txt	560	1994 Virology 204 403 408CrossRefMedline Order article via Infotrieve 42
0.41806388.11304544.html.plaintext.txt	561	2000 Protein Expression Purif
0.41806388.11304544.html.plaintext.txt	562	18 148 159CrossRefMedline Order article via Infotrieve 43
0.41806388.11304544.html.plaintext.txt	563	72 6893 6897AbstractFree Full Text 47
0.41806388.11304544.html.plaintext.txt	564	269 24058 24065AbstractFree Full Text 51
0.41806388.11304544.html.plaintext.txt	565	249 228 238CrossRefMedline Order article via Infotrieve 52
0.41806388.11304544.html.plaintext.txt	566	244 4406 4412AbstractFree Full Text 53
0.41806388.11304544.html.plaintext.txt	567	1992 Analytical Ultracentrifugation Biochemistry Polymer Science Harding S
0.41806388.11304544.html.plaintext.txt	568	203 295 301Medline Order article via Infotrieve 55
0.41806388.11304544.html.plaintext.txt	569	279 151 163CrossRefMedline Order article via Infotrieve 56
0.41806388.11304544.html.plaintext.txt	570	1989 Molecular Cloning A Laboratory Manual 2nd Ed
0.41806388.11304544.html.plaintext.txt	571	23 26 Cold Spring Harbor Laboratory Cold Spring Harbor NY 59
0.41806388.11304544.html.plaintext.txt	572	Acta 14 361 366CrossRefMedline Order article via Infotrieve 60
0.41806388.11304544.html.plaintext.txt	573	Acta 635 63 72Medline Order article via Infotrieve 61
0.41806388.11304544.html.plaintext.txt	574	1996 Virology 219 247 256CrossRefMedline Order article via Infotrieve 62
0.41806388.11304544.html.plaintext.txt	575	59 289 329CrossRefMedline Order article via Infotrieve 63
0.41806388.11304544.html.plaintext.txt	576	69 651 697CrossRefMedline Order article via Infotrieve 64
0.41806388.11304544.html.plaintext.txt	577	1998 Virology 241 312 322CrossRefMedline Order article via Infotrieve 69
0.41806388.11304544.html.plaintext.txt	578	267 14129 14137AbstractFree Full Text 70
0.41806388.11304544.html.plaintext.txt	579	263 383 392AbstractFree Full Text 72
0.41806388.11304544.html.plaintext.txt	580	256 11854 11858AbstractFree Full Text 74
0.41806388.11304544.html.plaintext.txt	581	1998 Biochemistry 37 15336 15344CrossRefMedline Order article via Infotrieve 75
0.41806388.11304544.html.plaintext.txt	582	1999 Structure Mechanism Protein Science A Guide Enzyme Catalysis Protein Folding pp
0.41806388.11304544.html.plaintext.txt	583	72 10256 10259AbstractFree Full Text 77
0.41806388.11304544.html.plaintext.txt	584	65 5314 5322Medline Order article via Infotrieve 79
0.41806388.11304544.html.plaintext.txt	585	20 34 41AbstractFree Full Text 80
0.41806388.11304544.html.plaintext.txt	586	272 30228 30236AbstractFree Full Text 81
0.41806388.11304544.html.plaintext.txt	587	259 88 96AbstractFree Full Text 82
0.41806388.11304544.html.plaintext.txt	588	1994 Biochemistry 33 11307 11314Medline Order article via Infotrieve 83
0.41806388.11304544.html.plaintext.txt	589	1999 Biochemistry 38 10919 10928CrossRefMedline Order article via Infotrieve 84
0.41806388.11304544.html.plaintext.txt	590	25 2620 2626AbstractFree Full Text 85
0.41806388.11304544.html.plaintext.txt	591	Copyright 2001 The American Society Biochemistry Molecular Biology Inc
0.25392318.12771418.html.plaintext.txt	0	Human papillomavirus type 6 virus like particles present overlapping yet distinct conformational epitopes Xin Min Wang1 James C
0.25392318.12771418.html.plaintext.txt	1	1 Merck Research Laboratories PO Box 4 West Point PA 19486 USA 2 The Jake Gittlen Cancer Research Institute Department Pathology Penn State University Milton S
0.25392318.12771418.html.plaintext.txt	2	Hershey Medical Center 500 University Drive Hershey PA 17033 USA
0.25392318.12771418.html.plaintext.txt	3	Correspondence William McClements williammcclementsatmerck
0.25392318.12771418.html.plaintext.txt	4	ABSTRACT Top ABSTRACT MAIN TEXT REFERENCES The epitope human papillomavirus HPV type 6 conformation dependent neutralizing monoclonal antibody mAb partially mapped using HPV L1 recombinant virus like particles VLPs
0.25392318.12771418.html.plaintext.txt	5	J54 cross reactive closely related HPV types 6 11
0.25392318.12771418.html.plaintext.txt	6	By making HPV 6 like amino acid substitutions cottontail rabbit papillomavirus CRPV major capsid protein L1 able transfer H6
0.25392318.12771418.html.plaintext.txt	7	J54 binding activity CRPVHPV 6 hybrid L1 protein
0.25392318.12771418.html.plaintext.txt	8	Full binding activity achieved nine amino acid changes identified region centred HPV 6 residues 49 54
0.25392318.12771418.html.plaintext.txt	9	This region previously shown critical part HPV 6 type specific epitopes
0.25392318.12771418.html.plaintext.txt	10	Fine mapping region scanning series alanine substitution mutations showed HPV 6 VLPs type common epitope overlaps HPV 6 type specific epitopes
0.25392318.12771418.html.plaintext.txt	11	MAIN TEXT Top ABSTRACT MAIN TEXT REFERENCES Human papillomavirus HPV infections among common sexually transmitted diseases Bauer et al
0.25392318.12771418.html.plaintext.txt	12	2001 implicated benign malignant disease genital epithelia Bosch et al
0.25392318.12771418.html.plaintext.txt	13	1995 Galloway 1994 Gissmann et al
0.25392318.12771418.html.plaintext.txt	14	1983 Munoz 2000 Pisani et al
0.25392318.12771418.html.plaintext.txt	15	To meet medical needs imposed HPV infection several experimental vaccines developed currently human clinical trials Brown et al
0.25392318.12771418.html.plaintext.txt	16	2001 one shown effective preventing persistent viral infection Koutsky et al
0.25392318.12771418.html.plaintext.txt	17	These vaccines based virus like particles VLPs assemble spontaneously papillomavirus major capsid protein L1 recombinantly expressed either alone together L2 minor capsid protein Hofmann et al
0.25392318.12771418.html.plaintext.txt	18	VLPs morphologically immunologically similar native virions Christensen et al
0.25392318.12771418.html.plaintext.txt	19	1993 induce neutralizing antibody responses Bryan et al
0.25392318.12771418.html.plaintext.txt	20	2000 animal models protect viral disease Breitburd et al
0.25392318.12771418.html.plaintext.txt	21	The amino acid sequences L1 proteins similar among papillomaviruses species well conserved among HPV genotypes
0.25392318.12771418.html.plaintext.txt	22	Alignment HPV L1 proteins reveals within well conserved proteins localized regions amino acid sequence divergence
0.25392318.12771418.html.plaintext.txt	23	These regions contain determinants type specificity Ludmerer McClements 1999
0.25392318.12771418.html.plaintext.txt	24	We others shown epitopes recognized HPV neutralizing monoclonal antibodies mAbs generally type specific conformation dependent map regions Christensen et al
0.25392318.12771418.html.plaintext.txt	25	1996 1997 2000 McClements et al
0.25392318.12771418.html.plaintext.txt	26	Furthermore structural studies HPV capsomers VLPs shown divergent sequence regions surface exposed Chen et al
0.25392318.12771418.html.plaintext.txt	27	2000 studies shown substitution regions non L1 sequences results presentation foreign epitopes VLPs Chackerian et al
0.25392318.12771418.html.plaintext.txt	28	Previously mapped type specific neutralizing epitopes closely related HPV types 6 11 demonstrating HPV 11 like amino acid substitutions HPV 6 L1 transferred type 11 specific epitopes VLPs assembled mutant type 6 L1 proteins reciprocal experiments transferred HPV 6 specific epitopes type 11 VLPs Ludmerer et al
0.25392318.12771418.html.plaintext.txt	29	1996 1997 2000 McClements et al
0.25392318.12771418.html.plaintext.txt	30	These studies mapped HPV 11 immunodominant neutralizing epitope sequence approximately 20 amino acids centred residue Y132 found second subdominant neutralizing epitope comprised residues 270 290 340 345
0.25392318.12771418.html.plaintext.txt	31	For HPV 6 neutralizing epitopes bipartite comprise two regions sequence divergence distinct regions identified HPV 11
0.25392318.12771418.html.plaintext.txt	32	The principal region centred residues 49 54 region I Fig
0.25392318.12771418.html.plaintext.txt	33	1a contains determinants H6
0.25392318.12771418.html.plaintext.txt	34	M48 three HPV 6 specific conformation dependent mAbs Christensen et al
0.25392318.12771418.html.plaintext.txt	35	1996b neutralizing HPV 6 pseudovirion assay Yeager et al
0.25392318.12771418.html.plaintext.txt	36	The second region centred residues 169 178 region II Fig
0.25392318.12771418.html.plaintext.txt	37	1a modulates binding region I
0.25392318.12771418.html.plaintext.txt	38	5 require region II well region I achieve full binding VLPs McClements et al
0.25392318.12771418.html.plaintext.txt	39	The physical association regions I II consistent crystal structure HPV 16 VLPs Chen et al
0.25392318.12771418.html.plaintext.txt	40	2000 HPV 16 L1 sequences analogous regions I II map loop B C segment G1 respectively predicted close proximity capsomers VLPs
0.25392318.12771418.html.plaintext.txt	41	Type specific bipartite epitopes also described HPV types 11 16 Christensen et al
0.25392318.12771418.html.plaintext.txt	42	1996b conformation dependent mAb cross reactive HPV types 6 11 suggested also recognizes bipartite epitope one part mapping N terminal region L1 N
0.25392318.12771418.html.plaintext.txt	43	Christensen unpublished observations
0.25392318.12771418.html.plaintext.txt	44	This raised possibility HPV 6 type common type specific epitopes may overlap could interfere precise serological characterization
0.25392318.12771418.html.plaintext.txt	45	View larger version 14K Fig
0.25392318.12771418.html.plaintext.txt	46	Amino acid sequence alignments HPV 6 HPV 11 CRPV L1 proteins
0.25392318.12771418.html.plaintext.txt	47	Alignment three complete amino acid sequences carried using Vector NTI software
0.25392318.12771418.html.plaintext.txt	48	Aligned N termini HPV 6 CRPV
0.25392318.12771418.html.plaintext.txt	49	Regions I II HPV 6 indicated
0.25392318.12771418.html.plaintext.txt	50	Arrowheads indicate residues CRPV replaced HPV 6 like residues CRH6 hybrids shaded areas denote extent amino acid identity HPV 6 hybrid L1 molecules
0.25392318.12771418.html.plaintext.txt	51	b Alignment HPV 11 region I HPV 6 region I
0.25392318.12771418.html.plaintext.txt	52	Residues HPV 11 identical HPV 6 indicated dots three differences residues 49 53 54 confer type 6 specificity shown
0.25392318.12771418.html.plaintext.txt	53	Residues HPV 6 replaced alanine scanning study underlined
0.25392318.12771418.html.plaintext.txt	54	To extend mapping studies address question epitope interference generate novel reagents monitoring immune responses HPV infection immunization experimental HPV vaccines attempted transfer HPV 6 specific epitopes less closely related papillomavirus VLP
0.25392318.12771418.html.plaintext.txt	55	one fewer epitopes common HPV 6 Fig
0.25392318.12771418.html.plaintext.txt	56	We chose cottontail rabbit papillomavirus CRPV L1 scaffold
0.25392318.12771418.html.plaintext.txt	57	The CRPV HPV 6 L1 molecules nearly identical length CRPV VLPs structurally similar HPV VLPs CRPV L1 amino acid sequence SWISS PROT accession
0.25392318.12771418.html.plaintext.txt	58	P03102 50 identical HPV 6
0.25392318.12771418.html.plaintext.txt	59	Using PCR mutagenesis transferred HPV 6 specific residues regions I II CRPV L1
0.25392318.12771418.html.plaintext.txt	60	The CRPVHPV 6 hybrid L1 CRH6I nine HPV 6 like substitutions region I making sequence identical HPV 6 20 residue sequence CRPV L1 aa 45 64
0.25392318.12771418.html.plaintext.txt	61	In addition region I changes CRH6I II generated also nine HPV 6 like substitutions region II making sequence identical HPV 6 22 residues aa 166 187
0.25392318.12771418.html.plaintext.txt	62	The alignment HPV 6 CRPV L1 sequences Fig
0.25392318.12771418.html.plaintext.txt	63	1a highlights changes also shows extended similarity two sequences
0.25392318.12771418.html.plaintext.txt	64	All constructions confirmed complete sequencing L1 genes
0.25392318.12771418.html.plaintext.txt	65	These hybrid proteins well wild type CPRV HPV 6 HPV 11 expressed using baculovirus vector pVL1393 Stratagene
0.25392318.12771418.html.plaintext.txt	66	Extracts prepared transfected Spodoptera frugiperda cells Sf9 Invitrogen assayed ELISA binding activity conformation dependent mAbs described previously Benincasa et al
0.25392318.12771418.html.plaintext.txt	67	2 shows results binding activity assay
0.25392318.12771418.html.plaintext.txt	68	With wild type L1 proteins type specificity mAbs H6
0.25392318.12771418.html.plaintext.txt	69	Also evident failure transfer quantitatively HPV 6 specific binding activity CRPV backbone
0.25392318.12771418.html.plaintext.txt	70	Lack binding due failure hybrid L1 proteins form high order structures including capsomers VLPs CRPV 5A conformation dependent CRPV specific mAb Christensen Kreider 1991 bound hybrid proteins well
0.25392318.12771418.html.plaintext.txt	71	Of three type 6 specific mAbs H6
0.25392318.12771418.html.plaintext.txt	72	N8 showed binding hybrid L1 signal well background binding clearly impaired
0.25392318.12771418.html.plaintext.txt	73	The surprising result H6
0.25392318.12771418.html.plaintext.txt	74	J54 neutralizing conformation dependent HPV 6 11 cross reactive mAb Christensen et al
0.25392318.12771418.html.plaintext.txt	75	1996b bound CRH6I well bound wild type HPV 6 11 VLPs
0.25392318.12771418.html.plaintext.txt	76	This indicated least part J54 epitope located region I
0.25392318.12771418.html.plaintext.txt	77	However second HPV 6 like substitution region II made resultant hybrid L1 protein recognized H6
0.25392318.12771418.html.plaintext.txt	78	This result contrast earlier data HPV 611 hybrid VLPs found sequences region II could stabilize binding HPV 6 type specific mAb interactions region I McClements et al
0.25392318.12771418.html.plaintext.txt	79	However consistent H6
0.25392318.12771418.html.plaintext.txt	80	J54 binding studies HPV 1116 chimeric VLPs suggested part J54 epitope maps HPV 11 residues 45 60 N
0.25392318.12771418.html.plaintext.txt	81	Christensen unpublished observations
0.25392318.12771418.html.plaintext.txt	82	J54 binding likely independent region II regions well separated linear L1 sequence affect secondary tertiary structure assembled VLPs introduction HPV 6 like amino acids site may distort one components J54 epitope
0.25392318.12771418.html.plaintext.txt	83	View larger version 20K Fig
0.25392318.12771418.html.plaintext.txt	84	Binding HPV 6 mAbs CRPV VLPs bearing HPV 6 like amino acid substitutions
0.25392318.12771418.html.plaintext.txt	85	Baculovirus expressed VLPs control extracts Sf9 assayed ELISA previously described
0.25392318.12771418.html.plaintext.txt	86	Assays carried duplicate results average assays two independently derived clones mutant
0.25392318.12771418.html.plaintext.txt	87	Error bars denote standard deviation
0.25392318.12771418.html.plaintext.txt	88	H6 wt wild type HPV 6 H11 wt wild type HPV 11 CRPV wt wild type CRPV CRH6I CRPV HPV 6 like substitutions region I CRH6I II CRPV HPV 6 like substitutions regions I II
0.25392318.12771418.html.plaintext.txt	89	These results suggested J54 type common epitope overlapped HPV 6 specific epitope might share determinants
0.25392318.12771418.html.plaintext.txt	90	To map region I portion J54 precisely next made series alanine substitution mutants scanned 22 residue stretch centred critical binding region I Fig
0.25392318.12771418.html.plaintext.txt	91	J54 cross reactive HPV 11 selected charged hydrophilic residues common HPV types likely contribute antibody binding
0.25392318.12771418.html.plaintext.txt	92	The mutant L1 proteins R40A S50A K52A N55A T57A P60A K61A expressed assayed binding H6
0.25392318.12771418.html.plaintext.txt	93	C6 recognizes distal linear epitope common type 6 11 Ludmerer et al
0.25392318.12771418.html.plaintext.txt	94	Binding results shown Fig
0.25392318.12771418.html.plaintext.txt	95	The signals conformation dependent mAbs indicated mutants formed ordered structures region I intact although reduced binding mAb H6
0.25392318.12771418.html.plaintext.txt	96	5 R40A K52A K61A mutants observed
0.25392318.12771418.html.plaintext.txt	97	While relative binding four antibodies varied across mutant set results one mutation N55A stood
0.25392318.12771418.html.plaintext.txt	98	J54 completely lost little impairment H6
0.25392318.12771418.html.plaintext.txt	99	To assess assembly state critical mutant partially purified material N55A extract characterized transmission electron microscopy found indistinguishable preparations either wild type T57A mutant showed presence 55 nm particles characteristic appearance VLPs data shown
0.25392318.12771418.html.plaintext.txt	100	We consider likely N55A mutation direct effect residue 55 asparagine critical H6
0.25392318.12771418.html.plaintext.txt	101	N8 recognized mutant VLP well indicating region I grossly distorted
0.25392318.12771418.html.plaintext.txt	102	5 seen R40A K52A K61A mutants suggests residues contribute region I type specific epitope
0.25392318.12771418.html.plaintext.txt	103	Taken together J54 epitope transfer CRPV described data confirm overlap type specific type common conformation dependent epitopes
0.25392318.12771418.html.plaintext.txt	104	View larger version 25K Fig
0.25392318.12771418.html.plaintext.txt	105	Binding HPV 6 mAbs mutant HPV 6 VLPs
0.25392318.12771418.html.plaintext.txt	106	VLPs alanine scanning mutants HPV 6 region I control extracts Sf9 assayed ELISA binding HPV 6 specific mAbs
0.25392318.12771418.html.plaintext.txt	107	For S50A K52A N55A K61A mutants results averages obtained assays two independently derived clones
0.25392318.12771418.html.plaintext.txt	108	Error bars denote standard deviation
0.25392318.12771418.html.plaintext.txt	109	H6 wt wild type HPV 6 alanine mutants indicated
0.25392318.12771418.html.plaintext.txt	110	These observations extend earlier study describing theoretical overlap linear epitope conformation dependent one Ludmerer et al
0.25392318.12771418.html.plaintext.txt	111	The linear epitope mapped residues 108 127 HPV 16 Christensen et al
0.25392318.12771418.html.plaintext.txt	112	1995 transferred HPV 11 VLPs making HPV 16 like substitutions V123L V126T two residues region HPV 16 11 L1 proteins differed
0.25392318.12771418.html.plaintext.txt	113	In hybrid VLP context linear HPV 16 epitope overlapped HPV 11 major neutralizing epitope mapped approximately 20 amino acid sequence centred residue 132
0.25392318.12771418.html.plaintext.txt	114	Residue 123 critical epitope differed two types L HPV 16 Y HPV 11 simultaneous presentation epitopes could occur
0.25392318.12771418.html.plaintext.txt	115	The present results greater significance epitopes exist simultaneously VLP conformation dependent yet distinguishable binding properties
0.25392318.12771418.html.plaintext.txt	116	J54 binding eliminated HPV 6 without affecting binding type specific mAbs transferred CRPV VLPs without reconstituting epitopes antibodies
0.25392318.12771418.html.plaintext.txt	117	This suggests alteration epitope structure significant impact yet highly localized effect
0.25392318.12771418.html.plaintext.txt	118	This important implications HPV serology
0.25392318.12771418.html.plaintext.txt	119	If cross reactive responses two closely related HPV types example types 16 31 18 45 hinder precise serological evaluation hybrid VLPs made cross reactive responses reduced eliminated thus creating serological typing reagents improved sensitivity selectivity
0.25392318.12771418.html.plaintext.txt	120	REFERENCES Top ABSTRACT MAIN TEXT REFERENCES Bauer H
0.25392318.12771418.html.plaintext.txt	121	Genital human papillomavirus infection female university students determined PCR based method see comments
0.25392318.12771418.html.plaintext.txt	122	Rapid high level transient expression papillomavirus like particles insect cells
0.25392318.12771418.html.plaintext.txt	123	Prevalence human papillomavirus cervical cancer worldwide perspective
0.25392318.12771418.html.plaintext.txt	124	International biological study cervical cancer IBSCC Study Group see comments
0.25392318.12771418.html.plaintext.txt	125	J Natl Cancer Inst 87 796 802
0.25392318.12771418.html.plaintext.txt	126	Immunization viruslike particles cottontail rabbit papillomavirus CRPV protect experimental CRPV infection
0.25392318.12771418.html.plaintext.txt	127	Neutralization human papillomavirus type 11 HPV 11 serum women vaccinated yeast derived HPV 11 L1 virus like particles correlation competitive radioimmunoassay titer
0.25392318.12771418.html.plaintext.txt	128	J Infect Dis 184 1183 1186
0.25392318.12771418.html.plaintext.txt	129	Human papillomavirus type 11 neutralization athymic mouse xenograft system correlation virus like particle IgG concentration
0.25392318.12771418.html.plaintext.txt	130	CO2 4linktypeDOI CrossRefMedline
0.25392318.12771418.html.plaintext.txt	131	Induction autoantibodies mouse CCR5 recombinant papillomavirus particles
0.25392318.12771418.html.plaintext.txt	132	Proc Natl Acad Sci U S A 96 2373 2378
0.25392318.12771418.html.plaintext.txt	133	Structure small virus like particles assembled L1 protein human papillomavirus 16
0.25392318.12771418.html.plaintext.txt	134	Neutralization CRPV infectivity monoclonal antibodies identify conformational epitopes intact virions
0.25392318.12771418.html.plaintext.txt	135	Human papillomavirus types 6 11 antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
0.25392318.12771418.html.plaintext.txt	136	Surface conformational linear epitopes HPV 16 HPV 18 L1 virus like particles defined monoclonal antibodies
0.25392318.12771418.html.plaintext.txt	137	Monoclonal antibodies HPV 6 L1 virus like particles identify conformational linear neutralizing epitopes HPV 11 addition type specific epitopes HPV 6
0.25392318.12771418.html.plaintext.txt	138	Immunization viruslike particles induces long term protection rabbits challenge cottontail rabbit papillomavirus
0.25392318.12771418.html.plaintext.txt	139	Hybrid papillomavirus L1 molecules assemble virus like particles reconstitute conformational epitopes induce neutralizing antibodies distinct HPV types
0.25392318.12771418.html.plaintext.txt	140	A Phase 1 study recombinant viruslike particle vaccine human papillomavirus type 11 healthy adult volunteers
0.25392318.12771418.html.plaintext.txt	141	J Infect Dis 183 1485 1493
0.25392318.12771418.html.plaintext.txt	142	Human papillomavirus vaccines warty problem
0.25392318.12771418.html.plaintext.txt	143	Infect Agents Dis 3 187 193
0.25392318.12771418.html.plaintext.txt	144	Human papillomavirus types 6 11 DNA sequences genital laryngeal papillomas cervical cancers
0.25392318.12771418.html.plaintext.txt	145	Proc Natl Acad Sci U S A 80 560 563
0.25392318.12771418.html.plaintext.txt	146	Safety immunogenicity trial adult volunteers human papillomavirus 16 L1 virus like particle vaccine
0.25392318.12771418.html.plaintext.txt	147	J Natl Cancer Inst 93 284 292
0.25392318.12771418.html.plaintext.txt	148	Human papillomavirus type 16 capsids expose multiple type restricted type common antigenic epitopes
0.25392318.12771418.html.plaintext.txt	149	Natural history cervicovaginal papillomavirus infection young women
0.25392318.12771418.html.plaintext.txt	150	Sequence determination human papillomavirus type 6a assembly virus like particles Saccharomyces cerevisiae
0.25392318.12771418.html.plaintext.txt	151	Vaccination yeast expressed cottontail rabbit papillomavirus CRPV virus like particles protects rabbits CRPV induced papilloma formation
0.25392318.12771418.html.plaintext.txt	152	Papillomavirus L1 major capsid protein self assembles virus like particles highly immunogenic
0.25392318.12771418.html.plaintext.txt	153	Proc Natl Acad Sci U S A 89 12180 12184
0.25392318.12771418.html.plaintext.txt	154	Efficient self assembly human papillomavirus type 16 L1 L1 L2 virus like particles
0.25392318.12771418.html.plaintext.txt	155	Virus like particles bovine papillomavirus type 4 prophylactic therapeutic immunization
0.25392318.12771418.html.plaintext.txt	156	Randomized clinical trial human papillomavirus type 16 vaccine
0.25392318.12771418.html.plaintext.txt	157	New Engl J Med 347 645 651
0.25392318.12771418.html.plaintext.txt	158	Human papillomavirus type 11 HPV 11 neutralizing antibodies serum genital mucosal secretions African green monkeys immunized HPV 11 virus like particles expressed yeast
0.25392318.12771418.html.plaintext.txt	159	J Infect Dis 176 1141 1145
0.25392318.12771418.html.plaintext.txt	160	Humoral responses human papillomaviruses neutralize infectivity
0.25392318.12771418.html.plaintext.txt	161	Two amino acid residues confer type specificity neutralizing conformationally dependent epitope human papillomavirus type 11
0.25392318.12771418.html.plaintext.txt	162	A neutralizing epitope human papillomavirus type 11 principally described continuous set residues overlap distinct linear surface exposed epitope
0.25392318.12771418.html.plaintext.txt	163	HPV11 mutant virus like particles elicit immune responses neutralize virus delineate novel neutralizing domain
0.25392318.12771418.html.plaintext.txt	164	A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions major capsid protein L1
0.25392318.12771418.html.plaintext.txt	165	Risks incident human papillomavirus infection low grade squamous intraepithelial lesion development young females
0.25392318.12771418.html.plaintext.txt	166	Human papillomavirus cancer epidemiological evidence
0.25392318.12771418.html.plaintext.txt	167	Expression major capsid protein human papillomavirus type 11 Saccharomyces cerevisae
0.25392318.12771418.html.plaintext.txt	168	NHPV16 VLP vaccine induces human antibodies neutralize divergent variants HPV16
0.25392318.12771418.html.plaintext.txt	169	Estimates worldwide mortality eighteen major cancers 1985
0.25392318.12771418.html.plaintext.txt	170	Implications prevention projections future burden
0.25392318.12771418.html.plaintext.txt	171	Characterization human papillomavirus type 16 variant dependent neutralizing epitope
0.25392318.12771418.html.plaintext.txt	172	Expression human papillomavirus type 11 L1 protein insect cells vivo vitro assembly viruslike particles
0.25392318.12771418.html.plaintext.txt	173	Human papillomavirus HPV type 11 recombinant virus like particles induce formation neutralizing antibodies detect HPV specific antibodies human sera
0.25392318.12771418.html.plaintext.txt	174	Chimeric papillomavirus like particles expressing foreign epitope capsid surface loops
0.25392318.12771418.html.plaintext.txt	175	Systemic immunization papillomavirus L1 protein completely prevents development viral mucosal papillomas
0.25392318.12771418.html.plaintext.txt	176	Proc Natl Acad Sci U S A 92 11553 11557
0.25392318.12771418.html.plaintext.txt	177	Assembly major minor capsid protein human papillomavirus type 33 virus like particles tubular structures insect cells
0.25392318.12771418.html.plaintext.txt	178	Neutralization human papillomavirus HPV pseudovirions novel efficient approach detect characterize HPV neutralizing antibodies
0.25392318.12771418.html.plaintext.txt	179	Expression vaccinia recombinant HPV 16 L1 L2 ORF proteins epithelial cells sufficient assembly HPV virion like particles
0.25392318.12771418.html.plaintext.txt	180	Received 1 October 2002 accepted 30 January 2003
0.18831623.8995253.html.plaintext.txt	0	Tripartite Hemolysin BL Bacillus cereus HEMOLYTIC ANALYSIS OF COMPONENT INTERACTIONS AND A MODEL FOR ITS CHARACTERISTIC PARADOXICAL ZONE PHENOMENON
0.18831623.8995253.html.plaintext.txt	1	Received publication June 25 1996 revised form October 11 1996
0.18831623.8995253.html.plaintext.txt	2	From Food Research Institute Department Food Microbiology Toxicology University Wisconsin Madison Wisconsin 53706 ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION FOOTNOTES Acknowledgments REFERENCES
0.18831623.8995253.html.plaintext.txt	3	Hemolysin BL HBL unique membrane lytic toxin Bacillus cereus composed three distinct proteins designated B L1 L2
0.18831623.8995253.html.plaintext.txt	4	HBL produces paradoxical zone phenomenon gel diffusion assays sheep blood agar
0.18831623.8995253.html.plaintext.txt	5	Lysis begin immediately adjacent source diffusion rather begins several millimeters away
0.18831623.8995253.html.plaintext.txt	6	Cells near source intersections lysis zones remain intact longer
0.18831623.8995253.html.plaintext.txt	7	Here developed spectrophotometric hemolysis assay system measures activities individual HBL components used analyze mechanisms hemolysis paradoxical zone phenomenon
0.18831623.8995253.html.plaintext.txt	8	The B component rate limiting erythrocytes slowly primed B optimal concentration 1
0.18831623.8995253.html.plaintext.txt	9	3 nM rapid lytic action combination L components L12
0.18831623.8995253.html.plaintext.txt	10	All individual components bound cells independently membrane associated HBL components neutralized specific antibodies suggesting lysis caused formation membrane attack complex cell surface
0.18831623.8995253.html.plaintext.txt	11	Osmotic protection experiments indicate colloid osmotic lysis mechanism
0.18831623.8995253.html.plaintext.txt	12	Concentrations B component 1
0.18831623.8995253.html.plaintext.txt	13	3 nM caused inhibition L1 mediated lysis L1 inhibited priming reaction B similar concentration range
0.18831623.8995253.html.plaintext.txt	14	From analyses spectrophotometric diffusion assays constructed basic model interactions HBL components paradoxical zone phenomenon blood agar
0.18831623.8995253.html.plaintext.txt	15	In latter areas slow lysis near diffusion sources caused primarily accumulation inhibitory levels L1 reached cells primed B
0.18831623.8995253.html.plaintext.txt	16	Bacillus cereus secretes hemolysin BL HBL1 membrane lytic system composed three antigenically distinct proteins thought contribute diarrheal food poisoning 1 necrotizing infections endophthalmitis 2
0.18831623.8995253.html.plaintext.txt	17	Separately HBL components nontoxic combined exhibit variety toxic activities including hemolysis cytotoxicity vascular permeability dermonecrosis enterotoxicity ocular toxicity 1 2 3 4
0.18831623.8995253.html.plaintext.txt	18	When HBL diffuses bacterial colony well blood agar produces unusual discontinuous hemolysis pattern 5 called paradoxical zone phenomenon 6
0.18831623.8995253.html.plaintext.txt	19	Lysis begins away well colony followed slow lysis nearer source 5
0.18831623.8995253.html.plaintext.txt	20	A similar zone phenomenon seen spectrophotometric assays decreased hemolysis HBL concentrations maximally effective dose 4
0.18831623.8995253.html.plaintext.txt	21	HBL first known three component bacterial toxin
0.18831623.8995253.html.plaintext.txt	22	The components designated B L1 L2
0.18831623.8995253.html.plaintext.txt	23	2 kDa pI values 5
0.18831623.8995253.html.plaintext.txt	24	33 4 determined electrophoretically
0.18831623.8995253.html.plaintext.txt	25	The genes three components cloned sequences determined 7 8
0.18831623.8995253.html.plaintext.txt	26	The amino acid sequences predicted nucleotide sequences complete agreement published N terminal amino acid sequences determined chemically 4
0.18831623.8995253.html.plaintext.txt	27	All proteins appear unique exhibit significant similarity known proteins
0.18831623.8995253.html.plaintext.txt	28	The three genes immediately adjacent one another apparently operon 8
0.18831623.8995253.html.plaintext.txt	29	Methods purification relatively large quantities pure HBL components developed recently 4 therefore little known mode action HBL molecular level
0.18831623.8995253.html.plaintext.txt	30	Here present novel hemolysis assay system provided significant insight mechanism interactions HBL components
0.18831623.8995253.html.plaintext.txt	31	These assays based fundamental difference activities B L components allow analysis activities individual HBL components
0.18831623.8995253.html.plaintext.txt	32	When sheep erythrocytes treated B lyse slowly became primed lysis combination two L components L12
0.18831623.8995253.html.plaintext.txt	33	The discrete proportion cells primed given time could used measure activity B
0.18831623.8995253.html.plaintext.txt	34	The priming reaction took less 1 h 42 degrees C could nearly stopped reducing temperature 22 degrees C creating quasistable population B primed red blood cells RBC B
0.18831623.8995253.html.plaintext.txt	35	The addition L12 RBC B 22 degrees C caused rapid lysis cells 3000 times faster priming rate temperature
0.18831623.8995253.html.plaintext.txt	36	Consequently numerous samples L components could analyzed RBC B preparation little change primed cells
0.18831623.8995253.html.plaintext.txt	37	All three HBL components bound erythrocytes independently others
0.18831623.8995253.html.plaintext.txt	38	Complete neutralization membrane bound L components specific antibodies suggest HBL causes hemolysis via interaction least L components membrane attack complex enzymatic degradation membrane
0.18831623.8995253.html.plaintext.txt	39	Osmotic protection experiments indicated lysis colloid osmotic mechanism transmembrane pores
0.18831623.8995253.html.plaintext.txt	40	Analysis also indicated concentrations B 1
0.18831623.8995253.html.plaintext.txt	41	3 nM caused inhibition lysis RBC B L1 presence L2
0.18831623.8995253.html.plaintext.txt	42	Conversely excess L1 inhibited priming reaction B
0.18831623.8995253.html.plaintext.txt	43	The data suggest B L1 inhibit threshold concentration relative concentration membrane component
0.18831623.8995253.html.plaintext.txt	44	The L2 component required lysis exhibited little interference components
0.18831623.8995253.html.plaintext.txt	45	From observations propose model paradoxical zone phenomenon seen gel diffusion assays
0.18831623.8995253.html.plaintext.txt	46	Hemolysis slow near HBL source excess therefore inhibitory concentrations B L1 accumulate cells primed B
0.18831623.8995253.html.plaintext.txt	47	The initial location lysis occurs point diffusion rate decreased enough rate priming B exceeds rate excess components accumulate
0.18831623.8995253.html.plaintext.txt	48	Erythrocytes HBL Components Antibodies
0.18831623.8995253.html.plaintext.txt	49	Except osmotic protection experiments described protein red blood cell RBC preparations Tris buffered saline TBS pH 7
0.18831623.8995253.html.plaintext.txt	50	4 containing 50 mM Tris Cl 150 mM NaCl
0.18831623.8995253.html.plaintext.txt	51	Pure HBL components purified described previously 4
0.18831623.8995253.html.plaintext.txt	52	The concentrations components stock solutions determined absorbance 280 nm 1 cm light path using extinction coefficients 1
0.18831623.8995253.html.plaintext.txt	53	83 B L1 L2 respectively 1
0.18831623.8995253.html.plaintext.txt	54	Sheep RBCs washed TBS centrifugation supernatant colorless held ice use day
0.18831623.8995253.html.plaintext.txt	55	Neutralization experiments carried IgG fractions specific polyclonal antisera described previously 1
0.18831623.8995253.html.plaintext.txt	56	The IgG fractions purified fast protein liquid chromatography system using Protein G Superose column per instructions manufacturer Pharmacia Biotech Inc
0.18831623.8995253.html.plaintext.txt	57	When tested double immunodiffusion dot blot assays titers antibodies components B L2 roughly equal 2 4 times higher antibodies L1
0.18831623.8995253.html.plaintext.txt	58	The antibodies highly specific respective antigens exhibited cross reactivity HBL components double immunodiffusion assays Western blots
0.18831623.8995253.html.plaintext.txt	59	Osmotic protection experiments performed essentially described Moayeri Welch 9
0.18831623.8995253.html.plaintext.txt	60	All samples final compositions 2
0.18831623.8995253.html.plaintext.txt	61	75 nM concentrations HBL component 25 mM Tris HCl pH 7
0.18831623.8995253.html.plaintext.txt	62	4 containing isotonic concentrations NaCl 154 mM carbohydrates 270 mM different sizes
0.18831623.8995253.html.plaintext.txt	63	Carbohydrates used ribose fucose glucose maltose maltotriose respective molecular weights 150
0.18831623.8995253.html.plaintext.txt	64	Assuming dimensions carbohydrates reported 9 carbohydrates identical molecular weights molecular diameters 0
0.18831623.8995253.html.plaintext.txt	65	Hemolysis initiated addition 0
0.18831623.8995253.html.plaintext.txt	66	9 ml preparations containing HBL respective carbohydrates controls
0.18831623.8995253.html.plaintext.txt	67	The samples held 37 degrees C 75 min centrifuged
0.18831623.8995253.html.plaintext.txt	68	Hemolysis determined absorbance supernatants 540 nm
0.18831623.8995253.html.plaintext.txt	69	Percentage hemolysis calculated comparing absorbances samples positive 100 lysis saponin negative controls containing NaCl HBL 6
0.18831623.8995253.html.plaintext.txt	70	All samples prepared triplicate
0.18831623.8995253.html.plaintext.txt	71	Spectrophotometric Determination Activities B L Components HBL
0.18831623.8995253.html.plaintext.txt	72	1 depicts main steps reactions assay HBL components
0.18831623.8995253.html.plaintext.txt	73	Standard RBC suspensions consisting 1
0.18831623.8995253.html.plaintext.txt	74	3 x 107 cells ml1 prepared diluting washed cells TBS optical density OD 630 nm 1 cm path length 0
0.18831623.8995253.html.plaintext.txt	75	Below value OD630 directly proportional number intact cells present
0.18831623.8995253.html.plaintext.txt	76	Naive standardized RBCs primed lytic action L components treatment B component
0.18831623.8995253.html.plaintext.txt	77	Cells B primed state referred RBC B
0.18831623.8995253.html.plaintext.txt	78	The priming reaction reaction 1 Fig
0.18831623.8995253.html.plaintext.txt	79	1 conducted desired times RBCs primed 100 RBC B 42 degrees C 1
0.18831623.8995253.html.plaintext.txt	80	3 nM B unless otherwise indicated
0.18831623.8995253.html.plaintext.txt	81	After priming cells cooled 22 degrees C lysis initiated 1 ml cuvettes addition 7 microl L component stock 100 times desired final concentration 693 microl RBC B
0.18831623.8995253.html.plaintext.txt	82	1 measured continually decrease OD630 time
0.18831623.8995253.html.plaintext.txt	83	The activity B component measured proportion cells primed RBC B Fig
0.18831623.8995253.html.plaintext.txt	84	This proportion evident distinct terminal plateau lysis curve proportion primed cells estimated illustrated Fig
0.18831623.8995253.html.plaintext.txt	85	For samples low hemolytic activity terminal plateau approached gradually long assay period
0.18831623.8995253.html.plaintext.txt	86	In cases plateau measured point OD630 change least 12
0.18831623.8995253.html.plaintext.txt	87	Spectrophotometric determination activities B L components HBL
0.18831623.8995253.html.plaintext.txt	88	A representation steps comprising spectrophotometric hemolysis assay individual HBL components
0.18831623.8995253.html.plaintext.txt	89	In reaction 1 standardized RBC 1
0.18831623.8995253.html.plaintext.txt	90	3 x 107 RBC ml1 treated 1
0.18831623.8995253.html.plaintext.txt	91	During treatment RBC lyse rather slowly become primed lytic action combined L components
0.18831623.8995253.html.plaintext.txt	92	The priming reaction stopped cooling cells 22 degrees C primed cells RBC B distributed cuvettes
0.18831623.8995253.html.plaintext.txt	93	The addition combination two L components L12 produces reaction 2 rapid lysis RBC B
0.18831623.8995253.html.plaintext.txt	94	absorbance primed RBC generally lower starting OD value due slight dilution sample small amount spontaneous lysis OD differ untreated control cells
0.18831623.8995253.html.plaintext.txt	95	B graph time trace lysis B primed cells upon addition L12 illustrating reaction 2 panel A
0.18831623.8995253.html.plaintext.txt	96	Cells underwent priming reaction 1 37 degrees C 60 100 145 min indicated curve
0.18831623.8995253.html.plaintext.txt	97	After cooling lysis initiated simultaneous addition 2 nM two L components 0
0.18831623.8995253.html.plaintext.txt	98	The decrease time OD630 curve due hemolysis RBC B L12
0.18831623.8995253.html.plaintext.txt	99	The difference starting OD value plateau curve reflects discrete proportion erythrocytes primed RBC B given time
0.18831623.8995253.html.plaintext.txt	100	The values maximum hemolysis velocity OD630 min1 shown beside curve
0.18831623.8995253.html.plaintext.txt	101	Velocity varies directly concentration L12 given RBC B preparation used measure L activity
0.18831623.8995253.html.plaintext.txt	102	C priming reaction B 42 37 22 degrees C
0.18831623.8995253.html.plaintext.txt	103	Cells underwent reaction 1 42 37 22 degrees C times indicated x axis
0.18831623.8995253.html.plaintext.txt	104	RBC B calculated terminal plateaus lysis curves reaction 2 HBL assay
0.18831623.8995253.html.plaintext.txt	105	values corresponding lysis curves shown B
0.18831623.8995253.html.plaintext.txt	106	View Larger Version Image 32K GIF file
0.18831623.8995253.html.plaintext.txt	107	Stabilization RBC B Comparison Lytic Samples
0.18831623.8995253.html.plaintext.txt	108	With standard concentrations B RBC priming rate 42 degrees C 4
0.18831623.8995253.html.plaintext.txt	109	7 RBC B min1 22 degrees C rate 0
0.18831623.8995253.html.plaintext.txt	110	04 RBC B min1 2 3 h1 Fig
0.18831623.8995253.html.plaintext.txt	111	1C priming detectable 0 degrees C
0.18831623.8995253.html.plaintext.txt	112	Practically means priming reaction nearly stopped 22 degrees C
0.18831623.8995253.html.plaintext.txt	113	Since L components cause rapid lysis RBC B 22 degrees C multiple samples tested sequentially temperature stabilized RBC B compared assumption cells identically primed
0.18831623.8995253.html.plaintext.txt	114	The gel diffusion assay performed blood agar gel prepared described previously 5
0.18831623.8995253.html.plaintext.txt	115	Each well 3 mm diameter received 4 pmol 150 ng appropriate HBL components
0.18831623.8995253.html.plaintext.txt	116	The gel photographed 8 h 24 degrees C
0.18831623.8995253.html.plaintext.txt	117	Osmotic Protection Lysis HBL
0.18831623.8995253.html.plaintext.txt	118	It generally thought pore forming hemolysins cause lysis colloid osmotic mechanism
0.18831623.8995253.html.plaintext.txt	119	When pores form membrane external solutes smaller pores enter cell creating osmotic gradient
0.18831623.8995253.html.plaintext.txt	120	This turn produces net flow water cell swells lyses excess osmotic pressure
0.18831623.8995253.html.plaintext.txt	121	Osmotic protection experiments standard methods detecting colloid osmotic lysis
0.18831623.8995253.html.plaintext.txt	122	Theoretically pores defined size produced diameters external solutes larger diameters pores solutes cannot enter cell
0.18831623.8995253.html.plaintext.txt	123	This prevents production osmotic gradient thereby protecting cells lysis 9
0.18831623.8995253.html.plaintext.txt	124	Hemolysis due HBL decreased presence isotonic concentrations carbohydrates increasing size shown Fig
0.18831623.8995253.html.plaintext.txt	125	These results indicate HBL lyses cells colloid osmotic mechanism suggest conditions functional pores 1
0.18831623.8995253.html.plaintext.txt	126	This pore size considered rough estimate calculated values vary greatly assay conditions 9
0.18831623.8995253.html.plaintext.txt	127	Osmotic protection sheep erythrocytes HBL carbohydrates increasing size
0.18831623.8995253.html.plaintext.txt	128	Sheep erythrocytes suspended isosmotic concentrations NaCl carbohydrates increasing sizes indicated treated 0
0.18831623.8995253.html.plaintext.txt	129	The percentage cells lysed determined 75 min 37 degrees C
0.18831623.8995253.html.plaintext.txt	130	Additional experimental details provided Experimental Procedures
0.18831623.8995253.html.plaintext.txt	131	View Larger Version Image 20K GIF file
0.18831623.8995253.html.plaintext.txt	132	The Slow Priming Reaction B Component Versus Rapid Lytic Reaction L12
0.18831623.8995253.html.plaintext.txt	133	RBC lyse treated isolated B became primed lytic action combined L components
0.18831623.8995253.html.plaintext.txt	134	1B depicts three lysis curves generated simultaneous addition L components L12 RBC treated 37 degrees C times indicated curve
0.18831623.8995253.html.plaintext.txt	135	The difference starting OD terminal plateau following lysis phase curve measures discrete proportion cells primed B lytic action L12 RBC B
0.18831623.8995253.html.plaintext.txt	136	This value 42 37 22 degrees C 1
0.18831623.8995253.html.plaintext.txt	137	3 nM B plotted versus time Fig
0.18831623.8995253.html.plaintext.txt	138	Note time scale hours priming reaction Fig
0.18831623.8995253.html.plaintext.txt	139	1C seconds lysis reaction primed cells L12 Fig
0.18831623.8995253.html.plaintext.txt	140	The priming reaction B 47 37 22 degrees C respectively 1 2 3 orders magnitude lower lysis velocity 100 RBC B caused comparable concentrations L12 22 degrees C
0.18831623.8995253.html.plaintext.txt	141	This slow priming rate B corresponds slow hemolysis reaction occurs presence three HBL components 4 required 1
0.18831623.8995253.html.plaintext.txt	142	5 h complete lysis 37 degrees C
0.18831623.8995253.html.plaintext.txt	143	This shows priming reaction B component rate limiting step HBL hemolysis
0.18831623.8995253.html.plaintext.txt	144	Independent Binding L Components RBC Neutralization Membrane bound L Components
0.18831623.8995253.html.plaintext.txt	145	Naive RBC treated 22 degrees C 20 min 5 10 50 nM L1 5 nM L2
0.18831623.8995253.html.plaintext.txt	146	The cells washed twice centrifugation cold TBS free L concentration reduced factor least 5 x 105
0.18831623.8995253.html.plaintext.txt	147	Washed cells diluted OD630 0
0.18831623.8995253.html.plaintext.txt	148	The washed L treated RBC naive RBC primed 42 degrees C B 1 h described
0.18831623.8995253.html.plaintext.txt	149	Lysis initiated addition appropriate L component 5 nM indicated Fig
0.18831623.8995253.html.plaintext.txt	150	Independent binding RBC L1 L2 components
0.18831623.8995253.html.plaintext.txt	151	Standardized naive RBC pretreated either L1 top L2 bottom concentrations indicated beside curve
0.18831623.8995253.html.plaintext.txt	152	The L treated cells washed primed B 1 h
0.18831623.8995253.html.plaintext.txt	153	Lysis primed cells initiated 0 addition 5 nM L2 L1 treated cells top 5 nM L1 L2 treated cells bottom
0.18831623.8995253.html.plaintext.txt	154	The control samples naive RBCs pretreated L1 L2 primed B 1 h
0.18831623.8995253.html.plaintext.txt	155	Each L component added separate control sample 0 lysis initiated 300 addition complementary L component
0.18831623.8995253.html.plaintext.txt	156	View Larger Version Image 31K GIF file
0.18831623.8995253.html.plaintext.txt	157	Cells pretreated either L component primed B lysed upon addition complementary L component
0.18831623.8995253.html.plaintext.txt	158	Control RBC B without pretreatment L component lyse upon addition either L component lysed rapidly upon subsequent addition complementary L component
0.18831623.8995253.html.plaintext.txt	159	Pretreatment L1 less effective L2 possibly due lower affinity L1 RBC
0.18831623.8995253.html.plaintext.txt	160	Neutralization Membrane associated HBL Components
0.18831623.8995253.html.plaintext.txt	161	In experiment depicted Fig
0.18831623.8995253.html.plaintext.txt	162	3 specific neutralizing antibodies L1 L2 added 0 RBC B L1 5 nM L1 RBC B L2 5 nM L2 respectively
0.18831623.8995253.html.plaintext.txt	163	Each antibody completely inhibited lysis complementary L component least 1 h
0.18831623.8995253.html.plaintext.txt	164	When specific antibodies B component mixed B prior addition naive RBC priming reaction completely inhibited
0.18831623.8995253.html.plaintext.txt	165	However antibodies added priming reaction
0.18831623.8995253.html.plaintext.txt	166	added 100 RBC B partial inhibition lysis L12
0.18831623.8995253.html.plaintext.txt	167	The simultaneous addition L12 B specific antibodies RBC B resulted 30 inhibition lysis velocity see point 0 Fig
0.18831623.8995253.html.plaintext.txt	168	Pretreatment RBC B antibodies increased inhibition lysis time dependent manner Fig
0.18831623.8995253.html.plaintext.txt	169	Inhibition also increased increasing antibody dose data shown
0.18831623.8995253.html.plaintext.txt	170	As control L12 preparation treated anti B antibody prior addition RBC B
0.18831623.8995253.html.plaintext.txt	171	There significant effect inhibition lysis although concentration antibody exposed L12 100 times exposed RBC B
0.18831623.8995253.html.plaintext.txt	172	This indicates inhibitory effect antibody due interaction B surface RBC B due interaction L12 preparation
0.18831623.8995253.html.plaintext.txt	173	These results demonstrate detectable difference B unprimed versus primed state
0.18831623.8995253.html.plaintext.txt	174	Inhibition L induced lysis RBC B antibodies specific component B
0.18831623.8995253.html.plaintext.txt	175	Hemolysis 100 RBC B initiated addition L12 presence absence specific antibodies B component HBL
0.18831623.8995253.html.plaintext.txt	176	The antibodies preincubated either RBC B cells L12 preparation distinguish whether inhibition specific B due cross reaction L12
0.18831623.8995253.html.plaintext.txt	177	The x axis indicates time RBC B L12 preincubated antibodies
0.18831623.8995253.html.plaintext.txt	178	At 0 x axis antibodies L12 RBC B mixed simultaneously
0.18831623.8995253.html.plaintext.txt	179	Circles RBC B incubated antibodies addition L12 times indicated x axis
0.18831623.8995253.html.plaintext.txt	180	Squares L12 incubated antibodies addition RBC B times indicated x axis
0.18831623.8995253.html.plaintext.txt	181	The inhibitory activity antibodies expressed y axis percentage maximum lysis velocity decreased compared simultaneously run control samples containing antibody inhibition
0.18831623.8995253.html.plaintext.txt	182	View Larger Version Image 21K GIF file
0.18831623.8995253.html.plaintext.txt	183	Inhibition Hemolysis Excess Component B
0.18831623.8995253.html.plaintext.txt	184	We previously found equal concentrations three HBL components simultaneously varied hemolysis exhibited paradoxical zone phenomenon 4
0.18831623.8995253.html.plaintext.txt	185	Hemolysis higher within certain low concentration range higher concentrations
0.18831623.8995253.html.plaintext.txt	186	The effect concentration B component priming rate B lysis velocity L12 illustrated Fig
0.18831623.8995253.html.plaintext.txt	187	The extent priming L induced lysis velocity maximal around 1
0.18831623.8995253.html.plaintext.txt	188	When time course priming 37 degrees C followed maximum priming rate inflection point sigmoidal priming curve 1
0.18831623.8995253.html.plaintext.txt	189	5 nM B supporting idea antagonistic effect excess B shown
0.18831623.8995253.html.plaintext.txt	190	5 nM B priming rate increased slightly lysis velocity inhibited
0.18831623.8995253.html.plaintext.txt	191	Inhibition L1 induced lysis excess component B
0.18831623.8995253.html.plaintext.txt	192	A effect concentration B priming reaction B lysis velocity L12
0.18831623.8995253.html.plaintext.txt	193	Erythrocytes primed 37 degrees C 60 min B concentrations indicated x axis
0.18831623.8995253.html.plaintext.txt	194	Lysis initiated addition 5 nM L12
0.18831623.8995253.html.plaintext.txt	195	The percentage primed cells RBC B lysis velocity measured described Experimental Procedures
0.18831623.8995253.html.plaintext.txt	196	B inhibition hemolysis RBC B Bi
0.18831623.8995253.html.plaintext.txt	197	Bi 5 nM added primed erythrocytes prior simultaneously following L12 2 nM
0.18831623.8995253.html.plaintext.txt	198	The labels curve indicate time min Bi added relative 0 x axis
0.18831623.8995253.html.plaintext.txt	199	Inset plot percentage inhibition velocity versus time addition Bi
0.18831623.8995253.html.plaintext.txt	200	C inhibition L1 L2 Bi
0.18831623.8995253.html.plaintext.txt	201	Lysis curves A B generated addition L components 100 RBC B 0 180 closed arrow order indicated beside curve
0.18831623.8995253.html.plaintext.txt	202	When excess B added 0 inhibition A B occurred
0.18831623.8995253.html.plaintext.txt	203	However Bi added 180 inhibition occurred B A
0.18831623.8995253.html.plaintext.txt	204	percentage inhibition lysis velocity curve A L1 0 L2 180 occurred Bi added 0 180
0.18831623.8995253.html.plaintext.txt	205	For symbol abscissa corresponds time Bi added ordinate corresponds percentage inhibition sample
0.18831623.8995253.html.plaintext.txt	206	Open arrow point RBC B completely lysed addition 0 combination L components 2 nM
0.18831623.8995253.html.plaintext.txt	207	View Larger Version Image 22K GIF file
0.18831623.8995253.html.plaintext.txt	208	The inhibitory effect excess B L12 observed even B added previously primed erythrocytes Fig
0.18831623.8995253.html.plaintext.txt	209	Erythrocytes completely primed 100 RBC B stabilized excess B inhibitory concentration Bi added prior simultaneously following L12
0.18831623.8995253.html.plaintext.txt	210	The addition Bi simultaneously L12 resulted nearly 60 inhibition lysis velocity
0.18831623.8995253.html.plaintext.txt	211	Inhibition increase B preincubated RBC B inhibition decreased drastically B added L12
0.18831623.8995253.html.plaintext.txt	212	This indicates conditions B alter cell surface interfere either binding intermediate step one L components B interfere lysis binding intermediate step occurred
0.18831623.8995253.html.plaintext.txt	213	The sequential addition L1 L2 Bi RBC B various permutations indicated Bi inhibits L1 L2 Fig
0.18831623.8995253.html.plaintext.txt	214	When either L component added RBC B cells lyse second L added Fig
0.18831623.8995253.html.plaintext.txt	215	When Bi added 0 lysis inhibited regardless order addition L components
0.18831623.8995253.html.plaintext.txt	216	But Bi added L component 180 inhibition occurred L1 added time curve B suggesting B interferes L1 L2
0.18831623.8995253.html.plaintext.txt	217	With respect curve A L1 0 L2 180 Bi inhibited lysis added 0 added 180
0.18831623.8995253.html.plaintext.txt	218	The kinetics loss inhibitory activity Bi graphically illustrated closed circle scatter plot Fig
0.18831623.8995253.html.plaintext.txt	219	When L1 added first 0 less inhibition occurred later Bi added inhibition occurred 180
0.18831623.8995253.html.plaintext.txt	220	RBC primed B presence increasing concentrations either L1 L2 extent priming measured addition complementary L component Fig
0.18831623.8995253.html.plaintext.txt	221	L1 drastically inhibited priming reaction 1
0.18831623.8995253.html.plaintext.txt	222	The inhibition dose response similar inhibition L1 B Fig
0.18831623.8995253.html.plaintext.txt	223	The priming reaction B could inhibited adding excess concentration L1 time 100 RBC B occurred Fig
0.18831623.8995253.html.plaintext.txt	224	The L2 component significantly inhibit priming reaction concentration range tested Bi inhibit L2
0.18831623.8995253.html.plaintext.txt	225	Inhibition component B excess L1
0.18831623.8995253.html.plaintext.txt	226	A effect concentrations L1 L2 priming reaction B
0.18831623.8995253.html.plaintext.txt	227	RBCs primed 42 degrees C 1
0.18831623.8995253.html.plaintext.txt	228	3 mM B presence either L1 L2 concentrations indicated x axis
0.18831623.8995253.html.plaintext.txt	229	The extent priming measured 1 h addition complementary L component 5 nM lyse susceptible cells described Experimental Procedures
0.18831623.8995253.html.plaintext.txt	230	Inset inhibition B component addition L1 5 nM time priming
0.18831623.8995253.html.plaintext.txt	231	Excess L1 either added circles added 5 squares 15 min triangles indicated arrows
0.18831623.8995253.html.plaintext.txt	232	The extent priming RBC B determined times indicated x axis addition L2 RBC B
0.18831623.8995253.html.plaintext.txt	233	B inhibition hemolysis gel diffusion assay excess L1
0.18831623.8995253.html.plaintext.txt	234	Lack lysis observed within intersections HBL hemolysis zones
0.18831623.8995253.html.plaintext.txt	235	The diffusion assay performed blood agar gel prepared described previously 10
0.18831623.8995253.html.plaintext.txt	236	Each well 3 mm diameter received 4 pmol 150 ng respective HBL components
0.18831623.8995253.html.plaintext.txt	237	Wells labeled H received three HBL components
0.18831623.8995253.html.plaintext.txt	238	The remaining wells received components B L1 L2 indicated
0.18831623.8995253.html.plaintext.txt	239	The gel photographed 8 h 24 degrees C
0.18831623.8995253.html.plaintext.txt	240	View Larger Version Image 46K GIF file
0.18831623.8995253.html.plaintext.txt	241	An implication observations blood agar inhibition lysis near HBL diffusion source intersections lysis zones 10 function mutual inhibitory activity B L1
0.18831623.8995253.html.plaintext.txt	242	To test idea separated components added wells adjacent wells containing three components Fig
0.18831623.8995253.html.plaintext.txt	243	Consistent observations L1 component inhibited lysis adjacent zone L2 component apparent effect adjacent pattern
0.18831623.8995253.html.plaintext.txt	244	Lysis enhanced adjacent B component
0.18831623.8995253.html.plaintext.txt	245	This superficially contradicts observation excess B inhibits lysis L1 consistent overall kinetics system discussed
0.18831623.8995253.html.plaintext.txt	246	Among greater 300 described bacterial toxins several require two different individually soluble proteins toxic activity 11 none require three components
0.18831623.8995253.html.plaintext.txt	247	These binary toxins include staphylococcal hemolysin related leukocidins 12 13 anthrax toxin 14 Clostridium botulinum C2 related toxins Clostridium perfringens Clostridium spiroforme Clostridium difficile 15 Bacillus sphaericus binary toxin 16
0.18831623.8995253.html.plaintext.txt	248	For except possibly B
0.18831623.8995253.html.plaintext.txt	249	sphaericus toxin components exhibit compulsory cell binding order
0.18831623.8995253.html.plaintext.txt	250	Also protective antigen anthrax toxin acts docking protein must cleaved cellular protease complementary proteins bind
0.18831623.8995253.html.plaintext.txt	251	The observations presented allowed us address related questions mechanism HBL helped answer three basic questions
0.18831623.8995253.html.plaintext.txt	252	Does HBL cause lysis enzymatically formation membrane attack complex Do HBL components act randomly compulsory order What basis paradoxical zone phenomenon exhibited HBL
0.18831623.8995253.html.plaintext.txt	253	Hemolysins thought lyse cells two general mechanisms 17
0.18831623.8995253.html.plaintext.txt	254	First cell surface may enzymatically altered extent causes membrane degeneration
0.18831623.8995253.html.plaintext.txt	255	This usually involves phospholipases numerous examples hemolysis require two enzymes acting compulsory order 18
0.18831623.8995253.html.plaintext.txt	256	In systems phospholipase acts cell subsequently lysed nonphospholipase enzyme nonenzymatic protein
0.18831623.8995253.html.plaintext.txt	257	In second hemolysis mechanism lysin molecules insert membrane form functional transmembrane pores 19 leaky patches 20
0.18831623.8995253.html.plaintext.txt	258	Such lesions generally composed oligomers one protein multiple proteins
0.18831623.8995253.html.plaintext.txt	259	Complement example lytic system produces lesions composed one different protein
0.18831623.8995253.html.plaintext.txt	260	Complement lesions called membrane attack complexes MACs account multicomponent composition 21
0.18831623.8995253.html.plaintext.txt	261	Hemolysins may also exhibit detergent like activity solubilize membranes mechanism may occur hemolytic proteins 17
0.18831623.8995253.html.plaintext.txt	262	3 demonstrates L components bound erythrocyte membranes independently HBL component
0.18831623.8995253.html.plaintext.txt	263	After priming L1 L2 treated washed cells B addition antibodies specific either membrane bound L component completely neutralized hemolysis complementary L component
0.18831623.8995253.html.plaintext.txt	264	This indicates L components remained associated membranes washing needed present competent lytic lesion formed
0.18831623.8995253.html.plaintext.txt	265	It also strongly suggests competent lesion formed L1 L2 physically interact cell surface definition describes MAC
0.18831623.8995253.html.plaintext.txt	266	If L components simple enzymes caused lysis independently damaging membranes antibodies L component would reverse membrane damage protect cells lysis HBL components
0.18831623.8995253.html.plaintext.txt	267	It appears therefore HBL ultimately causes lysis forming lesion analogous complement MAC minimum structure consisting L1 L2 heterodimer
0.18831623.8995253.html.plaintext.txt	268	Osmotic protection erythrocytes treated HBL Fig
0.18831623.8995253.html.plaintext.txt	269	2 suggests putative MAC results formation transmembrane pores indicate whether pores protein lined simply perturbations phospholipid bilayer surrounding HBL components
0.18831623.8995253.html.plaintext.txt	270	Antibodies specific B component also interfered ability L components lyse B primed cells Fig
0.18831623.8995253.html.plaintext.txt	271	4 suggesting L components interact B form integral three component heteromeric membrane lesion
0.18831623.8995253.html.plaintext.txt	272	However although anti B antibodies completely neutralized autonomous priming reaction B could partially inhibit lysis cells primed
0.18831623.8995253.html.plaintext.txt	273	If HBL lysis involve three component MAC several possibilities might occur priming reaction decreases ability anti B antibodies neutralize lysis
0.18831623.8995253.html.plaintext.txt	274	During priming B component may insert membrane possibly forming oligomers
0.18831623.8995253.html.plaintext.txt	275	This would allow antibodies bind exposed portions B portions sequestered within membrane
0.18831623.8995253.html.plaintext.txt	276	Any conformational changes experienced B might also decrease avidity antibodies prepared native conformation
0.18831623.8995253.html.plaintext.txt	277	It also possible B altered membrane component occurs proteolytic processing protective antigen component anthrax toxin 14
0.18831623.8995253.html.plaintext.txt	278	Antibodies prepared native B may bind poorly processed version
0.18831623.8995253.html.plaintext.txt	279	The inability anti B antibodies completely neutralize lysis RBC B L12 might also diagnostic enzymatic mechanism B
0.18831623.8995253.html.plaintext.txt	280	A situation envisioned B binds membrane converts substrate product subsequently recognized L components leading lysis
0.18831623.8995253.html.plaintext.txt	281	If product accumulate pool immediate vicinity membrane bound B partial inhibition might occur B associated antibody sterically prevented access L components product
0.18831623.8995253.html.plaintext.txt	282	Such mechanism seems rather unlikely cannot ruled present observations
0.18831623.8995253.html.plaintext.txt	283	The next question addressed data whether HBL components act ordered random manner
0.18831623.8995253.html.plaintext.txt	284	1 3 three HBL components bind erythrocytes independently
0.18831623.8995253.html.plaintext.txt	285	However pointed Ponder 1948 6 hemolysis relatively complex multistep process
0.18831623.8995253.html.plaintext.txt	286	Pore assembly models staphylococcal toxin streptolysin O provide examples multistep process 22
0.18831623.8995253.html.plaintext.txt	287	Toxin monomers bind membranes diffuse laterally prepore complex membrane surface subsequently insert form pores
0.18831623.8995253.html.plaintext.txt	288	SLO also binds monomers undergoes rate limiting nucleation process involving formation dimers membrane surface followed dimer insertion rapid accumulation monomers around dimer nucleus form functional lesion
0.18831623.8995253.html.plaintext.txt	289	The complexity processes demonstrates simple association toxin components erythrocytes provide picture overall hemolysis mechanism
0.18831623.8995253.html.plaintext.txt	290	Our evidence suggests HBL components form pores form complex
0.18831623.8995253.html.plaintext.txt	291	The L1 L2 components rapidly contribute complex manner appear depend sequence addition
0.18831623.8995253.html.plaintext.txt	292	However B component clearly must undergo autonomous rate limiting reaction functional lesion formed L components
0.18831623.8995253.html.plaintext.txt	293	Therefore although components bind independently cell final lesion formation appears follow specific order respect B L components
0.18831623.8995253.html.plaintext.txt	294	It possible appearance ordered reaction artifact kinetics individual components
0.18831623.8995253.html.plaintext.txt	295	All components might undergo analogous independent priming reactions reaction B extremely slow relative reactions L components
0.18831623.8995253.html.plaintext.txt	296	However data suggest priming process followed B fundamentally different followed L components antibodies could completely protect cells reacted either membrane associated L component reacted B primed cells
0.18831623.8995253.html.plaintext.txt	297	The cause paradoxical zone phenomenon HBL third major mechanistic question addressed data
0.18831623.8995253.html.plaintext.txt	298	5 6 indicate B L1 mutually inhibitory threshold concentration antagonism responsible paradoxical hemolysis behavior seen gel diffusion suspension assays
0.18831623.8995253.html.plaintext.txt	299	In dose response curve priming reaction B Fig
0.18831623.8995253.html.plaintext.txt	300	5A lysis velocity reaction 2 Fig
0.18831623.8995253.html.plaintext.txt	301	1A L12 decreased increasing concentrations B even cells primed
0.18831623.8995253.html.plaintext.txt	302	5B shows lysis velocity could inhibited even Bi added cells completely primed 100 RBC B
0.18831623.8995253.html.plaintext.txt	303	The inhibition lysis increase RBC B pretreated Bi Fig
0.18831623.8995253.html.plaintext.txt	304	5B inset indicating inhibition due enzymatic action Bi cells
0.18831623.8995253.html.plaintext.txt	305	Inhibition decreased however Bi added L1 Fig
0.18831623.8995253.html.plaintext.txt	306	5 B C indicating Bi interferes incorporation L1 lesion function preformed lesion
0.18831623.8995253.html.plaintext.txt	307	The kinetics inhibition L1 B Fig
0.18831623.8995253.html.plaintext.txt	308	Inhibition decreased linearly time r 0
0.18831623.8995253.html.plaintext.txt	309	This suggests first order process incorporation L1 lesions distinct contrast complex shape hemolysis curves
0.18831623.8995253.html.plaintext.txt	310	This type measurement possible special situation B appear interfere lysis L1 incorporated lesion
0.18831623.8995253.html.plaintext.txt	311	6 shows threshold concentration L1 also inhibited priming reaction B
0.18831623.8995253.html.plaintext.txt	312	The dose response L1 mediated inhibition priming reaction nearly identical inhibition L1 excess B Fig
0.18831623.8995253.html.plaintext.txt	313	In addition excess L1 inhibited hemolysis caused HBL placed adjacent wells blood agar Fig
0.18831623.8995253.html.plaintext.txt	314	The hemolysis data presented provide explanation paradoxical zone phenomenon HBL lysis patterns seen Fig
0.18831623.8995253.html.plaintext.txt	315	HBL hemolysis blood agar discontinuous begins away well containing components
0.18831623.8995253.html.plaintext.txt	316	However diffusing molecules create continuous concentration gradient components must therefore reach concentration promotes hemolysis every point well edge zone lysis begins paradox propose following model explain
0.18831623.8995253.html.plaintext.txt	317	A cell lyse unless primed B maximal priming occurs permissive concentrations B L1
0.18831623.8995253.html.plaintext.txt	318	When membrane bound B L1 exceeds critical ratio versus membrane constituent component inhibited forming functional lesion perhaps produces inefficient lesion
0.18831623.8995253.html.plaintext.txt	319	Priming B slow since L1 inhibit B time reaction Fig
0.18831623.8995253.html.plaintext.txt	320	6A insert priming inhibited near well L1 diffuses rapidly enough accumulate inhibitory levels cells primed
0.18831623.8995253.html.plaintext.txt	321	Hemolysis begins zone B concentration high enough prime cells diffusion rate L1 low reach inhibitory concentration cells primed
0.18831623.8995253.html.plaintext.txt	322	Inhibition intersections zones due accumulation excess L1 cells primed
0.18831623.8995253.html.plaintext.txt	323	It unlikely inhibition caused excess ratio B L1 vice versa paradoxical zone phenomenon occurs suspension assays simply increasing concentration three components constant ratio others 4
0.18831623.8995253.html.plaintext.txt	324	The influence hemolysis patterns inhibitory effect L1 seen Fig
0.18831623.8995253.html.plaintext.txt	325	Just lysis inhibited intersections HBL hemolysis zones lysis also inhibited intersection HBL hemolysis zone L1 diffusion zone
0.18831623.8995253.html.plaintext.txt	326	6A L2 appreciable effect adjacent hemolysis pattern
0.18831623.8995253.html.plaintext.txt	327	The enhanced lysis wells containing either HBL B seems contradictory light observation excess B inhibits lysis L1 consistent mechanism HBL
0.18831623.8995253.html.plaintext.txt	328	The B component primes cells independently components Fig
0.18831623.8995253.html.plaintext.txt	329	1 B C primed cells rapidly lysed concentration L12
0.18831623.8995253.html.plaintext.txt	330	The lysis within B diffusion zone occurred simply cells primed B absence inhibitory concentrations L1
0.18831623.8995253.html.plaintext.txt	331	The priming reaction B 1000 times slower lytic action L1 room temperature
0.18831623.8995253.html.plaintext.txt	332	Therefore even presence excess B lysis rate RBC B noticeably slower rate cells primed B
0.18831623.8995253.html.plaintext.txt	333	On hand inhibition L1 priming reaction B profoundly evident
0.18831623.8995253.html.plaintext.txt	334	This seems born lysis patterns Fig
0.18831623.8995253.html.plaintext.txt	335	Our hemolysis data provide insights mechanism HBL appears involve novel modes interactions proteins membranes
0.18831623.8995253.html.plaintext.txt	336	The three proteins comprise HBL collectively called toxin early simplifying assumption represent single functional unit bacterium produces
0.18831623.8995253.html.plaintext.txt	337	This work supports assumption
0.18831623.8995253.html.plaintext.txt	338	New findings show genes three components arranged immediately adjacent one another probably operon 8 lending additional weight idea three proteins comprise functional unit
0.18831623.8995253.html.plaintext.txt	339	HBL unlike previously described cytolytic toxin complex composition unique hemolytic phenomena causes
0.18831623.8995253.html.plaintext.txt	340	Further study toxin promises add new perspective perceptions mechanisms utility cytolytic toxins
0.18831623.8995253.html.plaintext.txt	341	This work supported National Research Initiative Competitive Grants Program U
0.18831623.8995253.html.plaintext.txt	342	Department Agriculture Grant 93 37201 9194 College Agriculture Life Sciences University Wisconsin
0.18831623.8995253.html.plaintext.txt	343	The costs publication article defrayed part payment page charges
0.18831623.8995253.html.plaintext.txt	344	The article must therefore hereby marked advertisement accordance 18 U
0.18831623.8995253.html.plaintext.txt	345	Section 1734 solely indicate fact
0.18831623.8995253.html.plaintext.txt	346	To correspondence addressed Food Research Inst
0.18831623.8995253.html.plaintext.txt	347	Food Microbiology Toxicology University Wisconsin 1925 Willow Dr
0.18831623.8995253.html.plaintext.txt	348	608 263 1177 Fax 608 263 1114 E mail dbeecheratfacstaff
0.18831623.8995253.html.plaintext.txt	349	1 The abbreviations used HBL hemolysin BL L12 combination HBL components L1 L2 RBC red blood cells RBC B erythrocytes primed B component HBL lytic action combination two L components Bi inhibitory concentration B TBS Tris buffered saline MAC membrane attack complex
0.18831623.8995253.html.plaintext.txt	350	Cleland helpful discussion Jean L
0.18831623.8995253.html.plaintext.txt	351	Schoeni purification IgG fractions antisera Protein G chromatography
0.18831623.8995253.html.plaintext.txt	352	63 4423 4428 Abstract Beecher D
0.18831623.8995253.html.plaintext.txt	353	63 632 639 Abstract Beecher D
0.18831623.8995253.html.plaintext.txt	354	59 1778 1784 Medline Order article via Infotrieve Beecher D
0.18831623.8995253.html.plaintext.txt	355	62 980 986 Abstract Beecher D
0.18831623.8995253.html.plaintext.txt	356	58 2220 2227 Medline Order article via Infotrieve Ponder E
0.18831623.8995253.html.plaintext.txt	357	1948 Hemolysis Related Phenomena pp
0.18831623.8995253.html.plaintext.txt	358	168 257 Grune Stratton New York Heinrichs J
0.18831623.8995253.html.plaintext.txt	359	175 6760 6766 Abstract Ryan P
0.18831623.8995253.html.plaintext.txt	360	1996 96th General Meeting American Society Microbiology New Orleans May 19 23 p
0.18831623.8995253.html.plaintext.txt	361	384 American Society Microbiology Washington D
0.18831623.8995253.html.plaintext.txt	362	62 4124 4134 Abstract Beecher D
0.18831623.8995253.html.plaintext.txt	363	60 1646 1651 Abstract Alouf J
0.18831623.8995253.html.plaintext.txt	364	1994 Bacterial Protein Toxins Zentralblatt fur Bakteriologie Freer J
0.18831623.8995253.html.plaintext.txt	365	3 28 Gustav Fischer Stuttgart Prevost G
0.18831623.8995253.html.plaintext.txt	366	1994 Bacterial Protein Toxins Zentralblatt fur Bakteriologie Freer J
0.18831623.8995253.html.plaintext.txt	367	284 293 Gustav Fischer Stuttgart Prevost G
0.18831623.8995253.html.plaintext.txt	368	63 4121 4129 Abstract Leppla S
0.18831623.8995253.html.plaintext.txt	369	1991 Sourcebook Bacterial Protein Toxins Alouf J
0.18831623.8995253.html.plaintext.txt	370	277 302 Academic Press London Rappuoli R
0.18831623.8995253.html.plaintext.txt	371	1991 Sourcebook Bacterial Protein Toxins Alouf J
0.18831623.8995253.html.plaintext.txt	372	1 21 Academic Press London Baumann P
0.18831623.8995253.html.plaintext.txt	373	1991 Sourcebook Bacterial Protein Toxins Alouf J
0.18831623.8995253.html.plaintext.txt	374	101 115 Academic Press London Fehrenbach F
0.18831623.8995253.html.plaintext.txt	375	1991 Sourcebook Bacterial Protein Toxins Alouf J
0.18831623.8995253.html.plaintext.txt	376	187 213 Academic Press London Bhakdi S
0.18831623.8995253.html.plaintext.txt	377	Today 12 318 320 Medline Order article via Infotrieve Esser A
0.18831623.8995253.html.plaintext.txt	378	Today 12 316 318 Medline Order article via Infotrieve Esser A
0.18831623.8995253.html.plaintext.txt	379	1994 Toxicology 87 229 247 Medline Order article via Infotrieve Bhakdi S
0.18831623.8995253.html.plaintext.txt	380	165 71 79 CrossRef 1997 The American Society Biochemistry Molecular Biology Inc
0.25463712.11842080.html.plaintext.txt	0	Structural Requirements within Lipoyl Domain Ca2 dependent Binding Activation Pyruvate Dehydrogenase Phosphatase Isoform 1 Its Catalytic Subunit Ali Turkan Xiaoming Gong Tao Peng Thomas E
0.25463712.11842080.html.plaintext.txt	1	From Department Biochemistry Kansas State University Manhattan Kansas 66506
0.25463712.11842080.html.plaintext.txt	2	Received publication August 31 2001 revised form January 4 2002
0.25463712.11842080.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.25463712.11842080.html.plaintext.txt	4	The inner lipoyl domain L2 dihydrolipoyl acetyltransferase E2 60 mer forms Ca2 dependent complex pyruvate dehydrogenase phosphatase 1 PDP1 catalytic subunit PDP1c facilitating large enhancements activities PDP1 10 fold PDP1c 6 fold
0.25463712.11842080.html.plaintext.txt	5	L2 binding PDP1 PDP1c requires lipoyl lysine prosthetic group specificity residues distinguish L2 lipoyl domains L1 E2 L3 E3 binding component
0.25463712.11842080.html.plaintext.txt	6	The L2 surface structure contributing binding mapped comparing capacities well folded mutant lipoyl analog substituted L2 domains interfere E2 activation competitively binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	7	Our results reveal critical importance regional set residues near lipoyl group octanoyl dithiolane ring structure lipoyl group
0.25463712.11842080.html.plaintext.txt	8	At end lipoyl domain substitution Glu182 alanine glutamine removed L2 binding PDP1 PDP1c substitutions neighboring Glu179 also greatly hindered complex formation E179A E179Q
0.25463712.11842080.html.plaintext.txt	9	Among 11 substitutions L2 sites major surface residue differences L1 L2 domains conversion Val Gln181 located critical Glu179 Glu182 aligned Ser Leu sequence L1 domain greatly reduced L2 binding
0.25463712.11842080.html.plaintext.txt	10	Certain modified L2 altered E2 activation PDP1 differently PDP1c supporting significant impact regulatory PDP1r subunit PDP1 binding L2
0.25463712.11842080.html.plaintext.txt	11	Our results indicate hydrophobic binding via extended aliphatic structure lipoyl group required adjacent L2 structure anchor PDP1 acting concert acidic cluster end domain
0.25463712.11842080.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.25463712.11842080.html.plaintext.txt	13	The pyruvate dehydrogenase complex PDC1 catalyzes irreversible conversion pyruvate acetyl CoA reduction NAD via sequential action pyruvate dehydrogenase E1 dihydrolipoyl acetyltransferase E2 dihydrolipoyl dehydrogenase E3 components
0.25463712.11842080.html.plaintext.txt	14	Mammalian PDC organized around central framework formed assembly 60 E2 subunits
0.25463712.11842080.html.plaintext.txt	15	E2 consists four independently folded domains connected mobile linker regions 20 30 amino acids length 1 4
0.25463712.11842080.html.plaintext.txt	16	Association 20 trimer units E2s C terminal domain produces central cavity shape dodecahedron
0.25463712.11842080.html.plaintext.txt	17	At surface assembled inner core connected first linker region 5 kDa domain binds E1 component 5 6 20 30 E1 tetramers 22 anchored per E2 60 mer 7
0.25463712.11842080.html.plaintext.txt	18	Then set two linker regions E2 structure two 10 kDa lipoyl domains interior one L2 NH2 terminal one L1
0.25463712.11842080.html.plaintext.txt	19	An E3 binding protein E3BP multidomain structure similar E2 consisting three linker region connected globular domains 8 9
0.25463712.11842080.html.plaintext.txt	20	The C terminal domain E3BP binds E2s inner domain followed intervening linker regions first domain binds E3 single lipoyl domain designated L3 N terminus 5 8 10 12 14
0.25463712.11842080.html.plaintext.txt	21	Mammalian PDC tightly regulated phosphorylation dephosphorylation cycle determines proportion active nonphosphorylated E1 2 4 15
0.25463712.11842080.html.plaintext.txt	22	PDC inactivation E1 carried pyruvate dehydrogenase kinase PDK reactivation pyruvate dehydrogenase phosphatase PDP
0.25463712.11842080.html.plaintext.txt	23	PDC regulated least four PDK isoforms two PDP isoforms variably expressed different tissues 16 20
0.25463712.11842080.html.plaintext.txt	24	In Ca2 sensitive tissues pyruvate dehydrogenase phosphatase 1 PDP1 dominant phosphatase isoform 20
0.25463712.11842080.html.plaintext.txt	25	PDP1 catalyzes Mg2 requiring Ca2 stimulated dephosphorylation activation E1 15 21 22
0.25463712.11842080.html.plaintext.txt	26	PDP1 activity enhanced manyfold phosphorylated E1 PDP1 bound E2 60 mer 23 24
0.25463712.11842080.html.plaintext.txt	27	Indeed Ca2 stimulation requires E2 PDP1 binds E2 via interaction requires Ca2 23 micromolar levels 22
0.25463712.11842080.html.plaintext.txt	28	The magnitude enhancement typically 7 16 fold primarily depends level free phosphorylated E1 absence E2 kinetically results near saturated activity presence E2 compared activity varies greatly level phosphorylated E1
0.25463712.11842080.html.plaintext.txt	29	Thus major decrease apparent Km PDP1 phosphorylated E1 upon concentrating PDP1 along phosphorylated E1 surface E2 core 23
0.25463712.11842080.html.plaintext.txt	30	Ca2 also causes 2 fold decrease Km PDP1 Mg2 25
0.25463712.11842080.html.plaintext.txt	31	PDP1 composed two subunits 26 27
0.25463712.11842080.html.plaintext.txt	32	Its catalytic subunit PDP1c mass 52
0.25463712.11842080.html.plaintext.txt	33	6 kDa phosphatase 2C class shares 20 sequence identity rat cytosolic isoforms phosphatase 2C 28
0.25463712.11842080.html.plaintext.txt	34	The subunit PDP1r mass 96 kDa serves regulatory role elevating concentration Mg2 required efficient PDP1c catalysis 29
0.25463712.11842080.html.plaintext.txt	35	The PDP1r subunit flavoprotein bound FAD sequence PDP1r distantly related mitochondrial flavoprotein dimethylglycine dehydrogenase 30 functions choline degradation
0.25463712.11842080.html.plaintext.txt	36	Spermine lesser degree polyamines reduce Km PDP1 Mg2 31 probably binding PDP1r reverse effect subunit elevating Mg2 responsiveness 29
0.25463712.11842080.html.plaintext.txt	37	The PDP2 isoform even higher Km Mg2 reduced 15 mM 3 mM direct interaction spermine recombinantly produced PDP2 consists catalytic subunit
0.25463712.11842080.html.plaintext.txt	38	Rat PDP2 shares 55 sequence identity rat PDP1c PDP2 activated Ca2 20
0.25463712.11842080.html.plaintext.txt	39	A similar diminution concentration dependence PDP activity Mg2 produced insulin sustained permeabilized mitochondria prepared insulin treated adipose tissue 32
0.25463712.11842080.html.plaintext.txt	40	This probably involves change activity PDP2 located adipose tissue 20
0.25463712.11842080.html.plaintext.txt	41	The L2 domain E2 selectively binds PDP1 association specifically engages L2s lipoyl prosthetic group 33 34
0.25463712.11842080.html.plaintext.txt	42	PDP1 interact productively L1 domain E2 33 34 lipoyl domain E3BP reported herein
0.25463712.11842080.html.plaintext.txt	43	PDP1c alone undergoes Ca2 dependent binding activation 28 via association L2 domain Ref
0.25463712.11842080.html.plaintext.txt	44	Using gel anchored GST L2 Ca2 aided binding used selectively purify PDP1 33 PDP1c 35
0.25463712.11842080.html.plaintext.txt	45	Ca2 bind either PDP1c L2 alone binding requires combination catalytic subunit free lipoyl domain
0.25463712.11842080.html.plaintext.txt	46	2 This suggests either bridging role Ca2 L2 PDP1c stepwise interaction Ca2 stabilizes complex binding site induced precursory weaker interaction PDP1c L2 domain
0.25463712.11842080.html.plaintext.txt	47	To understand compare lipoyl domain specific Ca2 dependent binding L2 domain PDP1 PDP1c mapped effects changes L2 structure site specific changes surface amino acid residues substitution analogs lipoyl prosthetic group
0.25463712.11842080.html.plaintext.txt	48	Our results reveal importance residues near lipoyl group hydrophobic character lipoyl group well critical contribution specific acidic residues opposite half folded domain separated required L2 domain specific sequence
0.25463712.11842080.html.plaintext.txt	49	Some differences interactions PDP1 PDP1c also detected
0.25463712.11842080.html.plaintext.txt	50	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.25463712.11842080.html.plaintext.txt	51	Materials Bovine PDC resolved E1 containing bovine PDK isolated previously described 36 37
0.25463712.11842080.html.plaintext.txt	52	Human E1 E2 E2 E3BP prepared described elsewhere
0.25463712.11842080.html.plaintext.txt	53	3 Bovine PDP1 32P labeled phosphorylated PDC prepared previously described 27 33
0.25463712.11842080.html.plaintext.txt	54	Because PDP1 purified DEAE column step 27 stable highly purified PDP1 prepared affinity chromatography using GST L2 assays PDP1 employed PDP1 less purified fraction 40 50 PDP1 based PDP1 specific activity staining patterns SDS PAGE
0.25463712.11842080.html.plaintext.txt	55	Escherichia coli expressing PDP1c provided Lester J
0.25463712.11842080.html.plaintext.txt	56	Reed PDP1c prepared modification procedure described Choi et al
0.25463712.11842080.html.plaintext.txt	57	The primary modification extracts PDP1c allowed interact GST L2 anchored GSH Sepharose overnight 4 degrees C prior washing eluting Ca2 chelation using EGTA
0.25463712.11842080.html.plaintext.txt	58	From 10 g cells 25 30 mg nearly homogeneous PDP1c routinely obtained
0.25463712.11842080.html.plaintext.txt	59	L2 mutant L2 nonlipoylated L2 L2 lipoate analogs enzymatically attached nonlipoylated L2 prepared previously described 38 40
0.25463712.11842080.html.plaintext.txt	60	The sequences mutated cDNA expressing new L2 mutants confirmed DNA sequencing
0.25463712.11842080.html.plaintext.txt	61	Newly developed mutant L2 domains evaluated substrates E1 E3 reactions differential scanning calorimetry previously described 38 39
0.25463712.11842080.html.plaintext.txt	62	Based patterns native gel SDS PAGE electrophoresis lipoyl domains 99 pure inclusion low levels bands native gel pattern corresponding nonlipoylated L2 38 39
0.25463712.11842080.html.plaintext.txt	63	Lipoyl domain concentrations based calculated absorbance 280 nm appropriate adjustments tyrosine residues mutated previously described 38
0.25463712.11842080.html.plaintext.txt	64	This approach gives accurate protein concentrations 1
0.25463712.11842080.html.plaintext.txt	65	5 times higher protein levels estimated using BCA protein assay employed earlier studies 33
0.25463712.11842080.html.plaintext.txt	66	Phosphatase Activity Bovine PDP1 activity determined using phosphorylated bovine PDC PDCb measuring rate release 32Pphosphate PDCb 27 33
0.25463712.11842080.html.plaintext.txt	67	The inhibition PDP activity various lipoyl domain constructs added indicated levels determined previously described wild type L2 domain 33
0.25463712.11842080.html.plaintext.txt	68	Unless otherwise indicated PDP1 PDP1c added reaction mixtures equilibrated 30 degrees C 60 PDP activity initiated addition Mg2 final concentration 10 mM
0.25463712.11842080.html.plaintext.txt	69	Final reaction mixtures also contained 50 mM MOPS K pH 7
0.25463712.11842080.html.plaintext.txt	70	4 mgml bovine serum albumin 2 mgml Pluronic F 68 20 microg phosphorylated PDC 0
0.25463712.11842080.html.plaintext.txt	71	03 units PDP activity 27 final reaction volume 25 microl
0.25463712.11842080.html.plaintext.txt	72	After 120 reactions quenched 200 microl 10 trichloroacetic acid vortexed immediately 30 min incubation ice 90 microl withdrawn released 32Pphosphate determined 27 33
0.25463712.11842080.html.plaintext.txt	73	Assays either phosphatase source Mg2 added gave similar negligible backgrounds subtracted activities
0.25463712.11842080.html.plaintext.txt	74	Using standard assay procedure 10 mM Mg2 PDP1 DEAE purified specific activity range 500 650 nmol min1 mg1 PDP1c specific activities range 1300 1600 nmol min1 mg1
0.25463712.11842080.html.plaintext.txt	75	In limited studies free Ca2 level controlled EGTA Ca buffer level free Ca2 calculated previously described 36 appropriate corrections Mg2 binding Ca2 contamination reagents
0.25463712.11842080.html.plaintext.txt	76	All assays conducted least duplicate control assays lipoyl domain present conducted duplicate beginning end series assays
0.25463712.11842080.html.plaintext.txt	77	The deviations average values control E2 activated PDP1 PDP1c activities normally within plus minus 4 average value
0.25463712.11842080.html.plaintext.txt	78	Somewhat higher percentile usually lower absolute deviations typical data shown Figs
0.25463712.11842080.html.plaintext.txt	79	8 9 observed average values lower well inhibited rates
0.25463712.11842080.html.plaintext.txt	80	Given deviations percentage inhibition values shown tables difference average control rate average inhibited rate could high plus minus 7 5 inhibition within experimental error little inhibition
0.25463712.11842080.html.plaintext.txt	81	With given PDCb substrate average percentage inhibition values obtained specific L2 construct different experiments fell within deviations trends strong weak inhibition invariant PDCb substrates
0.25463712.11842080.html.plaintext.txt	82	However absolute percentage inhibition various L2 structures including wild type L2 varied somewhat different PDCb substrates
0.25463712.11842080.html.plaintext.txt	83	Tables I II IV combine data several experiments
0.25463712.11842080.html.plaintext.txt	84	The data normalized described legend Table I convenient comparison trends repeatedly observed
0.25463712.11842080.html.plaintext.txt	85	When full analysis L2 inhibition E2 activation PDP activity analyzed range L2 concentrations data fit assuming fraction PDP bound E2 operates maximum rate fraction PDP bound L2 operating minimum rate Vmin v VmaxPDPt L2 PDPPDPt VminL2 PDPPDPt
0.25463712.11842080.html.plaintext.txt	86	The PDPt denominator first term right correctly entered previously 33
0.25463712.11842080.html.plaintext.txt	87	For series L2 levels used L2 PDP concentrations estimated best iterative fitting data set optimum ratio dissociation constants binding PDP L2 versus E2 r KdL2KdE2 optimum Vmin 33 along assuming free phosphatase negligible
0.25463712.11842080.html.plaintext.txt	88	All assays conducted saturating levels phosphorylated PDC
0.25463712.11842080.html.plaintext.txt	89	higher rates observed higher levels therefore maximal binding PDP1 PDP1c E2 supported
0.25463712.11842080.html.plaintext.txt	90	Isothermal Titration Calorimetry ITC Titrations performed MSC titration calorimeter MicroCal Inc
0.25463712.11842080.html.plaintext.txt	91	Protein samples dialyzed Chelex 100 treated 30 mM Tris buffer pH 7
0.25463712.11842080.html.plaintext.txt	92	The Ca2 concentrate prepared dialysis buffer injected discrete intervals
0.25463712.11842080.html.plaintext.txt	93	The observed heat change corrected heat dilution ligand determined titration absence protein
0.25463712.11842080.html.plaintext.txt	94	RESULTS AND DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES
0.25463712.11842080.html.plaintext.txt	95	Modifications L2 Domain Goals The L2 domain elongated barrel structure Fig
0.25463712.11842080.html.plaintext.txt	96	1 one narrow ends containing E1 specificity loop tight turn contains lipoylated Lys173
0.25463712.11842080.html.plaintext.txt	97	One extended side domain see Fig
0.25463712.11842080.html.plaintext.txt	98	1B presents primarily hydrophilic residues rich acidic residues red orange opposite side see Fig
0.25463712.11842080.html.plaintext.txt	99	1C prominent hydrophobic face yellow residues mixture acidic basic residues
0.25463712.11842080.html.plaintext.txt	100	A C terminal lobe N terminal segment protrude domain opposite end lipoylation loop segments found stably folded structure determined NMR 41
0.25463712.11842080.html.plaintext.txt	101	However terminal regions distinct adherent Ala Pro rich linker regions mutation specific residues terminal regions affects thermal unfolding domain 38
0.25463712.11842080.html.plaintext.txt	102	Previously set single residue substitutions L2 domain made prominent amino acids located strategic positions surface L2 domain 38 initially screened effects characterized mutants L2 binding PDP1 based initial screening additional L2 mutants made achieve following goals
0.25463712.11842080.html.plaintext.txt	103	All residues undergoing single site mutations labeled Fig
0.25463712.11842080.html.plaintext.txt	104	View larger version 28K Fig
0.25463712.11842080.html.plaintext.txt	105	Ribbon diagram space filled presentations human L2 domain
0.25463712.11842080.html.plaintext.txt	106	These models based structure Howard et al
0.25463712.11842080.html.plaintext.txt	107	41 extra amino acids N terminus part L2 structure removed
0.25463712.11842080.html.plaintext.txt	108	Single letter code used amino acid residues
0.25463712.11842080.html.plaintext.txt	109	The ribbon diagram panel A shows L2 flattened barrel structure made two antiparallel sheet regions
0.25463712.11842080.html.plaintext.txt	110	The position Lys173 marked arrow specificity loop loop 1 star
0.25463712.11842080.html.plaintext.txt	111	Panel B shows space filled model positioned similar orientation ribbon diagram panel A panel C shows opposite side lipoyl domain
0.25463712.11842080.html.plaintext.txt	112	The positions mutated amino acids location specificity loop L2 structure indicated
0.25463712.11842080.html.plaintext.txt	113	Residues numbered according sequence mature E2 123 higher numbering used Ref
0.25463712.11842080.html.plaintext.txt	114	Asp red Glu orange Lys Arg dark blue except Lys173 magenta Gln Asn cyan Ser Thr green Pro Met Gly histidine His132 white Leu Ile Val yellow Phe Tyr gray
0.25463712.11842080.html.plaintext.txt	115	Ala residues white panel B yellow panel C
0.25463712.11842080.html.plaintext.txt	116	Cys Trp significant exposure surface L2 left white
0.25463712.11842080.html.plaintext.txt	117	Our objectives map surface L2 domain prosthetic group determine surface features important binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	118	Because lipoyl prosthetic group required binding 33 large number residues lipoylated end domain well structure within prosthetic group investigated
0.25463712.11842080.html.plaintext.txt	119	One goal detect acidic residues may directly contribute Ca2 dependent binding
0.25463712.11842080.html.plaintext.txt	120	Another goal detect structural features L2 domain contribute highly preferential binding PDP1 L2 domain rather closely related L1 domain
0.25463712.11842080.html.plaintext.txt	121	The L3 domain less closely related completely ineffective inhibiting E2 activation binding PDP1 gel anchored GST L3 tested data shown
0.25463712.11842080.html.plaintext.txt	122	2 shows aligned sequence domains places bold putative residues might contribute distinguishing L1 L2 domains
0.25463712.11842080.html.plaintext.txt	123	Mutations investigated sites
0.25463712.11842080.html.plaintext.txt	124	Finally sought determine whether differences profiles mutant induced changes L2 binding holo PDP1 compared catalytic subunit PDP1c
0.25463712.11842080.html.plaintext.txt	125	Differences suggest 96 kDa PDP1r either contributes specific binding alters conformation PDP1c affect binding L2
0.25463712.11842080.html.plaintext.txt	126	View larger version 17K Fig
0.25463712.11842080.html.plaintext.txt	127	Aligned sequences L1 L2 domains human E2 L3 domain E3BP
0.25463712.11842080.html.plaintext.txt	128	A star placed lipoylated lysine lipoyl domain sequences
0.25463712.11842080.html.plaintext.txt	129	Residues shown bold characters indicate positions L2 domain differs significantly closely related L1 domain positions mutated
0.25463712.11842080.html.plaintext.txt	130	The C terminal segments underlined
0.25463712.11842080.html.plaintext.txt	131	Comparison Inhibition PDP1 PDP1c Wild type L2 As indicated Introduction PDP1 PDP1c bind L2 domain E2 Ca2 dependent association greatly increases phosphatase activity
0.25463712.11842080.html.plaintext.txt	132	Competitive binding free L2 domain PDP1 reduces phosphatase activity preventing PDP1 binding L2 domain E2 component also anchors phosphorylated E1 substrate 33
0.25463712.11842080.html.plaintext.txt	133	3 compares capacity increasing concentrations wild type L2 domain prevent E2 activation PDP1 PDP1c activity
0.25463712.11842080.html.plaintext.txt	134	As previously described 33 data Fig
0.25463712.11842080.html.plaintext.txt	135	3 fit curve developed iterative fitting variation relative ratio binding dissociation constants E2 subunits versus free L2 along variation Vmin maximally inhibited rate PDP bound L2
0.25463712.11842080.html.plaintext.txt	136	Vmin estimated 9 Vmax indicates maximal inhibition E2 activated PDP1 activity projected 91
0.25463712.11842080.html.plaintext.txt	137	Half maximal inhibition realized 4
0.25463712.11842080.html.plaintext.txt	138	This value higher value reported previously 33 part method measuring protein concentration purified L2 A280 nm rather BCA assay gives 1
0.25463712.11842080.html.plaintext.txt	139	However observed nearly 2 fold variation concentration giving half maximal inhibition 3 6 microM primarily caused variation phosphorylated PDC substrate phosphorylated PDC used experiment shown Fig
0.25463712.11842080.html.plaintext.txt	140	Half estimated maximal inhibition 85 Vmin 15 Vmax E2 activated PDP1c activity reached somewhat higher L2 level 8
0.25463712.11842080.html.plaintext.txt	141	Again separate experiments different phosphorylated PDC value ranged 6 11 microM
0.25463712.11842080.html.plaintext.txt	142	Although concentrations giving half maximal inhibitions PDP1 PDP1c varied different phosphorylated PDC preparations trend comparing PDP1 PDP1c higher L2 required give half maximal inhibition PDP1c lesser maximal inhibition PDP1c repeatedly observed
0.25463712.11842080.html.plaintext.txt	143	The greater inhibition PDP1 consistent competitively hindering greater activation E2 E3BP 10 fold PDP1 activity 23 33 34 6 fold PDP1c 28
0.25463712.11842080.html.plaintext.txt	144	2 Indeed extrapolated PDP1 PDP1c Vmin rates appear nearly equivalent activities observed assays PDP1 33 PDP1c using level phosphorylated E1 absence E2
0.25463712.11842080.html.plaintext.txt	145	View larger version 13K Fig
0.25463712.11842080.html.plaintext.txt	146	Decrease E2 activation PDP1 PDP1c increasing L2 concentration
0.25463712.11842080.html.plaintext.txt	147	PDP1 PDP1c assays conducted data fit described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	148	Using fitting procedure described Experimental Procedures data PDP1 fit lines shown best r 0
0.25463712.11842080.html.plaintext.txt	149	7 Vmin 9 Vmax best fit data PDP1c r 1
0.25463712.11842080.html.plaintext.txt	150	The 100 activity 620 nmol min1 mg1 PDP1 1500 nmol min1 mg1 PDP1c
0.25463712.11842080.html.plaintext.txt	151	View larger version 14K Fig
0.25463712.11842080.html.plaintext.txt	152	Inhibition E2 activation L2 T143A L2
0.25463712.11842080.html.plaintext.txt	153	PDP1 assays conducted described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	154	For wild type L2 data fit best r 0
0.25463712.11842080.html.plaintext.txt	155	8 Vmin 9 T143A L2 r 0
0.25463712.11842080.html.plaintext.txt	156	Effects Mutant Modified L2 Region near Lipoyl Group All mutant L2 tested lipoylated end L2 domain well behaved L140A L2 midpoint transition temperature thermal melting Tm value 63 degrees C 38
0.25463712.11842080.html.plaintext.txt	157	Even construct well lipoylated gave single band native gel electrophoresis rate migration wild type L2 gave single reversible transition Tm 56 degrees C conditions thermal unfolding 38
0.25463712.11842080.html.plaintext.txt	158	Several substitutions located L2 near site lipoylation led substantial changes mostly decreases capacity free L2 structures compete L2 domains E2 60 mer thereby hinder E2 activation PDP1 PDP1c activity
0.25463712.11842080.html.plaintext.txt	159	Table I presents data comparing capacity 6 12 microM wild type mutant L2 modifications introduced lipoylated end L2
0.25463712.11842080.html.plaintext.txt	160	Not prevention lipoylation K173A mutation greatly hinder PDP1 binding L2 substitution residues flanking lipoylation site D172N A174S mutations greatly reduced competitive binding PDP1 PDP1c well lipoylated L2 mutants 38
0.25463712.11842080.html.plaintext.txt	161	However A174S mutation significantly effective blocking activation PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	162	Alanine substitution Leu140 located E1 specificity loop blocked binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	163	This exposed hydrophobic side chain probably makes significant direct contribution PDP1 binding
0.25463712.11842080.html.plaintext.txt	164	The large effect suggests replacement Leu140 alanine might also alter capacity neighboring residues productively interact PDP
0.25463712.11842080.html.plaintext.txt	165	However alanine substitution adjacent Ser141 center E1 specificity loop change L2 binding PDP1
0.25463712.11842080.html.plaintext.txt	166	In opposite direction findings S141A mutation marked effect rate E1 catalyzed acetylation L2 96 reduction 20 50 microM S141A L2 whereas L140A mutation modest effect E1 activity 38
0.25463712.11842080.html.plaintext.txt	167	View table Table I Percentage inhibition E2 activated PDP1 PDP1c activity native mutated L2 mutations introduced near lipoylated end L2 domain Assays conducted deviations individual phosphatase activities described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	168	The data L2 construct effects PDP1 PDP1c series experiments values ratio observed percentage inhibition determined percentage inhibition wild type L2 experiment times average value wild type L2 shown PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	169	For data incorporated table wild type L2 reduced E2 activation PDP1 45 56 6 microM L2 65 71 12 microM L2
0.25463712.11842080.html.plaintext.txt	170	Similar variation occurred normalized data PDP1c
0.25463712.11842080.html.plaintext.txt	171	Values rounded nearest percentage except value shown within 0
0.25463712.11842080.html.plaintext.txt	172	Although consequential substitutions L2 reduced level inhibition E2 activation PDP1 two mutant L2 T143A R196Q repeatedly gave enhanced potencies relative native L2 reducing E2 activation suggesting substitutions produced domains increased affinity PDP1
0.25463712.11842080.html.plaintext.txt	173	Thr143 located specificity loop forward position next tight turn appended end lysyl lipoyl prosthetic group
0.25463712.11842080.html.plaintext.txt	174	This mutant L2 similarly effective decreasing E2 enhancement activity PDP1c Table I
0.25463712.11842080.html.plaintext.txt	175	The concentration dependence shown Fig
0.25463712.11842080.html.plaintext.txt	176	4 demonstrate reflects stronger affinity T143A L2 wild type L2 PDP1 little change maximal inhibition
0.25463712.11842080.html.plaintext.txt	177	Similar results obtained PDP1c data shown
0.25463712.11842080.html.plaintext.txt	178	Equivalent effects PDP1 PDP1c found L2 construct glutamine substituted Arg196 prominent residue extending forward hydrophobic side lipoyl domain
0.25463712.11842080.html.plaintext.txt	179	Repeated experiments including assay set evaluated PDP1 PDP1c simultaneously supported slightly enhanced capacity R196Q L2 lessen E2 activation PDP1 activity exhibiting somewhat reduced capacity limiting activation PDP1c E2
0.25463712.11842080.html.plaintext.txt	180	Because A174S R196Q mutants affected E2 activation PDP1 PDP1c differently suggests PDP1r subunit influences PDP1 binding L2 support trend provided
0.25463712.11842080.html.plaintext.txt	181	Substitution alanine Asp197 adjacent Arg196 little effect PDP1 binding L2 whereas substitution marked effect reducing L2 activation PDK3
0.25463712.11842080.html.plaintext.txt	182	3 Conversion Thr145 located Thr143 Arg196 alanine modestly diminished capacity competitively lowering E2 activation PDP1 PDP1c activity
0.25463712.11842080.html.plaintext.txt	183	Thr145 replaced glutamine L1 domain glutamate L3 domain limited effect T145A mutation indicates Thr145 makes minor contribution high binding specificity L2 domain
0.25463712.11842080.html.plaintext.txt	184	Overall analysis amino acid residues located surface lipoylated end L2 indicate conserved lipoyl bearing turn Leu140 specificity loop particularly important contributors association PDP1 PDP1c L2
0.25463712.11842080.html.plaintext.txt	185	Although playing pivotal role none critical residues likely candidates directly liganding Ca2 provide explanation high binding specificity L2 L1 domain
0.25463712.11842080.html.plaintext.txt	186	Substitutions within Lipoyl Prosthetic Group To determine features important within lipoyl lysine side chain Lys173 additionally replaced Gln Met Leu lipoyl group replaced lipoate analogs
0.25463712.11842080.html.plaintext.txt	187	Like alanine substitution amino acid substitutions Lys173 greatly reduced eliminated capacity L2 bind PDP1 Fig
0.25463712.11842080.html.plaintext.txt	188	These results establish lipoyl lysine makes major contribution interaction cannot met amino acid side chains engage hydrophobic interactions Met Leu form H bonds Gln
0.25463712.11842080.html.plaintext.txt	189	Similarly nonlipoylated wild type L2 incapable binding PDP1
0.25463712.11842080.html.plaintext.txt	190	View larger version 44K Fig
0.25463712.11842080.html.plaintext.txt	191	Inhibition PDP1 activity L2 modified mutation lipoyl group substitution Lys173
0.25463712.11842080.html.plaintext.txt	192	coli lipoyl protein ligase used introduce nonlipoylated L2 nonlip
0.25463712.11842080.html.plaintext.txt	193	lipoate lip 8 thiol octanoate 8 SH octanoate oct
0.25463712.11842080.html.plaintext.txt	194	modified domains prepared free nonlipoylated L2 using hydrophobic interaction chromatography previously described 38
0.25463712.11842080.html.plaintext.txt	195	PDP1 activity analyzed described Experimental Procedures using indicated levels nonlipoylated cofactor modified Lys173 mutated L2
0.25463712.11842080.html.plaintext.txt	196	5 effective binding maintained L2 lipoate substituted 8 thiol octanoate octanoate heptanoate
0.25463712.11842080.html.plaintext.txt	197	Indeed octanoyl L2 appears effective L2 lipoyl group introduced lipoyl protein ligase treatment
0.25463712.11842080.html.plaintext.txt	198	Octanoyl L2 similarly effective PDP1c data shown
0.25463712.11842080.html.plaintext.txt	199	Apparently dithiolane ring lipoyl group particularly important hydrocarbon character lipoate crucial maintaining binding probably directly interacting hydrophobic region PDP1c structure
0.25463712.11842080.html.plaintext.txt	200	In contrast outcome none modifications supported significant binding E1 38 whereas 8 thiol octanoyl L2 directly activates PDK3 effectively octanoyl L2 gives small enhancement PDK3 activity heptanoyl L2 gives activation
0.25463712.11842080.html.plaintext.txt	201	Initial Screening Mutations Opposite End L2 Domain We also evaluated several prominent surface residues located end domain opposite site lipoylation
0.25463712.11842080.html.plaintext.txt	202	These encompass residues folded portion domain also residues extended terminal regions
0.25463712.11842080.html.plaintext.txt	203	The latter primarily involve examination residues larger C terminal lobe also include Tyr129 N terminal segment
0.25463712.11842080.html.plaintext.txt	204	Biophysical studies use E1 E3 reactions mutant L2 employed previously described 38
0.25463712.11842080.html.plaintext.txt	205	Only two substitutions reduced Tm values thermal unfolding 61 degrees C
0.25463712.11842080.html.plaintext.txt	206	These included alanine substitution Leu190 well exposed side chain centered middle cluster hydrophobic amino acids Phe217 C terminal tail
0.25463712.11842080.html.plaintext.txt	207	Both well lipoylated effectively used E1 reaction
0.25463712.11842080.html.plaintext.txt	208	Although results support considerable retention native structure L190A F217A constructs besides reduced Tm values tendency form dimer aggregates native gel electrophoresis
0.25463712.11842080.html.plaintext.txt	209	Based findings suggested reversible interaction C terminal region hydrophobic face involve Phe217 interacting Leu190 38
0.25463712.11842080.html.plaintext.txt	210	Among mutated surface residues end domain competitive binding significantly changed wild type L2 Q134A V156A K188A L190A D219N R221Q E224Q mutants data shown
0.25463712.11842080.html.plaintext.txt	211	Significant differences observed mutations shown Table II
0.25463712.11842080.html.plaintext.txt	212	A marked reduction inhibiting PDP1 PDP1c activation observed E179A mutation
0.25463712.11842080.html.plaintext.txt	213	Reductions PDP1 activation also observed Y129A Q181A D213N mutants smaller extent E162A Y220A mutations
0.25463712.11842080.html.plaintext.txt	214	The reproducible effects C terminal D213N Y220A N terminal Y129A mutants PDP1 detected PDP1c
0.25463712.11842080.html.plaintext.txt	215	This adds support differences binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	216	Given tendency F217A L2 aggregate modest reduction modification C terminus cannot considered conclusive even though observed PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	217	However L190A mutation tendency form dimer aggregates 38 similar F217A mutant retained native L2 capacity bind PDP1
0.25463712.11842080.html.plaintext.txt	218	Overall data suggest C N terminal lobes make greater contribution Ca2 aided binding PDP1r associated PDP1c
0.25463712.11842080.html.plaintext.txt	219	The data also indicate Glu179 makes significant contribution L2 binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	220	View table Table II Percentage inhibition E2 activated PDP1 PDP1c activity native mutated L2 mutants introduced L2 back half domain lipoylated Lys173 Assays conducted described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	221	The deviations normalization adjustments combining data different experiments PDP1 PDP1c table made described Table I
0.25463712.11842080.html.plaintext.txt	222	Selection Properties Additional L2 Mutants The screening detect set residues likely acidic residues candidates making essential contribution binding Ca2 clarify definitive preference PDP1 bind L2 rather L1 domain E2
0.25463712.11842080.html.plaintext.txt	223	Glu179 located cluster acidic residues includes Glu162 also glutamate residues positions 182 183 209 211
0.25463712.11842080.html.plaintext.txt	224	All Glu residues except Glu183 least exposed side chain NMR structure 41 converted alanine
0.25463712.11842080.html.plaintext.txt	225	Glu209 Glu211 particular interest near Asp213 alanine substitution caused reduction inhibitory binding Table II also aligned sequence L1 domain acidic residues positions Fig
0.25463712.11842080.html.plaintext.txt	226	To assess importance Glu179 converted Gln Glu182 also converted Gln based results
0.25463712.11842080.html.plaintext.txt	227	Because alanine substitution Tyr129 N terminus reduced E2 activation PDP1 leucine residue located position L1 domain Y129L mutant made
0.25463712.11842080.html.plaintext.txt	228	Finally greater focus area around Glu179 Glu182 sort distinguishes structure L2 domain L1 domain Val180 Gln181 replaced Ser Leu found aligned positions also located two glutamates L1 domain
0.25463712.11842080.html.plaintext.txt	229	This double substitution results reversal hydrophobic residue followed hydrophilic one opposite order
0.25463712.11842080.html.plaintext.txt	230	Amino acid residues 179 181 strand L2 hydrophobic Val180 side chain facing interior domain Gln181 projecting surface Fig
0.25463712.11842080.html.plaintext.txt	231	With change polarity introduction Ser Leu sequence unlikely reversal positioning side chains strand need maintain exposure Glu179 L2 aligned Glu52 L1 shown important specificity residue E1 reaction 38
0.25463712.11842080.html.plaintext.txt	232	All mutant L2 used E3 reaction rate fully lipoylated wild type L2 establishing full lipoylation
0.25463712.11842080.html.plaintext.txt	233	The E1 reaction evaluated near Km range E1 wild type L2
0.25463712.11842080.html.plaintext.txt	234	As expected conversion Glu179 glutamine greatly reduced use L2 substrate E1 reaction Fig
0.25463712.11842080.html.plaintext.txt	235	With Glu182 mutants E1 reaction slowed average 58 E182A L2 63 E182Q L2 Fig
0.25463712.11842080.html.plaintext.txt	236	Surprisingly V180SQ181L mutant somewhat improved E1 substrate giving 22 higher rates concentrations
0.25463712.11842080.html.plaintext.txt	237	This indicates key specificity residue Glu179 38 still interacting well E1
0.25463712.11842080.html.plaintext.txt	238	Also supporting conclusion mutant L2 gave single tight band native gel electrophoresis expected small decreases mobilities 38 mutants negative charge removed data shown
0.25463712.11842080.html.plaintext.txt	239	Only trace levels nonlipoylated slower moving bands 38 39 detected native gel electrophoresis
0.25463712.11842080.html.plaintext.txt	240	View larger version 21K Fig
0.25463712.11842080.html.plaintext.txt	241	Use new mutants E1 reaction
0.25463712.11842080.html.plaintext.txt	242	The initial rates E1 reaction measured using 0
0.25463712.11842080.html.plaintext.txt	243	05 microg human E1 indicated level L2 construct reaction initiated 120 microM 2 C14pyruvate conditions previously described 38 39
0.25463712.11842080.html.plaintext.txt	244	The assay mixture also contained 0
0.25463712.11842080.html.plaintext.txt	245	5 mgml bovine serum albumin 50 mM sodium phosphate buffer pH 7
0.25463712.11842080.html.plaintext.txt	246	Average values standard deviations shown
0.25463712.11842080.html.plaintext.txt	247	The base line corrected DSC profiles thermal unfolding mutants gave single bell shaped melting transitions reversible repeated folding unfolding cycles data shown
0.25463712.11842080.html.plaintext.txt	248	Table III shows Tm H S differences folded unfolded states mutants
0.25463712.11842080.html.plaintext.txt	249	Like E162A L2 mutant 38 conversion neighboring Glu182 either alanine glutamine raised Tm additionally caused significant increase H
0.25463712.11842080.html.plaintext.txt	250	This higher stability E182A E182Q mutants largely explained resulting reduction electrostatic repulsion neighboring acidic residues particularly Glu162 Glu183 also Glu179 would expected stabilize folding
0.25463712.11842080.html.plaintext.txt	251	The decrease entropy difference folded unfolded E179Q mutant domain versus observed native L2 consistent greater freedom movement cluster acidic side chains folded domain also observed E179A mutant 38
0.25463712.11842080.html.plaintext.txt	252	However observed Glu182 mutations Table III indeed E182Q significant increase entropy indicated
0.25463712.11842080.html.plaintext.txt	253	Glu182 closely surrounded Glu162 Gln181 Glu183 based NMR derived L2 structure 41 neutralization resulting E182Q mutation may introduce greater local order removal electrostatic repulsion
0.25463712.11842080.html.plaintext.txt	254	Even double mutation V180SQ181L 2
0.25463712.11842080.html.plaintext.txt	255	8 degrees C decrease Tm 64
0.25463712.11842080.html.plaintext.txt	256	6 degrees C insignificant change wild type L2 entropy difference folded unfolded states
0.25463712.11842080.html.plaintext.txt	257	Finally Y129A mutation produced less stable domain gain entropy folded domain suggesting increased flexibility N terminal segment 38
0.25463712.11842080.html.plaintext.txt	258	In contrast Y129L mutant thermal melting properties close native L2 hydrophobic character Tyr129 apparently important local interactions limit movement N terminal segment
0.25463712.11842080.html.plaintext.txt	259	View table Table III Tm H values thermal unfolding mutant L2 domain structures Values determined DSC scans mutant domains
0.25463712.11842080.html.plaintext.txt	260	Tm values transition mid point temperatures
0.25463712.11842080.html.plaintext.txt	261	H values determined fitting data first scan mutant L2 domain two state model using Origin software
0.25463712.11842080.html.plaintext.txt	262	Base line corrections made using smooth transition pre post melting transition base lines
0.25463712.11842080.html.plaintext.txt	263	Capacity Additional Mutant L2 Inhibit PDP1 PDP1c Activation E2 Table IV shows effects new mutant L2
0.25463712.11842080.html.plaintext.txt	264	Conversion Glu179 glutamine still reduced competitive binding PDP1 PDP1c appear potent E179A modification Table II
0.25463712.11842080.html.plaintext.txt	265	That confirmed direct comparison two substitutions assay set PDP1 PDP1c evaluated higher levels lipoyl domains
0.25463712.11842080.html.plaintext.txt	266	The increase inhibition PDP1 change 6 18 microM lipoyl domain 10 33 E179A 26 53 E179Q 51 73 wild type L2
0.25463712.11842080.html.plaintext.txt	267	The corresponding increase inhibition activation PDP1c 6 19 E179A 18 41 E179Q 40 67 wild type L2
0.25463712.11842080.html.plaintext.txt	268	Thus polarized amide group glutamine substituted yields mutant L2 binds 3 fold weaker affinity wild type L2 alanine substitution effects nearly another 3 fold decrease affinity
0.25463712.11842080.html.plaintext.txt	269	These results consistent possibility amide oxygen glutamine side chain via negative dipole could contribute weaker interaction native glutamate positively charged region PDP1c
0.25463712.11842080.html.plaintext.txt	270	View table Table IV Percentage inhibition E2 activated PDP1 PDP1c activity native additional mutated L2 structures Assays conducted described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	271	Conversion Glu182 alanine almost completely prevented competitive binding mutant L2 PDP1 PDP1c Table IV little inhibition gained even concentrations E182A L2 high 42 microM Fig
0.25463712.11842080.html.plaintext.txt	272	This strongest effect mutation outside tight turn holding lipoyl group
0.25463712.11842080.html.plaintext.txt	273	Unlike situation Glu179 conversion Glu182 glutamine restore discernible binding PDP1 PDP1c Table IV even levels high 42 microM E182Q L2 Fig
0.25463712.11842080.html.plaintext.txt	274	Thus Glu182 appears particularly critical residue candidate residue participating PDP1c Ca2 L2 bridge directly liganding Ca2
0.25463712.11842080.html.plaintext.txt	275	View larger version 22K Fig
0.25463712.11842080.html.plaintext.txt	276	Comparison effects E182A E182Q L2 mutants E2 activated activity PDP1 panel A PDP1c panel B
0.25463712.11842080.html.plaintext.txt	277	PDP1 PDP1c assays conducted described Experimental Procedures
0.25463712.11842080.html.plaintext.txt	278	Although Glu209 located nearby region behind Glu182 found L1 conversion Glu209 alanine decrease competitive binding PDP1 may slightly enhanced binding PDP1c 12 microM Table IV
0.25463712.11842080.html.plaintext.txt	279	Conversion Glu211 alanine like mutation neighboring Asp213 Table II caused reduction binding PDP1
0.25463712.11842080.html.plaintext.txt	280	Again position differs L1 Glu211 aligns Gly82 Fig
0.25463712.11842080.html.plaintext.txt	281	Although combination Glu211 conserved Asp213 might contribute specific PDP1 binding L2 selective substitution residues modest impacts furthermore D213N mutant effective inhibiting E2 activation PDP1c
0.25463712.11842080.html.plaintext.txt	282	Conversion Tyr129 leucine found L1 gave results significantly different Y129A mutation retaining excellent competitive binding PDP1 PDP1c Table IV
0.25463712.11842080.html.plaintext.txt	283	With Y129A mutant increased flexibility N terminal segment see DSC consideration may somehow interfere lipoyl domain binding PDP1
0.25463712.11842080.html.plaintext.txt	284	Although glutamate maintained L1 domain aligned positions residues 179 182 L2 intervening residues quite distinct emphasized
0.25463712.11842080.html.plaintext.txt	285	The V180SQ181L mutation make L2 like L1 substantially reduced competitive binding L2 PDP1 change extremely potent preventing binding PDP1c Table IV
0.25463712.11842080.html.plaintext.txt	286	We would note single site Q181A mutation significant substantially smaller effect Table II reducing competitive binding removal critical H bonding insufficient explaining large effect double mutation
0.25463712.11842080.html.plaintext.txt	287	The dual mutation favorable effect E1 reaction Glu179 aligned residue Glu52 L1 also critically important E1 reaction 38
0.25463712.11842080.html.plaintext.txt	288	Because Glu182 clearly important PDP1 PDP1c binding L2 combination results suggests preceding Val Gln provides structure helps properly position Glu182 participate effectively binding PDP1c
0.25463712.11842080.html.plaintext.txt	289	Limiting Ca2 The studies conducted saturating Ca2
0.25463712.11842080.html.plaintext.txt	290	The effects wild type L2 two mutant L2 E179A A174S gave strong partial inhibition PDP1c4 compared saturating limiting Ca2
0.25463712.11842080.html.plaintext.txt	291	E2 activated PDP1c activity 64 saturating Ca2 3
0.25463712.11842080.html.plaintext.txt	292	The fractional inhibition 3
0.25463712.11842080.html.plaintext.txt	293	8 microM Ca2 saturating Ca2 levels 60 18 microM wild type L2
0.25463712.11842080.html.plaintext.txt	294	18 microM E179A L2 caused 18 inhibition saturating 14 inhibition 3
0.25463712.11842080.html.plaintext.txt	295	Thus effectiveness relative wild type L2 competition E179A L2 reducing E2 activation PDP1c significantly reduced lower level Ca2
0.25463712.11842080.html.plaintext.txt	296	At lipoylated end domain relative decrease PDP1c activation 18 microM A174S L2 mutation 30 versus wild type 60 observed saturating limiting Ca2
0.25463712.11842080.html.plaintext.txt	297	Overall data indicate formed complexes PDP1c E179A L2 A174S L2 retain high affinity Ca2
0.25463712.11842080.html.plaintext.txt	298	Thus mutations consequential secondary sites regions L2 play decisive roles complex formation directly affect Ca2 binding
0.25463712.11842080.html.plaintext.txt	299	Nonetheless data eliminate possibility Glu182 contributes directly indirectly high affinity L2 PDP1c complex Ca2 interest could similarly investigated high levels L2 mutants substituted Glu182 gave little inhibition
0.25463712.11842080.html.plaintext.txt	300	The results indicate complete removal extraordinarily weak binding PDP1c
0.25463712.11842080.html.plaintext.txt	301	Requirement Two Binding Regions L2 As described elsewhere2 analytical ultracentrifuge studies detected binding L2 PDP1c high concentrations presence free Ca2 signal Ca2 binding detected combination L2 PDP1c ITC experiments
0.25463712.11842080.html.plaintext.txt	302	These findings suggested possibility weaker Ca2 dependent binding nonlipoylated Glu182 modified L2 might observed ITC
0.25463712.11842080.html.plaintext.txt	303	That would allow interactions two regions L2 independently analyzed importance Glu182 Ca2 dependent binding evaluated
0.25463712.11842080.html.plaintext.txt	304	However using much higher levels PDP1c 20 microM 40 microM either K173A L2 E182A L2 detectable Ca2 binding observed ITC studies
0.25463712.11842080.html.plaintext.txt	305	These data support critical contribution combination two binding regions Ca2 dependent L2 PDP1c complex formation however findings limit approaches used independently dissecting roles two regions L2 binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	306	8 shows location residues whose modification significantly altered binding L2 domain PDP1
0.25463712.11842080.html.plaintext.txt	307	Our results indicate two major regions interaction within L2 domain
0.25463712.11842080.html.plaintext.txt	308	The first region includes lipoyl prosthetic group neighboring residues
0.25463712.11842080.html.plaintext.txt	309	Substitution adjacent residues D172N A174A greatly hindered binding L140A substitution E1 specificity loop
0.25463712.11842080.html.plaintext.txt	310	T143A substitution E1 specificity loop enhanced L2 binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	311	Based effective binding octanoyl L2 several Lys173 substituted nonlipoylated L2 lipoyl cofactor probably interacts extended hydrophobic pocket surface structure PDP1c
0.25463712.11842080.html.plaintext.txt	312	In contrast dithiolane ring character lipoyl prosthetic group decisive L2 binding E1 38 8 thiol crucial L2 activation PDK3
0.25463712.11842080.html.plaintext.txt	313	3 We suggest interactions PDP1 lipoylated end L2 domain make significant contribution binding affinity contribute lipoyl domain specificity
0.25463712.11842080.html.plaintext.txt	314	View larger version 74K Fig
0.25463712.11842080.html.plaintext.txt	315	Key residues L2 Ca2 dependent binding PDP1 PDP1c
0.25463712.11842080.html.plaintext.txt	316	Most C terminal lobe L2 structure deleted
0.25463712.11842080.html.plaintext.txt	317	The red label indicates gain rather loss binding affinity upon mutation
0.25463712.11842080.html.plaintext.txt	318	The second region involves interactions end L2 domain
0.25463712.11842080.html.plaintext.txt	319	The large effect mutations Glu182 hindering binding PDP1 PDP1c L2 domain suggests acidic residue performs key role binding
0.25463712.11842080.html.plaintext.txt	320	8 distinct pocket exists center fully protruding Glu182 Gln181 Glu179 Glu162 side chains binding interactions remove mutual repulsion three acidic residues favored
0.25463712.11842080.html.plaintext.txt	321	Because mutation residues hindered L2 binding PDP1 appealing prospect form strong electrostatic interaction positively charged regions PDP1c
0.25463712.11842080.html.plaintext.txt	322	An aspect might directly involve Ca2 binding particularly Glu182
0.25463712.11842080.html.plaintext.txt	323	However finding E179A mutation fails greater impact restricting competitive binding presence limiting Ca2 makes possibility less likely
0.25463712.11842080.html.plaintext.txt	324	Although results support critical importance Glu182 complete three dimensional structure establish proteins interact
0.25463712.11842080.html.plaintext.txt	325	Further isolation binding regions indirect approaches difficult obtain weak binding PDP1c detected biophysical studies performed either nonlipoylated Glu182 mutated L2 even presence Ca2
0.25463712.11842080.html.plaintext.txt	326	Toward understanding high specificity PDP1 L2 domain expressly eliminated found minimal contributions several residues differ L2 domain aligned residues L1 domain
0.25463712.11842080.html.plaintext.txt	327	However conversion residues preceding Glu182 Val Gln sequence Ser Leu sequence found L1 substantially reduced binding PDP1 L2
0.25463712.11842080.html.plaintext.txt	328	A logical explanation native Ser Leu residues L1 allow corresponding Glu55 side chain properly positioned abetting binding L1 PDP1
0.25463712.11842080.html.plaintext.txt	329	The positioning Glu179 may also slightly altered Ser Leu substitution unfavorable impact E1 reaction resulting change positioning key residue E1 reaction PDK3 activation also well maintained
0.25463712.11842080.html.plaintext.txt	330	For part PDP1 PDP1c binding L2 domain altered similar manner modifications L2 structure five single site mutants A174S R196Q lipoylated end L2 D213N Y220A C terminal lobe Y129A N terminal segment greater effects PDP1 PDP1c removing influence E2 activated phosphatase activity
0.25463712.11842080.html.plaintext.txt	331	Among pronounced differences PDP1 PDP1c binding observed A174S
0.25463712.11842080.html.plaintext.txt	332	The A174S mutation rendered binding PDP1 almost undetectable reducing inhibition PDP1c roughly half wild type L2
0.25463712.11842080.html.plaintext.txt	333	This mutant L2 well lipoylated fairly good E1 substrate 60 wild type L2
0.25463712.11842080.html.plaintext.txt	334	Upon substitution buried Ala174 side chain faces E1 specificity loop hydroxyl group serine may amend allowed conformations somewhat flexible outer structure 41
0.25463712.11842080.html.plaintext.txt	335	Whatever change interaction PDP1 much sensitive PDP1c indicating presence PDP1r subunit PDP1 places demand precise interaction
0.25463712.11842080.html.plaintext.txt	336	In opposite direction single site mutations V180SQ181L mutant potent effect eliminating detectable binding PDP1c strong reduction PDP1
0.25463712.11842080.html.plaintext.txt	337	This indicates either without PDP1r PDP1c requires structural precision end domain additional binding interactions resulting presence PDP1r PDP1 compensate extent loss interactions small pivotal conformational adjustments elicited double mutation
0.25463712.11842080.html.plaintext.txt	338	A sequence firmly supporting Ca2 binding EF hand apparent either PDP1c L2
0.25463712.11842080.html.plaintext.txt	339	One distantly related acidic region mutated PDP1c interfered Ca2 dependent binding 42
0.25463712.11842080.html.plaintext.txt	340	However local sequence including mutated residue conserved PDP2 isoform although activity PDP2 influenced Ca2 20
0.25463712.11842080.html.plaintext.txt	341	Thus PDP1c L2 complex formation creates tight site binding Ca2 probably involve EF hand
0.25463712.11842080.html.plaintext.txt	342	Because binding PDP1 engages requires domain aided hydrophobic binding exterior lipoyl group one end L2 electrostatic binding opposite end L2 domain seems likely essential regions L2 act coordinated purpose
0.25463712.11842080.html.plaintext.txt	343	An appealing prospect two interactions foster stabilize conformational change PDP1c produces Ca2 binding site
0.25463712.11842080.html.plaintext.txt	344	Expending binding energy inducing change would explain extensive interaction surface L2 domain needed effect net affinity micromolar level
0.25463712.11842080.html.plaintext.txt	345	Further insight constitution Ca2 dependent complexes formed L2 PDP1 PDP1c require detailed structures probably depend crystallizing complexes
0.25463712.11842080.html.plaintext.txt	346	We thank Xioahua Yan Yasuaki Hiromasa Shane A
0.25463712.11842080.html.plaintext.txt	347	Kasten preparing components used studies
0.25463712.11842080.html.plaintext.txt	348	We thank Lester Reed providing expression systems PDP1c information PDP1c preparation prior publication
0.25463712.11842080.html.plaintext.txt	349	This work supported National Institutes Health Grant DK18320 Kansas Agriculture Experiment Station contribution 02 86 J
0.25463712.11842080.html.plaintext.txt	350	The costs publication article defrayed part payment page charges
0.25463712.11842080.html.plaintext.txt	351	The article must therefore hereby marked advertisement accordance 18 U
0.25463712.11842080.html.plaintext.txt	352	Section 1734 solely indicate fact
0.25463712.11842080.html.plaintext.txt	353	Present address Rhode Island Hospital Brown Medical School Providence RI 02903
0.25463712.11842080.html.plaintext.txt	354	To correspondence addressed Dept
0.25463712.11842080.html.plaintext.txt	355	Biochemistry 104 Willard Hall Kansas State University Manhattan KS 66506
0.25463712.11842080.html.plaintext.txt	356	785 532 6116 Fax 785 532 7278 E mail bchterksu
0.25463712.11842080.html.plaintext.txt	357	Published JBC Papers Press February 12 2002 DOI 10
0.25463712.11842080.html.plaintext.txt	358	2 ITC studies indicate neither PDP1c L2 alone directly interact 100 microM Ca2 ITC analytical ultracentrifugation studies indicate L2 PDP1c bind forming tight Ca2 binding site Kd 3 microM similar complex formation PDP1 enhanced Mg2 A
0.25463712.11842080.html.plaintext.txt	359	Roche manuscript preparation
0.25463712.11842080.html.plaintext.txt	360	Portions studies described elsewhere 11
0.25463712.11842080.html.plaintext.txt	361	Roche manuscript preparation
0.25463712.11842080.html.plaintext.txt	362	Portions studies capacity mutant L2 activate PDK3 described elsewhere 43
0.25463712.11842080.html.plaintext.txt	363	4 The equivalent comparison could performed PDP1 A174S mutation much larger effects removing competitive binding PDP1 Table I
0.25463712.11842080.html.plaintext.txt	364	Other mutations lipoylated end L2 either great effect binding various Lys173 D172A L140A mutants small effect make similar comparisons
0.25463712.11842080.html.plaintext.txt	365	The abbreviations used PDC pyruvate dehydrogenase complex E1 pyruvate dehydrogenase component E2 dihydrolipoyl acetyltransferase component L1 domain NH2 lipoyl domain E2 L2 domain interior lipoyl domain E2 PDP pyruvate dehydrogenase phosphatase PDP1 pyruvate dehydrogenase phosphatase isoform 1 PDP1c catalytic subunit PDP1 PDP1r FAD containing regulatory subunit PDP1 PDP2 pyruvate dehydrogenase phosphatase isoform 2 E3 dihydrolipoyl dehydrogenase E3BP E3 binding protein L3 N terminal lipoyl domain E3BP GST glutathione S transferase ITC isothermal titration calorimetry PDK pyruvate dehydrogenase kinase MOPS 4 morpholinepropanesulfonic acid
0.25463712.11842080.html.plaintext.txt	366	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES 1
0.25463712.11842080.html.plaintext.txt	367	240 45 48CrossRefMedline Order article via Infotrieve 2
0.25463712.11842080.html.plaintext.txt	368	1996 Keto Acid Dehydrogenase Complexes Patel M
0.25463712.11842080.html.plaintext.txt	369	33 52 Birkhauser Verlag Press Basel 4
0.25463712.11842080.html.plaintext.txt	370	70 33 75Medline Order article via Infotrieve 5
0.25463712.11842080.html.plaintext.txt	371	264 2221 2227AbstractFree Full Text 6
0.25463712.11842080.html.plaintext.txt	372	265 14512 14517AbstractFree Full Text 7
0.25463712.11842080.html.plaintext.txt	373	261 1858 1867AbstractFree Full Text 9
0.25463712.11842080.html.plaintext.txt	374	272 19746 19751AbstractFree Full Text 10
0.25463712.11842080.html.plaintext.txt	375	264 1245 1251AbstractFree Full Text 11
0.25463712.11842080.html.plaintext.txt	376	264 3655 3657AbstractFree Full Text 13
0.25463712.11842080.html.plaintext.txt	377	160 715 721Medline Order article via Infotrieve 14
0.25463712.11842080.html.plaintext.txt	378	319 109 116Medline Order article via Infotrieve 15
0.25463712.11842080.html.plaintext.txt	379	268 26602 26602AbstractFree Full Text 17
0.25463712.11842080.html.plaintext.txt	380	269 29720 29724AbstractFree Full Text 18
0.25463712.11842080.html.plaintext.txt	381	270 28989 28994AbstractFree Full Text 19
0.25463712.11842080.html.plaintext.txt	382	273 17680 17688AbstractFree Full Text 21
0.25463712.11842080.html.plaintext.txt	383	151 328 340Medline Order article via Infotrieve 22
0.25463712.11842080.html.plaintext.txt	384	128 161 163Medline Order article via Infotrieve 23
0.25463712.11842080.html.plaintext.txt	385	49 563 571Medline Order article via Infotrieve 24
0.25463712.11842080.html.plaintext.txt	386	272 6361 6369AbstractFree Full Text 25
0.25463712.11842080.html.plaintext.txt	387	238 83 91Medline Order article via Infotrieve 26
0.25463712.11842080.html.plaintext.txt	388	1982 Biochemistry 21 5585 5592Medline Order article via Infotrieve 27
0.25463712.11842080.html.plaintext.txt	389	1993 Biochemistry 32 8987 8993Medline Order article via Infotrieve 29
0.25463712.11842080.html.plaintext.txt	390	93 4953 4956AbstractFree Full Text 30
0.25463712.11842080.html.plaintext.txt	391	272 31625 31629AbstractFree Full Text 31
0.25463712.11842080.html.plaintext.txt	392	124 95 99Medline Order article via Infotrieve 32
0.25463712.11842080.html.plaintext.txt	393	238 93 101Medline Order article via Infotrieve 33
0.25463712.11842080.html.plaintext.txt	394	271 28064 28070AbstractFree Full Text
0.25463712.11842080.html.plaintext.txt	395	273 14130 14137AbstractFree Full Text 35
0.25463712.11842080.html.plaintext.txt	396	20 128 131CrossRefMedline Order article via Infotrieve 36
0.25463712.11842080.html.plaintext.txt	397	183 664 677Medline Order article via Infotrieve 37
0.25463712.11842080.html.plaintext.txt	398	148 327 342Medline Order article via Infotrieve 38
0.25463712.11842080.html.plaintext.txt	399	275 13645 13653AbstractFree Full Text 39
0.25463712.11842080.html.plaintext.txt	400	386 123 135CrossRefMedline Order article via Infotrieve 40
0.25463712.11842080.html.plaintext.txt	401	316 926 940CrossRefMedline Order article via Infotrieve 41
0.25463712.11842080.html.plaintext.txt	402	1998 Gastroenterology 115 139 146Medline Order article via Infotrieve 42
0.25463712.11842080.html.plaintext.txt	403	1996 Keto Acid Dehydrogenase Complexes Patel M
0.25463712.11842080.html.plaintext.txt	404	131 138 Birkhauser Verlag Press Basel 43
0.25463712.11842080.html.plaintext.txt	405	Copyright 2002 The American Society Biochemistry Molecular Biology Inc
0.20839827.15659744.html.plaintext.txt	0	The cytoplasmic tail herpes simplex virus envelope glycoprotein D binds tegument protein VP22 capsids Jung Hee I
0.20839827.15659744.html.plaintext.txt	1	Harley Aparna Mukhopadhyay Duncan W
0.20839827.15659744.html.plaintext.txt	2	Department Developmental Molecular Biology Albert Einstein College Medicine 1300 Morris Park Avenue Bronx NY 10461 USA
0.20839827.15659744.html.plaintext.txt	3	ABSTRACT Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Herpes simplex virus HSV capsids assemble mature package viral genome nucleoplasm
0.20839827.15659744.html.plaintext.txt	4	They exit nucleus cytoplasm acquire final tegument envelope
0.20839827.15659744.html.plaintext.txt	5	The molecular mechanism cytoplasmic envelopment unclear evidence suggests viral glycoprotein tails play important role recruitment tegument capsids final envelopment site
0.20839827.15659744.html.plaintext.txt	6	However due redundancy protein protein interactions among viral glycoproteins genetic analysis role individual glycoproteins assembly difficult
0.20839827.15659744.html.plaintext.txt	7	To overcome problem glutathione S transferase fusion protein binding assay used study test interaction cytoplasmic tail one specific viral glycoprotein gD tegument proteins
0.20839827.15659744.html.plaintext.txt	8	The study demonstrated 38 kDa tegument protein VP22 bound specifically gD tail
0.20839827.15659744.html.plaintext.txt	9	This association dependent arginine lysine residues positions 5 6 gD tail
0.20839827.15659744.html.plaintext.txt	10	In addition HSV 1 capsids bound gD tail exhibited similar sequence dependence
0.20839827.15659744.html.plaintext.txt	11	It concluded VP22 may serve linker protein mediating interaction HSV capsid gD
0.20839827.15659744.html.plaintext.txt	12	Present address Pfizer Global Research Development Groton Laboratories Eastern Point Road Groton CT 06430 USA
0.20839827.15659744.html.plaintext.txt	13	INTRODUCTION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Herpes simplex virus HSV complex DNA virus
0.20839827.15659744.html.plaintext.txt	14	The viral genome packaged within icosahedral capsid surrounded amorphous layer proteins termed tegument
0.20839827.15659744.html.plaintext.txt	15	This turn contained within lipid envelope bearing numerous virally encoded glycoproteins Roizman Pellett 2001
0.20839827.15659744.html.plaintext.txt	16	It generally agreed HSV capsids acquire final tegument envelope cytoplasm
0.20839827.15659744.html.plaintext.txt	17	However molecular mechanism HSV 1 envelopment cytoplasm poorly characterized
0.20839827.15659744.html.plaintext.txt	18	During infection viral membrane glycoproteins expressed traffic via cytoplasmic organelles cell surface
0.20839827.15659744.html.plaintext.txt	19	Several lines evidence suggest cytosolic domains glycoproteins may provide platform tegument assembly recruitment capsids followed envelopment Mettenleiter 2002
0.20839827.15659744.html.plaintext.txt	20	In recent study double mutant pseudorabies virus PrV lacking viral glycoproteins gM gE gM cytoplasmic tail gE showed failure envelopment instead accumulating cytoplasmic nucleocapsids immersed dense layer tegument Brack et al
0.20839827.15659744.html.plaintext.txt	21	Following single deletion either glycoprotein production infectious virions affected suggesting cytoplasmic tails gE gM act redundant fashion assembly likely interacting tegument proteins indirectly surface nucleocapsids
0.20839827.15659744.html.plaintext.txt	22	In HSV 1 simultaneous deletion two glycoproteins dramatically affect production infectious virions Browne et al
0.20839827.15659744.html.plaintext.txt	23	2004 although simultaneous deletion gD gE resulted striking defect particle assembly Farnsworth et al
0.20839827.15659744.html.plaintext.txt	24	This apparent redundancy makes analysis specific glycoprotein tegument interactions difficult perform vivo
0.20839827.15659744.html.plaintext.txt	25	To overcome obstacle developed glutathione S transferase GST fusion protein binding assay investigate interaction envelope glycoprotein tails tegument partners vitro
0.20839827.15659744.html.plaintext.txt	26	This approach previously used demonstrate interaction cytoplasmic tail glycoprotein H gH tegument component VP16 Gross et al
0.20839827.15659744.html.plaintext.txt	27	In current study focused analysing tail glycoprotein D gD highly abundant component envelope Spear Roizman 1972 short cytoplasmic tail 30 amino acid residues easily manipulated mutagenesis studies
0.20839827.15659744.html.plaintext.txt	28	Moreover shown play key albeit redundant role assembly Farnsworth et al
0.20839827.15659744.html.plaintext.txt	29	Additionally Pomeranz Blaho 1999 reported gD co localizes least one tegument protein VP22 infection
0.20839827.15659744.html.plaintext.txt	30	We prepared GST fusion proteins contained cytoplasmic tail gD mutants thereof carboxy terminus
0.20839827.15659744.html.plaintext.txt	31	Following binding GST fusion proteins glutathione Sepharose beads incubation HSV infected cell extracts fusion proteins tested ability interact tegument proteins
0.20839827.15659744.html.plaintext.txt	32	Here report cytoplasmic tail gD bound tegument protein VP22 manner independent viral polypeptides
0.20839827.15659744.html.plaintext.txt	33	Additionally results indicated VP22 may one tegument components mediate interaction cytoplasmic tail gD HSV capsid
0.20839827.15659744.html.plaintext.txt	34	METHODS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Construction GST gD expressing vector
0.20839827.15659744.html.plaintext.txt	35	The predicted cytoplasmic tail HSV 1 gD encoded 3 end US6 gene amplified PCR genomic DNA using oligonucleotides 5 GCGAATTCTACACCGCCGCACTCGGAAAG 3 upstream primer 5 GGGAAGCTTAACTAGTTCACTAGTAAAACAAGGGCTG 3 downstream primer
0.20839827.15659744.html.plaintext.txt	36	The PCR product encoded entire carboxyl terminal tail gD two stop codons flanked EcoRI HindIII restriction sites
0.20839827.15659744.html.plaintext.txt	37	Digestion two restriction enzymes followed ligation EcoRIHindIII digested pGEX KG plasmid Guan Dixon 1991 resulted frame fusion GST gD cytoplasmic tail ORF
0.20839827.15659744.html.plaintext.txt	38	This construct referred gDc
0.20839827.15659744.html.plaintext.txt	39	A truncation mutant expressing first 17 amino acids cytoplasmic tail gD termed T17 constructed using complementary oligonucleotides 5 AATTCTACACCGCCGCACTCGGAAAGCCCCAAAGCGCATACGCCTCCCCCACATCCGGTGATGAA 3 5 AGCTTTCATCACCGGATGTGGGGGAGGCGTATGCGCTTTGGGGCTTTCCGAGTGCGGCGGTGTAGAATT 3
0.20839827.15659744.html.plaintext.txt	40	To anneal oligonucleotides 5 microg top bottom strands mixed TE 10 mM Tris 1 mM EDTA placed 95 degrees C water bath
0.20839827.15659744.html.plaintext.txt	41	This allowed cool slowly room temperature produce dsDNA fragment EcoRI HindIII terminal ends
0.20839827.15659744.html.plaintext.txt	42	The dsDNA fragment ligated frame pGEX KG
0.20839827.15659744.html.plaintext.txt	43	Generation alanine mutants T17 conducted manner using annealed complementary oligonucleotides except appropriate codons mutated encode alanine
0.20839827.15659744.html.plaintext.txt	44	The oligonucleotides annealed manner described ligated frame GST gene pGEX KG
0.20839827.15659744.html.plaintext.txt	45	gDR5K6 gDK9R10 gDR gDK mutants generated using upstream primers 5 GCGAATTCACCGCCGCACTGCTGCT3 5 GCGAATTCACCGCCGCACTCGGAAAGCCCCAGCTGCT 3 5 GCGAATTCACCGCCGCACTGCTAAA 3 5 GCGAATTCACCGCCGCACTCGGGCT 3 respectively common downstream primer 5 GCAGCTTCACTAGTAAAACA 3
0.20839827.15659744.html.plaintext.txt	46	The gDc plasmid expressing full length gD cytoplasmic tail used DNA template
0.20839827.15659744.html.plaintext.txt	47	Expression GST fusion proteins
0.20839827.15659744.html.plaintext.txt	48	Appropriate expression plasmids transformed Escherichia coli strain BL21 Stratagene
0.20839827.15659744.html.plaintext.txt	49	Overnight stationary phase cultures used inoculate fresh medium following day OD600 0 2 cultures grown shaker OD600 0 9
0.20839827.15659744.html.plaintext.txt	50	IPTG added cells concentration 1 mM induce expression fusion protein
0.20839827.15659744.html.plaintext.txt	51	After 3 h cells collected centrifugation 8000 r
0.20839827.15659744.html.plaintext.txt	52	10 min 4 degrees C JA20 rotor medium discarded pellet frozen 20 degrees C overnight
0.20839827.15659744.html.plaintext.txt	53	The following day pellet thawed resuspended lysis buffer 0 05 Tween 20 50 mM EDTA 1 mM PMSF 5 microg aprotinin ml 1 5 microg leupeptin ml 1 1 mg lysozyme ml 1 PBS sonicated using probe sonicator six times 10 30 intervals ice
0.20839827.15659744.html.plaintext.txt	54	Debris unbroken cells pelleted 10 000 r
0.20839827.15659744.html.plaintext.txt	55	10 min 4 degrees C JA20 rotor
0.20839827.15659744.html.plaintext.txt	56	Supernatants subjected SDS PAGE stained Coomassie blue visualize fusion proteins
0.20839827.15659744.html.plaintext.txt	57	Preparation HSV 1 infected cell extracts
0.20839827.15659744.html.plaintext.txt	58	Confluent monolayers COS cells infected HSV 1 strain SC16 m
0.20839827.15659744.html.plaintext.txt	59	10 DMEM 10 fetal bovine serum FBS 1 penicillinstreptomycin PS
0.20839827.15659744.html.plaintext.txt	60	After 1 h fresh medium added incubation proceeded additional 18 h 37 degrees C
0.20839827.15659744.html.plaintext.txt	61	Cells collected post nuclear supernatant PNS prepared previously described Harley et al
0.20839827.15659744.html.plaintext.txt	62	Briefly cells washed twice cold homogenization buffer 0 25 M sucrose 2 mM MgCl2 10 mM TrisHCl pH 7 6 scraped pelleted 1000 g 5 min 4 degrees C resuspended 1 ml homogenization buffer containing 5 microg leupeptin ml 1 5 microg aprotinin ml 1 1 mM PMSF
0.20839827.15659744.html.plaintext.txt	63	Cells broken passing 25 gauge 58 inch needle eight times spun 2000 g 10 min 4 degrees C remove unbroken cells nuclei
0.20839827.15659744.html.plaintext.txt	64	The PNS adjusted 150 mM NaCl 0 5 NP 40 50 mM TrisHCl pH 7 6 incubated 1 h ice solubilize tegument proteins centrifuged 53 000 r
0.20839827.15659744.html.plaintext.txt	65	The supernatant S100 aliquotted frozen 70 degrees C
0.20839827.15659744.html.plaintext.txt	66	Production radiolabelled VP22
0.20839827.15659744.html.plaintext.txt	67	A VP22myc His encoding plasmid Invitrogen Redivue 35Smethionine added TNT Rabbit Reticulocyte Lysate vitro transcriptiontranslation system Promega following manufacturers protocol
0.20839827.15659744.html.plaintext.txt	68	The resulting vitro translated VP22 mixed PBS containing 5 microg leupeptin ml 1 5 microg antipain ml 1 incubated GST fusion protein coated glutathione Sepharose beads described
0.20839827.15659744.html.plaintext.txt	69	Material bound beads subjected SDS PAGE gel treated 30 methanol 10 acetic acid 30 min En3Hance NEN Life Sciences Products 1 h 1 glycerol 30 min
0.20839827.15659744.html.plaintext.txt	70	The gel dried using Bio Rad gel drier exposed film 1 2 days
0.20839827.15659744.html.plaintext.txt	71	Preparation 3Hthymidine labelled capsids
0.20839827.15659744.html.plaintext.txt	72	Prior infection confluent monolayers COS cells overlaid DMEM containing 1 dialysed FBS 1 PS 2 h infected HSV 1 strain SC16 m
0.20839827.15659744.html.plaintext.txt	73	After 1 h fresh medium 3Hthymidine NEN added final concentration 25 microCi ml 1 incubated 18 h
0.20839827.15659744.html.plaintext.txt	74	Cells harvested PNS prepared adjusted final concentration 2 5 mM magnesium acetate 50 mM potassium acetate 150 mM NaCl 0 5 Triton X 100 5 mM DTT incubated ice 1 h
0.20839827.15659744.html.plaintext.txt	75	The treatment removed membranes solubilized tegument associated cytoplasmic virions
0.20839827.15659744.html.plaintext.txt	76	Following incubation debris removed clearing spin 1500 g
0.20839827.15659744.html.plaintext.txt	77	The treated PNS used test binding capsids fusion proteins bound glutathione Sepharose beads
0.20839827.15659744.html.plaintext.txt	78	The protein concentration PNS determined using BCA assay Pierce BSA protein standard
0.20839827.15659744.html.plaintext.txt	79	Glutathione Sepharose beads dispensed microcentrifuge tube washed three times cold PBS
0.20839827.15659744.html.plaintext.txt	80	BSA 100 microl 10 mg ml 1 solution equivalent amount GST fusion protein containing bacterial extract PBS total volume 1 ml added washed beads incubated 4 degrees C 1 h rotator
0.20839827.15659744.html.plaintext.txt	81	The beads washed twice wash buffer 1 50 mM TrisHCl pH 7 6 150 mM NaCl 0 5 Triton X 100 wash buffer 2 50 mM TrisHCl pH 7 6 1 3 M NaCl 0 5 Triton X 100 wash buffer 1
0.20839827.15659744.html.plaintext.txt	82	Infected cell cytosol S100 vitro translated VP22 cell extracts containing 3Hthymidine labelled capsids added GST fusion protein bound beads incubated 37 degrees C 1 h washed six times wash buffer 1
0.20839827.15659744.html.plaintext.txt	83	For detection bound tegument proteins beads resuspended 500 microl 50 mM TrisHCl pH 7 6
0.20839827.15659744.html.plaintext.txt	84	SDS PAGE sample buffer added mixture heated 95 degrees C 5 min subjected SDS PAGE Western blotted using appropriate antibodies
0.20839827.15659744.html.plaintext.txt	85	Measurement packaged viral DNA
0.20839827.15659744.html.plaintext.txt	86	A TCA precipitation assay measure DNA packaging carried previously described Church et al
0.20839827.15659744.html.plaintext.txt	87	Briefly performing GST vitro binding assay 3Hthymidine labelled capsid containing extracts beads incubated 2 mM MgCl2 280 U DNase I type II Sigma ml 1 90 min 37 degrees C
0.20839827.15659744.html.plaintext.txt	88	EDTA SDS added final concentrations 10 mM 0 3 respectively incubation continued additional 15 min
0.20839827.15659744.html.plaintext.txt	89	The treated material spotted individual GFC Whatman filter papers allowed dry
0.20839827.15659744.html.plaintext.txt	90	Each filter subjected one 4 degrees C wash two consecutive 65 degrees C washes TP buffer 5 TCA 20 mM sodium pyrophosphate rinsing 70 ethanol drying
0.20839827.15659744.html.plaintext.txt	91	The level TCA precipitable radioactivity determined liquid scintillation counting
0.20839827.15659744.html.plaintext.txt	92	Electron microscopy analysis bead associated capsids
0.20839827.15659744.html.plaintext.txt	93	GST GST fusion proteins bound glutathione Sepharose beads incubated HSV capsid containing extracts beads washed pelleted fixed 2 5 glutaraldehyde SC 100 mM sodium cacodylate pH 7 43 room temperature 45 min
0.20839827.15659744.html.plaintext.txt	94	The pellet rinsed SC post fixed 1 osmium tetroxide SC followed 1 uranyl acetate dehydrated graded series ethanols embedded LX112 resin LADD Research Industries
0.20839827.15659744.html.plaintext.txt	95	Ultrathin sections cut Reichert Ultracut E stained uranyl acetate followed lead citrate viewed JEOL 1200EX transmission electron microscope 80 kV
0.20839827.15659744.html.plaintext.txt	96	Co immunoprecipitation endogenous gD VP22
0.20839827.15659744.html.plaintext.txt	97	COS cells infected HSV 1 strain PAAr5 Jones et al
0.20839827.15659744.html.plaintext.txt	98	At 15 h post infection cells collected resuspended lysis buffer 50 mM TrisHCl pH 7 6 150 mM NaCl 0 5 NP 40 0 5 mM EDTA 0 5 mM PMSF 2 mM DTT 200 microg protease inhibitor cocktail tablets Roche Diagnostics ml 1 incubated ice 30 min
0.20839827.15659744.html.plaintext.txt	99	The resulting lysate cleared centrifugation 20 min 15 000 g pre cleared incubation Protein G agarose beads Sigma 20 min 37 degrees C
0.20839827.15659744.html.plaintext.txt	100	After pelleting beads supernatants collected mixed fresh Protein G beads either anti gD Virusys anti HA Roche Diagnostics monoclonal antibody mAb
0.20839827.15659744.html.plaintext.txt	101	After 15 min incubation 37 degrees C beads washed four times wash buffer PBS
0.20839827.15659744.html.plaintext.txt	102	Bound material subjected SDS PAGE Western blotted using anti VP22 antibody
0.20839827.15659744.html.plaintext.txt	103	RESULTS Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Generation GST gD tail fusion protein test interaction tegument proteins A PCR amplified DNA fragment encoding gD cytoplasmic tail cloned frame coding sequence GST using vector pGEX KG Guan Dixon 1991 Fig
0.20839827.15659744.html.plaintext.txt	104	coli strain BL21 transformed pGEX KG gDc treated IPTG induce expression cell extracts subjected SDS PAGE
0.20839827.15659744.html.plaintext.txt	105	1b Coomassie blue staining shows fusion protein predicted size approximately 30 kDa abundant protein gel
0.20839827.15659744.html.plaintext.txt	106	View larger version 54K Fig
0.20839827.15659744.html.plaintext.txt	107	Construction expression GST gD fusion protein
0.20839827.15659744.html.plaintext.txt	108	Schematic diagram fusion protein expressing region pGEX KG
0.20839827.15659744.html.plaintext.txt	109	Ptac IPTG inducible promoter arrow indicating direction transcription
0.20839827.15659744.html.plaintext.txt	110	The GST ORF indicated filled box followed polyglycine flexible hinge GGGGG
0.20839827.15659744.html.plaintext.txt	111	The gD cytoplasmic tail cloned EcoRI HindIII sites
0.20839827.15659744.html.plaintext.txt	112	The protein sequence gD tail shown followed two stop codons
0.20839827.15659744.html.plaintext.txt	113	coli BL21 cells expression fusion proteins induced IPTG cell extracts subjected 10 SDS PAGE
0.20839827.15659744.html.plaintext.txt	114	Coomassie blue staining readily showed GST fusion protein abundant proteins cell extract arrows
0.20839827.15659744.html.plaintext.txt	115	The positions sizes kDa standard molecular mass markers indicated left
0.20839827.15659744.html.plaintext.txt	116	c Equivalent amounts GST gDc gHc expressing bacterial extracts added vitro GST binding assay incubated S100 fraction HSV infected cells
0.20839827.15659744.html.plaintext.txt	117	Bound B unbound U polypeptides resolved SDS PAGE transferred PVDF membrane probed various antibodies indicated left Tub
0.20839827.15659744.html.plaintext.txt	118	Input indicates total amount S100 fraction added binding reaction
0.20839827.15659744.html.plaintext.txt	119	Binding tegument protein VP22 gD fusion protein To prepare source tegument polypeptides binding assay followed methodology previously described isolating HSV 1 containing organelles putative assembly intermediates cytoplasm HSV 1 infected cells Harley et al
0.20839827.15659744.html.plaintext.txt	120	PNS HSV infected COS cells first treated NP 40 NaCl solubilize viral structural proteins previously found many tegument polypeptides insoluble PNS perhaps due incorporation assembling virions
0.20839827.15659744.html.plaintext.txt	121	The detergent solubilized extract incubated glutathione Sepharose beads previously bound equivalent amounts GST gDc gHc fusion protein viral gH tail GST well characterized laboratory Gross et al
0.20839827.15659744.html.plaintext.txt	122	Bound unbound material resolved SDS PAGE Western blotted analysed probing various antibodies
0.20839827.15659744.html.plaintext.txt	123	1c shows binding tegument protein VP22 GST gD fusion protein
0.20839827.15659744.html.plaintext.txt	124	VP22 remained mostly unbound fraction incubated GST alone suggesting binding tail specific
0.20839827.15659744.html.plaintext.txt	125	To test specificity binding also examined association abundant cellular viral proteins gD tail
0.20839827.15659744.html.plaintext.txt	126	The cellular protein tubulin abundant capsid scaffold proteins Pra ICP35 failed bind gD gH tails indicating glycoprotein tails bind cellular viral proteins non specifically VP22 bound gD tail gH tail
0.20839827.15659744.html.plaintext.txt	127	We also observed gD bound tegument protein VP16 manner similar gH
0.20839827.15659744.html.plaintext.txt	128	This consistent previous study Zhu Coutney 1994 demonstrated VP16 could cross linked gD gH purified virions
0.20839827.15659744.html.plaintext.txt	129	Binding VP22 gD tail independent viral proteins The interaction VP22 gD may direct mediated viral proteins
0.20839827.15659744.html.plaintext.txt	130	To examine question used rabbit reticulocyte lysate vitro transcriptiontranslation system generate 35S labelled VP22 added vitro GST binding assay
0.20839827.15659744.html.plaintext.txt	131	Autoradiography showed vitro translated VP22 running molecular mass 45 kDa bound gD tail Fig
0.20839827.15659744.html.plaintext.txt	132	Since rabbit reticulocyte lysate contained vitro translated VP22 viral proteins could conclude VP22 binding require viral polypeptides
0.20839827.15659744.html.plaintext.txt	133	Although could discount possibility cellular polypeptide reticulocyte lysate mediated gD VP22 interaction host protein abundance VP22 ever described HSV particle
0.20839827.15659744.html.plaintext.txt	134	View larger version 42K Fig
0.20839827.15659744.html.plaintext.txt	135	VP22 binds gD tail absence viral proteins
0.20839827.15659744.html.plaintext.txt	136	35S labelled VP22 generated using rabbit reticulocyte lysate vitro transcriptiontranslation system
0.20839827.15659744.html.plaintext.txt	137	gDc GST coated glutathione Sepharose beads incubated radiolabelled VP22 duplicate subjected SDS PAGE fixed exposed film 1 2 days
0.20839827.15659744.html.plaintext.txt	138	Input corresponds amount vitro translated product included binding reaction
0.20839827.15659744.html.plaintext.txt	139	Smaller fragments VP22 might result either early termination protein synthesis partial degradation also found bound lane gDc
0.20839827.15659744.html.plaintext.txt	140	We assumed smallest fragment 23 kDa Fig
0.20839827.15659744.html.plaintext.txt	141	2 vitro translated VP22 contained region required binding gD tail
0.20839827.15659744.html.plaintext.txt	142	Alanine scanning mutagenesis gD cytoplasmic tail To simplify identification amino acids within gD cytoplasmic tail play important role VP22 binding generated truncation mutant tail retained amino terminal 17 residues named T17 Fig
0.20839827.15659744.html.plaintext.txt	143	When GST T17 fusion protein tested ability bind VP22 present cytosolic extracts prepared HSV infected cells found bind VP22 similar manner full length gD tail Fig
0.20839827.15659744.html.plaintext.txt	144	Next identify residues might critical binding VP22 carried alanine scanning mutagenesis
0.20839827.15659744.html.plaintext.txt	145	Clusters amino acids mutated simultaneously alanine named according amino acid residues mutated Fig
0.20839827.15659744.html.plaintext.txt	146	These mutants along gDc GST expressed incubated infected cell extracts relative amounts VP22 binding detected Western blotting
0.20839827.15659744.html.plaintext.txt	147	3c shows mutations arginine lysine residues positions 56 910 diminished binding VP22 indicating amino acid residues important
0.20839827.15659744.html.plaintext.txt	148	Although HRR mutant showed slightly decreased binding VP22 level binding variable commonly HRR mutant bound VP22 level similar wild type gD tail
0.20839827.15659744.html.plaintext.txt	149	Next examined role key lysine arginine residues context full length gD tail Fig
0.20839827.15659744.html.plaintext.txt	150	Similar truncated mutant mutation R5K6 showed dramatic decrease binding VP22
0.20839827.15659744.html.plaintext.txt	151	Individual mutation residues less dramatic effect indicating amino acid residues contribute VP22 binding may play somewhat redundant role
0.20839827.15659744.html.plaintext.txt	152	View larger version 52K Fig
0.20839827.15659744.html.plaintext.txt	153	Alanine scanning mutagenesis gD tail
0.20839827.15659744.html.plaintext.txt	154	Amino acid sequence gD tail corresponding mutants
0.20839827.15659744.html.plaintext.txt	155	b T17 fusion protein containing first 17 amino acid residues gD tail binds VP22 S100 equivalent level full length gD tail
0.20839827.15659744.html.plaintext.txt	156	Binding gD tail VP22 bound B unbound U fractions shown
0.20839827.15659744.html.plaintext.txt	157	c Clusters basic residues T17 changed alanines indicated
0.20839827.15659744.html.plaintext.txt	158	The residues mutated alanines indicated lane
0.20839827.15659744.html.plaintext.txt	159	When fusion proteins examined ability bind VP22 R5K6 K9R10 mutants showed diminished binding comparison others
0.20839827.15659744.html.plaintext.txt	160	d The full length gD tail containing substitutions arginine lysine residues positions 56 910 alanine showed diminished binding VP22
0.20839827.15659744.html.plaintext.txt	161	Individual mutations containing alanine substitutions either lysine 5 arginine 6 residue showed binding VP22
0.20839827.15659744.html.plaintext.txt	162	The Western blots c d also revealed quantity GST fusion protein binding reaction since anti VP22 antiserum cross reactive GST
0.20839827.15659744.html.plaintext.txt	163	Co immunoprecipitation endogenous gD VP22 So far gD VP22 interaction demonstrated using vitro GST binding assay
0.20839827.15659744.html.plaintext.txt	164	In order confirm protein protein interaction vivo co immunoprecipitation experiment performed using infected cell lysate prepared COS cells infected wild type HSV 1 strain PAAr5
0.20839827.15659744.html.plaintext.txt	165	Infected cell lysates incubated protein G agarose beads containing either anti gD anti HA mAb described Methods
0.20839827.15659744.html.plaintext.txt	166	The immunoprecipitated materials subjected SDS PAGE Western blotted VP22
0.20839827.15659744.html.plaintext.txt	167	The amount VP22 total cell lysate shown Fig
0.20839827.15659744.html.plaintext.txt	168	VP22 present immunoprecipitation carried anti gD mAb Fig
0.20839827.15659744.html.plaintext.txt	169	4 lane 2 anti HA mAb used Fig
0.20839827.15659744.html.plaintext.txt	170	Therefore gD indeed co immunoprecipitated VP22 indicating two proteins interact vivo
0.20839827.15659744.html.plaintext.txt	171	View larger version 8K Fig
0.20839827.15659744.html.plaintext.txt	172	Co immunoprecipitation VP22 gD
0.20839827.15659744.html.plaintext.txt	173	Infected cell lysate prepared incubated either anti gD lane 2 anti HA lane 3 mAb
0.20839827.15659744.html.plaintext.txt	174	Immunoprecipitated material subjected SDS PAGE Western blotted anti VP22 antibody
0.20839827.15659744.html.plaintext.txt	175	Lane 1 contained total cell lysate
0.20839827.15659744.html.plaintext.txt	176	Binding capsids gD tail presence tegument proteins To examine interaction glycoprotein tail capsids prepared cell extracts containing capsids viral genome labelled 3Hthymidine described Methods
0.20839827.15659744.html.plaintext.txt	177	The packaged radiolabelled viral genome enabled us monitor presence HSV capsids scintillation counting
0.20839827.15659744.html.plaintext.txt	178	It noted since relatively crude extract tegument polypeptides vhs VP22 VP16 also present determined Western blotting Fig
0.20839827.15659744.html.plaintext.txt	179	This extract incubated glutathione Sepharose beads pre coated equivalent amounts GST gDc gHc previously described
0.20839827.15659744.html.plaintext.txt	180	After washing beads incubated DNase I conditions previously shown destroy DNA packaged within icosahedral capsid Church et al
0.20839827.15659744.html.plaintext.txt	181	1998 Dasgupta Wilson 1999 Harley et al
0.20839827.15659744.html.plaintext.txt	182	Any surviving full length previously packaged DNA collected TCA precipitation subjected scintillation counting
0.20839827.15659744.html.plaintext.txt	183	5b low levels protected encapsidated DNA became bound beads coated GST gHc
0.20839827.15659744.html.plaintext.txt	184	In contrast much higher levels binding apparent capsids incubated bead bound gDc
0.20839827.15659744.html.plaintext.txt	185	View larger version 21K Fig
0.20839827.15659744.html.plaintext.txt	186	Binding HSV 1 capsids cytosolic tail gD
0.20839827.15659744.html.plaintext.txt	187	Capsids prepared detergent solubilized HSV infected cell PNS described Methods
0.20839827.15659744.html.plaintext.txt	188	The capsid preparation resolved 12 SDS PAGE transferred nitrocellulose filter probed antibodies specific capsid subunit VP23 tegument polypeptides vhs VP22 VP16 indicated
0.20839827.15659744.html.plaintext.txt	189	The positions sizes kDa standard molecular mass markers indicated left
0.20839827.15659744.html.plaintext.txt	190	b Equivalent amounts GST gDc gHc fusion protein bound glutathione Sepharose beads incubated crude preparation 3Hthymidine labelled capsids
0.20839827.15659744.html.plaintext.txt	191	After washing beads incubated DNase I digest DNA protected within capsid
0.20839827.15659744.html.plaintext.txt	192	EDTA 10 mM added inactivate DNase plus 0 3 SDS release capsids beads disrupt
0.20839827.15659744.html.plaintext.txt	193	Released viral DNA collected TCA precipitation subjected scintillation counting
0.20839827.15659744.html.plaintext.txt	194	precipitated 3H labelled DNA
0.20839827.15659744.html.plaintext.txt	195	Plotted values represent mean plus minus SD triplicate samples
0.20839827.15659744.html.plaintext.txt	196	c Increasing amounts crude capsid preparation incubated glutathione Sepharose beads bound either GST filled circles gDc fusion protein open squares
0.20839827.15659744.html.plaintext.txt	197	Following incubation samples treated DNase I followed EDTA SDS TCA precipitated subjected scintillation counting b
0.20839827.15659744.html.plaintext.txt	198	If capsids binding specific site gD tail constant amount gDc fusion protein bound beads capsid binding saturable
0.20839827.15659744.html.plaintext.txt	199	5c shows result experiment increasing amounts radiolabelled capsid containing extract incubated GST gDc coated glutathione Sepharose beads scored capsid binding described
0.20839827.15659744.html.plaintext.txt	200	Under conditions binding capsids gD tail appeared saturable 500 750 microg cytosolic protein Fig
0.20839827.15659744.html.plaintext.txt	201	In contrast binding GST much lower level increased linearly relation quantity extract added consistent lack saturable binding site
0.20839827.15659744.html.plaintext.txt	202	This indicated capsids binding specifically gD tail likely indirectly via tegument proteins
0.20839827.15659744.html.plaintext.txt	203	Visualization HSV 1 capsids bound gDc coated glutathione Sepharose beads Although rapid convenient monitoring c
0.20839827.15659744.html.plaintext.txt	204	labelled packaged viral DNA indirect method testing presence capsids
0.20839827.15659744.html.plaintext.txt	205	As direct test gD tail capsid interaction GST gDc coated glutathione Sepharose beads incubated capsid preparation fixed processed ultrastructural analysis
0.20839827.15659744.html.plaintext.txt	206	6 shows representative images capsids bound gDc coated beads
0.20839827.15659744.html.plaintext.txt	207	For gDc coated beads relatively easy identify icosahedral capsids
0.20839827.15659744.html.plaintext.txt	208	Capsids never found within beads always perimeter suggesting non specifically trapped within glutathione Sepharose matrix
0.20839827.15659744.html.plaintext.txt	209	View larger version 159K Fig
0.20839827.15659744.html.plaintext.txt	210	Visualization bead bound capsids electron microscopy
0.20839827.15659744.html.plaintext.txt	211	Capsid containing cell extracts incubated bead bound gDc
0.20839827.15659744.html.plaintext.txt	212	After washing mixture fixed glutaraldehyde processed thin section electron microscopy
0.20839827.15659744.html.plaintext.txt	213	c Representative bead perimeters
0.20839827.15659744.html.plaintext.txt	214	Bound capsids indicated arrows
0.20839827.15659744.html.plaintext.txt	215	d Sevenfold magnification capsid indicated b
0.20839827.15659744.html.plaintext.txt	216	In study attempt discriminate B C capsids since believed similar surface compositions Newcomb et al
0.20839827.15659744.html.plaintext.txt	217	1996 B C capsids capable becoming enveloped Baines et al
0.20839827.15659744.html.plaintext.txt	218	Interestingly capsids scored internal structure either DNA core scaffold suggesting conditions A capsids present data shown
0.20839827.15659744.html.plaintext.txt	219	Table 1 shows quantification number capsids bound GST gDc coated beads
0.20839827.15659744.html.plaintext.txt	220	Quantification bead bound capsids
0.20839827.15659744.html.plaintext.txt	221	Capsid binding gD tail dependent arginine lysine residues important binding VP22 The capsid preparation known contain tegument polypeptides vhs VP16 VP22 Fig
0.20839827.15659744.html.plaintext.txt	222	To test possibility VP22 might play role capsid gD tail interactions made use GST gDR5K6 fusion protein previously shown diminished ability bind VP22
0.20839827.15659744.html.plaintext.txt	223	Beads previously bound either GST gDc gDR5K6 incubated cell extract containing capsids
0.20839827.15659744.html.plaintext.txt	224	capsids bound gDR5K6 fusion protein similar background levels
0.20839827.15659744.html.plaintext.txt	225	This correlative result consistent possibility VP22 plays essential role attachment capsids gD tail
0.20839827.15659744.html.plaintext.txt	226	View larger version 16K Fig
0.20839827.15659744.html.plaintext.txt	227	Mutation arginine lysine residues essential VP22 binding abolishes binding capsids
0.20839827.15659744.html.plaintext.txt	228	Equivalent amounts GST gDc gDR5K6 added GST vitro binding reaction incubated crude capsid preparation Fig
0.20839827.15659744.html.plaintext.txt	229	The level capsid binding seen mutant gDR5K6 similar background binding seen negative control GST
0.20839827.15659744.html.plaintext.txt	230	DISCUSSION Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES The cytoplasmic tails HSV 1 glycoproteins shown interact various tegument proteins Brack et al
0.20839827.15659744.html.plaintext.txt	231	2003 Zhu Courtney 1994 may facilitate capsid recruitment site envelopment
0.20839827.15659744.html.plaintext.txt	232	So far dissecting molecular mechanism assembly using genetic approach complicated redundancy among viral glycoproteins deletion single glycoprotein generally lead apparent defects cytoplasmic envelopment instead multiple simultaneous deletions necessary
0.20839827.15659744.html.plaintext.txt	233	In study took biochemical approach towards analysing protein protein interactions might important virus assembly
0.20839827.15659744.html.plaintext.txt	234	We generated fusion protein GST cytoplasmic tail gD order test interaction HSV 1 tegument proteins
0.20839827.15659744.html.plaintext.txt	235	Our results showed gD tail specifically bound tegument protein VP22 interact abundant cellular protein tubulin capsid scaffold proteins ICP35 Pra
0.20839827.15659744.html.plaintext.txt	236	Furthermore co immunoprecipitation experiments confirmed interaction gD VP22 could detected infected cells
0.20839827.15659744.html.plaintext.txt	237	Additionally alanine scanning mutagenesis gD tail identified two amino acid residues arginine lysine amino terminal end tail positions 5 6 respectively critical VP22 binding
0.20839827.15659744.html.plaintext.txt	238	Since VP22 VP16 form complex Elliott et al
0.20839827.15659744.html.plaintext.txt	239	1995 observed VP16 binding gD tail interested test whether VP22 bound gD tail directly via VP16 viral proteins
0.20839827.15659744.html.plaintext.txt	240	Therefore synthesized 35S labelled VP22 using rabbit reticulocyte lysate vitro transcriptiontranslation system tested ability bind gD tail
0.20839827.15659744.html.plaintext.txt	241	We found vitro translated VP22 bind specifically gD tail showing binding independent viral polypeptides
0.20839827.15659744.html.plaintext.txt	242	Under conditions also observed capsid binding gD tail
0.20839827.15659744.html.plaintext.txt	243	This binding saturable unlike low level binding seen GST alone
0.20839827.15659744.html.plaintext.txt	244	We speculated capsid binding gD tail mediated tegument components present crude capsid preparation
0.20839827.15659744.html.plaintext.txt	245	Our results showed gD mutant tail gDR5K6 failed bind VP22 also failed bind capsids
0.20839827.15659744.html.plaintext.txt	246	This suggested VP22 mediating capsid tail interactions
0.20839827.15659744.html.plaintext.txt	247	However also possible tegument proteins mediate binding capsids gD tail utilizing residues VP22
0.20839827.15659744.html.plaintext.txt	248	Although VP16 present capsids Fig
0.20839827.15659744.html.plaintext.txt	249	5a bind gH tail Gross et al
0.20839827.15659744.html.plaintext.txt	250	2003 appeared unable tether capsids gH tail Fig
0.20839827.15659744.html.plaintext.txt	251	Additionally observed VP16 capable binding gD mutant tail gDR5K6 bind capsids data shown
0.20839827.15659744.html.plaintext.txt	252	This also suggested VP16 involved capsid tail interactions conditions
0.20839827.15659744.html.plaintext.txt	253	The association VP22 gD may one many interactions glycoprotein tails tegument proteins facilitate budding capsids organelles incorporation tegumentglycoproteins nascent virions
0.20839827.15659744.html.plaintext.txt	254	In HSV 1 deletion cytoplasmic tail gD relatively little effect normal virus production Feenstra et al
0.20839827.15659744.html.plaintext.txt	255	However simultaneous deletion gD gE showed elimination cytoplasmic envelopment accumulation large numbers unenveloped nucleocapsids within dense layer tegument cytoplasm Farnsworth et al
0.20839827.15659744.html.plaintext.txt	256	2003 indicating gD gE may share overlapping roles cytoplasmic envelopment
0.20839827.15659744.html.plaintext.txt	257	Our data suggest least one roles may VP22 recruitment predict cytoplasmic tail gE may also bind VP22
0.20839827.15659744.html.plaintext.txt	258	Interestingly Farnsworth et al
0.20839827.15659744.html.plaintext.txt	259	2003 reported cytoplasmic tail gE fused GST indeed able bind VP22
0.20839827.15659744.html.plaintext.txt	260	Thus gD gE may act redundant manner incorporate VP22 newly forming virions
0.20839827.15659744.html.plaintext.txt	261	Alternatively could argued VP22 serves gather gD gE sites capsid envelope interaction
0.20839827.15659744.html.plaintext.txt	262	Our findings regarding HSV 1 somewhat similar data reported alphaherpesvirus PrV
0.20839827.15659744.html.plaintext.txt	263	gE gM shown interact UL49 protein homologue HSV 1 VP22 Fuchs et al
0.20839827.15659744.html.plaintext.txt	264	2002 following simultaneous deletion two glycoproteins UL49 product become incorporated PrV particle Fuchs et al
0.20839827.15659744.html.plaintext.txt	265	However absence UL49 protein gE gM incorporated virions implying may interact redundantly tegument proteins purpose
0.20839827.15659744.html.plaintext.txt	266	ACKNOWLEDGEMENTS This work supported National Institutes Health grant AI38265 D
0.20839827.15659744.html.plaintext.txt	267	NIH training grant T32 AI07506 J
0.20839827.15659744.html.plaintext.txt	268	We thank Jim Smiley HSV 1 strain PAAr5 Analytical Imaging Facility Albert Einstein College Medicine help electron microscopy
0.20839827.15659744.html.plaintext.txt	269	We thank Dr John Blaho Dr Richard J
0.20839827.15659744.html.plaintext.txt	270	Courtney providing anti VP22 anti sera
0.20839827.15659744.html.plaintext.txt	271	REFERENCES Top ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES Baines J
0.20839827.15659744.html.plaintext.txt	272	The UL15 gene herpes simplex virus type 1 contains within second exon novel open reading frame translated frame UL15 gene product
0.20839827.15659744.html.plaintext.txt	273	Inhibition virion maturation simultaneous deletion glycoproteins E I M pseudorabies virus
0.20839827.15659744.html.plaintext.txt	274	Role cytoplasmic tail pseudorabies virus glycoprotein E virion formation
0.20839827.15659744.html.plaintext.txt	275	Analysis requirement glycoprotein M herpes simplex virus type 1 morphogenesis
0.20839827.15659744.html.plaintext.txt	276	Herpes simplex virus DNA packaging without measurable DNA synthesis
0.20839827.15659744.html.plaintext.txt	277	ATP depletion blocks herpes simplex virus DNA packaging capsid maturation
0.20839827.15659744.html.plaintext.txt	278	VP16 interacts via activation domain VP22 tegument protein herpes simplex virus relocated novel macromolecular assembly coexpressing cells
0.20839827.15659744.html.plaintext.txt	279	Herpes simplex virus glycoproteins gD gEgI serve essential redundant functions acquisition virion envelope cytoplasm
0.20839827.15659744.html.plaintext.txt	280	Deletions herpes simplex virus glycoprotein D define nonessential essential domains
0.20839827.15659744.html.plaintext.txt	281	Physical interaction envelope glycoproteins E M pseudorabies virus major tegument protein UL49
0.20839827.15659744.html.plaintext.txt	282	The cytoplasmic tail herpes simplex virus glycoprotein H binds tegument protein VP16 vitro vivo
0.20839827.15659744.html.plaintext.txt	283	Eukaryotic proteins expressed Escherichia coli improved thrombin cleavage purification procedure fusion proteins glutathione S transferase
0.20839827.15659744.html.plaintext.txt	284	Characterization herpes simplex virus containing organelles subcellular fractionation role organelle acidification assembly infectious particles
0.20839827.15659744.html.plaintext.txt	285	Mutational analysis herpes simplex virus virion host shutoff protein evidence vhs functions absence viral proteins
0.20839827.15659744.html.plaintext.txt	286	Herpesvirus assembly egress
0.20839827.15659744.html.plaintext.txt	287	Assembly herpes simplex virus capsid characterization intermediates observed cell free capsid formation
0.20839827.15659744.html.plaintext.txt	288	Modified VP22 localizes cell nucleus synchronized herpes simplex virus type 1 infection
0.20839827.15659744.html.plaintext.txt	289	The family Herpesviridae brief introduction
0.20839827.15659744.html.plaintext.txt	290	In Fields Virology 4th edn vol
0.20839827.15659744.html.plaintext.txt	291	Philadelphia Lippencott Williams Wilkins
0.20839827.15659744.html.plaintext.txt	292	Proteins specified herpes simplex virus
0.20839827.15659744.html.plaintext.txt	293	Purification structural proteins herpesvirion
0.20839827.15659744.html.plaintext.txt	294	The herpes simplex virus procapsid structure conformational changes upon maturation roles triplex proteins VP19c VP23 assembly
0.20839827.15659744.html.plaintext.txt	295	Chemical cross linking virion envelope tegument proteins herpes simplex virus type 1
0.20839827.15659744.html.plaintext.txt	296	Received 15 July 2004 accepted 25 October 2004
0.21750095.15117959.html.plaintext.txt	0	Herpes Simplex Virus Type 1 Capsid Protein VP26 Interacts Dynein Light Chains RP3 Tctex1 Plays Role Retrograde Cellular Transport Mark W
0.21750095.15117959.html.plaintext.txt	1	Homa Monica Miranda Saksena Frazer J
0.21750095.15117959.html.plaintext.txt	2	Rixon Valerio Vittone Karen Byth Anthony L
0.21750095.15117959.html.plaintext.txt	3	From Centre Virus Research Westmead Millennium Institute University Sydney Westmead Hospital P
0.21750095.15117959.html.plaintext.txt	4	Box 412 Westmead 2145 New South Wales Australia Infectious Disease Biology Pharmacia Corp
0.21750095.15117959.html.plaintext.txt	5	Kalamazoo Michigan 49001 MRC Virology Unit Institute Virology Glasgow G11 5JR Scotland United Kingdom
0.21750095.15117959.html.plaintext.txt	6	Received publication October 24 2003 revised form April 22 2004
0.21750095.15117959.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Cytoplasmic dynein major molecular motor involved minus end directed cellular transport along microtubules
0.21750095.15117959.html.plaintext.txt	8	There increasing evidence retrograde transport herpes simplex virus type 1 along sensory axons mediated cytoplasmic dynein viral cellular proteins involved known
0.21750095.15117959.html.plaintext.txt	9	Here report herpes simplex virus outer capsid protein VP26 interacts dynein light chains RP3 Tctex1 sufficient mediate retrograde transport viral capsids cellular model
0.21750095.15117959.html.plaintext.txt	10	A library herpes simplex virus capsid tegument structural genes constructed tested interactions dynein subunits yeast two hybrid system
0.21750095.15117959.html.plaintext.txt	11	A strong interaction detected VP26 homologous 14 kDa dynein light chains RP3 Tctex1
0.21750095.15117959.html.plaintext.txt	12	In vitro pull assays confirmed binding VP26 RP3 Tctex1 intact cytoplasmic dynein complexes
0.21750095.15117959.html.plaintext.txt	13	Recombinant herpes simplex virus capsids constructed either without VP26
0.21750095.15117959.html.plaintext.txt	14	In pull assays VP26 capsids bound RP3 VP26 capsids
0.21750095.15117959.html.plaintext.txt	15	To investigate intracellular transport recombinant viral capsids microinjected living cells incubated 37 degrees C
0.21750095.15117959.html.plaintext.txt	16	After 1 h VP26 capsids observed co localize RP3 Tctex1 microtubules
0.21750095.15117959.html.plaintext.txt	17	After 2 4 h VP26 capsids moved closer cell nucleus whereas VP26 capsids remained random distribution
0.21750095.15117959.html.plaintext.txt	18	We propose VP26 mediates binding incoming herpes simplex virus capsids cytoplasmic dynein cellular infection interactions dynein light chains
0.21750095.15117959.html.plaintext.txt	19	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Herpes simplex virus type 1 HSV 11 infects 40 80 people worldwide cause potentially fatal meningoencephalitis adults disseminated infection neonates addition common mucocutaneous disease
0.21750095.15117959.html.plaintext.txt	20	After inoculation skin mucous membrane HSV 1 transported along sensory axons retrograde direction neuronal cell body establishes life long latent infection
0.21750095.15117959.html.plaintext.txt	21	Periodic reactivation results HSV 1 transported anterograde direction nerve terminals causes recurrent clinical disease asymptomatic viral shedding 1
0.21750095.15117959.html.plaintext.txt	22	The double stranded DNA virus HSV 1 1250 A icosahedral protein capsid surrounded less structured protein tegument layer turn surrounded lipid envelope containing several glycoproteins
0.21750095.15117959.html.plaintext.txt	23	The major capsid proteins VP5 VP19C VP23 VP26 self assembling expressed vitro using recombinant baculoviruses 2 3
0.21750095.15117959.html.plaintext.txt	24	During infection HSV 1 binds cell surface receptors via glycoproteins enters cell membrane fusion tegument proteins dissociate nucleocapsid phosphorylation 4 5
0.21750095.15117959.html.plaintext.txt	25	The nucleocapsid tegument complex transported outer nuclear membrane docks releases viral DNA nucleus capsid enter nucleus 6
0.21750095.15117959.html.plaintext.txt	26	There evidence rapid retrograde transport complex cell nucleus involves microtubules mediated minus end directed molecular motor cytoplasmic dynein 7 9
0.21750095.15117959.html.plaintext.txt	27	Retrograde transport closely related alphaherpesvirus pseudorabies virus PRV observed live cells saltatory brief rapid transport events 10
0.21750095.15117959.html.plaintext.txt	28	The herpes viral proteins mediate retrograde transport unknown likely involve outer capsid inner tegument proteins
0.21750095.15117959.html.plaintext.txt	29	In support HSV 1 capsids stripped envelope much tegument protein detergent lysis move retrograde direction injection giant squid axons 11
0.21750095.15117959.html.plaintext.txt	30	The site attachment dynein complex capsid confirmed
0.21750095.15117959.html.plaintext.txt	31	Cytoplasmic dynein large 1
0.21750095.15117959.html.plaintext.txt	32	2 MDa complex heavy chains providing motive force whereas intermediate light chains contribute cargo binding 12
0.21750095.15117959.html.plaintext.txt	33	Regulation dynein function well understood thought involve multisubunit complex dynactin also involved binding membranous cargo 13
0.21750095.15117959.html.plaintext.txt	34	Light chain LC8 reported interact proteins rabies virus 14 15 African swine fever virus 16 human adenovirus vaccinia virus human papillomavirus 17 whereas Tctex1 interacts poliovirus receptor CD155 18
0.21750095.15117959.html.plaintext.txt	35	Despite recently reported interaction dynein intermediate chain DIC HSV 1 protein UL34 19 role retrograde transport yet confirmed
0.21750095.15117959.html.plaintext.txt	36	The protein product UL34 absent mature virions HSV 1 20 PRV 21
0.21750095.15117959.html.plaintext.txt	37	Furthermore deletion UL34 HSV 1 prevent infection cells 22
0.21750095.15117959.html.plaintext.txt	38	Previous work laboratory concentrated anterograde axonal transport HSV 1
0.21750095.15117959.html.plaintext.txt	39	We shown newly formed HSV 1 capsids acquired much tegument neuron cell body 23 transported anterograde direction along axons separate glycoproteins 24 25
0.21750095.15117959.html.plaintext.txt	40	Similar observations made PRV 26
0.21750095.15117959.html.plaintext.txt	41	Fast anterograde microtubule dependent transport mediated kinesin family molecular motors 27
0.21750095.15117959.html.plaintext.txt	42	We shown previously 28 HSV 1 tegument protein US11 interacts ubiquitous heavy chain kinesin motor KIF5B likely play important role anterograde axonal transport
0.21750095.15117959.html.plaintext.txt	43	By using similar approach retrograde transport report interaction HSV 1 capsid protein VP26 14 kDa dynein light chains RP3 Tctex1
0.21750095.15117959.html.plaintext.txt	44	These light chains 55 homologous amino acid level mutually exclusive cytoplasmic dynein complexes 29 31
0.21750095.15117959.html.plaintext.txt	45	We propose VP26 mediates binding HSV 1 nucleocapsid cytoplasmic dynein via interactions RP3 probably Tctex1 retrograde axonal transport virus neurons well infection non neuronal cells
0.21750095.15117959.html.plaintext.txt	46	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Expression Constructs Genes amplified PCR using Geneamp XL PCR Kit Applied Biosystems
0.21750095.15117959.html.plaintext.txt	47	The entire open reading frame gene cloned recombinant expression vectors cases except HSV 1 UL36 N terminal two thirds gene amino acids 1 1874 cloned
0.21750095.15117959.html.plaintext.txt	48	Oligonucleotide primers incorporating EcoRI andor XhoI restriction endonuclease sites constructs designed using Primer3 software 32 BioManager ANGIS www
0.21750095.15117959.html.plaintext.txt	49	For UL36 3 BglII site used insertion BamHI sites UL32 NcoI sites used
0.21750095.15117959.html.plaintext.txt	50	Human DIC 1c amplified pBluescript plasmid kindly provided Dr
0.21750095.15117959.html.plaintext.txt	51	Lap Chee Tsui University Toronto 34
0.21750095.15117959.html.plaintext.txt	52	Genes dynein light chains Tctex1 RP3 LC8 amplified human brain cDNA library Display Biosystems Biotech
0.21750095.15117959.html.plaintext.txt	53	HSV 1 genes amplified overlapping DNA cosmids encoding strain 17 35 except US11 amplified plasmid pRB4766 strain 17 kindly provided Bernard Roizman University Chicago 36
0.21750095.15117959.html.plaintext.txt	54	UL19 excised plasmid pE19 33 BglII inserted BamHI site
0.21750095.15117959.html.plaintext.txt	55	Digested PCR products inserted expression plasmids using ClonablesTM kit Novagen
0.21750095.15117959.html.plaintext.txt	56	Genes cloned pGEX 5X 1 Amersham Biosciences glutathione S transferase GST tag fusion protein expression pET 28a Novagen hexahistidine His6 tag fusion protein expression
0.21750095.15117959.html.plaintext.txt	57	For LexA yeast two hybrid system genes cloned displayBait andor displayTarget vectors Display Systems Biotech
0.21750095.15117959.html.plaintext.txt	58	All constructs sequenced confirm gene sequence correct reading frame
0.21750095.15117959.html.plaintext.txt	59	Construction His6 tag fusions kinesin heavy chain KIF5B amino acids 771 963 37 HSV 1 US11 28 described previously
0.21750095.15117959.html.plaintext.txt	60	LexA Yeast Two hybrid Assay Potential interactions dynein subunits HSV 1 proteins tested Clontech Matchmaker LexA yeast two hybrid system described previously 38
0.21750095.15117959.html.plaintext.txt	61	Expression Purification His6 tagged Proteins His6 tag constructs expressed Escherichia coli BL21 DE3 induced 1 mM isopropyl 1 thio D galactopyranoside 3 h 37 degrees C
0.21750095.15117959.html.plaintext.txt	62	Proteins harvested lysed described previously 38
0.21750095.15117959.html.plaintext.txt	63	His VP1112 expressed soluble protein low levels whereas His6 VP26 insoluble
0.21750095.15117959.html.plaintext.txt	64	present inclusion bodies
0.21750095.15117959.html.plaintext.txt	65	His6 KIF5B purified described previously 38
0.21750095.15117959.html.plaintext.txt	66	To solubilize His6 VP26 inclusion bodies resuspended denaturing buffer 8 M urea 100 mM NaH2PO4 10 mM Tris HCl pH 8
0.21750095.15117959.html.plaintext.txt	67	After 1 h solution centrifuged 16000 x g 30 min supernatant 10 min
0.21750095.15117959.html.plaintext.txt	68	Supernatant passed nickel beads His
0.21750095.15117959.html.plaintext.txt	69	Bind kit Novagen beads washed denaturing buffer containing 20 mM imidazole His6 VP26 eluted denaturing buffer containing 200 mM imidazole
0.21750095.15117959.html.plaintext.txt	70	Fractions highest protein concentration 5 mgml pooled stored 4 degrees C
0.21750095.15117959.html.plaintext.txt	71	To refold His6 VP26 200 microl stock His6 VP26 solution 8 M urea slowly diluted 18 buffer containing 100 mM NaH2PO4 10 mM Tris HCl pH 8
0.21750095.15117959.html.plaintext.txt	72	0 final urea concentration 1 M
0.21750095.15117959.html.plaintext.txt	73	In Vitro Pull Assays GST fusion tag constructs expressed E
0.21750095.15117959.html.plaintext.txt	74	1 mM isopropyl 1 thio D galactopyranoside 3 h 37 degrees C harvested lysed described previously 38
0.21750095.15117959.html.plaintext.txt	75	Soluble bacterial lysates 1 ml containing GST fusion proteins incubated 50 microl glutathione Sepharose beads Amersham Biosciences 3 h rocking 4 degrees C
0.21750095.15117959.html.plaintext.txt	76	The beads washed three times lysis buffer minus protease inhibitors addition purified His6 tag fusion proteins HSV 1 capsids
0.21750095.15117959.html.plaintext.txt	77	Beads incubated overnight 4 degrees C rocking washing five times
0.21750095.15117959.html.plaintext.txt	78	Protein complexes eluted buffer 50 mM Tris HCl pH 8
0.21750095.15117959.html.plaintext.txt	79	0 10 mM reduced glutathione rocking 4 degrees C 2 h
0.21750095.15117959.html.plaintext.txt	80	For pull assays dynein complexes refolded His6 VP26 prepared bound nickel beads His
0.21750095.15117959.html.plaintext.txt	81	Bind kit Novagen incubated cell lysates bound complexes eluted described previously 37
0.21750095.15117959.html.plaintext.txt	82	Cell lysates prepared Hep2 cells grown 80 confluence
0.21750095.15117959.html.plaintext.txt	83	Cells detached trypsin washed phosphate buffered saline resuspended lysis buffer containing phosphate buffered saline 0
0.21750095.15117959.html.plaintext.txt	84	1 Triton X 100 protease inhibitor mixture Sigma
0.21750095.15117959.html.plaintext.txt	85	Cells subjected sonication cup horn water bath three times 20 100 duty cycle centrifuged 12000 x g 30 min
0.21750095.15117959.html.plaintext.txt	86	Western Blots Proteins separated SDS PAGE identified immunoblotting described previously 37
0.21750095.15117959.html.plaintext.txt	87	Antibodies used included mouse monoclonal antibodies Santa Cruz Biotechnology fusion tags hemagglutinin LexA His6
0.21750095.15117959.html.plaintext.txt	88	Monoclonal antibody DIC Chemicon also used
0.21750095.15117959.html.plaintext.txt	89	Preparation Recombinant HSV 1 Capsids Recombinant HSV 1 capsids prepared described previously 3
0.21750095.15117959.html.plaintext.txt	90	Briefly recombinant baculoviruses used express either five six HSV 1 capsid genes UL18 UL19 UL26 UL26
0.21750095.15117959.html.plaintext.txt	91	5 UL38 without UL35 insect Sf9 cells
0.21750095.15117959.html.plaintext.txt	92	The resulting capsids purified sucrose gradient centrifugation morphology HSV B capsids 3 39
0.21750095.15117959.html.plaintext.txt	93	All recombinant capsids contain major capsid proteins VP5 VP19C VP23 scaffolding proteins VP21 VP22a VP24
0.21750095.15117959.html.plaintext.txt	94	Capsids formed presence UL35 also contain capsid protein VP26
0.21750095.15117959.html.plaintext.txt	95	For microinjection capsids diluted 110 20 mM Tris HCl buffer pH 7
0.21750095.15117959.html.plaintext.txt	96	5 M NaCl 1 mM EDTA subjected sonication cup horn water bath three times 40 50 duty cycle centrifuged 12000 x g 30
0.21750095.15117959.html.plaintext.txt	97	The approximate final protein concentration measured Bio Rad Protein Assay 0
0.21750095.15117959.html.plaintext.txt	98	Microinjection Recombinant HSV 1 Capsids Hep2 cells grown 37 degrees C 5 CO2 CELLocate glass coverslips Eppendorf Dulbeccos modified Eagles medium Invitrogen 9 fetal calf serum JRH Bioscience
0.21750095.15117959.html.plaintext.txt	99	Microinjection performed room temperature using Dulbeccos modified Eagles medium 2 fetal calf serum buffered 25 mM HEPES NaOH pH 7
0.21750095.15117959.html.plaintext.txt	100	For co localization experiments PTK2 cells grown minimum Eagles medium Invitrogen supplemented nonessential amino acids 0
0.21750095.15117959.html.plaintext.txt	101	1 mM sodium pyruvate 1 mM 10 fetal calf serum JRH Biosciences
0.21750095.15117959.html.plaintext.txt	102	An Eppendorf FemtoJet microinjector InjectMan NI2 micromanipulator attached Nikon DM IRB inverted microscope used inject recombinant HSV 1 capsids Femtotip glass micropipette Hep2 PTK2 cells
0.21750095.15117959.html.plaintext.txt	103	The injection parameters used follows compensation pressure 50 hPa injection pressure 280 300 hPa range 200 400 hPa injection time 0
0.21750095.15117959.html.plaintext.txt	104	Between 200 400 cells injected experimental group time point
0.21750095.15117959.html.plaintext.txt	105	Immunofluorescence Confocal Microscopy Microinjected Hep2 cells fixed permeabilized described previously 25 either immediately 2 4 h incubation 37 degrees C
0.21750095.15117959.html.plaintext.txt	106	Sensitive specific labeling intra cytoplasmic capsids obtained rabbit polyclonal anti VP5 antibody NC1 kindly provided Dr
0.21750095.15117959.html.plaintext.txt	107	Eisenberg University Pennsylvania Philadelphia 40
0.21750095.15117959.html.plaintext.txt	108	Some nonspecific labeling antigens within nucleus observed involve nuclear membrane cytoplasm
0.21750095.15117959.html.plaintext.txt	109	Mouse anti bovine tubulin antibody monoclonal antibody 236 10501 Molecular Probes used label microtubules
0.21750095.15117959.html.plaintext.txt	110	Immunolabeling described previously 25 except antibodies diluted Tris buffered saline goat serum 1
0.21750095.15117959.html.plaintext.txt	111	5 vv bovine serum albumin 0
0.21750095.15117959.html.plaintext.txt	112	Secondary antibodies CyTM 3 conjugated goat anti mouse IgG Amersham Biosciences Alexa Fluor 488 conjugated goat anti rabbit IgG Molecular Probes
0.21750095.15117959.html.plaintext.txt	113	For co localization experiments microinjected PTK2 cells incubated 1 h 37 degrees C fixed permeabilized 25
0.21750095.15117959.html.plaintext.txt	114	Dynein light chains detected rabbit polyclonal antibodies kind gift Dr
0.21750095.15117959.html.plaintext.txt	115	Stephen King University Connecticut Health Centre Farmington CT
0.21750095.15117959.html.plaintext.txt	116	Primary antibody R5270 RP3 30 R5205 Tctex1 41 used followed CyTM 3 conjugated goat anti rabbit IgG Amersham Biosciences
0.21750095.15117959.html.plaintext.txt	117	Microtubules labeled
0.21750095.15117959.html.plaintext.txt	118	Capsids detected using anti VP5 antibodies either rabbit polyclonal NC1 mouse monoclonal antibody DM165 raised purified VP5 42
0.21750095.15117959.html.plaintext.txt	119	Confocal images acquired using Leica TCS SP2 Confocal System software version 2
0.21750095.15117959.html.plaintext.txt	120	00 Build 0871 attached Leica DMRE microscope
0.21750095.15117959.html.plaintext.txt	121	Dual channel images overlaid using Leica software co localization determined using Boolean AND operator
0.21750095.15117959.html.plaintext.txt	122	For redgreen overlay red green pixel colocalize bright pixel displayed pixels co localize black pixel displayed
0.21750095.15117959.html.plaintext.txt	123	Measurement Intracellular Distribution Capsids To assess quantitatively distribution microinjected capsids distances fluorescent particle cell nucleus nearest part cell membrane b measured aid image analysis software ImageJ version 1
0.21750095.15117959.html.plaintext.txt	124	29 National Institutes Health
0.21750095.15117959.html.plaintext.txt	125	A Nuclear Migration Index ba b calculated particle particles near cell periphery values close 0 whereas particles near nucleus values close 1 43
0.21750095.15117959.html.plaintext.txt	126	Image analysis performed blinded remove potential observer bias
0.21750095.15117959.html.plaintext.txt	127	Fluorescent particles confirmed within cytoplasm rather sitting cell membrane using serial z sections
0.21750095.15117959.html.plaintext.txt	128	In areas several fluorescent particles congregated individual particles visually separated image analysis using threshold functions z sections
0.21750095.15117959.html.plaintext.txt	129	Statistical Analysis The statistical software package SPSS Windows version 11
0.21750095.15117959.html.plaintext.txt	130	0 used analyze data
0.21750095.15117959.html.plaintext.txt	131	For comparison quantitative galactosidase activity yeast two hybrid system analysis variance performed
0.21750095.15117959.html.plaintext.txt	132	Tukeys correction multiple comparisons used investigate pairwise differences Target dynein inserts Bait HSV insert
0.21750095.15117959.html.plaintext.txt	133	To investigate formally intracellular movement capsids microinjection experiments general linear models used experiment random effect time VP26 status fixed effects
0.21750095.15117959.html.plaintext.txt	134	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES VP26 VP1112 Bind RP3 Tctex1 Yeast Two hybrid System A yeast two hybrid matrix approach used screen interactions HSV 1 capsid tegument proteins cytoplasmic dynein
0.21750095.15117959.html.plaintext.txt	135	Genes dynein subunits DIC LC8 RP3 Tctex1 well HSV 1 capsid tegument proteins cloned Bait vector fusion construct LexA DNA binding domain Target vector fusion construct B42 DNA activation domain
0.21750095.15117959.html.plaintext.txt	136	The proteins tested pairwise interactions available combinations
0.21750095.15117959.html.plaintext.txt	137	A strong interaction indicated growth media lacking leucine blue color change yeast colonies within 48 h
0.21750095.15117959.html.plaintext.txt	138	Interactions confirmed quantitative galactosidase assay
0.21750095.15117959.html.plaintext.txt	139	Known interactions DIC dynein light chains 31 44 45 well LC8 dimerization confirmed system Table I
0.21750095.15117959.html.plaintext.txt	140	View table TABLE I Yeast two hybrid screen HSV 1 proteins inserted Bait vector tested interaction dynein subunits inserted Target vector LexA yeast two hybrid system
0.21750095.15117959.html.plaintext.txt	141	Positive interactions defined growth leucine deficient media blue color change yeast colonies within 48 h confirmed using quantitative galactosidase assay shown arbitrary units
0.21750095.15117959.html.plaintext.txt	142	The symbols used follows 10 50 20 300 300 1000 1000 color change 48 h color change protein poorly expressed AA strong auto activation 48 h ND determined due autoactivation ve display Target protein insert
0.21750095.15117959.html.plaintext.txt	143	With HSV 1 proteins Bait vector strong interaction detected VP26 UL35 VP1112 UL46 homologous 14 kDa dynein light chains RP3 Tctex1 Table I
0.21750095.15117959.html.plaintext.txt	144	Galactosidase activity protein interaction measured using quantitative assay statistically examined using analysis variance Fig
0.21750095.15117959.html.plaintext.txt	145	Galactosidase activity significantly greater interactions RP3 Tctex1 DIC p 0
0.21750095.15117959.html.plaintext.txt	146	004 negative control p 0
0.21750095.15117959.html.plaintext.txt	147	The apparent small increase interactions DIC LC8 statistically significant
0.21750095.15117959.html.plaintext.txt	148	The known interaction HSV 1 capsid proteins VP23 VP19C 46 confirmed system
0.21750095.15117959.html.plaintext.txt	149	View larger version 17K FIG
0.21750095.15117959.html.plaintext.txt	150	HSV 1 proteins VP26 VP1112 interact dynein light chains RP3 Tctex1 yeast two hybrid system
0.21750095.15117959.html.plaintext.txt	151	Positive interactions yeast two hybrid screen Table I confirmed using quantitative galactosidase assay
0.21750095.15117959.html.plaintext.txt	152	This figure summarizes mean galactosidase activity interactions VP26 VP1112 including standard errors replicate experiments
0.21750095.15117959.html.plaintext.txt	153	Analysis variance Tukeys correction multiple comparisons confirmed galactosidase activity significantly greater interactions RP3 Tctex1 DIC p 0
0.21750095.15117959.html.plaintext.txt	154	004 negative control p 0
0.21750095.15117959.html.plaintext.txt	155	The apparent small increase interactions DIC LC8 statistically significant
0.21750095.15117959.html.plaintext.txt	156	With dynein subunits Bait vector RP3 Tctex1 strongly auto activated could tested
0.21750095.15117959.html.plaintext.txt	157	No interactions detected DIC LC8 Bait vector HSV 1 proteins tested Target vector data shown
0.21750095.15117959.html.plaintext.txt	158	The previously reported interaction DIC UL34 could confirmed UL34 poorly expressed inserted Target vector
0.21750095.15117959.html.plaintext.txt	159	His6 VP26 Binds GST RP3 GST Tctex1 Vitro His6 fusion constructs HSV 1 proteins VP26 VP1112 expressed E
0.21750095.15117959.html.plaintext.txt	160	His6 VP26 formed insoluble inclusion bodies solubilized denaturing 8 M urea slowly refolded dilution 1 M urea
0.21750095.15117959.html.plaintext.txt	161	VP26 expressed bacteria denatured refolded shown previously bind HSV 1 capsids either CHAPS buffer 1 M urea 47 48
0.21750095.15117959.html.plaintext.txt	162	His6 VP1112 expressed low concentrations
0.21750095.15117959.html.plaintext.txt	163	In vitro pull assays performed incubating His6 tagged HSV 1 proteins GST fusion constructs dynein subunits DIC LC8 RP3 Tctex1 bound glutathione Sepharose beads
0.21750095.15117959.html.plaintext.txt	164	Expression subsequent elution glutathione Sepharose beads confirmed GST dynein construct GST DIC present lower concentrations constructs Fig
0.21750095.15117959.html.plaintext.txt	165	Refolded His6 VP26 bound GST Tctex1 GST RP3 GST DIC GST LC8 GST alone Fig
0.21750095.15117959.html.plaintext.txt	166	Binding mediated via His6 tag His6 tagged kinesin heavy chain fragment His6 KIF5B residues 771 963 bind RP3 Tctex1 Fig
0.21750095.15117959.html.plaintext.txt	167	There evidence dynein binding His6 VP1112 may simply reflect low expression levels data shown
0.21750095.15117959.html.plaintext.txt	168	View larger version 53K FIG
0.21750095.15117959.html.plaintext.txt	169	His6 VP26 binds GST RP3 GST Tctex1 vitro
0.21750095.15117959.html.plaintext.txt	170	Purified His6VP26 His6 KIF5B amino acids 771 963 His6 tag negative control incubated GST tagged dynein subunits bound glutathione Sepharose beads pull assay
0.21750095.15117959.html.plaintext.txt	171	His6 VP26 bound dynein light chains GST RP3 GST Tctex1 GST DIC GST LC8 GST control
0.21750095.15117959.html.plaintext.txt	172	His6 VP26 initially detected Coomassie Blue stain A confirmation Western blots using anti His6 B anti VP26 C antibodies
0.21750095.15117959.html.plaintext.txt	173	Expression binding elution GST dynein fusion constructs confirmed Coomassie Blue stain A
0.21750095.15117959.html.plaintext.txt	174	GST DIC present lower concentrations fusion constructs
0.21750095.15117959.html.plaintext.txt	175	His6 VP26 Binds Intact Dynein Complexes Vitro To confirm VP26 binds dynein light chains dynein complex well solution vitro pull assay cytoplasmic dynein complexes performed
0.21750095.15117959.html.plaintext.txt	176	His6 fusion constructs HSV 1 proteins VP26 refolded US11 negative control bound nickel beads incubated lysates uninfected Hep2 cells eluted complexes analyzed SDS PAGE Western blot Fig
0.21750095.15117959.html.plaintext.txt	177	Dynein complexes detected cell lysates bound His6 VP26 His6 US11 Fig
0.21750095.15117959.html.plaintext.txt	178	The presence DIC bound complex used surrogate marker intact dynein complexes found evidence direct interaction VP26 DIC vitro
0.21750095.15117959.html.plaintext.txt	179	An equivalent concentration His6 VP26 His6 US11 eluted fractions confirmed Coomassie Blue stain Fig
0.21750095.15117959.html.plaintext.txt	180	View larger version 33K FIG
0.21750095.15117959.html.plaintext.txt	181	His6 VP26 binds intact cytoplasmic dynein complexes vitro
0.21750095.15117959.html.plaintext.txt	182	In pull assay Hep2 cell lysates incubated His6 tagged VP26 US11 HSV 1 tegument protein negative control bound nickel beads
0.21750095.15117959.html.plaintext.txt	183	Eluted complexes analyzed SDS PAGE Western blot dynein complexes detected anti DIC antibody
0.21750095.15117959.html.plaintext.txt	184	Dynein complexes detected cell lysates bound His6 VP26 His6 US11 A
0.21750095.15117959.html.plaintext.txt	185	An equivalent concentration His6 VP26 His6 US11 eluted fractions confirmed Coomassie Blue stain B
0.21750095.15117959.html.plaintext.txt	186	Recombinant HSV 1 Capsids Containing VP26 Bind GST RP3 To investigate behavior capsid proteins usual tertiary quaternary structure recombinant HSV 1 capsids constructed without VP26 VP26 VP26
0.21750095.15117959.html.plaintext.txt	187	These capsids examined electron microscopy shown single particle suspension data shown
0.21750095.15117959.html.plaintext.txt	188	They used pull assays GST tagged dynein subunits bound beads
0.21750095.15117959.html.plaintext.txt	189	The presence absence VP26 confirmed Coomassie Blue stain Western blot Fig
0.21750095.15117959.html.plaintext.txt	190	VP26 capsids bound GST RP3 dynein subunits replicate experiments Fig
0.21750095.15117959.html.plaintext.txt	191	VP26 capsids bind significantly background either experiment
0.21750095.15117959.html.plaintext.txt	192	The presence capsids bound dynein chains detected using polyclonal NC1 antibody major capsid protein VP5
0.21750095.15117959.html.plaintext.txt	193	View larger version 52K FIG
0.21750095.15117959.html.plaintext.txt	194	Composition recombinant HSV 1 capsids VP26
0.21750095.15117959.html.plaintext.txt	195	Recombinant HSV 1 capsids VP26 without VP26 12 kDa capsid protein VP26 formed expressing capsid proteins Sf9 insect cells using baculovirus vectors purified sucrose gradient
0.21750095.15117959.html.plaintext.txt	196	The presence VP26 VP26 capsids confirmed Coomassie Blue stain A Western blot B
0.21750095.15117959.html.plaintext.txt	197	There similar content VP5 capsid preparation shown Western blot B using NC1 polyclonal antibody
0.21750095.15117959.html.plaintext.txt	198	Proteolytic fragments VP5 also present
0.21750095.15117959.html.plaintext.txt	199	View larger version 44K FIG
0.21750095.15117959.html.plaintext.txt	200	VP26 VP26 capsids bind GST RP3 vitro
0.21750095.15117959.html.plaintext.txt	201	Recombinant HSV 1 capsids incubated GST tagged dynein subunits bound glutathione Sepharose beads pull assay
0.21750095.15117959.html.plaintext.txt	202	Capsids bound GST tag fusion proteins detected Western blot using NC1 polyclonal anti VP5 antibody replicate experiments A B
0.21750095.15117959.html.plaintext.txt	203	VP26 capsids bound GST RP3 dynein subunits
0.21750095.15117959.html.plaintext.txt	204	Proteolytic fragments VP5 also detected
0.21750095.15117959.html.plaintext.txt	205	VP26 capsids bind significantly background
0.21750095.15117959.html.plaintext.txt	206	Recombinant HSV 1 Capsids Co localize RP3 Tctex1 Microtubules Living Cells To confirm vivo interaction HSV 1 capsids cytoplasmic dynein PTK2 cells cultured glass coverslips microinjected suspension recombinant HSV 1 capsids VP26
0.21750095.15117959.html.plaintext.txt	207	Cells fixed 1 h 37 degrees C labeled capsids anti VP5 antibody well either dynein light chains anti RP3 anti Tctex1 antibody microtubules anti tubulin antibody
0.21750095.15117959.html.plaintext.txt	208	Image overlays show distribution capsids within cell demonstrate co localization capsids dynein light chains RP3 Tctex1 Fig
0.21750095.15117959.html.plaintext.txt	209	6A well microtubules Fig
0.21750095.15117959.html.plaintext.txt	210	Formal image analysis using Boolean AND operator confirmed co localization dynein microtubules majority HSV 1 capsids Fig
0.21750095.15117959.html.plaintext.txt	211	RP3 Tctex1 also present cytoplasm Hep2 cells data shown
0.21750095.15117959.html.plaintext.txt	212	View larger version 60K FIG
0.21750095.15117959.html.plaintext.txt	213	HSV 1 capsids co localize Tctex1 RP3 microtubules
0.21750095.15117959.html.plaintext.txt	214	PTK2 cells grown glass coverslips microinjected recombinant HSV 1 capsids VP26
0.21750095.15117959.html.plaintext.txt	215	After 1 h 37 degrees C cells fixed immunolabeled examined confocal microscopy
0.21750095.15117959.html.plaintext.txt	216	Capsids labeled anti VP5 antibody green cells anti Tctex1 anti RP3 anti tubulin antibody red
0.21750095.15117959.html.plaintext.txt	217	Over half capsids found co localize dynein light chains Tctex1 A B RP3 A B insets microtubules C D
0.21750095.15117959.html.plaintext.txt	218	To look co localization red green images initially overlaid A C co localization formally analyzed using confocal software B D
0.21750095.15117959.html.plaintext.txt	219	The Boolean AND operator used red green pixel co localized bright pixel displayed co localization black pixel displayed
0.21750095.15117959.html.plaintext.txt	220	Recombinant HSV 1 Capsids Containing VP26 Migrate toward Nucleus Living Cells To confirm functional biological significance interaction VP26 dynein Hep2 cells cultured glass coverslips microinjected suspension recombinant HSV 1 capsids VP26 VP26
0.21750095.15117959.html.plaintext.txt	221	Cells fixed either immediately 2 4 h replicate experiments labeled anti VP5 antibody distribution capsids within cell determined confocal microscopy Fig
0.21750095.15117959.html.plaintext.txt	222	Immediately following injection VP26 VP26 capsids diffusely distributed throughout cytoplasm Fig
0.21750095.15117959.html.plaintext.txt	223	After 2 h 37 degrees C VP26 capsids remained similar distribution Fig
0.21750095.15117959.html.plaintext.txt	224	7B whereas VP26 capsids congregated near nuclear rim many cells Fig
0.21750095.15117959.html.plaintext.txt	225	Similar distributions observed 4 h data shown
0.21750095.15117959.html.plaintext.txt	226	View larger version 77K FIG
0.21750095.15117959.html.plaintext.txt	227	VP26 VP26 capsids move toward nucleus Hep2 cells
0.21750095.15117959.html.plaintext.txt	228	Recombinant HSV 1 capsids VP26 VP26 microinjected Hep2 cells grown glass coverslips
0.21750095.15117959.html.plaintext.txt	229	The cells incubated 0 2 h 37 degrees C fixed
0.21750095.15117959.html.plaintext.txt	230	Capsids labeled using NC1 polyclonal anti VP5 antibody green microtubules monoclonal anti tubulin antibody red
0.21750095.15117959.html.plaintext.txt	231	Fluorescent particles arrows clearly visible cytoplasm injected cells A D present uninjected cells E
0.21750095.15117959.html.plaintext.txt	232	After 2 h redistribution VP26 D VP26 B capsids toward cell nucleus observed typical images
0.21750095.15117959.html.plaintext.txt	233	Nonspecific labeling cell nuclei observed NC1 antibody E intra nuclear fluorescence included analysis
0.21750095.15117959.html.plaintext.txt	234	To quantify movement HSV 1 capsids time distance individual fluorescent particles measured cell periphery b nuclear membrane aid image analysis software F
0.21750095.15117959.html.plaintext.txt	235	Relative nuclear migration particle expressed Nuclear Migration Index calculated ba b 43
0.21750095.15117959.html.plaintext.txt	236	Thus particles near cell periphery received values close 0 particles near nucleus received values close 1
0.21750095.15117959.html.plaintext.txt	237	To quantify distribution capsids different time points Nuclear Migration Index assigned visible fluorescent particle particles near plasma membrane received values close 0 whereas particles near cell nucleus received values close 1 Fig
0.21750095.15117959.html.plaintext.txt	238	Over thousand fluorescent particles analyzed two separate experiments
0.21750095.15117959.html.plaintext.txt	239	Fluorescent particles observed within nucleus injected uninjected cells Fig
0.21750095.15117959.html.plaintext.txt	240	7E background fluorescence included see Experimental Procedures
0.21750095.15117959.html.plaintext.txt	241	There nonspecific labeling nuclear membrane fluorescent particles adjacent nuclear membrane could clearly distinguished
0.21750095.15117959.html.plaintext.txt	242	General linear models used formally investigate data experiments
0.21750095.15117959.html.plaintext.txt	243	Within experiments involving VP26 capsids Nuclear Migration Index increased average 0
0.21750095.15117959.html.plaintext.txt	244	001 2 4 h confirming overall movement toward nucleus Fig
0.21750095.15117959.html.plaintext.txt	245	In contrast within experiments involving VP26 capsids Nuclear Migration Index decreased average 0
0.21750095.15117959.html.plaintext.txt	246	View larger version 24K FIG
0.21750095.15117959.html.plaintext.txt	247	Movement VP26 VP26 capsids toward nucleus statistically significant
0.21750095.15117959.html.plaintext.txt	248	Recombinant HSV 1 capsids VP26 VP26 microinjected Hep2 cells incubated 0 2 4 h 37 degrees C examined confocal microscopy
0.21750095.15117959.html.plaintext.txt	249	The Nuclear Migration Indices Fig
0.21750095.15117959.html.plaintext.txt	250	7 thousand fluorescent particles analyzed two separate experiments
0.21750095.15117959.html.plaintext.txt	251	General linear modeling performed experiments A B confirmed VP26 VP26 capsids moved toward cell nucleus 2 4 h
0.21750095.15117959.html.plaintext.txt	252	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Our results suggest binding HSV 1 outer capsid protein VP26 dynein light chains RP3 probably Tctex1 important retrograde transport viral capsids toward cell nucleus infection
0.21750095.15117959.html.plaintext.txt	253	Cytoplasmic dynein major minus end directed microtubule associated molecular motor dynein complex contains two copies 14 kDa light chain either RP3 Tctex1
0.21750095.15117959.html.plaintext.txt	254	The two chains although 55 homologous amino acid level 30 mutually exclusive complex compete binding sites DIC differing binding specificities 31
0.21750095.15117959.html.plaintext.txt	255	We initially demonstrated binding VP26 dynein light chains RP3 Tctex1 yeast two hybrid system confirmed strong expression galactosidase reporter quantitative assay
0.21750095.15117959.html.plaintext.txt	256	Subsequent work confirmed binding recombinant soluble VP26 RP3 Tctex1 vitro using bacterial expression GST pull assays
0.21750095.15117959.html.plaintext.txt	257	We also confirmed immobilized His6 VP26 able bind intact cytoplasmic dynein complexes cell lysates
0.21750095.15117959.html.plaintext.txt	258	Most important confirmed binding dynein RP3 VP26 biologically relevant form part recombinant viral capsid bound VP5
0.21750095.15117959.html.plaintext.txt	259	Thus confirmed specific binding VP26 dynein light chain RP3 three separate assays including part viral capsid
0.21750095.15117959.html.plaintext.txt	260	This suggests binding VP26 RP3 utilizes different VP26 epitopes involved binding VP5 capsids 49 consistent interaction playing significant role vivo
0.21750095.15117959.html.plaintext.txt	261	Furthermore microinjected cells shown co localization HSV 1 capsids containing VP26 RP3 Tctex1 microtubules supporting functional role VP26 dynein interactions
0.21750095.15117959.html.plaintext.txt	262	Despite strong interaction VP26 Tctex1 yeast two hybrid system vitro pull assays using His6 VP26 co localization HSV 1 capsids Tctex1 unable confirm binding VP26 capsids Tctex1 vitro
0.21750095.15117959.html.plaintext.txt	263	We believe result likely reflects lower sensitivity particular assay light vitro binding results
0.21750095.15117959.html.plaintext.txt	264	The ability bind either RP3 Tctex1 would expected offer HSV 1 evolutionary advantage allowing retrograde transport HSV 1 capsids cytoplasmic dynein complex cell types
0.21750095.15117959.html.plaintext.txt	265	We cannot exclude recombinant Tctex1 may bind soluble VP26 vitro VP26 incorporated recombinant HSV 1 capsids
0.21750095.15117959.html.plaintext.txt	266	However co localization VP26 capsids Tctex1 live cells suggests VP26 interacts Tctex1 well RP3 biologically relevant model
0.21750095.15117959.html.plaintext.txt	267	HSV 1 readily infects mucous membranes adults children transported retrograde direction along neuronal axons establish latent infection
0.21750095.15117959.html.plaintext.txt	268	RP3 particular attractive candidate mediate retrograde transport expressed high levels cells infected HSV 1 including adult brain many tissue types whereas Tctex1 expressed predominantly fetal tissue testis 30
0.21750095.15117959.html.plaintext.txt	269	Furthermore proposed RP3 containing dynein complexes play predominant role retrograde transport post synaptic nerve terminals 29 site HSV 1 entry
0.21750095.15117959.html.plaintext.txt	270	VP26 hexon tips ideally located interact molecular motors 48 tegument lost soon cell entry 6
0.21750095.15117959.html.plaintext.txt	271	Tegument proteins VP1112 VP1314 VP16 VP22 known dissociate virus early stages infection whereas major tegument protein VP12 minor capsid protein UL25 probably remain attached incoming capsids 4 5 8 50 51
0.21750095.15117959.html.plaintext.txt	272	VP12 appears attach capsids vertical pentons 52 whereas VP26 found exclusively hexons 39 48 53 interfere capsid tegument interaction 54
0.21750095.15117959.html.plaintext.txt	273	This specific binding probably due differing orientations upper domain VP5 structure recently solved 55
0.21750095.15117959.html.plaintext.txt	274	Binding tegument protein VP1112 RP3 Tctex1 detected yeast two hybrid system could confirmed pull assays due poor expression soluble His6 tag fusion proteins E
0.21750095.15117959.html.plaintext.txt	275	The significance results unclear role likely later viral replication cycle rather retrograde transport
0.21750095.15117959.html.plaintext.txt	276	It seems unlikely VP1112 involved retrograde transport capsid tegument complex dissociates incoming capsids cell infection 50 although retention residual VP1112 retrograde transport difficult exclude
0.21750095.15117959.html.plaintext.txt	277	An interaction VP1112 dynein may play role tegument assembly however newly synthesized VP1112 observed perinuclear particles undergoing rapid microtubule dependent movement 50
0.21750095.15117959.html.plaintext.txt	278	To confirm interaction VP26 dynein important cellular transport recombinant viral capsids microinjected living cells
0.21750095.15117959.html.plaintext.txt	279	On average significant movement VP26 capsids toward cell nucleus 2 4 h absent VP26 capsids
0.21750095.15117959.html.plaintext.txt	280	VP26 capsids fact redistributed slightly toward cell periphery may simply reflect diffusion truly random distribution
0.21750095.15117959.html.plaintext.txt	281	These results therefore suggest important role VP26 retrograde transport interactions cytoplasmic dynein
0.21750095.15117959.html.plaintext.txt	282	The relative contribution tegument capsid proteins HSV 1 transport unclear requires study
0.21750095.15117959.html.plaintext.txt	283	We cannot exclude VP12 one minor capsid proteins UL25 may also contribute dynein binding vivo suggested others 8 10
0.21750095.15117959.html.plaintext.txt	284	Any binding HSV 1 proteins dynein would imply redundancy viral proteins available retrograde transport may explain VP26 essential protein replication vitro 56
0.21750095.15117959.html.plaintext.txt	285	Redundancy important process may advantageous virus precedents functional redundancy HSV 1 proteins 57
0.21750095.15117959.html.plaintext.txt	286	In yeast two hybrid system evidence interaction dynein large fragment VP12 N terminal two thirds possible clone rest protein
0.21750095.15117959.html.plaintext.txt	287	Neither possible test UL25 system possible interaction RP3 Tctex1 due autoactivation
0.21750095.15117959.html.plaintext.txt	288	The role VP26 viral transport vivo remains determined
0.21750095.15117959.html.plaintext.txt	289	There one previous study mouse eye model dissecting role VP26 retrograde transport HSV 1 replication trigeminal ganglia 56
0.21750095.15117959.html.plaintext.txt	290	Deletion VP26 decreased amount infectious virus trigeminal ganglia 100 fold whereas titers cell culture retrograde transport less critical decreased 2 fold
0.21750095.15117959.html.plaintext.txt	291	Simultaneous deletion thymidine kinase thus replication ablated effects VP26 deletion 72 h ocular infection suggesting virus could still transported absence VP26
0.21750095.15117959.html.plaintext.txt	292	However earlier time points may needed detect decrease transport velocity efficiency wild type virus arrive early 19 h postinfection 58
0.21750095.15117959.html.plaintext.txt	293	In current study set determine viral cellular proteins mediate retrograde axonal transport HSV 1
0.21750095.15117959.html.plaintext.txt	294	Our use protein protein interaction assays minimal recombinant capsids sensitive way detect HSV dynein interactions traditional approaches relying single gene null mutants miss important interactions multifunctional redundant proteins exist 10
0.21750095.15117959.html.plaintext.txt	295	We demonstrated two different assays VP26 binds dynein light chains RP3 Tctex1 vitro confirmed binding VP26 intact dynein complexes
0.21750095.15117959.html.plaintext.txt	296	We demonstrated co localization cells micro injected HSV 1 capsids RP3 Tctex1 microtubules
0.21750095.15117959.html.plaintext.txt	297	We shown VP26 biologically relevant form able mediate binding recombinant HSV 1 capsids RP3 vitro absence minor capsid tegument proteins
0.21750095.15117959.html.plaintext.txt	298	Finally shown VP26 incorporated recombinant capsids necessary sufficient mediate retrograde intracellular transport capsids
0.21750095.15117959.html.plaintext.txt	299	We therefore propose VP26 although essential viral replication vitro likely one two HSV proteins mediating retrograde axonal transport vivo perhaps another example redundancy key viral functions
0.21750095.15117959.html.plaintext.txt	300	FOOTNOTES This work supported National Health Medical Research Council Grants 107374 253617 A
0.21750095.15117959.html.plaintext.txt	301	Post graduate Medical Scholarship 165713 M
0.21750095.15117959.html.plaintext.txt	302	The costs publication article defrayed part payment page charges
0.21750095.15117959.html.plaintext.txt	303	This article must therefore hereby marked advertisement accordance 18 U
0.21750095.15117959.html.plaintext.txt	304	Section 1734 solely indicate fact
0.21750095.15117959.html.plaintext.txt	305	Both authors contributed equally work
0.21750095.15117959.html.plaintext.txt	306	Molecular Genetics Biochemistry University Pittsburgh School Medicine Pittsburgh PA 15261
0.21750095.15117959.html.plaintext.txt	307	To correspondence addressed Centre Virus Research Westmead Millennium Institute P
0.21750095.15117959.html.plaintext.txt	308	Box 412 Westmead 2145 New South Wales Australia
0.21750095.15117959.html.plaintext.txt	309	61 2 9845 9111 Fax 61 2 9845 9103 E mail russelldiefenbachatwmi
0.21750095.15117959.html.plaintext.txt	310	1 The abbreviations used HSV 1 herpes simplex virus type 1 DIC dynein intermediate chain PRV pseudorabies virus GST glutathione S transferase CHAPS 3 3 cholamidopropyldimethylammonio 1 propanesulfonic acid
0.21750095.15117959.html.plaintext.txt	311	ACKNOWLEDGMENTS We thank Dr
0.21750095.15117959.html.plaintext.txt	312	Eve Diefenbach help yeast two hybrid system
0.21750095.15117959.html.plaintext.txt	313	Graham Robertson Nina Clifford Eppendorf help capsid microinjection protocol
0.21750095.15117959.html.plaintext.txt	314	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES Roizman B
0.21750095.15117959.html.plaintext.txt	315	1996 Fields Virology Fields B
0.21750095.15117959.html.plaintext.txt	316	2231 2294 Lippincott Raven Philadelphia PA Tatman J
0.21750095.15117959.html.plaintext.txt	317	75 1101 1113Abstract Thomsen D
0.21750095.15117959.html.plaintext.txt	318	68 2442 2457Abstract Morrison E
0.21750095.15117959.html.plaintext.txt	319	79 2517 2528Abstract Morrison E
0.21750095.15117959.html.plaintext.txt	320	72 7108 7114AbstractFree Full Text Ojala P
0.21750095.15117959.html.plaintext.txt	321	20 4922 4931AbstractFree Full Text Sodeik B
0.21750095.15117959.html.plaintext.txt	322	136 1007 1021AbstractFree Full Text Dohner K
0.21750095.15117959.html.plaintext.txt	323	Cell 13 2795 2809AbstractFree Full Text Lycke E
0.21750095.15117959.html.plaintext.txt	324	65 55 64Abstract Tomishima M
0.21750095.15117959.html.plaintext.txt	325	2001 Traffic 2 429 436CrossRefMedline Order article via Infotrieve Bearer E
0.21750095.15117959.html.plaintext.txt	326	97 8146 8150AbstractFree Full Text King S
0.21750095.15117959.html.plaintext.txt	327	Acta 1496 60 75Medline Order article via Infotrieve Holleran E
0.21750095.15117959.html.plaintext.txt	328	182 69 109Medline Order article via Infotrieve Raux H
0.21750095.15117959.html.plaintext.txt	329	74 10212 10216AbstractFree Full Text Jacob Y
0.21750095.15117959.html.plaintext.txt	330	74 10217 10222AbstractFree Full Text Alonso C
0.21750095.15117959.html.plaintext.txt	331	75 9819 9827AbstractFree Full Text Martinez Moreno M
0.21750095.15117959.html.plaintext.txt	332	544 262 267CrossRefMedline Order article via Infotrieve Mueller S
0.21750095.15117959.html.plaintext.txt	333	277 7897 7904AbstractFree Full Text Ye G
0.21750095.15117959.html.plaintext.txt	334	74 1355 1363AbstractFree Full Text Reynolds A
0.21750095.15117959.html.plaintext.txt	335	76 8939 8952AbstractFree Full Text Klupp B
0.21750095.15117959.html.plaintext.txt	336	74 10063 10073AbstractFree Full Text Roller R
0.21750095.15117959.html.plaintext.txt	337	74 117 129AbstractFree Full Text Miranda Saksena M
0.21750095.15117959.html.plaintext.txt	338	76 9934 9951AbstractFree Full Text Holland D
0.21750095.15117959.html.plaintext.txt	339	73 8503 8511AbstractFree Full Text Miranda Saksena M
0.21750095.15117959.html.plaintext.txt	340	74 1827 1839AbstractFree Full Text Enquist L
0.21750095.15117959.html.plaintext.txt	341	86 5 16CrossRefMedline Order article via Infotrieve Goldstein L
0.21750095.15117959.html.plaintext.txt	342	23 39 71CrossRefMedline Order article via Infotrieve Diefenbach R
0.21750095.15117959.html.plaintext.txt	343	76 3282 3291AbstractFree Full Text Chuang J
0.21750095.15117959.html.plaintext.txt	344	21 5501 5512AbstractFree Full Text King S
0.21750095.15117959.html.plaintext.txt	345	1998 Biochemistry 37 15033 15041CrossRefMedline Order article via Infotrieve Tai A
0.21750095.15117959.html.plaintext.txt	346	153 1499 1509AbstractFree Full Text Rozen S
0.21750095.15117959.html.plaintext.txt	347	2000 Bioinformatics Methods Protocols Methods Molecular Biology Krawetz S
0.21750095.15117959.html.plaintext.txt	348	75 1091 1099Abstract Crackower M
0.21750095.15117959.html.plaintext.txt	349	1999 Genomics 55 257 267CrossRefMedline Order article via Infotrieve Cunningham C
0.21750095.15117959.html.plaintext.txt	350	1993 Virology 197 116 124CrossRefMedline Order article via Infotrieve Cassady K
0.21750095.15117959.html.plaintext.txt	351	72 8620 8626AbstractFree Full Text Diefenbach R
0.21750095.15117959.html.plaintext.txt	352	1998 Biochemistry 37 16663 16670CrossRefMedline Order article via Infotrieve Diefenbach R
0.21750095.15117959.html.plaintext.txt	353	2002 Biochemistry 41 14906 14915CrossRefMedline Order article via Infotrieve Trus B
0.21750095.15117959.html.plaintext.txt	354	69 7362 7366Abstract Cohen G
0.21750095.15117959.html.plaintext.txt	355	34 521 531Medline Order article via Infotrieve King S
0.21750095.15117959.html.plaintext.txt	356	271 32281 32287AbstractFree Full Text McClelland D
0.21750095.15117959.html.plaintext.txt	357	76 7407 7417AbstractFree Full Text McDonald D
0.21750095.15117959.html.plaintext.txt	358	159 441 452AbstractFree Full Text Mok Y
0.21750095.15117959.html.plaintext.txt	359	276 14067 14074AbstractFree Full Text Makokha M
0.21750095.15117959.html.plaintext.txt	360	2002 Biochemistry 41 4302 4311CrossRefMedline Order article via Infotrieve Desai P
0.21750095.15117959.html.plaintext.txt	361	1996 Virology 220 516 521CrossRefMedline Order article via Infotrieve Macnab Bain S
0.21750095.15117959.html.plaintext.txt	362	1999 Analysis Protein Protein Interactions Shell Herpes Simplex Virus Type 1 HSV 1 Caspids
0.21750095.15117959.html.plaintext.txt	363	thesis University Glasgow Glasgow Wingfield P
0.21750095.15117959.html.plaintext.txt	364	71 8955 8961Abstract Desai P
0.21750095.15117959.html.plaintext.txt	365	77 391 404CrossRefMedline Order article via Infotrieve Willard M
0.21750095.15117959.html.plaintext.txt	366	76 5220 5232AbstractFree Full Text Elliott G
0.21750095.15117959.html.plaintext.txt	367	73 4110 4119AbstractFree Full Text Zhou Z
0.21750095.15117959.html.plaintext.txt	368	73 3210 3218AbstractFree Full Text Zhou Z
0.21750095.15117959.html.plaintext.txt	369	2 1026 1030Medline Order article via Infotrieve Chen D
0.21750095.15117959.html.plaintext.txt	370	75 11863 11867AbstractFree Full Text Bowman B
0.21750095.15117959.html.plaintext.txt	371	22 757 765AbstractFree Full Text Desai P
0.21750095.15117959.html.plaintext.txt	372	1998 Virology 247 115 124CrossRefMedline Order article via Infotrieve Farnsworth A
0.21750095.15117959.html.plaintext.txt	373	77 481 8494CrossRefMedline Order article via Infotrieve Kramer M
0.21750095.15117959.html.plaintext.txt	374	72 1177 1185AbstractFree Full Text
0.37472588.12560332.html.plaintext.txt	0	Interaction L2 Actin Directs Intracellular Transport Papillomavirus Infection Rongcun Yang William H
0.37472588.12560332.html.plaintext.txt	1	From Departments Pathology Pediatrics Gynecology Obstetrics The Johns Hopkins School Medicine Baltimore Maryland 21205
0.37472588.12560332.html.plaintext.txt	2	Received publication August 23 2002 revised form January 23 2003
0.37472588.12560332.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37472588.12560332.html.plaintext.txt	4	Viruses replicate nucleus including primary causative agent cervical cancer human papillomavirus type 16 HPV16 must first cross cytoplasm
0.37472588.12560332.html.plaintext.txt	5	We compared uptake HPV16 virus like particles VLPs either without minor capsid protein L2
0.37472588.12560332.html.plaintext.txt	6	Whereas VLPs containing major capsid protein L1 diffusely distributed within cytoplasm even 6 h post infection VLPs comprising L1 L2 exhibited radial distribution cytoplasm accumulated perinuclear region BPHE 1 cells within 2 h
0.37472588.12560332.html.plaintext.txt	7	L2 HPV16 bovine papillomavirus shown bind 43 kDa cellular protein subsequently identified actin matrix assisted laser desorption ionization time flight analysis
0.37472588.12560332.html.plaintext.txt	8	A conserved domain comprising residues 25 45 HPV16 L2 sufficient interaction actin
0.37472588.12560332.html.plaintext.txt	9	HPV16 L2 residues 25 45 fused green fluorescent protein green fluorescent protein alone colocalized actin caused cell retraction disruption microfilament network
0.37472588.12560332.html.plaintext.txt	10	Finally wild type L2 L2 residues 25 45 deleted facilitated HPV16 pseudovirion infection
0.37472588.12560332.html.plaintext.txt	11	Thus binding actin L2 residues 25 45 facilitates transport HPV16 across cytoplasm infection blockade novel interaction may useful prophylaxis
0.37472588.12560332.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37472588.12560332.html.plaintext.txt	13	Passive diffusion molecules within cytoplasm limited molecular crowding provide targeting particular subcellular domain 1
0.37472588.12560332.html.plaintext.txt	14	Thus many intracellular pathogens subvert existing transport mechanisms cytoskeletal components efficiently reach site replication also exit progeny 2
0.37472588.12560332.html.plaintext.txt	15	The cytoskeleton highly dynamic role locomotion regulated plethora actin tubulin binding proteins kinases phosphatases multiple signaling cascades
0.37472588.12560332.html.plaintext.txt	16	Changes tyrosine phosphorylation actin regulatory proteins induce condensation actin comet tails behind endosomes 3 well bacteria Listeria Shigella Rickettsia 4 viruses including vaccinia baculovirus SV40 propulsion cytoplasm 5 6
0.37472588.12560332.html.plaintext.txt	17	Other viruses employ cellular motors dyneins kinesins transport along microtubules
0.37472588.12560332.html.plaintext.txt	18	A single virus type employ several intracellular transport mechanisms
0.37472588.12560332.html.plaintext.txt	19	Indeed vaccinia particles driven along microtubules kinesin whereupon actin tails take propulsion 7 8
0.37472588.12560332.html.plaintext.txt	20	Compelling epidemiologic molecular virologic studies demonstrate infection oncogenic type human papillomavirus HPV1 typified HPV16 necessary cause cervical cancer 9
0.37472588.12560332.html.plaintext.txt	21	In absence effective screening programs cervical cancer leading cause cancer death women 10
0.37472588.12560332.html.plaintext.txt	22	Furthermore oncogenic HPV infection also strongly associated vulval anal penile cancers non melanoma skin cancers esophageal salivary cancers 11
0.37472588.12560332.html.plaintext.txt	23	An understanding infectious process critical rational development approaches prevention HPV related cancers
0.37472588.12560332.html.plaintext.txt	24	Although several cellular molecules including heparan sulfate glycosaminoglycans 12 6 integrin 13 CD16 14 implicated cell surface receptors papillomavirus little else known cellular proteins mediate cytoplasmic transport papillomavirus delivery viral genome nucleus
0.37472588.12560332.html.plaintext.txt	25	The papillomavirus capsid comprises major capsid protein L1 arranged 72 pentamers capsomers T7d icosahedral surface lattice 15 16 minor capsid protein L2 17 one molecule may located vertex 18
0.37472588.12560332.html.plaintext.txt	26	Overexpression L1 alone sufficient form empty capsids termed virus like particles VLPs 19
0.37472588.12560332.html.plaintext.txt	27	L1 VLPs bind cell surfaces compete bovine papillomavirus type 1 BPV1 infection vitro 20
0.37472588.12560332.html.plaintext.txt	28	However L1 L2 necessary efficient production papillomavirus infection 21 23
0.37472588.12560332.html.plaintext.txt	29	Recent studies Kawana et al
0.37472588.12560332.html.plaintext.txt	30	24 25 suggest residues 108 120 L2 displayed upon virion exterior bind cell surface resulting internalization
0.37472588.12560332.html.plaintext.txt	31	Furthermore anti L2 antiserum neutralizes papillomavirus without preventing virion binding cell surface 26
0.37472588.12560332.html.plaintext.txt	32	We recently demonstrated L2 plays critical role infection required interaction papillomavirus particles cell surface 23
0.37472588.12560332.html.plaintext.txt	33	Taken together data suggest L1 mediates initial binding virions cell surface whereas L2 provides later functions critical infection
0.37472588.12560332.html.plaintext.txt	34	EXPERIMENTAL PROCEDURES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37472588.12560332.html.plaintext.txt	35	Preparation Papillomavirus VLPs L2 VLPs containing L1 L2 L1 L1 L2 lacking residues 25 45 generated infection Sf9 recombinant baculoviruses purified previously reported 27
0.37472588.12560332.html.plaintext.txt	36	The HPV16 L225 45 deletion mutant prepared two rounds PCR using oligonucleotides CGCGGATCCATGCGACACAAACGTTCTGC CCCATACTTCCATATTGTAACTGTTTGCATGTTTTATAAAG TCCCCCCGGGCTAGGCAGCCAAAGAGAC CTTTATAAAAACATGCAAACAGTTACAATATGGAAGTATGGG followed outside primers
0.37472588.12560332.html.plaintext.txt	37	The quantity quality VLP preparations analyzed SDS PAGE electron microscopy respectively
0.37472588.12560332.html.plaintext.txt	38	His6 tagged BPV1 L2 fusion proteins prepared previously described 26
0.37472588.12560332.html.plaintext.txt	39	For generation glutathione S transferase GST tagged L2 green fluorescent protein GFP fusion proteins L2 oligonucleotides EcoRI SalI overhangs directly synthesized HPV16 L2 13 31 AATTCGCATCGGCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCCACCTGACGG TCGACCGTCAGGTGGACATGTACCTGCCTGTTTGCATGTTTTATAAAGTTGGGTAGCCGATGCG HPV16 L2 25 45 AATTCGCAGGTACATGTCCACCTGACATTATACCTAAGGTTGAAGGCAAAACTATTGCTGAT CAAATAGG TCGACCTATTTGATCAGCAATAGTTTTGCCTTCAACCTTAGGTATAATGTCAGGTGGACATGTACCTGCG HPV16 L2 61 81 AATTCGGAACAGGGTCGGGTACAGGCGGACGCACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGG TCGACCTGTGGGAGGCCTTGTTCCCAATGGAATATACCCAGTGCGTCCGCCTGTACCCGACCCTGTTCCG HPV16 L2 108 126 AATTCTTAGTGGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATCGG TCGACCGATGGAAGGTACAGATGTTGGTGCACCAGCATCAATAAAACTAGTTTCTTCCACTAAG amplified PCR using HPV16 L2 1 128 primers GCAGAATTCATGCGACACAAACGTTCTGCA GCAGGTCGACTGGGGGAATGGAAGGTAC HPV16 L2 299 333 primers GCAGAATTCACTGGCATTAGGTACAGT GCAGGTCGACTTCTTCTGCAGGATCAATAGT
0.37472588.12560332.html.plaintext.txt	40	Expression recombinant GST tagged proteins Escherichia coli BL21 purification GSTrapTM FF column Amersham Biosciences performed according manufacturers instructions
0.37472588.12560332.html.plaintext.txt	41	Metabolic Labeling Immunoprecipitation Cells grown overnight Dulbeccos modified Eagles medium 10 fetal calf serum containing 35S radiolabeled methionine cysteine 0
0.37472588.12560332.html.plaintext.txt	42	2 mCiml harvested ice cold buffer A 10 mM HEPES pH 7 1 mM EDTA 0
0.37472588.12560332.html.plaintext.txt	43	1 mM EGTA 10 mM KCl 1 mM dithiothreitol 20 mM n octyl D glucopyranoside Complete protease inhibitor mixture Roche Molecular Biochemicals
0.37472588.12560332.html.plaintext.txt	44	The nuclei removed centrifugation 12000 x g 15 min 4 degrees C lysate precleared 100 microl protein G Sepharose 20 microgml isotypic control antibody 2 h 4 degrees C
0.37472588.12560332.html.plaintext.txt	45	After addition His6 GFP tagged fusion protein immunoprecipitation performed anti His5 anti GFP monoclonal antibody respectively protein G Sepharose 16 h 4 degrees C slow agitation
0.37472588.12560332.html.plaintext.txt	46	The immunoprecipitates washed six times ice cold lysis buffer resolved 10 SDS PAGE
0.37472588.12560332.html.plaintext.txt	47	After treating 50 vv methanol 10 vv acetic acid AmplifyTM Amersham Biosciences 30 min gel dried vacuum 60 80 degrees C incorporated 35S visualized autoradiography
0.37472588.12560332.html.plaintext.txt	48	43 kDa Protein Purification Identification GST HPV16 L2 1 128 GFP bound GSTrap FF column detergent extracts 109 SiHa cells buffer A passed column
0.37472588.12560332.html.plaintext.txt	49	After extensive washing column eluted 50 mM Tris HCl 10 mM reduced glutathione pH 8
0.37472588.12560332.html.plaintext.txt	50	Eluates analyzed SDS PAGE silver staining
0.37472588.12560332.html.plaintext.txt	51	The 43 kDa protein band excised digested TPCK treated sequencing grade trypsin Worthington previously described 28
0.37472588.12560332.html.plaintext.txt	52	The masses resulting peptides measured matrix assisted laser desorption ionization time flight MALDI TOF analysis Voyager DE STR apparatus Applied Biosystems Foster City CA
0.37472588.12560332.html.plaintext.txt	53	Positive ion mass spectra analyzed using Data Explorer Version 3
0.37472588.12560332.html.plaintext.txt	54	Mass accuracy better 100 ppm
0.37472588.12560332.html.plaintext.txt	55	Actin identified using monoisotopic masses acquired 43 kDa protein search NCBI Non redundant Database using MS Fit search engine Protein Prospector Web site
0.37472588.12560332.html.plaintext.txt	56	Flow Cytometric Analysis L2 GFP Binding After fixation 5 min 3
0.37472588.12560332.html.plaintext.txt	57	7 paraformaldehyde phosphate buffered saline PBS cells permeabilized 1 vv Triton X 100 20 min
0.37472588.12560332.html.plaintext.txt	58	The cells incubated L2 GFP fusion protein 1 h room temperature washed analyzed flow cytometry FACScan BD Biosciences
0.37472588.12560332.html.plaintext.txt	59	Transfection The HPV16 L2 25 45 fragment subcloned EcoRI SalI restriction sites pEGFP C2 Clontech
0.37472588.12560332.html.plaintext.txt	60	The constructs transfected COS 7 cells using LipofectAMINE 2000 Invitrogen according recommended protocol
0.37472588.12560332.html.plaintext.txt	61	Three days transfection cells stained rhodamine phalloidin Molecular Probes Inc
0.37472588.12560332.html.plaintext.txt	62	examined confocal fluorescence microscopy UltraView confocal imaging system PerkinElmer Life Sciences
0.37472588.12560332.html.plaintext.txt	63	Indirect Immunofluorescence Rhodamine Phalloidin Staining Confocal Microscopy BPHE 1 cells incubated VLPs 1 h 4 degrees C Dulbeccos PBS washed medium 37 degrees C
0.37472588.12560332.html.plaintext.txt	64	At time points indicated cells washed PBS fixed 3
0.37472588.12560332.html.plaintext.txt	65	7 formaldehyde solution 10 min permeabilized 0
0.37472588.12560332.html.plaintext.txt	66	1 vv Triton X 100 PBS 5 min blocked PBS containing 1 bovine serum albumin 30 min
0.37472588.12560332.html.plaintext.txt	67	V5 used 1100 dilution detection HPV16 L1 fluorescein isothiocyanate conjugated goat anti mouse IgG Sigma added 5 microgml 20 min 4 degrees C
0.37472588.12560332.html.plaintext.txt	68	Actin stained rhodamine phalloidin
0.37472588.12560332.html.plaintext.txt	69	Samples examined confocal fluorescence microscopy using Nikon Eclipse TE 200 inverted microscope equipped x 40 plan fluor x 60 x 100 plan apochromatic objective lens corresponding 1 0
0.37472588.12560332.html.plaintext.txt	70	Twelve bit images merged analyzed UltraView acquisition software RGB mode
0.37472588.12560332.html.plaintext.txt	71	Electron Microscopy HPV16 VLPs bound BPHE 1 cells 1 h 4 degrees C
0.37472588.12560332.html.plaintext.txt	72	The cells washed shifted 37 degrees C 15 min fixed 2 glutaraldehyde 0
0.37472588.12560332.html.plaintext.txt	73	05 M sodium cacodylate 3 mM CaCl2 pH 7
0.37472588.12560332.html.plaintext.txt	74	4 30 min room temperature gentle rocking
0.37472588.12560332.html.plaintext.txt	75	8 potassium ferrocyanide buffer 15 min ice cells dehydrated graded series ethanol embedded Eponate 12 Ted Pella Inc
0.37472588.12560332.html.plaintext.txt	76	15 tannic acid 1 min rinsed stained en bloc uranyl acetate 2 h dark
0.37472588.12560332.html.plaintext.txt	77	The sections cut examined Phillips CM120 transmission electron microscope operating 80 kV
0.37472588.12560332.html.plaintext.txt	78	Generation Infectivity HPV16 Pseudovirions HPV16 pseudovirions generated infectivity assayed described previously 22
0.37472588.12560332.html.plaintext.txt	79	The HPV16 L225 45 deletion mutant prepared described generation HPV16 particles
0.37472588.12560332.html.plaintext.txt	80	The resulting DNA inserted BamHI XmaI restriction sites pSFV4
0.37472588.12560332.html.plaintext.txt	81	RESULTS TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37472588.12560332.html.plaintext.txt	82	L2 Facilitates Perinuclear Trafficking To define role L2 infectious process compared binding uptake intracellular transport HPV16 VLPs containing L1 L2 L1L2 VLPs VLPs comprising L1 L1 VLPs 27 permissive cell line BPHE 1 29
0.37472588.12560332.html.plaintext.txt	83	HPV16 VLPs incubated BPHE 1 cells 1 h 4 degrees C visualized indirect immunofluorescence
0.37472588.12560332.html.plaintext.txt	84	As previously demonstrated 20 VLPs comprising L1 L2 L1 bound cell surfaces similar pattern degree data shown
0.37472588.12560332.html.plaintext.txt	85	Upon shifting 37 degrees C 15 min initiate synchronized uptake cells fixed sectioned examined transmission electron microscopy
0.37472588.12560332.html.plaintext.txt	86	No differences noted cellular ultrastructure plasma membrane associated L1 VLPs Fig
0.37472588.12560332.html.plaintext.txt	87	1 A1 A2 L1L2 VLPs B1 B2 engulfment invagination plasma membrane A2 B2
0.37472588.12560332.html.plaintext.txt	88	At 30 min 1 2 6 h shifting BPHE 1 cells 37 degrees C VLPs localized Fig
0.37472588.12560332.html.plaintext.txt	89	2 indirect immunofluorescence using HPV16 L1 specific conformationally dependent neutralizing monoclonal antibody H16
0.37472588.12560332.html.plaintext.txt	90	Interestingly L1L2 VLPs aligned along distinct radial tracks across cytoplasm within 2 h 37 degrees C arrived perinuclear region Fig
0.37472588.12560332.html.plaintext.txt	91	However L1 VLPs aligned along radial tracks
0.37472588.12560332.html.plaintext.txt	92	Rather L1 VLPs remained widely distributed throughout whole cell showed less clear cut tropism toward nucleus 6 h time course Fig
0.37472588.12560332.html.plaintext.txt	93	These differences uptake L1L2 L1 VLPs suggest L2 contributes transport virions across cytoplasm
0.37472588.12560332.html.plaintext.txt	94	View larger version 123K Fig
0.37472588.12560332.html.plaintext.txt	95	Ultrastructural analysis L1L2 L1 VLP uptake BPHE 1 cells
0.37472588.12560332.html.plaintext.txt	96	HPV16 VLPs bound BPHE 1 cells 1 h 4 degrees C
0.37472588.12560332.html.plaintext.txt	97	The cells washed shifted 37 degrees C 15 min A1 A2 B1 B2 30 min B3 B5 fixed 2 glutaraldehyde 0
0.37472588.12560332.html.plaintext.txt	98	05 M sodium cacodylate 3 mM CaCl2 pH 7
0.37472588.12560332.html.plaintext.txt	99	4 30 min room temperature gentle rocking
0.37472588.12560332.html.plaintext.txt	100	8 potassium ferrocyanide buffer 15 min ice cells dehydrated graded series ethanol embedded Eponate 12 overnight
0.37472588.12560332.html.plaintext.txt	101	15 tannic acid 1 min rinsed stained en bloc uranyl acetate 2 h dark
0.37472588.12560332.html.plaintext.txt	102	The sections cut examined Phillips CM120 transmission electron microscope operating 80 kV
0.37472588.12560332.html.plaintext.txt	103	A1 A2 binding engulfment L1 VLPs B1 B2 binding engulfment L1L2 VLPs B3 L1L2 VLPs bound surface BPHE 1 cells arrow 1 particles within vesicle exhibits pinching arrow 2 particles free cytoplasm arrow 3 B4 fine filaments radiating L1L2 VLPs cytoplasm B5 fine filament emanating L1L2 VLPs toward microtubule arrow 1 microtubule arrow 2
0.37472588.12560332.html.plaintext.txt	104	View larger version 67K Fig
0.37472588.12560332.html.plaintext.txt	105	L2 promotes rapid transport across cytoplasm radial distribution VLPs
0.37472588.12560332.html.plaintext.txt	106	Subconfluent BPHE 1 cells incubated 10 microg HPV16 VLPs comprising L1L2 A panels L1 alone B panels L1 L2 lacking residues 25 45 C panels 1 h 4 degrees C shifted 37 degrees C various times
0.37472588.12560332.html.plaintext.txt	107	The cells fixed 30 min A1 C1 1 h A2 C2 2 h A3 C3 respectively 3
0.37472588.12560332.html.plaintext.txt	108	7 formaldehyde solution 10 min permeabilized 0
0.37472588.12560332.html.plaintext.txt	109	1 vv Triton X 100 PBS 5 min blocked PBS containing 1 bovine serum albumin 30 min
0.37472588.12560332.html.plaintext.txt	110	Murine monoclonal antibody H16
0.37472588.12560332.html.plaintext.txt	111	V5 used 1100 dilution detection HPV16 L1 fluorescein isothiocyanate conjugated goat anti mouse IgG green added 5 microgml 20 min 4 degrees C
0.37472588.12560332.html.plaintext.txt	112	Actin stained rhodamine phalloidin red
0.37472588.12560332.html.plaintext.txt	113	Samples examined confocal fluorescence microscopy UltraView confocal imaging system
0.37472588.12560332.html.plaintext.txt	114	D cytochalasin B 10 microM depolymerizes actin prevents uptake L1L2 VLPs cells E actins normal BPHE 1 cell F localization tubulin red L1 VLPs green 2 h shifting physiologic temperature
0.37472588.12560332.html.plaintext.txt	115	Because cytoskeleton provides framework intracellular transport L1L2 VLPs exhibited radial distribution Fig
0.37472588.12560332.html.plaintext.txt	116	2 A1 A2 transit perinuclear region determined subcellular localization cytoskeletal components VLP uptake
0.37472588.12560332.html.plaintext.txt	117	32 observed interaction L1 tubulin well blockade particle uptake microtubule depolymerizing agent nocodazole
0.37472588.12560332.html.plaintext.txt	118	Thus examined relative localization HPV16 L1 VLPs tubulin immunofluorescent staining
0.37472588.12560332.html.plaintext.txt	119	However limited overlap L1 VLP tubulin signals noted 2 h uptake Fig
0.37472588.12560332.html.plaintext.txt	120	Cytochalasin B disrupted microfilament network depolymerizing actin Fig
0.37472588.12560332.html.plaintext.txt	121	2 compare D E inhibited uptake HPV16 L1 data shown L1L2 Fig
0.37472588.12560332.html.plaintext.txt	122	2D VLPs consistent previous studies 33
0.37472588.12560332.html.plaintext.txt	123	Therefore compared localization actin using rhodamine phalloidin VLPs uptake
0.37472588.12560332.html.plaintext.txt	124	Upon initial uptake VLPs colocalized cortical actin periphery cell
0.37472588.12560332.html.plaintext.txt	125	At later time points radially distributed L1L2 VLPs colocalized actin filaments Fig
0.37472588.12560332.html.plaintext.txt	126	2A2 whereas little overlap observed L1 VLPs actin compare A B panels
0.37472588.12560332.html.plaintext.txt	127	Thus actin polymerization critical early VLP uptake particles colocalize actin microfilaments traversing cytoplasm
0.37472588.12560332.html.plaintext.txt	128	Although viruses including structurally related SV40 induce formation actin comet tails 34 phenomenon observed HPV16 VLP uptake suggesting different mode transport
0.37472588.12560332.html.plaintext.txt	129	Residues 25 45 L2 Bind Actin BPV1 frequently exploited virologic studies unlike HPVs 35 BPV readily prepared milligram quantities infectivity readily assayed vitro 36
0.37472588.12560332.html.plaintext.txt	130	To identify cellular targeting molecules recognized L2 generated E
0.37472588.12560332.html.plaintext.txt	131	coli six His6 tagged polypeptides spanning residues 1 88 45 173 130 257 216 340 300 425 384 469 together encompass entire open reading frame BPV1 L2 26
0.37472588.12560332.html.plaintext.txt	132	These polypeptides incubated 35Smethioninecysteine radiolabeled SiHa cell lysates data shown HeLa cell lysates immunoprecipitated monoclonal antibody specific tag
0.37472588.12560332.html.plaintext.txt	133	BPV1 L2 residues 1 88 co immunoprecipitated cellular protein 43 kDa whereas fragments including overlapping BPV1 L2 peptide comprising amino acids 45 173 Fig
0.37472588.12560332.html.plaintext.txt	134	This implies residues 1 45 L2 mediate binding 43 kDa cellular protein
0.37472588.12560332.html.plaintext.txt	135	View larger version 37K Fig
0.37472588.12560332.html.plaintext.txt	136	The conserved N terminus BPV1 HPV16 L2 binds 43 kDa cellular protein
0.37472588.12560332.html.plaintext.txt	137	A detergent lysates 35S radiolabeled HeLa cells subjected centrifugation 12000 x g 15 min 4 degrees C precleared 100 microl protein G Sepharose 20 microgml isotypic control contr
0.37472588.12560332.html.plaintext.txt	138	antibody 2 h 4 degrees C
0.37472588.12560332.html.plaintext.txt	139	After addition His6 tagged BPV1 L2 fragments comprising residues indicated immunoprecipitation performed His5 specific monoclonal antibody protein G Sepharose 16 h 4 degrees C slow agitation
0.37472588.12560332.html.plaintext.txt	140	The immunoprecipitates washed six times ice cold lysis buffer resolved 10 SDS PAGE autoradiography
0.37472588.12560332.html.plaintext.txt	141	B purified GST GFP alone GFP fused HPV16 L2 residues 1 128 1 128 incubated 35S radiolabeled precleared SiHa cell lysates immunoprecipitated using monoclonal antibody GFP isotype matched control antibody
0.37472588.12560332.html.plaintext.txt	142	C coprecipitation performed described B using GST GFP fused different regions HPV16 L2
0.37472588.12560332.html.plaintext.txt	143	D HeLa cell lysate ice cold buffer A clarified centrifugation 16000 x g 30 min passed glutathione Sepharose precoated GST GFP either alone fused HPV16 L2 residues 25 45 1 128 299 333 GST fused full length HPV16 L2
0.37472588.12560332.html.plaintext.txt	144	After extensive washing bound proteins eluted 50 mM Tris HCl 10 mM reduced glutathione pH 8
0.37472588.12560332.html.plaintext.txt	145	0 analyzed Western blotting mouse anti actin monoclonal antibody AC 15 Sigma
0.37472588.12560332.html.plaintext.txt	146	E purified GST GFP alone fused HPV16 L2 fragment 25 45 control fragment 299 333 incubated purified rabbit muscle actin PBS 1 h passed GSTrap FF column
0.37472588.12560332.html.plaintext.txt	147	After extensive washing bound proteins eluted visualized SDS PAGE Coomassie staining
0.37472588.12560332.html.plaintext.txt	148	Unlike C terminal sequence first 120 amino acids L2 well conserved among 70 known papillomavirus genotypes
0.37472588.12560332.html.plaintext.txt	149	To examine whether N terminal domain L2 derived papillomavirus genotypes also able bind 43 kDa cellular protein next generated E
0.37472588.12560332.html.plaintext.txt	150	coli chimera comprising GST fused frame amino acids 1 128 HPV16 L2 GFP form GST HPV16 L2 1 128 GFP
0.37472588.12560332.html.plaintext.txt	151	The purified fusion protein incubated 35Smethioninecysteine radiolabeled SiHa cell lysates immunoprecipitated using monoclonal antibody GFP
0.37472588.12560332.html.plaintext.txt	152	The GST HPV16 L2 1 128 GFP GST GFP fusion protein also bound 43 kDa cellular protein Fig
0.37472588.12560332.html.plaintext.txt	153	3B showing interaction conserved two evolutionarily distant papillomavirus types BPV1 HPV16
0.37472588.12560332.html.plaintext.txt	154	When testing smaller N terminal subfragments HPV16 L2 residues 25 45 co immunoprecipitated 43 kDa cellular protein detergent lysates radiolabeled SiHa cells Fig
0.37472588.12560332.html.plaintext.txt	155	3C suggesting motif sufficient interaction
0.37472588.12560332.html.plaintext.txt	156	To determine distribution cellular protein interacts HPV16 L2 GFP fusion protein examined confocal fluorescence microscopy Fig
0.37472588.12560332.html.plaintext.txt	157	4 binding detergent permeabilized human cervical carcinoma derived cell lines GST GFP chimeric proteins either without HPV16 L2 residues 1 128
0.37472588.12560332.html.plaintext.txt	158	Whereas GST GFP fusion protein failed bind SiHa cells GFP fusion proteins containing either residues 1 128 25 45 HPV16 L2 bound similar extent within cytoplasm detergent permeabilized SiHa cells Fig
0.37472588.12560332.html.plaintext.txt	159	To eliminate possible effects GST binding fusion protein cells GST HPV16 L2 GFP fusion proteins digested PreScission protease Fig
0.37472588.12560332.html.plaintext.txt	160	Thus binding SiHa cells PreScission protease digested Fig
0.37472588.12560332.html.plaintext.txt	161	4 GST HPV16 L2 25 45 GFP fusion protein compared
0.37472588.12560332.html.plaintext.txt	162	L2 GFP GFP alone bound SiHa cells similar extent either without GST indicating neither GST GFP mediates binding
0.37472588.12560332.html.plaintext.txt	163	Flow cytometric analysis showed HPV16 L2 residues 1 128 bound HPV positive cervical carcinoma derived cell lines HeLa data shown SiHa Fig
0.37472588.12560332.html.plaintext.txt	164	2 similar extent HPV negative human cervical carcinoma derived cell line C33A Fig
0.37472588.12560332.html.plaintext.txt	165	4 indicating HPV16 L2 binds cytoplasmic component derived papillomavirus
0.37472588.12560332.html.plaintext.txt	166	View larger version 43K Fig
0.37472588.12560332.html.plaintext.txt	167	Residues 25 45 HPV16 L2 bind non viral component cytoplasm
0.37472588.12560332.html.plaintext.txt	168	4 cervical carcinoma derived cell lines washed PBS fixed 3
0.37472588.12560332.html.plaintext.txt	169	7 paraformaldehyde permeabilized 1 vv Triton X 100 20 min
0.37472588.12560332.html.plaintext.txt	170	The cells incubated 1 h room temperature purified fusion protein comprising GST GFP alone A1
0.37472588.12560332.html.plaintext.txt	171	3 fused residues 1 128 HPV16 L2 A1
0.37472588.12560332.html.plaintext.txt	172	4 washed examined confocal fluorescence microscopy A1 panels scale bars 10 microm flow cytometry A2 panels
0.37472588.12560332.html.plaintext.txt	173	B1 GST GFP fusion proteins containing various HPV16 L2 fragments shown residues 25 45 affinity purified digested PreScission protease PreS
0.37472588.12560332.html.plaintext.txt	174	P analyzed SDS PAGE Coomassie staining
0.37472588.12560332.html.plaintext.txt	175	2 binding GFP alone HPV16 L2 25 45 GFP fragment respectively SiHa cells detected laser scanning confocal microscopy
0.37472588.12560332.html.plaintext.txt	176	4 binding HPV16 L2 25 45 GFP fragment SiHa cells independent GST tag
0.37472588.12560332.html.plaintext.txt	177	Shown results flow cytometric analysis binding SiHa cells PreScission protease digested B3
0.37472588.12560332.html.plaintext.txt	178	4 GFP GST fusion protein either lacking B3
0.37472588.12560332.html.plaintext.txt	179	To identity 43 kDa cellular protein detergent lysate SiHa cells passed GST HPV16 L2 1 128 GFP coated column
0.37472588.12560332.html.plaintext.txt	180	After extensive washing proteins bound eluted visualized SDS PAGE silver staining data shown
0.37472588.12560332.html.plaintext.txt	181	The 43 kDa protein band recovered excised subjected gel trypsin digestion MALDI TOF analysis
0.37472588.12560332.html.plaintext.txt	182	This analysis resulted identification 13 peptides whose protein sequences consistent actin Fig
0.37472588.12560332.html.plaintext.txt	183	View larger version 35K Fig
0.37472588.12560332.html.plaintext.txt	184	Tryptic mass fingerprint identifies 43 kDa band actin
0.37472588.12560332.html.plaintext.txt	185	A 43 kDa protein band bound residues 1 128 HPV16 L2 excised digested TPCK treated sequencing grade trypsin previously described 28
0.37472588.12560332.html.plaintext.txt	186	Masses resulting peptides measured MALDI TOF analysis Voyager DE STR apparatus
0.37472588.12560332.html.plaintext.txt	187	Positive ion mass spectra analyzed using Data Explorer Version 3
0.37472588.12560332.html.plaintext.txt	188	Mass accuracy better 100 ppm
0.37472588.12560332.html.plaintext.txt	189	B predicted measured peptide masses listed
0.37472588.12560332.html.plaintext.txt	190	Actin identified using acquired monoisotopic masses search NCBI Non redundant Database using MS Fit search engine Protein Prospector Web site see Footnote 2
0.37472588.12560332.html.plaintext.txt	191	Because peptides L2 used actin binding experiments possible truncations resulted exposure nonphysiologic cryptic epitope
0.37472588.12560332.html.plaintext.txt	192	To demonstrate interaction full length L2 actin detergent lysate HeLa cells passed glutathione Sepharose beads precoated GST fused full length HPV16 L2
0.37472588.12560332.html.plaintext.txt	193	The bound proteins separated electrophoresis subjected Western blot analysis using mouse monoclonal antibody actin Fig
0.37472588.12560332.html.plaintext.txt	194	Full length HPV16 L2 fragments 1 128 25 45 bound actin whereas fragment 299 333 GFP control Fig
0.37472588.12560332.html.plaintext.txt	195	Thus binding actin property full length L2
0.37472588.12560332.html.plaintext.txt	196	It unclear whether L2 binds directly actin
0.37472588.12560332.html.plaintext.txt	197	Therefore address question purified GST GFP fusion proteins containing HPV16 L2 residues 25 45 negative control residues 299 333 incubated 1 h ambient temperature actin purified rabbit muscle A 2522 Sigma
0.37472588.12560332.html.plaintext.txt	198	Upon pull glutathione Sepharose actin copurified GST GFP fusion protein containing residues 25 45 residues 299 333 HPV16 L2 Fig
0.37472588.12560332.html.plaintext.txt	199	This observation strongly supports existence direct interaction HPV16 L2 residues 25 45 actin
0.37472588.12560332.html.plaintext.txt	200	L2 Residues 25 45 Are Necessary Efficient Transport Perinuclear Region HPV16 Infection Studies viral systems suggest interaction actin facilitate intracellular transport viral particles infection
0.37472588.12560332.html.plaintext.txt	201	Therefore address biologic significance putative actin binding domain HPV16 L2 compared uptake HPV16 VLPs comprising wild type L1 alone L1 L2 L1 L2 residues 25 45 deleted L1L225 45
0.37472588.12560332.html.plaintext.txt	202	Whereas wild type HPV16 L1L2 VLPs rapidly transported perinuclear region along radial tracts Fig
0.37472588.12560332.html.plaintext.txt	203	2A1 L1L2 VLPs lacking residues 25 45 failed align along radial tracts cytoplasm reach perinuclear region 6 h time course Fig
0.37472588.12560332.html.plaintext.txt	204	Rather L1L225 45 VLPs remained widely distributed throughout cell described L1 VLPs Fig
0.37472588.12560332.html.plaintext.txt	205	Because papillomavirus exhibits high particle infectivity ratio vitro 22 possible uptake HPV16 VLPs shown Fig
0.37472588.12560332.html.plaintext.txt	206	1 represent true infectious pathway
0.37472588.12560332.html.plaintext.txt	207	Therefore examine significance interaction L2 actin infectious process generated HPV16 pseudovirions lacking conserved actin binding domain viz
0.37472588.12560332.html.plaintext.txt	208	6A tested infectivity using previously described system
0.37472588.12560332.html.plaintext.txt	209	Briefly hamster fibroblast cell line BPHE 1 harbors 50 200 episomal copies bovine papillomavirus genomecell 29 produces virus L1 L2 genes expressed
0.37472588.12560332.html.plaintext.txt	210	However ectopic expression HPV16 L1 L2 BPHE 1 cells via infection recombinant defective Semliki Forest viruses results generation infectious HPV16 pseudovirions containing BPV genome within capsids formed HPV16 L1 L2 22
0.37472588.12560332.html.plaintext.txt	211	Like native BPV1 virions infectivity HPV16 BPV1 pseudovirions readily quantified using vitro focal transformation mouse C127 cells 36
0.37472588.12560332.html.plaintext.txt	212	HPV16 pseudovirions lacking residues 25 45 L2 showed dramatically reduced infectivity Fig
0.37472588.12560332.html.plaintext.txt	213	6 suggesting interaction L2 actin indeed plays critical role infectious process papillomavirus
0.37472588.12560332.html.plaintext.txt	214	View larger version 32K Fig
0.37472588.12560332.html.plaintext.txt	215	L2 residues 25 45 required efficient HPV16 pseudovirion infection
0.37472588.12560332.html.plaintext.txt	216	A putative actin binding motif residues 25 45 HPV16 L2 highly conserved among different papillomavirus types
0.37472588.12560332.html.plaintext.txt	217	EEPV European Elk Papillomavirus RhPV Rhesus papillomavirus
0.37472588.12560332.html.plaintext.txt	218	B shown effect L225 45 deletion mutation infection C127 cells HPV16 pseudovirions
0.37472588.12560332.html.plaintext.txt	219	HPV16 pseudovirions generated BPHE 1 cells infectivity assayed described previously 22
0.37472588.12560332.html.plaintext.txt	220	The presence infectious HPV16 pseudovirions extracts BPHE 1 cells expressing wild type HPV16 L1 L2 L1L2 L1 L2 lacking residues 25 45 L1L22545 L1 alone assessed using focus forming assay monolayers C127 cells compared untreated control Contr
0.37472588.12560332.html.plaintext.txt	221	Mouse C127 cells maintained 3 weeks Dulbeccos modified Eagles medium containing 10 fetal calf serum
0.37472588.12560332.html.plaintext.txt	222	The plates stained 0
0.37472588.12560332.html.plaintext.txt	223	25 wv carbol fuchsin methanol highlight transformed foci counting
0.37472588.12560332.html.plaintext.txt	224	C foci counted four experiments plotted
0.37472588.12560332.html.plaintext.txt	225	Cytoplasmic Overexpression HPV16 L2 Residues 25 45 Disrupts Actin Architecture Actin one abundant proteins eukaryotic cells role primary determinant cell shape cytoplasmic structure locomotion highly regulated plethora binding proteins
0.37472588.12560332.html.plaintext.txt	226	Given ability L2 bind actin karyophilic nature full length L2 hypothesized overabundance L2 within cytoplasm might induce changes cytoskeleton cell morphology
0.37472588.12560332.html.plaintext.txt	227	To test hypothesis fragment HPV16 L2 encoding residues 25 45 inserted 3 GFP gene mammalian expression vector pEGFP C2 form pEGFP L2 25 45
0.37472588.12560332.html.plaintext.txt	228	COS 7 cells transfected either pEGFP C2 pEGFP L2 25 45
0.37472588.12560332.html.plaintext.txt	229	Three days transfection equivalent expression GFP alone fused HPV16 L2 residues 25 45 confirmed Western blot analysis monoclonal antibody GFP data shown
0.37472588.12560332.html.plaintext.txt	230	The subcellular localization actin upon staining rhodamine phalloidin either GFP alone fused HPV16 L2 residues 25 45 examined confocal fluorescence microscopy
0.37472588.12560332.html.plaintext.txt	231	Transient expression GFP fused HPV16 L2 residues 25 45 within cytoplasm COS 7 cells induced dramatic retraction transfected cells culture surface Fig
0.37472588.12560332.html.plaintext.txt	232	In contrast expression GFP alone transfected cells noticeably influence cell morphology Fig
0.37472588.12560332.html.plaintext.txt	233	7A1 compared parental untransfected cells data shown
0.37472588.12560332.html.plaintext.txt	234	Interestingly staining revealed apparent reorganization filamentous actin cytoplasmic bundles colocalized GFP fusion proteins containing HPV16 L2 residues 25 45 Fig
0.37472588.12560332.html.plaintext.txt	235	GFP significantly colocalize actin staining even dividing cells retracted culture dish Fig
0.37472588.12560332.html.plaintext.txt	236	Thus cytoplasmic overexpression actin binding domain HPV16 L2 sufficient induce retraction COS 7 cells actin reorganization
0.37472588.12560332.html.plaintext.txt	237	View larger version 26K Fig
0.37472588.12560332.html.plaintext.txt	238	Expression HPV16 L2 residues 25 45 COS 7 cells alters cell morphology actin structure
0.37472588.12560332.html.plaintext.txt	239	COS 7 cells two well chamber slides transfected using LipofectAMINE 2000 1 microg plasmid vector pEGFP encoding GFP A panels pEGFP L2 25 45 encoding GFP fused HPV16 L2 residues 25 45 B panels
0.37472588.12560332.html.plaintext.txt	240	After 3 days cells stained rhodamine phalloidin analyzed confocal microscopy
0.37472588.12560332.html.plaintext.txt	241	A1 B1 phase contrast light microscopy A2 B2 GFP fluorescence A3 B3 actin stained rhodamine phalloidin A4 B4 overlays fluorescence channels
0.37472588.12560332.html.plaintext.txt	242	Furthermore examined transmission electron microscopy sections BPHE 1 cells 30 min addition HPV16 VLPs association intracellular L1L2 L1 particles actin microfilament like structures
0.37472588.12560332.html.plaintext.txt	243	1B3 shows surface bound HPV16 L1L2 VLPs large groups particles within vesicles individual particles free cytoplasm
0.37472588.12560332.html.plaintext.txt	244	The majority 50 HPV16 L1L2 VLPs present cytoplasm associated fine filamentous structures whose width consistent actin microfilaments
0.37472588.12560332.html.plaintext.txt	245	HPV16 L1L2 VLPs occasionally formed star like structures Fig
0.37472588.12560332.html.plaintext.txt	246	1B4 fine filaments radiating capsid surface halo around particle dense cortical actin data shown suggestive actin rearrangement
0.37472588.12560332.html.plaintext.txt	247	1B5 arrow 1 seemed link HPV16 L1L2 particles microtubules arrow 2 also found
0.37472588.12560332.html.plaintext.txt	248	However observe structures association 50 L1 VLPs free cytoplasm BPHE 1 cells data shown
0.37472588.12560332.html.plaintext.txt	249	DISCUSSION TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES
0.37472588.12560332.html.plaintext.txt	250	During infectious process intracellular pathogen hijacks normal cellular function receptor molecules transportation site replication
0.37472588.12560332.html.plaintext.txt	251	Thus study infectious pathways enhance understanding normal cellular transport well identify targets intervention
0.37472588.12560332.html.plaintext.txt	252	Although intracellular pathogens use diverse primary secondary receptors gain entry cell mechanisms employed intracellular transport restricted
0.37472588.12560332.html.plaintext.txt	253	For example microorganisms diverse Listeria Shigella Rickettsia vaccinia SV40 employ different receptors gain entry cell similar mode intracellular transport 6 34
0.37472588.12560332.html.plaintext.txt	254	However despite structural similarity SV40 18 papillomaviruses use distinct cell surface receptor entry pathway little known
0.37472588.12560332.html.plaintext.txt	255	Indeed three different surface molecules 12 14 proposed bind major capsid protein L1 function primary receptor papillomavirus
0.37472588.12560332.html.plaintext.txt	256	Papillomavirus L1 pseudovirions prepared vitro infectious although significantly less containing L2 38 40
0.37472588.12560332.html.plaintext.txt	257	We provided genetic evidence L2 also plays critical role papillomavirus infection initial binding particle cell surface 23
0.37472588.12560332.html.plaintext.txt	258	By virtue ability bind enter cells L2 recently proposed bind secondary viral receptor facilitate uptake 24
0.37472588.12560332.html.plaintext.txt	259	The inability L1 VLPs enter nucleus 41 importance DNA binding karyophilic domains L2 infectious process suggest interaction L2 viral genome may play key role delivery nucleus 23 42
0.37472588.12560332.html.plaintext.txt	260	The high local protein concentration high 300 mgml organelles cytoskeleton contribute molecular crowding within cell restricts free diffusion molecules 500 kDa 1
0.37472588.12560332.html.plaintext.txt	261	Because papillomavirus capsid 55 nm diameter 2000 kDa free diffusion within cell extremely slow 15
0.37472588.12560332.html.plaintext.txt	262	During infection virus needs rapidly traffic nucleus site viral replication rather organelles lysosomes
0.37472588.12560332.html.plaintext.txt	263	To efficiently transport particles across cytoplasm infection residues 25 45 HPV16 L2 bind actin interaction influences microfilament structure
0.37472588.12560332.html.plaintext.txt	264	However understanding mechanism locomotion requires investigation
0.37472588.12560332.html.plaintext.txt	265	The high degree sequence conservation L2 motif Fig
0.37472588.12560332.html.plaintext.txt	266	6A ability BPV1 HPV16 L2 bind actin suggest interaction common papillomavirus genotypes therefore may represent useful target development pan papillomavirus preventative treatments
0.37472588.12560332.html.plaintext.txt	267	Indeed antibody L2 L1 neutralizes diverse papillomavirus genotypes suggesting conserved functional domain L2 displayed capsid surface 25 43
0.37472588.12560332.html.plaintext.txt	268	Furthermore L2 specific neutralizing antibodies predominantly recognize N terminus prevent virions binding cell surface 26 suggesting neutralization may occur blockade virion uptake intracellular transport
0.37472588.12560332.html.plaintext.txt	269	Several pathogens independently evolved mechanisms harness power actin polymerization get cells 34
0.37472588.12560332.html.plaintext.txt	270	Indeed entry wide variety viruses including papillomavirus human immunodeficiency virus vaccinia Autographa californica M nucleopolyhedrovirus adenovirus type 2 echoviruses dependent upon actin polymerization demonstrated blockade inhibitor cytochalasin D 44
0.37472588.12560332.html.plaintext.txt	271	However necessarily reflect direct interaction virus actin actin function necessary receptor mediated endocytosis many cellular processes
0.37472588.12560332.html.plaintext.txt	272	californica M nucleopolyhedrovirus induces formation thick actin cables frequently project toward nucleus
0.37472588.12560332.html.plaintext.txt	273	These actin cables transiently formed association viral nucleocapsids prior viral gene expression concomitantly nucleocapsid transport nucleus 45
0.37472588.12560332.html.plaintext.txt	274	Two virus encoded capsid proteins p39 p7883 A
0.37472588.12560332.html.plaintext.txt	275	californica M nucleopolyhedrovirus found bind actin directly therefore could involved observed acceleration actin polymerization viral actin binding proteins 46
0.37472588.12560332.html.plaintext.txt	276	It unclear effect relates changes actin structure produced overexpression L2 residues 25 45 within cytoplasm neither papillomavirus L1L2 VLPs L2 induces actin cables
0.37472588.12560332.html.plaintext.txt	277	Both endosomes diverse pathogens able recruit host cytoskeletal factors induce polymerization actin filaments surface structure known comet tail intracellular propulsion 34
0.37472588.12560332.html.plaintext.txt	278	However presence L2 L1L2 VLPs infection promote formation actin comet tails suggesting interaction L2 actin facilitates particle transport another mechanism
0.37472588.12560332.html.plaintext.txt	279	Actin ATPase ATP hydrolysis affects kinetics polymerization 47
0.37472588.12560332.html.plaintext.txt	280	In vivo actin polymerization highly regulated process controlled ATP binding hydrolysis action number actin binding proteins initiate cleave cross link stabilize destabilize filaments 48
0.37472588.12560332.html.plaintext.txt	281	Actin comet tails result depolymerization filamentous actin re polymerization behind particle 34
0.37472588.12560332.html.plaintext.txt	282	Interestingly overexpression actin binding motif comprising residues 25 45 HPV16 L2 cytoplasm associated redistribution actin COS 7 cells altered cell morphology
0.37472588.12560332.html.plaintext.txt	283	This consistent functional interaction L2 actin vivo orchestrates intracellular motility papillomavirus infection
0.37472588.12560332.html.plaintext.txt	284	In addition promoting uptake actin cytoskeleton facilitates egress vaccinia infected cells 8 34
0.37472588.12560332.html.plaintext.txt	285	The spread vaccinia enhanced actin tail formation triggered via tyrosine phosphorylation A36R
0.37472588.12560332.html.plaintext.txt	286	Herpesvirus type 1 VP22 exploits microfilaments promote intercellular spreading 49
0.37472588.12560332.html.plaintext.txt	287	Furthermore interaction Black Creek Canal virus N protein actin microfilaments required virion morphogenesis release infection 50
0.37472588.12560332.html.plaintext.txt	288	However papillomavirus accumulates microcrystalline arrays within nucleus productively infected cells currently evidence egress pathway mediated L2 actin interaction
0.37472588.12560332.html.plaintext.txt	289	Wu The Johns Hopkins University Andrew Lewis Food Drug Administration donating cell lines Neil D
0.37472588.12560332.html.plaintext.txt	290	Christensen Pennsylvania State University antibody H16
0.37472588.12560332.html.plaintext.txt	291	Cole assistance protein identification Mass Spectrometry Facility The Johns Hopkins School Medicine Mike Delannoy Microscopy Facility The Johns Hopkins School Medicine expert confocal electron microscopy Hung Chien Fu Lin Ken Yu discussion molecular biotechnology Liang Mei He technical assistance Drs
0.37472588.12560332.html.plaintext.txt	292	Wu Douglas Robinson The Johns Hopkins University John T
0.37472588.12560332.html.plaintext.txt	293	Lowy National Cancer Institute providing critiques preparation manuscript
0.37472588.12560332.html.plaintext.txt	294	This work supported Grants AI48203 CA83706 National Institutes Health Cancer Research Institute American Cancer Society Grant RSG MBC 103111 R
0.37472588.12560332.html.plaintext.txt	295	The work performed Mass Spectrometry Facility The Johns Hopkins School Medicine supported National Center Research Resources Shared Instrumentation Grant 1S10 RR14702 Johns Hopkins Fund Medical Discovery
0.37472588.12560332.html.plaintext.txt	296	The costs publication article defrayed part payment page charges
0.37472588.12560332.html.plaintext.txt	297	The article must therefore hereby marked advertisement accordance 18 U
0.37472588.12560332.html.plaintext.txt	298	Section 1734 solely indicate fact
0.37472588.12560332.html.plaintext.txt	299	To correspondence addressed Dept
0.37472588.12560332.html.plaintext.txt	300	Pathology The Johns Hopkins School Medicine Ross 512B 720 Rutland Ave
0.37472588.12560332.html.plaintext.txt	301	410 502 5161 Fax 443 287 4295 E mail rodenjhmi
0.37472588.12560332.html.plaintext.txt	302	Published JBC Papers Press January 30 2003 DOI 10
0.37472588.12560332.html.plaintext.txt	303	The abbreviations used HPV human papillomavirus VLP virus like particle BPV bovine papillomavirus GST glutathione S transferase GFP green fluorescent protein TPCK L 1 tosylamido 2 phenylethyl chloromethyl ketone MALDI TOF matrix assisted laser desorption ionization time flight PBS phosphate buffered saline
0.37472588.12560332.html.plaintext.txt	304	REFERENCES TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES 1
0.37472588.12560332.html.plaintext.txt	305	192 189 221Medline Order article via Infotrieve 2
0.37472588.12560332.html.plaintext.txt	306	8 465 472CrossRefMedline Order article via Infotrieve 3
0.37472588.12560332.html.plaintext.txt	307	148 519 530AbstractFree Full Text 4
0.37472588.12560332.html.plaintext.txt	308	14 137 166CrossRefMedline Order article via Infotrieve 5
0.37472588.12560332.html.plaintext.txt	309	5 142 148CrossRefMedline Order article via Infotrieve 6
0.37472588.12560332.html.plaintext.txt	310	2002 Science 296 535 539AbstractFree Full Text 7
0.37472588.12560332.html.plaintext.txt	311	3 992 1000CrossRefMedline Order article via Infotrieve 8
0.37472588.12560332.html.plaintext.txt	312	3 E245 E246CrossRefMedline Order article via Infotrieve 9
0.37472588.12560332.html.plaintext.txt	313	CO2 F 2 IlinktypeDOI CrossRefMedline Order article via Infotrieve 42
0.37472588.12560332.html.plaintext.txt	314	2000 Virology 270 254 257CrossRefMedline Order article via InfotrieveW
0.37472588.12560332.html.plaintext.txt	315	13 97 105CrossRefMedline Order article via Infotrieve 45
0.37472588.12560332.html.plaintext.txt	316	1993 Virology 197 245 254CrossRefMedline Order article via Infotrieve 46
0.37472588.12560332.html.plaintext.txt	317	1998 Virology 243 167 177CrossRefMedline Order article via Infotrieve 47
0.37472588.12560332.html.plaintext.txt	318	1987 Science 238 638 644Medline Order article via Infotrieve 48
0.37472588.12560332.html.plaintext.txt	319	14 305 338CrossRefMedline Order article via Infotrieve 49
0.37472588.12560332.html.plaintext.txt	320	1997 Cell 88 223 233Medline Order article via Infotrieve 50
0.37472588.12560332.html.plaintext.txt	321	72 2865 2870AbstractFree Full Text
0.37472588.12560332.html.plaintext.txt	322	Copyright 2003 The American Society Biochemistry Molecular Biology Inc
